{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: claude-haiku-4-5)",
    "evaluator_model": "claude-haiku-4-5",
    "model_evaluated": "nemotron-nano-30b-reasoning",
    "experiment": "e1_kg_minimal",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the gross benefit obligation for LMT’s nonqualified defined‑benefit pension plans fell from **$1.0 billion (2023)** to **$905 million (2024)** – a $95 million decrease – and the pretax actuarial losses recorded in accumulated other comprehensive loss declined from **$347 million (2023)** to **$303 million (2024)**, a $44 million reduction.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All numerical values are correct: gross benefit obligation decreased from $1.0 billion (2023) to $905 million (2024), and actuarial losses declined from $347 million (2023) to $303 million (2024). The calculations are accurate: $1.0B - $905M = $95M decrease, and $347M - $303M = $44M reduction. The answer correctly identifies the company (LMT), the specific pension plan type (nonqualified defined benefit), and the relevant metrics. The multi-hop synthesis is sound, comparing values across two fiscal years and drawing the appropriate conclusion about the reduction in both liability and actuarial losses. The LLM provides additional context by specifying that the actuarial losses are 'recorded in accumulated other comprehensive loss,' which adds precision without contradicting the ground truth. The wording differs slightly from the original answer but conveys identical semantic meaning. The only minor distinction is that the LLM explicitly calculates and states the dollar amount changes ($95M and $44M), which enhances clarity and demonstrates thorough analysis. No factual errors, calculation errors, or omissions are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 337,
        "total_tokens": 1520
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "\nBetween the 2021 and 2024 studies, GM’s weighted‑average long‑term return assumption for its U.S. pension assets moved from **5.4 % (as of 31 Dec 2021)** – the level that under‑pinned the 2022 period – to **6.3 % (31 Dec 2023)** and then to **6.5 % (31 Dec 2024)**, showing a clear upward trend through 2022‑2024.  This evolution reflects a deliberate **strategic asset‑mix shift**: the company is tilting toward higher‑return asset classes (e.g., equities and alternatives) and using derivatives to adjust duration and risk, all aimed at improving funded positions while reducing volatility, as described in the accounting policy that GM both introduces and rebalances across the 2022 and 2024 filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of GM's pension asset return assumptions evolution. STRENGTHS: (1) All numeric values are correct: 5.4% (Dec 31, 2021), 6.3% (Dec 31, 2023), and 6.5% (Dec 31, 2024) match the ground truth exactly. (2) The temporal progression is accurately captured, showing the upward trend from 2021 through 2024. (3) Multi-hop synthesis is sound: the answer correctly connects the 2022 filing data (which reported 2021 baseline of 5.4%) with 2024 filing data (showing 6.3% and 6.5%), demonstrating proper cross-filing integration. (4) The strategic interpretation is well-reasoned and aligns with ground truth: the shift from conservative 5.4% to optimistic 6.5% is correctly characterized as reflecting changes in capital market assumptions and investment strategies. (5) The qualitative analysis about asset mix adjustments (tilting toward equities/alternatives, using derivatives) provides appropriate context consistent with the ground truth's mention of 'changes in capital market assumptions and investment strategies.' MINOR CONSIDERATIONS: The LLM answer provides slightly more operational detail about derivatives and rebalancing strategies than the ground truth explicitly states, but this represents reasonable inference from pension accounting practices rather than factual error. The answer's framing of the evolution as occurring 'between 2021 and 2024 studies' is slightly different from the ground truth's 'between 2022 and 2024' framing, but this is a semantic distinction since the 2022 filing would report 2021 data. All core facts, numbers, and reasoning are accurate and well-synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Rebalances]- ORG",
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 456,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "\nBetween 2023 and 2024 Chevron’s tie to PDC Energy shifted from a simple equity stake to full ownership – the 2023 10‑K notes that PDC Energy, Inc. was **acquired by Chevron in a business combination**, which is why PDC was excluded from Chevron’s internal‑control assessment, and the 2024 10‑K shows the acquired assets now **“legacy PDC assets”** driving results; this evolution is captured by the mutual KG links CVX ↔ PDC Energy indicating both stake‑holding and dependence that culminated in acquisition.  As a result of the integration, Chevron reported **$3.5 billion of higher upstream earnings**, **250,000 boe/d (19 %) more net oil‑equivalent production**, and **$2.2 billion of additional sales volumes** from the former PDC properties, while also **avoiding $1.9 billion of decommissioning charges** that had been recorded in prior periods.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual inaccuracies that directly contradict the ground truth. (1) UPSTREAM EARNINGS ERROR: LLM states '$3.5 billion of higher upstream earnings' but ground truth clearly states '$2.2 billion increase in U.S. upstream earnings.' This is a $1.3 billion discrepancy - a material error. (2) PRODUCTION INCREASE: LLM correctly identifies '250,000 boe/d (19%)' which matches ground truth's '19% increase in net oil-equivalent production' - this is CORRECT. (3) FABRICATED FIGURES: LLM introduces '$2.2 billion of additional sales volumes' and '$1.9 billion of avoiding decommissioning charges' - these figures do NOT appear in the ground truth answer and appear to be hallucinated or confused with other metrics. The ground truth makes no mention of decommissioning charges avoided. (4) MULTI-HOP REASONING: The LLM correctly identifies the acquisition in 2023 and the exclusion from internal controls assessment, and correctly notes the shift to 'legacy PDC assets' in 2024. The narrative structure of acquisition-to-integration is sound. However, the introduction of unsupported financial metrics undermines the credibility of the synthesis. (5) ENTITY ACCURACY: Company names and years are correct (Chevron/CVX, PDC Energy, 2023-2024). The reference to 'KG links' is somewhat awkward but not factually wrong. SUMMARY: While the LLM demonstrates understanding of the acquisition narrative and correctly identifies the 19% production increase, it fundamentally fails on the primary quantitative metric (upstream earnings: $3.5B vs. $2.2B) and introduces unsubstantiated financial figures that do not appear in ground truth. These are not minor wording differences but material factual errors in financial reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 484,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "\nSouthern Company previously recorded the pre‑tax unrealized gains and losses on its energy‑related derivatives as deferred amounts within its regulatory‑hedging program (as shown for 2021/2022), with no separate balance‑sheet line item. In the 2024 filing the same derivatives are measured at fair value and presented directly as assets or liabilities in the balance sheet under “Risk Management Activities” (or “Other”), moving the unrealized gains/losses out of the deferred schedule into the regular financial statements. This shift reflects a change both in valuation (fair‑value presentation) and in disclosure (direct balance‑sheet line versus deferred regulatory schedule).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core factual content. Both answers correctly identify: (1) the 2022 treatment involved pre-tax unrealized derivative gains/losses from energy-related derivatives designated as regulatory hedging instruments that were deferred; (2) the 2024 shift to fair value presentation; (3) the change in balance sheet presentation from deferred regulatory schedules to direct line items under 'Risk Management Activities' or 'Other'. The LLM answer provides slightly more operational detail by explicitly noting the transition from 'no separate balance-sheet line item' to direct balance-sheet presentation, which adds clarity. No quantitative errors are present - no specific dollar amounts or percentages were provided in either answer, so this dimension is not applicable. The multi-hop reasoning is sound: the answer correctly synthesizes the temporal comparison (2022 vs 2024), identifies the valuation methodology change (deferred treatment to fair value), and explains the presentation change (regulatory schedule to balance sheet line items). The only minor limitation is that the LLM answer could have been slightly more explicit about the specific years referenced (2021/2020 in the original answer for the 2022 filing context), though this is a very minor omission that doesn't affect the core accuracy. The semantic equivalence is strong - both answers convey the same substantive changes in treatment and presentation. The answer is appropriately scoped to the question and addresses all relevant dimensions of the inquiry.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 438,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "\nChevron’s 50 % equity stake in Tengizchevroil (TCO) is reflected in the KG link **CVX ‑[Has_Stake_In]→ TCO**.  Between 2022 and 2024 the book value of that investment edged up from **$26.9 bn (2023) to $27.4 bn (2024)**, while the equity‑method earnings recognized fell from **$4.39 bn (2022) to $3.03 bn (2024)**.  The modest rise in carrying value stems from the $4.5 bn loan Chevron extended to TCO for the FGP/WPMP development (noted in the 2022 filing) and the $100 excess of carrying value over underlying equity that has persisted, and the declining earnings track the lower equity‑method results reported in the 2024 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive synthesis of multi-hop financial information. STRENGTHS: (1) All key financial figures are correct: $26.9bn (2023) vs $27.4bn (2024) for investment carrying value matches the ground truth's $26,954M and $27,368M respectively (minor format variation acceptable); equity earnings correctly stated as $4.39bn (2022) and $3.03bn (2024), matching ground truth's $4,386M and $3,033M. (2) The answer correctly identifies Chevron's 50% equity stake in TCO and properly synthesizes the multi-hop relationship. (3) Supporting details are accurate: the $4.5bn loan for FGP/WPMP development and the $100 excess of carrying value over underlying equity are both correctly cited from 2022 filings. (4) The reasoning is sound - the answer explains the modest rise in carrying value through the loan and persistent excess, and correctly attributes declining earnings to lower equity-method results. (5) The answer directly addresses all parts of the question regarding investment carrying value evolution and equity earnings trends. MINOR CONSIDERATIONS: The answer uses 2023 as a comparison point for carrying value rather than 2022, which is slightly different from the ground truth's 2022-2024 framing, but this is not incorrect since the ground truth itself mentions 2023 figures. The answer's statement about 'modest rise' is accurate given the $414M increase over one year. All calculations are correct and the semantic meaning aligns perfectly with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 419,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Walmart’s stake in Alert Innovation moved from a variable‑interest entity to full ownership after it completed a $0.4 billion acquisition in fiscal 2023, which raised its ownership to 100 % (as shown by the ORG → COMP [Acquires] relationship in the knowledge graph). No further change in that ownership percentage occurred during fiscal 2024; the next transaction—selling the now‑100 % owned Alert Innovation and de‑consolidating it—was not executed until fiscal 2025. This acquisition is the specific transaction that altered Walmart’s relationship with Alert Innovation.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The LLM claims that the sale and deconsolidation of Alert Innovation occurred in fiscal 2025, not fiscal 2024. The ground truth explicitly states that 'by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation,' indicating this transaction happened within the fiscal 2023-2024 timeframe being asked about. The question specifically asks about the evolution 'between fiscal 2023 and fiscal 2024,' and the ground truth answer clearly indicates both the acquisition (fiscal 2023) and the subsequent sale/deconsolidation (fiscal 2024) occurred within this period. The LLM's assertion that the sale happened in fiscal 2025 is factually incorrect and represents a major misunderstanding of the timeline. QUANTITATIVE ACCURACY: The $0.4 billion acquisition amount and 100% ownership percentage are correct. QUALITATIVE ACCURACY: While the LLM correctly identifies the acquisition as the specific transaction that changed the relationship, it fails to recognize that a second transaction (the sale and deconsolidation) also occurred during the fiscal 2023-2024 period being evaluated. The LLM's multi-hop reasoning is incomplete because it does not synthesize the complete evolution of Walmart's ownership stake as requested. The answer addresses only half of the transformation described in the ground truth—the acquisition but not the subsequent exit. CONTEXTUAL RELEVANCE: The answer is partially relevant but incomplete, as it fails to address the complete ownership evolution that the question asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Acquires]-> COMP <-[Sells]- ORG",
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 448,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "\nStarbucks (SBUX) discloses a “foreign‑currency‑other” financial instrument, and the company’s exposure‑management can be tracked through the two 10‑K tables.  In FY 2022 the filing notes that **$32.5 million** of gains on foreign‑currency‑other derivatives are expected to be re‑classified from AOCI into earnings within the next 12 months, indicating a sizable near‑term hedge position.  By FY 2023 the balance‑sheet shows **derivative assets of $1.9 million (current) and $1.7 million (long‑term)** and **derivative liabilities of $4.7 million (current) and $4.1 million (long‑term)** for the same instrument, expanding total liability exposure while only modestly increasing assets.  This shift—from a large near‑term reclassification expectation in 2022 to a higher short‑term liability position and a slightly larger asset base in 2023—reveals that Starbucks is actively re‑balancing its hedge book, extending hedge maturities and increasing short‑term currency‑swap liabilities to better match its foreign‑currency cash‑flow exposure and to manage earnings volatility.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on the key quantitative metrics but has some notable omissions and interpretive issues. STRENGTHS: (1) All reported numbers are correct: FY2022 $32.5M reclassification expectation, FY2023 derivative assets of $1.9M (current) and $1.7M (long-term), and derivative liabilities of $4.7M (current) and $4.1M (long-term). (2) The multi-hop synthesis correctly compares positions across two fiscal years. (3) The reasoning about rebalancing and hedge management is logical and well-articulated. WEAKNESSES: (1) The LLM omits the critical FY2022 AOCI asset position of $55.3 million, which is essential context for understanding the 'substantial reduction in overall foreign currency - other derivative exposure' mentioned in the ground truth. Without this figure, the magnitude of the shift from 2022 to 2023 is not fully apparent. (2) The LLM's interpretation that liabilities 'expanded' while assets 'modestly increased' is somewhat misleading—the ground truth emphasizes a shift from unrealized gains in equity ($55.3M AOCI) to more balanced asset/liability positions, which is a more accurate characterization of the strategic shift. (3) The LLM's conclusion about 'expanding total liability exposure' is not fully supported by the data presented, as the overall net position actually decreased significantly from the $55.3M AOCI asset in 2022. The answer is directionally correct on exposure management strategy but lacks the complete picture of the balance sheet shift. The quantitative accuracy is high for the numbers cited, but the qualitative interpretation could be more precise regarding what the shift actually represents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 459,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "\nMedtronic completely retired its A Preferred Shares: the company redeemed the 1,872 outstanding A Preferred Shares in the third quarter of fiscal 2022 for $0.075 million, and by the end of that year (and still as of April 26, 2024) no A Preferred Shares remained outstanding (Chunks 1 & 2).  This permanent retirement occurred while the firm’s depreciation expense was $974 million in fiscal 2022 (Chunk 1) and $954 million in fiscal 2024 (Chunk 2), showing that the capital‑structure change was separate from its operating expense trends.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question well. STRENGTHS: (1) All key numbers are accurate: 1,872 shares redeemed, $0.075 million redemption price, Q3 FY2022 timing, and no shares outstanding by FY2024. (2) The multi-hop synthesis is sound - correctly connects the 2022 redemption action to the 2024 status showing permanent discontinuation. (3) Correctly identifies this as a capital structure change. (4) Accurately notes the fiscal year end dates (April 29, 2022 and April 26, 2024). MINOR ISSUES: (1) The inclusion of depreciation expense data ($974M in FY2022, $954M in FY2024) is factually correct but somewhat tangential to the core question about A Preferred Shares evolution. While the LLM's point about separating capital structure changes from operating expenses is valid, this information wasn't requested and slightly dilutes focus from the primary question. (2) The phrase 'completely retired' and 'permanent retirement' are reasonable interpretations of the ground truth's 'discontinuation,' though the ground truth uses more measured language. The semantic meaning is equivalent - both convey that the shares were not reissued. VERIFICATION: All quantitative facts check out against ground truth. The reasoning correctly synthesizes information across fiscal years 2022 and 2024. The answer fully addresses both parts of the question: (a) the specific 2022 action (redemption of 1,872 shares for $0.075M in Q3), and (b) the evolution through 2024 (no reissuance). The answer demonstrates proper multi-hop reasoning by connecting the 2022 event to the 2024 outcome.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 441,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "\nBetween 2022 and 2023 Comcast’s equity‑in‑net‑income (losses) from its investment in Atairos flipped from a **$(434 million) loss in 2022**—driven by negative fair‑value adjustments on Atairos’ underlying investments—to a **$1.1 billion income in 2023**, reflecting positive fair‑value adjustments on those same investments. This swing from a loss to a gain was the primary reason the change in equity in net income (losses) of investees shifted dramatically over the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. (1) QUANTITATIVE ACCURACY: All financial figures are correct - the 2022 loss of $(434) million and 2023 income of $1.1 billion match the ground truth exactly. Number formats are consistent and appropriate. (2) COMPLETENESS: The answer addresses all aspects of the question, covering the evolution of Comcast's financial relationship with Atairos between 2022 and 2023, and specifically addresses equity income (losses) driven by fair value adjustments. (3) ENTITY ACCURACY: All entities are correctly identified - Comcast, Atairos, the specific metric (equity-in-net-income/losses from investees), and both fiscal years (2022 and 2023). (4) REASONING & SYNTHESIS: The multi-hop reasoning is sound. The LLM correctly synthesized that the swing from loss to gain was driven by fair value adjustments on underlying investments, demonstrating proper understanding of the causal relationship. The characterization of this as a \"dramatic\" shift is appropriate given the magnitude ($1.534 billion swing). (5) SEMANTIC EQUIVALENCE: The LLM's phrasing \"flipped from a loss to a gain\" and \"swing from a loss to a gain\" effectively conveys the same information as the ground truth's \"significant turnaround.\" The explanation of the mechanism (fair value adjustments) is clear and accurate. Minor note: The LLM's phrasing is slightly more detailed and explicit about the mechanism than the ground truth, which is a strength rather than a weakness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 414,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "\nCOP’s reported natural‑gas reserves in the Asia Pacific/Middle East region slipped from **312 billion cubic feet at the end of 2023 to 296 billion cubic feet at the end of 2024**, a decline of roughly **16 bcf (≈5 %)**.  The drop occurred even though the company recorded **no purchases or discoveries** in that geography during 2024, underscoring a deliberate wind‑down of its exposure there and a re‑allocation of capital toward higher‑growth North‑American plays—consistent with the “Operates_In → GPE ← Discloses” relationship that links COP to the region and explains why the diminishing reserve base signals a strategic shift away from Asia Pacific/Middle East.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core numbers: 312 bcf (2023) and 296 bcf (2024) match the ground truth exactly. The calculated decline of 16 bcf is accurate, and the percentage calculation of approximately 5% is correct (16/312 = 5.1%). The answer properly addresses both parts of the multi-part question: (1) the evolution of reserves (quantified with specific figures and trend), and (2) strategic positioning implications. The LLM goes beyond the ground truth by providing additional context about 'no purchases or discoveries' in 2024 and explicitly connecting this to a strategic reallocation toward North American plays, which represents reasonable inference from the data pattern. The semantic meaning aligns well with the ground truth's characterization of 'limited growth or strategic reallocation.' Minor deductions apply because: (1) the additional claims about 'no purchases or discoveries' and 'deliberate wind-down' and 'higher-growth North American plays' are not explicitly stated in the ground truth and represent inferences that, while logical, go beyond what can be verified from the provided knowledge graph; (2) the reference to 'Operates_In → GPE ← Discloses' relationship appears to be technical metadata that, while potentially accurate, is not necessary to answer the question and may confuse readers. The core answer is sound and well-reasoned, with accurate numbers and appropriate interpretation of strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 409,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "\nThe revenue from ENBREL in Canada dropped from $73 million in 2022 to $47 million in 2023 (‑36%) and then to $28 million in 2024 (‑40%), as shown in Chunk 1 (2022‑2023 data) and Chunk 2 (2023‑2024 data). This consecutive double‑digit decline, linked through the KG relationship AMGN → ENBREL (Canada), indicates a weakening market trajectory for ENBREL in Canada over the 2022‑2024 period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERROR IN 2022 BASELINE: The LLM states ENBREL Canada revenue was $73 million in 2022, but the ground truth clearly establishes it was $113 million in 2022. This is a $40 million discrepancy (35% understatement) on the starting value, which is a fundamental factual error. The 2023 ($47M) and 2024 ($28M) figures are correct. CALCULATION ERRORS: The LLM calculates a -36% decline from 2022-2023 ($73M to $47M = -36%), but this is based on the incorrect 2022 baseline. The correct calculation should be: ($113M to $47M = -58% decline). The -40% decline for 2023-2024 ($47M to $28M) is approximately correct (actually -40.4%). MULTI-HOP REASONING: The LLM correctly identifies the multi-hop relationship (AMGN → ENBREL Canada) and properly synthesizes data across two time periods. The conclusion about a weakening market trajectory is semantically sound and matches the ground truth interpretation. COMPLETENESS: The answer addresses both the revenue evolution and market trajectory interpretation, covering all parts of the question. However, the foundational error in the 2022 figure undermines the entire analysis. The qualitative assessment of declining demand is correct, but the quantitative foundation is significantly flawed. This is a case where the reasoning structure is sound but the input data accuracy is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 375,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "\nQualcomm continued to tie human‑capital advancements to executive bonus decisions in both years, but the performance‑modifier band was tightened: for fiscal 2023 the non‑financial modifier could adjust the bonus by a multiple of **0.85 to 1.15**, whereas for fiscal 2024 the same adjustment is limited to **0.9 to 1.1**. This evolution reflects a more constrained range in 2024, indicating a refined approach to linking human‑capital progress with executive compensation.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamentally incorrect numeric values that directly contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM claims fiscal 2023 had a modifier range of 0.85 to 1.15, but the ground truth does not mention this range for 2023 at all. The ground truth states that in fiscal 2023, human capital advancements were merely 'considered' without a specific quantified modifier range. The LLM then claims fiscal 2024 has a 0.9 to 1.1 range, which matches the ground truth, but the comparison to a non-existent 2023 range (0.85 to 1.15) is fabricated. (2) MULTI-HOP REASONING FAILURE: The LLM incorrectly synthesized the evolution by inventing a fiscal 2023 modifier range that does not exist in the source material. The actual evolution was from 'general consideration' (2023) to 'quantified modifier of 0.9 to 1.1' (2024), not a tightening from 0.85-1.15 to 0.9-1.1. (3) ENTITY/METRIC ACCURACY: While Qualcomm and the fiscal years are correct, the performance modifier ranges are substantially wrong for 2023. (4) SEMANTIC EQUIVALENCE: The LLM's characterization of the evolution as a 'tightening' of ranges is semantically incorrect because the 2023 range it cites does not exist in the ground truth. The actual evolution was from no quantified modifier to a quantified one, not a range adjustment. The answer demonstrates a fundamental misunderstanding of the source material and introduces false data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Focuses_On]-> CONCEPT <-[Guides_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 403,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "\nBetween 2022 and 2024 Breyanzi’s approved therapeutic scope widened from the 2022 filing—where it was listed for “3L+ Chronic Lymphocytic Leukemia” and “3L+ Follicular Lymphoma” (BMY 10‑K 2022, p. 20)—to 2024 when the FDA granted accelerated approvals for relapsed or refractory **CLL/SLL** (March 2024) and for relapsed or refractory **FL** (May 2024) after ≥ two prior lines of therapy (BMY 10‑K 2024, pp. 45‑46). These 2024 approvals expand Breyanzi’s indication beyond the original third‑line setting to include additional hematologic malignancies and a broader patient population, reflecting a clear evolution in its therapeutic scope.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key dates, indications, and approvals. Strengths: (1) Correctly identifies both 2024 FDA accelerated approvals with accurate dates (March 2024 for CLL/SLL, May 2024 for FL); (2) Accurately specifies the prior lines of therapy requirement (≥2 prior lines); (3) Properly identifies the specific indications: relapsed or refractory CLL/SLL and FL; (4) Correctly notes the shift from trials in 2022 to concrete approvals in 2024; (5) Appropriately cites source documents (BMY 10-K 2022 p.20, BMY 10-K 2024 pp.45-46). Minor areas for improvement: (1) The LLM states the approvals 'expand Breyanzi's indication beyond the original third-line setting to include additional hematologic malignancies' - however, the ground truth indicates both 2022 trials and 2024 approvals were for 3L+ (third-line or later) settings, so the characterization of 'expanding beyond the original third-line setting' is slightly imprecise; the evolution is more accurately described as moving from trials to approved indications rather than expanding the line-of-therapy scope; (2) The phrase 'broader patient population' is somewhat vague - the ground truth specifies the additional requirement of prior BTK inhibitor and B-cell lymphoma 2 inhibitor exposure for CLL/SLL, which actually narrows rather than broadens the eligible population for that indication. The multi-hop reasoning is sound in synthesizing 2022 trial information with 2024 approval data, and the semantic meaning of the answer aligns well with the ground truth despite these minor characterization issues.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 446,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "\nDisney’s Resorts & Vacations segment revenue rose from **$7.95 billion in 2023 to $8.38 billion in 2024**, a **5 % year‑over‑year increase** (Chunk 2), reflecting the segment’s disclosed growth in hotel‑room nights, cruise sales and vacation‑club operations (Chunk 1). This 5 % growth is essentially identical to the **overall Parks & Experiences segment’s revenue rise from $32.55 billion to $34.15 billion**, also **5 %** (Chunk 2), showing that the Resorts & Vacations performance contributed proportionally to the segment‑wide revenue expansion. The relationship is captured by the knowledge‑graph triplets **DIS →[Produces]→ Resorts & Vacations** and **Resorts & Vacations →[Discloses]→ DIS**, linking the segment’s financial results directly to Disney’s reporting.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop reasoning. QUANTITATIVE VERIFICATION: All numbers are correct - Resorts & Vacations revenue of $7.95B (2023) to $8.38B (2024) matches ground truth ($7,949M to $8,375M with appropriate format conversion); Parks & Experiences revenue of $32.55B to $34.15B matches ground truth ($32,549M to $34,151M); both growth rates calculated as 5% are accurate. COMPLETENESS: The answer addresses all parts of the multi-part question: (1) Resorts & Vacations evolution from 2023-2024, (2) comparison to overall Parks & Experiences growth, and (3) contextual relationship between the two. ENTITY ACCURACY: All entities correctly identified (Disney, Resorts & Vacations segment, Parks & Experiences segment, fiscal years 2023-2024). MULTI-HOP REASONING: The answer successfully synthesizes information across multiple data points - comparing segment-level performance to division-level performance and drawing the correct conclusion that growth rates are essentially identical (both 5%). MINOR OBSERVATIONS: The LLM includes knowledge-graph triplet references (DIS →[Produces]→ Resorts & Vacations) which adds technical detail but is not essential to answering the question. The phrase 'essentially identical' is slightly more interpretive than the ground truth's 'slightly below' - however, mathematically both 5% figures are identical when rounded, so this is a reasonable characterization. The answer provides additional context about operational drivers (hotel-room nights, cruise sales, vacation-club operations) which enhances understanding without introducing errors. Overall, the response is factually sound, well-structured, and demonstrates clear understanding of the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 482,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "\nBetween 2023 and 2024 the size of CVS’s forward‑contract component in its ASR transactions grew substantially: the 2023 $2.0 billion ASR carried a $0.4 billion forward contract (recorded in capital surplus and later re‑classified to treasury stock when the remaining shares were received in February 2023), while the 2024 $3.0 billion ASR with Morgan Stanley featured a $0.4 billion forward contract tied to a larger $3.0 billion notional (again classified as an equity instrument, recorded in capital surplus and re‑classified to treasury stock in March 2024). Thus, although the forward‑contract amount remained $0.4 billion, it was now attached to a higher notional value and settled later, reflecting an evolution in structure and scale of the ASR‑related forward contracts.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key financial figures and structure of both ASR transactions. All dollar amounts are accurate: $2.0 billion ASR in 2023 with $0.4 billion forward contract, and $3.0 billion ASR in 2024 with $0.4 billion forward contract. The dates are correct (February 2023 and March 2024 for share receipt). The accounting treatment is properly described - both forward contracts classified as equity instruments and recorded in capital surplus before reclassification to treasury stock.\n\nHowever, there are some issues with the answer:\n\n1. The LLM states the forward contract was \"later re-classified to treasury stock when the remaining shares were received in February 2023\" - this is slightly imprecise. The ground truth indicates the final 20% of shares were received in February 2023, but the forward contract itself was reclassified upon settlement, not necessarily at the same time as share receipt.\n\n2. The LLM characterizes the evolution as \"the forward-contract amount remained $0.4 billion, it was now attached to a higher notional value\" - while this is technically accurate, it could be clearer that the forward contract value stayed constant while the overall ASR size increased from $2.0B to $3.0B, meaning the forward contract represented a smaller proportion (20% vs 13.3%).\n\n3. The ground truth explicitly notes \"the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component\" - the LLM captures this concept but doesn't explicitly state the proportional shift.\n\n4. Minor: The LLM says \"the remaining shares were received later, in March 2024\" but doesn't specify the 15% figure mentioned in the ground truth.\n\nThe multi-hop reasoning is sound - the LLM correctly synthesizes information across both years and identifies the key structural evolution. The answer demonstrates understanding of the accounting treatment and the relationship between ASR size and forward contract value. The main weakness is incomplete articulation of the proportional shift and some minor imprecision in describing the timing of reclassification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reclassifies]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 584,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "\nDuke Energy’s 2023 filing (Chunk 1) merely noted that certain investments measured at fair value using the net‑asset‑value‑per‑share practical expedient “have not been categorized in the fair‑value hierarchy,” providing no further detail on how those assets are valued. In the 2024 filing (Chunk 2), the company added a reconciliation table for qualified pension and other post‑retirement assets and explicitly stated that the fair‑value determination “includes significant unobservable inputs (Level 3),” thereby increasing transparency around Level 3 categorization while still not assigning those investments to the hierarchy. The allocation percentages of the Master Retirement Trust among Duke Energy’s subsidiaries remain unchanged across the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2023 disclosure limitation regarding net asset value per share practical expedient investments not being categorized in the fair value hierarchy; (2) Accurately describes the 2024 addition of a reconciliation table for Level 3 assets; (3) Properly notes that allocation percentages remained unchanged between years; (4) Correctly characterizes the evolution as an increase in transparency regarding fair value categorization; (5) Accurately identifies that Level 3 (significant unobservable inputs) is the focus of the new disclosure. MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than the ground truth (e.g., 'reconciliation of beginning and ending balances' vs 'reconciliation table') but conveys the same substantive information. The LLM also adds interpretive language about 'still not assigning those investments to the hierarchy' which, while reasonable inference, goes slightly beyond what the ground truth explicitly states, though it doesn't contradict it. MULTI-HOP REASONING: The answer successfully synthesizes information across two years (2023 vs 2024) and correctly identifies the comparative evolution in disclosure practices. The connection between the practical expedient investments and Level 3 categorization is properly maintained. QUANTITATIVE ACCURACY: No specific numbers or percentages are provided in either answer, which is appropriate given the question's focus on disclosure methodology evolution rather than specific asset values. The answer correctly maintains that percentages remained 'unchanged' or 'the same' across years, matching the ground truth. ENTITY ACCURACY: Duke Energy is correctly identified, years are correct (2023 and 2024), and the Master Retirement Trust is properly referenced throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 513,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "\nIn 2023 Pfizer recorded a $3.5 billion non‑cash revenue reversal linked to the expected return of roughly 6.5 million EUA‑labeled Paxlovid courses bought by the U.S. government and announced that, beginning in 2024, it would create a U.S. Strategic National Stockpile of 1 million treatment courses to be supplied at no cost. In 2024 the company reversed $771 million of that prior reversal after the government returned only 5.1 million courses (instead of the full 6.5 million) and recognized $442 million of revenue from the newly created stockpile, converting the returned courses into a volume‑based credit and a patient‑assistance program that will provide up to 6.5 million NDA‑labeled courses free through 2028, with revenue recognized only as those courses are delivered.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of all key financial figures and dates. Quantitative verification: (1) 2023 revenue reversal of $3.5 billion - CORRECT; (2) Expected return of 6.5 million EUA-labeled courses - CORRECT; (3) 2024 adjustment of $771 million - CORRECT; (4) Actual return of 5.1 million courses - CORRECT; (5) SNS revenue recognition of $442 million - CORRECT; (6) SNS stockpile of 1.0 million courses - CORRECT. All numeric values match the ground truth precisely. The multi-hop reasoning is sound, correctly synthesizing the transition from 2023 revenue reversal to 2024 adjustments and new revenue recognition. The answer properly captures the shift from inventory return dynamics to strategic stockpile establishment. Minor deviations from ground truth: (1) The LLM adds contextual details about the patient-assistance program providing up to 6.5 million NDA-labeled courses free through 2028 with revenue recognized as delivered - this information goes beyond the ground truth but is not contradictory and adds relevant context about revenue recognition methodology; (2) The phrasing 'converting the returned courses into a volume-based credit and a patient-assistance program' is interpretive language not explicitly in the ground truth, though it appears to reflect the underlying transaction structure. These additions represent reasonable elaboration rather than factual errors. The answer comprehensively addresses all parts of the multi-part question regarding financial obligations and revenue recognition changes between 2023 and 2024. Entity identification is accurate (Pfizer, U.S. government, SNS). The semantic meaning aligns well with the ground truth despite some additional explanatory detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 482,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "\nERLEADA’s revenue grew from **$1.88 bn in 2022 to $2.39 bn in 2023**, a **26.9 % increase** (operations + 27.5 %) as reported in J&J’s 2023 10‑K (Chunk 2), positioning it as one of the fastest‑growing contributors within the company’s oncology portfolio and helping lift total oncology sales by **10.5 %** over the same period.  This performance underscores ERLEADA’s strategic importance as a next‑generation androgen‑receptor inhibitor for prostate cancer—highlighted in Chunk 1 as a key oncology product—and demonstrates that it is a primary driver of growth for J&J’s cancer‑focused business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis. QUANTITATIVE VERIFICATION: All key numbers are correct - ERLEADA revenue of $1.88bn (2022) and $2.39bn (2023) matches ground truth ($1,881M and $2,387M with acceptable format variation); the 26.9% growth rate is accurate; the 10.5% oncology segment growth is correct. The additional detail about 27.5% operations growth adds context without contradicting the core answer. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple sources - connecting ERLEADA's individual performance to J&J's broader oncology portfolio performance, and correctly identifying it as a growth driver relative to the overall segment. COMPLETENESS: The answer addresses both parts of the question: (1) financial performance evolution with specific numbers and growth rates, and (2) role in J&J's oncology portfolio with strategic context. ENTITY ACCURACY: All entities correctly identified (ERLEADA, J&J, oncology segment, prostate cancer indication). MINOR STRENGTHS: The LLM provides additional valuable context by identifying ERLEADA as a next-generation androgen-receptor inhibitor and noting it as one of the fastest-growing contributors. The ground truth mentions contrasts with IMBRUVICA and ZYTIGA decline, which the LLM answer doesn't explicitly state, but this is a minor omission that doesn't affect the core answer's accuracy. SEMANTIC EQUIVALENCE: The LLM's phrasing 'primary driver of growth' is semantically equivalent to the ground truth's 'increasingly important role in sustaining J&J's oncology revenue.' Overall, the answer is factually sound, well-reasoned, and appropriately contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 464,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "\nERLEADA’s global sales rose from $1.881 billion in 2022 to $2.387 billion in 2023, a 26.9 % year‑over‑year increase (Chunk 2). However, the product‑level breakdown in the 2022 filing shows worldwide ERLEADA revenue falling from $1.291 billion to $0.760 billion over the same period, a decline of roughly 41 % (Chunk 1). These contrasting figures reveal that, while the overall oncology portfolio is expanding, ERLEADA’s performance exhibits regional volatility, pointing to a mixed but overall positive market trajectory.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies that contradict the ground truth. (1) INCORRECT 2022 FIGURE: LLM states $1.881 billion for 2022, but ground truth clearly shows $1,291 million ($1.291 billion). This is a $590 million overstatement. (2) CONTRADICTORY DATA: LLM then claims a separate product-level breakdown shows ERLEADA revenue falling from $1.291 billion to $0.760 billion, which is internally inconsistent and contradicts the ground truth showing growth from $1.291B (2022) to $2.387B (2023). (3) INCORRECT GROWTH RATE ATTRIBUTION: While the 26.9% growth rate is correct for 2023, the LLM misapplies it to a $1.881B baseline rather than the correct $1.291B baseline. (4) FAILED MULTI-HOP SYNTHESIS: The LLM appears to have confused or conflated different data sources, presenting contradictory figures without resolving them. The claim of a 41% decline contradicts the ground truth's clear growth narrative. (5) INCORRECT MARKET TRAJECTORY CONCLUSION: The ground truth indicates ERLEADA continued strong growth (26.9% in 2023) with a maturing growth phase, while the LLM's conclusion of 'mixed' performance and 'regional volatility' is unsupported by the actual data and misrepresents the product's trajectory. The answer fundamentally misrepresents ERLEADA's performance evolution from 2022 to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 376,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "\nIn fiscal 2023 the 0.584% Notes Due 2024 were an unsecured senior obligation with only 0.4 year of remaining maturity, a 0.66 % effective interest rate and a net carrying amount of $9.71 bn (including a $1.25 bn short‑term portion) as disclosed in the 2023 10‑K (Chunk 1).  By fiscal 2024 NVIDIA changed its debt‑management approach, planning to retire the entire $1.25 bn note in fiscal 2025—using cash flow and its $575 m commercial‑paper program—while noting that the notes are senior to subsidiary debt, can be redeemed early subject to a make‑whole premium, and that covenant compliance was maintained as of Jan 26 2025 (Chunk 2).  This repayment, occurring alongside a $30.8 bn rise in purchase obligations for new‑product supply, signals a strategic shift toward simplifying the capital structure and reducing low‑yield near‑term debt.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM claims a 'net carrying amount of $9.71 bn' which is completely incorrect and unsupported by the ground truth. The ground truth clearly states the balance was $1,250 million ($1.25 bn) in fiscal 2023. The $9.71 bn figure appears to be fabricated or confused with a different metric entirely. This is a critical factual error. (2) The LLM correctly identifies the 0.584% rate and 0.66% effective interest rate, which matches ground truth. (3) The LLM correctly states the $1.25 bn short-term portion and the plan to retire in fiscal 2025, which aligns with ground truth. (4) MULTI-HOP REASONING - The LLM attempts to synthesize information but introduces extraneous details (make-whole premium, covenant compliance, $575m commercial paper program, $30.8bn purchase obligations) that are not part of the ground truth answer and appear to be hallucinated or from unrelated sections. While these details might exist in the filings, they are not relevant to answering the specific question about debt management strategy evolution. (5) The core narrative about retiring the notes rather than rolling them over is correct, but the answer is significantly contaminated by the $9.71 bn error and irrelevant details. (6) The ground truth is concise and focused: FY2023 balance of $1,250M with 0.66% rate → FY2024 disclosure of repayment in FY2025 with zero balance. The LLM answer obscures this with incorrect figures and tangential information. The $9.71 bn error is disqualifying for a higher score despite some correct elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 434,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "\nHoneywell’s exposure to mortgage/asset‑backed securities fell sharply from 2022 to 2023 – the 2022 filing (U.S. Plans, Level 2) lists $982 million of such securities, while the 2023 filing (Non‑U.S. Plans, Level 2) shows only $10 million, a decline of $972 million (about a 99 % reduction) in the size of its mortgage/asset‑backed securities investment.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. Verification of key facts: (1) 2022 amount of $982 million - CORRECT; (2) 2023 amount of $10 million - CORRECT; (3) Reduction of $972 million - CORRECT (982 - 10 = 972); (4) Percentage reduction calculation - MINOR DISCREPANCY: LLM states 'about a 99% reduction' while ground truth states 'over 98%'. The actual calculation is 972/982 = 98.98%, which rounds to 99%, making the LLM's statement technically more precise than the ground truth's 'over 98%'. (5) Multi-hop synthesis - CORRECT: The answer properly identifies the shift from U.S. Plans in 2022 to Non-U.S. Plans in 2023, and correctly synthesizes this as a major strategic shift. The LLM appropriately notes the classification levels (Level 2) which adds helpful context. The answer addresses all parts of the question: the evolution (sharp decline), the specific amounts in each year, and the magnitude of change (both absolute and percentage). The semantic meaning aligns well with the ground truth - both convey a dramatic reduction in mortgage/asset-backed securities holdings. Minor note: The LLM's percentage calculation (99%) is actually more accurate than the ground truth's characterization of 'over 98%', though this is a negligible difference. The answer demonstrates sound multi-hop reasoning by connecting the 2022 and 2023 data points and calculating the change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 391,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "\nCapital One continued to rely on securitized debt obligations as a component of its wholesale funding mix in both 2022 and 2023, using them alongside deposits, senior notes and other sources to maintain a diversified funding base; the 2023 filing reports a carrying value of **$18.0 bn** and a fair‑value of **$18.07 bn** for these obligations, placing them in **Level 2** of the fair‑value hierarchy (observable inputs but not actively quoted), which reflects a more transparent valuation approach compared with the earlier period. This shows that while the role of securitized debt in the overall funding structure remained steady, its classification evolved to Level 2 in 2023, underscoring its ongoing importance in Capital One’s funding composition.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct financial figures and appropriate synthesis of multi-hop information. STRENGTHS: (1) All numeric values are correct - carrying value of $18,043 million (presented as $18.0 bn, acceptable format variation), fair value of $18,067 million (presented as $18.07 bn, acceptable format variation), and Level 2 classification all match ground truth. (2) Multi-hop reasoning is sound - the answer correctly synthesizes information about Capital One's funding mix evolution between 2022 and 2023, identifying securitized debt obligations' role alongside deposits and senior notes. (3) Fair value hierarchy classification is accurately identified as Level 2 with appropriate explanation of observable inputs. (4) The answer correctly conveys the shift toward more detailed disclosure and transparency. MINOR WEAKNESSES: (1) The phrase 'classification evolved to Level 2 in 2023' could be slightly misleading - the ground truth indicates this is 2023 disclosure data, not necessarily that it changed from a different level in 2022 (though the LLM does hedge with 'compared with the earlier period'). (2) The answer could have been slightly more explicit about the 2022 description being more general/less specific compared to 2023's detailed metrics, though this is implied. (3) The mention of 'FHLB advances and federal funds purchased' from the ground truth is omitted, though these are secondary details. Overall, the answer accurately addresses the core question about evolution in securitized debt obligations' role and fair value classification with correct numbers and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Raises]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 448,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "\nJPMorgan’s CECL capital‑transition benefit fell from **$1.4 bn** in CET1 capital as of 31 Dec 2023 to **$0.72 bn** as of 31 Dec 2024 – a **$0.68 bn reduction** – as the transition provision was fully phased in on 1 Jan 2025, with the remaining benefit being netting‑off against goodwill and intangibles (Note 27).  The 2023‑2024 evolution also reflects the use of the transition rules to include an **incremental $655 m allowance for credit‑loss reserves on First Republic assets** and to allow up to **1.25 % of credit‑risk RWA** in Tier 2 capital, with any excess deducted from RWA (Chunks 1 (b)‑(e) and 2 (a)‑(c)).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on the core quantitative elements. Verification of key numbers: (1) $1.4 billion CECL benefit in 2023 CET1 capital - CORRECT; (2) $720 million ($0.72 bn) benefit in 2024 - CORRECT; (3) $680 million reduction ($0.68 bn) - CORRECT (1.4 - 0.72 = 0.68); (4) Full phase-in by January 1, 2025 - CORRECT. The multi-hop synthesis is sound: the answer correctly identifies the evolution of the CECL transition provisions across the two years and explains the phased reduction mechanism. Entity identification is accurate (JPMorgan, CET1 capital, U.S. capital rules). The answer goes beyond the ground truth by providing additional context about the $655 million allowance for First Republic assets and the 1.25% Tier 2 capital rule, which adds relevant detail but was not explicitly required by the question. Minor weakness: The phrase 'netting-off against goodwill and intangibles' adds interpretive detail not explicitly stated in the ground truth, though it appears to be a reasonable inference about how the phased-in benefit would be treated. The calculation of the reduction ($1.4B - $0.72B = $0.68B) is mathematically accurate. Overall, the answer successfully synthesizes multi-hop information across 2023 and 2024 filings and provides accurate quantitative and qualitative analysis of the CECL capital transition evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 382,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "\nIn fiscal 2023 the company’s Revolving Loan Credit Agreement consisted of a $3.0 billion unsecured facility that matured in December 2025 (with only minor administrative amendments in 2022‑23), and as of January 31 2024 no borrowings were outstanding under it. In October 2024 the prior agreement was replaced by a new Revolving Loan Credit Agreement that increased the facility to $5.0 billion and extended the maturity to October 2029, again with no outstanding borrowings as of the latest reporting date.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key financial figures are correct: $3.0 billion facility in fiscal 2023 maturing December 2025, replaced by $5.0 billion facility maturing October 2029. The dates are accurate (October 2024 for the replacement, January 31, 2024 as reporting date). The multi-hop synthesis is sound - the answer correctly traces the evolution of the agreement across two fiscal years and identifies the key changes (capacity increase from $3.0B to $5.0B, maturity extension from December 2025 to October 2029). The LLM answer actually provides additional relevant context not in the ground truth (no outstanding borrowings as of reporting dates, timing of October 2024 replacement), which adds value without contradicting the original answer. The reasoning is logical and clearly explains the progression. Minor note: The LLM specifies 'October 2024' as the replacement date while the ground truth simply states 'fiscal 2024' - this is more precise and consistent with SEC filing conventions. The answer fully addresses all parts of the question regarding terms (maturity dates) and capacity (facility amounts) evolution between the two fiscal periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 337,
        "total_tokens": 1567
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "\nFrom 2022 through 2023 UPS operated a partnership with Coyote, leveraging the Coyote‑branded subsidiary for truckload brokerage and giving its customers access to UPS’s air‑freight, customs brokerage, global forwarding and UPS Capital services. In the third quarter of 2024 UPS completed the divestiture of Coyote, recording a **$156 million pre‑tax gain** ($152 million after tax) that directly increased 2024 earnings and was presented as a non‑recurring item in its financial statements. This transaction was part of UPS’s broader 2024 transformation program (Fit‑to‑Serve and Efficiency Reimagined), but the key financial impact of the Coyote evolution was the $156 million gain realized in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All financial figures are correct - $156 million pre-tax gain and $152 million after-tax gain match the ground truth exactly. The timing (Q3 2024 completion) is accurate. ENTITY ACCURACY: UPS and Coyote are correctly identified; the divestiture transaction is properly characterized. MULTI-HOP SYNTHESIS: The answer successfully synthesizes the evolution across time periods: (1) 2022-2023 operational period with Coyote as branded subsidiary providing truckload brokerage services, (2) 2024 divestiture completion with specific financial impact. COMPLETENESS: The answer addresses both parts of the question - the relationship evolution AND the financial impact. The LLM provides additional context about integrated services (air-freight, customs brokerage, global forwarding, UPS Capital) and mentions the broader strategic context (Fit-to-Serve and Efficiency Reimagined programs), which adds helpful context without contradicting the ground truth. MINOR DIFFERENCES: The ground truth mentions Coyote operated in 'U.S. and Europe' while the LLM answer focuses on truckload brokerage without geographic specification - this is a minor omission but not a factual error. The LLM correctly identifies the gain as a non-recurring item in financial statements, which is accurate and relevant. The characterization of the relationship evolution from 'active business relationship' to 'divested asset' is semantically equivalent to the LLM's description of the transition. All calculations are implicit and correct (the after-tax figure of $152M is consistent with the pre-tax $156M). The answer is well-structured, directly addresses the question, and provides appropriate financial context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Divests]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 483,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "\nBetween 2023 and 2024 Union Pacific’s chassis fleet contracted dramatically—total units fell from **48,340** (30,635 owned, 17,705 leased) in 2023 to **5,553** (4,356 owned, 1,197 leased) in 2024, an ≈ 88 % reduction.  The share of owned chassis rose from roughly **63 %** to **79 %** of the fleet, while leased chassis dropped sharply, indicating a shift toward greater ownership control.  This evolution is reflected in the knowledge‑graph pattern where **UNP Depends_On Chassis** and **Chassis Has_Stake_In UNP**, underscoring a continued strategic dependence despite the substantial scale‑down.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensive synthesis of multi-hop information. QUANTITATIVE VERIFICATION: All numbers are correct - 2023 totals (48,340 units, 30,635 owned, 17,705 leased) and 2024 totals (5,553 units, 4,356 owned, 1,197 leased) match ground truth exactly. The calculated percentage reduction of approximately 88% is accurate (5,553/48,340 ≈ 11.5% remaining, or 88.5% reduction). The ownership percentages are correctly calculated: 2023 owned share = 30,635/48,340 ≈ 63.4%, and 2024 owned share = 4,356/5,553 ≈ 78.4%, both properly rounded. COMPLETENESS: The answer addresses all key aspects of the question - total units, ownership structure, and the evolution between years. It provides both absolute numbers and relative comparisons. ENTITY ACCURACY: Union Pacific (UNP) and chassis are correctly identified. Years 2023 and 2024 are properly specified. REASONING QUALITY: The multi-hop synthesis is sound - the model correctly identifies the dramatic contraction, calculates the percentage reduction, analyzes the shift in ownership composition, and draws a logical conclusion about strategic implications. The reference to knowledge graph patterns (UNP Depends_On Chassis, Chassis Has_Stake_In UNP) adds appropriate contextual depth. MINOR CONSIDERATION: The knowledge graph notation, while sophisticated, goes slightly beyond what was explicitly stated in the ground truth answer, though it doesn't contradict it and demonstrates deeper semantic understanding. The answer is well-structured, quantitatively precise, and provides clear insight into the strategic shift in Union Pacific's chassis management.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 451,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "\nBoeing has consistently classified its long‑term aluminum purchase and sales agreements as derivatives that are **not designated for hedge accounting** – in 2022 the 10‑K notes that these agreements are derivatives whose fair‑value changes are recorded directly in earnings, and the 2024 filing repeats this treatment while adding that the commodity contracts hedge forecasted aluminum purchases **through 2028**, thereby extending the time horizon. Both years stress that the agreements are entered into to meet **long‑term strategic sourcing objectives and non‑U.S. business requirements**, and the 2024 disclosure further explains that the notional quantities are priced at prevailing market prices and are reflected in the Consolidated Statements of Financial Position.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies the consistent classification of aluminum agreements as derivatives not designated for hedge accounting in both 2022 and 2024; (2) Accurately captures the key evolution: the shift from strategic sourcing context to a more structured hedging strategy with defined time horizon through 2028; (3) Properly synthesizes multi-hop information across two years of filings; (4) Correctly notes that fair value changes are recorded directly in earnings; (5) Accurately references the long-term strategic sourcing objectives and non-U.S. business requirements language appearing in both years; (6) Adds relevant detail about notional quantities priced at prevailing market prices and reflection in financial statements, which provides appropriate context. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed than the ground truth (mentioning Consolidated Statements of Financial Position), but this additional detail is accurate and relevant rather than contradictory. The core narrative of evolution from 2022 to 2024 is clearly articulated. All dates (2022, 2024, 2028) are correct. The characterization of the shift from 'purely strategic sourcing to a more structured hedging strategy' is accurately conveyed through the LLM's phrasing about extending the time horizon and hedging forecasted transactions. No quantitative errors detected. The multi-hop reasoning correctly synthesizes information across both filing years and identifies the key evolution in disclosure and treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 442,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "\nProcter & Gamble’s currency‑rate exposure and its hedging approach have remained essentially unchanged between the fiscal years ended June 30 2023 and June 30 2024.  In both years the company manages exchange‑rate risk primarily through forward contracts and currency swaps with maturities of less than 18 months, leveraging its diversified global portfolio as a natural hedge, and it continues to rely on a 95 % confidence‑level, historical‑movement analysis that indicates a near‑term shift in rates would not materially affect its financial statements.  Consequently, the evolution of its currency‑rate risk exposure shows no material increase or change in either the magnitude of exposure or the confidence in mitigating it through these hedging instruments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. (1) CORRECTNESS: All factual information matches the ground truth. The answer correctly identifies that P&G's currency rate exposure remained materially unchanged between FY2023 and FY2024, accurately states the hedging instruments used (forward contracts and currency swaps with maturities less than 18 months), and correctly cites the 95% confidence level based on historical currency rate movements. The conclusion that near-term exchange rate changes would not materially affect financial statements is accurate for both periods. (2) QUANTITATIVE ACCURACY: All numeric values are correct - the 95% confidence level is precisely stated, the maturity timeframe of less than 18 months is accurate, and the fiscal year dates (June 30, 2023 and June 30, 2024) are correct. No calculations are required for this question, and all presented numbers match the ground truth. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound. The answer successfully synthesizes information across two fiscal years and correctly identifies the consistency in P&G's approach. The mention of the diversified global portfolio as a natural hedge adds relevant context not explicitly in the ground truth but consistent with typical P&G disclosures. The logical flow from hedging instruments to confidence assessment is clear and accurate. (4) CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the question - the evolution (or lack thereof) of currency exposure, the hedging instruments used, and the confidence level in mitigating exchange rate fluctuations. The phrasing \"no material increase or change\" effectively captures the essence of the ground truth's \"remained materially unchanged.\" Minor note: The LLM uses slightly different formatting (spaces in \"June 30 2023\" without comma) but this is inconsequential to accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacts]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 511,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "\nIn 2022 Adobe’s Form 10‑K simply listed **Frame.io** among its registered trademarks, confirming that the service was part of the company’s portfolio (Chunk 1). By 2024 the same filing described Frame.io as a **cloud‑native collaboration platform** that now **integrates with Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, Adobe Express and Firefly Services**, adds Camera‑to‑Cloud ingest, frame‑accurate commenting and Content Credentials, and is available within Adobe GenStudio—showing a dramatic expansion of its functional scope and deeper embedding across Adobe’s Creative Cloud ecosystem (Chunk 2). This progression illustrates Adobe’s strategy of **producing Frame.io (ADBE → Frame.io) and introducing it as a core, AI‑enabled hub that ties together multiple Adobe products and services** (KG pattern).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies the 2022 positioning as a trademarked asset with minimal description, matching the ground truth. (2) Accurately describes the 2024 evolution to a 'cloud-native collaboration platform' (exact match to ground truth terminology). (3) Correctly lists all integrated products mentioned in ground truth: Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront. (4) Accurately identifies key functional capabilities: real-time upload/review, frame-accurate commenting, and Camera to Cloud functionality. (5) Correctly notes integration with Adobe GenStudio. (6) Properly synthesizes the multi-hop information showing evolution from 2022 to 2024. (7) No quantitative errors (dates, numbers all correct). MINOR CONSIDERATIONS: (1) The LLM answer includes 'Adobe Express and Firefly Services' in the integration list, which are not explicitly mentioned in the ground truth answer. While these may be accurate additions from the source documents, they represent a slight expansion beyond what was stated in the original answer. (2) The LLM adds 'Content Credentials' as a capability, which is also not in the ground truth. (3) The phrase 'AI-enabled hub' appears in the LLM answer but not in the ground truth, though this is a reasonable characterization. These additions do not contradict the ground truth but go slightly beyond it. The core narrative of evolution from trademark to integrated collaborative platform is accurately captured. The reasoning about Adobe's strategic positioning is sound and well-articulated. Overall, this is a high-quality answer that correctly addresses all major aspects of the question with accurate synthesis of multi-hop information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 487,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 AMD kept its 15 % equity interest in the ATMP joint venture and continued to account for it under the equity‑method, with no obligation to fund the JV; the carrying value of the investment was $69 million at the end of FY 2021 (the most recent figure disclosed in the 2022 filing) and, as reflected in the 2023 filing, remained unchanged and was not subject to goodwill impairment after the segment realignment noted in Q2 2022.  Disclosures in both years present purchases and resales with the JV within AMD’s own income statement and report equity‑method income of $6 million in FY 2021 (and $5 million in FY 2020), underscoring a stable financial relationship and consistent equity‑method accounting across the two fiscal years.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations of the ground truth:\n\n1. CRITICAL ERRORS - Carrying Value Claims:\n   - LLM states the carrying value \"remained unchanged\" at $69 million in the 2023 filing\n   - Ground truth explicitly states the 2023 filing \"omits any mention of the carrying value of the investment\"\n   - This is a fundamental mischaracterization of the key finding about reduced disclosure\n\n2. TRANSACTION FIGURES - Major Omission:\n   - Ground truth specifies purchases of $1.1 billion in 2021 and $831 million in 2020\n   - LLM mentions \"purchases and resales with the JV\" but provides NO specific dollar amounts\n   - This is a critical omission since the question specifically asks about \"the nature of its financial disclosures\"\n   - The absence of these figures in the 2023 filing is the core point of the ground truth answer\n\n3. EQUITY-METHOD INCOME:\n   - LLM reports $6 million in FY 2021 and $5 million in FY 2020\n   - Ground truth does not mention these figures at all\n   - These appear to be introduced without verification against the source documents\n\n4. GOODWILL IMPAIRMENT CLAIM:\n   - LLM states the carrying value \"was not subject to goodwill impairment after the segment realignment noted in Q2 2022\"\n   - Ground truth contains no mention of goodwill impairment analysis\n   - This appears to be an unsupported inference\n\n5. CORE FINDING MISSED:\n   - Ground truth's main point: \"reduction in the level of financial disclosure regarding the ATMP JV\"\n   - LLM characterizes the relationship as \"stable\" and \"consistent\"\n   - This directly contradicts the ground truth's conclusion about declining disclosure\n\n6. STRUCTURAL ACCURACY:\n   - 15% equity interest: Correct\n   - Equity-method accounting: Correct\n   - No funding obligation: Correct\n   - But these correct elements don't compensate for the major factual errors about disclosure changes\n\nThe LLM answer fundamentally misrepresents the evolution of AMD's financial disclosures by claiming consistency where the ground truth identifies a significant reduction in disclosure detail between 2022 and 2023 filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 581,
        "total_tokens": 1977
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "\nHoneywell’s Commercial Aviation Original Equipment sales slipped from **$2,397 million in 2023 to $2,223 million in 2024** – a decline of roughly **$174 million (≈7 %)** year‑over‑year.  This dip signals a modest contraction in that specific aerospace sub‑segment, yet the company’s broader aerospace business still expanded (net aerospace‑technologies sales rose from $13.624 B to $15.458 B), underscoring Honeywell’s continued status as a major, diversified player whose other aerospace and industrial streams offset the softness in original‑equipment revenue.  The KG relationship **HON → Commercial Aviation Original Equipment ← HON** ties the product line directly to Honeywell, confirming that the revenue shift reflects a change in the company’s aerospace‑equipment portfolio performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All numbers are correct - 2023 revenue of $2,397 million, 2024 revenue of $2,223 million, decline of $174 million, and the calculated percentage decline of approximately 7% (174/2,397 = 7.26%). The broader aerospace division figures ($13.624B to $15.458B) are also accurate. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) the revenue evolution between 2023-2024 with specific numbers and calculations, and (2) what this indicates about Honeywell's aerospace position. ENTITY ACCURACY: Honeywell is correctly identified, the Commercial Aviation Original Equipment segment is properly named, and the fiscal years 2023-2024 are correct. MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple levels - it connects the specific segment decline to the broader Aerospace Technologies division growth, demonstrating understanding that the decline is localized to one product line while the overall division expanded. The reasoning that 'other aerospace and industrial streams offset the softness' shows proper synthesis. SEMANTIC EQUIVALENCE: The LLM's interpretation that this 'signals a modest contraction' and indicates 'potential weakening in original equipment demand' aligns with the ground truth's assessment of 'contraction' and 'weakening in original equipment demand.' The additional context about Honeywell's diversified position and offsetting growth in other segments adds valuable insight without contradicting the ground truth. MINOR OBSERVATION: The reference to the knowledge graph relationship (HON → Commercial Aviation Original Equipment ← HON) is somewhat tangential but not incorrect - it confirms data provenance without detracting from the core answer. Overall, the LLM provides a more detailed and nuanced analysis than the ground truth while maintaining complete factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 530,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "\nHeart‑Failure devices—classified under Abbott’s Medical‑Devices portfolio—generated **$1,161 million in total revenue in 2023** (ABT 2023 10‑K) and **$1,279 million in 2024** (ABT 2024 10‑K), representing an **$118 million increase or 10.2 % year‑over‑year growth** (the 2024 filing lists the change as 10.2 %/10.3 % excl. exchange). This uptick contributed to the broader Medical‑Devices segment’s expansion, which grew from roughly **$16.9 billion in 2023 to about $19.0 billion in 2024**, underscoring a double‑digit rise in the segment’s overall revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All key numbers are correct - $1,161 million (2023), $1,279 million (2024), $118 million increase, and 10.2% growth rate all match the ground truth exactly. The calculation of the percentage change is accurate: ($1,279 - $1,161) / $1,161 = 10.17%, which rounds to 10.2%. The additional context about Medical Devices segment growth ($16.9B to $19.0B) is factually accurate and provides helpful context. ENTITY ACCURACY: Abbott (ABT) correctly identified, fiscal years 2023 and 2024 correctly specified, Heart Failure Devices segment properly classified under Medical Devices portfolio. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple 10-K filings (2023 and 2024) and correctly connects the Heart Failure Devices segment performance to the broader Medical Devices segment context. COMPLETENESS: The answer addresses all parts of the question - evolution between years, absolute revenue figures, and percentage change. The mention of exchange rate impacts and market expansion aligns with the ground truth's note about 'minimal impact from exchange rate fluctuations.' MINOR NOTES: The LLM provides slightly more detail than the ground truth (mentioning the 10.3% figure excluding exchange, broader segment context) but this is additive and accurate rather than contradictory. The formatting and presentation are clear and well-organized. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 409,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "\nIBM first introduced the 0.300 % Notes due 2028 in a 2020 Form 8‑K, and in the 2022 filing they were disclosed only as part of a group of notes (0.300 % due 2028, 0.650 % due 2032 and 1.200 % due 2040) referenced under Exhibits 4.1‑4.3, without a separate ticker symbol. By the 2023 filing the same security appears as an independently registered class titled “0.300 % Notes due 2028” with the NYSE ticker IBM 28B, showing that IBM’s treatment evolved from a grouped, exhibit‑referenced description to a distinct, separately identified security on the exchange.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of IBM's treatment of the 0.300% Notes due 2028 between 2022 and 2023 filings. STRENGTHS: (1) Correctly identifies the 2020 Form 8-K origin date, (2) Accurately captures the shift from grouped/exhibit-referenced disclosure to distinct, separately identified security, (3) Correctly identifies the NYSE ticker symbol IBM 28B, (4) Properly synthesizes the multi-hop comparison across two filing years, (5) All numeric values (0.300%, 2028 maturity date) are accurate. MINOR ISSUES: (1) The LLM mentions Exhibits 4.1-4.3 and groups the notes with 0.650% due 2032 and 1.200% due 2040, which adds contextual detail not explicitly confirmed in the ground truth statement. While this detail appears reasonable and doesn't contradict the ground truth, it goes slightly beyond what was verified in the original answer. (2) The ground truth specifically mentions 'Exhibit 4.1 to Form 8-K filed February 10, 2020' while the LLM only references '2020 Form 8-K' without the specific date - a minor omission but not factually incorrect. MULTI-HOP REASONING: The answer correctly synthesizes information across two filing years and identifies the key transformation in disclosure treatment. The logic is sound: 2022 = grouped/referenced approach; 2023 = explicit/registered approach. SEMANTIC EQUIVALENCE: The LLM's characterization of the evolution ('grouped, exhibit-referenced description to a distinct, separately identified security') matches the ground truth's description ('shift from general incorporation by reference to explicit disclosure and formal registration'). Overall, this is a strong answer with accurate core facts and sound reasoning, with only minor contextual additions that don't contradict the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 484,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "\nApple’s Rest of Asia Pacific segment showed modest growth between 2022 and 2023: net sales rose from **$29.38 bn** in 2022 to **$30.66 bn** in 2023 (≈ 4 % increase), and operating income climbed from **$11.57 bn** to **$12.07 bn** (≈ 4 % increase). This improvement is reflected in the segment‑level data presented in the 2023 10‑K table (Chunk 2), and the methodology for evaluating such performance—based on net sales and operating income exclusive of certain corporate costs—is outlined in the segment‑reporting discussion in Chunk 1.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual errors in the core financial numbers that are the primary focus of the question. (1) NET SALES ERROR: LLM states 2023 net sales as $30.66 bn, but ground truth shows $29.615 million ($29.615 bn). This is a major discrepancy of approximately $1.045 billion (3.5% overstatement). The 2022 figure of $29.38 bn is approximately correct (ground truth: $29.375 bn). (2) PERCENTAGE CALCULATION ERROR: LLM claims a ~4% increase in net sales, but the correct calculation is ($29.615 - $29.375) / $29.375 = 0.8%, not 4%. This is a fundamental calculation error. (3) OPERATING INCOME: The 2023 figure of $12.07 bn is approximately correct (ground truth: $12.066 bn), and the 2022 figure of $11.57 bn is approximately correct (ground truth: $11.569 bn). The percentage increase of ~4% is correct for operating income (actual: 4.3%). (4) MULTI-HOP REASONING: While the LLM correctly identifies this as a Rest of Asia Pacific segment analysis and attempts to synthesize the data, the fundamental numerical errors undermine the entire analysis. The LLM appears to have confused or misread the 2023 net sales figure. (5) POSITIVE ASPECTS: The LLM correctly identifies the segment, the metrics being analyzed (net sales and operating income), the time period (2022-2023), and the general direction of change (growth). The contextual framing about segment-level data and methodology is appropriate. However, these qualitative strengths cannot compensate for the critical quantitative errors in the primary data points being requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> GPE <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 438,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "\nThe 2022 Form 10‑K discloses that options granted **prior to 2022** under the 2007 Omnibus Incentive Plan generally vest pro‑rata over a **five‑year** period (and then terminate after ten years), while options granted **after December 31, 2021** under the amended and restated plan vest pro‑rata over a **four‑year** period (also terminating after ten years); the 2024 filing confirms this shift, noting that the newer four‑year schedule applies to post‑2021 grants and that outside‑director options are fully vested at grant, with the Compensation Committee setting the specific terms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key factual elements are correct: (1) Pre-2022 grants vested pro rata over 5 years - CORRECT; (2) Post-December 31, 2021 grants vested pro rata over 4 years - CORRECT; (3) Both 2022 and 2024 10-K filings confirm these terms - CORRECT; (4) The structural change from 5-year to 4-year vesting is accurately identified - CORRECT. The LLM answer adds valuable contextual details (10-year termination periods, outside-director full vesting at grant, Compensation Committee discretion) that enhance understanding without contradicting the ground truth. The multi-hop synthesis across two filing years (2022 and 2024) is sound and demonstrates proper information integration. The answer uses clear formatting with bold text to highlight key distinctions between pre-2022 and post-2021 grants. Minor point: The LLM answer includes additional details about outside-director vesting and Compensation Committee discretion that, while accurate and relevant, go slightly beyond the specific scope of the original question about the evolution of vesting periods. However, this represents an enhancement rather than an error. All numeric values (5-year, 4-year, 10-year periods) are precisely correct. The semantic meaning perfectly aligns with the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 367,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "\nFrom 2022 to 2023 CVS maintained the same validation workflow for its Level 2 debt‑security fair‑value estimates—quarterly cross‑checking of each price against a secondary source, review of variances and internal fair‑value comparisons—but the timing of the “no‑adjustment” statement shifted: the 2022 filing noted that no prices were adjusted at December 31 2021 or 2020, while the 2023 filing reports that no prices were adjusted at December 31 2023 or 2022. Thus, the company’s approach to obtaining a single observable price per security, comparing it to secondary‑source quotes, and confirming that no adjustments were needed remained unchanged, with only the fiscal‑year references updated.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about CVS's fair value validation approach evolution from 2022 to 2023. STRENGTHS: (1) All dates and fiscal year references are correct—accurately noting that 2022 filing referenced Dec 31, 2021/2020 while 2023 filing referenced Dec 31, 2023/2022. (2) The core methodology elements are correctly identified: obtaining one price per Level 2 debt security, quarterly secondary source comparisons, variance review, and no price adjustments. (3) The multi-hop synthesis is sound—the answer correctly synthesizes information across two filing years to show continuity in approach while noting the temporal shift in reporting periods. (4) The semantic equivalence is strong—phrases like 'quarterly cross-checking,' 'secondary-source quotes,' and 'no adjustments were needed' accurately convey the ground truth concepts. (5) The answer appropriately emphasizes the key insight that the methodology remained unchanged despite the updated fiscal year references. MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than the ground truth (e.g., 'quarterly cross-checking' vs 'compared selected sample prices quarterly') but these are semantically equivalent. The ground truth mentions 'emphasis on consistent internal validation by the investment team' which the LLM answer doesn't explicitly highlight, though it does reference 'internal fair-value comparisons.' This is a very minor omission that doesn't materially affect the answer's correctness. The answer successfully captures the evolution (or lack thereof) in CVS's approach, which was the core question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Obtains]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 456,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "\nBetween 2022 and 2023 CVS continued to **classify its privately‑placed equity securities as Level 3** and to measure them through an **internal analysis of each investment’s financial statements and cash‑flow projections**.  The fair‑value determination in both years relied on **significant unobservable inputs**—principally earnings and revenue multiples, a discount for lack of marketability, and comparability adjustments—derived from the company’s own valuation models, with no broker‑quoted prices or external pricing sources used for these securities.  Consequently, the **methodology and the nature of the unobservable inputs remained essentially unchanged from 2022 to 2023**, even though the same descriptive language and review processes were applied in each year’s disclosure.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the core facts: CVS classified privately-placed equity securities as Level 3 in both years, used internal analysis of financial statements and cash flow projections, and relied on earnings/revenue multiples, discount for lack of marketability, and comparability adjustments as unobservable inputs. The numeric and factual elements are accurate. However, there is a significant semantic/interpretive error in the conclusion. The LLM states that 'the methodology and the nature of the unobservable inputs remained essentially unchanged from 2022 to 2023,' which contradicts the ground truth's key finding that there was an evolution in the company's approach. The ground truth explicitly notes that in 2023, CVS added 'an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs.' This represents a meaningful evolution in the valuation process and disclosure approach, not a static continuation. The LLM's conclusion that the methodology 'remained essentially unchanged' misses this important distinction about how CVS's treatment of these inputs evolved between the two years. The answer is factually accurate on the classification and input types but fails to capture the qualitative evolution in emphasis and scrutiny that the question specifically asks about. This is a case where the LLM correctly identified the components but drew an incorrect conclusion about their evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Classifies]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 424,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "\nThe Alphagan/Combigan line generated **$272 million in total net revenue in 2023** (Chunk 1) but **$248 million in 2024** (Chunk 2), a **decline of about 8.8 %** (as reported in both years’ tables).  At the same time, its **international sales rose modestly from $151 million to $153 million**, an increase of roughly **1.5 %** over the same period (Chunk 2).  This reflects the overall downward trend in total net revenue while the international segment shows a slight upward movement.  (The entity relationship shown in the KG triplets links AbbVie (ORG) to the Alphagan/Combigan product, underscoring the source of these figures.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: (1) Total net revenue 2023: $272 million ✓, 2024: $248 million ✓, decline of 8.8% ✓; (2) International revenue 2023: $151 million ✓, 2024: $153 million ✓, growth of 1.5% ✓. The multi-hop reasoning is sound - the model correctly synthesized information across two years and two metrics (total vs. international revenue), properly identifying the contrasting trends (overall decline vs. international growth). Entity identification is accurate (Alphagan/Combigan product, AbbVie as source). The answer addresses all parts of the multi-part question: the change in total revenue AND the trend in international revenue. The calculations are verified as accurate. The only minor observation is that the answer includes some parenthetical references to 'Chunk' citations and KG triplets that, while not incorrect, are slightly more verbose than necessary, but this does not detract from factual accuracy. The semantic meaning perfectly matches the ground truth, with clear explanation of the contrasting trends between total and international segments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 322,
        "total_tokens": 1553
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 Chevron moved from **acquiring** PDC Energy (the 2023 10‑K notes that PDC was excluded from the internal‑control assessment because it had been bought in a 2023 business combination) to **fully integrating** PDC’s assets into its own reporting, reflecting the mutual Has_Stake_In/Depends_On relationship in the KG.  In 2024 Chevron’s worldwide oil‑equivalent production rose to **3.3 million bbl/d**, about a **7 % increase** over 2023, with the growth attributed primarily to the **full‑year contribution of legacy PDC Energy production** and related Permian‑Basin expansion.  Thus the acquisition’s completion turned PDC from an external partner into an internal production driver that directly lifted Chevron’s overall output.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The 7% increase in worldwide oil-equivalent production is correctly stated and matches the ground truth. The production figure of 3.3 million bbl/d is provided (not in ground truth but appears reasonable for context). The 2023 acquisition timing is correctly identified. QUALITATIVE ACCURACY: The answer correctly synthesizes the multi-hop relationship evolution: (1) 2023 acquisition status with internal control exclusion, (2) 2024 full integration into operations, (3) attribution of production growth to PDC's full-year contribution. The reasoning about PDC transitioning from 'external partner' to 'internal production driver' accurately captures the semantic meaning of the ground truth's 'newly acquired entity to integral operational component.' COMPLETENESS: The answer addresses both parts of the question - the relationship evolution AND the operational impact on production performance. The mention of Permian Basin expansion adds relevant contextual detail. MULTI-HOP SYNTHESIS: The answer correctly connects the acquisition event (2023) to the operational integration (2024) to the production impact (7% growth), demonstrating sound multi-hop reasoning. Minor note: The LLM introduces the concept of 'Has_Stake_In/Depends_On relationship' from the KG structure, which adds technical precision but is not contradicted by ground truth. The answer is semantically equivalent to ground truth while providing slightly more operational detail (Permian Basin reference, specific production volume). No calculation errors detected. No factual contradictions with ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 464,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "\nFrom 2023 to 2024 UPS systematically expanded its cold‑chain logistics capacity: in 2023 it “recently acquired Bomi Group and MNX Global Logistics” to broaden its complex healthcare‑logistics network in the U.S. and internationally, and in 2024 it completed the purchase of Germany‑based **Frigo‑Trans** and **Biotech & Pharma Logistics** for roughly **$440 million**, a move explicitly described as expected to “increase our complex cold‑chain logistics capabilities internationally.” These acquisitions, together with the company’s ongoing investment in facility automation and strategic placement of facilities near transportation hubs, illustrate a clear evolution from targeted 2023 expansions to a larger, internationally‑focused upgrade of UPS’s cold‑chain infrastructure by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. QUANTITATIVE VERIFICATION: All numbers are correct - the $440 million acquisition price for Frigo-Trans and Biotech & Pharma Logistics is accurate. The years (2023 and 2024) are correctly identified. ENTITY ACCURACY: All four acquisitions are correctly named (Bomi Group, MNX Global Logistics, Frigo-Trans, Biotech & Pharma Logistics), and the geographic distinction (U.S./international in 2023 vs. Germany-based in 2024) is properly captured. MULTI-HOP REASONING: The answer successfully synthesizes information across two years, correctly identifying the evolution from 2023 to 2024 and the shift from general expansion to targeted international acquisitions. The connection between acquisitions and strategic intent (healthcare logistics, complex cold-chain capabilities) is properly established. COMPLETENESS: The answer addresses all parts of the question - how capabilities evolved, which acquisitions contributed, and the nature of the change. SEMANTIC EQUIVALENCE: The LLM's characterization of the evolution as moving from 'targeted 2023 expansions to a larger, internationally-focused upgrade' aligns well with the ground truth's description of 'shift from general expansion to targeted, high-value international acquisitions.' The additional context about facility automation and strategic placement, while not in the ground truth, is relevant and doesn't contradict it. MINOR OBSERVATION: The LLM includes slightly more contextual detail about facility automation and transportation hubs, which adds value without introducing errors. The quotation marks around phrases suggest direct sourcing from filings, enhancing credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enhances]-> PRODUCT <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 471,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "\nLinde plc’s non‑employee director RSU program has been administered under the 2021 Long‑Term Incentive Plan (the plan disclosed in Exhibit *10.02 of the 2021 10‑Q and referenced in Chunk 1), which added performance‑metric RSU forms (*10.02c–*10.02d) that tie portions of the award to Return‑on‑Capital and Total‑Shareholder‑Return metrics—an explicit long‑term shareholder‑alignment mechanism.  Building on that framework, the Board adopted the Linde plc Non‑employee Director Deferral Program on 30 July 2024 (Exhibit *10.16 in Chunk 2), a governance enhancement that requires directors to defer a slice of their RSU awards and links any accelerated vesting to sustained shareholder returns, thereby strengthening both the governance structure and the alignment of director interests with long‑term shareholders.  (The KG relationship LIN → Non‑Employee Director Restricted Stock Unit Award → LIN captures that the policy is both introduced by and disclosed for Linde plc.)",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2021 Long-Term Incentive Plan as the foundational framework for the RSU program. (2) The date of July 30, 2024 for the Board adoption of the Non-employee Director Deferral Program is accurate. (3) The LLM correctly identifies that the deferral program represents a governance enhancement and strengthens long-term alignment. (4) The mention of performance metrics (Return-on-Capital and Total-Shareholder-Return) adds specificity beyond the ground truth. (5) The reference to exhibit numbers and chunks demonstrates document-level traceability.\n\nWEAKNESSES: (1) The LLM introduces specific performance metrics (ROC and TSR) that are not mentioned in the ground truth answer. While these may be accurate from the actual filings, they represent information not validated by the ground truth, creating potential factual uncertainty. (2) The LLM's claim about 'accelerated vesting linked to sustained shareholder returns' is more specific than the ground truth's simpler statement that the deferral program 'allows directors to defer receipt of stock units.' The ground truth does not explicitly mention vesting acceleration conditions. (3) The LLM's statement that the deferral program 'requires directors to defer a slice of their RSU awards' is more prescriptive than the ground truth's 'allowing directors to defer,' suggesting optionality rather than requirement. (4) The temporal framing is slightly different: the ground truth emphasizes the evolution from 2022 to 2024, while the LLM focuses more on the 2024 enhancement without clearly establishing the 2022 baseline.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across the 2021 plan framework and the 2024 deferral program adoption, demonstrating appropriate multi-hop reasoning. However, the addition of specific performance metrics and vesting conditions not in the ground truth suggests either over-specification or reliance on information beyond the validated knowledge graph.\n\nQUANTITATIVE ACCURACY: The date (July 30, 2024) is correct. No calculations are required. The reference to exhibit numbers appears plausible but cannot be verified against the ground truth.\n\nSEMANTIC EQUIVALENCE: The core message about evolution from basic RSU awards to a more sophisticated deferral mechanism is preserved, though with added specificity that may or may not be accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 639,
        "total_tokens": 2128
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "\nBetween 2022 and 2024 GM recorded a $0.2 billion gain from its Stellantis warrants in non‑operating income (Chunk 1) while its legal exposure to Stellantis remained anchored to the 2017 sale of Opel/Vauxhall, under which GM agreed to indemnify Stellantis for losses arising from mis‑representations, warranty breaches, emissions claims, product‑liability and certain recall costs, with caps and time‑limits that have so far produced only immaterial payments (Chunk 2).  At the same time GM accrued $2.6 billion for the Chevrolet‑Bolt recall and recognized $1.6 billion of receivables from LG Energy Solution, illustrating the broader financial impact of its warranty and recall exposures that intersect with its Stellantis‑related indemnities (Chunk 2), and it continues to respond to European Commission and UK CMA information requests concerning Opel’s end‑of‑life vehicle activities, underscoring ongoing regulatory risk that could affect its indemnity exposure (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures several key elements of the GM-Stellantis relationship evolution but introduces problematic information and lacks clarity on the core narrative. STRENGTHS: (1) Correctly identifies the $0.2 billion warrant gain in 2022; (2) Accurately describes the indemnification obligations tied to the 2017 Opel/Vauxhall sale; (3) Properly notes the indemnity covers emissions claims, product liabilities, and recalls; (4) Mentions ongoing European regulatory investigations (EC and UK CMA); (5) Contextualizes the relationship shift from gains to contingent liabilities. CRITICAL ISSUES: (1) The introduction of $2.6 billion Chevrolet Bolt recall and $1.6 billion LG Energy Solution receivables is problematic—while these illustrate broader warranty/recall exposure, they are NOT part of the GM-Stellantis relationship evolution and dilute focus on the core question. The ground truth specifically contrasts 2022 gains with 2024 contingent liabilities from Stellantis, not unrelated recalls; (2) The statement that indemnity payments have been 'only immaterial' is not explicitly confirmed in the ground truth and may be inaccurate; (3) The answer lacks clear temporal progression—it doesn't strongly emphasize the shift from positive financial relationship (2022) to complex legal/contingent liability relationship (2024). MULTI-HOP REASONING: The answer attempts to synthesize information across years and topics but conflates GM's broader recall/warranty issues with Stellantis-specific obligations, which weakens the focused analysis required. The connection between Chevrolet Bolt and Stellantis indemnities is tangential at best. QUANTITATIVE ACCURACY: The $0.2 billion figure is correct; however, the introduction of unrelated financial figures ($2.6B, $1.6B) without clear connection to Stellantis creates confusion about what numbers are actually relevant to answering the question. SEMANTIC EQUIVALENCE: The core narrative about warrant gains transitioning to indemnification obligations is present, but the answer's structure and additional details obscure rather than clarify the evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Guarantees]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 575,
        "total_tokens": 2007
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "\nSouthern Company previously disclosed the pre‑tax effect of energy‑related derivatives that were not designated as hedging instruments in the income statement (2022 10‑K, p. 327), presenting them only as an earnings impact, whereas by 2024 the same derivatives are reported at fair value on the balance sheet and explicitly categorized under “Risk Management Activities” (2024 10‑K, p. 283), moving from a purely income‑statement quantification to a balance‑sheet asset/liability classification. This evolution reflects a shift in presentation and categorization from an earnings‑effect footnote to a distinct risk‑management line item.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Southern Company's energy-related derivatives disclosure from 2022 to 2024. STRENGTHS: (1) Correctly identifies the shift from income statement focus (pre-tax effects in 2022) to balance sheet orientation (fair value presentation in 2024); (2) Accurately captures the categorization change from earnings impact footnote to 'Risk Management Activities' line item; (3) Properly synthesizes multi-hop information across two different 10-K filings (2022 and 2024); (4) Correctly names the company and years; (5) Appropriately cites page numbers (327 for 2022, 283 for 2024) which adds credibility; (6) The semantic meaning matches ground truth - both describe a shift from income-focused to balance-sheet-oriented transparency. MINOR CONSIDERATIONS: (1) The LLM answer is slightly more specific with page citations and terminology ('earnings-effect footnote' vs. ground truth's 'income statement impacts'), but this represents enhanced detail rather than error; (2) The LLM answer mentions 'asset/liability classification' which aligns with ground truth's 'assets or liabilities on the balance sheets'; (3) Both answers correctly identify the categorization under 'Risk Management Activities' or 'Other'. NO QUANTITATIVE ERRORS DETECTED: No dollar amounts, percentages, or calculations are present in either answer, so quantitative accuracy is based on correct identification of years (2022, 2024) and document references, which are accurate. The reasoning is sound and the multi-hop synthesis across the two filing years is properly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 446,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "\nIn 2023 GILD owned roughly 19.9 % of Arcus (≈14.8 million shares) and held two designees on Arcus’ board under a purchase agreement that permitted a 35 % stake by 2025; in January 2024 the companies amended their collaboration and GILD injected an additional $320 million, raising its ownership to 33 % and expanding its board representation to three members while also triggering a $100 million option‑continuation fee.  This increase in equity and governance influence reflects the deeper strategic partnership described in GILD’s 2024 filing, which cautions that equity investments in partners such as Arcus can fluctuate in value and that the rights secured through such transactions are a core element of the company’s broader acquisition, licensing and collaboration strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and provides accurate core information with good multi-hop synthesis. STRENGTHS: (1) All primary numbers are correct - 19.9% ownership in 2023, $320 million investment in January 2024, 33% ownership post-investment, two board designees in 2023 expanding to three in 2024. (2) Dates are accurate (2023, January 2024). (3) Multi-hop reasoning is sound - correctly synthesizes the evolution of the relationship across two time periods and connects equity investment to governance changes. (4) Additional context provided (share count approximation of 14.8 million, 35% stake option by 2025, $100 million option-continuation fee, strategic context from 2024 filing) adds depth and demonstrates thorough understanding. MINOR ISSUES: (1) The $100 million option-continuation fee is additional information not in the ground truth answer - while this appears factually accurate based on the filing context mentioned, it goes beyond what was explicitly stated in the original answer. This is not an error but represents supplementary detail. (2) The mention of the 35% stake option by 2025 and the broader strategic context, while relevant and accurate, slightly expands beyond the core question focus on the 2023-2024 evolution. VERIFICATION: All quantitative claims check out - the percentages, dollar amounts, and board seat counts match the ground truth exactly. The temporal progression is clear and logical. The answer successfully addresses both equity ownership and governance influence components of the question. The semantic meaning is fully preserved and enhanced with contextual detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 446,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "\nBetween 2022 and 2023 the 2021 Multicurrency Credit Facility was amended again on June 29 2023, which pushed its maturity from the June 30 2025 date set in the December 8 2021 amendment to July 1 2026 while leaving the total commitment amount unchanged at $6.0 billion (the same $6.0 billion borrowing capacity reported as of December 31 2023).  The amendment also retained the existing sub‑limits ($3.5 billion multicurrency, $200 million letters of credit, $50 million swingline) and did not alter the overall borrowing capacity, even though the facility’s maturity was extended and the benchmark rate was switched from LIBOR to SOFR.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key facts are correct: (1) The 2021 Multicurrency Credit Facility had a maturity date of June 30, 2025 in 2022 and was extended to July 1, 2026 in 2023 - both dates match ground truth exactly. (2) The borrowing capacity remained constant at $6.0 billion in both years - correct. (3) The amendment date of June 29, 2023 is provided with appropriate specificity. (4) The one-year extension is correctly identified. The LLM answer goes beyond the ground truth by providing additional relevant context: the specific sub-limits ($3.5 billion multicurrency, $200 million letters of credit, $50 million swingline), the benchmark rate change from LIBOR to SOFR, and the December 8, 2021 amendment date. These additions are factually accurate and enhance understanding without introducing errors. The multi-hop reasoning is sound - the answer correctly synthesizes the evolution of the facility across the two-year period and explains the strategic implications. The only minor distinction is that the LLM provides more granular detail than the ground truth answer, but this represents added value rather than inaccuracy. All numbers, dates, and financial metrics are precisely correct with no calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Modifies]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 354,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "\nChevron’s 10‑K filings show that imported crude oil remained the dominant feedstock for its U.S. refineries, accounting for **about 60 percent of refinery inputs in both 2023 and 2024** (Chunk 1 & Chunk 2), a relationship captured by the KG pattern **ORG → RAW_MATERIAL ← Depends_On ORG**.  However, the **crude‑unit distillation capacity utilization fell markedly** – from **89.8 % in 2023 to 87.9 % in 2024 globally** and from **90.8 % to 86.6 % in U.S. refineries** (Chunk 1 & Chunk 2) – indicating that overall refinery throughput was scaled back even though the share of imported crude stayed steady.  This decline is tied to ongoing refinery‑modernisation projects (e.g., the 2024 Pasadena Refinery upgrade that will raise light‑crude throughput to 125,000 bbl/d and enable more Permian equity crude processing), which are intended to reshape utilization patterns going forward (Chunk 1 & Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant numerical discrepancies that undermine its credibility. Ground truth states U.S. refinery crude-unit distillation capacity utilization was 90.8% in 2023 and 86.6% in 2024. The LLM correctly reports the 2024 U.S. figure (86.6%) but INCORRECTLY states 2023 as 90.8% in one place while also claiming 89.8% globally in 2023 and 87.9% globally in 2024 - these global figures are not in the ground truth and appear to be fabricated or confused. The statement '90.8% to 86.6% in U.S. refineries' is correct, but the preceding claim of '89.8% in 2023 to 87.9% in 2024 globally' introduces unverified data that contradicts the ground truth's focus on U.S. operations. CORRECT ELEMENTS: (1) Imported crude oil at ~60% in both 2023 and 2024 - CORRECT; (2) U.S. refinery utilization decline from 90.8% to 86.6% - CORRECT; (3) Overall reasoning that imported crude share remained stable while utilization declined - CORRECT and well-synthesized. PROBLEMATIC ADDITIONS: The LLM introduces information about Pasadena Refinery upgrades and Permian crude processing that, while potentially relevant context, are not part of the ground truth answer and may represent hallucination or over-elaboration beyond what was asked. MULTI-HOP REASONING: The core multi-hop synthesis (comparing imported crude percentages across years AND comparing capacity utilization across years) is sound and correctly identifies the key insight that these metrics moved independently. However, the introduction of unverified global figures and refinery-specific projects weakens confidence in the answer's accuracy. The answer demonstrates good qualitative reasoning but fails on quantitative precision by mixing verified and unverified data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Processes]-> RAW_MATERIAL <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 483,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "\nUPS cut its British Pound Sterling hedge from $663 million in 2023 to $536 million in 2024 – a decline of roughly 19 % (Chunk 1 → Chunk 2).  At the same time the company trimmed its Euro hedge, expanded its Hong Kong‑Dollar position and added a new Chinese Renminbi hedge of $6.1 billion (Chunk 2), indicating a deliberate re‑balancing of its currency‑risk portfolio.  The reduction in the GBP hedge, captured by the “FIN_INST → decreases → ORG” relationship in the knowledge graph, reflects UPS’s strategy to lower exposure to pound‑related fluctuations and to diversify its hedging mix across other currencies.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) UNIT MISMATCH - The LLM incorrectly converted the hedge position from 'million units' (GBP) to dollar amounts ($663M, $536M). The ground truth clearly states '663 million units' and '536 million units' - these are currency units, not dollar values. The LLM's conversion to dollars is factually incorrect and represents a fundamental misunderstanding of the data. (2) PERCENTAGE CALCULATION - While the LLM states 'roughly 19%' which approximates the correct 19.15%, this is only correct by coincidence given the wrong base numbers. The calculation (127/663 = 19.15%) is mathematically sound in the ground truth but the LLM applied it to incorrect dollar figures. (3) UNSUPPORTED CLAIMS - The LLM introduces information about Euro hedge reductions, Hong Kong Dollar expansion, and Chinese Renminbi hedges ($6.1B) that are NOT present in the ground truth answer. These appear to be hallucinated details not verified against the source data. (4) PARTIAL CREDIT - The LLM correctly identifies: (a) the directional change (decrease), (b) the approximate percentage decline, (c) the strategic interpretation about reducing GBP exposure and diversifying. However, these correct elements are undermined by the fundamental unit/currency error. (5) MULTI-HOP REASONING - The LLM attempts to synthesize broader currency strategy but does so with unverified information, weakening the analysis. The core answer should focus on the GBP position evolution (663M to 536M units) without introducing unsubstantiated currency positions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 423,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "\nBank of America’s money‑market holdings grew modestly: the 2023 filing shows a fair‑value of **$1.2 bn** (with a prior‑year $868 mn), while the 2024 filing reports **$1.3 bn** at the end of 2024 versus **$1.2 bn** at the end of 2023 – an increase of roughly **$0.1 bn (≈8 %)**.  \n\nThis uptick, together with the disclosed shift in underlying collateral (prime exposure rising from 17 % to 25 % and sub‑prime falling from 83 % to 75 %), indicates that BAC is deliberately expanding its short‑term, high‑quality liquid assets—likely to strengthen liquidity buffers, meet regulatory coverage requirements, and position the firm to capture favorable short‑term interest‑rate conditions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core numbers: $1.2 billion (2023) and $1.3 billion (2024) are accurate, and the $0.1 billion increase calculation is correct. The percentage increase of approximately 8% is also accurate (0.1/1.2 ≈ 8.3%). The answer properly addresses the multi-hop question by synthesizing the evolution of fair values across two years and providing strategic interpretation. The inclusion of additional context about collateral composition (prime exposure rising from 17% to 25%, sub-prime falling from 83% to 75%) goes beyond the ground truth but appears to be supplementary detail from the filings that adds analytical depth without contradicting the core answer. The reasoning about liquidity management, regulatory compliance, and interest-rate positioning is sound and logically connected to the observed data. Minor strengths: the answer includes prior-year context ($868 million in 2022) which provides useful perspective. Minor consideration: the ground truth answer is more concise and focused, while the LLM answer adds interpretive layers about collateral shifts and regulatory motivations. These additions are reasonable inferences from the data but represent elaboration beyond what the ground truth explicitly states. The semantic equivalence is strong—both answers convey that money market investments grew modestly and this reflects strategic liquidity management. No calculation errors detected. All entities (Bank of America, years 2023-2024, fair value metric) correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 426,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "\nThe maximum expected volume of natural‑gas supply contracts that include a sell‑back feature fell from **26 million mmBtu in 2022** to **15 million mmBtu in 2024** – a reduction of 11 million mmBtu across Southern Company’s subsidiaries (Alabama Power 6 → 4 mmBtu, Georgia Power 8 → 6 mmBtu, Mississippi Power 4 → 2 mmBtu, Southern Power 8 → 3 mmBtu). Both the 2022 and 2024 10‑K excerpts disclose this volume figure and also contain the same interest‑rate‑derivative accounting discussion, but the quantitative change is the decline from 26 mmBtu to 15 mmBtu.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All numbers are correct - 2022 total of 26 million mmBtu, 2024 total of 15 million mmBtu, and the calculated difference of 11 million mmBtu. All subsidiary-level figures match exactly: Alabama Power (6→4), Georgia Power (8→6), Mississippi Power (4→2), Southern Power (8→3). The arithmetic is correct throughout. ENTITY ACCURACY: All four subsidiaries are correctly identified and their respective volumes properly attributed. Years (2022 and 2024) are correct. The metric (maximum expected volume of natural gas subject to physical supply contracts with sell-back options) is accurately described. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple subsidiaries and years, showing the consistent reduction pattern across all entities as stated in the ground truth. The comparison structure (2022→2024) is logically sound. COMPLETENESS: The answer addresses all required elements - the overall company-wide change, individual subsidiary changes, and the direction/magnitude of change. MINOR OBSERVATION: The LLM includes a parenthetical note about interest-rate-derivative accounting discussion which, while not incorrect, is somewhat tangential to the core question about volume changes. However, this does not detract from the accuracy of the primary answer. The wording 'fell from...to' and 'reduction' clearly conveys the directional change. Overall, this is a factually correct, well-structured answer that properly synthesizes multi-hop information across subsidiaries and time periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 440,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "\nIn 2023 Adobe first embedded the Firefly Vector Model in Illustrator and Fresco (and later in Adobe Express) so users could generate fully editable vector graphics from text prompts, with support for 100+ languages and a free tier limited by Generative Credits. By 2024 the model’s reach broadened across the entire suite—being leveraged in InDesign, Premiere Pro, After Effects, Photoshop, Stock and the new Firefly Services/GenStudio, adding capabilities such as Generative Recolor, Objects on Path, enhanced Image Trace, a public Video Model, and enterprise IP indemnification—significantly deepening its integration and commercial availability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) TIMELINE ERROR - The LLM claims Firefly Vector Model was embedded in Illustrator and Fresco in 2023, but the ground truth states it was integrated into Adobe Express in 2023 and only expanded to Illustrator by 2024. This is a fundamental chronological error. (2) INCOMPLETE/INACCURATE 2023 BASELINE - The ground truth clearly establishes that in 2023, the model was specifically in Adobe Express enabling image and text effect generation. The LLM's claim about Illustrator and Fresco in 2023 is unsupported by the ground truth. (3) OVERSTATED 2024 EXPANSION - While the LLM mentions multiple applications (InDesign, Premiere Pro, After Effects, Photoshop, Stock, GenStudio) in 2024, the ground truth only confirms Illustrator integration by 2024 with the Generative Recolor feature. The LLM appears to have fabricated or conflated information about broader suite integration. (4) FEATURE ACCURACY - The ground truth confirms Generative Recolor as a 2024 feature in Illustrator, which the LLM correctly mentions. However, other features listed (Objects on Path, enhanced Image Trace, Video Model, IP indemnification) are not mentioned in the ground truth and may be speculative. (5) LANGUAGE SUPPORT - Both mention 100+ languages, which is consistent. (6) MULTI-HOP REASONING - The LLM failed to correctly synthesize the evolution from 2023 (Express only) to 2024 (Express + Illustrator), instead presenting an incorrect 2023 baseline. The answer demonstrates poor adherence to the ground truth timeline and scope of integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 446,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "\nIn 2023 Biktarvy generated $11.85 billion of sales—about 65 % of GILD’s total HIV revenue of $18.175 billion—underscoring its central role in the portfolio (as reflected by the KG triplets GILD → Biktarvy and Biktarvy → GILD).  The 2024 risk disclosures, however, warn that sales of TAF‑containing HIV products like Biktarvy are vulnerable to competitive pressure, generic erosion and potential shifts away from nucleoside‑based regimens, which could erode its commercial significance.  Accordingly, GILD’s HIV strategy is likely to shift toward diversifying its pipeline, advancing next‑generation regimens and alternative mechanisms, and reducing reliance on a single TAF‑based product to sustain long‑term growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies Biktarvy's 2023 sales as $11.85 billion (matches ground truth $11,850 million). (2) The calculation of Biktarvy representing ~65% of HIV revenue is mathematically sound ($11.85B / $18.175B ≈ 65%). (3) The LLM accurately captures the evolution from 2023 to 2024, noting the shift from Biktarvy's dominance to increased risk awareness. (4) The multi-hop reasoning is sound: correctly synthesizes that despite Biktarvy's continued importance, 2024 risk disclosures highlight vulnerabilities to generic competition, TAF-based product erosion, and treatment paradigm shifts. (5) The strategic implications are well-articulated: diversification, next-generation regimens, and reduced reliance on single products. (6) Entity identification is correct (GILD, Biktarvy, HIV portfolio, TAF). MINOR WEAKNESSES: (1) The LLM does not explicitly mention the 2022 comparison ($10,390 million) that the ground truth includes, which would have provided fuller context on the growth trajectory. (2) The reference to 'KG triplets' is somewhat awkward phrasing and not necessary for answering the question. (3) The ground truth emphasizes 'mounting pressure' and 'sustain revenue growth' more explicitly, while the LLM uses slightly softer language ('likely to shift'). VERIFICATION: All key numbers are accurate. The 2023 figure of $11.85B is correct. The percentage calculation is accurate. The risk factors (generic competition, TAF vulnerability, treatment paradigm shifts) align with ground truth. The strategic implications (diversification, innovation, reduced reliance) match the ground truth assessment. The answer successfully addresses both parts of the multi-part question: (1) how Biktarvy's significance evolved, and (2) implications for HIV strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 486,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "\nThe Series 2018‑1A Securities remained outstanding throughout 2022‑23 as a pass‑through interest in the loan made by American Tower Trust I to the AMT Asset Subs, a structure first described in the 2018 securitization (Chunk 1).  Their fixed coupon stayed at **3.652 %** and, according to the 2022 and 2023 financial statements, the outstanding principal was essentially flat—$496.1 million as of the 2022 reporting date and $496.8 million as of the 2023 reporting date (Chunk 2).  Consequently, while the securities continue to accrue interest at the same 3.652 % rate and are still scheduled for repayment of the remaining balance in March 2028 (with a final maturity in March 2048), their principal balance showed only a modest increase between the two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding the 2022 principal amount. Ground truth states the 2022 principal was $500.0 million, but the LLM claims it was $496.1 million. This is a material discrepancy of $3.9 million. The 2023 figure of $496.8 million is correct. The interest rate of 3.652% is correctly stated for both years. DIRECTIONAL ERROR: The LLM characterizes the principal change as 'a modest increase between the two years' ($496.1M to $496.8M = +$0.7M), when the actual evolution was a decrease from $500.0M to $496.8M (a -$3.2M reduction). This represents a fundamental mischaracterization of the financial trend. CORRECT ELEMENTS: The interest rate constancy (3.652%) is accurate, the maturity dates (March 2028 repayment, March 2048 final maturity) appear reasonable, and the general structure description is contextually appropriate. MULTI-HOP REASONING: The answer attempts to synthesize information across years and documents but fails on the primary quantitative metric (2022 principal amount), which undermines the core analysis. The comparison between years is logically structured but based on incorrect baseline data. COMPLETENESS: The answer addresses both principal and interest rate evolution as requested, but the principal evolution is factually wrong, making the answer incomplete in its core requirement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 387,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "\nIn 2023 UPS performed impairment testing on the Coyote trade‑name (part of its Supply‑Chain Solutions unit), recorded an $111 million goodwill impairment that left a carrying value of only $89 million and explicitly evaluated strategic alternatives because the name had limited excess of fair value and was sensitive to market conditions. By September 2024 UPS divested Coyote, which accounted for a $976 million revenue drop in Supply‑Chain Solutions, and shifted its strategic focus toward growing other logistics businesses—such as its expanded Logistics, healthcare, MNX Global Logistics, Roadie and Happy Returns platforms—signaling a clear move away from the Coyote brokerage unit.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and provides more detailed information than the ground truth. Key strengths: (1) Correctly identifies the $111 million impairment charge in 2023 - this matches ground truth exactly. (2) Correctly identifies September 2024 divestiture of Coyote - timing and event are accurate. (3) Provides additional accurate detail about the $89 million remaining carrying value after impairment, which is mathematically correct ($111M impairment from an implied original value). (4) Correctly characterizes the strategic evaluation and market sensitivity issues. (5) Accurately describes the $976 million revenue impact from Coyote's exit in Supply Chain Solutions. (6) Appropriately contextualizes the strategic shift toward other logistics platforms (Logistics, healthcare, MNX Global Logistics, Roadie, Happy Returns). Multi-hop reasoning is sound: the answer correctly synthesizes the 2023 impairment event with the 2024 divestiture and its financial/strategic consequences. The evolution narrative is clear and well-supported. Minor consideration: The ground truth mentions 'decline in Supply Chain Solutions revenue' while the LLM specifies '$976 million revenue drop' - this is actually more precise and appears to be accurate based on typical SEC filing disclosures. The LLM answer goes beyond ground truth by providing the specific revenue impact figure and naming specific alternative business units, which adds valuable context without contradicting the ground truth. No calculation errors detected. All dates, entities, and financial metrics are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 437,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "\nLinde plc first introduced its Performance Share Unit Awards in 2019, disclosing two distinct performance‑metric formulas—Return on Capital and Total Shareholder Return—in Exhibits 10.11k/l (Chunk 1) and their equivalents 10.10l/m (Chunk 2); the KG pattern ORG → FIN_INST ← ORG confirms that Linde (ORG) both introduces and discloses the PSU award. Both the 2022 and 2024 Form 10‑K filings retain the same award language, showing that the structure and the 2019‑era performance metrics have remained unchanged through 2022‑2024. Thus, the evolution is one of continuity rather than alteration, with the original Return on Capital and Total Shareholder Return criteria still governing all PSU grants that began in 2019.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the question. STRENGTHS: (1) All key facts are correct - correctly identifies the two performance metrics (Return on Capital and Total Shareholder Return), correctly references the exhibit numbers (10.11k/l for 2022 and 10.10l/m for 2024), correctly identifies the underlying plan (Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan), and correctly identifies the company (Linde plc). (2) Quantitative accuracy is perfect - all dates (2019, 2022, 2024) are correct, all exhibit references match the ground truth. (3) Multi-hop reasoning is sound - the answer correctly synthesizes information across multiple years and documents, establishing the connection between 2019 grants and their continued presence in 2022 and 2024 filings. (4) The core conclusion is accurate: the structure remained unchanged, representing continuity rather than evolution. (5) The answer appropriately addresses the specific question about how the structure 'evolved' by correctly identifying that it did not evolve but rather remained stable. MINOR CONSIDERATIONS: The LLM answer includes some interpretive language about 'KG pattern ORG → FIN_INST ← ORG' which, while not incorrect, is somewhat tangential to the core question and adds technical jargon that the ground truth answer avoids. However, this does not detract from factual accuracy. The phrasing 'evolution is one of continuity rather than alteration' is semantically equivalent to the ground truth's statement that the company 'maintained the same dual structure...without introducing new metrics or eliminating existing ones.' Overall, the answer successfully synthesizes multi-hop information across years and documents while maintaining factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 487,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "\nTrodelvy (the sacituzumab govitecan conjugate) was first approved under an FDA **accelerated‑approval** pathway for metastatic triple‑negative breast cancer, HR⁺/HER2‑negative breast cancer and metastatic urothelial cancer, with the filing noting that continued approval is contingent on confirming clinical benefit (Chunk 1).  In the 2024 update the agency granted a **second Breakthrough Therapy designation** to Trodelvy for extensive‑stage small‑cell lung cancer, signaling that the FDA is now expediting its development for yet another serious‑illness indication (Chunk 2).  This progression—from an initial accelerated approval to a second Breakthrough Therapy label—demonstrates an accelerating regulatory trajectory and growing confidence in Trodelvy’s clinical potential as a product of GILD (ORG → PRODUCT).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2024 Breakthrough Therapy designation for extensive-stage small cell lung cancer as a key regulatory development. (2) The 2023 indications (triple-negative breast cancer, HR+/HER2- breast cancer, urothelial cancer) are accurately stated. (3) The conclusion about strategic expansion into new oncology indications is sound. (4) The mention of accelerated approval pathway is contextually relevant background information.\n\nWEAKNESSES: (1) CRITICAL ERROR - The LLM states this is a 'second Breakthrough Therapy designation,' implying Trodelvy had a prior Breakthrough Therapy designation. The ground truth does not support this claim. The original answer indicates the 2024 designation was the first Breakthrough Therapy designation mentioned, not a second one. This is a significant factual error that mischaracterizes the regulatory trajectory. (2) The LLM adds information about 'accelerated approval' and 'continued approval contingent on confirming clinical benefit' that, while potentially accurate, goes beyond what the ground truth specifies and introduces complexity not directly addressed in the original answer. (3) The phrase 'from an initial accelerated approval to a second Breakthrough Therapy label' creates a false narrative about prior designations. (4) The LLM's interpretation of 'accelerating regulatory trajectory' based on a 'second' designation is logically flawed if the 'second' designation claim is incorrect.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2023 and 2024 timeframes and connect regulatory status to development trajectory, which is appropriate. However, the factual error about 'second' designation undermines the validity of the synthesis.\n\nNUMERIC/DATE ACCURACY: Years (2023, 2024) are correct. No calculations required. The indications listed are accurate.\n\nJUSTIFICATION: The answer demonstrates partial understanding but contains a material factual error regarding the 'second' Breakthrough Therapy designation that significantly impacts the accuracy of the regulatory trajectory assessment. The core information about the 2024 SCLC designation and 2023 indications is correct, but the characterization of this as a 'second' designation is unsupported and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 612,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "\nFrom 2023 to 2024 Vertex AI moved from a general generative‑AI development environment to the core engine of Google Cloud’s AI stack, now tightly coupled with the Gemini multimodal model (launched December 2023) and enriched with services such as vector search, grounding and model distillation that improve cost and quality.  In 2024 the platform enables developers to train, tune, augment and deploy applications using Gemini and other leading generative‑AI models, and it is embedded across Google Cloud’s AI‑optimized infrastructure, Duet AI for Cloud, Enterprise Search, Conversations and cybersecurity, making Vertex AI the primary conduit through which Google’s generative‑AI capabilities are delivered to enterprises and developers.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key capabilities mentioned in the ground truth (train, tune, augment, deploy) and accurately names the new services added by 2024 (vector search, grounding, distillation). The mention of Gemini integration and the shift toward more advanced AI integration aligns with the ground truth. The date reference to Gemini's December 2023 launch is factually accurate and adds helpful context.\n\nWEAKNESSES: (1) The LLM answer introduces significant new information not present in the ground truth, including claims about Vertex AI becoming 'the core engine of Google Cloud's AI stack,' being 'embedded across Google Cloud's AI-optimized infrastructure,' and serving as 'the primary conduit' for generative AI delivery. While these may be true, they exceed what the ground truth specifies and represent unsupported elaboration. (2) The ground truth explicitly mentions 'Enterprise Search and Conversations' as services in 2023, but the LLM answer lists these as 2024 integrations, potentially misrepresenting the timeline. (3) The LLM introduces 'Duet AI for Cloud' and 'cybersecurity' applications not mentioned in the ground truth, again going beyond the source material. (4) The characterization of the 2023 platform as merely a 'general generative-AI development environment' understates its actual capabilities as described in the ground truth.\n\nMULTI-HOP REASONING: The answer demonstrates sound reasoning in connecting Gemini's launch to Vertex AI's evolution and synthesizing the capability changes across years. However, the reasoning is partially compromised by introducing unsupported claims.\n\nFACTUAL ACCURACY: Core facts about capabilities (train, tune, augment, deploy, vector search, grounding, distillation) and Gemini integration are correct. The date of Gemini's launch (December 2023) is accurate. However, the timeline and scope of service integrations appear misrepresented.\n\nJUSTIFICATION: The answer captures the essential evolution described in the ground truth but significantly expands beyond it with claims not supported by the source material. This represents a moderate accuracy issue—the core answer is directionally correct but contains material additions that cannot be verified against the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 609,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "\nSouthern Company (SO) continues to treat the premium and intrinsic value of its weather‑derivative contracts as immaterial and therefore excludes that amount from the fair‑value measurement of the derivatives in both its 2022 and 2024 Form 10‑K filings.  The 2022 filing notes that cash collateral held in broker margin accounts—$3 million, $28 million and $99 million at the end of 2021, 2020 and 2019, respectively—was excluded along with the immaterial premium/intrinsic value, whereas the 2024 filing reports larger collateral balances of $17 million (as of Dec 31 2024) and $62 million (as of Dec 31 2023) that are now disclosed, indicating a shift in the scale of collateral considered material while the derivative’s intrinsic value remains excluded.  Thus, from 2022 to 2024 the treatment of the weather‑derivative’s intrinsic component as immaterial stays constant, but the disclosed collateral amounts have increased, reflecting a change in what is presented as material in SO’s financial disclosures.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM introduces collateral amounts ($3M, $28M, $99M for 2021, 2020, 2019) that are NOT present in the ground truth answer. The ground truth only mentions $17M (2024) and $62M (2023). The LLM appears to have fabricated or confused historical data not supported by the original answer. (2) MISCHARACTERIZATION - The LLM claims collateral amounts 'have increased' and represents a 'shift in the scale of collateral considered material,' but the ground truth states the collateral disclosure represents 'more specific context' and 'more detailed and structured approach,' NOT a change in materiality treatment. The ground truth explicitly states weather derivative premium/intrinsic value 'remained immaterial' - the collateral disclosure is separate and additional context, not evidence of changed materiality thresholds. (3) INCOMPLETE SYNTHESIS - The LLM fails to properly synthesize the key insight from the ground truth: that SO provided MORE SPECIFIC CONTEXT in 2024 (the $17M and $62M figures) compared to 2022 (no specific amounts given), while maintaining the same immaterial treatment of the weather derivative component itself. (4) LOGICAL ERROR - The statement 'reflecting a change in what is presented as material' contradicts the ground truth's assertion that the weather derivative component 'remained immaterial.' The collateral amounts being disclosed does not mean they became 'material' - they are simply additional disclosure details. (5) CORE ANSWER PARTIALLY CORRECT - The LLM correctly identifies that weather derivatives are treated as immaterial in both years and excluded from fair-value measurement, and correctly cites the 2024 collateral figures ($17M and $62M). However, the introduction of unsupported historical figures and the misinterpretation of what changed between 2022 and 2024 significantly undermines the answer's accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 517,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "\nBased on GILD’s 2023 10‑K (Chunk 1), Biktarvy retains U.S. and EU exclusivity through 2033, meaning its market life and pricing power remain secure for the next decade. In the 2024 filing (Chunk 2), the FDA granted Biktarvy an expanded indication for patients with M184V/I resistance and updated its label to include use in pregnant women, broadening its therapeutic niche and reinforcing its competitive positioning despite the unchanged exclusivity horizon.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and appropriate multi-hop synthesis across 2023 and 2024 GILD filings. STRENGTHS: (1) Correctly identifies the 2033 U.S. patent expiration date from 2023 filing; (2) Accurately captures the FDA expanded indication for M184V/I resistance in 2024; (3) Correctly notes the updated label for pregnant women with HIV-1; (4) Properly synthesizes the evolution from patent protection focus to expanded therapeutic applications; (5) Appropriately contextualizes the unchanged exclusivity horizon while highlighting new clinical applications. MINOR ISSUES: (1) The LLM mentions 'EU exclusivity through 2033' which is not explicitly confirmed in the ground truth answer - the ground truth only specifies 'U.S. patent expiration year of 2033.' This represents a slight expansion beyond what was verified in the knowledge graph, though it may be accurate from the actual filing; (2) The phrase 'unchanged exclusivity horizon' is accurate but could be clearer that the 2033 date remained consistent between years. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years (2023 and 2024) and correctly identifies the shift in positioning from patent-based protection to expanded clinical indications. The logic connecting regulatory approvals to market positioning is sound. QUANTITATIVE ACCURACY: All dates and timeframes are correct (2033 exclusivity, 2023 vs 2024 comparison). No calculations required. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as the ground truth while using slightly different framing ('therapeutic niche' vs 'therapeutic application'). The core message about evolution from patent protection to expanded indications is preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 478,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "\nIn 2022 AMT recorded net additional borrowings of **$850 million** under the 2021 Multicurrency Credit Facility (Chunk 1), while in 2023 it **drew $3.0 billion** of revolving borrowings under the same facility but **repaid $6.1 billion**, producing a net reduction of outstanding debt (Chunk 2).  At the same time the facility was **amended on June 29 2023**—its maturity was extended to July 1 2026, the total commitment was raised to **$6 billion**, sub‑limits for multicurrency, letters of credit and swing‑line loans were defined, and the LIBOR benchmark was replaced with SOFR (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) 2022 net borrowings of $850 million - CORRECT; (2) 2023 borrowings of $3.0 billion - CORRECT; (3) 2023 repayments of $6.1 billion - CORRECT; (4) Amendment date of June 29, 2023 - CORRECT; (5) Extended maturity to July 1, 2026 - CORRECT; (6) Total commitment of $6.0 billion - CORRECT (LLM states '$6 billion' which is equivalent formatting); (7) LIBOR to SOFR replacement - CORRECT. The LLM answer successfully synthesizes multi-hop information comparing 2022 vs 2023 usage patterns and facility amendments. One minor omission: the ground truth specifically mentions the EUR repayment of 842.6 million EUR ($919.1 million) as a significant component of the 2023 repayments, which the LLM answer does not include. However, this is a relatively minor detail that doesn't affect the core answer about overall borrowing/repayment amounts and facility amendments. The LLM correctly identifies the net reduction in outstanding debt (borrowing $3.0B while repaying $6.1B), demonstrates proper multi-hop reasoning across years and facility changes, and accurately captures all major structural amendments. The answer is well-organized, clearly presented, and directly addresses all parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 359,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "\nBetween 2023 and 2024 Alphabet’s assessment of its role over Google Network inventory—including ads sold through **Google Ad Manager**—remained anchored to a **gross‑basis** revenue model, but the 2024 disclosure sharpens the rationale: it emphasizes Alphabet’s **“sole ability to monetize the advertising inventory before it is transferred”** and its **pricing discretion**, thereby tightening the integration of Ad Manager into the revenue‑recognition framework.  The 2023 note already described the principal‑vs‑agent evaluation and gross reporting for Network properties, while the 2024 note refines that evaluation and explicitly links Ad Manager’s inventory control to the overall advertising‑revenue reporting model, reinforcing the same gross‑basis treatment while adding clearer criteria for when Alphabet is deemed the principal.  (KG: GOOGL → Google Ad Manager ← GOOGL, illustrating the mutual dependence of the firm and the product.)",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Google Ad Manager's role in Alphabet's revenue recognition strategy between 2023 and 2024. STRENGTHS: (1) Correctly identifies the shift from transactional reporting to control-based evaluation; (2) Accurately captures the emphasis on 'sole ability to monetize' and 'pricing discretion' as key 2024 refinements; (3) Properly notes that both years employed gross-basis revenue recognition; (4) Correctly synthesizes the multi-hop relationship between Alphabet, Google Ad Manager, and revenue recognition principles; (5) No quantitative errors or incorrect dates/entities. MINOR WEAKNESSES: (1) The phrase 'sole ability to monetize the advertising inventory before it is transferred' is slightly more specific/technical than the ground truth's 'controlling advertising inventory before transfer,' though semantically equivalent; (2) The KG notation at the end (GOOGL → Google Ad Manager ← GOOGL) adds interpretive commentary not present in ground truth, though it doesn't contradict it; (3) Could have been slightly more explicit about the 'principal-vs-agent' framework evolution, though this is adequately covered. The answer successfully demonstrates multi-hop reasoning by connecting Alphabet's strategic assessment, Google Ad Manager's operational role, and revenue recognition principles across two fiscal years. The semantic meaning matches the ground truth: both convey that the company refined its justification for gross revenue recognition while maintaining the same treatment, with Google Ad Manager becoming more explicitly central to that justification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 453,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "\nUPS acquired Roadie in 2021, funded the purchase with cash and reported the business within Supply Chain Solutions, with the transaction reflected in a purchase‑price allocation that now forms part of the $4.3 billion goodwill balance (Chunk 1).  In 2023 the company recorded a $56 million goodwill impairment for Roadie, and in 2024 it performed annual impairment testing that showed Roadie—along with Global Freight Forwarding and Global Logistics and Distribution—had only limited excess of fair value, making the unit sensitive to a 100‑basis‑point rise in cost of capital or a 10 % decline in cash flows; although no impairment was recognized in 2024, roughly $1.1 billion of the consolidated goodwill balance is attributed to these three reporting units (Chunk 2).  Consequently, while UPS’s financial exposure to Roadie remains tied to that goodwill balance and the risk of future impairment, the company continues to monitor the unit and is reviewing its finite‑lived intangible assets under the Efficiency Reimagined initiative, underscoring the strategic positioning of Roadie in its 2023‑2024 evolution (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. QUANTITATIVE VERIFICATION: All numbers are correct - $56 million goodwill impairment in 2023 (matches ground truth), 100-basis-point sensitivity threshold (accurate), 10% cash flow decline threshold (accurate), $1.1 billion goodwill attributed to three reporting units (accurate), $4.3 billion consolidated goodwill balance (accurate). The 2021 acquisition date is correct. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple dimensions: (1) historical context (2021 acquisition, Supply Chain Solutions segment), (2) 2023 impairment event ($56M), (3) 2024 impairment testing results (no impairment but limited excess fair value), and (4) risk sensitivity metrics. The logical progression from active impairment to cautious monitoring is clearly articulated. COMPLETENESS: The answer addresses all aspects of the question - financial exposure (goodwill balance, impairment risk), strategic positioning (segment placement, Efficiency Reimagined initiative), and the evolution between 2023-2024 (from impairment to monitoring). ENTITY ACCURACY: All entities correctly identified (UPS, Roadie, Global Freight Forwarding, Global Logistics and Distribution). SEMANTIC EQUIVALENCE: The answer conveys the same core message as ground truth - a shift from active impairment to cautious monitoring due to ongoing financial risk. The additional context about the $1.1 billion goodwill balance and sensitivity metrics enhances understanding without contradicting the ground truth. MINOR CONSIDERATION: The LLM provides more granular detail than the ground truth (e.g., specific sensitivity thresholds, Efficiency Reimagined initiative), which adds value rather than detracting. No factual errors or calculation mistakes identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 500,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "\nIn the 2022 filing (Chunk 1) helium is listed under the “Other” segment, establishing the baseline supply relationship that the KG link LIN → Helium ← Negatively_Impacts describes; by 2024 that same segment shows a $32 million (2 %) sales decline driven by lower helium volumes (Chunk 2) while operating profit rises $19 million (44 %) as insurance recoveries offset the higher helium‑related costs (Chunk 2). Thus, although helium continues to negatively affect Linde’s results, the quantitative impact shifted from a drag on profit in 2022 to a modest profit increase in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides specific dollar amounts ($32 million sales decline, $19 million operating profit increase, 44% increase) that are NOT present in the ground truth answer. The ground truth only mentions '2% underlying sales decrease' and does not quantify the operating profit impact in absolute dollars or percentages. The LLM appears to have fabricated these specific numbers. (2) DIRECTIONAL CONTRADICTION - The LLM claims operating profit 'rises $19 million (44%)' and describes 'a modest profit increase in 2024,' which directly contradicts the ground truth stating helium had 'a negative impact on performance' in 2024 with 'increased costs related to helium.' The ground truth explicitly notes costs were 'partially offset by an insurance recovery' - meaning the net effect was still negative, not positive. (3) INCOMPLETE SYNTHESIS - The LLM fails to properly synthesize the multi-hop relationship. The ground truth describes a SHIFT from 2022 (positive/neutral) to 2024 (negative), but the LLM's conclusion that 'helium continues to negatively affect Linde's results' while simultaneously claiming profit increased is logically inconsistent. (4) MISSING CONTEXT - The LLM does not adequately address the 2022 baseline or the nature of the shift described in the ground truth. The mention of LAMT (Linde Advanced Materials Technology) is present but not integrated into the narrative properly. (5) INSURANCE RECOVERY MISCHARACTERIZATION - While the LLM mentions insurance recovery, it incorrectly uses this to justify a profit increase, when the ground truth indicates this only 'partially offset' the negative impact. The LLM's interpretation fundamentally misrepresents the financial outcome.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> RAW_MATERIAL <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 478,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "\nThe long‑term credit‑protection agreements with FNMA and FHLMC covered $8.7 billion of residential‑mortgage loans at the end of 2023, but that amount fell to $8.0 billion by the end of 2024 (the 2024 figure is $8.0 bn for 2024 and $8.7 bn for 2023, down from $9.5 bn in the prior‑year comparison). Because the covered loans are fully insured, the Corporation does not record an allowance for credit losses on them, so the decline in the insured pool signals a reduced reliance on external credit protection and therefore a lower level of transferred credit‑risk exposure on its residential‑mortgage portfolio—even though the actual non‑performing residential‑mortgage balance remained essentially flat at roughly $2.6‑2.7 billion in both years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core figures ($8.7 billion in 2023, $8.0 billion in 2024) and accurately explains that these loans are fully insured with no allowance for credit losses recorded. The reasoning about reduced reliance on external credit protection is sound and matches the ground truth interpretation. The answer appropriately addresses both parts of the question: the evolution of loan values and what this indicates about credit risk exposure.\n\nWEAKNESSES: The LLM introduces a confusing and potentially incorrect reference to a \"$9.5 bn in the prior-year comparison.\" The ground truth does not mention $9.5 billion, and this figure appears to be either fabricated or misinterpreted from the source material. This creates ambiguity about whether there's a three-year comparison being made (2022-2023-2024) or if this is an error. The phrase \"down from $9.5 bn in the prior‑year comparison\" is unclear and potentially contradicts the stated 2023 figure of $8.7 billion if it's meant to be a prior year to 2023.\n\nADDITIONAL INFORMATION: The LLM adds context about non-performing residential mortgage balances remaining flat at $2.6-2.7 billion, which is not mentioned in the ground truth. While this additional detail could be accurate from the source documents, it goes beyond what was provided in the original answer and cannot be verified against the ground truth.\n\nMULTI-HOP REASONING: The synthesis is generally sound - the model correctly connects the decline in covered loans to reduced credit risk exposure and explains the accounting treatment (no allowance for credit losses). However, the unexplained $9.5 billion reference undermines confidence in the multi-hop synthesis.\n\nQUANTITATIVE ACCURACY: The primary figures (8.7B and 8.0B) are correct, but the introduction of the $9.5B figure without clear explanation or verification against ground truth reduces confidence. The calculation of the decline ($700 million or ~8% reduction) is implicit but correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 540,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "\nAdobe deepened Firefly’s strategic role from 2023 to 2024 by positioning it as a natively integrated, commercially‑safe generative‑AI engine that differentiates Adobe’s Creative Cloud through seamless AI‑enhanced features, brand trust and easy‑to‑use workflows (Chunk 1). By 2024, however, that same capability introduced heightened regulatory risk—subject to the EU AI Act, evolving global AI rules, and potential liability for model governance, compliance costs and third‑party data exposure (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: The answer correctly identifies the core evolution of Adobe Firefly's positioning from 2023 to 2024, accurately capturing the shift from competitive differentiation emphasis to risk-aware strategic positioning. The specific mention of EU AI Act adoption in 2024 is factually correct and matches the ground truth. The characterization of Firefly as 'natively integrated' and 'commercially-safe' in 2023 aligns with the original answer. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either the question or answers, so this dimension is not applicable. The answer appropriately avoids introducing unsupported numerical claims. (3) ENTITY ACCURACY: All entities are correctly identified - Adobe, Adobe Firefly, Creative Cloud, EU AI Act, and the 2023-2024 timeframe. The answer properly synthesizes information across these entities. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across multiple dimensions: (a) competitive positioning in 2023, (b) regulatory environment changes in 2024, (c) the causal relationship between Firefly's capabilities and emerging regulatory risks. The reasoning chain is logical and well-structured. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth with slightly different wording. Terms like 'commercially-safe' (LLM) vs 'safe for commercial use' (ground truth) are semantically equivalent. The mention of 'brand trust' and 'easy-to-use workflows' in the LLM answer adds minor contextual detail not explicitly in the ground truth but is consistent with typical Adobe positioning. The reference to 'third-party data exposure' as a regulatory concern is a reasonable elaboration on the compliance risks mentioned in the ground truth. Minor deduction: The LLM answer could have been slightly more explicit about the 'shift' or 'evolution' aspect, though this is clearly implied in the structure. Overall, the answer demonstrates accurate multi-hop synthesis and appropriate contextual understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 581,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "\nIn 2023 Trodelvy generated **$1.063 bn in net product sales** (up 56 % YoY) and was a key driver of GILD’s overall product revenue of **$26.93 bn**, illustrating a strong financial trajectory for the asset within GILD’s portfolio (Chunk 1).  Building on that performance, the FDA in 2024 granted **Breakthrough Therapy designation to Trodelvy for extensive‑stage small‑cell lung cancer**, marking the product’s second such designation and signaling an accelerating regulatory pathway for the drug (Chunk 2).  The relationship is captured by the KG triplets **GILD → Produces → Trodelvy** and **Trodelvy → Produced‑by → GILD**, linking the company’s financial results directly to the product’s evolving regulatory landscape.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. (1) QUANTITATIVE VERIFICATION: All numbers are correct - Trodelvy 2023 sales of $1.063 billion (formatted as $1,063 million in ground truth, $1.063 bn in LLM answer - acceptable format variation), 56% YoY growth rate confirmed, and GILD's total product revenue of $26.93 billion accurately cited. No calculation errors detected. (2) ENTITY ACCURACY: All entities correctly identified - Trodelvy as the product, GILD as the manufacturer, FDA as the regulatory body, and the specific indication (extensive-stage small cell lung cancer post-platinum chemotherapy) accurately described. Years 2023 and 2024 correctly referenced. (3) MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across multiple dimensions: financial performance (2023 sales data), regulatory trajectory (2024 FDA designation), and the relationship between company and product (GILD-Trodelvy connection). The logical flow from financial strength to regulatory recognition is sound. (4) COMPLETENESS: The answer addresses both parts of the question - financial performance evolution (2023 sales with growth rate) and regulatory trajectory (2024 Breakthrough Therapy designation, noting it was the second such designation). The additional context about GILD's portfolio and KG relationships adds value without detracting from accuracy. (5) MINOR CONSIDERATIONS: The LLM answer includes slightly more contextual detail than the ground truth (mentioning GILD's total product revenue and KG relationships), but this is supplementary and does not contradict the original answer. The semantic meaning is fully preserved and enhanced with relevant context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 464,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "\nChevron’s 36.4 % equity interest in Angola LNG Limited has been a steady pillar of its upstream portfolio, and from 2022 to 2024 its financial involvement deepened rather than shifted: the company’s net loan exposure to affiliates rose from **$4.28 bn (2022) → $4.49 bn (2023) → $4.73 bn (2024)**, while “sales and other operating revenues” from affiliated entities—including Angola LNG—grew to **$13.85 bn in 2024** (up from $13.62 bn in 2023 and $16.29 bn in 2022), and accounts receivable/payable with affiliates increased modestly.  This expansion of loan‑based financing and higher affiliate‑related earnings reflects a reinforced strategic positioning in Angola LNG, building on the equity stake first highlighted in the 2022 10‑K where Angola LNG contributed to the improvement in income from equity affiliates.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) UNVERIFIED NUMBERS: The LLM provides specific loan exposure figures ($4.28bn→$4.49bn→$4.73bn for 2022-2024) and affiliate revenue figures ($13.85bn in 2024, $13.62bn in 2023, $16.29bn in 2022) that are NOT present in the ground truth and cannot be verified against the original SEC filings. These appear to be fabricated or hallucinated data points. (2) CONTRADICTORY REVENUE TREND: The LLM claims affiliate revenues grew to $13.85bn in 2024 from $13.62bn in 2023, but then states they were $16.29bn in 2022—this shows a DECLINE from 2022 to 2024, contradicting the narrative of 'deepened' financial involvement and 'expansion.' (3) MISSING CORE GROUND TRUTH: The LLM fails to emphasize the key ground truth finding that in 2022, Chevron reported improved income from equity affiliates totaling $5,657 million (not mentioned in LLM answer). The ground truth specifically notes this 2022 figure as important context. (4) PARTIAL ACCURACY: The LLM correctly identifies the 36.4% ownership stake in Angola LNG Limited and correctly notes it as a strategic LNG asset, which aligns with ground truth. It also correctly references that Angola LNG contributed to equity affiliate improvements in 2022. (5) UNSUPPORTED CLAIMS: References to 'net loan exposure to affiliates' and specific year-over-year changes lack grounding in the provided ground truth and appear speculative. (6) MULTI-HOP REASONING: While the LLM attempts to synthesize 2022-2024 evolution, it does so with unverified numbers that undermine the credibility of the analysis. The ground truth provides a clearer narrative: 2022 showed earnings contribution ($5,657M from equity affiliates), and 2024 showed a defined 36.4% stake with clear strategic positioning. The LLM's answer introduces financial metrics not confirmed in ground truth, making it unreliable despite some correct elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 509,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "\nThe outstanding principal of META’s Fixed‑Rate Senior Unsecured Notes grew from **$18.5 billion at the end of 2023** to **$29.0 billion at the end of 2024** (Chunk 2).  This increase reflects active issuance: the company recorded **$8.46 billion of net proceeds from a May 2023 note issuance** (Chunk 1) and later added **$10.5 billion of new notes in August 2024** (Chunk 2), driving the total balance up by roughly $10.5 billion over the year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data is correct: (1) $18.5 billion outstanding at end of 2023 - matches ground truth exactly; (2) $29.0 billion outstanding at end of 2024 - matches ground truth exactly; (3) $8.46 billion net proceeds from May 2023 issuance - matches ground truth exactly; (4) $10.5 billion issued in August 2024 - matches ground truth exactly. The calculation logic is sound: the increase from $18.5B to $29.0B equals $10.5B, which corresponds to the August 2024 issuance amount, correctly demonstrating the year-over-year evolution. The multi-hop synthesis is properly executed, connecting the 2023 issuance activity with 2024 activity and showing how both contributed to the overall debt position. The answer correctly identifies META as the company and properly distinguishes between the May 2023 and August 2024 issuances. The only minor observation is that the LLM answer slightly emphasizes the August 2024 issuance as the primary driver of the increase (\"driving the total balance up by roughly $10.5 billion over the year\"), which is accurate but could have been slightly more explicit about the May 2023 issuance's role in establishing the $18.5B baseline. However, this is a very minor point and does not detract from the overall accuracy. The answer fully addresses the evolution question by showing both value progression and issuance activity across the two-year period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 402,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "\nIn the 2023 filing LIN characterized helium merely as a purchased supply, noting that its exposure was confined to normal market‑price fluctuations under existing supply contracts. By contrast, the 2024 filing reclassifies helium as a strategic dependency, disclosing that the company now sources helium from a single external vendor and that year‑over‑year helium costs have risen roughly 12 %, underscoring a material increase in financial exposure since 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. QUANTITATIVE ERRORS: (1) The ground truth specifies helium costs at 4.2% of raw material expenses in 2023 and 6.8% in 2024 - these are the key quantitative metrics. The LLM answer instead claims a '12% year-over-year cost increase' which is a different metric entirely and not supported by the ground truth. (2) The LLM provides no percentage-of-total-expenses figures, which are the primary quantitative disclosures in the original answer. ENTITY/CATEGORIZATION ERRORS: (1) The LLM correctly identifies the shift from 'supply' to 'dependency' categorization, which is accurate. (2) However, the LLM introduces unsupported claims about 'single external vendor' sourcing, which does not appear in the ground truth. MULTI-HOP REASONING: The LLM fails to synthesize the correct financial metrics across the two years. The ground truth clearly establishes the comparison through percentage-of-raw-material-expenses (4.2% → 6.8%), demonstrating a 2.6 percentage point increase. The LLM's claim of '12% year-over-year cost increase' is a different calculation that may or may not be accurate, but it is not what the ground truth specifies. COMPLETENESS: The LLM addresses the categorization change (supply to dependency) but misses the specific cost disclosures that are central to the question. The question explicitly asks for 'specific cost or sourcing disclosures,' and the ground truth provides precise percentage figures; the LLM provides different metrics. SEMANTIC EQUIVALENCE: While the LLM correctly identifies the conceptual shift in helium's importance, it fails to provide the actual financial exposure metrics that constitute the core answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> RAW_MATERIAL <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 472,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "\nPayPal’s European customer balances that could be designated for credit activities rose from $2.7 billion (about 27 % of European balances) as of the end of 2021 (Chunk 1) to $3.8 billion (≈ 37 % of balances) approved for 2022 and then to $3.0 billion (≈ 39 % of balances) approved for 2023 (Chunk 2). This means the approved amount fell from $3.8 billion in 2022 to $3.0 billion in 2023—a decline of roughly 21 % (Chunk 2). The shift occurs alongside the CSSF’s expanded permission to use up to 50 % of European balances for credit and PayPal’s ongoing effort to align credit‑product liquidity with external funding partnerships (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and incorrect information. CORRECT ELEMENTS: (1) The 2022 figure of $3.8 billion at ~37% is accurate; (2) The 2023 figure of $3.0 billion at ~39% is accurate; (3) The calculation of the decline from $3.8B to $3.0B as roughly 21% is mathematically correct ($0.8B/$3.8B ≈ 21%); (4) The identification of a more conservative approach is appropriate; (5) The mention of CSSF permissions and external funding partnerships provides relevant context. INCORRECT/PROBLEMATIC ELEMENTS: (1) The LLM introduces 2021 data ($2.7 billion at ~27%) which was NOT part of the original question asking specifically about 2022-2023 evolution. This is extraneous information that wasn't requested; (2) The question asks specifically about evolution \"between 2022 and 2023\" but the LLM starts from 2021, creating a three-year comparison rather than the requested two-year comparison; (3) While the core 2022-2023 comparison is correct, the inclusion of 2021 data dilutes focus on the specific time period requested. QUANTITATIVE ACCURACY: The numbers for 2022 and 2023 are all correct, and the 21% calculation is accurate. However, the introduction of 2021 data that wasn't in the original answer or requested in the question reduces quantitative focus. QUALITATIVE ACCURACY: The reasoning about the conservative approach and the synthesis of information is sound. The multi-hop reasoning correctly connects the dollar amounts, percentages, and the year-over-year change. CONTEXTUAL RELEVANCE: The answer appropriately addresses the core question about 2022-2023 evolution, though it goes beyond the scope by including 2021. The additional context about CSSF permissions and funding partnerships is relevant but not essential to answering the specific question asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 485,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "\nStarbucks’ foreign‑currency‑other instrument exposure declined from **$1,164 million (Oct 1 2023)** to **$920 million (Sep 29 2024)**, a reduction of roughly $244 million.  The fair‑value gains recorded in AOCI for this line fell from **$39.6 million in 2023 to $11.5 million in 2024**, and the amount expected to be reclassified into earnings within the next 12 months dropped from **$39.6 million to $9.5 million**, indicating a markedly smaller earnings impact from foreign‑currency‑other instruments going forward.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the main trend (decline in fair value from $1,164M to $920M) and provides accurate dates and most key figures. However, there is a critical error in one of the reclassification amounts. The LLM states the amount expected to be reclassified dropped from '$39.6 million to $9.5 million,' but the ground truth clearly indicates it should be '$55.3 million to $9.5 million.' This is a significant factual error - the LLM appears to have confused the AOCI net gain figure ($39.6M) with the reclassification amount ($55.3M). The calculation of the fair value reduction ($244M) is correct. The LLM correctly identifies the AOCI net gain figures ($39.6M in 2023, $11.5M in 2024) and the 2024 reclassification amount ($9.5M). The reasoning about reduced short-term earnings impact is sound and well-articulated. The multi-hop synthesis across fair value, AOCI gains, and reclassification amounts is mostly correct except for the one critical number error. The answer addresses all parts of the question but the quantitative accuracy is compromised by the reclassification figure mistake, which is a key metric requested in the original question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 332,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "\nBased on the 2022 and 2023 fair‑value tables (SO_10k_2022.pdf and SO_10k_2023.pdf), Alabama Power’s energy‑related derivative assets fell from **$55 million** to **$15 million**, while its liabilities rose from **$11 million** to **$110 million**; Georgia Power’s assets declined from **$75 million** to **$13 million**, and its liabilities increased from **$8 million** to **$124 million**. Thus, each utility’s portfolio moved from a net‑asset position in 2022 to a net‑liability position in 2023, showing a clear downward shift in asset values and an upward shift in liability values for both Alabama Power and Georgia Power.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All financial figures are correct - Alabama Power assets ($55M→$15M), liabilities ($11M→$110M); Georgia Power assets ($75M→$13M), liabilities ($8M→$124M). All numbers match the ground truth exactly. (2) CALCULATIONS: The directional analysis is accurate - both companies shifted from net-asset positions in 2022 to net-liability positions in 2023 (Alabama Power: $44M net asset to $95M net liability; Georgia Power: $67M net asset to $111M net liability). The LLM correctly identified the downward asset trend and upward liability trend. (3) MULTI-HOP SYNTHESIS: The answer successfully synthesizes data across two companies and two years, correctly comparing year-over-year changes and identifying the parallel directional shift in both entities' derivative positions. (4) ENTITY ACCURACY: Company names, years, and financial metrics are all correctly identified. (5) COMPLETENESS: The answer addresses all aspects of the question - the evolution of fair values from 2022 to 2023, asset positions, liability positions, and directional changes. The characterization of the shift as 'substantial' and 'clear' appropriately reflects the magnitude of the changes. Minor note: The LLM provides slightly more analytical interpretation than the ground truth (explicitly stating 'net-asset' and 'net-liability' positions), which enhances clarity without introducing errors. The sourcing reference to specific PDF documents adds credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 423,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "\nThe U.S. Retiree Health Care Plan’s asset mix was roughly 65 % fixed‑income and 35 % equity in 2022, representing about $248 million of fixed‑income securities and cash equivalents versus $137 million of equity (as shown in Chunk 1 and echoed by the 65 %/35 % figures in Chunk 2).  In 2023 the plan shifted to an 80 % fixed‑income and 20 % equity allocation (Chunk 2), increasing fixed‑income exposure by roughly 15 percentage points while reducing equity exposure by the same amount.  These disclosures are made by TXN, which holds a stake in the plan and reports the details in its SEC filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. CORRECT ELEMENTS: (1) All percentage allocations are accurate - 2022: 65% fixed income/35% equity; 2023: 80% fixed income/20% equity. (2) The dollar amounts provided ($248M fixed income, $137M equity in 2022) are correctly cited and support the percentage calculations. (3) The calculation of the shift (15 percentage point increase in fixed income, 15 percentage point decrease in equity) is mathematically correct. (4) The characterization of the shift as 'more conservative' is appropriate and accurate. (5) The multi-hop synthesis is sound - the answer correctly identifies TXN as the reporting company and references multiple chunks of source material. (6) All entities and time periods are correctly identified. MINOR CONSIDERATIONS: The answer includes additional context (company identification as TXN, reference to chunks) that goes slightly beyond the ground truth answer but adds value and transparency about sources. The wording differs from the ground truth but conveys identical semantic meaning. The answer fully addresses the question about how the asset allocation strategy evolved from 2022 to 2023. No factual errors, calculation errors, or omissions detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 347,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "\nGILD’s Trodelvy was already approved in 2022 for metastatic triple‑negative breast cancer and metastatic urothelial cancer, and in 2023 the company obtained both European Commission and FDA approvals for a new monotherapy indication in HR⁺/HER2‑ breast cancer after endocrine therapy and ≥ two prior systemic treatments, thereby adding a distinct tumor type to its label. This regulatory expansion occurred alongside GILD’s 2023 strategic moves—including a collaboration with Arcellx, an equity investment in the Arcellx‑related ACLX‑001 program, the acquisition of XinThera (and later Tmunity), and a $2 billion senior‑note issuance—demonstrating that the approval milestones were part of a broader set of corporate activities.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is substantially correct on the core facts requested. Strengths: (1) Correctly identifies the 2022 indications for TNBC and metastatic urothelial cancer; (2) Accurately describes the 2023 approvals for HR+/HER2- breast cancer with the correct treatment history requirement (endocrine therapy + ≥2 prior systemic treatments); (3) Correctly notes both EC and FDA approvals were obtained in 2023; (4) Uses appropriate medical terminology and notation (HR+/HER2-). Quantitative accuracy is high - all dates (2022, 2023) and therapeutic details are correct. Minor issues: (1) The LLM answer includes substantial contextual information about GILD's 2023 corporate activities (Arcellx collaboration, XinThera/Tmunity acquisitions, $2B senior notes) that, while factually accurate, goes beyond the scope of the question about Trodelvy's regulatory evolution. This adds length without directly addressing the core question. (2) The answer could have been more explicit about the specific prior therapy requirements for each indication to fully parallel the ground truth's detail level. The multi-hop reasoning is sound - the answer correctly synthesizes information about regulatory approvals across two years and identifies the new indication. The semantic equivalence is strong; the LLM conveys the same regulatory progression as the ground truth. The contextual relevance score is slightly lower because while the corporate activities mentioned are interesting, they dilute focus from the direct question about regulatory approval status evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 428,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "\nIn its 2023 filing Meta warned that falling user sentiment—fuelled by concerns over content quality, privacy, safety, and the ability to keep users engaged—could shrink usage, force costly policy changes and ultimately jeopardize revenue and operational stability. By 2024 the company broadened the risk narrative to include negative perceptions of its strategic acquisitions, regulatory scrutiny and policy decisions (such as Oversight‑Board rulings) that could trigger user backlash, litigation and divert management attention, while also noting the substantial integration costs and distraction associated with acquiring new businesses. Together, these disclosures show a shift from a narrow focus on platform‑user experience risks in 2023 to a wider set of perception‑driven threats in 2024 that could impair growth, increase compliance and integration expenses, and affect Meta’s overall business operations.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution between 2023 and 2024 - from user perception risks focused on privacy/safety/content quality to broader operational risks. (2) Accurately captures specific 2023 concerns (user sentiment, engagement, data practices, content policies). (3) Correctly identifies 2024 shift toward acquisition integration challenges, regulatory scrutiny, and investor sentiment. (4) No quantitative errors present (no specific numbers to verify). (5) Properly synthesizes multi-hop information across two fiscal years.\n\nWEAKNESSES: (1) The LLM's characterization of 2024 risks as 'broader operational and financial risks' is somewhat overstated compared to ground truth. The ground truth states the focus 'shifted toward broader operational and financial risks' but the LLM emphasizes 'perception-driven threats' in 2024, which partially contradicts the ground truth's assertion that 'explicit mention of user perception as a direct risk factor was notably reduced in 2024.' (2) The LLM states 2024 includes 'negative perceptions of strategic acquisitions' and 'perception-driven threats,' which suggests user perception remained prominent in 2024. However, the ground truth explicitly notes that user perception as a 'direct risk factor was notably reduced in 2024.' This is a semantic contradiction. (3) The LLM's framing of 2024 as including 'perception-driven threats' somewhat misses the ground truth's key point: that Meta de-emphasized user perception specifically and shifted to OTHER operational/financial risks instead.\n\nMULTI-HOP REASONING: The model correctly synthesizes information across 2023 and 2024 filings and identifies the comparative shift. However, the characterization of what that shift entails contains a logical inconsistency with the ground truth's emphasis on REDUCTION of user perception focus.\n\nSEMANTIC ACCURACY: While the LLM captures many correct elements, it frames the 2024 evolution as an expansion/broadening of perception-related risks rather than a strategic de-emphasis of user perception in favor of other risk categories. This represents a meaningful deviation from the ground truth's core insight about the 'notable reduction' of user perception as a direct risk factor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 604,
        "total_tokens": 2001
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "\nLockheed Martin’s variable‑interest‑rate swaps grew from a $500 million notional amount disclosed for 2021 (Chunk 1) to $1.3 billion reported for 2024 (Chunk 2), more than doubling over the period.  This expansion shows that the company is deliberately scaling its fair‑value hedging program—using variable‑rate swaps to convert an increasing share of its fixed‑rate borrowings into floating‑rate exposure—thereby strengthening its ability to manage interest‑rate risk while maintaining a diversified, counterparty‑monitored derivative portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Lockheed Martin's interest rate risk management strategy. QUANTITATIVE VERIFICATION: Both key figures are correct—$500 million for 2021 and $1.3 billion for 2024. The characterization of this as 'more than doubling' is mathematically accurate (1.3B/0.5M = 2.6x increase). ENTITY ACCURACY: Company name, metric (variable interest rate swaps/notional amount), and time period (2021-2024) are all correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and correctly interprets the strategic implications—converting fixed-rate borrowings to variable-rate exposure. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth, with slightly more detailed explanation of the hedging mechanics ('fair-value hedging program,' 'counterparty-monitored derivative portfolio'). MINOR DIFFERENCES: The LLM provides additional context about the company's strategic intent ('deliberately scaling,' 'strengthening ability to manage interest-rate risk') that goes slightly beyond the ground truth but remains consistent with it. The ground truth mentions 'likely in response to changes in the interest rate environment' while the LLM focuses on the mechanics of the strategy itself—both perspectives are valid and complementary. No factual errors detected. The answer fully addresses both parts of the question: the evolution of notional amounts and what it indicates about risk management strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Uses]- ORG",
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 426,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "\nPayPal continues to treat its Seller‑Protection Programs as “assurance‑type” warranties and records the estimated cost of potential losses — primarily transaction and credit losses — at the moment a payment is completed.  In the 2022 filing the company disclosed an allowance for transaction losses of **$66 million**, and in the 2023 filing that allowance was reduced slightly to **$64 million**, indicating that the financial provision for expected seller‑protection losses was trimmed modestly year‑over‑year while the underlying risk (loss rates of roughly 0.09‑0.15 % of TPV and exposure to regulatory or merchant‑failure events) remained unchanged.  This reduction reflects the company’s updated loss‑experience estimates and its ongoing practice of recognizing the associated costs in the period the transaction occurs, a practice that is consistent across both years and across all of the disclosed protection‑program disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensiveness. QUANTITATIVE VERIFICATION: All numbers are correct - $66 million (2022) and $64 million (2023) match the ground truth exactly, as do the loss rate percentages (0.09%-0.15% of TPV). The year-over-year comparison ($2 million reduction) is accurate. COMPLETENESS: The answer addresses all key aspects of the question: (1) evolution of approach between 2022-2023, (2) financial provisions for transaction losses, (3) specific dollar amounts, (4) loss rate context. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two years and connects the quantitative changes to qualitative shifts in approach (from more qualitative risk assessment to more structured financial disclosures). ENTITY ACCURACY: PayPal correctly identified, years correct (2022 and 2023), financial metrics properly labeled (allowance for transaction losses). REASONING QUALITY: The LLM provides superior context by explaining that PayPal treats these as 'assurance-type' warranties and records costs when transactions complete - this adds valuable detail beyond the ground truth while remaining consistent with it. The explanation of why the reduction occurred (updated loss-experience estimates) is logical and well-reasoned. SEMANTIC EQUIVALENCE: The answer conveys all information from the ground truth with enhanced clarity and additional relevant context about accounting treatment. Minor enhancement: The LLM provides slightly more operational detail about the accounting methodology than the ground truth, which strengthens rather than detracts from the answer. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Risk]-> ACCOUNTING_POLICY <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 452,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "\nStarbucks’ foreign‑currency‑other derivative position declined from $1.164 bn in fiscal 2023 to $0.920 bn in fiscal 2024—a $0.244 bn (≈24 %) reduction.  The shift reflects a $51 m drop in derivative assets (from $54.9 m to $3.6 m) and a $6.8 m increase in derivative liabilities (from $2.0 m to $8.8 m), producing a net balance‑sheet decrease of roughly $58 m.  This change is captured by the disclosure relationship SBUX → Foreign currency – other in the SEC filings.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that fundamentally contradict the ground truth: (1) DERIVATIVE ASSETS - Ground truth states assets decreased from $1,164M (2023) to $1.9M (2024), a reduction of ~$1,162M. LLM claims assets dropped from $54.9M to $3.6M, a $51M decrease. These numbers are completely incorrect and don't match the ground truth at all. (2) DERIVATIVE LIABILITIES - Ground truth shows liabilities increased from $2.0M (2023) to $4.7M (2024), a $2.7M increase. LLM claims liabilities increased from $2.0M to $8.8M, a $6.8M increase. The ending liability figure of $8.8M is wrong. (3) NET POSITION - Ground truth indicates the major change was the $1,162M reduction in assets (from $1,164M to $1.9M), with a modest $2.7M increase in liabilities. LLM's calculation of a $58M net decrease is vastly understated and based on incorrect component numbers. (4) MAGNITUDE MISCHARACTERIZATION - The LLM describes this as a '$0.244 bn reduction' and '24% decrease,' which appears to be based on fabricated intermediate numbers rather than the actual $1,162M asset reduction that occurred. (5) MULTI-HOP SYNTHESIS - While the LLM correctly identifies Starbucks and the foreign currency derivative category, it fails to accurately extract or synthesize the actual financial data from the filings. The answer demonstrates a fundamental failure in quantitative accuracy with nearly every number being incorrect. The only correct element is the identification of the company and general category.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 418,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "\nFrom 2022 to 2023 the hedge results moved sharply from a modest $59 million gain on total non‑designated derivatives (Chunk 2) and an almost‑zero cost‑hedge impact, to a $59 million gain on cost hedges and a positive (rather than the $‑11 million loss seen in 2021) revenue‑hedge result, pushing the overall derivatives position from a $59 million gain in 2022 toward breakeven in 2023; this contrasts with the $(144) million total hedge loss recorded in 2021 (Chunk 1), showing that the financial impact of the energy‑related derivatives on natural‑gas cost and revenue hedging improved markedly from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations of the ground truth data. CRITICAL ERRORS: (1) The LLM states a '$59 million gain on total non-designated derivatives' in 2022, but the ground truth shows a NEGATIVE $117 million impact on natural gas revenues and NEGATIVE $27 million on cost of natural gas in 2022. (2) The LLM claims the 2022 position was '$59 million gain' when ground truth shows net negative impacts totaling $144 million ($117M + $27M). (3) The LLM incorrectly references a '$59 million gain in 2022' when this figure actually appears in 2023 for cost hedges only. (4) The LLM confuses the 2023 data by stating '$59 million gain on cost hedges and a positive revenue-hedge result' when ground truth shows $59 million gain on cost of natural gas and $0 (neutral) on revenue. (5) The LLM references 2021 data ($144 million loss, $-11 million) which is not part of the ground truth answer and creates confusion about the 2022-2023 comparison. MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the 2022 vs 2023 comparison. Ground truth shows: 2022 (negative $117M revenue, negative $27M cost) → 2023 (positive $59M cost, $0 revenue). The LLM reversed and conflated these figures. COMPLETENESS: The LLM does attempt to address the evolution from 2022 to 2023 but with fundamentally incorrect numbers. The core narrative of 'transformation' is correct conceptually but built on wrong data points. The answer demonstrates poor data extraction and synthesis from source materials.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 423,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "\nIn the 2023 Form 10‑K the Deferred Compensation Matching Plan was presented as “amended and restated effective November 8, 2023,” while the 2024 filing repeats that the plan remains “amended and restated effective November 8, 2023” but now explicitly states that it is incorporated by reference to Exhibit 10.1 of the 2024 filing. Thus, the plan’s effective date stayed the same, but its documentation shifted from a narrative description in 2023 to a formal cross‑reference in the 2024 filing.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key factual elements: (1) the effective date of November 8, 2023 is accurate in both filings, (2) the shift from narrative description to incorporated by reference is correctly captured, and (3) the dates and plan name are accurate. However, there is a notable omission in the LLM answer compared to the ground truth. The ground truth explicitly states that in the 2023 filing, the plan was 'newly introduced,' which is an important characterization of its status. The LLM answer does not mention this 'newly introduced' designation from 2023, which represents a meaningful distinction in how the plan was presented. The ground truth emphasizes that the treatment shifted 'from being newly introduced to being formally integrated into the company's long-term compensation framework,' which provides important context about the evolution of the plan's status. The LLM answer focuses more on the mechanical shift from narrative to cross-reference but misses the conceptual shift from 'newly introduced' to 'established, ongoing plan.' The quantitative accuracy is perfect (dates and numbers are correct), and the reasoning about the documentation shift is sound, but the answer is incomplete in capturing the full scope of how the plan's treatment evolved between the two filings. This is a partial omission rather than an error, which justifies a score in the 7-8 range rather than higher.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 396,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "\nThe 2023 filing (Chunk 1) discloses LTIP Units as exchangeable for common stock and lists them among “potentially dilutive securities,” but explicitly states that **no securities—including the LTIP Units—had a material dilutive effect for the years ended December 31 2023, 2022 and 2021**, and that the company **accrues dividends when they are declared**.  \nThe 2024 filing (Chunk 2) repeats the same language for 2024, again identifying LTIP Units as potentially dilutive, reporting that **they still have no material dilutive effect for 2024, 2023 and 2022**, and confirming that **distributions are accrued when declared**.  \n\nThus, between 2023 and 2024 the disclosure and treatment of LTIP Units have remained consistent: they continue to be reported as potentially dilutive with **no material dilutive impact**, and the **accrual policy unchanged—dividends (or distributions) are accrued only when declared**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. (1) CORRECTNESS: All factual claims are correct. The answer accurately identifies that LTIP Units were described as potentially dilutive in both 2023 and 2024, with no material dilutive effect reported for the specified years (2023, 2022, 2021 in the 2023 filing; 2024, 2023, 2022 in the 2024 filing). The accrual policy is correctly stated as consistent across both years—distributions/dividends accrued when declared. (2) QUANTITATIVE ACCURACY: All dates and year references are correct. The answer properly cites the specific years covered in each filing's disclosure. No calculations are required for this question, and all numeric/temporal references are accurate. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound. The answer correctly synthesizes information from two separate filings (2023 and 2024) and properly compares them to identify the evolution (or lack thereof) in disclosure and treatment. The conclusion that treatment remained stable is well-supported by the evidence presented. The answer correctly identifies both the dilutive effect aspect and the accrual policy aspect of the question. (4) CONTEXTUAL RELEVANCE: The answer directly addresses all components of the multi-part question: disclosure evolution, dilutive effect treatment, and accrual policy. The structure clearly delineates 2023 vs. 2024 findings before synthesizing the comparison. Minor note: The LLM uses 'dividends' and 'distributions' interchangeably, which is semantically appropriate given the context and matches the ground truth's use of both terms. The answer is well-organized and provides appropriate emphasis through formatting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Grants]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 462,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "\nBetween 2023 and 2024 Meta shifted from being penalised for relying on Standard Contractual Clauses—subject to an Irish DPC final decision, a €1.2 bn fine and corrective orders to suspend EU‑U.S. data transfers (which it appealed and obtained an interim stay)—to formally adopting the newly‑adopted EU‑U.S. Data Privacy Framework after the July 2023 adequacy decision, while also adjusting its advertising practices under fresh regulatory scrutiny; in 2024 the European Commission opened formal DMA proceedings against Meta’s “subscription‑for‑no‑ads” model, issued preliminary findings of non‑compliance in July 2024 and the European Data Protection Board issued an opinion, leading Meta to introduce a “see less personalised ads” option and to modify its legal bases for behavioural advertising.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Meta's compliance evolution but contains some issues: (1) CORRECT ELEMENTS: The €1.2 billion fine is accurate, the July 2023 adequacy decision timing is correct, the November 2023 'subscription for no ads' model introduction is accurate, the July 2024 preliminary findings of non-compliance are correct, and the shift from SCC-based transfers to EU-U.S. DPF adoption is properly characterized. (2) QUANTITATIVE ACCURACY: All financial figures (€1.2 bn fine) and dates (July 2023, July 2024, November 2023) are correct. (3) ISSUES IDENTIFIED: The LLM answer introduces details not in the ground truth (mention of interim stay on appeal, EDPB opinion, 'see less personalised ads' option, modification of legal bases for behavioral advertising). While these may be factually accurate from actual filings, they represent information beyond what the ground truth specifies, which could indicate either: (a) the LLM synthesized additional accurate information from the source documents, or (b) the LLM added plausible-sounding but unverified details. The ground truth does not mention these specific implementation details. (4) MULTI-HOP REASONING: The LLM correctly synthesizes the progression from 2023 (SCC penalties, DPF implementation) to 2024 (DMA scrutiny, subscription model challenges). The logical flow is sound. (5) SEMANTIC EQUIVALENCE: The core narrative matches—Meta moved from foundational DPF compliance to navigating complex regulatory scrutiny around business models. However, the additional details about interim stays, EDPB opinions, and specific technical modifications create uncertainty about whether these are verified facts or inferences. The answer is more detailed than the ground truth but this additional detail cannot be verified against the provided ground truth, creating a minor accuracy concern despite the core facts being correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 517,
        "total_tokens": 1983
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "\nBetween 2023 and 2024 Linde moved from a general description of green‑hydrogen production—electrolysis powered by renewable electricity or steam‑methane reforming of biomethane (Chunk 1)—to a more explicit strategy that ties green hydrogen to renewable‑energy‑driven electrolysis using water as the feedstock, introduces carbon‑intensity labeling, and expands the use of recovered by‑product hydrogen for ultra‑high‑purity applications (Chunk 2). This evolution reflects a stronger emphasis on renewable energy sources and cleaner production methods in Linde’s green‑hydrogen portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy in capturing Linde's evolution in green hydrogen strategy between 2023 and 2024. STRENGTHS: (1) Correctly identifies the shift from general descriptions to more explicit renewable energy emphasis; (2) Accurately captures the 2023 approach (electrolysis with renewable energy OR steam methane reforming of biomethane); (3) Properly describes the 2024 evolution toward renewable-energy-driven electrolysis with water feedstock; (4) Correctly notes the introduction of carbon-intensity labeling as a differentiating metric; (5) No quantitative errors or date inaccuracies; (6) Multi-hop reasoning is sound, synthesizing information across both years appropriately. MINOR WEAKNESSES: (1) The LLM introduces a detail about 'recovered by-product hydrogen for ultra-high-purity applications' that is not explicitly mentioned in the ground truth answer, which focuses on the core evolution of green hydrogen production methods and renewable energy emphasis. This addition, while potentially accurate from the source documents, goes slightly beyond what the ground truth emphasizes; (2) The ground truth explicitly mentions the clear differentiation from 'low-carbon (blue) hydrogen' in 2024, which the LLM answer addresses implicitly but could have stated more explicitly; (3) The ground truth emphasizes this as a 'more refined and strategic framing' within broader clean energy solutions, which the LLM captures in spirit but with slightly different emphasis. SEMANTIC EQUIVALENCE: The core message aligns well - Linde moved toward stronger renewable energy emphasis, more explicit production method descriptions, and carbon-intensity metrics. The answer is semantically equivalent to the ground truth on the main points, with the by-product hydrogen detail being a minor addition that doesn't contradict the ground truth but extends beyond its stated scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 515,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "\nSouthern Company divested its stake in Sequent in July 2021 (Chunk 1), completing a cash sale for $159 million that generated a $121 million pre‑tax gain ($92 million after‑tax) and triggered an additional $85 million tax expense; by the 2023 reporting period these effects were the only remaining financial entries tied to Sequent, appearing in the “All Other” column of the 2023 statements (Chunk 2). Consequently, the original selling relationship evolved into a closed‑out transaction whose financial implications in 2023 were limited to the recognized gain, the after‑tax proceeds and the associated tax expense, with no ongoing operational or negative impact on Southern Company.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: (1) TIMING ERROR - LLM states the divestiture occurred in July 2021, but the ground truth clearly indicates the sale was completed in 2022. This is a fundamental factual error that undermines the entire answer's credibility. (2) INCOMPLETE ANSWER - The question specifically asks about the evolution between 2022 and 2023. The ground truth explains that in 2022 Southern Company Gas completed the sale, and by 2023 Sequent was no longer part of the portfolio. The LLM's answer focuses on the 2021 transaction and its 2023 reporting implications, missing the key 2022-2023 evolution narrative. (3) FINANCIAL NUMBERS - While the LLM correctly cites $159 million sale price, $121 million pre-tax gain, and $85 million tax expense, it introduces an unsupported figure of $92 million after-tax gain that is not mentioned in the ground truth. (4) MULTI-HOP REASONING - The LLM fails to properly synthesize the temporal evolution requested. The ground truth shows a clear progression: 2022 (sale completed, gain recognized, tax impact), then 2023 (no longer in portfolio, financial impact fully reflected). The LLM conflates the 2021 sale date with 2022-2023 reporting, creating confusion about when events occurred. (5) MISSING CONTEXT - The ground truth emphasizes the relationship transformation from 'business ownership' to 'completed divestiture,' showing the operational integration to full separation. The LLM mentions 'closed-out transaction' but doesn't clearly articulate this relationship evolution. The answer demonstrates partial knowledge of the financial mechanics but fails on the critical temporal accuracy and the specific 2022-2023 evolution narrative that the question requires.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> COMP <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 466,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "\nWalmart’s 2023 filing lists “Allswell” among its private‑brand merchandise, and the 2024 filing retains Allswell while expanding the roster with new private‑brand names such as “bettergoods,” confirming that the retailer continues to **introduce** the Allswell product and that Allswell **produces** for Walmart under the same ORG‑>PRODUCT‑>ORG relationship. This persistence of Allswell in both years shows that Walmart is using the brand as a stable component of its broader strategy to diversify and strengthen its private‑label portfolio, positioning it alongside a growing set of value‑focused proprietary brands.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies that Allswell appears in both 2023 and 2024 filings, and accurately notes that other brands like 'bettergoods' are mentioned. The core observation that Allswell persists across both years is factually correct. The answer appropriately recognizes this as indicating stability in Walmart's private brand strategy.\n\nWEAKNESSES: (1) The LLM introduces confusing and potentially inaccurate language about Allswell 'producing for Walmart' and describes an 'ORG->PRODUCT->ORG relationship' that is not clearly supported by the ground truth and appears to mischaracterize the brand relationship. Allswell is a private brand owned/controlled by Walmart, not a separate entity producing for Walmart. (2) The LLM states that 'bettergoods' and other brands are 'new' in 2024, but the ground truth indicates these were 'mature private brands' already established, suggesting they existed before 2024. This is a factual error about the timeline of brand introduction. (3) The LLM's characterization of the evolution is less precise than the ground truth - it says Allswell 'continues to introduce' which is awkward phrasing, whereas the ground truth clearly states Allswell transitioned from 'newly introduced' (2023) to 'established' (2024). (4) The LLM misses the key insight that Allswell moved from being a new introduction to being grouped with 'mature' brands, which is the critical indicator of strategic positioning.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2023 and 2024 filings but introduces inaccuracies in the process. The reasoning about persistence is sound, but the characterization of other brands as 'new' contradicts the ground truth's description of them as 'mature.'\n\nFACTUAL ACCURACY: While the basic facts about Allswell's presence in both years are correct, the mischaracterization of the brand relationship and the incorrect timeline of other brands' introduction represent material errors that undermine the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 543,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "\nFrom 2022 to 2023 TXN kept Embedded‑Processing products at the heart of its strategy—listing them alongside Analog as a “strategic focus” and directing extra attention to the industrial and automotive end‑markets that are viewed as the longest‑term growth engines (Chunk 2).  Although total revenue slipped, the data show that the decline in Analog sales was “partially offset by higher revenue from Embedded Processing,” indicating that the embedded‑processing segment’s contribution grew relative to the other segment (Chunk 2), and the 2022 description of these products as the digital “brains” of electronic equipment underscores how TXN has elevated their strategic importance over the year (Chunk 1).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the strategic positioning of Embedded Processing alongside Analog in both 2022 and 2023; (2) Accurately captures the key insight that Embedded Processing 'partially offset' the decline in Analog revenue, showing the compensatory role; (3) Properly synthesizes multi-hop information about the strategic evolution and revenue dynamics; (4) Appropriately references industrial and automotive end-markets as growth drivers; (5) The metaphor of 'digital brains' is correctly attributed and used to illustrate elevated strategic importance. QUANTITATIVE ACCURACY: The answer correctly references the $17.52 billion total revenue figure from the ground truth and accurately conveys the relationship between Analog decline and Embedded Processing growth without misquoting specific percentages. MINOR WEAKNESSES: (1) The phrase 'the embedded-processing segment's contribution grew relative to the other segment' is slightly imprecise—the ground truth indicates it 'partially offset' decline rather than necessarily growing in absolute terms, though the LLM's interpretation is reasonable given the context; (2) The answer could have been more explicit about the lack of specific revenue figures disclosed for Embedded Processing in 2022, though this omission is minor. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings, connecting strategic positioning language with revenue composition changes and end-market focus. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as the ground truth while using slightly different phrasing, which is appropriate and acceptable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Focuses_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 489,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "\nFrom 2022 to 2024 Chevron’s role in Angola LNG shifted from simply reporting a share of its output in the 2022 volume disclosures (e.g., 7.1 billion Mcf of “as‑sold” natural‑gas volumes linked to Angola LNG) to securing a formal 36.4 % equity stake in Angola LNG Limited and providing a $4.5 bn loan to fund its development (2024).  This deepening ownership and financing reflects Chevron’s intent to lock in long‑term LNG supply and to use Angola as a cornerstone of its global LNG growth strategy, positioning the company as a key strategic player in the expanding LNG market.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution from 2022 to 2024 and accurately states the 36.4% equity stake in Angola LNG Limited. However, there are significant issues with unverified claims: (1) The $4.5 billion loan figure is introduced without any corroboration in the ground truth answer and cannot be verified from the provided context. This is a major factual claim that goes beyond what the original answer supports. (2) The 7.1 billion Mcf natural gas volume figure is cited as 2022 data but is not mentioned in the ground truth, making it difficult to verify its accuracy or relevance. (3) The qualitative reasoning about 'locking in long-term LNG supply' and positioning as a 'key strategic player' represents reasonable inference but extends beyond what the ground truth explicitly states. The ground truth is more measured, describing a 'strategic shift toward securing a stable position' rather than the more assertive claims in the LLM answer. (4) Multi-hop synthesis is present but partially unsupported - the answer correctly connects 2022 production volumes to 2024 equity stake, but the loan financing claim appears to be fabricated or sourced from outside the provided knowledge graph. The answer demonstrates good structural understanding of the evolution but introduces unverified quantitative claims that significantly undermine its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 383,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "\nBetween 2021 and 2024 the CH‑53K evolved from a modest but profit‑generating line‑item into a major revenue driver for RMS: in 2021 it accounted for roughly **$540 million of net‑sales growth** and **≈$140 million of operating‑profit uplift** within Sikorsky helicopters, while by 2024 its **higher production volume helped generate about $1.1 billion of the $3 billion RMS product‑sales increase** (LMT 10‑K 2024, p.34). This upward trajectory—reflected in the KG link **LMT → CH‑53K → LMT** that shows mutual dependence—demonstrates that the CH‑53K program has become a strategic cornerstone of Lockheed Martin’s RMS division, underpinning both its sales expansion and profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of multi-hop information. QUANTITATIVE VERIFICATION: All key numbers are correct—$540 million net sales increase (2021), ~$140 million operating profit increase (2021), and $1.1 billion contribution to product sales (2024). The LLM correctly contextualizes the $1.1 billion within the broader $3 billion RMS product-sales increase, showing proper understanding of relative magnitude. ENTITY ACCURACY: Correctly identifies Lockheed Martin (LMT), RMS division, CH-53K program, and Sikorsky helicopters. Fiscal years (2021, 2024) are accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and documents, tracing the program's evolution from 2021 contribution levels to 2024 production ramp-up status. The logical progression from 'modest but profit-generating' to 'major revenue driver' and 'strategic cornerstone' accurately reflects the ground truth's characterization of transition from developing program to mature, high-volume production phase. SEMANTIC EQUIVALENCE: The LLM's description of 'production ramp-up' phase aligns with ground truth's characterization. The phrase 'key growth driver' is semantically equivalent to 'strategic cornerstone.' MINOR OBSERVATIONS: The LLM adds interpretive context (e.g., 'mutual dependence' reference to knowledge graph structure) that goes slightly beyond the ground truth but does not contradict it. The citation format (LMT 10-K 2024, p.34) adds credibility without introducing errors. All calculations and comparisons are logically sound. The answer fully addresses both parts of the multi-part question: financial contribution evolution and production status evolution, plus implications for RMS role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 482,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal expanded and refined how it embeds macro‑economic inputs in the loss‑curve calculations for its revolving consumer credit portfolio. In 2022 the company applied a single external forecast of unemployment and benchmark credit‑card charge‑off rates over a ~2‑year horizon to generate loss curves for revolving receivables (Chunk 1). By 2023 the forecast horizon was lengthened to roughly 5 years (or 7 months – 3.5 years for specific segments) and additional macro‑economic variables—such as household disposable‑income trends and retail‑e‑commerce sales (and, through Q1 2023, unemployment)—were incorporated, still using one externally‑sourced scenario and applying the resulting loss rates to the principal amount of receivables; the Q2 2023 model update did not materially affect the provision but reflects this broader, more granular use of macro‑economic factors (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of PayPal's macroeconomic factors in loss curves between 2022 and 2023, but introduces problematic quantitative details not present in the ground truth. STRENGTHS: (1) Correctly identifies the core shift from unemployment/benchmark credit card charge-off rates in 2022 to household disposable income and retail e-commerce sales in 2023; (2) Accurately notes the replacement of unemployment after Q1 2023; (3) Properly identifies that a single external scenario was used in both years; (4) Correctly captures the multi-hop synthesis across years and model updates. WEAKNESSES: (1) QUANTITATIVE ERROR - The LLM introduces specific forecast horizons ('~2-year horizon' for 2022, 'roughly 5 years or 7 months – 3.5 years for specific segments' for 2023) that are NOT mentioned in the ground truth. These appear to be fabricated details that add specificity without source support; (2) The mention of 'Q2 2023 model update did not materially affect the provision' adds detail not in the ground truth, though this is less problematic than invented numbers; (3) The phrase 'lengthened to roughly 5 years' is presented as fact but lacks grounding in the original answer. REASONING ASSESSMENT: The multi-hop synthesis is sound - the model correctly identifies the temporal evolution and the shift in macroeconomic variables. However, the addition of unsupported quantitative details (forecast horizons) represents a significant accuracy concern, as these are specific numbers that could mislead readers about PayPal's actual methodologies. The core semantic content matches the ground truth, but the fabricated quantitative specificity reduces confidence in the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 469,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "\nStarbucks’ foreign‑currency‑debt gains recorded in AOCI slipped from **$140.2 million in fiscal 2023** (Oct 1 2023) to **$135.2 million in fiscal 2024** (Sep 29 2024), a reduction of roughly **$5 million (≈3.5 %)**.  This decline—reflected in the “Net Gains/(Losses) Included in AOCI” column of the 2024 10‑K and corroborated by the swing from a $19.1 million gain to a $6.3 million loss for the debt component in the prior‑year table—indicates that the unrealized benefit from its foreign‑currency‑denominated debt fell, pointing to a modest easing of the company’s exposure to foreign‑currency fluctuations, though a material currency‑risk remains.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamental factual inaccuracies that directly contradict the ground truth. (1) QUANTITATIVE ERRORS - The LLM claims 2023 had a $140.2 million GAIN, but the ground truth explicitly states 2023 had a $6.3 million LOSS. This is a directional error of massive magnitude (loss vs. gain). The LLM correctly identifies the 2024 figure of $135.2 million gain, but mischaracterizes the 2023 baseline entirely. The LLM's calculation of a $5 million decline ($140.2M to $135.2M) is mathematically correct for those numbers, but those numbers are wrong. (2) MULTI-HOP REASONING FAILURE - The LLM failed to correctly synthesize the year-over-year comparison. The ground truth shows a swing FROM a $6.3 million loss (2023) TO a $135.2 million gain (2024), representing a positive swing of approximately $141.5 million. The LLM instead describes a modest $5 million decline, which is the opposite directional interpretation. (3) ENTITY/METRIC CONFUSION - The LLM references 'prior-year table' data showing '$19.1 million gain to $6.3 million loss' which appears to be conflating different line items or periods, creating confusion rather than clarity. (4) SEMANTIC MEANING - The ground truth indicates a 'significant shift' and 'reversal' in exposure, suggesting improved currency conditions. The LLM's characterization of a 'modest easing' and 'decline' in unrealized benefit fundamentally misrepresents the story. The correct interpretation is that Starbucks went from a loss position to a substantial gain position, indicating a major positive swing in foreign currency exposure, not a decline. The LLM answer is internally inconsistent and factually incorrect on the primary numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 467,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "\nAlabama Power’s energy‑related derivative liability grew to **$110 million** in 2023 (up from the prior‑year $(117) million loss position), and Georgia Power’s liability rose to **$124 million** (also up from the prior‑year loss).  Combined, the two utilities’ derivative liabilities increased from **$(117) million** to **$234 million**, showing a clear upward trend in the size of their combined liabilities.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamental and pervasive factual errors that make it largely incorrect:\n\n(1) CRITICAL QUANTITATIVE ERRORS:\n- LLM states Alabama Power's 2023 liability was $110 million (correct), but claims it was \"up from the prior-year $(117) million loss position\" - this is fabricated. Ground truth shows 2022 net liability was $144 million, not $(117) million.\n- LLM states Georgia Power's 2023 liability was $124 million (correct), but again references a non-existent prior-year $(117) million figure.\n- LLM claims combined liabilities increased from \"$(117) million to $234 million\" - both numbers are wrong. Ground truth shows: 2022 combined net liability was $255 million (not $(117) million), and 2023 combined net liability was $206 million (not $234 million).\n- The calculation of $110M + $124M = $234M is arithmetically correct, but this ignores the asset positions that must be netted: Alabama Power had $15M in assets and Georgia Power had $13M in assets in 2023, which should be subtracted from the liability figures.\n\n(2) INCOMPLETE ASSET ACCOUNTING:\n- Ground truth explicitly includes both assets and liabilities for 2023: Alabama Power ($15M assets, $110M liabilities = $95M net liability) and Georgia Power ($13M assets, $124M liabilities = $111M net liability).\n- LLM completely ignores the asset positions, presenting only gross liabilities without netting, which distorts the true exposure picture.\n\n(3) DIRECTIONAL TREND ERROR:\n- Ground truth clearly states the combined net liability DECREASED from $255 million to $206 million (a reduction of $49 million).\n- LLM claims liabilities INCREASED from $(117) million to $234 million, which is the opposite direction and based on fabricated numbers.\n\n(4) MISSING 2022 DETAIL:\n- Ground truth provides specific 2022 breakdown for Alabama Power ($144M net liability).\n- LLM provides no meaningful 2022 comparison and invents a $(117) million figure that doesn't appear in ground truth.\n\n(5) MULTI-HOP SYNTHESIS FAILURE:\n- The question requires synthesizing data across two companies and two years. LLM failed to correctly identify or combine any of these data points.\n- The synthesis is not just incomplete but fundamentally wrong in direction and magnitude.\n\nThe answer demonstrates a complete failure to accurately retrieve or synthesize the required financial data, with invented numbers and reversed trend direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 644,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "\nIn fiscal 2023 Walmart acquired 100 % of Alert Innovation for about $0.4 billion, a transaction explicitly noted in both the 2023 and 2024 10‑K filings; by the close of fiscal 2024 the company still held Alert Innovation as a wholly‑owned subsidiary, with no further acquisition or disposal of that entity reported in that year. The relationship then evolved to a full exit when the Alert Innovation entity was sold and de‑consolidated in fiscal 2025, completing the acquisition‑to‑disposition cycle.",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a fundamental factual error regarding the timeline of events. The ground truth states that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, completing the acquisition-to-divestiture cycle within a one-year span (fiscal 2023 to fiscal 2024). However, the LLM answer incorrectly claims that: (1) Alert Innovation was still held as a wholly-owned subsidiary at the close of fiscal 2024 with no disposal reported, and (2) the sale and deconsolidation occurred in fiscal 2025, not fiscal 2024. This represents a major temporal error that fundamentally misrepresents the evolution of Walmart's financial relationship with Alert Innovation. QUANTITATIVE ACCURACY: The LLM correctly identifies the $0.4 billion acquisition amount and the 100% ownership stake in fiscal 2023, which matches the ground truth. However, the quantitative accuracy score is reduced because the temporal placement of the divestiture is incorrect. QUALITATIVE ACCURACY: The LLM demonstrates poor multi-hop reasoning by failing to correctly synthesize the timeline across fiscal years. The answer contradicts the ground truth's explicit statement that the exit occurred in fiscal 2024, not fiscal 2025. The LLM appears to have introduced information about fiscal 2025 that is not supported by the question's scope (which asks about fiscal 2023 and fiscal 2024). CONTEXTUAL RELEVANCE: The answer addresses the general topic of Walmart's relationship with Alert Innovation but fails to answer the specific question about how the relationship evolved between fiscal 2023 and fiscal 2024. By pushing the divestiture to fiscal 2025, the LLM fails to capture the key finding that the complete acquisition-to-divestiture cycle occurred within the one-year period specified in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Acquires]- ORG",
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 490,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "\nBetween 2022 and 2023, Trodelvy progressed from an already‑approved, growth‑generating oncology product (its contribution to Gilead’s oncology franchise was noted as rising in the 2022 Business Highlights) to securing two new pivotal regulatory approvals—European Commission approval and U.S. FDA approval for monotherapy in HR⁺/HER2⁻ metastatic breast cancer (Chunk 2).  This expansion of its indication portfolio demonstrates Gilead’s strategy of broadening Trodelvy’s clinical reach in solid‑tumor oncology, using the drug to deepen its oncology pipeline and drive further growth across the company’s cancer‑focused portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of Trodelvy's regulatory evolution. Strengths: (1) Correctly identifies that Trodelvy was already an approved, marketed product in 2022 contributing to oncology franchise growth; (2) Accurately specifies the 2023 regulatory approvals (FDA and EC) for HR+/HER2- metastatic breast cancer; (3) Correctly notes the indication details including prior endocrine therapy and systemic therapy requirements; (4) Properly synthesizes the multi-hop information showing progression from 2022 to 2023; (5) Accurately interprets Gilead's strategic intent regarding oncology expansion and pipeline strengthening. Minor considerations: The LLM answer uses slightly different phrasing than ground truth (e.g., 'monotherapy in HR+/HER2- metastatic breast cancer' vs. 'treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer') but this represents semantic equivalence rather than factual error. The ground truth specifies 'unresectable locally advanced or metastatic' while the LLM says 'metastatic'—this is a minor omission of the 'locally advanced' descriptor, though both capture the essential indication. The LLM's characterization of Gilead's strategy as 'broadening Trodelvy's clinical reach in solid-tumor oncology' and 'deepening its oncology pipeline' aligns well with the ground truth's assessment of 'expanding therapeutic applications' and 'strengthening its position in the oncology market.' No numerical errors, dates are correct, entity identification (Gilead, Trodelvy, FDA, EC) is accurate, and multi-hop reasoning correctly synthesizes the 2022-2023 progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 461,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Simon Property Group’s financial tie to ABG shifted from a series of equity dilutions and gains—$36.4 M pre‑tax gain in Q2 2023 and $145.8 M gain in Q3 2023, each accompanied by deferred‑tax expenses of $9.1 M and $36.9 M, plus a $100 M cash purchase of additional ABG interests—to a deeper strategic alliance that builds on earlier capital recycling such as the 2021 50 % Jamestown acquisition ($173.4 M cash) and the 2022 sale of the Eddie Bauer licensing venture ($159 M gain), and now includes a long‑term licensing partnership with Reebok; concurrently, SPG’s capital‑expenditure outlook shows $1.3 B of total consolidated capex with about $552 M of remaining net cash funding needed for ongoing development projects, and the company has raised its targeted stabilized return on invested capital to 8‑10 % (up from 7‑10 % in 2023), underscoring both the cumulative gains from prior disposals and the evolving strategic positioning with ABG.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth:\n\n1. QUANTITATIVE ERRORS:\n- The LLM correctly identifies the $36.4M Q2 2023 gain and $145.8M Q3 2023 gain, which match the ground truth\n- However, the LLM introduces a '$100 M cash purchase of additional ABG interests' that is NOT mentioned in the ground truth\n- The LLM cites '$173.4 M cash' for a 2021 Jamestown acquisition - this is NOT in the ground truth, which only mentions a 2021 sale of ABG interest for $18.8M gain\n- The LLM cites '$159 M gain' for 2022 Eddie Bauer licensing venture sale - this is NOT in the ground truth. The ground truth mentions Eddie Bauer as a licensing venture but does NOT provide this specific gain figure\n- The LLM introduces '$1.3 B total consolidated capex' and '$552 M remaining net cash funding' - these numbers are NOT in the ground truth\n- The LLM cites ROIC targets of '8-10% (up from 7-10% in 2023)' - these metrics are NOT in the ground truth\n\n2. ENTITY/FACT ERRORS:\n- The LLM mentions a '2021 50% Jamestown acquisition' - the ground truth does not mention Jamestown at all\n- The LLM references 'Reebok' as a 2024 partnership - the ground truth mentions Reebok as a 2022 acquisition alongside strategic partnership, not a 2024 development\n- The LLM conflates the 2022 Reebok acquisition with 2024 positioning, creating temporal confusion\n\n3. MULTI-HOP REASONING:\n- The LLM fails to capture the core insight from the ground truth: the SHIFT from active 2023 capital transactions (dilution gains) to 2024 where SPG 'no longer reported active capital transactions with ABG'\n- Instead, the LLM describes a 'deeper strategic alliance' in 2024, which contradicts the ground truth's finding of reduced active engagement\n- The LLM incorrectly frames 2024 as building on capital recycling when the ground truth indicates 2024 only references historical transactions\n\n4. SEMANTIC ISSUES:\n- The LLM's overall narrative suggests continued active engagement and evolution, when the ground truth indicates a transition to historical references and reduced active involvement\n- The introduction of unsubstantiated financial metrics (capex, ROIC targets) dilutes the answer's credibility\n\n5. WHAT WAS CORRECT:\n- The $36.4M Q2 2023 gain is correct\n- The $145.8M Q3 2023 gain is correct\n- The general concept that 2023 involved dilution gains is correct\n- The mention of licensing ventures (Forever 21, Brooks Brothers, Eddie Bauer) is correct\n- The 2021 and 2022 transactions are mentioned (though with incorrect figures)\n\nThe answer demonstrates partial understanding of the 2023 transactions but fundamentally misrepresents the 2024 relationship and introduces numerous unsupported financial figures that appear to be fabricated or confused with other company data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1510,
        "completion_tokens": 748,
        "total_tokens": 2259
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "\nChevron first disclosed its stake in **Chevron Phillips Chemical Company LLC** in the 2022 10‑K (Note 8), listing the entity under “Summarized Financial Data – Chevron Phillips Chemical Company LLC” as part of its downstream segment and reporting it using the equity‑method. In the 2024 10‑K (Chunk 2) the carrying value of that investment rose to **$8.571 billion** (up from $7.765 billion in 2023), and equity‑method earnings increased to **$903 million** for 2024 (versus $608 million in 2023 and $867 million in 2022), indicating a clear growth in both the balance‑sheet investment value and the earnings contribution from the joint venture over the 2022‑2024 period. This evolution reflects Chevron’s ongoing disclosure of the relationship (ORG → COMP via Discloses) and its continued investment in the company (ORG → COMP via Invests_In).",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth explicitly states that in 2022, Chevron Phillips Chemical was a 'consolidated subsidiary' (full consolidation), and by 2024 it became an 'equity method investee' - representing a SHIFT from consolidation to equity method. However, the LLM answer claims the entity was reported using 'equity-method' in the 2022 10-K, which is INCORRECT. This is a major mischaracterization of the evolution described in the question. The LLM failed to capture the key structural change: the transition FROM consolidated subsidiary TO equity method investee. QUANTITATIVE ACCURACY: The dollar amounts are correct ($8.571 billion for 2024, $7.765 billion for 2023), and the equity-method earnings figures ($903M, $608M, $867M) appear reasonable, though these specific earnings numbers are not verified in the ground truth. The format variations ($8.571 billion vs $8,571 million) are acceptable. QUALITATIVE ACCURACY: The LLM fundamentally misunderstood the nature of the relationship evolution. The ground truth emphasizes a structural change in accounting treatment (consolidation → equity method), which is the core insight of the question. The LLM instead presents a narrative of consistent equity-method reporting with growing investment value, missing the critical transition. This represents a failure in multi-hop reasoning and synthesis. COMPLETENESS: While the LLM addresses financial reporting and investment value, it fails to address the most important aspect - the change in accounting methodology and what that implies about Chevron's ownership/control relationship with the entity. REASONING: The multi-hop synthesis is weak because the LLM did not correctly identify or explain the key relationship evolution between 2022 and 2024. The answer reads as if the entity was always an equity-method investment, rather than transitioning from consolidated to equity-method.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 538,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "\nBy the end of 2023 Meta had **substantially completed** its facilities‑consolidation initiatives, but by the end of 2024 the company reported that the **entire 2022 restructuring—including the facilities‑consolidation component—was fully completed**. The 2024 filing quantifies the remaining financial impact, disclosing pre‑tax restructuring charges (and subsequent adjustments) for the 2022 plan across 2024, 2023 and 2022, which reflects the final financial exposure of the consolidation strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Meta's Facilities Consolidation Strategy evolution. STRENGTHS: (1) Correctly identifies the status progression from 'substantially completed' at end of 2023 to 'fully completed' by end of 2024, matching the ground truth exactly. (2) Accurately captures the scope of completion—that the entire 2022 restructuring (including facilities consolidation) was completed by 2024. (3) Properly synthesizes the multi-hop information: status change + financial impact disclosure across three years (2022-2024). (4) Correctly notes that 2024 provided a retrospective financial summary not explicitly detailed in 2023. (5) No numeric errors or date inaccuracies. (6) Appropriate use of formatting (bold text for key status terms) enhances clarity. MINOR CONSIDERATIONS: The LLM answer phrases the financial disclosure as 'quantifies the remaining financial impact' and mentions 'subsequent adjustments,' which is slightly more interpretive than the ground truth's more neutral 'financial summary.' However, this interpretation is reasonable and not factually incorrect—it reflects a valid understanding that the 2024 disclosure provided final quantification. The phrase 'final financial exposure' is semantically equivalent to the ground truth's concept of retrospective quantification. The answer demonstrates sound multi-hop reasoning by connecting status progression to financial disclosure timing and scope. All entities (Meta, 2022 Restructuring, facilities consolidation, years 2022-2024) are correctly identified and synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 446,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "\nFrom 2022 to 2024 Lockheed Martin’s hypersonics effort shifted from a “key growth area” flagged in its 2022 risk disclosures—where progress was tied to budget continuity and funding uncertainty (Chunk 1)—to a concrete program element within its Advanced Development Programs (Skunk Works) that is actively designing, developing and building hypersonic strike weapons for the U.S. Air Force and Army (Chunk 2).  This evolution reflects a strategic move toward mature program execution while the company remains dependent on congressional appropriations, as illustrated by the bidirectional KG link LMT ↔ Hypersonics Programs (LMT is impacted by and produces the hypersonics product).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022-2024 timeframe and the evolution from 'key growth area' to active production; (2) Accurately captures the shift from funding-dependent development phase to concrete program execution; (3) Properly identifies the programs as involving U.S. Air Force and Army; (4) Correctly notes the transition from uncertain future funding to active production of hypersonic strike weapons; (5) Appropriately references Advanced Development Programs (Skunk Works) as the organizational context; (6) Maintains awareness of ongoing congressional appropriations dependency. MINOR CONSIDERATIONS: (1) The LLM answer includes additional contextual detail about the bidirectional KG link (LMT ↔ Hypersonics Programs) which, while accurate and relevant, goes slightly beyond the ground truth's scope but adds valuable context rather than detracting; (2) The reference to 'risk disclosures' in 2022 is a reasonable inference about why hypersonics was flagged as dependent on authorization and funding, though the ground truth doesn't explicitly use this terminology. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension is not applicable but receives full marks as there are no errors. MULTI-HOP REASONING: The answer successfully synthesizes information across the 2022-2024 period and correctly identifies the causal relationship between funding availability and program maturity. The semantic equivalence between 'key growth area dependent on funding' (2022) and 'active production program' (2024) is properly captured. Overall, this is a high-quality response that accurately conveys the evolution of Lockheed Martin's hypersonics involvement with appropriate nuance and supporting detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 506,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "\nSouthern Company previously reported unrealized gains and losses on **energy‑related derivatives that were designated as regulatory‑hedging instruments** and **deferred** those amounts (as shown in the 2021 filing, Chunk 1).  \nIn its 2023 Form 10‑K (Chunk 2) the company discloses the **pre‑tax effects of energy‑related derivatives that are *not* designated as hedging instruments** for the years ended 2023, 2022 and 2021, presenting those effects directly in the statements of income rather than in other‑comprehensive income.  \nThus, from 2022 to 2023 Southern Company shifted the accounting treatment and disclosure of such derivatives—from deferring gains/losses under a regulatory‑hedging framework to recognizing the pre‑tax impact in earnings—reflecting a change in both designation and financial‑statement presentation, consistent with the ORG ↔ FIN_INST disclosure relationship (SO ↔ Energy‑Related Derivatives).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Southern Company's derivative disclosure evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from regulatory hedging instruments (designated, deferred) in 2022 to non-designated hedging instruments in 2023; (2) Accurately captures the change in financial statement presentation (from other comprehensive income to statements of income); (3) Properly synthesizes multi-hop information across 2021, 2022, and 2023 filings; (4) Correctly identifies the three-year comparative disclosure (2023, 2022, 2021); (5) No quantitative errors in dates or time periods. MINOR WEAKNESSES: (1) The LLM answer adds interpretive language about 'shifting accounting treatment' and 'recognizing pre-tax impact in earnings' that goes slightly beyond the ground truth's more neutral description of 'expanded disclosure' and 'shift from focusing only on regulatory hedging instruments to providing a broader view'; (2) The phrase 'from deferring gains/losses under a regulatory-hedging framework to recognizing the pre-tax impact in earnings' could be interpreted as suggesting a change in actual accounting treatment rather than disclosure expansion, though the ground truth indicates this is primarily a disclosure evolution; (3) The reference to 'ORG ↔ FIN_INST disclosure relationship' adds metadata not present in ground truth. SEMANTIC EQUIVALENCE: The core factual content aligns well with ground truth - both identify the shift from designated regulatory hedging instruments to non-designated derivatives disclosure, and both note the expanded scope of disclosure. The LLM's characterization of this as a 'shift in accounting treatment and disclosure' is reasonable though slightly more interpretive than the ground truth's 'expanded disclosure.' Overall, the answer correctly addresses the multi-hop question about derivative treatment evolution across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 519,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "\nGilead’s 2022 Form 10‑K (Chunk 1) simply lists Truvada as one of its marketed products within the portfolio but does not provide any explicit patent‑expiration details for it. In contrast, the 2023 Form 10‑K (Chunk 2) adds a dedicated table that discloses the actual/estimated U.S. and EU patent‑expiration dates—including extensions, supplementary protection certificates and pediatric exclusivity—for Truvada’s core composition‑of‑matter patents, marking a clear shift toward detailed patent‑term reporting. This evolution reflects Gilead’s move from an implicit intellectual‑property stance in 2022 to a proactive, transparent disclosure of Truvada’s patent expirations in 2023, consistent with the KG relationship where Truvada (produced by GILD) discloses its patent‑expiration information.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Gilead's IP strategy evolution regarding Truvada between 2022 and 2023. STRENGTHS: (1) Correctly identifies the key shift from implicit/minimal disclosure in 2022 to explicit, structured patent-expiration disclosures in 2023; (2) Accurately references the October 2020 loss of exclusivity (though indirectly through context); (3) Properly identifies the addition of a dedicated table in 2023 with U.S. and EU patent-expiration dates; (4) Correctly notes the inclusion of extensions, supplementary protection certificates, and pediatric exclusivity details; (5) Accurately characterizes the evolution as moving from implicit to proactive/transparent disclosure; (6) Correctly identifies Truvada as a Gilead product. MINOR GAPS: (1) The LLM answer does not explicitly mention the October 2020 loss of exclusivity date that was highlighted in the 2022 filing as a 'transitory headwind,' which was a key element of the ground truth answer. The ground truth emphasizes that 2022 acknowledged a PAST loss of exclusivity, while 2023 shifted to FUTURE patent timelines. The LLM answer focuses on the structural change in disclosure format but doesn't fully capture this temporal/strategic shift from past-focused to future-focused IP communication; (2) The LLM doesn't explicitly state that the 2022 disclosure characterized the loss as a 'transitory headwind,' which provides important context about management's framing. QUANTITATIVE ACCURACY: All dates mentioned (October 2020, 2022, 2023) are correct. No calculations required. MULTI-HOP REASONING: The answer correctly synthesizes information across two years of filings and identifies the relationship between Gilead and Truvada. The reasoning about the strategic shift is sound. SEMANTIC EQUIVALENCE: The core message aligns with ground truth—both describe a shift from minimal/past-focused IP disclosure to detailed/future-focused disclosure. The LLM's emphasis on 'implicit to proactive' is semantically equivalent to the ground truth's 'acknowledging past loss to proactively disclosing future timelines.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 566,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "\nBetween 2022 and 2024 SPG’s use of the Supplemental Facility moved from a single, $1.05 bn draw in December 2021 that was completely retired on January 12 2022 (the repayment being funded by the $1.2 bn senior‑note issuance noted in the 2022 filing), to a second round of Euro‑denominated borrowing in 2023 – €750 m of borrowings under the facility that were swapped to a fixed 3.81 % rate and then fully repaid on November 17 2023 using proceeds from a €750 m bond issuance (the same repayment pathway described in the 2024 filing).  By the end of 2024 the Supplemental Facility showed **zero outstanding balance**, indicating that all borrowings had been extinguished and no further draws remained.  This evolution is captured by the KG relationship SPG → [Decreases]→ Supplemental Facility ← [Discloses]→ SPG, reflecting the successive borrowing and subsequent repayments across the two periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several significant factual errors that undermine its credibility:\n\n1. CRITICAL DATE ERROR: The LLM states the initial $1.05 billion draw occurred in 'December 2021' and was 'completely retired on January 12 2022.' The ground truth clearly states this borrowing occurred in 'January 2022' and was 'repaid shortly after issuance.' This is a fundamental chronological error.\n\n2. INCORRECT USAGE CONTEXT: The ground truth specifies the $1.05 billion in January 2022 was used to 'fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion.' The LLM omits this critical detail entirely, instead claiming the repayment was 'funded by the $1.2 bn senior-note issuance.' While a senior note issuance may have occurred, the ground truth does not attribute the repayment to this source.\n\n3. EURO BORROWING DETAILS: The LLM correctly identifies the €750 million November 2023 borrowing and November 17, 2023 repayment date, matching the ground truth. However, the LLM adds details about a 'fixed 3.81% rate' and 'swap' that are not mentioned in the ground truth, and claims repayment was funded by a '€750 m bond issuance' - the ground truth does not specify the repayment funding source.\n\n4. INCOMPLETE 2024 INFORMATION: The ground truth mentions that 'in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy.' The LLM completely omits this 2024 activity.\n\n5. ZERO BALANCE CLAIM: The LLM states 'By the end of 2024 the Supplemental Facility showed zero outstanding balance.' While this may be true, the ground truth does not explicitly state this, and the LLM appears to be inferring rather than reporting from the source.\n\n6. GRAPH NOTATION: The LLM's reference to 'KG relationship SPG → [Decreases]→ Supplemental Facility ← [Discloses]→ SPG' is confusing and not clearly explained in relation to the actual borrowing/repayment activities.\n\nThe answer demonstrates partial understanding of the evolution but contains material factual errors in dates, usage context, and omits key 2024 refinancing information. The quantitative accuracy is particularly weak due to the date discrepancy and missing contextual details about the purpose of borrowings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 610,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "\nFrom 2022 to 2024 MetLife moved from highlighting ample liquidity—$223 billion of liquid assets and a $12.4 billion short‑term liquidity position in the 2022 filing—to explicitly treating cash‑buffer needs as a binding constraint on capital allocation; the 2024 filing states that legal, regulatory and cash‑buffer requirements may limit dividend payments and share‑repurchases and could force the company to hold a larger buffer, thereby reducing funds available for other uses. This evolution reflects the cash‑buffer risk factor that **negatively impacts** MetLife (ORG → Cash Buffer Needs ← Negatively_Impacts ORG), shaping its capital‑management decisions over the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All financial figures are precisely correct—$223.0 billion in total liquid assets and $12.4 billion short-term liquidity position for 2022 are accurately cited. No calculation errors detected. ENTITY ACCURACY: MetLife correctly identified; 2022 and 2024 time periods properly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across two years, correctly identifying the evolution from emphasis on 'ample liquidity' in 2022 to treating cash-buffer needs as a 'binding constraint' in 2024. The logical connection between maintaining larger buffers and reduced capital availability for other uses is sound. COMPLETENESS: The answer addresses all aspects of the question—liquidity levels (specific dollar amounts), their evolution over time, and impact on capital allocation decisions (dividends, share repurchases, acquisitions, innovation). SEMANTIC EQUIVALENCE: The LLM's characterization of the shift from 'ample liquidity' to 'binding constraint' semantically matches the ground truth's description of a 'shift to a more cautious tone' and recognition that 'implications of holding larger cash buffers became more pronounced.' The additional detail about regulatory and legal requirements constraining capital allocation adds valuable context without contradicting the ground truth. MINOR CONSIDERATIONS: The LLM includes a knowledge graph notation (ORG → Cash Buffer Needs ← Negatively_Impacts ORG) which, while not explicitly in the ground truth, represents a reasonable structural interpretation of the relationship described. This adds analytical depth rather than introducing error. The answer is comprehensive, factually precise, and demonstrates clear understanding of the multi-year evolution in MetLife's capital management strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Faces]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 512,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "\nStarbucks’ “Foreign currency – other” derivative moved from an almost‑pure liability position in fiscal 2022—where the designated instrument was recorded only as a $0.3 million accrued‑liability and the non‑designated foreign‑currency position as a $5.8 million accrued‑liability (see Chunk 1)—to a mixed classification in fiscal 2023, with the same line item now appearing both as derivative assets (e.g., $1.9 million in prepaid expenses and other current assets and $1.7 million in other long‑term assets) and as liabilities (e.g., $4.7 million in accrued liabilities and $4.1 million in other long‑term liabilities) (see Chunk 2). This shift reflects a re‑classification of the exposure from solely a liability in 2022 to a portfolio that includes both assets and liabilities in 2023, illustrating how the “Foreign currency – other” financial instrument’s balance‑sheet presentation evolved for SBUX over the two periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM introduces numbers NOT in the ground truth: $5.8M accrued liability for 'non-designated foreign-currency position' in 2022, $1.7M in other long-term assets in 2023, and $4.1M in other long-term liabilities in 2023. The ground truth only mentions: 2022: $0.3M liability (accrued liabilities), no asset; 2023: $1.9M asset (prepaid expenses), $4.7M liability (accrued liabilities). The LLM appears to have conflated or added data not supported by the ground truth. (2) INCOMPLETE ACCURACY - While the LLM correctly identifies the shift from liability-only to mixed asset/liability classification, it introduces extraneous figures that contradict the ground truth's specific numbers. (3) MULTI-HOP REASONING - The core logic about the evolution from 2022 to 2023 is sound (liability-only to mixed), but the execution is compromised by incorrect supporting numbers. (4) ENTITY ACCURACY - Correctly identifies Starbucks/SBUX and the correct fiscal years (2022-2023). (5) CRITICAL FLAW - The LLM cites 'Chunk 1' and 'Chunk 2' references that suggest source material, but the numbers provided do not align with the ground truth. The $5.8M, $1.7M, and $4.1M figures are either fabricated or from incorrect sources. The ground truth is explicit about the specific values, and the LLM's answer contradicts these with additional unverified numbers. This is a significant factual error that undermines the credibility of the response despite the correct directional narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 419,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "\nFrom 2023 to 2024 the link moved from a pure bottling partnership to a deeper strategic investment: in 2023 Coca‑Cola FEMSA was one of the company’s five largest independent bottlers, together accounting for **42 % of worldwide unit‑case volume** and operating under long‑standing “bottler’s agreements” as an independent contractor [Chunk 1]. By 2024 the company holds a **28 % equity stake** in FEMSA and accounts for that interest through the equity‑method, reporting a proportionate share of FEMSA’s earnings and a $7.8 bn valuation difference in its consolidated statements [Chunk 2]. This evolution reflects a shift from merely contracting with an independent bottler to a **strategic equity partnership** that integrates FEMSA into Coca‑Cola’s financial results and ownership structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the evolution of Coca-Cola's relationship with Coca-Cola FEMSA from 2023 to 2024. STRENGTHS: (1) All key quantitative facts are correct: 42% of worldwide unit case volume in 2023, 28% equity stake in 2024, and the $7.8 billion valuation are all accurate. (2) The multi-hop reasoning is sound - the answer correctly synthesizes information across two time periods and identifies the fundamental shift from independent bottler to equity method investee. (3) Entity identification is precise: correctly names Coca-Cola FEMSA, The Coca-Cola Company, and identifies the countries of operation (Mexico, Brazil, Argentina). (4) The characterization of the relationship evolution is semantically equivalent to the ground truth - both describe a transition from traditional bottler-concentrate supplier model to deeper strategic equity partnership. (5) The answer appropriately contextualizes the shift within the broader framework of financial reporting (equity method accounting) and ownership structure. MINOR CONSIDERATIONS: The LLM answer includes additional detail about the $7.8 billion valuation and equity method accounting treatment, which adds valuable context beyond the ground truth but does not contradict it. The reference to 'bottler's agreements' and 'independent contractor' status in 2023 provides helpful context about the nature of the prior relationship. The answer is well-structured and clearly explains the progression from 2023 to 2024. No calculation errors detected. All numbers are presented in formats consistent with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 448,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "\nFrom 2022 to 2024 Intel moved FPGAs from a discrete product into the core of its adjacent‑product suite—embedding them in modems, Ethernet, silicon photonics, Mobileye, NSG and PSG and bundling them with platform solutions across CCG, DCG and IOTG (as defined in the 2022 10‑K). The 2024 Restructuring Plan refocuses capital and OpEx to produce FPGAs within Intel’s broader foundry and packaging ecosystem (e.g., EMIB, Foveros) and to leverage CHIPS‑Act incentives, shifting production from a dedicated fab to an integrated, cost‑saving model. This transition is underscored by the bidirectional KG relationship INTC ↔ FPGA, showing that the FPGA’s strategic role is tightly coupled to Intel’s overall production focus and adjacent‑product strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution from 2022 to 2024, acknowledging the shift in FPGA positioning. (2) Correctly names the business groups (CCG, DCG, IOTG) from the 2022 10-K. (3) Accurately references the 2024 Restructuring Plan and CHIPS Act incentives. (4) Mentions relevant adjacent products (modems, Ethernet, silicon photonics, Mobileye, NSG, PSG). (5) Correctly identifies the shift from 'adjacent products' to more central positioning.\n\nWEAKNESSES: (1) The ground truth states FPGAs moved from 'adjacent products' role to 'explicitly listed under direct product definitions,' but the LLM answer conflates this by saying they moved 'from a discrete product into the core of its adjacent-product suite'—this is somewhat contradictory and unclear. The ground truth indicates a shift AWAY from adjacent products categorization, not deeper INTO it. (2) The LLM introduces specific technical details (EMIB, Foveros, foundry/packaging ecosystem) that, while potentially accurate, are not explicitly confirmed in the ground truth and represent speculation beyond what was provided. (3) The reference to 'bidirectional KG relationship INTC ↔ FPGA' is meta-commentary about the knowledge graph structure rather than substantive analysis of the strategic evolution. (4) The answer is somewhat verbose and includes technical jargon that obscures rather than clarifies the core strategic shift.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2024 filings and connect it to the restructuring plan, which is appropriate. However, the synthesis is muddled—it's unclear whether FPGAs became MORE central or remained in adjacent products but with different production methods. The ground truth is clearer: they moved from 'supporting role' to 'core product offering.'\n\nFACTUAL ACCURACY: No specific numbers, dates, or calculations are provided in either answer, so quantitative verification is limited. The entities and years (2022, 2024, Intel, CCG, DCG, IOTG) are correctly identified. The 2024 Restructuring Plan reference is appropriate.\n\nSEMANTIC ISSUES: The phrase 'embedded them in modems, Ethernet, silicon photonics, Mobileye, NSG and PSG' suggests FPGAs are components within these products, but the ground truth doesn't explicitly state this level of detail. This may be accurate but goes beyond the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 637,
        "total_tokens": 1956
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "\nIn 2023 ConocoPhillips expanded its Lower 48 operations through the Concho acquisition, which drove purchases in that region (Chunk 1). As a result, depreciation, depletion and amortization expenses allocated to the Lower 48 rose to **$5,729 million in 2023**, up from **$4,854 million in 2022** (Chunk 2), underscoring the impact of the newly acquired assets on the company’s DDA spending.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key financial figures and demonstrates sound multi-hop reasoning. STRENGTHS: (1) All numeric values are accurate - $5,729 million for 2023 and $4,854 million for 2022 are correct; (2) The year-over-year comparison is properly presented; (3) The connection between the Concho acquisition and increased DDA expenses is appropriately made; (4) The metric terminology (depreciation, depletion, and amortization) is correct; (5) The answer correctly synthesizes information across multiple data points. WEAKNESSES: (1) The LLM states the Concho acquisition occurred in 2023 ('In 2023 ConocoPhillips expanded...through the Concho acquisition'), but the ground truth indicates the acquisition was completed in 2022 with purchases driven by it in 2022 - this is a temporal inaccuracy; (2) The answer omits the calculated increase of $875 million ($5,729M - $4,854M), which was explicitly mentioned in the ground truth as 'showing a significant rise of $875 million'; (3) The answer lacks the nuance that the acquisition was a 2022 event that continued to impact 2023 operations. The core financial data and the relationship between acquisition and DDA expenses are correct, but the timing of the acquisition event is misrepresented, and the specific dollar increase calculation is missing. These are moderate issues that affect the completeness and precision of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 390,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "\nEmerson paid roughly $6 billion (≈ $87.69 per fully‑diluted share) to acquire Heritage AspenTech, leaving about $168 million of cash on AspenTech’s balance sheet and giving it a 55 % fully‑diluted stake while the company continued under its former name; the transaction added intangible assets that are now being amortized.  The integration lifted Emerson’s gross margin to 50.8 % in 2024 (up 1.8 pp from 2023) thanks to higher pricing and the Test & Measurement acquisition, but a $231 million inventory‑step‑up amortization shaved about 1.3 pp off margin, while SG&A rose to 29.4 % of sales and other deductions reflected $560 million of intangible amortization and $48 million of divestiture losses from the 2024 sale of a 40 % Copeland equity interest and its $1.9 billion note receivable (which generated a $539 million gain).  Parallel to these results, Emerson recognized a $438 distribution gain from a Vertiv subordinated interest in 2022 and realized the $1.5 billion gain on the Copeland equity sale, illustrating how its broader investment portfolio complemented the evolution of its ownership and financial performance in AspenTech between 2022 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies key facts: (1) ~$6 billion acquisition price at $87.69/share, (2) $168 million retained cash, (3) 55% fully-diluted ownership, (4) AspenTech continued under former name/ticker AZPN, (5) 50.8% gross margin in 2024, (6) 1.8 percentage point margin improvement, (7) $231 million inventory step-up amortization reducing margins by 1.3 pp. The multi-hop synthesis across 2022-2024 is generally sound.\n\nWEAKNESSES AND ERRORS: (1) The LLM introduces significant extraneous information not in the ground truth answer (Vertiv subordinated interest $438M gain in 2022, Copeland equity sale details, $1.9B note receivable, $539M gain, $560M intangible amortization, $48M divestiture losses, SG&A at 29.4%) - while some of this may be factually correct from filings, it dilutes focus from the core question about AspenTech's evolution. (2) The LLM states the margin improvement was \"thanks to higher pricing and the Test & Measurement acquisition\" - the ground truth does not attribute the improvement to these specific factors; this represents unsupported causal reasoning. (3) The answer conflates multiple acquisition impacts (AspenTech, Test & Measurement, Copeland) without clearly delineating which impacts relate specifically to AspenTech's evolution. (4) The 2023 margin impact of 0.6 percentage points mentioned in ground truth is omitted, breaking the chronological evolution narrative. (5) The statement about \"intangible assets that are now being amortized\" is vague and doesn't specify the $231M inventory step-up amortization timing/impact clearly in relation to 2023 vs 2024.\n\nMULTI-HOP REASONING: The answer attempts to synthesize across 2022-2024 but introduces parallel information about Vertiv and Copeland that, while potentially relevant to Emerson's broader portfolio, are not directly part of the AspenTech relationship evolution requested. This creates confusion about what specifically drove AspenTech's financial impact.\n\nCALCULATION VERIFICATION: All numeric values stated are accurate where verifiable against ground truth (6B, 87.69, 168M, 55%, 50.8%, 1.8pp, 1.3pp, 231M). No calculation errors detected in stated figures.\n\nCONTEXTUAL RELEVANCE: While the answer addresses the core question about ownership structure and financial impact, it significantly expands scope beyond what was asked, introducing unrelated acquisition details that reduce focus on the specific AspenTech evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Involved_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1484,
        "completion_tokens": 656,
        "total_tokens": 2140
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "\nUnder the 2015 Director Stock Plan, any award that terminates, is settled in cash, or requires the holder to tender shares for exercise is cancelled and the cancelled shares are re‑authorized for future issuance using the same 1‑for‑1 reduction rule described in the accounting policy (Chunk 1).  The 2024 filing quantifies this flow: cumulatively since the plan’s inception 37,608,213 shares have been recovered and added back to the pool, and after accounting for new awards and reinvested dividends the plan shows 30,660,961 shares remaining available for future issuance (Chunk 2), meaning that the pool of shares grew through recoveries up to 2023 but showed no additional 2024 recoveries, so availability stabilized between 2022 and 2024.  Because each share issued reduces the remaining authorization by one and recovered shares are re‑added using the identical ratio, the plan’s issuance mechanics have remained consistent from 2022 through 2024, preserving the same treatment of net shares delivered after any tendering (Chunk 1) while the numerical pool reflected in the 2024 table demonstrates the net effect of those recoveries on current availability.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies all key numeric values from the 2024 filing: 37,608,213 shares recovered cumulatively, 42,343,146 shares covered by new awards and reinvested dividends, and 30,660,961 shares available for future issuance. (2) The mechanics description of the 1-for-1 reduction rule and share recovery process is accurate. (3) The answer correctly notes that recovered shares are re-authorized for future issuance. WEAKNESSES: (1) The LLM fails to address the 2022 baseline data point mentioned in the ground truth ('In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one'). The question explicitly asks about evolution 'between 2022 and 2024,' requiring comparison of both years. (2) The LLM states 'the plan shows 30,660,961 shares remaining available for future issuance' and then claims 'availability stabilized between 2022 and 2024' with 'no additional 2024 recoveries,' but this conclusion is not supported by the ground truth data provided. The ground truth presents 2024 data but does not provide 2022 comparative data to support a 'stabilization' claim. (3) The LLM's assertion about 'no additional 2024 recoveries' appears speculative and is not explicitly stated in either the ground truth or the LLM's source chunks. (4) The answer misses the ground truth's key insight about 'a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.' This represents incomplete synthesis of the evolution narrative. (5) The LLM does not mention the 35,395,894 shares authorized for issuance as of January 1, 2015, which provides important context for understanding the plan's evolution. CALCULATION VERIFICATION: All numeric values cited are accurate (37,608,213; 42,343,146; 30,660,961), but the LLM's interpretation of what these numbers mean for the 2022-2024 evolution is incomplete and partially unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1482,
        "completion_tokens": 545,
        "total_tokens": 2028
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023, Starbucks’ partnership with the Global Coffee Alliance shifted from a tactical revenue‑boosting channel to a core strategic pillar of its Channel Development business.  In FY 2022 the Alliance generated a $250 million (≈16 %) increase in segment revenue through higher product sales to and royalty income from Nestlé, and the FY 2023 filing re‑affirms that those same sales and royalties continue to drive segment growth while also helping to offset margin pressure—demonstrating a sustained, deeper‑level emphasis on the Alliance as a key contributor to Starbucks’ top‑line.  The mutual positive‑impact relationship (SBUX ↔ Global Coffee Alliance) underscores how the Alliance’s role has evolved from a supplemental source of income in FY 2022 to a central element of Starbucks’ long‑term growth strategy by FY 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the core evolution of Starbucks' Global Coffee Alliance relationship from FY2022 to FY2023. STRENGTHS: (1) Correctly identifies the $250 million revenue increase in FY2022 from the alliance; (2) Accurately captures the shift from tactical revenue driver to strategic pillar; (3) Properly synthesizes the multi-hop information about Nestlé licensing and product distribution; (4) Correctly notes the ongoing importance and deeper integration in FY2023; (5) Number format and quantitative data are accurate. WEAKNESSES: (1) The LLM introduces a calculated percentage (≈16%) that is not present in the ground truth and appears to be an inference not explicitly stated in the original filings - while mathematically reasonable, this adds information not confirmed in the source material; (2) The phrase 'helping to offset margin pressure' is introduced without explicit support from the ground truth, which focuses on strategic positioning rather than margin mitigation; (3) The notation 'SBUX ↔ Global Coffee Alliance' is stylistic embellishment not found in source material; (4) Minor: The ground truth emphasizes 'licensing relationship with Nestlé' more explicitly as the mechanism, while LLM uses broader language about 'partnership' and 'sales and royalties.' MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and identifies the evolution in strategic emphasis. The connection between Channel Development segment growth and the alliance's role is properly established. SEMANTIC EQUIVALENCE: The core message aligns well - the alliance evolved from a revenue contributor to a strategic enabler of global reach. The LLM's characterization of the shift is semantically equivalent to the ground truth's distinction between 'revenue driver' and 'strategic enabler.' The answer is substantively correct but includes some inferred details not explicitly confirmed in the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 532,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "\nNEE’s equity‑method investment in the Mountain Valley Pipeline grew from a peripheral entry in 2022 to a formally listed principal investment in 2023, where the company disclosed an ownership range of roughly **32.8 %–52.6 %** and tied the stake to the pipeline’s natural‑gas infrastructure.  At the same time, NEE’s total equity‑method holdings slipped slightly from **$6.582 billion (2022)** to **$6.156 billion (2023)**, indicating that the firm is reallocating capital toward strategic pipeline assets like Mountain Valley while trimming other holdings.  This shift reflects NEE’s intent to deepen its exposure to gas‑transportation infrastructure as a core component of its long‑term, diversified investment strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - MAJOR FAILURE: The LLM states NEE's total equity-method investments were '$6.582 billion (2022)' but the ground truth clearly states '$6,159 million' for 2022. This is a significant discrepancy ($6.582B vs $6.159B = $423M error). The 2023 figure of $6.156 billion is approximately correct (ground truth: $6,156 million). This represents a fundamental calculation/data error. (2) OWNERSHIP RANGE ACCURACY: The LLM correctly identifies the 2023 range as 32.8%-52.6%, which matches ground truth. However, the LLM fails to mention the 2022 range (32%-55%) from ground truth, missing the key comparative analysis. (3) MULTI-HOP REASONING FLAW: The LLM's interpretation that 'equity-method holdings slipped slightly from $6.582 billion (2022) to $6.156 billion (2023)' is based on the incorrect 2022 figure. Using correct numbers, the change is minimal ($6.159B to $6.156B = $3M decrease), not a meaningful 'slip' that would support the narrative of capital reallocation. (4) STRATEGIC NARRATIVE ISSUE: The LLM claims NEE is 'reallocating capital toward strategic pipeline assets like Mountain Valley while trimming other holdings,' but this conclusion is not well-supported by the actual data. The ground truth indicates the Mountain Valley Pipeline was already listed among key investees in 2022, not a 'peripheral entry.' The LLM mischaracterizes the evolution. (5) MISSING CONTEXT: The LLM fails to mention the 'Nonrecurring Fair Value Measurements' notation in 2023, which the ground truth identifies as potentially significant. (6) CORRECT ELEMENTS: The LLM correctly identifies the 2023 ownership range and correctly notes the pipeline's natural-gas infrastructure focus. The general strategic intent discussion is reasonable but not well-grounded in the actual data changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 497,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 Medtronic broadened the InterStim platform with new implantable neurostimulators—including the rechargeable Intellis and Vanta devices, the miniaturized InterStim Micro, and the next‑generation InterStim X—while extending its therapeutic reach from overactive bladder and urinary retention to bowel incontinence, chronic pain, and diabetic peripheral neuropathy, the latter gaining FDA approval on the Intellis rechargeable SCS in January 2022 (Chunk 1).  In 2024 the company further accelerated adoption of these devices, reporting growth in Specialty Therapies driven by InterStim X and InterStim II/Micro neurostimulators for pelvic‑health indications and obtaining FDA approval for the closed‑loop Inceptiv SCS in April 2024, underscoring continued product diversification and market acceptance (Chunk 2).  This evolution reflects a strategic expansion of both hardware offerings and clinical indications across Medtronic’s neurostimulation portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. Key issues: (1) INCORRECT PRODUCTS: The LLM mentions 'Intellis' and 'Vanta' rechargeable devices and 'Inceptiv SCS' - none of these are mentioned in the ground truth for InterStim therapy evolution. The ground truth specifically identifies InterStim II, InterStim Micro, and InterStim X as the relevant products. (2) INCORRECT INDICATIONS: The LLM claims expansion to 'chronic pain' and 'diabetic peripheral neuropathy' - these are NOT mentioned in the ground truth, which only references overactive bladder, urinary retention, and chronic fecal incontinence. (3) INCORRECT DATES: The LLM cites 'January 2022' for FDA approval of Intellis for diabetic peripheral neuropathy - this appears to be confusing SCS (spinal cord stimulation) products with InterStim (sacral neuromodulation) products, and this date/approval is not part of the InterStim evolution described in ground truth. (4) PRODUCT CHARACTERIZATION ERROR: The ground truth emphasizes 'recharge-free' positioning for InterStim II and InterStim X in 2024, while the LLM incorrectly characterizes these as 'rechargeable' devices. (5) MISSING KEY DETAIL: The LLM fails to note the specific removal of InterStim Micro from the 2024 product line description, which is implicit in the ground truth's 2024 listing. (6) MULTI-HOP SYNTHESIS FAILURE: The LLM appears to have conflated InterStim (sacral neuromodulation for pelvic health) with SCS (spinal cord stimulation) products, mixing product lines and indications. The answer demonstrates fundamental confusion about which products belong to the InterStim platform versus other neurostimulation platforms. While the LLM correctly identifies Medtronic as the company and the 2022-2024 timeframe, the core factual content about specific products and indications is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 514,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "\nFrom December 2021 through 2024 Simon Property Group (SPG) reshaped its stake in Authentic Brands Group (ABG) and deepened their collaboration: it first sold a portion of its ABG holding in Dec 2021, booking an $18.8 million pre‑tax gain, then repurchased additional ABG interests for $100 million cash, expanding its ownership; subsequently, in Q1 2022 SPARC Group (SPG’s joint‑venture vehicle) acquired Reebok and entered a long‑term strategic partnership with ABG, making ABG the core licensee and operating partner for Reebok in the United States—an alliance that the knowledge‑graph captures as a mutual Partners_With relationship between SPG and ABG.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IN TIMELINE AND FACTS: (1) The LLM answer places the $18.8M gain sale in December 2021, but the ground truth clearly states this occurred in 2024. This is a critical factual error that fundamentally misrepresents the timeline of events. (2) The ground truth specifies Simon held a 1.37% interest in ABG in 2022 and increased its stake to 50% in SPARC Group (a joint venture with ABG for Forever 21), but the LLM answer does not mention the 1.37% figure or the Forever 21 merger context. (3) The LLM correctly identifies the $100 million cash acquisition for additional ABG interests, but places it out of chronological order relative to the $18.8M gain. (4) The LLM introduces the Reebok acquisition in Q1 2022 as part of the narrative, which is not mentioned in the ground truth answer and appears to conflate different transactions. (5) The ground truth describes an evolution FROM 2022 TO 2024, but the LLM answer starts from December 2021 and misplaces the 2024 transaction (the $18.8M gain) to 2021. (6) Multi-hop reasoning is compromised because the temporal sequence is incorrect—the answer should show progression from 2022 (1.37% stake, 50% SPARC stake) through 2024 (sale with $18.8M gain, then $100M acquisition), but instead presents events in wrong chronological order. The semantic meaning of 'evolution from 2022 to 2024' is lost when key 2024 events are placed in 2021.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 388,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "\nConocoPhillips’ depreciation, depletion and amortization (DD&A) expense for its Lower 48 operations rose from **$4.07 bn in 2021 to $4.85 bn in 2022 and $5.73 bn in 2023**, reflecting the region’s expanding asset base.  The first filing shows that Lower 48 “developed + undeveloped” volumes jumped from **2.1 tn (end‑2020) to 4.66 tn (end‑2021)** and were bolstered by sizable purchase and extension activity, while the 2023 filing breaks out the DD&A by region, listing **$5.729 bn for Lower 48 in 2023** (up from $4.854 bn in 2022 and $4.067 bn in 2021).  This increase is directly tied to the corporate relationship **COP Operates_In Lower 48**, linking the company’s investment activity in that GPE to the rising DD&A figures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. QUANTITATIVE VERIFICATION: All key numbers are correct - DD&A expenses of $4,067M (2021), $4,854M (2022), and $5,729M (2023) match the ground truth exactly (format variations $4.07bn vs $4,067M are acceptable). The intermediate 2022 figure ($4.85bn) is correctly included, providing fuller context than the ground truth answer. Volume figures (2.1 tn end-2020, 4.66 tn end-2021) are accurately cited. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across multiple filing years, connecting DD&A expense trends to underlying asset base growth and purchase/extension activity. The corporate relationship notation (COP Operates_In Lower 48) demonstrates proper entity linking. COMPLETENESS: The answer addresses the core question about DD&A evolution from 2021-2023 and goes beyond by including 2022 data and contextual information about volume growth and acquisition activity. MINOR CONSIDERATIONS: The ground truth answer is more concise and focused solely on the 2021-2023 comparison, while the LLM answer provides additional supporting detail (2022 intermediate year, volume data, acquisition context). This additional detail is accurate and relevant but slightly expands scope. The semantic meaning is fully aligned - both convey that DD&A expenses rose significantly in the Lower 48 region, reflecting growing investment activity. No calculation errors detected. All entities (ConocoPhillips, Lower 48, DD&A metric) correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 427,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "\nVerizon’s 2023 10‑K only described the general methodology for valuing international bonds—using matrix pricing with inputs from independent third‑party sources—without disclosing any specific fair‑value amounts. In the 2024 filing, the company quantifies that exposure, reporting $12 million of international bonds at fair value ($10 million Level 1 and $2 million Level 2), showing a shift from a broad description to a detailed, hierarchical valuation breakdown of the same asset class. This evolution reflects a more transparent, granular treatment of Verizon’s international bond holdings between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. QUANTITATIVE ACCURACY (10/10): All financial figures are correct - $12 million total value, $10 million Level 1, $2 million Level 2. The years (2023 vs 2024) are correctly identified. QUALITATIVE ACCURACY (9/10): The multi-hop reasoning is sound, correctly synthesizing the evolution from 2023 to 2024. The LLM accurately identifies the shift from general methodology description to specific quantified disclosure with hierarchical breakdown. The characterization of valuation methods (matrix pricing with third-party sources) is accurate. The semantic interpretation of the evolution as moving from 'broad description to detailed, hierarchical valuation breakdown' and 'more transparent, granular treatment' aligns well with the ground truth's characterization of 'shift from general description to more transparent and segmented valuation approach.' COMPLETENESS: The answer addresses all key aspects of the question - the treatment approach in both years, the valuation methodology, the specific amounts, and the nature of the evolution. MINOR OBSERVATION: The LLM uses slightly different phrasing than ground truth ('quantifies that exposure' vs 'specifically itemized') but these are semantically equivalent and both accurately convey the same information. The answer is well-structured and clearly explains the progression between the two years. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 406,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s stake in AspenTech expanded from the $8.326 billion investment recorded on its 2022 balance sheet (Chunk 1) to a 55 % fully‑diluted ownership after the Heritage AspenTech acquisition that created “New AspenTech” and gave Emerson control (Chunk 2).  The deal integrated AspenTech’s operations under the former “Aspen Technology, Inc.” name and is reflected in the post‑acquisition financial impact—$231 million of inventory‑step‑up amortization and $560 million of intangible‑amortization that lifted cost‑of‑sales and SG&A expenses in 2024 (Chunks 2 & 4)—while Emerson later monetized its Copeland equity and note for $1.5 billion and $1.9 billion, illustrating the continued evolution of its relationship with AspenTech captured by the mutual Has_Stake_In link (KG).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS: The LLM states '$8.326 billion investment' but ground truth shows '$8,326 million' (which equals $8.326 billion) - this is technically correct but the notation is inconsistent. More critically, the LLM introduces UNSUPPORTED NUMBERS: '$231 million of inventory-step-up amortization,' '$560 million of intangible-amortization,' '$1.5 billion' and '$1.9 billion' from Copeland equity/note monetization are NOT mentioned in the ground truth answer and cannot be verified against it. These appear to be hallucinated or from unverified sources. (2) INCOMPLETE CORE INFORMATION: The LLM fails to mention the critical '$6.0 billion in cash' that Emerson contributed to form New AspenTech, which is explicitly stated in the ground truth as a key component of the 2024 restructuring. This is a significant omission. (3) REASONING ISSUES: While the LLM correctly identifies the 55% ownership stake and the transformation from simple investment to operational integration, it conflates multiple transactions (Heritage AspenTech acquisition, Copeland monetization) without clearly distinguishing them or explaining their relationship to the core question about Emerson-AspenTech evolution. The mention of 'Copeland equity and note' appears tangential and unverified. (4) ENTITY CONFUSION: The statement 'integrated AspenTech's operations under the former \"Aspen Technology, Inc.\" name' is confusing and potentially inaccurate - the ground truth refers to 'New AspenTech' as the restructured entity, not a reversion to old naming. (5) MULTI-HOP SYNTHESIS: The answer attempts to synthesize across multiple chunks but introduces unverified financial details that distract from the core narrative. The ground truth focuses on the strategic restructuring (2022 stake → 2024 New AspenTech with 55% ownership + $6B cash contribution), while the LLM adds extraneous transaction details. CORRECT ELEMENTS: The 55% ownership stake, the transformation from investment to operational control, and the 2022-2024 timeframe are correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 557,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Starbucks’ interest‑rate swap portfolio shifted from a single, fully‑designated instrument that appeared only as a $34.0 million liability in “Other long‑term liabilities” (Chunk 1) to a mixed‑classification position: the designated swap’s liability fell to $19.2 million in long‑term liabilities (with an additional $0.4 million recorded in the current “Accrued liabilities” column) and began to carry a small derivative‑asset of $0.4 million, while a new non‑designated swap component was added, showing liabilities of $0.1‑$1.8 million across “Accrued liabilities” and “Other long‑term liabilities” (Chunk 2).  This evolution reflects both a reduction in the magnitude of the designated swap liability and the introduction of non‑designated swaps that are now reported as modest liabilities and, for the first time, as derivative assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. CRITICAL ERRORS: (1) The LLM claims a derivative asset of $0.4 million was created in 2023, but the ground truth makes no mention of any derivative assets - only liabilities are reported. (2) The LLM introduces non-designated swaps with liabilities of $0.1-$1.8 million, which are not mentioned in the ground truth answer. (3) The LLM's total liability calculation appears inconsistent with ground truth: it lists $19.2M + $0.4M = $19.6M (which matches ground truth), but then adds unsubstantiated non-designated swap amounts. CORRECT ELEMENTS: (1) The 2022 figure of $34.0 million in long-term liabilities is correct. (2) The 2023 breakdown of $0.4 million in current liabilities and $19.2 million in long-term liabilities is correct. (3) The overall net decrease from $34.0M to $19.6M is correctly identified. (4) The shift from single classification to mixed classification (current + long-term) is correctly noted. REASONING ISSUES: The LLM appears to have hallucinated details about non-designated swaps and derivative assets that are not present in the ground truth. The answer goes beyond what can be verified from the provided information, introducing complexity that contradicts the simpler, more straightforward ground truth answer. The multi-hop synthesis is partially sound for the core facts but is undermined by the introduction of unsupported details. The answer demonstrates some understanding of the classification shift but fails on factual accuracy regarding the complete composition of the 2023 position.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 448,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "\nFrom 2022 to 2023 NextEra Energy Resources moved from a near‑complete exit to a continued, though reduced, stake in the Mountain Valley Pipeline. In 2022 it recorded a $0.8 billion impairment and fully wrote off its $0.6 billion equity‑method investment (plus a $0.2 billion liability for future ARO costs) after determining that legal challenges left the pipeline’s completion probability “very low.” By 2023 the company still held a 32.8 % equity interest in the joint‑venture pipeline and disclosed a 20‑year natural‑gas transportation agreement that includes upcoming equity‑contribution commitments, showing that despite the 2022 write‑down it remained financially engaged in the project’s future.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core narrative of NextEra's evolution from 2022 to 2023 - a $0.8 billion impairment in 2022 followed by continued 32.8% equity involvement in 2023. The qualitative reasoning about the shift from near-exit to continued engagement is sound. The 20-year natural gas transportation agreement with ~$70 million annual obligation is correctly referenced. The explanation of 'very low probability' of completion is accurate.\n\nWEAKNESSES - QUANTITATIVE ISSUES: The LLM introduces specific numbers ($0.6 billion equity-method investment + $0.2 billion liability for ARO costs) that are NOT present in the ground truth answer. While these may be accurate details from the actual filing, they represent information beyond what the ground truth specifies. The ground truth only states 'approximately $0.8 billion' impairment charge with no breakdown into component parts. This is a critical issue because the evaluation task requires matching the ground truth, not adding unreferenced details.\n\nMULTI-HOP REASONING: The synthesis across 2022-2023 is logically sound and addresses the evolution question well. The model correctly connects the impairment event to the subsequent continued involvement.\n\nCOMPLETENESS: The answer addresses all key elements: the 2022 impairment ($0.8B), the write-off, the 2023 equity stake (32.8%), and the transportation agreement (~$70M annually). However, the ground truth specifies the annual obligation as 'approximately $70 million' while the LLM says 'upcoming equity-contribution commitments' which is slightly less precise about the specific $70M figure.\n\nSCORING RATIONALE: The correctness score of 6 reflects that while the core narrative and major figures are correct, the introduction of unverified component breakdowns ($0.6B + $0.2B) and slightly imprecise language around the $70M commitment represent deviations from ground truth. The answer is directionally correct but contains details not supported by the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 543,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "\nThe Coca‑Cola Company’s equity stake in the captive insurance vehicle that backs its group‑annuity reinsurance contracts rose from **$1.64 billion (as of 31 Dec 2023)** to **$1.88 billion (as of 31 Dec 2024)**, and its debt‑security holdings grew from **$1.38 billion (2022)** to **$1.64 billion (2023)** and remained at **$1.64 billion (2024)**.  These marketable equity and debt securities—classified as “other non‑current assets” because they cannot be used to meet current insurance obligations—are the primary way the company funds the solvency capital of the captive that reinsures the European and Canadian pension‑plan annuity contracts.  In short, both the equity and debt portions of the captive’s portfolio have expanded markedly from 2023 to 2024, reflecting a continued allocation of solvency capital to support the group‑annuity reinsurance arrangement.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains significant factual errors that contradict the ground truth. Ground truth states: 2023 = $1,643 million total, 2024 = $1,883 million total. The LLM breaks this into separate equity and debt components with different numbers: equity $1.64B (2023) to $1.88B (2024), and debt $1.38B (2022) to $1.64B (2023) to $1.64B (2024). These component figures do not match or reconcile with the ground truth totals. The ground truth presents a single combined figure of $1,643M (2023) and $1,883M (2024) for 'equity and debt securities,' not separate equity and debt line items. The LLM appears to have fabricated or misinterpreted the breakdown into equity vs. debt components. CALCULATION VERIFICATION: Ground truth shows growth of $240M ($1,883M - $1,643M = $240M). The LLM's equity component shows $240M growth ($1.88B - $1.64B), which coincidentally matches, but this appears to be conflating the total with just the equity portion. MULTI-HOP REASONING: The LLM correctly identifies the captive insurance company, group annuity reinsurance contracts, and the 2023-2024 timeframe. However, the synthesis of the financial data is fundamentally flawed. CONTEXTUAL RELEVANCE: The answer appropriately discusses the purpose (solvency capital, reinsuring European and Canadian pension plans) and classification (non-current assets), which adds context. However, this contextual accuracy cannot overcome the core quantitative errors. The answer structure and reasoning flow are reasonable, but the underlying numbers are incorrect, making this a partially correct answer with significant factual errors in the primary quantitative data requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 462,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "\nFrom 2022 – when Intel 4 was still in the ramp‑up stage and generated $565 M of period charges tied to its development (Chunk 1) – to 2024, the node has progressed to high‑volume manufacturing in Ireland and began shipping in Intel’s first high‑volume client product, the Core Ultra processor, with its share of overall processor production set to grow in 2025 (Chunk 2).  Strategically, Intel 4 serves as the foundation of Intel’s EUV‑based roadmap, feeding into the subsequent Intel 3, 18A and 14A nodes and supporting both internal CPUs (e.g., Xeon 6) and external foundry customers, a positioning that reflects the company’s broader investment in leading‑edge process technology, capital‑intensive fab capacity and the protection of the underlying IP portfolio (Chunks Manufacturing Capital, IP Rights).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Intel 4's evolution from 2022 to 2024 and correctly synthesizes multi-hop information across the timeline. STRENGTHS: (1) Accurately captures the core narrative: 2022 ramp-up stage → 2024 high-volume manufacturing transition; (2) Correctly identifies Ireland as the manufacturing location; (3) Properly identifies Core Ultra as the first high-volume client product; (4) Provides excellent strategic context about Intel 4's role in the broader roadmap (feeding into Intel 3, 18A, 14A nodes); (5) Mentions both internal (Xeon 6) and external foundry applications; (6) Demonstrates sound multi-hop reasoning by connecting production status to strategic positioning. MINOR ISSUES: (1) The $565M figure for 2022 period charges is cited but not explicitly verified against ground truth - while the number appears specific and sourced, the ground truth only mentions 'higher period charges' without specifying the exact amount, creating slight uncertainty about whether this specific number is from the actual filing or inferred; (2) The answer goes beyond the ground truth by adding forward-looking information about 2025 production growth and detailed roadmap specifics (Intel 3, 18A, 14A nodes, Xeon 6), which while likely accurate and relevant, extends beyond what the ground truth explicitly confirms. QUANTITATIVE ACCURACY: The $565M figure is the only specific number provided. Without independent verification against the actual 10-K, this creates a minor deduction, though the figure appears reasonable and properly sourced. QUALITATIVE ACCURACY: Excellent synthesis of multi-hop information showing clear understanding of the progression and strategic importance. CONTEXTUAL RELEVANCE: Highly relevant, directly addressing both production status evolution and strategic positioning within the roadmap as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 506,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "\nEmerson’s tie‑up with AspenTech moved from a pure partnership (the ORG‑Partners_With→COMP link shown in the KG) to a controlling equity stake, because in 2023‑2024 Emerson acquired Heritage AspenTech, paid roughly $6 bn in cash and stock and ended up owning 55 % of the combined “New AspenTech” (Chunk 2 notes the 55 % fully‑diluted ownership and that AspenTech now operates under Heritage’s former name).  The acquisition was financially integrated: the purchase price and related inventory step‑up appear in Emerson’s 2024 cost‑of‑sales (+$869) and SG&A (+$956) and are reflected in acquisition‑related amortization of $231 (cost‑of‑sales) and $560 (intangibles) reported in Chunk 2, showing that AspenTech’s software portfolio—described in Chunk 1 as a global asset‑optimization business—is now part of Emerson’s consolidated results.  Thus, between 2022 and 2024 the relationship evolved from a collaborative partnership to a majority‑owned, financially‑integrated subsidiary, as captured by the mutual KG triplets (EMR↔AspenTech) and the detailed financial impacts in the 2024 filing.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core evolution from partnership to majority-owned subsidiary, accurately states the 55% ownership stake, and properly characterizes the financial integration. The multi-hop reasoning connecting 2022 partnership status to 2024 ownership structure is sound. The answer appropriately references the 'New AspenTech' entity and acknowledges the shift in relationship type.\n\nWEAKNESSES - QUANTITATIVE: The LLM provides specific dollar amounts ($6bn acquisition price, $869M cost-of-sales impact, $956M SG&A impact, $231M amortization in cost-of-sales, $560M intangibles amortization) that are NOT present in the ground truth answer. The ground truth only mentions: (1) 55% ownership, (2) 0.6 percentage point gross margin improvement in 2023, and (3) SG&A expense influence in 2024. The LLM's specific financial figures cannot be verified against the ground truth and appear to be either fabricated or sourced from unstated chunks. This is a significant accuracy concern.\n\nWEAKNESSES - COMPLETENESS: The ground truth explicitly mentions the 0.6 percentage point gross margin impact in 2023, which the LLM omits entirely. This is a specific quantitative metric from the original answer that should have been included.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the temporal evolution (2022→2024) and connects partnership status to ownership structure. However, the introduction of unverified financial figures undermines the reliability of the synthesis.\n\nSEMANTIC ISSUES: The LLM's reference to 'Heritage AspenTech' and 'Heritage's former name' is confusing and potentially inaccurate - the ground truth simply refers to 'New AspenTech' without this naming convention detail.\n\nOVERALL ASSESSMENT: While the LLM captures the essential narrative arc and key structural facts (partnership→subsidiary, 55% stake, financial integration), it introduces specific financial metrics not in the ground truth and omits the 0.6pp gross margin figure that was explicitly mentioned. The unverified dollar amounts are particularly problematic in a financial context where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 573,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "\nIntel first introduced the Intel 4 designation as part of its 2021‑2022 process‑node naming overhaul, establishing it as a new product in the company’s roadmap (Chunk 1). By 2024 Intel 4 became the firm’s first EUV lithography node, delivering roughly 20 % better performance‑per‑watt than Intel 7, moving to high‑volume manufacturing in Ireland and expanding its share of production for 2025 while being produced alongside the data‑center‑focused Intel 3 node (Chunk 2). This evolution reflects Intel’s broader strategy of advancing EUV and gate‑all‑around/back‑side‑power technologies—supported by substantial capital investment and a robust IP portfolio that protects its innovations and signals a shift from cancelled nodes like 20A to the upcoming Intel 18A in 2025 (Chunk 2, IP/capital sections).",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) Intel 4 as first EUV lithography node - correct; (2) 20% performance-per-watt improvement over Intel 7 - correct; (3) High-volume manufacturing in Ireland - correct; (4) Core evolution narrative from roadmap to production - correct. PROBLEMATIC ELEMENTS: (1) DATING ERROR - LLM states Intel 4 was introduced in '2021-2022 process-node naming overhaul' while ground truth specifies it was 'newly introduced' in 2022 specifically. The earlier 2021 date is not supported by ground truth; (2) INCOMPLETE CONTEXT - LLM mentions Intel Core Ultra processor but fails to note it 'began shipping in 2023,' which is a key temporal marker in the evolution narrative; (3) SCOPE CREEP - LLM introduces information about Intel 3, Intel 18A, cancelled 20A node, and capital investment/IP portfolio that, while potentially accurate, goes beyond the specific question about Intel 4's evolution and dilutes focus on the core answer; (4) SYNTHESIS ISSUE - The multi-hop reasoning should focus on Intel 4's specific trajectory (2022 conceptual → 2024 production), but LLM expands into adjacent nodes and strategic context that wasn't requested. QUANTITATIVE VERIFICATION: The 20% figure is correct. The manufacturing location (Ireland) is correct. No calculation errors detected. MULTI-HOP REASONING: The answer does synthesize information across time periods and connects naming convention to manufacturing readiness to performance metrics, but the additional strategic context (Intel 3, 18A, IP portfolio) represents over-elaboration rather than necessary synthesis for this specific question. The answer is partially correct with accurate core facts but contains dating imprecision and unnecessary scope expansion that reduces focus on the specific evolution question asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 499,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "\nBetween 2022 and 2024 MDT’s Pelvic Health portfolio evolved from offering InterStim Micro alongside the InterStim X and II devices (Chunk 1) to making the **rechargeable InterStim Micro the flagship therapy** highlighted for growth, as the 2024 outlook explicitly cites “continued acceptance and growth of our Pelvic Health therapies, including our InterStim Micro rechargeable neurostimulator” (Chunk 2).  This shift reflects MDT’s strategic positioning of InterStim Micro as a core, market‑gaining product within its Neuromodulation/Pelvic Health division, driving the overall rise in Pelvic Health sales reported for fiscal 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of InterStim Micro's positioning. STRENGTHS: (1) Correctly identifies the 2022 baseline where InterStim Micro was one of several neurostimulators alongside InterStim X and II; (2) Accurately captures the 2024 positioning emphasizing InterStim Micro as the rechargeable variant; (3) Properly synthesizes the multi-hop information across years showing strategic differentiation; (4) Correctly identifies the therapeutic indications (overactive bladder, urinary retention, fecal incontinence are implied through context); (5) Appropriately emphasizes growth and adoption themes. MINOR ISSUES: (1) The phrase 'flagship therapy' in the LLM answer is slightly more emphatic than the ground truth's 'specifically highlighted' and 'more defined strategic positioning' - this represents a minor interpretive enhancement rather than factual error; (2) The LLM adds context about 'Pelvic Health sales reported for fiscal 2024' which, while contextually relevant, goes slightly beyond what the ground truth explicitly states about the evolution itself; (3) No quantitative metrics (sales figures, growth percentages) are provided in either answer, so no calculation errors to assess. MULTI-HOP REASONING: The LLM correctly synthesizes information across the 2022-2024 timeframe and identifies the key differentiation (rechargeable positioning) that distinguishes InterStim Micro from its counterparts. The reasoning chain is sound and logically connects the portfolio evolution to strategic positioning. SEMANTIC EQUIVALENCE: The core message matches - InterStim Micro evolved from being one option among several to being specifically positioned as the rechargeable neurostimulator option with emphasis on growth. The LLM's characterization as 'flagship' is a reasonable interpretation of 'specifically highlighted' though slightly stronger in tone.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 520,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "\nFrom 2022 through 2024 SPG repeatedly identifies LTIP Units as “potentially dilutive securities” but, in each filing, concludes that “no securities had a material dilutive effect” for the reported periods (2022, 2023 and 2024). Thus, the disclosure has remained consistent – LTIP Units are noted as potentially dilutive, yet their impact has been deemed immaterial across all reporting periods from 2022 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misses the core evolution described in the ground truth. Key issues: (1) FACTUAL ERROR - The LLM claims the disclosure 'remained consistent' across 2022-2024, but the ground truth explicitly states there was a 'reduction in the level of detail provided about LTIP units' conversion features.' The 2022 disclosure explicitly referenced exchangeability into common stock, while the 2024 disclosure did not. This is a material change in disclosure approach, not consistency. (2) MISSING CRITICAL DETAIL - The LLM fails to capture that the 2022 disclosure covered periods 2021, 2020, and 2019, while the 2024 disclosure covers 2024, 2023, and 2022. This shift in reporting periods is important context for understanding the evolution. (3) INCOMPLETE CHARACTERIZATION - While the LLM correctly notes that no material dilutive effect was concluded in both periods, it misses the key evolution: the simplification/reduction of detail about conversion features. The ground truth emphasizes this as a notable change ('reduction in the level of detail'), not consistency. (4) TERMINOLOGY ISSUE - The LLM introduces 'potentially dilutive securities' language that is not explicitly mentioned in the ground truth, which focuses on exchangeability and material dilutive effect conclusions. (5) MULTI-HOP REASONING - The LLM failed to synthesize the evolution across the two time periods correctly, instead characterizing it as static when the ground truth indicates a deliberate change in disclosure approach. The answer demonstrates incomplete understanding of what 'evolution' means in this context - it's not about consistency but about how the disclosure changed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 466,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "\nFrom 2022 through 2024 MetLife’s repurchase strategy has become increasingly tied to preserving a cash buffer; the 2021 Board authorization permitted up to $3 billion of common‑stock buy‑backs with roughly $1.5 billion still available at the end of 2021 (the latest figure disclosed before 2022), but the 2024 filing explicitly warns that legal and regulatory restrictions or cash‑buffer needs may block further repurchases and that the company may deliberately raise its liquidity buffer, thereby shrinking the capital left for share purchases. Consequently, the once‑substantial remaining authorization has been curtailed by the need to maintain sufficient cash, reflecting a shift from an open‑ended buy‑back window in 2022 to a more conservative stance in 2024 where cash‑buffer considerations now directly limit MetLife’s ability to repurchase stock.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All numeric values are correct - the $3.0 billion authorization and $1.5 billion remaining as of December 31, 2021 are accurately cited. The dates (2021, 2022, 2024) are properly referenced. ENTITY ACCURACY: MetLife is correctly identified throughout, and the financial metrics (common stock repurchase authorization, liquidity buffers, capital allocation) are properly named. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years, correctly identifying the evolution from 2022 (when repurchase capacity was more available) to 2024 (when cash buffer needs constrain repurchases). The causal logic is sound - the model correctly links regulatory/market considerations to the shift in strategy. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as the ground truth: a shift from active repurchase posture to conservative liquidity strategy. Phrases like 'once-substantial remaining authorization has been curtailed' and 'shift from an open-ended buy-back window to a more conservative stance' effectively capture the evolution described in the original answer. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and explicit about the mechanisms (legal/regulatory restrictions, deliberate liquidity buffer increases) compared to the ground truth, but this adds helpful context rather than introducing inaccuracy. The parenthetical note about '2021 (the latest figure disclosed before 2022)' demonstrates careful temporal reasoning. No calculation errors, no factual contradictions, and the synthesis across the 2022-2024 period is logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Faces]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 471,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "\nStarbucks (SBUX) discloses the financial instrument “foreign‑currency – other,” which in fiscal 2022 showed $103.9 million of gains recorded in OCI before reclassification and $22.0 million reclassified into earnings (Chunk 1), with the liability side reflected only through those OCI reclassifications. In fiscal 2023 the same instrument is presented on the balance sheet as derivative assets of $1.9 million in “prepaid expenses and other current assets” and $1.7 million in “other long‑term assets,” while derivative liabilities of $4.7 million appear in “accrued liabilities” and $4.1 million in “other long‑term liabilities” (Chunk 2), indicating a shift from OCI‑only reporting to explicit classification under prepaid‑expense and long‑term asset/liability line items. This evolution reflects the KG relationship ORG – [Discloses]→ FIN_INST (“foreign currency – other”) and the corresponding change in how SBUX records the asset and liability positions from 2022 to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative data is correct: FY2022 OCI gains of $103.9 million, reclassifications of $22.0 million, and FY2023 balance sheet positions ($1.9M current assets, $1.7M long-term assets, $4.7M current liabilities, $4.1M long-term liabilities). The multi-hop synthesis is sound, correctly tracing the evolution of foreign currency derivative positions across two fiscal years and identifying the shift from OCI-only reporting to explicit balance sheet classification. The answer properly identifies Starbucks (SBUX) and the specific financial instrument. The reasoning about the 'significant reduction in asset positions' is implicit but well-supported by the numbers presented. The LLM appropriately references the knowledge graph structure (ORG-[Discloses]→FIN_INST relationship), demonstrating understanding of the data model. Minor deduction: The answer could have been slightly more explicit in quantifying the magnitude of the reduction (from $103.9M in OCI gains to $1.9M+$1.7M=$3.6M in balance sheet assets), though this is a minor omission that doesn't affect the core accuracy. The semantic equivalence is excellent, with clear explanation of the classification shift and its significance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 354,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "\nProcter & Gamble’s global cash‑management strategy—disclosed as an accounting policy that governs the use of cash generated by its corporate‑level operations—has been progressively aligned with larger restructuring outlays: in fiscal 2022 the company spent roughly $250‑$500 million on restructuring (with $147 million of accruals and about 65 % settled in cash), whereas by fiscal 2024 restructuring costs jumped to $659 million (including a $216 million non‑cash foreign‑currency translation loss and $166 million of accruals, with roughly 64 % settled in cash).  This increase coincides with a decline in corporate‑level performance—net sales fell from $744 million in 2022 to $601 million in 2024 and net earnings dropped by about $1 billion due to an impairment charge and higher restructuring expenses—yet operating cash flow remained strong, allowing PG to continue funding shareholder dividends, share repurchases and debt while maintaining a high‑quality cash position that reflects its liquidity, economic and tax considerations.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) INCORRECT NUMBERS - The LLM introduces net sales figures ($744M in 2022, $601M in 2024) that are NOT mentioned in the ground truth and appear to be fabricated or confused with other metrics. These are presented as fact but cannot be verified against the original answer. (2) CORPORATE EARNINGS DISCREPANCY - Ground truth states 'Corporate net earnings improved by $872 million to $485 million' in fiscal 2022, but LLM does not address this improvement figure at all, only mentions the decline in fiscal 2024. (3) IMPAIRMENT CHARGE - Ground truth specifies '$1.4 billion impairment charge of the Gillette intangible asset' but LLM only vaguely references 'an impairment charge' without the specific amount. (4) ACCRUALS DETAIL - LLM states '$166 million of accruals' for fiscal 2024, but ground truth does not provide this specific figure for 2024 (only $147M for 2022). (5) CASH SETTLEMENT PERCENTAGES - LLM introduces '65% settled in cash' and '64% settled in cash' figures that are not in the ground truth, suggesting unsupported calculations. CORRECT ELEMENTS: (1) Restructuring costs range of $250-$500M in fiscal 2022 is correct. (2) $147M accruals for 2022 is correct. (3) $659M restructuring costs for fiscal 2024 is correct. (4) $216M non-cash foreign currency translation loss is correct. (5) $1.0 billion decline in corporate net earnings is correct. (6) General narrative about alignment of cash management with restructuring is reasonable. MULTI-HOP REASONING: The LLM attempts to synthesize information across fiscal years and connect restructuring activities to financial performance, which is appropriate. However, the introduction of unverified net sales figures and cash settlement percentages undermines the credibility of the synthesis. The answer conflates corporate-level metrics with company-wide performance without clear distinction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1517,
        "completion_tokens": 510,
        "total_tokens": 2028
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "\nBetween 2022 and 2023 NVIDIA shifted Omniverse from a subscription‑based 3D‑collaboration platform for enterprise and individual users (2022) to a full‑stack enterprise simulation engine that is embedded in the NVIDIA AI Enterprise suite and paired with DGX Cloud, DRIVE Software and DRIVE Sim (2023).  This evolution lets industrial customers run on‑prem or cloud‑based digital‑twin, real‑time product‑configurator and autonomous‑vehicle/robot validation workloads, tightly integrating Omniverse’s 3D simulation capabilities with enterprise AI, computing and automotive simulation solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the 2022-2023 timeframe and evolution trajectory; (2) Accurately captures the shift from subscription-based 3D collaboration platform to enterprise simulation engine; (3) Correctly names key integrations (DRIVE Sim, DRIVE Software, DGX Cloud, NVIDIA AI Enterprise); (4) Properly synthesizes multi-hop information about industrial applications (digital twins, product configurators, autonomous vehicle validation); (5) Accurately conveys the integration with enterprise-grade computing infrastructure both on-premises and cloud-based. MINOR ISSUES: (1) The LLM answer introduces 'NVIDIA AI Enterprise suite' and 'DGX Cloud' as 2023 integrations, which are mentioned but the ground truth emphasizes 'accelerated computing infrastructure' more broadly without explicitly naming these specific products in the evolution narrative; (2) The phrase 'full-stack enterprise simulation engine' is the LLM's characterization rather than explicitly stated in ground truth, though it semantically captures the evolution accurately; (3) The ground truth mentions 'operating system for building virtual world simulation applications' which the LLM doesn't explicitly state, though 'development platform' is mentioned in ground truth and the LLM's framing captures the essence. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations present in either answer, so this dimension is not applicable but scores high due to no errors. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2023 positioning, enterprise solutions, and simulation technologies as required. The logical flow from subscription platform to enterprise simulation engine is sound and well-supported. SEMANTIC EQUIVALENCE: The core message matches - Omniverse evolved from a collaboration/simulation platform to a more integrated enterprise solution with stronger ties to AI and computing infrastructure. The answer is comprehensive and addresses all parts of the multi-part question effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 567,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 AMT’s financial commitments for its communications‑site portfolio shifted dramatically: in the 2023 filing the company disclosed an **anticipated $450 million spend** to construct roughly **2,500‑3,500 new sites** (Chunk 1), whereas by the 2024 filing it reported a **$4.5 billion undiscounted future cash outlay for asset‑retirement obligations** and noted that it must make **non‑cancellable renewal payments** to keep those sites operational—failure to renew would forfeit the sites and their tenant‑lease revenues (Chunk 2).  This evolution shows that AMT moved from a modest capital‑expenditure forecast for new sites to a much larger, long‑term fiscal responsibility centered on maintaining and renewing its existing communications‑site portfolio.  The KG relationship — AMT produces Communications Sites and discloses them — links these spending and obligation disclosures across the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensiveness. All quantitative data is correct: the $450 million anticipated spend for 2,500-3,500 new communications sites in 2023, and the $4.5 billion undiscounted future cash outlay for asset retirement obligations in 2024. The multi-hop synthesis is sound—the answer correctly traces the evolution of AMT's financial commitments across two fiscal years and identifies the shift from near-term capital expenditure planning to long-term obligation management. The answer goes beyond the ground truth by adding valuable context about non-cancellable renewal payments and the consequences of non-renewal (forfeiture of sites and tenant revenues), which enriches understanding without introducing inaccuracy. Entity identification is correct (AMT, communications sites, asset retirement obligations). The reasoning clearly explains the nature of the shift: from construction/capex planning to maintenance/renewal obligations. The semantic equivalence is strong—the LLM's characterization of the evolution as moving from 'modest capital-expenditure forecast' to 'much larger, long-term fiscal responsibility' accurately captures the ground truth's description of shifting from 'near-term capital allocation planning' to 'more mature and substantial obligation structure.' Minor note: The LLM references 'Chunk 1' and 'Chunk 2' which are source citations rather than part of the substantive answer, but this does not detract from accuracy. The answer fully addresses all aspects of the multi-part question regarding how commitments evolved, anticipated spending, and future obligations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 449,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "\nExxonMobil’s 2023 and 2024 disclosures both frame asset‑sale proceeds as a component of “cash flow from operations and asset sales,” linking the proceeds directly to the corporation’s ongoing, disciplined review of whether assets are still contributing to its strategic objectives.  The 2024 wording adds a brief note that the regular nature of these divestitures makes it useful for investors to consider the proceeds together with operating cash, but the core language—describing proceeds as part of the cash generated from assets that are sold when they no longer meet strategic goals—remains essentially unchanged between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations of the ground truth. (1) MAJOR ERRORS: The LLM claims both 2023 and 2024 describe proceeds as 'cash flow from operations and asset sales' - this is NOT supported by the ground truth. The ground truth explicitly states 2023 used 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments' while 2024 used 'proceeds from asset sales and returns of investments.' The LLM fundamentally mischaracterizes the actual language evolution. (2) MISSING KEY DETAILS: The LLM fails to identify the specific linguistic shift that occurred - the removal of explicit mention of 'subsidiaries' and 'property, plant and equipment' in 2024, which is the core of the ground truth answer. The ground truth emphasizes this consolidation/streamlining as a significant evolution. (3) INCORRECT FRAMING: The LLM suggests the language 'remains essentially unchanged' when the ground truth explicitly describes an evolution toward 'more consolidated framing' and 'more generalized narrative.' This is a direct contradiction. (4) ADDED CLAIMS NOT IN GROUND TRUTH: The LLM introduces claims about 'adding a brief note that regular nature of divestitures makes it useful for investors' - this specific detail does not appear in the ground truth and appears to be fabricated. (5) MULTI-HOP REASONING: The LLM failed to properly synthesize the comparative analysis between 2023 and 2024 language, which was the core requirement of the question. The answer demonstrates a fundamental misunderstanding of the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 446,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "\nComcast’s consolidated exposure to Universal Beijing Resort fell sharply between the 2022‑ and 2023‑reporting periods: the resort’s reported assets dropped from **$9.7 billion** (as of Dec 31 2021, the latest figure in the 2022 filing) to **$7.8 billion** in 2023, while its liabilities fell from **$8.1 billion** to **$7.2 billion** over the same span.  This reduction—driven by debt repayments and the runoff of construction‑related borrowings—reflects a modest decline in the amount of Comcast‑consolidated assets and obligations tied to the VIE, even though Comcast’s equity stake (≈30 %) and its maximum financial‑loss exposure remain unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies all four key financial figures from the ground truth: assets decreased from $9.7B to $7.8B, and liabilities decreased from $8.1B to $7.2B. The directional analysis and conclusion about reduction in financial footprint are accurate. However, there is a significant dating issue: the LLM states the 2022 figures are 'as of Dec 31 2021, the latest figure in the 2022 filing,' which is confusing and potentially misleading. The ground truth clearly indicates these are 2022 and 2023 figures, not 2021 and 2022. This parenthetical clarification, while attempting to explain source documentation, introduces ambiguity about which fiscal years are actually being compared. The LLM also adds interpretive details about 'debt repayments and runoff of construction-related borrowings' and mentions Comcast's '≈30% equity stake' and 'maximum financial-loss exposure,' which go beyond the ground truth but appear reasonable given the context of a VIE (Variable Interest Entity) relationship. These additions demonstrate sound reasoning about the nature of the changes, though they are not explicitly confirmed in the ground truth. The core quantitative comparison is accurate, and the multi-hop synthesis correctly connects the asset/liability changes to broader financial exposure implications. The main weakness is the confusing date reference that could mislead readers about which fiscal periods are being analyzed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Consolidates]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 399,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "\nCustomer Demand Volatility remains a core risk for Caterpillar, but its character has shifted from a 2023 view of cyclical sales swings driven mainly by macro‑economic slowdown, pandemic‑related uncertainty and commodity‑price swings — risks that could depress revenue and trigger higher allowances for doubtful accounts — to a 2024 reality in which sustained commodity‑price increases, material‑cost inflation and persistent shortages of steel, components and labor — exacerbated by logistics constraints — directly squeeze margins, force tighter production schedules and threaten the company’s ability to meet customer orders.  Consequently, the volatility now impacts Caterpillar’s financial performance more sharply through higher costs and margin pressure, while also heightening supply‑chain instability that can disrupt production and inventory availability.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with excellent alignment to the ground truth on key factual points. STRENGTHS: (1) Correctly identifies the evolution of Customer Demand Volatility as a risk factor between 2023 and 2024; (2) Accurately captures the 2023 focus on pandemic-related uncertainty, economic uncertainties, and inflationary pressures; (3) Properly identifies the 2024 shift toward commodity price changes, material cost inflation, and supply chain/labor shortages; (4) Correctly synthesizes the multi-hop relationship between demand volatility and its impacts on financial performance and supply chain stability; (5) No quantitative errors - no specific numbers were provided in either answer, so quantitative accuracy is perfect by default; (6) Appropriately emphasizes the broadening of the risk profile from demand-side to supply-side challenges. MINOR WEAKNESSES: (1) The LLM answer adds interpretive language about 'margin pressure,' 'tighter production schedules,' and 'logistics constraints' that, while logically sound and contextually reasonable, go slightly beyond what the ground truth explicitly states - these are reasonable inferences but represent minor elaboration rather than direct synthesis from the filings; (2) The phrasing 'cyclical sales swings driven mainly by macro-economic slowdown' is a reasonable characterization but uses slightly different terminology than the ground truth's 'economic uncertainties'; (3) The answer emphasizes financial performance impacts through 'higher costs and margin pressure' more explicitly than the ground truth, though this is a reasonable elaboration of the stated impact on 'financial performance.' MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the causal relationships between demand volatility, supply chain factors, and financial performance impacts. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The core message is semantically equivalent to the ground truth - both convey that the risk evolved from pandemic/macro-driven demand uncertainty to a broader supply-side challenge profile. The LLM answer is more detailed and interpretive but remains factually grounded.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 603,
        "total_tokens": 2012
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "\nThe fair‑value of COF’s net derivative assets (liabilities) grew from **$31 million at the end of 2022** (shown in the 2022 10‑K Level‑3 reconciliation) to **$58 million at the end of 2023** (the latest 2024 filing), a $27 million increase. Both periods use a **discounted‑cash‑flow methodology**, but the 2024 disclosure expands the observable input set to **swap‑rate ranges of 3‑5 % (weighted‑average 4 %)** together with unobservable prepayment, default and loss‑severity ranges, whereas the 2022 schedule details Level‑3 movements such as purchases, sales, settlements and transfers that feed the $31 million balance. This evolution reflects a larger valuation base and more granular input ranges while maintaining the same core discounted‑cash‑flow approach.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: (1) STARTING VALUE ERROR: LLM states the fair value was $31 million at end of 2022, but ground truth indicates $19 million as of December 31, 2021 (which would be the 2022 10-K reporting). This is a critical $12 million discrepancy. (2) ENDING VALUE CORRECT: Both answers agree on $58 million as of December 31, 2023 (reported in 2024 filing). (3) CALCULATION ERROR: LLM calculates a $27 million increase ($58M - $31M), but if the correct starting point is $19 million, the increase should be $39 million ($58M - $19M). This is a significant calculation error. (4) METHODOLOGY ASSESSMENT - PARTIALLY CORRECT: LLM correctly identifies that both periods use discounted cash flow methodology and correctly cites the 3-5% swap rate range (weighted average 4%) for 2024. However, the ground truth indicates a SHIFT in methodology from 'realized and unrealized gains/losses reported in net income' to 'discounted cash flows with observable inputs,' suggesting the 2022 approach was NOT primarily discounted cash flow. LLM's claim that 'both periods use discounted-cash-flow methodology' contradicts the ground truth's indication of methodological evolution. (5) MISSING DETAILS: LLM omits the specific derivative activity components mentioned in ground truth (issuances $68M, settlements -$37M, transfers $6M) that explain the 2022 movements. (6) ENTITY IDENTIFICATION: LLM correctly identifies COF (Capital One Financial) as the company. OVERALL: While the LLM captures some correct elements (ending value, swap rate ranges, general methodology discussion), it contains a critical starting value error, a resulting calculation error, and mischaracterizes the nature of the methodological evolution. The answer demonstrates partial understanding but fails on quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Included_in_Net_Income]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 490,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "\nFrom 2022 to 2023 NVIDIA’s GeForce NOW moved from being presented as a stand‑alone cloud‑gaming service that simply streams PC titles to any device—positioned alongside its broader graphics stack (e.g., vGPU for enterprise and Omniverse‑enabled collaboration)—to a core node of the company’s full‑stack accelerated‑computing platform.  In 2023 the service is tightly coupled with RTX‑based GPUs, AI‑driven DLSS, the CUDA‑X software ecosystem, and new data‑center offerings such as DGX Cloud, AI Enterprise and DPU/CPU extensions, so that GeForce NOW now operates as the cloud‑gaming arm of an end‑to‑end GPU‑centric platform that spans enterprise graphics, AI workloads and broader cloud services.  This evolution reflects the shift from a pure “gaming‑on‑the‑cloud” offering to an integrated component of NVIDIA’s unified GPU‑cloud ecosystem, where the same software stack and hardware portfolio that power data‑center AI and enterprise graphics also deliver high‑performance gaming experiences.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of GeForce NOW from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from stand-alone cloud gaming service to integrated component of broader GPU/accelerated computing platform; (2) Accurately references key related offerings (vGPU, DGX Cloud, DLSS, CUDA-X, DPU/CPU extensions, AI Enterprise); (3) Properly synthesizes the multi-hop relationship between GeForce NOW and NVIDIA's expanding cloud infrastructure and software ecosystem; (4) No quantitative errors or incorrect dates/numbers; (5) Semantic meaning matches ground truth - both emphasize strategic alignment and integration into broader platform narrative. MINOR WEAKNESSES: (1) The LLM answer is more detailed and specific than the ground truth (mentions RTX-based GPUs, DLSS, CUDA-X, DPU/CPU extensions explicitly), which could be seen as either elaboration or slight over-specification beyond what was explicitly stated in the ground truth; (2) The ground truth mentions 'gaming as a service' framing which the LLM answer doesn't explicitly use, though the concept is implied; (3) The LLM answer's characterization of GeForce NOW as 'core node' and 'cloud-gaming arm' is more assertive than the ground truth's 'more specifically integrated' language, though both convey the same directional shift. MULTI-HOP REASONING: The answer correctly synthesizes information across multiple NVIDIA offerings and time periods, properly connecting GeForce NOW's evolution to the broader accelerated computing platform narrative. The reasoning is sound and logically structured. OVERALL: The answer is factually accurate, comprehensive, and demonstrates solid understanding of the question's multi-hop nature. The additional specificity, while not explicitly in the ground truth, does not contradict it and represents reasonable elaboration based on NVIDIA's actual product portfolio.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 522,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "\nInlyta generated $642 million in U.S. sales and $394 million internationally in 2023, up 4 % and 3 % respectively from $618 million and $385 million in 2022, producing an overall operational revenue increase of roughly 5 % (from $1.003 billion to $1.036 billion).  The rise was driven by broader adoption of Inlyta in combination regimens for advanced renal‑cell carcinoma, expansion into emerging markets and a favorable channel mix, while being partially offset by lower volumes and price reductions in certain European markets.  This growth occurred while Inlyta’s basic patents remain in force through 2025 (as shown in the patent‑expiration table) and is linked to Pfizer via the KG triplet PFE → Inlyta, indicating the revenue gains are taking place before any patent‑expiration pressure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All key numbers are correct - 2022 total revenue of $1,003 million ($1.003 billion), 2023 total revenue of $1,036 million, U.S. sales of $642M (2023) and $618M (2022), international sales of $394M (2023) and $385M (2022). The growth percentages are accurate: U.S. up 4% (618→642), international up 3% (385→394), overall up 3.3% (1,003→1,036), though the LLM states 'roughly 5%' which is slightly imprecise - the actual overall growth is approximately 3.3%, not 5%. This is a minor calculation discrepancy. QUALITATIVE ASSESSMENT: The LLM correctly identifies all key drivers of growth: (1) continued adoption in combination with immune checkpoint inhibitors for first-line RCC treatment in the U.S., (2) expansion into emerging markets, (3) favorable channel mix (additional detail not in ground truth but not contradictory). The LLM also correctly notes the offsetting factors: lower volumes and price reductions in certain European markets. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple dimensions - geographic breakdown (U.S. vs. international), year-over-year comparison, growth drivers, and headwinds. The additional context about patent expiration through 2025 and Pfizer linkage adds relevant context though not explicitly required by the question. MINOR ISSUES: The stated 'roughly 5%' overall growth is inaccurate (should be ~3.3%), which slightly undermines the quantitative precision. However, the detailed breakdown showing 4% U.S. and 3% international growth is correct, and these do mathematically produce the stated total revenues. The semantic meaning and core facts are all correct despite this minor percentage discrepancy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 481,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "\nFrom 2023 to 2024 the Company continued to amortize its network‑location intangibles on a straight‑line basis, but the driver shifted from “the shorter of the ground‑lease term (capped at 20 years)” to a broader useful‑life range of 2‑30 years, with the weighted‑average remaining period still about 15 years as of 31 Dec 2023 (Chunk 1).  In 2024 the impairment review was expanded to an individual‑tower level, requiring recoverability testing via projected undiscounted cash flows and fair‑value measurements that incorporate renewal, turnover and market‑based assumptions (Chunk 2).  A 2024 revision of the asset‑retirement‑obligation settlement dates altered the cash‑flow assumptions used in those tests, producing a $75 million reduction in accretion expense for 2024 and reflecting the updated valuation approach for the intangibles (Chunk 2).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM states a '$75 million reduction in accretion expense for 2024' but the ground truth specifies a '$470 million increase in liability due to revised settlement dates.' This is a major factual error - the direction (reduction vs. increase) and magnitude ($75M vs. $470M) are both incorrect. This represents a fundamental misreading of the source material. (2) AMORTIZATION ASSUMPTIONS - The LLM introduces a new claim about the driver shifting 'from the shorter of the ground-lease term (capped at 20 years) to a broader useful-life range of 2-30 years' which is NOT mentioned in the ground truth. The ground truth only confirms the weighted average amortization period of 15 years in 2023 and straight-line basis treatment. This appears to be fabricated detail. (3) IMPAIRMENT REVIEW PROCESS - The LLM correctly identifies the expansion to individual-tower level assessment and mentions recoverability testing and fair-value measurements, which aligns with the ground truth's mention of 'individual tower basis' and 'specific triggers.' This portion is reasonably accurate. (4) MULTI-HOP SYNTHESIS - The LLM attempts to connect asset retirement obligations to intangible asset valuation, which is conceptually sound per the ground truth, but the specific financial impact is stated incorrectly. (5) MISSING ELEMENTS - The LLM does not mention specific impairment triggers like 'lack of tenant leases or expenses exceeding revenues' that are highlighted in the ground truth. OVERALL: While the LLM demonstrates understanding of the general evolution (straight-line amortization, expanded impairment review, connection to ARO), the critical error regarding the $470M liability increase (stated as $75M reduction) and the unsupported claim about the 2-30 year useful life range significantly undermine credibility and accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amortizes]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 510,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "\nExxonMobil moved from early development in 2023—when the Prosperity FPSO began production in November 2023 and combined gross output from the Stabroek Block rose from ~390 kb/d (2023) to nearly 440 kb/d by Q4 2023—to a clear capacity‑building phase in 2024, targeting six FPSO vessels on the block (including the Whiptail project under regulatory review) and positioning Guyana as a core “Advantaged Asset” in its upstream growth portfolio; the 2024 filing explicitly lists Guyana alongside Permian and LNG as a driver of earnings, underscoring that the company now measures its strategic emphasis on Guyana through concrete production‑capacity targets and its contribution to the expected rise in the Americas‑share of oil‑equivalent output.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of ExxonMobil's Guyana strategy evolution between 2023 and 2024. STRENGTHS: (1) All key numeric values are correct: ~390 kb/d (2023) and nearly 440 kb/d by Q4 2023 match ground truth; (2) Correctly identifies the Prosperity FPSO startup in November 2023; (3) Accurately captures the strategic reclassification of Guyana as an 'Advantaged Asset' in 2024 alongside Permian and LNG; (4) Properly synthesizes the multi-hop information showing transition from discovery/early production phase (2023) to mature, financially impactful asset (2024); (5) Adds valuable context about six FPSO vessels targeting and Whiptail project, which enriches the answer without contradicting ground truth; (6) Correctly identifies the shift in measurement framework from production milestones to capacity targets and earnings contribution. MINOR CONSIDERATIONS: (1) The LLM answer is more detailed and includes additional context (Whiptail project, Americas-share metrics) not explicitly mentioned in the ground truth, but this represents appropriate elaboration rather than error; (2) The phrasing differs from ground truth but semantic meaning is equivalent and arguably more comprehensive. QUANTITATIVE VERIFICATION: Production figures (390 kb/d to 440 kb/d) are accurate; timeline (November 2023 Prosperity startup, Q4 2023 production levels) is correct; FPSO vessel count (six targeting) aligns with 2024 strategic positioning. MULTI-HOP REASONING: Successfully synthesizes information across 2023 and 2024 filings, correctly identifying the strategic elevation and its implications for earnings drivers. The answer demonstrates sound understanding of how Guyana's role evolved from a discovery-focused asset to a core earnings contributor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 490,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "\nBetween 2022 and 2023 Comcast deepened the X1 platform’s integration with third‑party streaming—from the 2022 Flex‑device model that simply aggregated Peacock Premium and a handful of DTC services (and generated commission revenue on those sales) to a 2023 unified X1/NOW offering that delivers DTC streams—including the ad‑supported Peacock tier, Xumo Play, NBC and Sky content—directly through X1 and the international Sky Q platform without a separate set‑top box, and bundles those streams into a residential‑broadband‑only NOW service.  This evolution shows Comcast’s strategy of keeping cord‑cutters inside its ecosystem, using tightly integrated streaming to increase customer engagement and drive higher ARPU through premium subscriptions, advertising‑sales revenue and ongoing commission from third‑party streaming services.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key services integrated in both 2022 and 2023 (Peacock Premium, Disney+, Netflix in 2022; Xumo Play, NBC, Sky in 2023). It accurately captures the strategic pivot toward broadband bundling and the commission-revenue model. The answer correctly identifies the strategic goal of reducing cord-cutting and increasing ARPU through deeper integration. WEAKNESSES: (1) The LLM introduces details not present in the ground truth, specifically mentioning 'Flex-device model,' 'ad-supported Peacock tier,' 'Sky Q platform,' and 'advertising-sales revenue' - these appear to be inferences or additional context not confirmed in the original answer. (2) The LLM's description of the 2023 offering as 'unified X1/NOW offering that delivers DTC streams...directly through X1 and the international Sky Q platform without a separate set-top box' adds specificity about technical implementation that goes beyond the ground truth statement. (3) The ground truth mentions 'NOW TV service, which was specifically marketed to residential broadband customers' while the LLM says 'residential-broadband-only NOW service' - a subtle but potentially significant distinction. (4) The LLM adds 'advertising-sales revenue' as a revenue stream not explicitly mentioned in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes the evolution across years and connects it to strategic implications (cord-cutting reduction, ARPU increase), matching the ground truth's reasoning structure. However, the additional details suggest the LLM may have extrapolated beyond the provided knowledge graph. NUMERIC/DATE ACCURACY: Years (2022, 2023) are correct. No specific financial figures are provided in either answer, so quantitative comparison is limited. The core factual framework is sound, but the LLM's embellishments with unverified details reduce confidence in overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 516,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "\nBetween 2023 and 2024 Caterpillar’s distribution network for FG Wilson‑branded electric‑power‑generation systems changed from **110 distributors covering 109 countries** (2023) to **108 distributors covering 158 countries** (2024).  This reflects a slight reduction in the number of distributors but a marked expansion of geographic coverage, illustrating how the CAT ↔ FG Wilson relationship evolved in terms of market reach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All numeric values are correct - 110 distributors in 2023, 109 countries in 2023, 108 distributors in 2024, and 158 countries in 2024. These match the ground truth exactly. (2) ENTITY ACCURACY: Correctly identifies Caterpillar, FG Wilson, and the relationship between them. Properly references the 2023-2024 timeframe and the specific product category (electric power generation systems). (3) MULTI-HOP REASONING: Successfully synthesizes the evolution of the distribution network across two years, correctly identifying the dual trend of distributor reduction (110→108) and geographic expansion (109→158 countries). The interpretation that this represents 'a slight reduction in the number of distributors but a marked expansion of geographic coverage' is logically sound and matches the ground truth analysis. (4) SEMANTIC EQUIVALENCE: The LLM's phrasing 'marked expansion' is semantically equivalent to the ground truth's 'expansion in the geographic reach.' The conclusion about 'optimizing distributor efficiency while broadening market access' is implicit in the LLM's characterization. Minor difference: The LLM uses 'CAT ↔ FG Wilson relationship' notation which is a stylistic choice that doesn't affect accuracy. The answer is complete, accurate, and appropriately addresses all aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 391,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "\nCapital One reports its securitized debt obligations as liabilities of consolidated VIEs (the structure described in the 2022 filing), and the most recent 2024 data (as of Dec 31 2023) show a carrying amount of **$18,043 million** and a fair value of **$18,067 million** (both Level 2), indicating that the exposure to these obligations was essentially unchanged between 2022 and 2024, with fair value modestly exceeding carrying value.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the 2024 carrying value ($18,043 million) and fair value ($18,067 million) of securitized debt obligations, both categorized as Level 2. The numbers are accurate and properly formatted. The observation that fair value modestly exceeds carrying value is correct. WEAKNESSES: (1) The LLM states the data is 'as of Dec 31 2023' when the question asks about 2024 data - this is a significant dating error that creates confusion about the time period being referenced. (2) The LLM claims exposure was 'essentially unchanged between 2022 and 2024' but provides NO 2022 comparative data or numbers. The ground truth mentions 2022 had securitized debt obligations but doesn't provide specific carrying/fair values for that year. The LLM's assertion of 'unchanged' exposure cannot be verified without 2022 figures and represents incomplete multi-hop synthesis. (3) The answer lacks the contextual detail from the ground truth about the composition of VIE assets (loan receivables and debt securities) and the nature of the securitization activities. (4) The LLM doesn't adequately address the 'change between 2022 and 2024' aspect of the question - it merely states the 2024 figures and makes an unsupported claim about stability. The quantitative data provided is accurate, but the temporal framing is problematic and the comparative analysis is incomplete. The answer partially addresses the question but fails to properly synthesize the multi-hop comparison requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reports]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 414,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s financing cash outflow grew from **$4.4 bn** to **$7.5 bn**—a $3.1 bn increase—because the company issued fewer bonds in 2024 and therefore leaned more heavily on its **revolving line‑of‑credit and commercial‑paper facilities** to meet debt‑service, dividend and share‑repurchase needs; the 2023 filing notes that access to these credit agreements is a key source of short‑term liquidity, and the 2024 filing shows that this access was stepped up as bond issuances declined, even as cash provided by operations fell to $9.4 bn and free cash flow slipped to $6.7 bn, underscoring a shift toward greater reliance on its credit lines for cash‑flow management.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information about McDonald's financing evolution. STRENGTHS: (1) All primary financial figures are correct: $4.4bn (2023 financing cash outflow), $7.5bn (2024), and the $3.1bn increase are all accurate. (2) The core narrative is sound: correctly identifies the shift from bond issuances in 2023 to reduced bond issuances in 2024, driving increased reliance on credit facilities. (3) Multi-hop reasoning is solid: properly connects the decline in bond issuances to increased use of line-of-credit and commercial paper facilities. (4) Correctly identifies the shift from surplus liquidity to cash-constrained environment. (5) Appropriately mentions operational cash flow ($9.4bn) and free cash flow ($6.7bn) as supporting context. MINOR GAPS: (1) The answer does not explicitly mention the cash and equivalents balances ($4.6bn in 2023 declining to $1.1bn in 2024), which are important indicators of the liquidity shift described in the ground truth. (2) Does not explicitly reference the timing of debt issuances that funded 2024's cash outflows, though this is implied in the narrative. (3) The ground truth emphasizes that 2023's higher cash balance was specifically attributed to timing of debt issuances; the LLM captures the concept but doesn't explicitly state this causal relationship. CALCULATION VERIFICATION: The $3.1bn difference ($7.5bn - $4.4bn) is correctly calculated. The characterization of the financing activities change is accurate. SEMANTIC EQUIVALENCE: The LLM's description of 'greater reliance on existing credit facilities' and 'stepped up' access to credit lines effectively conveys the same meaning as the ground truth's 'greater reliance on existing credit facilities.' The answer successfully addresses the core question about how McDonald's use of line of credit agreements evolved, though it could have been more comprehensive by including the cash balance metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 535,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "\nThe Worldwide Business Conduct Manual continues to serve as the core accounting‑policy instrument that the Company discloses as its framework for ethical conduct, and the KG link — PG → Worldwide Business Conduct Manual → PG — confirms that the Manual is both an ACCOUNTING_POLICY and an ORG‑level control.  In the 2022 filing the Manual is cited only as a general commitment to “conduct business with integrity,” whereas the 2024 filing explicitly ties it to the Audit Committee’s review of “critical accounting policies and estimates” and to the Global Leadership Council’s oversight of controls, underscoring a more granular, governance‑driven use of the Manual.  This evolution demonstrates that Procter & Gamble’s approach to governance has matured from a broad‑brush ethics statement to a structured, board‑level reinforcement of internal‑control rigor and risk‑aware financial reporting.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the core evolution described in the ground truth but introduces some analytical elements not explicitly supported by the original answer. STRENGTHS: (1) Correctly identifies the 2022 description as emphasizing 'conduct business with integrity' - matches ground truth exactly; (2) Accurately captures the 2024 shift toward governance frameworks and structured mechanisms; (3) Correctly names the Global Leadership Council as a 2024 governance element; (4) Properly synthesizes the multi-hop comparison across years; (5) No quantitative errors or date misstatements. WEAKNESSES: (1) The LLM introduces technical terminology ('ACCOUNTING_POLICY', 'ORG-level control', 'KG link') that appears to be metadata/system language rather than information from the actual filings - this is not present in the ground truth answer and suggests the model may be conflating its internal representation with filing content; (2) The specific reference to 'Audit Committee's review of critical accounting policies and estimates' is mentioned in the LLM answer but not explicitly stated in the ground truth, which mentions the Disclosure Committee instead - this is a potential entity confusion; (3) The characterization of the Manual as 'the core accounting-policy instrument' is more specific than the ground truth supports; (4) The phrase 'board-level reinforcement' is an inference not directly stated in either source. MULTI-HOP REASONING: The answer correctly synthesizes information across 2022 and 2024 filings and identifies the governance evolution. However, the introduction of technical metadata language and the potential Audit Committee/Disclosure Committee distinction suggest some confusion between actual filing content and system representations. The core insight about evolution from ethics to structured governance is sound and matches the ground truth's conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 518,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "\nExxon’s long‑lived asset base in Guyana expanded sharply—from $4.9 bn in 2021 to $6.8 bn in 2022 and $9.7 bn in 2023, as shown in the 2023 10‑K table—signaling a deliberate deepening of its upstream presence in the country. The 2024 earnings‑driver definitions now classify Guyana as an “Advantaged Asset” (alongside the Permian and LNG), placing it at the core of the company’s “Advantaged Volume Growth” and high‑value, lower‑emission fuel initiatives; this classification is reflected in the KG relationship XOM → Guyana (Operates_In) and Guyana → XOM (Discloses), underscoring that Guyana is both a key operational asset and a disclosed, strategically prioritized growth driver for Exxon.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core strategic evolution—Guyana transitioning from a quantitatively notable asset to a strategically emphasized growth engine. The classification of Guyana as an 'Advantaged Asset' in 2024 is accurate, and the connection to 'Advantaged Volume Growth' earnings driver is correct. The qualitative reasoning about deepening upstream presence and strategic prioritization is sound. The mention of Guyana alongside Permian and LNG as key growth drivers is appropriate.\n\nCRITICAL ERRORS: (1) QUANTITATIVE ACCURACY FAILURE: The LLM provides historical asset values ($4.9bn in 2021, $6.8bn in 2022, $9.7bn in 2023) that are NOT in the ground truth answer. The ground truth only states $9,689 million ($9.7bn) for 2023. The LLM appears to have fabricated or misattributed the 2021-2022 figures, which cannot be verified against the provided ground truth. (2) The LLM rounds $9,689 million to $9.7bn, which is acceptable formatting, but the introduction of unverified historical data is problematic. (3) The LLM adds extraneous detail about KG relationships (XOM → Guyana Operates_In, etc.) that, while potentially accurate, goes beyond what the ground truth explicitly confirms and may represent inference rather than direct disclosure.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2023 and 2024 disclosures and connects asset values to earnings driver definitions. However, the introduction of unverified 2021-2022 data undermines the reliability of the multi-hop synthesis.\n\nCOMPLETENESS: The answer addresses both components of the question (long-lived assets and earnings driver definitions) and shows the evolution between 2023-2024. However, it adds information not confirmed by ground truth.\n\nJUSTIFICATION: The correctness score of 6 reflects that while the core narrative and 2023-2024 evolution are correct, the introduction of unverified historical financial data (2021-2022 figures) represents a significant factual accuracy problem. The quantitative accuracy score of 4 reflects this critical error in presenting numbers not confirmed by ground truth. Qualitative accuracy is 7 because the reasoning and strategic positioning analysis are sound despite the data issues. Contextual relevance is 8 because the answer appropriately addresses the question's focus on 2023-2024 evolution, though it strays into unverified territory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 642,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "\nCapital One’s 2022 filing (Chunk 1) describes securitized debt obligations as one of several wholesale funding sources—alongside deposits, senior notes and other borrowings—used to maintain a diversified mix of financing. By the end of 2024, the company reported $14,264 million of securitized debt obligations on its balance sheet (Chunk 2), underscoring the continued and expanded role of this funding channel within its capital structure. The knowledge‑graph pattern (ORG → raises → FIN_INST ← discloses → ORG) captures the reciprocal relationship between Capital One and the securitized debt obligations it issues, illustrating how the firm’s reliance on this instrument has persisted and grown from 2022 to 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct identification of Capital One's securitized debt obligations evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2024 carrying value of $14,264 million, matching the ground truth exactly. (2) Accurately characterizes 2022 as lacking specific dollar disclosure while emphasizing strategic importance. (3) Properly synthesizes multi-hop information across years and documents. (4) Correctly identifies securitized debt obligations as part of a diversified funding mix including deposits and other instruments. (5) Appropriately describes the evolution as 'continued and expanded role.' MINOR WEAKNESSES: (1) The LLM omits the 2024 fair value figure of $14,335 million that was disclosed in the ground truth, which represents a minor completeness gap. (2) The phrase 'expanded role' is slightly interpretive—the ground truth uses 'increased transparency and continued use' which is more measured. The ground truth explicitly states the 2024 figures represent 'concrete quantification' and 'increased transparency,' whereas the LLM's 'expanded role' could imply growth beyond what the data strictly shows (the ground truth doesn't claim the dollar amount increased, only that it became quantified). (3) The knowledge-graph notation explanation, while interesting, is somewhat tangential to the core question and doesn't add substantive financial analysis. QUANTITATIVE VERIFICATION: The $14,264 million figure is correct and properly formatted. No calculations are required or performed. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024 filings, correctly identifying the progression from qualitative description to quantitative disclosure. The reasoning is sound and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Raises]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 489,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "\nNVIDIA first introduced Omniverse in FY 2022 as a real‑time 3‑D design‑collaboration and simulation platform that “empowers artists, designers and creators” and made it available to enterprises through cloud services such as vGPU, positioning it as a creator‑focused extension of its graphics and AI ecosystem. By FY 2023 the company reframed Omniverse as an enterprise‑grade subscription service (offered alongside a free individual tier) that industrial customers were already using to build digital twins of factories, product configurators and autonomous‑vehicle simulations, embedding the platform in NVIDIA’s full‑stack GPU/DPU/CPU and AI‑Enterprise software and driving adoption through its sales, partner network and developer program. This evolution reflects the shift from a creator‑centric tool to a monetized, enterprise‑focused offering that leverages NVIDIA’s broader accelerated‑computing platform.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively captures the evolution of NVIDIA's Omniverse platform between FY2022 and FY2023. STRENGTHS: (1) Correctly identifies the FY2022 positioning as 'real-time 3D design collaboration and simulation platform' with creator focus; (2) Accurately describes FY2023 evolution to enterprise-grade subscription service with free individual tier; (3) Correctly identifies specific enterprise use cases: digital twins of factories, product configurators, and autonomous-vehicle simulations; (4) Properly synthesizes the strategic shift from creator-centric to enterprise-focused monetized offering; (5) Adds valuable context about integration with NVIDIA's broader GPU/DPU/CPU and AI-Enterprise stack, sales channels, and partner network. MINOR ISSUES: (1) The LLM mentions 'cloud services such as vGPU' for FY2022 positioning, which adds detail not explicitly in the ground truth but is contextually reasonable and not contradictory; (2) The mention of 'autonomous-vehicle simulations' in FY2023 is not explicitly stated in the ground truth (which mentions factories and product configurators), though this represents a reasonable inference about enterprise simulation use cases and doesn't contradict the source material. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations present in either answer - both correctly reference FY2022 and FY2023 without specific financial metrics. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the positioning evolution and adoption patterns. The connection between subscription model, enterprise adoption, and digital twin applications is logically sound. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as the ground truth while providing additional strategic context about NVIDIA's broader platform integration and go-to-market approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 521,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 Pfizer’s outstanding payable to Viatris under the post‑separation agreements fell sharply—from **$94 million** (as of Dec 31 2022) to **$33 million** (as of Dec 31 2023), a reduction of roughly two‑thirds.  This decline reflects the winding‑down of the interim TSAs and MSAs (including the transitional billing, rebate‑remittance and manufacturing arrangements) that were originally set for four‑to‑seven‑year terms, with the related cash flows still reported in operating cash flow (except for the $277 million 2021 financing‑activity payment).  Earlier figures from 2020‑2021 showed much larger balances ($401 million in 2020 and $53 million in 2021), underscoring the progressive reduction of Pfizer’s net amounts due under the various separation‑related agreements.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core numbers: $94 million (Dec 31, 2022) and $33 million (Dec 31, 2023) match the ground truth exactly. The calculation of 'roughly two-thirds' reduction is accurate (61 million reduction / 94 million = ~65%). The answer correctly identifies the entities (Pfizer and Viatris), time periods (2022-2023), and the nature of the agreements (post-separation TSAs and MSAs). Multi-hop reasoning is sound: the answer synthesizes the relationship evolution and contextualizes it within the broader separation framework. The inclusion of additional historical context (2020-2021 figures: $401M and $53M) adds depth and demonstrates understanding of the progressive trend, though this information was not explicitly required by the question. Minor strengths include the explanation of cash flow treatment and reference to the $277 million 2021 financing payment, which provides helpful context. The only minor limitation is that the ground truth answer is more concise and focused, while the LLM answer provides additional contextual details that, while accurate and relevant, go slightly beyond what was explicitly asked. The semantic equivalence is strong—both answers convey the same core finding of significant reduction in net amounts due. No calculation errors detected, and all numeric values are correctly stated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 383,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "\nExxonMobil’s Guyana focus moved from an aggressive 2023 development phase—where the company held 4.6 million offshore acres, completed 12.6 net exploratory/development wells and launched the Payara project while funding the Uaru development—to a 2024 strategic framing that lists Guyana as an “Advantaged Asset” and “Advantaged Project” in its earnings‑driver definitions, highlighting its role as a high‑return growth driver; this re‑classification, disclosed under the ORG‑[Operates_In]-> GPE relationship (XOM operates in Guyana, which discloses to XOM), shows the evolution from pure project execution to positioning Guyana as a core, advantaged growth asset.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of ExxonMobil's Guyana strategy evolution. STRENGTHS: (1) All key quantitative data is correct - 4.6 million offshore acres, 12.6 net exploratory/development wells, and the specific projects (Payara, Uaru) are accurately cited. (2) The core narrative is sound: correctly identifies the 2023 operational phase and 2024 strategic reclassification as 'Advantaged Assets' and 'Advantaged Project.' (3) Multi-hop synthesis is well-executed, connecting operational metrics from 2023 to strategic positioning in 2024. (4) The answer appropriately contextualizes the shift from 'pure project execution' to 'core, advantaged growth asset' positioning. (5) Correctly identifies the strategic elevation alongside Permian Basin and LNG. MINOR WEAKNESSES: (1) The reference to 'ORG-[Operates_In]->GPE relationship' and knowledge graph notation, while technically accurate, adds unnecessary complexity and may confuse readers unfamiliar with knowledge graph terminology - this is more of a presentation issue than factual error. (2) The phrase 'Advantaged Project' appears in the LLM answer but the ground truth specifically mentions 'Advantaged Volume Growth' earnings driver - while semantically related, this is a slight terminology variation. (3) The answer could have been slightly clearer in explicitly stating this represents a formal reclassification in strategic reporting frameworks. VERIFICATION: All numbers check out (4.6M acres, 12.6 wells), project names are correct (Payara, Uaru, Yellowtail mentioned in ground truth), and the 2023-2024 timeline is accurate. The multi-hop reasoning correctly synthesizes operational data with strategic positioning. The answer is more detailed and comprehensive than the ground truth while maintaining accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 497,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "\nFrom 2022 to 2023 the weighted‑average interest rate on CMCSA’s senior notes that mature after 10 years stayed flat at **3.8 %**, while the face amount of those notes modestly rose from **$52.8 billion (2022)** to **$53.4 billion (2023)** – a small increase reflected in the 2023 filing’s “Senior notes with maturities greater than 10 years, at face value” line. This evolution aligns with the disclosure pattern where CMCSA (ORG) discloses the senior‑note instrument (FIN_INST) and shows an “Increases” relationship, indicating the notes’ carrying amount grew while the borrowing cost remained unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - Multiple significant number errors: LLM states 2022 face value was $52.8B, but ground truth shows $54.536B (error of ~$1.7B or 3.1%). LLM states 2023 face value was $53.4B which matches ground truth, but the 2022 baseline is wrong. LLM claims the interest rate 'stayed flat at 3.8%' for both years, but ground truth shows 2022 was 3.67% and 2023 was 3.8% - this is NOT flat/unchanged, it's a 13 basis point INCREASE. (2) DIRECTION OF CHANGE - LLM incorrectly characterizes the face value change as 'modestly rose from $52.8B to $53.4B' when the correct data shows it DECREASED from $54.536B to $53.4B (a $1.136B reduction). This is a fundamental error in describing the evolution. (3) INTEREST RATE CHARACTERIZATION - LLM states the rate 'stayed flat' and 'remained unchanged' when it actually increased from 3.67% to 3.8%. The ground truth explicitly states 'the interest rate remained unchanged at 3.8%' which appears to be an error in the ground truth itself (should say 'increased to 3.8%'), but the LLM's claim of 'stayed flat at 3.8%' is still incorrect since 2022 was 3.67%. (4) MULTI-HOP REASONING - While the LLM attempts to synthesize information and mentions CMCSA and financial instruments, the core numerical facts are wrong, undermining the entire analysis. The reasoning structure is present but built on incorrect data. (5) SEMANTIC ISSUES - The LLM's conclusion that 'the notes' carrying amount grew' contradicts the actual face value decrease from $54.536B to $53.4B.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 424,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "\nBetween the 2023 and 2024 reporting periods the nuclear‑decommissioning trusts managed by Alabama Power and Georgia Power increased their domestic‑equity exposure and moved a larger share of that exposure into Level 2 valuation inputs.  In the 2023 data (Chunk 1) Alabama Power’s domestic equity was classified as Level 2 at **$169 million**, while Georgia Power’s was only **$1 million** (Level 2); by 2024 (Chunk 2) those amounts rose to **$208 million** and **$321 million**, respectively, still under Level 2 classification.  Throughout both years the domestic‑equity holdings were never placed in Level 1, indicating that the trusts continued to rely on observable market inputs rather than quoted‑price Level 1 measurements, but they expanded the observable‑input (Level 2) portion of their portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that fundamentally misrepresent the data: (1) MAJOR ERROR - Level 1 vs Level 2 Classification: The LLM claims domestic equity holdings were 'never placed in Level 1' and that the trusts 'expanded the observable-input (Level 2) portion.' This is completely incorrect. Ground truth shows Alabama Power had $396M in Level 1 (2023) and $443M in Level 1 (2024), and Georgia Power had $255M in Level 1 (2023) and $321M in Level 1 (2024). Level 1 inputs represent quoted prices in active markets - the most transparent valuation method, not Level 2. (2) CRITICAL NUMBER ERROR - Georgia Power 2024: The LLM states Georgia Power's Level 2 rose to '$321 million' in 2024. This is factually wrong - $321M was Georgia Power's Level 1 amount in 2024, not Level 2. Level 2 remained at $1M. (3) INCOMPLETE DATA - Alabama Power Level 1: The LLM completely omits Alabama Power's Level 1 figures ($396M in 2023, $443M in 2024), which represent the majority of their domestic equity holdings and are central to understanding the allocation shift. (4) INVERTED INTERPRETATION: The ground truth indicates a 'strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments,' but the LLM claims the opposite - that holdings moved into Level 2. (5) CALCULATION VERIFICATION: Ground truth totals are correct ($565M for Alabama 2023, $651M for Alabama 2024, $256M for Georgia 2023, $322M for Georgia 2024), but the LLM provides incomplete and misclassified data. The LLM fundamentally misunderstood the valuation hierarchy and misattributed numbers to the wrong classification levels, resulting in a completely inverted narrative about the investment strategy shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 479,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "\nFrom 2022 to 2023 CUDA moved from being a market‑specific accelerator—used in the automotive DRIVE stack, data‑center AI training, and Omniverse‑powered simulation—to the central, programmable layer of NVIDIA’s **full‑stack computing platform** that spans GPUs, networking (Mellanox), DPUs and the new Grace CPU.  In 2023 the company emphasized that **CUDA underpins a unified software stack (libraries, SDKs, AI Enterprise, Omniverse, DRIVE, etc.)** that delivers end‑to‑end solutions across automotive, data‑center, healthcare, manufacturing and other verticals, enabling continuous, software‑defined innovation and order‑of‑magnitude performance gains across every end‑market.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of CUDA's strategic evolution from 2022 to 2023 and correctly identifies the core shift from market-specific positioning to a foundational full-stack computing platform role. STRENGTHS: (1) Correctly identifies the 2023 positioning of CUDA as the central programmable layer of NVIDIA's full-stack platform; (2) Accurately lists domain-specific verticals (automotive, data-center, healthcare, manufacturing) matching the ground truth; (3) Properly emphasizes the 2023 focus on CUDA underpinning hundreds of libraries, SDKs, and APIs; (4) Correctly mentions integration with hardware components (GPUs, networking/Mellanox, DPUs, Grace CPU); (5) No quantitative errors or incorrect dates. WEAKNESSES: (1) The characterization of 2022 CUDA as 'market-specific accelerator' is somewhat imprecise—the ground truth describes it as a 'fundamental building block' supporting multiple end markets through unified architecture, not as market-specific; (2) The LLM answer adds specific product references (Omniverse, DRIVE, AI Enterprise) that, while contextually relevant, go slightly beyond what the ground truth explicitly states about the evolution; (3) The phrase 'order-of-magnitude performance gains' is not explicitly mentioned in the ground truth and represents an inference rather than documented positioning; (4) The 2022 description could be more accurate—it wasn't primarily about 'market-specific' use but rather about supporting multiple markets through unified architecture. MULTI-HOP REASONING: The answer successfully synthesizes the evolution across the two-year period and correctly identifies the shift from foundational component to core enabler of a broader software stack. The reasoning about full-stack integration is sound. SEMANTIC EQUIVALENCE: The core message aligns well with ground truth—CUDA evolved from foundational building block to central platform enabler with expanded software ecosystem. Minor wording differences don't affect the fundamental correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 546,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "\nThe 2020 spin‑off that created Viatris (Chunk 1) established transitional manufacturing and supply agreements and a suite of MSAs—including interim TSAs—between Pfizer and Viatris.  During 2022‑2023 those TSAs were largely completed, causing the net amount payable to Viatris under the agreements to fall from **$94 million at December 31 2022 to $33 million at December 31 2023** (Chunk 2), indicating a winding‑down of the transitional services while the longer‑term MSAs continued but were no longer material to Pfizer’s results.  Cash flows associated with these arrangements are reported in operating activities, except for a $277 million payment to Viatris in 2021 that is classified in financing activities, underscoring that Pfizer’s financial obligations to Viatris have markedly decreased by 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive coverage of the question. QUANTITATIVE VERIFICATION: All key financial figures are correct - the net amounts owed decreased from $94 million (December 31, 2022) to $33 million (December 31, 2023), exactly matching the ground truth. The $277 million payment to Viatris in 2021 is also correctly cited. COMPLETENESS: The answer addresses all major aspects of the question: (1) the evolution of TSAs from 2022 to 2023, (2) the completion status of transitional services, (3) the specific net amounts owed in both years, and (4) the broader context of winding down obligations post-2020 spin-off. ENTITY ACCURACY: Pfizer and Viatris are correctly identified, years are accurate (2020 spin-off, 2022-2023 period), and financial metrics (TSAs, MSAs, net amounts payable) are properly labeled. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple time periods and documents, connecting the 2020 spin-off event to the 2022-2023 TSA completion and financial obligation reduction. The logic is sound - TSAs being completed explains the decrease in net amounts owed. MINOR CONSIDERATIONS: The LLM answer includes additional context about cash flow classification and the distinction between TSAs and longer-term MSAs, which adds value beyond the ground truth but remains accurate. The phrasing 'net amount payable to Viatris' is semantically equivalent to 'net amounts due to Viatris.' The answer correctly characterizes the materiality status and the winding-down nature of the relationship. No factual errors or calculation mistakes detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 446,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "\nFrom 2022 to 2023 Duke Energy’s exposure to retail‑deregulation remained a source of adverse financial pressure—both years warn that deregulation can impair assets, trigger stranded‑cost recoveries, erode profit margins and increase capital‑cost exposure—while the company’s environmental‑regulation compliance costs intensified.  The 2023 filing adds new EPA rules on cooling‑water, CCR management and, critically, stricter carbon‑reduction and greenhouse‑gas reporting requirements that may force additional capital expenditures, limit the ability to recover those costs through rates, and compel earlier retirement of generation assets.  Consequently, the negative nexus between deregulation‑driven financial risk and rising environmental‑compliance costs deepened over the two years.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively synthesizes the multi-hop relationship between deregulation pressures and environmental compliance costs across 2022-2023. STRENGTHS: (1) Correctly identifies the core nexus between deregulation and environmental compliance challenges; (2) Accurately references specific regulatory developments (EPA cooling-water rules, CCR management, carbon reduction/GHG reporting); (3) Properly captures the temporal evolution showing intensification from 2022 to 2023; (4) Correctly identifies the financial mechanism (inability to recover costs through rates in competitive markets); (5) Appropriately emphasizes the compounding negative effect of these two pressures. MINOR GAPS: (1) The LLM answer mentions 'CCR management' and 'stricter carbon-reduction and greenhouse-gas reporting requirements' which are reasonable inferences but not explicitly detailed in the ground truth; (2) The ground truth specifically mentions 'above-market purchased power commitments from qualifying facilities (QFs) under PURPA' as a 2022 concern, which the LLM answer does not explicitly reference, though it captures the broader stranded-cost concept; (3) The ground truth mentions 'new state-level carbon reduction goals more aggressive than the company's own plans' which adds important context about regulatory stringency that the LLM answer doesn't explicitly state. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not applicable. The dates (2022, 2023) are correctly referenced. MULTI-HOP REASONING: The LLM successfully synthesizes information across two years and two regulatory domains (deregulation and environmental compliance), correctly identifying how they interact to create compounded financial pressure. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The LLM's phrasing 'negative nexus' effectively conveys the same relationship as the ground truth's 'deregulation pressures have compounded the challenge.' The answer is semantically equivalent while using slightly different terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> REGULATORY_REQUIREMENT <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 576,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "\nThe retail share of Skoal fell from **9.3 % in 2023 to 7.6 % in 2024** (Chunk 2), a drop of roughly 1.7 percentage points.  At the same time, USSTC repeatedly raised the list price of Skoal during 2023 – $0.09 per can in January 2023 and $0.10 per can in April 2023, with an additional $0.11 increase announced for January 2024 – illustrating a strategy of frequent price hikes (Chunk 1, KG ORG‑Increases‑PRODUCT).  These pricing moves are embedded in the company’s broader capital‑resource plan, which relies on subsidiary cash flows and access to credit markets to fund dividends, share repurchases and other financing needs (Chunk 3 & 4).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN PRICING DATA: The LLM answer contains significant factual errors regarding the 2023 pricing increases. Ground truth states increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022 respectively, PLUS a $0.11 increase announced in 2023 for January 2024. The LLM incorrectly reports $0.09 in January 2023 and $0.10 in April 2023, which do not match the ground truth. The $0.11 January 2024 increase is correctly identified. CORRECT ELEMENTS: (1) Retail share decline from 9.3% to 7.6% is accurate, (2) The 1.7 percentage point calculation is correct, (3) The identification of multiple price increases in 2023 is correct in concept, (4) The connection between pricing strategy and market share decline is appropriately made. INCOMPLETE SYNTHESIS: The LLM answer fails to mention the earlier 2022 price increases ($0.09, $0.09, $0.08) that are part of the cumulative pricing context provided in the ground truth. The answer also adds extraneous information about capital-resource plans and financing that, while potentially accurate, is not directly relevant to answering the specific question about retail share change and pricing strategy contrast. MULTI-HOP REASONING: The answer does synthesize information across multiple chunks and correctly identifies the contrast between aggressive pricing and declining market share, but the specific pricing figures are materially incorrect. The reasoning that cumulative price increases may have impacted demand is sound but based on incomplete/incorrect pricing data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 426,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "\nAmgen’s holding of “Other short‑term interest‑bearing securities” was unchanged between the two reports – the amortized cost and fair‑value amount stayed at **$138 million** in both the 2023 and 2024 tables (Chunk 1 and Chunk 2).  This stability reflects a consistent short‑term investment approach in which Amgen maintains a modest, low‑risk position in short‑term interest‑bearing instruments, using the disclosed security as a stable liquidity‑management tool rather than expanding or reducing its exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-reasoned. (1) QUANTITATIVE ACCURACY: The key financial figure of $138 million for both 2023 and 2024 is correct and matches the ground truth exactly. The answer correctly identifies that the amount remained unchanged between the two periods. (2) ENTITY ACCURACY: Amgen is correctly identified, the metric 'Other short-term interest-bearing securities' is accurately referenced, and both fiscal years (2023 and 2024) are correctly cited. (3) MULTI-HOP REASONING: The answer successfully synthesizes information across two reporting periods and correctly identifies the stability pattern. The reasoning that this reflects a 'consistent short-term investment approach' is sound and logically derived from the unchanged figures. (4) COMPLETENESS: The answer addresses both parts of the question - how the investment evolved (unchanged at $138M) and what this indicates about strategy (consistent, modest, low-risk approach focused on liquidity management). (5) SEMANTIC EQUIVALENCE: The LLM answer goes slightly beyond the ground truth by providing additional interpretive context about the company's liquidity management strategy and characterizing the position as 'modest' and 'low-risk,' which is reasonable inference from the stability and magnitude of the investment. This additional context is appropriate and enhances understanding without contradicting the ground truth. The only minor distinction is that the ground truth uses simpler language ('maintained a consistent approach') while the LLM provides more detailed strategic interpretation, but both convey the same core finding. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 461,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "\nFrom FY 2021 (the 2022 reference point) through FY 2024, GD’s Abrams Main Battle Tank Upgrade program broadened both its functional scope and its value: the earlier $360 million award (Chunk 1) covered only tank upgrades, mission‑control units and systems technical support, whereas the 2024 award (Chunk 2) adds $350 million for engineering, logistics and sustainment support services and includes a separate $285 million contract to produce SEPv3‑configured tanks for Romania, expanding the effort internationally; this evolution is reflected in the reciprocal KG relationship (GD ↔ Abrams Main Battle Tank Upgrades) where GD both receives the upgrade contract and produces the upgraded tanks, a dynamic also evident in the Technologies segment’s $48.1 billion backlog—up 18 % year‑over‑year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the multi-hop question. QUANTITATIVE VERIFICATION: All dollar amounts are correct ($360M for 2022, $350M and $285M for 2024), and the 18% year-over-year backlog increase is accurately cited. The total contract value evolution is properly synthesized ($360M in 2022 vs. $635M combined in 2024). COMPLETENESS: The answer addresses all key aspects of the question: (1) 2022 contract scope (upgrades, mission control units, technical support), (2) 2024 contract evolution (engineering, logistics, sustainment support), (3) international expansion (Romania SEPv3 production), and (4) the shift from upgrade-focused to broader production/support scope. ENTITY ACCURACY: General Dynamics, Abrams Main Battle Tank Upgrades, Romania, and SEPv3 configuration are all correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple contracts and years, correctly identifying the evolution pattern and explaining the relationship between upgrade contracts and production contracts. The mention of the Technologies segment backlog ($48.1B, +18% YoY) adds relevant contextual support, though this is somewhat tangential to the core question. MINOR OBSERVATIONS: The reference to 'FY 2021 (the 2022 reference point)' is slightly confusing in phrasing but technically accurate. The KG relationship notation (GD ↔ Abrams) is appropriate technical language. The answer could have been slightly more explicit about the total value increase ($360M to $635M), but this is a minor omission. Overall, the answer demonstrates excellent synthesis of multi-hop information with accurate numbers and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Receives]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 467,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "\nFrom 2023 to 2024, AIG’s borrowing relationship with Corebridge was extended—Corebridge could keep the facility in place through **February 25, 2025** (Chunk 1). In 2024, AIG began recognizing income from Corebridge on an **equity‑method basis**, recording the dividends it received and the change in Corebridge’s stock price for the period **June 10 – December 31, 2024** (Chunk 2). This shows the evolution from simply maintaining a credit line to actively capturing earnings through AIG’s equity stake, consistent with the mutual “Has_Stake_In” relationship that impacts both entities.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with minor discrepancies. STRENGTHS: (1) Correctly identifies the February 25, 2025 borrowing facility deadline, matching ground truth exactly. (2) Accurately captures the shift from borrowing-based to equity-method income recognition in 2024. (3) Properly synthesizes multi-hop information showing the evolution of the relationship across years. (4) Correctly identifies the time period for equity method income recognition (June-December 2024). (5) Appropriately explains the conceptual shift from credit line maintenance to equity stake earnings capture. MINOR ISSUES: (1) Date discrepancy: LLM states 'June 10 – December 31, 2024' while ground truth indicates 'June 9, 2024' as the start date. This is a one-day difference that may reflect rounding or source variation, but represents a minor quantitative inaccuracy. (2) The LLM adds interpretive language about 'mutual Has_Stake_In relationship' which, while contextually relevant, goes slightly beyond the ground truth answer's scope. QUANTITATIVE VERIFICATION: The February 25, 2025 date is correct. The 2024 equity method income period is substantially correct (June 9/10 vs December 31). QUALITATIVE ASSESSMENT: The reasoning correctly identifies the transformation from borrowing arrangement to equity-based returns, demonstrating sound multi-hop synthesis across 2023 and 2024 data. The answer appropriately addresses both components of the question (borrowing arrangements and income recognition). Overall, this is a high-quality response with one minor date discrepancy that does not materially affect the correctness of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 449,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla moved from emphasizing Solar Roof’s design refinements, aesthetic‑durability integration and improved installation workflow—including collaborations with builders and the use of its own solar inverter and Powerwall linkage (Chunk 1)—to openly acknowledging that delivering the product now depends on overcoming production bottlenecks, securing reliable component supplies and scaling manufacturing across multiple sites, with the 2024 filing explicitly citing supplier delivery risks, raw‑material inflation and factory construction delays as critical strategic dependencies for the Roof’s ramp (Chunk 2). This evolution reflects a shift from product‑centric innovation to a manufacturing‑ and supply‑chain‑focused strategy that ties the Solar Roof’s success directly to Tesla’s own production capabilities and external supplier performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024 with accurate characterization of each period - 2022 focused on design refinements, aesthetics, durability integration, and installation workflow improvements; 2024 focused on production challenges and dependencies. (2) Accurately captures the shift in strategic emphasis from product-centric innovation to manufacturing and supply-chain focus. (3) Properly synthesizes multi-hop information by connecting 2022 product development activities (collaborations with builders, solar inverter and Powerwall integration) to 2024 production challenges (bottlenecks, supplier risks, cost control). (4) Correctly identifies specific 2024 challenges: supplier delivery risks, raw-material inflation, and factory construction delays. (5) No quantitative errors - no specific numbers or percentages were required for this question, and the temporal references (2022, 2024) are accurate. (6) The reasoning is sound and demonstrates proper understanding of the evolution narrative. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and specific than the ground truth (mentioning solar inverter, Powerwall linkage, and specific challenges like raw-material inflation), but these additions are factually accurate enhancements that strengthen rather than contradict the core answer. The semantic equivalence is excellent - phrases like 'depends in large part' (ground truth) align with 'depends on overcoming' (LLM answer). The multi-hop synthesis correctly bridges the 2022-2024 comparison across multiple dimensions of the Solar Roof strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 466,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "\nSkoal’s U.S. oral‑tobacco retail share fell from **9.3 % in 2023 to 7.6 % in 2024**—a decline of about 1.7 percentage points (≈ 18 % relative)—while the overall oral‑tobacco market share dropped from **42.5 % to 37.5 %**. This reduction, disclosed by Altria (MO) which **produces Skoal**, signals a weakening competitive position as the brand loses ground to rivals such as **on!** and as inflation‑driven discretionary‑income pressures and the industry’s shift toward smoke‑free products reshape adult tobacco purchasing behavior.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) Core Skoal market share numbers are correct: 9.3% (2023) → 7.6% (2024), matching ground truth exactly. (2) Correctly identifies the 1.7 percentage point decline and calculates the relative decline (~18%). (3) Properly identifies Altria as Skoal's producer. (4) Correctly mentions on! as a competing product gaining share. (5) Reasoning about weakening competitive positioning is sound and matches ground truth interpretation. (6) Contextual discussion of market dynamics (inflation, smoke-free products) is relevant and reasonable.\n\nWEAKNESSES: (1) CRITICAL ERROR - Introduces unsupported claim about 'overall oral-tobacco market share dropped from 42.5% to 37.5%'. This information does NOT appear in the ground truth and appears to be fabricated or confused with different metrics. The ground truth makes no mention of overall market share percentages at these levels. (2) The LLM conflates Skoal's individual brand share with some undefined 'overall oral-tobacco market share' metric that is not substantiated. (3) This additional claim, while not directly contradicting the core answer, introduces unverified information that could mislead readers about market-wide trends.\n\nMULTI-HOP REASONING: The model correctly synthesizes that Skoal (produced by Altria) lost share while on! gained share, demonstrating proper multi-hop synthesis. However, the introduction of unverified market-wide statistics undermines the overall credibility.\n\nCALCULATION VERIFICATION: The 1.7 percentage point decline (9.3 - 7.6 = 1.7) is correct. The ~18% relative decline calculation (1.7/9.3 ≈ 0.183 or 18.3%) is accurate.\n\nJUSTIFICATION: The answer correctly addresses the primary question about Skoal's share change and competitive positioning. However, the introduction of unsubstantiated market share figures (42.5% → 37.5%) represents a significant factual error that cannot be verified against the ground truth. This reduces the correctness score despite the core answer being sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 538,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "\nThe risk tied to Concentration_of_Device_Share has remained a material concern from the 2023 filing through the 2024 filing, with both Item 1A sections explicitly warning that premium‑tier handset share is now concentrated among a few OEMs—especially certain Chinese manufacturers and Apple—granting them outsized purchasing power that can compress Qualcomm’s average selling prices.  This concentration also makes Qualcomm’s revenue highly dependent on the timing and success of those customers’ flagship product launches, and the possibility that they will vertically integrate (e.g., develop their own integrated‑circuit solutions) or shift to competitors further threatens pricing power and revenue stability.  Consequently, the 2024 filing shows the same structural risk that was highlighted in 2023, indicating that the exposure has not diminished and continues to pose a downward pressure on prices and a volatility risk to Qualcomm’s top line.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the core risk - concentration of device share among premium tier OEMs (Chinese manufacturers and Apple) - matching the ground truth's emphasis on Chinese OEMs and premium tier companies. (2) Accurately captures the mechanism of risk: outsized purchasing power leading to compressed average selling prices (ASPs), which directly addresses Qualcomm's pricing power. (3) Properly synthesizes the multi-hop evolution between 2023 and 2024: both years show the same structural risk persisting, with the 2024 filing emphasizing broader implications including revenue fluctuation from product launch timing and vertical integration threats. (4) Correctly identifies secondary risks: customer vertical integration (developing own ICs) and switching to competitors, which aligns with ground truth's mention of 'using competitors.' (5) Accurately characterizes the impact trajectory: risk has 'not diminished' and 'continues to pose downward pressure' - semantically equivalent to ground truth's 'not only persisted but potentially intensified.' (6) No quantitative errors - no specific numbers were required or provided, which is appropriate given the qualitative nature of risk disclosures. MINOR CONSIDERATIONS: The LLM answer explicitly names Apple alongside Chinese OEMs, while the ground truth emphasizes 'particularly Chinese OEMs' without explicitly naming Apple. However, this is not an error - Apple is indeed a premium tier OEM with significant purchasing power, and the LLM's inclusion adds specificity without contradicting the ground truth. The answer demonstrates sound multi-hop reasoning by synthesizing information across 2023 and 2024 filings to show evolution (or lack thereof) in the risk profile. The semantic equivalence is strong throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 510,
        "total_tokens": 2004
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "\nAmgen’s short‑term liquidity strategy continued to hold roughly the same amount of money‑market exposure – $10,266 million in fair‑value assets – in both 2023 and 2024, as shown in the “Money market mutual funds” line of the available‑for‑sale investment tables for each year. This stability means the fund’s allocation to money‑market mutual funds remained essentially unchanged (representing about 98‑99 % of the $10,404 million total short‑term investment portfolio), reflecting Amgen’s consistent approach to managing liquidity over the two periods. The repeated disclosure of this position also aligns with the KG relationship **ORG → Has_Stake_In → FIN_INST** and **FIN_INST → Discloses → ORG** for Amgen and its money‑market holdings.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core fact that Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The key financial figure is accurate and properly formatted. The answer appropriately characterizes this as 'essentially unchanged' and 'stable,' which aligns with the ground truth statement that the allocation 'remained unchanged.' The LLM also correctly identifies these as available-for-sale investments and notes the consistency in Amgen's short-term investment strategy. However, there are some issues: (1) The percentage calculations (98-99% of $10,404 million total) are not verified in the ground truth and appear to be inferred rather than explicitly stated in the source documents. While the math is plausible ($10,266/$10,404 ≈ 98.7%), introducing unverified percentages adds information not in the original answer. (2) The reference to KG relationships (ORG → Has_Stake_In → FIN_INST, etc.) is somewhat tangential and not directly relevant to answering the specific question about allocation evolution. This adds conceptual framework but doesn't strengthen the core answer. (3) The phrase 'fund's allocation' is slightly imprecise - it should be 'company's allocation' since Amgen is the company, not a fund. The multi-hop reasoning is sound (comparing 2023 and 2024 values), and the answer correctly synthesizes the information. The core message matches the ground truth: no change in allocation between the two years. The answer is more detailed than necessary but remains factually grounded on the primary metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 437,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "\nGeneral Dynamics’ pledged U.S. government accounts receivable to the Capital Construction Fund rose from **$295 million** (as reported for Dec 31 2021/2022 in the 2022 filing) to **$315 million** as of Dec 31 2023 and further to **$333 million** as of Dec 31 2024 (2024 filing), demonstrating a steady increase in the amount of funds pledged over the 2022‑2024 period. This growth reflects the deepening participation of GD in the CCF program, consistent with the ORG → FIN_INST ↔ ORG relationship linking GD to the Capital Construction Fund.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All financial figures are correct: $295 million (Dec 31, 2021), $315 million (Dec 31, 2023), and $333 million (Dec 31, 2024). The dates are accurately presented, and the progression clearly shows the steady increase in pledged accounts receivable. The multi-hop synthesis is sound—the answer correctly connects General Dynamics' participation in the CCF across the 2022-2024 period by extracting and comparing data points from multiple filing years. The reasoning about 'deepening participation' and 'growing utilization of tax deferral benefits' aligns with the ground truth's characterization of 'steady increase' and reflects appropriate interpretation of the data. The only minor distinction is that the LLM includes a reference to 'ORG → FIN_INST ↔ ORG relationship' which, while not incorrect, is somewhat technical/meta-commentary that goes slightly beyond what the ground truth explicitly states. However, this does not detract from factual accuracy. The answer fully addresses the question's focus on evolution between 2022 and 2024, properly contextualizes the amounts pledged, and maintains semantic equivalence with the ground truth throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Participates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 344,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "\nBetween 2023 and 2024 AIG’s stake in Corebridge fell below the 80 % threshold that had previously allowed the two entities to file a consolidated U.S. federal tax return, so the IPO‑induced deconsolidation removed Corebridge (and its subsidiaries) from AIG’s tax‑group filing — Corebridge now files its own return and retains any net operating losses and tax‑credit carryforwards that were unused before the split, while AIG can no longer benefit from those attributes. Consequently, AIG’s remaining interest in Corebridge is now accounted for under the equity‑method, and the company reports “investment income” that consists of dividends received plus the unrealized gains from the change in the stock’s market value (e.g., Corebridge’s pre‑tax income for June 10 – Dec 31 2024 and the corresponding equity‑method income disclosed in the 2024 filing). This shift eliminates the prior tax‑consolidation effects and replaces them with equity‑method earnings that are subject only to AIG’s own tax rate on the recognized income.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the multi-hop relationship between AIG and Corebridge's financial evolution from 2023-2024. STRENGTHS: (1) Correctly identifies the 80% ownership threshold and its tax implications; (2) Accurately describes the deconsolidation mechanics and tax consequences (NOL/credit carryforward retention by Corebridge); (3) Properly explains the shift from consolidated to equity-method accounting; (4) Correctly notes the timing of the IPO (September 19, 2022) and its effects materializing in 2023; (5) Accurately describes equity-method income components (dividends + unrealized gains from stock price changes); (6) Sound multi-hop reasoning synthesizing tax, accounting, and investment relationship changes. WEAKNESSES: (1) The original answer references '$X in equity method income for the period from June 10, 2024, to December 31, 2024' but the LLM answer does not provide the specific dollar amount - this is a notable omission since the ground truth explicitly mentions a quantifiable figure was disclosed; (2) The LLM answer states 'Corebridge's pre-tax income for June 10 – Dec 31 2024' which is somewhat vague and doesn't clearly specify the actual equity-method income amount that should have been disclosed; (3) Minor imprecision: the LLM says the relationship shift 'eliminates the prior tax-consolidation effects' which is accurate but could be clearer that this occurred in 2023 specifically when ownership fell below 80%. QUANTITATIVE ACCURACY: The 80% threshold and date references are correct. However, the missing specific dollar amount for equity-method income (referenced as '$X' in ground truth) represents an incomplete quantitative disclosure. QUALITATIVE ACCURACY: The reasoning about tax consolidation mechanics, NOL/credit treatment, and equity-method accounting is sound and demonstrates proper synthesis of multi-hop information. CONTEXTUAL RELEVANCE: Highly relevant to the question, addressing all major aspects of the financial relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 545,
        "total_tokens": 2032
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "\nIn 2022 Tesla accelerated Solar Roof output by expanding installer training, partnering with developers, and tightening battery‑cell supply—efforts backed by a $5‑7 billion capital‑expenditure plan and the need to hire additional skilled electricians to meet rising demand. By 2024 the company shifted to a more resilient supply‑chain strategy, diversifying single‑source suppliers, investing in localized procurement and improving component forecasting to offset supplier failures, raw‑material price spikes and logistics disruptions that had previously caused bottlenecks. Throughout both years Solar Roof, produced by TSLA, remained tightly linked to Tesla’s broader energy‑storage and manufacturing footprint, requiring coordinated global component sourcing, factory construction timelines and cross‑selling of Powerwall to sustain margin expansion.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS: The LLM introduces a '$5-7 billion capital-expenditure plan' that does NOT appear in the ground truth and cannot be verified from the original answer. This is a significant factual fabrication. (2) UNSUPPORTED CLAIMS: The LLM adds specific details about 'diversifying single-source suppliers,' 'localized procurement,' 'component forecasting,' and 'cross-selling of Powerwall' that are NOT mentioned in the ground truth. While these may be plausible business strategies, they are not supported by the original answer and represent hallucination. (3) PARTIAL CORRECTNESS: The LLM correctly identifies the 2022 focus on installer training, developer partnerships, battery cell supply, and hiring electricians. It also correctly identifies the 2024 shift toward supply chain resilience and managing global component procurement. (4) MULTI-HOP REASONING: The core evolution narrative is partially correct—the shift from localized installer development to systemic supply chain concerns is captured. However, the LLM embellishes this with unsupported details. (5) ENTITY ACCURACY: Tesla/TSLA identification is correct, years are correct. (6) SEMANTIC ISSUES: The phrase 'tightening battery-cell supply' in 2022 is somewhat ambiguous compared to ground truth's 'maintain adequate battery cell supply'—the LLM's phrasing could imply constraint rather than adequacy. The ground truth emphasizes the NEED to maintain supply, not that they were actively tightening it. VERDICT: While the LLM captures the general trajectory and some key facts, it introduces multiple unverified claims and specific numbers/strategies not in the ground truth, which violates the requirement for factual accuracy in financial analysis. The fabricated $5-7B capex figure is particularly problematic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 493,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "\nDuke Energy’s total‑cost estimate for permanently closing all of its North Carolina and South Carolina coal‑ash basins fell from **about $8 billion–$9 billion in the 2022 filing (with roughly $3.1 billion already spent by end‑2021)** to **about $7 billion–$8 billion in the 2023 filing (with roughly $4 billion spent through 2023)**, a reduction of roughly $1‑$2 billion after the 2019 settlement and the completion of excavations at several sites.  This downward revision and the higher cumulative spend show that the company is making tangible progress under the Coal Ash Act—moving from planning and legal challenges toward actual closure implementation and cost‑saving execution of the mandated basin closures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data points are correct: (1) 2022 estimate of $8-9 billion matches ground truth exactly; (2) 2023 estimate of $7-8 billion matches ground truth exactly; (3) cumulative spend through 2021 of $3.1 billion is correct; (4) cumulative spend through 2023 of $4 billion is correct. The calculation of the reduction ($1-2 billion) is accurate. The multi-hop synthesis is sound—the answer correctly connects the cost estimate evolution across years with the cumulative spending progress, demonstrating understanding that both metrics indicate forward progress. The LLM appropriately identifies the Coal Ash Act context and references the 2019 settlement as relevant background. The reasoning that 'downward revision and higher cumulative spend show tangible progress' is logically sound and semantically equivalent to the ground truth's conclusion about 'measurable progress' and 'cost estimates refined over time.' Minor enhancement: the LLM adds interpretive context about 'moving from planning and legal challenges toward actual closure implementation' which, while reasonable inference, goes slightly beyond what the ground truth explicitly states, but this is a minor elaboration that doesn't contradict the facts. All entities (Duke Energy, North Carolina, South Carolina, Coal Ash Act) are correctly identified. The answer fully addresses both parts of the multi-part question: the evolution of cost estimates AND what it indicates about progress.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 421,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "\nThe retail share of **on!** rose from **6.8 % (2023) to 8.3 % (2024)** – an increase of roughly 1.5 percentage points – as shown in the 2024 10‑K table (Chunk 2). At the same time the **total oral‑tobacco segment’s retail share fell from 42.5 % to 37.5 %** (Chunk 2), a contraction that the 2023 filing notes is driven by “discretionary‑income pressures” and a shift toward smokefree products (Chunk 1). Thus, while the overall oral‑tobacco market is shrinking, **on!** is gaining ground within that segment, indicating that the product is strengthening its relative market position for Altria’s innovative smokefree portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive synthesis. All quantitative data is correct: 'on!' retail share increased from 6.8% (2023) to 8.3% (2024), representing a 1.5 percentage point increase; total oral tobacco segment declined from 42.5% to 37.5%. The calculation of the 1.5 percentage point difference is accurate. The multi-hop reasoning is sound—the answer correctly synthesizes information across multiple data points to show the divergence between 'on!' gaining share while the overall segment contracts. Entity identification is accurate (on! product, oral tobacco segment, Altria context). The answer goes beyond the ground truth by providing contextual explanation about discretionary-income pressures and smokefree product shifts, which adds valuable insight without contradicting the core facts. The semantic meaning perfectly matches the ground truth: 'on!' strengthened its position within the broader oral tobacco market despite overall segment decline. Minor note: The LLM includes source references (Chunk 1, Chunk 2) and contextual business drivers that enhance understanding, though these weren't explicitly required. The conclusion that 'on!' is 'strengthening its relative market position' directly aligns with the ground truth statement about strengthening position within the broader market.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 373,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "\nFrom the 2023 and 2024 filings, Qualcomm continues to derive a **significant portion of its revenue from a small number of Chinese OEMs**, a dependence that both years’ risk‑factor sections explicitly note has been **growing as those OEMs increase their device share in China and abroad**.  The filings warn that any slowdown—whether from U.S./China trade or security tensions, customers vertically integrating (building their own chips), or policy‑driven restrictions—could sharply cut those revenues, directly threatening Qualcomm’s cash flow and its ability to sustain expected operating results, thereby underscoring a **persistent stability risk tied to that concentration**.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core facts: (1) Qualcomm derives significant revenue from a small number of Chinese OEMs in both 2023 and 2024, (2) this dependency persists across both years, (3) risks include U.S./China trade tensions and security concerns, (4) vertical integration by customers poses a threat. The answer appropriately synthesizes multi-hop information across the two filing years and identifies relevant risk factors. WEAKNESSES: (1) The LLM claims the dependency has been 'growing' - the ground truth states it 'persisted' or 'continued,' which is a subtle but important distinction. The ground truth does not explicitly state growth in the dependency itself, only that Chinese OEMs are increasing their device share. This represents a minor but meaningful overstatement. (2) The LLM introduces specific risks (vertical integration, policy-driven restrictions) that are reasonable inferences but are not explicitly confirmed in the ground truth provided. While these may be accurate from the filings, they go beyond what the ground truth explicitly states. (3) The answer adds interpretive language about 'sharply cut those revenues' and 'directly threatening Qualcomm's cash flow' which, while logically sound, represents inference beyond the ground truth's more measured statement about 'risk to Qualcomm's revenue stability.' QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is neutral (7/10 - no errors but also no specific metrics to verify). QUALITATIVE ACCURACY: The core reasoning is sound (5/10 because of the 'growing' vs 'persisted' distinction and the introduction of unstated specific risks). CONTEXTUAL RELEVANCE: The answer appropriately addresses the evolution question and implications for business stability (7/10 - good coverage but slightly overstated in places).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Derives_Revenues_From]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 513,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "\nBetween 2022 and 2023 Amgen’s total available‑for‑sale investments jumped from **$4.3 billion** (2022) to **$10.4 billion** (2023) — the increase is evident in the consolidated balance‑sheet figures shown in Chunk 1. In 2023 the portfolio was composed almost entirely of **money‑market mutual funds ($10.266 billion) and other short‑term interest‑bearing securities ($0.138 billion)**, with no U.S. Treasury bills, whereas the 2022 balance consisted of **$1.676 billion of marketable securities** (the only security‑type detail disclosed for that year) and no money‑market funds, as reported in Chunk 2. Thus, the composition shifted from a modest mix of marketable securities to a near‑total holdings of cash‑equivalent money‑market instruments and short‑term securities.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) Total available-for-sale investments 2022: $4,335M stated in ground truth, LLM correctly rounds to $4.3B - acceptable format variation. (2) Total available-for-sale investments 2023: $10,404M in ground truth, LLM states $10.4B - correct format variation. (3) 2023 composition: Ground truth specifies $10,266M in money market mutual funds and $138M in other short-term interest-bearing securities. LLM states $10.266B and $0.138B respectively - correct with proper format conversion. (4) 2022 composition: Ground truth mentions $1,676M in marketable securities; LLM correctly identifies $1.676B. (5) Strategic shift: Both answers correctly identify the shift from marketable securities to money market mutual funds and short-term interest-bearing securities. The LLM properly synthesizes the multi-hop comparison across two years and correctly identifies the absence of U.S. Treasury bills in 2023 (though ground truth mentions they were absent in 2023, not present in 2022). Minor note: The ground truth mentions $2,659M in cash and cash equivalents in 2022, which the LLM does not explicitly state, but this is a minor omission that doesn't affect the core answer about available-for-sale investments composition. The LLM's characterization of the shift as moving toward 'more liquid and short-term interest-bearing instruments' aligns with the ground truth's assessment. All calculations are implicit and correct. The answer directly addresses the question about evolution of composition between the two years with proper multi-hop reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 446,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "\nBetween 2022 and 2023 Shake Shack moved from SPG’s Woodbury Common Premium Outlets (NY) – where it appears in the 2022 tenant list (Chunk 1) – to joining the tenant roster at SPG’s Las Vegas Outlets (NV) in 2023, as shown in the 2023 list (Chunk 2); this shift reflects the mutual ORG‑[Supplies]→COMP and COMP‑[Discloses]→ORG relationship between SPG and Shake Shack that the knowledge‑graph triplets capture.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth states that Shake Shack was present at Woodbury Common in 2022 AND remained there in 2023 (expansion to a second location). However, the LLM answer incorrectly characterizes this as a MOVE ('moved from...to joining'), implying Shake Shack left Woodbury Common and relocated to Las Vegas Outlets. This is a significant misrepresentation of the actual evolution. The correct narrative is one of EXPANSION (presence at both locations by 2023), not relocation. Additionally, the LLM answer includes extraneous knowledge graph notation (ORG-[Supplies]→COMP, COMP-[Discloses]→ORG) that is not relevant to answering the question and appears to be internal system artifacts rather than substantive analysis. The answer does correctly identify the two properties (Woodbury Common Premium Outlets in NY and Las Vegas Outlets North Premium in Nevada) and the two years (2022 and 2023), but the core interpretation of how Shake Shack's presence 'evolved' is inverted. The question asks about evolution/growth, and the ground truth shows expansion across multiple properties, but the LLM describes a relocation. This is a multi-hop reasoning failure where the model failed to properly synthesize the tenant information across both years and both properties.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 383,
        "total_tokens": 1565
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "\nBetween 2022 and 2024 GD continued to classify retirement‑annuity contracts as **Level 3** assets—i.e., they are valued using significant unobservable inputs rather than quoted market prices (both years list Level 3 as “insurance deposit contracts, retirement annuity contracts and real‑estate funds”).  The only evolution is that the surrounding hierarchy shifted: Level 1 moved from publicly‑traded equities (2022) to commingled equity/fixed‑income funds priced by NAV (2024), and Level 2 now emphasizes observable inputs for similar assets, but the **retirement‑annuity line remains in Level 3**, confirming that GD’s valuation methodology for these contracts has been consistent—relying on internal models and unobservable assumptions with no re‑classification to a lower tier.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that retirement annuity contracts remained classified as Level 3 assets in both 2022 and 2024, which matches the ground truth. However, there are significant issues with the response: (1) CORRECT ELEMENTS: The core fact that retirement annuity contracts stayed in Level 3 is accurate, and the characterization of Level 3 as using unobservable inputs is correct. (2) MISSING KEY INSIGHT: The LLM completely misses the critical evolution identified in the ground truth—that by 2024, investments valued using NAV as a practical expedient were now included in reconciliation tables, which was not explicitly stated in 2022. This is a material disclosure refinement that the question specifically asks about. (3) INCORRECT FOCUS: The LLM spends considerable effort discussing how Level 1 and Level 2 changed between years, which is tangential to the question about retirement annuity contracts specifically. The statement about Level 1 moving from 'publicly-traded equities' to 'commingled equity/fixed-income funds priced by NAV' is not directly supported by the ground truth and distracts from the main answer. (4) INCOMPLETE SYNTHESIS: While the LLM correctly notes consistency in classification, it fails to capture the nuanced point that the ground truth makes: the evolution was in disclosure practices and transparency (how NAV-valued investments are now explicitly included in reconciliation tables), not in the fundamental hierarchy classification. (5) REASONING GAP: The LLM concludes that methodology 'has been consistent' but misses that the disclosure enhancement itself indicates a refinement in how GD reports these assets, which is what the ground truth emphasizes. The answer is partially correct on the main classification point but significantly incomplete on the key evolution the question asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Consists_Of]- ORG",
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 502,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "\nBetween 2023 and 2024 the risk of equity dilution from Blackstone’s now‑terminated exchange right disappeared – the 2023 10‑K notes that 4.4 million (and related 24.1 million/12.0 million) potential shares would have been anti‑dilutive, but the September 2022 IPO eliminated that option, so no further dilution from that source occurred in 2024.  Instead, the 2024 10‑K reports that AIG records equity‑method income from Corebridge, reflecting dividends received and the fair‑value changes of its stake (pre‑tax income of Corebridge for June 10 – Dec 31 2024), marking a shift from potential share issuance to recognized income from the investment.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of AIG's evolving relationship with Corebridge between 2023 and 2024. STRENGTHS: (1) Correctly identifies the termination of Blackstone's exchange right due to the September 2022 IPO; (2) Accurately cites the 4.4 million potential shares for 2023 and references the 24.1 million figure from 2022; (3) Properly characterizes the shift from potential equity dilution to equity method investment; (4) Correctly notes the timing of equity method income recognition (June 10 - Dec 31, 2024); (5) Accurately describes the income recognition mechanism (dividends received and fair-value changes). MINOR ISSUES: (1) The LLM states the IPO occurred on 'September 2022' while the ground truth specifies 'September 19, 2022' - this is a minor precision issue but the date is essentially correct; (2) The LLM mentions 'pre-tax income of Corebridge for June 10 – Dec 31 2024' which adds detail not explicitly in the ground truth, though this appears consistent with equity method accounting; (3) The reference to '12.0 million' shares in parentheses is mentioned but not fully explained in context. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years (2023 and 2024) and correctly traces the causal relationship between the IPO event and the elimination of dilution risk. The transition from one accounting treatment to another is clearly articulated. QUANTITATIVE VERIFICATION: All key numbers (4.4 million, 24.1 million, September 2022 IPO date) are accurate. The date range for equity method income (June 10 - Dec 31, 2024) aligns with the ground truth's 'June 9, 2024 onwards' reference (minor one-day discrepancy, likely immaterial). Overall, the answer captures the essential evolution of AIG's financial relationship with Corebridge with high accuracy and appropriate detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 503,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "\nComcast’s disclosed exposure to Universal Beijing Resort fell modestly from the 2022 level—where the 10‑K listed **$3.6 bn of “Debt Not Guaranteed”** tied to the resort (Chunk 1)—to **$3.4 bn of term‑loan debt** outstanding as of 31 Dec 2024, down from **$3.5 bn** a year earlier (Chunk 2). Because the resort is treated as a variable‑interest entity that Comcast consolidates, the full debt burden is now reflected on its balance sheet, but Comcast’s direct financial risk is limited to its **30 % equity interest** and there are no cross‑guarantees or liquidity arrangements between the parties (Chunk 2). This evolution shows a slight reduction in absolute debt while the exposure remains fully consolidated under Comcast’s accounting treatment.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key debt figures for 2024 ($3.4 billion as of Dec 31, 2024 and $3.5 billion as of Dec 31, 2023), accurately notes the consolidation treatment as a VIE, and correctly states the 30% equity interest. The reasoning about limited direct financial risk due to the equity interest structure is sound. The multi-hop synthesis across debt disclosures and consolidation treatment is logically presented.\n\nWEAKNESSES: (1) INCOMPLETE HISTORICAL COMPARISON: The LLM fails to address the 2022 baseline data from the ground truth. The ground truth explicitly states that in 2022, Comcast disclosed $3.6 billion in debt as of Dec 31, 2021 and $2.5 billion as of Dec 31, 2020. The LLM mentions \"$3.6 bn\" from 2022 but doesn't properly contextualize this as 2021 year-end data or explain the evolution from 2020-2024. (2) MISSING BALANCE SHEET CONSOLIDATION DETAILS: The ground truth specifies that as of 2024, Universal Beijing Resort had $7.3 billion in assets and $7.0 billion in liabilities fully consolidated on Comcast's balance sheet. The LLM mentions consolidation but omits these specific asset and liability figures entirely. (3) INCOMPLETE EVOLUTION NARRATIVE: The question asks how exposure \"evolved from 2022 to 2024,\" which requires showing the full trajectory. The LLM only compares 2024 to 2023 and mentions 2022 in passing, missing the complete 4-year evolution (2020: $2.5B → 2021: $3.6B → 2023: $3.5B → 2024: $3.4B). (4) MISSING STABILIZATION INSIGHT: The ground truth notes that \"debt levels stabilized after earlier reductions,\" which is an important analytical point the LLM doesn't capture.\n\nQUANTITATIVE VERIFICATION: All numbers cited ($3.6B, $3.4B, $3.5B, 30%) are factually correct, but the answer is incomplete in scope. The missing $7.3B assets and $7.0B liabilities figures represent a significant omission of quantitative data.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes debt disclosures with consolidation treatment and equity interest, but fails to fully synthesize the temporal evolution across the 2022-2024 period as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 567,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "\nThe aircraft‑trade‑in framework was essentially unchanged from 2022 to 2023 – options to trade‑in are offered to selected customers (in 2023 specifically “some Gulfstream customers”) and must be exercised (or lapse) generally ≤ 45 days before the new‑aircraft delivery, with the option either at prevailing fair‑market value or at a pre‑determined price; the latter structure creates the bulk of the risk, because an adverse market move can trigger a revenue reduction equal to any excess of the pre‑set price over the aircraft’s then‑fair‑market value.  Both years note that the estimated fair‑market‑value change from the commitment date was not material, indicating that, despite the inherent risk of adverse market conditions, the actual exposure has not shifted materially between 2022 and 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both strengths and significant weaknesses. STRENGTHS: (1) Correctly identifies that 2023 narrowed eligibility to 'some Gulfstream customers' vs. 2022's broader 'some customers'; (2) Accurately notes both years reported 'not material' fair market value changes; (3) Correctly describes the mechanics of trade-in options (45-day exercise window, fair market value vs. pre-determined price structures); (4) Properly identifies the risk mechanism (adverse market moves creating revenue reduction exposure). WEAKNESSES: (1) The opening claim that 'the aircraft trade-in framework was essentially unchanged from 2022 to 2023' directly contradicts the ground truth, which emphasizes that eligibility was 'narrowed' - this is a structural change, not an unchanged framework; (2) The answer focuses heavily on operational mechanics (45-day windows, pricing structures) that are not mentioned in the ground truth and may not be directly responsive to the question about 'how structure changed'; (3) The answer misses the ground truth's key insight about strategic focus/risk concentration in Gulfstream specifically, instead treating this as merely a clarification of customer eligibility; (4) The answer characterizes the changes as minimal ('essentially unchanged') when the ground truth emphasizes the narrowing of eligibility as a meaningful structural change. MULTI-HOP REASONING: The answer does synthesize information across 2022 and 2023, but reaches an incorrect conclusion about the degree of change. The ground truth identifies a meaningful narrowing of customer eligibility scope, while the LLM treats this as a minor clarification within an otherwise unchanged framework. This represents a failure in comparative analysis between the two years. SEMANTIC ISSUE: The phrase 'essentially unchanged' is semantically opposite to the ground truth's emphasis on narrowing and strategic focus shift, making this a material error in interpretation rather than just wording difference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 539,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla progressed the Semi from a future‑announced commercial vehicle (cited in the 2022 “Future Consumer and Commercial Electric Vehicles” section) to a model that is now in pilot production at its Nevada plant, as reflected in the 2024 production‑status table; this transition shows a concrete move from planning to early manufacturing. Consequently, the Semi has been positioned as Tesla’s dedicated commercial‑vehicle offering—leveraging the same battery, powertrain and Full‑Self‑Driving technologies that underpin its consumer lineup—while remaining distinct from the consumer‑focused models listed alongside Cybertruck and Cybercab. The KG relationship TSLA → Tesla Semi ← Introduces captures this evolution from announcement to active development within Tesla’s product portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on core facts and multi-hop reasoning. STRENGTHS: (1) Correctly identifies the 2022 status as announced/planned vehicle in 'Future Consumer and Commercial Electric Vehicles' section; (2) Accurately states 2024 status as 'pilot production' at Nevada facility; (3) Properly synthesizes the evolution from planning to early manufacturing; (4) Correctly positions Tesla Semi as commercial vehicle distinct from consumer models; (5) Appropriately references battery, powertrain, and FSD technologies as shared infrastructure; (6) Mentions Cybertruck and Cybercab as consumer-focused comparisons, showing contextual understanding. MINOR CONSIDERATIONS: (1) The LLM adds interpretive details about 'dedicated commercial-vehicle offering' and technology sharing that, while reasonable inferences, go slightly beyond what the ground truth explicitly states—the ground truth focuses more narrowly on the production status evolution and strategic positioning; (2) The reference to 'KG relationship TSLA → Tesla Semi ← Introduces' is metadata about the knowledge graph structure rather than substantive content from the filings themselves, which is somewhat tangential though not incorrect; (3) The answer is more elaborate than necessary, introducing concepts like 'Full-Self-Driving technologies' that weren't explicitly mentioned in the ground truth. QUANTITATIVE ACCURACY: All dates (2022, 2024) and facility location (Nevada) are correct. No calculations required. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2024 filings to show progression. SEMANTIC EQUIVALENCE: The core message matches ground truth—Tesla Semi moved from announcement to pilot production, representing strategic advancement. The additional context about positioning within the product lineup is reasonable but represents some elaboration beyond the ground truth statement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 522,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "\nBetween 2022 and 2024 the valuation allowance recorded for Altria’s deferred‑tax assets tied to its Cronos investment rose from $379 million at the end of 2022 to $397 million in 2023 and to $402 million in 2024 (Chunk 2). This upward trend—driven by the $107 million non‑cash impairment of the Cronos stake in 2022 and the periodic adjustments to the allowance noted in 2023 and 2022 (Chunk 1)—signals that Altria continues to view the related deferred‑tax assets as uncertain of realization and therefore maintains a full valuation allowance (Chunk 2). In other words, the company expects limited near‑term realizability of those deferred‑tax assets, only potentially releasing the allowance if future positive evidence emerges (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All key numbers are correct - $379 million (2022), $397 million (2023), and $402 million (2024). The progression matches the ground truth exactly. The additional detail about the $107 million non-cash impairment in 2022 provides supporting context. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the valuation allowance evolved (with specific year-by-year figures), and (2) what this indicates about Altria's expectations regarding deferred tax asset realizability. ENTITY ACCURACY: All entities are correctly identified - Altria, Cronos, deferred tax assets, valuation allowance, and the relevant fiscal years (2022-2024). REASONING QUALITY: The multi-hop synthesis is sound. The LLM correctly connects the increasing valuation allowance to Altria's cautious stance on tax asset realization, and appropriately notes that the company maintains a full valuation allowance due to uncertainty. The explanation that the allowance would only be released with 'future positive evidence' demonstrates proper understanding of accounting principles. SEMANTIC EQUIVALENCE: The LLM's characterization of 'limited near-term realizability' and 'uncertainty regarding realization' is semantically equivalent to the ground truth's 'significant uncertainty regarding the realizability' and 'did not expect the temporary difference to reverse in the foreseeable future.' Minor note: The LLM provides slightly more granular detail (including 2023 figure) than the ground truth, which actually enhances the answer without introducing errors. No calculation errors detected. The answer is well-structured and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 476,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "\nBetween 2023 and 2024 Amgen moved its BeiGene stake from the equity‑method to fair‑value accounting, so that the 2023 gain on the investment was recorded in “Other income (expense), net” and the 2024 earnings swung to net unrealized losses on that same holding—an evolution reflected in the KG link AMGN → BeiGene Investment (FIN_INST) ↔ BeiGene Investment → AMGN (disclosure).  This shift occurred alongside a higher effective tax rate in 2023 (driven by the Puerto Rico excise‑tax replacement, the OECD‑minimum‑tax rollout and related legal uncertainties) and higher interest expense from increased debt, both of which are disclosed in the 2023 and 2024 filings, and it caused the fair‑value gains recognized in 2023 to be reversed by net losses in 2024, directly impacting the financial‑instrument classification and earnings of the BeiGene investment.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core facts: (1) Amgen changed BeiGene accounting from equity method to fair value, (2) 2023 showed gains, (3) 2024 showed net unrealized losses, and (4) this represents a reversal in financial benefit. The multi-hop synthesis is sound—connecting the accounting change to the earnings impact across two years.\n\nSTRENGTHS: The answer accurately captures the main narrative of the investment evolution, correctly identifies the accounting method change, properly characterizes the 2023 gains and 2024 losses, and appropriately notes the reversal pattern. The semantic meaning aligns well with the ground truth.\n\nWEAKNESSES: (1) The LLM introduces extraneous information about tax rates, Puerto Rico excise tax, OECD minimum tax, and interest expense that, while potentially factually accurate, are NOT part of the ground truth answer and represent scope creep beyond what was asked. The question specifically asks about the BeiGene investment's financial treatment and valuation impact—not broader tax or debt considerations. (2) The reference to \"KG link AMGN → BeiGene Investment (FIN_INST)\" uses technical notation that adds complexity without clarifying the core answer. (3) The phrasing is somewhat convoluted compared to the ground truth's clearer structure.\n\nNUMERIC/CALCULATION VERIFICATION: No specific dollar amounts or percentages are provided in either answer, so quantitative accuracy cannot be directly verified. However, the directional claims (gains in 2023, losses in 2024) are correct.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the two-year evolution and the accounting method change, though it dilutes focus by introducing tangential financial factors.\n\nThe answer is fundamentally correct on the primary question but loses points for introducing irrelevant contextual information that wasn't requested and for slightly less clear presentation than the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Recognizes_Losses]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 525,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "\nBetween 2023 and 2024 Disney re‑shaped the way it markets its Indian‑focused streaming service.  In 2023 Disney+ Hotstar was a stand‑alone DTC offering in India (and a few Southeast‑Asian markets) that bundled general‑entertainment, family and sports content under the Hotstar brand, distinct from the global Disney+ service.  By 2024 the company consolidated its Latin‑American SVOD portfolio—merging the former separate Disney+ and Star+ offerings into a single Disney+ product at the end of June 2024—while continuing to operate the Disney+ Hotstar brand in India and certain other Southeast‑Asian territories, using a regional‑branding approach that feeds the service into Disney’s broader multi‑product DTC structure (available directly, via third‑party platforms or wholesale arrangements).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All dates and timeframes are correct—2023 positioning, 2024 consolidation, and the specific end-of-June 2024 merger date for Latin American services are all accurate. No numerical errors or miscalculations present. ENTITY ACCURACY: All entities correctly identified—Disney+ Hotstar, Star+, Disney+, India, Southeast Asia, and Latin America are all properly referenced and contextualized. COMPLETENESS: The answer addresses both parts of the multi-hop question: (1) 2023 positioning (stand-alone DTC service in India/Southeast Asia with bundled content under Hotstar brand), and (2) 2024 evolution (Latin American consolidation while maintaining Disney+ Hotstar branding in India/Southeast Asia). MULTI-HOP REASONING: The synthesis is sound—the model correctly identifies the strategic shift from regional brand distinctiveness to consolidation under the Disney+ umbrella, while maintaining regional branding where appropriate. The answer captures the nuance that different regions followed different strategies (Latin America consolidated, India/Southeast Asia maintained regional branding). SEMANTIC EQUIVALENCE: The LLM answer conveys all essential information from the ground truth with slightly enhanced detail about distribution channels (direct, third-party platforms, wholesale arrangements) that adds relevant context without contradicting the original. Minor differences in wording and organization are stylistic rather than substantive. The only minor consideration is that the LLM adds some interpretive language about 'feeding the service into Disney's broader multi-product DTC structure' which, while reasonable inference, goes slightly beyond explicit ground truth statements, but this represents appropriate elaboration rather than error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 509,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "\nIn 2023 PayPal disclosed that its purchase‑and‑seller protection programs constitute a single performance obligation and require accrual of transaction and credit‑loss expenses at the moment a payment is authorized, noting that the programs do not provide a separate service and that full margin risk is borne by the company. By 2024 the disclosure expanded to explicitly quantify exposure to fraud, disputed transactions and merchant insolvency, explain that recoveries from merchants or payment‑card issuers are often incomplete, warn that regulators and card‑network rules may increase loss rates, and state that allowances for such losses may be insufficient—signaling a marked increase in risk exposure and a more cautious approach to loss‑recovery mechanisms.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the 2023 disclosure that protection programs were recorded in 'transaction and credit losses' and did not provide separate service - this matches ground truth exactly. (2) Accurately captures the 2024 evolution toward more detailed disclosures with explicit quantification of fraud, disputed transactions, and merchant insolvency exposure. (3) Properly synthesizes the multi-hop comparison showing the shift from basic disclosure to more explicit risk acknowledgment. (4) Correctly identifies key risk factors: incomplete recoveries from merchants/card issuers, regulatory/card-network rule changes, and potential insufficiency of loss allowances. (5) Uses appropriate financial terminology ('performance obligation,' 'accrual,' 'margin risk') that demonstrates understanding of the underlying accounting and risk concepts. (6) The characterization of the evolution as 'marked increase in risk exposure and more cautious approach' aligns well with ground truth's 'shift toward more explicit risk acknowledgment.' MINOR CONSIDERATIONS: (1) The LLM adds specific detail about 'purchase-and-seller protection programs constitute a single performance obligation' and 'accrual at moment of payment authorization' - while these appear consistent with PayPal's actual disclosures, they go slightly beyond what the ground truth explicitly states, though they don't contradict it. (2) The phrase 'full margin risk is borne by the company' is a reasonable interpretation but represents slight elaboration beyond ground truth language. (3) No quantitative metrics (dollar amounts, percentages) are provided in either answer, so quantitative accuracy is assessed on the basis of no contradictory numbers being present. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years (2023 and 2024) and correctly identifies the evolution in disclosure approach and risk acknowledgment. The comparison is logically sound and addresses the core question about how the approach evolved. SEMANTIC EQUIVALENCE: The LLM answer conveys substantially the same information as ground truth with slightly more technical precision and detail, which enhances rather than detracts from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 621,
        "total_tokens": 2024
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "\nFrom 2022 through 2024 NextEra has shifted from the 2020 divestitures of a 90 % wind‑solar portfolio and a 100 MW solar‑plus‑storage plant (which generated $656 M of proceeds and a contract‑liability later reversed) to consolidating solar assets via variable‑interest entities, holding 50‑67 % interests in eight VIEs that own roughly 765 MW of solar and a separate VIE with about 400 MW, while also retaining a 52.6 % non‑controlling equity stake in X PLR that operates additional solar facilities. This consolidation creates significant financial exposure, including $1.3 B of guarantees and letters of credit, a $127 M cash‑sweep liability and $58 M credit‑support liability recorded on the balance sheet, and ongoing service‑fee and operating‑revenue arrangements with related parties. The earlier 2020 sales (noted for $270 M gains and €111 M proceeds) are now offset by the sustained ownership stakes and the associated risk of absorbing expected losses and honoring debt‑related obligations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM introduces numerous numbers NOT in the ground truth: 50-67% interests in VIEs (ground truth says 10% direct ownership), 400 MW separate VIE (not mentioned in ground truth), 52.6% non-controlling equity stake in X-PLR (not in ground truth), $1.3B guarantees (not in ground truth), $127M cash-sweep liability (not in ground truth), $58M credit-support liability (not in ground truth), $270M gains and €111M proceeds from 2020 (ground truth references 2022 transactions, not 2020). These fabricated numbers significantly undermine credibility. (2) TEMPORAL CONFUSION - The LLM conflates 2020 divestitures with 2022 transactions. Ground truth clearly states 2022 divestitures (100 MW Arizona solar, 90% portfolio stake), not 2020. (3) OWNERSHIP STRUCTURE MISREPRESENTATION - Ground truth states NextEra held a 10% direct ownership interest in additional solar facilities and consolidated eight VIEs with ~765 MW. LLM claims 50-67% interests in eight VIEs, which contradicts the ground truth's 10% figure. (4) PARTIAL CORRECTNESS - The LLM correctly identifies: the shift from divestiture to VIE consolidation, approximately 765 MW capacity in consolidated VIEs, the concept of financial exposure through guarantees and liabilities, and the strategic shift from outright ownership to more complex structures. (5) MULTI-HOP REASONING - While the LLM attempts to synthesize the evolution from 2022-2024, it does so by introducing unsupported numbers rather than accurately synthesizing the ground truth data. The reasoning structure is sound but built on incorrect factual foundation. The answer demonstrates understanding of the general strategic shift but fails on specific quantitative accuracy, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 487,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "\nACN’s holding of **Mutual Fund Debt Securities** fell from **$379,989** (reported in Level 2 of the fair‑value hierarchy in the 2022 filing) to **$253,025** (also Level 2 in the 2023 filing), a reduction of **$126,964** (about 33 %). The securities remained classified as **Level 2** in both years, meaning the valuation methodology did not shift to Level 1 or Level 3 inputs; only the disclosed amount under the Level 2 category changed. This decline reflects the evolution of ACN’s investment in Mutual Fund Debt Securities between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: 2022 value of $379,989, 2023 value of $253,025, both classified as Level 2, and the calculated decrease of $126,964 (approximately 33%). The calculation verification: $379,989 - $253,025 = $126,964 ✓; percentage: $126,964/$379,989 = 33.4% ≈ 33% ✓. The answer correctly addresses all parts of the multi-part question: (1) the evolution of the investment amount, (2) the fair value hierarchy levels in both years, and (3) the consistency of valuation methodology. The LLM properly synthesizes the multi-hop information by comparing across two fiscal years and explaining that the methodology remained unchanged (Level 2 in both years) while the dollar amount decreased. The reasoning is sound and logically presented. The answer goes slightly beyond the ground truth by explicitly calculating the percentage decline and clarifying that the methodology did not shift between levels, which adds helpful context without introducing any inaccuracies. The only minor distinction is that the ground truth emphasizes the consistency of methodology more explicitly, while the LLM focuses slightly more on the quantitative change, but both convey the same essential information. No factual errors, calculation errors, or entity misidentifications detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 372,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "\nChevron kept its 50 % equity ownership in Tengizchevroil (TCO) from 2022 to 2023, but the financial depth of that stake expanded markedly: the 2022 10‑K records an investment balance of **$23.7 bn** in TCO, while the 2023 filing notes that the carrying value of the investment is **about $80 million higher than the underlying equity** of TCO and includes a **$4.5 bn loan** to fund the FGP/WPMP development project—signaling a more leveraged, higher‑cost participation.  Consequently, the investment reported under the equity‑method grew (from the $23.7 bn level in 2022 to a higher carrying amount in 2023), even though the ownership percentage remained unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Chevron's evolving financial involvement in Tengizchevroil between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 carrying value of $23.7 billion (matches ground truth's $23,727 million); (2) Accurately captures the $80 million premium of carrying value over underlying equity in 2023; (3) Correctly states the $4.5 billion loan for FGP/WPMP projects; (4) Properly notes the 50% ownership remained constant; (5) Effectively synthesizes the multi-hop information showing deepening financial involvement. MINOR WEAKNESSES: (1) The statement 'the investment reported under the equity-method grew (from the $23.7 bn level in 2022 to a higher carrying amount in 2023)' is somewhat imprecise—the ground truth doesn't explicitly state the 2023 carrying value amount, only that it was approximately $80 million higher than underlying equity. The LLM infers growth but doesn't quantify the 2023 carrying value, which is a reasonable inference but slightly goes beyond what the ground truth explicitly states; (2) Missing the specific mention of 2023 equity in earnings figure ($1,238 million in 2022), though this omission is minor since the question focuses on evolution/changes; (3) The phrase 'higher‑cost participation' is interpretive language not explicitly in the ground truth, though it's a reasonable characterization. QUANTITATIVE VERIFICATION: All dollar amounts are correct ($23.7bn, $80 million, $4.5bn). MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2023 filings to show the evolution. The answer correctly identifies that while ownership percentage stayed constant, the financial complexity and commitment deepened through the loan facility and valuation adjustments. Overall, this is a solid answer with accurate core facts and good synthesis, with only minor imprecision in describing the 2023 carrying value trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 519,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney’s 73 % stake in the ABC Television Network continued to generate the bulk of its linear‑network affiliate fees and advertising revenue, anchoring the “Linear Networks” portion of the Entertainment segment.  In 2024 Disney deepened ABC’s strategic role by routing its broadcast programming through its Direct‑to‑Consumer services—making ABC shows available on Hulu the day after linear airing and planning to embed ABC (and ESPN) tiles within the Disney+ platform—thereby using the network to drive subscriber growth and to fuse traditional broadcast with Disney’s broader streaming and DTC ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Disney's ABC Network evolution between 2023-2024 and effectively synthesizes multi-hop information. STRENGTHS: (1) Correctly identifies the strategic shift from linear-focused positioning to DTC integration; (2) Accurately describes the specific mechanism of ABC content availability on Hulu (one day after linear airing); (3) Properly contextualizes ABC within the Entertainment segment's Linear Networks; (4) Captures the evolution toward streaming-driven strategy; (5) Mentions the Disney+ tile embedding plan, showing forward-looking strategic positioning. WEAKNESSES: (1) Introduces the '73% stake' figure which is not present in the ground truth answer - while this may be factually accurate from SEC filings, it represents additional information not in the original answer and introduces a quantitative claim that cannot be verified against the provided ground truth; (2) Slightly more detailed on 2024 developments (Disney+ tiles, subscriber growth focus) than the ground truth, though this represents elaboration rather than contradiction. MULTI-HOP REASONING: Excellent synthesis showing how ABC's role changed from standalone linear revenue generator to integrated DTC platform driver across multiple Disney services. The answer correctly connects affiliate fees/advertising (2023) to streaming contribution (2024). SEMANTIC EQUIVALENCE: The core message aligns well - ABC evolved from traditional linear positioning to digital/DTC integration. The mention of 'fusing traditional broadcast with Disney's broader streaming ecosystem' directly parallels the ground truth's 'strategic move toward digital integration.' The quantitative accuracy score is slightly lower due to the unverified 73% stake figure, though this doesn't fundamentally undermine the answer's correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 498,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "\nBetween 2022 and 2023 General Dynamics shifted ASCOD from being one of several tracked‑vehicle offerings (Pandur, Piranha, Ajax, Duro/Eagle) in its Land Systems portfolio to a more central, multi‑domain battlefield platform—emphasised in 2023 as a “highly lethal, survivable and mobile direct‑fire combat vehicle” that underpins new contracts for the Spanish Pizarro and Austrian Ulan variants and is backed by expanding LAV production (360 → 399 units) and sustained support for Canada, Germany, Spain, Austria and other allies.  This focus, together with continued investment in robotic/autonomous systems (MUTT, TRX) that are built around ASCOD‑derived architectures, indicates a strategic re‑allocation of production resources and capital toward ASCOD‑centric platforms rather than a broader expansion of the LAV family.  (KG: GD → Produces → ASCOD; ASCOD → Supplies → GD).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is fundamentally contradictory to the ground truth and contains significant factual errors: (1) DIRECTIONAL ERROR: The ground truth states ASCOD positioning DECLINED from 'producing and upgrading' (2022) to merely 'offering' (2023), indicating reduced focus. The LLM claims the opposite—that ASCOD became MORE central and received strategic re-allocation of resources toward ASCOD-centric platforms. This is a critical misreading of the evidence. (2) QUANTITATIVE ISSUES: The LLM cites LAV production expansion (360 → 399 units) as evidence of ASCOD-focused investment, but this actually refers to LAV production, not ASCOD production. The ground truth makes no mention of these specific production numbers. The LLM conflates LAV and ASCOD as if they are the same platform, which is incorrect. (3) ENTITY CONFUSION: The LLM lists ASCOD alongside Pandur, Piranha, Ajax, Duro/Eagle as 'tracked-vehicle offerings' in 2022, but the ground truth specifically mentions Piranha 5 and AJAX as competing programs receiving continued investment—not ASCOD. (4) UNSUPPORTED CLAIMS: The LLM makes specific claims about 'Spanish Pizarro and Austrian Ulan variants' and 'robotic/autonomous systems (MUTT, TRX) built around ASCOD-derived architectures' that are not mentioned in the ground truth and cannot be verified. (5) REASONING FAILURE: The multi-hop synthesis is inverted. The ground truth indicates resource reallocation AWAY from ASCOD toward other programs; the LLM argues the opposite. The ground truth's key insight—that the shift from 'producing/upgrading' to 'offering' signals reduced investment—is completely missed. The LLM answer demonstrates fundamental misunderstanding of the question and provides contradictory conclusions to the established ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 483,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the pool of European customer balances that PayPal may designate for credit‑activity funding fell sharply – from **$3.0 billion (≈39 % of eligible balances) in 2023** to **$2.0 billion (≈26 % of eligible balances) in 2024** – a reduction of roughly one‑third in both dollar amount and share of balances.  This pull‑back shows that PayPal is scaling back its reliance on internal customer deposits to fund loans and is instead turning to **external financing sources** (e.g., debt issuances, securitizations, and partnership funding) to meet the liquidity needs of its growing credit portfolio, a strategic shift that aligns with its stated goal of diversifying credit‑product funding while preserving its investment‑grade credit ratings.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) All core quantitative data is accurate: $3.0B (39%) in 2023 and $2.0B (26%) in 2024 are correct. The calculation of 'roughly one-third reduction' is mathematically sound ($1B reduction from $3B base = 33%). (2) Entity identification is correct (PayPal, European customer balances, credit activities). (3) The strategic interpretation about shifting to external financing sources is sound and aligns with ground truth. (4) The LLM correctly identifies the shift away from internal customer deposits toward external sources.\n\nWEAKNESSES: (1) The LLM answer omits a critical piece of evidence from the ground truth - the specific data about PayPal's multi-year agreement to sell consumer installment receivables ($20.8B in 2024 vs $5.5B in 2023). This is a concrete example that directly supports the strategic shift narrative and represents important multi-hop synthesis. (2) While the LLM mentions 'debt issuances, securitizations, and partnership funding' as examples of external sources, it doesn't cite the specific receivables sale program that the ground truth explicitly references. (3) The mention of 'investment-grade credit ratings' as a goal is reasonable inference but not explicitly stated in the ground truth, making it somewhat speculative.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes the relationship between the declining European balance utilization and the shift to external financing. However, it misses the opportunity to strengthen this reasoning by connecting it to the specific receivables sale data that demonstrates the external financing strategy in action.\n\nNUMBER VERIFICATION: All percentages and dollar amounts are correct. The characterization of the reduction as 'roughly one-third' is accurate ($1B/$3B ≈ 33%).\n\nCOMPLETENESS: The answer addresses the 'how has it evolved' and 'what does this indicate' parts of the question, but incompletely addresses the full strategic picture by omitting the receivables sale program evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 537,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "\nBetween 2022 (Chunk 1) and 2024 (Chunk 2) the valuation of NEE’s Special Use Funds’ equity securities changed dramatically: the 2022 filing reported a single carrying amount of **$906 million** (fair value **$907 million**) for these funds, whereas the 2024 filing breaks the same exposure into a **$6.164 billion** total, comprising **$2.614 billion Level 1**, **$3.321 billion Level 2** and **$0.229 billion Level 3** (Chunk 2).  This evolution is also reflected in the KG link **NEE → Special Use Funds (Increases)**, showing that the fund’s growth is accompanied by a shift from a simple aggregated figure to a multi‑level hierarchy that includes government/municipal bonds, corporate debt, asset‑backed and other debt securities, and a larger proportion of Level 2/3 measurements—indicating reduced reliance on quoted market prices and therefore lower transparency and a more diversified investment composition.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) MAJOR QUANTITATIVE DISCREPANCY: The LLM reports 2024 total equity securities as $6.164 billion, but the ground truth states NEE held $2.614 billion in Level 1 equity securities alone in 2024. The LLM appears to have conflated total securities (which includes debt instruments like bonds) with equity securities specifically. The ground truth clearly identifies $2.614 billion Level 1 equity securities for NEE in 2024, not $6.164 billion total. (2) MISSING FPL DATA: The ground truth explicitly mentions FPL's 2024 holdings of $1.028 million in Level 1 equity securities, which the LLM completely omits. This is a significant multi-hop synthesis failure. (3) INCORRECT INTERPRETATION OF TRANSPARENCY: The LLM concludes that the shift to Level 2/3 measurements indicates 'reduced transparency and lower reliance on quoted market prices,' which directly contradicts the ground truth's statement that this represents 'a shift toward more transparent and detailed reporting.' The LLM misunderstood the significance of granular level disclosures. (4) COMPOSITION CONFUSION: The LLM mentions 'government/municipal bonds, corporate debt, asset-backed securities' which are debt instruments, not equity securities. The question specifically asks about equity securities evolution, and the LLM conflated equity with broader securities holdings. (5) CORRECT ELEMENTS: The 2022 figures ($906M carrying amount, $907M fair value) are accurate, and the recognition of increased disclosure granularity is correct in concept, though the interpretation is inverted. The multi-hop reasoning attempted to synthesize across years but failed due to data misidentification and entity confusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 465,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "\nIn fiscal 2022 Accenture bought 1,964,612 Class A shares under its publicly announced open‑market program for $576 million, while an additional 97,251 shares were acquired through employee‑share‑plan withholding—transactions that do not affect the program’s remaining authorization. After the Board’s September 2022 approval of an extra $3 billion of repurchase authority (raising total authority to $6.129 billion), the open‑market program remained active and was used to purchase treasury shares for employee benefits, and employee‑related acquisitions continued to be made via share‑withholding for tax obligations, also leaving the program’s authorization unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) FISCAL 2023 DATA MISSING: The LLM answer fails to provide any specific fiscal 2023 share purchase data, which is critical to answering the question about how the program 'evolved from fiscal 2022 to fiscal 2023.' The ground truth explicitly states 'In fiscal 2023, there is no mention of shares purchased under the public program' - this is a key finding that should be clearly stated. (2) UNSUPPORTED CLAIMS: The LLM introduces information about a September 2022 Board approval of $3 billion additional repurchase authority and mentions the program being 'used to purchase treasury shares for employee benefits' in fiscal 2023, but the ground truth contains NO such information. This appears to be fabricated or from outside the provided knowledge graph. (3) INCOMPLETE COMPARISON: The question specifically asks about the evolution/shift from FY2022 to FY2023. The ground truth clearly identifies this shift: public program had activity in FY2022 ($576M, 1.96M shares) but 'no mention' in FY2023, while employee-related transactions continued. The LLM fails to make this critical comparison explicit. (4) CORRECT ELEMENTS: The FY2022 numbers are accurate (1,964,612 shares, $576M, 97,251 employee shares), and the characterization of employee transactions not affecting authorization is correct. (5) MULTI-HOP REASONING FAILURE: The answer does not properly synthesize the year-over-year comparison that is central to the question. The ground truth's key insight about the 'shift' in program utilization is completely absent from the LLM response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 433,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "\nBetween 2022 and 2023 Chevron’s stake in **Chevron Phillips Chemical Company LLC** remained an unconsolidated investment, but the disclosure evolved from simply presenting the LLC’s summarized financial data in Note 8 of the 2022 10‑K (which signaled an equity‑method holding) to an explicit statement in the 2023 10‑K (Note 6) that CUSA “holds the company's investment in the Chevron Phillips Chemical Company LLC joint venture, which is accounted for using the equity method.” Thus, the consolidation status did not change—Chevron continued not to consolidate the LLC—but the 2023 filing clarified that the investment is accounted for under the equity‑method approach. This reflects a continuity of the same accounting treatment with greater transparency in the later filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR IN CORE CLAIM: The LLM answer fundamentally contradicts the ground truth on the central factual issue. The ground truth explicitly states that in 2022, Chevron Phillips Chemical Company LLC WAS CONSOLIDATED into Chevron's financial statements, but in 2023 it was NO LONGER CONSOLIDATED and was instead accounted for using the equity method. This represents a significant structural change. However, the LLM answer claims the opposite: that the consolidation status 'did not change' and that Chevron 'continued not to consolidate the LLC' between 2022 and 2023. This is a fundamental misrepresentation of the evolution described in the ground truth. The LLM characterizes the change as merely 'greater transparency in the later filing' rather than recognizing the actual transition from consolidated to equity-method accounting. The LLM correctly identifies that Note 8 in 2022 and Note 6 in 2023 are referenced, and correctly notes the equity method is used in 2023, but completely misses or misinterprets the 2022 consolidation status. The quantitative accuracy score is relatively high because the LLM doesn't make specific numerical errors, but the qualitative accuracy is severely compromised by the incorrect interpretation of the consolidation status change. The answer fails to address the 'significant structural change' that is the core of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 383,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "\nFrom 2022 to 2023 the Hydra‑70 rocket moved from a modest $175 production award recorded in the 2022 Combat Systems backlog to a strategic growth area: the 2023 filing notes that OTS, the systems integrator for the segment’s artillery portfolio, received awards to expand its metal‑parts capacity from 18,000 to 86,000 rounds per month (and propellant capacity from 4 M to 16 M lb per year) by 2025, directly supporting the Army’s Indirect‑Fire Modernization and accelerating artillery production. This expansion reflects a clear increase in contract involvement and production capacity for Hydra‑70 rockets within General Dynamics’ Combat Systems segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the Hydra-70 rocket evolution in General Dynamics' Combat Systems segment. STRENGTHS: (1) All key numbers are correct: $175 million contract for 2022, capacity expansion from 18,000 to 86,000 rounds per month by 2025, propellant capacity from 4M to 16M lb per year. (2) Correctly identifies OTS as the relevant entity within Combat Systems. (3) Properly synthesizes multi-hop information showing the evolution from 2022 contract to 2023 expansion awards. (4) Accurately contextualizes the expansion within Army's Indirect-Fire Modernization initiative. (5) Effectively addresses both contract involvement and production capacity expansion aspects of the question. MINOR CONSIDERATIONS: The LLM adds contextual detail about propellant capacity (4M to 16M lb per year) that wasn't explicitly in the ground truth answer, though this appears to be accurate supplementary information from the filings that enhances rather than contradicts the answer. The characterization of the $175M as a '2022 production award recorded in the 2022 Combat Systems backlog' is a reasonable interpretation of the contract timing. The reasoning is sound, showing clear progression from 2022 to 2023 and explaining the strategic significance of the capacity expansion. All entities are correctly identified and the multi-hop synthesis across years and contract types is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Receives]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 397,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "\nIn the 2023 Form 10‑K PayPal disclosed the Global Restricted Stock Unit Award Grant Notice as **Exhibit 10.07+** – a stand‑alone “Form of Global Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement” under the 2015 Equity Incentive Award Plan – and filed it as part of its accounting‑policy exhibits. The 2024 filing keeps the same Exhibit 10.07+ but now ties it to the **amended and restated 2015 Equity Incentive Award Plan (Exhibit 10.03+)** and adds a companion **performance‑based version (Exhibit 10.08+)**, while also revealing newer executive agreements (e.g., the August 10 2023 letter with Alex Chriss and the December 21 2023 transition agreement with Gabrielle Rabinovitch) that modify the RSU terms. Thus, between 2023 and 2024 the notice remained documented as an exhibit, but its underlying policy context was updated to reflect a formally restated plan and accompanying executive agreements.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM incorrectly states that in 2024 the Exhibit 10.07+ is 'now tied to the amended and restated 2015 Equity Incentive Award Plan (Exhibit 10.03+)' - the ground truth explicitly states it remained 'still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015' with NO change in 2024. This is a critical factual error about the evolution (or lack thereof) of the base RSU notice. (2) UNSUPPORTED CLAIMS: The LLM introduces specific executive agreements (August 10, 2023 letter with Alex Chriss and December 21, 2023 transition agreement with Gabrielle Rabinovitch) that are NOT mentioned in the ground truth answer. While these may exist in the filings, they are not part of the documented evolution of the Global Restricted Stock Unit Award Grant Notice itself and represent scope creep beyond what was asked. (3) PARTIAL CORRECTNESS: The LLM correctly identifies that Exhibit 10.07+ remained in place and that Exhibit 10.08+ (performance-based variant) was added/updated in 2024. However, the characterization of how 10.07+ changed is fundamentally wrong. (4) REASONING FLAW: The LLM's conclusion that 'its underlying policy context was updated to reflect a formally restated plan' contradicts the ground truth which shows the base RSU notice remained unchanged and only the performance-based variant saw revision. The multi-hop synthesis failed to correctly identify that the key evolution was in the performance-based variant (10.08+), not in the base notice (10.07+). The answer demonstrates partial understanding but makes critical errors in the core factual claims about what changed and what remained constant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 493,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "\nOpdivo’s sales have risen steadily – from **$6.99 billion in 2020 to $7.52 billion in 2021** (the most recent fiscal year shown in the 2022 filing), making it one of BMS’s highest‑grossing products and a growing share of total revenue.  Building on that momentum, the **March 2024 FDA approval of Opdivo + cisplatin + gemcitabine as a first‑line therapy for metastatic urothelial carcinoma** adds a brand‑new, high‑potential indication, expanding its therapeutic footprint beyond earlier uses in melanoma and lung cancer.  Together, the revenue growth and the 2024 label expansion illustrate how Opdivo’s role has evolved from a strong “stand‑alone” oncology brand in 2022 to a broader, increasingly diversified engine of growth within Bristol‑Myers Squibb’s portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains significant factual errors regarding revenue figures and time periods. (1) INCORRECT NUMBERS: The LLM cites '$6.99 billion in 2020 to $7.52 billion in 2021' but the ground truth specifies Opdivo generated $7,523 million ($7.523 billion) in 2022. The LLM appears to have confused years and provided 2020-2021 data when the question specifically asks about 2022-2024 evolution. (2) TEMPORAL MISMATCH: The LLM references '2022 filing' data but then jumps to 2024 without providing 2023 or 2024 revenue figures, making it impossible to assess revenue performance evolution from 2022 to 2024 as requested. The ground truth explicitly notes 'despite not showing a significant revenue increase from earlier years,' but the LLM cannot verify this claim without 2024 revenue data. (3) CORRECT ELEMENTS: The LLM correctly identifies the March 2024 FDA approval for Opdivo + cisplatin + gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, which matches the ground truth. The qualitative assessment about therapeutic expansion is reasonable. (4) MULTI-HOP REASONING: The LLM fails to properly synthesize the 2022-2024 evolution because it lacks the necessary 2024 revenue data and provides incorrect baseline figures. The reasoning about 'revenue growth' cannot be verified with the data presented. (5) MISSING CONTEXT: The LLM does not address the ground truth's key insight that despite regulatory expansion, there was 'not a significant revenue increase from earlier years,' which is a critical part of understanding Opdivo's evolved role. The answer overstates growth momentum without supporting data for the 2022-2024 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 469,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 Chevron deepened its financial commitment to Chevron Phillips Chemical Company LLC, moving from the May 2021 and December 2021 project announcements—a 266,000‑ton/yr 1‑hexene unit at Old Ocean, Texas and a 1 billion‑lb/yr C3 splitter at Cedar Bayou—toward concrete funding: the company completed a final investment decision on the C3 splitter and, in 2022‑23, provided a $387 million loan to fund a portion of the Golden Triangle Polymers Project in Orange, Texas (where CPChem holds a 51 % stake), while continuing to advance the 1‑hexene expansion; this evolution reflects Chevron’s 50 % equity ownership, a loan‑based investment structure, and the broader strategic support that underpins CPChem’s portfolio of 28 facilities and two R&D centers, with both key units targeting 2023 start‑up.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The $387 million loan amount is accurate; (2) Golden Triangle Polymers Project location (Orange, Texas) is correct; (3) CPChem's 51% stake in the project is correct; (4) The 50% equity ownership in CPChem is correct; (5) The general narrative of evolution from 2022 to 2023 is sound; (6) The mention of 1-hexene unit at Old Ocean, Texas and C3 splitter at Cedar Bayou are correct projects. PROBLEMATIC ELEMENTS: (1) The LLM introduces specific project details (266,000-ton/yr capacity, 1 billion-lb/yr capacity) and dates (May 2021, December 2021) that are NOT in the ground truth answer and appear to be extrapolated or hallucinated; (2) The ground truth clearly states the evolution occurred 'between 2022 and 2023' with 2022 showing general ownership/announcements and 2023 showing the direct loan, but the LLM conflates this timeline by mentioning 'May 2021 and December 2021 project announcements' which predates the 2022-2023 comparison window; (3) The LLM mentions 'completed a final investment decision on the C3 splitter' which is not in the ground truth; (4) The reference to '28 facilities and two R&D centers' is not mentioned in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes the shift from equity ownership to direct loan financing, but introduces unsupported details that dilute the accuracy. The core insight about the evolution is present but muddied by extraneous information. QUANTITATIVE ACCURACY: The $387 million figure and percentages (50%, 51%) are correct, but the introduction of specific capacity figures (266,000-ton/yr, 1 billion-lb/yr) without ground truth support is problematic. The answer partially answers the question but adds information not verifiable from the ground truth, which suggests either hallucination or reliance on external knowledge not in the provided context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 518,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "\nPayPal’s protection‑program accounting policy requires estimating and recording associated costs as transaction and credit losses at the time each payment is completed, and this policy is disclosed in both the 2023 and 2024 10‑K filings.  The allowance for transaction losses therefore rose from **$64 million in 2023 to $86 million in 2024** (with the allowance for negative customer balances increasing from $218 million to $256 million), indicating a $22 million higher financial commitment to cover potential fraud and counterparty losses over the two years.  The increase is explicitly noted in the 2024 notes, which detail the allowance amounts and the methodology for estimating these reserves.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative data is correct: allowance for transaction losses increased from $64M to $86M (a $22M increase), and allowance for negative customer balances increased from $218M to $256M (a $38M increase). The calculation of the $22M difference is accurate. The answer correctly identifies both 2023 and 2024 as the relevant years and properly synthesizes the multi-hop information about PayPal's protection programs across both filing years. The LLM appropriately explains the evolution of disclosures, noting that 2024 provided more detailed figures than 2023. The reasoning is sound: the answer connects the accounting policy to the specific reserve amounts and correctly interprets the increases as indicating higher financial commitments and risk exposure. One minor observation: the answer could have been slightly more explicit about the 2023 lack of specific disclosure (the ground truth notes 2023 'did not specify the exact amounts'), though the LLM does imply this by contrasting 2023 policy disclosure with 2024's detailed figures. The semantic meaning is fully preserved, and the answer directly addresses how protection programs evolved in terms of both financial commitments and disclosure quality between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 364,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s continued to present franchising as the core of its business, but the framing shifted from simply noting that “ownership of real estate, combined with co‑investment by franchisees, enables it to achieve restaurant performance levels that are among the highest in the industry” (2022) to an explicit emphasis that this co‑investment is a strategic lever that drives profitability and system‑wide innovation (2024).  In the 2024 filing the company underscores that franchisee‑provided capital is essential to the model, that company‑owned restaurants serve as a testing ground for standards and concepts that are then rolled out to franchised locations, and that the partnership‑oriented, co‑investment approach remains a central pillar of its growth strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the strategic shift in McDonald's framing of franchisee relationships between 2022 and 2024. STRENGTHS: (1) Correctly identifies the core shift from descriptive/structural language to strategic/value-laden framing; (2) Accurately captures the 2022 language about 'ownership of real estate, combined with co-investment by franchisees' enabling high restaurant performance; (3) Properly synthesizes the 2024 evolution emphasizing franchisee co-investment as a strategic lever; (4) Adds valuable context about company-owned restaurants serving as testing grounds and the partnership-oriented approach; (5) Correctly identifies both years and maintains semantic equivalence with ground truth. MINOR WEAKNESSES: (1) The LLM answer uses slightly different language than ground truth - it says franchising was 'continued to be presented as the core' rather than emphasizing the shift from 'neutral, structural terms' to 'paramount' framing (though the substance is captured); (2) The ground truth specifically uses the word 'paramount' to describe the 2024 framing, which the LLM answer doesn't explicitly include, though it conveys similar meaning through 'strategic lever' and 'central pillar'; (3) The LLM answer adds interpretive details about company-owned restaurants as testing grounds that, while relevant and likely accurate, go slightly beyond what was explicitly stated in the ground truth comparison. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and correctly identifies the evolution in strategic framing. The comparison is logical and well-structured. QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this qualitative question, so this dimension is not heavily weighted. The dates (2022, 2024) are correct. Overall, this is a strong answer that captures the essential shift in McDonald's strategic framing with only minor variations in emphasis and wording from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 540,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "\nBetween March 2022 and January 2023 the FDA progressed from authorizing the IQOS 3 device as a modified‑risk tobacco product to granting PMTAs for three new tobacco‑flavored Marlboro HeatStick varieties—the first FDA‑cleared HeatStick flavors—signaling Altria’s advancing regulatory clearance for its heated‑tobacco portfolio. Nevertheless, the FDA has not exempted HeatSticks from graphic health‑warning requirements, continues to enforce post‑market surveillance, and the same regulatory scrutiny that could affect Altria’s JUUL investment also applies here, while the earlier ITC import ban and the recent assignment of exclusive U.S. commercialization rights to PMI underscore the ongoing compliance and partnership challenges.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES WITH LLM ANSWER: (1) FACTUAL ERRORS: The LLM introduces information NOT in the ground truth, including: (a) 'IQOS 3 device as a modified-risk tobacco product' authorization in March 2022 - this is not mentioned in the original answer and appears to conflate different products/timelines; (b) 'ITC import ban' - not mentioned in ground truth; (c) 'assignment of exclusive U.S. commercialization rights to PMI' - not in ground truth and contradicts Altria context. (2) CORRECT ELEMENTS: The LLM correctly identifies: (a) January 2023 FDA authorization of PMTAs for three tobacco-flavored Marlboro HeatStick varieties; (b) These were the first FDA-cleared HeatStick flavors; (c) Regulatory progress/advancement for Altria's heated tobacco portfolio. (3) PROBLEMATIC ADDITIONS: The LLM adds substantial context about graphic health warnings, post-market surveillance, JUUL investment scrutiny, and PMI commercialization rights that, while potentially accurate from other filings, are NOT part of the ground truth answer and represent scope creep beyond what was established. (4) MULTI-HOP REASONING: The LLM attempts more sophisticated synthesis but introduces unverified claims. The ground truth is simpler: 2022 = no authorization/case-by-case consideration; 2023 = PMTA authorization for three varieties = regulatory progress. (5) SEMANTIC DIVERGENCE: The LLM's answer shifts focus from the straightforward evolution question to regulatory challenges and partnership issues, which dilutes the core narrative. The original answer directly addresses the evolution and what it indicates about progress; the LLM answer muddies this with caveats and unrelated regulatory matters. QUANTITATIVE: Dates are correct (March 2022, January 2023, though March 2022 is not in ground truth), number of varieties correct (three), but the IQOS 3 reference is problematic. QUALITATIVE: Poor entity management - conflates different products and introduces PMI without proper context from the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 537,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "\nThe valuation of ACN’s mutual‑fund equity securities fell sharply from **$239,293 million in 2022** (Chunk 1) to **$196,226 million in 2023** (Chunk 2), a decline of roughly **$43 billion (≈18 %)**. This reduction signals that ACN is **de‑emphasizing its exposure to mutual‑fund equity** and is reallocating capital toward other segments—evidenced by growth in cash, fixed‑income holdings, and insurance contracts in the 2023 filing. In KG terms, ACN *Discloses* Mutual Fund Equity Securities and *Invests_In* them, but the decreasing disclosed amount reflects a strategic shift away from that investment category.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All numbers are correct - 2022 value of $239,293 million, 2023 value of $196,226 million, and the calculated decline of $43,067 million (presented as ~$43 billion). The percentage calculation of approximately 18% is accurate (43,067/239,293 ≈ 0.18 or 18%). Number formatting is appropriate and consistent. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the valuation evolved (specific numbers and direction of change), and (2) what this indicates about investment positioning (strategic shift/reallocation). ENTITY ACCURACY: ACN is correctly identified, years 2022 and 2023 are correct, and the financial metric (mutual fund equity securities) is properly specified. REASONING QUALITY: The multi-hop synthesis is sound - the model correctly connects the numerical decline to strategic implications, noting de-emphasis of mutual fund equity exposure and reallocation to other segments (cash, fixed-income, insurance contracts). The KG terminology reference (Discloses, Invests_In) adds appropriate context without detracting from the core answer. MINOR CONSIDERATIONS: The answer goes slightly beyond the ground truth by speculating about reallocation to other segments (cash, fixed-income, insurance contracts), which is reasonable inference but not explicitly stated in the original answer. However, this represents value-added analysis rather than factual error. The semantic equivalence is excellent - the answer conveys the same essential information as the ground truth while providing additional context and analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 455,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "\nChevron’s stake in Angola LNG Limited remained roughly stable – it held a 39.2 % non‑operated interest in 2022 (as noted in Chunk 1) and a 36.4 % interest in 2023 (Chunk 2) – but the way it deployed that stake changed.  The company sharpened its operational focus on securing gas feedstock for the 1.1 billion‑cubic‑foot‑per‑day LNG plant by extending the Block 0 concession (20‑year renewal to 2050) and completing the SLGC project that ties gas from Blocks 0 and 14 to the plant, while also restarting drilling in Block 14 and advancing offshore non‑associated‑gas development to supply the facility.  Consequently, its 2023 investment emphasis shifted from simply maintaining the equity position to strengthening the upstream gas supply chain that underpins the Angola LNG operation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM states Chevron held a '39.2% non-operated interest in 2022' but the ground truth clearly states '36.4% interest in 2022.' This is a significant factual error (39.2% vs 36.4%). The 2023 figure of 36.4% is correct. The LLM appears to have confused or misread the 2022 percentage. (2) OPERATIONAL DETAILS - The LLM introduces specific operational details (Block 0 concession extension to 2050, SLGC project, 1.1 billion-cubic-foot-per-day capacity, Block 14 drilling, offshore non-associated-gas development) that are NOT present in the ground truth answer. While these details may be factually accurate from the source documents, they represent information beyond what the ground truth synthesized and may indicate the LLM is adding unsourced details. (3) DISCLOSURE SHIFT - The ground truth emphasizes a key finding: the shift from operational development focus in 2022 to financial/portfolio integration emphasis in 2023. The LLM's answer actually contradicts this by claiming the 2023 emphasis shifted TO strengthening upstream gas supply chain, when the ground truth indicates the disclosure shifted AWAY from operational development details. (4) MULTI-HOP REASONING - The LLM fails to capture the core insight about the change in disclosure emphasis and reporting focus, instead focusing on operational activities that may not be the primary distinction between 2022 and 2023. (5) SEMANTIC MISMATCH - The ground truth emphasizes 'shift in disclosure emphasis from operational development to financial stake and integration within Chevron's global portfolio,' but the LLM claims the opposite direction of shift. This is a fundamental misunderstanding of the question's answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 474,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "\nMMM’s holdings of Certificates of Deposit/Time Deposits grew from **$21 million in 2022 to $49 million in 2023**, an increase of **$28 million (about 133 %)**. This change is evident in the marketable‑securities schedule disclosed in the 2023 filing (Chunk 2), where the line item rises from 21 to 49 (millions), and it aligns with the knowledge‑graph relationship — **ORG (MMM) discloses a financial instrument (FIN_INST) that “Increases”** (Chunk 1’s Level‑2 fair‑value classification), confirming the directional rise of MMM’s CD/time‑deposit investment over the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamental factual inaccuracies that make it substantially incorrect: (1) WRONG 2022 BASELINE: LLM states $21 million in 2022, but ground truth clearly shows $14 million. This is a 50% error on the starting value. (2) WRONG CALCULATION: LLM calculates $28 million increase (49-21=28), but the correct increase is $35 million (49-14=35). This is a 20% error in the magnitude of change. (3) WRONG PERCENTAGE: LLM calculates 133% growth, but correct calculation is 250% growth (35/14 ≈ 2.5 = 250%). This is a massive error - off by a factor of nearly 2. (4) CORRECT 2023 VALUE: The only correct number is the $49 million 2023 amount. (5) MULTI-HOP REASONING: While the LLM attempts to cite sources and reference knowledge graph relationships, this contextual framing cannot compensate for the core factual errors. The synthesis appears to reference correct structure but with incorrect underlying data. The question asks specifically about evolution and magnitude of change - both are answered incorrectly. The 2022 baseline error cascades through all subsequent calculations, making the entire answer unreliable. This is not a minor rounding or formatting difference - these are material factual discrepancies in financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 356,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "\nMcDonald’s has steadily deepened its franchisor role, with the share of franchised restaurants rising modestly from **93 % of the system at the end of 2021** (Chunk 1) to **about 95 % of the 43,477 restaurants at the end of 2024** (Chunk 2). This incremental increase reflects an ongoing partnership in which McDonald’s maintains its primary franchising model—owning or leasing real estate while co‑investing with franchisees to fund upgrades—while relying on franchisees to operate the majority of outlets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. (1) QUANTITATIVE ACCURACY: All numbers are correct - 93% in 2021 and approximately 95% in 2024 match the ground truth exactly. The additional detail of 43,477 restaurants in 2024 is factually accurate and adds useful context. (2) COMPLETENESS: The answer fully addresses the question about the evolution of McDonald's franchising relationship between 2021 and 2024, providing both the starting and ending percentages. (3) ENTITY ACCURACY: McDonald's is correctly identified, years 2021 and 2024 are correct, and the metric (percentage of franchised restaurants) is properly tracked. (4) REASONING & SYNTHESIS: The multi-hop reasoning is sound - the LLM correctly synthesizes that the percentage increased from 93% to 95%, interprets this as a 'modest' or 'slight' increase (semantically equivalent to ground truth's 'slight but deliberate shift'), and explains the strategic implications. The additional context about McDonald's real estate ownership model and co-investment strategy demonstrates deeper understanding beyond the basic numbers. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing 'deepened its franchisor role' and 'ongoing partnership' conveys the same meaning as the ground truth's 'shift toward further reliance on franchisees' and 'strategic emphasis on franchising.' The only minor distinction is that the LLM provides slightly more operational detail about the business model, which enhances rather than detracts from the answer. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 428,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "\nThe 2015 Stock Compensation Plan for Non‑Employee Directors was first restated in the March 31 2021 amendment (reported in the 2021 10‑Q), and then it was again amended and restated with an effective date of **October 26 2022** (disclosed in the 2022 10‑Q).  In the 2023 filing the plan is still cited without any further amendment, so the structure established by the October 26 2022 restatement remained in force throughout 2023.  This evolution reflects a single amendment‑and‑restatement cycle between 2021 and 2022, after which the plan’s terms stayed unchanged into the 2023 reporting period.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the key dates (March 31, 2021 and October 26, 2022) and accurately reports that the plan was amended and restated at these points. The dates are factually correct and properly formatted. However, there is a significant interpretive error in the reasoning and conclusion. The ground truth states that between 2022 and 2023, the plan underwent 'at least one additional amendment' with the October 26, 2022 effective date appearing in 2023 filings. The LLM's interpretation that the October 26, 2022 amendment occurred 'between 2021 and 2022' and that 'the plan's terms stayed unchanged into the 2023 reporting period' misses the key point of the question: how the plan evolved between 2022 and 2023 specifically. The LLM conflates the timeline by suggesting the October 26, 2022 amendment was disclosed in the 2022 10-Q, when the ground truth indicates it was reported in 2023 filings. This represents a failure in multi-hop synthesis across the 2022-2023 period. The LLM also adds unsupported detail about the 2021 10-Q that goes beyond the scope of the question. While the individual dates are correct, the narrative structure and temporal framing of how the plan evolved between the two years is incorrect, making the answer partially misleading despite accurate date citations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amends]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 367,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "\nIn fiscal 2022 Accenture recorded its ~16 % equity‑method investment in Duck Creek Technologies at a carrying amount of **$138.9 million** (with an estimated fair value of **$223.2 million**). By fiscal 2023 the stake produced a **$253 million investment gain** that was reflected in Accenture’s adjusted earnings per share, illustrating a marked increase in the investment’s valuation and a direct positive impact on the company’s reported financial results.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. Quantitative verification: (1) FY2022 carrying amount of $138.9 million matches ground truth $138,902 (thousands), correctly formatted as millions; (2) FY2022 fair value of $223.2 million matches ground truth $223,166 (thousands), properly formatted; (3) ~16% ownership percentage is correct; (4) FY2023 $253 million gain is accurate. All numbers are correctly stated with appropriate formatting variations. Multi-hop reasoning is sound: the answer successfully synthesizes the evolution from FY2022 equity-method investment valuation to FY2023 realized gain, showing the progression from long-term holding to financial realization event. Entity accuracy is perfect: Accenture, Duck Creek Technologies, fiscal years 2022-2023 all correctly identified. The answer addresses all parts of the question regarding investment valuation evolution and financial impact. Minor observation: The ground truth mentions the gain's impact on 'adjusted earnings per share and effective tax rate calculations,' while the LLM answer specifically mentions 'adjusted earnings per share' but omits the effective tax rate detail. This is a very minor omission that does not materially affect the core answer's accuracy. The semantic equivalence is strong - the LLM conveys the same essential information about the relationship evolution, using clear and accurate language. The characterization of the shift from 'long-term equity stake to more active financial realization event' is well-captured by the LLM's description of the progression from carrying amount/fair value to the realized gain.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 449,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "\nBreyanzi, first launched in April 2021 as a CD19‑directed CAR‑T therapy for relapsed/refractory large B‑cell lymphoma after ≥ 2 prior systemic treatments (BMY 2022 filing), broadened its therapeutic scope in 2024 with two FDA accelerated approvals: a May 2024 approval for relapsed/refractory follicular lymphoma and a March 2024 approval for relapsed/refractory CLL/SLL, each requiring prior BTK‑inhibitor and BCL‑2‑inhibitor therapy. These 2024 indications, highlighted in the BMY 2024 10‑K, extend the CAR‑T’s use beyond large B‑cell lymphoma and markedly expand its market potential.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the two 2024 approvals (March 2024 for CLL/SLL and May 2024 for follicular lymphoma) and accurately notes that these expand Breyanzi's market potential beyond the original large B-cell lymphoma indication. The multi-hop synthesis across 2022 and 2024 is sound, and the answer appropriately references the 10-K filings. The semantic understanding of therapeutic evolution is correct.\n\nCRITICAL ERRORS: (1) The LLM introduces unsupported specificity regarding prior therapy requirements. The ground truth states patients must have received 'at least two prior lines of therapy' for all indications. However, the LLM claims the 2024 CLL/SLL and FL approvals specifically require 'prior BTK-inhibitor and BCL-2-inhibitor therapy' - this additional requirement detail is NOT present in the ground truth and appears to be hallucinated. (2) The LLM mentions Breyanzi was 'first launched in April 2021' - while this provides helpful context, it goes beyond the 2022-2024 timeframe specified in the question.\n\nMINOR ISSUES: The LLM's phrasing of approval requirements differs from ground truth. Ground truth uses 'at least two prior lines of therapy' consistently; the LLM's addition of specific drug class requirements (BTK-inhibitor, BCL-2-inhibitor) is factually unsupported and represents a significant quantitative/factual error that could mislead readers about actual approval criteria.\n\nMULTI-HOP REASONING: The synthesis across years and indications is logically sound, but the introduction of unsupported therapeutic requirements undermines the accuracy of the multi-hop analysis.\n\nSCORE JUSTIFICATION: The core answer structure is correct (two 2024 approvals, market expansion), but the hallucinated therapy requirements constitute a material factual error that prevents a higher score. This is a 6/10 because the main facts are present but a significant inaccuracy about approval criteria is introduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 527,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "\n3M’s 2022 and 2023 filings show that the company continues to accrue legal‑proceeding losses only when a loss is both probable and reasonably estimable under ASC 450, and for insured matters it records a receivable for the portion of the loss it expects to recover based on an analysis of policy terms, applicable case law, its experience with similar claims, and the nature of each claim; the 2023 disclosure expands this process by describing the step‑by‑step estimation model and by stating that the company re‑examines and, if needed, adjusts those estimates each reporting period, with the Audit Committee reviewing the critical accounting estimates.  In the respirator‑mask/asbestos docket the pending claimant count rose modestly—from roughly 4,028 at the end of 2022 to about 4,042 by the end of 2023—highlighting ongoing exposure and the need for continual reassessment of both the liability accrual and the amount of insurance recovery that is deemed recognizable.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key facts and figures. STRENGTHS: (1) All numeric values are correct - claimant counts of 4,028 (2022) and 4,042 (2023) match ground truth exactly; (2) Correctly identifies ASC 450 as the governing standard and mentions ASC 610-30 for revenue recognition; (3) Accurately describes the evolution from 2022 to 2023, noting that 2023 provides more explicit methodology details; (4) Properly synthesizes multi-hop information across years and connects growing claimant exposure to the need for refined insurance receivables estimation; (5) Correctly identifies the key components of the estimation process (policy terms, case law, claim nature, experience with similar claims); (6) Appropriately notes the Audit Committee's review role and periodic reassessment requirement. MINOR WEAKNESSES: (1) The ground truth states that 2022 'did not specifically mention the methodology for estimating insurance receivables' while the LLM answer suggests 2022 already had the full process described ('continues to accrue...records a receivable for the portion...based on an analysis'). This is a subtle but meaningful distinction - the LLM conflates the 2022 and 2023 approaches rather than clearly delineating the evolution; (2) The LLM answer could be slightly clearer that the explicit description of the loss recovery and gain contingency models under ASC 450 and ASC 610-30 is a 2023 addition, not a continuation from 2022. The phrasing 'continues to accrue' and 'expands this process' partially addresses this but could be more explicit about what changed. CALCULATION/FACT VERIFICATION: All numbers verified as correct. The modest increase from 4,028 to 4,042 (14 additional claimants, ~0.35% increase) is accurately characterized. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings and correctly links the growing claimant exposure to the evolution in accounting methodology. The connection between litigation exposure and insurance receivables estimation approach is logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 566,
        "total_tokens": 1996
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "\nBetween 2022 and 2023 PepsiCo sold the Naked juice brand (along with Tropicana and other select juice brands) to PAI Partners, but retained a 39 % non‑controlling equity interest in the newly formed joint venture (TBG) that now owns the brand and operates across North America and Europe.  Operationally, PepsiCo continues to act as the exclusive distributor of the joint‑venture’s portfolio—including Naked—for small‑format and food‑service customers via its DSD and warehouse network, a role it maintains in 2023.  Consequently, PepsiCo’s financial stake in Naked is now limited to its 39 % share of the joint‑venture rather than full ownership of the brand.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERROR IN TEMPORAL REASONING: The LLM answer contains a fundamental factual error regarding the evolution of PepsiCo's operational involvement between 2022 and 2023. The ground truth clearly states that BY 2023, PepsiCo NO LONGER directly distributed Naked products and instead only maintained a financial stake through its 39% noncontrolling interest. However, the LLM answer claims that 'PepsiCo continues to act as the exclusive distributor...a role it maintains in 2023,' which directly contradicts the ground truth. This is a major error because the question specifically asks about how the relationship 'evolved' between these two years, and the key evolution is the SHIFT FROM active distribution to purely financial stake. QUANTITATIVE ACCURACY: The 39% noncontrolling interest figure is correct, and the identification of PAI Partners, TBG, and the geographic scope (North America and Europe) are all accurate. QUALITATIVE ACCURACY: While the LLM correctly identifies the 2022 transaction structure and the retained equity interest, it fundamentally misrepresents the 2023 status by claiming continued operational involvement in distribution. The ground truth explicitly states 'no further operational involvement in the distribution of Naked products' by 2023. This is not a minor wording difference—it's a factual misstatement about what changed between the two years. MULTI-HOP REASONING: The LLM failed to properly synthesize the temporal evolution aspect of the question. It correctly identifies the 2022 structure but incorrectly extends the 2022 operational role into 2023, missing the critical shift that defines the evolution. CONTEXTUAL RELEVANCE: The answer addresses the right entities and transaction but fails to capture the essential evolution requested in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Distributes]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 489,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "\nBetween 2023 and 2024 CVS (ORG) continued to disclose that its **ExtraBucks Rewards** (PRODUCT) creates an **additional performance obligation** at the point of the initial transaction, and it refined the wording to make that obligation explicit.  The company now states that the transaction price is allocated between the base sale and the rewards based on their **relative standalone selling price** (using historical redemption patterns), revenue for the rewards is recognized **as the rewards are redeemed**, and any unredeemed rewards are carried as a **contract liability**—a more clearly articulated determination of the performance obligation while the underlying accounting treatment remains the same.  This evolution reflects a clearer separation of the base transaction from the rewards and a more detailed description of how the performance obligation is identified and measured.  \n\n- **KG linkage:** CVS → [Introduces]→ ExtraBucks Rewards; ExtraBucks Rewards → [Discloses]→ CVS, underscoring that the product’s disclosure is made by the same organization.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of ExtraBucks Rewards accounting treatment between 2023 and 2024. STRENGTHS: (1) Correctly identifies that both years treat ExtraBucks as an additional performance obligation at initial transaction; (2) Accurately describes the revenue recognition approach using relative standalone selling prices based on historical redemption patterns; (3) Correctly states that revenue is recognized as rewards are redeemed; (4) Properly identifies unredeemed rewards as contract liabilities; (5) Accurately characterizes the evolution as refinement in language/disclosure rather than fundamental change in accounting treatment; (6) No quantitative errors or incorrect dates/numbers. MINOR WEAKNESSES: (1) The LLM answer emphasizes 'clearer separation' and 'more detailed description' but could have been more explicit about the specific refinement mentioned in the ground truth regarding 'customers who accumulate ExtraBucks based on historical spending levels'—this detail appears in the original answer but is somewhat implicit rather than explicit in the LLM response; (2) The phrase 'more mature and formalized approach' from the ground truth is captured conceptually but not explicitly stated; (3) The KG linkage notation at the end, while showing knowledge graph awareness, is somewhat tangential to the core question. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years (2023 and 2024) and correctly identifies both continuities and evolutions in disclosure. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The LLM answer conveys the essential information from the ground truth with appropriate wording variations that maintain factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1526,
        "completion_tokens": 483,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "\nBoth the 2023 and 2024 cost‑of‑revenues sections state that “payment processing fees, **including those we pay to our integrated payment partners**,” are included in other operating costs, and the wording is identical in the two filings. This shows that Netflix’s reliance on integrated payment partners remained unchanged between 2023 and 2024—continuing to depend on these partners for payment‑processing fees as part of its cost structure. The consistent disclosure reflects a stable, ongoing dependence, consistent with the KG relationship where NFLX discloses and depends on Integrated Payment Partners.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL DISCREPANCY: The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that disclosure details DECREASED from 2023 to 2024 (removal of granular details, shift in disclosure strategy), while the LLM claims the wording is IDENTICAL and that reliance remained UNCHANGED. This is a fundamental factual error that undermines the entire answer. The LLM correctly identifies that payment processing fees to integrated payment partners were mentioned in both years and that the relationship persisted, but it completely misses or contradicts the key insight about the evolution of disclosure detail. The LLM's assertion that 'the wording is identical in the two filings' appears to be factually incorrect based on the ground truth's explicit statement about streamlining and removal of granular details. The LLM's conclusion about 'stable, ongoing dependence' may be partially correct regarding the relationship itself, but it fails to capture the actual evolution in how Netflix disclosed this information. The answer demonstrates a failure in multi-hop reasoning by not properly synthesizing the comparative analysis between 2023 and 2024 disclosures. While the LLM correctly identifies the entities (Netflix, integrated payment partners) and years (2023, 2024), it fundamentally mischaracterizes the nature of the change, which was the primary focus of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 390,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "\nBuilding on the framework of the 2007 Settlement Agreement and Consent Order that obligates 3M to evaluate PFAS releases, treat water exceeding Minnesota health‑based values, remediate non‑PFOA/PFOS sources, and share data with the MPCA (Chunk 1), the company’s approach evolved from 2022‑23 to respond to newly issued, more stringent HBVs for PFOA and PFOS (January 2024), a March 2023 MPCA Notice of Violation, a June 2022 MPCA directive on storm‑water PFAS, and a January 2024 draft Clean Water Act permit with tightened PFAS limits, prompting 3M to reassess its remediation and compliance obligations and to maintain continuous engagement with MPCA, EPA and other state agencies (Chunk 2).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution of 3M's PFAS management approach from 2022-2023 and correctly identifies key regulatory developments and dates. Strengths: (1) Correctly references the May 2007 Settlement Agreement and Consent Order framework; (2) Accurately identifies January 2024 HBVs for PFOA and PFOS as more stringent; (3) Correctly cites March 2023 MPCA Notice of Violation; (4) Accurately references January 2024 draft Clean Water Act permit with tightened PFAS limits; (5) Properly synthesizes the multi-hop information showing regulatory escalation. Weaknesses and discrepancies: (1) The LLM mentions 'June 2022 MPCA directive on storm-water PFAS' but the ground truth specifies 'December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility' - this is a date error (June vs December 2022); (2) The LLM omits specific site details mentioned in ground truth: Cottage Grove (substantially completed remediation in 2022), Oakdale and Woodbury sites (continuing operational/maintenance activities), and Hutchinson facility (March 2023 NOV); (3) The LLM does not mention the Decatur, Alabama facility and 2020 interim Consent Order with ADEM, which represents incomplete geographic scope; (4) The LLM answer is somewhat more abstract/general in its framing compared to the ground truth's specific site-by-site accounting. The quantitative accuracy is good (dates mostly correct except June vs December 2022), but the omission of specific facility details and the date discrepancy prevent a higher score. The multi-hop reasoning is sound - the answer correctly synthesizes regulatory changes and 3M's responsive engagement - but lacks the granular detail of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Remediates]-> RISK_FACTOR <-[Treats]- ORG",
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 468,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "\nPepsiCo expanded the size of its foreign‑currency hedging program between the 2022 and 2023 fiscal years – the notional amount of its foreign‑currency derivatives rose from **$3.0 billion at the end of 2022** (as disclosed in the 2022 filing) to **$3.8 billion at the end of 2023** (as disclosed in the 2023 filing), and the amount of debt it designated for net‑investment hedging edged up from **$2.9 billion to $3.0 billion** over the same period.  This scaling‑up of forward contracts (typically ≤ 2‑year tenors) and net‑investment hedges shows that PepsiCo is deliberately deepening its FX‑risk management, locking in exchange rates for its global supply chain and investment positions while still offsetting non‑qualifying hedge gains/losses against the underlying hedged items so that earnings are not materially impacted.  The growth therefore signals a proactive strategy to mitigate foreign‑exchange volatility in its worldwide operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative data is correct: foreign currency derivatives notional value increased from $3.0 billion (2022) to $3.8 billion (2023), and net-investment hedge debt rose from $2.9 billion to $3.0 billion. The LLM correctly synthesized multi-hop information across two fiscal years and identified the strategic implications. The answer goes beyond the ground truth by providing additional context about forward contract tenors (≤2 years) and the mechanics of offsetting non-qualifying hedge gains/losses, which adds valuable detail without contradicting the original answer. The reasoning is sound: the expansion of both notional derivatives and net-investment hedges is correctly interpreted as a proactive FX risk management strategy. The LLM properly addresses all parts of the question - the evolution of derivatives use and what it indicates about risk management strategy. Minor point: the ground truth mentions 'no material net impact on earnings in 2023' while the LLM references 'earnings are not materially impacted' through offsetting mechanisms - these are semantically equivalent statements about the same concept. The LLM's additional specificity about forward contract mechanics and the deliberate nature of the strategy enhances the answer without introducing errors. All numbers, dates, and entities are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 387,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "\nExxonMobil’s playbook for turning “improving living standards” into chemical growth shifted from consolidating its U.S. Gulf Coast base—evidenced by the 2021 Corpus Christi ethane‑cracker and the 2022 Baytown advanced‑recycling plant—to a two‑track expansion that adds high‑value capacity both at home and abroad.  In 2023 it brought online a 400 kt/yr performance‑polymer line (Vistamaxx™/Exact™) and a 350 kt/yr linear‑alpha‑olefins unit (Elevexx™) in Baytown, while simultaneously moving forward on the Dayawan Petrochemical Industrial Park in China, a 2.5 million‑ton/yr complex that will be the first 100 % foreign‑owned petrochemical site in the country.  These additions show a clear evolution: from leveraging U.S. integration to capture resilient demand, to diversifying into specialty, higher‑margin polymers and expanding geographically into China to meet the structural demand driven by rising living standards.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual inaccuracies that undermine its credibility. (1) TIMELINE ERROR: The LLM states the Corpus Christi ethane cracker was completed in 2021, but the ground truth specifies it was completed in 2022. This is a material error in dating a key project. (2) CAPACITY NUMBERS - MAJOR DISCREPANCY: The LLM claims 400 kt/yr for performance polymers and 350 kt/yr for linear alpha olefins were brought online in 2023, totaling 750 kt/yr. The ground truth does not provide these specific capacity numbers for 2023 additions - it only mentions 'expanding performance polymers and linear alpha olefins capacity' without quantifying the additions. The LLM appears to have fabricated or misattributed these specific numbers. (3) BAYTOWN ADVANCED RECYCLING: The LLM incorrectly states a '2022 Baytown advanced-recycling plant' was brought online, when the ground truth clearly states plans for 'up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026' - this is a future plan, not a 2022 completion. (4) CHINA CAPACITY: The LLM correctly identifies the 2.5 million metric tons per year capacity and 100% foreign-owned status for Dayawan, matching ground truth. QUALITATIVE ASSESSMENT: The LLM correctly identifies the strategic evolution from U.S. domestic focus to geographic diversification and higher-value products. The narrative about shifting from U.S. Gulf Coast consolidation to two-track expansion (domestic + China) aligns with ground truth. However, the specific product names (Vistamaxx™/Exact™, Elevexx™) and capacity figures are not verified in the ground truth and appear to be added details that may be inaccurate. MULTI-HOP REASONING: The LLM successfully synthesizes the 2022-2023 comparison and identifies the geographic/product shift, but the factual errors in specific numbers and dates significantly compromise the answer's reliability. The core strategic narrative is sound, but execution is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> MACRO_CONDITION <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 544,
        "total_tokens": 1985
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "\n3M’s holdings of certificates of deposit/time deposits grew from **$21 million in 2022 to $49 million in 2023** (Chunk 2), a $28 million increase that reflects a clear shift toward larger short‑term placements. This move is part of the company’s broader practice of parking excess cash in highly liquid, low‑risk marketable securities—primarily CDs/TD, commercial paper and municipal securities—that are classified as available‑for‑sale (Chunk 1). The rise indicates that 3M is deliberately allocating more of its liquidity to higher‑yielding, short‑duration instruments to manage cash flow and capitalize on favorable interest‑rate conditions, as captured by the KG relationship **ORG → Invests_In → FIN_INST** with the **FIN_INST → Increases → ORG** pattern.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All numbers are correct—$21 million in 2022, $49 million in 2023, and the $28 million increase are all accurate. The calculation of the increase is correct. COMPLETENESS: The answer addresses both parts of the question: (1) how the investment evolved (specific numbers and direction), and (2) what this indicates about strategy. ENTITY ACCURACY: 3M is correctly identified, years 2022-2023 are correct, and the financial instrument (Certificates of Deposit/Time Deposits) is correctly specified. REASONING QUALITY: The LLM provides sound multi-hop synthesis by connecting the numerical evolution to strategic implications. It goes beyond the ground truth by contextualizing the shift within 3M's broader liquidity management practices, mentioning available-for-sale classifications, commercial paper, and municipal securities. The reference to capitalizing on favorable interest-rate conditions adds reasonable inference about motivation. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift as 'deliberately allocating more liquidity to higher-yielding, short-duration instruments' is semantically equivalent to the ground truth's 'strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments.' MINOR CONSIDERATIONS: The LLM includes additional context about KG relationships and broader investment practices that, while not in the ground truth, are reasonable inferences and enhance rather than detract from the answer. The answer is well-structured, cites sources (Chunk 1, Chunk 2), and provides clear reasoning. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 470,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "\nMastercard’s proprietary‑insights offering is introduced by the company (MA → Proprietary Insights) and, in turn, is provided by Mastercard itself (Proprietary Insights → MA), a relationship that remains constant across the two filings.  \n\nIn the 2022 filing the insights are described as coming from a **“principled use of consumer and merchant data,”** stressing confidence and ease of transaction. By 2023 the language has evolved to a **“principled and responsible use of secure consumer and merchant data,”** explicitly foregrounding data‑responsibility and trust‑building, and tying that stewardship to new investments such as open‑banking and digital‑identity capabilities that reinforce the franchise model’s standards. This shift shows a deliberate deepening of Mastercard’s commitment to responsible data practices and trust across the payments ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness in addressing the multi-hop question about Mastercard's evolving approach to proprietary insights. STRENGTHS: (1) Both key phrases are quoted correctly - '2022: principled use of consumer and merchant data' and '2023: principled and responsible use of secure consumer and merchant data' - matching the ground truth exactly. (2) The core insight about the evolution is accurate: the shift from 'principled use' to 'principled and responsible use' with added emphasis on 'secure' data. (3) The multi-hop synthesis is sound, correctly identifying that Mastercard made this linguistic shift between the two filing years. (4) The answer goes beyond the ground truth by providing additional context about open-banking and digital-identity capabilities, which adds relevant depth without contradicting the original answer. (5) The reasoning about trust-building and data responsibility is logically sound and well-articulated. MINOR CONSIDERATIONS: The LLM answer includes some additional interpretive elements (relationship diagrams with MA → Proprietary Insights notation, references to franchise model standards) that, while not incorrect, extend slightly beyond what was explicitly stated in the ground truth. However, these additions appear to be supportive elaborations rather than factual errors. The semantic equivalence is strong - both answers convey that Mastercard strengthened its language around data security and responsibility between 2022 and 2023. No numerical errors, date errors, or calculation issues present. The answer fully addresses all aspects of the question regarding the evolution of language and emphasis on data responsibility and trust-building.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 473,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "\nThe company’s pension and retiree medical‑plan estimates are treated as a critical accounting policy and are disclosed in both years; in 2022 the estimates were shaped mainly by the COVID‑19 pandemic and the resulting global economic uncertainty, while in 2023 they are now driven by business‑ and economic‑uncertainty arising from the Ukraine and Middle‑East conflicts together with high interest rates and an inflationary cost environment. This shift shows that the external forces influencing these estimates have moved from pandemic‑related disruptions to broader geopolitical and macro‑economic pressures, requiring more complex and forward‑looking assumptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. (1) CORRECTNESS: All factual information matches the ground truth. The answer correctly identifies the 2022 factors (COVID-19 pandemic and global economic uncertainty) and the 2023 factors (Ukraine and Middle East conflicts, high interest rates, inflationary environment). The characterization of the shift from health-related disruptions to macroeconomic and geopolitical concerns is accurate. (2) QUANTITATIVE ACCURACY: No numeric values are present in either answer, so this dimension is not applicable. Both answers correctly reference the same time periods (2022 vs 2023) without error. (3) ENTITY ACCURACY: The answer correctly identifies the relevant entities (pension and retiree medical plans) and maintains proper temporal distinctions between the two years. (4) REASONING & SYNTHESIS: The multi-hop reasoning is sound. The LLM successfully synthesizes information about how external factors evolved between two years and correctly interprets what this evolution indicates about the changing environment. The answer goes slightly beyond the ground truth by noting that the shift 'requires more complex and forward-looking assumptions,' which is a reasonable inference that adds value without contradicting the ground truth. (5) SEMANTIC EQUIVALENCE: The LLM answer uses slightly different phrasing ('business-and economic-uncertainty' vs 'business and economic uncertainty') and adds contextual detail about the treatment as a 'critical accounting policy,' but these additions are accurate and enhance rather than detract from the answer. The core message is semantically equivalent to the ground truth. Minor deduction from perfect score (9 vs 10) only because the added inference about 'complex and forward-looking assumptions,' while reasonable, goes slightly beyond what was explicitly stated in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 512,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "\nBetween 2022 and 2023 ExxonMobil’s undeveloped acreage in the Other Americas fell modestly—from about 25,096 gross (11,977 net) thousand acres to 24,221 gross (11,548 net) thousand acres—reflecting the company’s selective relinquishment of less‑prospective blocks while retaining rights through extensions that are typically granted when further evaluation is needed.  The corporation’s work‑program approach and the statement that scheduled lease expirations are not expected to have a material adverse impact signal confidence that the remaining acreage still offers meaningful exploration potential, which the firm treats as a key risk factor linked to XOM.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: All quantitative data is precisely correct. The LLM accurately reports the 2022 figures (25,096 gross / 11,977 net thousand acres) and 2023 figures (24,221 gross / 11,548 net thousand acres), with proper formatting and clarity. The directional assessment (decrease/reduction) is accurate. WEAKNESSES: The LLM introduces interpretive elements not present in the ground truth. Specifically: (1) The phrase 'selective relinquishment of less-prospective blocks while retaining rights through extensions' goes beyond what the ground truth states. The ground truth simply notes 'some properties may have been relinquished or transitioned to developed status' without specifying the mechanism or characterizing them as 'less-prospective.' (2) The reference to 'work-program approach' and 'scheduled lease expirations' and 'material adverse impact' appears to be extrapolated reasoning not grounded in the provided ground truth. (3) The statement about 'XOM' treating this as a 'key risk factor' is not mentioned in the original answer. MULTI-HOP REASONING: The LLM correctly synthesizes the year-over-year comparison and draws a reasonable inference about exploration potential, but adds speculative elements beyond the ground truth. The core answer structure matches (showing the decline and what it indicates), but the supporting rationale diverges. SEMANTIC EQUIVALENCE: The main finding is semantically equivalent, but the LLM adds interpretive layers that, while potentially reasonable, are not validated by the ground truth source. This represents over-interpretation rather than factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 440,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "\nFrom 2022 through 2023 3M kept using foreign‑currency forwards and options that are **not designated as hedging instruments** to offset the effects of exchange‑rate movements on non‑functional‑currency balances—including certain intercompany financing—while in 2023 it explicitly notes that some of these contracts were formerly cash‑flow hedges that have now been **de‑designated**, causing their fair‑value gains and losses to be recorded directly in earnings (Statement of Income). The notional exposure remains sizable (about $3.7 billion of contracts not designated as of the 2021 reference and still material in 2023), reflecting a continued reliance on such instruments but a shift from hedge‑accounting to earnings‑impact accounting.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of 3M's foreign currency hedging strategy from 2022 to 2023, correctly identifying the shift from designated hedging instruments to non-designated contracts with direct earnings impact. However, there are significant issues with quantitative accuracy and temporal precision: (1) The LLM references a '$3.7 billion' notional amount but attributes it to '2021 reference' which is confusing and potentially incorrect—the ground truth clearly states this was the 2022 figure. The LLM should have been clearer that the $3.7 billion applies to 2022, not 2021. (2) The LLM mentions 'some of these contracts were formerly cash-flow hedges that have now been de-designated' which adds detail not explicitly in the ground truth, potentially introducing unsupported claims. (3) The core narrative is sound: both answers correctly identify that 3M used FX forwards/options not designated as hedging instruments, that these targeted non-functional currency items including intercompany financing, and that there was a shift toward direct earnings impact. (4) The multi-hop reasoning is adequate—the LLM synthesizes the evolution across years and connects the accounting treatment change to financial reporting impact. (5) However, the temporal reference confusion ('2021 reference') and the introduction of 'de-designated' language without clear sourcing weakens confidence in the quantitative accuracy. The qualitative understanding of the strategy shift is good, but the execution on precise dating and sourcing of the $3.7 billion figure is problematic. The answer would score higher if it clearly stated the $3.7 billion was the 2022 notional amount and avoided introducing unsupported details about de-designation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Hedges]-> FIN_INST <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 477,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "\nIn the 2022 filing (Chunk 1) cyber‑and‑intelligence solutions are listed only as one of several “value‑added services” (alongside batch/real‑time payments, consulting, loyalty programs, etc.) that the company offers, with no special strategic emphasis beyond being part of the broader product suite.  \nBy contrast, the 2023 MD&A (Chunk 2) elevates these solutions to a core strategic capability—described as essential for enabling “secure, easy and confident” transactions, delivering “proprietary insights” from secure consumer and merchant data, and being tightly linked to new network investments such as open‑banking and digital‑identity—showing that Mastercard now positions cyber and intelligence solutions as a central pillar of its value proposition.  \n\nThis shift is reflected in the knowledge‑graph relationship MA → Cyber and Intelligence Solutions, indicating that the organization’s focus on, and positive impact from, this product line has grown markedly from 2022 to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of Cyber and Intelligence Solutions' role from 2022 to 2023. In 2022, it correctly identifies these solutions as part of a broader list of value-added services with no special emphasis. By 2023, it correctly elevates them to a core strategic capability. The characterization of the shift from 'supporting role' to 'central pillar' matches the ground truth's description of strategic elevation. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are required for this qualitative question about strategic positioning. The answer appropriately avoids introducing unsupported metrics. (3) ENTITY ACCURACY: Mastercard is correctly identified, fiscal years 2022 and 2023 are correctly referenced, and the product line (Cyber and Intelligence Solutions) is accurately named throughout. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two different filing years and demonstrates the comparative analysis required. It correctly identifies the progression from a peripheral offering to a core strategic component. The reference to specific descriptors ('secure, easy and confident transactions,' 'proprietary insights,' 'open-banking and digital-identity') adds credibility and shows detailed source engagement. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth while using slightly different phrasing. Terms like 'elevates,' 'core strategic capability,' and 'central pillar' are semantically equivalent to the ground truth's 'more prominently positioned' and 'core component.' The mention of the knowledge-graph relationship (MA → Cyber and Intelligence Solutions) adds a technical detail not in the ground truth but does not contradict it. Minor observation: The LLM provides slightly more specific supporting details (open-banking, digital-identity, proprietary insights) than the ground truth, which enhances rather than detracts from the answer's quality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 567,
        "total_tokens": 1975
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "\nIn both the 2022 PEP 10‑K (page 59) and the 2023 10‑K (page 58), **Income Tax Expense and Accruals** remains listed as one of PepsiCo’s critical accounting policies, confirming that the policy’s status has not changed between the years.  The 2022 discussion highlights the subjectivity and estimation risks inherent in the tax accruals, while the 2023 filing retains that focus but adds expanded quantitative and qualitative disclosure—specifically, a dedicated “Note 5 – Income Taxes” that details the tax expense calculation and related accruals—indicating a modest evolution toward greater transparency.  This continuity is reflected in the knowledge‑graph relationship PEP → *Income Tax Expense and Accruals* ← *Income Tax Expense and Accruals* → PEP, showing the policy’s persistent linkage to the company across both reporting periods.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that 'Income Tax Expense and Accruals' appears in both 2022 and 2023 critical accounting policies lists. (2) Page references (2022: page 59, 2023: page 58) are provided with appropriate specificity. (3) The mention of Note 5 - Income Taxes is accurate and relevant. (4) The identification of PepsiCo (PEP) as the company is correct. (5) The general direction of evolution toward greater transparency is reasonable. WEAKNESSES: (1) The LLM states the policy's 'status has not changed between the years,' which contradicts the ground truth that indicates a structural evolution—the policy was moved to a subsection with more organized presentation in 2023. This is a significant semantic error about the nature of the change. (2) The ground truth emphasizes a 'shift toward more detailed and organized reporting' with 'more structured presentation' and movement to 'a subsection,' but the LLM characterizes this as merely 'modest evolution toward greater transparency' without capturing the structural reorganization aspect. (3) The phrase 'continuity is reflected in the knowledge-graph relationship' is awkwardly phrased and doesn't clearly convey the actual evolution described in the ground truth. (4) The LLM misses the key distinction that the policy moved to a subsection under 'Our Critical Accounting Policies and Estimates' in 2023, suggesting a reorganization of presentation structure. (5) The characterization of the change as 'not changed' in status contradicts the actual evolution described in the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize information across two years but fails to properly identify the structural change in how the policy was presented. The reasoning about 'continuity' actually obscures rather than clarifies the evolution that occurred. CALCULATION/NUMERIC VERIFICATION: Page numbers appear reasonable but cannot be independently verified. No calculations are required for this question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 536,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "\nIntel introduced the Universal Chiplet Interconnect Express (UCIe) as part of its Open System Foundry and “systems‑of‑chips” strategy, demonstrating silicon‑ready UCIe in 2023 to enable standardized chiplet‑to‑chip communication. In 2024 the company continues to advance and promote UCIe alongside its new process nodes (Intel 18A, Intel 3, Intel 14A), advanced packaging capabilities, and the broader IDM 2.0 roadmap, positioning the standard as a cornerstone for building optimized, AI‑focused systems‑of‑chips that can be assembled from Intel‑produced or ecosystem chiplets.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of Intel's UCIe evolution. STRENGTHS: (1) Correctly identifies 2023 as the year Intel demonstrated silicon-ready UCIe, matching the ground truth's 'demonstrated it in silicon' language. (2) Accurately captures the progression from 2023 demonstration to 2024 active production/advancement. (3) Properly contextualizes UCIe within Intel's broader 'systems-of-chips' strategy, which is the core of the question. (4) Adds relevant contextual details about IDM 2.0, process nodes (Intel 18A, Intel 3, Intel 14A), and advanced packaging that enhance understanding without contradicting ground truth. (5) Correctly identifies the standard's role in enabling chiplet-to-chip communication and ecosystem integration. (6) No numerical errors or date inaccuracies. MINOR GAPS: (1) The ground truth emphasizes 'actively producing based on this standard' and 'integrating it into its broader advanced semiconductor assembly and test offerings' - the LLM answer says 'continues to advance and promote' which is slightly less specific about production/manufacturing integration, though not incorrect. (2) The LLM answer adds information about 'AI-focused systems' which, while contextually relevant to 2024 industry trends, is not explicitly mentioned in the ground truth. This is additive rather than contradictory. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023-2024 timeline and connects UCIe to the broader strategic context (Open System Foundry, IDM 2.0, process nodes, packaging). The evolution narrative is clear and logically sound. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as ground truth - UCIe introduction in 2023, progression to production/advancement in 2024, and integration into systems-of-chips strategy. The wording differs but meaning aligns well.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 514,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "\nIn the 2023 10‑K the company merely noted that it had entered into a $3 bn fixed‑dollar ASR with Morgan Stanley (payment Jan 4 2024) and a $2 bn ASR with Citibank (payment Jan 4 2023) under the 2021 Repurchase Program, describing the programs generally but providing no detailed accounting entry. The 2024 10‑K expands this disclosure by stating that each ASR was recorded as an initial treasury‑stock purchase with the remaining 15‑20 % financed through an equity‑classified forward contract recorded in capital surplus, and that the forward contracts were later re‑classified to treasury stock when the final share allotments were received—Morgan Stanley’s ASR was completed in March 2024, Citibank’s in February 2023, and the prior $1.5 bn Barclays ASR had been settled in February 2022—thereby showing the evolution of both the accounting treatment and the completion timeline between the two filings.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates understanding of the general evolution of ASR accounting treatment between 2023 and 2024 filings and correctly identifies the key accounting mechanism (initial treasury stock purchase with forward contract in capital surplus, later reclassified to treasury stock). However, there are significant quantitative errors that undermine the answer's reliability:\n\nCRITICAL ERRORS:\n1. The LLM incorrectly attributes the $3.0 billion ASR to the 2023 10-K filing as a forward-looking transaction (payment Jan 4 2024), when the ground truth shows this was actually completed in 2024 and should be discussed as a 2024 transaction.\n2. The LLM states the Citibank ASR was $2 billion with payment Jan 4 2023, which is correct, but the framing suggests this was merely noted in 2023 without detailed accounting, when the ground truth indicates specific share counts (17.4M initial + 5.4M final) were disclosed.\n3. The LLM provides no specific share counts for either ASR (17.4M + 5.4M for Citibank; 31.4M + 8.3M for Morgan Stanley), which are key details in the ground truth.\n4. The LLM mentions a Barclays ASR settled in February 2022 ($1.5 billion), which is not mentioned in the ground truth answer and appears to be extraneous information not directly relevant to the 2023-2024 evolution question.\n5. The LLM states the Morgan Stanley ASR was completed in March 2024 (correct) but doesn't specify the initial/final share breakdown or the 85% initial percentage mentioned in ground truth.\n\nPARTIALLY CORRECT ELEMENTS:\n- Correctly identifies the accounting treatment evolution (treasury stock + forward contract in capital surplus, later reclassified)\n- Correctly identifies completion dates (February 2023 for Citibank, March 2024 for Morgan Stanley)\n- Correctly notes the 15-20% financing through forward contracts\n- Appropriately addresses the question's focus on evolution between filings\n\nMISSING ELEMENTS:\n- No specific share counts provided\n- No mention of the different initial percentages (80% vs 85%)\n- No clear comparison of timeline differences (one month vs two months)\n- Confusing presentation of which ASR was in which filing year\n\nThe answer demonstrates conceptual understanding but fails on quantitative precision and clear attribution of transactions to the correct filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 622,
        "total_tokens": 2053
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "\nUPS disclosed in its 2022 filing a $2.3 billion pre‑tax estimate of additional coordinating benefits that may be owed to the Central States Pension Fund (part of a $10.1 billion pre‑tax actuarial loss), explaining that the figure reflects the change in discount rates, demographic assumptions and other actuarial inputs. In the 2023 filing the company refined its reporting by quantifying the exposure through sensitivity analysis—stating that the amount is calculated based on a ±25‑basis‑point increase or decrease in the expected (and actual) return on plan assets—and again directs readers to note 5 for the full potential liability, illustrating how the actuarial estimate and its sensitivity analysis evolved from 2022 to 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution from 2022 to 2023 in UPS's reporting approach regarding the Central States Pension Fund, and accurately captures the shift from specific obligation quantification to sensitivity analysis. However, there are significant quantitative accuracy issues: (1) The LLM introduces a $10.1 billion figure as part of a 'broader pension obligation' context that is not present in the ground truth answer. The ground truth only mentions the $2.3 billion pre-tax actuarial loss related to coordinating benefits—the $10.1 billion appears to be an unsupported addition that conflates or misrepresents the scope of the disclosure. (2) The LLM's explanation of the $2.3 billion as reflecting 'change in discount rates, demographic assumptions and other actuarial inputs' adds interpretive detail not explicitly confirmed in the ground truth, which simply states it was disclosed as part of 'broader pension obligation disclosures.' (3) The 25 basis point sensitivity analysis is correctly identified in both answers, though the LLM's phrasing of '±25-basis-point increase or decrease' is slightly more precise than the ground truth's 'a 25 basis point change.' On the positive side: The LLM correctly identifies both the 2022 and 2023 timeframes, correctly names the Central States Pension Fund, accurately captures the shift in reporting methodology, and correctly references Note 5. The multi-hop reasoning is sound in connecting the evolution of reporting approaches across years. The main weakness is the introduction of unsupported quantitative information ($10.1 billion) that creates factual inaccuracy despite otherwise sound qualitative reasoning about the reporting shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 468,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "\nMastercard has consistently marketed Cyber and Intelligence Solutions as a value‑added service that lets all participants “transact securely, easily and with confidence” and that draws on proprietary, responsibly‑used consumer and merchant data.  In the 2023 filing the company deepened this positioning by tying the solutions to new network investments—open‑banking and digital‑identity capabilities—and describing them as part of a multi‑layered, interdependent security architecture that “builds upon and strengthens” its core payments network, thereby framing the offering as a broader, ecosystem‑wide value proposition for stakeholders.  (MA → Offers → Cyber and Intelligence Solutions; Cyber and Intelligence Solutions → Provides → MA.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the core 2022 positioning emphasizing 'transact easily and with confidence' with responsible data use - semantically equivalent to ground truth's phrasing. (2) Accurately captures the 2023 evolution, specifically mentioning the expansion to include open banking and digital identity investments, which directly matches the ground truth. (3) Properly synthesizes the multi-hop reasoning by showing how the solutions evolved from value-added services to being positioned as central to ecosystem-wide security architecture. (4) The phrase 'multi-layered, interdependent security architecture' effectively conveys the deeper integration narrative mentioned in ground truth's 'broader integration of cyber solutions into the company's overall infrastructure narrative.' (5) No quantitative errors - no numbers, dates, or calculations to verify, and all temporal references (2022 vs 2023) are correct. (6) Entity accuracy is perfect - correctly identifies Mastercard and its Cyber and Intelligence Solutions. MINOR CONSIDERATIONS: (1) The LLM answer includes slightly more specific detail about the 'multi-layered, interdependent security architecture' framing than explicitly stated in ground truth, though this appears to be a reasonable elaboration consistent with the filing language rather than an error. (2) The notation at the end '(MA → Offers → Cyber and Intelligence Solutions; Cyber and Intelligence Solutions → Provides → MA.)' appears to be knowledge graph syntax that adds no material information but doesn't detract from accuracy. The answer fully addresses the question's requirement to explain the evolution between 2022 and 2023 and the value proposition communicated to stakeholders.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 494,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "\nIn the 2022 filing (PEP 2022 10‑K, p. 129) the 4.450 % Senior Note due 2046 is disclosed as being incorporated by reference to **Exhibit 4.12** of the **Form 8‑K filed on October 14 2015**.  \nBy the 2023 filing (PEP 2023 10‑K, p. 126) the same note is now presented under **Exhibit 4.13** and is referenced to a **Form 8‑K filed on February 24 2016**, showing that PepsiCo updated the exhibit numbering and shifted the source‑document date from the 2015 filing to the later 2016 filing when disclosing the 4.450 % Senior Note due 2046.  \n\nThus, between the 2022 and 2023 SEC filings the presentation evolved from citing Exhibit 4.12 (Oct 14 2015) to citing Exhibit 4.13 (Feb 24 2016), reflecting a revision in the documentation date and exhibit identifier for the same debt issuance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness in addressing the multi-hop question about PepsiCo's 4.450% Senior Note presentation evolution. STRENGTHS: (1) All numeric values are correct - the note percentage (4.450%), maturity year (2046), and both exhibit numbers (4.12 in 2022, 4.13 in 2023) match the ground truth exactly. (2) All dates are accurate - October 14, 2015 for the 2022 filing reference and February 24, 2016 for the 2023 filing reference are both correct. (3) The multi-hop synthesis is sound - the answer correctly identifies the shift across two filing years and connects the exhibit number change with the source document date change. (4) Entity identification is precise - PepsiCo is correctly identified, the specific debt instrument is properly characterized, and the filing years (2022 vs 2023) are accurate. (5) The reasoning is logical and well-structured, explaining both what changed (exhibit number and source date) and the implication (administrative reclassification/documentation update). (6) Page references (p. 129 for 2022, p. 126 for 2023) add credibility though these weren't in the ground truth to verify. MINOR CONSIDERATIONS: The answer uses slightly different phrasing than the ground truth (e.g., 'incorporated by reference to' vs 'incorporated by reference from') but this is semantically equivalent and actually more precise. The explanation of the shift as reflecting 'revised documentation or administrative reclassification' is well-articulated and matches the ground truth's interpretation. No calculation errors, no missing information, and no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 450,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "\nIntel’s interaction with Positive Technologies stayed confined to security‑research coordination that was originally re‑established after the firm’s 2021 designation and has continued unchanged through 2023‑2024 under OFAC’s General License 1B; both the 2023 and 2024 10‑K filings note that, following the April 15 2021 OFAC license, Intel resumed communications with Positive Technologies, that no gross revenues or net profits arise from these dealings, and that it plans to keep conducting them in full compliance with the license.  Consequently, the relationship has not expanded financially but has persisted as a licensed, sanction‑compliant channel for vulnerability‑disclosure coordination between the two entities.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility: (1) CRITICAL DATE ERROR: The LLM states 'April 15 2021 OFAC license' but the ground truth indicates the sanctions and OFAC licensing occurred in 2023, not 2021. This is a fundamental chronological error that misrepresents the timeline of events. (2) LICENSE DESIGNATION ERROR: The LLM specifies 'General License 1B' but the ground truth does not mention this specific license designation. This appears to be an unsupported detail. (3) INCOMPLETE EVOLUTION ANALYSIS: While the ground truth emphasizes the evolution from 'disclosure of past communication' in 2023 to 'explicit statement of intent to continue' in 2024, the LLM states the relationship 'stayed confined' and 'has continued unchanged,' which contradicts the ground truth's characterization of an evolution toward a 'more forward-looking and sustained partnership posture.' (4) CORRECT ELEMENTS: The LLM correctly identifies that no gross revenues or net profits were associated with these activities, and that communications involved IT security research and vulnerability disclosure coordination. (5) REASONING QUALITY: The LLM's reasoning about compliance and the licensed nature of the relationship is sound, but it fails to capture the key distinction between 2023 and 2024 filings regarding the shift from retrospective disclosure to prospective intent. The answer demonstrates partial understanding but misses the core evolution that the question specifically asks about.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Partners_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 419,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "\nThe 4.78 % Senior Notes due March 2038 are listed in both the 2023 and 2024 tables with an identical outstanding balance of **$5,000 million**, showing that the amount has remained unchanged between the two years. This continuity indicates that CVS is maintaining a large, long‑dated fixed‑rate tranche as a stable component of its capital structure, relying on a sizable, recurring issuance rather than frequent refinancing to fund its long‑term obligations. (Both the 2023 10‑K and the 2024 10‑K disclose the same $5 bn balance for this note, underscoring a consistent long‑term debt profile.)",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the key quantitative fact: the 4.78% Senior Notes due March 2038 remained at $5,000 million in both 2023 and 2024. (2) All numeric values are accurate and properly formatted. (3) The LLM correctly cites both the 2023 and 2024 10-K filings as sources. (4) The interpretation that this represents stability in the capital structure is reasonable. WEAKNESSES: (1) The LLM answer is INCOMPLETE - it fails to address the comparative context provided in the ground truth. The original answer specifically mentions the 2.7% senior notes due August 2040 as a contrasting example (decreased from $1,250M to $367M), which demonstrates selective debt management and refinancing activity. This comparative analysis is crucial to fully answering 'what does this indicate about the company's long-term debt structure?' (2) The LLM's characterization of the notes as 'a sizable, recurring issuance rather than frequent refinancing' is somewhat vague and less precise than the ground truth's explanation of 'selective debt management and refinancing activity in other long-term obligations.' (3) The LLM does not synthesize the multi-hop aspect of the question as thoroughly - it focuses only on the 4.78% notes without comparing to other debt instruments to show the broader debt management strategy. QUANTITATIVE VERIFICATION: All numbers are correct ($5,000M for both years, 4.78%, March 2038). MULTI-HOP REASONING: Partially addressed - the LLM identifies the stability of one debt instrument but misses the comparative analysis across multiple debt instruments that would better illustrate CVS's long-term debt structure strategy. The answer would score higher (8-9) if it included the comparative context about other senior notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 480,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "\nThe 0.835 % Notes due 2032 remained continuously listed on the New York Stock Exchange (ticker XOM32) in both the 2022 filing (Chunk 1) and the 2024 Form 10‑K (Chunk 2), confirming that the security was still outstanding and disclosed at each filing.  This consistency is reflected in the knowledge‑graph link XOM → 0.835 % Notes due 2032 → XOM, showing that Exxon Mobil continues to have a stake in, and disclose, the same FIN_INST across the two periods.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that the 0.835% Notes due 2032 remained listed with ticker XOM32 in both 2022 and 2024 filings, which matches the ground truth. The numeric values (0.835%, 2032, XOM32) are accurate. However, the LLM answer has significant gaps in completeness and reasoning quality. The ground truth provides crucial context about the evolution of Exxon Mobil's debt structure by noting that the 0.142% Notes due 2024 (XOM24B) appeared in 2022 but disappeared by 2024, suggesting redemption or delisting. This comparative analysis is the key insight demonstrating how the debt portfolio evolved. The LLM answer completely omits this critical comparison and the insight about the removal of the 2024 notes, which is essential to answering 'how has the status evolved.' The LLM's statement about 'Exxon Mobil continues to have a stake in' the notes is also somewhat awkwardly phrased and potentially confusing—Exxon Mobil is the issuer, not a stakeholder in its own debt. The reference to 'knowledge-graph link XOM → 0.835% Notes due 2032 → XOM' is unclear and doesn't add meaningful analysis. While the LLM correctly identifies the persistence of the 0.835% Notes, it fails to provide the comparative analysis that demonstrates the actual evolution of the debt structure between the two periods. The answer is partially correct but incomplete in addressing the multi-hop nature of the question, which requires synthesizing information about multiple debt instruments across two filing periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 417,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "\nAmerican Express held $477 million of U.S. Government treasury obligations in 2021 (with only a $1 million gross unrealized loss), but by 2024 that exposure had fallen to $287 million, which is now laddered across maturities—$189 million maturing within one year, $98 million maturing in 1‑5 years and none beyond five years—showing a clear shift toward shorter‑term holdings and a lower overall fair‑value allocation; this evolution is reflected in the persistent ORG → FIN_INST ↔ ORG relationship linking AXP to U.S. Government treasury obligations in both the 2021 and 2024 filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) WRONG YEAR REFERENCE: LLM states '$477 million in 2021' but ground truth clearly indicates this was 2022 data. The question asks about 2022-2024 evolution, and the LLM incorrectly shifted the baseline year backward to 2021. (2) INCORRECT TOTAL CALCULATION: LLM claims 2024 total is $287 million, but the ground truth shows $189M + $98M = $287M, which is arithmetically correct. However, the LLM's framing of this as a 'fall' from $477M is misleading because it's comparing 2021 (wrong year) to 2024, not 2022 to 2024 as requested. (3) DIRECTIONAL ERROR IN CHARACTERIZATION: Ground truth describes a shift toward DIVERSIFICATION (adding intermediate-term holdings), while LLM characterizes it as a shift toward 'shorter-term holdings' - this is contradictory since adding 1-5 year instruments represents lengthening, not shortening. The LLM states 'shift toward shorter-term holdings' which contradicts the actual data showing addition of intermediate-term instruments. (4) INCOMPLETE ANSWER TO QUESTION: The question specifically asks about 'fair value allocation and maturity distribution' evolution. While LLM provides maturity distribution for 2024, it fails to properly establish the 2022 baseline (using 2021 instead) and doesn't clearly articulate the strategic shift from exclusively short-term to diversified maturity profile. (5) POSITIVE ELEMENTS: The LLM correctly identifies the 2024 maturity breakdown ($189M short-term, $98M intermediate-term, $0 long-term) and correctly notes the relationship to U.S. Government treasury obligations. The graph notation is extraneous but not incorrect. CORE ISSUE: The fundamental error of using 2021 as the baseline instead of 2022 undermines the entire answer's validity for a question specifically about 2022-2024 evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 490,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "\nAmazon first created the 2.500 % Note due 2050 in the June 3 , 2020 Officers’ Certificate (Chunk 1 §4.5), and the identical instrument was re‑filed unchanged in the 2024 annual report (Chunk 2 §4.6), showing that no new issuance or modification of that tranche occurred between 2022 and 2024.  The note remained on Amazon’s long‑term‑debt schedule through the 2022 certificate (Chunk 2 §4.8) and was still listed in the 2024 “Description of Securities” (Chunk 2 §4.9), indicating that Amazon’s treatment was simply to continue carrying the 2050 tranche without amendment or repayment during that period.  This evolution is captured by the KG relationship ORG‑[Issues]->FIN_INST←[Introduces]-ORG, which links Amazon both to the issuance and the ongoing obligation of the 2.5 % Note due 2050.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and correctly synthesizes multi-hop information across the 2022-2024 period. STRENGTHS: (1) All numeric values are correct - 2.500% rate, June 3, 2020 date, 2050 maturity year all match ground truth. (2) Multi-hop reasoning is sound: correctly traces the note from its 2020 introduction through 2022 and 2024 filings, establishing continuity without modification. (3) Entity identification is accurate - Amazon, the specific note instrument, and exhibit references (4.5, 4.6, 4.8, 4.9) are all correct. (4) The answer properly conveys that the note was introduced in 2020, maintained through 2022, and reintroduced unchanged in 2024. (5) Semantic equivalence is strong - 'reintroduction in 2024 reaffirmed the note's role' matches 'identical instrument was re-filed unchanged in the 2024 annual report.' MINOR WEAKNESSES: (1) The LLM answer includes additional technical detail about KG relationships and chunk references that, while not incorrect, goes slightly beyond what was in the ground truth answer and could be seen as over-specification. (2) The phrasing 'no new issuance or modification of that tranche occurred' is slightly more technical than the ground truth's simpler 'continued to maintain this long-term debt instrument without modification,' though both convey the same meaning. (3) The answer references exhibit 4.8 and 4.9 which are not mentioned in the ground truth, though these appear to be accurate supporting details. Overall, the answer correctly answers the question about how the note evolved (or didn't evolve) between 2022 and 2024, with accurate dates, percentages, and logical synthesis across the time period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 462,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "\nThe 2022 filing (Chunk 1) lists the Co‑Branded Credit Card Agreement with Citibank, N.A. as having been amended eight times, the latest being the Eighth Amendment filed on 3/10/2022. The 2023 filing (Chunk 2) shows that four additional amendments— the Ninth, Tenth, Eleventh and Twelfth—were adopted, with the Eleventh and Twelfth amendments filed in 2023 (3/9/2023 and 10/11/2023, respectively). Consequently, the total number of amendments grew from eight in 2022 to twelve by the end of 2023, reflecting four new amendments during that period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) 2022 status: Correctly identifies the Eighth Amendment filed on 3/10/2022 as the most recent in 2022 - matches ground truth exactly. (2) 2023 amendments: Correctly identifies four additional amendments (Ninth, Tenth, Eleventh, Twelfth) with the Twelfth Amendment filed on 10/11/2023 - matches ground truth. (3) Dates: The LLM provides additional detail showing the Eleventh Amendment was filed on 3/9/2023 and Twelfth on 10/11/2023, which is consistent with ground truth's mention of 10/11/2023 for the Twelfth Amendment. (4) Calculation: Correctly calculates the growth from 8 amendments in 2022 to 12 by end of 2023, representing 4 new amendments - this arithmetic is accurate. (5) Multi-hop synthesis: The answer effectively synthesizes information across two different filing periods (2022 and 2023) to show the evolution of amendments. The reasoning is sound and logically presented. Minor note: The LLM provides slightly more detail than the ground truth (specific dates for Ninth, Tenth, Eleventh amendments) but this is supplementary information that enhances rather than contradicts the answer. The semantic meaning and all core facts align perfectly with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amends]-> FIN_INST <-[Amends_Agreement]- ORG",
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 355,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "\nNVIDIA has transformed CUDA from a pure GPU‑centric programming model into a full‑stack, cross‑architecture engine that now spans accelerated CPUs, DPUs and the newly introduced Blackwell data‑center architecture (launched in FY 2025 but designed through 2024), embedding it in every vertical—from the DRIVE Hyperion/Orin automotive stack and Omniverse‑powered simulation to gaming RTX 50 “neural‑graphics” and professional‑visualization workflows.  By coupling CUDA‑X libraries, the AI‑Enterprise software suite, vGPU and DGX Cloud services with these hardware advances, NVIDIA delivers a unified software ecosystem that enables continuous over‑the‑air updates, AI‑driven features and order‑of‑magnitude performance gains across gaming, data‑center, automotive and professional‑visualization markets.  This evolution reflects a deliberate shift from “CUDA = GPU” to “CUDA = the core of NVIDIA’s end‑to‑end computing platform,” tightly coupled with new silicon (Orin, Blackwell, DPUs/CPUs) and software pillars such as Omniverse, DRIVE Software and AI‑Enterprise.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES WITH TEMPORAL ACCURACY AND SPECIFICITY: The LLM answer contains significant factual errors regarding timing and product launches that undermine its credibility. (1) TEMPORAL ERRORS: The answer references 'Blackwell data-center architecture (launched in FY 2025 but designed through 2024)' - this is problematic because the question specifically asks about evolution between 2022 and 2024, yet the answer introduces FY 2025 products as if they're part of the 2024 narrative. The ground truth correctly limits discussion to fiscal 2024 developments. (2) UNVERIFIED CLAIMS: The LLM introduces specific product names and features (RTX 50 'neural-graphics', DRIVE Hyperion/Orin automotive stack, Omniverse-powered simulation, continuous over-the-air updates, DGX Cloud services) that are not mentioned in the ground truth and cannot be verified against the SEC filing data. While some may be accurate, they represent speculation beyond what the knowledge graph confirms. (3) CORRECT ELEMENTS: The LLM does correctly identify several key points from the ground truth: (a) CUDA's evolution from GPU-centric to cross-architecture (CPUs, DPUs), (b) the full-stack platform concept with CUDA-X libraries, (c) integration across multiple markets (gaming, data center, automotive, professional visualization), (d) the shift from 'CUDA = GPU' to 'CUDA = core platform'. (4) MISSING GROUND TRUTH ELEMENTS: The answer fails to explicitly mention that CPUs were 'introduced in fiscal 2024' as a specific milestone, instead conflating this with later Blackwell developments. (5) SYNTHESIS QUALITY: While the LLM demonstrates good understanding of CUDA's strategic evolution, it overextends beyond the 2022-2024 timeframe specified in the question and introduces unverified product details that dilute the answer's reliability. The reasoning about full-stack integration is sound but contaminated by temporal inaccuracies. The answer reads more like marketing material than a factual synthesis of SEC filing data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Develops]- ORG",
      "token_usage": {
        "prompt_tokens": 1512,
        "completion_tokens": 541,
        "total_tokens": 2053
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "\nPfizer recorded only $1.279 billion of Paxlovid revenue in 2023—a 92 % decline caused by the anticipated return of roughly 6.5 million EUA‑labeled U.S. government courses, lower international contractual deliveries and the end of strong Chinese demand after the April 2023 NRDL expiration—while the 2024 filing shows a $771 million favorable reversal of the prior $3.5 billion non‑cash revenue adjustment, an additional $442 million from the U.S. Strategic National Stockpile, a $129 million true‑up settlement, and roughly $1 billion of remaining performance‑obligation revenue for future Paxlovid deliveries expected through 2028. This evolution reflects the KG‑modeled positive impact of Pfizer (ORG) on Paxlovid (PRODUCT) and the reciprocal contractual obligations that now underpin a modest, forward‑looking revenue stream for the product.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several correct core facts but introduces significant errors and unsupported claims that reduce overall accuracy. CORRECT ELEMENTS: (1) 2023 revenue of $1.279 billion is accurate; (2) $3.5 billion non-cash revenue reversal is correct; (3) 6.5 million treatment courses return estimate is accurate; (4) $771 million favorable reversal in 2024 is correct; (5) $442 million SNS revenue is accurate; (6) ~$1 billion remaining performance obligations is correct; (7) The characterization of the shift from government-driven to contracted model is appropriate. SIGNIFICANT ERRORS: (1) The '92% decline' claim is unsupported and misleading—the ground truth does not provide a prior-year comparison to calculate this percentage, making this a fabricated statistic; (2) The '$129 million true-up settlement' is introduced without any mention in the ground truth, representing an unsupported addition; (3) The claim about 'lower international contractual deliveries and end of strong Chinese demand after April 2023 NRDL expiration' goes beyond the ground truth, which only mentions the $3.5 billion reversal due to expected U.S. government returns; (4) The phrase 'expected through 2028' adds a specific timeline not present in the ground truth; (5) The final sentence about 'KG-modeled positive impact' and 'reciprocal contractual obligations' uses awkward phrasing and appears to mischaracterize the relationship. MULTI-HOP REASONING: The answer correctly synthesizes the 2023-2024 evolution and connects revenue reversals to actual returns, demonstrating sound multi-hop reasoning on the core narrative. However, the introduction of unsupported details undermines the synthesis quality. QUANTITATIVE ACCURACY: While the main figures are correct, the fabricated 92% decline statistic and unexplained $129 million settlement significantly damage quantitative credibility. The answer demonstrates partial understanding but fails the strict standard required for financial data accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 539,
        "total_tokens": 1975
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 the share reserve under the 2003 Incentive Program fell sharply—from ≈ 65.8 million unallocated shares disclosed in the 2022 10‑K to only ≈ 47 million shares remaining at the end of 2024, meaning roughly 19 million shares were granted, forfeited or otherwise consumed during the period.  The program’s structure has broadened: awards now include larger numbers of restricted‑stock units (10.4 million granted in 2024 versus 9.4 million in 2022), may be settled in cash (recorded as liabilities) and, following the Pioneer acquisition, converted Pioneer RSUs that vest in three annual installments, while the underlying vesting schedule still follows the standard 50 % after three years and 50 % after seven years (with accelerated schedules for certain executives).  The 2003 Incentive Program, which ExxonMobil discloses as its accounting policy, has no fixed termination date and can be ended by the Board, and shares that are forfeited, expired or settled in cash do not count against the 220‑million maximum issuance limit.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the core quantitative evolution and provides valuable additional context about program structure. STRENGTHS: (1) Correctly identifies the 2022 baseline of ~65.8 million shares available (ground truth: 65,754,069); (2) Accurately states 47 million remaining at end of 2024; (3) Correctly calculates the ~19 million share consumption during the period (65.8M - 47M ≈ 18.8M); (4) Accurately reports RSU grants increasing from 9.4M (2022) to 10.4M (2024), matching ground truth of 9,392 thousand to 10,393 thousand; (5) Mentions the 220 million maximum issuance limit, which is correct per ground truth; (6) Provides valuable additional structural details about cash settlement, Pioneer acquisition RSU conversions, vesting schedules, and Board termination provisions that enhance understanding. WEAKNESSES: (1) The LLM answer introduces substantial detail about Pioneer acquisition RSU conversions, three-year vesting installments, and specific vesting schedules (50% after 3 years, 50% after 7 years) that are NOT present in the ground truth answer. While these details may be factually accurate from the filings, they represent information synthesis beyond what the ground truth explicitly confirms, creating potential verification concerns; (2) The statement about shares forfeited/expired/settled in cash not counting against the 220-million limit is a structural detail not mentioned in ground truth; (3) The answer is notably longer and more detailed than ground truth, which could indicate either superior research or potential over-interpretation. QUANTITATIVE VERIFICATION: All core numbers check out correctly (65.8M → 47M, 9.4M → 10.4M RSUs, 220M maximum). The calculation of ~19M shares consumed is mathematically sound. MULTI-HOP REASONING: The answer successfully synthesizes information about program capacity changes, share availability evolution, and usage patterns across the 2022-2024 period. The connection between declining available shares and increased RSU grants is logically sound. SEMANTIC EQUIVALENCE: The core message matches ground truth—significant expansion in program capacity (65.8M to 220M maximum) with moderate actual usage growth. The additional structural details, while potentially accurate, exceed the scope of ground truth confirmation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 620,
        "total_tokens": 1994
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "\nBetween 2022 and 2024 AdSense evolved from being highlighted as a key driver of Google Network revenue growth—alongside AdMob and Google Ad Manager (which together lifted network revenues by $8.6 billion in 2021) —to becoming part of a broader, AI‑powered advertising technology suite that also includes Performance Max, Demand Gen and Product Studio, with its earnings now flowing within Google’s overall performance‑and‑brand‑advertising engine across Search, YouTube and partner properties.  This shift reflects Google’s move toward an integrated, AI‑driven portfolio where AdSense continues to monetize its publisher network and generate positive impact for Alphabet, while being embedded in a larger ecosystem of advertising products and services.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERROR IN QUANTITATIVE DATA: The LLM states the $8.6 billion revenue increase occurred in 2021, but the ground truth explicitly states this was a 2022 figure (year-over-year increase in 2022). This is a significant factual error that undermines the temporal analysis central to the question. CORRECT ELEMENTS: The LLM accurately captures the core strategic shift - AdSense moving from being explicitly highlighted as a growth driver to becoming a more foundational offering within a broader AI-powered portfolio. The mention of newer products like Demand Gen and Performance Max aligns with ground truth. The characterization of AdSense as 'no longer specifically quantified as a growth lever' matches the ground truth's observation. INCOMPLETE/PROBLEMATIC ELEMENTS: (1) The LLM introduces 'Product Studio' which is not mentioned in the ground truth answer, potentially adding unsupported information. (2) The phrase 'earnings now flowing within Google's overall performance-and-brand-advertising engine' is vague and not directly supported by the ground truth, which focuses on product positioning rather than earnings flows. (3) The LLM's framing of the evolution is somewhat muddled - it conflates the 2021 data point with the 2022-2024 evolution being discussed. MULTI-HOP REASONING: The LLM does attempt to synthesize the evolution across the time period and connect AdSense's role to the broader portfolio, but the temporal error and introduction of unsupported details weaken the synthesis. The core insight about the strategic shift is present but compromised by factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Generates_Revenue_From]- ORG",
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 439,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "\nBetween 2022 and 2023 the UPS Retirement Plan’s accrual mechanism was unchanged in form — it remained a non‑contributory, average‑compensation‑based defined‑benefit plan subject to IRS limits (as described in the 2022 filing) — but in early 2023 the company amended the plan so that **no additional benefits will accrue for future service or compensation for non‑union participants**. Both the 2022 note (which notes the plan’s existing structure) and the 2023 note (which states that the UPS Retirement Plan and the UPS Excess Coordinating Benefit Plan “will cease accruals of additional benefits for future service and compensation for non‑union participants effective January 1, 2023”) confirm that the evolution culminated in a freeze of benefit growth for that participant group.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and directly addresses the question about the UPS Retirement Plan's benefit accrual structure evolution between 2022 and 2023. STRENGTHS: (1) All dates are correct - specifically identifies January 1, 2023 as the effective date of the accrual freeze, matching the ground truth exactly. (2) Accurately describes the plan structure in both years - noncontributory, average-compensation-based defined benefit plan subject to IRS limits. (3) Correctly identifies the key change: cessation of benefit accruals for non-union participants effective January 1, 2023. (4) Properly synthesizes multi-hop information by comparing 2022 and 2023 filings and identifying the evolution. (5) Uses appropriate terminology ('freeze of benefit growth') that captures the transformational nature of the change. (6) Correctly distinguishes that the plan structure itself remained unchanged while the accrual mechanism was frozen. MINOR CONSIDERATIONS: The LLM answer could have been slightly more explicit about the characterization of this as a 'transformational change' or 'strategic shift' as mentioned in the ground truth, though the phrase 'freeze of benefit growth' conveys similar meaning. The answer focuses on the specific change (accrual freeze) rather than elaborating on the broader strategic implications, but this is not a deficiency since the question asks specifically about 'how the structure evolved' and 'what specific changes were made.' The answer demonstrates sound multi-hop reasoning by correctly synthesizing information from both 2022 and 2023 filings to show the before-and-after state. No numerical errors, date errors, or entity misidentifications present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 464,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "\nAmazon’s short‑term credit structure expanded and refined between 2022 and 2024: the 2022 filing disclosed a $7 bn unsecured revolving facility (maturing June 2023, LIBOR‑based + 0.50% spread, 0.04% commitment fee) with no borrowings outstanding, while the 2024 filing replaced it with a larger $15 bn revolving line (maturing Nov 2028, benchmark + 0.45% spread, 0.03% fee) and added a new $5 bn 364‑day revolving facility (SOFR + 0.45% spread, 0.03% fee), both of which also had zero outstanding borrowings as of Dec 31 2023/2024; only modest borrowings of $147‑151 m under other short‑term facilities appeared on the balance sheet, and unused letters of credit grew from $7.2 bn (2021) to $8.3 bn (2024). This evolution reflects a higher credit capacity, slightly lower interest‑rate spreads and commitment fees, and continued reliance on undrawn commitments rather than active borrowing.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Amazon's credit facility evolution and addresses the multi-hop question comprehensively. STRENGTHS: (1) Correctly identifies the main credit facility expansion from $7.0B (2022) to $15.0B (2024); (2) Accurately captures interest rate improvements (0.50% to 0.45% spread) and commitment fee reductions (0.04% to 0.03%); (3) Properly notes the new $5.0B 364-day facility added in October 2024; (4) Correctly states zero borrowings under main facilities; (5) Accurately reports $147-151M in other short-term borrowings; (6) Correctly tracks unused letters of credit growth from $7.2B to $8.3B; (7) Provides sound multi-hop synthesis across 2022-2024 period; (8) Reasoning about lower spreads and continued reliance on undrawn commitments is logical and well-supported. MINOR ISSUES: (1) The LLM states the 2022 facility matured in June 2023 and was LIBOR-based, while the ground truth simply states it existed in 2022 without specifying maturity date or LIBOR vs. benchmark terminology - this additional detail appears reasonable but goes slightly beyond ground truth specificity; (2) The phrasing 'Dec 31 2023/2024' for zero borrowings is slightly ambiguous (ground truth specifies Dec 31, 2024 for the main facilities); (3) Minor formatting inconsistency in how dates are presented. QUANTITATIVE VERIFICATION: All key numbers are accurate ($7B→$15B, $5B new facility, 0.50%→0.45%, 0.04%→0.03%, $147-151M, $7.2B→$8.3B). The answer successfully synthesizes information across multiple years and credit instruments, demonstrating solid multi-hop reasoning. The semantic meaning aligns well with ground truth despite some minor wording variations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Borrows]- ORG",
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 462,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "\nCostco continued to rely on index‑based variable‑priced contracts for electricity, natural‑gas and fuel‑station purchases in both years, and in the 2023 filing it explicitly highlighted the use of such contracts for “some purchases of natural gas, in addition to fuel for its gas stations” while still noting that they qualify for the “normal purchases and normal sales” exception and require no mark‑to‑market adjustment.  This consistency—coupled with the parallel description of fixed‑price contracts that mitigate exposure in its warehouses—shows that Costco’s commodity‑price risk management strategy has not changed materially: it manages energy‑price volatility by entering into variable‑priced contracts that are treated as ordinary purchases (thus avoiding earnings volatility) while supplementing that approach with fixed‑price hedges for its facilities.  The evolution is therefore one of expanded reference to variable contracts (e.g., adding natural‑gas and fuel‑station fuel) rather than a shift in strategy, underscoring a risk‑management stance that limits balance‑sheet impact and depends on operational hedging through index‑based pricing.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Costco's commodity price risk management strategy and correctly identifies the key elements from the ground truth. Strengths: (1) Accurately captures the use of index-based variable-priced contracts for electricity, natural gas, and fuel for gas stations in both years; (2) Correctly notes the 'normal purchases and normal sales' exception and lack of mark-to-market adjustment; (3) Properly synthesizes the multi-hop information showing consistency between 2022 and 2023; (4) Adds valuable context about fixed-price contracts and operational hedging that aligns with the ground truth's characterization of strategy stability. Quantitative accuracy is high—no numbers or dates are incorrect. The reasoning about 'expanded reference' to variable contracts rather than a fundamental strategy shift matches the ground truth's conclusion about consistency. Minor areas for improvement: (1) The LLM introduces the concept of 'fixed-price hedges for its facilities' which, while reasonable and consistent with typical risk management, is not explicitly mentioned in the ground truth answer provided; (2) The phrase 'expanded reference to variable contracts (e.g., adding natural-gas and fuel-station fuel)' could be slightly misleading—the ground truth indicates these were already present in 2022, just more explicitly called out in 2023, rather than newly added. The LLM's interpretation of 'expanded reference' rather than 'expanded usage' is semantically appropriate and shows good analytical judgment. Overall, the answer correctly addresses both parts of the question (how usage evolved and what it indicates about strategy) with sound multi-hop reasoning across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Into]-> FIN_INST <-[Uses]- ORG",
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 471,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "\nBetween 2022 and 2024, NVIDIA AI Enterprise moved from being listed merely as part of the Compute & Networking segment’s data‑center software portfolio (Chunk 1) to a flagship, revenue‑generating offering that is sold as a paid enterprise‑grade license and delivered through NVIDIA’s full‑stack data‑center platform (Chunk 2).  This shift reflects a more strategic commercial role: the 2022 addition of DPUs and the 2024 launch of CPUs expanded the underlying hardware stack, allowing AI Enterprise to be positioned as the software layer that ties together GPUs, DPUs and CPUs, and by 2024 the suite was being bundled with services such as DGX Cloud and the Blackwell architecture, cementing its status as the primary vehicle for monetising NVIDIA’s AI‑accelerated infrastructure across cloud, OEM and enterprise customers.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of NVIDIA AI Enterprise's evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning within Compute & Networking segment; (2) Accurately describes the 2024 evolution to a revenue-generating, enterprise-grade licensed offering; (3) Properly synthesizes the multi-hop connection between hardware expansion (DPUs in 2022, CPUs in 2024) and software positioning; (4) Correctly identifies the full-stack platform strategy and bundling with DGX Cloud; (5) Accurately characterizes the shift from strategic initiative to monetization vehicle. MINOR ISSUES: (1) The LLM introduces 'Blackwell architecture' as a 2024 bundling element, which is not explicitly mentioned in the ground truth answer - while this may be factually accurate from the filings, it represents a slight expansion beyond what the ground truth explicitly states; (2) The answer is more detailed and specific than the ground truth (mentioning cloud, OEM, and enterprise customers explicitly), which adds value but goes slightly beyond the provided ground truth scope. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The dates (2022, 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple dimensions - temporal evolution, product positioning, hardware/software integration, and commercial strategy - demonstrating sound multi-hop reasoning. The logical flow from foundational role to monetization vehicle is clear and well-supported. SEMANTIC EQUIVALENCE: The core message matches the ground truth: evolution from strategic initiative to key commercial offering within a full-stack platform. The wording differs but conveys equivalent meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 506,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "\nPfizer’s contractual duties for Paxlovid changed markedly from 2023 to 2024: in 2023 the company recorded a $3.5 bn non‑cash revenue reversal because it expected the return of roughly 6.5 million EUA‑labeled government courses, but in 2024 it revised that estimate after only 5.1 million courses were actually returned, yielding a $771 m favorable adjustment and leaving about $1 bn of remaining performance‑obligation revenue for future Paxlovid deliveries (scheduled for 2025‑2028). This evolution—reflected in the KG link PFE → Paxlovid and the updated remaining‑obligation figures—shows that the bulk of the supply contracts have been satisfied and that Pfizer now expects only modest, contract‑bound revenue from Paxlovid going forward.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core narrative about Pfizer's Paxlovid contractual obligations evolving between 2023 and 2024, and accurately captures the $3.5 billion revenue reversal in 2023 and the ~$1 billion remaining performance obligations in 2024. However, there are significant quantitative accuracy issues: (1) The LLM introduces a claim about 5.1 million courses actually being returned and a $771 million favorable adjustment in 2024 that are NOT present in the ground truth answer. These appear to be fabricated details not supported by the original knowledge graph data. (2) The LLM correctly states the $3.5 billion reversal and 6.5 million expected returns from 2023, and correctly identifies the ~$1 billion remaining obligations for 2024. (3) The LLM adds specific future delivery dates (2025-2028) that are not mentioned in the ground truth, suggesting potential hallucination or unsupported inference. The qualitative reasoning is sound—the LLM correctly interprets the shift from uncertainty (2023 reversal) to stabilization (2024 obligations) and understands the multi-hop synthesis across years. However, the introduction of unverified numbers (5.1 million, $771 million adjustment) significantly undermines credibility. The answer demonstrates good understanding of the overall narrative but fails on strict quantitative accuracy by adding details not in the ground truth. The semantic interpretation of what the data indicates about future revenue expectations is reasonable and aligns with the ground truth conclusion about improved demand forecasting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 435,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "\nGoogle’s exposure to new regulatory costs in international markets broadened markedly from 2022 to 2024: in 2022 the primary regulatory risk was tied to evolving foreign‑policy and data‑privacy issues (e.g., cross‑border data transfers between the EU and the U.K. and supplier‑compliance obligations), whereas by 2024 the risk landscape had expanded to include sanctions, export‑control restrictions, geopolitical conflict, anti‑corruption enforcement, divergent labor laws and uncertain local‑law liabilities, reflecting a far wider scope of potential costs. Both years treat “New Regulatory Costs” as a risk factor that directly impacts GOOGL, but the 2024 disclosures enumerate many more regulatory vectors—sanctions, trade barriers, and foreign‑policy‑driven liabilities—than the 2022 filing, even as international revenues remain a substantial share of total sales (≈54 % in 2021, ≈51 % in 2024).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of Google's regulatory exposure from 2022 to 2024, capturing the shift from primarily data-transfer and privacy concerns to a broader spectrum of risks including sanctions, export controls, geopolitical conflicts, and uncertain local-law liabilities. The qualitative characterization of the expansion in scope is accurate and well-articulated. The answer appropriately synthesizes multi-hop information across years and identifies the key regulatory vectors mentioned in 2024 filings.\n\nWEAKNESSES - QUANTITATIVE ERRORS: The LLM introduces specific revenue percentages (≈54% in 2021, ≈51% in 2024) that are NOT present in the original answer and appear to be unsupported by the ground truth. These numbers are presented as factual data points but cannot be verified against the provided knowledge graph answer. This is a significant quantitative accuracy issue as it adds unverified numerical claims.\n\nWEAKNESSES - COMPLETENESS: While the LLM answer goes beyond the original answer by adding specific regulatory vectors (sanctions, export controls, anti-corruption enforcement, divergent labor laws), the original answer emphasizes 'uncertainty regarding regulatory outcomes' and 'other liabilities under local laws that may not offer due process or clear legal precedent' as key distinguishing features of 2024. The LLM mentions these concepts but doesn't emphasize the uncertainty and due-process elements as prominently as the ground truth does.\n\nWEAKNESSES - ENTITY/CONTEXT: The LLM uses 'GOOGL' ticker notation and references 'supplier-compliance obligations' in 2022 that aren't explicitly mentioned in the original answer. While not necessarily incorrect, these additions go beyond what can be verified from the ground truth.\n\nMULTI-HOP REASONING: The multi-hop synthesis is sound—the LLM correctly compares 2022 vs 2024 regulatory landscapes and identifies the evolution. However, the introduction of unverified revenue percentages undermines confidence in the factual foundation.\n\nOVERALL ASSESSMENT: The answer demonstrates good qualitative understanding of the regulatory evolution but introduces quantitative claims that cannot be verified against the ground truth, which is a critical flaw in financial analysis contexts where precision is essential.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Faces]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 623,
        "total_tokens": 2065
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "\nUPS’s funding approach for post‑retirement medical benefits has remained unchanged between 2022 and 2023: both the 2022 and 2023 disclosures state that expected benefit payments for these benefits will be paid **from plan trusts and corporate assets**, consistent with the company’s policy of meeting legal and regulatory requirements while making discretionary contributions when appropriate. Consequently, the source of funding for post‑retirement medical liabilities has not evolved—it continues to rely on the same combination of plan‑trust resources and corporate assets in both years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. Both answers correctly identify that UPS's funding approach for postretirement medical benefits remained unchanged between 2022 and 2023, with expected benefit payments coming from both plan trusts and corporate assets. The LLM answer provides the same core conclusion as the ground truth while adding appropriate context about the company's policy regarding legal/regulatory requirements and discretionary contributions. No quantitative errors are present (no numbers, dates, or calculations to verify). The multi-hop reasoning is sound—the model correctly synthesized information across both years and identified the continuity in funding sources. The entity identification is correct (UPS, postretirement medical benefits, 2022-2023 comparison). The only minor distinction is that the LLM answer includes additional contextual language about 'legal and regulatory requirements' and 'discretionary contributions,' which, while not explicitly stated in the ground truth, represents reasonable elaboration that doesn't contradict the core finding. The answer directly addresses the question about evolution (or lack thereof) in funding approach and sources. The semantic equivalence is excellent—both answers convey that there was no change in the funding sources between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 379,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "\nSince its debut in 2022, NVIDIA AI Enterprise was positioned as a software offering within the Compute & Networking segment of NVIDIA’s portfolio (Chunk 1), but by 2024 it had expanded into a full‑stack, enterprise‑wide platform that is now embedded in automotive solutions (DRIVE Hyperion), simulation via Omniverse, and delivered as a managed service (DGX Cloud) with tools such as NIM, NeMo and AI Blueprints (Chunk 2). This evolution reflects a shift from a standalone AI‑software product to a broadly supplied, integrated stack that spans data‑center, automotive and cloud ecosystems, enabling end‑to‑end generative‑AI development and deployment across multiple industries.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2022 introduction and 2024 evolution timeline. (2) Accurately mentions key components (NIM, NeMo, AI Blueprints) that appear in the ground truth. (3) Correctly characterizes the shift from foundational offering to full-stack platform. (4) Properly identifies the Compute & Networking segment context. WEAKNESSES: (1) CRITICAL OMISSION: The ground truth specifically mentions a '2.5x increase in token throughput' performance metric - the LLM completely fails to include this quantitative detail, which is a key factual element. (2) SCOPE EXPANSION ISSUE: The LLM introduces new information about automotive solutions (DRIVE Hyperion), Omniverse simulation, and DGX Cloud that are NOT mentioned in the ground truth answer. While these may be factually accurate from SEC filings, they represent scope expansion beyond what the knowledge graph answer specifies, potentially introducing unverified claims. (3) The ground truth emphasizes 'broader supply and integration' and 'production-grade generative AI platform' - the LLM captures the integration aspect but doesn't explicitly address the supply chain/distribution evolution. (4) The LLM's framing of 'end-to-end generative-AI development' is reasonable but adds interpretation not explicitly in the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize across multiple product lines and ecosystems, but this synthesis goes beyond what the ground truth validates. The core 2022-to-2024 evolution is captured, but the additional ecosystem details (automotive, Omniverse, DGX Cloud) represent either hallucination or unverified expansion. QUANTITATIVE ACCURACY: The 2.5x token throughput metric is completely missing, which is a significant factual gap. All other information is qualitatively aligned but lacks the specific performance improvement data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 504,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "\nExxonMobil’s proved reserves that are reported by its equity‑company partners grew dramatically from the 2022 figure shown in Chunk 1 (where the “Total Equity Companies” row lists only 14 units, with the United States holding 12 units and minor amounts in Europe and Asia) to the 2024 total of **1,481 million boe** disclosed in Chunk 2, of which Asia alone accounts for **1,276 million boe**, Africa **143 million boe**, Europe **45 million boe** and the United States just **17 million boe**.  This evolution is reflected in the knowledge‑graph link **XOM ‑[Has_Stake_In]→ Equity Companies ←[Discloses] Reserves**, demonstrating that ExxonMobil is deliberately concentrating its equity‑partnered resource base in high‑growth regions—especially Asia‑Pacific and Africa—while scaling back its relatively small North‑American equity portfolio, thereby reshaping its strategic positioning toward those continents.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: The LLM answer contains significant quantitative errors that fundamentally undermine its credibility. (1) QUANTITATIVE ACCURACY FAILURES: The ground truth specifies 2024 reserves as 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas. The LLM converts these to a single 'boe' (barrels of oil equivalent) figure of 1,481 million boe, which cannot be verified from the ground truth data and appears to be an incorrect aggregation. More critically, the regional breakdown in the LLM answer (Asia 1,276 million boe, Africa 143 million boe, Europe 45 million boe, US 17 million boe) totals 1,481 million boe, but the ground truth does not provide these specific regional breakdowns in boe terms. The ground truth states 'the majority of this growth concentrated in Asia' but does not quantify Asia's reserves as 1,276 million boe. (2) 2022 DATA HANDLING: The LLM correctly identifies 2022 reserves as 14 million barrels gross (1 million net), matching the ground truth. However, the LLM's characterization of the 2022 regional distribution (US 12 units, minor Europe/Asia) cannot be verified against the ground truth provided. (3) MULTI-HOP REASONING: While the LLM correctly identifies the strategic shift toward Asia and Africa, the specific numerical claims about regional allocations lack support in the ground truth. The reasoning about 'deliberately concentrating' and 'scaling back' is sound directionally but is built on unverified quantitative claims. (4) SEMANTIC ISSUES: The conversion to boe and the specific regional percentages appear to be LLM-generated inferences rather than ground truth data. The ground truth provides specific commodity volumes (barrels of crude, barrels of NGL, cubic feet of gas) but the LLM aggregates these into a single boe metric without clear justification. (5) WHAT WAS CORRECT: The directional analysis (growth from 2022 to 2024, strategic shift to Asia/Africa, scaling back US presence) aligns with ground truth. The identification of equity companies as the mechanism is correct. The overall strategic positioning conclusion is reasonable. CRITICAL ISSUE: The LLM appears to have fabricated or incorrectly calculated the specific regional boe figures, which are central to answering the question quantitatively. This is a fundamental failure in multi-hop financial analysis where precision is essential.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 650,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "\nBetween 2022 and 2024 Google’s reliance on Google Network Partners deepened on both the top‑line and the bottom‑line: the 2022 filing explains that ads placed on partner sites are treated on a **gross‑basis**—the full amount billed to advertisers is recorded as revenue and the amount paid to the partners is recorded as **cost of revenues**, making the partners a key source of advertising revenue; and the 2024 cash‑flow note shows that **cash payments to distribution and Google Network partners have risen**, contributing to higher cost‑of‑revenues and overall operating outflows, even as revenue from Google Search, YouTube and other properties continues to grow. This mutual dependence—captured by the KG triplets (GOOGL Depends_On Google Network Partners ← Supplies Google Network Partners)—illustrates how the partners have evolved from a supplemental channel into a central driver of both revenue generation and cost structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core structural difference between 2022 and 2024 reporting: (1) 2022 used gross-basis revenue recognition with partner payments as cost of revenues, and (2) 2024 shifted focus to cash flow impact. The semantic understanding of the evolution is sound—from revenue-centric to cost/cash-flow-centric framing. The answer appropriately addresses both revenue generation and cost structure components of the question.\n\nWEAKNESSES: (1) QUANTITATIVE CLAIMS WITHOUT SUPPORT: The LLM states 'cash payments to distribution and Google Network partners have risen' but provides NO specific numbers, percentages, or dollar amounts to substantiate this claim. The ground truth does not quantify this increase either, but the LLM's assertion goes beyond what can be verified from the provided context. (2) UNSUPPORTED INFERENCE: The phrase 'deepened on both the top-line and the bottom-line' is an interpretation not explicitly stated in the ground truth. The ground truth notes a shift in framing emphasis, not necessarily a deepening of reliance. (3) KNOWLEDGE GRAPH REFERENCE: The LLM references specific KG triplets ('GOOGL Depends_On Google Network Partners ← Supplies Google Network Partners') that are not present in the ground truth answer and cannot be verified. This appears to be hallucinated structure. (4) OVERSTATEMENT: Characterizing partners as 'evolved from a supplemental channel into a central driver' is stronger language than the ground truth supports—the ground truth says they 'played a central role' in 2022 and 'continued to pay' in 2024, not that they evolved from supplemental to central.\n\nMULTI-HOP REASONING: The answer does synthesize information across 2022 and 2024 correctly in terms of the structural shift in reporting. However, it adds interpretive layers (rising payments, deepened reliance, mutual dependence) that exceed the ground truth's more measured assessment.\n\nFACTUAL ACCURACY: Core facts about gross-basis accounting in 2022 and cost-of-revenues treatment are correct. The shift to cash-flow emphasis in 2024 is correct. However, claims about rising payments and deepened reliance lack quantitative support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 587,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "\nUPS’s foreign‑currency risk‑management shifted from merely using non‑designated forwards to offset re‑measurement risk in 2022 to a more active practice in 2023 of terminating those contracts and creating offsetting positions, which “de‑designates” the original forwards and records their fair‑value changes and settlements directly in earnings; this mechanism—captured by the KG relationship UPS → Offsetting Foreign Currency Positions → UPS—produces the earnings‑volatility impact disclosed in the 2023 and 2022 income‑statement amounts for non‑designated foreign‑currency forwards.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant conceptual and factual errors that diverge substantially from the ground truth. MAJOR ISSUES: (1) The LLM introduces a mechanism of 'terminating contracts and creating offsetting positions' that is NOT mentioned in the original answer and appears to be speculative interpretation rather than factual disclosure from the filings. The ground truth states contracts were used to 'economically offset' risk, not that they were terminated and re-designated. (2) The LLM's claim about 'de-designates' the original forwards is not supported by the ground truth, which discusses undesignated contracts, not a process of de-designation. (3) The LLM references a KG relationship 'UPS → Offsetting Foreign Currency Positions → UPS' which is not mentioned in the ground truth and appears to be an invented construct. (4) The LLM conflates the evolution of disclosure practices with an actual change in strategy mechanics - the ground truth emphasizes that the 2023 change was primarily about 'more transparent and systematic approach to disclosing' rather than a fundamental shift in how contracts are managed. CORRECT ELEMENTS: The LLM correctly identifies that undesignated foreign currency forwards impact earnings volatility and that there are 2023 and 2022 comparative disclosures. However, the core narrative about HOW the strategy evolved is fundamentally misrepresented. The answer demonstrates weak multi-hop reasoning by inventing causal mechanisms not present in the source material. The semantic meaning diverges significantly from ground truth - this is not merely a wording difference but a factual mischaracterization of the strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 459,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "\nCostco’s 2022 and 2023 filings both treat the **membership format as an integral accounting policy whose purpose is to “reinforce member loyalty and provide continuing fee revenue,”** and they each stress that profitability hinges on growing the overall membership base, deepening Executive‑member penetration, and sustaining high renewal rates — all of which are tied to the company’s cost‑control discipline and to the fact that new‑warehouse openings in existing markets can dampen paid‑membership growth — while the KG relationship (COST ↔ Membership Format) confirms that the format is formally embedded in Costco’s financial reporting. In 2023 the narrative adds a specific caution that “lower renewal rates in newer markets” could adversely affect worldwide renewal rates, indicating an evolution toward a stronger focus on preserving loyalty across expanding, younger markets as a driver of fee revenue, even as the core message that the membership model underpins profitability remains unchanged across both years.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key facts and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the core message that membership format is 'integral' to profitability in both years; (2) Accurately captures the evolution in language from 2022 to 2023; (3) Correctly identifies the new concern about lower renewal rates in newer markets introduced in 2023; (4) Properly synthesizes the multi-hop relationship between membership format, member loyalty, and fee revenue; (5) No quantitative errors - no specific numbers were required and none were provided incorrectly. MINOR WEAKNESSES: (1) The phrase 'accounting policy whose purpose is to reinforce member loyalty and provide continuing fee revenue' appears to be a direct quote or paraphrase, but the ground truth doesn't explicitly confirm this exact wording - this is a minor semantic issue rather than factual error; (2) The reference to 'cost-control discipline' and 'new-warehouse openings in existing markets can dampen paid-membership growth' adds contextual detail not explicitly mentioned in the ground truth, though these are reasonable inferences from Costco's business model; (3) The mention of 'KG relationship (COST ↔ Membership Format)' is somewhat awkward phrasing that doesn't add clarity. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings, correctly identifying both continuity (membership as integral to profitability) and evolution (new focus on renewal rate challenges in newer markets). The reasoning connecting membership format to member loyalty and fee revenue is sound and well-articulated. OVERALL: The answer is substantively correct and addresses all parts of the question with appropriate emphasis on the evolution between years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1483,
        "completion_tokens": 494,
        "total_tokens": 1977
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA transformed CUDA from a standalone parallel‑programming model into the core software engine of a full‑stack data‑center platform, adding CPU and DPU support (DPUs introduced in FY 2022, CPUs in FY 2024), coupling it with the CUDA‑X library suite, and delivering it through enterprise offerings such as AI Enterprise and the managed DGX Cloud; the 2025 Blackwell architecture then extended this integrated stack to generative‑AI workloads.  This evolution is underpinned by a worldwide ecosystem of nearly 3 million developers and the Deep Learning Institute, and is reflected in NVIDIA’s partnerships with universities, startups and OEMs that now span cloud, enterprise and professional‑visualization domains, as documented in both the 2022 and 2024 disclosures.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution narrative correctly but introduces problematic factual claims not supported by the ground truth. STRENGTHS: (1) Correctly identifies the shift from standalone tool to integrated platform component; (2) Accurately mentions CUDA-X library suite; (3) Correctly references ~3 million developers; (4) Appropriately notes Deep Learning Institute and ecosystem partnerships; (5) Properly frames the 2022-2024 timeframe. CRITICAL ISSUES: (1) QUANTITATIVE ERROR - Claims 'DPUs introduced in FY 2022, CPUs in FY 2024' - the ground truth makes no mention of specific fiscal years for DPU/CPU introduction, and the LLM appears to have fabricated these dates; (2) UNSUPPORTED CLAIMS - References 'AI Enterprise,' 'managed DGX Cloud,' and 'Blackwell architecture' extending to 'generative-AI workloads' - none of these specific products/architectures appear in the ground truth, suggesting the LLM added information beyond what was documented; (3) SCOPE CREEP - The answer extends beyond 2024 to discuss 2025 Blackwell, which goes beyond the question's 2022-2024 timeframe. REASONING ASSESSMENT: The multi-hop synthesis is logically sound in structure (showing evolution across time), but the addition of unverified specific product names and dates undermines credibility. The answer reads as more detailed than the ground truth but this detail appears to be extrapolation rather than synthesis from actual filings. The semantic equivalence on core concepts (platform integration, CUDA-X, developer ecosystem) is good, but the factual additions are problematic for a task requiring strict adherence to documented information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Develops]- ORG",
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 452,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "\nPfizer (PFE) produces Paxlovid (the oral COVID‑19 treatment listed in the 2023 10‑K), and the 2024 filing quantifies the company’s remaining performance obligations for that product: as of 31 Dec 2024, about **$1 billion of contracted revenue** from long‑term Paxlovid supply agreements is expected to be recognized from **2025 through 2028**, with deliveries scheduled in that window and subject to possible renegotiation.  This contrasts with the 2023 10‑K, which recorded a **$3.5 billion non‑cash revenue reversal** tied to an estimated return of 6.5 million EUA‑labeled courses; in 2024 Pfizer reversed $771 million of that estimate and added $442 million of revenue from the U.S. SNS, reflecting a reduced return expectation (5.1 million courses returned) and a one‑time $129 million settlement true‑up.  Consequently, Pfizer’s financial commitment to Paxlovid has shifted from a large anticipated reversal in 2023 to a backlog of roughly $1 billion of future revenue and firm delivery timelines extending to 2028.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core narrative shift from 2023 to 2024 regarding Pfizer's Paxlovid financial commitments and provides relevant context. However, there are significant quantitative accuracy issues that prevent a higher score.\n\nCORRECT ELEMENTS:\n- $3.5 billion non-cash revenue reversal in 2023 Q4 (correct)\n- 6.5 million treatment courses estimated return (correct)\n- ~$1 billion remaining performance obligations as of Dec 31, 2024 (correct)\n- Expected delivery/revenue realization from 2025-2028 (correct)\n- Overall narrative of shift from reversals to defined forward-looking obligations (correct)\n\nPROBLEMATIC ELEMENTS:\n- The LLM introduces specific numbers ($771 million reversal, $442 million revenue, 5.1 million courses, $129 million settlement) that are NOT present in the ground truth answer. These appear to be fabricated or sourced from unstated filings.\n- The ground truth answer makes no mention of a $771 million reversal in 2024, a $442 million U.S. SNS revenue addition, a reduction to 5.1 million courses, or a $129 million settlement true-up.\n- While these details might exist in the actual 2024 10-K, they are NOT part of the ground truth knowledge graph provided, making them unverifiable against the source material.\n- The phrase \"subject to possible renegotiation\" is not mentioned in the ground truth and adds interpretive language not supported by the provided answer.\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesizes information across 2023 and 2024 filings and properly identifies the temporal evolution of Pfizer's Paxlovid obligations. The reasoning structure is sound: comparing 2023 reversals to 2024 forward obligations.\n\nQUANTITATIVE ACCURACY ISSUES:\nThe introduction of unverified numbers ($771M, $442M, 5.1M courses, $129M) significantly undermines quantitative accuracy. While the core figures ($3.5B, 6.5M, $1B, 2025-2028) are correct, the additional details cannot be confirmed against the ground truth and may represent hallucination or information from sources beyond the provided knowledge graph.\n\nSEMANTIC EQUIVALENCE:\nThe core semantic meaning aligns with ground truth (shift from reversals to defined obligations), but the addition of unverified quantitative details creates factual discrepancies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 611,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "\nExxonMobil (XOM) operates in Guyana and discloses its reserves there; in the 2022 filing the company noted ~1.3 billion‑barrel additions to proved undeveloped reserves and $8 bn of upstream spend linked to Guyana’s development, marking the early stage of reserve‑development focus. By 2024 the same reserve base is elevated in the earnings‑driver framework, where Guyana is explicitly listed among “Advantaged Assets” and “Advantaged Projects,” signaling that the company now treats Guyana as a core, high‑return growth engine within its advantaged‑volume strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of ExxonMobil's strategic evolution regarding Guyana. STRENGTHS: (1) Correctly identifies the ~1.3 billion barrel addition to proved undeveloped reserves in 2022, matching the ground truth exactly. (2) Accurately captures the 2024 shift where Guyana is explicitly listed as an 'Advantaged Asset,' reflecting the strategic repositioning. (3) Properly synthesizes the multi-hop reasoning: 2022 reserves growth → 2024 earnings driver framework elevation. (4) Correctly identifies the company (ExxonMobil/XOM) and time periods (2022 vs 2024). (5) The semantic meaning aligns well with ground truth - both convey a transition from reserves growth focus to earnings/production visibility. (6) Adds contextual detail about '$8bn upstream spend' which provides additional supporting evidence of strategic commitment. MINOR CONSIDERATIONS: (1) The LLM introduces '$8bn upstream spend' which is not explicitly mentioned in the ground truth answer, though this appears to be accurate supporting detail rather than an error. (2) The phrasing 'same reserve base is elevated' is slightly different from ground truth's 'transition from reserves growth region to earnings source,' but the semantic meaning is equivalent - both convey elevation/repositioning. (3) The answer uses 'Advantaged Projects' in addition to 'Advantaged Assets' - the ground truth only mentions 'Advantaged Assets,' though this may reflect accurate filing language. QUANTITATIVE VERIFICATION: The 1.3 billion barrel figure is correct and properly formatted. No calculations are required for this question. MULTI-HOP REASONING: The answer successfully synthesizes information across two years (2022 and 2024) and correctly identifies the strategic shift in how Guyana is positioned within the company's framework. The logic is sound and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 510,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "\nThe forward‑looking fleet tables show the ATR 72‑600F commitment falling from **11 aircraft in 2023 (Chunk 1)** to **6 aircraft in 2024**, and then to **7 in 2025 and just 3 by 2026 (Chunk 2)**, while the overall fleet size contracts from 38 to 36 (2023‑24) and later to 20 (2026) – a clear downward trend in the turboprop’s planned utilization. This pattern is reflected in the knowledge‑graph link **ORG → Decreases → ATR 72‑600F**, indicating that FedEx is intentionally scaling back the ATR 72‑600F and reallocating capacity to larger jet freighters (B767F/B777F), signalling a strategic shift toward a higher‑capacity, jet‑centric fleet rather than continued reliance on the ATR 72‑600F.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) WRONG NUMBERS: The LLM states ATR 72-600F units were '11 aircraft in 2023...to 6 aircraft in 2024, and then to 7 in 2025 and just 3 by 2026.' However, the ground truth clearly indicates: 2022 projections showed 11→1 trajectory, while 2024 projections showed 7 (2025) and 3 (2026). The LLM incorrectly introduces a '6 in 2024' figure that doesn't appear in the ground truth and misrepresents the 2022 baseline. (2) MISSING KEY COMPARISON: The ground truth emphasizes the EVOLUTION from 2022 to 2024 - comparing two different projection periods. The LLM fails to clearly distinguish between the 2022 projections (11→1 decline) versus 2024 projections (7→3, more sustained). This is the core of the question. (3) INCOMPLETE SYNTHESIS: While the LLM correctly identifies the overall downward trend and strategic shift toward larger aircraft, it doesn't properly synthesize the key insight: that the 2024 projections showed a LESS AGGRESSIVE phase-out than 2022 projections, indicating a strategic recalibration. (4) REASONING QUALITY: The LLM's reasoning about fleet strategy shift is sound and well-articulated, but it's built on incorrect numerical foundations. The multi-hop synthesis (comparing projections across years) is attempted but executed poorly due to data errors. (5) CONTEXTUAL RELEVANCE: The answer addresses the right question about fleet strategy evolution, but the factual errors undermine the credibility of the analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 431,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA shifted Omniverse from a primarily simulation‑and‑collaboration tool for automotive and design workflows—used together with DRIVE Sim to create digital twins of factories and vehicles and offered as a free‑for‑individuals/subscription‑for‑enterprises platform—to a broader AI‑centric development platform that is now integrated with the NVIDIA AI Enterprise software suite and the Blackwell architecture, enabling enterprises to build and run AI‑driven digital twins and generative‑AI simulations across industries. This evolution reflects tighter coupling of Omniverse with AI‑accelerated computing (e.g., Blackwell GPUs, AI Enterprise libraries, and DRIVE Sim) while retaining its subscription model and expanding its role beyond automotive to general industrial digital‑twin and simulation use cases.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "ASSESSMENT: The LLM answer contains both accurate and inaccurate elements when compared to the ground truth.\n\nCORRECT ELEMENTS:\n1. Correctly identifies the time period (2022-2024)\n2. Accurately notes the shift from general 3D collaboration to enterprise-focused simulation\n3. Correctly mentions the subscription model for enterprises and free for individuals\n4. Accurately identifies digital twins and factory digitalization as key use cases\n5. Correctly notes integration with accelerated computing infrastructure\n6. Properly identifies the evolution toward AI-centric capabilities\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. INTRODUCES UNSUPPORTED CLAIMS: The LLM answer mentions \"integration with NVIDIA AI Enterprise software suite\" and \"Blackwell architecture\" as part of Omniverse's evolution. The ground truth does not mention these specific integrations in the context of Omniverse's evolution between 2022-2024. These appear to be inferences or additions not supported by the source material.\n2. OVERSTATES AUTOMOTIVE FOCUS IN 2022: The LLM describes 2022 Omniverse as \"primarily simulation-and-collaboration tool for automotive and design workflows,\" but the ground truth indicates it was more broadly described as a \"virtual world simulation and collaboration platform for 3D workflows\" with automotive being one example among VR/AR enterprise applications.\n3. MENTIONS DRIVE SIM INTEGRATION: While DRIVE Sim is mentioned in the LLM answer as integrated with Omniverse in 2022, the ground truth does not explicitly state this integration in the 2022 description.\n4. ADDS \"GENERATIVE-AI SIMULATIONS\": The LLM introduces \"generative-AI simulations\" as a 2024 capability, which is not mentioned in the ground truth.\n\nMULTI-HOP REASONING: The LLM demonstrates reasonable synthesis of the evolution narrative, but introduces elements not present in the ground truth, suggesting either hallucination or inference beyond the source material.\n\nSEMANTIC EQUIVALENCE: While the overall narrative arc is similar (evolution from general 3D collaboration to specialized enterprise digital twin platform), the specific technical details added by the LLM diverge from the ground truth.\n\nJUSTIFICATION: The answer captures the main evolution trajectory but introduces specific technical integrations (Blackwell, AI Enterprise) and use cases (generative AI) that are not supported by the ground truth. This represents a moderate level of accuracy with significant additions that may be factually incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 670,
        "total_tokens": 2120
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "\nBetween 2022 and 2023 Google Play moved from being an implicit part of the company’s “non‑advertising revenues” bucket—where it generated income from app and in‑app sales alongside Cloud, hardware and other services (Chunk 1)—to a stand‑alone line‑item within the newly disclosed “Google Subscriptions, Platforms, and Devices” segment, explicitly identified as a source of platform revenue from app and in‑app purchases (Chunk 2). This re‑classification signals that Google Play’s contribution to non‑advertising revenue has grown and is now tracked separately, with its performance influenced by usage trends, subscriber growth and product‑launch timing.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Google Play's role between 2022 and 2023. Key strengths: (1) Correctly identifies the transition from implicit inclusion in non-advertising revenues to explicit standalone line-item status; (2) Accurately captures the shift from general diversification strategy to structured categorization under 'Google Subscriptions, Platforms, and Devices' segment; (3) Properly synthesizes the multi-hop information showing Google Play's evolution across two fiscal years; (4) Correctly identifies the revenue sources (app sales, in-app purchases); (5) Appropriately notes the strategic implications of this reclassification. Minor areas for improvement: (1) The LLM answer adds interpretive details about 'usage trends, subscriber growth and product-launch timing' that, while reasonable inferences, are not explicitly stated in the ground truth and represent some extrapolation beyond the documented facts; (2) The phrase 'contribution to non-advertising revenue has grown' implies quantitative growth that is not explicitly confirmed in the ground truth, which focuses on structural/categorical changes rather than revenue magnitude changes. The answer is semantically equivalent to the ground truth in its core message about the evolution from implicit to explicit categorization and the strategic shift toward solidifying Google Play's role. No numerical errors or date inaccuracies present. The multi-hop reasoning correctly synthesizes information across the 2022-2023 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 429,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "\nAIG continues to apply its accounting policy of using **expected‑loss‑ratio methods** for workers‑compensation reserves, but the way it weights those methods has evolved: for **guaranteed‑cost business** it still relies mainly on the most recent accident year, whereas for **excess‑of‑deductible business** it now gives weight to the most recent **five accident years** and segments the portfolio by deductible size and whether claims are handled by AIG or a third‑party administrator—reflecting the growing share of large‑deductible and insured‑risk‑retention structures that slow claim emergence.  The company also adjusts the underlying loss‑ratio inputs for higher legal‑cost trends, inflation and COVID‑19‑related frequency/severity disruptions, and it separates California and New York from other states to capture their distinct development patterns.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core methodological distinction between guaranteed cost and excess of deductible business, accurately noting that guaranteed cost relies on the most recent accident year while excess of deductible uses the most recent five accident years. The mention of segmentation by deductible size and third-party administrator involvement is accurate and relevant. The reference to adjustments for legal costs, inflation, and COVID-19 impacts is appropriate context.\n\nWEAKNESSES: (1) The LLM answer fails to explicitly address the evolution/change between 2022 and 2023. The ground truth emphasizes that methodology 'remained broadly consistent' between years, but the LLM presents the information as if describing a single time period without clearly delineating what changed or stayed the same. (2) The LLM omits the important 2022-specific detail about claims strategy changes and loss mitigation efforts accelerating settlements and increasing paid losses along latest diagonals. (3) The LLM does not mention the 2023 refinement regarding incurred and paid losses being presented net of reinsurance and undiscounted, which the ground truth identifies as a potential reporting transparency change. (4) The LLM does not explicitly note that the increased proportion of large deductible business continued to slow reporting patterns, which is mentioned in the ground truth as a consistent trend. (5) The answer lacks temporal specificity—it doesn't clearly distinguish between 2022 and 2023 findings, which is central to the question's focus on 'evolution between 2022 and 2023.'\n\nMULTI-HOP REASONING: The LLM demonstrates adequate synthesis of information about the two business types and their respective methodologies, but fails to synthesize the temporal dimension (2022 vs 2023 comparison) that is essential to answering the question about evolution.\n\nNUMERIC/FACTUAL VERIFICATION: All specific numbers mentioned (most recent accident year for guaranteed cost, five accident years for excess of deductible) are correct. No calculation errors detected. However, the omission of temporal context represents a significant gap in addressing the core question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 589,
        "total_tokens": 2067
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "\nCisco retained a “Collaboration” line item in both fiscal‑2022 and fiscal‑2024 disclosures, but the surrounding taxonomy shifted: in FY 2022 it was grouped with five other buckets—Secure, Agile Networks; Internet for the Future; End‑to‑End Security; Optimized Application Experiences; and Other Products—whereas by FY 2024 the company consolidated its product‑revenue reporting into just four categories—Networking, Security, Collaboration, and Observability—and restated prior periods to match this new layout.  This evolution reflects a strategic refocus that kept Collaboration as a distinct pillar while moving the other segments into broader “Networking” and “Observability” groupings, a change that aligns with Cisco’s updated product‑category strategy disclosed in the 2024 filing.  (The KG link CSCO → Webex → CSCO underscores that Webex, a key Collaboration offering, remains part of Cisco’s portfolio throughout the transition.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness in addressing the multi-hop question about Cisco's product category segmentation evolution. STRENGTHS: (1) All factual information is correct - FY 2022 had six categories (Collaboration, Secure Agile Networks, Internet for the Future, End-to-End Security, Optimized Application Experiences, Other Products) and FY 2024 consolidated to four (Networking, Security, Collaboration, Observability). (2) The answer correctly identifies that Collaboration was retained as a distinct category in both periods. (3) The multi-hop synthesis is sound - the answer properly traces how the taxonomy shifted and what happened to the removed/reclassified categories. (4) The answer goes beyond the ground truth by noting that prior periods were restated to match the new layout, which is a valuable contextual detail. (5) The mention of Webex as a key Collaboration offering adds relevant context about the portfolio continuity. (6) No numerical errors or calculation mistakes. MINOR CONSIDERATIONS: The answer is slightly more verbose than the ground truth and includes the parenthetical about the KG link (CSCO → Webex → CSCO), which, while not incorrect, is somewhat tangential to the core question. However, this does not detract from factual accuracy. The semantic meaning aligns perfectly with the ground truth - both convey consolidation from six to four categories, retention of Collaboration, and strategic realignment. All entities (Cisco, fiscal years, product categories) are correctly identified and synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 432,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "\nAmgen’s 3.125% 2025 Notes are shown in the 2022 Form 10‑K as a fixed‑coupon security with a $1,000 carrying value (and $1,000 in 2021) and no explicit spread disclosed; by the 2023 filing the same $1,000‑notional note is presented with an effective interest rate of **SOFR + 2.1%**, and it is placed in a table of other senior unsecured notes that use comparable SOFR‑plus‑spread terms, indicating a shift from a static coupon description to a floating‑rate framework. This evolution is captured by the KG relationship — **AMGN (ORG) issues and discloses the 3.125% 2025 Notes (FIN_INST)** — and is reflected in the 2022 chunk’s carrying‑value table and the 2023 chunk’s notional‑amount/effective‑rate table.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY FAILURE: The LLM states the 3.125% 2025 Notes have an 'effective interest rate of SOFR + 2.1%' in 2023. This is fundamentally incorrect. The ground truth clearly states the notes are identified as 'SOFR + 2.1%' in the 2023 table, but the 3.125% coupon is a FIXED rate, not a floating rate. The LLM incorrectly characterizes this as a 'shift from a static coupon description to a floating-rate framework,' which is factually wrong. The notes maintain their 3.125% fixed coupon; the SOFR + 2.1% reference appears to be a separate disclosure mechanism or comparison framework, not a replacement of the coupon. (2) SEMANTIC MISREPRESENTATION: The LLM's claim that 2023 shows 'a floating-rate framework' directly contradicts the ground truth, which describes the evolution as 'a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023.' The notes are not floating-rate instruments. (3) CARRYING VALUE ACCURACY: The LLM correctly identifies the $1,000 million carrying value for both years, which matches ground truth. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize the 2022 vs 2023 comparison, it fundamentally misinterprets what the SOFR + 2.1% disclosure represents. The ground truth indicates this is an interest rate mechanism disclosure, not a conversion to floating-rate terms. (5) ENTITY ACCURACY: Amgen (AMGN) and the 3.125% 2025 Notes are correctly identified. (6) STRUCTURAL ISSUE: The LLM's interpretation that the notes shifted to a 'floating-rate framework' is a major factual error that undermines the entire answer. The correct interpretation is that the disclosure framework evolved to include more detailed interest rate information, not that the instrument's nature changed. This is a critical distinction in financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 507,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "\nFrom the end of 2022 through 2024, COP’s reported natural‑gas reserves in the Asia Pacific/Middle East segment declined from **326 billion cubic feet** to **312 bcf** and then to **296 bcf**, a net reduction of roughly **30 bcf** despite modest positive revisions and limited new discoveries.  \nThe decline is driven by production that outpaced additions—2023‑24 revisions were only **+9 bcf** while production removed **24 bcf** and extensions added just **87 bcf**—indicating stagnant reserve growth in that geography.  \nTogether with the knowledge‑graph link that **COP Operates_In Asia Pacific/Middle East** and the lower exploration‑spending levels recorded for that segment in the 2021‑23 financial tables (Chunk 1), the trend signals that COP is scaling back its strategic focus on the region and reallocating capital to other basins.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core numbers: 326 bcf (2022), 312 bcf (2023), and 296 bcf (2024). The net reduction of ~30 bcf is accurately calculated. The answer goes beyond the ground truth by providing detailed year-by-year progression and component analysis (revisions +9 bcf, production -24 bcf, extensions +87 bcf), which adds valuable context about reserve dynamics. The strategic interpretation aligns with the ground truth conclusion about scaling back focus in the region. Minor strengths: (1) All numeric values are correct and properly formatted; (2) Multi-hop synthesis is sound, connecting reserve trends to strategic positioning; (3) The answer correctly identifies COP's operations in the region and links financial data to strategic conclusions. One minor consideration: The LLM provides additional granular detail (2023 intermediate figure of 312 bcf and component breakdown) not explicitly in the ground truth, but this is supplementary and accurate rather than contradictory. The reasoning about stagnant reserve growth and capital reallocation is well-supported by the data presented. The answer fully addresses both parts of the question (reserve evolution and strategic positioning) with appropriate depth and accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 358,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "\nAlphabet’s repurchase of Class C Capital Stock grew from **$59.3 billion in 2022 to $62.2 billion in 2023**—an increase of roughly **$2.9 billion (≈4.9 %)**—and the Board subsequently expanded the authorized buy‑back reserve to **$70 billion**, leaving **$36.3 billion** available as of 31 Dec 2023. This upward trajectory and the larger authorisation show that the company is deliberately channeling excess cash into **equity retirements**, underscoring a capital‑allocation strategy that prioritises returning surplus capital to shareholders through aggressive share‑buy‑backs rather than holding cash or funding new investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data is correct: $59.3 billion (2022), $62.2 billion (2023), the $2.9 billion increase, the 4.9% growth calculation, $70 billion authorization, and $36.3 billion remaining as of December 31, 2023. The calculation of the year-over-year change ($62.2B - $59.3B = $2.9B) and percentage increase (2.9/59.3 ≈ 4.9%) are both accurate. The LLM correctly synthesizes multi-hop information: comparing repurchase amounts across two years, incorporating the Board authorization detail, and connecting these facts to capital allocation strategy interpretation. The answer properly identifies that the repurchases involve both Class A and Class C shares (though the question specifically asks about Class C, the ground truth mentions both classes were repurchased together). The reasoning about capital allocation strategy is sound and well-articulated, explaining that the company prioritizes returning capital to shareholders through buybacks. The only minor consideration is that the ground truth mentions 'Class A and Class C shares' collectively while the LLM focuses on 'Class C Capital Stock' as stated in the question, but this is not an error since the repurchase figures apply to both classes combined. The answer is comprehensive, addresses all aspects of the question, and provides appropriate context about the company's strategic direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 395,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "\nBetween 2022 and 2023 AIG continued to apply frequency‑severity techniques to its short‑tail property lines (U.S. Property and program‑business property) and to liability classes, using them alone or together with loss‑development and expected‑loss‑ratio methods to estimate IBNR for low‑frequency, moderate‑severity exposures; however, the 2023 disclosure adds that the same frequency‑severity approach is now also employed within the long‑tail U.S. Workers’ Compensation book—segmented by deductible size, third‑party administrator handling and state/industry subsets—to capture the evolving development patterns of large‑deductible and excess‑of‑deductible business, while the company still refrains from using frequency‑severity methods for high‑severity, less‑predictable lines such as aviation. This evolution reflects a shift from using the methods only for short‑tail property reserving to extending them into a structured, risk‑sharing workers‑comp portfolio, with continual reevaluation of factors to reflect emerging claim trends and inflation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of AIG's evolution in frequency/severity methods between 2022 and 2023. STRENGTHS: (1) Correctly identifies the core evolution: expansion from short-tail property lines to long-tail U.S. Workers' Compensation; (2) Accurately captures the 2022 baseline where frequency/severity was used for U.S. Property and explicitly avoided for aviation due to high severity and unpredictable claims; (3) Properly synthesizes the 2023 expansion to Workers' Compensation with appropriate segmentation details (by deductible size, third-party administrator, state/industry); (4) Correctly notes the continued exclusion of aviation from frequency/severity methods; (5) Provides sound reasoning for the shift, linking it to risk-sharing features and large deductible business growth; (6) No quantitative errors or incorrect dates/entities. MINOR CONSIDERATIONS: (1) The LLM answer provides additional contextual details beyond the ground truth (e.g., mention of 'program-business property,' specific segmentation factors, inflation considerations) that, while accurate and relevant, go slightly beyond what was explicitly stated in the original answer; (2) The phrasing is more elaborate and technical than the ground truth, but this represents enhanced clarity rather than inaccuracy. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, correctly identifying the methodological shift and its business drivers. The comparison between 2022 and 2023 is logically sound and well-structured. All entities (AIG, U.S. Property, Workers' Compensation, aviation) are correctly identified and contextualized. The answer demonstrates proper understanding of the distinction between short-tail and long-tail business and why frequency/severity methods would be extended to the latter.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 507,
        "total_tokens": 1947
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "\nFrom 2022 to 2023 Amgen’s collaboration with BeiGene shifted markedly: cost recoveries fell to **$109 million in 2023** (down from **$199 million in 2022**), product sales to BeiGene rose to **$125 million in 2023** (up from **$64 million in 2022**), and profit‑and‑loss‑sharing expenses declined to **$40 million in 2023** (versus **$53 million in 2022**); these amounts are recorded respectively as an offset to R&D expense, as revenue in “Product sales,” and as SG&A expense, with the receivables for sales and cost recoveries shown in trade‑receivables ($16 million as of Dec 2023).  The partnership, originally formed when Amgen acquired a 20.5 % equity stake in BeiGene in January 2020, continues to be accounted for under the equity‑method (with basis‑difference amortization and share of BeiGene’s net losses affecting income) and remains governed by a collaboration that shares profits equally during the initial product‑specific commercialization periods, after which product rights may revert to Amgen and royalties are paid on China sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensiveness. All core financial figures are correct: cost recovery ($199M in 2022 → $109M in 2023), product sales ($64M in 2022 → $125M in 2023), and profit-and-loss sharing expenses ($53M in 2022 → $40M in 2023). The year-over-year comparisons and directional changes are accurately characterized. The answer goes beyond the ground truth by providing valuable additional context: (1) accounting treatment details (cost recovery as R&D offset, product sales as revenue, P&L sharing as SG&A), (2) trade receivables information ($16M as of Dec 2023), (3) historical partnership formation details (20.5% equity stake in January 2020), (4) equity-method accounting treatment with basis-difference amortization, and (5) profit-sharing structure and reversion terms. This additional information is accurate and relevant to understanding the financial relationship evolution. The multi-hop reasoning is sound—the answer correctly synthesizes information across multiple dimensions (financial metrics, accounting treatment, partnership structure, and strategic implications). The interpretation that the shift represents 'maturation of the collaboration' aligns with the ground truth's conclusion. Minor note: The answer includes specific details not explicitly in the ground truth (like the $16M trade receivables and equity-method accounting specifics), but these appear to be accurate supplementary information from the filings that enhances rather than contradicts the core answer. All quantitative data is precise with no calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 438,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "\nCOP’s Asia Pacific/Middle East natural‑gas reserves declined from 326 bcf at the end of 2022 to 296 bcf at the end of 2024, a net drop of roughly 30 bcf. The reduction stems from modest positive revisions (6 bcf in 2022 and 9 bcf in 2023), production of 84 bcf in 2022 and 25 bcf in 2023, and purchases of 4 bcf in 2022 with essentially zero purchases thereafter, as shown in the reserve tables (chunk 2). This reserve trajectory is consistent with the region’s $2.5 billion in sales reported for 2021 (chunk 1), providing the operational context for the reserve changes.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides significantly incorrect production figures. Ground truth states production was 25 bcf in 2024, but LLM claims 84 bcf in 2022 and 25 bcf in 2023. The question asks about 2022-2024 evolution, and the LLM conflates different years and provides numbers not supported by ground truth. The net decline calculation of 30 bcf is correct (326-296=30), but the component breakdown is wrong. (2) REVISIONS - LLM claims 6 bcf in 2022 and 9 bcf in 2023, but ground truth only mentions 9 bcf in 2023 with no 2022 revision figure provided. (3) PURCHASES - LLM states 4 bcf in 2022 with zero thereafter, but ground truth explicitly states 'no purchases reported directly affecting this region in 2024,' which the LLM partially captures but with incorrect 2022 data. (4) PRODUCTION TIMING - Critical error: LLM attributes 25 bcf production to 2023, but ground truth clearly states this occurred in 2024. (5) IRRELEVANT CONTEXT - The LLM introduces $2.5 billion in sales from 2021, which is not part of the ground truth answer and appears to be extraneous information not requested. (6) MULTI-HOP REASONING - While the LLM attempts to synthesize information across years, it does so with incorrect data points and misaligned timeframes. The core narrative of declining reserves is correct, but the specific mechanisms (revisions, production, purchases) are substantially misrepresented. The answer fails to accurately track the 2022-2024 period as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 416,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "\nFedEx originally planned to receive **14 B767F freighters each in 2023 and 2024** (Chunk 1), a figure that kept the type steady through the 2023‑2024 horizon and was reflected in the overall fleet totals of 38 (2023) and 36 (2024).  Subsequent disclosures show a **revision downward to 11 B767Fs for 2025 and only 3 B767Fs slated for 2026** (Chunk 2), while the broader fleet shrinks from 38 aircraft in 2023 to 14 in 2026, as the company increasingly leans on newer models such as the Cessna SkyCourier 408 and ATR 72‑600F (Chunk 1 & 2 totals).  This evolution—from a stable 14‑aircraft commitment to a rapid scaling‑back—signals a **strategic pivot away from the B767F toward more modern, fuel‑efficient cargo jets**, underscoring FedEx’s intent to reshape its freighter portfolio in line with long‑term cost and capacity objectives.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core strategic shift from 14 B767F aircraft to reduced numbers (11 for 2025, 3 for 2026), matching the ground truth. The reasoning about a pivot toward modern, fuel-efficient aircraft is sound and well-articulated. The multi-hop synthesis across multiple time periods is logically structured.\n\nCRITICAL ERRORS: (1) The LLM states FedEx planned to 'receive 14 B767F freighters each in 2023 and 2024' - this misinterprets the ground truth. The ground truth says FedEx 'projected using 14 B767F aircraft in both 2023 and 2024' from a 2022 perspective. The LLM's phrasing about 'receiving' suggests new acquisitions rather than planned usage/fleet count. (2) The LLM introduces unsupported details about broader fleet totals (38 aircraft in 2023, 36 in 2024, shrinking to 14 in 2026) and mentions specific aircraft models (Cessna SkyCourier 408, ATR 72-600F) that are NOT in the ground truth answer. These appear to be hallucinated details not verified against the source documents.\n\nPARTIAL ACCURACY: The 2025 (11 aircraft) and 2026 (3 aircraft) figures are correct. The characterization of the evolution as a 'strategic pivot' and 'rapid scaling-back' accurately reflects the ground truth's conclusion about accelerated reduction.\n\nMULTI-HOP REASONING: The model correctly synthesizes the 2022 projections versus 2024 actual projections, showing understanding of the temporal comparison required. However, the introduction of unverified fleet composition details undermines confidence in the synthesis.\n\nQUANTITATIVE ISSUES: While the key B767F numbers (14→11→3) are correct, the introduction of unverified total fleet numbers and aircraft model details that cannot be confirmed against ground truth represents a significant accuracy concern. The quantitative accuracy score reflects correct core numbers but penalizes the unsubstantiated additional figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Uses]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 516,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "\nAIG’s Expected‑Loss‑Ratio (ELR) methodology remained part of its core accounting policy from 2022 through 2023 (as shown by the ORG ↔ ACCOUNTING_POLICY KG links), but the lines of business to which it was applied and the rationale evolved.  \n\n- **2022** – ELRs were used primarily for the **latest accident‑year reserves in aviation** (a high‑severity, relatively short‑tail line) and for **program business across property and liability classes**, chosen because those exposures are driven by claim severity and require ground‑up projections rather than pure development methods.  \n- **2023** – The company extended ELRs to the **U.S. Workers’ Compensation line**, an extremely long‑tail line where claim emergence spans decades; here ELRs are combined with loss‑development and frequency/severity techniques to capture delayed claim development and to fit the line’s risk‑sharing structures (high deductibles, retroactive rating, etc.).  \n\nThus, while the underlying policy did not change, the 2023 application broadened to a long‑tail line and retained its use where severity or complexity demanded a reserve approach based on expected loss ratios rather than pure development.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the evolution of ELR methods from 2022 to 2023; (2) Accurately names the specific lines of business (aviation in 2022, U.S. Workers' Compensation in 2023); (3) Properly characterizes aviation as high-severity/short-tail and Workers' Compensation as long-tail; (4) Correctly notes the shift from focused application to broader application; (5) Accurately describes the combination of methods used in 2023 (ELR with loss-development and frequency/severity techniques); (6) Properly identifies structural complexity factors (risk-sharing features, high deductibles, retroactive rating); (7) No numerical errors or date inaccuracies. MINOR WEAKNESSES: (1) The 2022 description adds 'program business across property and liability classes' which is not explicitly mentioned in the ground truth - this appears to be an inference or additional detail not directly supported by the original answer; (2) The phrase 'ground-up projections' is introduced without explicit grounding in the original answer, though it is semantically reasonable; (3) The answer emphasizes 'the underlying policy did not change' which is a reasonable interpretation but adds interpretive framing beyond what the ground truth explicitly states. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple lines of business, correctly identifying the evolution and reasoning. The logical flow from 2022 to 2023 is sound and well-articulated. SEMANTIC EQUIVALENCE: The core message matches the ground truth - a shift from focused high-severity/short-tail application to broader long-tail application with combined methodologies. The reasoning about why these methods were chosen (severity, complexity, extended emergence periods) aligns well with the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 513,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "\nCisco’s 2022 filing framed Enterprise Data Center Transformation as the convergence of computing, networking, storage and software and explicitly warned that many of its strategic‑alliance partners could also be competitors—a risk highlighted in the “Item 1A. Risk Factors” of its 10‑K. By 2024 the same convergence narrative remained, but the filing sharpened the warning that alliance partners may acquire or form new alliances with rivals, thereby eroding Cisco’s share, while the competitive landscape broadened to include additional cloud, security and observability vendors; it also underscored continued R&D spending across networking, security, collaboration and observability to sustain its positioning amid intensifying competition and evolving alliance dynamics.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2022 framing of Enterprise Data Center Transformation as convergence of computing, networking, storage, and software. (2) Accurately captures the 2022 risk factor about alliance partners being competitors. (3) Correctly notes the 2024 evolution showing broadened competitive landscape. (4) Appropriately references R&D spending across multiple domains. (5) No quantitative errors in dates or timeframes. WEAKNESSES: (1) The LLM answer diverges significantly from ground truth on a critical point: Ground truth explicitly mentions 'Nvidia Corporation' as a new entrant in 2024, but the LLM answer generalizes this to 'cloud, security and observability vendors' without naming Nvidia specifically. This is a material omission of a key competitive landscape shift. (2) Ground truth emphasizes Cisco's shift toward 'strategic alliances aimed at industry advancement and new market creation' in 2024, but the LLM answer focuses more on the warning about alliance partners acquiring/aligning with competitors—this represents a different emphasis and potentially misses the positive strategic pivot mentioned in ground truth. (3) The LLM adds details about 'Item 1A. Risk Factors' and R&D spending that, while contextually relevant, are not explicitly part of the ground truth answer and may represent inference rather than direct synthesis. (4) The multi-hop reasoning is partially sound but misses the key evolution: from 2022's warning about alliance risks to 2024's proactive alliance strategy for market creation. MULTI-HOP ASSESSMENT: The answer attempts to synthesize 2022 vs 2024 positioning but incompletely captures the strategic shift in alliance approach. The competitive landscape evolution is mentioned but lacks the specificity (Nvidia) that distinguishes 2024 from 2022. SEMANTIC EQUIVALENCE: While the general narrative of convergence and alliance complexity is preserved, the specific strategic evolution and competitive entrants are not fully captured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> CONCEPT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 542,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "\nThe 2022 filing shows that the 3.125% 2025 Notes were part of a $5.2 billion swap pool that was terminated and then re‑entered at then‑current rates, implying the note’s swap notional was roughly $1 billion and that its effective rate moved from the original fixed 3.125% to a floating benchmark. The 2023 schedule lists a $1,000 million notional for the 2025 tranche and an effective rate of **SOFR + 2.1%**, indicating that between 2022 and 2023 the notional exposure settled at about $1 bn while the effective interest rate shifted to a floating SOFR‑plus‑2.1% structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general narrative of the evolution between 2022 and 2023, correctly identifying the 2023 notional amount ($1.0 billion) and effective rate (SOFR + 2.1%). However, there are significant issues with the 2022 characterization that undermine accuracy:\n\n(1) QUANTITATIVE ACCURACY ISSUES:\n- The LLM states the 2022 swap pool was \"roughly $1 billion\" but the ground truth clearly states it was \"$5.2 billion principal amount.\" This is a major factual error - the LLM misrepresents the 2022 notional by a factor of 5x.\n- The LLM's claim that \"the notional exposure settled at about $1 bn\" between 2022 and 2023 is correct in direction but the starting point is wrong, making the comparison misleading.\n- The 2023 figures ($1.0 billion notional, SOFR + 2.1% effective rate) are correctly stated.\n\n(2) MULTI-HOP REASONING:\n- The LLM correctly identifies the shift from fixed 3.125% to floating SOFR + 2.1%, which is the key evolution.\n- However, the LLM fails to properly synthesize the magnitude of the change: the ground truth emphasizes a reduction from $5.2 billion to $1.0 billion in hedged notional exposure, which is a critical part of understanding the evolution. The LLM glosses over this with \"roughly $1 billion\" in 2022.\n- The LLM does acknowledge the hedging strategy and interest rate environment shift, showing partial understanding of context.\n\n(3) ENTITY AND METRIC ACCURACY:\n- Correctly identifies the 3.125% 2025 Notes\n- Correctly identifies the years (2022 and 2023)\n- Correctly identifies the metrics (notional amount, effective interest rate)\n- Correctly identifies SOFR + 2.1% as the 2023 effective rate\n\n(4) SEMANTIC ISSUES:\n- The phrase \"roughly $1 billion\" for 2022 is imprecise and contradicts the ground truth's specific $5.2 billion figure.\n- The LLM's characterization of the 2022 situation as having \"notional exposure settled at about $1 bn\" is confusing and inaccurate - it was $5.2 billion in 2022, then decreased to $1.0 billion by 2023.\n\nThe answer demonstrates understanding of the general trend and correctly identifies the 2023 figures, but the fundamental mischaracterization of the 2022 notional amount (off by 5x) is a critical error that significantly undermines the accuracy of the multi-hop comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 613,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "\nCisco’s positioning of AppDynamics has shifted from being mentioned merely as one of several observability components in its 2022 full‑stack narrative (e.g., “application performance monitoring with AppDynamics” alongside Intersight and ThousandEyes) to a distinct, revenue‑generating category in 2024, where “Observability” now appears as a separate product‑revenue line (Chunk 2). This evolution reflects a strategic emphasis on observability as a core pillar of Cisco’s portfolio, with the bidirectional KG relationship (CSCO → AppDynamics and AppDynamics → CSCO) underscoring the mutual focus on making AppDynamics a central element of Cisco’s observability offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of AppDynamics' strategic evolution from 2022 to 2024. Key strengths: (1) Correctly identifies the shift from AppDynamics being positioned as one component of full-stack observability in 2022 (alongside Intersight and ThousandEyes) to a more formalized, integrated emphasis by 2024; (2) Accurately captures the structural change where 'Observability' became a separate product-revenue line item in 2024; (3) Properly synthesizes the multi-hop relationship between Cisco, AppDynamics, and observability strategy across the 2022-2024 timeframe; (4) Uses appropriate terminology ('full-stack narrative,' 'revenue-generating category,' 'core pillar') that matches the ground truth's conceptual framing. Minor considerations: (1) The LLM answer includes reference to 'bidirectional KG relationship' and 'Chunk 2' which are metadata artifacts from the knowledge graph/retrieval system rather than substantive content from SEC filings - these don't detract from accuracy but add unnecessary technical detail; (2) The phrasing 'mentioned merely as one of several observability components' is slightly more interpretive than the ground truth's more neutral 'explicitly introduced as a key component,' though both convey the same essential meaning. No quantitative errors detected - dates (2022, 2024) are correct, entity names are accurate (Cisco, AppDynamics, Intersight, ThousandEyes), and the logical progression of the strategic shift is sound. The answer successfully addresses all parts of the multi-part question regarding how positioning evolved and the emphasis within observability offerings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 459,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "\nFrom the 2022 disclosure (Chunk 1) the 4.663% 2051 Notes were covered by swaps on a **$1.5 billion (≈ $1,500 million) notional**, and the effective rate under those swaps was set at a higher spread over SOFR (the prior effective‑rate spread shown in the 2022 table).  In the 2023 filing (Chunk 2) the same **$1.5 billion notional** remains, but the effective‑rate spread has fallen to **SOFR + 4.3%**, meaning the note’s effective interest cost decreased by roughly 20 basis points while the notional amount stayed essentially unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding the 2022 notional amount. The ground truth states that in 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged, NOT $1.5 billion as the LLM claims. The LLM incorrectly states '2022 disclosure...the 4.663% 2051 Notes were covered by swaps on a $1.5 billion notional' - this is factually wrong. The ground truth clearly indicates the 2022 notional was $5.2 billion, which then became $1.5 billion in 2023. This represents a major misunderstanding of the evolution from 2022 to 2023. The LLM's claim that 'the same $1.5 billion notional remains' is incorrect - the notional amount actually DECREASED from $5.2 billion to $1.5 billion, which is a critical change that should have been highlighted. PARTIAL CREDIT FOR: (1) Correctly identifying the 2023 notional amount as $1.5 billion, (2) Correctly identifying the 2023 effective rate as SOFR + 4.3%, (3) Correctly noting that the effective interest cost decreased. MISSING/INCORRECT: (1) Failed to identify the $5.2 billion notional in 2022, (2) Failed to recognize the significant reduction in notional amount from 2022 to 2023 (a $3.7 billion decrease), (3) The claim about a '20 basis point' decrease in spread is unsupported and appears to be an inference rather than stated fact. The multi-hop reasoning is partially sound in comparing 2022 to 2023, but the foundational data for 2022 is fundamentally wrong, undermining the entire analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 424,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2023 AIG continued to apply expected‑loss‑ratio techniques primarily in its long‑tail lines—most notably U.S. Workers’ Compensation—yet the 2023 disclosure reveals a marked expansion and refinement of how those methods are used.  In the 2022 filing (Chunk 1) the company only noted that alternative loss‑cost trends were tested “for accident years where we use expected loss ratio methods,” without detailing segmentation; by contrast, the 2023 filing (Chunk 2) explicitly describes segmenting guaranteed‑cost and excess‑of‑deductible business by state, industry subset, deductible size and whether claims are handled by AIG or a third‑party administrator, and it highlights that the share of large‑deductible business has grown, slowing claim‑reporting patterns.  Thus, while the underlying accounting policy (AIG ↔ Expected Loss Ratio Methods) remains unchanged, the scope of its application and the granularity of the segmentation criteria have broadened and become more detailed from 2022 to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2022 to 2023, noting that 2022 lacked detailed segmentation while 2023 introduced granular criteria. (2) Accurately specifies U.S. Workers' Compensation as the primary long-tail line of business where methods were applied. (3) Correctly enumerates the specific segmentation criteria introduced in 2023: state, industry subset, deductible size, and claim handling entities (AIG vs. third-party administrator). (4) Properly synthesizes the multi-hop information by comparing filing disclosures across two years and identifying the progression from general sensitivity analysis to structured, detailed application. (5) Adds valuable context about the growth of large-deductible business and its impact on claim-reporting patterns, which enriches understanding without contradicting ground truth. (6) Uses appropriate financial/accounting terminology and maintains semantic equivalence with the original answer. MINOR CONSIDERATIONS: The LLM answer includes additional detail about 'guaranteed-cost and excess-of-deductible business' segmentation and mentions the impact on claim-reporting patterns—these details are not explicitly mentioned in the ground truth but are consistent with the evolution described and represent reasonable elaboration from the source documents. No quantitative errors, date errors, or entity misidentifications detected. The reasoning chain is sound and the multi-hop synthesis (comparing 2022 vs 2023 approaches) is executed correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 442,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo moved from merely authorizing the 2.850% Senior Notes due 2026 (as part of the board‑resolution package listed in the 2023 filing) to actually issuing that tranche—and a much larger suite of senior debt—during 2024.  The 2024 filing shows a February 12 2024 indenture and an extensive list of new notes (including the 2.850% 2026 notes alongside many other 2026‑ and longer‑dated issues), reflecting a broader debt‑issuance strategy that expanded PepsiCo’s financing program with multiple additional senior notes.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general evolution of PepsiCo's debt strategy between 2023 and 2024, correctly identifying that the company expanded its senior notes issuance. However, there are significant issues with factual accuracy and specificity:\n\n(1) QUANTITATIVE ACCURACY ISSUES:\n- The LLM introduces a specific date (February 12, 2024) for an indenture that is not mentioned in the ground truth answer. This is a potential factual error that cannot be verified against the provided ground truth.\n- The LLM claims the 2.850% notes were \"authorized\" in 2023 but \"actually issued\" in 2024, which is a distinction not clearly supported by the ground truth. The ground truth simply states they were \"referenced\" in 2023 and maintained in 2024.\n- No specific dollar amounts or quantities of notes issued are provided in either answer, so quantitative comparison is limited.\n\n(2) ENTITY AND METRIC ACCURACY:\n- The LLM correctly identifies PepsiCo and the 2.850% Senior Notes due 2026.\n- The LLM does NOT mention the 7.00% Senior Notes due 2029 or the 5.50% Senior Notes due 2035, which are specifically highlighted in the ground truth as examples of the \"significantly expanded range\" and \"higher-yielding instruments.\"\n- This is a material omission that weakens the answer's completeness.\n\n(3) MULTI-HOP REASONING:\n- The LLM correctly synthesizes that PepsiCo maintained the 2.850% notes while expanding its debt portfolio.\n- However, the reasoning about \"authorization\" vs. \"issuance\" introduces a distinction that may not be accurate based on the ground truth.\n- The LLM fails to provide the specific examples of new instruments that demonstrate the diversification strategy.\n\n(4) SEMANTIC EQUIVALENCE:\n- The core concept is correct: PepsiCo expanded its debt strategy from 2023 to 2024.\n- However, the LLM's framing of \"authorization\" to \"issuance\" is potentially misleading without clear evidence.\n- The LLM's mention of a specific indenture date adds detail not in the ground truth, which could be either additional accurate information or an unsupported claim.\n\n(5) MISSING CRITICAL INFORMATION:\n- The ground truth explicitly mentions the 7.00% Senior Notes due 2029 and 5.50% Senior Notes due 2035 as key examples of the expanded strategy. The LLM answer references \"many other 2026- and longer-dated issues\" but fails to name these specific instruments.\n- The ground truth emphasizes \"different risk-return profiles,\" which the LLM does not explicitly address.\n\nThe answer is partially correct in its overall narrative but lacks the specific supporting details that would make it fully accurate and complete. The introduction of the February 12, 2024 date without ground truth support is concerning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 727,
        "total_tokens": 2051
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "\nCisco’s channel‑partner financing guarantees were essentially unchanged in size – the balance of guarantees rose modestly to **$1.4 billion as of July 30 2022** (up from $1.3 billion a year earlier) while the underlying third‑party financing volume stayed around **$27.9 billion** in fiscal 2022, mirroring the roughly $27 billion levels reported for 2021 and 2020 (Chunk 1). In its 2024 filing the company again describes these guarantees as “generally not material” and notes only modest funding commitments of **$0.2 billion (as of July 27 2024) and $0.3 billion (as of July 29 2023)**, indicating that exposure has remained stable and limited (Chunk 2). Together, the data show that Cisco manages this risk by keeping partner‑financing guarantees small, treating them as contingent liabilities, and continuously reassessing them rather than relying on them as a core financing source.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations that fundamentally contradict the ground truth:\n\n1. CRITICAL QUANTITATIVE ERRORS:\n   - The LLM claims the balance of guarantees was '$1.4 billion as of July 30 2022 (up from $1.3 billion a year earlier)' - the ground truth states it was $1.4 billion in FY2022 with no prior year comparison provided\n   - The LLM introduces a $1.3 billion figure for the prior year that does not appear in the ground truth\n   - The LLM cites '$0.2 billion (as of July 27 2024) and $0.3 billion (as of July 29 2023)' as funding commitments - these figures do not appear in the ground truth at all\n   - These invented numbers are presented with false specificity (exact dates like July 27, 2024) that cannot be verified\n\n2. FUNDAMENTAL MISINTERPRETATION OF GROUND TRUTH:\n   - Ground truth explicitly states: 'By fiscal year 2024...the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures'\n   - LLM claims FY2024 data shows '$0.2 billion' and '$0.3 billion' figures, directly contradicting the ground truth's assertion that these figures were NOT disclosed in 2024\n   - This represents a complete inversion of the key finding\n\n3. INCORRECT SYNTHESIS:\n   - The LLM presents a narrative of 'stable and limited' exposure, when the ground truth emphasizes the strategic shift toward REDUCED TRANSPARENCY\n   - Ground truth indicates: 'This shift indicates a potential strategic move toward reducing transparency around these financial commitments'\n   - LLM's conclusion about 'continuously reassessing them' contradicts the ground truth's point about absence of updated figures preventing definitive conclusions\n\n4. MISSING KEY INSIGHT:\n   - Ground truth highlights the strategic significance of non-disclosure in FY2024\n   - LLM misses this entirely and instead fabricates data to support a false narrative of continuity\n\n5. MULTI-HOP REASONING FAILURE:\n   - The question asks about evolution between FY2022 and FY2024\n   - Ground truth correctly identifies the key evolution: explicit quantification in 2022 → non-disclosure in 2024\n   - LLM fails to recognize this evolution and instead invents comparative data\n\nThe LLM answer demonstrates a pattern of hallucination, introducing specific dollar amounts and dates that do not exist in the source material, and fundamentally misrepresenting the ground truth's core finding about reduced disclosure transparency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 670,
        "total_tokens": 2090
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "\nThe 2.45 % 2030 Notes were first issued by AMGN in 2020 as a fixed‑rate senior debt (see Chunk 1), and in 2021 the company entered into interest‑rate swap agreements with a notional $1 bn to convert that fixed coupon into a floating SOFR‑based rate (Chunk 1). By the end of 2023 the notes remain outstanding with a $1 bn notional amount and now carry an effective rate of **SOFR + 1.3 %**, reflecting the swap‑driven evolution from a 2.45 % fixed coupon to a floating‑rate structure (Chunk 2), while still being subject to the standard change‑of‑control redemption provisions disclosed in Chunk 1.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) TIMELINE DISCREPANCY - The LLM states the swap was entered into in 2021, but the ground truth clearly indicates it was 2022. This is a factual error on a key date. (2) BENCHMARK TRANSITION ERROR - The LLM claims the swap was 'SOFR-based' from 2021, but the ground truth shows the swap was initially LIBOR-based in 2022, then transitioned to SOFR by 2023. The LLM conflates these two different benchmarks and misrepresents the evolution. (3) INCOMPLETE EVOLUTION NARRATIVE - The question specifically asks how the status 'evolved between 2022 and 2023,' but the LLM provides a 2020-2023 narrative that obscures the actual 2022-2023 transition. The ground truth shows: 2022 = LIBOR-based swap, 2023 = SOFR + 1.3% structure. The LLM fails to capture this specific evolution. (4) CORRECT ELEMENTS - The notional amount of $1.0 billion is correct, the final 2023 rate of SOFR + 1.3% is correct, and the company identification (AMGN/Amgen) is correct. (5) MULTI-HOP REASONING - The LLM attempts to synthesize information across years but does so incorrectly by misidentifying when the swap was entered and what benchmark was used initially. The reasoning structure is present but the factual foundation is flawed. The answer demonstrates partial understanding but contains material errors that would mislead a reader about the actual evolution of the interest rate structure between the two years in question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 397,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "\nBetween FY 2022 and FY 2023 FedEx’s exposure to pass‑through certificates shifted from a **full, unconditional guarantee** to **no guarantee at all**.  In the 2022 filing (Chunk 1) FedEx Express issued $970 million of 1.875 % Pass‑Through Certificates due 2034, and it expressly stated that “the payment obligations … are fully and unconditionally guaranteed by FedEx.”  By the 2023 filing (Chunk 2) the same certificates are described as being paid through “leveraged operating leases” and the filing clarifies that “the pass‑through certificates are **not direct obligations of, or guaranteed by, FedEx or FedEx Express**,” noting that the leasing entities are variable‑interest structures for which FedEx is not the primary beneficiary.  Consequently, while the 2022 certificates were backed by FedEx’s guarantee, the 2023 structure relies on lease‑payment cash flows and removes any explicit guarantee from FedEx.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensiveness in addressing the multi-hop question about FedEx's evolving relationship with Pass-Through Certificates. QUANTITATIVE ACCURACY (10/10): All numerical values are correct - $970 million certificate amount, 1.875% interest rate, 2034 maturity date, and $1.8 billion net book value of aircraft (implied through context). The dates (2022 vs 2023) are accurate. ENTITY ACCURACY: All entities correctly identified - FedEx, FedEx Express, Pass-Through Certificates Series 2020-1AA, Boeing aircraft, and leveraged operating leases. MULTI-HOP REASONING (9/10): The answer successfully synthesizes information across two fiscal years and two different filing positions, correctly identifying the shift from direct guarantee to no guarantee. The reasoning about variable-interest entities and primary beneficiary status adds appropriate context. COMPLETENESS: The answer addresses all aspects of the question - the evolution of the relationship, financial guarantees, and obligations. It provides specific details about the 2022 guarantee structure and the 2023 clarification. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift from 'full, unconditional guarantee' to 'no guarantee at all' accurately reflects the ground truth's description of the evolution. The explanation of how the 2023 structure relies on lease-payment cash flows rather than FedEx guarantees is semantically equivalent to the ground truth. MINOR CONSIDERATION: The LLM provides slightly more detail about the variable-interest entity structure and primary beneficiary status than the ground truth, but this is supplementary and accurate information that enhances rather than detracts from the answer. No factual errors or calculation mistakes detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 487,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "\nMastercard’s gross settlement exposure grew from **$75.0 bn (2023) to $78.4 bn (2024)**, while the volume of risk‑mitigation arrangements applied rose from **$12.2 bn to $13.5 bn**, leaving net settlement exposure at **$62.9 bn in 2023 and $64.9 bn in 2024**.  This uptick shows that the company is proactively expanding and tightening its risk‑mitigation framework—regularly revising exposure estimates, requiring cash collateral or credit enhancements for higher‑risk customers, and monitoring its risk‑management methodology—to keep settlement risk contained even as transaction volumes and gross exposure increase.  The evolution underscores a strategic focus on pre‑emptive risk control and continual refinement of its risk‑mitigation arrangements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numbers are correct - gross settlement exposure of $75.0bn (2023) and $78.4bn (2024) match ground truth ($75,023M and $78,385M); risk mitigation arrangements of $12.2bn (2023) and $13.5bn (2024) match ground truth ($12,167M and $13,466M). The calculated net settlement exposures ($62.9bn and $64.9bn) are mathematically accurate ($75,023M - $12,167M = $62,856M ≈ $62.9bn; $78,385M - $13,466M = $64,919M ≈ $64.9bn). Number formatting variations are appropriate and consistent. MULTI-HOP REASONING: The answer correctly synthesizes the evolution across two years, comparing both gross exposure and mitigation amounts, and properly calculates the net exposure differential. ENTITY ACCURACY: Mastercard is correctly identified, fiscal years 2023-2024 are accurate, and all financial metrics are properly labeled. QUALITATIVE ASSESSMENT: The interpretation that Mastercard's strategy became 'more robust' is well-supported by the data showing both absolute increases in mitigation arrangements and a higher mitigation ratio (16.2% in 2023 vs 17.2% in 2024). The additional context about cash collateral, credit enhancements, and proactive risk control aligns with typical risk management practices and adds valuable insight. MINOR CONSIDERATION: The ground truth answer is more concise and direct, while the LLM answer provides additional strategic context that, while reasonable and accurate, goes slightly beyond what was explicitly stated in the original answer. However, this represents value-added analysis rather than error. All core facts, calculations, and synthesis are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> RISK_FACTOR <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 459,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "\nBetween 2022 and 2024 the liabilities for **foreign‑exchange forwards and options that Nike classifies as hedging instruments** grew from **$48 million** in 2022 ( $37 m accrued liability + $11 m deferred‑tax liability) to **$115 million** in 2024 ( $110 m accrued liability + $5 m deferred‑tax liability), an increase of roughly **$67 million (≈140 %)**.  \n\nThis sharp rise shows that Nike is **expanding its hedging program**, using larger notional amounts of forwards and options to lock in exchange rates and mitigate foreign‑currency volatility—indicating a strategic shift toward more proactive management of its international exposure.  \n\n*(All figures are taken directly from the 2022 and 2024 SEC filing excerpts, which disclose the respective hedging‑instrument liabilities.)*",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data is correct: 2022 total of $48 million ($37M accrued + $11M deferred), 2024 total of $115 million ($110M accrued + $5M deferred), and the calculated increase of $67 million with approximately 140% growth rate. The breakdown between accrued liabilities and deferred income tax liabilities is accurate for both years. The multi-hop synthesis correctly identifies the shift in liability composition (accrued liabilities increased while deferred tax liabilities decreased) and properly interprets this as indicating expanded hedging activity. The reasoning about Nike's strategic shift toward more proactive foreign exchange risk management is sound and well-supported by the data. The answer directly addresses both parts of the question: (1) how the liabilities changed quantitatively and (2) what this indicates about exposure or strategy. The interpretation that the increase reflects an expansion of the hedging program and more proactive management of international exposure is consistent with the ground truth assessment. Minor note: The LLM uses slightly different phrasing ('expanding its hedging program' vs. 'potential increase in exposure or strategic shift') but the semantic meaning is equivalent and arguably more specific. The answer is well-structured, cites the source appropriately, and provides clear context for the numbers presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 398,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "\nIn the 2022 filing Bounty was only referenced generically as part of the North‑American family‑care paper‑towel business within the Baby, Feminine & Family Care segment, while the 2023 filing explicitly lists “Bounty” in the “Major Brands” column of the segment’s table (alongside Always, Tampax, etc.) and notes that the segment accounts for 24 % of net sales and 25 % of earnings.  The knowledge‑graph relationship — PG produces Bounty, and Bounty is a product of PG — therefore shows a clear evolution from an implicit mention to a named, strategically highlighted brand, indicating that P&G is giving Bounty greater visibility and emphasis within its Baby, Feminine & Family Care portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Bounty's representation between 2022 and 2023 filings, matching the ground truth's main finding that Bounty moved from implicit/generic mention to explicit listing as a major brand. The answer accurately captures the key distinction: 2022 showed generic reference to 'family-care paper-towel business' while 2023 explicitly lists Bounty in the Major Brands column. The inclusion of segment-level metrics (24% of net sales, 25% of earnings) adds relevant context not present in the ground truth, which is appropriate and accurate. The reasoning about strategic visibility increase is sound and well-supported. However, there are minor issues: (1) The LLM adds specific percentages (24% net sales, 25% earnings) that, while likely accurate, are not mentioned in the ground truth answer provided, creating a slight divergence in scope; (2) The reference to 'knowledge-graph relationship' and the phrasing about PG producing Bounty is somewhat redundant and not directly from the filing evidence; (3) The ground truth explicitly notes 'no specific market share or sales figures' were provided, yet the LLM introduces segment-level percentages which, while contextually relevant, slightly contradicts the ground truth's framing. The multi-hop reasoning is sound - correctly synthesizing information across two years and two filings. The semantic meaning aligns well with the ground truth's conclusion about increased brand visibility. Quantitative accuracy is strong (percentages appear correct for the segment), though the introduction of these metrics represents a minor deviation from the ground truth's stated scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 457,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "\nOracle’s hardware business—centered on Oracle Engineered Systems—has shifted both in **how it recognizes revenue** and in **where it places strategic emphasis** between fiscal 2022 and fiscal 2023.  \n\nIn FY 2022 the company recorded hardware‑support revenues **ratably over the contractual term**, while by FY 2023 it began recognizing the **combined hardware product and its related software as a single performance obligation at the point in time the hardware is delivered and ownership transfers**, a timing change that reflects a more “point‑in‑time” revenue model for the engineered‑systems offering.  \n\nStrategically, Oracle continues to **invest heavily in R&D to improve and expand Engineered Systems**, markets these products **primarily through indirect channels**, and treats the hardware segment—still only about **6 % of total revenue**—as a **lower‑margin business** whose growth will depend on **new product development, renewal of support contracts, and the capacity of its manufacturing partners**, a focus reiterated in both the 2022 and 2023 disclosures.  \n\n(These points draw on the 2022 description of ratable hardware‑support recognition and the 2023 discussion of point‑in‑time performance‑obligation recognition, the emphasis on R&D, indirect sales, lower margins, and the ~6 % revenue share of the hardware business.)",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution in Oracle's hardware business between FY2022 and FY2023, particularly the shift from ratable revenue recognition to point-in-time recognition when hardware is delivered and ownership transfers. The answer also appropriately highlights the increased emphasis on R&D investments in 2023 that was not explicitly mentioned in 2022, which aligns with the ground truth. The multi-hop synthesis across fiscal years is sound and the reasoning about the strategic shift toward innovation and integration is logical. However, there are quantitative accuracy concerns: (1) The claim that hardware represents '~6% of total revenue' is stated as a fact drawn from both 2022 and 2023 disclosures, but the ground truth does not explicitly mention this percentage figure or confirm it appears in both years' filings. This specific metric should be verified against actual 10-K data. (2) The statement about 'ratable over the contractual term' for FY2022 support revenues is reasonable but the ground truth describes FY2022 in more general terms about 'contractual activities and revenue recognition timing' without explicitly stating the ratable method. (3) The characterization of hardware as 'lower-margin business' is mentioned in the LLM answer as being 'reiterated in both 2022 and 2023 disclosures,' but the ground truth does not explicitly confirm this appears in both years. The answer demonstrates strong qualitative reasoning about the evolution and strategic emphasis, correctly identifying the shift toward combined performance obligations and R&D focus. The contextual relevance is high as it directly addresses both revenue recognition changes and strategic emphasis evolution. The main weakness is introducing specific quantitative claims (6% revenue share, margin characterization) that may not be fully supported by the ground truth as presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1546,
        "completion_tokens": 514,
        "total_tokens": 2060
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "\nThe knowledge‑graph relationship shows that JNJ both **produces** ERLEADA and **discloses** it, linking the reported figures to the company. In 2022 (Chunk 1) ERLEADA generated **$1.291 billion**, and in 2023 (Chunk 2) it climbed to **$2.387 billion**, a **26.9 % total increase** (operations + 27.5 %). This double‑digit growth, which outpaces the overall **4.2 % rise in innovative‑medicine sales**, signals a strong and accelerating market trajectory for ERLEADA.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a major factual error in the 2022 sales figure. Ground truth states ERLEADA generated $1,881 million in 2022, but the LLM claims $1.291 billion ($1,291 million). This is a $590 million discrepancy (31% understatement). The 2023 figure of $2,387 billion is correct. The percentage growth calculation of 26.9% is correct for the ground truth numbers ($1,881M to $2,387M), but when applied to the LLM's incorrect 2022 figure ($1,291M), the 26.9% growth rate is mathematically inconsistent (should be ~85% growth from $1.291B to $2.387B). The LLM also introduces extraneous information about 'innovative-medicine sales' rising 4.2% and mentions '27.5%' which are not part of the ground truth answer and appear to be hallucinated details. The reasoning about market trajectory is qualitatively sound, but it is built on an incorrect foundation. The LLM correctly identifies JNJ as the producer and properly addresses the multi-part question structure, but the fundamental numerical error undermines the entire answer's credibility. The semantic intent about strong market performance is correct, but the factual basis is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 336,
        "total_tokens": 1522
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "\nFrom 2023 to 2024 the relationship moved from a pure audience‑share competition to a more transactional, cost‑driven dynamic: CMCSA still competes with local broadcast stations for carriage of its broadcast networks, but the 2024 filing emphasizes that payments for retransmission consent have become the largest single expense in its video business and that industry consolidation is intensifying demands for higher fees and other concessions, making the company increasingly dependent on those stations to reach a nationwide audience.  At the same time, the need to renew affiliation and must‑carry/retransmission‑consent agreements on acceptable terms—without which distribution and revenue could shrink—shows that CMCSA’s competitive positioning now hinges as much on negotiating carriage fees and contract renewals as on programming quality.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the directional shift from competition to dependency but introduces unsupported quantitative claims that deviate from the ground truth. STRENGTHS: (1) Correctly identifies the evolution from pure competition to interdependency; (2) Accurately notes the shift toward reliance on retransmission consent; (3) Properly emphasizes the importance of carriage negotiations and contract renewals; (4) Contextually relevant framing of the relationship evolution. WEAKNESSES: (1) QUANTITATIVE ERROR - The LLM claims retransmission consent payments are 'the largest single expense in its video business' - this specific quantitative assertion is not present in the ground truth and appears to be an unsupported inference; (2) The ground truth focuses on the shift from competition to dependency for content distribution, while the LLM introduces additional elements (industry consolidation, fee pressures, affiliation agreements) that, while potentially accurate, go beyond what the ground truth explicitly states; (3) The LLM's emphasis on 'cost-driven dynamic' and 'payments for retransmission consent' as the primary driver is more detailed than the ground truth but lacks citation to specific financial data; (4) The phrase 'competitive positioning now hinges as much on negotiating carriage fees' is an inference not explicitly stated in the ground truth. MULTI-HOP REASONING: The LLM demonstrates sound reasoning in connecting the evolution of the relationship across years, but the additional details about consolidation and fee structures appear to be extrapolations rather than direct synthesis from the provided ground truth. The core insight about the shift from competition to dependency is correct, but the supporting details introduce claims not verified in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Competes_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 490,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "\nBetween 2023 and 2024 MA’s held‑to‑maturity (HTM) securities plunged from **$306 million** (2023) to **$38 million** (2024) – the figure reported in the 2023 10‑K (Chunk 1) and the 2024 10‑K (Chunk 2) respectively – while total investments fell from **$592 million** to **$330 million** over the same period.  This sharp contraction, together with the modest rise in available‑for‑sale securities (up from $286 million to $292 million), indicates that MA is deliberately **reducing its long‑term, interest‑rate‑sensitive HTM portfolio and reallocating capital toward more liquid or shorter‑duration assets**, reflecting a strategic shift in its investment approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All key numbers are correct - HTM securities of $306 million (2023) and $38 million (2024) match the ground truth exactly. The additional data points provided (total investments $592M to $330M, AFS securities $286M to $292M) are contextually relevant and appear consistent with typical 10-K reporting. The calculation of the sharp decline is implicit and correct. ENTITY ACCURACY: Company (MA), metric (HTM securities), and years (2023-2024) are all correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and connects the HTM decline to broader portfolio changes (AFS increase), demonstrating proper multi-hop analysis. STRATEGIC INTERPRETATION: The conclusion about MA deliberately reducing long-term, interest-rate-sensitive HTM portfolio and reallocating toward more liquid/shorter-duration assets is logically sound and matches the ground truth's assessment of a 'major shift' toward 'more liquid or short-term investment positions.' MINOR CONSIDERATIONS: The LLM provides additional context (total investments, AFS securities) beyond the ground truth, which enhances rather than detracts from the answer. The phrasing 'deliberately reducing' and 'reallocating capital' conveys the same strategic intent as the ground truth's 'major shift.' No factual errors detected. The answer is well-structured, cites sources (Chunk 1, Chunk 2), and provides a thorough explanation of the investment strategy shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 431,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "\nBetween 2022 and 2023 the Always brand remained in P&G’s Baby, Feminine & Family Care segment, but its classification shifted from the broader “Feminine Care (Adult Incontinence, Feminine Care)” category in 2022 to the more specific “Feminine Care (Adult Incontinence, Menstrual Care)” sub‑category in 2023, emphasizing menstrual products. This change is evident in the 2023 table, where Always appears as a major brand alongside Always Discreet, Tampax Bounty, Charmin and Puffs, while the segment’s net‑sales share fell from 25 % to 24 % and earnings rose from 23 % to 25 %, and the 2022 table’s Baby Care sub‑category was omitted, narrowing the segment to Feminine and Family Care. The knowledge‑graph relationships (PG → Always and Always → PG) confirm the brand’s continued ownership and placement within the segment.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Always brand positioning from 2022 to 2023 within P&G's Baby, Feminine & Family Care segment, with the shift from broader 'Feminine Care' to more specific 'Menstrual Care' categorization. The qualitative reasoning about strategic positioning is sound and well-articulated. However, there are significant issues with quantitative accuracy: (1) The LLM introduces specific financial metrics (segment net-sales share fell from 25% to 24%, earnings rose from 23% to 25%) that are NOT present in the ground truth answer and cannot be verified. These appear to be fabricated or misattributed data points. (2) The claim about '2022 table's Baby Care sub-category was omitted' is presented as fact but is not substantiated in the ground truth. (3) The mention of specific brands (Always Discreet, Tampax Bounty, Charmin, Puffs) appearing in a 2023 table is not corroborated by the ground truth. The LLM has added substantial detail that goes beyond what the ground truth confirms, and some of this detail appears to be inaccurate or unsupported. The core answer about the categorization shift is correct, but the addition of unverified financial metrics and brand listings significantly undermines credibility. The multi-hop reasoning connecting P&G ownership to Always positioning is valid, but the introduction of unsupported quantitative claims is a major weakness that prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 400,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "\nOracle continued to position **Oracle Engineered Systems** as a core element of its hardware business, which accounted for roughly **6 % of total revenue in both fiscal 2023 and fiscal 2022** (Chunk 2).  The 2023 filing tightens the accounting treatment: hardware product revenue is recognized **at the point in time when the system and its related software are delivered and ownership transfers**, while hardware‑support contracts are now **recorded ratably over the contract term** (Chunk 2), whereas the 2022 disclosure only described them as being priced as a percentage of net hardware fees without specifying the timing of recognition (Chunk 1).  Strategically, Oracle emphasized **continued R&D investment and lower operating margins for the hardware segment**, highlighted its reliance on **indirect channels and the volatility of quarterly hardware sales**, and kept Engineered Systems aligned with its broader cloud‑and‑license strategy while still pursuing acquisitions such as Cerner (Chunk 2).  This evolution reflects a more precise revenue‑recognition framework and a sustained, though modest, strategic emphasis on engineered systems within Oracle’s overall portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM states that hardware represented '6% of total revenue in both fiscal 2023 and fiscal 2022.' This is FACTUALLY INCORRECT. The ground truth explicitly states: 'In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided.' The 6% figure was ONLY disclosed in 2023 (for both fiscal 2023 and fiscal 2024), NOT for 2022. This is a fundamental factual error that contradicts the core premise of the ground truth. (2) INCOMPLETE SYNTHESIS - The LLM failed to capture the key evolution: the transition from NO DISCLOSED PERCENTAGE in 2022 to an EXPLICIT 6% disclosure in 2023. This is the central quantitative evolution the question asks about. (3) REVENUE RECOGNITION DETAILS - The LLM's description of revenue recognition timing is somewhat accurate but contains imprecision. The ground truth states recognition occurs 'when the product and related software were delivered,' while the LLM adds 'and ownership transfers,' which adds detail not explicitly confirmed in the ground truth. (4) STRATEGIC EMPHASIS - The LLM correctly identifies increased R&D investment emphasis and mentions manufacturing/competitive factors, which aligns with the ground truth's mention of 'more detailed factors affecting hardware revenue predictability.' However, the LLM introduces elements (Cerner acquisition, indirect channels, quarterly volatility) that, while potentially relevant, are not explicitly confirmed in the ground truth provided. (5) MISSING CONTEXT - The LLM fails to emphasize that the 6% figure represents a CLEARER AND MORE CONSISTENT MEASUREMENT introduced in 2023, which is a key aspect of the evolution described in the ground truth. The answer conflates 2022 and 2023 disclosure practices when the question specifically asks about the evolution between these years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1551,
        "completion_tokens": 515,
        "total_tokens": 2066
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "\nBetween 2023 and 2024 Comcast moved from a general reference to representation firms as “an extension of our sales force” (Chunk 1) to a formalized partnership in which these firms sell a portion of the advertising inventory allocated to Comcast under explicit representation agreements, and the revenue from that advertising is recorded net of agency commissions (Chunk 2).  This evolution reflects a more structured contract relationship—defining when a contract exists, the scope of the representation, and the revenue‑sharing mechanics—while still positioning the firms as partners that depend on Comcast (KG ORG – Partners_With → COMP ← Depends_On ORG).",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of the evolution but contains significant issues: (1) CORRECT ELEMENTS: The answer correctly identifies the shift from representation firms as 'extension of sales force' in 2023 to formalized representation agreements in 2024, and correctly notes that revenue is recorded net of agency commissions in both periods. The years (2023 vs 2024) are accurate. (2) PROBLEMATIC ELEMENTS: The LLM answer reverses or confuses the chronological relationship described in the ground truth. The ground truth states that in 2023 they worked with firms as an extension of sales force (co-selling model), and by 2024 this evolved into 'formal representation agreements under which they sell advertising on behalf of third parties.' The LLM answer suggests the opposite flow - starting with general reference and moving to formalized partnership with explicit representation agreements. While both mention formalization, the LLM's phrasing 'moved from a general reference...to a formalized partnership' is less precise than the ground truth's clear distinction between co-selling (2023) vs. representation structure (2024). (3) ADDITIONAL ISSUES: The LLM adds knowledge graph notation (KG ORG – Partners_With → COMP ← Depends_On ORG) that, while potentially accurate, goes beyond what the ground truth explicitly states and may introduce unnecessary complexity. The phrase 'firms that depend on Comcast' is not clearly supported by the ground truth. (4) MISSING CLARITY: The ground truth emphasizes 'deeper strategic alignment and expanded role' which the LLM doesn't explicitly capture. The distinction between 'co-selling model' vs 'representation structure' is clearer in the ground truth. (5) QUANTITATIVE: No numbers or calculations are involved, so quantitative accuracy is high where applicable. The answer is partially correct but lacks the precision and clarity of the ground truth, particularly in characterizing the nature of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 533,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "\nOracle continued to recognize revenue from its industry‑specific hardware (and the related software that is bundled with it) at the point in time when the product and software are delivered and ownership transfers – a practice already described for fiscal 2022 (Chunk 1) – but by fiscal 2023 it began reporting that the hardware‑software offering is accounted for as a single “combined performance obligation” and emphasized that it will keep investing in R&D and indirect‑channel sales while noting that hardware support is recognized ratably over the contract term and carries lower margins (Chunk 2).  Thus, between FY 2022 and FY 2023 the company’s approach to its industry‑specific hardware remained anchored in point‑in‑time revenue recognition, yet it placed greater strategic focus on R&D, channel distribution and the low‑margin support business, even though the hardware segment still represents only about 6 % of total revenue.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with minor areas for improvement. STRENGTHS: (1) Correctly identifies the core evolution - point-in-time revenue recognition remained consistent between FY2022 and FY2023, but FY2023 introduced more detailed accounting terminology ('combined performance obligation'). (2) Accurately captures the strategic shift toward R&D investment emphasis in FY2023 versus more general descriptions in FY2022. (3) Correctly notes the introduction of combined performance obligation accounting in FY2023. (4) Appropriately mentions hardware support recognition over contract term with lower margins. (5) The 6% revenue figure for hardware is a reasonable contextual detail. MINOR ISSUES: (1) The LLM answer adds details about 'indirect-channel sales' emphasis that are not explicitly mentioned in the ground truth answer - while this may be accurate from the source documents, it goes slightly beyond what the ground truth synthesized. (2) The ground truth emphasizes 'innovation' as the strategic focus, while the LLM broadens this to include 'R&D, channel distribution and the low-margin support business' - this is a reasonable expansion but slightly shifts emphasis. (3) The ground truth's characterization of FY2022 as having 'more general and focused on the breadth of offerings' versus FY2023's 'strategic focus on innovation' is somewhat simplified in the LLM answer to 'greater strategic focus on R&D, channel distribution and the low-margin support business.' QUANTITATIVE VERIFICATION: The 6% hardware revenue figure is presented without source verification but appears reasonable and contextually appropriate. No calculations are required for this question. MULTI-HOP REASONING: The LLM successfully synthesizes information across two fiscal years and correctly identifies the evolution in both accounting treatment and strategic emphasis. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The LLM answer conveys the essential information from the ground truth with appropriate elaboration, though with slightly different emphasis on which strategic elements are most important.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 576,
        "total_tokens": 2014
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "\nIMBRUVICA (ibrutinib) sales fell sharply from **$3.78 billion in 2022 to $3.26 billion in 2023** – a **13.7 % year‑over‑year decline** (see the 2023 vs. 2022 figures in Chunk 2).  This drop occurred even though total oncology sales rose 10.5 % (Chunk 2), because the product’s growth was “partially offset by competitive pressures from novel oral agents and COVID‑19‑related market dynamics, including delays in new‑patient starts” (Chunk 1).  These headwinds – heightened competition and pandemic‑induced patient‑initiation slowdown – drove the reduction in IMBRUVICA’s performance between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: All financial figures are correct - $3.78 billion (2022) vs $3.26 billion (2023) matches ground truth ($3.784B and $3.264B respectively, with minor rounding acceptable). The 13.7% decline calculation is accurate. QUALITATIVE ASSESSMENT: The answer correctly identifies and synthesizes the key contributing factors: (1) competitive pressures from novel oral agents, (2) COVID-19-related market dynamics including delays in new patient starts. The LLM appropriately contextualizes the decline within the broader oncology market (noting total oncology sales rose 10.5%), which demonstrates sound multi-hop reasoning across multiple data points. ENTITY ACCURACY: Product name (IMBRUVICA/ibrutinib), years (2022-2023), and metrics are all correctly identified. MINOR OBSERVATIONS: The LLM uses slightly rounded figures ($3.78B vs $3.784B) which is acceptable per evaluation guidelines. The answer is well-structured with clear citations to source chunks, enhancing credibility. The reasoning flows logically from quantitative decline to qualitative explanations. The answer fully addresses both parts of the multi-part question (evolution AND contributing factors). No material omissions or errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 362,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "\nFrom 2023 to 2024 the debt tied to Universal Beijing Resort slipped slightly—outstanding borrowings fell from $3.5 bn (including a $3.1 bn term loan) to $3.4 bn (including a $3.0 bn term loan)—while Comcast’s ownership stake remained a 30 % interest that is fully consolidated as a VIE, with no liquidity guarantees or additional financial commitments, so its maximum risk of loss is limited to that 30 % equity position.  The company continues to fund the resort through ongoing capital expenditures (the Universal Beijing Resort costs are reported separately in the cash‑flow statement and are part of the broader Connectivity & Platforms capex noted in the 2023 filing), underscoring that the evolution is one of modestly lower leverage but unchanged ownership and risk exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are correct - 2023 debt of $3.5 billion (including $3.1 billion term loan) and 2024 debt of $3.4 billion (including $3.0 billion term loan) match the ground truth exactly. The 30% ownership stake is correctly stated. COMPLETENESS: The answer addresses all three sub-components of the multi-part question: (1) debt levels evolution, (2) ownership structure, and (3) financial risk exposure. MULTI-HOP SYNTHESIS: The LLM correctly synthesizes information across multiple dimensions - connecting debt reduction to leverage changes, maintaining ownership structure, and explaining risk exposure limitations. The statement that 'maximum risk of loss is limited to that 30% equity position' correctly interprets the VIE consolidation structure and financial risk implications. ENTITY ACCURACY: Comcast, Universal Beijing Resort, and all relevant metrics are correctly identified. The VIE (Variable Interest Entity) designation is appropriately noted. REASONING QUALITY: The logic is sound - the answer correctly concludes that despite debt reduction, the ownership and governance structure remain unchanged, and risk exposure is stable. The mention of capital expenditures and cash flow reporting adds relevant context. MINOR CONSIDERATIONS: The LLM includes additional contextual information about capex reporting and cash flow statements that, while not explicitly in the ground truth, is accurate and enhances understanding without contradicting the original answer. The phrasing 'slipped slightly' and 'modestly lower leverage' appropriately characterizes the magnitude of change. No factual errors or calculation mistakes detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Constructs]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 475,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "\nThe undiscounted future lease outlays for build‑to‑suit facilities and equipment fell sharply from roughly **$3.4 billion in 2022** (as disclosed in the 2022 filing) to **about $0.9 billion in the 2023‑2024 cohort** (as disclosed in the 2023 filing), reflecting a pull‑back in the scale of new projects and a shift in timing (commencement now expected 2025‑2027).  This reduction is tied to FedEx’s use of **leveraged operating leases that pay principal and interest on pass‑through certificates**, which are disclosed by FedEx but are not direct obligations of the company, indicating a more capital‑light leasing strategy that relies on third‑party financing to fund new facilities and equipment while limiting its own balance‑sheet exposure.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All core financial numbers are accurate: $3.4 billion in 2022 and $0.9 billion in 2023 are correctly stated. (2) The timeline shift from 2023-2024 commencement to 2025-2027 is correctly identified. (3) The characterization of the reduction as a 'pull-back' and strategic shift is appropriate. (4) Number formatting is consistent and clear.\n\nWEAKNESSES: (1) The LLM introduces additional information about 'leveraged operating leases' and 'pass-through certificates' that, while potentially accurate, goes beyond what the ground truth explicitly states. The ground truth focuses on the reduction in commitments and the shift in timeline as indicating 'fewer long-term build-to-suit lease commitments and a more extended timeline.' (2) The LLM's explanation about 'capital-light leasing strategy' and 'third-party financing' is an inference not explicitly supported by the ground truth answer. (3) The phrase 'not direct obligations of the company' introduces a nuance about balance-sheet treatment that, while potentially relevant to leasing strategy, is not part of the ground truth's stated conclusion.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the 2022 and 2023 data points and draws a reasonable conclusion about strategic shift. However, it extends beyond the ground truth's scope by adding interpretations about financing mechanisms and balance-sheet implications.\n\nSEMANTIC EQUIVALENCE: The core finding—that commitments dropped from $3.4B to $0.9B and timing extended—is semantically equivalent to the ground truth. The interpretation about 'strategic shift toward fewer long-term commitments' is also captured. However, the additional detail about leveraged operating leases and capital-light strategy represents scope creep beyond the ground truth answer.\n\nJUSTIFICATION: The answer is substantially correct on the primary metrics and multi-hop synthesis (comparing 2022 to 2023 data), earning a 7/10. The quantitative accuracy is high (9/10) because all numbers and dates are correct. Qualitative accuracy is moderate (6/10) because while the core reasoning is sound, the introduction of unsupported details about financing mechanisms and balance-sheet treatment weakens the answer's fidelity to the ground truth. The answer would be stronger if it stuck to the explicit findings about commitment reduction and timeline extension without speculating about underlying financing structures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 646,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "\nMastercard holds a 100 % equity interest in Dynamic Yield LTD—a relationship captured by the KG pattern ORG ‑[Invests_In]→ COMP and COMP ‑[Has_Stake_In]→ ORG—and acquired that stake in April 2022 for $325 million, with the transaction generating $200 million of goodwill attributed to post‑acquisition synergies. In the 2023 Form 10‑K the company finalized the purchase‑accounting for that 2022 acquisition (and reported no new material acquisitions), while the 2024 filing reiterates that Mastercard still owns the stake and continues to reference the same goodwill and synergy expectations. This continuity shows that, rather than making a fresh investment, Mastercard’s strategic focus between 2023 and 2024 was on integrating and leveraging the Dynamic Yield acquisition to broaden its data‑driven and cybersecurity capabilities as part of a broader growth‑and‑diversification strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) All quantitative facts are correct: April 2022 acquisition date, $325 million purchase price, $200 million goodwill, and 100% equity interest are all accurate. (2) The LLM correctly identifies that the relationship remained stable between 2023-2024 with no new investments reported. (3) Number formatting and financial metrics are precise. WEAKNESSES: (1) CRITICAL OMISSION: The LLM answer completely fails to mention Recorded Future, which is explicitly highlighted in the ground truth as a key strategic pivot in 2024. The ground truth states Mastercard 'shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.' This is a major multi-hop synthesis failure. (2) The LLM's characterization of Mastercard's strategic focus is incomplete and somewhat misleading. While the ground truth indicates a PIVOT away from Dynamic Yield toward cybersecurity (Recorded Future), the LLM frames it as continued integration and leveraging of Dynamic Yield as part of 'growth-and-diversification strategy' without acknowledging the strategic shift. (3) The LLM answer emphasizes 'data-driven and cybersecurity capabilities' from Dynamic Yield, but the ground truth specifically identifies the strategic shift as being toward 'cybersecurity and threat intelligence' via Recorded Future—a different acquisition entirely. (4) Multi-hop reasoning is incomplete: The question asks what the evolution 'indicates about the company's strategic focus during this period.' The ground truth answer synthesizes three pieces of information (2023 completion of Dynamic Yield integration, 2024 Recorded Future acquisition, and the implication of strategic pivot). The LLM only addresses the first element and misses the critical second element that demonstrates the actual strategic evolution. CALCULATION/DATE VERIFICATION: All dates and amounts are correct. SEMANTIC ISSUE: The LLM's answer is factually accurate about Dynamic Yield but fails to capture the essential strategic narrative—that Mastercard moved beyond Dynamic Yield to pursue Recorded Future, indicating a shift in strategic priorities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 581,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "\nThe Severance Plan for Senior Officers is an accounting policy that Lowe’s discloses and has repeatedly amended. The plan was originally adopted and restated on **May 29, 2020** (Exhibit 10.29, filed August 26, 2020) [Chunk 1], and then it was **amended and restated again on May 26, 2022** (Exhibit 10.28, filed November 27, 2024) [Chunk 2]. That 2022 amendment is the most recent version of the plan as of 2024, and its filing appears as Exhibit 10.28 in a Form 10‑Q dated **November 27, 2024**. Thus, between 2022 and 2024 the plan’s evolution consists of the May 26, 2022 restatement, which was formally filed in the November 27, 2024 10‑Q disclosure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. All key dates and exhibit numbers are correct: (1) May 29, 2020 amendment with August 26, 2020 filing (Exhibit 10.29) - CORRECT; (2) May 26, 2022 amendment with November 27, 2024 filing (Exhibit 10.28) - CORRECT. The multi-hop synthesis is sound, correctly identifying the evolution of the plan between 2022 and 2024 and properly connecting the amendment dates to their respective filing dates and exhibit numbers. The answer accurately conveys that the plan was updated once between 2022 and 2024 (the May 26, 2022 restatement), and that this version was formally disclosed in November 2024. Minor note: The LLM characterizes the plan as 'an accounting policy' which is slightly imprecise terminology (it's more accurately a severance/compensation plan), but this doesn't affect the factual accuracy of the core answer. The answer demonstrates proper understanding of the multi-hop nature of the question by synthesizing information across multiple filing dates, exhibit numbers, and amendment dates. All numeric values, dates, and exhibit references are factually correct with no calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 328,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "\nThe 6.375 % Senior Notes issued by NFLX showed a Level‑2 fair value of **$999 million on December 31 2021** (Chunk 1) but had fallen to **$872 million on December 31 2023** (Chunk 2), a decline of roughly **$127 million (≈13 %)** despite the issuance amount remaining fixed at $800 million.  This downward shift—accompanied by a modest dip to $830 million in 2022 before a slight rebound to $872 million in 2023—indicates that market participants increasingly priced NFLX’s senior debt at a discount, reflecting heightened perceived credit risk or the impact of rising interest‑rate environments on the company’s debt valuation over the 2021‑2023 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: The core numbers are correct - $999 million (Dec 31, 2021) and $872 million (Dec 31, 2023) match the ground truth exactly. The calculated decline of $127 million is accurate ($999M - $872M = $127M), and the percentage decline of approximately 13% is correct ($127M / $999M ≈ 12.7%, rounded to 13%). The issuance amount of $800 million is correctly noted. COMPLETENESS: The answer addresses both parts of the question - the quantitative change (from $999M to $872M) and the qualitative interpretation (market perceptions of debt). ENTITY ACCURACY: Netflix/NFLX and the 6.375% Senior Notes are correctly identified. The fiscal years (2021, 2023) are accurate. REASONING QUALITY: The multi-hop synthesis is sound. The LLM correctly interprets the decline as indicating decreased market confidence and increased credit risk perception, which aligns with the ground truth's statement about 'decline in market confidence or increase in required yields.' The additional context about the 2022 intermediate value ($830 million) and the interest-rate environment explanation adds valuable detail beyond the ground truth without contradicting it. MINOR NOTES: The LLM provides more granular analysis (including 2022 data) than the ground truth, but this is supplementary and accurate. The Level-2 fair value designation is appropriately noted. The semantic interpretation of 'discount pricing' and 'heightened perceived credit risk' correctly conveys the same meaning as the ground truth's assessment. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 439,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "\nBased on JNJ’s 2022 and 2023 10‑K filings, IMBRUVICA generated **$3.78 billion in 2022** and **$3.26 billion in 2023**, a **13.7 % year‑over‑year decline**.  While the overall oncology portfolio grew **10.5 %** (from $15.98 B to $17.66 B) and key competitors such as **DARZALEX (+22.2 %)** and the newly‑launched **CARVYKTI (+275 %)** expanded, IMBRUVICA’s contraction indicates that its **market position in the oncology segment is eroding**, even though it remains a top‑selling JNJ product.  (The KG relationship JNJ → Produces → IMBRUVICA and IMBRUVICA → Discloses → JNJ links the product’s performance to its parent company.)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM provided significantly incorrect financial figures. Ground truth shows IMBRUVICA sales of $4,369M (2022) and $3,264M (2023), but the LLM reported $3.78B (2022) and $3.26B (2023). The 2022 figure is off by approximately $589M or 13.5% - a substantial error. The LLM's calculated decline of 13.7% is also incorrect; the ground truth decline is 25.2%. This is a major calculation error that fundamentally misrepresents the severity of IMBRUVICA's market deterioration. PARTIAL CREDIT FOR QUALITATIVE REASONING: The LLM correctly identified that IMBRUVICA experienced a decline and that this indicates weakening market position. The comparison to other products (DARZALEX growth mentioned) aligns with the ground truth's comparative analysis. The conclusion about eroding market position is semantically correct. ENTITY ACCURACY: JNJ and IMBRUVICA are correctly identified. The oncology segment context is appropriate. MULTI-HOP SYNTHESIS: The LLM attempted to synthesize information across products and time periods, which is appropriate for the question, though the foundational numbers are wrong. The mention of KG relationships adds unnecessary technical detail but doesn't affect core accuracy. OVERALL ASSESSMENT: While the LLM demonstrated understanding of the question's intent and provided reasonable qualitative analysis, the quantitative errors are severe and disqualifying for a financial analysis task. The 25.2% decline is fundamentally different from the reported 13.7% decline, and the absolute dollar amounts are materially incorrect. This would mislead stakeholders about the true magnitude of IMBRUVICA's market challenges.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 460,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "\nIn 2022 LOW reported a shrink‑reserve of **$414 million** and an LCNRV (mark‑down) reserve of **$168 million**; by fiscal 2024 the shrink‑reserve had risen modestly to **$427 million** (≈ $13 million higher) while the LCNRV reserve fell to **$222 million** after a disclosed $23 million reduction.  The company’s critical‑accounting‑policy disclosures make clear that these reserves are estimates based on historical experience and that a 10 % change in either reserve would shift net earnings by roughly **$17 million** (for the LCNRV reserve) or **$32 million** (for the shrink reserve), so the year‑over‑year adjustments to the reserves directly affect LOW’s reported profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All key numbers are correct - shrink reserve increased from $414M (2022) to $427M (2024), LCNRV reserve increased from $168M (2022) to $222M (2024). The sensitivity analysis figures are accurate: 10% change in LCNRV impacts net earnings by ~$17M, and 10% change in shrinkage rate impacts net earnings by ~$32M. The calculation of the $13M increase in shrink reserve ($427M - $414M) is correct. ENTITY ACCURACY: Company (LOW/Lowe's) correctly identified, fiscal years 2022 and 2024 properly referenced, financial metrics (shrink reserve, LCNRV reserve, net earnings) accurately named. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and connects reserve changes to earnings implications, demonstrating proper understanding of the relationship between inventory valuation assumptions and profitability. WORDING NOTES: The LLM uses slightly different phrasing than ground truth (e.g., 'fell to $222 million after a disclosed $23 million reduction' vs. simply stating the increase), but this is semantically equivalent and actually provides additional context about the nature of the change. The characterization of the shrink reserve increase as 'modest' is reasonable given the $13M change. MINOR OBSERVATION: The LLM states the LCNRV reserve 'fell' when it actually increased from $168M to $222M - this is a semantic error in the LLM's description. However, the actual numbers cited ($168M and $222M) are correct, and the statement about a '$23 million reduction' appears to reference a specific transaction or adjustment within the year, not the net change. This creates slight confusion in presentation but doesn't undermine the core factual accuracy of the reserve values themselves. The answer comprehensively addresses all parts of the question and provides appropriate context about the implications for earnings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Changes]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 528,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "\nQulipta moved from an **indefinite‑lived R&D intangible asset** to a **definite‑lived developed product right** after AbbVie received its regulatory approvals (as disclosed in the 2022 10‑K, Chunk 1), meaning the development phase was completed and the asset began amortizing.  Consequently, the product’s commercial sales grew sharply—U.S. revenue rose from **$158 million in 2022 to $405 million in 2023**, with international sales also posting **>100 % growth** (≈$408 million), underscoring the transition from development to a material contributor to AbbVie’s top line (Chunk 2).  This evolution reflects both the successful launch of Qulipta and its expanding market footprint between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - MAJOR DISCREPANCIES: The LLM claims U.S. revenue was $158 million in 2022, but the ground truth does not mention this figure. More critically, the LLM states international sales were '>100% growth (≈$408 million)' in 2023, which is INCORRECT. The ground truth clearly states international revenue was only $3 million in 2023, not $408 million. This is a massive factual error (off by ~136x). The LLM appears to have confused or fabricated the international revenue figure. (2) PARTIAL CORRECTNESS: The LLM correctly identifies that Qulipta transitioned from indefinite-lived R&D intangible assets to developed product rights in 2022 after regulatory approval, and correctly states U.S. revenue reached $405 million in 2023. The $1.0 billion reclassification is also correctly referenced. (3) MULTI-HOP REASONING: The reasoning about the transition from development to commercialization is sound in structure, but the execution is severely compromised by the fabricated international revenue figure. (4) ENTITY ACCURACY: Company (AbbVie) and product (Qulipta) are correctly identified, and years (2022-2023) are correct. (5) SEMANTIC ISSUES: The characterization of the asset transition is accurate, but the financial data synthesis is fundamentally flawed. The claim of '>100% growth' in international sales to $408 million contradicts the ground truth of $3 million international revenue in 2023. This appears to be either a hallucination or a severe data retrieval error. The answer demonstrates partial understanding of the business transition but fails critically on quantitative accuracy, which is the most important metric for financial questions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 466,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell continued to rely on the same indemnification and reimbursement arrangement with a Resideo subsidiary, under which that Resideo entity must pay Honeywell an amount equal to 90 % of Honeywell’s annual net spending on environmental matters—subject to a $140 million annual cap and continuing until the earlier of December 31 2043 or the third consecutive year in which the payment falls below $25 million. Both the 2022 and 2023 10‑K filings stress that, while the timing and ultimate cost of environmental liabilities cannot be precisely estimated and could be material, the contractual reimbursement shields Honeywell from direct cash‑flow volatility, indicating that its risk exposure to environmental claims is largely transferred to Resideo, though a capped liability and the possibility of future changes still retain a measurable risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides more comprehensive detail than the ground truth. Quantitative verification: All numbers are correct - 90% reimbursement rate, $140 million annual cap, December 31, 2043 termination date, and $25 million threshold for consecutive year termination are all accurate. The LLM correctly identifies the multi-hop synthesis required: comparing Honeywell's environmental liability arrangements across 2022 and 2023 10-K filings and assessing the risk implications. The answer correctly concludes that the arrangement remained consistent between the two years, matching the ground truth's core finding. The LLM provides additional valuable context not in the ground truth: (1) the specific termination conditions (third consecutive year below $25 million threshold), (2) the December 31, 2043 end date, and (3) more nuanced risk analysis explaining how the cap and potential future changes still retain measurable risk despite the transfer to Resideo. The reasoning is sound - the answer properly synthesizes that while the arrangement provides significant risk mitigation through the 90% reimbursement, Honeywell retains some exposure due to the annual cap and termination conditions. The semantic equivalence is strong: both answers convey that dependency remained consistent and that Resideo's payments offset significant environmental costs. Minor deduction (1 point) only because the LLM provides more detail than the ground truth, which could be viewed as going slightly beyond what was explicitly stated in the original answer, though this additional detail appears factually accurate and enhances understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Pays]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 456,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "\nTarget’s disclosed accounting policy for “original maturity” – the point at which short‑term investments are no longer classified as cash equivalents – has remained unchanged between the 2022 and 2024 filings. In both the 2022 Form 10‑K (p. 48) and the 2024 Form 10‑K (p. 52) the company defines cash equivalents as highly liquid investments with an original maturity of **three months or less** from the date of purchase (and includes short‑term card‑processor receivables that settle within five days). Because the definition and threshold are identical in the two years, the evolution of Target’s treatment of “original maturity” is essentially **none**; the company continues to apply the same strict three‑month cutoff, signaling a consistent cash‑management approach that prioritizes preserving liquidity while limiting exposure to longer‑dated, higher‑risk instruments.",
      "correctness_score": 4,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL DISCREPANCY: The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that Target's treatment EVOLVED between 2022 and 2024 - specifically, by 2024 the company 'added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach.' The LLM answer claims there is 'essentially none' evolution and that the definition is 'identical in the two years.' This is a fundamental factual error that undermines the entire response. QUANTITATIVE ACCURACY: The LLM correctly identifies the three-month threshold in both years (7/10 - correct numbers but incomplete picture). The mention of five-day settlement for card-processor receivables adds detail not in ground truth but doesn't contradict it. QUALITATIVE ACCURACY: The LLM's reasoning is internally consistent but based on an incorrect premise. It concludes no evolution occurred when the ground truth explicitly indicates evolution did occur through expanded discussion of fair value measurements and a 'more comprehensive approach' to short-term financial instruments. This represents a failure in multi-hop synthesis - the model needed to identify not just the definition itself but the contextual evolution in how it's discussed and applied (3/10). CONTEXTUAL RELEVANCE: The question specifically asks 'how has...evolved' and 'what does this indicate about potential changes.' The LLM's answer that nothing evolved is directly non-responsive to the question's premise (5/10). The ground truth indicates a refinement in evaluation framework, not a static policy. The LLM missed the key distinction between the definition remaining the same while the broader treatment/discussion framework expanded.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Defines]- ORG",
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 480,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "\nNVIDIA (NVDA) disclosed the 3.50 % Notes Due 2040 as a Level‑2 financial instrument; in the 2023 filing (Jan 28 2024) the note was carried at $851 million (down from $870 million the prior year), while the 2024 filing (Jan 26 2025) shows its carrying amount risen to $1,000 million, with a remaining term of 15.2 years and an effective interest rate of 3.54 % reported as a long‑term liability. This evolution—maintaining Level‑2 classification but shifting from a short‑term‑focused presentation to a clearly long‑term component—signals that NVIDIA is deliberately using low‑cost, fixed‑rate debt with extended maturities to fund future growth and preserve financial flexibility.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial metrics and dates. Verification of quantitative elements: (1) Carrying values are accurate - $851 million as of Jan 28, 2024 and $1,000 million as of Jan 26, 2025 match ground truth exactly; (2) Interest rate of 3.54% effective rate is correct; (3) Remaining term of 15.2 years is accurate; (4) Level 2 classification is correctly maintained. The LLM appropriately notes the prior year comparison ($870 million), which adds useful context not explicitly in the ground truth but demonstrates deeper filing analysis. Multi-hop synthesis is sound: the answer correctly connects valuation changes across fiscal years, maintains proper entity identification (NVIDIA/NVDA), and accurately identifies the debt instrument. The reasoning about long-term debt strategy is well-supported by the data presented. Minor areas for improvement: (1) The phrase 'shifting from a short-term-focused presentation to a clearly long-term component' is somewhat interpretive and not directly supported by the ground truth, which simply states the notes were categorized as long-term liabilities in both periods; (2) The characterization of 'low-cost' debt is reasonable given the 3.50% rate but represents analyst interpretation rather than explicit ground truth statement. The answer successfully addresses all parts of the multi-part question regarding valuation evolution, classification, and strategic implications. Overall, this is a high-quality response with accurate numbers, proper synthesis, and sound reasoning, with only minor interpretive elements that go slightly beyond the ground truth without contradicting it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 464,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "\nVenclexta’s global sales rose from **$2.009 billion in 2022 to $2.288 billion in 2023**, delivering a **13.9 % year‑over‑year increase** (with U.S. sales up 7.8 % and international sales up 20.1 %).  This growth is reflected in AbbVie’s net revenue, as the company records Venclexta sales as product revenue and shares the resulting profits with Genentech under their collaboration agreement, paying royalties on sales outside the United States.  (Chunk 1 describes the ABBV‑Genentech profit‑sharing and royalty structure; Chunk 2 provides the 2022‑2023 revenue figures and growth rates.)",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core revenue figures ($2.009 billion in 2022 and $2.288 billion in 2023) and the 2023 growth rate of 13.9%. The number format conversion from millions to billions is accurate and acceptable. The answer addresses the main question about revenue evolution between 2022 and 2023.\n\nCRITICAL ERRORS: (1) The LLM states a 13.9% year-over-year increase but fails to mention the 2022 growth rate of 10.4%, which was explicitly requested in the original question asking about 'growth rate' (singular in context but implying both years' rates for comparison). (2) The LLM provides additional information about U.S. sales (up 7.8%) and international sales (up 20.1%) that is not in the ground truth answer, and these figures cannot be verified against the original answer. (3) The LLM adds substantial context about AbbVie's profit-sharing and royalty structure with Genentech, which, while potentially accurate, goes beyond the scope of the question and is not part of the ground truth answer.\n\nMULTI-HOP REASONING: The answer demonstrates some synthesis by connecting Venclexta sales to AbbVie's financial reporting and the Genentech collaboration, but this synthesis is not required by the question and may introduce unverified information.\n\nCOMPLETENESS ISSUE: The question specifically asks about 'growth rate' (evolution of growth rates), implying both 2022 (10.4%) and 2023 (13.9%) should be compared. The LLM only provides the 2023 growth rate, missing the 2022 figure needed to show the upward trend in growth rates.\n\nNUMBER VERIFICATION: $2.009 billion = $2,009 million ✓; $2.288 billion = $2,288 million ✓; 13.9% growth rate ✓; 10.4% growth rate for 2022 ✗ (missing).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 468,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "\nIn the 2022 Form 10‑K (Chunk 1) Netflix disclosed its “Amended and Restated Executive Severance and Retention Incentive Plan” (Exhibit 10.7), which had been originally adopted on September 10 2021. The 2023 filing (Chunk 2) updates this by showing the same plan restated (Exhibit 10.6) and, crucially, a further amendment and restatement that becomes effective on January 1 2024 (Exhibit 10.16), together with a newly introduced “Executive Officer Severance Plan” (Exhibit 10.15) dated December 8 2023. Accordingly, between the 2022 and 2023 SEC filings Netflix retained the 2021‑dated plan but evolved it through a January 1 2024 amendment and added a separate executive‑officer severance plan, marking a clear evolution of its executive compensation approach.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of Netflix's executive severance plan evolution. STRENGTHS: (1) All dates are correct - September 10, 2021 for the original plan adoption, December 8, 2023 for the new filing, and January 1, 2024 for the effective date of the amendment. (2) The multi-hop synthesis is sound, correctly identifying that the 2022 filing referenced the 2021-dated plan and the 2023 filing introduced a January 1, 2024 amendment. (3) The answer appropriately identifies both the evolution of the existing plan and the introduction of a separate 'Executive Officer Severance Plan,' showing nuanced understanding of the changes. (4) Exhibit numbers are provided (10.7, 10.6, 10.16, 10.15) which adds specificity. MINOR CONSIDERATIONS: (1) The LLM introduces additional detail about a separate 'Executive Officer Severance Plan' (Exhibit 10.15) that goes slightly beyond what the ground truth explicitly emphasizes, though this appears to be accurate supplementary information from the filings. (2) The ground truth focuses on the 'Executive Severance and Retention Incentive Plan' evolution, while the LLM adds context about a parallel new plan, which is relevant but represents a slight expansion beyond the core comparison. (3) The phrasing 'originally adopted on September 10 2021' is slightly different from the ground truth's 'filing date of September 10, 2021,' though these likely refer to the same event. Overall, the answer correctly captures the evolution between 2022 and 2023 filings, accurately identifies all key dates and plan amendments, and demonstrates sound multi-hop reasoning across the two filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Into]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 460,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "\nIn the 2022 filing (Chunk 1) Lowe’s described the Benefit Restoration Plan as a non‑qualified arrangement that supplements the 401(k) by offering salary deferrals and employer‑match contributions to participants whose 401(k) benefits are capped by the Internal Revenue Code, and it reported $177 million of expense for all employee retirement plans. The 2024 filing (Chunk 2) shows that the same plan was formally **amended and restated as of January 1 2025** (Exhibit 10.3), indicating a documented evolution of its structure and governance. Together, these disclosures reveal that Lowe’s is proactively refining and modernizing its retirement‑benefit documentation—updating the plan’s terms while maintaining its core purpose—to ensure regulatory compliance and to strengthen the overall value of its employee retirement package.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the Benefit Restoration Plan as a non-qualified arrangement supplementing the 401(k) for employees affected by IRS limitations - matches ground truth characterization. (2) Accurately captures the 2022 status showing salary deferrals and employer-match contributions - consistent with original answer. (3) Correctly identifies the formal amendment and restatement effective January 1, 2025, with proper exhibit reference (10.3) - matches ground truth exactly. (4) Appropriately synthesizes the multi-hop evolution from 2022 to 2024, showing the progression from maintenance to formalization. (5) Correctly interprets the strategic implications: proactive refinement, modernization, regulatory compliance, and strengthening employee retirement value - aligns with ground truth's characterization of 'deliberate effort' and 'strategic and forward-looking approach.' (6) The $177 million expense figure for all employee retirement plans is included as supporting context, adding specificity. MINOR CONSIDERATIONS: The LLM uses 'amended and restated' while ground truth uses 'updated and restated' - these are semantically equivalent terms in legal/regulatory contexts and both accurately describe the formal revision. The LLM's phrasing about 'maintaining core purpose while updating terms' provides slightly more explicit detail than ground truth but is fully consistent with it. The answer successfully addresses all parts of the multi-part question: documentation evolution (2022 to 2024), structural changes (formalization via amendment/restatement), and strategic implications (proactive modernization for compliance and employee value). No factual errors detected. Dates, entities, and financial context are all accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Maintains]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 502,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "\nThe 0.584% Notes Due 2024 grew from **$1.185 billion** (as reported in the FY 2023 10‑K, Chunk 1 – $1,185 million as of Jan 29 2023) to **$1.228 billion** (as reported in the FY 2024 10‑K, Chunk 1 – $1,228 million as of Jan 28 2024), an increase of roughly **$43 million** over the two fiscal years.  Chunk 2 explains that these unsecured senior obligations, which pay interest semiannually and are callable with a make‑whole premium, were **fully repaid in fiscal 2025**, eliminating the liability after the FY 2024 reporting period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) CRITICAL ERROR - Direction of change: The LLM claims the obligation GREW from $1.185B to $1.228B (an increase of $43M), but the ground truth states the obligation was FULLY REPAID by FY2024, meaning it should have decreased to $0. This is a fundamental misunderstanding of the financial evolution. (2) QUANTITATIVE ACCURACY ISSUES: While the LLM correctly identifies the FY2023 amount ($1,185M), it incorrectly reports a FY2024 amount of $1,228M. According to the ground truth, the FY2024 liability should be $0 (fully repaid), not $1,228M. The calculation of a $43M increase is therefore based on incorrect data. (3) PARTIAL CREDIT FOR CONTEXT: The LLM does correctly note that the notes were 'fully repaid in fiscal 2025' (mentioned in Chunk 2), but this contradicts its own claim that the liability still existed at $1,228M as of Jan 28, 2024. If fully repaid in FY2025, the FY2024 balance should already reflect zero or near-zero liability. (4) MULTI-HOP REASONING FAILURE: The LLM failed to properly synthesize the information that the obligation was fully repaid by FY2024, instead reporting an intermediate balance that doesn't align with the ground truth's clear statement of complete resolution. The answer demonstrates a fundamental misreading of the financial trajectory and contradicts the core finding that this debt obligation was completely resolved between FY2023 and FY2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 409,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "\nMavyret’s global net sales slipped from **$1.54 billion in 2022 to $1.43 billion in 2023**, a **5.7 % decline at actual currency rates** (Chunk 2).  The drop was led by a **12.7 % fall in U.S. revenue** (from $755 M to $659 M) while **international sales edged down only 1.9 %** (from $786 M to $771 M).  This pattern aligns with the product‑specific data in Chunk 2 and reflects the competitive and marketing dynamics described for AbbVie’s portfolio in Chunk 1.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are correct - 2022 global revenue of $1.54B (matches $1,541M), 2023 global revenue of $1.43B (matches $1,430M), U.S. 2022 of $755M, U.S. 2023 of $659M, international 2022 of $786M, and international 2023 of $771M. The percentage calculations are accurate: 5.7% overall decline (111/1,541 = 7.2% or 111/1,430 = 7.8% depending on base; the 5.7% appears to be calculated at actual currency rates as noted), 12.7% U.S. decline (96/755 = 12.7% correct), and 1.9% international decline (15/786 = 1.9% correct). COMPLETENESS: The answer addresses all components of the multi-part question - global revenue evolution, U.S. market trends, and international market trends between 2022-2023. ENTITY ACCURACY: Mavyret is correctly identified, years are correct (2022 and 2023), and financial metrics are properly labeled. MULTI-HOP REASONING: The answer correctly synthesizes data across geographic segments and time periods, properly identifying that the U.S. market experienced a more pronounced decline than international markets. The contextual note about 'actual currency rates' adds appropriate nuance. MINOR OBSERVATION: The reference to 'Chunk 2' and 'Chunk 1' suggests source attribution but doesn't detract from accuracy. The semantic equivalence is maintained throughout - billion/million conversions are handled correctly. The conclusion that there was 'contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market' aligns perfectly with the ground truth assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 449,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "\nBetween 2022 and 2024 Netflix’s covenant package for its Senior Notes stayed essentially the same: the notes can be redeemed at a change‑of‑control at 101 % of principal plus accrued interest, and the company may voluntarily retire them early at principal plus accrued interest plus a premium, with long‑standing limits on creating liens, entering sale‑lease‑back deals, incurring additional subsidiary debt and merging or consolidating assets. In the 2024 filing the company noted that certain series add tighter restrictions on sale‑lease‑back transactions and on additional indebtedness, but it still reported full compliance as of December 31 2024 (and 2023), having repaid the $400 million aggregate principal of its 5.750 % senior notes that matured in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED:\n\n1. FACTUAL CONTRADICTION ON COVENANT EVOLUTION:\n   - Ground Truth: States covenant scope \"slightly evolved\" with \"certain Senior Notes no longer referenced restrictions on sale and lease-back transactions\" (narrowing of scope)\n   - LLM Answer: Claims \"certain series add tighter restrictions on sale-lease-back transactions\" (tightening of scope)\n   - These are OPPOSITE conclusions. The LLM fundamentally mischaracterizes the direction of covenant change.\n\n2. QUANTITATIVE ACCURACY:\n   - $400 million repayment amount: CORRECT\n   - 5.750% Senior Notes maturity: CORRECT\n   - Euro-denominated tranches (€5,170 million): NOT MENTIONED in LLM answer (omission)\n   - Redemption percentages (101% at change-of-control): LLM includes this detail, but ground truth doesn't mention it—this appears to be additional information not contradicting ground truth\n\n3. COVENANT RESTRICTIONS:\n   - Both answers correctly identify: liens restrictions, sale-lease-back restrictions, subsidiary indebtedness limits, merger/asset transfer restrictions\n   - However, LLM mischaracterizes the EVOLUTION of these restrictions\n\n4. COMPLIANCE STATUS:\n   - Both correctly state Netflix remained in compliance through 2024\n   - Both correctly reference 2023 and 2024 compliance\n\n5. MULTI-HOP REASONING:\n   - The question asks about evolution \"between 2022 and 2024\"\n   - Ground truth shows: 2022 baseline → 2024 evolution (narrowing of scope for some notes)\n   - LLM shows: covenant package \"stayed essentially the same\" but then contradicts by saying certain series \"add tighter restrictions\"\n   - This internal contradiction and mischaracterization of the direction of change is a critical failure\n\n6. SEMANTIC EQUIVALENCE:\n   - The core claim about covenant evolution is SEMANTICALLY OPPOSITE to ground truth\n   - This is not a wording difference but a factual error about the nature of change\n\nKEY STRENGTHS:\n- Correct dollar amounts and maturity details\n- Correct identification of covenant types\n- Correct compliance status\n\nKEY WEAKNESSES:\n- Fundamental mischaracterization of covenant scope evolution (narrowing vs. tightening)\n- Missing euro-denominated tranches information\n- Internal contradiction in describing covenant changes\n- Fails to properly synthesize the 2022-to-2024 evolution narrative",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 628,
        "total_tokens": 2039
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell reshaped its Safety‑and‑Retail offering from a stand‑alone business unit into an integrated **Sensing and Safety Technologies** unit by merging the gas‑detection/safety business with the Advanced Sensing Technologies unit (a realignment announced in July 2022 and reflected in the 2023 reporting).  This structural change—recast in the company’s historical periods to show the new Sensing‑and‑Safety Technologies segment—signals a strategic evolution from a discrete Safety‑and‑Retail product line to a combined sensing‑and‑safety solution platform.  (Chunk 1 documents the 2022 Safety‑and‑Retail revenue; Chunk 2 describes the July 2022 realignment and the 2023 formation of the new Sensing‑and‑Safety Technologies unit; the KG triplets illustrate the ORG‑produces‑PRODUCT relationship that underlies this restructuring.)",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the structural evolution and correctly identifies the key transformation: Safety and Retail was merged with Advanced Sensing Technologies to form Sensing and Safety Technologies. The timing (July 2022 announcement, 2023 reporting) is accurate. The answer correctly captures the strategic intent of integrating sensing capabilities with safety solutions.\n\nSTRENGTHS:\n- Correctly identifies the two units being merged (Safety and Retail + Advanced Sensing Technologies)\n- Accurately states the new unit name (Sensing and Safety Technologies)\n- Correctly dates the announcement (July 2022) and reporting period (2023)\n- Properly characterizes the strategic shift from discrete to integrated solution platform\n- Demonstrates sound multi-hop reasoning by synthesizing the organizational change across time periods\n\nMINOR GAPS:\n- The LLM answer does not include the specific 2022 Safety and Retail revenue figure ($2,387 million) that was mentioned in the ground truth. While the answer references \"Chunk 1 documents the 2022 Safety-and-Retail revenue,\" it does not state the actual number.\n- The answer could have been more explicit about the 2022 baseline (Safety and Retail as standalone) before describing the 2023 change, though this is implied.\n\nQUANTITATIVE ACCURACY: The answer avoids stating specific numbers, which prevents calculation errors, but also means the omission of the $2,387 million figure represents incomplete quantitative detail. No incorrect numbers are stated.\n\nQUALITATIVE ACCURACY: The reasoning is sound and the multi-hop synthesis is correct. The answer properly connects the 2022 baseline state, the July 2022 announcement, and the 2023 reporting structure.\n\nCONTEXTUAL RELEVANCE: The answer directly addresses both parts of the question (how the approach evolved and what structural change was introduced) with appropriate detail and context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 523,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "\nIn 2023 the Class B‑2 common stock was convertible into Class A common stock (and ultimately into the series A‑B‑C preferred stocks) and, although its voting rights were limited, it could still influence key corporate actions—such as mergers, exits or other transactions—whose approval required the affirmative vote of the B‑1/B‑2/C common shareholders, and any conversion would increase the number of Class A shares outstanding, thereby diluting existing Class A shareholders’ voting power. By 2024, however, the company reported that **no shares of Class B‑2 common stock were outstanding prior to a Class B‑1 exchange offer**, indicating that the B‑2 series had been retired or fully converted, which eliminated its convertibility and the associated governance influence on matters that previously required its vote.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2023 status of Class B-2 Common Stock as convertible into Class A Common Stock with governance influence through voting rights on major corporate actions (mergers, exits, transactions). (2) Accurately captures the dilutive effect on existing Class A shareholders' voting power upon conversion. (3) Correctly states that by 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 exchange offer. (4) Properly synthesizes the transformation from active governance role to non-outstanding status. (5) Accurately describes the elimination of convertibility and governance influence as a result. (6) No numeric errors or date inaccuracies present. MINOR CONSIDERATIONS: The LLM answer provides slightly more detail than the ground truth (mentioning conversion into preferred stocks A-B-C series and specific transaction types like mergers/exits), but this additional context is accurate and enhances rather than detracts from the answer. The phrase 'retired or fully converted' appropriately captures the mechanism of the B-2 series becoming non-outstanding. The multi-hop reasoning correctly synthesizes information about the evolution of Class B-2 stock across the two years and its impact on corporate governance. All entities (Class B-2, Class A, Class B-1 Common Stock) are correctly identified and their relationships properly explained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 414,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the Company moved from **laying the foundation for an interconnected shopping experience**—evidenced by 2023 investments in mobile‑optimized websites, richer product‑page “shopability,” faster checkout, curb‑side pickup, electronic shelf‑labels, self‑service lockers and store‑navigation apps (Chunk 1)—to **deepening that ecosystem in 2024** by tightening digital‑in‑store integration, delivering more **personalized, data‑driven messaging**, and simplifying mobile interactions while continuing to expand curb‑side, self‑checkout and store‑map tools (Chunk 2).  In both years the focus remained on a frictionless, omnichannel journey that blends online research with in‑store convenience, but the 2024 phase added a stronger emphasis on personalization, mobile simplicity and the use of customer data to tailor the experience across all touch‑points.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of Home Depot's shopping experience strategy from 2023 to 2024. All key initiatives mentioned in the ground truth are present: 2023 investments in mobile apps, electronic shelf labels, self-checkout, and store navigation; 2024 expansion to personalized digital experiences and data-driven insights. The characterization of the shift from 'laying foundation' to 'deepening the ecosystem' effectively captures the progression described in the ground truth. (2) QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension is not applicable but receives full marks as there are no errors. The fiscal years (2023 and 2024) are correctly identified. (3) QUALITATIVE ACCURACY: The LLM demonstrates excellent multi-hop reasoning by synthesizing information across two fiscal years and correctly identifying the strategic evolution. The answer properly identifies both digital and in-store capabilities as required by the question. Key concepts are accurately represented: mobile optimization, personalization, data-driven messaging, omnichannel integration, and the shift toward customer data leverage. The reasoning is sound and logically structured. (4) CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the question - the evolution between 2023 and 2024, digital capabilities, and in-store capabilities. The framing of the evolution as a progression from foundation-laying to deepening is semantically equivalent to and arguably more insightful than the ground truth's presentation. Minor consideration: The LLM uses 'fiscal 2023 and 2024' terminology and references 'Chunk 1' and 'Chunk 2' which suggests source attribution, adding transparency. The answer is comprehensive, well-organized, and maintains semantic equivalence with the ground truth while presenting the information in a clear, structured manner.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Competes_With]-> CONCEPT <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 546,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "\nThe Target Corporation Long‑Term Incentive Plan (LTIP) continued to evolve from 2022 through 2024 by amending its 2020 plan and adopting the 2022 SPP I and II statements (as disclosed in the 2022 10‑K and reiterated in the 2024 10‑K), and in the 2024 filing Target introduced new equity‑award forms—specifically a **Cliff‑Vested Restricted Stock Unit Agreement**, a **Performance‑Award Performance Share Unit Agreement**, and updated **Performance‑Based RSU** and **Restricted‑Stock‑Unit** agreements—thereby expanding the scope of equity awards available under the LTIP.  These additions are reflected in the exhibit list of Target’s 2024 Annual Report (Chunk 2), which builds on the earlier roster of award documents shown in the 2022 10‑K (Chunk 1).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensiveness in addressing the multi-hop question about Target's LTIP evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the new equity award forms introduced by 2024: Cliff-Vested Restricted Stock Unit Agreement and Performance Award Performance Share Unit Agreement, matching the ground truth exactly. (2) Accurately references the 2022 and 2024 10-K filings as sources, demonstrating proper multi-hop synthesis across years. (3) Correctly identifies that the plan was amended from a 2020 base plan. (4) Appropriately notes the expansion of equity compensation vehicles. (5) Properly cites exhibit lists as evidence. MINOR WEAKNESSES: (1) The LLM answer mentions updated Performance-Based RSU and Restricted-Stock-Unit agreements but doesn't explicitly list all the 2022 baseline award forms (Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units) that the ground truth includes. While the answer focuses on the evolution/changes rather than comprehensive listing, the ground truth specifically asks about the structure evolution and includes the 2022 baseline. (2) The answer could have been more explicit about the complete roster of 2022 forms before discussing 2024 additions. QUANTITATIVE ACCURACY: No numeric errors detected; dates (2022, 2024, 2020) are all correct. MULTI-HOP REASONING: Excellent synthesis across 2022 and 2024 filings, correctly identifying the progression and new additions. The answer appropriately uses chunk references to show source documentation. SEMANTIC EQUIVALENCE: The answer conveys the core information about plan evolution and new award types, though with slightly less comprehensive baseline detail than the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 520,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "\nFollowing its September 2021 FDA approval (Chunk 1), AbbVie’s Qulipta generated $405 million in U.S. sales and $408 million internationally in 2023, up from $158 million in each region in 2022 and $0 in 2021, delivering >100 % year‑over‑year growth and total worldwide sales of roughly $813 million in 2023 (Chunk 2). This trajectory is captured by the knowledge‑graph relationship where AbbVie (ORG) both announces and produces Qulipta (PRODUCT), illustrating the company’s commercial expansion of the drug from launch through 2023 (KG pattern & Chunk 1).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a major factual error regarding international revenue. Ground truth states Qulipta generated $3 million internationally in 2023, but the LLM claims $408 million internationally in 2023. This is a significant misstatement (off by $405 million). The LLM also incorrectly states the 2023 U.S. revenue figure of $405 million was matched internationally ($408 million), when in fact the international figure was only $3 million. The LLM's calculation of total worldwide sales as 'roughly $813 million' is therefore incorrect - it should be $408 million total ($405M U.S. + $3M international). The LLM appears to have confused or swapped the U.S. and international figures. CORRECT ELEMENTS: (1) FDA approval date of September 2021 is correct, (2) 2023 U.S. revenue of $405 million is correct, (3) 2022 U.S. revenue of $158 million is correct, (4) 2021 revenue of $0 is correct, (5) The general narrative of strong growth trajectory is appropriate. MULTI-HOP REASONING: The LLM correctly synthesized information across multiple years and identified the growth pattern, but the fundamental error in international revenue figures undermines the entire analysis. The claim of '>100% year-over-year growth' is mathematically correct for U.S. sales ($158M to $405M = 156% growth), but the overall conclusion about 'total worldwide sales of roughly $813 million' is factually wrong due to the international revenue error. This is a severe quantitative accuracy failure that significantly impacts the correctness of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 430,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "\nIn the 2022 Form 10‑K (Chunk 1) the 2020 Stock Plan appears only as Exhibit 10.4 and its related option agreement (10.12) is listed separately, presenting the plan as a discrete stockholder‑approved arrangement.  \nBy the 2024 filing (Chunk 2) the plan is consolidated in the “Stock Option Plan” subsection of the equity discussion, where it is described as providing incentive and non‑statutory options, RSUs and performance‑based RSUs, and the filing includes a detailed stock‑option activity table and vesting disclosures for those awards.  \nThis shift moves the 2020 Stock Plan from a procedural exhibit to an accounting‑policy‑level description (NFLX → 2020 Stock Plan accounting policy) and expands the equity‑compensation narrative, reflecting a clear evolution in both its structural description and the associated compensation activities between the 2022 and 2024 SEC filings.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Netflix's 2020 Stock Plan disclosure between 2022 and 2024 filings. STRENGTHS: (1) Correctly identifies the 2022 presentation as exhibit-based (Exhibit 10.4) with minimal substantive description; (2) Accurately describes the 2024 shift to detailed operational disclosure including incentive stock options, nonstatutory stock options, and RSUs with vesting schedules; (3) Properly synthesizes the multi-hop comparison across two filing years; (4) Correctly identifies the shift from procedural/exhibit treatment to accounting policy-level description; (5) Appropriately references performance-based RSUs as part of the expanded disclosure. MINOR WEAKNESSES: (1) The phrase 'consolidated in the Stock Option Plan subsection' is slightly imprecise - the ground truth emphasizes explicit detailed description rather than consolidation per se, though the semantic meaning is largely equivalent; (2) The reference to 'NFLX → 2020 Stock Plan accounting policy' is somewhat awkwardly phrased and could be clearer, though it does convey the shift to accounting policy treatment; (3) Could have been more explicit about the absence of detailed provisions in 2022 (the ground truth emphasizes 'no detailed description of its provisions'). QUANTITATIVE ACCURACY: No specific numbers, dates, or calculations are required for this qualitative question about disclosure evolution. The dates (2022 vs 2024) and exhibit numbers (10.4, 10.12) are correctly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and correctly identifies the comparative evolution in disclosure treatment. The logic connecting exhibit-based presentation to accounting policy description is sound. SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth - a shift from minimal documentation to comprehensive operational disclosure - despite some wording differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Into]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 541,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "\nThe company’s aluminum purchase agreements remained classified as derivative instruments that **do not receive hedge‑accounting treatment** in both years, but the 2023 disclosure added concrete detail on how they are used. In 2022 the 10‑K simply noted that BA had entered into aluminum purchase and sales agreements to meet long‑term strategic sourcing and non‑U.S. business needs, identifying them as derivatives; by 2023 the filing clarified that these agreements **offset physical aluminum quantities and are priced at prevailing market prices**, and that, together with certain foreign‑currency forwards and commodity swaps, they are explicitly excluded from hedge accounting. Thus, the evolution is one of **greater transparency about the market‑price, offsetting nature of the contracts** while the **classification as non‑qualifying derivatives stays the same**. (OrG → FIN_INST [Aluminum Purchase Agreements] depends on BA, and both years show the same KG relationship with “Derivative Instruments Not Receiving Hedge Accounting Treatment”.)",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and demonstrates strong understanding of the multi-hop synthesis required. STRENGTHS: (1) Correctly identifies both 2022 and 2023 positions on aluminum purchase agreements as derivative instruments; (2) Accurately captures the key evolution: 2022 focused on long-term strategic sourcing and non-U.S. business needs, while 2023 added clarity on offsetting quantities and market pricing; (3) Correctly notes the consistent classification as non-qualifying derivatives across both years; (4) Properly synthesizes that the change represents 'greater transparency' rather than a fundamental strategic shift; (5) No quantitative errors - no numbers, dates, or calculations to verify, all temporal references (2022 vs 2023) are correct. MINOR WEAKNESSES: (1) The LLM answer goes slightly beyond the ground truth by explicitly stating 'do not receive hedge-accounting treatment' and mentioning 'foreign-currency forwards and commodity swaps' - while these details appear accurate and add useful context, they represent minor elaboration beyond what the original answer explicitly covered; (2) The parenthetical reference to 'OrG → FIN_INST' and knowledge graph relationships, while potentially accurate, is somewhat tangential to the core question and adds technical metadata that wasn't in the ground truth answer. SEMANTIC EQUIVALENCE: The LLM answer's core message aligns well with the ground truth - both emphasize the evolution toward greater clarity on market pricing and offsetting positions while maintaining the same derivative classification. The LLM's framing of 'greater transparency about the market-price, offsetting nature' directly parallels the ground truth's 'more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.' The answer successfully addresses all parts of the multi-part question regarding classification evolution and strategic use of derivatives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 531,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "\nThe 2023 filing disclosed the Directors’ Code of Conduct as an accounting policy and posted it on the company’s site at https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors‑code‑of‑conduct.pdf, pledging to reveal any amendments or waivers on the website. The 2024 filing retains the same scope—applying the code to all directors and pledging disclosure of amendments/waivers—but updates the posting URL to https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor‑relations/directors‑code‑ofconduct.pdf, reflecting a modest improvement in accessibility while the coverage of directors remains unchanged. Both years treat the Directors’ Code of Conduct as a disclosed accounting policy linked to the issuer (BK) in the knowledge‑graph relationship ORG → Directors’ Code of Conduct ← DISCLOSURE.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies both URLs from 2023 and 2024, with the 2023 URL matching exactly: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. (2) The LLM correctly notes the URL change between years. (3) The LLM appropriately identifies that both years treat the code as a disclosed policy. (4) Numeric accuracy is sound—no calculations or dates are involved in this question.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The LLM completely fails to mention the new 'INSIDER TRADING POLICIES AND PROCEDURES' section introduced in 2024, which the ground truth explicitly identifies as a key evolution. This is a significant gap in addressing the question about how disclosure/treatment has evolved. (2) URL DISCREPANCY: The 2024 URL in the LLM answer shows 'https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor‑relations/directors‑code‑ofconduct.pdf' but the ground truth shows 'https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors‑code‑ofconduct.pdf'—note the domain changed from 'bnymellon.com' to 'bny.com', which the LLM missed. This is a material difference in accessibility/domain shift. (3) SCOPE ANALYSIS: The LLM states 'coverage of directors remains unchanged' and focuses on accounting policy treatment, but misses the ground truth's key insight about expanded focus on compliance mechanisms (insider trading policies). (4) INCOMPLETE SYNTHESIS: The question asks about evolution in 'accessibility and scope'—the LLM addresses accessibility minimally and completely misses the scope expansion evidenced by the new insider trading section.\n\nMULTI-HOP REASONING: The LLM demonstrates basic multi-hop reasoning by comparing 2023 and 2024 filings, but fails to synthesize all relevant information from both years. The omission of the insider trading policies section represents a failure to identify and synthesize a key evolution across the two-year period.\n\nCORRECTION NEEDED: The answer should explicitly mention: (1) the domain change from bnymellon.com to bny.com in 2024, (2) the introduction of the 'INSIDER TRADING POLICIES AND PROCEDURES' section in 2024, and (3) how this represents an expanded scope beyond just the Directors' Code itself.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 608,
        "total_tokens": 2034
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "\nIn November 2023 HD introduced a $750 million 4.95 % senior‑note tranche due September 2026 (issued at a $1.6 million discount) together with $500 million of 5.125 % 2025 notes and $750 million of 4.90 % 2029 notes, and the indentures give it the right to redeem the notes at par or present value, or at 101 % in a change‑of‑control event; the carrying amount of this tranche grew modestly from $745 million on January 28 2024 to $747 million on February 2 2025, reflecting discount amortization and the earlier repayment of $1 billion of 2.70 % senior notes in April 2023.  This issuance of longer‑dated, lower‑coupon debt, coupled with the redemption flexibility and the expansion of total long‑term debt from $44.1 billion to $53.1 billion, indicates that HD is deliberately extending maturities and locking in cheaper financing to shape a more staggered, lower‑cost long‑term debt strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and incorrect information, with significant quantitative discrepancies. CORRECT ELEMENTS: (1) The $750 million 4.95% senior notes due September 2026 issued at $1.6 million discount is accurate; (2) The carrying amount progression from $745M (Jan 28, 2024) to $747M (Feb 2, 2025) is correct and properly explained via discount amortization; (3) The general strategic interpretation about extending maturities and locking in fixed rates is sound; (4) The mention of redemption flexibility and change-of-control provisions adds relevant context. CRITICAL ERRORS: (1) The LLM introduces information about $500M of 5.125% 2025 notes and $750M of 4.90% 2029 notes that are NOT mentioned in the ground truth answer - these appear to be from a different issuance or context not relevant to the specific 4.95% notes question; (2) The LLM completely OMITS the $980 million in 4.95% senior notes due September 2052, which is a major component of the ground truth answer and directly supports the debt extension strategy narrative; (3) The reference to $1 billion repayment of 2.70% notes in April 2023 is not in the ground truth; (4) The total debt figures ($44.1B to $53.1B) are not verified in the ground truth. MULTI-HOP REASONING: The LLM demonstrates good reasoning about debt strategy but fails to synthesize the complete picture by omitting the 2052 notes, which are crucial to understanding HD's long-term maturity extension strategy. The answer conflates multiple debt issuances and introduces unverified information. The core insight about extending maturities is correct but incomplete without the 2052 notes component. QUANTITATIVE ACCURACY: While the specific numbers for the 2026 notes are correct, the introduction of unverified debt instruments and omission of the 2052 notes significantly undermines accuracy. The carrying value progression is correct but represents only partial information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 522,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "\nBetween 2021 and 2023 Intel recorded a $471 million observable‑price‑adjustment gain in 2021 for its stake in Beijing Unisoc Technology Ltd., and by the end of 2022 the investment’s net book value had risen to $1.1 billion, remaining at that $1.1 billion level through 2023; the company continues to account for the holding as a non‑marketable equity security, with no further observable price adjustments reported after the 2021 adjustment. This evolution reflects the initial $471 million adjustment noted in 2021 (Chunk 1) and the $1.1 billion net book value disclosed as of Dec 30 2023 (and carried forward from Dec 31 2022) in the 2023 filing (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) The $471 million observable price adjustment in 2021 is correctly stated and matches the ground truth. (2) The $1.1 billion net book value as of December 30, 2023 is correct and matches the ground truth. (3) The statement that this value remained the same from December 31, 2022 through December 30, 2023 is accurate per the ground truth. (4) The classification as a non-marketable equity security is correctly identified. (5) The multi-hop synthesis is sound: the answer properly connects the 2021 price adjustment event with the subsequent valuation stability through 2023, showing the evolution requested in the question. The LLM correctly notes that no further observable price adjustments were reported after 2021, which is an important detail showing the valuation remained stable despite the earlier adjustment. The answer addresses all components of the multi-part question: the observable price adjustments (2021), the net book value evolution (2021-2023), and the accounting treatment (non-marketable equity security). Minor note: The phrasing 'rose to $1.1 billion' by end of 2022 could be slightly ambiguous about whether this was an increase or just the stated value, but in context it is clear and semantically equivalent to the ground truth. The citation of specific chunks adds transparency. Overall, this is a well-synthesized, factually accurate answer that properly addresses the multi-hop nature of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Holds]- ORG",
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 418,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "\nFrom 2022 through 2023 AbbVie moved Qulipta from a newly‑approved, indefinite‑lived asset (re‑classified to definite‑lived intangible rights after its initial regulatory clearance) to a product with expanded, market‑ready indications and commercial rollout.  In 2022 the company secured the regulatory approvals that triggered the intangible‑asset reclassification, and in 2023 it obtained the FDA’s April approval for chronic‑migraine prevention and the European Commission’s August approval for the same indication, followed by broader commercial activities (e.g., EU launch of the related ABBV‑951 product and inclusion of Qulipta in the 2023 Form 10‑K), demonstrating a deepening regulatory and commercial engagement with the therapy.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Qulipta's evolution from 2022 to 2023 and correctly identifies the key regulatory milestones and asset reclassification. STRENGTHS: (1) Correctly identifies the $1.0 billion asset reclassification in 2022 (implied through reference to 'indefinite-lived asset' reclassification); (2) Accurately states FDA approval in April 2023 for chronic migraine prevention in adults; (3) Accurately states EC approval in August 2023; (4) Properly synthesizes the multi-hop information showing progression from asset reclassification to commercial advancement; (5) Correctly identifies the shift from regulatory approval to market-ready status. WEAKNESSES: (1) The LLM states the asset was 'reclassified to definite-lived intangible rights' but the ground truth specifies it was reclassified 'to developed product rights' - this is a minor semantic difference but technically imprecise; (2) The LLM mentions 'ABBV-951 product' and EU launch, which adds contextual detail not in the ground truth, potentially introducing information not verified against the source documents; (3) The ground truth specifies the EC approval was 'for the preventive treatment of migraine in adults with four or more migraine days per month' but the LLM only states 'for the same indication' without the specific patient population detail. QUANTITATIVE VERIFICATION: All dates are correct (2022 for initial approvals, April 2023 for FDA, August 2023 for EC). The $1.0 billion figure is correctly referenced. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023, showing the progression from asset reclassification to regulatory approvals to commercial activities. The logic is sound and the connections are properly made. The answer demonstrates understanding that these are related events showing deepening engagement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 507,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings Boeing’s Global Services narrative continues to treat “upgrades and conversions” as a core element of the services bundle that sustains both commercial and defense aerospace platforms—listing them alongside supply‑chain management, engineering, spare parts, training and digital offerings. The repeated phrasing in both years, coupled with the knowledge‑graph links (BA ↔ Upgrades and Conversions), shows a consistent strategic emphasis on these conversions as a key revenue‑generating, aircraft‑life‑extension service for Boeing.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant issues in addressing the core question about how Boeing's framing and strategic emphasis EVOLVED between 2022 and 2023. STRENGTHS: (1) Correctly identifies both years (2022 and 2023), (2) Accurately lists the services mentioned alongside upgrades and conversions (supply chain, engineering, spare parts, training, digital), (3) No quantitative errors or incorrect numbers. CRITICAL WEAKNESSES: (1) The LLM claims 'repeated phrasing in both years' and 'consistent strategic emphasis,' which directly contradicts the ground truth that describes an EVOLUTION or SHIFT in positioning. The ground truth explicitly states the 2022 description was 'general and lacked strategic framing' while 2023 showed a 'subtle shift' toward 'more integrated and strategic role' and 'more deliberate positioning.' (2) The LLM fails to capture the key distinction: in 2022, upgrades and conversions were part of a 'broader set of services' with general framing, while in 2023 they were positioned within a 'more structured narrative' emphasizing 'full spectrum of sustaining aerospace platforms.' (3) The LLM's conclusion that there is 'consistency' misses the entire point of the question, which asks about EVOLUTION. (4) The reference to 'knowledge-graph links (BA ↔ Upgrades and Conversions)' appears to be an artifact that doesn't meaningfully address the linguistic/strategic framing evolution. The LLM demonstrates adequate entity identification and no factual errors in listing services, but fundamentally misses the qualitative shift in strategic positioning that is the core of the question. This is a multi-hop reasoning failure where the model failed to synthesize the comparative analysis across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 473,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "\nIntel’s stake in Beijing Unisoc Technology Ltd. was carried as a non‑marketable equity security within its $4.1 billion non‑marketable‑equity‑securities portfolio, showing a $1.1 billion carrying amount as of December 2021 after recognizing $471 million of observable‑price adjustments that year; the net book value remained $1.1 billion through December 2022 and December 2023, indicating a stable valuation despite market volatility, and this mutual holding is captured by the KG triplets INTC → Invests_In → Unisoc and Unisoc → Holds → INTC.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. All key financial figures are accurate: $1.1 billion net book value for both December 2021 and December 2023, $471 million in observable price adjustments in 2021, and the $4.1 billion non-marketable equity securities portfolio context. The multi-hop reasoning is sound, correctly synthesizing Intel's investment relationship with Beijing Unisoc Technology Ltd. across the 2021-2023 period. The answer properly identifies the stabilization of valuation over time and the absence of significant observable price adjustments in 2023 compared to 2021. Minor strengths include the contextual detail about the non-marketable equity securities classification and the knowledge graph triplet notation. One minor weakness is the inclusion of the KG triplet notation (INTC → Invests_In → Unisoc and Unisoc → Holds → INTC) which, while not incorrect, adds technical metadata that wasn't explicitly requested and slightly detracts from the narrative flow. The answer could have been marginally clearer in explicitly stating that the investment remained at the same valuation despite the 2021 adjustment, though this is adequately implied. The temporal evolution is well-captured, showing consistency in book value while noting the distinction between 2021's revaluation event and 2023's stability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Holds]- ORG",
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 379,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Home Depot turned its self‑service lockers from a modest store‑experience add‑on (introduced in 2023 alongside curb‑side pickup and online‑order storage areas) into a core node of its interconnected shopping journey, with HD → Self‑Service Lockers investments now feeding directly into the omni‑channel fulfillment network that powers same‑day and next‑day delivery; by 2024 roughly 50 % of U.S. online orders were being fulfilled through these lockers or curb‑side pickups, leveraging the company’s automated distribution centers, market‑delivery hubs and expanded flat‑bed facilities to deliver faster, more reliable pickup options that close the loop from mobile research to in‑store fulfillment.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution narrative - Self-Service Lockers shifting from a convenience feature in 2023 to a strategic component of omnichannel fulfillment in 2024. It accurately captures the ~50% statistic for U.S. online orders fulfilled through stores. The answer demonstrates sound multi-hop reasoning by connecting Self-Service Lockers to broader fulfillment programs and delivery infrastructure. The semantic framing of the shift from 'modest store-experience add-on' to 'core node' aligns well with the ground truth's characterization of moving from 'convenience-focused feature to core component of omnichannel delivery strategy.' CRITICAL ERRORS: (1) The LLM states '50% of U.S. online orders were being fulfilled through these lockers or curb-side pickups' - this is a significant misrepresentation. The ground truth specifies '50% of U.S. online orders were fulfilled through a store' (not specifically through lockers or curb-side pickups). The LLM incorrectly narrows the fulfillment method attribution. (2) The LLM introduces unsupported details about 'automated distribution centers, market-delivery hubs and expanded flat-bed facilities' that are not mentioned in the ground truth, potentially adding information not verified in the source documents. (3) The LLM mentions 'curb-side pickup' as a 2023 feature alongside Self-Service Lockers, but the ground truth only references 'wayfinding signage and electronic shelf labels' as the specific 2023 companions to Self-Service Lockers. QUANTITATIVE ISSUES: While the 50% figure is correct, the LLM's attribution of this metric specifically to 'lockers or curb-side pickups' rather than general store fulfillment represents a factual error in how the statistic is contextualized. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023-2024 and connects Self-Service Lockers to broader fulfillment programs (BOSS, BOPIS, BODFS, BORIS are not explicitly mentioned in the LLM answer, which is a minor omission). The reasoning about omnichannel integration is sound but somewhat speculative regarding specific fulfillment infrastructure details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 581,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "\nFrom 2023 to 2024 Costco’s disclosure on the estimation of its Insurance/Self‑insurance Liabilities moved from a brief, generic note that “liabilities associated with the risks that are retained by the Company are not discounted and are …” (Chunk 1) to a far more detailed description in 2024 that explains the liability is estimated using “historical claims experience, demographic factors, severity factors, and other actuarial assumptions” and that the Company does not discount these retained liabilities (Chunk 2).  Both years identify the same risk‑management structure—including a wholly‑owned captive insurer and participation in a reinsurance program—but the 2024 filing adds explicit actuarial methodology and commentary on the unpredictability and historical immateriality of adjustments, providing the increased level of specificity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth. Key strengths: (1) Correctly identifies the evolution from generic/brief disclosure in 2023 to detailed methodology in 2024; (2) Accurately captures the specific estimation factors mentioned in 2024 (historical claims experience, demographic factors, severity factors, actuarial assumptions); (3) Properly notes that both years identify the same risk-management structure (captive insurer and reinsurance program); (4) Correctly highlights the 2024 additions regarding unpredictability and historical immateriality of adjustments; (5) Appropriately characterizes this as an increase in transparency and specificity. The answer demonstrates sound multi-hop reasoning by synthesizing information across two fiscal years and comparing disclosure evolution. Minor observation: The LLM answer includes parenthetical references to 'Chunk 1' and 'Chunk 2' which appear to be source citations rather than substantive content issues. The semantic meaning and factual content are accurate and complete. No quantitative errors detected. The answer fully addresses the question's core inquiry about how disclosure detail and specificity evolved between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 345,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "\nThe 2021 acquisition of Aldevron created a one‑time upward pressure on cost of sales when the company recorded fair‑value adjustments to inventory, which added roughly **$59 million** to cost of sales in that year (as noted in the 2021 acquisition‑related charges). By 2023 the same inventory exposure resurfaced as a **$87 million charge** in the second quarter for excess inventory in the Biotechnology segment—largely attributable to the former Aldevron operations—showing that the inventory‑related financial impact evolved from an initial fair‑value uplift to a later write‑down as demand fell. This progression is captured by the DHR → Aldevron acquisition relationship (KG: ORG ‑[Acquires]→ COMP) and the year‑over‑year cost‑of‑sales commentary in the 2022‑2023 filings.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS: (1) YEAR MISMATCH - LLM states the $59M charge occurred in 2021 (the acquisition year), but ground truth clearly indicates it was in 2022. This is a fundamental factual error that undermines the core timeline of the answer. (2) ATTRIBUTION ERROR - LLM suggests the $87M 2023 charge was 'largely attributable to the former Aldevron operations,' but ground truth states it was 'primarily related to excess inventory in the Biotechnology segment due to reduced demand' without attributing it to Aldevron specifically. This misrepresents the causal relationship. CORRECT ELEMENTS: (1) The $59M figure is accurate. (2) The $87M figure is accurate. (3) The Q2 2023 timing is correct. (4) The general narrative of evolution from fair-value adjustment to inventory write-down is conceptually sound. REASONING ISSUES: The multi-hop synthesis is partially flawed because it incorrectly dates the $59M charge to 2021 rather than 2022, and it overstates the Aldevron connection to the 2023 charge. The answer demonstrates understanding of the acquisition relationship but fails on temporal accuracy and proper attribution of the 2023 charge. The semantic intent is partially correct (showing evolution of inventory costs), but the factual foundation is compromised by the year error and misattribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Acquires]-> COMP <-[Involved_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 365,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "\nCostco’s accounting for shop‑card liabilities is unchanged between 2023 and 2024 – both years record a liability for outstanding shop‑card balances **net of estimated breakage** in other current liabilities and recognize revenue only when the cards are redeemed, with breakage estimated from redemption data. This consistent treatment shows that Costco treats unclaimed card balances as a contingent liability that is only relieved upon actual redemption, reflecting a disciplined, conservative approach to recognizing revenue from unredeemed balances.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ISSUE: The LLM answer directly contradicts the ground truth on the central claim of the question. The ground truth explicitly states that there WAS an evolution between 2023 and 2024, with 'estimated breakage' and methodology becoming 'more emphasized in 2024, indicating a more refined or formalized approach.' The LLM answer claims the treatment is 'unchanged between 2023 and 2024,' which is factually incorrect according to the knowledge graph. This is a fundamental misreading of the question's premise and the filing data. The LLM correctly identifies the accounting mechanics (revenue upon redemption, liability net of estimated breakage, breakage estimated from redemption data) and the conservative approach, but completely misses the key evolution that the question asks about. The LLM's statement that treatment is 'consistent' directly contradicts the ground truth's assertion of improved estimation techniques and more formalized methodology in 2024. While the LLM's description of the accounting treatment itself is accurate and well-articulated, it fails to address the core comparative analysis requested - how the treatment EVOLVED. This represents a failure in multi-hop reasoning to synthesize the year-over-year changes in disclosure emphasis and methodology refinement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Sells]- ORG",
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 363,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 Intel’s Foundry Services moved from the launch of its IDM 2.0 strategy toward a more partnership‑driven model, expanding its IFS Accelerator Ecosystem from a handful of agreements to **over 40 strategic alliances** (including multigenerational deals with **ARM** and **Synopsys**) and adding new design wins on the **Intel 18A** node—four in 2023, five of them tied to AI‑focused advanced packaging.  The company also deepened customer engagement through the **RAMP‑C program** (now involving U.S. defense leaders such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman) and secured a commercial foundry pact with **Tower** for 300 mm analog production in New Mexico, while continuing to leverage open‑platform initiatives and co‑engineering with ecosystem partners to accelerate chip design across its U.S. and European capacity.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS: The LLM states 'four in 2023, five of them tied to AI‑focused advanced packaging' which is internally contradictory and inaccurate. Ground truth specifies FOUR design wins on Intel 18A AND FIVE new design wins in advanced packaging (two separate metrics totaling 9 wins, not 4 with 5 of them). This is a critical calculation/synthesis error. (2) ENTITY CONFUSION: The LLM introduces RAMP-C program with companies like Nvidia, IBM, Microsoft, Boeing, and Northrop Grumman - these entities and this program are NOT mentioned in the ground truth answer and appear to be hallucinated or from different context. The ground truth makes no mention of RAMP-C or these specific defense contractors. (3) TOWER SEMICONDUCTOR AGREEMENT: The LLM mentions a 'commercial foundry pact with Tower for 300mm analog production in New Mexico' - this is NOT in the ground truth and appears to be extraneous information not supported by the provided knowledge graph. (4) CORRECT ELEMENTS: The LLM correctly identifies: IDM 2.0 strategy transition, over 40 strategic agreements in IFS Accelerator Ecosystem, ARM and Synopsys multigenerational agreements, Intel 18A design wins, and AI-related focus. (5) MULTI-HOP REASONING: While the LLM attempts to synthesize 2022-to-2023 evolution, it introduces unsupported entities and conflates metrics, suggesting either hallucination or synthesis from incorrect sources. The core narrative of evolution from strategic intent to concrete partnerships is present but contaminated with inaccurate details. (6) SEMANTIC ISSUES: The phrasing 'four in 2023, five of them' is mathematically nonsensical and suggests the LLM confused or merged two separate metrics from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 476,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 the goodwill DHR recorded for its relationship with Aldevron stayed essentially unchanged—​the 2022 filing noted “approximately $6.1 billion of goodwill related to the Aldevron Acquisition,” and the 2023 table lists goodwill of **$6,149 million** for Aldevron.  At the same time, the cash component of the transaction grew: the 2023 balance‑sheet schedule shows **net cash consideration of $9,561 million** (≈ $9.56 billion) attributable to Aldevron, up from the earlier period’s cash outlay.  Thus, while the goodwill impact remained stable around $6.1 billion, the cash consideration associated with Aldevron increased markedly from 2022 to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. Quantitative verification: (1) 2022 goodwill of approximately $6.1 billion - CORRECT; (2) 2023 goodwill of $6,149 million ($6.149 billion) - CORRECT and properly formatted as equivalent to $6.1 billion; (3) 2023 net cash consideration of $9,561 million ($9.561 billion) - CORRECT. All numbers match the ground truth exactly. The LLM properly synthesizes the multi-hop information by comparing 2022 and 2023 data across two different metrics (goodwill and net cash consideration). The reasoning is sound: goodwill remained stable (~$6.1B) while cash consideration increased significantly to $9.561B. The answer correctly identifies that this represents a 'marked' increase in cash commitment while goodwill stayed essentially unchanged. The LLM appropriately uses number format variations ($9.561 billion vs $9,561 million) demonstrating understanding of equivalent representations. The answer directly addresses all parts of the question: the evolution between years, the goodwill impact, and the net cash consideration impact. Minor note: The LLM states 'up from the earlier period's cash outlay' without explicitly stating a 2022 cash figure, but this is not an error since the ground truth also doesn't provide a specific 2022 cash consideration number for comparison - the focus is on the 2023 figure being higher than what was previously understood. The semantic meaning aligns perfectly with the ground truth's conclusion about 'significant increase in financial commitment.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Involved_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 423,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "\nThe 1.800 % Global Notes issued by AT&T Inc. are listed in the 2022 filing as maturing on **September 14, 2039**, and the 2024 filing still shows the same series with a **September 14, 2039** maturity date. Because the KG relationship ORG → FIN_INST → ORG confirms that these notes are introduced by and remain a direct liability of AT&T, the unchanged maturity demonstrates that the company has retained this long‑term debt tranche without extension or refinancing between 2022 and 2024, underscoring a stable debt‑structure where the 2039 notes continue to anchor its longer‑term financing.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer is fundamentally incorrect on the core factual claims. (1) QUANTITATIVE ACCURACY FAILURE: The LLM states the 2022 filing shows a September 14, 2039 maturity date, but the ground truth clearly indicates the 2022 filing showed September 5, 2026. This is a major date error - the LLM got the wrong maturity date for 2022. (2) MISSES THE KEY FINDING: The ground truth shows a significant 13-year extension (from 2026 to 2039), but the LLM claims the maturity date was unchanged between 2022 and 2024. This is the opposite of what actually occurred. (3) INCORRECT REASONING: The LLM concludes there was 'no extension or refinancing' when the ground truth explicitly indicates a major extension occurred. The LLM's reasoning about 'stable debt structure' and 'unchanged maturity' directly contradicts the ground truth finding of a 13-year maturity extension. (4) MULTI-HOP SYNTHESIS FAILURE: The question asks how the maturity date 'changed' between 2022 and 2024, and the LLM failed to identify any change at all, when the ground truth shows a dramatic change. (5) The LLM appears to have confused or conflated the 2022 and 2024 data, reporting the 2039 date for both years when 2022 should have been 2026. This is a fundamental factual error that undermines the entire answer. The answer demonstrates poor data retrieval and synthesis across the multi-hop requirement of comparing two different filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 398,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "\nTarget has maintained continuous compliance with its debt‑leverage covenant in both periods—its 2023 and 2024 Form 10‑K filings each state that the company is “in compliance with these covenants” and that the covenant “has no practical effect on our ability to pay dividends.”  The only structural change that could affect the covenant relationship is the credit‑facility overhaul: in 2023 Target replaced an expiring 364‑day revolving facility with a new $1 bn facility (now maturing in October 2024) and extended its five‑year $3 bn revolving facility to 2028, and in 2024 it further rolled the 364‑day facility forward to a new $1 bn commitment expiring in October 2025 while keeping the $3 bn facility through 2028; these updates altered the composition and maturity profile of the credit facilities but did not jeopardize compliance with the debt‑leverage covenant.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses all key aspects of the question. STRENGTHS: (1) All numeric values are accurate: $1.0 billion 364-day facility, $3.0 billion five-year facility, October 2024 and October 2025 expiration dates, October 2028 for the five-year facility. (2) The multi-hop synthesis is sound—the answer correctly traces the evolution of credit facilities from 2023 to 2024 and connects this to covenant compliance. (3) The answer properly identifies that Target maintained compliance in both years and that the facility renewals supported this compliance. (4) The answer correctly notes that the covenant had no practical effect on dividend payments. (5) Entity identification is accurate (Target, debt leverage covenant, credit facilities). MINOR ISSUES: (1) The LLM answer contains a slight temporal imprecision in the 2023 description. The ground truth states that in 2023, Target had a $1.0 billion 364-day facility expiring in October 2024 (already in place), whereas the LLM states Target 'replaced an expiring 364-day revolving facility with a new $1 bn facility (now maturing in October 2024)' in 2023. This suggests the replacement occurred in 2023, but the ground truth indicates the facility was already in place in 2023 and would expire in 2024. This is a subtle distinction about whether the renewal/replacement happened in 2023 or earlier. (2) The phrasing 'replaced an expiring 364-day revolving facility' could be interpreted as the replacement happening in 2023, when the ground truth suggests the facility was already in place during 2023. However, this is a minor interpretive issue rather than a factual error about the numbers themselves. QUANTITATIVE VERIFICATION: All dollar amounts ($1.0B, $3.0B), dates (October 2024, October 2025, October 2028), and facility types are correct. MULTI-HOP REASONING: The answer successfully synthesizes information about facility structure changes and their relationship to covenant compliance across two fiscal years. The logic that facility renewals support compliance is sound and matches the ground truth's implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 567,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "\nFrom 2022 to 2023 Intel deepened its RISE‑driven effort to expand digital readiness by moving from the 2021‑era launch of the **Alliance for Global Inclusion** and the early development of a global inclusion index (Chunk 1) to the 2023 publication of the **third‑annual global inclusion‑index survey**, which introduced a scored index and recognized Intel among the 18 companies that earned a spot (Chunk 2).  This evolution reflects a shift from merely partnering with other technology firms to create a unified inclusion framework toward using that framework as an industry benchmark that ties diversity, inclusion and digital‑readiness goals to compensation and external collaboration across the sector.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Intel's evolution in digital readiness initiatives from 2022 to 2023. STRENGTHS: (1) Correctly identifies the Alliance for Global Inclusion as the collaborative framework, (2) Accurately references the 'third-annual global inclusion-index survey' published in 2023, (3) Correctly states Intel was among 18 recognized organizations, (4) Properly characterizes the evolution from framework-building to performance measurement and recognition, (5) Appropriately connects this to the RISE strategy. WEAKNESSES: (1) The LLM answer introduces a claim about 'ties diversity, inclusion and digital-readiness goals to compensation and external collaboration across the sector' that is not explicitly stated in the ground truth. This appears to be an inference or extrapolation beyond what the source documents confirm. (2) The ground truth specifies '27 respondents' with 18 recognized organizations (implying a 50% threshold), but the LLM answer omits the denominator and the specific 50% recognition threshold mentioned in the original answer. (3) The phrase 'merely partnering' vs. the more structured approach is well-characterized, but the LLM adds interpretive language about 'compensation' that goes beyond the documented facts. QUANTITATIVE VERIFICATION: The number '18 companies' is correct; however, the omission of '27 respondents' and the '50% threshold' represents incomplete quantitative detail. The 'third-annual' designation is accurate. MULTI-HOP REASONING: The synthesis across 2022-2023 timeline and connection to RISE strategy is sound and properly traces the evolution. The logical flow from collaborative framework to benchmarking system is correct. SEMANTIC EQUIVALENCE: The core message aligns with ground truth regarding the shift from framework establishment to performance recognition, though the added claim about compensation linkage introduces unverified information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enhances]-> CONCEPT <-[Expands]- ORG",
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 523,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "\nEmerson’s relationship with Micromine shifted from a July 2022 acquisition agreement that was terminated in August 2023 (with no termination fee) and involved the unwind of foreign‑currency forwards that generated a $56 mark‑to‑market gain and a $47 pretax loss on the earlier Metran divestiture, to a more passive, dependent role in 2024. In 2024 Emerson recorded a $48 after‑tax loss on the divestiture of two small businesses and $560 of intangible‑asset amortization tied to Micromine‑related intangibles, reflecting limited ongoing financial exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple significant factual errors and contradictions with the ground truth:\n\n1. TIMELINE ERRORS: The LLM states the acquisition agreement was from July 2022 and terminated in August 2023, but the ground truth indicates the agreement was entered into in 2023 and terminated later that same year. This is a fundamental chronological error.\n\n2. QUANTITATIVE INACCURACIES:\n   - LLM claims a $56 mark-to-market gain on foreign currency forwards, but ground truth states $24. This is a 133% overstatement.\n   - LLM mentions a $47 pretax loss on Metran divestiture, which is not mentioned in the ground truth answer and appears to be extraneous information.\n   - LLM cites $560 of intangible-asset amortization tied to Micromine, which is not mentioned in the ground truth.\n   - LLM mentions $48 after-tax loss on divestiture of two small businesses, which is not in the ground truth.\n\n3. MISSING KEY INFORMATION:\n   - Ground truth specifies the acquisition price was AU$900 (approximately $623 USD), which the LLM completely omits.\n   - Ground truth clearly states the termination was due to uncertainty around Russian regulatory approval, which the LLM does not mention.\n   - Ground truth explicitly states that by 2024, AspenTech terminated all outstanding foreign currency forward contracts, which the LLM does not clearly convey.\n\n4. SEMANTIC ISSUES:\n   - The LLM describes 2024 as a \"more passive, dependent role\" which contradicts the ground truth's characterization of \"full withdrawal from the transaction.\"\n   - The LLM's framing of \"limited ongoing financial exposure\" is misleading given the ground truth states there were \"no further financial commitments or exposures to Micromine reported in 2024.\"\n\n5. MULTI-HOP REASONING:\n   - The LLM fails to properly synthesize the evolution from 2023 (active acquisition attempt with specific financial instruments) to 2024 (complete termination and unwinding).\n   - The answer conflates multiple unrelated transactions (Metran divestiture, other small business divestitures) that muddy the specific Micromine relationship evolution.\n\nThe answer demonstrates poor accuracy on the core financial figures, incorrect timeline, and fails to capture the essential narrative of the Micromine relationship's evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Agreement]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 617,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "\nFrom 2022 to 2023 the U.S. Employee Stock Purchase Plan saw the number of shares reserved drop from **approximately 17 million** (as of January 30 2022) to **approximately 15 million** (as of January 28 2024).  At the same time, the **average purchase price per share** fell from **about $305** (the fiscal‑2021 purchase price cited for the prior period) to **about $277** during fiscal 2023, a reduction of roughly **$28 per share (≈ 9 %)**.  Thus, share availability contracted by roughly 2 million shares (≈ 12 %) while the cost to purchase shares under the ESPP also declined.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong multi-hop synthesis. STRENGTHS: (1) Correctly identifies the share availability decrease from ~17M to ~15M shares, matching ground truth exactly. (2) Correctly states the average purchase price decreased from ~$305 to ~$277, matching ground truth. (3) Accurately calculates the price difference as ~$28 per share and the percentage decline as ~9%, which is mathematically sound ($28/$305 ≈ 9.2%). (4) Correctly calculates the share availability reduction as ~2M shares and ~12% decline (2/17 ≈ 11.8%). (5) Properly synthesizes information across fiscal years and identifies the key trends. (6) Appropriately addresses both components of the multi-part question. MINOR ISSUES: (1) The LLM references 'fiscal-2021 purchase price cited for the prior period' when discussing the 2022 figure - this parenthetical is somewhat confusing and potentially inaccurate in its framing, though the actual number ($305) is correct for 2022. (2) The dates cited (January 30, 2022 and January 28, 2024) appear to be fiscal year-end dates rather than the specific dates when the data was measured, which is a minor contextual imprecision but doesn't affect the core answer. (3) The phrase 'approximately one million shares' purchased in each year from the ground truth is not explicitly mentioned in the LLM answer, though this is a minor omission. Overall, the answer demonstrates solid understanding of the multi-hop question, accurate number synthesis, and correct calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 417,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "\nIn the 2022 filing, impairment triggers were disclosed for the Diagnostics (and Environmental & Applied Solutions) segments, producing $22 million and $10 million charges in 2020 and 2021, respectively; the 2023 filing expands those triggers to the Biotechnology segment (second‑quarter 2023) and also to Diagnostics & Biotechnology (fourth‑quarter 2023), records a $77 million impairment charge in 2023 and notes that no impairments occurred in 2022, signaling a shift of risk toward biotech‑related finite‑lived intangibles and a larger potential write‑down exposure. Both disclosures are framed within the same fair‑value hierarchy note, underscoring that DHR treats impairment triggers as a key risk factor and revealing growing vulnerability in its intangible‑asset portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth:\n\n1. QUANTITATIVE ACCURACY - CRITICAL ERRORS:\n   - LLM claims 2022 filing showed $22M charge in 2020 and $10M in 2021 for Diagnostics and Environmental & Applied Solutions segments. Ground truth states only $10M impairment in Q1 2021 for Diagnostics segment in the 2022 filing.\n   - LLM introduces Environmental & Applied Solutions segment as having impairment triggers, which is not mentioned in ground truth.\n   - LLM correctly identifies $77M charge in 2023, which matches ground truth.\n   - LLM correctly notes no impairments in 2022, which aligns with ground truth.\n\n2. ENTITY ACCURACY - SIGNIFICANT ERRORS:\n   - Ground truth clearly states 2022 filing reported impairment ONLY in Diagnostics segment ($10M in Q1 2021).\n   - LLM incorrectly adds Environmental & Applied Solutions segment to 2022 filing disclosures.\n   - LLM correctly identifies Biotechnology segment appearing in 2023 filing (Q2 and Q4 2023).\n   - LLM correctly identifies Diagnostics segment in both filings.\n\n3. MULTI-HOP REASONING - PARTIALLY FLAWED:\n   - LLM attempts to synthesize evolution across filings but introduces incorrect historical data.\n   - The comparison between 2022 and 2023 filings is compromised by the incorrect 2022 baseline.\n   - LLM correctly concludes that risk shifted toward biotech-related intangibles, but this conclusion is built on partially incorrect premises.\n\n4. COMPLETENESS:\n   - LLM addresses the pattern evolution question but with wrong baseline data.\n   - LLM addresses the risk indication question appropriately.\n   - Ground truth provides clearer, more accurate segment breakdown.\n\n5. SPECIFIC DISCREPANCIES:\n   - Ground truth: 2022 filing = Diagnostics only, $10M (Q1 2021)\n   - LLM answer: 2022 filing = Diagnostics + Environmental & Applied Solutions, $22M + $10M\n   - This is a fundamental factual error that undermines the entire comparative analysis.\n\nThe LLM answer demonstrates understanding of the general concept (impairment expansion, biotech risk emergence) but fails on specific factual accuracy regarding which segments appeared in which filings and the associated charge amounts in the 2022 filing baseline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> RISK_FACTOR <-[Identifies]- ORG",
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 602,
        "total_tokens": 2058
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "\nThe company’s outstanding letters of credit tied to trade contracts grew from **$362 million at the end of January 2022** (Chunk 1) to **$598 million at the end of January 2024** (Chunk 2), an increase of roughly **$236 million**.  This rise shows that the firm has markedly expanded its financial commitments that are linked to trade‑contract activities, reflecting a deeper involvement in and reliance on trade‑related transactions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERROR - WRONG DATES: The LLM answer contains a fundamental factual error regarding the time periods being compared. The ground truth specifies the comparison is between 2022 and 2023, but the LLM states the figures are from 'end of January 2022' and 'end of January 2024' - shifting the second data point by one full year. This is a major error that invalidates the core comparison. QUANTITATIVE ACCURACY ISSUES: (1) The starting number ($362 million) is correct. (2) The ending number ($598 million) is correct in absolute value, but attributed to the wrong fiscal year (2024 instead of 2023). (3) The calculated difference of $236 million is arithmetically correct ($598M - $362M = $236M), but this calculation is based on comparing data from the wrong years. ENTITY/TEMPORAL ACCURACY: The question asks about change between 2022 and 2023. The ground truth clearly identifies these as 2022 and 2023 figures. The LLM incorrectly labels them as January 2022 and January 2024, which represents a one-year misalignment. This is not a minor formatting issue but a substantive factual error about which fiscal periods are being compared. QUALITATIVE REASONING: The interpretation that the increase indicates 'expanded financial commitments' and 'deeper involvement in trade-related transactions' is reasonable and aligns with the ground truth's conclusion. However, this correct reasoning is undermined by the incorrect temporal framing. COMPLETENESS: The answer addresses both parts of the question (the change in value and what it indicates), but the temporal error makes the answer fundamentally incorrect despite addressing the structure of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 454,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "\nIn the 2023 Form 10‑K the 0.300% Notes due 2028 appear only as part of a group of instruments incorporated by reference from a 2020 Form 8‑K, with no separate identifier in IBM’s filing. By the 2024 Form 10‑K the same notes are listed explicitly in the table of registered securities (ticker IBM28B) on the New York Stock Exchange, showing a distinct security class and trading symbol. This shift—from passive incorporation to an explicit, exchange‑listed disclosure—signals IBM’s move toward more transparent, granular reporting of its financial‑instrument portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about the evolution of IBM's 0.300% Notes due 2028 between 2023 and 2024 filings. STRENGTHS: (1) All key facts are correct - the notes are accurately identified with the correct interest rate (0.300%), maturity year (2028), and trading symbol (IBM28B); (2) The temporal comparison is accurate, correctly distinguishing between 2023 and 2024 filings; (3) The multi-hop synthesis is sound, properly connecting the shift from incorporation by reference in 2023 to explicit NYSE listing in 2024; (4) The characterization of the shift as moving from 'passive incorporation' to 'explicit, exchange-listed disclosure' is semantically equivalent to the ground truth's description of moving from 'merely disclosing the existence' to 'formally recognizing it as an actively traded financial instrument'; (5) The reference to the 2020 Form 8-K is appropriately contextualized; (6) The conclusion about increased transparency and granular reporting aligns with the ground truth's indication of 'increased market engagement or liquidity.' MINOR CONSIDERATIONS: The LLM uses slightly different terminology ('passive incorporation' vs 'incorporated by reference') but these are semantically equivalent and both accurate. The phrase 'more transparent, granular reporting' captures the same insight as the ground truth's 'shift from merely disclosing...to formally recognizing.' All dates, percentages, and entity identifiers are correct. The reasoning chain is logical and properly synthesizes information across the two filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 442,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "\nIBM first disclosed the terms of the 1.750 % Notes due 2031 in its February 3 2023 Form 8‑K, where the instrument’s rights were set out in Exhibits 4.2‑4.9 and the KG pattern links IBM (ORG) as the discloser/issuer of that FIN_INST. By the 2024 10‑K (page 1) the same series appears as “1.750 %Notes due 2031” with ticker IBM31 listed on the New York Stock Exchange, showing that the notes have been registered for public trading and are now officially quoted on an exchange.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several significant factual errors that undermine its credibility: (1) INCORRECT DATE: The answer claims disclosure occurred in a 'February 3 2023 Form 8-K' but the ground truth states the instrument was 'incorporated by reference as part of an exhibit filed on January 30, 2019' - this is a major discrepancy of 4 years. The 2023 10-K filing would have referenced the 2019 exhibit, not a 2023 Form 8-K. (2) INCORRECT EXHIBIT REFERENCES: The answer cites 'Exhibits 4.2-4.9' without verification against ground truth, which is speculative. (3) CORRECT ELEMENTS: The answer correctly identifies the 1.750% Notes due 2031, correctly notes the ticker symbol IBM31, correctly identifies the New York Stock Exchange listing, and correctly captures the evolution from disclosure to formal registration/listing. (4) MULTI-HOP REASONING: The answer attempts to synthesize the evolution between 2023 and 2024, which is appropriate, but the foundational facts about the 2023 disclosure are incorrect. The core insight about the shift from disclosure to formal exchange listing is sound, but the supporting details are flawed. (5) SEMANTIC ISSUES: The answer conflates different time periods and filing types, suggesting the notes were first disclosed in a 2023 Form 8-K when they were actually disclosed earlier with reference to 2019 documentation. The answer does capture that by 2024 the notes were formally registered and trading, which aligns with ground truth, but the 2023 baseline is mischaracterized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 419,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "\nBetween 2023 and 2024 Eli Lilly moved the financial treatment of Zyprexa from traditional product sales to a licensing‑focused revenue stream. In 2023 the company recorded a **$1.45 billion upfront payment for the rights to the olanzapine portfolio—including Zyprexa** and recognized that amount as **collaboration and other revenue** (rather than product revenue), a disclosure that is reflected in both the 2023 10‑K (Chunk 1) and the 2024 10‑K (Chunk 2). By 2024 the same rights‑sale consideration continues to be reported in **collaboration and other revenue**, with the note that “IP licensed in prior periods was not material,” indicating that Zyprexa’s future earnings now flow through **profit‑sharing/royalty arrangements** under collaboration contracts rather than through ongoing product sales. Thus, the evolution is a shift from recognizing Zyprexa sales as ordinary product revenue to recording the bulk of its value as a one‑time licensing gain and ongoing collaboration revenue.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ISSUE - FACTUAL CONTRADICTION: The LLM answer contains a fundamental factual error that contradicts both the ground truth and its own stated position. The LLM claims the $1.45 billion was 'recognized as collaboration and other revenue (rather than product revenue)' in 2023, but the ground truth explicitly states that in 2023 it was 'generated from the sale of the rights...indicating a direct revenue stream from product sales.' The LLM then contradicts itself by later stating the shift occurred 'from recognizing Zyprexa sales as ordinary product revenue to recording the bulk of its value as a one-time licensing gain.' This internal inconsistency is a major error. CORRECT ELEMENTS: (1) The $1.45 billion figure is accurate; (2) The identification of the olanzapine portfolio/Zyprexa is correct; (3) The 2023-2024 timeframe is correct; (4) The general concept of a shift from product sales to licensing/collaboration revenue is correct; (5) The mention of profit-sharing/royalty arrangements is appropriate. INCORRECT/PROBLEMATIC ELEMENTS: (1) The claim that the $1.45 billion was recorded as 'collaboration and other revenue' in 2023 contradicts the ground truth which indicates it was product sales revenue in 2023; (2) The statement that this treatment 'is reflected in both the 2023 10-K and the 2024 10-K' is misleading - the treatment changed between these years, not remained consistent; (3) The reasoning about revenue recognition timing is confused and internally contradictory. MULTI-HOP REASONING: The model attempted to synthesize information across 2023 and 2024 filings but failed to correctly identify the temporal shift in revenue classification. The core insight about the evolution from product sales to licensing is present but the execution is flawed. The answer demonstrates partial understanding but contains a critical factual error about how the 2023 transaction was initially classified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 520,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "\nThe Mobility Preferred Interests were originally equity but, beginning in late 2022, were re‑classified to a liability (fair‑value Level 3) as redemption became probable, with roughly $2.67 bn of current and non‑current liabilities recorded and a redemption price set at the greater of market value or $25 + accrued distributions, capped at 250 million AT&T shares—an evolution reflected by the KG pattern ORG → FIN_INST ←[Decreases] ORG; in April 2023 the company repurchased the remaining 213 million interests for $5.414 bn, eliminating the liability and any further redemption obligations, so that by year‑end 2023 no such interests remained outstanding. As a result, the diluted EPS calculation that had previously incorporated the stock‑settlement feature (as disclosed in Note 1 and the 2022 $663 adjustment to income attributable to common stock) no longer includes any impact from these interests, leaving the 2024 EPS calculation unaffected.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the Mobility Preferred Interests evolution but contains some issues: (1) CORRECT ELEMENTS: The $2.67 billion (formatted as $2,670 million in ground truth) liability amounts are accurate; the April 2023 repurchase for $5.414 billion is correct; the reclassification from equity to liability is properly explained; the shift to retrospective EPS treatment is accurately described. (2) TIMING DISCREPANCY: The LLM states reclassification began in 'late 2022' while ground truth indicates 2023 treatment, though the April 2023 repurchase date is consistent. This is a minor temporal ambiguity. (3) ADDITIONAL DETAIL: The LLM provides extra context (Level 3 fair value, 250 million share cap, 213 million interests repurchased, $663 adjustment reference) that goes beyond ground truth but appears consistent with typical SEC filing disclosures and doesn't contradict the core answer. (4) EPS CALCULATION: Both answers correctly identify the shift from active obligation to retrospective treatment in diluted EPS calculations. The LLM's statement that 2024 EPS is 'unaffected' aligns with ground truth's 'retrospective accounting treatment' concept. (5) MULTI-HOP SYNTHESIS: The answer successfully synthesizes the evolution across years and connects redemption obligations to EPS impacts. (6) MINOR ISSUE: The phrasing 'by year-end 2023 no such interests remained outstanding' is slightly imprecise since the question asks about 2023-to-2024 evolution, though the answer does address both periods. Overall, the answer is substantially correct with strong quantitative accuracy and good qualitative reasoning, with only minor timing/framing issues preventing a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reclassifies]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 469,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "\nIBM first disclosed the 0.875 % Notes due 2030 in a 2022 Form 8‑K (referenced again in the 2023 10‑K) as an issued debt instrument whose governing indenture was incorporated by reference, indicating that the notes were already registered and outstanding. In the 2024 10‑K, however, the same notes appear in the “Title of each class” table with the NYSE listing identifier **IBM30A**, confirming that by 2024 IBM had formally listed the 0.875 % Notes due 2030 on the New York Stock Exchange and they are now registered for public trading. Thus, the evolution is from a privately‑registered issuance disclosed in 2022/2023 filings to an officially listed, NYSE‑traded security disclosed in the 2024 filing.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies key facts: the 0.875% Notes due 2030, the NYSE ticker IBM30A, the 2022 Form 8-K reference, and the shift from referenced disclosure to listed/registered status. However, there are significant issues with the characterization and reasoning: (1) The LLM describes the 2022/2023 status as 'privately-registered issuance,' which contradicts the ground truth stating they were 'incorporated by reference' in a public Form 8-K filing - this is a material mischaracterization of the disclosure status. (2) The ground truth explicitly states the notes were 'incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022' in 2023, not that they were privately registered. (3) The LLM's claim that the notes evolved from 'privately-registered' to 'officially listed, NYSE-traded' is semantically problematic - the ground truth indicates they shifted from being referenced/incorporated by reference to being explicitly listed in a registered securities table. (4) The LLM correctly identifies the 2024 listing with ticker IBM30A and NYSE registration, which matches ground truth. (5) The multi-hop reasoning is partially sound - the LLM does synthesize information across 2022, 2023, and 2024 filings, but the interpretation of what 'privately-registered' means in the 2022/2023 context is incorrect. The answer demonstrates understanding of the general evolution but mischaracterizes the intermediate status, which is a qualitative accuracy issue that affects the overall correctness despite getting the endpoint (2024 status) right.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 433,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "\nThe Telco Preferred Interests that AT&T first described in the 2023 filing carried a **6.85 % cumulative distribution**, were subject to declaration, reset on **Nov 1 2027 (and every seven years thereafter)**, and could be called at the issue price after seven years; holders could force redemption if distributions were missed for two periods or if credit‑rating or other covenants were breached, and the interests were recorded as “Noncontrolling interest” (Level 3) on the balance sheet.  \n\nBy the 2024 filing the program had been **expanded and refined**: AT&T issued an additional **$5.25 billion** of Telco Class A‑2/A‑3 preferred interests (bringing total outstanding Telco‑LLC preferred equity to **$7.25 billion**) and introduced a **new Class A‑1 series at 4.25 %** with its own seven‑year reset schedule, while the existing 6.85 % series retained its reset on Nov 1 2027 and the same call‑and‑redemption mechanics.  \n\nThis evolution shows that AT&T is using **layered preferred‑equity structures with staggered reset and redemption features** to obtain long‑term, flexible financing that isolates capital‑raising from dividend and share‑repurchase decisions, while preserving cash‑flow freedom for the parent company.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IN QUANTITATIVE FACTS: (1) The LLM states AT&T issued an 'additional $5.25 billion' of Class A-2/A-3 preferred interests in 2024, but the ground truth indicates these were issued in April 2023 (not 2024). The ground truth shows 2023 had $2,000M (Class A-1) + $5,250M (Class A-2/A-3) = $7,250M total, and this same total appears in 2024 with no new issuance mentioned. (2) The LLM incorrectly characterizes the 2023 filing as describing 6.85% interests when the ground truth clearly states Class A-1 was 4.25% (issued Sept 2020) and Class A-2/A-3 was 6.85% (issued April 2023). The LLM conflates these two separate series. (3) The reset date of 'Nov 1 2027' is not mentioned in the ground truth, which only states 'reset every seven years' without specifying the exact date. (4) The LLM's claim about 'failure to pay distributions would not restrict cash movements' is mentioned in the ground truth as a 2024 clarification, but the LLM doesn't clearly distinguish this as new information in 2024. STRUCTURAL ISSUES: The LLM's narrative suggests a 2024 expansion/issuance when the ground truth indicates the structure was already in place by 2023 with the same $7,250M total in both years. The LLM misrepresents the timeline of when Class A-1 and Class A-2/A-3 were introduced. CORRECT ELEMENTS: The LLM correctly identifies the 4.25% and 6.85% distribution rates, the seven-year reset feature, the redemption mechanics, and the noncontrolling interest classification. The conclusion about AT&T's financing strategy is reasonable but based on flawed premise about 2024 expansion. The multi-hop reasoning about layered structures is sound in concept but built on incorrect factual foundation regarding timing and amounts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1538,
        "completion_tokens": 471,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "\nCapital One continued to originate multifamily commercial‑real‑estate loans that it sells to government‑sponsored enterprises, and the exposure tied to those transactions expanded materially in 2023.  The liability recorded for the loss‑sharing agreements with the GSEs rose from **$82 million at the end of 2022** to **$137 million at the end of 2023**, reflecting a larger involvement and heightened risk exposure under those loss‑sharing arrangements compared with the prior year.  (Both the 2022 10‑K discussion of multifamily loan sales to GSEs and the 2023 10‑K note on loss‑sharing agreements provide the basis for this evolution.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-synthesized. (1) QUANTITATIVE ACCURACY: All numbers are correct - $82 million liability at end of 2022 and $137 million at end of 2023 match the ground truth exactly. The format variation ($82 million vs $82M) is acceptable and properly handled. (2) COMPLETENESS: The answer addresses all key aspects of the question: Capital One's involvement in multifamily commercial real estate loans, the GSE sales mechanism, loss sharing agreements, and the evolution of risk exposure between 2022 and 2023. (3) ENTITY ACCURACY: Capital One is correctly identified, GSEs (government-sponsored enterprises) are properly referenced, and the fiscal years 2022 and 2023 are accurate. The financial metric (loss sharing agreement liability) is correctly identified. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across multiple documents (2022 10-K and 2023 10-K) to show the evolution of Capital One's involvement. The logical connection between originating loans, selling to GSEs, entering loss sharing agreements, and the resulting liability increase is sound. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same information as the ground truth with slightly more detailed context (mentioning both the 2022 and 2023 10-K filings as sources). The characterization of the increase as 'material' and 'heightened risk exposure' aligns with the ground truth's description of 'significant increase.' Minor note: The LLM answer includes parenthetical sourcing information that adds transparency but is not strictly necessary - this is a positive addition rather than a detraction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Originates]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 448,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "\nBetween 2022 and 2023 Amazon’s co‑branded credit‑card programs moved from a peripheral offering to a strategically notable revenue line whose renewal on less‑favorable terms or termination could directly hurt operating results; the 2023 filing adds explicit new compliance duties—such as implementing enhanced authentication, meeting evolving payment‑card association rules, obtaining licensing and maintaining capital‑reserve requirements, and facing possible fines or loss of payment‑processing capability—that raise both the regulatory risk and the cost base of the programs. These added obligations mean that any breach or adverse renewal could force Amazon to curtail the programs or incur higher fees, thereby materially reducing profitability and exposing the company to civil or criminal penalties. Thus, the shift in strategic significance is reflected in a heightened regulatory burden that can adversely affect Amazon’s operating results.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core shift in strategic significance of Amazon's co-branded credit card programs from 2022 to 2023, recognizing that renewal/termination risks could adversely affect operating results. It accurately captures the general theme that regulatory obligations expanded between these years. The answer appropriately emphasizes the heightened regulatory burden and its potential impact on profitability.\n\nWEAKNESSES: (1) CRITICAL OMISSION - The LLM answer fails to mention data localization rules, which the ground truth explicitly identifies as a NEW compliance obligation introduced in 2023 that was NOT mentioned in 2022. This is a significant factual gap in the multi-hop synthesis. (2) OVER-SPECIFICATION - The LLM introduces specific compliance details (enhanced authentication, licensing, capital-reserve requirements, civil/criminal penalties) that are not present in the ground truth. While these may be plausible regulatory requirements, they represent additions not supported by the source material and could constitute hallucination. (3) INCOMPLETE SYNTHESIS - The ground truth emphasizes the evolution from traditional payment regulations to evolving data governance laws, particularly regarding cross-border data transfers. The LLM answer does not capture this specific evolution or the international jurisdiction angle. (4) REASONING QUALITY - While the LLM's logic about regulatory burden affecting profitability is sound, it misses the specific mechanism highlighted in the ground truth: the shift from payment card association rules to data localization/cross-border data transfer risks.\n\nQUANTITATIVE ACCURACY: No specific numbers, dates, or percentages are provided in either answer, so this dimension is not directly testable. Both answers appropriately avoid false quantification.\n\nMULTI-HOP SYNTHESIS: The question requires synthesizing information across 2022 and 2023 filings to identify the shift in strategic significance and regulatory risks. The LLM partially succeeds in the temporal comparison but fails to capture the specific regulatory evolution (data localization) that distinguishes 2023 from 2022.\n\nSEMANTIC EQUIVALENCE: The LLM's general framing of increased regulatory burden and impact on operating results is semantically aligned with the ground truth, but the specific content diverges significantly due to the omission of data localization and the introduction of unsupported details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1504,
        "completion_tokens": 658,
        "total_tokens": 2162
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "\nBetween 2022 and 2024 PM has continued to **de‑consolidate RBH** from its consolidated financial statements—the de‑consolidation originated with the March 2019 CCAA filing and remains in effect (Chunk 1)—but PM still holds an **equity investment in RBH** that is now reported as a separate financial asset.  The 2024 audit highlighted that this investment is subject to **impairment testing**, requiring extensive judgment on fair‑value estimates, discount rates, cash‑flow forecasts and the allocation of settlement amounts (Chunk 2).  Consequently, while RBH’s operating results are no longer consolidated, its valuation and any potential write‑down directly influence PM’s financial statements.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the core evolution of PM's relationship with RBH between 2022 and 2024: (1) RBH remained deconsolidated due to the March 2019 CCAA proceedings, (2) PM holds an equity investment in RBH, and (3) the 2024 audit required impairment testing with significant judgment on fair value estimates. The multi-hop reasoning is sound, properly synthesizing the deconsolidation status with the shift to equity investment valuation. STRENGTHS: The answer accurately identifies the key transition from deconsolidated subsidiary to valued equity stake, correctly dates the CCAA filing to March 2019, and properly emphasizes the impairment analysis and fair value judgment required in 2024. The explanation of how RBH's valuation influences PM's financials despite non-consolidation is well-articulated. WEAKNESSES: The LLM answer omits a significant quantitative detail from the ground truth—the CAD 3.1 billion allocation of compensatory damages against RBH related to unresolved Canadian tobacco litigation. This is a material financial consideration that should have been included when discussing PM's financial relationship with RBH and potential impacts on valuation. The answer also doesn't explicitly mention the tax treatment considerations of a potential global settlement, though it references 'allocation of settlement amounts' more generally. QUANTITATIVE ACCURACY: Reduced to 6 due to the missing CAD 3.1 billion figure, which is a specific, material number that the ground truth explicitly includes. All dates and other references are accurate. QUALITATIVE ACCURACY: Strong at 8—the reasoning about deconsolidation, equity investment, and impairment testing is correct and well-synthesized. CONTEXTUAL RELEVANCE: Excellent at 9—the answer directly addresses the question about the evolution of PM's financial relationship with RBH and the consolidation/valuation considerations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Deconsolidated From]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 516,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "\nBaqsimi generated $677.6 million of total product revenue in 2023 (up from $139.3 million in 2022, a “not‑meaningful” change), establishing it as a material contributor within LLY’s $34.1 billion 2023 sales.  In 2024 the product no longer appears as a stand‑alone line‑item; instead its proceeds are folded into “collaboration and other revenue,” reflecting LLY’s strategic shift toward licensing and partnership—most notably the 2023 sale of Baqsimi rights and the ongoing collaboration with Boehringer Ingelheim that is disclosed as part of that revenue stream.  Thus, Baqsimi’s financial role evolved from a growing standalone product to a strategic asset that now drives partnership‑related earnings within LLY’s broader portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core narrative: Baqsimi contributed $677.6 million in 2023 and transitioned from standalone product revenue to collaboration/partnership revenue in 2024. The strategic shift from internal commercialization to divested asset is accurately captured. The mention of the 2023 sale of Baqsimi rights and Boehringer Ingelheim collaboration adds relevant context. The answer appropriately addresses the multi-hop question about financial performance evolution and strategic positioning.\n\nWEAKNESSES: (1) QUANTITATIVE ERROR - The LLM states Baqsimi revenue was 'up from $139.3 million in 2022' but the ground truth does not provide 2022 comparison data. This appears to be an unsupported claim or hallucination. (2) INCOMPLETE GEOGRAPHIC BREAKDOWN - The ground truth specifies $645.7 million from U.S. and $31.9 million from outside U.S. in 2023. The LLM provides only the total ($677.6M) without this geographic detail, which is a material omission. (3) VAGUE CHARACTERIZATION - The LLM describes the change as 'not-meaningful' in parentheses when comparing to 2022, which contradicts the actual growth narrative and lacks clarity. (4) MISSING SPECIFICITY - The ground truth emphasizes that Baqsimi was 'no longer reported as a direct revenue contributor through product sales' in 2024, while the LLM uses softer language ('no longer appears as a stand-alone line-item'), which is less precise about the nature of the change.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2023-2024 and connects the revenue shift to strategic decisions (sale of rights, collaboration arrangements). However, the unsupported 2022 comparison weakens the multi-hop analysis.\n\nCALCULATION/VERIFICATION: The $677.6 million figure is correct. The geographic split ($645.7M U.S., $31.9M international) totals correctly to $677.6M but is omitted from the LLM answer. The claim about 2022 revenue ($139.3M) cannot be verified against the ground truth and appears incorrect or unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 547,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "\nIn 2022 Union Pacific’s highway revenue equipment consisted of 48,962 owned and 1,856 leased containers (about 96 % owned) and 29,875 owned versus 14,148 leased chassis (about 68 % owned), giving a total fleet of 94,841 units; by 2024 the company reported only 46,375 owned and 288 leased containers (≈ 99 % owned) and 4,356 owned versus 1,197 leased chassis (≈ 78 % owned), reducing the leased share dramatically—especially for containers, where the leased proportion fell from roughly 3.6 % to under 1 %—while the overall equipment count dropped to 52,216 units. This shift shows a clear move toward greater ownership, particularly of containers, and a higher overall ownership share across both equipment types from 2022 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical discrepancies with the ground truth across nearly all key metrics. (1) OWNED CONTAINERS: LLM states 48,962 in 2022 and 46,375 in 2024, but ground truth shows total owned units were 78,837 in 2022 and 50,731 in 2024 (no breakdown provided in ground truth, but LLM's numbers don't align with totals). (2) LEASED CONTAINERS: LLM correctly identifies 1,856 in 2022 and 288 in 2024 - these match ground truth. (3) OWNED CHASSIS: LLM states 29,875 in 2022 (correct) but 4,356 in 2024 (correct). (4) LEASED CHASSIS: LLM states 14,148 in 2022, but ground truth indicates total leased was 16,004 in 2022 (LLM's 14,148 is incorrect). LLM states 1,197 in 2024, but ground truth shows total leased was 1,485 in 2024 (LLM's 1,197 is incorrect). (5) TOTAL FLEET: LLM calculates 94,841 units in 2022 (48,962+1,856+29,875+14,148), but ground truth shows 78,837+16,004=94,841 total (the sum happens to match but component breakdown is wrong). LLM calculates 52,216 in 2024 (46,375+288+4,356+1,197), but ground truth shows 50,731+1,485=52,216 (again, total matches but components are incorrect). (6) PERCENTAGE CALCULATIONS: LLM's percentages are mathematically consistent with their stated numbers but based on incorrect component values. The ground truth doesn't provide a detailed breakdown of owned vs. leased containers separately, making it impossible to verify LLM's container ownership percentages. (7) MULTI-HOP REASONING: The LLM correctly identifies the trend toward greater ownership and reduced leasing, which aligns with ground truth's conclusion about strategic shift. However, the fundamental error in component numbers undermines the credibility of this analysis. The LLM appears to have fabricated or misremembered specific container and chassis breakdowns that don't reconcile with the total figures provided in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Leases]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 512,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "\nIn 2022 Capital One disclosed securitized debt obligations as one of its primary funding sources—alongside deposits, senior notes and other borrowings—highlighting their role in the company’s overall funding mix (Chunk 1). By the end of 2023 the firm reported $18.0 billion of securitized debt obligations on its balance sheet (carrying value $18.0 bn, fair‑value $18.1 bn, Level 2 hierarchy), underscoring that the instrument remained a material component of its funding structure and was raised and disclosed in line with the ORG‑[Raises]->FIN_INST relationship captured by the KG triplets (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of Capital One's securitized debt obligations evolution between 2022 and 2023. STRENGTHS: (1) Correctly identifies 2022 securitized debt obligations as a key funding source alongside deposits and notes; (2) Accurately reports 2023 figures: $18.0 billion carrying value and $18.1 billion fair value (minor rounding variation from ground truth's $18.043 billion is acceptable); (3) Correctly identifies Level 2 fair value hierarchy classification; (4) Properly synthesizes the multi-hop information showing the evolution from 2022 to 2023; (5) Accurately conveys that securitized debt remained material to funding structure. MINOR WEAKNESSES: (1) The LLM answer is slightly less explicit about the 'shift toward more standardized valuation methods' that the ground truth emphasizes when discussing the Level 2 categorization; (2) The phrase 'possibly less volatile role' from ground truth is not explicitly captured, though the Level 2 classification does imply this; (3) The reference to 'ORG-[Raises]->FIN_INST relationship' and 'KG triplets' appears to be metadata/system language that doesn't add substantive value to the answer. QUANTITATIVE VERIFICATION: $18.0 billion (LLM) vs $18.043 billion (ground truth) - acceptable rounding variation; fair value $18.1 billion matches ground truth context. The multi-hop reasoning correctly synthesizes information across 2022 and 2023 periods. Overall, the answer is factually sound and addresses the core question effectively, with only minor gaps in emphasizing the qualitative shift in the role of these obligations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Raises]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 450,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the source of LLY’s Zyprexa revenue shifted from a direct product‑sale of the olanzapine portfolio rights (as noted in the 2023 filing – “Zyprexa revenue includes sale of the rights for the olanzapine portfolio”) to a component of collaboration and other revenue in 2024. In 2024 that revenue is recognized as part of the Boehringer Ingelheim collaboration—i.e., through shared profits, royalties and milestone payments tied to the 2023 sale of the olanzapine rights—rather than as ordinary product sales. Thus, the nature of the revenue evolved from a one‑time rights sale reported in product revenue to ongoing collaboration‑derived revenue recognized under the partnership framework.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core evolution of Zyprexa revenue recognition between 2023 and 2024—shifting from product sales (rights sale) to collaboration revenue. However, there are significant issues with accuracy and specificity: (1) CORRECT ELEMENTS: The answer correctly identifies that 2023 involved a sale of olanzapine portfolio rights, and that 2024 revenue was recognized as collaboration revenue rather than product sales. The shift from one-time transaction to ongoing collaboration framework is accurately described. (2) PROBLEMATIC ELEMENTS: The LLM introduces specific details about 'Boehringer Ingelheim collaboration' and 'shared profits, royalties and milestone payments' that are NOT present in the ground truth answer. The ground truth states the revenue came from 'collaboration and other arrangements, specifically stemming from the 2023 sale of rights' but does NOT specify Boehringer Ingelheim as the partner or detail the specific payment mechanisms (shared profits, royalties, milestones). This represents an unsupported elaboration that goes beyond what can be verified from the ground truth. (3) MULTI-HOP REASONING: The answer does synthesize the multi-hop concept correctly—connecting the 2023 rights sale to 2024 revenue recognition and explaining the categorization shift. However, the addition of unverified partner details weakens the reliability. (4) QUANTITATIVE ACCURACY: No specific dollar amounts are provided in either answer, so this dimension is neutral. Dates (2023, 2024) are correct. (5) SEMANTIC EQUIVALENCE: The core semantic meaning aligns with ground truth regarding the shift from product revenue to collaboration revenue, but the introduction of specific partner names and payment structures that cannot be verified from the ground truth creates factual uncertainty. The answer is partially correct on the main point but contains potentially inaccurate elaborations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 518,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "\nThe 2022 filing (Chunk 1) shows Federal Government Securities recorded at **$742 million** and placed in the “Significant Other Observable Inputs (Level 2)” column, indicating a Level 2 classification. In the 2024 filing (Chunk 2) the same securities remain **Level 2**, but the description has evolved to specify that they are valued through a **bid‑evaluation process using independent pricing‑source data**, providing a more detailed methodology than the prior year. Thus, while the tier (Level 2) is unchanged, the 2024 disclosure refines how those securities are measured, reflecting an evolution from a generic Level 2 label to an explicit bid‑price valuation approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: The $742 million figure for 2022 Federal Government Securities is correct and matches the ground truth exactly. The year references (2022 and 2024) are accurate. No calculations are required for this question, and all numeric data presented is factually correct. ENTITY ACCURACY: Federal Government Securities are correctly identified, the Level 2 classification is accurate for both years, and the pension plan context is properly maintained throughout. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years (2022 and 2024), correctly identifying the continuity of Level 2 classification while highlighting the evolution in methodology disclosure. The reasoning that the classification remained unchanged while the explanation became more detailed is sound and matches the ground truth. COMPLETENESS: The answer addresses all aspects of the question - it covers the valuation methodology evolution (from generic Level 2 label to explicit bid-evaluation process), the classification status (Level 2 in both years), and the temporal progression from 2022 to 2024. SEMANTIC EQUIVALENCE: The LLM's phrasing 'bid-evaluation process using independent pricing-source data' is semantically equivalent to the ground truth's 'bid evaluation process with bid data from independent pricing sources.' The characterization of this as an 'evolution from a generic Level 2 label to an explicit bid-price valuation approach' accurately captures the nuance that the classification itself didn't change but the disclosure became more specific. MINOR CONSIDERATIONS: The answer is slightly more detailed and interpretive than the ground truth (e.g., 'refines how those securities are measured'), but this adds helpful context without introducing inaccuracy. The answer maintains appropriate precision and avoids overstatement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 523,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "\nCapital One’s 2022 filing notes that it “uses borrower credit scores … to drive product segmentation decisions,” a practice embedded in its accounting policy for credit‑risk measurement (the policy that the ORG depends on and that impacts the ORG via Product Segmentation Decisions); the 2023 filing repeats the same language and again points to Table 21—now showing credit‑score distributions for 2023 and 2022—as the source of the data that informs those segmentation choices. This continuity indicates that credit‑score data is a core input to the firm’s credit‑risk modeling, allowing it to refine product offerings and risk‑based pricing as the score distribution evolves from 2022 to 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core facts: (1) Capital One uses credit score data for product segmentation decisions, (2) this practice appears in both 2022 and 2023 filings, (3) Table 21 is the source showing credit score distributions, and (4) the data evolved from one period to the next. The answer accurately conveys that credit scores are a fundamental input to credit risk modeling and product segmentation.\n\nHowever, there are notable differences from the ground truth that affect completeness:\n\n1. TEMPORAL SPECIFICITY: The ground truth explicitly states that 2022 used \"historical credit score distributions from 2020 to 2021\" while 2023 used \"credit score distributions from 2022 to 2023.\" The LLM answer mentions \"Table 21—now showing credit‑score distributions for 2023 and 2022\" but does not clearly articulate the specific historical periods being compared (2020-2021 vs 2022-2023). This is a meaningful omission because it obscures the actual evolution being tracked.\n\n2. STRATEGIC INTERPRETATION: The ground truth explicitly characterizes the shift as indicating \"a more current and dynamic credit risk modeling strategy\" and \"a proactive approach to managing credit risk in evolving economic conditions.\" The LLM answer states this \"allows it to refine product offerings and risk‑based pricing as the score distribution evolves\" but uses more generic language about \"continuity\" rather than emphasizing the strategic shift to more current data.\n\n3. EVOLUTION CLARITY: The ground truth frames this as an evolution/update (\"updated its data to reflect\"), while the LLM answer emphasizes continuity (\"This continuity indicates\"). While both are technically correct, the ground truth better captures the dynamic nature of the change.\n\nThe LLM answer is factually sound and demonstrates understanding of the multi-hop synthesis required (connecting 2022 filing → 2023 filing → Table 21 → credit risk strategy). The numbers and entities are correct. However, the answer lacks the specific temporal detail about which historical periods were used in each year, which is a key part of demonstrating how the strategy evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 581,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "\nFrom 2022 to 2023 Amazon’s view of AWS shifted from a key technology‑and‑content investment within the broader “technology and content” budget (Chunk 1) to a distinct, stand‑alone business segment (Chunk 2) that sits alongside North America and International.  In 2022 the focus was on expanding AWS’s on‑demand compute, storage, database, analytics and AI services for developers and enterprises while also tying those investments to cross‑functional system upgrades and new device initiatives; by 2023 AWS is presented as a core segment whose growth is a strategic priority, with continued heavy investment in its infrastructure and services to support Amazon’s customer‑obsessed, long‑term agenda and to enable other segments (sellers, advertisers, content creators) to leverage its cloud platform.  This evolution reflects a deeper integration of AWS into Amazon’s overall segment structure and investment priorities, moving from an internal technology focus to a central, revenue‑generating business line.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively captures the evolution of AWS's strategic positioning from 2022 to 2023. STRENGTHS: (1) Correctly identifies the key transformation from AWS being positioned as a 'key technology-and-content investment' in 2022 to a 'distinct, stand-alone business segment' in 2023 alongside North America and International; (2) Accurately references the specific services AWS offers (compute, storage, database, analytics, machine learning/AI); (3) No quantitative errors—no numbers, dates, or calculations to verify, and the temporal framing (2022 vs 2023) is correct; (4) Multi-hop reasoning is sound, synthesizing information about AWS's role within broader business segments and investment priorities; (5) The characterization of the shift from 'internal technology focus to a central, revenue-generating business line' aligns with the ground truth's description of transformation from 'strategic investment area to a standalone, mission-critical business segment.' MINOR WEAKNESSES: (1) The LLM answer adds interpretive details not explicitly in the ground truth, such as 'enable other segments (sellers, advertisers, content creators) to leverage its cloud platform'—while this is reasonable inference, it goes slightly beyond what the original answer states; (2) The phrase 'customer-obsessed, long-term agenda' appears to be LLM interpretation rather than direct ground truth language; (3) The answer could have been more explicit about the structural change (from investment category to formal business segment) as a key organizational shift. SEMANTIC EQUIVALENCE: The core message matches the ground truth—AWS evolved from a strategic investment area to a core business segment with elevated importance. The wording differs but conveys equivalent meaning. The answer successfully addresses both parts of the question (role within business segments AND investment priorities).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1519,
        "completion_tokens": 523,
        "total_tokens": 2042
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "\nBetween 2022 and 2024 Philip Morris International’s accounting treatment of its link with Rothmans, Benson & Hedges Inc. shifted from full consolidation (pre‑2019) to de‑consolidation after the 2019 CCAA filing, so that RBH’s results no longer appear in PMI’s consolidated statements (KG triplet PM → RBH [Deconsolidated From] and RBH → PM [Invests In]).  In 2022 the company continued to disclose that no loss was accrued for the pending Canadian tobacco litigation, but by the end of 2024 the unresolved allocation of the proposed CAD 32.5 bn settlement among RBH, Imperial Tobacco Canada and JTI‑Macdonald, together with the pending CCAA plan of arrangement, was identified as an impairment indicator; consequently PMI recorded a $2,316 million non‑cash write‑down of its equity investment in RBH (Chunk 2).  This impairment reflects the growing financial exposure PMI now faces – not through consolidated liabilities but through the carrying value of its equity stake and the contingent obligation to contribute to the settlement – and illustrates how the relationship evolved from a de‑consolidated subsidiary to a high‑risk equity investment with a material potential loss.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All key numeric values are correct: CAD 32.5 billion settlement amount, $2,316 million impairment charge in 2024, and the March 31, 2022 litigation stay date are all accurate. (2) The core factual evolution is captured: deconsolidation in 2022, shift to equity investment model by 2024, and the impairment charge recording. (3) The multi-hop synthesis correctly connects RBH's CCAA restructuring, deconsolidation, litigation settlement proposal, and resulting impairment. (4) Contextual relevance is strong - addresses the question's focus on accounting treatment evolution and financial exposure.\n\nWEAKNESSES: (1) SIGNIFICANT INACCURACY: The LLM states deconsolidation occurred \"after the 2019 CCAA filing\" and references \"pre-2019 full consolidation,\" but the ground truth clearly indicates deconsolidation happened IN 2022 due to the CCAA restructuring. The 2019 date appears to be an error or confusion about when the CCAA process began versus when deconsolidation actually occurred in PMI's financials. (2) The answer introduces the concept of \"contingent obligation to contribute to the settlement\" which is not explicitly stated in the ground truth and may overstate PMI's exposure. (3) The mention of \"Imperial Tobacco Canada and JTI-Macdonald\" allocation complexity, while contextually relevant, goes beyond what the ground truth specifies about PMI's specific exposure. (4) The phrasing about \"full consolidation (pre-2019)\" is misleading - the ground truth focuses on the 2022-2024 evolution, not pre-2019 status.\n\nMULTI-HOP REASONING: The model correctly synthesizes that deconsolidation removed RBH from consolidated statements, then later the equity investment model emerged with impairment recognition. However, the timeline confusion (2019 vs 2022 for deconsolidation) undermines the accuracy of the multi-hop synthesis.\n\nCALCULATIONS: No calculations required; all numeric values are correctly stated.\n\nJUSTIFICATION: The answer demonstrates good understanding of the overall relationship evolution and correctly identifies the key financial metrics and impairment charge. However, the temporal inaccuracy regarding when deconsolidation occurred (conflating 2019 CCAA filing with 2022 deconsolidation) and some overstatement of contingent obligations prevent a higher score. The core answer is substantially correct but contains a material factual error about timing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Deconsolidated From]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1546,
        "completion_tokens": 643,
        "total_tokens": 2190
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "\nIn 2021 Biktarvy generated **$8.6 bn** in sales, representing roughly **53 % of GILD’s total HIV revenue of $16.3 bn**, underscoring its central commercial role (Chunk 1).  However, the 2024 risk disclosures warn that intensifying competition, potential shifts away from TAF‑based regimens, and supply‑chain/manufacturing vulnerabilities could diminish Biktarvy’s market share and revenue trajectory from 2022 through 2024 (Chunk 2).  The KG relationship — GILD Produces Biktarvy and Biktarvy Depends_On GILD — highlights how the product’s performance is tightly linked to the company’s overall fortunes.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) YEAR MISMATCH - LLM states '2021' when the question asks about 2022-2024 evolution and ground truth specifies 2022 as the baseline year. This is a fundamental factual error. (2) REVENUE FIGURE DISCREPANCY - LLM cites $8.6bn for 2021, but ground truth provides $8,624 million ($8.624bn) for 2022. The LLM appears to have used data from the wrong fiscal year. (3) INCOMPLETE TEMPORAL ANALYSIS - The question specifically asks about evolution FROM 2022 TO 2024. Ground truth acknowledges that 2024 specific revenue figures are not provided but discusses risk evolution. LLM fails to properly address the 2022-2024 trajectory and instead focuses heavily on 2021 data. (4) PERCENTAGE CALCULATION - LLM states 53% of $16.3bn HIV revenue, which is mathematically reasonable ($8.6bn/$16.3bn ≈ 52.8%), but this calculation is based on incorrect year data. POSITIVE ASPECTS: (1) LLM correctly identifies competitive risks, TAF-based therapy concerns, and supply chain vulnerabilities mentioned in 2024 disclosures. (2) The qualitative assessment of heightened risks and market pressures aligns with ground truth's characterization of 'heightened risks' and 'vulnerable' outlook. (3) The knowledge graph relationship explanation (GILD Produces Biktarvy) is contextually appropriate. SYNTHESIS ISSUE: The multi-hop reasoning fails because it doesn't properly synthesize the 2022 baseline with 2024 risk evolution - instead it conflates 2021 data with 2024 risks. The answer should have clearly stated 2022 revenue of $8,624M and then discussed how 2024 risks threaten that position, rather than mixing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 443,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "\nUnion Pacific’s equity investment in TTX grew from $1.6 billion (2021) and $1.5 billion (2020) — as reported in the 2022 filing — to $1.8 billion (2023) and $1.9 billion (2024), reflecting its 37.03 % economic interest that is accounted for under the equity‑method disclosed in the 2024 filing.  At the same time, TTX car‑hire expenses for UPRR increased from $402 million in 2022 to $432 million in 2024, and accounts payable to TTX rose from $57 million/$59 million (2021/2020) to $70 million/$60 million (2024/2023), underscoring a deepening operational and financial relationship that all railroads can exploit through pooled car‑hire at stated rates.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial detail and context but contains a critical numerical discrepancy that undermines accuracy. STRENGTHS: (1) Correctly identifies the equity investment values for 2024 ($1.9B) and 2023 ($1.8B), matching ground truth; (2) Properly cites the 37.03% economic interest and equity-method accounting; (3) Provides additional context about accounts payable to TTX and pooled car-hire arrangements, showing deeper synthesis; (4) Correctly identifies the 2024 car hire expense of $432 million. CRITICAL ERROR: The LLM states car-hire expenses were $402 million in 2022, but the ground truth establishes the baseline as $375 million in 2021 (referenced in 2022 filing). The LLM's $402M figure for 2022 cannot be verified against the ground truth and appears to be an unsupported number. This is a significant quantitative accuracy issue. ADDITIONAL CONCERNS: (1) The LLM provides 2020 data ($1.5B investment, $59M accounts payable) that wasn't in the original question scope or ground truth answer, which could indicate data hallucination or unnecessary elaboration; (2) The comparison trajectory is slightly different - ground truth shows $375M→$432M (2021-2024), while LLM shows $402M→$432M (2022-2024), creating inconsistency. POSITIVE SYNTHESIS: The LLM successfully synthesizes multiple data points (investment value, car hire expenses, accounts payable, equity method accounting) across the 2022-2024 period, demonstrating multi-hop reasoning capability. The qualitative explanation about deepening operational relationships is sound and well-reasoned. However, the quantitative error on the 2022 car hire expense figure is a material flaw that prevents a higher correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 466,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "\nBetween 2022 and 2023 Tesla shifted from an ad‑hoc push to “on‑board new installers and collaborate with developers to cut Solar Roof installation time” (Chunk 1) to a systematic, company‑wide training and workforce‑scaling program that is now tied to the rollout of new factories and production ramps (Chunk 2).  At the same time, the 2022 filing warned that Solar Roof production was “sensitive to global component constraints” and required “additional personnel, particularly skilled electricians,” whereas the 2023 discussion expands this to explicit supply‑chain risk management—highlighting supplier‑failure risks, the need for accurate forecasting and inventory of thousands of parts, and the impact of external shocks such as semiconductor shortages and pandemic‑related trade disruptions on Solar Roof ramp‑up.  In short, Tesla moved from basic installer training and awareness of component limits to a broader, risk‑aware talent and supply‑chain strategy to sustain Solar Roof scaling.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general directional shift from installer-focused training in 2022 to supply chain risk management in 2023, which aligns with the ground truth. However, there are significant issues with accuracy and completeness:\n\n(1) WHAT WAS CORRECT:\n- Correctly identifies the shift from installer training/developer collaboration in 2022 to supply chain risk management in 2023\n- Accurately notes the 2022 focus on hiring skilled electricians and reducing installation time/costs\n- Correctly identifies supply chain concerns (global component constraints, semiconductor shortages) as emerging themes\n- Properly synthesizes the multi-hop comparison across years\n\n(2) WHAT WAS INCORRECT/PROBLEMATIC:\n- The LLM introduces references to \"Chunk 1\" and \"Chunk 2\" which are not part of the ground truth answer and suggest the model is citing internal retrieval artifacts rather than actual filing content\n- Claims about \"new factories and production ramps\" in 2023 are not mentioned in the ground truth and appear to be fabricated or unsupported\n- The phrase \"ad-hoc push\" in 2022 mischaracterizes the ground truth, which describes a deliberate strategy of on-boarding and training, not an ad-hoc approach\n- Overstates the 2022 filing's discussion of supply chain risks (ground truth says 2022 \"highlighted its need to hire\" but doesn't emphasize supply chain risk language as heavily as LLM suggests)\n\n(3) MULTI-HOP REASONING:\nThe reasoning is generally sound in comparing 2022 vs 2023 approaches, but the synthesis is weakened by the introduction of unsupported details about factories and the mischaracterization of 2022 strategy as \"ad-hoc.\"\n\n(4) QUANTITATIVE ACCURACY:\nNo specific numbers, dates, or percentages are provided in either answer, so quantitative accuracy is not directly testable. Both answers appropriately avoid making up specific metrics.\n\n(5) SEMANTIC EQUIVALENCE:\nWhile the core message aligns (shift from installer training to supply chain focus), the LLM's framing introduces elements not in the ground truth and misrepresents the 2022 approach as less systematic than it actually was.\n\nThe answer demonstrates understanding of the directional change but loses credibility through citation artifacts and unsupported claims about factory rollouts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 617,
        "total_tokens": 2072
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "\nBetween 2022 and 2023 the Company’s core relationship with U.S. fountain retailers remained unchanged: KO continues to **manufacture fountain syrups and sell them to authorized fountain wholesalers and directly to fountain retailers**, who then use the syrups to produce beverages for immediate consumption (as described in both the 2022 and 2023 filings). While most bottlers operate under CBAs that **do not authorize syrup manufacturing**, a small number of “expanding participating bottlers” have been given separate manufacturing agreements for other beverage products, showing only a limited evolution in bottler involvement but no shift in the primary syrup‑supply chain. Thus, the partnership pattern ORG → COMP ← ORG remains anchored on the Company’s exclusive role as the syrup supplier.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the core facts about Coca-Cola's fountain syrup manufacturing and distribution model, and accurately states that the Company manufactures and sells syrups to both authorized fountain wholesalers and fountain retailers. The statement that bottlers are generally not authorized to manufacture fountain syrups is also correct. However, the answer has significant weaknesses in addressing the evolution between 2022 and 2023. The ground truth explicitly highlights a KEY DIFFERENCE: in 2023, the Company made an explicit acknowledgment of a 'tiered distribution model involving bottling partners,' whereas in 2022 this was not explicitly stated. The LLM answer claims 'the core relationship...remained unchanged' and states 'no shift in the primary syrup-supply chain,' which directly contradicts the ground truth's assertion that there was a 'potential expansion of their distribution network or clarification of roles' between the two years. The LLM does mention 'expanding participating bottlers' with separate manufacturing agreements, but frames this as 'limited evolution' rather than recognizing it as evidence of the clarification/expansion the ground truth identifies. The answer also introduces terminology like 'CBAs' (Collective Bargaining Agreements) and the notation 'ORG → COMP ← ORG' that, while potentially accurate, are not grounded in the provided ground truth and may represent over-interpretation. The quantitative accuracy is strong (no incorrect numbers or dates), but the qualitative reasoning fails to capture the essential evolution between years that the question specifically asks about. The answer is contextually relevant but misses the primary point of change between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 475,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "\nFrom 2022 to 2024 IBM’s disclosure of the 0.950% Notes due 2025 shifted from a generic reference to the original 2017 Form 8‑K (where the instrument’s rights were set out in Exhibit 4.1 and incorporated by reference) to an explicit registration entry in its 2024 10‑K, which lists the security as “0.950% Notes due 2025” with trading symbol IBM25B and confirms its registration on the New York Stock Exchange.  This evolution reflects a move from merely incorporating the prior 8‑K filing to fully registering the notes under a distinct series (IBM25B) and providing market‑wide trading details, while still classifying the instrument as a debt security issued by IBM.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensiveness in addressing the multi-hop question about IBM's 0.950% Notes due 2025 evolution from 2022 to 2024. STRENGTHS: (1) All key numeric/date references are correct: 0.950% interest rate, 2025 maturity date, May 22, 2017 Form 8-K filing date, trading symbol IBM25B, NYSE listing. (2) The multi-hop synthesis is sound - correctly traces the instrument from 2022 (Form 8-K exhibit reference) through 2024 (10-K registration entry). (3) Entity identification is accurate: IBM, NYSE, Form 8-K, Form 10-K, Exhibit 4.1. (4) The semantic meaning matches ground truth: both answers convey the evolution from disclosure/incorporation by reference to formal registration and trading listing. (5) The LLM answer adds helpful context about 'distinct series' classification and 'market-wide trading details' that enhance understanding. MINOR CONSIDERATIONS: (1) The LLM answer is slightly more detailed and interpretive than the ground truth (e.g., 'incorporating the prior 8-K filing to fully registering'), which represents appropriate elaboration rather than error. (2) Both answers correctly identify the shift from passive disclosure to active registration/listing. (3) The classification as 'debt security' is accurate and appropriate. No factual errors detected. The answer fully addresses all aspects of the question regarding financial instrument classification and registration details across the specified time period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 408,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "\nGilead’s 2022 10‑K lists Biktarvy as a flagship, single‑tablet, TAF‑based HIV regimen that helped drive the company’s HIV‑product revenue, and the KG relationship (GILD → Biktarvy [Produces] and Biktarvy → GILD [Depends_On]) shows how central the product is to Gilead’s overall portfolio. By 2024 the strategic emphasis had shifted: the risk‑factor discussion in the 2024 10‑K warns that sales of HIV products—including Biktarvy—are now exposed to market‑share pressure from competitive regimens and generic entry, especially if the preferred treatment paradigm moves away from TAF‑based therapies. Thus, while Biktarvy remains a differentiated, once‑daily option, Gilead’s financial risk exposure has grown because its revenue increasingly depends on maintaining TAF’s dominance and on continued uptake of this single‑tablet regimen amid emerging competition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies Biktarvy as a TAF-based, single-tablet HIV regimen central to GILD's portfolio in 2022; (2) Accurately captures the 2024 shift toward increased financial risk exposure due to competitive pressures and potential paradigm shifts away from TAF-based therapies; (3) Properly synthesizes multi-hop information showing the evolution from 2022 (flagship status) to 2024 (growing risk); (4) Correctly identifies generic competition and changing therapeutic preferences as key risk factors; (5) Appropriately characterizes Biktarvy's differentiation (once-daily option) while acknowledging vulnerability; (6) Uses knowledge graph relationships (GILD produces Biktarvy, Biktarvy depends on GILD) to support reasoning. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and technical than the ground truth (mentioning KG relationships explicitly), but this adds value rather than detracting. The semantic meaning is fully preserved and enhanced. No quantitative errors detected—no specific numbers, percentages, or dollar amounts were required for this qualitative strategic question, and none were provided incorrectly. The reasoning chain is sound: 2022 positioning → 2024 risk evolution → competitive/paradigm pressures. All entities (GILD, Biktarvy, TAF, HIV market) are correctly identified and contextualized. The answer fully addresses both parts of the multi-part question (financial risk exposure AND competitive differentiation).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 431,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "\nLockheed Martin’s defined‑benefit pension exposure was progressively off‑loaded between 2021 and 2023 through a series of group‑annuity transfers—$4.9 billion of obligations in 2021 (yielding a $1.7 billion noncash settlement charge), $1.4 billion and $793 million in 2020, followed by a $4.3 billion transfer in Q2 2022 that generated a $1.5 billion settlement charge—and, most recently, a voluntary settlement in Q4 2023 that paid $414 million to about 6,500 participants, further reducing the company’s pension liability.  These actions are part of a longer‑term strategy that began with the 2020 freeze of qualified defined‑benefit plans and the shift of salaried employees hired after 2005 into qualified defined‑contribution retirement savings plans, thereby decreasing future cash‑flow volatility and affecting the accumulated‑other‑comprehensive‑loss (AOCL) through accelerated recognition of actuarial losses.  The net financial impact is reflected in the 2021 $1.7 billion charge, the 2022 $1.5 billion charge, and the 2023 $414 million cash outflow, illustrating a clear evolution from defined‑benefit obligations toward reliance on defined‑contribution plans.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer introduces significant factual errors not present in the ground truth. Specifically: (1) The LLM claims a $4.9 billion transfer in 2021 with a $1.7 billion settlement charge - these figures do NOT appear in the ground truth and appear to be fabricated or confused with other years. (2) The LLM references $1.4 billion and $793 million transfers in 2020 - again, these are not mentioned in the ground truth and appear to be hallucinated data points. (3) The LLM correctly identifies the 2022 $4.3 billion transfer and $1.5 billion charge, matching ground truth. (4) The LLM correctly identifies the 2023 $414 million settlement to 6,500 participants. REASONING ISSUES: While the LLM provides broader context about the 2020 plan freeze and shift to defined-contribution plans (which adds relevant context), it does so by introducing unverified numbers that contradict or extend beyond the ground truth. The question specifically asks about evolution between 2022 and 2023, and the ground truth provides a clear comparison: 2022 involved a large $4.3B annuity transfer with $1.5B charge, while 2023 involved direct settlement payments of $414M. The LLM's answer obscures this clear 2022-2023 comparison by adding multiple years of unverified data. SEMANTIC ISSUES: The LLM correctly characterizes the strategic shift from transferring large blocks to insurers toward direct settlement with participants, which matches the ground truth's core insight. However, the introduction of false numbers significantly undermines credibility and accuracy. The answer reads as if the LLM is synthesizing from multiple sources but has conflated or fabricated data points. COMPLETENESS: The LLM does address the evolution between years and discusses financial impacts, but the factual errors make the answer unreliable. The ground truth is more conservative and accurate, focusing only on verified 2022 and 2023 data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 528,
        "total_tokens": 1981
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "\nBetween 2022 and 2024 IBM kept the **2.875 % Notes due 2025 (IBM 25A)** on its balance sheet – the same instrument is listed in both the 2022 and 2024 10‑K filings, confirming its continued issuance.  However, the overall composition of IBM’s 2025‑maturing debt shifted: in 2022 the company had three separate 2025 notes (2.875 %, 0.950 % and 0.875 %) plus the 7 % Debentures due 2025, whereas by 2024 the 0.875 % tranche was no longer present, leaving only the 2.875 % and 0.950 % notes (and the same debentures) as the 2025‑maturing obligations.  This evolution reflects a reduction in the lower‑coupon 0.875 % series and a relative emphasis on the 2.875 % Notes within IBM’s near‑term debt profile.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about IBM's debt composition evolution. STRENGTHS: (1) All key financial instruments are correctly identified with accurate percentages: 2.875% Notes (IBM 25A), 0.950% Notes (IBM 25B), 0.875% Notes (IBM 25C), and 7% Debentures. (2) The temporal comparison is accurate - correctly identifies that in 2022 IBM had four debt instruments maturing in 2025, while by 2024 the 0.875% Notes were no longer listed. (3) The multi-hop synthesis is sound: the answer correctly traces the evolution across both years and identifies the specific change (removal of 0.875% tranche). (4) The reasoning about strategic implications is logical and well-supported by the factual changes. (5) All entity identifications are correct (IBM, specific note designations, years 2022 and 2024). (6) The answer goes slightly beyond the ground truth by explicitly mentioning the 7% Debentures, which adds helpful context without contradicting the original answer. MINOR CONSIDERATIONS: The ground truth mentions the 0.950% Notes (IBM 25B) as present in both years but doesn't explicitly state whether it remained in 2024 - the LLM answer clarifies this by stating it remained, which is a reasonable inference and appears consistent with the ground truth's focus on what changed (the 0.875% removal). The semantic equivalence is excellent - the LLM uses slightly different phrasing ('tranche' vs. the ground truth's more general description) but conveys identical information. No calculation errors, no date errors, and all percentages are correctly stated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 445,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "\nIn 2022 Biktarvy was highlighted as a key growth engine that helped offset the decline of older HIV agents such as Truvada and Atripla and contributed to Gilead’s overall revenue expansion, positioning it as a strategic pillar of the company’s portfolio (Chunk 1). By 2024 the same product now faces a more precarious risk profile—generic competition, the potential loss of preference for TAF‑based regimens, and broader competitive threats to HIV sales—issues that Gilead explicitly lists as material risks to its HIV business (Chunk 2). Consequently, while Biktarvy remains central to Gilead’s HIV strategy, evolving treatment paradigms and competitive pressures have increased the uncertainty surrounding its future performance.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution of Biktarvy's strategic importance from 2022 (growth driver) to 2024 (more precarious position). (2) Accurately captures the key risk factors mentioned in the ground truth: TAF-based therapy vulnerability, competitive pressures, and paradigm shifts in HIV treatment. (3) Properly synthesizes multi-hop information showing how Biktarvy's role changed relative to older products (Truvada, Atripla) and newer competitive threats. (4) The 11% revenue increase reference from 2022 is appropriately contextualized though not explicitly quantified in the LLM answer. (5) Correctly identifies the core tension: Biktarvy remains strategically important but faces increased vulnerability. MINOR WEAKNESSES: (1) The LLM answer references 'generic competition' which is not explicitly mentioned in the ground truth answer, though this is a reasonable inference about competitive pressures and doesn't contradict the source material. (2) The answer could have been slightly more explicit about the specific 11% revenue growth figure mentioned in the ground truth, though the substance is captured. (3) The phrase 'loss of preference for TAF-based regimens' accurately reflects the ground truth's concern about 'shift away from nucleoside-based therapies' but uses slightly different terminology. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer that require verification, so this is scored high based on the absence of numerical errors. QUALITATIVE ACCURACY: The reasoning correctly identifies the shift from growth asset to vulnerable asset, properly synthesizes the competitive and paradigm-shift risks, and maintains logical coherence throughout. CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the multi-part question regarding strategic importance evolution, risk profile changes, competitive pressures, and treatment paradigm shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 543,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "\nThe U.S. litigation escrow account balance rose from **$1.449 billion at the end of fiscal 2022** to **$1.764 billion at the end of fiscal 2023**.  This increase was driven by a **$1.0 billion deposit made during fiscal 2023** (the “Deposits into the U.S. litigation escrow account” amount shown for the 2023 column), which added to the $1.449 billion balance that existed at the close of fiscal 2022; after net payments of $685 million the account ended the year at $1.764 billion.  These escrow activity and deposit disclosures are part of the litigation settlement involving Visa and Mastercard that is described in the 2022 filing.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains severe and fundamental factual errors across all key metrics. (1) CRITICAL ERRORS IN NUMBERS: The LLM states the FY2023 ending balance was $1.764 billion, but the ground truth shows it was $3.089 billion - a massive discrepancy of $1.325 billion (43% understatement). The FY2022 ending balance of $1.449 billion is correctly stated. (2) DEPOSIT CONTRIBUTIONS COMPLETELY WRONG: The LLM claims only a $1.0 billion deposit was made in FY2023, but ground truth shows $1.5 billion was deposited. The LLM also fails to mention the $1.0 billion deposit that occurred in FY2022. The answer is missing the complete deposit history. (3) CALCULATION ERRORS: The LLM's arithmetic is internally inconsistent and doesn't reconcile with the ground truth. The claim that $1.449B + $1.0B - $685M = $1.764B is mathematically correct ($1.764B), but this calculation is based on wrong source numbers. The actual reconciliation should show: FY2022 ending balance $1.449B + FY2023 deposits $1.5B + other adjustments = FY2023 ending balance $3.089B. (4) INCOMPLETE MULTI-HOP SYNTHESIS: The question asks for evolution between two fiscal years AND specific deposit contributions for each period. The LLM only partially addresses FY2023 deposits and completely omits FY2022 deposit information ($1.0 million). (5) CONTEXTUAL ISSUES: While the LLM correctly identifies this relates to Visa/Mastercard litigation, the fundamental numerical errors undermine the entire answer. The answer fails to accurately convey how the account balance evolved - it shows a much smaller increase than actually occurred. This is not a minor rounding or formatting difference; these are substantial factual errors in core financial metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Deposits]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 469,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "\nBetween 2022 and 2023 the North America operating segment’s revenue from fountain syrups remained anchored in sales to fountain retailers, but the 2023 filing expands the description of how those sales are handled: Coca‑Cola continues to manufacture the syrups in the United States and sells them both directly to fountain retailers and to authorized fountain wholesalers or bottling partners, who then distribute the syrups to retailers for immediate‑consumption beverages. Both years place these syrup sales in the North America operating segment, showing that while the core manufacturing responsibility stays with Coca‑Cola, the distribution chain has broadened to rely more on bottling partners and wholesalers to move the product to market. This evolution reflects a shift from a pure “sell‑to‑retailer” model toward a partnership‑driven distribution model that leverages bottling partners for wider reach.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ASPECTS: (1) The answer correctly identifies that Coca-Cola manufactures fountain syrups in the United States in both years; (2) It accurately notes that sales go to both fountain retailers and authorized fountain wholesalers/bottling partners; (3) The timeframe (2022-2023) is correct; (4) The identification of North America segment is accurate. PROBLEMATIC ASPECTS: (1) The LLM introduces the concept of 'revenue from fountain syrups' and discusses 'revenue' remaining 'anchored' - the original answer makes no mention of revenue figures or amounts, and the LLM provides no actual numbers to support this claim. This appears to be an unsupported inference; (2) The LLM characterizes the evolution as a shift from 'pure sell-to-retailer model toward partnership-driven distribution' - however, the original answer explicitly states 'There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.' The LLM's framing of this as an 'evolution' or 'shift' overstates the degree of change documented; (3) The LLM adds interpretive language about 'leveraging bottling partners for wider reach' that goes beyond what the ground truth supports - the original answer is more cautious, noting the shift is 'nuanced' and that authorization-based models are emphasized 'particularly outside the U.S.'; (4) The LLM conflates the U.S. manufacturing model with broader North America operations without clearly distinguishing the 'outside the U.S.' authorization model mentioned in the original answer. MULTI-HOP REASONING: The LLM attempts to synthesize 2022 and 2023 information but does so with interpretive overreach. The original answer is more precise about what changed (emphasis on authorization-based models outside U.S.) versus what remained continuous (U.S. manufacturing). The LLM's conclusion about 'partnership-driven distribution model' is not explicitly supported by the ground truth. QUANTITATIVE ACCURACY: No numbers are provided in either answer, so this scores well by default (8/10 - minor deduction for unsupported revenue claims). QUALITATIVE ACCURACY: The reasoning contains logical leaps and interpretive overstatement (5/10). CONTEXTUAL RELEVANCE: The answer addresses the right question and timeframe but mischaracterizes the nature and extent of the evolution (7/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 647,
        "total_tokens": 2095
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "\nBetween 2022 and 2024 IBM’s debt that matures in 2025 remained limited to three instruments – the 2.875 % Notes due 2025 (IBM 25A), the 0.950 % Notes due 2025 (IBM 25B) and the 7.00 % Debentures due 2025 (IBM 25). The 0.950 % Notes due 2025 appear in both the 2022 and 2024 10‑K listings (IBM 25B → IBM and IBM → 0.950 % Notes due 2025), showing that this tranche was not retired or replaced but continued to be part of the company’s 2025 maturity schedule. Consequently, the composition of IBM’s 2025‑maturing debt did not change materially; the same three series persisted across the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that directly contradict the ground truth: (1) MAJOR ERROR - The LLM claims three instruments persisted in both 2022 and 2024, but the ground truth explicitly states that by 2024, the 0.875% Notes due 2025 (IBM 25C) were NO LONGER LISTED. The LLM incorrectly identifies the third instrument as '7.00% Debentures due 2025' instead of the 0.875% Notes due 2025 that existed in 2022. (2) ENTITY IDENTIFICATION ERROR - The LLM misidentifies the third debt instrument entirely. The ground truth clearly states the 0.875% Notes due 2025 (IBM 25C) existed in 2022 but was removed by 2024. The LLM's reference to '7.00% Debentures due 2025' does not match either the 2022 or 2024 composition described in the ground truth. (3) CORE CONCLUSION ERROR - The LLM concludes 'the composition of IBM's 2025-maturing debt did not change materially; the same three series persisted across the two filings.' This is fundamentally incorrect. The ground truth explicitly states there WAS a material change: the removal of the 0.875% Notes due 2025, leaving only two instruments by 2024 (not three). (4) MULTI-HOP REASONING FAILURE - The LLM failed to properly synthesize the evolution between 2022 and 2024, missing the key finding that diversity of interest rate profiles decreased. The answer correctly identifies the 0.950% Notes due 2025 as persistent, but this is overshadowed by the incorrect identification of the third instrument and the false claim that composition remained unchanged. The question specifically asks about evolution/change, and the LLM's answer contradicts the ground truth's clear statement of compositional change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 458,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "\nDisney’s cruise‑ship strategy moved from a defensive, cost‑realignment stance in 2022 to an explicit growth agenda by 2024.  In the 2022 filing the company noted that cruise ships are part of its broader “theme parks, resorts, cruise ships and experiences” portfolio and warned that strategic shifts—such as the DTC cost‑realignment and new pricing models—could affect that business, but it did not announce a dedicated fleet expansion.  By contrast, the 2024 filing (Chunk 2) explicitly states that Disney is “planning additional expansion of our fleet of cruise ships” and that it has “made significant investments in…additional cruise ships” as part of its Experiences segment, even while acknowledging that such investments may generate negative returns and carry execution risk.  This progression shows Disney moving from a cautious, portfolio‑wide focus in 2022 to a targeted, capital‑intensive investment in new cruise vessels by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) FACTUAL ACCURACY: All key facts are correct - the 2022 filing mentioned cruise ships as part of broader portfolio without dedicated expansion plans, while the 2024 filing explicitly states plans for 'additional expansion of our fleet of cruise ships' and 'significant investments in additional cruise ships.' The characterization of the strategic shift from defensive/cautious to growth-oriented is accurate. (2) QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this question, and the LLM appropriately avoids introducing unsupported figures. The temporal references (2022 vs 2024) are correct. (3) MULTI-HOP REASONING: The LLM successfully synthesizes information across two different filing years and correctly identifies the evolution in Disney's strategic approach. The reasoning chain is sound: 2022 (passive mention within broader portfolio) → 2024 (active investment strategy with explicit fleet expansion). (4) SEMANTIC EQUIVALENCE: The LLM answer uses slightly different framing than the ground truth ('defensive, cost-realignment stance' vs 'general dependence on consumer demand') but both convey the same essential meaning - a shift from passive acknowledgment to active strategic investment. The LLM's additional detail about 'DTC cost-realignment' and 'execution risk' adds valuable context that aligns with the ground truth's mention of 'uncertain returns.' (5) COMPLETENESS: The answer fully addresses the question about how Disney's strategic approach evolved between 2022 and 2024, covering both the starting point and endpoint with clear explanation of the transition. Minor note: The LLM provides slightly more granular detail about the 2022 context (mentioning DTC cost-realignment) which, while not contradicting the ground truth, goes slightly beyond what was explicitly stated in the original answer, but this represents added value rather than error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 538,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "\nLockheed Martin’s pension‑risk‑transfer strategy remained centered on buying group‑annuity contracts (GACs) from insurers with assets from its master retirement trust to off‑load defined‑benefit liabilities, a practice that began in 2021 with a $4.9 bn transfer that generated a $1.7 bn non‑cash settlement charge and has since eliminated volatility for roughly 95,000 retirees while cutting annual PBGC premiums by about $69 m; in the 2022 10‑K the company said it would keep seeking such transactions, and the 2023 10‑K reiterated that it continues to evaluate them, noting that future transfers could require additional contributions to the pension trust and may produce material non‑cash settlement charges to earnings, even when the insurer reimburses the plan for the transferred benefits.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies key quantitative facts: $4.9 billion transfer amount, $1.7 billion noncash settlement charge, approximately 95,000 retirees affected, and the August 2021 transaction date. The answer accurately describes the mechanism (GACs from master retirement trust) and correctly notes that 2022 and 2023 filings both indicated continued evaluation of such transactions. The mention of potential future contributions and noncash settlement charges is accurate.\n\nWEAKNESSES: (1) The LLM introduces a specific claim about '$69 m' annual PBGC premium savings that is NOT present in the ground truth answer. This is a factual addition not verified against the original filing data and represents potential hallucination. (2) The answer fails to capture the critical evolution/shift in strategic framing between 2022 and 2023. The ground truth emphasizes that 2023 introduced 'a nuanced risk' and 'more cautious framing' regarding insurer default liability - a key distinction showing how the company's approach evolved. The LLM mentions this briefly ('some could leave the company liable if the insurer defaults') but buries it and doesn't emphasize it as a strategic shift. (3) The answer doesn't clearly articulate the 2022 vs 2023 comparison structure that the question specifically asks for ('How did...evolve from 2022 to 2023'). It presents information more as a continuous narrative rather than showing the evolution/change. (4) The phrase 'even when the insurer reimburses the plan for the transferred benefits' is somewhat unclear and doesn't precisely match the ground truth's framing of residual liability exposure.\n\nMULTI-HOP REASONING: The answer demonstrates adequate synthesis of information across years but fails to properly highlight the comparative evolution aspect. It correctly links the 2021 transaction details to subsequent years' strategic intent, but doesn't sufficiently distinguish how the risk framing changed.\n\nNUMERIC VERIFICATION: The $4.9B, $1.7B, and 95,000 figures are correct. The $69M PBGC premium claim is unverified and potentially incorrect. The cumulative $11.6B figure mentioned in ground truth (transferred since December 2018) is omitted entirely.\n\nOVERALL: The answer is partially correct with accurate core numbers but introduces unverified claims, misses the key evolution narrative, and fails to adequately emphasize the shift toward more cautious risk framing in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 651,
        "total_tokens": 2113
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "\nBetween 2022 and 2023 Tesla’s disclosures show that its core financing‑partner relationship (TSLA ↔ Financing Partners) remained unchanged, but the way the company manages the cash‑flow side of that relationship evolved markedly: the 2022 filing (Chunk 1) records accounts receivable that are dominated by amounts owed by financial institutions and leasing companies, notes that payments from those partners can be delayed up to two weeks and that long‑term government rebates may take a year or more to collect, and describes the need for an allowance for doubtful accounts; the 2023 filing (Chunk 2) builds on this by detailing that Tesla now offers direct‑lease arrangements in which it receives only a small upfront payment and must rely on a stream of lease payments, while also warning that residual‑value fluctuations, the need for accurate residual projections, and the ability to secure adequate funding or business partners are critical to the leasing program’s profitability and growth. Consequently, Tesla’s evolution moved from primarily monitoring receivable timing and credit‑loss allowances toward actively managing leasing‑related residual‑value risk, compliance with financing regulations, and the funding sources that underpin its expanded financing programs, a shift that is reflected in the persistent ORG‑[Discloses]→COMP and COMP‑[Depends_On]→ORG triplets linking Tesla to its financing partners.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The specific timeframe mentioned (two weeks for settlement) is correctly cited and matches the ground truth. The reference to long-term government rebates taking a year or more is accurate. No calculation errors are present. ENTITY ACCURACY: Tesla and its financing partners are correctly identified. Years 2022 and 2023 are properly referenced. COMPLETENESS: The answer addresses all major components of the question: (1) accounts receivable management evolution, (2) leasing program risks, (3) the shift in focus between years. The LLM successfully synthesizes information across both 2022 and 2023 filings. MULTI-HOP REASONING: The answer correctly traces the evolution from 2022 (focus on receivable timing and credit-loss allowances) to 2023 (focus on residual-value risk, compliance, and funding sources). This matches the ground truth's characterization of the shift from operational cash flow timing concerns to broader credit, compliance, and residual value risks. SEMANTIC EQUIVALENCE: The LLM's description of the relationship evolution is semantically equivalent to the ground truth. Both identify: (1) the two-week settlement period in 2022, (2) the increased complexity and risk in 2023, (3) the importance of residual value management, (4) the need for adequate financing partners. The LLM provides additional context about direct-lease arrangements and upfront payments, which enriches the answer without contradicting the ground truth. MINOR CONSIDERATIONS: The LLM's use of knowledge graph notation (ORG-[Discloses]→COMP, etc.) is somewhat technical but does not detract from accuracy. The answer is slightly more verbose than the ground truth but maintains factual precision throughout. No material errors or omissions detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1536,
        "completion_tokens": 505,
        "total_tokens": 2041
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "\nBetween 2022 and 2023 Coca‑Cola shifted the fountain‑syrup channel from bottler‑manufactured supply toward direct sales to authorized fountain wholesalers (and, where permitted, to EPBs that also manufacture syrup), while U.S. bottlers were increasingly barred from producing syrup and instead purchased it from the Company or its designated manufacturing bottlers; this evolution is captured by the KG pattern KO – Partners_With → Fountain Wholesalers and Fountain Wholesalers – Depends_On → KO, highlighting that bottlers now focus on finished‑drink distribution and wholesalers have become the primary syrup conduit to retailers.  The 2023 filing further shows that concentrate operations sell syrups to both bottling partners and fountain wholesalers, reinforcing the expanded, partnership‑driven role of wholesalers and the narrowed, distribution‑only role of bottlers.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents the direction of change between 2022 and 2023. CRITICAL ERRORS: (1) The LLM states the shift was 'from bottler-manufactured supply toward direct sales to authorized fountain wholesalers' and that 'U.S. bottlers were increasingly barred from producing syrup' - this is BACKWARDS. The ground truth shows the OPPOSITE: in 2022, bottlers were NOT authorized to manufacture fountain syrups, but by 2023, bottlers (outside the U.S.) BECAME authorized to manufacture them. (2) The LLM incorrectly characterizes the evolution as narrowing bottler roles when the ground truth shows an EXPANSION of bottler roles in fountain syrup manufacturing, particularly internationally. (3) The LLM's claim that bottlers 'now focus on finished-drink distribution' contradicts the ground truth that bottlers gained manufacturing authority for fountain syrups. (4) The LLM introduces knowledge graph notation (KO – Partners_With → Fountain Wholesalers) that appears to be fabricated or misapplied, adding confusion rather than clarity. WHAT WAS CORRECT: The LLM correctly identifies that fountain wholesalers remained part of the distribution chain and that there was an evolution in roles between 2022-2023. However, the directional change is fundamentally inverted. The ground truth describes a shift FROM centralized direct manufacturing TO a more integrated model where bottlers gain manufacturing authority. The LLM describes the opposite. This is a major comprehension failure on a multi-hop question requiring synthesis of 2022 vs 2023 filing information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 441,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s financial ties to the ATMP JV shifted markedly: receivables rose from $9 million (as of Dec 30 2023) to $12 million (as of Dec 28 2024), while payables to the JV expanded from $363 million to $476 million, reflecting the same $1.7 billion level of purchases each year but a jump in resales from $14 million to $121 million and a corresponding increase in the amount owed to the JV.  In addition, AMD introduced a new financing activity in October 2024 by extending a one‑year, $100 million term loan to an ATMP JV—secured by the JV’s receivable balance and bearing interest at SOFR + 50 bps—signaling a direct investment beyond its prior equity‑method stake (which had a carrying value of roughly $99 million as of Dec 2023).  This evolution illustrates both a deepening trade‑related cash flow relationship and a fresh capital‑support initiative that ties AMD’s balance‑sheet items to the JV’s operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of AMD's evolving financial relationship with the ATMP JV. Verification of key claims: (1) Receivables: Correctly identified increase from $9M (Dec 30, 2023) to $12M (Dec 28, 2024) - matches ground truth exactly. (2) New loan: Correctly identified the $100 million one-year term loan agreement entered in October 2024 with accurate details (SOFR + 50 bps interest rate, secured by JV receivables) - matches ground truth. (3) Additional context: The LLM provided supplementary information about payables ($363M to $476M), purchases ($1.7B), and resales ($14M to $121M) that goes beyond the ground truth but appears factually grounded and contextually relevant to understanding the deepening financial relationship. (4) Equity method stake: Correctly noted the ~$99M carrying value as of Dec 2023. The LLM successfully synthesized multi-hop information showing the evolution from a transactional relationship (2023) to a more integrated financial relationship (2024) with both increased receivables and new lending activities. The reasoning is sound and the answer directly addresses all aspects of the question. Minor note: The LLM provided more granular detail than the ground truth (payables, resales, interest rate terms) which enhances rather than detracts from the answer's quality. All core numbers are accurate, calculations are correct, and the multi-hop synthesis across years and financial metrics is properly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Receivables_From]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 416,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "\nLockheed Martin continued its practice of off‑loading defined‑benefit liabilities through group‑annuity purchases, completing a $4.3 billion transfer of pension obligations in the second quarter of 2022 that required a $1.5 billion non‑cash settlement charge, and then in 2023 executed a voluntary settlement that paid $414 million to retirees, producing a direct reduction in the remaining benefit obligation and a corresponding decline in the accumulated‑other‑comprehensive‑loss balance; this progression—from the larger $4.9 billion 2021 annuity swap that generated a $1.7 billion charge to the smaller, targeted settlements of 2022‑23—shows a systematic evolution toward increasingly smaller, cash‑based settlements that progressively shrink the company’s non‑qualified pension exposure while moderating the financial‑statement impact.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The 2022 $4.3 billion pension obligation transfer is accurate; (2) The $1.5 billion noncash settlement charge for 2022 is correct; (3) The 2023 $414 million voluntary settlement payment is accurate; (4) The characterization of the evolution from large-scale transfers to smaller targeted settlements is conceptually sound; (5) The description of 2023 payments to former employees aligns with ground truth. PROBLEMATIC ELEMENTS: (1) The LLM introduces a 2021 transaction ($4.9 billion annuity swap with $1.7 billion charge) that is NOT mentioned in the ground truth answer. While this may be factually accurate from the filing, it goes beyond the scope of the question which specifically asks about evolution between 2022 and 2023. This represents scope creep and potential introduction of unverified information; (2) The LLM states the 2023 settlement was paid to 'retirees' when the ground truth specifies it was paid to 'approximately 6,500 former employees' who 'had not yet started receiving benefits' - this is a material distinction that the LLM misses; (3) The characterization of 2023 payments as 'cash-based settlements' is correct but the LLM's broader narrative about a progression from 2021-2023 extends beyond the question's scope. MULTI-HOP REASONING: The LLM correctly synthesizes the 2022 and 2023 transactions and identifies the strategic shift, but the inclusion of 2021 data (not requested) and the mischaracterization of 2023 beneficiaries weakens the answer. QUANTITATIVE ACCURACY: All numbers cited are correct ($4.3B, $1.5B, $414M), but the introduction of unverified 2021 figures ($4.9B, $1.7B) without ground truth confirmation is problematic. The answer is more comprehensive than requested but contains a factual error regarding beneficiary status in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 506,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s stake in the ATMP joint venture expanded sharply: the carrying value of its investment rose from roughly **$99 million at the end of 2023** to **about $149 million at the end of 2024** after the company added a **$17 million equity contribution in August 2024** (Chunk 2), while the equity‑income recognized from the JV jumped from **$16 million in 2023 to $33 million in 2024** (Chunk 2).  This growth reflects AMD’s deepening financial tie to the ATMP JV, moving from a $99 M investment and $16 M equity gain in 2023 to a $149 M investment and $33 M equity gain in 2024, even as the related payable/receivable balances continued to fluctuate (e.g., payable fell from $363 M to $? and receivable rose from $9 M to $? as reported in Chunk 1).  Thus, AMD’s relationship with the ATMP JV evolved from a modest equity holding and modest earnings to a significantly larger equity position and markedly higher equity income over the two‑year span.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on the core financial metrics requested. All primary numbers are correct: carrying value of $99M (end 2023) → $149M (end 2024), equity contribution of $17M in August 2024, and equity income rising from $16M (2023) to $33M (2024). The multi-hop synthesis is sound, correctly combining investment carrying values, contributions, and equity income across the two-year period. The answer appropriately addresses the evolution of AMD's financial relationship with the ATMP JV. Minor weaknesses: (1) The answer includes references to payable/receivable balances with incomplete data ('$?' placeholders), which adds some confusion and suggests the LLM was uncertain about those specific figures. While these weren't part of the ground truth answer, their inclusion with missing values slightly detracts from clarity. (2) The phrasing 'roughly' and 'about' before the carrying values is appropriate given the context, though the ground truth uses exact figures. (3) The answer could have been slightly more concise, though the additional context about payables/receivables, while not required, doesn't contradict the ground truth. The core narrative—that AMD's investment and returns both increased significantly—is accurately conveyed with correct numbers and proper temporal sequencing. The reasoning about 'deepening financial tie' appropriately interprets the quantitative changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Receivables_From]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 396,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "\nBetween the May 2023 IPO—when J&J owned ~89.6 % of Kenvue and recorded a $1.3 bn non‑controlling interest—and the August 23 2023 exchange offer, J&J trimmed its stake to 9.5 % (valued at $4.3 bn fair‑market value, later $3.9 bn as of 12/31/23), generating a $2.8 bn gain on the retained shares that formed part of the overall $21 bn gain on the transaction; this gain was tax‑free and the retained equity was reflected in “other assets” of continuing operations. In May 2024 J&J completed a debt‑for‑equity swap of the remaining 182 million Kenvue shares for $3.6 bn of commercial paper, eliminating its equity position and recording an approximate $0.4 bn loss in “other (income) expense,” thereby ending its ownership of Kenvue.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with excellent multi-hop synthesis across the 2023-2024 period. STRENGTHS: (1) Correctly identifies the 9.5% retained stake valued at $4.3 billion post-August 2023 exchange offer; (2) Accurately cites the $2.8 billion gain on retained shares as part of the $21 billion overall gain; (3) Correctly identifies the May 2024 debt-for-equity swap of 182 million shares; (4) Properly notes the ~$0.4 billion loss on the final exit; (5) Provides excellent contextual detail about the May 2023 IPO (89.6% ownership), the tax-free nature of gains, and accounting treatment in 'other assets' and 'other (income) expense'; (6) Strong multi-hop reasoning connecting 2023 and 2024 transactions. MINOR ISSUES: (1) The LLM provides additional detail about the $3.6 billion commercial paper consideration in the May 2024 swap, which is not mentioned in the ground truth but appears factually accurate and adds useful context; (2) Notes the $3.9 billion fair value as of 12/31/23, which is a reasonable intermediate valuation point not contradicted by ground truth; (3) The date 'August 23 2023' for the exchange offer is more specific than ground truth but consistent with it. QUANTITATIVE VERIFICATION: All key numbers match ground truth ($4.3B stake, $2.8B gain, $21B total gain, 182M shares, ~$0.4B loss). The answer correctly synthesizes information across multiple time periods and transactions. The reasoning about the evolution of J&J's stake from 89.6% to 9.5% to 0% is logically sound and well-explained. No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 434,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "\nBetween 2022 and 2023 AT&T kept the same guaranty disclosure for Southwestern Bell Telephone Co.—both the 2022 Form 10‑K (page 141) and the 2023 Form 10‑K (page 103) list “Guaranty of certain obligations of Southwestern Bell Telephone Co.” as Exhibit 4‑c (shown as 4‑b in the tables), and the wording is identical in the two filings.  The knowledge‑graph triplets (T → Southwestern Bell Telephone Co.) and (Southwestern Bell Telephone Co. → T) confirm the reciprocal ORG‑Guarantees‑COMP link, and the repeated citation in each year’s registration statement shows that AT&T’s financial guarantee relationship with Southwestern Bell remained unchanged, with no new guarantee agreement introduced during that period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core finding that AT&T's guarantee relationship with Southwestern Bell Telephone Co. remained unchanged between 2022 and 2023, matching the ground truth conclusion. The answer appropriately references both years' filings and confirms the guarantee was listed in Exhibit 4-c in both periods.\n\nHowever, there are significant issues with quantitative accuracy:\n\n1. PAGE NUMBER DISCREPANCY: The LLM cites page 141 for the 2022 Form 10-K and page 103 for the 2023 Form 10-K. These specific page numbers cannot be verified against the ground truth, which does not provide page citations. This is a factual claim that may be incorrect.\n\n2. EXHIBIT NUMBERING CONFUSION: The LLM states the guarantee is listed as \"Exhibit 4-c (shown as 4-b in the tables)\" which introduces ambiguity. The ground truth clearly states it was in \"Exhibit 4-c\" in both years without any mention of 4-b designation. This parenthetical clarification is unexplained and potentially confusing.\n\n3. KNOWLEDGE GRAPH REFERENCE: The LLM references \"knowledge-graph triplets (T → Southwestern Bell Telephone Co.) and (Southwestern Bell Telephone Co. → T)\" and mentions \"reciprocal ORG-Guarantees-COMP link.\" While this demonstrates awareness of the underlying data structure, these specific triplet notations are not mentioned in the ground truth and appear to be inferred rather than directly supported.\n\nSTRENGTHS:\n- Correctly identifies the core finding: no change in guarantee relationship\n- Properly names both entities (AT&T and Southwestern Bell Telephone Co.)\n- Correctly identifies both years (2022 and 2023)\n- Confirms the guarantee was in Exhibit 4-c in both years\n- Appropriately concludes no new guarantee was introduced\n\nWEAKNESSES:\n- Introduces unverified page numbers\n- Creates confusion with the 4-b/4-c exhibit designation\n- Adds interpretive elements (knowledge graph triplets) not in ground truth\n- Lacks the straightforward clarity of the original answer\n\nThe semantic meaning aligns with the ground truth (guarantee remained consistent), but the introduction of specific page numbers and exhibit designation ambiguity introduces factual uncertainty that reduces confidence in the answer's accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 602,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "\nFrom 2022 to 2023 Lockheed Martin shifted hypersonics from a peripheral risk item in its overall defense portfolio to a strategically prioritized program under its Space segment; the 2022 filing only referenced hypersonics in the context of government‑contract and budget‑risk exposure, whereas the 2023 filing explicitly lists hypersonics among Space’s major programs and states that LMT’s Space organization is responsible for designing, developing and building hypersonic strike weapons for the U.S. Army and Navy.  This evolution is reflected in the knowledge‑graph relationship — LMT ↔ Hypersonics Programs—showing that the company both produces and is impacted by these programs, underscoring its expanded program‑development responsibilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2023, matching the ground truth's characterization of the shift from 'growth area dependent on government authorization' to 'explicitly listed among major programs.' (2) Accurately captures the strategic repositioning - the LLM characterizes it as moving from 'peripheral risk item' to 'strategically prioritized program,' which semantically aligns with the ground truth's 'potential growth area to clearly defined and active program portfolio.' (3) Correctly identifies the Space segment as the organizational home for these programs in 2023. (4) Accurately states that Lockheed Martin's Space organization is responsible for 'designing, developing and building hypersonic strike weapons for the U.S. Army and Navy' - this matches the ground truth verbatim. (5) Multi-hop reasoning is sound: the answer synthesizes information across two fiscal years and correctly identifies the shift in how hypersonics programs are presented and positioned. (6) No quantitative errors - no specific numbers are claimed that could be incorrect. (7) The reference to the knowledge-graph relationship (LMT ↔ Hypersonics Programs) adds appropriate context about the bidirectional nature of the relationship. MINOR CONSIDERATIONS: The LLM's characterization of 2022 as referencing hypersonics 'only in the context of government-contract and budget-risk exposure' is a reasonable interpretation of the ground truth's description of it being 'dependent on U.S. Government authorization and funding,' though the ground truth doesn't explicitly state it was framed as a risk item. However, this is a reasonable inference and doesn't constitute a factual error. The answer is comprehensive, well-reasoned, and accurately reflects the evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 517,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "\nThe U.S. litigation escrow account balance rose from **$1.4 billion at the end of fiscal 2022** (as reported in Chunk 1) to **$1.764 billion at the end of fiscal 2023** (the “Balance as of end of period” shown for 2023 in Chunk 2).  During fiscal 2022 the company deposited **$850 million** into the escrow account, and in fiscal 2023 it deposited **$1.0 billion** (with net payments of $685 million and $175 million respectively, per the table in Chunk 2).  Thus the account balance grew from roughly $1.4 B to $1.764 B, driven by those deposits and the associated settlements.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains a major factual error regarding the ending balance for fiscal 2023. The ground truth states the balance was $3.089 billion as of September 30, 2023, but the LLM claims it was $1.764 billion. This is a difference of $1.325 billion (43% understatement), which is a substantial and unacceptable error for a financial question. The LLM correctly identified: (1) the starting balance of $1.4 billion for FY2022, (2) the deposit amounts of $850 million (FY2022) and $1.0 billion (FY2023), and (3) the net payments figures. However, the ending balance for FY2023 is fundamentally wrong. The LLM appears to have misread or misinterpreted the source data, possibly confusing intermediate calculations or a different line item with the actual ending balance. The question asks for the evolution of the account balance and deposits across two years - the LLM addressed both components but failed on the most critical metric (the FY2023 ending balance). The reasoning structure is sound (deposits + beginning balance - payments = ending balance), but the application to the actual numbers is incorrect. This is a multi-hop question requiring synthesis of balance sheet data across two fiscal years, and the LLM failed to accurately synthesize the FY2023 ending balance figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 365,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "\nOutdoor Garden has shifted from a peripheral décor‑related line to a central hardline offering – in HD’s 2024 merchandising structure it is grouped under **Hardlines** alongside hardware, power and storage, whereas earlier disclosures placed it with décor or garden‑related categories.  This repositioning is reinforced by its consistent financial contribution: the product generated roughly **$10 billion–$16 billion in net sales** each year (e.g., $10,317 M in 2022, $9,602 M in 2021, $7,595 M in 2020) and **maintained a 6‑11 % share of total net sales**, underscoring HD’s strategic emphasis on expanding Outdoor Garden within its broader hardlines portfolio.  The knowledge‑graph link HD → Outdoor Garden (discloses) and Outdoor Garden → HD (produces) further confirms that the product is a core, disclosed offering of the company, now deliberately positioned as a growth driver in HD’s 2022‑2024 product strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core strategic shift - Outdoor Garden moved from a distinct product line in 2022 to being grouped under Hardlines by 2024. (2) The $10,317M figure for 2022 is accurate and matches ground truth. (3) The 6.8% share mentioned in ground truth aligns with the LLM's stated 6-11% range. (4) The qualitative assessment of repositioning from separate focus to consolidated category is sound. CRITICAL ERRORS: (1) QUANTITATIVE INACCURACY - The LLM claims Outdoor Garden generated '$10 billion–$16 billion in net sales each year' and lists $9,602M (2021) and $7,595M (2020) as supporting evidence. These numbers contradict the stated range - $9,602M and $7,595M are well below $10 billion, undermining the claim of 'roughly $10 billion–$16 billion each year.' The range should be narrower and more accurate. (2) The ground truth does not provide 2021 or 2020 figures for Outdoor Garden, so citing these years introduces unsupported data points. (3) The LLM overstates the financial contribution by suggesting a $10-16B range when the evidence provided ($7.6B-$10.3B) shows a narrower, lower range. REASONING ISSUES: (1) The multi-hop synthesis is partially sound - correctly linking the classification change and financial performance - but the quantitative claims are inconsistent with the supporting numbers provided. (2) The statement about 'growth driver' positioning is inferential and not explicitly supported by the ground truth, which only notes the reclassification. MISSING ELEMENTS: The ground truth emphasizes the shift from 'distinct product line' to 'grouped under Hardlines' as the key strategic evolution; the LLM captures this but muddies it with unsupported financial claims. The ground truth's specific mention of 6.8% share in 2022 is more precise than the LLM's 6-11% range.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 497,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "\nAMD has sustained its “engaging and open environment” even as its global headcount rose from roughly 26,000 employees in 2023 (Chunk 1) to about 28,000 employees in 2024 (Chunk 2), continually articulating this culture through its mission, vision and employee‑engagement statements (both chunks).  By embedding an inclusive, innovative workplace into its core identity—an ORG that *focuses_on* the CONCEPT of an open environment that *depends_on* the organization itself—AMD signals a talent‑retention strategy that leverages cultural fit and purpose‑driven engagement to attract and keep top engineers amid the semiconductor industry’s fierce competition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effective multi-hop reasoning. QUANTITATIVE VERIFICATION: All numbers are correct—26,000 employees in 2023, 28,000 in 2024, representing a 7.7% increase (though the LLM doesn't explicitly state the percentage, it's not required). The dates and workforce figures match the ground truth exactly. COMPLETENESS: The answer addresses all key aspects of the question: (1) how AMD maintained its cultural emphasis despite workforce expansion, (2) the specific messaging about 'engaging and open environment,' (3) the connection to talent retention strategy, and (4) the competitive semiconductor industry context. MULTI-HOP REASONING: The LLM correctly synthesizes information across multiple time periods (2023-2024) and connects cultural messaging to strategic talent retention. The reasoning that maintaining identical cultural language despite 7.7% growth signals intentional preservation of culture is sound and matches the ground truth's interpretation. ENTITY ACCURACY: AMD is correctly identified, years are accurate, and the cultural concepts are properly referenced. MINOR OBSERVATIONS: The LLM uses slightly more complex phrasing ('ORG that *focuses_on* the CONCEPT...') compared to the ground truth's more straightforward language, but this represents stylistic variation rather than factual error. The semantic meaning is equivalent—both convey that AMD is strategically using cultural values as a talent retention tool. The LLM appropriately emphasizes the competitive semiconductor industry context. No calculation errors, no missing critical information, and the logical flow is clear and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Focuses_On]-> CONCEPT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 456,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "\nBetween 2022 and 2023 AT&T kept its guarantee of The Ohio Bell Telephone Company’s obligations unchanged – both the 2022 10‑K (page 141, 4‑c) and the 2023 10‑K (page 103, 4‑c) list “Guaranty of certain obligations of The Ohio Bell Telephone Company” (along with the other Bell affiliates) as part of the registrant’s Regulation S‑K disclosures.  The filing shows that AT&T’s guaranty obligation continued to cover the same set of Ohio Bell liabilities in both years, reflecting a stable, ongoing guarantee relationship rather than any new or removed guarantee terms during that period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. Strengths: (1) Correctly identifies the guarantee obligation for The Ohio Bell Telephone Company in both 2022 and 2023; (2) Accurately cites specific exhibit references (Exhibit 4-c) and page numbers (2022 10-K page 141, 2023 10-K page 103); (3) Properly synthesizes the multi-hop information showing continuity of the guarantee relationship across both years; (4) Correctly characterizes the relationship as stable and unchanged, matching the ground truth's conclusion about continuation without explicit discontinuation or expansion; (5) Appropriately notes that documentation practices were maintained in line with reporting standards. Minor considerations: The LLM uses 'guaranty' spelling (which is a valid legal variant) while the ground truth uses 'guarantee,' but this is a semantic equivalence issue, not a factual error. The answer provides slightly more specific detail (page numbers, exact exhibit citations) than the ground truth, which adds value without contradicting it. The reasoning about the stable, ongoing nature of the relationship is sound and directly addresses the question about how the relationship 'evolved' (or in this case, remained stable). All factual claims are verifiable and accurate based on the ground truth provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 366,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "\nIn 2023, corporate operating profit rose $5.7 billion, driven largely by $5.7 billion of higher gains on retained and sold ownership interests tied to the AerCap (and GE HealthCare) investments. By 2024, those gains receded by $5.2 billion, producing a $2.5 billion decline in continuing earnings—even though the drop was partially offset by higher segment profit, increased run‑off insurance earnings and lower separation costs—thereby reversing the positive financial impact the AerCap relationship had delivered the prior year.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the core financial evolution but contains some issues: (1) CORRECT ELEMENTS: All key numbers are accurate - $5.7B increase in 2023, $5.2B decrease in 2024, correct identification of AerCap and GE HealthCare as drivers, correct years. The multi-hop synthesis correctly connects gains on retained/sold ownership interests to corporate operating profit changes. (2) QUANTITATIVE ACCURACY: Numbers are precise and correctly formatted. The $5.7B and $5.2B figures match ground truth exactly. (3) PROBLEMATIC ELEMENTS: The LLM introduces a $2.5B figure for 'decline in continuing earnings' which is NOT in the ground truth answer. While this may be a valid calculation or inference from additional filing data, it goes beyond what the ground truth specifies and introduces unverified quantitative claims. This represents an addition not supported by the provided ground truth. (4) REASONING QUALITY: The multi-hop reasoning is sound - correctly synthesizing that 2023 gains reversed in 2024, and appropriately noting offsetting factors (higher segment profit, insurance earnings, lower separation costs). However, the introduction of the $2.5B figure suggests the LLM may be making calculations or inferences beyond the scope of the ground truth. (5) SEMANTIC EQUIVALENCE: The core message matches - gains increased in 2023, decreased significantly in 2024, reversing the positive impact. The wording differs but conveys equivalent information about the evolution. (6) MINOR ISSUE: The phrasing 'producing a $2.5 billion decline' is presented as fact but isn't in the ground truth, which could mislead if this figure is incorrect or from a different calculation method. This prevents a higher score despite otherwise strong accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 483,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "\nHome Depot’s use of HD Supply has moved from the 2020 acquisition of the wholesale‑distribution business to a deliberate, growth‑focused platform that now serves as the core vehicle for its professional‑customer strategy; by 2024 the company was investing heavily in differentiated Pro channels—such as the Pro Xtra loyalty program, expanded credit and fulfillment options, and a broader MRO product lineup delivered through its HD Supply subsidiary—while also pursuing cost‑saving initiatives and a $3.5 billion capital‑expenditure push that includes the recent acquisition of SRS to accelerate growth with specialty‑trade Pros. This evolution reflects a sustained strategic emphasis on deepening relationships with professional remodelers, contractors and maintenance professionals, leveraging HD Supply’s distribution network and MRO capabilities to drive higher‑margin sales and shareholder value.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer introduces a specific $3.5 billion capital expenditure figure and mentions an SRS acquisition that are NOT present in the ground truth answer. These appear to be hallucinated or incorrectly attributed details that cannot be verified against the original filing data. The ground truth makes no mention of a $3.5B capex push or SRS acquisition in relation to HD Supply strategy. CORRECT ELEMENTS: The LLM correctly identifies (1) HD Supply as a 2020 acquisition, (2) its evolution from post-acquisition integration concerns to a mature strategic role, (3) its focus on professional customers and MRO services, (4) specific market segments (multifamily, hospitality, healthcare, government), and (5) the Pro Xtra loyalty program. The semantic understanding of the strategic shift from 2022 to 2024 is sound. SYNTHESIS QUALITY: The multi-hop reasoning connecting HD Supply's role across years is generally sound, but the introduction of unverified financial figures and acquisitions undermines credibility. The answer goes beyond the ground truth by adding details about capital expenditures and SRS that cannot be confirmed. COMPLETENESS: The answer addresses the core question about HD Supply's evolution and its professional customer focus, but adds extraneous information that may be inaccurate. The ground truth is more conservative and focused on what can be directly verified from filings. RECOMMENDATION: The answer demonstrates good understanding of the strategic narrative but fails on quantitative accuracy due to unsubstantiated claims about specific dollar amounts and acquisitions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Involved_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 450,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s patent portfolio showed only modest growth – the company still held roughly 7,500 U.S. patents, but worldwide issued matters rose from about 12,800 (2023) to 13,200 (2024) and total patent matters (issued + pending) grew from ≈18,500 to ≈18,800, while U.S. pending applications stayed near 5,600.  Both the 2023 and 2024 filings stress that AMD maintains “numerous cross‑licensing and technology‑exchange agreements” with other firms and has acquired licenses from external parties for IP cores, software and related technologies, underscoring that these agreements remain a core, non‑material part of its business model and continue to facilitate the transfer and receipt of technology across the industry.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct patent portfolio numbers and growth trends. All key quantitative data points are accurate: 2023 portfolio of ~18,500 total matters (12,800 issued + 5,600 pending) growing to ~18,800 in 2024 (13,200 issued + 5,600 pending). The LLM correctly identifies the modest growth trajectory and accurately captures the cross-licensing agreement emphasis from both years' filings. The introduction of U.S. patent data (~7,500) adds useful context not explicitly in the ground truth but appears factually sound. The LLM appropriately characterizes these agreements as 'core' to AMD's business model and correctly notes their role in technology transfer and IP exchange. Minor strengths: The answer provides slightly more nuanced detail about the agreements being 'non-material' in business impact while remaining strategically important. Minor weaknesses: The ground truth emphasizes that the expanded patent portfolio 'likely enhances leverage in cross-licensing agreements' and suggests AMD's reliance 'possibly more strategically advantageous in 2024' - the LLM doesn't explicitly draw this forward-looking inference about enhanced negotiating position, though it does note the portfolio growth. The phrasing 'non-material part of its business model' could be slightly clearer (the agreements are strategically important even if not material to financials). Overall, the answer successfully synthesizes multi-hop information across years and correctly addresses how reliance has evolved, with accurate numbers and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 435,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "\nFrom the May 2023 IPO through the August 2023 exchange offer, JNJ trimmed its ownership of Kenvue from roughly 89.6 % to about 9.5 % (the 9.5 % stake, valued at $4.3 bn, was recorded in “Other assets” and the Consumer‑Health business was de‑consolidated, generating a $21 bn gain while JNJ remained bound to Kenvue by transition‑service, manufacturing and other agreements.  In May 2024 JNJ executed a debt‑for‑equity swap, exchanging the remaining 182 million Kenvue shares for $3.6 bn of commercial paper, thereby eliminating any equity holding and registering a $0.4 bn loss in other expense; the 2024 filing confirms the final de‑consolidation and the end of JNJ’s share ownership.  The earlier partnership, however, continues to be governed by the TSAs/TMAs that will run for up to 24 months after the separation.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. STRENGTHS: (1) All key numbers are correct: 9.5% stake valued at $4.3 billion in 2023, 182 million shares (182,329,550 rounded appropriately), $3.6 billion commercial paper exchange in May 2024, $0.4 billion loss. (2) Dates are accurate: May 2023 IPO, August 2023 exchange offer, May 2024 debt-for-equity swap. (3) Multi-hop synthesis is excellent - the answer correctly traces the evolution from 89.6% ownership through the IPO/exchange offer to 9.5% stake, then to complete exit via the 2024 swap. (4) The answer goes beyond the ground truth by providing additional context about the $21 billion gain from de-consolidation, TSAs/TMAs, and transition service agreements, which adds valuable context without contradicting the ground truth. (5) Entity identification is perfect - correctly identifies Johnson & Johnson, Kenvue, and the specific financial instruments involved. MINOR CONSIDERATIONS: The ground truth mentions a '$0.4 billion expense by year-end' in 2023 due to subsequent changes, while the LLM answer doesn't explicitly detail this 2023 expense separate from the 2024 loss. However, the LLM does mention the $0.4 billion loss in 2024, which aligns with the ground truth. The additional detail about the $21 billion gain and TSAs/TMAs represents supplementary information that enhances rather than contradicts the answer. The reasoning chain is logical and well-structured, moving chronologically through the relationship evolution. All calculations and comparisons are sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 425,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "\nIn the 2022 Form 10‑K (Item 4‑c) and the 2023 Form 10‑K (Item 4‑c) AT&T continues to list **Indiana Bell Telephone Co. Inc.** as one of the entities whose obligations are guaranteed, and the wording of that entry is identical in both filings—showing that Indiana Bell remained in the guarantee schedule throughout the 2022‑2023 period.  This persistence aligns with the knowledge‑graph relationship **ORG ‑[Guarantees]→ COMP** where Indiana Bell (COMP) is a guaranteed party under AT&T (ORG), confirming that AT&T’s inclusion of Indiana Bell in its guarantee disclosures has not changed between 2022 and 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question appropriately. STRENGTHS: (1) Correctly identifies Indiana Bell Telephone Co. Inc. as the entity in question; (2) Accurately states that the guarantee was listed in both 2022 and 2023 filings; (3) Correctly concludes that there was no change in the guarantee relationship between the two years; (4) Properly references the relevant exhibit locations (Item 4-c); (5) The semantic meaning aligns with the ground truth that the guarantee 'remained in place without any modification or removal.' MINOR ISSUES: (1) The LLM references 'Item 4-c' while the ground truth specifically mentions 'Exhibit 4-d' - this is a discrepancy in the exhibit/item designation that could indicate a minor factual error or confusion between item and exhibit numbering; (2) The LLM adds interpretive language about 'knowledge-graph relationship' and 'ORG-[Guarantees]→COMP' which, while conceptually sound, goes beyond what was explicitly stated in the ground truth and may introduce unnecessary technical jargon; (3) The statement about 'identical wording' in both filings is not explicitly confirmed in the ground truth, though the ground truth does confirm the guarantee remained unchanged. MULTI-HOP REASONING: The answer correctly synthesizes information across two years (2022 and 2023) and properly concludes that the relationship remained static. The logic is sound and the conclusion is justified. The answer demonstrates understanding that the absence of change is itself the key finding. QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this question, so this dimension scores high based on the correct identification of years and entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 470,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "\nFrom 2023 to 2024 GE’s cash tie‑up with AerCap remained anchored by the $203 million net cash payment that the company made to AerCap for ongoing note‑receivable, sales/lease and transition‑service activities (as disclosed in the 2023 filing).  However, the financial upside from that stake shifted dramatically: the 2024 filing notes a $5.2 billion decline in gains on retained and sold AerCap ownership interests, a loss that offset other earnings improvements and helped drive the overall reduction in continuing earnings, even though adjusted earnings later rose from other sources.  Thus, while the cash outflow to AerCap stayed roughly the same, the investment’s contribution to GE’s earnings turned from a sizable gain in 2023 to a substantial drag in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general narrative of GE's transition from operational involvement with AerCap to investment-based returns, and correctly identifies the $203 million cash payment and $5.2 billion decline in gains. However, there are significant issues with accuracy and interpretation:\n\n(1) QUANTITATIVE ACCURACY ISSUES:\n- The LLM states the $203 million payment was made \"for ongoing note-receivable, sales/lease and transition-service activities\" in 2023, but this is imprecise. The ground truth indicates this was a 2023 cash payment related to continuing involvement, not necessarily an ongoing pattern into 2024.\n- The LLM incorrectly suggests the cash outflow \"stayed roughly the same\" between 2023 and 2024, but the ground truth indicates that by 2024, GE \"no longer had continuing operational involvement.\" This is a critical distinction - the nature of the relationship fundamentally changed.\n- The $5.2 billion figure is correctly cited, but the LLM's characterization of it as a \"decline in gains\" is somewhat ambiguous about whether this represents a loss or a reduction in previously reported gains.\n\n(2) MULTI-HOP REASONING ISSUES:\n- The LLM fails to clearly articulate the strategic shift from operational collaboration (2023) to pure investment stake (2024). It conflates the 2023 cash payment with ongoing 2024 activities.\n- The ground truth emphasizes a \"transition\" - the LLM presents it more as a continuation with changed financial outcomes, missing the structural change in the relationship.\n- The LLM's statement that \"the investment's contribution to GE's earnings turned from a sizable gain in 2023 to a substantial drag in 2024\" is an inference not explicitly stated in the ground truth, which only mentions the $5.2 billion decrease.\n\n(3) ENTITY AND TEMPORAL ACCURACY:\n- The LLM correctly identifies GE and AerCap.\n- However, it conflates 2023 and 2024 activities by suggesting the cash payment pattern continued, when the ground truth clearly indicates the relationship structure changed.\n- The reference to \"adjusted earnings later rose from other sources\" is not mentioned in the ground truth and appears to be an unsupported inference.\n\n(4) WHAT WAS CORRECT:\n- The $203 million figure is accurate.\n- The $5.2 billion decline in gains is accurate.\n- The general theme of transition from operational to investment-based relationship is captured.\n- The recognition that this shift had significant financial impact is correct.\n\n(5) WHAT WAS INCORRECT/INCOMPLETE:\n- The LLM suggests the cash outflow \"stayed roughly the same,\" implying continuation into 2024, when the ground truth indicates no continuing operational involvement in 2024.\n- The characterization of the financial impact is somewhat muddled - the ground truth is clearer that this represents a shift in the nature of the relationship, not just a change in financial outcomes.\n- Missing the explicit statement that by 2024, GE held only an investment stake with no operational involvement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 797,
        "total_tokens": 2142
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "\nFrom 2022 to 2024 Home Depot moved store appearance from a stand‑alone physical differentiator toward a core component of an omnichannel “interconnected shopping experience.”  The 2022 filing notes that the company was investing in more locations, tools and better technology to improve the in‑store experience and compete on location, presentation and ease of shopping, while the 2024 filing emphasizes enhancements to websites, mobile apps, shopability, search and personalized digital interactions that tie the look and feel of its stores to online inventory, curb‑side pickup and Pros‑focused services—making store appearance a conduit for digital integration rather than an isolated competitive factor.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024, accurately capturing the shift from store appearance as a standalone competitive factor to integration within an omnichannel strategy. (2) Accurately synthesizes the multi-hop information: 2022 focus on location/presentation/ease of shopping AND 2024 expansion to digital platforms (websites, mobile apps, search, personalization). (3) Properly identifies the core strategic shift toward 'interconnected shopping experience' and digital integration as a conduit rather than isolated factor. (4) Correctly names specific 2024 elements: curbside pickup, Pros-focused services, inventory integration. (5) No quantitative errors present (no numbers to verify). (6) Semantic equivalence is strong - the phrase 'store appearance a conduit for digital integration' effectively captures the ground truth's concept of 'digital integration as a core component.' MINOR CONSIDERATIONS: (1) The LLM answer is slightly more detailed and specific in naming particular digital touchpoints (websites, mobile apps, search, personalization, curbside pickup, Pros services) compared to the ground truth's more general reference to 'digital platforms.' This is a strength, not a weakness, as it demonstrates deeper synthesis. (2) The phrasing 'stand-alone physical differentiator' vs ground truth's 'competitive factor alongside customer experience, price, and product availability' captures the same concept with slightly different emphasis. (3) The LLM answer effectively conveys the transformation without losing any core factual content from the ground truth. The multi-hop reasoning is sound, correctly synthesizing information across the 2022 and 2024 filings to demonstrate evolution in strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Competes_With]-> CONCEPT <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 502,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 AMD’s commercial tie‑up with the ATMP joint venture expanded both in volume and in new financing.  Purchases from the JV stayed roughly flat at about **$1.7 billion** each year, while **resales to the JV jumped from $14 million in 2023 to $121 million in 2024**, and the related‑party balances grew – payables rose to **$476 million** (from $363 million) and receivables to **$12 million** (from $9 million).  In addition, on **October 9 2024** AMD signed a **one‑year, $100 million term loan** with one of the ATMP JVs (secured by the JV’s receivable from AMD, bearing SOFR + 50 bps and repayable with possible extensions), which is recorded in “Receivables from related parties” on AMD’s balance sheet.  Thus, the relationship evolved from a steady purchase‑resale pattern in 2023 to a markedly larger resale flow and the introduction of a new debt‑financing arrangement in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) Resales figures are correct - $14 million in 2023 and $121 million in 2024, matching ground truth exactly. (2) The October 2024 term loan is correctly identified as $100 million for one year with accurate details (SOFR + 50 bps, secured by JV's receivable from AMD). (3) The date is correctly stated as October 9, 2024. (4) Related-party balance sheet items are provided ($476 million payables, $12 million receivables) which add useful context not in the ground truth but are factually accurate enhancements. (5) The LLM correctly notes purchases from the JV at ~$1.7 billion annually, which provides fuller context of the relationship. Multi-hop reasoning is sound: the answer synthesizes resale volume changes, balance sheet impacts, and the new loan arrangement to show the evolution of the relationship. The characterization of the relationship evolution from 'steady purchase-resale pattern' to 'larger resale flow and debt-financing arrangement' accurately captures the substantive change. Minor note: The ground truth mentions 'one of the ATMP JVs' while the LLM also says 'one of the ATMP JVs,' maintaining consistency. The answer directly addresses all aspects of the question: resales evolution ($14M→$121M), new financial arrangements (the $100M loan), and the overall relationship deepening. No calculation errors detected. The additional context about related-party balances and purchase volumes, while not in the ground truth, is accurate and enhances understanding without contradicting the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 441,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "\nJohnson & Johnson treats its privacy compliance programs as an accounting policy (ORG → Complies_With → ACCOUNTING_POLICY) and, as disclosed in its 2023 filing, formally established global privacy programs to meet expanding data‑protection statutes and cross‑border data‑flow requirements; the 2024 filing shows the company is now strengthening those controls amid heightened geopolitical risk, AI‑driven threats and newly anticipated privacy laws that emphasize data‑localization and international transfers, while also acknowledging that the recent Kenvue separation—and its associated tax uncertainties—may affect the resources available to sustain those programs.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces unsupported information not present in the ground truth. Key issues: (1) INCORRECT ENTITY CLASSIFICATION: The LLM incorrectly frames privacy compliance as an 'accounting policy' using graph notation (ORG → Complies_With → ACCOUNTING_POLICY), which is not supported by the ground truth. Privacy compliance programs are operational/regulatory matters, not accounting policies. (2) UNSUPPORTED CLAIMS: The answer introduces claims about 'Kenvue separation' and 'associated tax uncertainties' affecting resource availability - this information is not mentioned in the ground truth and appears to be fabricated or confused with unrelated corporate events. (3) INCOMPLETE SYNTHESIS: While the LLM mentions 'heightened geopolitical risk' and 'AI-driven threats,' the ground truth focuses specifically on data localization, international data flows, and the evolution from 'other territories' to 'globally' - the LLM's additions are speculative and not grounded in the source material. (4) MISSING KEY EVOLUTION: The ground truth emphasizes the specific shift from addressing privacy laws in 'other territories' (2023) to 'globally' (2024), indicating a broadening scope. The LLM fails to capture this critical distinction. (5) PARTIAL ACCURACY: The LLM correctly identifies that J&J has privacy compliance programs and mentions data-flow requirements and data localization, which aligns with ground truth, but these correct elements are overshadowed by the errors and unsupported additions. The answer demonstrates poor multi-hop reasoning by conflating unrelated corporate matters (Kenvue separation) with privacy compliance evolution, suggesting the model either hallucinated or misread source documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 480,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 GE’s estimated borrower‑litigation losses tied to Bank BPH fell from **$2.669 billion to $2.461 billion**, and the corresponding valuation allowance against financing receivables declined from **$1.963 billion to $1.594 billion**—a reduction of roughly **$200 million in loss estimates and $369 million in allowance**.  Cash equivalents held for Bank BPH slipped only slightly from **$1.391 billion to $1.324 billion**, and the 2024 allowance now fully offsets the receivables balance, though the 2023 filing still warns that additional contingent liabilities and upward pressure on loss estimates could materially affect GE’s financial position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant numerical inaccuracies that undermine the entire response. (1) VALUATION ALLOWANCE ERROR - Ground truth shows $1,712M (2023) and $1,517M (2024), but LLM reports $1,963M (2023) and $1,594M (2024). The 2023 figure is off by $251M and the 2024 figure is off by $77M. This is a major factual error. (2) CALCULATION ERROR - LLM claims the allowance declined by $369M ($1,963M - $1,594M = $369M), but this calculation is based on incorrect starting numbers. The correct reduction should be $195M ($1,712M - $1,517M). (3) MISSING COMPONENT - Ground truth explicitly breaks down the $2,669M (2023) and $2,461M (2024) into two components: valuation allowances AND other liabilities ($957M and $944M respectively). The LLM answer completely omits the 'other liabilities' component, which is a critical part of understanding the total exposure structure. (4) CASH EQUIVALENTS - The LLM introduces 'cash equivalents held for Bank BPH' ($1.391B to $1.324B) which does not appear in the ground truth answer and appears to be extraneous information not directly relevant to the question about litigation losses and valuation allowances. (5) CORRECT ELEMENTS - The LLM correctly identifies the total loss reduction from $2.669B to $2.461B and correctly notes that the 2024 allowance fully offsets the receivables balance. The general direction of the analysis (reduction in exposure) is correct. MULTI-HOP REASONING: The LLM failed to properly synthesize the two-component structure of the estimated losses (valuation allowances + other liabilities) and instead appears to have conflated or misreported the valuation allowance figures. The answer lacks the comprehensive breakdown that characterizes the ground truth. SEMANTIC ISSUES: While the LLM captures the general trend, the specific numerical errors are too significant to overlook in a financial context where precision is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 526,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "\nIn fiscal 2022 (Chunk 1) Indoor Garden delivered $15.5 billion in net sales—about 10.3 % of HD’s total revenue—and grew from $14.6 billion the prior year, underscoring its strong financial performance. By 2024, HD’s merchandising structure (Chunk 2) places Indoor Garden inside the Hardlines department alongside Outdoor Garden and other hard‑line categories, reflecting a strategic shift from treating it as a standalone product line to integrating it within a broader hardlines portfolio; this evolution is consistent with the bidirectional relationship (HD discloses Indoor Garden, and Indoor Garden is produced by HD) captured in the knowledge‑graph triplets.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the multi-hop question. QUANTITATIVE VERIFICATION: The key financial figures are correct - $15.5 billion (formatted as $15.5B vs ground truth's $15,546 million, which are equivalent: $15,546M = $15.5B with minor rounding) and 10.3% of total revenue match exactly. The prior year figure of $14.6 billion is also provided, showing growth context. ENTITY ACCURACY: HD (Home Depot) is correctly identified, fiscal years 2022 and 2024 are correct, and the product line (Indoor Garden) is properly named. The merchandising department categorization (Hardlines) is accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across two separate data points: (1) 2022 financial performance showing Indoor Garden as a significant standalone category, and (2) 2024 merchandising structure showing integration into Hardlines. The logical connection between these facts - representing a strategic shift from standalone to integrated positioning - is sound and well-articulated. COMPLETENESS: The answer addresses all aspects of the question: financial performance in 2022, merchandising categorization in 2024, and the evolution/strategic shift between these periods. MINOR CONSIDERATIONS: The LLM includes additional context about the prior year ($14.6B) and mentions the knowledge-graph relationship, which adds value but goes slightly beyond the ground truth answer. The formatting of $15.5 billion vs $15,546 million represents a negligible rounding difference (0.3%) that is acceptable. The semantic meaning is fully preserved - both answers convey the same core narrative of strategic repositioning from standalone to integrated category.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 471,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "\nFrom 2022 to 2024 Colgate‑Palmolive’s approach to managing commodity‑price volatility shifted from a risk‑management model that **used sourcing strategies together with selective commodity‑hedging derivatives** (as disclosed in the 2022 10‑K, which described sourcing, cost‑containment, working‑capital actions and derivative instruments classified by Level 2/3 valuation) to a **broader, program‑wide sourcing strategy embedded in its “funding‑the‑growth” initiatives** (highlighted in the 2024 filing, which emphasizes sourcing, productivity, price‑adjustment and limited hedging as ways to offset raw‑material cost swings and protect margins).  In other words, the company moved from relying mainly on hedging and cost‑containment tools in 2022 to depending more heavily on sourcing‑driven cost efficiencies and price actions—while curbing formal commodity‑hedge usage—to address ongoing commodity price fluctuations.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the evolution of Colgate-Palmolive's sourcing strategies from 2022 to 2024, with generally accurate characterization of the shift in approach. STRENGTHS: (1) Correctly identifies the 2022 approach involving derivative instruments and risk management framework; (2) Accurately captures the 2024 emphasis on sourcing strategies, productivity initiatives, and cost containment; (3) Properly synthesizes multi-hop information across two fiscal years; (4) Correctly identifies specific commodities mentioned (resins, essential oils, soybeans align with raw material cost volatility focus); (5) Appropriately characterizes the shift from hedging-focused to sourcing-driven strategies; (6) Mentions 'funding-the-growth' initiatives which aligns with 2024 strategic framing. WEAKNESSES: (1) The phrase 'curbing formal commodity-hedge usage' is somewhat speculative and not explicitly confirmed in the ground truth, which states 'limited hedging' rather than a clear reduction; (2) The characterization of 2022 as 'mainly on hedging' may overstate the emphasis—the ground truth indicates hedging was part of a 'broader risk management framework' alongside sourcing; (3) Minor semantic issue: the answer frames this as moving 'from relying mainly on hedging' when the ground truth suggests sourcing was always part of the strategy, just with different emphasis; (4) Does not explicitly mention the increased exposure to geopolitical and climatic disruptions noted in the ground truth as a driver of the shift. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. The dates (2022, 2024) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the evolution in strategy, though the characterization of the magnitude of change (from 'mainly hedging' to 'heavily sourcing') is slightly overstated relative to ground truth. SEMANTIC EQUIVALENCE: The core message aligns well with ground truth—the company shifted from a balanced risk management approach to a more sourcing and productivity-focused strategy—though the framing emphasizes the reduction in hedging more than the ground truth does.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Utilizes]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 614,
        "total_tokens": 2039
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 TREMFYA sales jumped from **$3.15 bn to $3.67 bn** – a **16.6 % total increase** (operations + 18.1 %, currency ‑ 1.5 %).  This rise continues the pattern noted in the 2023 filing, where the product’s growth was attributed to **market expansion, strong demand in psoriasis and psoriatic‑arthritis (PsO/PsA) and favorable patient‑mix**, and is reflected in the 2024 table’s “Operations Change = 18.1 %” for TREMFYA.  The upside is further supported by the company’s ongoing label extensions and the absence of biosimilar competition (unlike STELARA), allowing JNJ’s disclosed immunology product to sustain its upward trajectory.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "STRENGTHS: (1) All core financial numbers are correct: 2023 sales of $3.15bn ($3,147M), 2024 sales of $3.67bn ($3,670M), 16.6% total increase, 18.1% operations change, and -1.5% currency impact. Number formatting variations are acceptable and properly handled. (2) Calculations are accurate - the 16.6% increase correctly reflects the difference between $3,147M and $3,670M. (3) Multi-hop synthesis is sound: the answer correctly connects 2023 performance drivers (market expansion, PsO/PsA strength, favorable patient mix) to 2024 results and properly attributes the growth to operational factors despite currency headwinds. (4) Entity identification is correct (TREMFYA/guselkumab, JNJ, fiscal years 2023-2024). (5) Contextual relevance is high - addresses both the 'how' (numbers/percentages) and 'what factors' (market expansion, therapeutic area strength, patient mix) components of the question.\n\nWEAKNESSES: (1) The LLM introduces additional context about 'label extensions' and 'absence of biosimilar competition (unlike STELARA)' that, while potentially accurate, are not explicitly mentioned in the ground truth answer. This represents a minor addition beyond the provided knowledge graph data. (2) The reference to 'JNJ's disclosed immunology product' is somewhat redundant phrasing compared to simply stating TREMFYA. (3) The phrase 'continues the pattern noted in the 2023 filing' could be slightly clearer in its attribution.\n\nVERIFICATION: All quantitative data matches ground truth exactly. The qualitative factors (market expansion, PsO/PsA strength, patient mix) are all present and correctly attributed. The multi-hop reasoning connecting 2023 drivers to 2024 performance is logically sound. The answer successfully synthesizes information across the two fiscal years as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 489,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "\nIn 2022 Disney listed A&E (and the companion History and Lifetime channels) as having roughly 69 million subscribers each, reporting those figures as part of its consolidated linear‑network portfolio. By 2023 the arrangement was reshaped into the A+E joint venture—50 % owned by Disney and 50 % by Hearst—so Disney no longer consolidates the full subscriber count; instead it reports the domestic audience of about 58 million subscribers per channel and records its stake as an “Equity in the income of investees” on the consolidated income statement. This structural shift changed both the way subscriber numbers are disclosed (from total network totals to shared, lower‑level figures) and how Disney’s financial interest in the partnership is presented (equity‑method investment rather than consolidated ownership).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Disney's structural change in its A&E relationship. STRENGTHS: (1) All key numbers are correct - 69 million subscribers in 2022, 58 million in 2023, and the 50% ownership stake are all accurate. (2) The multi-hop synthesis is sound: the answer correctly traces the evolution from 2022 partnership reporting to 2023 joint venture structure, and properly explains how this affected both subscriber reporting methodology and financial statement presentation. (3) Entity identification is precise - correctly names A&E, History, Lifetime channels, and identifies Hearst as the co-owner. (4) The explanation of reporting changes is accurate: moving from consolidated subscriber counts to equity-method accounting under 'Equity in the income of investees' is correctly stated. (5) The answer addresses all aspects of the question: structural change, subscriber number reporting, and financial stake presentation. MINOR CONSIDERATIONS: The LLM adds helpful detail by mentioning 'History and Lifetime channels' alongside A&E, which provides useful context though not explicitly required. The phrase 'roughly 69 million subscribers each' could be slightly ambiguous (does 'each' apply to all three channels?), but in context it's clear this refers to the combined portfolio. The explanation of why subscriber numbers changed (from consolidated to shared reporting) demonstrates solid reasoning about the accounting implications. No calculation errors detected. The semantic equivalence is strong - the LLM conveys the same substantive information as the ground truth while using slightly different phrasing that is equally accurate and arguably more detailed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 471,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "\nIn 2023 GE recorded a **$129 million realized/unrealized gain** on its investment in AerCap (the “Investment in and note with AerCap realized and unrealized gain (loss)” line in the 2023 10‑K), which helped drive the $5.78 billion total gains on retained and sold ownership interests. By contrast, the 2024 filing notes a **$5.2 billion drop in gains on retained and sold interests**, explicitly attributing the decline to lower results from its AerCap (and GE HealthCare) stakes, indicating that the AerCap investment moved from a modest gain in 2023 to a source of substantially reduced or negative returns in 2024. This shift reflects the evolving financial impact of GE’s relationship with AerCap over the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of GE's AerCap relationship evolution. STRENGTHS: (1) Correctly identifies the 2023 unrealized gain of $129 million from the AerCap investment. (2) Accurately cites the $5.2 billion drop in gains on retained and sold ownership interests between 2023 and 2024. (3) Properly synthesizes the multi-hop relationship: 2023 modest gain → 2024 significantly reduced/negative returns. (4) Correctly identifies AerCap as a primary contributor to the decline. (5) Appropriately contextualizes the shift as a negative evolution in financial performance. (6) Includes helpful reference to the specific line item in the 10-K filing. (7) Mentions the $5.78 billion total gains figure for 2023, which provides useful context. MINOR CONSIDERATIONS: The answer characterizes the 2023 gain as 'modest' and describes 2024 as 'substantially reduced or negative returns' - these are reasonable interpretations of the data but involve some inference beyond the strict ground truth statement. However, this inference is logically sound given the $5.2 billion decline. The answer goes slightly beyond the ground truth by providing additional context (total gains figure, specific filing references) but this adds value without introducing errors. All numeric values are accurate, the multi-hop reasoning correctly synthesizes information across 2023 and 2024 filings, and the semantic meaning aligns perfectly with the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 412,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "\nMastercard’s multi‑layered security framework, disclosed as an accounting policy in both the 2022 and 2024 Form 10‑K filings, has deepened its focus on third‑party risk.  The 2022 filing describes a robust, benchmark‑driven program that protects the network through industry standards, Fusion Centers and regular vulnerability testing, while the 2024 filing explicitly calls out “threats … associated with the use of services provided by third‑party providers” and adds insurance, enterprise‑resilience measures, and expanded collaboration with external experts and public‑private partnerships.  This evolution—captured in the KG relationship ORG → ACCOUNTING_POLICY ← IMPLEMENTS —shows that Mastercard is tightening security and embedding third‑party risk management into its franchise strategy, signaling a proactive strategic response to emerging cybersecurity threats.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2022 to 2024, noting the absence of explicit third-party provider risk language in 2022 and its explicit inclusion in 2024. (2) Accurately captures the shift toward ecosystem-wide resilience and third-party risk management integration. (3) Properly synthesizes multi-hop information across two fiscal years and multiple security framework components. (4) Correctly identifies the strategic response to emerging cybersecurity threats. (5) Appropriately references Form 10-K filings as the source documents. (6) Adds relevant contextual details (Fusion Centers, vulnerability testing, insurance, enterprise-resilience measures) that enhance understanding without contradicting ground truth. MINOR CONSIDERATIONS: (1) The LLM introduces specific mechanisms (Fusion Centers, insurance, enterprise-resilience measures) that are not explicitly mentioned in the ground truth answer, though these appear to be reasonable inferences from 10-K disclosures and don't contradict the ground truth. (2) The reference to 'KG relationship ORG → ACCOUNTING_POLICY ← IMPLEMENTS' is technical metadata that, while not incorrect, goes beyond what the ground truth explicitly states about the relationship structure. (3) The phrase 'embedding third-party risk management into its franchise strategy' is a reasonable interpretation but slightly more specific than the ground truth's 'strengthening the ecosystem-wide resilience.' QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension is not directly testable. The dates (2022, 2024) are correct. QUALITATIVE ACCURACY: The reasoning is sound and properly synthesizes the evolution across years. The multi-hop logic correctly connects the 2022 baseline, 2024 advancement, and strategic implications. CONTEXTUAL RELEVANCE: The answer directly addresses all parts of the multi-part question: the evolution of the security approach, the specific focus on third-party provider risks, and the strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has]-> ACCOUNTING_POLICY <-[Implements]- ORG",
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 579,
        "total_tokens": 2041
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "\nTarget has continued to satisfy its debt‑leverage covenant in both years, explicitly stating that it is “in compliance” and expects to remain so; the covenant is tied to the terms of its revolving credit facilities, which were restructured between 2022 and 2023 – the $2.5 bn facility expiring in 2023 was replaced by a new $1 bn 364‑day facility maturing in 2024 and the existing $3 bn five‑year facility was extended to 2028, with no balances outstanding under either facility, so the leverage metrics used in the covenant have not breached any thresholds and the company’s compliance status has remained unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding the credit facility amounts. The LLM states 'the $2.5 bn facility expiring in 2023 was replaced by a new $1 bn 364‑day facility' but the ground truth clearly indicates Target had a $3.0 billion unsecured revolving credit facility in 2022 (not $2.5 billion), and this facility was extended to October 2028 in 2023 (not replaced). The new $1.0 billion 364-day facility was ADDED, not a replacement. This is a material error in understanding the credit facility structure. CORRECT ELEMENTS: (1) Target remained in compliance with debt leverage covenant in both years - CORRECT; (2) New $1.0 billion 364-day facility expiring in October 2024 - CORRECT; (3) Five-year facility extended to 2028 - CORRECT; (4) No balances outstanding - CORRECT; (5) Leverage metrics not breached - CORRECT. MULTI-HOP REASONING: The LLM correctly synthesized that compliance status remained unchanged despite structural changes, which is sound reasoning. However, the fundamental mischaracterization of the facility changes (replacement vs. extension/addition) undermines the accuracy of the answer. The LLM also added unsupported detail about 'no balances outstanding' which, while possibly correct, is not explicitly stated in the ground truth. SEMANTIC ISSUES: The answer conflates the facility changes in a way that misrepresents the actual evolution of Target's credit structure. The ground truth shows an ADDITION of a new facility plus an EXTENSION of an existing facility, while the LLM describes a REPLACEMENT scenario. This is a material factual error that affects the core understanding of how Target's financing arrangements evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 469,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "\nThe 2023 risk narrative focused on brand‑ and reputation‑related threats—dependence on third‑party developers, social‑ethical controversies, ESG scrutiny and the volatility of strategic investments—while 2024’s disclosures show those same exposures persisting but now layered with AI‑specific dangers: accuracy, bias, toxicity, copyright and privacy liabilities, heightened regulatory attention (e.g., DSA, emerging AI governance rules), and the costly governance and testing required for generative and agentic AI such as Agentforce. In short, the nature of the risks has evolved from general brand/reputational concerns to a more acute set of AI‑centric hazards that can directly impair Salesforce’s reputation, trigger legal liability and increase operating costs.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the evolution of Salesforce's risk profile from 2023 to 2024, accurately capturing that 2024 risks expanded to include AI-specific concerns (accuracy, bias, copyright, privacy). The mention of Agentforce, regulatory scrutiny (DSA), and increased governance/testing costs aligns with the ground truth. The answer appropriately synthesizes the multi-hop comparison across years. WEAKNESSES: (1) The LLM introduces 'brand-and-reputation-related threats' and 'dependence on third-party developers' as 2023 primary risks, but the ground truth specifically states the 2023 risk centered on 'third-party integrations and applications' with 'potential claims or liabilities stemming from customer expectations for warranties.' The LLM's framing of 2023 risks as 'general brand/reputational concerns' is somewhat broader and less precise than the ground truth's specific focus on third-party warranty liability. (2) The LLM mentions 'social-ethical controversies' and 'ESG scrutiny' as 2023 risks, which are not explicitly mentioned in the ground truth for 2023. (3) The LLM adds 'toxicity' as a 2024 AI risk, which is not mentioned in the ground truth. (4) The ground truth emphasizes that AI governance, compliance, and testing costs 'were not specifically tied to AI in 2023,' but the LLM doesn't clearly articulate this distinction. QUANTITATIVE ACCURACY: No specific numbers or dates are provided in either answer, so this dimension is not directly testable. Both answers correctly reference 2023 and 2024. MULTI-HOP REASONING: The LLM successfully synthesizes the evolution across years and identifies the shift from third-party/general risks to AI-specific risks. However, the characterization of 2023 risks is less precise than the ground truth. SEMANTIC EQUIVALENCE: While the LLM captures the general evolution narrative, it introduces elements not in the ground truth and slightly mischaracterizes the 2023 risk focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 530,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Lowe’s tightened its parcel‑eligible delivery promise—while in 2023 “most parcel‑eligible items can be delivered within two business days at standard shipping rates,” by 2024 the company states that “most parcel‑eligible items can be delivered within two business days **or less** at standard rates” and it has added **next‑day delivery for major appliances in almost every ZIP code**.  The evolution also includes a **nationwide expansion of its gig‑provider network for same‑day options**, the **completion of the market‑based delivery model rollout across additional geographic areas**, and **enhanced capacity in flat‑bed, import and bulk distribution centers** to handle larger, bulky items more efficiently.  These upgrades collectively accelerate delivery speed, broaden service windows and increase the reach of Lowe’s parcel‑eligible fulfillment network.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies the core improvements from FY2023 to FY2024: (1) the shift from 'two business days' to 'two business days or less' for parcel-eligible items, and (2) next-day delivery for major appliances in nearly every/almost every ZIP code. These key facts match the ground truth. However, the LLM introduces several claims NOT present in the original answer: (1) 'nationwide expansion of its gig-provider network for same-day options,' (2) 'completion of the market-based delivery model rollout across additional geographic areas,' and (3) 'enhanced capacity in flat-bed, import and bulk distribution centers.' While these may be factually accurate from the 10-K filings, they were not included in the ground truth answer, suggesting either: (a) the LLM is adding information beyond what was synthesized in the knowledge graph, or (b) the LLM is hallucinating details. The ground truth answer is more conservative and focused, stating only the specific improvements that were clearly documented. The LLM's use of 'almost every ZIP code' vs. the ground truth's 'nearly every zip code' is semantically equivalent. The quantitative accuracy is good for the core claims (two business days/or less, major appliances, ZIP code coverage), but the introduction of unverified additional details reduces overall correctness. The answer demonstrates reasonable multi-hop synthesis of the FY2023 vs FY2024 comparison but overextends beyond what the ground truth supports.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Delivers]- ORG",
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 409,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "\nThe February 2021 sale of Dermstore LLC generated a one‑time $335 million pretax gain for Target, which is reported in “Net Other (Income) / Expense,” and the transaction was reflected in both the 2022 and 2023 Form 10‑K filings.  In each of those years Dermstore contributed **less than 1 percent of Target’s consolidated revenues, operating income and net assets**, meaning that after the initial gain the business no longer has a material effect on Target’s top‑line sales or operating profitability.  Consequently, the financial impact of the Dermstore sale has essentially disappeared from Target’s consolidated results in 2022 and 2023, remaining negligible (<1 % of each metric).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. QUANTITATIVE VERIFICATION: All key numbers are correct - the $335 million pretax gain is accurate, the February 2021 sale date is correct, and the '<1 percent' threshold for revenues, operating income, and net assets matches the ground truth exactly. COMPLETENESS: The answer addresses all aspects of the question: (1) the sale date and gain amount, (2) the financial impact in 2022, (3) the financial impact in 2023, (4) the comparison/evolution between the two years. ENTITY ACCURACY: All entities are correctly identified - Target, Dermstore LLC, the specific financial metrics (consolidated revenues, operating income, net assets), and the reporting location (Net Other Income/Expense). MULTI-HOP REASONING: The answer correctly synthesizes information across multiple years and demonstrates understanding that the sale occurred in 2021 but its impact is being evaluated in 2022-2023. The logic is sound: the one-time gain was recorded in 2021, and by 2022-2023, Dermstore no longer contributes materially to Target's results. SEMANTIC EQUIVALENCE: The LLM's phrasing 'essentially disappeared from Target's consolidated results' and 'remaining negligible (<1% of each metric)' conveys the same meaning as the ground truth's 'remained minimal' and 'no significant post-sale financial contribution.' The answer goes slightly beyond the ground truth by explicitly noting the gain was a one-time event and explaining why there's no material impact in subsequent years, which adds helpful context without introducing errors. Minor note: The LLM could have been slightly more explicit about the 'evolution' aspect by stating that the impact remained constant (minimal) from 2022 to 2023 rather than evolved, but this is a very minor semantic distinction and doesn't affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> COMP <-[Involved_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 500,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "\nBetween 2023 and 2024 Salesforce’s Data Cloud shifted from being a **hyperscale, trusted data engine that unifies disconnected enterprise data to deliver a 360‑degree customer view across Marketing, Commerce and Service clouds** (2023 chunk) to a **strategic, consumption‑based service that underpins new AI‑driven offerings such as Agentforce and must compete in a crowded market of data‑ and AI‑focused rivals**, a positioning that brings pricing uncertainty, the need for continual enhancements, and heightened competitive pressure (2024 chunk). This evolution reflects Data Cloud’s expanded role within Salesforce’s broader service portfolio while navigating a more complex competitive landscape.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with sound multi-hop reasoning across 2023-2024 filings. STRENGTHS: (1) Correctly identifies the 2023 positioning of Data Cloud as a 'hyperscale, trusted data engine' that unifies enterprise data for 360-degree customer view - this matches ground truth exactly. (2) Accurately captures the 2024 shift toward consumption-based models and competitive risk acknowledgment. (3) Properly synthesizes the evolution from product-centric messaging to risk/monetization-focused positioning. (4) Correctly identifies new AI-driven offerings (Agentforce) as part of 2024 context. (5) No quantitative errors - no numbers, dates, or calculations to verify. (6) Multi-hop reasoning is sound: correctly connects Data Cloud's role across different time periods and relates it to broader competitive landscape. MINOR WEAKNESSES: (1) The LLM adds 'Commerce' to the 2023 description ('Marketing, Commerce and Service clouds') - the ground truth specifically mentions 'Marketing and Analytics' as the integration examples. This is a minor addition that doesn't contradict ground truth but represents slight elaboration beyond what was explicitly stated. (2) The answer could have been more explicit about the 'limited experience in pricing consumption-based models' aspect mentioned in ground truth, though this concept is captured in the phrase 'pricing uncertainty.' (3) The phrase 'crowded market of data- and AI-focused rivals' is a reasonable interpretation of 'increasing competition as AI and data platforms evolve' but uses slightly different language. Overall, the answer successfully captures the strategic evolution and demonstrates proper synthesis of multi-year filing information with appropriate contextual framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 479,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "\nBetween 2023 and 2024 the company shifted the hedge accounting for its forward interest‑rate swaps from **cash‑flow hedge designation** (where the effective portion of gains/losses was recorded in other comprehensive income and earnings) to **fair‑value hedge accounting using the shortcut method** (where the swap’s fair‑value changes offset the hedged debt’s fair‑value changes and have no net impact on consolidated earnings).  Both years reference the same $2.0 billion, $1.5 billion and $1.3 billion notional swaps settled in connection with the 2023, March 2022 and September 2022 note issuances, but the 2023 disclosures note that the swaps were designated as cash‑flow hedges, whereas the 2024 disclosures state they are now accounted for as fair‑value hedges under the shortcut method, resulting in an offsetting fair‑value change with no earnings effect.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core shift in hedge accounting treatment from cash flow hedges (2023) to fair value hedges using the shortcut method (2024), and accurately describes the accounting mechanics and earnings impact. However, there are significant quantitative accuracy issues: (1) The LLM introduces notional amounts of $1.5 billion and $1.3 billion related to March 2022 and September 2022 note issuances that are NOT mentioned in the ground truth answer. The ground truth only references the $2.0 billion notional amount from March 2023 Notes and the $247 million settlement amount. (2) The LLM does not mention the $247 million settlement amount that was explicitly disclosed in 2023, which is a material financial detail. (3) The LLM's reference to multiple note issuances (2023, March 2022, September 2022) appears to introduce information not present in the ground truth, potentially confusing the timeline. The qualitative reasoning about the shift from cash flow to fair value hedge accounting and the resulting earnings impact is sound and well-explained. The answer demonstrates good understanding of the accounting mechanics and multi-hop synthesis of the hedge designation change. However, the introduction of unverified notional amounts and omission of the $247 million settlement figure represent material factual gaps that reduce confidence in the answer's accuracy relative to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Settles]- ORG",
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 396,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "\nFrom 2022 to 2023 Target moved owned‑brand management from a passive “wide‑range” offering (the 2022 filing lists dozens of categories such as A New Day™, Goodfellow & Co™, Heyday™, etc.) to a deliberate growth lever, explicitly stating that its strategy now “strengthens our owned‑brands portfolio, curates leading national brands, and expands the breadth and depth of signature partnerships” (2023 filing).  This evolution reflects a strategic objective to deepen portfolio emphasis on owned brands in order to increase consumer relevance, drive traffic and market‑share growth, while leveraging its store‑fulfillment network— which ships more than 96 % of sales—to support the expanded brand suite and generate additional revenue from the owned‑brand product line.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Target's owned brands strategy evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from passive/descriptive approach in 2022 to active strategic leverage in 2023, matching the ground truth's core thesis; (2) Accurately references specific brand examples (A New Day™, Goodfellow & Co™, Heyday™) from 2022 filings; (3) Correctly captures the 2023 strategic positioning language about strengthening portfolio, curating national brands, and expanding partnerships; (4) Accurately includes the 96% store-fulfillment metric, which is a specific quantitative detail; (5) Properly synthesizes multi-hop information showing how owned brands connect to broader strategic objectives (traffic, sales, market share growth). MINOR WEAKNESSES: (1) The LLM answer adds contextual detail about the store-fulfillment network and revenue generation that, while accurate and relevant, goes slightly beyond what the ground truth explicitly emphasizes—the ground truth focuses more narrowly on the portfolio emphasis shift and strategic positioning; (2) The phrase 'passive \"wide-range\" offering' is the LLM's characterization rather than direct language from filings, though it accurately represents the 2022 approach; (3) Ground truth mentions 'over 40 brands' but LLM says 'dozens'—while semantically similar, 'dozens' is less precise than 'over 40.' QUANTITATIVE VERIFICATION: The 96% fulfillment metric appears accurate and adds credibility. No calculation errors detected. MULTI-HOP REASONING: Successfully synthesizes information across 2022 and 2023 filings to show strategic evolution. The connection between owned brands and broader business objectives (traffic, market share) is properly established. SEMANTIC EQUIVALENCE: The core message matches ground truth—movement from showcasing brands to leveraging them strategically. The additional fulfillment network detail enhances rather than contradicts the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Expands]- ORG",
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 533,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "\nFrom 2022 to 2023 GM shifted from offering isolated software‑enabled services (e.g., OnStar, Super Cruise) toward a unified, over‑the‑air software platform that will roll out a broader suite of subscription‑based features—such as security, climate, personalized themes and EV‑ownership experiences—across its model lineup, beginning with the 2024 Cadillac LYRIQ and Chevrolet Silverado EV and extending to most vehicles in the coming years; this expansion reflects a deliberate, large‑scale investment in a scalable digital architecture that can be continuously updated and monetized, underscoring GM’s strategic pivot to a software‑centric, digitally enabled business model.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of GM's software evolution from 2022 to 2023 and correctly identifies key elements: (1) the shift from isolated services to a unified platform, (2) specific features like over-the-air updates, Super Cruise, active safety, infotainment, and EV ownership experience, (3) concrete deployment examples (2024 Cadillac LYRIQ and Chevrolet Silverado EV), and (4) the strategic pivot toward scalable digital architecture. The answer appropriately synthesizes multi-hop information showing the evolution trajectory and investment implications. However, there are some minor issues: (1) The LLM introduces 'subscription-based features' with examples like 'security, climate, personalized themes' that are not explicitly mentioned in the ground truth, which focuses on platform capabilities rather than subscription monetization specifics. (2) The phrase 'extending to most vehicles in the coming years' adds forward-looking detail not present in the ground truth. (3) The ground truth emphasizes the transition from 'general involvement' to 'concrete platform deployment,' while the LLM frames it as 'isolated services' to 'unified platform'—a slightly different characterization, though semantically similar. The core narrative is accurate: GM moved from describing software services generally in 2022 to detailing specific platform deployment in 2023. All key entities (companies, years, specific models, features) are correctly identified. The reasoning about scalable digital solutions and investment maturity is sound and well-supported. The answer is comprehensive and addresses all parts of the multi-part question effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Provides]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 457,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "\nThousandEyes is a key driver of growth in both the Optimized Application Experiences category (FY 2022) and the broader Observability segment (FY 2023).  In FY 2022 the Optimized Application Experiences product line posted an 11 % ($75 million) revenue rise “driven by growth in our ThousandEyes and Intersight offerings,” and in FY 2023 the Observability category grew 14 % ($80 million) “driven by growth in our ThousandEyes and monitoring‑and‑analytics offerings.”  Thus, ThousandEyes’ contribution accelerated the segment’s revenue expansion from an 11 % increase in FY 2022 to a 14 % increase in FY 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-structured. All quantitative data is correct: FY 2022 shows 11% growth ($75 million) for Optimized Application Experiences driven by ThousandEyes and Intersight; FY 2023 shows 14% growth ($80 million) for Observability driven by ThousandEyes and monitoring-and-analytics offerings. The multi-hop synthesis is sound - the model correctly identifies the category name change (Optimized Application Experiences to Observability) and traces ThousandEyes' contribution across both years. The reasoning that ThousandEyes' contribution 'accelerated' from 11% to 14% growth is logically valid and supported by the data. The answer directly addresses the evolution question by showing both absolute dollar growth ($75M to $80M) and percentage growth acceleration (11% to 14%). Minor note: The LLM uses quotation marks around the quoted text from filings, which adds credibility. The only very minor consideration is that the ground truth explicitly states 'continued upward trend' while the LLM uses 'accelerated' - these are semantically equivalent in this context. All entities (ThousandEyes, product categories, fiscal years, metrics) are correctly identified and synthesized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 342,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "\nLockheed Martin continued to disclose Amendment No. 4 to its Executive Severance Plan in both the 2023 and 2024 Form 10‑K filings—listed as Item 10.34 in the 2023 filing (page 104) and as Item 10.36 in the 2024 filing (page 105), each time referencing the same Quarterly Report filing from September 25 2022—showing that the company has not removed or revised the amendment but rather retains it as part of its periodic accounting‑policy disclosures.  This consistent treatment, underscored by the KG relationship LMT ‑ [Discloses]→ Amendment No. 4 (AcCOUNTING_POLICY), indicates that the amendment is deliberately included in Lockheed Martin’s disclosure strategy as a stable component of its executive‑compensation framework.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. Key issues: (1) EXHIBIT NUMBER ERRORS: The LLM claims Amendment No. 4 was listed as 'Item 10.34' in 2023 and 'Item 10.36' in 2024. The ground truth indicates it was Exhibit 10.34 in 2023, not 'Item 10.34'. The LLM appears to have confused exhibit numbering with item numbering and provided incorrect exhibit numbers for 2024. (2) TREATMENT EVOLUTION MISSED: The ground truth explicitly states that Amendment No. 4's treatment 'shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024.' The LLM incorrectly characterizes this as 'consistent treatment' and claims the amendment was 'not removed or revised,' missing the key evolution that the question specifically asks about. (3) STRUCTURAL CHANGE OVERLOOKED: The ground truth indicates a meaningful shift in how the amendment was presented - from standalone exhibit to part of a sequence including amendments 2, 3, 4, and 5. The LLM fails to capture this structural reorganization. (4) DISCLOSURE STRATEGY MISINTERPRETATION: The LLM concludes the amendment is a 'stable component' with 'consistent treatment,' when the ground truth indicates a deliberate shift toward a 'more consolidated and retrospective approach.' This represents a fundamental misunderstanding of the evolution being described. (5) PAGE NUMBERS: The LLM provides specific page numbers (104 and 105) that cannot be verified against the ground truth and may be inaccurate. The answer demonstrates poor multi-hop reasoning by failing to synthesize the comparative analysis between 2023 and 2024 filings that the question requires.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 462,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "\nJPMorgan’s Tier 1 leverage ratio remained flat at **7.2 %** in 2024—well above the 4.0 % regulatory minimum—so the bank continued to satisfy the leverage‑ratio requirement disclosed in both the 2023 and 2024 filings.  At the same time, its **standardized CET1 capital ratio was 15.0 % at the end of 2023** (up from 13.2 % in 2022), reflecting a strong capital position that underpins compliance with the broader capital‑ratio requirements, including the 5.0 % supplementary leverage ratio threshold shown in the 2024 data.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer demonstrates substantial accuracy but has some notable issues: (1) CORRECT ELEMENTS: The Tier 1 leverage ratio of 7.2% in 2024 is correct and properly compared to the 4.0% requirement. The Standardized CET1 capital ratio of 15.0% in 2023 is correct. The characterization of JPMorgan maintaining compliance is accurate. (2) PROBLEMATIC ELEMENTS: The LLM states the Tier 1 leverage ratio 'remained flat at 7.2%' in 2024, implying it was also 7.2% in 2023, but the ground truth only specifies the 2024 figure. This creates ambiguity about whether the ratio actually remained flat or if the LLM is making an unsupported inference. The ground truth mentions the requirement of 11.4% for the Standardized CET1 ratio in 2023, but the LLM does not reference this specific requirement figure. (3) ADDITIONAL INFORMATION: The LLM introduces the 5.0% supplementary leverage ratio threshold, which is not mentioned in the ground truth. While this may be factually accurate from the filings, it goes beyond what the ground truth specifies and could represent either additional context or potential confusion about which metrics were being tracked. (4) MULTI-HOP REASONING: The answer does synthesize information across 2023 and 2024 data and connects capital ratios to regulatory compliance, which is appropriate. However, the synthesis is incomplete—it doesn't clearly establish the evolution from 2023 to 2024 for the Tier 1 leverage ratio since only 2024 data is provided for that metric. (5) COMPLETENESS: The answer addresses both metrics mentioned in the question (Tier 1 leverage ratio and Standardized CET1 capital ratio) but doesn't fully capture the 'evolution' aspect since comparative 2023 data for the leverage ratio is missing. The inclusion of the 13.2% figure for 2022 CET1 ratio adds helpful context but wasn't in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 501,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "\nBetween 2022 and 2023 GM Financial moved from a peripheral reference – “we provide automotive financing services through our GM Financial segment” – to a fully‑fledged reportable segment (listed alongside GMNA, GMI and Cruise) whose results are now shown in the consolidated financial statements after eliminating all inter‑segment transactions and adjusting for the impact of GM Financial’s deferred‑tax positions on the parent’s consolidated tax return; this tighter integration is highlighted in the 2023 note, which explains that the amounts presented for GM Financial are adjusted to remove the effect of transactions with other consolidated entities and to reflect the company’s share of income‑tax provisions, causing the segment’s reported figures to differ from a stand‑alone GM Financial statement.  (The relationship is captured by the KG triplets GM → Automotive Financing Services and Automotive Financing Services → GM, showing that GM Financial is the vehicle through which GM offers its financing product.)",
      "correctness_score": 4,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ISSUES WITH CORE CLAIMS: The LLM answer makes several significant factual errors that contradict the ground truth: (1) The claim that GM Financial 'moved from a peripheral reference' to 'a fully-fledged reportable segment (listed alongside GMNA, GMI and Cruise)' is NOT supported by the ground truth. The original answer explicitly states GM Financial was 'described as a segment' in 2022, meaning it was already a reportable segment in 2022, not a peripheral reference. This is a fundamental mischaracterization of the evolution. (2) The LLM invents details about 'eliminating all inter-segment transactions' and 'removing the effect of transactions with other consolidated entities' that are not present in the ground truth answer. The ground truth mentions 'intercompany transactions' in 2022 and 'deferred tax positions' in 2023, but does not describe the specific mechanics of elimination or adjustment in the way the LLM claims. (3) The LLM's characterization of the evolution as moving from 'peripheral' to 'fully-fledged' contradicts the ground truth, which describes both years as presenting GM Financial as a segment, with the evolution being about MORE DETAILED DESCRIPTION of tax adjustments, not about segment status change. WHAT WAS CORRECT: The LLM correctly identifies that the evolution involves increased detail about tax adjustments and deferred tax positions between 2022 and 2023. The mention of consolidated tax return impacts is accurate. The reference to inter-segment/intercompany transactions is directionally correct. MULTI-HOP REASONING: The LLM failed to properly synthesize the ground truth information. It over-interpreted the 'more detailed' description in 2023 as a fundamental change in segment status, when the ground truth indicates GM Financial was already a segment in both years. The KG triplet reference at the end is somewhat tangential and doesn't strengthen the core answer. QUANTITATIVE ACCURACY: No specific numbers or dates are provided in either answer, so this dimension is neutral (7/10 for not introducing false numbers). QUALITATIVE ACCURACY: Significantly compromised by the false claim about segment status evolution and the invention of specific adjustment mechanics not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Provides]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 601,
        "total_tokens": 2049
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "\nBetween 2022 and 2024 Cost continued to recognize step‑rent provisions by allocating the total lease payments—including periodic rent increases tied to price indices or the greater of minimum guaranteed amounts or sales volume—on a straight‑line basis over the lease term (including any renewal options that are reasonably certain to be exercised). The 2024 filing makes this treatment more explicit, describing such periodic increases as “variable lease payments” while retaining the same straight‑line recognition method, indicating a clarification and enhanced disclosure rather than a fundamental change in accounting policy. Both years note that the leases contain no material residual‑value guarantees or restrictive covenants, and the step‑rent provisions remain part of Cost’s accounting policy (COST → Step‑Rent Provisions ↔ COST).",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR IN CORE CLAIM: The LLM answer fundamentally contradicts the ground truth on the key evolution between 2022 and 2024. Ground truth states: (1) 2022 = straight-line accounting, (2) 2024 = shift to variable lease payment recognition (NOT straight-lined). LLM answer claims: both 2022 and 2024 use straight-line basis, with 2024 being merely a 'clarification and enhanced disclosure rather than a fundamental change.' This is the opposite of what the ground truth indicates. The ground truth explicitly states 'a shift in accounting treatment' and 'a more dynamic approach,' while the LLM claims 'retaining the same straight-line recognition method.' QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension scores well (8/10) - the dates (2022, 2024) are correct. QUALITATIVE ACCURACY: The LLM fundamentally misunderstands the nature of the change. It incorrectly characterizes the evolution as merely enhanced disclosure when the ground truth indicates an actual change in accounting treatment methodology (from straight-line to variable lease payment recognition). The mention of 'Cost' company appears to be an entity reference, but the core accounting treatment claim is inverted. CONTEXTUAL RELEVANCE: The answer addresses the right topic (step-rent provisions, price indices, sales volume) but reaches the wrong conclusion about how treatment evolved. The question specifically asks about evolution/change, and the LLM fails to identify the actual shift from straight-line to variable lease payment treatment. This is a fundamental failure in multi-hop reasoning - the model failed to correctly synthesize the temporal comparison between 2022 and 2024 filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 467,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "\nThe 2023 filing (Chunk 1) projects the qualified defined‑benefit pension plan at **$1.79 bn in 2024** and **$1.86 bn in 2025**, with a cumulative **$10.02 bn** expected to be paid over the **2029‑2033** horizon. The subsequent 2024 filing (Chunk 2) revises those figures to **$1.80 bn for 2025** and a long‑term total of **$9.99 bn for 2030‑2034**, showing a modest downward shift in both the near‑term and long‑term payment outlooks. The accompanying retiree medical and life‑insurance obligations also decline slightly over the same periods, reinforcing the overall reduction in projected funding obligations.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key comparison between 2023 and 2024 filings, properly recognizes the time periods (2025 payment, 2029-2033 vs 2030-2034), and accurately captures the overall trend of modest reductions in pension obligations. The semantic understanding of the multi-hop synthesis is sound. CRITICAL ERRORS: (1) The 2023 figure for 2025 payments is stated as $1.86 bn in the LLM answer, which matches ground truth ($1,860 million), but the LLM also introduces a $1.79 bn figure for 2024 that is NOT mentioned in the ground truth answer - this appears to be extraneous information not requested. (2) More significantly, the 2024 figure for 2025 is stated as $1.80 bn in the LLM answer, but the ground truth states it remained at $1,860 million (or $1.86 bn) - this is a discrepancy of $0.04 billion that contradicts the ground truth's claim of 'marginal' or 'slight' change. (3) The long-term figures are correctly stated: $10.02 bn (2029-2033) in 2023 and $9.99 bn (2030-2034) in 2024. QUANTITATIVE ACCURACY ISSUES: The $1.80 bn vs $1.86 bn discrepancy for the 2025 payment in 2024 is a material error in the primary comparison metric. The introduction of the 2024 payment figure ($1.79 bn) adds complexity not present in the ground truth answer. QUALITATIVE ASSESSMENT: The reasoning about the trend (downward shift, modest reduction) is correct and well-articulated. The multi-hop synthesis across years is properly executed. The mention of retiree medical and life-insurance obligations, while contextually relevant, goes beyond what the ground truth specifies. OVERALL: The answer demonstrates good understanding of the question structure and multi-hop requirements but contains a specific numeric discrepancy on a key metric (2025 payment in 2024) that undermines confidence in the quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 498,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "\nJPMorgan Chase’s 2023 filing framed its resolution‑plan obligations as a set of liquidity‑risk triggers—asset‑sale limits, CCP defaults, unexpected deposit outflows and the consequent need to tap higher‑cost alternative funding if stable, low‑cost sources (e.g., deposits or FHLB borrowings) shrink—while stressing that meeting the required liquidity‑coverage and net‑stable‑funding ratios, pre‑positioning liquidity in material subsidiaries and satisfying cross‑border regulatory rules are essential to its compliance; the 2024 filing builds on this by linking those triggers to broader credit‑quality concerns (deteriorating counterparty credit, higher credit‑loss allowances, market‑dislocation impacts on RWA and funding costs) and by reiterating the same regulatory‑compliance actions (satisfying coverage ratios, addressing resolution‑plan obligations, and pre‑positioning liquidity) as integral to its liquidity‑risk management, thereby showing an evolution from a pure “trigger‑list” description to a more integrated narrative that ties resolution‑plan compliance, subsidiary dividend constraints, rating‑driven funding‑cost risks, and regulatory pre‑positioning requirements together across both years.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key elements from both 2023 and 2024 filings, including liquidity coverage ratio (LCR) and net stable funding ratio (NSFR) requirements, the role of deposits and FHLB borrowings, subsidiary liquidity pre-positioning, and the shift toward broader regulatory/macroeconomic context. The answer accurately captures that 2024 expanded disclosures to include dynamic regulatory expectations and systemic events. No quantitative errors are present (no specific numbers were claimed). WEAKNESSES: (1) The LLM answer introduces concepts not clearly present in the ground truth, such as 'asset-sale limits,' 'CCP defaults,' 'credit-quality concerns,' 'deteriorating counterparty credit,' 'higher credit-loss allowances,' 'market-dislocation impacts on RWA,' and 'rating-driven funding-cost risks.' While these may be reasonable inferences about resolution plan mechanics, they are not explicitly mentioned in the ground truth answer and represent potential over-specification. (2) The LLM frames the evolution as moving from a 'trigger-list' description to an 'integrated narrative,' but the ground truth emphasizes a shift toward framing risks 'within a broader context of regulatory evolution and macroeconomic uncertainty'—a subtly different characterization. (3) The LLM's mention of 'subsidiary dividend constraints' is not explicitly supported by the ground truth. (4) The answer is somewhat verbose and complex, making it harder to verify against the ground truth's clearer structure. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 filings and identifies the evolution in disclosures. However, the specific details added (CCP defaults, credit-loss allowances, RWA impacts) go beyond what the ground truth explicitly states, suggesting either inference or potential hallucination. SEMANTIC EQUIVALENCE: The core message—that 2023 focused on liquidity constraints and funding costs while 2024 expanded to include regulatory evolution and systemic events—is preserved, but the LLM adds substantial detail not in the ground truth, which reduces confidence in accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1568,
        "completion_tokens": 575,
        "total_tokens": 2143
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "\nOptum Rx, the Pharmacy Care Services product that UnitedHealth Group (UNH) controls, continues to record product revenue on a gross basis when prescriptions are dispensed and to recognize service revenue over time as contractual services are performed—a pattern reiterated in both the 2022 and 2023 filings. Accounts receivable grew from $7.1 billion at the end of 2022 to $8.6 billion at the end of 2023, and the company expects $11.8 billion of revenue from remaining performance obligations (about half to be recognized in the next three years), underscoring the expansion of its long‑term backlog (≈$22 billion) and the resulting increase in receivable exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core financial metrics - accounts receivable growing from $7.1 billion (2022) to $8.6 billion (2023), matching the ground truth exactly. The revenue recognition model (gross basis for product revenue, over-time for service revenue) is accurately described and consistent with both years. The company identification (Optum Rx/UnitedHealth Group) is correct.\n\nWEAKNESSES AND CONCERNS: (1) UNVERIFIED INFORMATION: The LLM introduces specific figures not present in the ground truth - '$11.8 billion of revenue from remaining performance obligations' and 'approximately $22 billion' long-term backlog. These numbers cannot be verified against the provided ground truth and represent potential hallucination or information from sources outside the knowledge graph. (2) SCOPE CREEP: The original question asks specifically about 'evolution between 2022 and 2023' in revenue recognition and accounts receivable. The LLM adds forward-looking information about remaining performance obligations and future revenue expectations, which goes beyond the comparative analysis requested. (3) INCOMPLETE EVOLUTION ANALYSIS: The ground truth emphasizes that 'the financial structure remained aligned with this model' - suggesting continuity rather than significant evolution. The LLM's answer doesn't clearly articulate whether there was actual structural change or merely growth in receivables. (4) REASONING QUALITY: While the LLM synthesizes information logically, the introduction of unverified figures undermines confidence in the multi-hop reasoning.\n\nNUMBER VERIFICATION: $7.1B (2022) ✓, $8.6B (2023) ✓, $11.8B (unverified), $22B (unverified). The verified numbers are correct, but the unverified figures represent a significant accuracy concern.\n\nMULTI-HOP SYNTHESIS: The answer correctly connects Optum Rx to UnitedHealth Group and synthesizes revenue recognition policy with accounts receivable growth, but the addition of unverified forward-looking metrics suggests either hallucination or reliance on information not in the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Controls]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 560,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "\nUPS’s quantitative exposure to Floating‑to‑Fixed Interest Rate Swaps dropped sharply – the 2021 filing shows only $28 million of such swaps (down from $778 million in 2020), and the 2024 filing discloses essentially no material swap position, indicating a deliberate reduction in the size of the hedge.  At the same time, the company’s risk‑management strategy evolved: it now primarily uses interest‑rate swaps as cash‑flow hedges for forecasted fixed‑rate debt issuances and no longer relies on them to manage existing floating‑rate liabilities, a shift reflected in the 2024 Note 17 discussion of hedge designation, revised counterparty‑credit thresholds ($250 million) and the elimination of cash‑collateral posting requirements.  This progression is captured by the KG relationship UPS – [Discloses]→ Floating‑to‑Fixed Interest Rate Swaps ← [Designates] UPS, highlighting that the firm both reports and strategically designates these instruments as part of its broader interest‑rate risk management program.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) WRONG YEAR REFERENCE: LLM cites '2021 filing' and '2020' data ($778 million), but the question explicitly asks about 2022-2024 evolution. Ground truth specifies 2022 had $28 million notional amount. LLM appears to have pulled data from wrong fiscal years entirely. (2) CONTRADICTORY QUANTITATIVE CLAIMS: LLM states 2024 shows 'essentially no material swap position' but ground truth indicates 2024 shows a MORE STRATEGIC approach to managing interest rate swaps, not elimination. The $28 million figure in ground truth is attributed to 2022, not 2021. (3) INCORRECT NARRATIVE DIRECTION: Ground truth shows EVOLUTION FROM LIMITED USE (2022: $28M) TO MORE COMPREHENSIVE STRATEGY (2024), emphasizing INCREASED strategic deployment. LLM incorrectly characterizes this as a 'sharp drop' and 'deliberate reduction,' which contradicts the ground truth's emphasis on strategic expansion. (4) UNSUPPORTED CLAIMS: LLM introduces specific details about 'Note 17,' '$250 million counterparty-credit thresholds,' and 'elimination of cash-collateral posting requirements' that are not mentioned in ground truth and cannot be verified. (5) MULTI-HOP REASONING FAILURE: LLM failed to correctly synthesize the 2022-2024 comparison. The core finding should be: 2022 = limited quantitative use ($28M) → 2024 = broader strategic framework. Instead, LLM presents a reduction narrative with wrong years. (6) SEMANTIC MISMATCH: Ground truth emphasizes strategic EVOLUTION and INTENTIONAL DEPLOYMENT; LLM emphasizes REDUCTION and ELIMINATION, which are opposite conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Designates]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 433,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "\nBetween 2022 and 2023 GM deepened its partnership with LG Energy Solution through the equally‑owned **Ultium Cells LLC** joint venture, expanding battery‑cell production to three U.S. sites (Ohio, Tennessee, Michigan) and planning a fourth plant, while the 2021‑2022 Chevrolet Bolt EV recall—rooted in defects in LG‑supplied cells—generated **$2.6 billion of accrued costs** that GM recorded through 2023, of which **$1.6 billion was recognized as receivables** and a **remaining $0.6 billion accrual** persisted at year‑end 2023; LG Energy Solution agreed to **reimburse GM for a substantial portion of these recall expenses**, turning the financial relationship from pure joint‑venture investment into a cost‑sharing arrangement that is reflected in the “ORG – Partners_With → COMP ← Pays ORG” KG pattern.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of multi-hop information. STRENGTHS: (1) All key numbers are correct: $2.6 billion accrued costs, $1.6 billion recognized as receivables, and the implied $0.6 billion remaining accrual (2.6 - 1.6 = 1.0, though LLM states $0.6B which appears to be a minor discrepancy). (2) Correctly identifies Ultium Cells LLC as the joint venture and accurately describes the 2022 strategic collaboration phase. (3) Properly synthesizes the 2023 transition from strategic partnership to cost-sharing arrangement due to Bolt EV battery defects. (4) Accurately captures the multi-hop relationship: GM → LG Energy Solution partnership → recall costs → LG reimbursement receivables. (5) Correctly identifies the three U.S. production sites and mentions fourth plant planning. (6) Appropriately characterizes the shift from 'strategic collaboration to transactional/cost-driven dynamic.' MINOR ISSUE: The remaining accrual calculation shows $0.6 billion, but 2.6 - 1.6 = 1.0 billion, not 0.6 billion. This is a mathematical inconsistency, though it's possible the LLM is referencing a different accounting treatment or year-end position not fully explained. The ground truth doesn't specify the remaining accrual amount, so this cannot be definitively marked wrong, but it represents a potential calculation error. OVERALL: The answer comprehensively addresses all aspects of the question (joint venture activities, recall costs, financial relationship evolution) with strong multi-hop reasoning connecting strategic partnership to financial liabilities. The semantic meaning aligns well with ground truth despite the minor accrual discrepancy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Pays]- ORG",
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 465,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "\nIn fiscal 2023 the Observability product category—of which ThousandEyes is a core component (providing a 360‑degree view of hybrid digital ecosystems)—generated an additional $80 million in revenue, a 14 % increase over fiscal 2022; this growth was explicitly driven by stronger sales of the ThousandEyes offering (and its associated monitoring and analytics). Thus, ThousandEyes’s contribution to the Observability segment expanded noticeably from fiscal 2022 to fiscal 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that fundamentally misrepresent the ground truth: (1) QUANTITATIVE ERRORS: The LLM states Observability generated 'an additional $80 million in revenue' in fiscal 2023 with '14% increase' - this is incorrect. Ground truth shows fiscal 2023 saw a 27% increase of $176 million, not $80 million at 14%. The $80 million figure actually refers to fiscal 2022, not 2023. (2) MISSING KEY INFORMATION: The LLM completely fails to mention the Splunk acquisition/inclusion as a major contributor to the fiscal 2023 growth, which is explicitly highlighted in the ground truth as a key driver of the 27% increase. (3) INCOMPLETE SYNTHESIS: The ground truth provides crucial context that excluding Splunk, Observability still grew 15%, demonstrating organic growth from ThousandEyes. The LLM provides no such nuanced analysis. (4) MISATTRIBUTION: The LLM attributes the $80M figure to fiscal 2023 when it actually belongs to fiscal 2022. This is a fundamental chronological error that inverts the evolution being asked about. (5) PERCENTAGE ERROR: The 14% figure is not supported by ground truth data for fiscal 2023. The correct metric is 27% for the full category or 15% excluding Splunk. The LLM answer does correctly identify ThousandEyes as a core component and mentions monitoring/analytics, but these correct elements are overshadowed by the major quantitative and temporal errors. The answer fails to properly show the evolution from fiscal 2022 to fiscal 2023 as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 420,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "\nUPS first listed the $276 million 7.620% debentures in its 2022 10‑K (carrying value $280 million, maturity 2030) – the filing only noted the amount and maturity without detailing any redemption rights. In the 2024 10‑K (page 108) the company explicitly described the debentures as redeemable in whole or in part at any time, with a redemption price equal to the greater of principal + accrued interest or the present‑value of remaining payments discounted at the benchmark Treasury yield + 5 bps (plus accrued interest), and confirmed that interest continues to be paid semi‑annually in April and October with no sinking‑fund obligations. Thus, between 2022 and 2024 the relationship evolved from a simple balance‑sheet disclosure to a fully defined, callable debt instrument with a specified redemption formula and unchanged semi‑annual interest schedule.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about UPS's 7.620% Debentures evolution between 2022 and 2024. QUANTITATIVE VERIFICATION: All numeric values are correct - $276 million principal amount, $280 million carrying value in 2022, April 1, 2030 maturity date, 7.620% interest rate, and 5 basis points in the redemption formula. The semi-annual payment schedule (April and October) is accurately stated. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two fiscal years (2022 and 2024), identifying the key evolution from minimal disclosure to detailed redemption terms. The comparison structure effectively highlights the progression from 'simple balance-sheet disclosure' to 'fully defined, callable debt instrument.' ENTITY ACCURACY: UPS is correctly identified, the debenture percentage and dates are accurate, and the financial metrics are properly contextualized. REASONING QUALITY: The answer demonstrates sound logic in explaining how the relationship evolved - moving from basic identification to explicit redemption flexibility and interest payment specifications. The characterization of the 2022 filing as lacking redemption details while the 2024 filing provides comprehensive redemption formulas aligns with the ground truth. MINOR CONSIDERATIONS: The LLM answer adds the phrase 'with no sinking-fund obligations' which, while not explicitly mentioned in the ground truth, is a reasonable clarification that doesn't contradict the source material. The answer is well-structured and clearly explains the temporal evolution requested. The semantic equivalence is strong - both answers convey that the debentures became more explicitly defined regarding redemption terms and interest payment structure between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Pays_Interest_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 493,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "\nMET’s Fixed‑Maturity Securities AFS grew sharply, with the fair‑value‑reported total rising from $2.164 billion (as shown in the 2021 balance‑sheet snapshot of Chunk 1) to $6.714 billion in 2023 (Chunk 2), reflecting both portfolio expansion and higher market valuations. In 2023 the portfolio was composed of roughly $3.083 billion of corporate securities (≈46 % of the total) and $1.575 billion of U.S. government bonds (≈23.5 % of the total), while foreign bonds, municipal securities and other categories made up the remainder (Chunk 2). This evolution is disclosed by MET’s own reporting of the AFS holdings (KG relationship ORG‑[Has_Stake_In]→FIN_INST and FIN_INST‑[Discloses]→ORG), illustrating how the mix shifted toward a larger share of corporate and sovereign U.S. debt over the two‑year period.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct financial figures and appropriate multi-hop synthesis. STRENGTHS: (1) All key numbers are accurate: $2.164 billion (2021), $6.714 billion (2023), $3.083 billion corporate securities, $1.575 billion U.S. government bonds. (2) Percentage calculations are correct: 46% for corporate securities ($3.083B/$6.714B ≈ 45.9%) and 23.5% for U.S. government bonds ($1.575B/$6.714B ≈ 23.5%). (3) The answer correctly identifies the composition breakdown and notes that other categories (foreign bonds, municipal securities) comprise the remainder. (4) Multi-hop reasoning is sound, synthesizing information about MET's portfolio evolution across the two-year period. (5) The answer appropriately addresses both the composition and fair value evolution aspects of the question. MINOR ISSUES: (1) The original ground truth mentions Level 1 and Level 2 fair value hierarchy classifications ($3.029M at Level 2 for corporate securities, $1.537M at Level 1 for U.S. government bonds), which the LLM answer does not include. While this is additional detail from the ground truth, it's not strictly required to answer the core question about composition and total fair value evolution. (2) The reference to 'KG relationship' and knowledge graph notation adds technical context that, while not incorrect, is somewhat tangential to the core financial analysis. (3) The phrasing 'as shown in the 2021 balance-sheet snapshot' could be slightly clearer about whether this is from the 2022 filing reporting 2021 year-end data. VERIFICATION: The core financial narrative is accurate - the portfolio grew from ~$2.2B to ~$6.7B, with corporate securities and U.S. government bonds being the primary components in 2023. The percentages and composition breakdown are mathematically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 494,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "\nFrom 2022 to 2023 GM’s monetary involvement with Ultium Cells LLC remained modest—a $0.5 million cash outflow recorded in the 2021 investing‑activities section of the 2022 10‑K (the most recent investment figure disclosed), showing a continued but relatively small equity commitment.  At the same time, the relationship acquired a regulatory dimension when, in February 2023, GM self‑disclosed potential TSCA violations tied to the joint venture; in November 2023 the EPA settled the matter, imposing roughly $5.1 million of civil penalties that are assessed **jointly and severally** to both GM and Ultium Cells LLC, thereby linking the partnership to shared compliance risk and a possible additional financial exposure if import activity expands.  (The joint‑venture nature of the relationship is reflected in the KG pattern ORG ‑ Invests_In → COMP ← Partners_With ORG.)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) QUANTITATIVE ACCURACY - The LLM states '$0.5 million' when the ground truth clearly states '$0.5 billion' - this is a 1000x error in magnitude. This is a fundamental factual error that severely undermines the answer's credibility. (2) The LLM correctly identifies the February 2023 TSCA violation disclosure and November 2023 EPA settlement with ~$5.1 million in joint civil penalties, which matches the ground truth. (3) MULTI-HOP REASONING - The LLM correctly synthesizes the evolution from investment-based to operationally integrated partnership with regulatory implications, which is sound reasoning. (4) ENTITY ACCURACY - All entities (GM, Ultium Cells LLC, EPA, TSCA) are correctly identified. (5) CONTEXTUAL RELEVANCE - The answer appropriately addresses both financial involvement and regulatory implications as requested. STRENGTHS: The LLM correctly identifies the shift from passive investment to active partnership, accurately describes the regulatory violations and settlement, and notes the joint and several liability structure. The mention of the KG pattern shows understanding of the relationship structure. WEAKNESSES: The $0.5 million vs $0.5 billion error is catastrophic for a financial question - it misrepresents GM's financial commitment by an order of magnitude. This is not a formatting difference but a fundamental numerical error that would mislead any reader about the scale of GM's investment. The answer otherwise demonstrates good understanding of the regulatory evolution but the quantitative error is disqualifying for a high score on a financial question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Partners_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 442,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "\nThe company has continued to procure natural‑gas and fuel through index‑based **variable‑priced contracts**, a practice first noted in the 2022 filing where such contracts “meet the characteristics of derivative instruments” but were not accounted for as hedges, and reaffirmed in the 2024 filing where they “generally qualify for the ‘normal purchases and normal sales’ exception” and therefore require no mark‑to‑market adjustment; in both years the contracts are used alongside fixed‑price agreements for certain warehouses to partially mitigate energy‑price volatility, reflecting a consistent strategy of employing variable‑priced, index‑linked purchases to manage commodity‑price risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) TEMPORAL MISATTRIBUTION - The LLM claims that in 2022 the contracts 'meet the characteristics of derivative instruments' and were 'not accounted for as hedges,' but the ground truth explicitly states that in 2022 'the specific volume or value of these contracts was not disclosed' and makes NO mention of derivative instrument characterization in 2022. The derivative instrument language and 'normal purchases and normal sales' exception are 2024 developments, not 2022. (2) FACTUAL INVERSION - The LLM reverses the evolution: it suggests the derivative characterization existed in 2022, when the ground truth indicates this formalized accounting framework treatment is a 2024 development, representing a shift toward more strategic/formalized management. (3) UNSUPPORTED CLAIMS - The LLM introduces details not in the ground truth: 'fixed-price agreements for certain warehouses' and 'alongside fixed-price agreements' are not mentioned in the original answer. The ground truth does not discuss fixed-price contracts being used in parallel. (4) INCOMPLETE EVOLUTION NARRATIVE - The ground truth emphasizes the evolution FROM unspecified contracts in 2022 TO explicitly derivative-qualified contracts with accounting exceptions in 2024. The LLM fails to capture this progression and instead conflates both years as having the same derivative characterization. (5) MULTI-HOP REASONING FAILURE - The question asks how use 'evolved' between 2022 and 2024. The LLM does not properly synthesize the temporal change; it treats both years as equivalent rather than showing progression. The core finding that 2024 represents 'a more formalized or strategic use' is completely absent from the LLM response. QUANTITATIVE: No specific numbers were required, but the temporal/chronological accuracy is fundamentally wrong. QUALITATIVE: The reasoning conflates years and introduces unsupported details about fixed-price contracts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Uses]- ORG",
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 526,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "\nCisco (CSCO) continues to measure APJC segment performance by excluding the same set of operating expenses—research and development, sales and marketing, general and administrative costs, amortization and impairment of acquisition‑related intangible assets, share‑based compensation, significant litigation settlements, restructuring and asset‑impairment charges, and other specified items—both in fiscal 2022 and again in the fiscal 2023 filing (which now also references fiscal 2024 results).  The company’s internal management system, used by the CODM, has not altered this exclusion policy; it simply expands the historical range of summarized results (2022 → 2023 → 2024) while maintaining the identical expense‑exclusion framework for the APJC segment.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question effectively. STRENGTHS: (1) Correctly identifies that Cisco maintained consistent exclusion of the same expense categories between fiscal 2022 and fiscal 2023, which is the key finding. (2) Accurately lists all the excluded expense categories: R&D, sales and marketing, G&A, amortization and impairment of acquisition-related intangibles, share-based compensation, significant litigation settlements, and restructuring/asset impairment charges. (3) Properly identifies the APJC segment and CODM (Chief Operating Decision Maker) terminology. (4) Correctly emphasizes that there was NO CHANGE in the exclusion policy between the two fiscal years. (5) Accurately notes that the company expanded the historical range of results while maintaining the identical framework. MINOR ISSUES: (1) The LLM answer introduces fiscal 2024 results, which goes slightly beyond the scope of the original question that specifically asks about fiscal 2022 vs. fiscal 2023 evolution. While this is not incorrect per se, it adds information not directly requested and could be seen as slightly tangential. (2) The phrasing 'which now also references fiscal 2024 results' suggests the fiscal 2023 filing includes 2024 data, which is accurate for 10-K filings but adds complexity not present in the ground truth answer. VERIFICATION: The ground truth states the approach 'remained unchanged' with 'the same categories of expenses...not being allocated,' and the LLM answer confirms 'has not altered this exclusion policy' and maintains 'the identical expense-exclusion framework.' This semantic equivalence is strong. The list of excluded items in both answers matches comprehensively. The multi-hop reasoning (comparing two fiscal years' approaches) is sound in both answers. No numerical errors or calculation issues present. The answer correctly synthesizes that consistency, not evolution/change, is the key finding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> GPE <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 530,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 UNH moved its medical‑cost‑management strategy from a broad, risk‑based model—where roughly 80‑85 % of premium revenue was used to pay health‑care services and the focus was on predicting and pricing overall medical costs—to a targeted approach that specifically tackles the surge in senior outpatient procedures.  In 2023 the company leaned on data‑analytics, physician‑and‑consumer engagement, and value‑based, fully‑accountable care pathways (including integrated care‑coordination technology and physician training) to help seniors choose high‑quality, affordable outpatient services, while also adjusting provider networks, benefit designs and premiums to offset Medicare Advantage rate pressures.  This evolution reflects a shift from generic cost‑containment to coordinated, senior‑focused care delivery that seeks to curb rising outpatient costs while maintaining financial sustainability.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM introduces specific percentages (80-85% of premium revenue used for healthcare services) that are NOT present in the ground truth answer. This is a significant factual error as these numbers cannot be verified against the original answer and appear to be fabricated or from unverified sources. (2) COMPLETENESS - The LLM answer adds substantial detail about 'value-based, fully-accountable care pathways,' 'integrated care-coordination technology,' 'physician training,' 'provider networks,' 'benefit designs,' and 'Medicare Advantage rate pressures' that are NOT mentioned in the ground truth. While some of these details may be accurate from the actual filings, they go beyond what the ground truth specifies and cannot be verified. (3) CORE ACCURACY - The LLM correctly identifies the shift from 2022 to 2023 and mentions data-driven insights and physician-consumer engagement, which aligns with the ground truth. The characterization of the evolution from 'generic cost-containment to coordinated, senior-focused care delivery' is semantically consistent with the ground truth's 'shift from general concern in 2022 to targeted intervention in 2023.' (4) MULTI-HOP REASONING - The LLM demonstrates understanding of the temporal evolution and the shift in strategy, but introduces unverified details that weaken the answer's reliability. (5) CRITICAL FLAW - The introduction of specific percentages (80-85%) without ground truth support is a red flag for hallucination or unsupported claims. The ground truth makes no mention of these specific metrics. The answer would score higher if it stuck to verifiable information from the ground truth while potentially adding context, but the unverified quantitative claims significantly undermine credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Guides_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 492,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "\nFrom 2022 to 2024 UPS transformed its time‑definite delivery from a globally integrated air‑and‑ground small‑package operation—described in 2022 as a single “smart logistics network” that consolidates all air, ground, domestic and international shipments and delivers a broad portfolio of value‑added services (Chunk 1)—into a 2024 offering that expands the scope with same‑day, seven‑day‑a‑week pickups, a full suite of guaranteed international day‑and‑time‑definite services (Worldwide Expedited, Standard, Economy, Express Freight), and insourced residential delivery (UPS SurePost), all managed through an expanded hub network in Louisville, Germany, China, Hong Kong, Canada and Florida and embedded in e‑commerce and returns platforms across roughly 150 countries (Chunk 2). This evolution reflects both the deepening of service scope and the tighter network integration that underpin UPS’s time‑definite delivery product today.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the 2022 foundation as an integrated global air and ground network; (2) Accurately captures the 2024 expansion including same-day pickup seven days a week; (3) Correctly mentions insourced residential delivery through UPS SurePost; (4) Accurately states the geographic scope of approximately 150 countries; (5) Properly synthesizes the multi-hop evolution from 2022 to 2024; (6) Includes additional relevant details about specific service offerings (Worldwide Expedited, Standard, Economy, Express Freight) and hub locations (Louisville, Germany, China, Hong Kong, Canada, Florida) that enhance the answer without contradicting ground truth. MINOR ISSUES: (1) The LLM introduces specific hub locations and service names not explicitly mentioned in the ground truth, though these appear to be accurate contextual details that strengthen rather than weaken the answer; (2) The phrasing 'smart logistics network' is used but this terminology is not explicitly in the ground truth, though it semantically aligns with the described integrated network concept. QUANTITATIVE VERIFICATION: The '150 countries' figure matches exactly with ground truth. All dates (2022, 2024) are correct. No calculations are required for this qualitative question. MULTI-HOP REASONING: The answer successfully synthesizes information across the 2022-2024 timeframe and correctly identifies the evolution in both service scope and network integration as requested. The logical flow from 2022 foundation to 2024 expansion is sound and well-articulated. SEMANTIC EQUIVALENCE: The answer conveys all essential information from the ground truth while adding contextual depth that appears accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 490,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "\nIn both the 2022 Form 10‑K (Exhibit 4.14) and the 2023 Form 10‑K (Exhibit 4.14), Lowe’s continues to reference the 2.50 % Notes maturing in April 2026 as part of the **Thirteenth Supplemental Indenture dated April 20, 2016**—the same indenture that originally introduced the notes.  The company’s treatment of these notes therefore shows **no change or new amendment** between the two filings; the notes remain identified under the identical supplemental indenture and are consistently presented as a liability of Lowe’s Companies, Inc. in both annual reports.  This consistency is reflected in the KG relationship LOW → 2.50 % Notes ← Issues LOW, linking the same financial instrument across both reporting periods.",
      "correctness_score": 2,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR IN CORE ANSWER: The LLM fundamentally contradicts the ground truth on the central question. The ground truth explicitly states there WAS a shift in disclosure treatment between 2022 and 2023—from 'referenced as part of...historical documentation' in 2022 to 'explicitly recognized as issued instruments' in 2023. The LLM claims 'no change or new amendment' and states the notes are 'consistently presented' across both years, which directly contradicts the ground truth's assertion of 'a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition...in 2023.' QUANTITATIVE ACCURACY: The numeric values are correct (2.50%, April 2026, April 20, 2016 date). QUALITATIVE ACCURACY: The LLM correctly identifies the indenture reference and company name, but completely misses the evolution/change that is the core of the question. The LLM's statement that treatment 'shows no change' is factually incorrect per the ground truth. REASONING FAILURE: The question explicitly asks 'how did...treatment...evolve' implying change. The ground truth identifies a specific evolution from historical documentation to active recognition. The LLM's multi-hop synthesis fails because it concludes consistency where the ground truth identifies transition. The LLM appears to have focused on the static elements (same indenture, same terms) while missing the dynamic disclosure treatment change that is the actual answer to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Issues]- ORG",
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 410,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "\nFrom 2022 through 2024 Costco’s filings treat sovereign‑debt crises as a persistent macro‑economic shock that can impair its ability to buy merchandise at competitive prices—raising tariffs, inflating commodity (notably energy and gasoline) costs, and tightening overall cost‑structure pressure.  In the 2022 filing the risk was described as a potential to force inventory‑cost increases and alter product mixes, whereas the 2024 filing expands this view by linking sovereign‑debt‑driven inflation and higher energy prices to tighter margins and a reduced capacity to pass cost hikes to members, underscoring the continued negative impact of sovereign‑debt conditions on Costco’s sourcing and cost structure.  (The KG relationship ORG → Sovereign Debt Crises → ORG captures this negative, macro‑condition‑driven impact.)",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution from 2022 to 2024, capturing that sovereign debt crises shifted from a potential risk to an explicit negative impact statement. (2) The answer appropriately synthesizes the multi-hop relationship across years and identifies key mechanisms (tariffs, commodity costs, energy prices, margin pressure). (3) The temporal framing (2022 vs 2024) is accurate and addresses the question's core requirement. (4) The mention of product mix changes and cost structure pressures aligns with ground truth. WEAKNESSES: (1) The LLM introduces specific claims not explicitly supported by the ground truth, particularly regarding 'reduced capacity to pass cost hikes to members'—this is an inference not stated in the original answer. (2) The emphasis on 'energy and gasoline costs' as specific mechanisms is added detail not present in the ground truth, which mentions these more generally. (3) The KG relationship notation at the end (ORG → Sovereign Debt Crises → ORG) is metadata that doesn't add substantive value and may confuse rather than clarify. (4) The ground truth emphasizes 'supply chain risks, supplier adherence to standards, supply constraints, and geopolitical instability' as part of the 2024 framing, but the LLM answer downplays these broader supply chain concerns in favor of cost/tariff mechanisms. (5) The ground truth's specific mention of 'the degree of exposure depended on the type of goods, tariff rates, and timing' is not captured in the LLM answer. QUANTITATIVE ACCURACY: No specific numbers or calculations are present in either answer, so this dimension is less critical. Both answers correctly reference 2022 and 2024 without error. QUALITATIVE ACCURACY: The LLM demonstrates sound multi-hop reasoning but makes some unsupported inferences that go beyond the ground truth. The synthesis is logical but slightly overextended. CONTEXTUAL RELEVANCE: The answer directly addresses the question about evolution from 2022-2024 and is appropriately focused on Costco's merchandise sourcing and cost structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> MACRO_CONDITION <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 559,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "\nBetween 2021 and 2023 the shares reserved for future grants under the 2020 Stock Incentive Plan fell from **64 million** (as reported in the 2021 10‑K) to **53 million** (as disclosed in the 2023 10‑K), a reduction of about **11 million shares**.  This decline reflects the shares that have already been allocated for prior awards, yet the company still has **over 50 million shares** available, indicating that UnitedHealth Group retains substantial capacity to issue new share‑based awards despite the reduction.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: 64 million shares in 2021, 53 million shares in 2023, and the calculated reduction of 11 million shares. The multi-hop synthesis is sound - the answer correctly identifies the change across the two-year period and properly attributes the data to the respective 10-K filings. The LLM goes beyond the ground truth by providing additional context: (1) calculating the specific reduction (11 million shares), (2) noting that over 50 million shares remain available, and (3) interpreting what this means for the company's capacity to issue future awards. This additional analysis is logical and relevant - the observation that UnitedHealth Group 'retains substantial capacity' despite the reduction is a reasonable inference from the data. The entity identification is correct (UnitedHealth Group, 2020 Stock Incentive Plan, 2021 and 2023 fiscal years). The reasoning properly synthesizes information across multiple years and documents. The only minor distinction from the ground truth is that the LLM provides more detailed interpretation and context, which enhances rather than detracts from the answer. All numbers are formatted clearly and calculations are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 352,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "\nBetween 2022 and 2024 the IAM National Pension Fund / National Pension Plan’s collective‑bargaining agreement moved from an expiration of **July 31 2024** (documented in the 2022 filing) to **July 31 2029** (disclosed in the 2024 filing), extending the term by five years.  Throughout this period the fund has consistently contributed **more than 5 % of total plan contributions**—for 2021‑2019 in the 2022 report and for 2022‑2024 in the 2024 report—demonstrating its continued, material significance in UPS’s multi‑employer pension funding.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and effectively addresses the multi-hop question about the evolution of the IAM National Pension Fund relationship with UPS between 2022 and 2024. STRENGTHS: (1) All dates are correct - July 31, 2024 expiration in 2022 filing and July 31, 2029 in 2024 filing are accurately stated. (2) The five-year extension calculation is correct (2024 to 2029). (3) The contribution threshold of 'more than 5%' is correctly identified for both periods. (4) The year ranges are accurate - 2019-2021 contributions documented in 2022 report, and 2022-2024 contributions in 2024 report. (5) Multi-hop synthesis is sound: the answer correctly synthesizes information across two different filing years and identifies the evolution of both the expiration date and contribution significance. (6) The characterization of UPS as a 'significant contributor' and the relationship as having 'sustained significance' appropriately captures the ground truth meaning. MINOR OBSERVATION: The LLM uses 'July 31 2024' without commas/formatting, while the original uses 'July 31, 2024' - this is a negligible formatting variation that does not affect accuracy. The phrase 'for 2021-2019' in the LLM answer is slightly awkward ordering (should be 2019-2021) but the intent is clear and matches the ground truth. Overall, the answer demonstrates excellent comprehension of the complex multi-year, multi-entity relationship and correctly conveys all material facts from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Contributes_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 410,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "\nIn fiscal 2022 the 2020 Credit Agreement was a $2 billion five‑year revolving facility that matured in March 2025, and together with the third‑amended and restated agreement it delivered a total of $4 billion of combined availability (the company had no outstanding borrowings under either agreement as of January 28 2022).  \nIn fiscal 2023 the company amended and restated that same facility, extending its maturity to September 2028 while keeping the $2 billion capacity and the option to increase the aggregate availability by an additional $1 billion; the combined availability remained $4 billion, and although the commercial‑paper program had $499 million of borrowings that reduced the drawable amount, no borrowings were outstanding under the 2020 or the new 2023 Credit Agreement as of February 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All numbers are correct - $2.0 billion availability in 2022 (✓), March 2025 maturity in 2022 (✓), $4.0 billion combined availability in both years (✓), September 2028 maturity in 2023 (✓), $2.0 billion maintained in 2023 (✓), $1 billion increase option mentioned (✓), $499 million commercial paper borrowings (✓). COMPLETENESS: The answer addresses all key aspects of the question: (1) 2022 terms and availability, (2) 2023 evolution/amendment, (3) maturity date extension, (4) availability maintenance, (5) combined total consistency. ENTITY ACCURACY: Correctly identifies LOW (Lowe's), the 2020 Credit Agreement, the 2023 Credit Agreement (amended and restated version), and the Third Amended and Restated Credit Agreement. Fiscal years 2022 and 2023 are correctly referenced with appropriate dates (January 28, 2022 and February 2023). MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, showing the evolution from 2022 to 2023, including the amendment/restatement event in September 2023. The connection between the 2020 Credit Agreement becoming the 2023 Credit Agreement is clearly explained. ADDITIONAL VALUE: The LLM answer provides supplementary context not explicitly in the ground truth (no outstanding borrowings, commercial paper program details, increase option) that adds relevant detail without contradicting the original answer. MINOR OBSERVATION: The ground truth mentions 'Third Amended and Restated Credit Agreement' while the LLM refers to 'third‑amended and restated agreement' - these are semantically equivalent references to the same facility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Into]-> FIN_INST <-[Amends]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 462,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "\nMDLZ’s net‑investment‑hedge derivative contracts grew sharply: the notional amount rose from **$3.9 billion (as of Dec 31 2021, shown in the 2022 filing)** to **$8.6 billion (as of Dec 31 2024, shown in the 2024 filing)**, an increase of roughly **$4.7 billion or about 120 %**. This expansion reflects a marked scaling of MDLZ’s hedging program between 2022 and 2024, as captured by the “Increases” relationship in the knowledge‑graph triplets linking the firm to its disclosed financial instruments.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct identification of key figures and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the 2021 notional amount as $3.9 billion (matches ground truth $3,915 million), (2) Correctly identifies the 2024 notional amount as $8.6 billion (matches ground truth $8,647 million), (3) Calculation of the increase is accurate: $8,647M - $3,915M = $4,732M ≈ $4.7 billion, (4) Percentage calculation is correct: ($4,732M / $3,915M) × 100 ≈ 120.9%, (5) Properly synthesizes multi-hop information across 2022 and 2024 filings, (6) Correctly identifies the trend of growing reliance on hedging contracts. MINOR WEAKNESSES: (1) The answer omits intermediate data points from the ground truth (2020 figure of $4,551M and 2023 figure of $7,456M), which would have provided a more complete picture of the evolution across the full period. The ground truth explicitly mentions these intermediate values to show the progression, whereas the LLM only compares endpoints. (2) The reference to 'knowledge-graph triplets' is somewhat vague and could be more specific about the source documents. OVERALL ASSESSMENT: The core answer is factually correct with accurate numbers, proper calculations, and sound reasoning. The omission of intermediate years is a minor gap in completeness but does not undermine the accuracy of the stated figures or the main conclusion about the evolution of MDLZ's hedging program.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 402,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "\nBetween 2022 and 2024 Microsoft 365 evolved from an **AI‑backed** productivity suite into an **AI‑first** platform, embedding large‑language‑model assistance directly into Office, Windows, Teams, Viva and the Microsoft Graph data layer.  In 2024 the company added **Copilot for Microsoft 365** (with a consumer‑grade **Copilot Pro** subscription), **role‑specific Copilots** for Sales, Service and Finance, and **Copilot Studio** that lets customers build or customize their own Copilot experiences, while the **Power Platform** expanded low‑code/no‑code automation, virtual agents and BI tools.  The same year Microsoft also introduced purpose‑built AI infrastructure—**Azure Maia** and **Azure Cobalt** accelerators—giving the cloud the compute power to run large AI workloads and further tightening the integration of AI with Microsoft 365’s collaboration and productivity functions.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution from 'AI-backed' (2022) to 'AI-first' (2024), which matches the ground truth. It accurately names the key 2024 capabilities: Copilot for Microsoft 365, role-specific Copilots (Sales, Service, Finance), and Copilot Studio. The mention of Power Platform expansion and Azure infrastructure (Maia, Cobalt) shows additional context beyond the ground truth. The answer demonstrates sound multi-hop reasoning by synthesizing the 2022-to-2024 evolution across multiple product lines.\n\nWEAKNESSES: (1) The LLM introduces 'Copilot Pro' as a consumer-grade subscription option in 2024, which is NOT mentioned in the ground truth and appears to be an unsupported claim from the SEC filings context provided. This is a factual addition not verified against the original answer. (2) The mention of Azure Maia and Azure Cobalt accelerators, while potentially accurate, is NOT part of the ground truth answer and represents scope creep beyond what was documented in the knowledge graph. (3) The LLM's reference to 'Windows, Teams, Viva and the Microsoft Graph data layer' adds specificity not explicitly stated in the ground truth, though it's semantically consistent with the integration concept. (4) The answer doesn't explicitly state that these capabilities combine 'AI with business data from the Microsoft Graph and Microsoft 365 applications' as clearly as the ground truth does.\n\nQUANTITATIVE ACCURACY: No specific numbers, dates, or percentages are provided in either answer, so this dimension is neutral. Both answers correctly reference 2022 and 2024 as the comparison periods.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across the 2022-2024 timeframe and connects multiple product offerings (Office, Teams, Viva, Power Platform, Azure). However, the introduction of unverified elements (Copilot Pro, Azure infrastructure) suggests the model may have hallucinated or drawn from sources beyond the ground truth knowledge graph.\n\nSEMANTIC EQUIVALENCE: The core message aligns with ground truth regarding the evolution and key 2024 capabilities. However, the additional claims about Copilot Pro and Azure infrastructure create factual divergence that cannot be verified against the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 611,
        "total_tokens": 2023
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "\nIn the 2022 disclosure (Chunk 1) 3M first admitted that its Decatur NPDES permit did not fully characterize PFAS releases, temporarily idled affected processes, and filed an application with ADEM to add those PFAS to the permit while installing interim wastewater‑treatment controls. By 2024 (Chunk 2) the company had moved from that initial admission to a sustained effort to upgrade and optimize the treatment controls and continue pursuing the permit amendment, although ADEM had still not acted, showing an evolution from a reactive, interim response to an ongoing, more comprehensive characterization and mitigation strategy for PFAS in its wastewater discharge.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All dates (2022 and 2024) are correct, and no specific numeric values are present in either answer to verify, so this dimension scores perfectly. ENTITY ACCURACY: 3M, Decatur facility, NPDES permit, ADEM, and PFAS are all correctly identified and referenced. COMPLETENESS: The answer addresses the core evolution question by contrasting the 2022 and 2024 positions. The 2022 disclosure elements are accurately captured: (1) PFAS not fully characterized in NPDES permit, (2) application submitted to ADEM to add PFAS, (3) interim wastewater treatment controls installed. The 2024 elements are also accurate: (1) upgraded/optimized treatment controls, (2) ADEM had not yet acted on permit modification. MULTI-HOP REASONING: The answer correctly synthesizes information across two time periods and identifies the evolution pattern - from reactive/interim response to sustained/comprehensive strategy. This multi-hop synthesis is sound and matches the ground truth's characterization of the shift. SEMANTIC EQUIVALENCE: The LLM's phrasing 'moved from that initial admission to a sustained effort' and 'evolution from a reactive, interim response to an ongoing, more comprehensive characterization and mitigation strategy' conveys the same meaning as the ground truth's 'shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions.' The LLM adds slightly more detail about the interim nature of 2022 controls and the ongoing pursuit of permit amendment, which enriches rather than contradicts the ground truth. MINOR OBSERVATION: The LLM mentions 'temporarily idled affected processes' in 2022, which is a reasonable inference about interim response measures but is not explicitly stated in the ground truth provided. However, this does not contradict the ground truth and represents a reasonable elaboration on the interim response characterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discovers]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 544,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "\nBetween 2022 and 2023 Lowe’s continued to carry the 4.550 % Notes that were originally created on April 5 2019 under the Fifteenth Supplemental Indenture (the “4.550 % Notes due April 5 2049”).  Both the 2022 10‑K (Chunk 1, Exhibit 4.16) and the 2023 10‑K (Chunk 2, Exhibit 4.16) simply re‑file that same indenture—no new issuance, amendment, or refinancing of the 4.550 % Notes is reported in either filing, indicating that the instrument remained outstanding with its original terms and maturity throughout the 2022‑2023 period.  The KG relationship LOW → 4.550 % Notes ← Issues shows that Lowe’s introduced and issued the notes, and the two filings confirm their continued presence in the company’s capital structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All factual information is correct: (1) The 4.550% Notes were originally issued on April 5, 2019 under the Fifteenth Supplemental Indenture with a maturity date of April 5, 2049 - all dates and percentages match the ground truth exactly. (2) The quantitative accuracy is perfect - no calculations are required, and all numeric values (4.550%, April 5, 2019, April 5, 2049) are correct. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across 2022 and 2023 10-K filings, noting that both years reference the same indenture (Exhibit 4.16) with no modifications, amendments, or new issuances. (4) Entity identification is accurate - Lowe's Companies, Inc. is correctly identified, the specific note instrument is properly named, and the indenture reference is precise. (5) The semantic meaning aligns perfectly with the ground truth: both answers convey that the notes were introduced in 2019, continued unchanged through 2022-2023, and no new issuance occurred during the 2022-2023 period. The LLM answer actually provides slightly more detail by explicitly referencing the 10-K exhibits and the knowledge graph relationship, which adds helpful context without introducing any inaccuracies. The only minor distinction is that the LLM uses slightly more detailed language about the filings and exhibits, but this enhances rather than detracts from the answer's quality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Issues]- ORG",
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 402,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 MDLZ continued to hold roughly a 13 % equity stake in KDP that had been built through the 2020 secondary offering (which generated a $71 million pre‑tax gain and reduced its ownership to 13.1 %) and the earlier 2019 gain of $23 million, the 2020 JDE Peet’s transaction that produced about $121 million of gains and the exchangeable bonds issued in September 2021; under the equity‑method it recorded a $493 million pre‑tax gain on equity‑method transactions during 2023.  In 2024 MDLZ changed the accounting classification of the KDP investment to marketable securities, so that “gain on marketable securities sold” now reflects the difference between sale proceeds and the carrying value at the date of the accounting change, converting the previously deferred equity‑method gains into current earnings.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides substantial context about MDLZ's KDP relationship but contains significant issues with the core quantitative claims in the ground truth.\n\nCORRECT ELEMENTS:\n- Correctly identifies the 2022 $71 million pre-tax gain from KDP share sale\n- Correctly identifies the 13% equity stake maintained\n- Correctly identifies the 2024 accounting change from equity method to marketable securities classification\n- Provides relevant historical context (2019, 2020, 2021 transactions)\n- Correctly explains the mechanism of the 2024 change (converting deferred equity-method gains to current earnings)\n\nCRITICAL ERRORS:\n1. MAJOR QUANTITATIVE ERROR: The LLM states \"under the equity‑method it recorded a $493 million pre‑tax gain on equity‑method transactions during 2023.\" However, the ground truth clearly states this $493 million gain was recorded in 2024 due to the accounting change, not in 2023. This is a significant dating error.\n\n2. INCOMPLETE ANSWER TO CORE QUESTION: The ground truth explicitly states the $493 million gain was \"due to a change in accounting for its investment in KDP\" in 2024. While the LLM mentions the 2024 accounting change, it attributes the $493 million gain to 2023 equity-method transactions, creating confusion about when and why this gain was recognized.\n\n3. MISSING AFTER-TAX FIGURES: The ground truth provides after-tax amounts ($54 million for 2022, $368 million for 2024), which the LLM does not mention.\n\nMULTI-HOP REASONING:\nThe LLM demonstrates good multi-hop synthesis by connecting the 2022 transaction, the maintained equity stake, and the 2024 accounting change. However, the temporal misplacement of the $493 million gain undermines the core narrative of how the relationship \"evolved\" between 2022 and 2024.\n\nSEMANTIC ISSUES:\nThe LLM's explanation of the 2024 mechanism is actually quite clear and accurate, but the dating error creates a fundamental factual problem that contradicts the ground truth's clear statement that the $493 million gain was recorded in 2024.\n\nJUSTIFICATION:\nWhile the answer shows good contextual knowledge and reasoning, the misplacement of the $493 million gain from 2024 to 2023 is a critical error that affects the core answer to the question about how the relationship evolved between 2022 and 2024. This is not a minor wording difference but a factual error about timing of a major financial event.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 642,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "\nMicrosoft’s Xbox Game Pass has expanded dramatically in scale, growing from a curated library of **over 100 titles** highlighted in the 2022 10‑K (Chunk 1) to a catalog of **more than 400 first‑ and third‑party console and PC games** reported in the 2024 filing (Chunk 2).  This growth is coupled with a strategic shift: while the 2022 description framed the service as a community‑driven, cloud‑enabled subscription that complements console hardware, the 2024 outlook positions it as a **central gaming platform that expands first‑party studio investment, adds subscription/ad tiers, and reaches gamers across PC, mobile and other devices**—a move that leverages Microsoft’s broader ecosystem (as detailed in Chunk 2) and is reflected in the KG relationship **MSFT → Xbox Game Pass (Produces)** and **Xbox Game Pass ← MSFT (Introduces)**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive synthesis of multi-hop information. QUANTITATIVE ACCURACY: All numeric values are correct - 'over 100 titles' in 2022 and 'more than 400 first- and third-party titles' in 2024 match the ground truth exactly. The year references (2022 vs 2024) are accurate. COMPLETENESS: The answer addresses both key dimensions of the question: (1) scale evolution (100→400 titles) and (2) strategic positioning evolution. ENTITY ACCURACY: Microsoft, Xbox Game Pass, and relevant years are correctly identified. The answer properly synthesizes information across multiple filing years. REASONING QUALITY: The multi-hop synthesis is sound - the LLM correctly identifies the progression from a 'community-driven, cloud-enabled subscription' positioning in 2022 to a 'central gaming platform' positioning in 2024. The strategic shift toward subscriptions, ecosystem expansion (PC, mobile), and first-party investment is accurately captured and represents a logical evolution of Microsoft's gaming strategy. SEMANTIC EQUIVALENCE: The LLM's characterization of the 2024 positioning as 'cornerstone' aligns with the ground truth's description, though the LLM uses slightly different language ('central gaming platform'). This is semantically equivalent and arguably more descriptive. MINOR CONSIDERATIONS: The LLM includes additional context about 'subscription/ad tiers' and ecosystem expansion that, while not explicitly mentioned in the ground truth summary, represents reasonable elaboration from the source documents and doesn't contradict the ground truth. The reference to knowledge graph relationships adds helpful context without introducing errors. Overall, the answer is factually accurate, well-synthesized, and comprehensively addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 490,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "\nFrom 2022 to 2024, 3M’s Form 10‑K filings continue to disclose the identical “Form of Deferred Stock Unit Award Agreement for deferred stock units granted on or after January 1, 2019 to Non‑Employee Directors” under the 2016 Long‑Term Incentive Plan, a document first incorporated by reference from the 2018 10‑K. The 2022 filing cites the plan as “amended and restated effective May 11, 2021,” while the 2024 filing updates the reference to “amended through May 8, 2023” and adjusts the plan name formatting, but the core agreement language and incorporation remain unchanged. This shows a consistent structure with only the plan‑amendment citation and minor formatting updates evolving between the two years.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key dates and plan amendments. Strengths: (1) Correctly identifies the agreement as applying to grants on or after January 1, 2019 across both 2022 and 2024 filings; (2) Accurately cites the 2022 amendment date as May 11, 2021 and the 2024 amendment date as May 8, 2023; (3) Properly notes the incorporation by reference from the 2018 10-K; (4) Correctly characterizes the evolution as involving plan amendment citations and minor formatting updates rather than structural changes. Quantitative accuracy is high with all dates correct. The multi-hop reasoning is sound, synthesizing information about how the disclosure evolved across the three-year period. Minor weakness: The LLM answer provides slightly more specific detail about the 2018 10-K incorporation and amendment dates than the ground truth explicitly states, though this additional detail appears consistent with typical SEC filing practices and does not contradict the ground truth. The answer fully addresses the question about how the structure/disclosure evolved, correctly concluding that the core agreement remained unchanged while amendment citations and formatting were updated. The semantic equivalence is strong - both answers convey that the agreement structure remained consistent from 2022 to 2024 with only administrative/citation updates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 389,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "\nBetween 2023 and 2024 the direct origination costs recorded for the First Mortgages and HELOCs portfolio rose from **$100 million** (reported at Dec 31 2023 in Chunk 1) to **$112 million** (reported at Dec 31 2024 in Chunk 2), a $12 million increase.  At the same time the geographic concentration in California slipped slightly from **43 %** of the portfolio (Chunk 1) to **42 %** (Chunk 2).  Both years show no loans > 90 days past due and the same blanket‑lien pledging of the full portfolio to secure FHLB borrowing (Chunk 1 & Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All key quantitative metrics are correct: (1) $100 million in 2023 unamortized premiums/discounts/direct origination costs, (2) $112 million in 2024, (3) 43% California concentration in 2023, (4) 42% in 2024. The $12 million increase calculation is accurate. The multi-hop synthesis correctly combines information across two fiscal years and identifies the portfolio composition evolution. The answer appropriately addresses both main components of the question: origination costs and geographic concentration. Minor strengths include the additional contextual details about past-due loans and FHLB pledging arrangements, which provide useful context though not strictly required by the question. The only minor consideration is that the LLM uses 'direct origination costs' terminology while the ground truth uses 'unamortized premiums, discounts, and direct origination costs' - however, this is semantically equivalent as the LLM is referring to the same line item. The reasoning is sound, the entity identification (Charles Schwab Bank, First Mortgages and HELOCs portfolio) is correct, and the temporal comparison is properly executed. The answer conveys the same substantive information as the ground truth with appropriate emphasis on the key findings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 369,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "\nNike’s R&D narrative in both the fiscal 2023 and fiscal 2024 10‑K filings treats Dri‑FIT as a core “innovation” that is woven into the company’s broader technology portfolio (Air, Zoom, Free, Flyknit, etc.) and repeatedly emphasizes that such technologies “help to enhance athletic performance, reduce injury and maximize comfort” while advancing sustainability. The wording is virtually identical in the two filings—both list Dri‑FIT among the proliferating technologies that typify Nike’s dedication to innovative product design—showing that the strategic emphasis on Dri‑FIT has remained steady from 2023 to 2024. This continuity is reflected in the knowledge‑graph relationship NKE → **Dri‑FIT** (“expands to”) and **Dri‑FIT** → NKE (“produces”), underscoring that Dri‑FIT continues to be a key product through which Nike delivers its innovative, performance‑oriented offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. Strengths: (1) Correctly identifies that Dri-FIT's strategic emphasis remained stable/steady between fiscal 2023 and 2024, matching the ground truth conclusion; (2) Accurately lists the same supporting technologies (Air, Zoom, Free, Flyknit, etc.) as mentioned in the original answer; (3) Correctly notes that 'exact same language' or 'virtually identical' wording appears in both filings, demonstrating no change in emphasis; (4) Properly synthesizes the multi-hop information by comparing R&D narratives across two fiscal years; (5) No quantitative errors or date inaccuracies. Minor considerations: (1) The LLM adds interpretive language about 'innovation,' 'performance enhancement,' 'injury reduction,' and 'sustainability' that goes slightly beyond what the ground truth explicitly states, though this appears to be reasonable elaboration rather than factual error; (2) The reference to knowledge-graph relationships (NKE → Dri-FIT 'expands to') adds context not in the original answer but doesn't contradict it; (3) The phrasing 'virtually identical' vs. the ground truth's 'exact same language' is a minor semantic distinction that doesn't affect correctness. Overall, the LLM successfully answers the core question with accurate synthesis of multi-hop information across fiscal years, correct entity identification, and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Expands]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 394,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "\nFrom 2022 to 2024 Mondelez International has progressively deepened its financial and operational commitment to backup and disaster‑recovery as a direct response to escalating cyber threats.  In its 2022 filing the company disclosed that it “dedicates focused resources to … backup and disaster recovery” and enhances threat‑monitoring across its manufacturing and operational‑technology environments, while the 2024 filing details a broader augmentation—adding 24/7 security operations, multi‑factor authentication, privileged‑access management, advanced threat‑protection tools, and explicit investment in backup and disaster‑recovery solutions—to counter rising phishing, ransomware and state‑sponsored attacks amid greater remote work, cloud adoption and geopolitical instability.  Thus, the company’s investment in backup and disaster‑recovery has evolved from a baseline, alert‑level posture in 2022 to a comprehensive, continuously‑enhanced program in 2024 that is tightly linked to its overall cybersecurity risk‑mitigation strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024, matching the ground truth's timeframe; (2) Accurately captures the core narrative that Mondelez moved from a 'heightened alert' posture in 2022 to 'significantly expanded efforts' by 2024; (3) Properly synthesizes multi-hop information by connecting backup/disaster recovery investments to broader cybersecurity threats; (4) Correctly identifies specific threat types mentioned in the ground truth (state-sponsored actors, ransomware, phishing); (5) Appropriately contextualizes the evolution within the company's overall cybersecurity strategy; (6) Uses semantically equivalent language ('baseline, alert-level posture' for 2022 vs. 'heightened alert' in ground truth; 'comprehensive, continuously-enhanced program' for 2024 vs. 'significantly expanded efforts'). MINOR CONSIDERATIONS: (1) The LLM answer adds specific details about '24/7 security operations, multi-factor authentication, privileged-access management' that are not explicitly mentioned in the ground truth provided, though these appear to be legitimate enhancements from the actual 2024 filing and represent reasonable elaboration; (2) The ground truth mentions 'artificial intelligence' as an emerging technology threat, while the LLM answer does not explicitly reference this, though it does mention 'geopolitical instability' which captures the broader threat landscape; (3) No quantitative metrics (dollar amounts, percentages) are present in either answer, so quantitative accuracy is assessed as high given the absence of numerical claims to verify. The multi-hop reasoning is sound—the answer correctly synthesizes information across two years and connects specific security measures to threat categories. The answer fully addresses the question's core inquiry about evolution and response to threats.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enhances]-> RISK_FACTOR <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 526,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "\nMicrosoft’s financial commitment to Black‑ and African‑American‑owned suppliers grew markedly from FY 2022 to FY 2024. In FY 2022 the company reported being ≈ 90 % toward its $500 million target and said it was “double[ing] the number of Black‑ and African‑American‑owned suppliers,” while also pledging a $150 million investment to strengthen inclusion and grow the supplier pipeline. By FY 2024 Microsoft had **reached** that $500 million spend goal, **doubled** the supplier count, and **provided 162 low‑ or no‑interest loans** through its Partner Capital Fund, reinforcing the pipeline with additional $150 million directed to minority depository institutions and Black‑owned small‑business funds. This progression shows a clear escalation of both monetary investment and supplier engagement over the two‑year span.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates good understanding of the overall narrative of Microsoft's evolving commitment to Black and African American-owned suppliers, but contains a significant factual error that undermines accuracy. CORRECT ELEMENTS: (1) FY 2022 status of ~90% toward $500M goal - accurate; (2) Doubling the number of suppliers - correctly identified; (3) Achievement of $500M spending goal by FY 2024 - accurate; (4) $150M allocation to Minority Depository Institutions and Black-owned small business funds - accurate; (5) Overall narrative of escalation and deepening commitment - well-articulated. CRITICAL ERROR: The LLM introduces '162 low- or no-interest loans through its Partner Capital Fund' which does NOT appear in the ground truth answer. This is a factual insertion that cannot be verified against the provided knowledge graph data and represents either hallucination or information from an external source not in the ground truth. This is a significant accuracy issue. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and identifies the progression of commitments. The comparison structure is sound. QUANTITATIVE ACCURACY ISSUE: While the numbers that ARE mentioned are correct, the introduction of the '162 loans' figure is unverified and problematic. The answer also adds detail about 'doubling the supplier count' being achieved by FY 2024, which is reasonable inference but goes slightly beyond what the ground truth explicitly states (ground truth says they were 'doubling' in FY 2022, not that this was completed by FY 2024). SEMANTIC EQUIVALENCE: The core message aligns with ground truth regarding the evolution and deepening of commitment, but the unverified loan detail creates a factual discrepancy that cannot be overlooked in a financial context where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 500,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "\nThe availability of common shares reserved for future issuance under Abbott’s Employee Stock Purchase Plan for Non‑U.S. Employees dropped from the 10,638,639 shares disclosed in the 2022 Proxy filing (reflecting the status at the end of 2021) to 8,565,087 shares as of December 31 2023 – a reduction of roughly 2 million shares.  This contraction, coupled with the fact that the 2009 plan was replaced by the 2017 Incentive Stock Program and that the 2017 Plan’s share reserve is now being used more selectively, shows that Abbott is deliberately scaling back the equity pool earmarked for the non‑U.S. employee purchase plan.  In the knowledge‑graph terms, Abbott (ORG) issues common‑share financial instruments (FIN_INST) through this plan, and the declining reserve signals a strategic shift toward tighter control of dilution and a greater emphasis on other components of its 2017 stock‑based incentive framework.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All key numbers are correct: 10,638,639 shares in 2022 (as of Dec 31, 2021) and 8,565,087 shares in 2023 (as of Dec 31, 2023). (2) The calculation of the reduction (~2 million shares) is accurate. (3) The dates are properly identified. (4) The core finding about the decline in available shares is correct. (5) The answer correctly identifies this as reflecting Abbott's stock-based incentive strategy adjustment.\n\nWEAKNESSES: (1) The LLM introduces additional context about the 2009 plan being replaced by the 2017 Incentive Stock Program that is not present in the ground truth answer. While this may be factually accurate from the filings, it goes beyond what the original answer states and introduces information not verified against the ground truth. (2) The interpretation about 'tighter control of dilution' and 'greater emphasis on other components' is inferential reasoning that extends beyond the ground truth's more measured statement that this 'suggests a potential tightening or adjustment.' (3) The knowledge-graph notation (ORG, FIN_INST) is unnecessarily technical and not part of the original answer's framing.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the comparison across two time periods (2022 vs 2023) and connects the numerical change to strategic implications. However, it adds interpretive layers (plan replacement, selective use) that exceed the ground truth's scope.\n\nSEMANTIC EQUIVALENCE: The core message aligns - shares available decreased, indicating strategic adjustment. However, the LLM's additional claims about plan replacement and dilution control are not substantiated in the ground truth provided.\n\nOVERALL: The answer is substantially correct on the primary quantitative facts and the basic strategic interpretation, but adds unverified contextual claims that slightly overreach the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 506,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "\nNike’s treatment of Nike Air has continued to evolve from a standalone performance unit to a core element of a broader technology portfolio, with both the FY 2023 and FY 2024 10‑K filings emphasizing that research, design and development efforts—driven by athlete‑tested feedback, external expert committees and market intelligence—are deliberately expanding the use of Air‑based innovations (e.g., Air Max, ZoomX, React) across footwear, apparel and digital experiences.  The filings show a bidirectional relationship (NKE → Nike Air → NKE) that reflects Nike’s strategy of leveraging the Air platform to enhance athletic performance, reduce injury and meet consumer preferences, while simultaneously reinforcing the brand’s overall product‑development narrative.  This consistent focus, documented in both fiscal‑year disclosures, illustrates a sustained and deepening integration of Nike Air into the company’s product‑development strategy between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: (1) The LLM answer introduces technologies (ZoomX, Air Max) and claims about 'bidirectional relationships' and 'athlete-tested feedback' that are NOT present in the ground truth answer. The ground truth makes no mention of these specific product lines or methodologies. (2) The LLM fundamentally mischaracterizes the evolution: Ground truth states Nike Air shifted from being emphasized as an 'emerging innovation' to a 'standard component' and 'foundational offering' - a maturation narrative. The LLM instead claims 'deepening integration' and 'sustained focus,' which contradicts the ground truth's implication that Nike Air became less of a distinct growth driver. (3) The LLM invents a 'bidirectional relationship' framework not supported by the ground truth. (4) The LLM adds unsupported claims about 'reducing injury' and 'consumer preferences' that don't appear in the original answer. WHAT WAS CORRECT: (1) Both answers correctly identify fiscal years 2023 and 2024. (2) Both recognize Nike Air as part of Nike's technology portfolio. (3) Both acknowledge evolution in treatment between the two years. MULTI-HOP REASONING: The LLM failed to properly synthesize the key insight from the ground truth - that Nike Air transitioned from being highlighted as a distinct innovation to being grouped with mature technologies, indicating a strategic shift in positioning rather than deepening integration. The LLM's interpretation contradicts this core finding. The answer reads as speculative rather than grounded in the actual filing language provided in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Expands]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 437,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "\nBetween 2022 and 2023 Abbott kept **Osmolite** listed as a core enteral‑feeding product—appearing in the 2022 “nutritional products used in enteral feeding” list (Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego™ pump & sets, Nepro, Vital) and again in the 2023 edition (Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmot e, Oxepa, Freego™ pump & sets, Nepro, Vital).  This continuity shows that Abbott’s product‑line strategy for its Nutritional Products segment has been to maintain Osmolite as a flagship institutional‑grade enteral solution within a broader portfolio of enteral‑feeding brands, with no reported removal or major repositioning of the product across the two years.  (KG: ABT produces Osmolite; Osmolite is produced by ABT.)",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core finding that Osmolite maintained stable positioning in Abbott's enteral feeding portfolio between 2022 and 2023, with no major repositioning or discontinuation. The reasoning and overall conclusion align well with the ground truth. However, there is a critical transcription/spelling error that undermines quantitative accuracy: the LLM lists 'Osmot e' in the 2023 product list instead of 'Osmolite.' This appears to be a typo or OCR error, as the answer correctly references 'Osmolite' elsewhere and the ground truth confirms Osmolite was included in 2023. The product list in 2022 is correctly enumerated (Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego, Nepro, Vital), matching the ground truth. The 2023 list should also include Osmolite (not 'Osmot e'), which is a factual error in the specific product enumeration. The qualitative reasoning is sound—the answer correctly synthesizes that Abbott maintained Osmolite as a 'flagship institutional-grade enteral solution' with continuity across both years, which matches the ground truth's conclusion of 'stable strategic positioning.' The multi-hop synthesis across 2022 and 2023 filings is logically sound. The contextual relevance is strong as it directly addresses the question about positioning evolution and product line strategy. The error in the 2023 product name listing is a significant factual mistake that prevents a higher correctness score, despite the overall narrative and conclusion being accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 422,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "\nBetween 2022 and 2024 3M’s PFAS regulatory engagement in Minnesota moved from the long‑standing 2007 Settlement Agreement and the 2008‑09 MPCA remedial decisions toward active enforcement: the MPCA directed storm‑water controls in June 2022, issued a Notice of Violation in March 2023 (including the Hutchinson site), and in July 2024 released a draft Clean Water Act permit with substantially tighter PFAS effluent limits; after 3M’s public‑comment submission in August 2024 the MPCA issued a revised draft in December 2024, while the Minnesota Department of Health updated health‑based values for PFOA/PFOS in January 2024, prompting 3M to reassess its obligations under the 2007 SACO and to continue remediation, operational‑and‑maintenance activities, and corrective actions at Oakdale, Woodbury and Cottage Grove.  \n\nIn Alabama, 3M’s PFAS duties were codified by the July 2020 interim Consent Order with ADEM (and the underlying 2009 TSCA consent order), and from 2022 onward the company has been implementing that order—conducting required studies, capping historic sludge areas, correcting NPDES reporting errors disclosed in 2019, and carrying out capital improvements and ongoing remediation—while continuing to cooperate with EPA and ADEM and acknowledging that future investigations may generate additional operating costs and capital expenditures over the coming years.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several significant factual errors and introduces information not present in the ground truth, which substantially undermines its accuracy:\n\nCRITICAL ERRORS:\n1. DATES - The LLM claims MPCA issued a draft Clean Water Act permit in July 2024, but the ground truth states it was issued without a specific month, and the revised draft came in December 2024. The LLM's timeline is imprecise.\n2. FABRICATED DETAILS - The LLM introduces specific regulatory actions not in the ground truth: (a) \"MPCA directed storm-water controls in June 2022\" - no such date appears in ground truth; (b) \"Notice of Violation in March 2023 (including the Hutchinson site)\" - this is entirely absent from the ground truth; (c) references to \"2008-09 MPCA remedial decisions\" - not mentioned in ground truth.\n3. SITE REFERENCES - The LLM mentions Oakdale, Woodbury, and Hutchinson sites, but the ground truth only explicitly mentions Cottage Grove, Decatur, and references \"multiple locations\" without naming these specific sites. The Hutchinson reference appears to be fabricated.\n4. ALABAMA DETAILS - The LLM adds \"correcting NPDES reporting errors disclosed in 2019\" and \"capping historic sludge areas\" - while the ground truth mentions a \"multilayer cap at the Decatur facility,\" it does not reference NPDES reporting errors or 2019 disclosures.\n\nPARTIALLY CORRECT ELEMENTS:\n1. The 2007 Settlement Agreement and Consent Order (SACO) is correctly identified\n2. The July 2020 Interim Consent Order with ADEM is correct\n3. The January 2024 MDH health-based values update is correct\n4. The December 2024 revised draft permit is correct\n5. The general evolution toward stricter standards is captured\n6. The acknowledgment of future costs and capital expenditures is present\n\nMISSING ELEMENTS:\n1. The ground truth mentions \"proposed HRLs in October 2024\" - the LLM does not reference this\n2. The ground truth emphasizes that revised permit \"could have a significant adverse impact on the Cottage Grove facility's operations\" - the LLM does not convey this severity\n3. The ground truth notes remediation was \"substantially completed at the Cottage Grove site\" in 2022 - the LLM does not clarify this baseline\n\nMULTI-HOP REASONING:\nThe LLM attempts to synthesize information across Minnesota and Alabama, but the fabricated details and incorrect dates undermine the validity of the synthesis. The model appears to have hallucinated specific regulatory actions and site names not supported by the ground truth.\n\nQUANTITATIVE ACCURACY:\nWhile no specific dollar amounts or percentages are involved, the dates are critical quantitative elements. The LLM's date references are imprecise or incorrect (June 2022 storm-water controls, March 2023 NOV, July 2024 permit draft timing).\n\nOVERALL ASSESSMENT:\nThe answer demonstrates partial understanding of the regulatory evolution but introduces significant fabricated details that would mislead readers. The core narrative of increasing regulatory scrutiny is present, but the specific facts, dates, and regulatory actions are substantially inaccurate or unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discovers]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1721,
        "completion_tokens": 826,
        "total_tokens": 2547
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "\nBetween 2022 and 2024 Coca‑Cola’s investment in Coca‑Cola HBC AG shifted from a simple cost‑basis equity security (the $12 million “International‑based companies” line in the 2021 table of Chunk 1) to an equity‑method investment, and the company now reports owning **22 % of HBC AG’s outstanding shares** as of 31 December 2024 (Chunk 2).  Because the stake is accounted for using the equity method, Coca‑Cola includes its proportionate share of HBC AG’s net income and other comprehensive‑income items in its consolidated results, and the investment’s carrying value exceeds the underlying net assets by **$7,791 million**, a difference that is not amortized.  This evolution reflects a deeper financial relationship that is now disclosed through both the “Discloses” and “Has_Stake_In” KG links between KO and Coca‑Cola HBC AG.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution: Coca-Cola HBC AG moved from an equity method investee in 2022 to remaining an equity method investee in 2024, with a 22% ownership stake disclosed in 2024. However, there are significant issues with the quantitative claims and reasoning:\n\n(1) CORRECT ELEMENTS:\n- 22% ownership stake as of December 31, 2024 is accurate\n- Equity method investment classification is correct for both periods\n- The general characterization of formalization and quantification of the relationship is sound\n- Equity method accounting treatment (proportionate share of net income/OCI) is correctly described\n\n(2) PROBLEMATIC ELEMENTS:\n- The LLM claims the 2021 investment was a \"cost-basis equity security\" at \"$12 million\" for \"International-based companies.\" The ground truth does not provide evidence of this 2021 data point, and the LLM appears to be introducing information not verified in the ground truth.\n- The $7,791 million goodwill/excess carrying value claim is presented as fact but is not mentioned in the ground truth answer. This is a specific quantitative claim that cannot be verified against the provided ground truth.\n- The reference to \"Chunk 1\" and \"Chunk 2\" suggests the LLM is citing source documents, but these citations cannot be verified against the ground truth provided.\n\n(3) MULTI-HOP REASONING:\nThe LLM attempts to synthesize information across years (2021→2022→2024) and connect investment classification changes with stake percentage disclosure. However, the ground truth only addresses 2022 and 2024, not 2021. The LLM's introduction of 2021 data and the $7,791 million figure represents unsupported extrapolation beyond the ground truth.\n\n(4) ACCURACY ASSESSMENT:\nThe core answer about the 22% stake and equity method classification is correct. However, the introduction of unverified quantitative claims ($12 million, $7,791 million) and the 2021 reference reduce confidence in the response. The answer goes beyond what the ground truth supports, which is a significant issue for financial data accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 564,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "\nIn fiscal 2022 Oracle allocated $7.2 billion to research‑and‑development to broaden its hybrid‑deployment portfolio, explicitly framing “choice and flexibility” across on‑premise, cloud and hybrid models as a central growth strategy (Chunk 1). By fiscal 2024 the company’s filing reiterates hybrid deployments as a strategic pillar, describing how Oracle Cloud@Customer, OCI and SaaS integrate on‑premise and cloud environments and how continued investment across its cloud‑and‑license, hardware and services businesses advances this integrated model (Chunk 2). The knowledge‑graph pattern (ORCL → Hybrid Deployments ← ORCL) captures this bidirectional focus, showing that Oracle both produces and introduces hybrid deployments, underscoring the sustained and deepening emphasis on integrated deployment models from 2022 through 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The $7.2 billion R&D investment figure for fiscal 2022 is correctly cited and matches the ground truth exactly. No calculation errors or numeric discrepancies identified. ENTITY ACCURACY: Oracle, fiscal 2022, fiscal 2024, and specific product references (Oracle Cloud@Customer, OCI, SaaS) are all correctly identified and contextualized. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, showing the evolution from 2022 to 2024. It correctly identifies the progression from development-focused investment to integrated deployment model maturity. The knowledge graph reference (ORCL → Hybrid Deployments ← ORCL) appropriately illustrates the bidirectional relationship. COMPLETENESS: The answer addresses both sub-components of the question: (1) product development investment ($7.2B in FY2022) and (2) deployment model integration (evolution toward standard integrated choice). SEMANTIC EQUIVALENCE: The LLM's framing of 'choice and flexibility' as a central growth strategy aligns with the ground truth's emphasis on 'interoperability and customer choice.' The characterization of the evolution from 'development-focused approach to mature, integrated deployment model' is semantically equivalent to the LLM's description of progression from initial portfolio broadening to sustained deepening emphasis. MINOR CONSIDERATIONS: The LLM provides slightly more granular detail about specific business units (cloud-and-license, hardware, services) and explicitly references the knowledge graph structure, which adds analytical depth beyond the ground truth but does not contradict it. The answer is well-structured and demonstrates clear understanding of Oracle's strategic trajectory. No factual errors or omissions of significance detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 514,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "\nThe Mandatory Clawback Policy was first **filed as a distinct exhibit (Exhibit 97)** in Wells Fargo’s 2023 Form 10‑K (“Filed herewith”), and in the 2024 Form 10‑K it appears only as an exhibit that is **“incorporated by reference”** to the 2023 filing (“Incorporated by reference to Exhibit 97 to the Company's Annual Report on Form 10‑K for the year ended December 31, 2023”). Thus, between the 2023 and 2024 disclosures the policy moved from a newly‑filed exhibit to being referenced from the prior year’s filing, while remaining effective as of October 2, 2023 and continuing to be tied to WFC in the knowledge‑graph relationship.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. It correctly identifies the key evolution of the Mandatory Clawback Policy filing status between 2023 and 2024: (1) 2023: Filed directly as Exhibit 97 ('Filed herewith'), and (2) 2024: Incorporated by reference to the prior year's filing. The answer accurately captures the procedural change while noting that this represents a change in disclosure method rather than substantive policy change, which aligns with the ground truth. The LLM provides additional context by specifying the exact language used ('Filed herewith' vs 'Incorporated by reference') and includes the effective date (October 2, 2023), which adds helpful detail. The multi-hop reasoning is sound—the answer correctly synthesizes information about how the same policy was handled differently across two consecutive years' filings. All dates and entities (Wells Fargo, Form 10-K, Exhibit 97) are correctly identified. The only minor consideration is that the LLM includes some additional contextual information about the knowledge-graph relationship that, while not incorrect, goes slightly beyond what was explicitly stated in the ground truth, but this represents an enhancement rather than an error. The answer demonstrates clear understanding of SEC filing procedures and exhibit incorporation practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Files]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 371,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "\nBetween 2023 and 2024 Thermo Fisher moved from **acquiring** CorEvitas, LLC (a $0.91 billion cash outlay recorded in the 2023 investing activities and reflected in the KG link TMO → CorEvitas, LLC) to **integrating** its real‑world‑evidence platform into the Laboratory Products & Biopharma Services segment, a relationship highlighted in the 2023 10‑K filing and reinforced in the 2024 10‑K where the company reports the amortization of the acquired definite‑life intangibles (customer relationships, product technology and tradenames over 15‑19‑year weighted‑average periods).  The 2023 acquisition also generated non‑tax‑deductible goodwill and expanded Thermo Fisher’s portfolio, and the subsequent 2024 amortization schedule signals the ongoing financial impact of that deal on future earnings.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core evolution of the relationship (acquisition in 2023 to integration in 2024), correctly names CorEvitas, LLC and its business (real-world evidence provider), correctly identifies the segment (Laboratory Products & Biopharma Services), and correctly notes the amortization of intangible assets in 2024. The reasoning about integration and ongoing financial impact is sound. CRITICAL ERRORS: (1) QUANTITATIVE ACCURACY FAILURE - The LLM states the amortization period as '15-19-year weighted-average periods' (plural, suggesting multiple ranges) when the ground truth specifies a single '18 years' weighted average period. This is a material discrepancy in a key financial metric. (2) MISSING KEY FINANCIAL CONTEXT - The LLM fails to mention the $5.94 billion senior notes issuance and $3.00 billion stock repurchase that were part of the broader 2023 financing strategy associated with the acquisition. These are significant financial implications directly tied to the CorEvitas acquisition. (3) INCOMPLETE ANSWER - While the LLM mentions 'non-tax-deductible goodwill,' it doesn't quantify or elaborate on the $0.91 billion investment amount as clearly as the ground truth does. The LLM does reference the $0.91 billion but buries it in parenthetical context rather than highlighting it as a key financial implication. MULTI-HOP REASONING: The LLM demonstrates adequate multi-hop synthesis by connecting the 2023 acquisition to 2024 integration and amortization, but fails to synthesize the complete financial picture including the financing activities. The answer is partially correct but materially incomplete on quantitative specifics and missing important financial implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Acquires]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 471,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "\nRTX’s flight‑hour payment obligation under the 2012 Rolls‑Royce agreement remains tied to each hour flown through June 2027 and is reported in the “Other commercial aerospace commitments” line of its disclosures.  In both the 2022 and 2023 filings the company states that these payments are **capitalized as collaboration intangible assets at the time each payment is made**, with no change in the capitalization treatment between the two years—only the amount of hours accrued (and thus the intangible‑asset balance) grows as more flight hours are recorded.  The timing of the obligation (through June 2027) and the method of capitalizing each payment therefore stayed consistent from 2022 into 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. Strengths: (1) All key facts are correct - the flight hour payment obligation is tied to June 2027, payments are contingent on hours flown by V2500-powered aircraft, and capitalization treatment remained consistent between 2022 and 2023. (2) Quantitative accuracy is perfect - no numeric errors, dates are correct (June 2027), and the temporal comparison (2022 vs 2023) is accurate. (3) The multi-hop synthesis is sound: the answer correctly identifies that RTX disclosed the same structure in both years with no changes in timing or capitalization method. (4) The answer properly addresses all parts of the question: timing (through June 2027), capitalization treatment (as collaboration intangible assets), and the evolution between years (no change/stable). (5) The explanation of how the intangible asset balance grows as flight hours accrue demonstrates good understanding of the accounting mechanics. Minor consideration: The ground truth uses the phrase 'Other commercial aerospace commitments' while the LLM answer references 'Other commercial aerospace commitments' line - this is semantically equivalent and correctly cited. The LLM answer is slightly more detailed in explaining the mechanics (how the balance grows with hours) which adds helpful context without introducing errors. No factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reflects]-> FIN_INST <-[Pays]- ORG",
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 389,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "\nFrom 2022 through 2024 Coca‑Cola’s relationship with fairlife remains anchored to the 2020 acquisition of the remaining ownership interest—recorded in the 2020 acquisition totals—and the agreement now carries a performance‑contingent milestone payment whose fair value is still recognized in the 2024 filing; this payment, based on formulas tied to fairlife’s financial targets, must be achieved by the end of 2024 and will be settled in 2025.  Consequently, the financial tie has evolved from the initial equity acquisition into a milestone‑linked obligation that hinges on fairlife meeting those 2024 targets before the contingent amount becomes payable.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of Coca-Cola's evolving financial relationship with fairlife. STRENGTHS: (1) All key dates are correct - 2020 acquisition, 2024 targets, 2025 settlement timeline matches ground truth exactly. (2) The core narrative is accurate: the relationship evolved from a completed 2020 acquisition to one with an active performance-contingent milestone payment. (3) The LLM correctly identifies that the payment is tied to fairlife achieving financial targets by end of 2024, with settlement in 2025. (4) Multi-hop reasoning is sound - the answer synthesizes the historical context (2020 acquisition) with the current status (2024 contingent obligation) and future settlement (2025). (5) Entity identification is correct throughout (Coca-Cola, fairlife, acquisition, milestone payment). (6) The semantic meaning aligns perfectly with ground truth - both convey that the relationship has evolved from a simple acquisition to one with performance-linked obligations. MINOR CONSIDERATIONS: The LLM uses slightly more elaborate phrasing ('formulas tied to fairlife's financial targets,' 'fair value is still recognized') compared to the ground truth's more direct language, but this adds helpful context rather than introducing inaccuracy. The answer is more detailed and explanatory while remaining factually correct. No quantitative errors detected, no missing key information, and the logical flow of the multi-hop synthesis is clear and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Acquires]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 417,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "\nBetween 2022 and 2024 Oracle transformed its Cloud Services from a collection of enterprise‑grade applications and infrastructure technologies—described in 2022 as the building blocks of Oracle Cloud Services that are delivered through its cloud, license, hardware and services businesses and expanded via strategic acquisitions such as Cerner—into an integrated SaaS + OCI suite that is marketed as a flexible, lower‑cost, rapidly deployable offering across on‑premise, hybrid and pure‑cloud environments.  By 2024 the company had layered this stack with bundled license, hardware and support contracts that improve customer utilization of the combined application‑infrastructure portfolio, positioning the integrated cloud services as a central lever to grow its broader cloud and license business.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2022-2024 timeframe and Oracle as the subject company. (2) Accurately mentions Oracle Autonomous Database as a 2022 focus. (3) Correctly notes the evolution toward integrated SaaS + OCI positioning. (4) Appropriately references strategic acquisitions like Cerner. (5) Correctly identifies the shift toward flexible deployment models (on-premise, hybrid, cloud). (6) No quantitative errors detected (no specific numbers provided to verify). WEAKNESSES: (1) The LLM answer introduces details about 'bundled license, hardware and support contracts' that are not explicitly mentioned in the ground truth, potentially adding unsupported claims. (2) The framing of 2022 positioning as 'building blocks delivered through cloud, license, hardware and services businesses' is somewhat different from the ground truth's emphasis on 'transformational potential' and 'flexibility, interoperability, and customer choice.' (3) The LLM answer emphasizes business strategy (growing cloud and license business) rather than the customer-centric positioning shift that the ground truth highlights. (4) The ground truth emphasizes the shift from 'individual innovations' to 'holistic, integrated platform,' but the LLM answer frames it more as a business/commercial strategy evolution. (5) Missing explicit mention of the 'customer-centric' or 'choose the best option' messaging that the ground truth identifies as key to the 2024 positioning. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2024 filings and identifies the evolution correctly, though with some interpretive differences from the ground truth. The reasoning is logical but diverges in emphasis and some details. SEMANTIC EQUIVALENCE: While the core evolution is captured, the LLM's interpretation emphasizes commercial/business strategy more than the ground truth's emphasis on customer choice and holistic platform positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 528,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "\nThe Key/Specified Employee Policy is still disclosed in both the 2023 Form 10‑K (Chunk 1) and the 2024 Form 10‑K (Chunk 2) as “Exhibit 10(r)* Key/Specified Employee Policy,” and in each filing it is incorporated by reference to the same Exhibit 10(v) of the Company’s 2018 Annual Report on Form 10‑K. Thus, between the 2023 and 2024 SEC filings the policy’s documentation and incorporation by reference have not changed – it continues to be cited to the identical 2018 exhibit without any new amendment or separate filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a significant factual error regarding the exhibit reference. The ground truth states the policy is incorporated by reference to 'Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018,' but the LLM answer claims it is 'Exhibit 10(r)* Key/Specified Employee Policy' in the 2023 and 2024 filings. This is a fundamental discrepancy in entity identification - the exhibit designation itself is wrong (10(r) vs 10(v)). Additionally, the LLM answer introduces 'Chunk 1' and 'Chunk 2' references that are not part of the ground truth and appear to be fabricated source citations. The core conclusion that the policy 'continues to be cited to the identical 2018 exhibit without any new amendment' is correct and matches the ground truth's statement that 'there were no new amendments or updates to its documentation during this period.' However, the incorrect exhibit number (10(r) instead of 10(v)) is a material factual error that undermines the accuracy of the response. The LLM also fails to clearly articulate the distinction between the policy being 'newly introduced' in 2023 versus 'announced as a continuing policy' in 2024, which was a key element of the ground truth's explanation of the evolution between years. The multi-hop reasoning about the consistency of the policy across years is sound, but the factual errors regarding exhibit designation are disqualifying.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 402,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "\nThe 6.700 % notes due 2028 carried an outstanding principal of **$115 million** when first disclosed in the 2021 filing (Chunk 1), grew to **$285 million** by the end of 2022, and **remained flat at $285 million** in the 2023 column of the balance‑sheet table (Chunk 2, 2023 = 2022 = $285 million).  This year‑over‑year stability shows that RTX deliberately held the debt level of this senior note steady, reflecting a measured debt‑management strategy that prioritizes a consistent capital structure and financial flexibility rather than aggressive borrowing or rapid deleveraging.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURE: The LLM claims the principal balance was $115 million in 2021, grew to $285 million by end of 2022, and remained flat at $285 million in 2023. However, the ground truth clearly states: 2022 = $115 million, 2023 = $285 million. The LLM has reversed the year-over-year progression and misidentified which year had which balance. (2) MULTI-HOP REASONING FAILURE: The question specifically asks about evolution between 2022 and 2023. The ground truth shows a significant increase from $115M (2022) to $285M (2023). The LLM incorrectly states the balance was already $285M in 2022 and remained flat through 2023, completely inverting the actual debt trajectory. (3) INTERPRETATION ERROR: The LLM's conclusion about 'year-over-year stability' and 'holding the debt level steady' is factually wrong. The actual data shows a 148% increase ($115M to $285M) between 2022 and 2023, indicating debt expansion, not stability. The ground truth correctly identifies this as RTX increasing outstanding debt. (4) TEMPORAL CONFUSION: The LLM introduces a 2021 reference point not requested in the question and conflates the timeline, making it impossible to correctly answer the 2022-2023 comparison. The core answer to the question is inverted: instead of showing growth from $115M to $285M, the LLM shows stability at $285M, which is the opposite of what occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 412,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "\nThe 1.95% 12‑Year Senior Notes issued by TMO are listed in both filings: Chunk 1 shows a year‑end 2023 carrying value of **$773 million** and an effective interest rate of **2.08%**, while Chunk 2 reports a year‑end 2024 carrying value of **$725 million** and an effective rate of **2.07%**, marking a **$48 million decline** in carrying value and a modest drop in the effective rate. This reduction reflects the ongoing amortization of the note’s discount and issuance costs, which are part of the total borrowings of **$34,727 million** reported in the 2023 data (Chunk 1) and the updated figures in the 2024 data (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all key metrics. Quantitative verification: (1) 2023 carrying value of $773 million - CORRECT, (2) 2023 effective interest rate of 2.08% - CORRECT, (3) 2024 carrying value of $725 million - CORRECT, (4) 2024 effective interest rate of 2.07% - CORRECT, (5) Calculated decline of $48 million ($773M - $725M = $48M) - CORRECT. The answer correctly identifies all entities (TMO, the specific 1.95% 12-Year Senior Notes) and time periods (2023 vs 2024). Multi-hop synthesis is sound: the model properly extracted data from two different filing periods and compared them. The explanation of the decline reflecting amortization of discount and issuance costs is contextually appropriate and demonstrates understanding of debt accounting mechanics. Minor observation: The reference to total borrowings of $34,727 million, while factually accurate from the filings, is somewhat tangential to the specific question about the 1.95% notes evolution, though it does provide useful context. The answer fully addresses both components of the question (carrying value evolution AND effective interest rate evolution) with accurate numbers and logical reasoning. No calculation errors detected. Wording is clear and professional.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Issues]- ORG",
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 355,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "\nThe 2022 filing only **referenced** the Directors’ Code of Conduct and directed readers to a PDF on BNY Mellon’s website, pledging to disclose any future amendments or waivers on that site, whereas the 2024 filing **explicitly lists** the Directors’ Code of Conduct together with the company’s bylaws, governance guidelines and committee charters as a downloadable governance document.  This shift moves the code from a hidden policy link to a formally disclosed governance material, signalling a more transparent, investor‑focused presentation and reinforcing the board’s accountability under the updated corporate‑governance framework.  (Both the 2022 and 2024 filings treat the Directors’ Code of Conduct as an ACCOUNTING_POLICY subject to disclosure by BK.)",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that in 2022, the Code was explicitly detailed with a direct URL link, while in 2024 it was listed without a direct link or specific mention—a shift toward LESS visibility. The LLM claims the opposite: that 2022 only 'referenced' it (hidden), while 2024 'explicitly lists' it as a downloadable document (more transparent). This is a fundamental reversal of the actual change. The LLM also incorrectly characterizes the shift as moving from 'hidden policy link to formally disclosed governance material' and 'more transparent, investor-focused presentation,' when the ground truth indicates the opposite—a consolidation that reduces standalone visibility. Additionally, the LLM's claim that both filings treat the Code as an 'ACCOUNTING_POLICY' appears unsupported by the ground truth, which makes no such classification. The LLM correctly identifies the years (2022 vs 2024) and the company (BNY Mellon), and the general structure of comparing presentation changes is appropriate, but the directional analysis of what changed and its implications is inverted. The reasoning about governance accountability and stakeholder engagement is present but applied to the wrong direction of change. This represents a critical failure in multi-hop synthesis and factual accuracy on the core question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 390,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "\nBetween 2023 and 2024 Amazon kept the same $5 billion unsecured 364‑day revolving facility (the “Short‑Term Credit Agreement”), but its maturity was rolled forward: the first version was entered in November 2023 and maturities in October 2024, and in October 2024 the company entered a new $5 billion agreement that now matures in October 2025 (with a one‑year extension option).  Both filings note that the October 2024 agreement replaced the November 2023 facility, preserving the $5 billion size while extending the maturity date by one year.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong factual accuracy. Verification of key claims: (1) Facility size: Both answers correctly state $5.0 billion in both 2023 and 2024 - CORRECT. (2) Facility type: Both correctly identify as unsecured 364-day revolving credit facility - CORRECT. (3) 2023 establishment and maturity: LLM states 'entered in November 2023 and maturities in October 2024' - CORRECT per ground truth. (4) 2024 establishment and maturity: LLM states 'October 2024 agreement that now matures in October 2025' - CORRECT per ground truth. (5) Replacement relationship: LLM correctly notes October 2024 agreement replaced November 2023 facility - CORRECT. (6) One-year extension: LLM mentions 'one-year extension option' which is not explicitly stated in the ground truth, though the one-year maturity extension is confirmed. This is a minor addition not contradicted by ground truth. The multi-hop reasoning is sound - the LLM correctly synthesized information across two years, identified the facility evolution, and explained the procedural renewal nature. The only minor discrepancy is the mention of a 'one-year extension option' which appears to be an inference rather than explicitly stated in the ground truth. The ground truth mentions 'a procedural renewal rather than a substantive change' while the LLM focuses on the practical mechanics of the rollover. Both convey equivalent meaning. The answer addresses all parts of the question: facility size (same), maturity date (extended one year), and timing of establishment (shifted from November to October). Quantitative accuracy is very high with all dates and dollar amounts correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 455,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "\nFrom 2022 to 2024 AMD’s APU strategy shifted from the general‑purpose CPU‑GPU integration described in Chunk 1—used across Enterprise, Embedded and Semi‑Custom markets such as servers, thin‑clients and custom SoCs—to a tightly‑integrated AI‑centric SoC that places an x86 CPU, Radeon GPU and a dedicated neural‑processing unit on the same die, explicitly targeting AI‑enabled PCs and edge devices (Chunk 2).  This deeper product integration—leveraging chiplet architecture, higher‑bandwidth memory and a unified ROCm‑based software stack—expands the APU’s role from traditional consumer notebooks to AI PCs, gaming consoles and edge platforms while still serving semi‑custom and embedded customers.  Consequently, AMD is positioned to capture a growing AI‑PC revenue stream, using its first‑mover NPU advantage and ecosystem partnerships to drive higher‑margin sales across both consumer and enterprise markets.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and addresses the multi-hop question effectively. STRENGTHS: (1) Correctly identifies the strategic shift from 2022 to 2024, moving from external GPU-based solutions to integrated APUs with NPU cores; (2) Accurately captures the key innovation: first-mover advantage with dedicated NPU on same SoC as x86 CPU; (3) Properly synthesizes the evolution across multiple dimensions (product integration, target markets, revenue implications); (4) Correctly identifies AI PC segment as the emerging market opportunity; (5) Mentions relevant technical details (chiplet architecture, ROCm software stack, higher-bandwidth memory) that support the strategic narrative; (6) Appropriately emphasizes the revenue potential and differentiation strategy. MINOR WEAKNESSES: (1) The LLM answer references 'Chunk 1' and 'Chunk 2' which suggests source attribution but these chunks are not provided in the evaluation context, making verification of specific claims slightly difficult; (2) While the answer mentions 'first-mover NPU advantage,' the ground truth more explicitly states AMD became 'the first company' to include this feature, though the LLM does capture this concept; (3) The LLM adds contextual details about gaming consoles and edge platforms that, while plausible, are not explicitly mentioned in the ground truth, representing minor elaboration beyond the source material. QUANTITATIVE ACCURACY: No specific numbers, dates, or percentages are provided in either answer, so this dimension is not directly testable. Both answers appropriately avoid false specificity. MULTI-HOP REASONING: The LLM successfully synthesizes information across the 2022-2024 timeframe, connects product evolution to market positioning, and links this to revenue implications - all required for proper multi-hop reasoning. The logical flow from product integration → target market shift → revenue potential is sound. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same strategic narrative as the ground truth, with slightly more technical depth and broader market context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 567,
        "total_tokens": 2001
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "\nThe 2023 and 2024 Form 10‑K filings disclose that Irish dividend withholding tax continues to apply at a 25 % rate on Medtronic dividends to U.S. shareholders, but the conditions for exemption are unchanged – a U.S. beneficial owner (or record owner) who provides the required U.S. residence certification (Form 6166) or Irish Non‑Resident Form V2, and does not hold the shares through an Irish branch, is not subject to Irish income‑tax liability, and any withheld amount satisfies that liability. Thus, the regulatory relationship MDT – [Subject_To]→ Irish Income Tax – [Discloses]→ MDT remains the same in both years, indicating no evolution or change in the treatment of Irish income‑tax liability for U.S. shareholders between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative facts are correct: (1) The 25% Irish dividend withholding tax rate is accurately stated in both years; (2) The exemption conditions are correctly identified - U.S. beneficial/record owners with Form 6166 or Irish Non-Resident Form V2 documentation; (3) The requirement that shares not be held through an Irish branch is accurately captured; (4) The statement that withheld amounts satisfy Irish income tax liability is correct. The multi-hop reasoning is sound - the answer correctly synthesizes information across 2023 and 2024 filings to demonstrate no evolution in treatment. The answer directly addresses the core question by explicitly stating 'no evolution or change in the treatment of Irish income-tax liability for U.S. shareholders between 2023 and 2024.' The only minor observation is that the LLM includes a knowledge graph notation ('MDT – [Subject_To]→ Irish Income Tax – [Discloses]→ MDT') which, while not incorrect, is somewhat technical and could be seen as slightly tangential to the core answer. However, this does not detract from the factual accuracy or completeness of the response. The answer demonstrates proper synthesis of multi-hop information across years and correctly identifies that the regulatory framework remained stable. All entity references (Medtronic, U.S. shareholders, Irish tax authorities) are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 393,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "\nBetween 2022 and 2024 BNY Mellon’s risk disclosures continued to treat **new lines of business, new products and services, and transformational initiatives as additional sources of risk**—the same language appears in both the 2022 and 2024 filings and is captured by the KG pattern **ORG → New Products and Services → ORG** (BK introduces the product, which is subject to BK). However, the 2024 filing adds a distinct warning that the company **may not realize some or all of the expected benefits of its platforms operating‑model transition**, explicitly tying that strategic project to the “new products and services / transformational initiatives” risk category. Thus, the evolution is from a generic risk statement in 2022 to a more specific, initiative‑level disclosure in 2024 that highlights the uncertainty surrounding the platforms operating‑model’s expected outcomes while retaining the broader new‑product risk framework.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2022 to 2024 - generic risk language about new products/services/transformational initiatives in 2022 becoming more specific to the platforms operating model in 2024. (2) Accurately captures the specific 2024 language about 'may not realize some or all of the expected benefits of our transition to a platforms operating model.' (3) Properly synthesizes the multi-hop relationship showing how the platforms operating model became a concrete instantiation of the broader 'new products and services/transformational initiatives' risk category. (4) No quantitative errors - dates (2022, 2024) are correct, company (BNY Mellon) is correct. (5) The reasoning is sound: the answer explains that the evolution represents a shift from generic to specific while maintaining the broader framework. MINOR CONSIDERATIONS: (1) The LLM introduces the KG pattern notation (ORG → New Products and Services → ORG) which, while technically accurate to the knowledge graph structure, adds a layer of technical detail not present in the ground truth answer. This is not incorrect but represents a slightly different framing. (2) The phrasing 'platforms operating‑model' (with special character) appears to be a formatting artifact but doesn't affect accuracy. (3) The answer is slightly more technical/structural in its explanation compared to the ground truth's more narrative approach, but both convey identical substantive information. VERIFICATION: The core claim that 2024 filings explicitly state the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model' matches the ground truth exactly. The characterization of 2022 language as more general is accurate. The synthesis correctly identifies this as an evolution within the same risk category rather than a new risk category entirely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 534,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "\nAmazon’s 3.600% Note due 2032 remains disclosed in exactly the same way in the 2024 filing as it was in the 2023 filing—both years reference the April 13 2022 Supplemental Indenture (Exhibit 4.2), which lists the note among the series of senior unsecured debt instruments and specifies the trustee arrangement with Computershare. Thus, between 2023 and 2024 the issuer‑investor relationship for that debt instrument has not changed; the only new item in the 2024 filing is an unrelated 2017 certificate for a 5.200% Note due 2025, while the 3.600% Note continues to be governed by the unchanged indenture and officers’ certificate disclosed in both Exhibit 4.2 entries.",
      "correctness_score": 3,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM claims the trustee arrangement 'has not changed' and that both 2023 and 2024 filings reference only Computershare, but the ground truth explicitly states that in 2023, Wells Fargo Bank was listed as prior trustee alongside Computershare as successor trustee, and in 2024 only Computershare is referenced. This is a fundamental mischaracterization of the evolution described in the question. (2) The LLM states 'the issuer-investor relationship for that debt instrument has not changed' which directly contradicts the ground truth's core finding that there was 'a formal transition away from Wells Fargo Bank' and 'a shift in the trustee relationship.' (3) The LLM introduces irrelevant information about a 2017 certificate for a 5.200% Note due 2025, which is not part of the ground truth answer and appears to be a distraction from the actual evolution being asked about. CORRECT ELEMENTS: The LLM correctly identifies the April 13, 2022 Supplemental Indenture date, correctly names Computershare Trust Company, National Association, and correctly identifies the 3.600% interest rate and 2032 maturity date. The numeric/date values are accurate (7/10). However, the core reasoning about what changed between 2023 and 2024 is fundamentally wrong (2/10 qualitative accuracy). The answer fails to address the primary evolution question—the transition in trustee structure—and instead claims no change occurred, which is the opposite of the ground truth. This represents a failure in multi-hop synthesis and understanding of the filing evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 453,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "\nMDLZ continued to **use** net‑investment hedge derivative contracts (cross‑currency swaps, forwards and non‑U.S.‑dollar debt) and **disclose** them in its financial filings, but the way it presented their financial effect changed from 2023 to 2024.  \n\nIn the 2023 footnote the company detailed the composition of those hedges, recorded their fair‑value assets ($1.347 bn in other current assets and $250 m in other assets) and liabilities ($1.209 bn in other current liabilities and $350 m in other liabilities) and disclosed them in the Derivative Volume table and the “Hedges of Net Investments” section.  \n\nBy 2024 the firm **excluded** the portion of those contracts that no longer met hedge‑effectiveness testing (and the related foreign‑currency movements) from the hedge assessment and moved the related amounts into **Other income, net**, referencing Note 10, thereby shifting the presentation of the hedge’s financial impact from the balance‑sheet derivative balances to the income statement.  \n\nThus, the evolution reflects a move from explicit balance‑sheet disclosure and fair‑value measurement in 2023 to a presentation of the hedge’s net‑income effect in “Other income, net” in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates a reasonable understanding of the evolution in MDLZ's hedge derivative disclosure from 2023 to 2024, correctly identifying the shift from balance sheet focus to income statement presentation. However, there are significant quantitative discrepancies that undermine accuracy:\n\nQUANTITATIVE ISSUES:\n1. The LLM states 2023 derivative assets as '$1.347 bn in other current assets and $250 m in other assets' - this matches the ground truth ($1,347 million and $250 million).\n2. However, the LLM states liabilities as '$1.209 bn in other current liabilities and $350 m in other liabilities' - the ground truth shows $377 million and $413 million respectively for 2023. The LLM's figures appear to be incorrect or potentially from a different year.\n3. The ground truth also references 2022 comparatives ($250M and $413M in other assets), which the LLM conflates with 2023 liability figures.\n4. The discrepancy in liability amounts ($1.209bn vs. the implied correct figure) is a material error in financial reporting.\n\nQUALITATIVE STRENGTHS:\n1. Correctly identifies the shift from balance sheet valuation to income statement impact\n2. Properly recognizes the role of hedge effectiveness testing\n3. Accurately describes the movement to 'Other income, net'\n4. Correctly identifies the types of hedging instruments (cross-currency swaps, forwards, non-U.S.-dollar debt)\n5. Sound multi-hop reasoning connecting 2023 and 2024 presentations\n\nCOMPLETENESS:\nThe answer addresses the core question about evolution and presentation changes, but the quantitative errors regarding liability amounts represent incomplete or inaccurate synthesis of the filing data. The answer would have benefited from more precise citation of the specific liability figures.\n\nMULTI-HOP REASONING:\nThe reasoning connecting balance sheet presentation in 2023 to income statement effects in 2024 is logically sound and demonstrates proper synthesis across years and financial statement sections.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Uses]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 539,
        "total_tokens": 1999
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "\nFrom 2023 to 2024 GD’s Abrams modernization moved from the initial rollout of the SEPv3 “system‑enhancement package” – which added new communications, power‑generation, fuel‑efficiency, optics and armor upgrades to the M1A2 fleet – to a sustained focus on the next‑generation M1E3 variant that uses an open‑architecture design to enable faster technology refreshes, lower sustainment footprints and greater tactical mobility.  By 2024 the company was also leveraging that same open‑architecture approach to meet strong international demand, with NATO and other allies expanding their installed bases and ordering upgrades for the Abrams, while GD continues low‑rate initial production of the tank and offers the upgraded platform to non‑U.S. partners.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies both SEPv3 and M1E3 variants with accurate technical specifications (communications, power generation, fuel efficiency, optics, armor upgrades for SEPv3; open-architecture design for M1E3). (2) Accurately captures the evolution from 2023 to 2024: 2023 focused on SEPv3 rollout and M1E3 development announcement, 2024 emphasized international demand and global strategic relevance. (3) Properly synthesizes multi-hop information: connects technological development (SEPv3/M1E3 features) with international demand (NATO allies, expanded installed bases, non-U.S. partners). (4) Correctly identifies General Dynamics as the company and maintains accurate temporal progression. (5) No quantitative errors - no specific numbers were provided in either answer, so quantitative accuracy is perfect. (6) The semantic meaning is equivalent: both answers convey that modernization evolved from technical roadmap focus to global strategic/procurement emphasis. MINOR CONSIDERATIONS: The LLM answer adds slightly more operational detail (\"low-rate initial production,\" \"tactical mobility\") not explicitly mentioned in the ground truth, but these are reasonable inferences from the context and don't contradict the original answer. The phrasing \"M1A2 fleet\" in the LLM answer is a reasonable specification not contradicted by ground truth. Overall, the answer successfully addresses all parts of the multi-part question with accurate synthesis of technological and demand-related information across the 2023-2024 timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Upgrades]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 451,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "\nBetween 2022 and 2024 AMD’s APU strategy shifted from a niche role in the **Enterprise, Embedded and Semi‑Custom** markets—where APUs were highlighted as CPU‑GPU hybrids for servers, thin‑clients and custom SoCs (Chunk 1)—to a **cross‑segment cornerstone** that now appears in all four of AMD’s reportable divisions (Data Center, Client, Gaming and Embedded) and is explicitly listed alongside AI accelerators, CPUs and GPUs (Chunk 2). This evolution reflects a strategic emphasis on APUs as a unifying platform for AI‑ready data‑center workloads, mainstream client devices, and gaming/semi‑custom solutions, underscored by the mutual KG relationship **AMD ↔ APUs**.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FACTUAL INACCURACY - The LLM claims APUs appear in 'all four of AMD's reportable divisions' including Gaming and Embedded, but the ground truth explicitly states APUs were only included in TWO segments: Data Center and Client. The LLM fabricated the Gaming and Embedded inclusion. (2) INCOMPLETE SYNTHESIS - The ground truth clearly states that in 2022, APUs were part of 'Enterprise, Embedded and Semi-Custom' portfolio WITHOUT specific market segmentation, and by 2024 they appeared in only Data Center and Client segments. The LLM misrepresented this evolution. (3) UNSUPPORTED CLAIMS - The LLM's assertion about APUs being 'AI-ready data-center workloads' and 'unifying platform' goes beyond what the ground truth supports. The ground truth is more measured, noting APUs were 'listed alongside' these products, not that they became a unifying platform. (4) CORRECT ELEMENTS - The LLM correctly identified the shift from Enterprise/Embedded/Semi-Custom positioning to a more structured, segmented approach, and correctly noted the 2022-2024 timeframe. The mention of AI accelerators, CPUs, and GPUs in Data Center is accurate. (5) REASONING QUALITY - While the LLM attempted multi-hop synthesis, it introduced false information rather than accurately synthesizing the available data. The claim about 'all four reportable divisions' is a fundamental factual error that significantly undermines the answer's credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 402,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "\nMedtronic’s 2023 and 2024 Form 10‑K filings both disclose that the **Financial Transfers Act 1992** gives the Irish Minister for Finance authority to restrict financial transfers between Ireland and other countries, and that, as of the filing date, the Minister has already imposed restrictions on a number of third‑country jurisdictions—whose list is “subject to ongoing change.” Both filings also note that any transfer involving a government or party subject to UN or EU sanctions may be restricted under Irish law, and they repeat the same language about the Act’s scope (including E.U.‑style capital‑movement definitions) and the sanctions‑related limitation. Thus, from 2023 to 2024 the company’s disclosure has not evolved substantively; the 2024 filing simply reproduces the 2023 description of the Act’s implications, with only minor wording and formatting differences.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL DISCREPANCY: The LLM answer directly contradicts the ground truth on the core finding. Ground truth states that disclosure evolved from 2023 to 2024, with 2024 no longer emphasizing the dynamic nature of the restricted countries list. The LLM answer explicitly claims the opposite: 'from 2023 to 2024 the company's disclosure has not evolved substantively' and that the 2024 filing 'simply reproduces the 2023 description.' This is a fundamental factual error on the main question. The LLM correctly identifies the Financial Transfers Act 1992, the Irish Minister's authority, and the general regulatory framework (quantitative accuracy is good for these factual elements). However, the LLM fails the primary task of comparing how the disclosure evolved between years. The ground truth indicates a meaningful shift in emphasis regarding the 'ongoing change' language, while the LLM concludes there was no substantive evolution. This represents a failure in multi-hop reasoning and synthesis across the two filing years. The LLM provides additional accurate details about sanctions-related restrictions and EU-style capital movement definitions, but these additions do not address the core question about evolution of disclosure. The answer demonstrates good command of the regulatory details but fundamentally misses or misrepresents the comparative analysis that was the central requirement of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 393,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "\nIn 2023 Gulfstream disclosed that the ultra‑large‑cabin G700 would enter service after FAA certification in early 2024 (Chunk 1), positioning it as the next model to join the lineup. By 2024 the company reported a production ramp‑up that began G700 deliveries in the second quarter, causing inventories and customer deposits to rise and resulting in higher goodwill and intangible‑asset balances tied to the new product (Chunk 2), showing the G700’s transition from an anticipated 2024 entry to an active, revenue‑generating aircraft.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-synthesized. (1) CORRECTNESS: All factual information is correct. The 2023 status (G700 as next model, expected to enter service after FAA certification in early 2024) matches the ground truth. The 2024 status (began deliveries in Q2) also matches. The answer correctly identifies the evolution from anticipated future product to active revenue-generating aircraft. (2) QUANTITATIVE ACCURACY: All dates and time periods are correct - early 2024 for FAA certification/entry into service, Q2 2024 for delivery commencement. No calculations required for this question. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound. The LLM correctly synthesized information across two time periods (2023 and 2024) and identified the key transition point. The answer appropriately characterizes the G700's evolution from development/anticipation phase to production/delivery phase. The additional context about inventories, customer deposits, goodwill, and intangible assets adds relevant supporting detail that demonstrates deeper understanding of the business impact. (4) ENTITY ACCURACY: Company (Gulfstream/GD) correctly identified, aircraft model (G700) correct, regulatory body (FAA) correct, time periods (2023, 2024, Q2) all accurate. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth while adding slightly more business context about financial impacts. The phrasing 'transition from an anticipated 2024 entry to an active, revenue-generating aircraft' is semantically equivalent to 'evolution from a future product to a realized and delivered aircraft model.' Minor note: The LLM answer includes references to 'Chunk 1' and 'Chunk 2' which are source citations rather than part of the substantive answer, but this does not detract from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 499,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "\nFrom the 2023 announcement, PMI entered a 15‑year exclusive partnership with KT&G to commercialize the latter’s smoke‑free device and consumable portfolio worldwide (except South Korea), with volume‑based performance‑review cycles every three years that lock in PMI’s strategic reliance on KT&G’s innovation pipeline and give PMI continued exclusive access to KT&G’s brands and low‑/middle‑income market offerings. By 2024 this arrangement has moved from planning to actual revenue generation—PMI’s heat‑not‑burn products now include licensed KT&G products that contribute to its net‑revenue streams, underscoring a deepening strategic dependency and the progression of product commercialization that was only outlined in the 2023 agreement. The partnership, captured by the Partners_With and Depends_On KG links, also operates within the broader regulatory and trade‑compliance environment that PMI monitors (e.g., climate‑related laws, sanctions), but the core evolution is the shift from a long‑term collaboration framework to a revenue‑producing, strategically critical supply relationship.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of the PMI-KT&G relationship evolution. STRENGTHS: (1) All key numeric facts are correct: 15-year agreement, January 29, 2038 end date, worldwide exclusivity except South Korea. (2) The multi-hop synthesis is sound—correctly identifies the 2023 announcement phase and the 2024 operational/revenue-generation phase. (3) Accurately captures the shift from 'exclusive distribution framework' to 'integrated strategic dependency' with operational revenue contribution. (4) Correctly identifies the three-year performance-review cycles as a structural element. (5) Appropriately contextualizes the relationship within PMI's broader smoke-free strategy. MINOR WEAKNESSES: (1) The LLM introduces additional contextual elements (regulatory/trade-compliance environment, climate-related laws, sanctions) that, while potentially relevant to PMI's broader operations, are not explicitly mentioned in the ground truth answer and may represent inference beyond the specific question scope. (2) The phrase 'Partners_With and Depends_On KG links' references knowledge graph structure rather than substantive business information, which is somewhat tangential. (3) The answer is slightly more verbose than necessary, though this doesn't detract from accuracy. QUANTITATIVE VERIFICATION: All dates (2023, 2024, January 29, 2038), duration (15 years), and geographic scope (worldwide except South Korea) match ground truth exactly. QUALITATIVE ASSESSMENT: The reasoning correctly synthesizes the evolution from planning/announcement phase to operational integration, and accurately characterizes the deepening strategic dependency. The semantic meaning aligns well with the ground truth despite different wording. The answer successfully addresses both components of the question: strategic dependency evolution and product commercialization progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 519,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "\nAMD’s semi‑custom SoC business moved from a 2022 model that was essentially a high‑risk, fee‑based revenue stream dependent on securing third‑party design wins and on those chips being incorporated into customers’ products (as noted in the 2022 filing, where revenue = engineering fees and sales = customers’ product success), to a 2024 strategy that embeds those SoCs within AMD’s broader AI‑focused ecosystem—using Adaptive SoCs, chiplet‑ready platforms and the AMD Infinity Architecture and linking them to data‑center AI accelerators, EPYC CPUs, GPUs and embedded markets (see the 2024 overview, which describes semi‑custom SoCs as part of AMD’s AI hardware portfolio and highlights partnerships and the Silo AI acquisition to accelerate AI software deployment).  Consequently, the semi‑custom SoC product is no longer an isolated engineering‑fee line but a core component that AMD both **depends on** and **produces**, and it is now tightly integrated with the company’s CPUs, GPUs, DPUs, software stacks and end‑to‑end AI solutions across cloud, edge and device segments.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of AMD's semi-custom SoC evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 model as fee-based and dependent on third-party success, matching the ground truth characterization of risk and lack of control. (2) Accurately captures the 2024 shift toward integration with broader AI-focused ecosystem including CPUs, GPUs, and data-center solutions. (3) Properly synthesizes multi-hop information showing the transition from isolated engineering-fee business to integrated product strategy. (4) Mentions specific 2024 elements like Adaptive SoCs, AMD Infinity Architecture, and Silo AI acquisition, demonstrating detailed knowledge. (5) Correctly identifies the strategic positioning shift from dependency model to integrated leadership. MINOR WEAKNESSES: (1) The LLM answer mentions 'DPUs' which are not explicitly mentioned in the ground truth answer, though this is not necessarily incorrect—it represents additional detail not contradicted by ground truth. (2) The phrase 'AMD both depends on and produces' is slightly awkwardly worded compared to ground truth's clearer 'core components of a broader, more integrated product ecosystem,' though the semantic meaning is equivalent. (3) The answer could have been more explicit about the NPU integration for AI PCs mentioned in ground truth, though the broader AI ecosystem integration is captured. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required or provided in either answer, so this dimension scores high (9/10) for not introducing any false metrics. QUALITATIVE ACCURACY: The reasoning correctly traces the evolution across years and identifies the key strategic shift, though the wording could be slightly clearer. CONTEXTUAL RELEVANCE: Highly relevant to the question, addressing both strategic positioning and ecosystem integration as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1527,
        "completion_tokens": 517,
        "total_tokens": 2044
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "\nBetween 2023 and 2024 the Irish dividend‑withholding tax on payments to U.S. residents remained at 25 percent, but the conditions for exemption were made more explicit.  \nIn the 2023 filing (Chunk 1) a U.S. shareholder avoided the tax when the broker’s records showed the beneficial owner’s address in the United States and that information was passed to a qualifying intermediary; such shareholders were also told they would not face Irish income‑tax on the dividend, and the withholding payment could discharge any Irish income‑tax liability if they supplied a statement to the Irish Revenue.  \nThe 2024 filing (Chunk 2) reiterates the same 25 % rate but spells out the documentation required for the exemption – the address‑in‑U.S. condition in DTC records **or** a valid U.S. Certification of Residence (Form 6166) or Irish Non‑Resident Form V2 – and confirms that, when these criteria are met, the shareholder has no Irish income‑tax liability and the withholding tax itself satisfies any remaining Irish tax obligation.  \n\nThus, the evolution is a clarification and codification of the exemption process rather than a substantive change in the tax rate or the fundamental obligation to withhold.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the 25% withholding tax rate as unchanged between 2023 and 2024, which matches the ground truth. However, there are significant discrepancies in the characterization of the evolution and specific details:\n\nCORRECT ELEMENTS:\n- 25% withholding tax rate remained constant (correct)\n- General theme that 2024 provided more explicit/structured conditions (correct)\n- Recognition that this was clarification rather than substantive change (correct)\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. The LLM introduces specific documentation requirements (DTC records, Form 6166, Irish Non-Resident Form V2) that are NOT mentioned in the ground truth. The ground truth does not reference these specific forms or documentation methods.\n2. The LLM states that in 2023, shareholders \"would not face Irish income-tax on the dividend, and the withholding payment could discharge any Irish income-tax liability if they supplied a statement to the Irish Revenue.\" However, the ground truth indicates that in 2023, those exempt from withholding tax would not be subject to Irish income tax (different condition), and those SUBJECT to withholding tax had no further liability. The LLM conflates these two categories.\n3. The ground truth distinguishes between: (a) exempt shareholders who wouldn't be subject to Irish income tax unless they had an Irish connection, and (b) non-residents subject to withholding who had no further liability. The LLM's 2023 characterization blurs this distinction.\n4. The LLM's description of the 2024 evolution focuses on documentation requirements that are not present in the ground truth, which instead emphasizes the clarification of conditions for exemption and post-withholding procedures.\n\nMULTI-HOP REASONING:\nThe LLM attempts to synthesize information across 2023 and 2024 filings but introduces details not supported by the ground truth. The comparison between years is partially sound but relies on unsupported specifics about documentation.\n\nSEMANTIC ISSUES:\nWhile the overall narrative of \"clarification and codification\" aligns with the ground truth, the specific mechanisms described diverge significantly from what the ground truth states.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 592,
        "total_tokens": 2101
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "\nGeneral Dynamics’ Marine Systems segment saw 2023 revenue rise because of the Columbia‑class submarine program, but its operating margin fell about 110 basis points as cost growth and schedule pressure on the Virginia‑class and DDG‑51 (Arleigh Burke‑class) ships weighed on profitability; the 2024 outlook projects Marine Systems revenue of $12.8‑12.9 billion with a 7.6 % operating margin, reflecting a strategic shift toward the Columbia‑class while seeking to stabilize costs on legacy programs. This financial narrative is prepared under GAAP, where estimates and assumptions—such as those governing long‑term contract accounting—directly shape the reported margin and revenue figures. Within the ORG‑[Operates_In]-> Ship Construction relationship, GD’s ship‑construction focus has moved from managing cost pressures on existing programs in 2023 to pursuing revenue growth from the Columbia‑class initiative and targeting improved profitability in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the multi-hop question. STRENGTHS: (1) All key numeric values are correct: 110 basis point margin decline in 2023, $12.8-12.9 billion revenue projection for 2024, 7.6% operating margin projection. (2) Correctly identifies all three programs: Virginia-class, DDG-51, and Columbia-class submarine. (3) Accurately captures the temporal shift from 2023 cost pressures to 2024 optimistic outlook. (4) Properly synthesizes multi-hop information across years and programs. (5) Correctly identifies Marine Systems segment as the relevant business unit. (6) Semantic equivalence is maintained throughout - 'Arleigh Burke-class' is an acceptable alternative name for DDG-51. MINOR WEAKNESSES: (1) The LLM adds contextual information about GAAP accounting and ORG relationships that, while not incorrect, goes beyond the ground truth answer and introduces technical jargon that wasn't in the original. This represents slight over-elaboration rather than error. (2) The phrasing 'strategic shift toward the Columbia-class while seeking to stabilize costs on legacy programs' is a reasonable interpretation but slightly more interpretive than the ground truth's more straightforward 'shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024.' (3) The answer could have been more explicit about supply chain disruptions as a specific 2023 challenge, though this is a minor omission. QUANTITATIVE VERIFICATION: All numbers match exactly - 110 basis points, $12.8-12.9B, 7.6% margin. No calculation errors detected. MULTI-HOP REASONING: Successfully synthesizes information across 2023 and 2024, connects program-level challenges to segment-level margin impacts, and links revenue drivers to strategic direction. The reasoning is sound and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 502,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "\nBetween 2022 and 2023 the share of BKNG’s total revenue that comes from online accommodation‑reservation services stayed essentially flat—about 89 % in both years (89 % for 2023 and 89 % for 2022, versus 87 % in 2021).  This stability reflects that the “majority of the Company’s merchant revenues and substantially all of its agency revenues are from Booking.com’s accommodation reservations,” underscoring a consistent financial dependency on Booking.com for the bulk of BKNG’s accommodation‑related earnings over that period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-supported. QUANTITATIVE ACCURACY: All percentages are correct - 89% for both 2022 and 2023, with the additional context of 87% in 2021 providing useful comparative perspective. The numbers match the ground truth exactly. COMPLETENESS: The answer fully addresses the question about how BKNG's financial dependency on Booking.com evolved between 2022 and 2023. It correctly identifies that the proportion remained essentially flat/unchanged at 89% in both years. ENTITY ACCURACY: All entities are correctly identified - BKNG, Booking.com, the years 2022 and 2023, and the metric (proportion of revenue from accommodation reservations). REASONING & SYNTHESIS: The multi-hop reasoning is sound. The LLM correctly synthesized that: (1) the revenue proportion stayed flat between the two years, (2) this indicates sustained dependency, and (3) the majority of revenues come from Booking.com's accommodation reservations. The inclusion of the 2021 figure (87%) adds valuable context showing the slight increase from 2021 to 2022-2023, though this wasn't explicitly required. SEMANTIC EQUIVALENCE: The LLM's phrasing 'stayed essentially flat' and 'consistent financial dependency' conveys the same meaning as the ground truth's 'remained unchanged' and 'sustained and concentrated dependency.' The supporting quote about merchant and agency revenues strengthens the answer. MINOR CONSIDERATION: The ground truth states the dependency 'slightly increased' between 2022 and 2023, but then contradicts this by saying it 'remained unchanged' at 89% in both years. The LLM correctly interprets this as flat/unchanged between 2022-2023, which is the accurate reading of the data. The LLM's inclusion of 2021 data (87%) actually clarifies that any increase occurred between 2021-2022, not 2022-2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 496,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "\nThe company’s disclosed Swiss‑franc‑denominated note fell from **$299 million (due 2024) at the end of 2023** to **no amount listed for 2024**, showing that the note was either retired or re‑classified during the year. This decline signals a deliberate reduction in the firm’s foreign‑currency obligations, lowering its exposure to Swiss‑franc‑based debt and reflecting a shift in the composition of its overall foreign‑currency financing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: The key financial figures are correct - $299 million for 2023 and zero/no amount for 2024 match the ground truth exactly. The date reference '(due 2024)' adds helpful specificity about the note's maturity. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the position evolved (from $299M to $0), and (2) what this indicates about foreign currency obligations (reduction in exposure, strategic shift). ENTITY ACCURACY: All entities are correctly identified - Swiss Franc note, 2023-2024 timeframe, foreign currency obligations. REASONING QUALITY: The multi-hop synthesis is sound. The LLM correctly connects the numerical change to its implications: removal of the obligation → deliberate reduction in foreign currency exposure → shift in financing composition. The language 'either retired or re-classified' appropriately captures the uncertainty about the mechanism while correctly identifying the outcome. SEMANTIC EQUIVALENCE: The LLM's phrasing 'fell from $299 million...to no amount listed' and 'was either retired or re-classified' conveys the same meaning as the ground truth's 'completely removed' and 'either repaid or restructured.' The additional context about 'lowering its exposure to Swiss-franc-based debt' and 'shift in the composition of its overall foreign-currency financing' provides valuable elaboration without introducing errors. MINOR OBSERVATION: The LLM adds the maturity date '(due 2024)' which, while helpful context, is not explicitly mentioned in the ground truth but is consistent with the 2023 disclosure timing. This represents appropriate elaboration rather than error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 470,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "\nThe 2023 Form 10‑K (Chunk 1) only reproduces the pre‑2015 “Form of Non‑Employee Director RSU Award Agreement” (Exhibit 10.8) as the current governing document, while the 2024 Form 10‑K (Chunk 2) repeats that same pre‑2015 agreement (Exhibit 10.9) **and** adds a specific reference to “Amendments to Certain Non‑Employee Director Equity Award Agreements” (Exhibit 10.69), signalling that the RSU award terms were revised between the two filings.  This progression—from merely adopting the original RSU policy to formally introducing amended award agreements—matches the knowledge‑graph pattern where GS adopts an accounting policy and then introduces modified agreements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) EXHIBIT NUMBER ERROR: The ground truth states the 2024 filing references 'Exhibit 10.18' for the amendments, but the LLM claims it is 'Exhibit 10.69'. This is a major discrepancy in a specific, verifiable fact. (2) EXHIBIT LOCATION ERROR: The ground truth indicates the pre-2015 RSU Award Agreement is Exhibit 10.8 in 2023 and does not specify a different number for 2024, but the LLM claims it becomes 'Exhibit 10.9' in 2024. This represents another factual error in exhibit numbering. (3) CORE NARRATIVE ALIGNMENT: While the LLM correctly identifies that Goldman Sachs retained the pre-2015 agreement reference and introduced amendments in 2024, the specific exhibit numbers are wrong, which undermines the factual accuracy of the answer. (4) MULTI-HOP REASONING: The LLM's reasoning about the evolution from original policy to amended agreements is conceptually sound and matches the ground truth's narrative, but this is overshadowed by the quantitative errors in exhibit citations. (5) SEMANTIC ISSUES: The LLM's interpretation that 'RSU award terms were revised' is a reasonable inference, but the ground truth more carefully states the company 'expanded its disclosures to include amendments,' which is a subtly different characterization. The answer demonstrates understanding of the question's intent but fails on precise factual accuracy, particularly regarding exhibit numbers which are objective, verifiable data points that should be correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Adopts]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 433,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 the long‑term debt that PMI incurred specifically for the Swedish Match AB acquisition fell sharply—from **$6.1 bn** (recorded as “Euro credit facility borrowings related to Swedish Match AB acquisition” in 2023) to **$2.6 bn** in 2024—reflecting scheduled repayments (and possible refinancing) of that facility.  This reduction is mirrored in the consolidated long‑term‑debt schedule (Chunk 2), while Chunk 1 notes that the goodwill recorded from the Swedish Match AB purchase was adjusted downward in 2023 due to measurement‑period refinements and impairment, underscoring how the acquisition’s accounting and financing exposure have evolved over the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: The key financial figures are correct—$6.1 billion (2023) and $2.6 billion (2024) match the ground truth values of $6,121 million and $2,610 million respectively. The format variation ($6.1 bn vs $6,121 million) is acceptable and represents the same values. The calculation of the decrease is implicit and correct. ENTITY ACCURACY: Correctly identifies PM/PMI, Swedish Match AB acquisition, and the specific debt instrument (Euro credit facility borrowings). Years are correctly specified as 2023 and 2024. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple sources (Chunk 1 and Chunk 2 references), connecting the debt reduction to both scheduled repayments/refinancing and broader acquisition accounting adjustments (goodwill impairment). This demonstrates proper multi-hop synthesis. COMPLETENESS: The answer addresses all aspects of the question—the evolution of the financial relationship, the specific debt obligations, the magnitude of change, and the underlying drivers (repayments and refinancing). MINOR CONSIDERATIONS: The answer includes additional context about goodwill adjustments and measurement-period refinements, which adds depth but goes slightly beyond the core question. However, this is contextually relevant and enhances understanding rather than detracting from accuracy. The characterization of the reduction as 'sharp' is appropriate given the ~57% decrease. No factual errors or calculation mistakes detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 429,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "\nBMY adds Krazati, and Krazati is introduced by BMY, as the $4.8 B acquisition of Mirati brought the FDA‑approved KRAS inhibitor and its pipeline—including a PRMT5 inhibitor and a contingent value right contingent on FDA NDA acceptance within seven years—into BMY’s portfolio and accelerated its development into first‑line NSCLC combination therapy with a PD‑1 inhibitor. The transaction, recorded as a business combination with $1.7 B of indefinite‑lived IPRD, reflects BMY’s expanded KRAS‑inhibition strategy that also builds on its prior oncology collaborations with BridgeBio, 2seventy bio and Eisai (Chunk 1) and the 2023 context of Krazati as a best‑in‑class asset (Chunk 1, Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) Correctly identifies the $4.8B acquisition price for Mirati - this is accurate and matches ground truth. (2) Correctly identifies Krazati as a KRAS G12C inhibitor acquired through the Mirati deal. (3) Correctly mentions first-line NSCLC combination therapy with PD-1 inhibitor as a development trajectory. (4) Mentions the $1.7B indefinite-lived IPRD valuation, which adds specificity. (5) Acknowledges the 2023-2024 evolution timeframe appropriately.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The LLM answer completely fails to mention the FDA approval of Krazati for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab in 2024 - this is a significant therapeutic expansion explicitly stated in the ground truth. (2) The answer introduces tangential information about PRMT5 inhibitor, contingent value rights, and prior collaborations (BridgeBio, 2seventy bio, Eisai) that, while potentially accurate, are not directly relevant to the specific question about KRAS inhibition strategy evolution and Krazati development trajectory. (3) The phrasing is somewhat convoluted and harder to follow than the ground truth answer. (4) The answer doesn't clearly establish the 2023 baseline (that BMY did not have Krazati in 2023) before describing the 2024 evolution.\n\nMULTI-HOP REASONING: The answer does synthesize the acquisition with portfolio expansion, but it dilutes focus by including less relevant details about other collaborations and financial instruments. The core multi-hop connection (acquisition → Krazati addition → strategic positioning) is present but incomplete.\n\nNUMERIC VERIFICATION: $4.8B acquisition price is correct. $1.7B IPRD figure appears accurate based on typical disclosure patterns. No calculation errors detected.\n\nSEMANTIC ISSUES: While the answer conveys some correct information, the omission of the colorectal cancer indication is a material gap in describing how Krazati's therapeutic footprint expanded in 2024, which is explicitly part of the ground truth answer's explanation of strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Adds]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 555,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "\nBetween 2023 and 2024 Goldman Sachs continued to list its **Restricted Partner Compensation Plan** in its filings, but the way it is presented and the surrounding governance context evolved. In the 2023 Form 10‑K (Chunk 1) the plan appears as Exhibit 10.3, simply disclosed as an adopted accounting policy with no accompanying newer compensation‑governance document. In the 2024 filing (Chunk 2) the same plan is re‑referenced as Exhibit 10.4, yet it is now released together with the **Amended and Restated Clawback Policy** (Exhibit 10.1) and the 2021 Stock Incentive Plan, indicating that the plan is being positioned within a broader, newly introduced suite of compensation‑governance policies. This shift reflects an explicit integration of the Restricted Partner Compensation Plan into the firm’s more recent governance framework.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the exhibit number changes (10.3 in 2023 to 10.4 in 2024), which are factually accurate. (2) Accurately notes the introduction of the Clawback Policy (Exhibit 10.1) in 2024 as a new governance element. (3) Properly synthesizes the multi-hop information about how the plan's positioning evolved relative to other compensation governance documents. (4) Correctly characterizes the shift as reflecting integration into a broader governance framework. (5) The semantic meaning matches the ground truth regarding strategic repositioning and governance reforms. MINOR ISSUES: (1) The LLM refers to the Clawback Policy as 'Amended and Restated Clawback Policy' while the ground truth simply calls it 'Clawback Policy' - this is a minor wording variation that doesn't affect factual accuracy. (2) The LLM mentions '2021 Stock Incentive Plan' which adds contextual detail not explicitly in the ground truth, though this appears to be accurate supplementary information. (3) The phrase 'simply disclosed as an adopted accounting policy' in the LLM answer is slightly imprecise - the ground truth indicates it was 'listed early in the exhibit list' rather than being characterized as an accounting policy specifically. QUANTITATIVE ACCURACY: All exhibit numbers are correct (10.3→10.4, 10.1 for Clawback). Years are accurate (2023 vs 2024). No calculations required. QUALITATIVE ACCURACY: The multi-hop reasoning correctly connects the exhibit placement changes with the introduction of new governance policies and interprets this as strategic repositioning. The logic is sound and well-articulated. CONTEXTUAL RELEVANCE: The answer directly addresses the question about evolution of disclosure and positioning, and appropriately emphasizes the governance context shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Adopts]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 510,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "\nFrom 2022 to 2023 PMI shifted its heat‑not‑burn line from a distinct “reduced‑risk” offering (e.g., IQOS Platform 1 and the HEETS family described in the 2022 filing) into the core of its broader smoke‑free portfolio, now grouped together with e‑vapor, oral‑nicotine and wellness/healthcare products and reported as “smoke‑free products” that also include licensed KT&G heat‑not‑burn items (as noted in the 2023 revenue breakdown).  This re‑classification reflects deeper business integration—linking heat‑not‑burn sales to the wellness‑and‑healthcare segment built through the Vectura and Fertin Pharma acquisitions and positioning the category as a key growth driver alongside PMI’s traditional tobacco brands.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes the multi-hop information about PMI's heat-not-burn product evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from 'Reduced-Risk Products' (RRPs) categorization in 2022 to 'smoke-free products' in 2023; (2) Accurately names specific products (IQOS Platform 1, HEETS, Marlboro HeatSticks) and correctly identifies the inclusion of licensed KT&G heat-not-burn products in 2023; (3) No quantitative errors—no numbers, dates, or calculations are present to verify, and the temporal framing (2022 to 2023) is correct; (4) Multi-hop reasoning is sound, connecting the product categorization shift to broader business integration through acquisitions (Vectura and Fertin Pharma); (5) Semantic equivalence is maintained with the ground truth despite different wording. MINOR WEAKNESSES: (1) The LLM answer adds contextual information about Vectura and Fertin Pharma acquisitions and their connection to wellness/healthcare that, while accurate and relevant, goes slightly beyond what the ground truth explicitly states about the categorization evolution itself; (2) The phrase 'revenue breakdown' in parentheses is somewhat vague and could be more precise about the source of this information; (3) The answer could have been slightly more explicit about the positioning of these products as 'a key part of the company's long-term strategy to replace traditional cigarettes' as mentioned in the ground truth. OVERALL ASSESSMENT: The answer correctly captures the essential evolution of PMI's heat-not-burn product categorization and business integration, with accurate identification of all key entities and products, sound multi-hop reasoning connecting product categorization to broader business strategy, and no factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 495,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "\nBetween 2023 and 2024 Bristol‑Myers Squibb deepened the governance role that the Business Risk and Disclosure Group plays in meeting the 2004 SEC Consent Order.  The 2023 filing first set up the group as part of the required “formal review and certification” of SEC reports and a company‑wide policy to limit sales to direct customers, while the 2024 filing expands that framework by describing a formal escalation process, regular monitoring of policy compliance, and the integration of bottom‑up budgeting inputs and documentation—showing a clear evolution from the group’s initial creation to a more structured, continuously‑audited risk‑management function.  This progression is reflected in the KG relationship BMY → *Business Risk Group* (an ACCOUNTING_POLICY) that is both established by BMY and introduced as a core element of its SEC‑compliance program.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies Bristol-Myers Squibb and the 2004 SEC Consent Order as the relevant compliance framework. (2) The core narrative about the Business Risk and Disclosure Group's establishment in 2023 and continued role in 2024 aligns with the ground truth. (3) The LLM accurately captures that the group was created for SEC Consent Order compliance and involved formal review/certification processes. (4) The characterization of evolution from 2023 to 2024 is directionally correct.\n\nWEAKNESSES: (1) The LLM introduces a claim about 'a company-wide policy to limit sales to direct customers' in the 2023 filing that is NOT mentioned in the ground truth answer. This appears to be either fabricated or conflated from unrelated compliance policies, representing a factual error. (2) The LLM describes 'formal escalation process, regular monitoring of policy compliance, and integration of bottom-up budgeting inputs' as 2024 expansions, but the ground truth states the 2023 establishment already included 'a governance mechanism to escalate and resolve compliance-related questions.' The LLM may be overstating what changed between years. (3) The phrase 'deepened the governance role' is more assertive than the ground truth's more measured 'fully integrated...with no indication of modifications or reductions in scope.' (4) The LLM's reference to KG relationships and technical metadata (BMY → *Business Risk Group* as ACCOUNTING_POLICY) adds technical jargon that, while potentially accurate, doesn't substantively enhance the answer and may indicate over-reliance on knowledge graph structure rather than substantive filing analysis.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize 2023 and 2024 filings but introduces elements not supported by the ground truth, suggesting incomplete or inaccurate source document review. The evolution narrative is present but overstated.\n\nNUMERIC/DATE ACCURACY: All dates (2023, 2024, 2004) are correct. No calculations required.\n\nOVERALL: The answer captures the general evolution of the Business Risk and Disclosure Group's role but introduces unsupported claims about sales policies and potentially mischaracterizes the scope of changes between years. The core insight about continued compliance governance is correct, but execution has notable errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Establishes]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 622,
        "total_tokens": 2058
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "\nUNP continues to determine the expected return on its pension assets by applying the same asset‑allocation‑mix methodology in both periods—i.e., the expected return is derived from the mix of assets together with historical performance and current market outlooks, a relationship that the company explicitly “Considers” and that “Depends_On” its accounting policy. Because the wording and the accounting‑policy linkage are identical in the 2023 and 2024 filings, there is no indicated evolution or change in how the expected‑return‑vs‑asset‑allocation relationship is treated between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on all key points. (1) FACTUAL ERRORS: The LLM claims there is 'no indicated evolution or change' between 2023 and 2024, directly contradicting the ground truth which explicitly documents a clear shift in language and disclosure. The ground truth identifies specific changes: (a) 2023 included explicit mention of historical returns and market conditions; 2024 does not, (b) 2023 disclosed an actual return of 6%; 2024 has no such disclosure, (c) 2023 used comprehensive language; 2024 narrowed focus to asset allocation mix alone. (2) QUANTITATIVE ACCURACY: The LLM provides no specific numbers or data points from the filings. The ground truth references a 6% actual return for 2023 that should have been identified. The LLM fails to extract or compare any concrete metrics. (3) MULTI-HOP REASONING: The LLM fails to perform the required multi-hop synthesis across 2023 and 2024 filings. It should have compared the specific language and disclosures in each year's filing but instead asserts identical treatment without evidence. (4) SEMANTIC EQUIVALENCE: The LLM's core claim ('no evolution') is semantically opposite to the ground truth's core finding ('shift from comprehensive to narrower focus'). This is not a wording difference but a fundamental mischaracterization of the facts. (5) MISSING ANALYSIS: The LLM does not address the shift from 'based on' (2023) to 'depends on' (2024), the removal of historical returns and market conditions from the explanation, or the absence of the 6% actual return disclosure in 2024. The answer appears to misread or misinterpret the source documents entirely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Considers]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 459,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "\nBetween 2022 and 2023 BNY Mellon moved from merely referencing its Directors’ Code of Conduct in the governance narrative and posting it on its website (with a stated intent to disclose any amendments or waivers there) to explicitly listing the Code of Conduct as one of the key corporate‑governance documents made available on the site alongside the Board charters, bylaws and other governance materials.  This change makes the Code more readily accessible to investors and integrates it directly into the company’s annual governance reporting, reflecting the ORG → ACCOUNTING_POLICY ← Discloses relationship that ties the Directors’ Code of Conduct to BNY Mellon’s formal disclosure obligations.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing the evolution of BNY Mellon's disclosure approach between 2022 and 2023. STRENGTHS: (1) Correctly identifies the key shift from referencing the Directors' Code of Conduct to explicitly listing it among governance materials; (2) Accurately captures the 2022 approach (posted on website with intent to disclose amendments/waivers); (3) Accurately describes the 2023 approach (listed alongside Board charters, bylaws, and other governance materials); (4) Correctly identifies the improved accessibility and integration into formal governance reporting; (5) No quantitative errors - dates and entities are correct; (6) Multi-hop reasoning is sound, synthesizing the evolution across both years. MINOR WEAKNESSES: (1) The phrase 'ORG → ACCOUNTING_POLICY ← Discloses relationship' appears to be technical metadata or knowledge graph notation that, while potentially accurate, is somewhat awkwardly integrated into the narrative and may confuse readers unfamiliar with such notation; (2) The reference to 'Board charters, bylaws' is slightly more specific than the ground truth's 'Board Meetings and Committee Information' in 2022, though this represents a reasonable interpretation of governance materials rather than an error; (3) The answer could have been slightly more explicit about the 'structured and centralized approach' concept mentioned in the ground truth. OVERALL ASSESSMENT: The answer correctly captures the substantive evolution in disclosure approach, accurately represents both the 2022 and 2023 positions, and demonstrates proper multi-hop synthesis across the two-year period. The core message about moving from implicit to explicit listing and improved accessibility is accurate and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 482,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "\nOracle has expanded the deployment flexibility of Oracle Database by moving from the 2023‑era OCI services—Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud and Roving Edge Infrastructure—that let customers run the Database behind their own firewalls, in isolated regions or at the network edge—into a 2024 strategy that packages the same Database engine within its Engineered Systems portfolio and offers it as an on‑premise appliance, an OCI‑hosted service, or a hybrid cloud solution that can be consumed alongside Oracle Middleware, Java and other OCI services.  This evolution demonstrates Oracle’s intent to streamline cloud migration and support hybrid‑IT environments: customers can move workloads across on‑prem, OCI and other public clouds while leveraging pre‑integrated, high‑performance engineered systems that simplify operations, security patching and scalability.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Oracle's strategic evolution but contains some notable differences from the ground truth:\n\nSTRENGTHS:\n1. Correctly identifies the core strategic shift from flexible deployment models (2023) to integrated engineered systems (2024)\n2. Accurately names key 2023 offerings: Exadata Cloud@Customer, Roving Edge Infrastructure\n3. Correctly identifies Oracle Exadata Database Machine as the 2024 engineered systems focus\n4. Properly synthesizes the multi-hop concept: deployment flexibility → engineered systems integration → hybrid IT support\n5. Accurately conveys the business logic: pre-integrated systems simplify operations, security, and scalability\n6. Correctly identifies the strategic intent around cloud migration and hybrid environments\n\nWEAKNESSES/INACCURACIES:\n1. Introduces entities not mentioned in ground truth: 'OCI Dedicated Region' and 'Sovereign Cloud' are listed as 2023 offerings, but ground truth only mentions Exadata Cloud@Customer and Roving Edge Infrastructure. This represents potential over-specification or conflation of offerings.\n2. The phrase 'alongside Oracle Middleware, Java and other OCI services' adds specificity not present in ground truth, which focuses on the engineered systems themselves rather than middleware integration\n3. Ground truth emphasizes 'tightly integrated' engineered systems combining 'database, storage, operating system, and networking hardware' - the LLM answer mentions 'pre-integrated, high-performance engineered systems' but doesn't explicitly detail the hardware integration aspect\n4. Ground truth frames this as 'maturation of Oracle's cloud migration strategy' with emphasis on 'holistic, performance-optimized solutions' - LLM answer uses similar language but less explicitly frames it as strategic maturation\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesizes information across 2023-2024 timeframes and connects deployment flexibility to engineered systems to hybrid IT support. The reasoning chain is sound and logical.\n\nSEMANTIC EQUIVALENCE:\nThe core message is semantically equivalent: Oracle moved from flexible deployment options to integrated engineered systems to better support hybrid IT and cloud migration. Both answers convey this fundamental shift.\n\nNUMERIC/FACTUAL VERIFICATION:\nNo specific numbers, dates, or calculations to verify. All named offerings and systems are correctly identified (with the caveat about potentially over-specified 2023 offerings).\n\nJustification: Score of 7 reflects that the answer captures the essential strategic evolution correctly but introduces some specificity not grounded in the original answer and misses some nuanced details about hardware integration and strategic maturation framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Utilizes]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1564,
        "completion_tokens": 733,
        "total_tokens": 2297
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 BMY continued the formal review and certification process for its annual and quarterly SEC reports that was first put in place under the Consent settlement; the 2023 filing describes establishing that process together with a governance structure to escalate and regularly monitor compliance, and the 2024 filing reiterates that the same company‑wide policy, regular compliance‑monitoring and escalation of any questions to appropriate management levels remain in effect. Thus, the process has not undergone a substantive change—it has been sustained and consistently applied across both years, with ongoing governance and monitoring procedures to ensure adherence to the Consent.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and addresses the core question effectively. STRENGTHS: (1) Correctly identifies the company (BMY - Bristol Myers Squibb) and the Consent settlement framework; (2) Accurately captures the timeline - 2023 establishment of formal review/certification process and 2024 continuation; (3) Properly synthesizes multi-hop information showing evolution from initial implementation to sustained enforcement; (4) Correctly identifies key governance elements: escalation procedures, regular monitoring, compliance oversight; (5) Accurately characterizes the evolution as 'sustained and consistently applied' rather than substantive change; (6) No quantitative errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer emphasizes 'no substantive change' more strongly than the ground truth, which frames it as 'shift from initial implementation to sustained enforcement and integration into broader operational frameworks' - this is a subtle difference in emphasis rather than factual error; (2) The ground truth mentions integration 'into company-wide sales policies to ensure adherence to inventory and sales limitations' which the LLM answer doesn't explicitly detail, though it does reference 'company-wide policy'; (3) The LLM answer could have been slightly more explicit about the integration into broader operational frameworks mentioned in the ground truth. MULTI-HOP REASONING: The answer correctly synthesizes information across 2023 and 2024 filings, properly identifying the Consent agreement as the foundational framework and tracking how the process evolved. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth, with the main difference being a slightly different framing of the evolution (emphasizing continuity vs. shift to integration). Both interpretations are reasonable and not contradictory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Establishes]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 526,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "\nFrom 2022 to 2023 PMI moved heat‑not‑burn from being grouped broadly under “reduced‑risk products” (Platform 1 device and consumables that it shipped to Altria for U.S. sales) to a distinct “smoke‑free” category that also includes e‑vapor, oral‑nicotine, wellness and healthcare products, and it began offering licensed KT&G heat‑not‑burn products—signalling a strategic shift toward external partnerships and a clearer market segmentation (Chunk 1 & Chunk 2). This evolution is reflected in the KG relationship ORG (PMI) → PRODUCT (heat‑not‑burn) ← ORG, showing that PMI both produces and is introduced by its heat‑not‑burn offerings, now positioned as a separate smoke‑free product line.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and correctly captures the core evolution of PMI's heat-not-burn positioning from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from 'reduced-risk products' (RRPs) categorization in 2022 to 'smoke-free' category in 2023; (2) Accurately mentions Platform 1 device and consumables; (3) Correctly notes the Altria relationship for U.S. sales; (4) Properly identifies the inclusion of licensed KT&G heat-not-burn products; (5) Accurately characterizes this as a strategic shift toward external partnerships and clearer market segmentation; (6) All dates (2022, 2023) are correct; (7) All entity names (PMI, Altria, KT&G) are correctly identified. MINOR WEAKNESSES: (1) The LLM answer includes 'wellness and healthcare products' in the smoke-free category description, which is not explicitly mentioned in the ground truth answer as part of the heat-not-burn evolution narrative (though this may be accurate from the source documents, it's not part of the ground truth synthesis); (2) The final sentence about 'KG relationship ORG (PMI) → PRODUCT (heat-not-burn) ← ORG' is somewhat awkwardly phrased and adds technical metadata that doesn't enhance clarity of the business evolution; (3) Minor semantic difference: ground truth emphasizes 'various stages of development, scientific assessment, and commercialization' in 2022, while LLM focuses more on the product shipment to Altria. MULTI-HOP REASONING: The answer correctly synthesizes information across multiple time periods and entities (PMI, Altria, KT&G), demonstrating sound multi-hop reasoning. The comparison between 2022 and 2023 positioning is logically structured and accurate. QUANTITATIVE ACCURACY: No specific numbers or calculations are required for this question, but all dates and entity references are correct. Overall, this is a strong answer with minor presentation issues that don't significantly detract from factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 529,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Oracle expanded the deployment flexibility of Oracle Database by offering perpetual on‑premise licenses, native OCI cloud services, and hybrid‑cloud options, and it introduced “pivot‑to‑OCI” programs that let customers migrate existing workloads and purchase new licenses directly in the cloud; at the same time the database is now marketed as part of an integrated stack that bundles Oracle Middleware, Java subscriptions and Engineered Systems (e.g., Exadata) with flexible deployment choices across on‑premise, OCI and hybrid environments, a strategy reflected in the rise of cloud‑services revenue from 25 % of total sales in 2022 to 37 % in 2024. This evolution ties the database’s licensing and support to the broader Oracle portfolio, giving customers choice while deepening integration with the company’s middleware, Java and engineered‑system offerings.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key strategic elements present in the ground truth: (1) deployment flexibility across on-premise, cloud (OCI), and hybrid environments; (2) integration with Oracle Engineered Systems like Exadata; (3) bundling with broader Oracle technologies (middleware, Java); (4) the evolution toward deeper integration. The semantic understanding of the strategic shift is sound.\n\nCRITICAL WEAKNESSES: (1) QUANTITATIVE ERROR - The LLM cites cloud-services revenue rising from 25% in 2022 to 37% in 2024. This specific data point is NOT present in the ground truth and cannot be verified. The ground truth makes no mention of these percentages or revenue metrics. This is a significant factual claim that appears to be fabricated or from an unverified source. (2) UNSUPPORTED CLAIMS - The LLM introduces 'pivot-to-OCI' programs and specific bundling strategies (Java subscriptions, Middleware integration) that are not mentioned in the ground truth. While these may be real Oracle initiatives, they are not supported by the provided ground truth. (3) INCOMPLETE GROUNDING - The answer adds substantial detail about licensing models and revenue metrics that go beyond what the ground truth establishes.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the evolution from standalone product (2023) to integrated component (2024), which matches the ground truth's core narrative. However, the addition of unsupported quantitative data undermines the reliability of this synthesis.\n\nVERIFICATION ISSUES: The 25% to 37% cloud revenue claim is presented as fact but cannot be verified against the ground truth. This is a major accuracy concern for a financial question where precision is critical.\n\nOVERALL ASSESSMENT: While the LLM demonstrates good qualitative understanding of Oracle's strategic evolution, the introduction of unverified quantitative claims (cloud revenue percentages) and unsupported specific initiatives significantly reduces correctness. The answer conflates what may be true with what is grounded in the provided knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 562,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "\nFrom 2023 to 2024 BMY’s relationship with Krazati moved from a pipeline‑stage oncology asset highlighted in its 2023 strategy (Chunk 1) to a fully commercialized product after the January 2024 acquisition of Mirati, cementing Krazati’s role in BMY’s oncology portfolio (Chunk 2). The 2024 transaction comprised a $4.8 billion cash purchase (plus a $1 billion contingent value right) financed in part with debt, and BMY recorded $1.7 billion of indefinite‑lived IPRD and $2.0 billion of R&D technology—financial commitments that illustrate the deepened strategic partnership (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core evolution of BMY's relationship with Krazati from 2023 to 2024, accurately states the $4.8 billion acquisition price for Mirati in January 2024, and correctly mentions the $1 billion contingent value right. The answer properly synthesizes the multi-hop information showing progression from pipeline asset to commercialized product. WEAKNESSES: (1) The LLM introduces additional financial figures ($1.7 billion of indefinite-lived IPRD and $2.0 billion of R&D technology) that are not mentioned in the ground truth answer. While these may be accurate from the source documents, they represent a departure from the ground truth's focus on the core financial commitments. (2) The ground truth specifically highlights the $1.0 billion contingent value rights tied to PRMT5 Inhibitor development as a key commitment reflecting long-term investment, but the LLM presents the $1 billion CVR more generically without specifying it relates to PRMT5 Inhibitor development. This is a meaningful omission of context. (3) The ground truth emphasizes Krazati's FDA and EMA approvals for second-line NSCLC and clinical development status for first-line NSCLC, which the LLM mentions only as 'fully commercialized' without these specific regulatory details. QUANTITATIVE VERIFICATION: $4.8 billion acquisition price - CORRECT; $1 billion contingent value right - CORRECT; January 2024 timing - CORRECT. The additional figures ($1.7B IPRD, $2.0B R&D technology) cannot be verified against ground truth but don't contradict it. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024, showing the evolution correctly. However, the inclusion of unspecified additional financial commitments dilutes the focus on the specific commitments mentioned in ground truth (the $1B CVR tied to PRMT5 Inhibitor). The answer is directionally correct but adds extraneous detail and misses the specific linkage of the CVR to PRMT5 development.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 537,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "\nIn the 2022 Form 10‑K (Chunk 1) and the 2023 Form 10‑K (Chunk 2) the 6.244% Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV are listed identically – they carry the trading symbol **BK/P**, are registered on the New York Stock Exchange, and are described as “(fully and unconditionally guaranteed by The Bank of New York Mellon Corporation).” Thus, between 2022 and 2023 the securities retained their registration, trading symbol, exchange listing, and guarantee without any reported change. The knowledge‑graph relationship (BK → FIN_INST and FIN_INST → BK) reflects this ongoing, unchanged mutual stake between Bank of New York Mellon and the preferred‑capital instrument.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. (1) CORRECTNESS: All factual information matches the ground truth - the securities are correctly identified as 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV, with trading symbol BK/P, listed on NYSE, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. The conclusion that there was no change between 2022 and 2023 is correct. (2) QUANTITATIVE ACCURACY: All numeric identifiers are correct (6.244%, BK/P ticker symbol). No calculations were required for this question. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound - the LLM correctly synthesized information from both 2022 and 2023 Form 10-K filings to compare the status of the securities across years. The identification of entities (Bank of New York Mellon, Mellon Capital IV, NYSE) is accurate. (4) CONTEXTUAL RELEVANCE: The answer directly addresses the question about how the treatment/status evolved, correctly identifying that it remained unchanged. The only minor observation is that the LLM added a reference to 'knowledge-graph relationship (BK → FIN_INST and FIN_INST → BK)' which, while not incorrect, is somewhat tangential to the core question and not present in the ground truth answer. This is a very minor addition that doesn't detract from accuracy. The answer is well-structured, clear, and provides appropriate context about the guarantee structure and listing details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 408,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "\nPMI’s short‑term credit capacity expanded markedly—from roughly **$1.9 billion** of committed arrangements at the end of 2022 (Chunk 2) to about **$2.7 billion** a year later (Chunk 2), while the amount actually borrowed under those facilities slipped slightly from **$295 million** in 2022 to **$283 million** in 2023 (Chunk 2).  This increase in available credit combined with a modest decline in borrowings signals that PMI is building a larger liquidity buffer and relying less on short‑term financing, suggesting a stronger near‑term liquidity posture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. QUANTITATIVE VERIFICATION: All financial figures are precisely correct - capacity increased from $1.9 billion (2022) to $2.7 billion (2023), and utilization decreased from $295 million to $283 million. The numbers match the ground truth exactly with appropriate formatting. COMPLETENESS: The answer addresses all components of the multi-part question: (1) capacity change, (2) utilization change, (3) interpretation of the shift. ENTITY ACCURACY: PMI is correctly identified, years 2022-2023 are accurate, and the metrics (short-term credit arrangements, capacity, utilization) are properly labeled. REASONING QUALITY: The multi-hop synthesis is sound - the model correctly connects the two separate data points (capacity expansion and utilization decline) to draw a coherent conclusion about liquidity posture. The interpretation that 'expanding available credit combined with modest decline in borrowings signals a stronger near-term liquidity posture' is logically sound and semantically equivalent to the ground truth's characterization of 'more conservative approach to short-term financing.' SEMANTIC EQUIVALENCE: The LLM's phrasing 'building a larger liquidity buffer and relying less on short-term financing' conveys the same meaning as the ground truth's 'expanded its available liquidity buffer without increasing its drawdown.' Minor stylistic differences (e.g., 'markedly' vs. implicit emphasis, 'slipped slightly' vs. 'decreased slightly') enhance clarity without affecting accuracy. No calculation errors, no missing data points, and the conclusion appropriately reflects the data presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Maintains]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 458,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "\nBetween 2023 and 2024 Oracle shifted the Autonomous Database from a broadly‑positioned OCI service (introduced as part of its cloud‑and‑license portfolio and marketed with generic OCI compute, storage and AI‑Infrastructure capabilities) to a purpose‑built, **self‑driving** engine that is **deeply integrated with other Oracle Cloud services** and **expanded its automation**.  In the 2024 filing the database is described as “self‑driving, automating routine administration tasks — maintenance, tuning, patching, scaling, security and backup — using machine‑learning diagnostics,” and it is **tightly coupled with Java Cloud, Oracle APEX low‑code, Analytics Cloud and MySQL HeatWave**, enabling developers to build cloud‑native applications and to spin up data marts, warehouses or lake‑houses with on‑demand scaling and consumption‑based pricing.  The 2023 material only noted its availability on OCI as a managed service within the broader infrastructure technology suite, whereas the 2024 disclosure emphasizes **automation‑centric capabilities and multi‑service integration** (including hybrid deployments via Exadata Cloud@Customer and OCI Dedicated Region).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2023 to 2024, capturing the shift from a broadly-positioned OCI service to a purpose-built, automation-centric offering. (2) Accurately lists specific cloud service integrations mentioned in the ground truth: Java Cloud, Oracle APEX, and adds Analytics Cloud and MySQL HeatWave (which are consistent with the broader OCI ecosystem positioning). (3) Properly synthesizes the multi-hop information about automation capabilities, including machine learning diagnostics, fault prediction, error handling, and automatic threat detection. (4) Correctly emphasizes the 2024 focus on cloud-native application development, data lakes/warehouses, and real-time analytics. (5) Adds relevant contextual details about Exadata Cloud@Customer and OCI Dedicated Region that enhance understanding without contradicting the ground truth. (6) Uses appropriate terminology ('self-driving,' 'automation-centric') that aligns with Oracle's 2024 positioning language. (7) No quantitative errors or date misstatements. MINOR CONSIDERATIONS: (1) The LLM answer is more detailed and interpretive than the ground truth, adding some characterizations (e.g., 'purpose-built self-driving engine,' 'consumption-based pricing') that, while consistent with Oracle's 2024 messaging, go slightly beyond what was explicitly stated in the ground truth. However, these additions appear factually sound and enhance rather than detract from the answer. (2) The answer effectively captures the semantic essence of the evolution while providing richer context about the specific service integrations and deployment options. The multi-hop reasoning successfully synthesizes information across the 2023 and 2024 filings to show the progression in Oracle's positioning strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1553,
        "completion_tokens": 511,
        "total_tokens": 2064
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "\nBetween 2023 and 2024 GM’s financial stake in Ultium Cells Holdings LLC slipped modestly but remained material: the 2023 filing notes $0.8 billion of committed capital contributions to Ultium at year‑end 2023 (down from $1.4 billion committed in 2022), and the 2024 filing reports $0.7 billion of GM’s investment in Ultium for both 2024 and 2023, indicating a continued but slightly reduced funding level.  Although GM’s exposure to loss remains high—about $3.5 billion of maximum loss exposure inclusive of those capital commitments—it still lacks voting or similar rights to direct Ultium’s most economically significant activities, preserving a strategic partnership while maintaining a passive, minority‑investor position.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ELEMENTS: (1) The $0.8 billion committed capital contribution for 2023 is accurate. (2) The $0.7 billion investment figure for 2024 is accurate. (3) The characterization of GM lacking voting control is correct. (4) The reference to VIE classification is appropriate. (5) The overall narrative of a shift from contingent commitments to realized investment is sound. PROBLEMATIC ELEMENTS: (1) The LLM introduces the $1.4 billion figure from 2022 without being asked about it, which adds context but wasn't part of the ground truth answer and may confuse the evolution narrative. (2) The LLM states the $0.7 billion represents 'both 2024 and 2023,' which is confusing and potentially inaccurate—the ground truth indicates $0.7 billion was the 2024 investment, not that it applied to both years equally. (3) The LLM introduces a $3.5 billion maximum loss exposure figure that is not mentioned in the ground truth, which may be accurate but represents information beyond the scope of the original answer. (4) The characterization of GM's position as 'passive, minority-investor' somewhat contradicts the ground truth's suggestion of 'potentially greater influence,' though both could be technically correct depending on interpretation. MULTI-HOP REASONING: The LLM correctly synthesizes the evolution between 2023 and 2024, identifying the shift from contingent commitments to realized investment. However, the presentation of the $0.7 billion applying to 'both 2024 and 2023' is confusing and potentially misrepresents the data. QUANTITATIVE ACCURACY: The core numbers ($0.8B for 2023, $0.7B for 2024) are correct, but the presentation of how these relate to each other and the introduction of the $1.4B and $3.5B figures without clear grounding in the original answer creates ambiguity. The answer would have been stronger with clearer year-to-year comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 521,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "\nThe Litigation Management Deed’s anniversary releases show a clear decline in the protection unwound: in the 2022 sixth‑anniversary release the Company freed $3.5 billion of as‑converted value and issued 176,655 series A preferred shares (with $3 million cash paid for fractions), whereas the 2024 eighth‑anniversary release freed $2.7 billion of as‑converted value and issued only 99,264 series A preferred shares (with $5 million cash paid for fractions). Thus, between 2022 and 2024 the amount of as‑converted value released fell by roughly $0.8 billion and the number of series A shares issued was cut by more than 40 %, reflecting a reduced financial impact of the deed over time.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All key financial figures are correct: 2022 sixth-anniversary release ($3.5 billion as-converted value, 176,655 series A preferred shares) and 2024 eighth-anniversary release ($2.7 billion as-converted value, 99,264 series A preferred shares). The calculations are accurate: the difference of $0.8 billion ($3.5B - $2.7B) and the percentage decline in shares (99,264/176,655 ≈ 56.2% remaining, or ~43.8% reduction, which the LLM reasonably characterizes as 'more than 40%'). The LLM goes beyond the ground truth by including additional details about cash paid for fractions ($3 million in 2022, $5 million in 2024), which adds valuable context without contradicting the original answer. The multi-hop reasoning is sound: the answer correctly synthesizes information across two different years and anniversary releases, properly identifies the trend (decline in both metrics), and provides logical interpretation of what this means (reduced financial burden). The terminology is appropriate ('protection unwound,' 'as-converted value,' 'series A preferred shares'). The only minor distinction is that the LLM provides slightly more granular analysis (including the fraction cash payments and more precise percentage calculation) than the ground truth, but this represents enhancement rather than error. The answer fully addresses all parts of the question regarding the evolution of financial impact between 2022 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 411,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the relationship moved from the **de‑consolidation of the Aearo Entities in Q3 2022** (triggered by their Chapter 11 filing and the $1.2 bn pre‑tax charge 3M recorded in Q2 2022) to a **re‑consolidation in Q2 2023** after the bankruptcy dismissal lifted the automatic stay on the Combat‑Arms‑Earplug litigation; in **August 2023** 3M and the Aearo Entities executed the **CAE Settlement**, which was structured to resolve all ear‑plug claims and kept the related appeals stayed, thereby ending the stay‑order dispute.  The re‑consolidated Aearo Entities are now reflected in 3M’s **Transportation and Electronics segment**, where 2024 sales were down 1.4 % on a reported basis but up 3.1 % when adjusted for PFAS‑related divestiture impacts, and where **operating‑income margins were pressured by dis‑synergies from the Solventum spin and declining PFAS manufacturing**, even though margins improved on a non‑PFAS basis.  Thus, the litigation resolution and the 2023 re‑consolidation reshaped both the **financial exposure (immaterial income‑statement impact, $0.2 bn additional funding commitment)** and the **strategic footprint** of the Aearo Entities within 3M’s segment results through 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the multi-hop relationship evolution between 3M and Aearo Entities across 2023-2024, with generally accurate synthesis of litigation and financial impacts. STRENGTHS: (1) Correctly identifies the timeline: deconsolidation in Q3 2022, reconsolidation in Q2 2023, and CAE Settlement in August 2023; (2) Accurately notes the immaterial income statement impact from reconsolidation, matching ground truth; (3) Properly synthesizes the shift from litigation-focused (2023) to strategic financial treatment (2024); (4) Correctly identifies Transportation and Electronics segment as the reporting location; (5) Provides relevant context about segment performance metrics (1.4% decline reported, 3.1% adjusted for PFAS). WEAKNESSES/CONCERNS: (1) The $1.2 billion pre-tax charge from Q2 2022 is mentioned but not explicitly verified against ground truth - this appears reasonable but adds detail beyond the original answer; (2) The $0.2 billion additional funding commitment is stated but not present in the original ground truth answer, raising questions about whether this is accurate or an extrapolation; (3) References to 'Solventum spin' and 'PFAS manufacturing' pressures are contextually relevant but not explicitly mentioned in the ground truth, suggesting the LLM may be adding interpretive detail; (4) The specific percentage figures (1.4%, 3.1%) for segment performance are provided but cannot be verified against the ground truth provided. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple time periods and connects litigation outcomes to financial reporting treatment, which is the core requirement. The logic flow from bankruptcy dismissal → litigation stay lift → CAE Settlement → reconsolidation → segment reporting is sound. SEMANTIC EQUIVALENCE: The answer conveys the essential evolution described in the ground truth while providing additional supporting detail. The core message about the shift from litigation-focused to strategic financial treatment is preserved. QUANTITATIVE ACCURACY CONCERN: While most numbers appear reasonable, the introduction of specific figures ($0.2bn, 1.4%, 3.1%) that aren't in the ground truth creates uncertainty about whether these are accurate or inferred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reconsolidates]-> COMP <-[Involved_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 611,
        "total_tokens": 2101
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "\nBetween 2022 and 2024 V’s Class C common stock retained the same limited‑voting rights and capital‑structure constraints disclosed in the 2022 filing—holders can vote only on mergers, consolidations or exits and are subject to the 15 % ownership caps that also apply to Class A, while their interests may diverge from those of Class A shareholders because many are current or former financial‑institution clients.  The most recent 2023 data show that Class C generated $320 million of income on just 10 million weighted‑average shares, producing a diluted EPS of $33.13—over four times the $8.28 EPS of Class A and higher than the $13.24 EPS of Class B—reflecting a markedly higher per‑share earnings allocation and a much smaller, non‑dilutive share base relative to the other classes.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer addresses the core question about Class C Common Stock evolution between 2022 and 2024, correctly identifying governance structures, voting rights, and EPS comparisons. However, there are significant quantitative accuracy issues that prevent a higher score.\n\nCORRECT ELEMENTS:\n- Governance structure remained unchanged (voting rights on mergers/consolidations only)\n- 15% ownership caps correctly identified\n- Class C EPS of $33.13 diluted matches ground truth exactly\n- Class A EPS of $8.28 diluted matches ground truth exactly\n- Correct identification that Class C has higher per-share earnings than Class A\n- Correct characterization of divergent interests between Class C and Class A holders\n- Appropriate synthesis of multi-hop information across years\n\nCRITICAL ERRORS:\n1. YEAR MISMATCH: The LLM states \"most recent 2023 data\" but the ground truth specifies 2024 data. The question explicitly asks about evolution \"between 2022 and 2024,\" and the ground truth provides 2024 EPS figures ($33.17 basic, $33.13 diluted for Class C; $8.29 basic, $8.28 diluted for Class A). The LLM only provides diluted EPS and omits basic EPS figures.\n\n2. INCOMPLETE EPS REPORTING: Ground truth provides both basic and diluted EPS for Class C ($33.17 basic, $33.13 diluted) and Class A ($8.29 basic, $8.28 diluted). LLM only reports diluted EPS for Class C ($33.13) and Class A ($8.28), missing the basic EPS data entirely.\n\n3. UNSUPPORTED FINANCIAL DATA: The LLM introduces specific figures ($320 million income, 10 million weighted-average shares, Class B EPS of $13.24) that are not present in the ground truth answer. While these may be factually correct from the source documents, they represent information beyond what the ground truth validates, creating uncertainty about accuracy.\n\n4. TEMPORAL IMPRECISION: Stating \"most recent 2023 data\" when the question and ground truth focus on 2024 creates confusion about the time period being analyzed.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across multiple years and stock classes, correctly identifying the relationship between governance structures and financial performance. The logic connecting smaller share base to higher per-share earnings is sound.\n\nSEMANTIC EQUIVALENCE: The core message about Class C's unchanged governance but significantly higher EPS relative to Class A is conveyed correctly, though with incomplete data presentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 653,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2024 Qualcomm shifted ADAS/AD from a **strategic R&D and investment focus**—highlighted in the 2022 10‑K discussion of its QSI strategic investments and broad automotive‑related R&D efforts—**to a distinct, revenue‑generating product line**.  The 2024 10‑K now categorizes sales of “products sold for use in automobiles, including connectivity, digital cockpit **and ADAS/AD**” as a separate revenue stream, showing that the technology has moved from early‑stage development and venture‑backed investments to **commercialized chipset and royalty sales** that are explicitly tracked in the company’s financial reporting.  This evolution reflects Qualcomm’s progression in **developing ADAS/AD as a marketable product (QCOM → ADAS/AD) and producing it at scale for automotive customers**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from fiscal 2022 to fiscal 2024; (2) Accurately characterizes the shift from R&D/investment focus (QSI segment, venture-backed) to commercialization; (3) Properly identifies the key evidence: explicit categorization of ADAS/AD under automotive revenue streams in 2024 10-K; (4) Correctly notes the transition from development to revenue-generating product line; (5) Multi-hop reasoning is sound—synthesizes information about strategic activities (QSI investments in 2022) with revenue categorization changes (2024 automotive products listing); (6) No quantitative errors or date inaccuracies. MINOR CONSIDERATIONS: (1) The LLM answer includes slightly more specific detail about 'chipset and royalty sales' and 'QCOM → ADAS/AD' notation, which adds helpful context but goes marginally beyond the ground truth statement; (2) The phrase 'producing it at scale for automotive customers' is a reasonable inference from commercialization but represents slight extrapolation beyond explicitly stated facts. These additions are contextually appropriate and enhance clarity without contradicting the ground truth. The answer successfully captures the core evolution narrative: development/investment phase (2022) → commercialized revenue stream (2024), with proper identification of supporting evidence from both fiscal years' filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 409,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "\nBetween 2022 and 2024 Visa refined the U.S. Retrospective Responsibility Plan by expanding the roster of mechanisms that address liability in covered litigation—adding detailed loss‑sharing and escrow provisions, the conversion feature of its Class B shares, makewhole and indemnification agreements, and an omnibus agreement—while clarifying that the plan now covers only monetary settlements or final judgments (excluding fines or penalties) and that the accrued amount may differ from the escrow balance. This evolution shows that Visa is adopting a more layered, proactive approach to litigation risk, using multiple, overlapping safeguards (escrow, loss‑sharing, share‑based conversion and indemnity) to manage and limit potential financial exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the time period (2022-2024) and accurately captures the evolution of Visa's U.S. Retrospective Responsibility Plan; (2) All mechanisms mentioned in the ground truth are present in the LLM answer: U.S. litigation escrow agreement, conversion feature for Class B common stock, makewhole agreements, indemnification obligations, interchange judgment sharing agreement, loss sharing agreement, and omnibus agreement; (3) Accurately conveys that the accrued amount may differ from the escrow balance; (4) Correctly synthesizes the multi-hop reasoning that the evolution represents a shift toward a more 'layered, proactive approach' to litigation risk management; (5) No quantitative errors or date inaccuracies; (6) Semantic equivalence is strong - the LLM uses 'overlapping safeguards' and 'diversified approach' which align with the ground truth's 'comprehensive and layered strategy' and 'more proactive and diversified approach.' MINOR CONSIDERATIONS: (1) The LLM adds clarification that the plan 'covers only monetary settlements or final judgments (excluding fines or penalties)' - while this is a reasonable inference and appears consistent with the ground truth's reference to 'monetary liabilities from settlements or final judgments,' it represents a slight elaboration beyond what was explicitly stated in the ground truth; (2) The LLM's phrasing is slightly more concise than the ground truth but captures all essential information without loss of meaning. MULTI-HOP REASONING: The answer successfully synthesizes information across the 2022 and 2024 periods, correctly identifying what changed (mechanisms added/expanded) and what this suggests about company strategy (more proactive, layered approach). The reasoning is sound and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 511,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "\nIn 2023 Merck recorded a $1.5 billion intangible asset for Lynparza tied to its collaboration with AstraZeneca (Chunk 1), and by 2024 alliance revenue from Lynparza had risen 9 % with a January 2025 Chinese NMPA approval for an adjuvant BRCA‑mutated breast‑cancer indication, underscoring accelerating performance and heightened strategic value (Chunk 2).  The same 2024 filing also details expanded royalty arrangements for other key partnerships (e.g., Keytruda, Lenvima, Reblozyl), reflecting a broader uptick in partnership‑driven earnings that reinforces Lynparza’s growing importance within Merck’s portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information across 2023-2024 filings. STRENGTHS: (1) All key numbers are correct: $1.5 billion intangible asset in 2023, 9% alliance revenue growth in 2024, January 2025 China NMPA approval for adjuvant breast cancer treatment. (2) Multi-hop synthesis is sound: correctly connects the 2023 financial stake to 2024 performance metrics and 2025 regulatory milestone. (3) Entities properly identified: Merck, AstraZeneca, Lynparza, BRCA-mutated indication. (4) Reasoning is logical and supports the conclusion about enhanced strategic importance. (5) Semantic equivalence maintained with ground truth despite different wording. MINOR WEAKNESSES: (1) The LLM adds contextual information about other partnerships (Keytruda, Lenvima, Reblozyl) that, while potentially accurate, goes slightly beyond the ground truth answer's scope. This is not incorrect but represents modest scope expansion. (2) The phrase 'accelerating performance' is interpretive language not explicitly in ground truth, though it's a reasonable inference from the 9% growth figure. (3) Ground truth notes 'increased demand in most international markets' as a driver of growth, which the LLM doesn't explicitly mention, though this is a minor omission. CALCULATION VERIFICATION: No calculations required; all percentages and dollar amounts match ground truth exactly. DATE VERIFICATION: 2023, 2024, and January 2025 all correct. The answer successfully addresses both parts of the multi-part question: (1) how the financial stake evolved (from $1.5B asset in 2023 to performance-driven growth in 2024), and (2) indicators of changed performance/strategic importance (9% revenue growth, regulatory expansion).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 479,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "\nSkoal—identified in the knowledge‑graph as a product **produced by** Altria (MO) and disclosed by the same entity—has been losing ground in Altria’s oral‑tobacco segment.  The 2022 filing (Chunk 1) notes that the segment includes the premium brands **Copenhagen** and **Skoal**, and describes a highly competitive market where share is driven by brand loyalty, price and innovation.  In the 2024 filing (Chunk 2) the retail‑share data show Skoal’s slice falling from **9.3 % (2023) to 7.6 % (2024)**, while its key rival Copenhagen also slipped from **23.5 % to 19.1 %**, and the newer on! brand grew from **6.8 % to 8.3 %**.  Consequently, the overall oral‑tobacco share of total retail sales dropped from **42.5 % to 37.5 %**, indicating that between 2022 and 2024 Skoal’s competitive position eroded relative to both established premium competitors and emerging products.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of all key numeric values and entities. Quantitative verification: Skoal's retail share decline from 9.3% to 7.6% is correct; Copenhagen's drop from 23.5% to 19.1% is accurate; on!'s growth from 6.8% to 8.3% is correct; overall segment contraction from 42.5% to 37.5% is accurate. All percentages match the ground truth exactly. Entity identification is correct: Altria (MO), Copenhagen, Skoal, and on! are all properly identified. The multi-hop reasoning is sound—the answer correctly synthesizes information across multiple data points to show Skoal's relative underperformance compared to both Copenhagen and on!. The answer appropriately characterizes the competitive dynamics and market shifts. Minor weakness: The LLM answer references '2023 to 2024' for Skoal's decline (9.3% to 7.6%) while the question asks about 2022-2024 evolution. The ground truth states 'In 2022, Skoal...retail share of 9.3%' and 'By 2024...7.6%', suggesting the 9.3% figure is from 2022, not 2023. The LLM's parenthetical '(2023) to 7.6% (2024)' introduces a minor temporal ambiguity, though the actual numbers are correct. The answer could have been more explicit about the 2022 baseline. The contextual framing about brand loyalty, price, and innovation is appropriate and adds relevant context. Overall, the answer successfully addresses the multi-part question about market position evolution, competitive performance, and relationship to key competitors, with accurate synthesis across the required time period and entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 436,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "\nIn fiscal 2022 Microsoft reported that “Dynamics products and cloud services revenue increased 25 % driven by Dynamics 365 growth of 39 %,” and the overall Microsoft Cloud (which includes Dynamics 365) generated **$91.4 billion** (MS‑FT 10‑K 2022, p. 40). By fiscal 2023 the company disclosed that Microsoft Cloud revenue rose to **$111.6 billion**—a **~22 % increase** over the $91.4 billion recorded in FY 2022 (MS‑FT 10‑K 2023, p. 93)—with Dynamics 365 continuing to be a key contributor to that growth, building on its prior 39 % expansion. Thus, the revenue contribution from Dynamics 365 within Microsoft Cloud grew from $91.4 B in FY 2022 to $111.6 B in FY 2023, reflecting both the segment’s strong double‑digit growth and its expanding share of the broader cloud business.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM states Microsoft Cloud revenue was $91.4 billion in FY2022, but the ground truth clearly states $91.2 billion. This is a factual error of $0.2 billion. More problematically, the LLM then conflates the total Microsoft Cloud revenue ($111.6B in FY2023) with Dynamics 365's specific contribution, stating 'the revenue contribution from Dynamics 365 within Microsoft Cloud grew from $91.4 B in FY 2022 to $111.6 B in FY 2023.' This is fundamentally incorrect - the $91.4B and $111.6B figures represent TOTAL Microsoft Cloud revenue, not Dynamics 365 revenue specifically. Dynamics 365 is a COMPONENT of Microsoft Cloud, not equivalent to it. (2) MULTI-HOP REASONING FAILURE - The LLM failed to properly synthesize the distinction between total Microsoft Cloud revenue and Dynamics 365's contribution within that cloud portfolio. The ground truth explicitly states Dynamics 365 'contributed to' and is 'a component' of Microsoft Cloud, not that it equals the entire cloud revenue. (3) CALCULATION ERROR - The LLM calculates a ~22% increase from $91.4B to $111.6B, which is arithmetically correct for those numbers, but this calculation is applied to the wrong metric (total cloud vs. Dynamics 365 specifically). (4) MISSING INFORMATION - The LLM does not provide the actual Dynamics 365 revenue figures or growth rates for FY2023, which the ground truth acknowledges are not explicitly stated but notes the continued inclusion indicates sustained growth. The LLM's conclusion that 'the revenue contribution from Dynamics 365 within Microsoft Cloud grew from $91.4 B in FY 2022 to $111.6 B in FY 2023' is a major semantic and factual error that misrepresents the data structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 473,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "\nFrom 2023 to 2024 Merck broadened the scope of its Balance Sheet Risk Management Program: in 2023 it relied mainly on un‑designated forward contracts to remeasure monetary assets and liabilities and on designated forwards plus euro‑denominated debt to hedge net‑investment, with fair‑value changes recorded in OCI; by 2024 the program added a structured revenue‑hedging layering approach that uses forwards together with purchased put options and collars to hedge forecasted foreign‑currency sales up to two years out, while continuing to employ forwards and foreign‑currency debt for balance‑sheet and net‑investment hedges and now reclassifies cash‑flow hedge gains/losses from AOCL into earnings.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of Merck's FX hedging evolution but contains significant inaccuracies and introduces information not supported by the ground truth. CORRECT ELEMENTS: (1) Both answers correctly identify that 2023 used forward contracts; (2) Both mention expansion to include put options and collars by 2024; (3) Both reference the layering approach for forecasted sales hedging; (4) Both note continuation of forwards for balance sheet hedges. SIGNIFICANT ERRORS: (1) The LLM introduces 'designated forwards plus euro-denominated debt to hedge net-investment' for 2023 - the ground truth makes no mention of designated forwards or net-investment hedges in 2023, only that 2023 contracts were 'not designated as hedges'; (2) The LLM states fair-value changes were 'recorded in OCI' for 2023 - the ground truth explicitly states they were 'marked to market through Other (income) expense, net,' not OCI; (3) The LLM mentions 'reclassifies cash-flow hedge gains/losses from AOCL into earnings' for 2024 - this accounting treatment detail is not mentioned in the ground truth; (4) The LLM's characterization of 2023 as having 'un-designated forward contracts to remeasure monetary assets and liabilities' adds specificity not present in the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize the evolution across years but conflates different hedging strategies (balance sheet vs. net-investment vs. cash-flow hedges) in a way that doesn't align with the ground truth's clearer distinction. The answer suggests more complexity in 2023 than the ground truth supports. MISSING ELEMENTS: The ground truth emphasizes that 2023 contracts focused on specific currencies (euro, Swiss franc, Japanese yen, Chinese renminbi) and were marked through Other (income) expense - these details are absent from the LLM answer. The ground truth's emphasis on 'economically beneficial' timing and cost-benefit assessments is also missing. The LLM answer is partially correct on the 2024 expansion but significantly mischaracterizes the 2023 baseline and introduces unsupported accounting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 567,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "\nPayPal’s merchant‑receivables portfolio expanded materially between 2022 and 2024 – it purchased roughly $1.8 bn of receivables in 2024 (up from $1.7 bn in 2023) and grew the outstanding balance to $1.5 bn, reflecting its direct investment in merchant‑finance products such as PPWC and PPBL; at the same time the company’s allowance for credit losses on those receivables fell from $380 m (as of 31 Dec 2023) to $348 m (as of 31 Dec 2024), a decline that stems from improved credit quality of installment loans despite the larger portfolio and builds on the 2022 disclosure that allowances are estimated using historical loss curves and macro‑economic forecasts applied to merchant receivables. This evolution is captured by the knowledge‑graph link where PYPL both discloses and invests in Merchant Receivables, linking the disclosed allowance methodology to the growth of its direct merchant‑financing activities.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer addresses the core question about PayPal's merchant receivables evolution and provides relevant context about credit loss provisions and direct investment. However, there are significant quantitative discrepancies that undermine accuracy:\n\nCORRECT ELEMENTS:\n- Correctly identifies the $1.5 billion outstanding balance as of December 31, 2024\n- Correctly mentions the $1.8 billion in purchases during 2024\n- Correctly identifies PPWC and PPBL as merchant finance products\n- Correctly notes the allowance methodology using historical loss curves and macroeconomic forecasts\n- Correctly identifies the shift toward direct investment and operational involvement\n- Properly synthesizes multi-hop information across years and metrics\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. QUANTITATIVE ERROR - 2023 Purchases: LLM states \"$1.7 bn in 2023\" but ground truth does not provide this figure. This appears to be fabricated or incorrectly sourced.\n2. ALLOWANCE FIGURES: LLM provides specific allowance amounts ($380M in 2023, $348M in 2024) that are not mentioned in the ground truth answer. While these could be accurate from the actual filings, they cannot be verified against the provided ground truth and represent unsourced claims.\n3. MISSING KEY METRIC: Ground truth emphasizes the principal and interest coverage ratio (9% in 2021, down from 23% in 2020) which the LLM completely omits. This is a specific metric mentioned in the original answer.\n4. INCOMPLETE HISTORICAL CONTEXT: LLM does not reference the 2021-2022 coverage ratio data that demonstrates the evolution of credit quality metrics.\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesizes information across multiple years and connects the methodology disclosure (2022) to the operational expansion (2023-2024). The reasoning that improved credit quality led to lower allowances despite portfolio growth is sound and demonstrates good multi-hop synthesis.\n\nSEMANTIC ISSUES:\nThe statement about allowance decline \"stems from improved credit quality\" is interpretive and not explicitly stated in the ground truth, though it's a reasonable inference.\n\nOVERALL ASSESSMENT:\nThe answer demonstrates good understanding of the question's multi-hop nature and provides relevant context, but introduces unverified numerical claims and omits key metrics from the ground truth, particularly the coverage ratios that are central to understanding the evolution of credit loss provisions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 655,
        "total_tokens": 2089
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "\nMO’s goodwill continued to be allocated to smokeable products at **$99 million** (Chunk 1), a figure that has remained unchanged across the periods examined. Operating income from those products rose from **$10.67 billion in 2023 to $10.82 billion in 2024** (Chunk 2), lifting its share of total operating income from roughly **92 % to 96 %** even as net revenue slipped slightly from **$21.76 billion to $21.20 billion**. This stable goodwill allocation combined with the upward trend in operating income demonstrates that the financial significance of smokeable products to MO has grown from 2022 through 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ELEMENTS: (1) Goodwill allocation of $99 million for smokeable products is accurate; (2) Operating income figures are correct: $10.67 billion (2023) and $10.82 billion (2024); (3) The revenue figure of $21.76 billion (2023) is accurate; (4) The general conclusion about sustained/increased operational significance is sound. PROBLEMATIC ELEMENTS: (1) The claim that goodwill 'remained unchanged across the periods examined' is misleading - the ground truth explicitly states that 2022 goodwill was $99 million but 2024 goodwill is 'not disclosed specifically for smokeable products.' The LLM treats the absence of 2024 data as confirmation of stability, which is an unwarranted assumption; (2) The percentage calculations (92% to 96% share of total operating income) cannot be verified from the provided information and appear to be extrapolated without sufficient basis; (3) The revenue figure of $21.20 billion for 2024 is stated but not verified against ground truth; (4) The LLM misses the key insight from the ground truth that the lack of updated goodwill disclosure in 2024 represents a 'potential shift in reporting focus toward performance metrics rather than asset valuations' - this is an important contextual nuance. MULTI-HOP REASONING: The answer does synthesize goodwill and operating income data across years, but the synthesis is incomplete and makes unsupported inferences about unchanged goodwill when the actual situation is that 2024 data is undisclosed. The reasoning that 'stable goodwill allocation combined with upward trend in operating income demonstrates financial significance has grown' is logically sound IF the premise (stable goodwill) were correct, but it's not properly established. CALCULATION VERIFICATION: The operating income increase ($10.67B to $10.82B = $150M increase) is correctly identified directionally, though not explicitly calculated. The percentage claims cannot be independently verified from the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 549,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "\nThe commercial portion of LinkedIn is reported as part of Microsoft Cloud, and the FY 2022 filing shows that this segment contributed **$91.2 billion** to Microsoft Cloud revenue, while the FY 2023 filing lists Microsoft Cloud—including the same commercial LinkedIn contribution—at **$111.6 billion** for FY 2023.  Accordingly, the LinkedIn‑related contribution grew by roughly **$20.4 billion (≈22 %)** between fiscal 2022 and fiscal 2023, underscoring an increased revenue impact of LinkedIn within Microsoft’s cloud business.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer makes a fundamental logical error in its interpretation and calculation. While the numbers $91.2B (FY2022) and $111.6B (FY2023) are correct for Microsoft Cloud revenue, the LLM incorrectly attributes the entire $20.4B increase to LinkedIn's commercial portion. This is factually wrong. The ground truth states that Microsoft Cloud 'includes the commercial portion of LinkedIn' - meaning LinkedIn is ONE COMPONENT of the broader Microsoft Cloud segment, not the sole driver of growth. The LLM's claim that 'the LinkedIn-related contribution grew by roughly $20.4 billion' misrepresents the data by suggesting LinkedIn alone accounts for the entire increase between the two years. This is a multi-hop reasoning failure: the LLM correctly identified the two Microsoft Cloud figures but failed to properly synthesize the relationship between LinkedIn (a component) and Microsoft Cloud (the aggregate). The calculation of $111.6B - $91.2B = $20.4B is arithmetically correct, but the attribution of this entire amount to LinkedIn is logically unsound and contradicts the ground truth's more cautious language: 'This increase suggests a stronger revenue contribution from LinkedIn's commercial services' (emphasis on 'suggests' - indicating the increase cannot be directly attributed solely to LinkedIn). The LLM overstates the certainty and magnitude of LinkedIn's specific contribution. The answer should acknowledge that while Microsoft Cloud grew by $20.4B, this growth reflects the entire cloud segment including but not limited to LinkedIn's commercial portion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 439,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "\nLynparza’s commercial rollout began with FDA clearance in May 2023 (and Japan MHLW approval in August 2023) for BRCA‑mutated mCRPC and other advanced cancers, and by the end of 2024 the product’s alliance revenue had risen 9 % year‑over‑year, reflecting expanded demand across international markets and broader use in combination regimens; this growth was driven by the AstraZeneca collaboration and was underpinned by additional approvals in Europe and the United States.  A further geographic expansion occurred in January 2025 when China’s NMPA approved Lynparza as an adjuvant therapy for early‑stage BRCA‑mutated breast cancer, underscoring the continued global market expansion of the drug.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates substantial accuracy with mostly correct information but contains some issues: (1) CORRECT ELEMENTS: The 9% alliance revenue growth figure is accurate; the January 2025 China NMPA approval for adjuvant breast cancer treatment is correct; the mention of FDA and Japan MHLW approvals in 2023 is correct; the geographic expansion narrative is sound; the OlympiA trial reference is accurate. (2) QUANTITATIVE ACCURACY: The 9% growth figure is precisely correct. The dates (May 2023 FDA, August 2023 Japan MHLW, January 2025 China NMPA) align with ground truth. (3) ISSUES IDENTIFIED: The LLM answer mentions 'FDA clearance in May 2023' but the ground truth specifies FDA approval (not clearance) - this is a minor semantic distinction but technically imprecise terminology. The LLM adds details about 'AstraZeneca collaboration' and 'additional approvals in Europe and the United States' that are not explicitly mentioned in the ground truth, which could be accurate but represents information synthesis beyond what was provided. The ground truth specifically mentions the PROpel trial for mCRPC approval, which the LLM does not reference. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across 2023-2024-2025 timeline and connects geographic approvals to revenue growth. However, it doesn't explicitly link the 2023 approvals to the 2024 revenue growth mechanism as clearly as the ground truth does. (5) COMPLETENESS: The answer addresses both geographic approvals and revenue growth as requested, though the connection between specific 2023 approvals and 2024 revenue growth could be more explicit. The mention of 'combination regimens' is relevant but not specifically tied to the PROpel trial context. Overall, the answer is substantially correct with accurate key metrics and dates, but lacks some specific trial references and contains minor terminology imprecision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 519,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "\nRTX’s Powder Metal Matter contributed $644 million to future income‑tax benefits in 2023 but only $455 million in 2024—a drop of roughly $189 million (Chunk 2).  This decline mirrors the “reduction in sales from the Powder Metal Matter” highlighted in the 2023 filing (Chunk 1), and the KG relationship RTX → Powder Metal Matter (Depends_On) ← Discloses shows that the segment is both a risk factor and a disclosed item for RTX, so its lower tax‑benefit amount directly reduces the tax‑benefit portion of RTX’s overall future tax position despite the modest rise in total benefits.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) All numeric values are correct: $644M (2023), $455M (2024), $189M decline, and 29.3% decrease calculation is accurate. (2) Dates and years properly identified (2023 vs 2024). (3) The LLM correctly identifies the shift in financial treatment from sales reduction to tax benefit recognition. WEAKNESSES: (1) The LLM's explanation becomes muddled in the second half with references to 'KG relationship' and 'Depends_On' that add confusion rather than clarity. The statement 'its lower tax-benefit amount directly reduces the tax-benefit portion of RTX's overall future tax position despite the modest rise in total benefits' is speculative and not supported by the ground truth answer, which focuses on the evolution of treatment and the magnitude of change. (2) The LLM conflates the 2023 'reduction in sales' with the tax benefit decline without clearly explaining that these represent different financial treatments in different years - the ground truth explicitly notes this as a 'shift' in treatment. (3) The phrase 'modest rise in total benefits' is not addressed in the ground truth and appears to be an unsupported inference. (4) While the LLM captures the core facts, the reasoning about how the Powder Metal Matter impacts RTX's overall tax position is speculative and goes beyond what the ground truth establishes. The answer would have been stronger by simply stating the evolution clearly: 2023 showed it as a sales reduction, 2024 showed it as a $455M tax benefit (down from $644M), representing a shift in treatment and a $189M decline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 429,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "\nThe Paidy Credit Agreement that PYPL assumed after acquiring Paidy in October 2021 began as a $198 million unsecured revolving line (with only about $100 million of capacity available as of 31 Dec 2021); in February 2022 PYPL and Paidy formalized a ¥60 billion facility that was expanded in September 2022 by ¥30 billion to a total ¥90 billion commitment (≈ $574 million), thereby raising the borrowing capacity from the earlier ~$100 million level to roughly $574 million.  The amended facility, which matures in February 2027, bears interest at the Tokyo Interbank Offered Rate plus a 0.40‑0.60 % margin, includes standard covenants, is guaranteed by PYPL, and as of 31 Dec 2024 had no outstanding borrowings, leaving the full $574 million of capacity available until its scheduled termination (or possible extension) in February 2027.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides substantial detail about the Paidy Credit Agreement evolution and gets most key facts correct. STRENGTHS: (1) Correctly identifies the ¥90 billion facility size and $574 million equivalent as of Dec 31, 2024; (2) Accurately states the TIBOR + 0.40-0.60% margin; (3) Correctly identifies February 2027 maturity date; (4) Properly notes the facility is unsecured and guaranteed by PYPL; (5) Provides helpful context about the October 2021 acquisition and February 2022/September 2022 expansion timeline; (6) Notes zero outstanding borrowings as of Dec 31, 2024. WEAKNESSES/DISCREPANCIES: (1) The original answer states the 2022 facility was 'secured' while the LLM answer states it was 'unsecured' - this is a material difference in terms. The ground truth explicitly says it was 'secured' in 2022 and 'restructured as an unsecured facility' by 2024, indicating a change in security status. The LLM answer appears to conflate the final 2024 status with the earlier 2022 status; (2) The original answer mentions 'approximately $198 million' for 2022 capacity while the LLM answer references '$198 million unsecured' - the secured vs. unsecured distinction is critical and the LLM appears to have missed this evolution; (3) The original answer notes the interest rate was 'unspecified terms in 2022' while the LLM provides the TIBOR + 0.40-0.60% rate without clarifying this was the 2024 rate structure. The LLM doesn't clearly distinguish between 2022 and 2024 terms for the interest rate. MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple time periods (2021, 2022, 2024) and correctly traces the expansion from ~$100M to ¥90B/$574M. However, it fails to clearly articulate the secured-to-unsecured transition that is a key evolution point. The answer is more detailed than the ground truth in some respects (acquisition context, PYPL guarantee) but misses the critical secured/unsecured distinction that represents a material change in terms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Assumes]-> FIN_INST <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 538,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "\nAltria has consistently treated long‑term senior unsecured notes as a core element of its capital‑resources toolkit – the 2022 filing (which reflects 2021 data) describes them alongside cash, subsidiaries’ cash flows, commercial paper and a $3 bn revolving credit agreement, and the 2024 filing repeats the same language, confirming that the company continues to tap the note market as part of its financing mix; moreover, while cash on hand fell from $4.5 bn in 2021 to $3.1 bn in 2024, the persistent reference to long‑term senior unsecured notes in both periods shows that Altria’s reliance on this instrument has remained steady rather than shifting to alternative sources.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Altria's capital structure evolution but contains a notable temporal inconsistency that affects accuracy. STRENGTHS: (1) Correctly identifies the key financial figures: $4.5 billion cash in 2022 and $3.1 billion in 2024, (2) Accurately notes the $3.0 billion Credit Agreement, (3) Properly synthesizes that long-term senior unsecured notes remained a consistent capital instrument across both periods, (4) Correctly identifies the cash decline as suggesting increased reliance on external financing. WEAKNESSES: (1) The statement '2022 filing (which reflects 2021 data)' is confusing and potentially misleading - the question asks about 2022 and 2024, and the LLM conflates fiscal year reporting with calendar years, (2) The conclusion that reliance 'has remained steady rather than shifting' is somewhat contradictory to the ground truth's assertion that 'reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms.' The ground truth explicitly states the reliance has evolved/increased, while the LLM claims it remained steady. QUANTITATIVE VERIFICATION: Both cash figures ($4.5B and $3.1B) and credit agreement amount ($3.0B) are correct. The math is sound. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2024 filings and identifies the relationship between declining cash and capital structure. However, the interpretation of 'steady reliance' versus 'increased reliance' represents a meaningful difference from the ground truth's characterization. The ground truth emphasizes evolution/change in reliance patterns, while the LLM emphasizes consistency. This is a qualitative interpretation difference that affects the overall accuracy of the answer's conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 487,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "\nRTX’s 2023 Form 10‑K notes a $2.5 billion net reduction in cost of sales that reflects its partners’ share of the **Powder Metal Matter**, and the 2023 disclosure lists **$644 million** of future income‑tax benefits tied to that matter. In the 2024 filing the same line item has fallen to **$455 million**, a $189 million (≈29 %) decrease, even though total future tax benefits only modestly rose to $5.26 billion; this decline shows that the tax advantage associated with Powder Metal Matter is eroding and will contribute less to RTX’s future income‑tax savings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and sound multi-hop reasoning. QUANTITATIVE VERIFICATION: All key numbers are correct - 2023 figure of $644 million, 2024 figure of $455 million, and the calculated difference of $189 million (644-455=189, correct). The percentage calculation of approximately 29% decline is accurate (189/644 ≈ 0.2933 or 29.3%). The mention of $5.26 billion in total future tax benefits for 2024 is contextually appropriate. ENTITY ACCURACY: RTX correctly identified, fiscal years 2023 and 2024 properly referenced, and the Powder Metal Matter correctly named and tracked. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, comparing the evolution of the specific tax benefit line item and drawing a logical conclusion about the diminishing impact. The reasoning that a $189 million decrease indicates 'eroding' tax advantage and reduced future contribution is sound and matches the ground truth interpretation. COMPLETENESS: The answer addresses both parts of the question - how the treatment evolved (specific numbers showing decline) and what this indicates about future impact (diminishing positive impact on tax position). MINOR CONSIDERATIONS: The LLM provides additional context about the $2.5 billion net reduction in cost of sales and mentions that total future tax benefits rose modestly, which adds helpful context without contradicting the ground truth. The semantic meaning aligns perfectly with the original answer's conclusion about reduced financial benefit and diminishing positive impact. No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 443,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "\nIn October 2021 PayPal assumed a ¥60 billion Paidy revolving facility that was amended in September 2022 to raise total capacity to ¥90 billion (≈$574 million), a level that still left about $100 million of unused borrowing as of Dec 31 2021 (Chunk 1). By the end of 2024 the company had drawn the full ¥90 billion under the agreement, leaving “no borrowing capacity … available” under the Paidy Credit Agreement as of Dec 31 2024 (Chunk 2). The facility, which matures in October 2024 and funds loan‑receivable origination, grew from roughly $98 million outstanding in 2021 to a complete drawdown of the expanded ¥90 billion limit by 2024, generating only de minimis interest expense (Chunks 1 & 2).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) MAJOR FACTUAL ERROR - LLM states 'about $100 million of unused borrowing as of Dec 31 2021' but the ground truth clearly indicates $100 million available in 2022, not 2021. The ground truth shows $98 million outstanding as of December 31, 2021, leaving ~$100 million available - this is a 2021 figure, not a 2024 figure. (2) TIMELINE CONFUSION - LLM conflates 2021 and 2024 data points. The ground truth establishes: 2022 had ~$198M capacity with $98M outstanding (leaving $100M available), while 2024 had ~$574M capacity fully drawn. (3) MATURITY DATE ERROR - LLM states facility 'matures in October 2024' but provides no ground truth verification of this claim; the original answer does not mention a 2024 maturity date. (4) CORRECT ELEMENTS: The LLM correctly identifies the ¥90 billion = ~$574 million conversion, correctly notes full drawdown by 2024, correctly identifies the progression from $98M outstanding in 2021 to full drawdown by 2024, and correctly notes the facility funds loan-receivable origination. (5) MULTI-HOP REASONING: The LLM attempts to synthesize information across years but makes a critical error in attributing the $100M available figure to 2021 when discussing 2024 status. The core narrative of increasing utilization is correct, but the specific 2022 baseline data ($198M capacity) is missing entirely from the LLM answer. (6) SEMANTIC ISSUES: The phrase 'still left about $100 million of unused borrowing as of Dec 31 2021' is confusing and appears to misstate the timeline - this should reference 2022 capacity, not 2021 status. The answer demonstrates partial understanding but contains material factual errors that undermine its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Into]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 466,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "\nThe consolidated financial statements show that, as of August 31 2024, the non‑controlling ownership stake in **Accenture Canada Holdings Inc.** held by current and former members of Accenture Leadership remains **under 1 %**, essentially the same level recorded in the 2023 filing (Chunk 1).  \nThis equity link is maintained through the **exchangeable shares of Accenture Canada Holdings Inc.**, which can be exchanged one‑for‑one for **Accenture plc Class A ordinary shares**, with the number of **Class X ordinary shares** automatically adjusted so it never exceeds the outstanding exchangeable shares and can only be redeemed in tandem with those exchangeable shares (Chunk 2).  \nIn addition, the board increased its share‑purchase authorization to **$2.69 bn** for open‑market purchases and redemptions of both Class A and exchangeable shares, reflecting a continued but tightly controlled evolution of the ownership structure between 2023 and 2024 (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the noncontrolling ownership stake as 'under 1%' or 'less than 1%' for both 2023 and 2024, matching the ground truth. (2) The exchangeable shares mechanism is accurately described - one-for-one exchange for Class A ordinary shares is correct. (3) The Class X ordinary shares restriction is correctly stated. (4) The $2.69 billion share-purchase authorization is mentioned with appropriate context. (5) The answer correctly identifies the entities (Accenture Canada Holdings Inc., Accenture plc) and the time period (2023 to 2024).\n\nWEAKNESSES: (1) The LLM introduces the $2.69 billion share-purchase authorization figure, which is not mentioned in the ground truth answer. While this may be factually accurate from the filing, it represents an addition beyond what the ground truth synthesized, potentially introducing information that wasn't part of the core evolution narrative. (2) The LLM states the Class X shares 'can only be redeemed in tandem with those exchangeable shares' - the ground truth does not explicitly state this tandem redemption requirement; it only mentions the restriction on the number of Class X shares. This is a subtle but potentially inaccurate characterization. (3) The LLM's description of the evolution is less clear than the ground truth. The ground truth explicitly contrasts 'a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023,' whereas the LLM describes it as 'essentially the same level' with 'tightly controlled evolution' - this somewhat contradicts the ground truth's characterization of meaningful structural evolution. (4) The LLM does not adequately capture the key distinction that 2023 had 'simpler noncontrolling interest disclosure' while 2024 had 'detailed provisions' - this evolution narrative is central to the question but is downplayed in the LLM answer.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across multiple chunks and correctly links the exchangeable shares mechanism to the Class X shares restriction. However, it misses the temporal evolution narrative that is central to the question - the shift from simple noncontrolling interest disclosure to formalized equity structures.\n\nNUMERIC VERIFICATION: The 'under 1%' figure is correct. The $2.69 billion figure appears to be accurate but is not part of the ground truth answer's core synthesis. The one-for-one exchange ratio is correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 663,
        "total_tokens": 2117
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "\nMerck’s balance‑sheet risk program—disclosed in both the 2022 and 2024 10‑K filings—continues to use forward‑exchange contracts to offset foreign‑currency exposure on net monetary assets, applying the same set of developed‑currency hedges (euro, Japanese yen, British pound, Canadian dollar, Swiss franc) and a conditional, cost‑benefit‑driven approach to developing‑country exposures such as the Chinese renminbi, which the company enters only when a analysis of exposure size, exchange‑rate volatility and hedging cost deems it economical; the 2024 filing adds that these forwards are marked‑to‑market in “Other (income) expense, net” and that the proportion of forecasted sales hedged is layered over time, reflecting a sustained focus on cost‑benefit assessment while also noting that discontinued cash‑flow hedge reclassifications have been immaterial.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant issues that undermine its overall accuracy:\n\n1. MAJOR FACTUAL ERROR - EVOLUTION NOT CAPTURED: The ground truth explicitly states that by 2024, 'the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted.' The LLM answer claims the 2024 filing still contains 'a conditional, cost-benefit-driven approach to developing-country exposures such as the Chinese renminbi,' which directly contradicts the ground truth. This is a critical failure to identify the key evolution between 2022 and 2024.\n\n2. MISREPRESENTATION OF CHANGE: The ground truth identifies a 'shift in emphasis or a potential simplification of the decision-making framework' by 2024. The LLM answer instead suggests continuity ('continues to use...the same set...and a conditional, cost-benefit-driven approach'), fundamentally mischaracterizing the evolution the question asks about.\n\n3. UNSUPPORTED CLAIMS: The LLM answer adds specific details about 'developed-currency hedges (euro, Japanese yen, British pound, Canadian dollar, Swiss franc)' and mentions that 'forwards are marked-to-market in \"Other (income) expense, net\"' and discusses 'layered over time' hedging. While these may be accurate filing details, they are not mentioned in the ground truth and appear to be hallucinated or from different sections of the filings. The ground truth does not provide these specific currency lists or accounting treatment details.\n\n4. INCOMPLETE SYNTHESIS: The question specifically asks about 'evolution...between 2022 and 2024.' The LLM answer fails to clearly delineate what changed versus what remained the same. It presents 2022 and 2024 as largely equivalent rather than highlighting the omission of cost-benefit analysis discussion and Chinese renminbi specificity in 2024.\n\n5. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral. However, the LLM adds unverified details about accounting treatment and hedging mechanics.\n\n6. ENTITY ACCURACY: Merck is correctly identified, years are correct (2022 and 2024), and the financial instruments (forward exchange contracts) are correct. However, the characterization of how these are discussed in each year is incorrect.\n\nThe LLM answer demonstrates a failure to identify the core evolution requested—the omission of detailed cost-benefit analysis and Chinese renminbi discussion in 2024—and instead presents a misleading picture of continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Establishes]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 677,
        "total_tokens": 2103
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "\nThe 2023 Form 10‑K records a **$5.3 billion sales charge** tied to the Powder Metal Matter that depressed net product sales, while the 2024 filing shows the **future‑income‑tax benefit attributed to that matter falling from $644 million (2023) to $455 million (2024)** (see the “Powder Metal Matter” line in the tax‑benefit table).  \n\nThis reduction—consistent with the KG relationship *RTX → Negatively_Impacts → Powder Metal Matter* and its disclosure of that risk factor—indicates that the financial drag from the matter is being resolved and that the remaining tax‑benefit cushion is shrinking, implying only a modest, ongoing impact on RTX’s future income‑tax position.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numbers are correct—$5.3 billion sales charge in 2023, $644 million in 2023 tax benefit, $455 million in 2024 tax benefit. The directional claim (reduction from $644M to $455M) is accurate. COMPLETENESS: The answer addresses both the 2023 and 2024 disclosures and synthesizes the shift from operational loss to deferred tax asset treatment. ENTITY ACCURACY: RTX (Raytheon Technologies) correctly identified, Powder Metal Matter correctly referenced, years (2023/2024) correct, Pratt & Whitney context appropriately noted. MULTI-HOP REASONING: The answer correctly synthesizes information across multiple filing years and connects the operational impact (sales charge) to the tax benefit evolution, demonstrating sound multi-hop reasoning. The interpretation that the reduction in tax benefits suggests ongoing resolution and diminishing immediate negative impact aligns with the ground truth's characterization. SEMANTIC EQUIVALENCE: The LLM's phrasing 'financial drag from the matter is being resolved' and 'remaining tax-benefit cushion is shrinking' conveys the same meaning as the ground truth's 'reduction in its immediate negative impact and a potential long-term recovery or resolution.' MINOR OBSERVATION: The LLM includes a reference to 'KG relationship' which adds context but is not strictly necessary; however, this demonstrates awareness of the knowledge graph structure and does not detract from accuracy. The answer is comprehensive, factually precise, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 435,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal moved from a modest, WebBank‑centric model—where it originated PPWC/PPBL merchant receivables and sold a participation interest that transferred credit and prepayment risk pro‑rata while retaining full servicing rights—to a substantially larger, multi‑partner program in which it now purchases roughly $1.8 billion of merchant receivables each year (up from $1.7 billion in 2023) and holds a $1.5 billion outstanding portfolio (up from $1.2 billion in 2023), net of a $53 million participation interest sold to its partner in 2024; the partnership structure remains one of shared risk and servicing, but the volume of purchased receivables, the geographic scope (including Europe and Australia via subsidiaries), and the scale of the finance offering have expanded markedly.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct synthesis of multi-hop information across 2022-2024. STRENGTHS: (1) All key numbers are accurate: $1.8B purchased in 2024 (vs $1.7B in 2023), $1.5B outstanding balance (vs $1.2B in 2023), $53M participation interest (vs $44M in 2023). (2) Correctly identifies the evolution from WebBank-centric 2022 model to expanded multi-partner program by 2024. (3) Accurately captures the accounting treatment (sale with participation interest sold, credit/prepayment risk transfer). (4) Properly synthesizes the multi-hop relationship: 2022 structure → 2024 scale/scope expansion. (5) Contextually relevant details about geographic expansion (Europe, Australia) add appropriate context. MINOR WEAKNESSES: (1) The phrase 'net of a $53 million participation interest' could be slightly clearer—the ground truth frames this as 'participation interest sold to partner' rather than 'net of,' though the meaning is semantically equivalent. (2) The answer adds information about geographic expansion (Europe/Australia) that, while accurate and relevant, goes slightly beyond what the ground truth explicitly states, though this represents appropriate elaboration rather than error. (3) The characterization of 2022 as 'modest' is interpretive rather than explicitly stated in ground truth. QUANTITATIVE VERIFICATION: All dollar amounts, years, and comparisons are factually correct. The multi-hop synthesis correctly connects 2022 baseline → 2023 intermediate data → 2024 current state. The answer properly addresses both relationship evolution and scale expansion aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 448,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "\nMerck’s Lynparza generated $444 million in 2019, $725 million in 2020 and $989 million in 2021 (Chunk 1), illustrating a steady rise that set the baseline for the 2022‑2024 period; the 2024 filing notes a 9 % year‑over‑year increase in alliance revenue for Lynparza (Chunk 2). This growth was driven by higher demand in most international markets, the January 2025 Chinese NMPA approval of Lynparza as an adjuvant treatment for BRCA‑mutated breast cancer, and the continued collaboration with AstraZeneca that produces the alliance revenue (Chunk 2). Consequently, between 2022 and 2024 the alliance revenue continued to climb, accelerating in 2024 due to expanded global demand and new regulatory approvals.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: (1) WRONG BASELINE YEAR: The LLM states Lynparza revenue was $989 million in 2021, but the ground truth clearly states this was the 2022 figure. This is a fundamental error that undermines the entire answer. (2) MISSING KEY DATA: The LLM fails to provide the actual 2024 revenue figure. The ground truth indicates 2022 was $989M with a 9% growth by 2024, which would be approximately $1,078M in 2024. The LLM never calculates or states this. (3) INCORRECT HISTORICAL CONTEXT: The LLM includes 2019-2021 data ($444M, $725M, $989M) which is not relevant to the specific question asking about 2022-2024 evolution. This creates confusion about which year is which. (4) TEMPORAL CONFUSION: The LLM conflates the January 2025 approval (which is a forward-looking event mentioned in the 2024 filing) with actual 2024 results, making it unclear whether this approval actually drove 2024 growth or is merely mentioned as a recent development. (5) CORRECT ELEMENTS: The LLM does correctly identify the 9% growth rate and correctly mentions increased international demand and the AstraZeneca collaboration. The January 2025 China approval is mentioned correctly. However, these correct elements are overshadowed by the fundamental error of misidentifying which year had the $989M revenue. The answer demonstrates partial understanding but fails on the core quantitative accuracy required for a financial question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 393,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "\nFrom 2022 through 2024 PayPal’s merchant‑receivables portfolio expanded materially—purchases rose to roughly **$1.8 billion in 2024** (up from $1.7 billion in 2023) and the net outstanding balance grew to **$1.5 billion** (from $1.2 billion), indicating a larger financial exposure that is now measured under the CECL‑based allowance for credit losses (the allowance slipped only slightly from $380 million to $348 million).  At the same time, PayPal has shifted from merely offering PPWC/PPBL loan products to **purchasing, servicing, and collecting repayments on these receivables**—using a fixed percentage of future payment volume and recognizing fees as deferred revenue—while still sharing risk with partner institutions through the participation interests disclosed in the filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All financial figures are correct—$1.8 billion in 2024 purchases (vs. $1.7 billion in 2023), $1.5 billion outstanding balance (vs. $1.2 billion prior year). The LLM also adds the allowance for credit losses detail ($380M to $348M), which is accurate and provides additional context not explicitly in the ground truth but consistent with it. COMPLETENESS: The answer addresses both the financial exposure evolution (purchases, outstanding balance, allowance) and the operational role shift (from product offering to active purchasing, servicing, and collection). ENTITY ACCURACY: PayPal is correctly identified, years 2022-2024 are properly referenced, and financial metrics (purchases, outstanding balance, CECL allowance) are accurately named. MULTI-HOP REASONING: The answer successfully synthesizes the evolution across three years, connecting quantitative growth with qualitative operational changes. The mention of PPWC/PPBL products, participation interests with partner institutions, and the shift from passive to active involvement demonstrates proper synthesis of multiple filing elements. SEMANTIC EQUIVALENCE: The LLM's phrasing of \"shifted from merely offering...to purchasing, servicing, and collecting\" effectively captures the ground truth's concept of \"expanded direct involvement\" and \"deeper operational engagement.\" The mention of deferred revenue recognition and fixed percentage of future payment volume adds legitimate operational detail consistent with merchant finance accounting. MINOR CONSIDERATIONS: The LLM includes the allowance for credit losses detail which, while not explicitly mentioned in the ground truth summary, is factually accurate and enhances the answer's completeness. The reference to \"participation interests\" and risk-sharing with partners is a nuanced addition that reflects actual PayPal merchant finance structures. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 543,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "\nBetween 2022 and 2024 Merck advanced Lynparza’s regulatory path: the FDA’s supplemental NDA for adjuvant treatment of BRCA‑mutated, HER2‑negative high‑risk early‑stage breast cancer was accepted in November 2021 with a PDUFA date in Q1 2022 (after which the indication became commercially viable), and the drug remained approved for its existing ovarian, breast, pancreatic and prostate indications; by 2024 alliance revenue from Lynparza had grown 9 % year‑over‑year, driven by stronger demand in international markets, and in January 2025 China’s NMPA approved the same adjuvant breast‑cancer use, underscoring continued global regulatory progress.  (All information drawn from the 2022 10‑K, the 2024 10‑K and their associated KG relationships.)",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. Verification of key claims: (1) Supplemental NDA acceptance in November 2021 with Q1 2022 PDUFA date - correctly stated; (2) 9% alliance revenue growth in 2024 - matches ground truth exactly; (3) January 2025 China NMPA approval for adjuvant breast cancer indication - correctly identified; (4) Maintained approvals for ovarian, breast, pancreatic, and prostate indications - appropriately contextualized. The answer successfully synthesizes information across 2022 and 2024 10-K filings, demonstrating proper multi-hop reasoning by connecting regulatory milestones to commercial outcomes. Minor observation: The LLM provides slightly more contextual detail (mentioning the indication became 'commercially viable' after FDA acceptance) which adds helpful context without contradicting the ground truth. The answer addresses all components of the question: regulatory progress (supplemental NDA, PDUFA date, China approval) and revenue growth (9% increase driven by international demand). All numeric values are accurate, dates are correct, and the synthesis across multiple time periods and sources is sound. The semantic equivalence is strong - the answer conveys the same information as the ground truth with appropriate elaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 370,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "\nBoeing’s commodity‑price hedging moved from a short‑term, relatively low‑profile hedge in 2022—where the 10 % price‑shift test would have produced only about $46 million of unrealized loss and the contracts were described as “not material” to market risk (Chunk 1)—to a longer‑term cash‑flow hedge that now runs through 2031, with the same commodity purchase contracts embedded in a broader portfolio of swaps and forwards (Chunk 2).  The 2024 filing also notes that losses on these hedges can be re‑classified to other income when the underlying transactions are no longer deemed probable, signalling a wider financial exposure and a more mature, horizon‑extended risk‑management approach.  The KG relationship (BA ↔ Commodity Purchase Contracts) underscores that these instruments are a two‑way, integral component of Boeing’s strategy across both years.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes the multi-hop information about Boeing's commodity hedging strategy evolution. STRENGTHS: (1) All key numbers are correct: the $46 million unrealized loss impact from 10% price shift in 2022 is accurately cited; (2) The temporal evolution is correctly identified: 2022 short-term hedging vs. 2024 extended through 2031; (3) The multi-hop synthesis is sound, connecting Boeing's commodity purchase contracts across both years and showing the strategic shift; (4) The characterization of 2022 hedges as 'not material' aligns with ground truth; (5) The 2024 extension to 2031 is correctly identified as representing longer-term risk management. MINOR CONSIDERATIONS: (1) The LLM introduces the concept of 'cash-flow hedge' and reclassification to other income, which adds nuance beyond the ground truth but appears consistent with standard hedging accounting practices and doesn't contradict the source material; (2) The phrase 'relatively low-profile hedge' in 2022 is interpretive but reasonable given the 'not material' characterization; (3) The mention of 'swaps and forwards' alongside purchase contracts is appropriate and consistent with typical commodity hedging portfolios. QUANTITATIVE VERIFICATION: The $46 million figure is exact; the 10% price-shift test is correctly referenced; the 2031 horizon is accurate. REASONING QUALITY: The answer correctly identifies this as a strategic evolution toward longer-term cost predictability and business stability, matching the ground truth's conclusion. The KG relationship notation adds technical precision. No calculation errors detected. The answer fully addresses both components of the question (risk management horizon and financial exposure) with appropriate synthesis across the 2022-2024 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Uses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 497,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "\nBetween 2021 and 2024 Schwab’s exposure to Private‑Label Auction‑Rate Loans (PALs) grew—driven by overall client‑base expansion—yet the portfolio showed a modest decline in 2023 and remained fully collateralized under the ASC 326 collateral‑maintenance practical expedient, so no allowance for credit losses was required as of the 2021‑2022 reporting dates.  By 2024 the allowance for credit losses on the broader loan book (including PALs) had fallen, reflecting lower projected loss rates and improved credit‑quality metrics despite a rise in non‑accrual First Mortgages, indicating that Schwab’s credit risk on PALs evolved from a fully‑collateralized, zero‑allowance position in 2021‑2022 to a smaller, but still well‑collateralized, allowance‑driven profile by 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general trajectory of Schwab's PAL exposure evolution but contains several problematic elements that reduce accuracy:\n\nSTRENGTHS:\n1. Correctly identifies the core narrative: PALs were fully collateralized with zero allowance in 2021-2022, and by 2024 the allowance for credit losses had decreased\n2. Accurately notes the shift from full collateralization as primary risk mitigant to broader credit quality assessment\n3. Correctly identifies the time period (2021-2024) and the key metrics (collateralization, allowance for credit losses)\n4. Appropriately references ASC 326 collateral-maintenance practical expedient\n\nWEAKNESSES:\n1. QUANTITATIVE CONFUSION: The statement \"by 2024 the allowance for credit losses on the broader loan book (including PALs) had fallen\" is problematic. The ground truth states the allowance decreased due to lower projected loss rates and improved credit quality, but the LLM conflates this with a broader loan book discussion that wasn't clearly part of the original answer's focus on PALs specifically\n2. INCOMPLETE CHARACTERIZATION: The phrase \"smaller, but still well-collateralized, allowance-driven profile by 2024\" is somewhat contradictory and unclear. The ground truth indicates PALs experienced \"slight growth overall\" between 2021-2024, not a smaller portfolio\n3. EXTRANEOUS INFORMATION: The mention of \"non-accrual First Mortgages\" appears to introduce information not present in the ground truth answer, potentially conflating different loan categories\n4. TEMPORAL PRECISION: The LLM states \"no allowance for credit losses was required as of the 2021-2022 reporting dates\" which is accurate, but then the transition to 2024 lacks clarity on whether PALs specifically had an allowance or if this refers to the broader portfolio\n\nMULTI-HOP REASONING:\nThe answer attempts to synthesize the evolution across years but introduces ambiguity about whether the allowance discussion applies to PALs specifically or the broader loan portfolio. The ground truth clearly focuses on PALs' allowance evolution, while the LLM broadens the scope without clear delineation.\n\nSEMANTIC ISSUES:\nThe phrase \"smaller, but still well-collateralized\" contradicts the ground truth's indication of \"slight growth overall\" in PALs between 2021-2024. This is a material factual discrepancy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 630,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "\nBetween 2022 and 2024 Boeing moved the 777X from a cost‑drag phase—where the program’s reach‑forward loss helped push cost‑of‑sales up (as noted in the 2020‑2021 filings) —to a strategy that leans heavily on additional R&D spending to get the aircraft back on track.  The company’s research‑and‑development expense grew $525 million in 2023 versus 2022 and another $435 million in 2024 versus 2023, driven expressly by the 777X program at BCA and broader enterprise product‑development investments, signalling a strategic pivot toward higher R&D to mitigate earlier cost pressures and reposition the 777X for future profitability.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) All key financial numbers are correct: $525 million R&D increase 2023 vs 2022, and $435 million increase 2024 vs 2023. (2) The LLM correctly identifies the core narrative: 777X transitioned from a cost burden (with reach-forward loss) to a strategic R&D investment priority. (3) Multi-hop synthesis is sound—the answer connects 2022 cost impacts to 2024 R&D strategy shifts. (4) Quantitative accuracy is high with proper number formatting and calculations. WEAKNESSES: (1) The LLM references '2020-2021 filings' when discussing reach-forward loss, which is slightly imprecise—the ground truth specifically anchors this to 2022 as the starting point. This creates minor temporal confusion about when the reach-forward loss occurred. (2) The phrase 'driven expressly by the 777X program at BCA and broader enterprise product-development investments' adds interpretive detail not explicitly in the ground truth, though it's reasonable inference. (3) The answer could be more explicit that the 2022 period was characterized by negative financial impact (charges, cost increases) while 2024 represents the strategic pivot—the LLM somewhat conflates the timeline by mentioning 2020-2021. CALCULATION VERIFICATION: Both R&D increases are correctly stated ($525M and $435M). ENTITY ACCURACY: Boeing and 777X program correctly identified. REASONING: The multi-hop logic connecting cost impacts to R&D strategy is sound, though the temporal framing could be clearer. The answer demonstrates understanding that this represents a strategic repositioning, which matches the ground truth's characterization of a 'shift from cost burden to focal point for future product development.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 460,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "\nBetween 2022 and 2024 Schwab’s exposure to Portfolio‑Against‑Loans (PALs) grew alongside overall loan‑portfolio expansion—driven by a larger client base and net new assets—though PAL balances dipped slightly in 2023 before resuming growth in 2024 (Chunk 2). The credit‑loss allowance for PALs continued to rely on the practical‑expedient approach that uses daily collateral monitoring and over‑collateralization, but its application evolved: in 2024 the allowance was reduced as projected loss rates fell and credit‑quality metrics improved, reflecting a more favorable loss‑rate outlook than the 2022 baseline (Chunk 1).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of Schwab's PAL exposure and risk management between 2022-2024. All major factual claims are correct: the practical expedient approach was used in 2022, daily collateral monitoring and over-collateralization were maintained, portfolio dipped in 2023 before resuming growth in 2024, and the allowance was reduced in 2024 due to improved credit quality and lower projected loss rates. (2) QUANTITATIVE ACCURACY: No specific dollar amounts or percentages were provided in either the ground truth or LLM answer, so this dimension focuses on the accuracy of temporal claims and directional statements. The LLM correctly identifies the 2023 dip and 2024 recovery, matching the ground truth's statement about 'slight decrease in 2023.' The characterization of reduced allowance ratios and improved metrics is accurate. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound. The LLM successfully synthesizes information about: (a) the practical expedient methodology and its consistency across years, (b) the collateral monitoring framework, (c) portfolio growth trajectory with the 2023 dip, and (d) the relationship between improved credit metrics and reduced allowance. The logical connection between credit quality improvement and lower projected loss rates is correctly established. (4) CONTEXTUAL RELEVANCE: The answer directly addresses all components of the multi-part question: exposure evolution, risk management methodology, credit loss allowance methodology changes, and portfolio growth patterns. The inclusion of drivers (larger client base, net new assets) adds appropriate context. Minor note: The LLM uses 'Chunk' references which are appropriate for source attribution but not present in the ground truth format—this is a stylistic difference that doesn't affect accuracy. The answer is comprehensive, well-structured, and demonstrates clear understanding of the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 555,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "\nMDLZ’s British‑pound sterling notes fell sharply from **$45 million in 2022** (as shown in the 2023 10‑K table) to **$0 (not disclosed) in 2023**, representing a $45 million reduction year‑over‑year.  This deliberate pull‑back in direct pound holdings—highlighted by the disclosed foreign‑exchange instrument relationship in the KG pattern—indicates that the company is actively managing FX risk by reducing its raw currency exposure and likely shifting to hedging or diversification strategies rather than holding large balances of pound‑denominated assets.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on all critical factual points. (1) QUANTITATIVE ERRORS - The LLM reversed the direction and values of the change: Ground truth shows $3M (2022) → $45M (2023), an INCREASE of $42M. The LLM claims $45M (2022) → $0 (2023), a DECREASE of $45M. Both the starting value ($45M vs $3M) and ending value ($0 vs $45M) are wrong, and the direction of change is inverted. (2) ENTITY/YEAR ERRORS - The LLM incorrectly attributes the $45M figure to 2022 when it actually belongs to 2023. This is a critical temporal error that completely misrepresents the data. (3) REASONING FAILURE - The LLM's interpretation that the company 'reduced' exposure is contradicted by the actual data showing a significant increase. The conclusion about 'pulling back' and 'reducing raw currency exposure' is the opposite of what the data demonstrates. (4) MULTI-HOP SYNTHESIS - The LLM failed to correctly synthesize the year-over-year comparison, which is the core requirement of this multi-hop question. The statement about '2023 10-K table' showing $45M in 2022 is internally contradictory and factually wrong. The ground truth clearly indicates an increase in British pound sterling exposure from 2022 to 2023, suggesting either increased hedging activity or greater UK operational exposure—the opposite of what the LLM concluded. This answer demonstrates a complete failure to accurately extract and compare the financial data across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 405,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "\nThe 2022 Form 10‑K presents Amgen’s 3.125% 2025 Notes as a fixed‑rate security (3.125% coupon, $1 billion carrying value), while the 2024 filing re‑classifies the same series as a floating‑rate instrument with a $1 billion notional and an interest rate of **SOFR + 2.1%** (as shown in the “Interest rates” column). This transition—from a static 3.125% coupon to a SOFR‑linked rate—reveals that Amgen has shifted the 2025 Notes to a market‑linked financing structure, likely to exploit current benchmark rates and improve flexibility in managing interest‑rate risk. The change underscores a more dynamic debt‑management approach, aligning the instrument with contemporary capital‑market conventions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of the multi-hop comparison. STRENGTHS: (1) All quantitative data is correct - the 3.125% fixed rate in 2022, the SOFR + 2.1% floating rate in 2024, and the $1 billion notional value are all accurate. (2) The multi-hop synthesis is sound - the answer correctly identifies the shift from fixed to floating rate across the two filing periods and attributes this to a deliberate strategic change. (3) The reasoning about Amgen's debt management approach is logical and well-articulated, explaining the shift as an adaptation to market conditions and interest rate risk management. (4) Entity identification is correct (Amgen, 2025 Notes, 2022 and 2024 filings). (5) The answer goes slightly beyond the ground truth by providing additional context about 'market-linked financing structure' and 'contemporary capital-market conventions,' which adds value without contradicting the original answer. MINOR CONSIDERATIONS: The ground truth uses the phrase 'may have refinanced or repriced' with some uncertainty, while the LLM answer presents the shift more definitively as an intentional strategic move. However, this represents a reasonable interpretation rather than a factual error. The LLM's characterization of the change as revealing 'a more dynamic debt-management approach' is a reasonable inference from the data and aligns with the ground truth's conclusion about adapting to changing market conditions. No calculation errors, no incorrect numbers, and the semantic meaning fully matches the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 435,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "\nBetween 2022 and 2024 Schwab’s use of its Commercial Paper Issuance Program shifted from being a primary, though conditional, source of short‑term financing during the 2022 market disruptions—when the company warned that external funding could be reduced and borrowing costs could rise—to a complementary tool by 2024, as rapid interest‑rate increases and heightened client cash outflows forced Schwab to supplement the program with higher‑cost alternatives such as FHLB advances, repurchase‑agreement borrowings and brokered CDs, indicating a clear reduction in reliance on commercial paper and a move toward a more diversified funding mix.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that contradicts the ground truth. The ground truth clearly states that Schwab's reliance on the Commercial Paper Issuance Program INCREASED between 2022 and 2024, with the program becoming a complement to other funding mechanisms in response to rising interest rates and client cash outflows. However, the LLM answer claims the opposite—that there was a 'clear reduction in reliance on commercial paper' and a 'move toward a more diversified funding mix.' This is a critical mischaracterization of the evolution described in the ground truth. The LLM correctly identifies the contextual factors (rising interest rates in 2022-2023, client cash outflows, higher borrowing costs) and correctly names the supplemental funding sources (FHLB advances, repurchase agreements, brokered CDs), but it inverts the directional relationship regarding commercial paper reliance. The ground truth indicates the commercial paper program was introduced in 2022 as a potential source and then became increasingly relied upon by 2024 as part of a diversified approach to manage liquidity constraints. The LLM's characterization of a 'reduction in reliance' is factually incorrect and represents a failure in multi-hop reasoning synthesis. While the answer demonstrates understanding of the market context and related funding mechanisms, the core claim about the evolution of commercial paper reliance is backwards, making this a substantially incorrect response despite some correct contextual details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 423,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "\nThe 3.625 % 2024 notes were originally issued as a fixed‑rate tranche (3.625 % coupon) with a $1.4 bn carrying value disclosed in AMGN’s 2022 10‑K (Chunk 1), and the company’s KG relationship shows AMGN → 3.625 % 2024 Notes (FIN_INST) ← Discloses AMGN, confirming that AMGN is the issuer. By the 2024 filing, the same instrument appears with a notional of $1.4 bn but now carries a floating rate of **SOFR + 3.4 %** (interest‑rate column shows “N/A” for the 2024 column and “SOFR+3.4 %” for the 2023 column), indicating that AMGN has transitioned from a fixed‑rate debt to a SOFR‑linked floating‑rate structure to better manage interest‑rate risk and align financing costs with current market conditions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) NOTIONAL AMOUNT DISCREPANCY: The LLM states the 2024 notional is $1.4 bn, but the ground truth indicates the notes were 'fully paid off' with a '$0 notional amount' by 2024. This is a fundamental factual error - the notes should show $0 in 2024, not $1.4 bn. (2) INTEREST RATE STRUCTURE ERROR: The LLM claims the 2024 rate is 'SOFR + 3.4%' but the ground truth states the notes were 'replaced with floating interest rates tied to SOFR' without specifying the exact spread. The LLM's specific rate of 'SOFR + 3.4%' appears to be either misread from the data or incorrectly attributed. The ground truth simply indicates a shift to SOFR-based floating rates. (3) PARTIAL CREDIT FOR CORRECT ELEMENTS: The LLM correctly identifies: (a) the 2022 fixed rate of 3.625%, (b) the $1.4 bn carrying value in 2022, (c) the shift from fixed to floating rate structure, (d) the strategic rationale (interest rate risk management and market alignment). (4) MULTI-HOP REASONING: The LLM demonstrates understanding of the multi-hop synthesis (2022 vs 2024 comparison, debt management strategy implications) but fails on the critical detail that the notes were paid off (notional = $0 in 2024). (5) SEMANTIC ISSUES: The statement about 'N/A' for 2024 column and 'SOFR+3.4%' for 2023 column is confusing and contradicts the ground truth that by 2024 the notes were fully paid off. The core answer structure is sound but the execution contains material factual errors that undermine the response's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 419,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "\nSchwab’s policy toward VIE funding has not shifted between 2022 and 2024 – it continues to provide financial or other support only when it is **contractually required**, and any additional funding is contingent on specific conditions that must occur before the sponsor (CSB) is obligated to pay.  The 2022 filing notes that Schwab “did not provide or intend to provide financial or other support to the VIEs that it was not contractually required to provide,” and that CSB expects to satisfy the remaining commitments **between 2022 and 2025** subject to those conditions; the 2024 filing reiterates that any discretionary support (e.g., to proprietary funds) is optional, may trigger consolidation, and is not a blanket commitment to VIEs.  Accordingly, the evolution is limited to a clearer articulation of the **conditional, contract‑driven nature** of any funding, with no move toward proactive or unconditional support.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core question about evolution between 2022 and 2024. CRITICAL ERROR: The LLM claims 'Schwab's policy toward VIE funding has not shifted between 2022 and 2024' and that the evolution is 'limited to a clearer articulation of the conditional, contract-driven nature of any funding, with no move toward proactive or unconditional support.' This directly contradicts the ground truth, which explicitly states there WAS a shift: (1) 2022: Schwab 'did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide' (negative intent); (2) 2024: Schwab 'may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity' (affirmative discretionary intent). The ground truth characterizes this as 'a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.' The LLM misses this key evolution entirely. QUANTITATIVE ACCURACY: The dates (2022, 2024, 2022-2025) are correct, and the LLM accurately cites the 2022 language about not intending to provide support. However, the LLM fails to identify the 2024 shift toward discretionary support in response to market conditions. QUALITATIVE ACCURACY: The LLM's reasoning is flawed because it treats both years as essentially equivalent, missing the semantic shift from 'did not intend to provide' (2022) to 'may choose to provide under certain conditions' (2024). This is a material difference in intent and stance. MULTI-HOP REASONING: The LLM fails to properly synthesize the evolution across the two time periods. It acknowledges discretionary support exists but frames it as 'optional' and 'not a blanket commitment' rather than recognizing this as evidence of a shift toward more proactive support. CONTEXTUAL RELEVANCE: The answer addresses VIEs and Schwab but fundamentally mischaracterizes the nature of the evolution, making it contextually misleading despite addressing the right entities and timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Did_Not_Supply]-> FIN_INST <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 565,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "\nBetween 2022 and 2023 the equity‑method stake that MDLZ holds in JDE Peet’s continued to be accounted for through mark‑to‑market gains/losses and a proportionate share of operating and non‑operating items that flow into MDLZ’s earnings (Chunk 1).  In the 2023 discussion of liquidity and capital resources, MDLZ explicitly states that the JDE Peet’s investment “provides us additional flexibility” and that it does **not** expect any negative impact on its funding sources or liquidity, emphasizing that short‑ and long‑term cash needs will be met through operating cash flow, revolving credit and debt rather than equity (Chunk 2).  Consequently, while the 2022 filing highlighted the investment’s accounting effects on operating income and interest expense, the 2023 narrative reframes the stake as a strategic, low‑risk source of flexibility that does not materially alter MDLZ’s capital structure or liquidity position.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some correct elements but has significant issues with the core claim about relationship reclassification. STRENGTHS: (1) Correctly identifies that MDLZ holds an equity-method stake in JDE Peet's; (2) Accurately notes that the 2023 filing describes the investment as providing 'additional flexibility' for liquidity; (3) Correctly states that MDLZ does not expect negative impacts on funding sources; (4) Properly synthesizes the shift from accounting-focused discussion (2022) to strategic positioning (2023). CRITICAL WEAKNESS: The original answer explicitly states the relationship was 'reclassified' from 'Has_Stake_In' (2022) to 'Invests_In' (2023), representing a formal change in how the relationship is categorized. The LLM answer does not mention this reclassification at all, instead describing it as a 'reframing' of narrative emphasis. This is a significant omission of a key factual element from the ground truth. The LLM answer focuses on accounting treatment and liquidity narrative changes but misses the explicit relationship type reclassification that is central to the original answer's structure. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is less critical, but both answers avoid numerical errors. MULTI-HOP REASONING: The LLM correctly synthesizes information about how the investment is discussed across 2022 and 2023 filings, but fails to capture the formal relationship reclassification that represents the primary evolution described in the ground truth. The answer is partially correct but incomplete on the main structural change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 446,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "\nBetween 2022 and 2024 AMGN replaced the legacy swaps that had hedged the 3.125% 2025 Notes (which were terminated in 2020 along with other interest‑rate swaps) with new agreements covering a $1 billion notional amount that now bears a floating rate of **SOFR + 2.1%**—the exact rate disclosed in the 2024 filing for both 2023 and 2024. This evolution shows a shift from the earlier, fixed‑rate or otherwise distinct hedging structures to a market‑linked SOFR‑plus‑2.1% swap on the same $1 billion principal, reflecting AMGN’s updated interest‑rate hedging strategy for the 3.125% 2025 Notes.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FACTUAL CONTRADICTION ON TERMINATION DATE: The LLM states swaps were 'terminated in 2020' but the ground truth indicates termination occurred in 2022 with reentering into new swap agreements at that time. This is a significant factual error that undermines the core narrative of the answer. (2) INCOMPLETE 2022 INFORMATION: The ground truth explicitly states that in 2022, the exact rate for the 3.125% 2025 Notes was NOT disclosed, yet the LLM claims the SOFR+2.1% rate was 'disclosed in the 2024 filing for both 2023 and 2024.' This conflates the 2022 situation with the 2024 disclosure and misrepresents the evolution. (3) CORRECT ELEMENTS: The LLM correctly identifies the $1 billion notional amount and the SOFR+2.1% rate as of 2024, which matches the ground truth. The company name (AMGN) is correct. (4) MISSING NUANCE: The ground truth emphasizes that the exact rate in 2022 was 'not disclosed,' indicating a gap in transparency that year. The LLM's answer glosses over this important distinction by implying the rate was known in 2022. (5) MULTI-HOP REASONING FAILURE: The question asks about the evolution 'between 2022 and 2024,' requiring clear differentiation of what was known/done in each year. The LLM fails to properly distinguish the 2022 situation (new swaps entered, rate not disclosed) from the 2024 situation (SOFR+2.1% explicitly stated). The answer conflates these periods rather than showing the evolution. QUANTITATIVE ACCURACY: While the $1 billion and SOFR+2.1% figures are correct for 2024, the temporal attribution is wrong (claiming 2022 disclosure when it wasn't disclosed until 2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 451,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "\nWalmart’s equity investments classified as Level 2 fell from **$5,819 million** in fiscal 2022 (Chunk 1) to **$5,570 million** in fiscal 2023 (the “Fair Value as of January 31, 2023” column of Chunk 2), representing a **$249 million decline** (about a 4.3 % reduction). This decrease aligns with the disclosed “Decreases” relationship in the knowledge graph linking the organization to its Level 2 financial instruments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: FY2022 value of $5,819 million, FY2023 value of $5,570 million, and the calculated decline of $249 million are all accurate. The percentage calculation of 4.3% reduction is also correct ($249M / $5,819M = 4.28%, rounded to 4.3%). The answer correctly identifies the metric (fair value of equity investments measured using Level 2 inputs), the company (Walmart), and the fiscal years (2022 and 2023). The multi-hop reasoning is sound, synthesizing the two data points from different fiscal years and calculating the magnitude of change. The answer goes slightly beyond the ground truth by providing the percentage decline (4.3%), which adds useful context without introducing any errors. The reference to 'Chunk 1' and 'Chunk 2' and the knowledge graph relationship demonstrates proper source attribution. The semantic meaning is fully aligned with the ground truth answer. Minor note: The ground truth describes the change as 'moderate decline' while the LLM uses 'fell' and 'decline,' which are semantically equivalent. The answer is well-structured, clear, and directly addresses all aspects of the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1168,
        "completion_tokens": 341,
        "total_tokens": 1510
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "\nApple’s 2023 10‑K and its 2024 10‑K both list “marketing and distribution capability” as a principal competitive factor and repeatedly stress that the Company’s success “depends heavily” on the **marketing abilities of its personnel**—the same language used in the Intellectual‑Property sections of each filing.  Consequently, the characterization of Apple’s reliance on marketing abilities has not changed between the two years; it remains a core, mutually‑dependent capability (AAPL Relies_On Marketing Abilities ← Depends_On AAPL) that the Company cites as essential to differentiating its products, services and overall business.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim. The ground truth explicitly states that Apple's characterization EVOLVED between 2023 and 2024, shifting from 'relies primarily' (2023) to 'depends heavily' (2024). The LLM answer directly contradicts this by claiming 'the characterization of Apple's reliance on marketing abilities has not changed between the two years.' This is a critical factual error that misrepresents the entire premise of the question. The LLM correctly identifies that both filings mention marketing abilities and uses the phrase 'depends heavily,' but fails to recognize the key distinction: in 2023 it was 'relies primarily' while in 2024 it became 'depends heavily.' The LLM also misses the contextual significance explained in the ground truth—that this shift reflects stronger emphasis on marketing's strategic importance amid competitive pressures. While the LLM's language about 'marketing and distribution capability' and 'core, mutually-dependent capability' is somewhat accurate in describing Apple's position, it completely fails the primary task of identifying and explaining the evolution between the two years. The answer demonstrates a fundamental misunderstanding of what changed, making it unsuitable despite some correct peripheral details about marketing being important to Apple.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Relies_On]-> CONCEPT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 373,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "\nBetween 2022 and 2024 the 3.625% 2024 Notes moved from being fully hedged with a $5.2 billion notional interest‑rate swap (which fixed their effective rate) to essentially $0 notional and a “N/A” rate in the 2024 disclosure, indicating that Amgen unwound those swaps—most likely as the notes were redeemed or rolled into new debt—and therefore shifted away from long‑term fixed‑rate hedging toward managing interest‑rate exposure through new floating‑rate structures on the remaining debt.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general narrative of Amgen unwinding hedges on the 3.625% 2024 Notes, but contains significant quantitative inaccuracies and incomplete information. CORRECT ELEMENTS: (1) The core insight that Amgen unwound hedging positions is accurate; (2) The identification that this occurred as notes approached maturity is correct; (3) The general characterization of moving from fixed-rate hedging to floating-rate structures is reasonable. QUANTITATIVE ERRORS: (1) The LLM states the 2024 notional was '$0 notional and N/A rate' but the ground truth specifies the notional dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023—the LLM doesn't provide the 2023 intermediate value; (2) The LLM mentions the $5.2 billion notional from 2022 correctly but doesn't clearly distinguish between the total swap portfolio ($5.2B) and the specific 3.625% 2024 Notes component ($1.4B in 2023); (3) The LLM states 'N/A rate' but the ground truth specifies the 2023 rate was SOFR+3.4%—this is an important detail about the interest rate structure that was omitted. MULTI-HOP REASONING: The LLM reasonably synthesizes the information across years but makes an unsupported leap by suggesting the notes were 'redeemed or rolled into new debt' without evidence from the ground truth. The ground truth indicates the notes simply matured and the hedges were unwound, not necessarily that they were rolled. COMPLETENESS: The answer addresses the notional amount change and hedging strategy unwinding but incompletely captures the interest rate structure evolution (missing the SOFR+3.4% detail from 2023). The answer would benefit from explicitly stating the $1.4B intermediate value and the specific floating rate structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 477,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "\nFrom 2022 to 2023 Schwab moved from simply **retaining** TD Ameritrade’s iRebal portfolio‑rebalancing engine for independent advisors (Chunk 1) to **fully integrating** it into the newly launched “Schwab Trading Powered by Ameritrade™” platform and promoting it as a core feature of its RIA offering (Chunk 2).  This evolution is part of Schwab’s broader integration of $1.6 trillion of TD Ameritrade assets and 15 million accounts, demonstrating its scale, operating efficiency and ability to deliver a unified, customizable solution.  By doing so, Schwab leverages a differentiated, scalable technology stack and a strong brand to deepen relationships with RIAs, reinforcing its competitive positioning in the RIA market.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All quantitative data is accurate - correctly cites $1.6 trillion in assets and 15 million accounts transferred from TD Ameritrade. (2) Correctly identifies the 2022-2023 evolution from 'retaining' to 'fully integrating' iRebal. (3) Properly synthesizes the multi-hop connection between iRebal integration and broader TD Ameritrade integration. (4) Accurately captures the competitive positioning angle regarding RIA market differentiation. WEAKNESSES: (1) INTRODUCES UNSUPPORTED CLAIM: The LLM answer references 'Schwab Trading Powered by Ameritrade™' platform as the vehicle for iRebal integration in 2023. This specific platform name and its connection to iRebal integration does not appear in the ground truth, which only states iRebal was 'incorporated as a core part of its offerings' without specifying a particular platform launch. This is a factual addition not supported by the source material. (2) INCOMPLETE REASONING: The ground truth emphasizes Schwab's 'strong brand and corporate reputation' as a mechanism for credibly introducing new products - the LLM answer mentions 'strong brand' but omits the 'corporate reputation' element and the specific framing about credible product introduction. (3) VAGUE LANGUAGE: The LLM uses 'differentiated, scalable technology stack' which is more generic than the ground truth's specific reference to leveraging iRebal to 'differentiate its service offerings.' (4) MISSING NUANCE: The ground truth explicitly notes that in 2022 Schwab 'had not yet fully integrated or emphasized it' - the LLM captures the integration but doesn't clearly convey the lack of emphasis in 2022. The unsupported platform reference is the primary concern, as it introduces information not in the knowledge graph, reducing reliability despite correct synthesis of other elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Retains]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 495,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "\nApple’s 2023 Form 10‑K lists the iMac as part of the Mac product line that the company designs, manufactures and markets, establishing it as a core desktop offering. In the 2024 filing, Apple explicitly announced new iMac models in the first quarter of fiscal 2024—its first product announcement of the year—showing a deliberate refresh of the desktop portfolio and a continued focus on the iMac alongside other Mac and AI‑related updates. Thus, the iMac’s evolution from a steady presence in the 2023 Mac lineup to a highlighted 2024 announcement reflects Apple’s strategy of iteratively updating the product while navigating macro‑economic pressures that could affect its results.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Apple's iMac positioning between 2023 and 2024, matching the ground truth's main thesis: the iMac moved from a standard product line item to a highlighted announcement. The answer accurately captures that in 2023 the iMac was part of the Mac product line, and in 2024 it received elevated prominence as a key product announcement. The LLM provides additional specific detail (first quarter of fiscal 2024, first product announcement of the year) that adds credibility and specificity to the answer. However, there are some concerns: (1) The LLM introduces the phrase 'AI-related updates' which is not mentioned in the ground truth and may be an inference not directly supported by the 10-K disclosures cited. (2) The reference to 'macro-economic pressures' is also not present in the ground truth answer and represents additional interpretation. (3) The ground truth emphasizes this shift 'likely reflecting a product refresh or redesign' while the LLM states it more definitively as 'a deliberate refresh,' which is a minor semantic difference but the LLM's version is slightly more assertive. The multi-hop reasoning is sound—the LLM correctly synthesizes information across two fiscal years and identifies the strategic shift. The quantitative elements (fiscal year references, timing) appear accurate. The answer is well-structured and addresses the question comprehensively, though it adds interpretive elements beyond what the ground truth explicitly states. The core factual claim about the evolution is correct, making this a solid answer with minor issues around unsupported inferences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 452,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 RTX’s $1 billion 2.820% Notes Due 2051 remained on its balance sheet at the same $1,000 million principal amount (Chunk 1 shows the $1,000 million issuance in 2021 and Chunk 2 lists $1,000 million for both 2024 and 2023), indicating that the instrument has not been retired, increased or otherwise altered in size. This continuity reflects RTX’s practice of maintaining a stable, long‑dated fixed‑rate tranche within a broader long‑term debt portfolio that totaled $38.7 billion net of the current portion in 2024 (down from $42.4 billion in 2023, per Chunk 2), underscoring a capital structure that relies on a diversified mix of long‑maturity notes rather than frequent refinancing.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual errors regarding total long-term debt figures. The LLM states total long-term debt was '$38.7 billion net of current portion in 2024 (down from $42.4 billion in 2023)' - these numbers do not align with the ground truth which indicates $41,146 million ($41.146 billion) in 2024. The LLM's figures appear to be incorrect or sourced from different metrics. Additionally, the LLM references 2023 data ($42.4 billion) which is not part of the original question's 2022-2024 timeframe analysis. CORRECT ELEMENTS: The LLM correctly identifies that the 2.820% Notes Due 2051 remained at $1,000 million principal balance across the period with no repayment or additional issuance. The characterization of this as a 'stable, long-dated fixed-rate tranche' is semantically equivalent to the ground truth's description. MULTI-HOP REASONING: The LLM attempts to synthesize the specific note's stability with broader debt portfolio changes, which is appropriate to the question. However, the execution fails due to incorrect total debt figures. The ground truth shows total principal long-term debt increased from ~$40,078 million (2022) to $41,146 million (2024), indicating debt expansion - the LLM's figures suggest contraction, which is directionally opposite. MISSING CONTEXT: The LLM does not provide the specific 2022 baseline figure for total long-term debt, making it harder to assess the full evolution. The answer also conflates net debt figures with principal amounts, which may explain the discrepancy. The core insight about the 2051 notes remaining stable within a changing debt portfolio is present but undermined by incorrect supporting numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 471,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "\nBetween 2022 and 2023 Schwab amended its IDA agreement, cutting the service‑fee on client cash deposits at TD depository institutions from the 25 basis‑point rate paid under the prior arrangement to 15 basis‑points (a change highlighted in the 2022 10‑K’s pro‑forma notes). In 2023 the company completed the transition of that IDA agreement—and the related intercompany lending arrangements—away from LIBOR to alternative benchmark indices, thereby adjusting the reference‑rate provisions that govern the agreement (as disclosed in the 2023 10‑K’s discussion of LIBOR migration). These updates reflect both the fee reduction and the shift in reference‑rate methodology governing Schwab’s IDA terms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Schwab's IDA agreement evolution. QUANTITATIVE ACCURACY: All numeric values are correct - the service fee reduction from 25 basis points to 15 basis points is accurately stated, and the years (2022 and 2023) are correctly identified. The answer properly attributes the fee change to the 2022 10-K and the LIBOR transition to the 2023 10-K. QUALITATIVE ACCURACY: The multi-hop reasoning is sound. The answer correctly synthesizes information across two fiscal years, identifying two distinct types of changes: (1) fee structure modification in 2022, and (2) reference rate transition in 2023. The answer accurately characterizes the shift from LIBOR to alternative benchmarks and correctly notes this was part of broader LIBOR phase-out preparation. COMPLETENESS: The answer addresses all parts of the question - it covers both service fees and reference rate adjustments, and explains how these terms evolved between the two years. SEMANTIC EQUIVALENCE: The LLM answer conveys the same information as the ground truth with slightly more specific sourcing detail (mentioning pro-forma notes and LIBOR migration discussion sections). The phrasing is clear and professional. MINOR CONSIDERATIONS: The LLM answer adds contextual detail about \"intercompany lending arrangements\" which, while not explicitly mentioned in the ground truth, is a reasonable elaboration that doesn't contradict the source material. The answer maintains factual accuracy while providing slightly more granular sourcing information than the ground truth statement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 450,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "\nThe 2023 10‑K shows Filorga being tested as a distinct reporting unit with $221 million of goodwill (its fair value essentially equal to carrying value), while the 2024 filing simply lists Filorga among a group of other trademarks within broader segments, indicating that the company now treats the brand as part of an aggregated trademark portfolio rather than a separate unit. This shift suggests that Filorga’s strategic importance is being evaluated collectively with other brands and that the company is applying a more consolidated, market‑based valuation approach—using comparable‑company metrics and qualitative assessments—rather than a standalone goodwill impairment model.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the key quantitative facts: Filorga had $221 million in goodwill in 2023 as a standalone reporting unit and was consolidated into a broader trademark portfolio in 2024. The numeric values are accurate and properly formatted. The answer demonstrates sound multi-hop reasoning by synthesizing the change in reporting structure across two fiscal years and connecting it to strategic implications. However, there are some notable differences from the ground truth: (1) The LLM introduces specific valuation methodology details ('comparable-company metrics and qualitative assessments') that are not explicitly mentioned in the ground truth, which focuses more on the structural consolidation and its implications. (2) The LLM's characterization of the 2023 fair value as 'essentially equal to carrying value' is an inference not directly stated in the ground truth. (3) The ground truth emphasizes that the change 'affects how Filorga's valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization,' which provides more concrete implications. The LLM answer focuses more on the valuation methodology shift rather than the strategic decision-making implications. Both answers correctly identify the core insight that Filorga moved from standalone to aggregated treatment, but the LLM's interpretation of what this means strategically is somewhat narrower than the ground truth's broader discussion of potential strategic implications. The answer is substantively correct on the main facts but lacks some of the contextual depth regarding strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 458,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "\nThe 2023 10‑K (Chunk 1) presented the iPhone 16 Pro only as part of the “Fourth‑Quarter 2024” product announcements, positioning it as an upcoming release, while the 2024 10‑K (Chunk 2) now lists the iPhone 16 Pro within the established iPhone portfolio and details its features, services and forward‑looking impact, reflecting Apple’s shift from merely announcing future products to reporting on a launched flagship and its strategic role in the ecosystem. This evolution is highlighted by the inclusion of forward‑looking statements about macroeconomic conditions (Chunk 1’s macroeconomic discussion and Chunk 2’s risk‑factor disclosure) that could materially affect the iPhone 16 Pro’s performance, underscoring a more mature product‑development and reporting strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution in Apple's iPhone 16 Pro disclosure between the 2023 and 2024 10-K filings. The key factual claims are accurate: (1) the 2023 10-K presented iPhone 16 Pro as a Fourth Quarter 2024 announcement (forward-looking), and (2) the 2024 10-K lists it among established products. The answer demonstrates sound multi-hop reasoning by synthesizing information across two filing years and connecting product lifecycle stages to reporting strategy. However, there are some issues: (1) The LLM introduces additional context about macroeconomic conditions and risk-factor disclosures that, while potentially relevant, are not explicitly mentioned in the ground truth answer and may represent inference beyond what was directly stated in the filings. (2) The phrase 'details its features, services and forward-looking impact' is somewhat vague and not directly supported by the ground truth, which focuses on the transition from announcement to established product status. (3) The answer is slightly more elaborate than necessary, adding layers of interpretation about 'mature product-development and reporting strategy' that go beyond the core observation. The core insight—transition from planning/announcement phase to established product inclusion—is correctly captured and well-articulated. The answer maintains semantic equivalence with the ground truth while adding some interpretive elements that are reasonable but not explicitly grounded in the provided ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 418,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "\nThe company’s EVE simulations—disclosed as an accounting policy that SCHW depends on and that EVE simulations discloses back to SCHW—were first described in 2022 as measuring the long‑term impact of instantaneous interest‑rate shifts on the net present value of assets and liabilities, using internal assumptions such as rate floors, prepayment speeds, term‑structure models, non‑maturity deposit behavior and the presumption of non‑negative investment yields. In 2023 the methodology was refined: the firm began relying on independent third‑party models for term‑structure, prepayment and cash‑flow projections and, in the fourth quarter of 2023, updated its deposit‑beta assumptions to reflect a declining‑rate environment, while also explicitly simulating how client cash‑allocation changes affect the balance‑sheet structure. Thus, between 2022 and 2023 the EVE approach moved from a static, internally‑driven set of assumptions toward a more dynamic, externally‑sourced modeling framework that captures richer balance‑sheet dynamics and client‑behavior effects.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with excellent multi-hop synthesis across 2022 and 2023 data. STRENGTHS: (1) Correctly identifies all key 2022 assumptions: non-negative investment yields, prepayment speeds, non-maturity deposit behavior, and rate floors/term-structure models. (2) Accurately captures the 2023 evolution: shift to third-party models for term-structure/prepayment/cash-flow projections, Q4 2023 deposit beta updates for declining rate environment, and explicit modeling of client cash allocation impacts on balance sheet. (3) Provides excellent contextual framing by characterizing the evolution as moving from 'static, internally-driven' to 'dynamic, externally-sourced' framework. (4) No quantitative errors detected - all dates (2022, 2023, Q4 2023) and metrics are accurate. (5) Strong multi-hop reasoning correctly synthesizing information across two fiscal years. MINOR WEAKNESSES: (1) The phrase 'EVE simulations discloses back to SCHW' is awkwardly constructed and somewhat unclear in meaning, though it doesn't materially affect the substantive answer. (2) The opening parenthetical about SCHW dependency is somewhat tangential and could be clearer. (3) The answer adds some interpretive language ('static vs. dynamic,' 'externally-sourced') that goes slightly beyond the ground truth's more factual presentation, though this interpretation is reasonable and supported by the facts presented. The core factual content matches the ground truth well: both 2022 and 2023 modeling approaches are accurately described, the evolution is correctly characterized, and the specific methodological changes are properly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1492,
        "completion_tokens": 455,
        "total_tokens": 1947
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "\nBy shifting in 2023 from licensing and supplying only the chips and IP for wireless access‑points (the “enabling” role described in the 2022 market overview) to actually **producing complete access‑point hardware**, Qualcomm moved up the value chain and expanded its networking portfolio with end‑to‑end solutions built on its Snapdragon SoC, AI‑enhanced modem‑RF platform and integrated RFFE components—exactly the networking products (Wi‑Fi, Ethernet, PON chips, access‑points and routers) highlighted in the 2023 10‑K.  This leverages the surging edge‑networking demand for Wi‑Fi 6/6E and 5G‑backhaul access points noted in the 2022 analysis, giving Qualcomm higher‑margin hardware sales, a differentiated, AI‑driven offering for carriers and OEMs, and a stronger competitive position against traditional networking vendors across the broader networking market.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core strategic shift from 2022 (enabling role via chipsets) to 2023 (direct production of access points). It accurately names relevant product categories (Wi-Fi chips, routers, network processors, access points) and correctly identifies competitive positioning against vendors like Broadcom and Intel. The answer appropriately synthesizes the multi-hop concept of moving up the value chain and offering full-system solutions. The mention of Wi-Fi 6/6E and 5G-backhaul demand aligns with ground truth context.\n\nWEAKNESSES: (1) The LLM introduces specific technical details (Snapdragon SoC, AI-enhanced modem-RF platform, RFFE components, PON chips, Ethernet) that are NOT present in the ground truth answer. While these may be factually accurate from the 10-K, they represent unsupported elaboration beyond what the knowledge graph confirms. (2) The LLM claims 'higher-margin hardware sales' and 'AI-driven offering' without quantitative support or explicit ground truth confirmation. (3) The phrase 'exactly the networking products...highlighted in the 2023 10-K' overstates the specificity of what was confirmed in the ground truth. (4) The answer adds interpretive claims about 'differentiated' positioning and 'stronger competitive position' that go beyond the ground truth's more measured statement about 'positioning the company to compete more directly.'\n\nMULTI-HOP REASONING: The synthesis across 2022 and 2023 documents is sound and correctly identifies the strategic evolution. However, the reasoning includes inferences and technical specifications not explicitly validated by the ground truth.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers, percentages, or dollar amounts are provided in either answer, so quantitative accuracy cannot be directly verified. The dates (2022 vs 2023) are correct. Product categories mentioned are largely accurate but the LLM adds unconfirmed specifics.\n\nOVERALL ASSESSMENT: The answer captures the essential strategic shift and competitive implications correctly, but introduces unsupported technical details and makes stronger claims about competitive positioning than the ground truth warrants. This represents partial correctness with some overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 604,
        "total_tokens": 2024
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "\nFrom the 2022 disclosure the HELOC portfolio contained roughly 28 % of its adjustable‑rate mortgages with interest‑only payment terms, and about 89 % of those interest‑only balances were not scheduled to reset for three or more years; by the end of 2023 those figures had slipped to approximately 27 % and 86 %, respectively, showing a modest contraction in the interest‑only portion of Schwab’s HELOC product.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative metrics are correct: 2022 shows 28% of adjustable-rate mortgages with interest-only terms and 89% not scheduled to reset for 3+ years; 2023 shows 27% and 86% respectively. The multi-hop synthesis is sound - the answer correctly combines data across two fiscal years and two distinct metrics to show the evolution of Schwab's HELOC product structure. The reasoning is logical and the conclusion about 'modest contraction' accurately reflects the directional changes in both metrics. The wording 'slipped' and 'modest contraction' appropriately characterizes the minor decreases. The answer uses slightly different phrasing than the ground truth ('roughly' and 'approximately' vs. direct percentages, 'balances' vs. 'loans') but these are semantically equivalent and reflect appropriate hedging language for financial disclosures. The entity identification is correct (Schwab, HELOC product, adjustable-rate mortgages). Minor deduction only because the ground truth uses 'interest-only loans' while LLM uses 'interest-only payment terms' - these are semantically equivalent but represent a slight variation in terminology. Overall, this is a high-quality answer that accurately addresses all components of the multi-hop question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 365,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "\nFrom 2022 to 2023 Qualcomm shifted XR from a purely strategic‑investment focus to a measurable product‑revenue line. In the 2022 filing the company highlighted XR only as one of several target sectors for its Qualcomm Ventures investments, noting that such investments are generally aimed at early‑stage firms with exit strategies. By contrast, the 2023 10‑K explicitly lists “consumer (including … XR)” among the industries for which it sells products, showing that XR‑enabled chipsets and platforms are now part of Qualcomm’s shipped revenue stream, reflecting a clear evolution from investment to commercial production. This transition is captured by the KG relationship QCOM → XR (Invests_In) and XR → QCOM (Produces), illustrating that the XR product is both an investment target and a revenue‑generating offering that Qualcomm now produces and sells.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2023, matching the ground truth's timeline; (2) Accurately characterizes 2022 involvement as strategic investment through Qualcomm Ventures targeting early-stage companies, consistent with ground truth; (3) Properly identifies the 2023 shift to explicit product revenue listing in the 10-K filing, showing commercialization; (4) Correctly synthesizes the multi-hop relationship: investment activity → commercial product sales; (5) Uses appropriate terminology ('strategic investment focus,' 'measurable product-revenue line,' 'shipped revenue stream') that conveys the same meaning as ground truth; (6) No quantitative errors - no specific numbers are claimed that could be verified; (7) Correctly identifies both Qualcomm Ventures and the consumer/XR product categories. MINOR CONSIDERATIONS: (1) The LLM adds interpretive detail about 'exit strategies' for early-stage investments and mentions 'XR-enabled chipsets and platforms' which, while reasonable inferences, go slightly beyond what the ground truth explicitly states; (2) The reference to KG relationships (QCOM → XR Invests_In, XR → QCOM Produces) adds technical metadata not present in ground truth but doesn't contradict it; (3) The phrase 'consumer (including … XR)' with ellipsis accurately reflects the filing language without misrepresenting it. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and two different types of Qualcomm engagement (investment vs. revenue), demonstrating proper multi-hop reasoning. The logical progression from investment to commercialization is sound and well-supported. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as ground truth - a transition from supporting external innovation through investments to generating direct revenue from XR products - despite using different phrasing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 541,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "\nThe $1,100 million aggregate principal balance of the 3.030 % Notes Due 2052 that appears in the 2022 issuance table (Chunk 1) remains unchanged at $1,100 million in both 2023 and 2024 (Chunk 2), showing a flat evolution over the period. This stability signals that RTX is maintaining a steady, long‑dated fixed‑rate component in its capital structure—relying on a diversified pool of maturities rather than refinancing or expanding this particular series—thereby underscoring a long‑term debt strategy that emphasizes predictable, long‑horizon funding while the overall long‑term debt balance has actually contracted (from $43.7 B in 2023 to $41.1 B in 2024).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All numbers are correct - the $1,100 million principal balance is accurate for both 2022 and 2024, and the additional context about overall long-term debt contraction (from $43.7B in 2023 to $41.1B in 2024) is factually sound and adds valuable context. COMPLETENESS: The answer addresses both parts of the question - the evolution of the specific notes (stable at $1,100M) and what this indicates about RTX's long-term debt structure. MULTI-HOP REASONING: The LLM correctly synthesizes information across multiple years and connects the stability of this specific debt instrument to broader capital structure strategy. The reasoning that stability in this series, combined with overall debt contraction, indicates strategic consistency is sound. ENTITY ACCURACY: RTX is correctly identified, the 3.030% Notes Due 2052 are correctly referenced, and the years (2022, 2023, 2024) are properly tracked. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth while providing additional valuable context about the broader debt portfolio changes. The interpretation that this represents 'strategic consistency' and 'long-term debt strategy that emphasizes predictable, long-horizon funding' aligns well with the ground truth's assessment. MINOR CONSIDERATIONS: The LLM provides slightly more analytical depth by contextualizing the stable notes within the broader debt reduction trend, which enhances rather than detracts from the answer. The reference to 'Chunk 1' and 'Chunk 2' indicates proper source attribution. No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 453,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "\nAXP’s 2023 and 2024 filings both state that it is “building on our strong position in commercial payments by evolving our card‑value propositions, further differentiating our corporate card and accounts‑payable expense‑management solutions and designing innovative products and features, including financing, banking and payment solutions for our business customers,” showing that the corporate‑card focus has remained consistent but is now being framed as part of a broader, fully integrated commercial‑payments agenda. The 2024 filing adds that AXP has completed its 2021‑2024 ESG goals and is reviewing DE&I and climate initiatives, indicating the corporate‑card effort is maturing within a more comprehensive strategy. The KG relationship—AXP Enhances Corporate Card and Corporate Card Enhances AXP—underscores that the corporate card is treated as a core platform to expand financing, banking and expanded merchant services, reinforcing AXP’s overall push to deepen its commercial‑payments ecosystem.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution from 2023 to 2024, capturing the shift toward integrated solutions including 'financing, banking and payment solutions.' (2) The quote provided appears accurate and directly addresses the question. (3) Dates (2023, 2024, 2021-2024) are correct. (4) Entity identification (AXP, Corporate Card) is accurate. WEAKNESSES: (1) The LLM introduces extraneous information about ESG goals and DE&I/climate initiatives that are NOT mentioned in the original answer and appear tangential to the core question about Corporate Card strategy evolution. This dilutes focus and suggests the model may have conflated information from different sections of the filing. (2) The reference to 'KG relationship—AXP Enhances Corporate Card and Corporate Card Enhances AXP' is vague and not substantiated in the original answer; this appears to be model interpretation rather than grounded fact. (3) The LLM's framing that the focus 'remained consistent' somewhat contradicts the ground truth's emphasis on a meaningful SHIFT toward 'more integrated and solution-oriented approach' and 'expanding beyond just product differentiation.' The original answer emphasizes evolution/shift; the LLM emphasizes consistency. (4) The LLM does not clearly articulate the key insight from the original answer: that AXP is embedding the Corporate Card into a WIDER SUITE of business financial services, aligning with holistic commercial needs. Instead, it frames this as 'maturing within a more comprehensive strategy,' which is less precise. MULTI-HOP REASONING: The LLM attempts to synthesize 2023 and 2024 information but introduces unrelated ESG/DE&I content that breaks the logical flow. The core multi-hop synthesis (comparing 2023 vs 2024 strategy) is partially correct but imprecisely articulated. SEMANTIC EQUIVALENCE: While the LLM captures the general direction of change, it misses the nuance that the shift represents a strategic expansion beyond differentiation toward integration—a key distinction in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enhances]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 554,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "\nBetween 2023 and 2024 PCA SKIN remained classified under Colgate‑Palmolive’s Oral, Personal and Home Care segment, but the way it reaches customers shifted. In the 2023 filing the brand was sold “primarily to a variety of traditional and eCommerce retailers, wholesalers, distributors, dentists and, in some segments, skin‑health professionals,” whereas the 2024 disclosure adds that in “some geographies” it is marketed to skin‑health professionals and notes that “some of our products are also sold direct‑to‑consumer.” This indicates a strategic evolution from a wholesale‑retail focus toward a greater emphasis on professional skin‑care channels and direct‑to‑consumer sales for PCA SKIN.  \n\n*(KG triplets CL → PCA SKIN ← CL and PCA SKIN → CL ← CL confirm that PCA SKIN is a product of Colgate‑Palmolive and is disclosed within the same corporate entity, underscoring its continued placement in the Oral, Personal and Home Care portfolio while its distribution mix has broadened.)*",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES IDENTIFIED: (1) FACTUAL INACCURACY - The LLM answer claims the 2023 filing stated PCA SKIN was sold 'primarily to a variety of traditional and eCommerce retailers, wholesalers, distributors, dentists and, in some segments, skin-health professionals.' However, the ground truth explicitly states that in 2023, PCA SKIN was sold 'primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists' with NO mention of skin-health professionals in 2023. The LLM has incorrectly backdated the skin-health professional channel to 2023. (2) MISCHARACTERIZATION OF CHANGE - The ground truth indicates that by 2024, the filing 'specifically expanded the distribution channels to include sales to skin health professionals in some geographies' - this is a NEW addition in 2024, not a pre-existing channel. The LLM's framing suggests this was already present in 2023. (3) UNSUPPORTED CLAIM - The LLM introduces 'direct-to-consumer sales' as a 2024 addition, but the ground truth makes no mention of direct-to-consumer sales being added or emphasized. This appears to be an unsupported inference or hallucination. (4) MULTI-HOP REASONING - While the LLM correctly identifies PCA SKIN as part of the Oral, Personal and Home Care segment and attempts to synthesize the evolution, the fundamental factual errors about what was in 2023 vs 2024 undermine the entire analysis. (5) CORRECT ELEMENTS - The LLM does correctly identify that PCA SKIN remained a principal trademark and that there was an evolution in distribution channels, but the specific details of that evolution are misrepresented. The citation of KG triplets at the end, while attempting to add credibility, does not correct the underlying factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 474,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "\nBetween 2022 and 2023 BMY reshaped Opdivo’s commercial model from a primarily late‑stage, single‑agent therapy into an earlier‑line, multi‑indication platform—adding new tumor types such as expanded NSCLC, gastric/esophageal, RCC and renal‑cancer indications and pushing multiple combination regimens (e.g., Opdivo + Yervoy, Opdivo + Cabometyx, and next‑generation combos with Augtyro and Krazati) while advancing a subcutaneous formulation for the drug.  This strategic shift is underscored by the 2023 plan to “drive near‑term growth… by accelerating opportunities that enhance productivity” and to “expand the use of Opdivo into earlier lines and new tumor types,” a focus that builds on the double‑digit U.S. (7 %) and international (9 %, 7 % excl. FX) revenue gains recorded for Opdivo‑containing regimens in 2021 and the continued double‑digit growth of Opdivo + Yervoy sales (13 % U.S., 36 % international).  As a result, the broadened indication base and combination‑therapy emphasis are expected to sustain a strong, accelerating revenue‑growth trajectory for Opdivo within BMY’s oncology portfolio through the late 2020s.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM cites specific revenue growth percentages (7% U.S., 9% international, 7% excl. FX for 2021; 13% U.S., 36% international for Opdivo + Yervoy) that are NOT present in the ground truth answer. The ground truth mentions 'U.S. revenue growth driven by combinations' but does NOT provide these specific percentage figures. The LLM appears to have fabricated or misattributed these numbers. (2) ENTITY CONFUSION - The LLM introduces combination therapies (Opdivo + Cabometyx, Augtyro, Krazati) that are NOT mentioned in the ground truth answer. While these may be real therapies, they are not supported by the provided ground truth, representing unsupported expansion beyond the source material. (3) INCOMPLETE ALIGNMENT - The ground truth specifically mentions 'bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers' as 2022 indications, but the LLM only vaguely references 'expanded NSCLC, gastric/esophageal, RCC and renal-cancer indications' without the comprehensive list. (4) MULTI-HOP REASONING - While the LLM correctly identifies the strategic shift from late-stage to earlier-line therapy and mentions the subcutaneous formulation (both in ground truth), it does so while introducing unsupported quantitative claims. (5) POSITIVE ELEMENTS - The LLM correctly captures the core strategic evolution (single-agent to multi-indication platform), the emphasis on earlier lines of therapy, combination regimens with Yervoy, and the subcutaneous formulation. The overall narrative structure aligns with ground truth intent. However, the introduction of specific percentages and additional combination therapies without ground truth support is a critical flaw that undermines credibility. The answer reads as partially fabricated rather than synthesized from the provided source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1534,
        "completion_tokens": 507,
        "total_tokens": 2042
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "\nIn 2023 American Express reported an estimated fair value of **$549 million** for its foreign‑government‑bond portfolio, which the 2023 disclosure placed in the “12 months or more” maturity bucket (i.e., longer‑term exposure). By 2024 the fair value had risen to **$765 million**, and the maturity schedule shows **$764 million (≈99.9 %) maturing within one year**, $1 million maturing between 1‑5 years, and none beyond 5 years—demonstrating a clear shift toward much shorter‑term holdings. This evolution reflects both growth in the bond position and a strategic move to concentrate the exposure in the “due within 1 year” segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. QUANTITATIVE VERIFICATION: All dollar amounts are correct ($549M in 2023, $765M in 2024, $764M within one year, $1M in 1-5 year bucket). The percentage calculation (764/765 ≈ 99.9%) is accurate. COMPLETENESS: The answer addresses all required elements - fair value evolution, maturity distribution for both years, and the shift in composition. ENTITY ACCURACY: American Express correctly identified, years 2023 and 2024 properly referenced, financial metrics accurately labeled. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, comparing both absolute values and relative distributions, and correctly identifies the strategic shift from longer-term to short-term maturities. SEMANTIC EQUIVALENCE: The LLM's characterization of 2023 holdings as 'longer-term exposure' (all in 12+ months bucket) and 2024 as concentrated in 'due within 1 year' segment accurately reflects the ground truth data. The interpretation that this represents 'both growth in the bond position and a strategic move' is a reasonable inference from the data. Minor note: The ground truth states 2023 holdings were in '12 months or more' maturity, which the LLM correctly interprets as longer-term exposure. The only negligible difference is stylistic - the LLM provides slightly more analytical interpretation ('strategic move') which adds value without contradicting the facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 405,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "\nWalmart’s restricted cash that cannot be freely transferred to the United States fell from roughly **$4.3 billion in fiscal 2022**—of which about **$2.2 billion could only be accessed via dividends or intercompany financing that required approval of Flipkart’s minority shareholders** (Chunk 1)—to **approximately $3.3 billion in 2025 and $3.5 billion in 2024**, where the limitation now stems only from “local laws or other restrictions or are subject to the approval of the non‑controlling interest shareholders” (Chunk 2).  The company continues to rely on intercompany financing arrangements to move cash to the jurisdictions that need it at the lowest cost, and under current law such repatriations are generally free of U.S. federal tax, with no expectation that the remaining restrictions will materially affect liquidity or financial position.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) YEAR CONFUSION: LLM states '$3.3 billion in 2025 and $3.5 billion in 2024' - this is internally contradictory and introduces a year (2025) not in the original question or ground truth. The ground truth specifies 2024 as $3.3 billion, not 2025. (2) NUMERIC DISCREPANCY: LLM provides '$3.5 billion in 2024' but ground truth clearly states '$3.3 billion' for 2024. This is a material factual error of $200 million. (3) CORRECT ELEMENTS: LLM accurately captures the 2022 figures ($4.3 billion total, $2.2 billion Flipkart-related), correctly identifies the shift from Flipkart-specific language to broader 'noncontrolling interest shareholders' language, and appropriately notes the slight reduction in restricted cash. (4) MULTI-HOP SYNTHESIS: The model correctly synthesizes the evolution between years and identifies the shift in framing/conditions, which is sound reasoning. However, the quantitative errors undermine this synthesis. (5) ADDITIONAL CONTENT: LLM adds information about intercompany financing mechanisms and tax implications that, while contextually relevant, goes beyond the ground truth and may introduce unsourced claims. The core issue is the introduction of 2025 data and the incorrect 2024 figure ($3.5B vs. $3.3B), which are factual errors that significantly impact correctness despite otherwise reasonable qualitative analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 381,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "\nTexas Instruments discloses its U.S. Retiree Health Care Plan (a financial instrument in which it holds a stake) and, per the 2023 and 2024 filings, the plan’s asset mix is unchanged: fixed‑income securities and cash equivalents total $210 ($4 Level 1 plus $206 other), while equity securities total $54, yielding an identical $264 overall allocation in both years. This consistency reflects no shift in the relative weighting of fixed‑income versus equity holdings between the 2023 and 2024 disclosures.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question effectively. STRENGTHS: (1) All key financial figures are accurate: $210 million in fixed income securities and cash equivalents, $54 million in equity securities, and $264 million total - matching the ground truth exactly. (2) The breakdown of fixed income ($4 Level 1 plus $206 other) adds helpful detail not in the original answer. (3) Correctly identifies that the composition remained unchanged between 2023 and 2024 filings. (4) Properly synthesizes the multi-hop information comparing two years. (5) Correctly identifies Texas Instruments as the company. MINOR WEAKNESSES: (1) The LLM answer omits the specific percentage allocations (79.5% fixed income, 20.5% equity) that were included in the ground truth. While these percentages can be calculated from the provided numbers, their explicit inclusion would have been more complete. (2) The phrase 'a financial instrument in which it holds a stake' is slightly awkward and potentially confusing - the plan is a benefit obligation/liability, not an instrument TI 'holds a stake' in. This is a minor semantic issue that doesn't affect the core factual accuracy. (3) The answer could have been slightly more explicit about the 'no evolution' aspect, though this is clearly conveyed. QUANTITATIVE VERIFICATION: All dollar amounts ($210M, $54M, $264M, $4M, $206M) are correct. The implicit percentages (79.5% and 20.5%) can be verified from the numbers provided. No calculation errors detected. The answer successfully demonstrates multi-hop reasoning by comparing asset compositions across two fiscal years and correctly concluding no change occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 458,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "\nIn the 2022 10‑K (Chunk 1) the 2006 Stock Plan for Non‑Employee Directors was governed by the 2021 omnibus amendments that introduced only two award formats – the “Form of Option Agreement” (Exhibit 10.30*) and the “Form of Restricted Unit Agreement” (Exhibit 10.32*), both of which were periodically updated through the 2021‑2022 amendments listed as Exhibits 10.29*, 10.31* and 10.33*.  \n\nThe 2024 10‑K (Chunk 2) shows that the plan’s award suite expanded to include new “Form of Restricted Stock Unit Agreement” (Exhibits 10.44*, 10.45*), a “Form of Stock Option Agreement” (Exhibit 10.46*), and a “Form of Performance Plan Grant Agreement” (Exhibit 10.47*), while also referencing the separate 2016 Stock Plan for Non‑Employee Directors (Exhibit 10.48*) and its latest amendments (Exhibits 10.49*, 10.50*).  \n\nThus, between 2022 and 2024 Honeywell broadened the types of equity awards offered to its non‑employee directors—from solely options and restricted‑unit awards toward a mix that includes restricted‑stock‑unit and performance‑based grants under both the 2006 and the newer 2016 director plans—indicating a strategic shift to more flexible, performance‑linked compensation for directors.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM claims the 2024 10-K shows an 'expansion' to include 'Form of Restricted Stock Unit Agreement' and 'Form of Performance Plan Grant Agreement' as new awards, but the ground truth explicitly states that by 2024, the 'Form of Restricted Unit Agreement' was NO LONGER explicitly mentioned. The LLM mischaracterizes this as an expansion when it was actually a contraction/shift. (2) The LLM introduces a '2016 Stock Plan for Non-Employee Directors' (Exhibits 10.48-10.50) which is not mentioned in the ground truth at all. This appears to be fabricated or confused information. (3) The LLM's core conclusion is inverted: it claims a shift 'toward a mix that includes restricted-stock-unit and performance-based grants' suggesting expansion, when the ground truth indicates a shift AWAY from restricted units toward stock options. (4) The exhibit numbers cited differ from ground truth (LLM cites 10.29, 10.31, 10.33 for 2022 amendments; ground truth cites 10.30 and 10.32 for 2022). (5) The LLM's interpretation of the strategic shift is backwards - ground truth suggests emphasis on stock options over restricted units, while LLM suggests a move toward more flexible, performance-linked compensation including RSUs. CORRECT ELEMENTS: The LLM does correctly identify that the question concerns the 2006 Stock Plan for Non-Employee Directors and attempts to compare 2022 vs 2024. However, the fundamental factual errors about what awards were offered in each year, the introduction of non-existent plans, and the inverted conclusion about the strategic direction make this answer substantially incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amends]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 467,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Walmart’s equity stake in Flipkart was deliberately reduced – the company received $3.2 bn from a new equity funding that cut its ownership from roughly 83 % (as of Jan 2021) to about 75 % (as of Jan 2022), a change captured by the KG pattern **ORG ‑[Decreases]→ COMP ←[Has_Stake_In]‑ORG**.  This dilution lowered Walmart’s direct financial exposure to Flipkart but simultaneously heightened its regulatory exposure: Flipkart remains under a 2021 Indian Foreign‑Direct‑Investment show‑cause notice that could lead to share‑ownership restrictions or other penalties, and ongoing investigations in India and Mexico could materially affect Walmart’s financial position, results of operations and cash flows.  Consequently, while Walmart’s strategic ownership in Flipkart shrank, the company’s indirect risk profile expanded to include significant Indian regulatory and legal uncertainties.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the multi-hop question and captures the core narrative of Walmart's evolving Flipkart position. STRENGTHS: (1) Correctly identifies the $3.2 billion equity funding and ownership stake reduction from 83% to 75%. (2) Accurately references the July 2021 show cause notice and FDI regulatory scrutiny. (3) Properly synthesizes the paradox: reduced financial exposure but increased regulatory risk. (4) Correctly notes the pre-acquisition timing (2009-2015 violations, 2018 acquisition). (5) Appropriately mentions potential consequences like share ownership restrictions. WEAKNESSES: (1) The LLM states the ownership change occurred \"as of Jan 2021\" to \"as of Jan 2022,\" but the ground truth indicates this happened in 2022 (the funding was received in 2022, reducing stake from 83% to 75%). The timing reference is slightly imprecise—the ground truth says \"In 2022\" not \"between Jan 2021 and Jan 2022.\" (2) The LLM mentions \"ongoing investigations in India and Mexico\" but the ground truth only specifically references India regulatory issues. The Mexico reference appears to be an addition not supported by the ground truth. (3) Minor: The LLM uses the KG pattern notation which, while showing technical understanding, is not part of the ground truth answer and adds complexity without adding clarity. (4) The ground truth specifically mentions Walmart's \"inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders,\" which the LLM does not capture. QUANTITATIVE VERIFICATION: The $3.2 billion figure is correct. The 83% to 75% ownership reduction is correct. The 2021 show cause notice date is correct. MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple dimensions (financial stake reduction, regulatory exposure, timeline) and correctly identifies the inverse relationship between reduced ownership and increased risk exposure. The reasoning is sound and logically presented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 542,
        "total_tokens": 2011
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "\nBetween 2022 and 2024 HON’s cash base contracted modestly – from roughly **$11.5 billion** of cash and cash equivalents reported at the end of 2021 (the most recent figure in the 2022 filing) to **$11.0 billion** as of 31 December 2024 – while the **geographic split shifted markedly**: the 2024 filing notes that **$8.0 billion** (about 73 % of the total) was held in non‑U.S. subsidiaries, whereas the remainder was held in U.S. depository institutions.  This evolution reflects HON’s ongoing strategy of **prioritizing safety of principal and yield diversification** across multiple counterparties, maintaining ample access to both U.S. cash balances and the ability to mobilize the larger pool of foreign cash without tax or currency‑control constraints, even as total cash holdings have trended downward from the $15.2 billion level seen in 2020.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core numbers and sound multi-hop reasoning. STRENGTHS: (1) All primary figures are accurate: $11.5B (2021/2022 filing), $11.0B (2024), $8.0B non-U.S. holdings, and 73% calculation is correct ($8.0B/$11.0B = 72.7%, rounded to 73%). (2) Correctly identifies the geographic shift as the key evolution - from undifferentiated cash holdings to explicit disclosure of $8.0B in non-U.S. subsidiaries. (3) Properly synthesizes the strategic emphasis on safety and diversification across both time periods. (4) Accurately captures the multi-hop reasoning: comparing 2022 baseline to 2024 composition while noting the strategic continuity. (5) The reference to $15.2B in 2020 provides helpful context showing the longer-term trend. MINOR WEAKNESSES: (1) The ground truth states the 2022 filing reported $11.5B \"as of December 31, 2021\" - the LLM correctly identifies this but could have been slightly clearer about the temporal reference (2021 year-end data in 2022 filing). (2) The phrase \"without tax or currency-control constraints\" goes slightly beyond what the ground truth explicitly states about strategic positioning, though it's a reasonable inference from the stated strategy. (3) The answer adds contextual interpretation about \"mobilizing foreign cash\" which, while logical, isn't explicitly stated in the ground truth. VERIFICATION: All key numbers check out: $11.5B → $11.0B (modest contraction confirmed), $8.0B non-U.S. (exact match), 73% calculation accurate. The composition shift is correctly identified as the primary evolution. The answer successfully addresses both parts of the multi-part question: total cash holdings evolution AND geographic distribution changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 476,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "\nIn 2023 the company recorded deferred fees for Membership Rewards participants (Chunk 1), but by 2024 it had replaced that simplistic treatment with a formal liability model that estimates the future cost of points using an Ultimate Redemption Rate (URR) and a weighted‑average cost per point (WAC), applying these assumptions to current enrollees and updating them as enrollment, attrition and redemption patterns evolve (Chunk 2). The 2024 framework quantifies the sensitivity of the liability—e.g., a 25‑basis‑point increase in URR would raise the Membership Rewards liability and expense by roughly $197 million, and a 1‑basis‑point rise in WAC would add about $220 million—demonstrating a far more detailed, model‑driven approach, and the company also periodically reassesses its assumptions (including cost‑per‑point and partner‑contract changes) and evaluates goodwill recoverability as part of its overall financial reporting (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensiveness in addressing the multi-hop financial question about the evolution of Membership Rewards program accounting treatment from 2023 to 2024. (1) QUANTITATIVE ACCURACY: All numeric values are correct and properly formatted. The sensitivity analysis figures are accurate: 25 basis point increase in URR = $197 million impact, and 1 basis point increase in WAC = $220 million impact. These specific numbers match the ground truth exactly. (2) COMPLETENESS: The answer addresses all key aspects of the question: the shift from simple deferred fees recognition in 2023 to a comprehensive liability model in 2024, the specific methodological components (URR and WAC), and the quantified sensitivity analysis. The answer goes slightly beyond the ground truth by mentioning periodic reassessment of assumptions and goodwill recoverability evaluation, which adds relevant context without contradicting the original answer. (3) ENTITY ACCURACY: The answer correctly identifies the Membership Rewards program, the relevant years (2023 vs 2024), and the specific financial metrics (URR, WAC, basis points, liability amounts). (4) REASONING: The multi-hop synthesis is sound. The answer correctly traces the evolution from a simpler accounting treatment to a more sophisticated model-driven approach, and properly connects the sensitivity analysis to demonstrate the increased sophistication. The logical flow from 2023 to 2024 is clear and well-structured. (5) SEMANTIC EQUIVALENCE: The wording differs from the ground truth but conveys identical meaning. Phrases like 'replaced that simplistic treatment with a formal liability model' effectively capture the evolution described in the original answer. The characterization of the shift as 'far more detailed, model-driven approach' aligns perfectly with the ground truth's description. Minor note: The LLM answer includes additional context about periodic reassessment and goodwill recoverability that wasn't in the ground truth, but this appears to be supplementary information that enhances rather than contradicts the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 572,
        "total_tokens": 2024
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "\nAdobe acquired Frame.io in Q4 fiscal 2021 and initially routed it into its Digital Media segment (Chunk 1), but between 2022 and 2024 the company has expanded the platform from a stand‑alone collaboration tool into a core hub that is tightly woven into the Creative Cloud suite—directly integrated with Premiere Pro, After Effects, Photoshop, Lightroom and Adobe Express, and linked to Firefly AI services, GenStudio and Adobe Stock (Chunk 2).  This evolution positions Frame.io as the connective layer that aligns video‑focused workflows with Adobe’s broader AI‑driven, asset‑management and cloud‑based creative ecosystem, reinforcing Adobe’s end‑to‑end product strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with minor discrepancies. STRENGTHS: (1) Correctly identifies Frame.io acquisition timing (Q4 fiscal 2021) and initial $1.18B acquisition price (implied through context). (2) Accurately describes the evolution from standalone tool to integrated ecosystem component. (3) Correctly identifies key integration points: Premiere Pro, After Effects, Photoshop, and mentions of GenStudio and AI services. (4) Properly synthesizes multi-hop information showing progression from 2022 to 2024. (5) Accurately characterizes Frame.io's strategic role as connective layer and alignment with Adobe's ecosystem. MINOR ISSUES: (1) The LLM mentions 'Lightroom and Adobe Express' as integrated applications, while the ground truth specifically mentions 'Workfront' instead. The ground truth lists: Premiere Pro, After Effects, Photoshop, and Workfront. The LLM substitutes Lightroom and Adobe Express, which may or may not be accurate depending on actual filing data—this represents a potential entity accuracy issue. (2) The LLM adds contextual details about 'Firefly AI services' and 'Adobe Stock' integration that aren't explicitly mentioned in the ground truth, though these don't contradict it. (3) The ground truth emphasizes Workfront specifically (project management/collaboration tool), while LLM omits this. QUANTITATIVE ACCURACY: The acquisition price and timing are handled correctly (Q4 fiscal 2021). No calculation errors present. QUALITATIVE REASONING: The multi-hop synthesis is sound—correctly traces evolution from 2022 to 2024 and explains strategic positioning. The characterization of Frame.io as a 'connective layer' is insightful and aligns with the ground truth's concept of 'ecosystem incorporation.' CONTEXTUAL RELEVANCE: Directly addresses the question about strategic positioning evolution and ecosystem alignment. The answer is well-structured and comprehensive. The primary concern is the substitution of specific integrated applications (Lightroom/Express vs. Workfront), which affects entity accuracy slightly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Integrates]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 558,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "\nLLY reports that the equity‑like funds in its private alternative‑investment portfolio were valued at **$5.5** using significant unobservable inputs (Level 3) in 2022 (Chunk 1), but that figure jumped to **$25.4** in 2023 (Chunk 2).  This four‑fold increase shows a marked rise in the reliance on Level 3 fair‑value measurements for those funds over the two years.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key financial figures ($5.5 million in 2022 and $25.4 million in 2023) and properly attributes them to LLY (Eli Lilly). The answer accurately addresses the core question about the evolution of equity-like funds in private alternative investments measured using Level 3 inputs. However, there is a critical calculation error: the LLM states this is a 'four-fold increase' when the ground truth correctly identifies it as a 'fivefold increase.' Mathematically, $25.4M / $5.5M = 4.62x, which rounds to approximately 4.6-fold or 5-fold depending on rounding convention, but the ground truth explicitly states 'fivefold.' This represents a meaningful discrepancy in quantitative accuracy. The LLM also uses slightly different language ('four-fold increase shows a marked rise') versus the ground truth's 'fivefold increase...suggesting a shift toward more opaque or complex valuation methodologies,' missing the interpretive insight about the shift toward more opaque valuation methods. The answer is otherwise well-structured, properly cites sources (Chunk 1 and Chunk 2), and correctly synthesizes the multi-hop information across the two years. The entity identification (LLY, equity-like funds, Level 3 inputs, private alternative investments) is accurate. The main weaknesses are the calculation error and the omission of the interpretive context about valuation methodology opacity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 394,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe moved Frame.io from a freshly‑acquired video‑collaboration tool (noted in the 2022 10‑K as being integrated into the Digital Media segment in Oct 2021) to a core, cloud‑native hub that is tightly woven into Creative Cloud, Adobe Express, Firefly Services and the broader Digital Media portfolio; the 2024 filing highlights that Frame.io now powers real‑time upload, frame‑accurate commenting, Camera‑to‑Cloud ingest and is directly embedded in Premiere Pro, After Effects, Photoshop, Lightroom and Workfront, while also being offered through Adobe G EnStudio alongside Adobe Express and Firefly Services. This evolution positions Frame.io as the central collaboration layer for video and asset production across Adobe’s suite, enabling the company to accelerate workflow integration, expand generative‑AI‑enhanced content creation, and drive recurring revenue growth in its Digital Media business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of Frame.io's evolution between 2022 and 2024. STRENGTHS: (1) All key dates are correct - October 2021 acquisition timing, 2022 baseline, 2024 endpoint. (2) All product integrations mentioned are accurate: Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, Adobe GenStudio (note: LLM writes 'G EnStudio' which appears to be a minor typo but refers to the correct product). (3) Technical capabilities are correctly identified: real-time upload, frame-accurate commenting, Camera-to-Cloud ingest. (4) Multi-hop synthesis is sound - the answer correctly traces Frame.io's progression from 'freshly-acquired' (2022) to 'core, cloud-native hub' (2024) across multiple product lines. (5) Strategic positioning is accurately captured - the answer correctly identifies Frame.io as a collaboration layer and notes its role in driving recurring revenue. (6) The answer appropriately contextualizes Frame.io within the broader Digital Media segment and Creative Cloud ecosystem. MINOR ISSUES: (1) The typo 'G EnStudio' instead of 'GenStudio' is a minor formatting error that doesn't affect factual accuracy. (2) The LLM adds some interpretive analysis about 'accelerate workflow integration' and 'drive recurring revenue growth' which goes slightly beyond the ground truth but is reasonable inference from the filing data and doesn't contradict the original answer. (3) The mention of 'Adobe Express' and 'Firefly Services' as separate integration points is reasonable contextual addition, though not explicitly mentioned in the ground truth. Overall, the answer successfully addresses the multi-hop question by synthesizing information about Frame.io's positioning evolution across multiple years and product categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Involved_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 489,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "\nBetween 2022 and 2024 CVS deepened its **Medication‑Management** offering—originally disclosed as a product that helps PBM clients design lower‑cost, clinically appropriate formularies and real‑time benefit information (2022 chunk)—by layering a suite of clinical programs and digital tools.  In 2022 the focus was on generic‑substitution incentives, utilization‑management (UM) limits on opioids, and mail‑order/retail pharmacy processes that verified eligibility and performed drug‑utilization reviews.  By 2024 CVS added an **integrated, retrospective‑claims‑review strategy**, expanded **Pharmacy Advisor** and **Drug Savings Review** outreach (phone, digital, provider‑facing), introduced the **CVS Weight‑Management** program to optimize GLP‑1 use, and leveraged enhanced analytics and data‑sharing for real‑time lower‑cost alternatives (2024 chunk).  These programs are accredited (NCQA, URAC) and tied to **value‑based care** contracts—e.g., Oak Street Health primary‑care centers that assume full risk and contract with Medicare Advantage and CMS—creating a closed loop where adherence, cost‑efficiency, and quality incentives are coordinated across retail, mail‑order, specialty, and primary‑care sites.  Thus, CVS’s medication‑management approach evolved from basic formulary and generic‑substitution controls in 2022 to a comprehensive, digitally enabled, value‑based ecosystem by 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of CVS's medication management evolution between 2022 and 2024, with mostly accurate information and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the 2022 focus on formulary management, generic substitution, and opioid utilization limits; (2) Accurately captures 2024 additions including NovoLogix preauthorization platform, CVS Weight Management program with GLP-1 optimization, and enhanced analytics; (3) Properly synthesizes the shift from cost-containment to integrated, digitally-enabled model; (4) Correctly references Oak Street Health and value-based care integration; (5) Mentions accreditation bodies (NCQA, URAC) appropriately; (6) Good multi-hop reasoning connecting medication management across retail, mail-order, specialty, and primary care. MINOR ISSUES: (1) The LLM introduces 'Pharmacy Advisor' and 'Drug Savings Review' programs that are not explicitly mentioned in the ground truth answer, though these may be accurate from source documents—this represents potential over-specification beyond what was verified; (2) The ground truth specifically mentions '239 primary care centers across 27 states' for Oak Street Health, which the LLM answer does not include—this is a quantitative detail that should have been captured; (3) The LLM answer emphasizes 'retrospective claims review strategy' which is not highlighted in the ground truth, suggesting possible source document detail not in the knowledge graph answer. QUANTITATIVE ACCURACY: The answer lacks the specific Oak Street Health metrics (239 centers, 27 states) that appear in the ground truth. No calculation errors detected. QUALITATIVE ACCURACY: Multi-hop reasoning is sound—correctly synthesizes information across 2022 and 2024 timeframes and connects medication management to broader value-based care strategy. Entity identification is accurate (CVS, Oak Street Health, Medicare Advantage). CONTEXTUAL RELEVANCE: Directly addresses the question about evolution of medication management approach, clinical programs, and digital tools. The answer is well-structured and comprehensive, though it introduces some elements not in the ground truth verification source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1660,
        "completion_tokens": 592,
        "total_tokens": 2252
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "\nAdobe’s integration of Frame.io has deepened from the 2022 rollout of native review and approval tools in Premiere Pro and After Effects to a 2024 positioning of Frame.io as the core collaborative engine of Creative Cloud. The platform now offers real‑time, frame‑accurate commenting, Camera‑to‑Cloud upload, and direct integration with Photoshop, Lightroom, Premiere Pro, After Effects, Workfront, Adobe Express, Firefly Services and Adobe GenStudio, creating a unified workflow for video, design, 3D and document creation across Adobe’s ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in capturing Adobe's Frame.io integration evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 acquisition and initial integration into Premiere Pro and After Effects; (2) Accurately describes the 2024 positioning as a broader creative collaboration platform; (3) Correctly lists key features including real-time review/approval, Camera-to-Cloud functionality, and frame-accurate commenting; (4) Properly identifies expanded integrations across Photoshop, Lightroom, Workfront, and other Adobe products; (5) Accurately characterizes the strategic shift from video-specific to broader creative asset platform. MINOR ISSUES: (1) The LLM answer mentions additional integrations (Adobe Express, Firefly Services, Adobe GenStudio) not explicitly mentioned in the ground truth, though these represent reasonable extensions of the stated ecosystem expansion and don't contradict the original answer; (2) The ground truth mentions 'still images, design files, and PDFs' as specific file types supported, while the LLM answer uses broader language ('video, design, 3D and document creation') which is semantically equivalent but less specific; (3) The LLM answer adds 'frame-accurate commenting' which is a reasonable enhancement detail consistent with the evolution described but not explicitly stated in ground truth. MULTI-HOP REASONING: The answer successfully synthesizes the temporal evolution (2022 to 2024) and correctly identifies the progression from video-focused to broader platform. The integration across multiple Adobe products is properly synthesized. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not applicable. Dates (2022, 2024) are correct. Overall, the LLM answer provides a comprehensive and accurate response with only minor additions that enhance rather than contradict the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 526,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "\nThe 2023 disclosures show that recently executed transactions were used only as one of several inputs—alongside external price quotes, discounted‑cash‑flow models and comparable‑company multiples—to derive fair value for loans and other assets, with such inputs placed in Level 2 when supported by observable market liquidity and in Level 3 when they were unobservable. By 2024 the Firm deepened its reliance on those transactions, making them the primary basis for fair‑value measurements of assets held‑for‑sale (and other categories), calculating fair‑value changes from recently executed trades, market‑observable CDS spreads and basis adjustments, which reflects a clear evolution from a supplementary benchmark to a central, transaction‑driven valuation approach—consistent with the KG pattern that **MS Uses Recently Executed Transactions**.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that recently executed transactions were used as inputs in both 2023 and 2024, alongside other valuation methods (DCF, comparable multiples, market quotes). (2) Correctly notes the distinction between Level 2 (observable) and Level 3 (unobservable) classifications. (3) Accurately captures that by 2024, there was a more targeted/specific application to held-for-sale assets and other investments. (4) The general evolution narrative from supplementary to more central role is directionally correct.\n\nWEAKNESSES: (1) The LLM overstates the magnitude of change by claiming 2024 represents a shift to 'primary basis' and 'central, transaction-driven valuation approach'—the ground truth indicates the role 'remained significant' but was 'more specifically tied,' suggesting evolution rather than fundamental transformation. (2) The characterization of 2023 as using transactions 'only as one of several inputs' is somewhat misleading; the ground truth indicates they were already 'key inputs,' not merely supplementary. (3) The LLM introduces specific valuation components (CDS spreads, basis adjustments) that are not mentioned in the ground truth, which may be accurate but goes beyond what can be verified against the provided knowledge graph. (4) The phrase 'deepened its reliance' and 'clear evolution from supplementary to central' represents an interpretation that exceeds the ground truth's more measured description of 'more specifically tied' application.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize 2023 vs 2024 evolution correctly in structure, but the interpretation of magnitude and significance diverges from ground truth. The ground truth emphasizes continuity with refinement ('remained significant but more specifically tied'), while the LLM emphasizes transformation ('deepened reliance,' 'primary basis').\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers or dates are provided in either answer, so quantitative accuracy is not directly testable. However, the characterization of the evolution itself is the key factual claim, and here the LLM overstates the degree of change.\n\nSEMANTIC EQUIVALENCE: While the general direction is correct, the LLM's language choices ('primary basis,' 'central,' 'deepened reliance') suggest a more dramatic shift than the ground truth supports ('remained significant,' 'more specifically tied').",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Uses]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 641,
        "total_tokens": 2031
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe’s treatment of **Substance 3D Stager** shifted from being merely listed as a trademark in the 2022 10‑K (Chunk 1) to being presented as a core element of the **Substance 3D Collection** in the 2024 filing (Chunk 2).  The 2024 description emphasizes that Stager now lets customers **build and assemble 3D scenes** and works in concert with the other Substance 3D tools (Painter, Sampler, Designer, Modeler) and Adobe’s broader AI‑driven ecosystem, positioning it as a central, integrated platform rather than an isolated product.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024, matching the ground truth's timeframe; (2) Accurately captures the shift from Substance 3D Stager being 'merely listed as a trademark' in 2022 to being presented as part of the 'Substance 3D Collection' in 2024, which semantically matches the ground truth's description of moving from 'established product' to 'comprehensive view of ecosystem'; (3) Correctly identifies the specific functionality ('build and assemble 3D scenes') that matches the ground truth exactly; (4) Accurately lists all companion tools (Painter, Sampler, Designer, Modeler) as mentioned in the ground truth; (5) Properly synthesizes the multi-hop reasoning by connecting the product evolution across two filing years and positioning it within the broader ecosystem context; (6) Uses appropriate terminology ('core element,' 'integrated platform,' 'central') that conveys the strategic shift described in the ground truth. MINOR CONSIDERATIONS: The LLM answer adds contextual detail about 'AI-driven ecosystem' which, while not explicitly mentioned in the ground truth excerpt provided, represents reasonable inference from 2024 Adobe positioning and does not contradict the ground truth. The answer is slightly more detailed and interpretive than the ground truth but maintains factual accuracy. No quantitative errors, dates are correct, and the multi-hop synthesis across 2022 and 2024 filings is sound and complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 429,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "\nFrom 2022 to 2023 GE moved grid‑scale batteries from a peripheral, “potential‑technology” reference to a core, investment‑driven pillar of its energy‑transition roadmap. In the 2022 filing the company merely noted that deep decarbonisation would “depend in part on technologies that are not yet deployed… such as grid‑scale batteries or other storage solutions,” framing them as one uncertain option among several. By the 2023 filing GE explicitly groups grid‑scale batteries with other key storage technologies and states that “successfully navigating these changes will require significant investments in… new technology and products, both by GE and third parties,” signalling a deliberate strategic reliance on battery storage to enable the company’s broader decarbonisation goals. This evolution is captured by the knowledge‑graph relationship GE → Invests_In → Grid‑Scale Batteries and Grid‑Scale Batteries → Depends_On → GE, reflecting GE’s growing strategic commitment to and dependence on grid‑scale battery solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of GE's evolving strategic positioning on grid-scale batteries from 2022 to 2023. STRENGTHS: (1) Correctly identifies the core evolution from peripheral/speculative consideration to more central strategic component; (2) Accurately captures the shift in language from 'may become more important' to explicit strategic reliance; (3) Properly synthesizes the multi-hop relationship showing GE's growing dependence on grid-scale battery technologies; (4) Correctly references both 2022 and 2023 filings with appropriate temporal comparison; (5) Uses accurate characterizations like 'potential-technology reference' and 'core, investment-driven pillar'; (6) Appropriately notes the shift from uncertainty ('one uncertain option among several') to deliberate strategic commitment. MINOR ISSUES: (1) The LLM introduces knowledge-graph notation (GE → Invests_In → Grid-Scale Batteries) that, while conceptually sound, goes slightly beyond what the ground truth explicitly states about the relationship structure - the ground truth focuses on the narrative shift rather than formal relationship definitions; (2) The phrase 'Grid-Scale Batteries → Depends_On → GE' is somewhat inverted from the ground truth's framing, which emphasizes GE's dependence on grid-scale batteries rather than batteries depending on GE; (3) The LLM adds interpretive language about 'investment-driven pillar' that, while semantically aligned with the ground truth's concept of 'more central component,' represents slight extrapolation. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either answer, so this dimension scores high (9/10) - the temporal references (2022, 2023) are correct. QUALITATIVE ACCURACY: The reasoning is sound and multi-hop synthesis is correct (8/10) - minor deduction for the relationship notation interpretation. CONTEXTUAL RELEVANCE: Excellent alignment with the question's focus on strategic positioning evolution and level of reliance (9/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 546,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "\nCVS continued to disclose that it held **no broker‑quoted debt securities** in either the 2022 or the 2024 filing (the 2022 10‑K notes “the Company did not have any broker quoted debt securities for the years ended December 31, 2021 and 2020,” and the 2024 10‑K repeats “the Company did not have any broker quoted debt securities for the years ended December 31, 2024 and 2023”). Accordingly, the **negative‑impact relationship** between CVS and broker‑quoted instruments (CVS → Broker Quoted Debt Securities [Negatively_Impacts] and the reciprocal “Discloses” link) remained unchanged—there was no presence of such securities to affect fair‑value measurements or broader financial‑reporting outcomes. The company’s fair‑value hierarchy therefore relied exclusively on Level 2 inputs from secondary sources and Level 3 internally‑priced securities, a pattern that persisted from 2022 through 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that CVS had no broker-quoted debt securities in both 2022 and 2024 filings. (2) The specific years mentioned (2021, 2020, 2024, 2023) are accurate. (3) The quantitative facts about the absence of such securities are correct. (4) The mention of Level 2 and Level 3 inputs is appropriate context.\n\nWEAKNESSES: (1) The LLM introduces knowledge graph terminology ('Negatively_Impacts', 'Discloses' links) that appears to be metadata structure rather than actual filing content. This is problematic because the ground truth emphasizes that the 2024 disclosure 'no longer mentions any negative impact or specific review process,' suggesting a CHANGE in emphasis/relevance over time. The LLM states the negative-impact relationship 'remained unchanged,' which contradicts the ground truth's key finding about reduced emphasis. (2) The LLM fails to capture the critical evolution mentioned in the ground truth: that 2024 disclosures show 'reduced emphasis or relevance of this topic' compared to 2022. The ground truth explicitly notes the 2024 filing 'no longer mentions' negative impact, indicating a substantive change in disclosure approach. (3) The LLM's statement that the pattern 'persisted from 2022 through 2024' misses the nuance that while the absence of securities remained constant, the disclosure treatment/emphasis changed. (4) The LLM conflates knowledge graph structure with actual filing content, which is a reasoning error. The ground truth focuses on how disclosure EVOLVED (changed emphasis), while the LLM focuses on what remained constant (absence of securities).\n\nMULTI-HOP REASONING: The question asks about evolution/change between 2022 and 2024. The ground truth identifies both continuity (no securities in either year) AND change (reduced emphasis in 2024). The LLM identifies continuity but misses or downplays the change in disclosure emphasis, which is the core of the 'evolution' the question asks about. This is a significant reasoning gap.\n\nCORRECTION NEEDED: The LLM should have emphasized that while CVS continued to have no broker-quoted debt securities, the 2024 disclosure reduced or eliminated discussion of negative impacts/review processes that may have been present in 2022, representing an evolution in how the company addresses this topic in its fair value measurement disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 631,
        "total_tokens": 2038
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "\nBetween the 2023 filing (shown on page 88 of BLK_10k_2023.pdf, where equity‑securities‑at‑FVTNI = $1,211 million and total equity‑method holdings = $1,895 million) and the 2024 filing (page 94 of BLK_10k_2024.pdf, where equity‑securities‑at‑FVTNI = $1,950 million and total equity‑method holdings = $2,783 million), BlackRock’s disclosed stake grew noticeably: equity‑mutual‑fund securities rose by $0.74 bn (≈ 61 %) and equity‑method investments increased by $0.89 bn (≈ 47 %).  Moreover, the equity‑method portfolio shifted toward larger positions in mutual funds (up from $0.181 bn to $0.478 bn), private‑equity funds (up from $0.885 bn to $1.060 bn) and real‑asset funds (up from $0.304 bn to $0.520 bn), indicating a re‑allocation of BlackRock’s disclosed investments across these categories.  (Both tables are linked through the KG pattern ORG‑[Has_Stake_In]→ FIN_INST ←‑[Discloses] ORG.)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) FUNDAMENTAL MISINTERPRETATION: The LLM conflates 'equity securities/mutual funds' (a single line item of $1,211M in 2023, $1,950M in 2024) with 'equity method investments' ($1,895M in 2023, $2,783M in 2024). The ground truth clearly states these are TWO SEPARATE CATEGORIES. The LLM incorrectly labels the first category as 'equity-securities-at-FVTNI' and the second as 'total equity-method holdings,' then treats them as if they're the same thing. (2) CALCULATION ERRORS: The LLM calculates the change in 'equity-securities-at-FVTNI' as $0.74bn (≈61%), but the correct calculation is: $1,950M - $1,211M = $739M = $0.739bn, which is approximately 61% - this is correct. However, for equity method investments: $2,783M - $1,895M = $888M = $0.888bn (≈47%) - the LLM states $0.89bn which rounds correctly. (3) UNSUPPORTED DETAIL: The LLM provides granular breakdowns of equity method portfolio shifts (mutual funds $0.181bn to $0.478bn, private equity $0.885bn to $1.060bn, real assets $0.304bn to $0.520bn) that are NOT present in the ground truth answer. These appear to be fabricated or sourced from unstated data. (4) SEMANTIC CONFUSION: The LLM's statement 'equity-mutual-fund securities rose by $0.74 bn' is misleading - this is the total equity securities/mutual funds category, not a subcategory. (5) CORRECT ELEMENTS: The base numbers ($1,211M, $1,895M, $1,950M, $2,783M) and years (2023, 2024) are accurate. The percentage calculations for the main categories are approximately correct. (6) MULTI-HOP REASONING: While the LLM attempts to synthesize across two years and two categories, the fundamental misunderstanding of what constitutes each category undermines the analysis. The KG reference at the end appears to be an attempt to justify methodology but doesn't validate the factual claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 497,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "\nUnitedHealth Group (UNH) continued to view the vast majority of its unrealized losses on available‑for‑sale debt securities as driven by interest‑rate changes rather than credit deterioration—concluding in 2022 that the losses were temporary and that the allowance for credit losses was not material (Chunk 1). By 2024 the company had formalized the assessment of credit‑related impairment, applying present‑value cash‑flow testing, issuer financial condition and rating analysis to record an allowance that offsets investment and other income, while still reporting most unrealized declines through other comprehensive income (Chunk 2). The disclosed risk factor and the bidirectional link between UNH and Credit‑Related Impairment illustrate that the methodology evolved from a qualitative, non‑material view to a structured allowance process, even though the allowance remains immaterial.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: The answer correctly identifies the 2022 position (unrealized losses driven by interest rate increases, not credit deterioration; allowance for credit losses not material) and the 2024 position (formalized assessment methodology with structured allowance account). The core narrative of evolution from qualitative to formalized framework is accurate. (2) QUANTITATIVE ACCURACY: No specific dollar amounts or percentages were required in either the ground truth or LLM answer, so this dimension is not directly testable. However, the temporal references (2022, 2024) and the characterization of materiality ('not material' in 2022, 'remains immaterial' in 2024) are accurate. (3) ENTITY ACCURACY: UnitedHealth Group (UNH) is correctly identified. The financial metrics referenced (unrealized losses, allowance for credit losses, investment and other income) are all correct. The years 2022 and 2024 are properly cited. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and connects the evolution of methodology (present-value cash-flow testing, issuer credit condition analysis) with the shift in accounting treatment (from qualitative assessment to formalized allowance account). The logical progression is sound. (5) SEMANTIC EQUIVALENCE: The LLM answer uses slightly different phrasing than the ground truth ('formalized the assessment' vs 'shift from qualitative to formalized framework') but conveys identical meaning. The characterization of the allowance as 'recorded as a separate component through an allowance account' is semantically equivalent to 'recorded as a separate component through an allowance account.' Minor note: The LLM answer includes parenthetical references to 'Chunk 1' and 'Chunk 2' which are not part of the ground truth but do not detract from accuracy. The statement that the allowance 'remains immaterial' in 2024 is a reasonable inference from the ground truth's description of the evolution, though the ground truth does not explicitly state the 2024 allowance is immaterial—this is a minor interpretive addition that is consistent with the overall narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> RISK_FACTOR <-[Evaluates]- ORG",
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 603,
        "total_tokens": 2076
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2023 the ATMP JV’s carrying‑value of AMD’s equity investment rose from roughly **$83 million to $99 million**, and the equity‑income gain recorded in the consolidated statement increased from **$14 million to $16 million**, indicating a modest rise in both the stake’s book value and the earnings it generates.  This evolution is set against the backdrop of AMD’s expanding related‑party activity with the ATMP JV—purchases grew to **$1.7 billion in 2023** while payables to the JV fell to **$363 million**—and the company also continues to hold a separate **THATIC JV**, which has a **zero carrying value** but contributed **$34 million of licensing gain in 2023** (and $102 million in 2022), underscoring the broader related‑party portfolio while leaving the ATMP JV’s growth trajectory unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy on the core question about AMD's ATMP JV financial relationship evolution. All primary numbers are correct: carrying value increased from $83 million (2022) to $99 million (2023), and equity income rose from $14 million to $16 million. The answer correctly identifies these as indicators of growing financial stake and increased profitability. The quantitative accuracy is perfect—all dollar amounts, years, and the directional changes are accurate. The multi-hop reasoning is sound, synthesizing investment value and equity income data across two fiscal years. The LLM goes beyond the ground truth by providing additional context about related-party transactions ($1.7 billion in purchases, $363 million in payables) and the separate THATIC JV ($34 million licensing gain in 2023, $102 million in 2022), which adds valuable context without contradicting the core answer. The phrasing 'modest rise' appropriately characterizes the percentage increases (19% for carrying value, 14% for equity income). The only minor consideration is that the additional information about THATIC JV and related-party transactions, while accurate and contextually relevant, slightly expands beyond the specific question scope—however, this is presented as supplementary context rather than core answer material, making it a strength rather than a weakness. The answer demonstrates excellent synthesis of multi-hop financial data across years and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 409,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "\nUnitedHealth Group’s exposure to tort claims has remained material through 2022‑2024, continuing to arise chiefly from medical‑malpractice and other health‑care‑delivery claims brought against its affiliated physicians, hospitals and service providers; the company is largely self‑insured and records reserves for these risks, but the actual losses can exceed estimates and may result in substantial monetary damages, reputational harm and a material adverse effect on its results of operations, financial position and cash flows, as disclosed in both the 2022 and 2024 SEC filings.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly identifies that UnitedHealth Group faces material tort claims related to medical malpractice and healthcare delivery, and accurately notes the company is self-insured with reserves that may be exceeded by actual losses. The answer also correctly references both 2022 and 2024 filings. However, the answer has significant weaknesses in addressing the core question about how exposure has 'evolved' between these years. The LLM provides a largely static description of the tort claim landscape, stating claims 'remained material' and 'continued to arise' without substantively capturing the evolution requested. The ground truth identifies a meaningful shift: (1) In 2022, the focus was narrowly on self-insured liabilities for medical malpractice against affiliated physicians with emphasis on new theories of liability and damage cap concerns; (2) By 2024, the focus broadened to include clinical quality and patient safety standards, with greater emphasis on reputational harm and systemic business relationship risks. The LLM answer mentions 'reputational harm' and 'material adverse effect' but does not clearly articulate this evolution from narrow medical malpractice exposure to broader healthcare delivery and systemic risks. The answer reads more as a static summary of consistent risk factors rather than a comparative analysis of how the nature and scope of exposure changed. The LLM also fails to capture the important distinction that 2022 emphasized 'potential for actual losses to significantly exceed recorded liabilities' with specific concern about new liability theories, while 2024 shifted emphasis to broader systemic risks. No quantitative data is provided in either answer, so quantitative accuracy cannot be fully assessed, but the lack of specific financial impact metrics (which the question asks about) represents an omission. The answer is factually sound but incompletely addresses the evolution aspect of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> RISK_FACTOR <-[Faces]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 532,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "\nIn 2023 Boeing reported $12.7 bn of cash, $3.3 bn of short‑term investments and $10 bn of unused borrowing capacity on its revolving lines, including a $3.0 bn three‑year facility expiring August 2025 and a $3.2 bn five‑year line expiring October 2024, while rating upgrades from S&P, Moody’s and Fitch signaled an improving credit outlook. By the end of 2024 the company terminated the $0.8 bn 364‑day facility and the $3.2 bn five‑year line and entered a new $4.0 bn five‑year revolving credit agreement maturing May 2029, leaving the $3.0 bn three‑year agreement in place and raising total undrawn capacity to $10 bn as of December 31 2024. This evolution—extending maturities, expanding committed capacity and maintaining a large undrawn back‑up pool—shows Boeing’s liquidity strategy of relying on longer‑dated credit facilities and cash‑equivalent resources to fund operations and strategic initiatives.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key credit facilities and dates. Verified numbers: $3.0 billion three-year facility expiring August 2025 (correct), $4.0 billion five-year facility expiring May 2029 (correct), $0.8 billion 364-day facility termination (correct), $3.2 billion five-year line termination (correct). The answer properly synthesizes the multi-hop evolution between 2023 and 2024, correctly identifying which facilities were terminated and which remained. The reasoning about liquidity strategy is sound and well-supported by the structural changes described. Minor strengths: the answer provides additional context (cash positions, short-term investments, credit rating signals, total undrawn capacity) that enriches understanding beyond the ground truth baseline. The semantic meaning aligns well with the original answer's core conclusion about strategic shift toward longer-dated facilities and enhanced liquidity capacity. One minor consideration: the ground truth mentions 'two other credit facilities' being terminated while the LLM specifies the $0.8 billion 364-day facility and $3.2 billion five-year line—this is more precise and appears factually accurate based on the details provided. The answer comprehensively addresses both parts of the question (structure/capacity evolution AND strategic implications). No calculation errors detected. The multi-hop synthesis correctly connects 2023 baseline conditions with 2024 changes to draw conclusions about Boeing's liquidity strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 428,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "\nIn 2023 the company recorded $56 million of fair‑value expense from the vested portion of the 2017 performance‑based options and realized $44 million of intrinsic value when those options were exercised, while in 2024 the final tranche vested with $52 million of fair‑value expense and generated $373 million of intrinsic value from exercised options, completing the three‑year vesting schedule that began with the first two tranches in 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All quantitative values are correct: 2023 fair value ($56M), 2023 intrinsic value ($44M), 2024 fair value ($52M), and 2024 intrinsic value ($373M) match the ground truth exactly. The answer correctly identifies the evolution of these metrics between the two years and accurately characterizes the trends (slight decrease in fair value, substantial increase in intrinsic value). The LLM answer goes beyond the ground truth by providing additional context about the vesting schedule structure (three-year vesting with tranches in 2022, 2023, and 2024), which is relevant and helpful contextual information that enhances understanding without contradicting the original answer. The multi-hop synthesis is sound - the answer correctly combines information about both fair value and intrinsic value across both years. The terminology is precise (fair-value expense, intrinsic value, vested portion, exercised options). The only minor distinction is that the LLM uses slightly different phrasing ('recorded $56 million of fair-value expense' vs 'fair value...was $56 million'), but this is semantically equivalent and actually more precise in describing the accounting treatment. The answer fully addresses all parts of the question regarding how the financial impact evolved between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 378,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "\nBetween 2022 and 2023 AMD refined the way it estimates the adjustments needed for product‑return rights by moving from a general reliance on historical distributor incentives and market‑price trends to a more detailed model that explicitly incorporates **actual historical return rates, rebate‑attainment data and trended return‑rate information**, and that **adjusts those rates for known events or current economic conditions**.  The 2023 filing (Chunk 2) adds that these adjustments are evaluated under **ASC 606‑10‑32‑8 through 14** and that the estimate now “includes adjustments, if any, for known events or current economic conditions, or both,” whereas the 2022 discussion (Chunk 1) described the same process only in terms of “actual historical incentives … and known future price movements.”  Consequently, the methodology became more granular and formally tied to the variable‑consideration guidance, while still using trended historical return data and management judgment to arrive at estimates that have historically been “materially consistent with actual results.”",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the key evolution: 2022 used historical return rates adjusted for known events, while 2023 added explicit reference to ASC 606-10-32-8 through 14 and 'most likely amount' methodology. (2) The ASC 606 citation is accurate and represents a genuine methodological refinement. (3) The answer correctly captures that both years used historical data as a foundation. (4) The characterization of the 2023 approach as 'more structured and codified' aligns with ground truth. WEAKNESSES: (1) The LLM introduces language about 'distributor incentives and market-price trends' and 'rebate-attainment data' that is not explicitly mentioned in the ground truth answer. While these may be reasonable inferences about what 'variable consideration' entails, they represent additions beyond what the ground truth states. (2) The phrase 'actual historical incentives...and known future price movements' attributed to 2022 is not directly quoted in the ground truth, which uses 'trended actual historical product return rate information.' The LLM appears to be paraphrasing or inferring rather than directly referencing the source language. (3) The answer conflates 'rebates' with 'return rights' - while both are part of variable consideration, the question specifically asks about 'product return rights' adjustments. The ground truth maintains this distinction more clearly. (4) The statement about estimates being 'materially consistent with actual results' is not mentioned in the ground truth answer and appears to be an inference. MULTI-HOP REASONING: The LLM successfully synthesizes the evolution across two years and correctly identifies the ASC 606 standard as the key methodological anchor for 2023. However, the reasoning includes some inferred details not present in ground truth. SEMANTIC EQUIVALENCE: The core message is similar - methodology became more formal and standards-aligned - but the LLM adds interpretive layers that go beyond the ground truth's more direct statement of the changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 547,
        "total_tokens": 1991
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "\nThe 2017 Performance‑based Options fell from **1,549,080 shares outstanding at 31 Dec 2023** to **625,825 shares outstanding at 31 Dec 2024**—a net drop of 923,255 shares, which exactly equals the **905,219 shares that were exercised in 2023** plus the **18,036 shares that were forfeited** (Chunk 2). This decline shows that the majority of the vested tranche from 2023 was either exercised or lost, leaving only the final 2024 installment (still subject to vesting) as the remaining outstanding option shares, indicating a clear shift from vesting toward exercise and forfeiture of these performance‑based options (Chunk 1).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) CALCULATION ERROR: The LLM states the net drop is 923,255 shares (1,549,080 - 625,825 = 923,255), which is arithmetically correct. However, the LLM then claims this 'exactly equals the 905,219 shares that were exercised in 2023 plus the 18,036 shares that were forfeited.' This is FALSE: 905,219 + 18,036 = 923,255, which does match the net drop, BUT the ground truth explicitly states these exercises and forfeitures occurred in 2024, NOT 2023. The LLM incorrectly attributes the 905,219 exercises to 2023 when they should be attributed to 2024. (2) TEMPORAL MISATTRIBUTION: The ground truth clearly states 'during 2024' for both the 905,219 exercises and 18,036 forfeitures. The LLM says 'exercised in 2023' which is factually incorrect and contradicts the ground truth. (3) CORRECT ELEMENTS: The opening and closing share counts (1,549,080 and 625,825) are correct. The exercise (905,219) and forfeiture (18,036) numbers are correct. The overall narrative about completion of the option lifecycle is appropriate. (4) MULTI-HOP REASONING: The LLM attempted to synthesize the relationship between the share count change and the exercise/forfeiture activity, but made a critical error in the temporal attribution that undermines the accuracy of the answer. The reasoning structure is sound, but the execution contains a significant factual error regarding which year the exercises occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 394,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "\nBetween 2022 and 2024 Optum Rx’s Pharmacy Care Services moved from a traditional pharmacy‑benefit manager—operating a network of >67 k retail, specialty and infusion pharmacies, managing $112 billion of drug spend (including $45 billion specialty spend) and offering clinical programs, utilization‑management and adherence tools—to a central, data‑driven pillar of UnitedHealth Group’s integrated health‑care ecosystem; by 2024 it was explicitly positioned as one of Optum’s four reportable segments that “improve overall health‑system performance by optimizing quality, reducing costs and leveraging distinctive capabilities in data and analytics, pharmacy‑care services and whole‑person health,” directly feeding UnitedHealthcare’s coordinated‑care, cost‑containment and network‑access strategies. This evolution reflects Optum Rx’s expanded service offering and its strategic role as a key supplier of pharmacy‑care capabilities within the UNH‑controlled Optum portfolio, aligning with UnitedHealthcare’s use of Optum’s capabilities to coordinate patient care, improve affordability, analyze cost trends and deliver a seamless consumer experience.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) All quantitative data is accurate - correctly cites $112 billion in pharmaceutical spending, $45 billion in specialty pharmaceutical spending, and >67,000 retail pharmacies for 2022. (2) Correctly identifies the evolution from traditional PBM to integrated ecosystem component. (3) Accurately captures the 2024 positioning emphasizing data analytics, pharmacy care services, and health care operations. (4) Properly synthesizes multi-hop information across 2022-2024 timeframe and UnitedHealth Group structure. (5) Number formatting is consistent and correct.\n\nWEAKNESSES: (1) The LLM answer introduces additional detail about 'four reportable segments' and specific strategic alignment with UnitedHealthcare's coordinated-care strategies that, while plausible, goes beyond what the ground truth explicitly states. The ground truth does not mention 'four reportable segments' or provide this level of operational detail about UnitedHealthcare integration. (2) The phrase 'key supplier of pharmacy-care capabilities within the UNH-controlled Optum portfolio' adds interpretive language not present in the original answer. (3) While the LLM captures the essence of strategic evolution, it adds inferences about operational structure and reporting relationships that exceed the ground truth scope.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across the 2022-2024 period and identifies the shift from standalone PBM to integrated ecosystem component. The reasoning is sound and logically structured.\n\nSEMANTIC EQUIVALENCE: The core message aligns with ground truth - evolution from traditional PBM to integrated strategic component - but the LLM adds interpretive details about organizational structure and strategic alignment that go beyond the provided ground truth, creating minor factual overreach rather than errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Controls]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1561,
        "completion_tokens": 503,
        "total_tokens": 2065
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "\nBetween 2023 and 2024 the exposure to deferred‑cash‑compensation plans within BlackRock’s Equity Securities at FVTNI grew sharply – the 2023 filing listed only a $9 million balance of such investments (embedded in the overall equity‑securities amount), whereas the 2024 10‑K presents a separate “Investments related to deferred cash compensation plans” line item of $173 million, measured at quoted NAV prices (Level 1).  This shift reflects both a material increase in the amount held for those plans and a change in valuation methodology, and it occurs against a broader rise in the FVTNI portfolio (e.g., $1.95 billion of mutual‑fund holdings and $2.78 billion of equity‑method investments disclosed in the 2024 table).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key numbers ($9 million in 2023, $173 million in 2024) and accurately captures the core finding that there was a reclassification/realignment of how deferred cash compensation plan investments were reported. The numbers are factually accurate and properly formatted. The LLM correctly notes this represents a material increase and change in how the investments are categorized.\n\nWEAKNESSES: (1) The LLM introduces potentially misleading information about 'valuation methodology' change (claiming a shift to 'quoted NAV prices (Level 1)'), which is not explicitly stated in the ground truth and may be an inference not supported by the source data. (2) The LLM adds contextual details about '$1.95 billion of mutual-fund holdings and $2.78 billion of equity-method investments' which, while potentially accurate, are not part of the ground truth answer and may distract from the core finding about the deferred compensation plan reclassification. (3) The ground truth explicitly states the $173 million appeared 'under Equity Method section' but the LLM's phrasing about 'Level 1' valuation is not clearly aligned with this characterization.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the multi-hop requirement by comparing 2023 vs 2024 data and identifying the reclassification pattern. However, the addition of unsupported details about valuation methodology weakens the synthesis quality.\n\nFACTUAL VERIFICATION: Core numbers are correct ($9M → $173M), years are correct (2023 vs 2024), company is correct (BlackRock). The reclassification finding is accurate. However, the characterization of the change as involving a 'valuation methodology' shift is not supported by the ground truth and represents an inference that may be incorrect.\n\nOVERALL: The answer captures the essential facts and numbers correctly but adds interpretive details that are not grounded in the source material, which reduces confidence in the overall accuracy despite getting the core facts right.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 547,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "\nThe 2022 filing (Chunk 1) states that, as of 31 August 2022, Accenture’s aggregate available authorization for its publicly announced open‑market share‑purchase and related programs was **$3,129,296**, while the 2024 filing (Chunk 2) reports an authorization of **$2,694,281** as of 31 August 2024—a decline of roughly **$435 million (about 14 %)**.  \n\nThis reduction in the disclosed share‑purchase authority indicates that Accenture is scaling back the size of its buy‑back program, suggesting a shift in its capital‑allocation strategy toward preserving cash or directing resources to other strategic initiatives rather than expanding equity‑repurchase activities.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: The two key figures are correct—$3,129,296 (2022) and $2,694,281 (2024)—matching the ground truth exactly. The calculated difference of approximately $435 million is accurate ($3,129,296 - $2,694,281 = $435,015, which rounds to $435M). The percentage decline calculation of ~14% is also correct (435,015 / 3,129,296 ≈ 13.9%, rounds to 14%). ENTITY ACCURACY: Accenture is correctly identified, the fiscal years (2022 and 2024) are correct, and the metric (aggregate available authorization for open-market share purchase program) is properly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across two different fiscal years and correctly interprets the trend. The reasoning that a decrease in authorization indicates a shift toward more conservative capital allocation or redirection of resources is sound and aligns with the ground truth interpretation. COMPLETENESS: The answer addresses both parts of the multi-part question—the numerical change and what it indicates about capital allocation strategy. The LLM provides slightly more detailed interpretation than the ground truth (mentioning 'preserving cash or directing resources to other strategic initiatives'), which adds value without contradicting the original answer. MINOR NOTES: The LLM uses the format '$435 million (about 14%)' while the ground truth uses slightly different phrasing, but this is a semantic variation that does not affect correctness. The interpretation of 'more conservative approach' vs. 'scaling back the size of buy-back program' are semantically equivalent. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 463,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 Accenture’s disclosures moved from a broad 2022 statement that it would “use a significant portion of cash generated from operations for share repurchases” of its Canada‑Holdings exchangeable shares—describing the purchases could be made in the open market, via Rule 10b‑5 plans and could be accelerated, suspended or discontinued without notice (Chunk 1)—to a 2024 filing that spells out a concrete open‑market share‑purchase program with $2.69 bn of authorized funding for buying back Class A ordinary shares **and** for the redemption of Class X shares (the exchangeable shares) (Chunk 2).  The 2024 disclosure also clarifies shareholder rights that were only implied in 2022: Class X shares carry one vote but no dividend or liquidation entitlement, may be redeemed at par only if the redemption does not reduce a holder’s exchangeable‑share count below its current holdings, and can be exchanged one‑for‑one for Class A shares (subject to cash or market‑price pricing), thereby detailing both the evolving repurchase mechanics and the precise rights attached to the exchangeable shares.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) QUANTITATIVE ACCURACY - The LLM states '$2.69 bn of authorized funding' but the ground truth specifies '$2,694,281' (approximately $2.7 million, not $2.69 billion). This is a massive error - off by a factor of ~1000x. The ground truth explicitly states '$2,694,281 for share repurchase programs.' (2) FACTUAL INACCURACY - The LLM claims the 2024 authorization covers 'Class A ordinary shares AND for the redemption of Class X shares' with '$2.69 bn' total, but the ground truth indicates the remaining authorization is specifically $2,694,281, which is a much smaller amount and appears to be a specific remaining balance rather than a new authorization. (3) PARTIAL CORRECTNESS - The LLM correctly identifies: (a) the evolution from general 2022 intentions to more detailed 2024 disclosures, (b) the one-for-one exchangeability of Class X for Class A shares, (c) the alignment of Class X shares with exchangeable shares, (d) the shift toward more structured/quantified approach. (4) MISSING ELEMENTS - The LLM does not clearly articulate that the 2024 disclosure includes 'more detailed descriptions of the rights' as emphasized in the ground truth, though it does mention some rights (voting, no dividend/liquidation entitlement). (5) MULTI-HOP REASONING - The synthesis across 2022 and 2024 is conceptually sound, but the critical numerical error undermines the entire answer. The ground truth emphasizes the specific remaining authorization amount as evidence of a 'more structured and quantified approach,' but the LLM misrepresents this figure by three orders of magnitude. This is a fundamental factual error that cannot be overlooked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1538,
        "completion_tokens": 454,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "\nThe global revenue from **Electrophysiology Devices** grew from **$2,195 million in 2023** (ABT 2023 10‑K, “Electrophysiology” line under Medical Devices) to **$2,467 million in 2024** (ABT 2024 10‑K, same line), reflecting a **14.4 % increase on a constant‑currency basis**—the “Total Change Excl. Exchange” figure shown for Electrophysiology in the 2024 table. This constant‑currency growth excludes the modest foreign‑exchange headwind of –2.1 percentage points that is reported for the segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key quantitative facts are correct: (1) 2023 revenue of $2,195 million - correct, (2) 2024 revenue of $2,467 million - correct, (3) constant-currency growth of 14.4% - correct, (4) identification of the foreign exchange headwind of -2.1 percentage points - correct. The multi-hop reasoning is sound: the model correctly synthesized information from both the 2023 and 2024 10-K filings, identified the Electrophysiology Devices segment, extracted the relevant revenue figures, and properly distinguished between total change (12.3%, which can be calculated as (2,467-2,195)/2,195 = 12.3%) and the constant-currency change (14.4%). The answer correctly addresses all parts of the question: (1) how revenue evolved (from $2,195M to $2,467M), (2) the percentage change excluding FX impact (14.4%), and (3) provides context about the FX headwind. The only minor observation is that while the ground truth mentions the total change of 12.3%, the LLM answer emphasizes the constant-currency figure of 14.4% without explicitly stating the 12.3% total change figure, though this is not a factual error—just a different emphasis. The sourcing is properly attributed to ABT 10-K filings. All numbers are accurate and the reasoning is logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 363,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Accenture’s 16 % equity stake in Duck Creek Technologies grew markedly in value—its carrying amount of $138.9 M (with an estimated fair value of $223.2 M as of Aug 2022) was later reflected in a $253 M investment gain recorded in fiscal 2023, which is reported in “Other income (expense), net” and excluded from GAAP earnings but included in the company’s adjusted metrics.  This appreciation boosted adjusted earnings‑per‑share and helped lift operating margin, illustrating how the investment’s rising valuation positively impacted Accenture’s overall financial performance over the period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The 16% ownership stake is accurate; (2) The $253M investment gain figure is correct; (3) The fiscal 2023 timing of the gain is accurate; (4) The characterization of the gain being in 'Other income (expense), net' and excluded from GAAP earnings is correct; (5) The overall narrative about appreciation and positive impact on financial performance is sound. PROBLEMATIC ELEMENTS: (1) The carrying amount of $138.9M as of Aug 2022 is not mentioned in the ground truth and appears to be an additional/different figure than the $223,166 (or $223.2M) stated in the original answer - this creates confusion about which valuation is being referenced; (2) The ground truth states the investment was valued at '$223,166' in fiscal 2022, which the LLM interprets as '$223.2M' - this is a potential unit confusion (thousands vs millions), though the LLM's interpretation of $223.2M fair value aligns with context; (3) The LLM states the gain was 'recorded in fiscal 2023' while the question asks about evolution 'between fiscal 2022 and fiscal 2024' - the LLM does address this period but emphasizes fiscal 2023 specifically; (4) The claims about impact on 'adjusted earnings-per-share' and 'operating margin' are not substantiated in the ground truth provided. MULTI-HOP REASONING: The LLM successfully synthesizes the investment valuation change and its financial impact across the time period, though it introduces additional details not in the ground truth. The reasoning about how the investment appreciation affected financial metrics is logical but goes beyond what can be verified from the provided ground truth. QUANTITATIVE ACCURACY ISSUE: The $223,166 vs $223.2M discrepancy is significant - if the original figure is in thousands, the LLM's conversion is correct; if it's already in millions, there's a major error. The presence of both $138.9M and $223.2M figures without clear reconciliation in the LLM answer creates ambiguity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 543,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "\nBetween 2022 and 2023 the size of Union Pacific’s equity‑based awards grew sharply and their makeup changed: the 2022 filing (Chunk 1) shows 389,207 retention shares outstanding under the 2021 Plan, whereas the 2023 filing (Chunk 2) reports 954,405 retention shares plus 366,046 retention units (the latter not counted in the 2022 numbers) – more than doubling the share‑based component and adding a new unit‑based award class.  This expansion—driven by the newer 2021 Stock Incentive Plan and the phase‑out of the older 2004/2013 plans—signals that Union Pacific is moving toward a larger, equity‑focused compensation strategy that aligns executive pay with long‑term shareholder value and reduces reliance on cash‑based incentives.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with all key numbers correctly cited: 389,207 retention shares in 2022, 954,405 retention shares in 2023, and 366,046 retention units in 2023. The quantitative comparison is accurate—the retention shares more than doubled from 2022 to 2023. The multi-hop synthesis is sound, correctly identifying the shift in compensation composition and the introduction of retention units as a new award class. The answer appropriately addresses both parts of the question: (1) how composition and scale changed, and (2) what this indicates about strategy. The LLM provides additional context about the 2021 Stock Incentive Plan and the phase-out of older plans (2004/2013), which adds valuable interpretive depth beyond the ground truth. The reasoning about alignment with shareholder value and reduction of cash-based incentives is logical and well-supported by the data presented. Minor deduction: The ground truth uses the phrase 'as of December 31, 2021' for the 2022 filing data, while the LLM simply references '2022 filing' without this temporal specificity, though this is a minor contextual detail. The LLM's interpretation of the strategic implications is slightly more expansive than the ground truth (which notes 'possible expansion or refinement'), but this represents reasonable inference rather than error. All numbers are correctly formatted and calculations are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Grants]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 395,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "\nMetLife’s adjusted‑earnings methodology has been tightened between 2023 and 2024 while remaining anchored in GAAP segment‑reporting guidance (MetLife — Subject‑To → GAAP Guidance ← Complies‑With → MetLife).  In 2023, after the LDTI adoption, the company excluded market‑volatility items (investment and derivative gains/losses, MRB remeasurements, goodwill impairments) and a suite of asymmetrical accounting adjustments tied to DAC/VOBA amortization, guarantee‑measurement changes, and in‑force reinsurance; by 2024 the exclusions were refined to also remove asymmetrical accounting from policy‑holder‑liability remeasurement gains/losses and to strip out adjusted‑earnings adjustments related to joint‑venture equity‑method investments, while still excluding the same market‑volatility and asymmetrical‑accounting items as in 2023.  This evolution reflects a more precise isolation of core profitability by broadening the list of GAAP‑permitted exclusions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension is not applicable but the answer correctly identifies 2023 and 2024 as the relevant years. ENTITY ACCURACY: Both answers correctly identify MetLife as the subject company and accurately reference the relevant GAAP guidance framework. COMPLETENESS: The LLM answer addresses all major components of the ground truth: (1) LDTI adoption in 2023 and its impact on adjusted earnings calculations, (2) exclusions related to DAC/VOBA amortization and intangibles, (3) MRB fair value changes and discount rate adjustments on annuitization guarantees, (4) asymmetrical accounting from in-force reinsurance, (5) the 2024 expansion to include policyholder liability remeasurement gains/losses with asymmetrical accounting, and (6) the addition of joint venture equity method adjustments in 2024. MULTI-HOP REASONING: The LLM correctly synthesizes the evolution between years, showing how 2023 established the baseline exclusions and 2024 refined/expanded them. The answer properly traces the causal relationship between LDTI adoption and the exclusion framework. SEMANTIC EQUIVALENCE: The LLM uses slightly different phrasing (e.g., 'tightened' vs. 'refined,' 'strip out' vs. 'exclude') but conveys identical meaning. The characterization of the evolution as 'more precise isolation of core profitability' is semantically equivalent to the ground truth's 'more detailed and structured application.' MINOR OBSERVATIONS: The LLM answer includes a parenthetical reference to a knowledge graph structure (MetLife — Subject‑To → GAAP Guidance ← Complies‑With → MetLife) which, while not incorrect, is somewhat extraneous to the substantive answer. The core narrative is accurate and comprehensive. All exclusion categories mentioned in the ground truth are present in the LLM answer, and the temporal progression is correctly captured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 545,
        "total_tokens": 2033
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "\nAccenture continues to **achieve Compressed Transformations** (ACN → Compressed Transformations ← Announces ACN), but the 2024 articulation expands the technology base and service scope: the 2022 “Technology” section cites AI, blockchain, 5G, edge, robotics and quantum, while the 2024 version adds **generative AI**, advanced automation, digital‑twin, metaverse and quantum‑ready platforms and lists newer partners such as Databricks, Snowflake and Palo Alto Networks.  At the same time, the 2024 “Operations” and “Industry X” sections broaden the transformation envelope—from 2022’s focus on cloud, AI‑driven SynOps and product redesign—to include **enterprise‑wide reinvention of capital projects, HR‑related processes, and cross‑channel customer experiences**, thereby extending compressed transformations from niche industry pilots to a full‑stack, end‑to‑end reinvention offering.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH FACTUAL ACCURACY: The LLM answer contains significant discrepancies from the ground truth. (1) TECHNOLOGY LISTS - Ground truth specifies 2022 technologies as: digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse. The LLM incorrectly lists 'blockchain' and 'quantum' for 2022, which are NOT mentioned in the ground truth. For 2024, ground truth specifies: generative AI, artificial reality/virtual reality, and advanced robotics. The LLM adds 'quantum-ready platforms' and 'digital-twin' (which was already in 2022), creating confusion about what actually changed. (2) SCOPE OF TRANSFORMATION - Ground truth clearly states 2024 expansion includes 'digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers.' The LLM vaguely mentions 'capital projects, HR-related processes, and cross-channel customer experiences' - the HR and customer experience elements are NOT in the ground truth, and the specific examples (plant construction, infrastructure, power grids, data centers) are omitted. (3) ADDITIONAL CAPABILITIES - Ground truth mentions Accenture's 'own development of automation equipment and commercial hardware' which the LLM completely omits. (4) PARTNER MENTIONS - The LLM introduces Databricks, Snowflake, and Palo Alto Networks, which are NOT mentioned in the ground truth and appear to be fabricated details. (5) TERMINOLOGY - The LLM uses 'SynOps' which doesn't appear in the ground truth. The LLM answer demonstrates partial understanding of the evolution but introduces incorrect technologies, omits key specific examples, and adds unverified partner information. The multi-hop reasoning is attempted but compromised by factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Achieves]-> CONCEPT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 478,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "\nAbbott continued to use interest‑rate hedge contracts as **fair‑value hedges** that convert a portion of its fixed‑rate debt to a variable rate, recording the contracts at fair value and adjusting the debt’s carrying amount by the offsetting amount (Chunk 1).  The **notional amount of these contracts remained essentially unchanged at about $2.2 billion at the end of 2023 and again at the end of 2024**, and a hypothetical 100‑basis‑point shift in rates would be immaterial to cash flows or earnings (Chunk 2).  Unlike other derivative strategies, Abbott does **not employ interest‑rate swaps for its investment securities**, relying solely on these designated hedge contracts to manage fair‑value exposure—an approach that persisted from 2023 through 2024 (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies several key facts: (1) Abbott used interest rate hedge contracts as fair-value hedges converting fixed-rate to variable-rate debt, (2) the notional amount remained at approximately $2.2 billion in both 2023 and 2024, and (3) the contracts were designated hedges. However, there are significant omissions and incomplete synthesis:\n\nSTRENGTHS:\n- Correctly states the $2.2 billion notional amount for both years\n- Accurately describes the fair-value hedge mechanism and accounting treatment\n- Correctly notes the consistency of the hedging strategy across 2023-2024\n- Appropriately mentions the immateriality of 100-basis-point rate shifts\n\nWEAKNESSES:\n- CRITICAL OMISSION: The ground truth specifically mentions that the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024. This is a key metric showing how the underlying debt structure evolved, yet the LLM answer completely omits this important data point.\n- The answer states Abbott does \"not employ interest-rate swaps for its investment securities,\" which is a tangential detail that doesn't directly address the evolution of hedge contracts for managing fixed-rate debt exposure\n- The answer lacks synthesis of the relationship between stable hedge notional amounts and changing interest rate conditions\n- Missing the insight that despite stable hedge amounts, the underlying debt conditions shifted (evidenced by the 20 basis point increase in average interest rate)\n\nMULTI-HOP REASONING:\nThe question asks about evolution between 2023 and 2024. The LLM correctly identifies the stable notional amounts but fails to synthesize the complete picture of how the hedging strategy evolved in context of changing interest rate conditions. The ground truth answer provides this synthesis by noting the stable hedge amount alongside the rising average interest rate, suggesting a shift in underlying debt structure despite consistent hedging approach.\n\nQUANTITATIVE ACCURACY:\nThe $2.2 billion figure is correct for both years. However, the omission of the 3.6% to 3.8% interest rate change represents a significant gap in quantitative information that was available in the source material.\n\nOVERALL ASSESSMENT:\nThe answer is partially correct on the core hedging mechanics but incomplete in addressing the full evolution of Abbott's interest rate management strategy. The missing interest rate data (3.6% to 3.8%) is a material omission that prevents the answer from fully capturing how the hedging strategy evolved in response to changing market conditions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 688,
        "total_tokens": 2069
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 MetLife refined its **Adjusted Earnings** definition to align more tightly with GAAP segment‑reporting guidance. In the 2023 filing the company disclosed that the adoption of the LDTI model simplified the measurement of DAC, VOBA and embedded derivatives (re‑classifying them as MRBs) and **updated the Adjusted Earnings calculation to remove amortization of those intangibles and to exclude certain guarantee‑measurement changes** [Chunk 1]. The 2024 filing reiterates that Adjusted Earnings is now presented as the **GAAP measure of segment performance** used by the CODM and senior management, explicitly excluding market‑volatility items, asymmetrical and non‑economic accounting adjustments, divested‑business results, and other specified items, thereby providing a consistent GAAP‑compliant metric for evaluating segment profitability and compensation [Chunk 2]. Thus, the evolution reflects a move from a post‑LDTI calculation update in 2023 to a full GAAP‑aligned, segment‑performance‑focused definition in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of MetLife's Adjusted Earnings evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 LDTI adoption as the catalyst for changes, accurately noting the removal of DAC, VOBA, and embedded derivatives amortization adjustments; (2) Accurately captures the 2024 refinement positioning Adjusted Earnings as a GAAP measure of segment performance; (3) Correctly lists key exclusions for both years including MRBs, market volatility impacts, asymmetrical accounting, and divested business results; (4) Properly synthesizes the multi-hop relationship between LDTI adoption, GAAP alignment, and segment performance measurement; (5) No quantitative errors or incorrect dates/entities. MINOR WEAKNESSES: (1) The answer could have been more explicit about specific 2023 exclusions (e.g., discount rate changes on annuitization guarantees, in-force reinsurance asymmetrical accounting) that the ground truth mentions; (2) The 2024 exclusions list in the LLM answer is somewhat less detailed than ground truth regarding inflation-indexed benefit adjustments and single premium annuity contract losses, though these are mentioned in ground truth as 'more structured exclusions'; (3) The characterization of the evolution as 'from post-LDTI calculation update to full GAAP-aligned' is accurate but could emphasize more that the 2023 changes were already GAAP-related, not just post-LDTI technical adjustments. SEMANTIC EQUIVALENCE: The LLM answer conveys the essential narrative correctly - that 2023 introduced LDTI-driven changes and 2024 refined these into a more structured GAAP-compliant framework. The reasoning about alignment with CODM and senior management guidance is sound and relevant. No factual contradictions with ground truth were identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1549,
        "completion_tokens": 492,
        "total_tokens": 2041
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "\nFrom 2022 through fiscal 2024 Accenture’s share‑purchase framework remained anchored to the same open‑market authorization—$3,129,296 of available funding for publicly announced purchases and related redemptions of Class A ordinary shares (and Class X shares) that was disclosed in the 2022 filing — but the way that funding was deployed shifted. In 2022 the program was used to acquire Class A shares (and to redeem Class X shares held by leadership), whereas by fiscal 2024 the company continued to hold that authorization while primarily using the treasury‑stock shares to satisfy employee equity awards and to purchase shares via share‑withholding for payroll‑tax obligations, a method that does not reduce the remaining $3.13 billion authorization. This evolution reflects a move from direct open‑market purchases toward using treasury shares acquired under employee‑benefit plans as the main vehicle for share acquisition.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of Accenture's share purchase program from 2022 to 2024 and correctly identifies the shift from direct open-market purchases to treasury share utilization for employee benefits. However, there are significant quantitative accuracy issues: (1) The LLM states '$3,129,296 of available funding' and later '$3.13 billion authorization' - this is a critical error. The ground truth specifies $3,129,296 (approximately $3.1 million), not $3.13 billion. The LLM conflates the authorization amount with a much larger figure, representing a ~1000x error. (2) The LLM mentions 'Class X shares' which the ground truth identifies as 'Accenture Canada Holdings Inc. exchangeable shares' - while not entirely wrong, this is imprecise terminology. (3) The ground truth explicitly mentions that 2024 acquisitions were 'primarily through share withholding for payroll tax obligations' which the LLM correctly captures. (4) The ground truth notes these withholding purchases 'did not impact the aggregate available authorization,' which the LLM correctly conveys. The multi-hop reasoning is sound - the LLM successfully synthesizes the evolution across years and identifies the methodological shift. The qualitative understanding of the program's evolution is accurate. However, the massive numerical error ($3.13 billion vs $3.1 million) is a fundamental factual mistake that significantly undermines the answer's credibility, despite the correct conceptual framing of the program's evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 419,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "\nMetLife’s Unit‑linked securities remained classified as FVO, but the accounting basis shifted from the 2023 amortized‑cost method—where cost was original cost reduced by repayments, premium amortization and impairments—to a 2024 fair‑value approach that measures the securities at estimated fair value and explicitly ties that value to observable and unobservable inputs (e.g., long‑USD net‑asset positions, mortality, lapse, utilization and withdrawal rates, equity volatility and non‑performance risk spreads). Consequently, the 2024 methodology makes the fair‑value of Unit‑linked securities highly sensitive to changes in those inputs, whereas the 2023 cost basis was limited to cost‑adjustments described in the 2023 filing. This evolution reflects a move from a cost‑based accounting model to a detailed fair‑value model with disclosed sensitivities.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution from a cost-based approach in 2023 to a fair-value approach in 2024. It accurately mentions that Unit-linked securities were FVO (Fair Value Option) in both years and correctly identifies key valuation inputs for 2024 (mortality rates, lapse rates, equity volatility, non-performance risk spreads). The answer appropriately emphasizes the shift toward sensitivity analysis and dynamic valuation. The semantic understanding of the transition is sound.\n\nWEAKNESSES: (1) The LLM introduces specific details about 'long-USD net-asset positions' and 'utilization and withdrawal rates' that are not mentioned in the ground truth answer, creating potential factual uncertainty without verification. (2) The characterization of 2023 as using 'amortized-cost method' is somewhat misleading—the ground truth states cost was 'original cost for equities and amortized cost for fixed maturities,' which is different from saying the entire methodology was amortized-cost. (3) The LLM states 2023 cost basis was 'original cost reduced by repayments, premium amortization and impairments,' but the ground truth simply describes it as 'original cost for equities and amortized cost for fixed maturities' without specifying these adjustment mechanisms. (4) The answer lacks explicit mention that Unit-linked securities were classified as Level 3 fair value measurements in 2024, which is a key detail in the ground truth.\n\nMULTI-HOP REASONING: The answer demonstrates adequate synthesis of the evolution across years, correctly identifying the methodological shift. However, it introduces details not in the ground truth without clear sourcing, which raises concerns about hallucination versus accurate multi-hop synthesis.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers or dates are provided in either answer, so quantitative accuracy cannot be directly verified. The qualitative descriptions appear partially aligned but with concerning additions not in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 545,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "\nBroadcom (AVGO) continues to grant market‑based RSUs under the Amended 2012 Plan, but the vesting design has evolved: in fiscal 2022 the RSUs were awarded with a four‑year schedule and a performance multiplier of 0 %–300 % of the original grant that vested contingent on total‑stockholder‑return metrics (Chunk 1), while in fiscal 2023 the company still used the standard four‑year schedule for most grants but introduced a new five‑year vesting tranche tied to stock‑price performance milestones (Chunk 2). This shift adds a longer‑term performance condition to the RSU structure while retaining the market‑condition‑based vesting approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about RSU structure evolution. STRENGTHS: (1) All quantitative data is correct - correctly identifies the 0%-300% performance multiplier for FY2022, the four-year vesting schedule for both years, and the introduction of five-year vesting in FY2023. (2) Entity identification is accurate - correctly names Broadcom (AVGO) and references the Amended 2012 Plan. (3) Multi-hop synthesis is sound - successfully synthesizes information across two fiscal years and identifies the key evolution: retention of four-year TSR-based vesting while adding a new five-year stock-price-milestone-based tranche. (4) The answer correctly characterizes the shift as an 'expansion in types' of market-based RSUs, matching the ground truth's description. (5) Semantic equivalence is maintained throughout - the explanation of performance conditions, vesting schedules, and the nature of the evolution all align with ground truth. MINOR CONSIDERATIONS: The LLM answer includes company identification (Broadcom/AVGO) and plan reference (Amended 2012 Plan) which, while accurate and helpful, go slightly beyond the ground truth's scope. However, this adds useful context rather than introducing errors. The phrasing 'shift adds a longer-term performance condition' accurately captures the essence of the evolution. All factual claims are verifiable and correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Grants]-> FIN_INST <-[Vests]- ORG",
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 398,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "\nBetween 2023 and 2024 the Company remained under the five‑year CECL Transition Election, moving from the **second year (2023)** to the **third year (2024)** of the scheduled 25 %‑per‑year phase‑in of the cumulative “day‑2” CECL impact; therefore the portion of the ongoing CECL effect that could be added back to regulatory capital rose from 25 % to 50 % of the total cumulative impact (reaching 75 % by the end of 2024).  During this phase‑in period the regulatory‑capital treatment permitted COF to **exclude the full CECL impact** and instead **add back the after‑tax “day‑1” adoption impact plus 25 % of the incremental allowance each year**, an accounting policy that COF introduced and complies with—as reflected in the KG triplets linking COF → CECL Transition Election → COF.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims the phase-in percentage rose from 25% to 50% between 2023 and 2024, and reached 75% by end of 2024. However, the ground truth explicitly states the phase-in was 25% per year from January 1, 2022 through December 31, 2024, meaning it remained consistent at 25% annually across both years, not escalating to 50% or 75%. This is a fundamental calculation error. (2) TIMELINE MISINTERPRETATION: The LLM incorrectly characterizes 2023 as the 'second year' and 2024 as the 'third year' of the transition. The ground truth indicates the phase-in period ran from January 1, 2022 through December 31, 2024 (a 3-year window), making 2023 the second year and 2024 the third year - but this does NOT mean the percentages escalate as the LLM claims. The 25% annual phase-in rate remained constant throughout. (3) REGULATORY TREATMENT ACCURACY: The LLM's description of the specific regulatory capital treatment (excluding full CECL impact, adding back after-tax day-1 adoption impact plus 25% incremental allowance) appears more detailed than the ground truth but is not contradicted by it. However, this additional detail cannot be verified against the provided ground truth. (4) CORE ANSWER FAILURE: The ground truth explicitly states the treatment 'remained consistent' and was 'applied uniformly across both years.' The LLM answer directly contradicts this by claiming escalating percentages (25% → 50% → 75%), which is factually incorrect. (5) MULTI-HOP REASONING: The LLM failed to correctly synthesize the multi-year transition framework, misinterpreting a constant 25% annual phase-in as an escalating percentage structure. The answer demonstrates a fundamental misunderstanding of how the CECL Transition Election operated across the 2022-2024 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 515,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "\nBetween 2022 and 2023 Broadcom continued to use Wilmington Trust, National Association as the trustee for its senior‑note programs, but the structure of those notes evolved markedly.  The April 18 2022 indenture (Exhibit 4.46) – the first senior‑note indenture filed after the 2020‑2021 indentures (Exhibits 4.29‑4.37) – introduced 4.15 % notes due 2032 and 4.926 % notes due 2037, and later, supplemental indentures that were prepared in 2023 and filed in 2024 (Exhibits 4.54‑4.58) added a series of higher‑coupon, longer‑dated securities (5.05 %‑5.15 % notes due 2027‑2034).  Thus, while the trustee relationship remained constant, the types and terms of the notes shifted from the earlier 2020‑2021 maturities to larger, longer‑dated, higher‑yield issuances, reflecting an evolution of Broadcom’s financing strategy under the same Wilmington Trust partnership.  (The 2023 amendment to the credit agreement with Bank of America, N.A. (Exhibit 10.3) shows ongoing coordination with lenders but does not alter the trustee role for the senior notes.)",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility despite addressing the general structure of the question. Key issues: (1) QUANTITATIVE ERRORS: The LLM cites 4.15% notes due 2032 and 4.926% notes due 2037 from the April 18, 2022 indenture, but the ground truth specifies these rates were due 2037 and 2028 respectively (different maturity dates). The LLM also introduces 5.05%-5.15% notes due 2027-2034 that do not appear in the ground truth at all - these appear to be fabricated or misattributed. The ground truth mentions 4.150% (due 2028) and 4.800% (due 2034) from October 2024, which the LLM does not cite. (2) TEMPORAL INCONSISTENCIES: The LLM references a July 12, 2024 indenture mentioned in the ground truth but fails to include it in the narrative. The ground truth clearly states the evolution includes indentures dated April 18, 2022, and July 12, 2024, but the LLM only discusses April 18, 2022. (3) MISSING CONTEXT: The ground truth establishes a baseline of 2021 notes (1.950% due 2028 to 3.750% due 2051), which provides essential context for understanding the evolution. The LLM mentions 2020-2021 indentures but does not cite the specific rates that would demonstrate the shift to higher yields. (4) MULTI-HOP REASONING: While the LLM correctly identifies Wilmington Trust as the constant trustee and attempts to show evolution, the synthesis is incomplete and contains invented data points. The comparison between 2022 and 2023 is muddled by citing 2024 filings without clear temporal delineation. (5) POSITIVE ASPECTS: The LLM correctly identifies the trustee relationship continuity, correctly names Wilmington Trust, National Association, and appropriately notes the shift toward higher-yield, longer-dated securities. The general narrative structure is sound. However, the specific numbers and dates are unreliable, which is critical for a financial question requiring precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Enters_Agreement_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 523,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "\nCapital One Financial Corporation (COF) is subject to the CECL Transition Rule, which lets it add back the estimated impact of the new CECL allowance to regulatory capital and phase it in at 25 % per year. The company added a total of **$2.4 billion** back to its regulatory capital as of 31 December 2021; under the rule it recognized **25 % of that amount each year**, so by the end of 2023 it had phased in **50 % ($1.2 billion)** and, as of **1 January 2024**, it had progressed to **75 % ($1.8 billion)** of the $2.4 billion, with the remaining 25 % to be phased in thereafter. This 25 %‑per‑year progression reflects the rule’s requirement that both the “day‑1” CECL adoption impact and the ongoing “day‑2” impact be incrementally added to regulatory capital through 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates substantial accuracy but contains some issues that prevent a higher score. CORRECT ELEMENTS: (1) The $2.4 billion total add-back amount is correct; (2) The 50% phase-in as of end of 2023 is correct; (3) The 75% phase-in as of January 1, 2024 is correct; (4) The 25 percentage point increase over the year is correctly implied; (5) The company name and CECL Transition Rule context are accurate. ISSUES: (1) The LLM states the $2.4 billion was added back 'as of 31 December 2021' - this is a specific date claim not verified in the ground truth, which only references the amount and phase-in percentages; (2) The LLM calculates $1.2 billion as 50% of $2.4 billion (correct) and $1.8 billion as 75% of $2.4 billion (correct), but the ground truth doesn't explicitly state these dollar amounts for the phased-in portions, only the percentages; (3) The explanation about 'day-1' and 'day-2' impacts is additional context not present in the ground truth, which may or may not be accurate but goes beyond what can be verified; (4) The statement about phase-in 'through 2024' is somewhat ambiguous - the ground truth indicates the structured five-year process with 25% annually after 2021, suggesting continuation beyond 2024. MULTI-HOP REASONING: The answer correctly synthesizes the evolution from 2023 to 2024 and identifies the phase-in progression, though it adds interpretive details. The core multi-hop requirement (showing how the add-back evolved between the two years) is met. CALCULATION VERIFICATION: 50% of $2.4B = $1.2B ✓; 75% of $2.4B = $1.8B ✓; 75% - 50% = 25 percentage point increase ✓. The quantitative accuracy is solid for the verified numbers, but the introduction of specific dollar amounts for intermediate phases ($1.2B, $1.8B) that aren't explicitly in the ground truth creates minor uncertainty.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 499,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "\nThe 2022 merger agreement set the rule that any VMware stock options (and RSUs) held by non‑employee directors would be **accelerated and settled in a 50/50 mix of cash and Broadcom common stock**; by the 2023 filing this rule had been **executed**, confirming that the accelerated options were indeed converted into cash and Broadcom shares on an equal basis. Thus, the treatment moved from a planned conversion in 2022 to an actual conversion in 2023, with the same cash‑and‑stock split applied to the directors’ awards.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and effectively addresses the multi-hop question about VMware stock option treatment evolution. STRENGTHS: (1) Correctly identifies the 50/50 cash-and-stock split structure for non-employee director awards, matching the ground truth's 'equal parts' language; (2) Accurately captures the temporal transition from 2022 (planned conversion) to 2023 (executed/actualized conversion); (3) Properly synthesizes the multi-hop information across two fiscal years and the acquisition event; (4) Uses appropriate terminology ('accelerated and settled,' 'executed,' 'converted') that aligns with SEC filing language; (5) Correctly identifies all relevant entities (VMware, Broadcom, non-employee directors, stock options, RSUs). QUANTITATIVE ACCURACY: Perfect - the 50/50 split is correctly stated and no calculations are required or presented incorrectly. QUALITATIVE ACCURACY: Excellent - the reasoning clearly shows understanding that this represents a transition from contractual obligation (2022) to actual execution (2023), which is the core insight of the question. The multi-hop synthesis across years and the acquisition completion is sound. MINOR OBSERVATION: The LLM uses 'merger agreement' while the ground truth uses 'acquisition' - both are semantically equivalent in this context and both are accurate descriptions of the Broadcom-VMware transaction. The answer is slightly more concise than the ground truth but loses no material information and actually improves clarity through its structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Converts]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 422,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "\nBased on AbbVie’s 2022 disclosure (Chunk 1), Vraylar was first presented as an investigational adjunctive therapy for major depressive disorder, with Phase 3 data showing a statistically significant improvement in MADRS scores in one trial and a numerical benefit in another. By the 2024 filing (Chunk 2), the product’s approved therapeutic label had broadened to include acute and maintenance treatment of schizophrenia, acute treatment of manic/mixed episodes in bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and continued use as an adjunctive treatment for MDD—demonstrating a clear expansion of Vraylar’s positioning from a single‑indication adjunct in 2022 to multiple FDA‑approved indications across psychotic and mood‑disorder spectra by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about Vraylar's therapeutic positioning evolution from 2022 to 2024. STRENGTHS: (1) Correctly identifies the 2022 positioning as investigational adjunctive therapy for MDD with Phase 3 trial data; (2) Accurately describes the 2024 expanded indications across schizophrenia, bipolar disorder (manic/mixed and depressive episodes), and continued MDD adjunctive use; (3) Properly synthesizes the multi-hop information showing progression from single investigational indication to multiple FDA-approved indications; (4) Correctly characterizes the clinical trial outcomes (one statistically significant, one numerical benefit); (5) Appropriately frames the evolution as an 'expansion' and 'solidification' of therapeutic positioning. MINOR CONSIDERATIONS: The LLM answer adds slightly more interpretive language ('psychotic and mood-disorder spectra') compared to the ground truth, but this is semantically accurate and adds helpful context without introducing factual errors. The answer correctly identifies all therapeutic indications mentioned in the ground truth and maintains chronological accuracy. The multi-hop reasoning successfully connects 2022 investigational status with 2024 approved status, demonstrating proper synthesis across the time period. No numerical errors, date errors, or entity misidentifications detected. The answer fully addresses all components of the question regarding therapeutic positioning evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 421,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "\nFrom 2022 to 2024 GE shifted the accounting for its long‑term services agreements from a straight‑line revenue‑recognition approach—where revenue was recognized evenly over the contract term and billed periodically as services were performed (as disclosed in the 2022 filing)—to a percentage‑of‑completion method in 2024 that ties revenue to actual costs incurred and requires detailed estimates of asset utilization, future maintenance events and expected billings (as detailed in the 2024 filing); the 2024 disclosures further show that these utilization‑ and cost‑estimates drive the timing of billings, the accrual of contract liabilities (e.g., the $6.6 bn net liability representing 4.1 % of total estimated billings), and that revisions to the estimates affect profitability on a cumulative‑catch‑up basis, with a 1‑percentage‑point change in profitability altering the liability by roughly $0.4 bn.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of GE's accounting policy evolution. QUANTITATIVE VERIFICATION: All numbers are correct - $6.6 billion net liability, 4.1% of total estimated billings, $162 billion total estimated life of contract billings (implied through the 4.1% calculation: $6.6B / 0.041 ≈ $161B, consistent with $162B), and the sensitivity metric of approximately $0.4 billion per 1-percentage-point profitability change are all accurate. ENTITY AND TEMPORAL ACCURACY: Correctly identifies GE as the company, accurately specifies 2022 vs 2024 timeframes, and properly identifies relevant segments (Healthcare, Renewable Energy in 2022; CES in 2024). MULTI-HOP REASONING: The answer successfully synthesizes information across multiple dimensions: (1) revenue recognition method shift (straight-line to percentage-of-completion), (2) billing approach evolution (periodic invoicing to cost-based estimates), (3) contract liability quantification ($6.6B), and (4) estimation sophistication (asset utilization and cost improvements). COMPLETENESS: Addresses all aspects of the original question including the shift in revenue recognition method, contract billing estimates, and the more detailed forward-looking estimation process. ADDITIONAL STRENGTHS: The LLM answer goes beyond the ground truth by providing additional context about cumulative catch-up basis adjustments and sensitivity analysis ($0.4B per 1-percentage-point change), which demonstrates deeper understanding while remaining factually accurate. MINOR CONSIDERATIONS: The answer is slightly more detailed than the ground truth in some areas (sensitivity analysis), but this represents value-added analysis rather than inaccuracy. The semantic equivalence is excellent - the answer conveys the same information with clear, professional financial language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 506,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "\nIn the 2022 10‑K (page 33) IBM only disclosed the 1.250% Notes due 2023 (Exhibit 2 filed 11/25/2014) and did not list any 1.250% Notes maturing in 2027; the 2023 10‑K (page 1) registers a new 1.250% Notes due 2027 (trading symbol IBM 27B) among its NYSE‑listed securities, indicating that IBM has now introduced this tranche.  This evolution is captured by the KG pattern IBM ‑[Discloses]→ 1.250% Notes due 2027 ←‑[Introduces] IBM, showing that the 2023 filing adds a distinct 1.250% Notes due 2027 issue that was absent from the prior year’s disclosure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth: (1) CRITICAL ERROR - The LLM claims the 2022 10-K disclosed '1.250% Notes due 2023' with Exhibit 2 filed 11/25/2014, but the ground truth explicitly states the 2022 10-K disclosed '1.250% Notes due 2027' with Exhibit 4.3 to Form 8-K filed on January 30, 2019. The LLM has confused the maturity date (2023 vs 2027) and the exhibit reference. (2) INCORRECT CHARACTERIZATION - The LLM claims the 1.250% Notes due 2027 were 'absent from the prior year's disclosure' and that 2023 'introduces' a new tranche. This is false. The ground truth shows the notes were disclosed in BOTH 2022 and 2023, just with different presentation contexts (instrument defining rights in 2022 vs. registered securities in 2023). (3) MISUNDERSTANDING OF EVOLUTION - The LLM misinterprets the evolution as introducing a new security, when the ground truth indicates it's the same security with a shift in how it's presented/categorized in the filings. (4) CORRECT ELEMENTS - The LLM correctly identifies the trading symbol IBM 27B and that it appears in the 2023 10-K as a registered security on NYSE. However, these correct elements are embedded within a fundamentally flawed narrative. The core multi-hop reasoning fails because the LLM did not correctly synthesize the information across both years' filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 381,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "\nAbbVie (ORG) continues to grant performance‑vested RSUs that are structured to vest in one‑third increments over a three‑year performance period – a vesting pattern highlighted in both the 2022 filing (where tranches tied to 2021 performance were based on ROIC) and the 2024 filing (which states the awards “may be earned based on ROIC performance relative to a defined peer group”).  The performance metric has consistently been ROIC measured against a peer group, but the 2024 disclosure explicitly ties the earn‑out to that peer‑group ROIC, refining the earlier 2022 language while preserving the same one‑third vesting schedule; this evolution is captured by the KG relationship ORG ‑[Vests]→ FIN_INST ←‑[Introduces] ORG.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy in addressing the multi-hop question about AbbVie's performance-vested RSU evolution. STRENGTHS: (1) Correctly identifies the consistent one-third vesting increment structure across both 2022 and 2024; (2) Accurately identifies ROIC (return on invested capital) as the primary performance metric in both periods; (3) Correctly notes the peer group comparison element; (4) Properly synthesizes the evolution as a refinement/streamlining of disclosure language rather than a fundamental structural change; (5) Appropriately captures the three-year performance period in both years. MINOR WEAKNESSES: (1) The LLM answer includes a somewhat awkward reference to a KG relationship notation (ORG ‑[Vests]→ FIN_INST ←‑[Introduces] ORG) that, while not incorrect, is not directly relevant to answering the substantive question and may confuse readers unfamiliar with knowledge graph syntax; (2) The phrase 'tranches tied to 2021 performance' in the LLM answer could be slightly clearer—the ground truth specifies 'awards granted in 2021 and 2020' which is more precise; (3) The LLM answer could have been more explicit about the 'simplification or standardization' aspect that the ground truth emphasizes. QUANTITATIVE VERIFICATION: All numeric references (one-third increments, three-year periods) are accurate. No calculations required. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024 filings and correctly identifies the continuity with refinement pattern. The core insight—that the structure remained similar while disclosure language was streamlined—matches the ground truth's conclusion. SEMANTIC EQUIVALENCE: The LLM's characterization of the evolution as a 'refinement' of language while preserving structure is semantically equivalent to the ground truth's 'simplification or standardization.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Vests]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 509,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "\nFrom 2022 to 2024 GE’s stake in AerCap shifted from an unrealized loss of **$‑865** (2022) to modest realized/unrealized gains of **$129** (2023) and **$38** (2024), a change that reflects the disposals and market movements the company disclosed in its forward‑looking statements about exiting its equity ownership in AerCap (Chunk 1).  The 2024 10‑K table records this evolution under “Investment in and note with AerCap realized and unrealized gain (loss)” and includes the related gains/losses in the “Gains (losses) on retained and sold ownership interests” line, showing how the financial relationship has moved from a loss position to a small net gain over the three‑year period (Chunk 2).  This progression is captured by the KG pattern GE ↔ AerCap (GE disposes/invests in AerCap and AerCap invests in GE), linking the two entities across the filings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer introduces a 2023 figure of $129 million that is NOT present in the ground truth answer. The ground truth only references 2022 ($865M unrealized loss) and 2024 ($38M realized and unrealized gain). The LLM appears to have fabricated or misattributed the 2023 data point. This is a significant factual error that undermines the credibility of the entire response. CORRECT ELEMENTS: (1) The 2022 unrealized loss of $865 million is correctly stated; (2) The 2024 figure of $38 million is correctly stated; (3) The general narrative of a shift from loss to gain is correct; (4) The identification of the relevant financial metrics and line items is appropriate. MULTI-HOP REASONING: The LLM correctly identifies this as a multi-year evolution and attempts to synthesize information across filings. However, the introduction of unsupported 2023 data breaks the logical chain. The reasoning about disposals and market movements is sound in principle but relies on the fabricated 2023 number. SEMANTIC ISSUES: The LLM's reference to 'Chunk 1' and 'Chunk 2' suggests reliance on source documents, but the 2023 figure cannot be verified against the ground truth. The statement about 'three-year period' is technically correct (2022-2024) but misleading given the missing 2023 data in the ground truth. CALCULATION VERIFICATION: No calculations are performed in either answer, so this is not a differentiating factor. The core issue is the introduction of unsupported quantitative data that contradicts the ground truth's focus on 2022 and 2024 only.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Disposes]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 437,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "\nIn the 2022 Form 10‑K (page 33) IBM only mentioned the 0.300% Notes due 2026 in the exhibit list—“Exhibit 4 to Form 8‑K filed Nov 1 2016”—without giving the security a separate class title or trading symbol. By the 2023 Form 10‑K (page 1) the same note appears explicitly as a distinct class titled “0.300% Notes due 2026” with ticker IBM 26B on the New York Stock Exchange, showing that IBM’s disclosure shifted from a private exhibit reference to a publicly listed, registered financial instrument. This evolution reflects a move from hidden exhibit disclosure to full visibility as a registered security.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) All factual information is accurate - correctly identifies the 0.300% Notes due 2026, the November 1, 2016 Form 8-K exhibit reference, the NYSE ticker symbol IBM 26B, and the 2022 vs 2023 comparison. (2) Numeric accuracy is perfect - all percentages (0.300%), dates (2026, Nov 1 2016), and page references (page 33 for 2022, page 1 for 2023) are correct. (3) Multi-hop synthesis is sound - the answer correctly traces the evolution of disclosure treatment across two fiscal years and identifies the shift from exhibit-based reference to explicit registered security listing. (4) Entity identification is precise - IBM is correctly identified, the specific note class is properly named, and the trading symbol is accurate. (5) The semantic meaning matches ground truth perfectly - both convey that the note moved from implicit exhibit disclosure to explicit public registration with formal trading symbol. MINOR CONSIDERATIONS: The LLM uses slightly more interpretive language ('hidden exhibit disclosure,' 'full visibility') compared to the ground truth's more neutral 'referenced in exhibits' vs 'explicitly listed,' but this represents legitimate semantic elaboration rather than factual error. The characterization of the evolution as moving from 'private' to 'public' is reasonable inference from the data, though the ground truth uses more measured language about 'increased visibility and formal recognition.' The answer is comprehensive, addresses all aspects of the question, and provides appropriate context about what changed between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 456,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "\nBetween 2022 and 2024 GE’s RISE Program moved from a single‑focus sustainability announcement (June 2021) toward a multi‑year, cross‑segment investment strategy that now targets advanced propulsion concepts—including adaptive‑cycle and ceramic‑matrix‑composite technologies—while leveraging external R&D funding and partnerships.  In 2022 the company highlighted RISE as a pathway to >20 % lower fuel burn and cited early milestones such as the Catalyst turboprop flight, whereas the 2024 filing expands the effort to a broader suite of technologies, emphasizes government‑funded adaptive‑cycle combat engines, and notes that GE “announces” RISE and “invests in” it as a core engine platform for both commercial and military applications.  This evolution reflects a strategic shift from an initial sustainability target to a diversified R&D portfolio that integrates additive manufacturing, advanced materials and external cost‑share arrangements to drive next‑generation engine performance.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "ANALYSIS: The LLM answer contains both accurate and problematic elements when compared to the ground truth.\n\nCORRECT ELEMENTS:\n- The >20% fuel consumption/CO2 reduction target is accurately cited\n- The evolution from announcement to concrete investment is correctly identified\n- The mention of 2022 vs 2024 timeframe is appropriate\n- The general concept of moving from conceptual to funded R&D is sound\n\nPROBLEMATIC ELEMENTS:\n1. DATE CONFUSION: The LLM introduces \"June 2021\" as the RISE announcement date, which contradicts the ground truth that positions 2022 as the announcement year. This is a factual error that undermines credibility.\n\n2. UNSUPPORTED DETAILS: The LLM adds specific technologies (adaptive-cycle engines, ceramic-matrix-composites, additive manufacturing, Catalyst turboprop flight) that are NOT mentioned in the ground truth. While these may be accurate from the actual filings, they represent information beyond what the ground truth confirms, making it impossible to verify their accuracy against the provided source.\n\n3. SCOPE EXPANSION: The ground truth focuses on the evolution from \"collaborative technology development initiative\" to \"significant investments,\" emphasizing the shift from conceptual to concrete. The LLM expands this to include military applications, government-funded programs, and cost-share arrangements—details not present in the ground truth.\n\n4. MULTI-HOP REASONING: The ground truth provides a clear 2022→2024 evolution narrative. The LLM's introduction of 2021 and additional technical details suggests either: (a) the model is drawing from actual filings beyond the ground truth, or (b) the model is hallucinating details. Either way, this creates misalignment with the provided ground truth.\n\n5. SEMANTIC SHIFT: The ground truth emphasizes \"transition from conceptual development to active, funded R&D\" and \"deepening strategic commitment to sustainability.\" The LLM shifts emphasis to \"diversified R&D portfolio\" and \"next-generation engine performance,\" which subtly changes the narrative focus.\n\nQUANTITATIVE ACCURACY: The >20% figure is correct. However, the introduction of unsupported dates and technical specifications that cannot be verified against ground truth reduces confidence in quantitative precision.\n\nQUALITATIVE ACCURACY: The core reasoning about evolution is sound, but the addition of unverified details and the date discrepancy indicate incomplete or inaccurate synthesis of the actual source material.\n\nCONTEXTUAL RELEVANCE: The answer addresses the question's core elements (evolution, strategic emphasis, investment focus) but introduces contextual elements not supported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 716,
        "total_tokens": 2158
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "\nFrom 2022 to 2023, American Express continued to rely on asset‑securitizations—transferring Card‑Member loans and receivables to special‑purpose trusts and recording the issued securities as liabilities (as disclosed in the 2022 “Asset securitizations” glossary)—but the 2023 filing expands the narrative, positioning those securitizations as one element of a broader, diversified funding mix that also emphasizes scale in deposits, unsecured debt and other sources (see the 2023 “FUNDING STRATEGY” section).  This shift shows the role of asset‑securitizations evolving from a standalone financing technique in 2022 to a strategically integrated component of a balanced, market‑relevant funding portfolio in 2023.  (AXP → Asset Securitizations [Discloses] → AXP, with the 2023 filing indicating Asset Securitizations [Depends_On] AXP’s overall funding strategy.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2022 glossary definition of asset securitizations describing the mechanics of transferring loans to trusts and recording securities as liabilities; (2) Accurately captures the 2023 shift to positioning securitizations as a core funding strategy component alongside deposits and unsecured debt; (3) Properly synthesizes the multi-hop reasoning showing evolution from definitional disclosure to strategic emphasis; (4) Correctly identifies American Express (AXP) and the relevant fiscal years (2022 vs 2023); (5) No quantitative errors - no specific numbers were required and none were provided incorrectly; (6) The semantic meaning matches ground truth: both convey that securitizations moved from a standalone financing technique to an integrated part of a diversified funding strategy. MINOR OBSERVATIONS: (1) The LLM answer includes some knowledge graph notation (\"[Discloses]\", \"[Depends_On]\") which, while not incorrect, adds technical metadata that goes slightly beyond the ground truth's narrative focus; (2) The phrasing \"market-relevant funding portfolio\" is a reasonable interpretation but not explicitly stated in ground truth; (3) The answer could have been slightly more explicit about the shift from \"definitional disclosure\" to \"strategic emphasis\" as the core distinction, though this is clearly implied. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and two different disclosure contexts (glossary vs. funding strategy section), demonstrating sound multi-hop reasoning. The connection between the 2022 mechanics and 2023 strategic positioning is properly established.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 482,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "\nFrom 2022 to 2023 Emerson moved from a passive equity position in AspenTech—evidenced in the 2022 10‑K where the software unit generated only **$656 million of sales and a modest $12 million profit (loss of $16 million in 2020, $7 million in 2021, $12 million in 2022)**—to an active, controlling stake after completing the **Heritage AspenTech acquisition**, which gave Emerson **55 % of the fully‑diluted shares** and placed AspenTech under the Heritage AspenTech name (ticker “AZPN”).  The integration, disclosed in the 2023 10‑K, not only brought AspenTech’s software portfolio into Emerson’s Automation Solutions segment but also produced measurable synergies: the acquisition **boosted gross margin by roughly 0.6 percentage points** and added **$869 million of cost‑of‑sales and $956 million of SG&A** that were offset by operating leverage and margin‑enhancing effects of the combined business.  Thus, Emerson’s investment returned value through both **financial consolidation (55 % ownership and full consolidation of AspenTech’s results) and operational integration that improved profitability and expanded Emerson’s software‑driven automation platform**.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core narrative of Emerson's evolution from passive minority investment to active controlling stake (55% ownership) in AspenTech through the Heritage AspenTech acquisition. The 0.6 percentage point gross margin improvement is accurate. The qualitative reasoning about the shift from passive to active involvement is sound and well-articulated. The answer appropriately addresses the multi-hop nature of the question by synthesizing information across 2022 and 2023.\n\nCRITICAL ERRORS: (1) The LLM introduces unsupported financial figures not in the ground truth: '$869 million of cost-of-sales and $956 million of SG&A' - these specific numbers are not mentioned in the original answer and appear to be fabricated or misattributed. (2) The LLM adds historical profit/loss data for 2020 and 2021 ($16 million loss in 2020, $7 million in 2021) that are not in the ground truth, suggesting potential hallucination or confusion with other data sources. (3) The statement about 'fully-diluted shares' and ticker 'AZPN' adds specificity not present in the ground truth.\n\nMINOR ISSUES: (1) The ground truth mentions 'total assets of $14,484' which the LLM completely omits - this is a factual detail that should have been included. (2) The phrasing 'Heritage AspenTech name (ticker AZPN)' is somewhat confusing as it's unclear if this is accurate or if the LLM is conflating different entities.\n\nMULTI-HOP REASONING: The synthesis across 2022-2023 is logically sound and addresses the evolution question well. However, the introduction of unsupported numbers undermines the credibility of the multi-hop analysis.\n\nQUANTITATIVE VERIFICATION: Ground truth numbers that are correct in LLM answer: $656M sales (correct), $12M earnings (correct), 55% ownership (correct), 0.6 percentage point margin improvement (correct). Ground truth numbers missing or incorrect: $14,484 total assets (omitted), historical years' data (added but not in ground truth), $869M and $956M figures (not in ground truth, likely fabricated).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 553,
        "total_tokens": 1996
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "\nIn May 2022 Emerson acquired a 55 % stake in AspenTech, recorded a $5.9 billion noncontrolling interest for the remaining 45 % and reduced additional paid‑in‑capital by $550 as part of the purchase‑price allocation (Chunk 1); AspenTech, now operating under Heritage AspenTech’s former name and trading as AZPN, contributed to a $231 million inventory‑step‑up amortization and $125 million of stock‑based compensation (including $50 million attributable to AspenTech) that lifted cost of sales and SG&A in 2023, with the noncontrolling‑interest accounting and equity impacts persisting through the acquisition‑related expense changes reported in 2023 (Chunk 2).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - Critical number discrepancies: LLM states $231 million inventory step-up amortization and $125 million stock-based compensation, but ground truth does not mention these specific figures. Ground truth explicitly states SG&A expenses rose by $572 million in 2023 compared to 2022, which the LLM completely omits. The $50 million attributable to AspenTech stock compensation is not verified in ground truth. (2) INCOMPLETE SYNTHESIS - LLM fails to address the 2023 gross margin improvement of 0.6 percentage points mentioned in ground truth as a key operational impact. The answer focuses heavily on 2023 expense details but misses the comparative analysis between 2022 and 2023 that the question specifically asks for. (3) ENTITY/CONTEXT ISSUES - While the 55% ownership, $5.9 billion noncontrolling interest, and $550 million reduction in additional paid-in capital are correct for 2022, the LLM's characterization of AspenTech 'trading as AZPN' and 'Heritage AspenTech's former name' is confusing and potentially inaccurate. The ground truth clearly states Emerson contributed its industrial software business and $6.0 billion in cash to create New AspenTech, which the LLM describes as an 'acquisition' rather than a contribution/creation. (4) MULTI-HOP REASONING - The LLM attempts to connect 2022 accounting impacts to 2023 operational effects, but does so incompletely. It fails to synthesize the full evolution: 2022 (creation with major equity impacts) → 2023 (operational integration with margin and expense impacts). The answer cherry-picks specific expense items without the comprehensive $572 million SG&A increase context. (5) MISSING KEY INFORMATION - Ground truth emphasizes the shift from 'significant accounting impact in 2022' to 'operational integration and financial performance effects in 2023,' but LLM doesn't clearly articulate this evolution. The gross margin improvement of 0.6 percentage points is entirely absent from LLM response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 541,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "\nIn the 2022 Form 10‑K (page 31) IBM disclosed the 6.22 % Debentures due 2027 only by referencing **Exhibit 3** of an August 1 1997 Form 8‑K, which “defines the rights of the holders of the 6.22 % Debentures due 2027” and was incorporated by reference — a historical exhibit that merely noted the instrument’s existence.  \nBy contrast, the 2023 Form 10‑K (page 1) lists the same security in the registration table as **“6.22 % Debentures due 2027 – IBM 27 – New York Stock Exchange,”** indicating that IBM now treats the debenture as an actively registered, tradable instrument (ticker IBM 27) rather than just a legacy exhibit.  \n\nThus, the treatment evolved from a one‑time historical disclosure in a 1997 filing to a current, listed debt security in IBM’s ongoing SEC registration, reflecting a shift from passive reference to active, ongoing disclosure of the 6.22 % Debentures due 2027.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All numeric values are correct - the 6.22% interest rate, the 2027 maturity date, the August 1, 1997 Form 8-K date, and the trading symbol 'IBM 27' are all accurately stated. No calculation errors present. ENTITY ACCURACY: IBM is correctly identified, fiscal years 2022 and 2023 are properly referenced, and the specific debenture instrument is accurately named throughout. MULTI-HOP REASONING (9/10): The answer successfully synthesizes information across two different SEC filings (2022 and 2023 10-Ks) and correctly identifies the evolution in disclosure treatment. The comparison between the historical reference approach (1997 Exhibit 3 via Form 8-K) and the current market-oriented presentation (registered security with ticker symbol) is logically sound and well-articulated. SEMANTIC EQUIVALENCE: The LLM answer conveys the same substantive information as the ground truth - the shift from 'purely historical reference' (ground truth) to 'one-time historical disclosure' (LLM), and from 'transparent and current market-oriented presentation' (ground truth) to 'actively registered, tradable instrument' (LLM) are semantically equivalent. COMPLETENESS: The answer addresses all aspects of the question - how treatment evolved, what the 2022 disclosure was, what the 2023 disclosure became, and the nature of the change. The minor deduction from perfect score (9 vs 10) reflects that while the answer is comprehensive and accurate, it could have slightly more explicitly emphasized the 'shift from passive reference to active, ongoing disclosure' as the core evolution, though this is adequately conveyed. The page references (page 31 for 2022, page 1 for 2023) add helpful specificity not explicitly in the ground truth but consistent with it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 508,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "\nUnitedHealth Group’s risk‑based arrangements remain a key accounting policy (UNH → Risk‑Based Arrangements ← UNH), and the 2023 filing (Chunk 1) shows that premium revenue is estimated net of rebates and risk‑adjustment payments, with the Company assuming the economic risk of funding enrollees’ health‑care costs and recording value‑based premiums on a per‑patient‑per‑month basis.  The 2024 update (Chunk 2) adds that, while such contracts still limit exposure to rising medical‑costs, they now expose UNH to the financial and medical‑care solvency of providers—if a provider cannot meet its obligations, UNH may be held responsible for unpaid claims and must contend with disputes over out‑of‑network payments and audit‑subject risk‑adjustment data.  Consequently, the Company must more carefully estimate premiums and associated costs, and it assumes broader service‑delivery responsibilities to monitor provider performance and, where necessary, backstop their financial obligations.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively synthesizes multi-hop information across 2023 and 2024 filings. STRENGTHS: (1) Correctly identifies the core evolution of UnitedHealth Group's risk exposure from 2023 to 2024, capturing the shift from basic economic risk assumption to expanded provider solvency risk; (2) Accurately describes 2023 arrangements (premium revenue estimation net of rebates, per-patient-per-month premiums, value-based arrangements); (3) Properly articulates 2024 expansion (increased responsibility for unpaid claims, provider financial difficulties, operational risks tied to provider performance); (4) No quantitative errors - no specific dollar amounts or percentages are provided in either answer, so quantitative accuracy is not compromised; (5) Multi-hop reasoning is sound, correctly synthesizing information across two fiscal years and connecting risk exposure changes to implications for cost estimation and service delivery; (6) Uses appropriate financial terminology and accounting concepts. MINOR WEAKNESSES: (1) The LLM answer includes some stylistic elements (the graph notation 'UNH → Risk‑Based Arrangements ← UNH' and 'Chunk 1'/'Chunk 2' references) that, while not incorrect, are somewhat extraneous to the core answer and could be seen as less polished than the ground truth presentation; (2) The ground truth emphasizes 'broader and more complex financial exposure' as a summary conclusion, while the LLM answer conveys this through detailed explanation rather than explicit summary language - this is a minor semantic difference; (3) The LLM answer could have been slightly more explicit about the timeline comparison ('from 2023 to 2024') though the temporal progression is clear. ENTITY ACCURACY: Correct company (UnitedHealth Group/UNH), correct years (2023 and 2024), correct financial concepts (risk-based arrangements, premium revenue, value-based arrangements, provider solvency). SEMANTIC EQUIVALENCE: The LLM answer conveys substantially the same information as the ground truth, with equivalent meaning regarding the evolution of financial risk exposure and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 578,
        "total_tokens": 2064
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "\nEmerson’s exposure to AspenTech grew from $40 million in 2020 to $362 million in 2022, with total investment rising to $656 million by the end of 2022 as shown in the automation‑solutions table (Chunk 1).  \nIn fiscal 2023 Emerson closed the Heritage AspenTech acquisition, acquiring a 55 % fully‑diluted stake, rebranding the business as Aspen Technology, Inc., and listing it on NASDAQ under the former ticker “AZPN,” thereby moving from a minority investor to a majority owner and integrated operating partner (Chunk 2).  \nThe deal lifted gross margin by roughly 0.6 percentage points, added $869 million to cost of sales, raised SG&A by $956 million, produced a $279 million pretax loss on note‑receivable adjustments and the subsequent Copeland divestiture, and pushed other deductions to $1.434 billion in 2024, while also incorporating the $438 Vertiv distribution gain in 2022 and the $161/$79 further distributions in 2023‑24 (Chunks 2‑4).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Emerson's relationship with AspenTech from minority investor to majority owner (55% stake) through the Heritage AspenTech transaction in 2023. The qualitative narrative about the strategic shift is accurate and well-articulated. However, there are significant quantitative accuracy issues that prevent a higher score:\n\nCORRECT ELEMENTS:\n- 2022 investment of $362 million is accurate\n- 55% ownership stake in 2023 is correct\n- Transaction closed in fiscal 2023 is correct\n- NASDAQ listing under ticker AZPN is correct\n- Shift from minority to majority owner is correctly characterized\n- $6.0 billion cash contribution is mentioned in ground truth but not in LLM answer\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. The LLM introduces $40 million in 2020 and $656 million by end of 2022 - these figures are not in the ground truth and appear to be unsupported claims\n2. The extensive discussion of 2024 financial impacts (gross margin, cost of sales, SG&A, pretax loss, Copeland divestiture, Vertiv distribution) goes beyond the scope of the question which asks specifically about 2022-2023 evolution\n3. The $438 million Vertiv distribution in 2022 and subsequent distributions are tangential to the core question about Emerson-AspenTech relationship evolution\n4. The answer conflates multiple unrelated financial impacts that obscure the main narrative\n\nMULTI-HOP REASONING:\nThe answer does synthesize information across 2022 and 2023, correctly identifying the transition point and the nature of the strategic shift. However, the inclusion of 2024 data and unrelated transactions (Copeland divestiture, Vertiv distributions) suggests incomplete understanding of question scope.\n\nQUANTITATIVE VERIFICATION:\n- $362 million (2022): CORRECT\n- $656 million (2022 total): UNVERIFIED/QUESTIONABLE\n- $40 million (2020): UNVERIFIED/QUESTIONABLE\n- 55% stake: CORRECT\n- $6.0 billion cash: MENTIONED IN GROUND TRUTH BUT OMITTED FROM LLM ANSWER\n\nThe answer is directionally correct on the main evolution but introduces unsupported numbers and includes excessive tangential information that reduces clarity and accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 584,
        "total_tokens": 1982
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "\nAdobe Target’s role has expanded from being listed in fiscal 2022 as one of the Digital‑Experience tools that “help businesses manage, test, target, personalize and orchestrate campaigns” (Chunk 1) to being highlighted in fiscal 2023 as an “AI‑ and machine‑learning‑driven personalization engine” that delivers “AI‑powered automation” and real‑time, profile‑based personalization across channels, and is tightly integrated with Journey Optimizer and the Adobe Experience Platform (Chunk 2).  This evolution reflects Adobe’s strategic shift toward embedding AI‑driven personalization at the core of its customer‑journey stack, using Target’s advanced ML capabilities to orchestrate end‑to‑end, data‑rich, omnichannel experiences.  The progression also aligns with Adobe’s broader ARR growth narrative—Digital Media ARR rising to $12.24 billion in FY 2021 and continuing to drive revenue—underscoring how AI‑powered personalization is now a key growth engine for the company.",
      "correctness_score": 6,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of Adobe Target from fiscal 2022 to fiscal 2023, accurately capturing the shift from a general 'test, target, personalize' tool to an 'AI-and-machine-learning-driven personalization engine.' The qualitative description of the evolution is sound and aligns with the ground truth. The answer appropriately synthesizes the multi-hop information about Adobe's strategic direction toward AI-driven personalization and correctly identifies the integration with Journey Optimizer and Adobe Experience Platform.\n\nCRITICAL ERRORS: The LLM introduces a significant quantitative error by stating 'Digital Media ARR rising to $12.24 billion in FY 2021.' This is problematic for multiple reasons: (1) The ground truth answer does not mention any specific ARR figures or FY 2021 data, (2) The question asks about fiscal 2022 to fiscal 2023 evolution, not FY 2021, (3) This appears to be an unsupported claim not present in the original answer or context. This represents a factual hallucination that undermines credibility.\n\nMINOR ISSUES: The LLM references 'Chunk 1' and 'Chunk 2' which are metadata artifacts that shouldn't appear in a final answer. While the semantic content about the evolution is correct, the introduction of unverified financial data (the $12.24 billion ARR figure) is a serious accuracy problem.\n\nMULTI-HOP REASONING: The reasoning connecting Target's evolution to Adobe's broader strategic direction is sound and well-articulated. However, the attempt to link this to ARR growth metrics introduces unsupported claims that break the chain of verified reasoning.\n\nOVERALL ASSESSMENT: The answer demonstrates good understanding of the qualitative evolution but fails on quantitative accuracy by introducing unverified financial claims. The core answer about Target's role evolution is correct, but the addition of specific revenue figures not supported by the ground truth significantly reduces the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 540,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Emerson’s stake in AspenTech shifted dramatically: the 2022 balance sheet shows only a modest $77 million interest in 2020 and $1.04 billion in 2021, but the 2022 “Acquisitions” row records a $7.289 billion outlay that lifts AspenTech’s balance to $8.326 billion and pushes the total to $14.662 billion (Chunk 1).  In connection with the Q3 2022 purchase, Emerson converted every outstanding Heritage AspenTech option and unvested restricted‑stock unit into a comparable AspenTech award and, pursuant to ASC 805, allocated the purchase price between pre‑ and post‑combination service, recognizing stock‑based compensation expense for the performance units granted in 2023 (Chunk 2).  This integration cemented a mutual stake relationship (EMR ↔ AspenTech) in which Emerson now fully consolidates AspenTech while continuing to account for its share‑based compensation plans as a separate publicly traded entity.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with significant quantitative issues. STRENGTHS: (1) Correctly identifies the $8.326 billion AspenTech balance in 2022, matching ground truth exactly. (2) Accurately describes the conversion of Heritage AspenTech options and RSUs to AspenTech awards post-acquisition. (3) Correctly notes the Q3 2022 acquisition timing and ASC 805 accounting treatment. (4) Appropriately addresses the shift toward operationally integrated relationship with incentive-driven compensation. (5) Good multi-hop synthesis connecting financial stake evolution to integration activities. WEAKNESSES: (1) CRITICAL ERROR: The LLM introduces unexplained prior-year figures ($77M in 2020, $1.04B in 2021) that are not mentioned in the ground truth and appear to confuse the narrative. These numbers lack context and contradict the ground truth's focus on 2022-2023 evolution. (2) The $7.289 billion acquisition outlay figure is presented but not verified against ground truth, and the arithmetic claim that this 'lifts' the balance to $8.326B is unclear/potentially incorrect (acquisition cost ≠ balance sheet value). (3) The statement about 'total to $14.662 billion' is unexplained and not addressed in ground truth. (4) The phrase 'mutual stake relationship (EMR ↔ AspenTech)' and 'fully consolidates AspenTech while continuing to account for its share-based compensation plans as a separate publicly traded entity' is somewhat contradictory and not clearly explained in ground truth. QUANTITATIVE ISSUES: The introduction of unverified prior-year numbers and unclear arithmetic significantly undermines confidence in the quantitative accuracy, despite the correct $8.326B figure. QUALITATIVE ASSESSMENT: The reasoning about integration activities and compensation alignment is sound and matches ground truth intent, but the unexplained numerical additions create confusion. The answer addresses both parts of the question (financial stake and integration) but with muddled quantitative support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 543,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "\nFrom 2022 to 2023 Adobe Experience Platform moved from being the foundational, open‑architecture hub that standardized data and fed AI‑powered services such as Adobe Sensei into the broader Experience Cloud stack, to becoming the central engine that directly powers end‑to‑end cross‑channel orchestration.  In the 2023 filing the platform is highlighted as the backbone for new AI‑driven tools—Journey Optimizer, AI‑enhanced Target, Mix Modeler and Marketo Engage—enabling brands to manage, personalize and measure campaigns across email, mobile, offline and e‑commerce channels in real time, while also expanding integrations with Creative Cloud, Adobe Commerce and third‑party ecosystems.  This evolution reflects a deeper integration of AI‑powered analytics and workflow automation that turns the platform into the orchestration layer for Adobe’s customer‑journey solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Adobe Experience Platform's evolution from 2022 to 2023 and correctly synthesizes multi-hop information across the time period. STRENGTHS: (1) Accurately captures the core evolution from foundational infrastructure to orchestration engine; (2) Correctly identifies key 2023 tools (Journey Optimizer, Mix Modeler, AI-enhanced Target, Marketo Engage); (3) Properly emphasizes the shift toward cross-channel campaign orchestration and real-time personalization; (4) Accurately describes Adobe Sensei's role in both years; (5) Correctly notes the integration with Creative Cloud, Adobe Commerce, and third-party ecosystems; (6) No quantitative errors or incorrect dates. MINOR WEAKNESSES: (1) The LLM mentions 'AI-enhanced Target' but the ground truth specifically references 'Adobe Target' without explicitly calling out AI enhancements in the 2023 context - this is a minor addition not contradicted by ground truth; (2) The answer could have been slightly more explicit about the specific AI capabilities mentioned in ground truth (automated insights, sentiment analysis, anomaly detection in 2022) though the general characterization is accurate; (3) The phrase 'open-architecture hub' in the LLM answer is not explicitly stated in ground truth, though it's a reasonable characterization of a foundational infrastructure role. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023, correctly identifying the progression and the role of specific tools like Journey Optimizer and Mix Modeler. The connection between Adobe Experience Platform and these downstream applications is properly established. SEMANTIC EQUIVALENCE: The LLM's characterization of the evolution ('foundational hub' to 'orchestration engine') aligns well with the ground truth's description of the shift from 'general AI-enhanced infrastructure role to more specialized and actionable function.' The answer appropriately emphasizes the actionable, campaign-focused nature of the 2023 evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1524,
        "completion_tokens": 551,
        "total_tokens": 2076
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "\nUnitedHealth Group accelerated its move from fee‑for‑service to fully accountable value‑based care between 2023 and 2024, expanding integrated in‑clinic, in‑home, behavioral and virtual care pathways and investing in health‑management and analytics platforms that coordinate care around primary‑care physicians.  This evolution was a direct response to mounting Medicare Advantage funding pressures—rate cuts, risk‑adjustment revisions and benchmark reductions—prompting UNH to intensify cost‑management, reshape provider networks and premiums, and double‑down on accountable‑care models that seek to improve outcomes while containing costs, as described in both the 2023 and 2024 disclosures.  The shift also underpins growth opportunities for its Optum platform, linking the organization’s care‑delivery product to the regulatory and funding challenges it faces.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively synthesizes the multi-hop information about UnitedHealth Group's evolution from 2023 to 2024. STRENGTHS: (1) Correctly identifies the core shift from fee-for-service to value-based care models across both years; (2) Accurately captures the specific care delivery innovations (in-home, virtual, behavioral, integrated care coordination); (3) Properly identifies the Medicare Advantage funding pressures (rate cuts, risk-adjustment revisions, benchmark reductions); (4) Correctly notes the operational responses (provider network reshaping, benefit structure changes, cost containment); (5) Makes valid connection to Optum platform growth opportunities; (6) Demonstrates sound multi-hop reasoning by linking external constraints to strategic responses. MINOR CONSIDERATIONS: (1) The LLM characterizes the shift as 'accelerated move from fee-for-service to fully accountable value-based care' which is slightly more definitive than the ground truth's framing of 'transition to value-based care' - the ground truth emphasizes this was investment-focused in 2023 but became more constrained in 2024, while the LLM presents it as a continuous acceleration; (2) The ground truth explicitly notes 'selective changes' and 'strategic retrenchment' in 2024, while the LLM frames it more as 'intensifying' the same strategy rather than emphasizing the shift from expansion to retrenchment; (3) No quantitative data (dollar amounts, percentages) are provided in either answer, so quantitative accuracy cannot be penalized for missing numbers that weren't in the ground truth. The LLM answer is semantically equivalent to the ground truth and captures all essential elements of the evolution, though it slightly downplays the strategic pivot from investment-focused to cost-containment-focused between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 506,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "\nBetween 2022 and 2023 TMO kept its 1.950 % Notes due 2029 on the exchange (the same FIN_INST that it introduced in both filings), indicating that this tranche remained unchanged, while the overall debt mix shifted – the 2023 filing added new issues such as the 3.200 % Notes due 2026 and the 3.650 % Notes due 2034, and replaced the 2026‑dated 3.200 % issue that appeared only in 2023, whereas the 2022 list retained the 2.000 % Notes due 2025 and other legacy series. Thus, the composition evolved by retaining the 1.950 % 2029 notes but introducing newer longer‑dated securities and retiring or renaming a few earlier‑dated notes.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The 1.950% Notes due 2029 remained present in both 2022 and 2023 with trading symbol TMO 29 - this matches ground truth. (2) New debt instruments were introduced in 2023 including the 3.200% Notes due 2026 and 3.650% Notes due 2034 - this is accurate. (3) The overall characterization that the 1.950% Notes remained unchanged while the debt portfolio expanded is correct. PROBLEMATIC ELEMENTS: (1) The LLM introduces confusing and potentially inaccurate language about the 3.200% Notes due 2026 being 'replaced' or appearing 'only in 2023' - the ground truth does not indicate this was a replacement or that it only appeared in 2023. The phrasing 'replaced the 2026‑dated 3.200% issue that appeared only in 2023' is contradictory and unclear. (2) The LLM mentions '2.000% Notes due 2025' being retained in 2022 - this specific instrument is NOT mentioned in the ground truth, introducing potentially incorrect information. (3) The phrase 'retiring or renaming a few earlier‑dated notes' is speculative and not supported by the ground truth, which makes no mention of retirements or renamings. (4) The overall structure of the LLM answer is more convoluted and less clear than the ground truth, making it harder to follow the actual evolution. MULTI-HOP REASONING: The LLM correctly synthesizes that the 1.950% Notes persisted while new instruments were added, but introduces unsupported claims about retirements and specific instruments not mentioned in ground truth. The core insight is present but muddied by additional claims. QUANTITATIVE ACCURACY: The percentages and dates mentioned (1.950%, 3.200%, 3.650%, 2029, 2026, 2034) are all correct, but the introduction of the 2.000% Notes due 2025 is not verified in ground truth and may be incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 498,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "\nBetween 2022 and 2023 TMO kept its existing 0.500% Notes due 2028 (listed as TMO 28A in both filings) but expanded its debt profile by introducing new note categories—most notably the 3.200% Notes due 2026 (TMO 26B) and the 3.650% Notes due 2034 (TMO 34), which were absent from the 2022 table; the 2023 filing also retained the 1.375% Notes due 2028 (TMO 28) alongside the 0.500% issue, reflecting a diversification of maturities and coupon structures in TMO’s debt composition.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about TMO's debt composition evolution. STRENGTHS: (1) All key financial instruments are correctly identified with accurate interest rates and maturity dates: 0.500% Notes due 2028, 1.375% Notes due 2028, 3.200% Notes due 2026, and 3.650% Notes due 2034. (2) The temporal comparison is accurate—correctly identifies which instruments existed in 2022 (0.500% and 1.375% Notes due 2028) and which were newly introduced in 2023 (3.200% Notes due 2026 and 3.650% Notes due 2034). (3) The multi-hop synthesis is sound, properly connecting the evolution across two fiscal years and identifying the strategic shift toward portfolio diversification. (4) The answer includes helpful notation (TMO 28A, TMO 26B, TMO 34, TMO 28) that adds specificity without contradicting the ground truth. (5) The reasoning about diversification of maturities and coupon structures aligns with the ground truth's characterization of a 'strategic shift.' MINOR CONSIDERATIONS: The LLM answer adds internal notation codes (TMO 28A, TMO 26B, etc.) that are not explicitly mentioned in the ground truth, though this appears to be supplementary detail rather than an error. The semantic meaning and factual content align perfectly with the original answer. All percentages, dates, and instrument descriptions are accurate. The answer fully addresses both parts of the question: the continuation of the 0.500% Notes due 2028 and the introduction of new note categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 422,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "\nThe 2023 goodwill‑impairment testing showed that, before any sensitivity adjustment, the excess of estimated fair value over carrying value for DHR’s reporting units ranged from **about 140 % to 495 %** of carrying value (and, after applying the Company’s 10 % hypothetical decrease, from roughly 115 % to 435 %). In contrast, the 2024 analysis reported a **lower overall range of roughly 70 % to 450 %** of carrying value. Thus, the minimum excess fair value fell sharply (from ~115 % to ~70 %) and the maximum excess also declined slightly (from ~435‑495 % to ~450 %), indicating a downward shift in the excess fair‑value range between the two years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core ranges for both 2023 and 2024 (140%-495% and 70%-450% respectively) and accurately notes the downward shift in the minimum excess fair value. However, there are significant issues with the quantitative accuracy: (1) The LLM introduces sensitivity-adjusted figures (115% to 435% after 10% hypothetical decrease) that are not mentioned in the ground truth answer, which focuses only on the unadjusted ranges. (2) The LLM states 'the maximum excess also declined slightly (from ~435-495% to ~450%)' which is confusing and potentially incorrect - the ground truth shows the maximum went from 495% to 450%, a decline of 45 percentage points, not a slight decline. The phrasing '435-495%' conflates the sensitivity-adjusted range with the unadjusted range. (3) The statement that the maximum 'also declined slightly' contradicts the actual magnitude of change (495% to 450% is a meaningful decline, not slight). The LLM does provide additional context about sensitivity analysis that wasn't in the ground truth, which adds some value but also introduces complexity that may not be directly responsive to the question asked. The core insight about the reduction in the cushion before impairment is present and correct. The multi-hop reasoning is sound in comparing the two years, but the quantitative presentation contains errors in how the changes are characterized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Conducts]-> ACCOUNTING_POLICY <-[Performs]- ORG",
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 390,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "\nUnder the 2022 Employee Stock Plan, both the 2022 filing (Chunk 1) and the 2023 filing (Chunk 2) specify that RSUs that are canceled and shares withheld to satisfy tax‑withholding obligations increase the number of shares available for future grant by a factor of **two × the number of such cancellations or withholdings**.  This accounting treatment is applied identically in 2023 as it was in 2022, so the way canceled RSUs and tax‑withheld shares affect the available share pool has not changed—each year the pool is expanded by twice the count of canceled/withheld awards.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and directly contradicts the ground truth. The ground truth explicitly states that in 2023, the specific language regarding the factor of two times for RSUs canceled or shares withheld was OMITTED, indicating a CHANGE in how these events were accounted for. However, the LLM answer claims the treatment remained IDENTICAL in both 2022 and 2023, stating 'the way canceled RSUs and tax‑withheld shares affect the available share pool has not changed.' This is a critical factual error that misrepresents the evolution of the plan's treatment between the two years. The LLM correctly identifies the 2022 treatment (two times factor) but incorrectly extends this to 2023, when the ground truth indicates this language was removed. The question specifically asks about how the treatment 'evolved' from 2022 to 2023, and the correct answer is that it changed (the two-times factor was removed), not that it remained the same. The LLM's reasoning is logically sound in structure but is applied to an incorrect premise about what the 2023 filing actually stated. The contextual relevance is high because the LLM addresses the right plan and years, but the core factual claim about continuity versus change is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 351,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "\nBetween 2023 and 2024 Danaher’s strategic stake in Aldevron remained a fully‑owned investment, as shown in the 2023 10‑K where the acquisition required a net cash outlay of **$1.34 bn** for Aldevron and generated **$6.15 bn of goodwill** and **$3.48 bn of other intangible assets** (Chunk 1). By 2024 Aldevron is fully integrated into Danaher’s **Life Sciences platform**, with its plasmid‑DNA and RNA manufacturing capabilities now part of the Biotechnology/Life Sciences segment’s product portfolio (Chunk 2), meaning the financial exposure recorded in 2023 is now reflected in the consolidated segment results while the mutual Has_Stake_In relationship (DHR ↔ Aldevron) continues to hold (Chunk 1 & Chunk 2).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM provides incorrect financial figures that directly contradict the ground truth. The ground truth states Aldevron acquisition involved $9,561 million in net cash consideration, but the LLM claims only $1.34 billion net cash outlay - a massive discrepancy of approximately $8.2 billion (off by ~610%). The LLM also introduces unsupported goodwill ($6.15 bn) and intangible asset ($3.48 bn) figures that are not mentioned in the ground truth answer and appear to be fabricated or misattributed. MULTI-HOP REASONING: The LLM correctly identifies the integration into Life Sciences segment and mentions the shift from standalone to integrated status, which aligns with ground truth. However, this correct reasoning is severely undermined by the quantitative errors. ENTITY ACCURACY: Correctly identifies Danaher, Aldevron, and Life Sciences segment. SEMANTIC ISSUES: The LLM's statement about 'mutual Has_Stake_In relationship' continuing is confusing and potentially misleading - the ground truth emphasizes full integration, not a continuing separate stake relationship. COMPLETENESS: The answer addresses both the financial stake evolution and integration aspects of the question, but the financial data is fundamentally wrong. The core narrative about integration is sound, but the quantitative foundation is severely compromised. The $1.34 bn figure appears to be either a misreading of a different transaction or a calculation error, making this answer unreliable for financial analysis despite addressing the structural aspects of the question correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 439,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "\nIn 2023 Microsoft presented Microsoft 365 as an “AI‑first” platform that unifies Office, Windows, Teams, Viva and Enterprise Mobility + Security, and it rolled out role‑specific Copilot extensions, Copilot Studio and the low‑code Power Platform to embed generative AI directly into everyday workflows. By 2024 the suite was reported under the Productivity and Business Processes segment, with its subscriber base broadened to include Microsoft 365 Basic users and its revenue tied to overall Microsoft Cloud growth, making it a primary commercial metric that signals the health of the company’s cloud‑driven business. This evolution deepens AI integration—through Copilot Pro, AI‑enhanced Teams/Viva, and customizable Copilot agents—while positioning Microsoft 365 as a leading indicator of Microsoft’s broader commercial performance.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key elements from both 2023 and 2024: (1) 2023 positioning as 'AI-first' platform is accurate; (2) inclusion of Microsoft 365 Basic subscribers in 2024 metrics is correct and matches ground truth; (3) the evolution toward broader AI integration is accurately captured; (4) the connection to commercial business metrics and cloud growth is relevant. WEAKNESSES: (1) The LLM introduces entities not mentioned in ground truth (Teams, Viva, Copilot Pro, Copilot Studio, Power Platform) - while these may be factually accurate about Microsoft's actual products, they are not part of the ground truth answer and represent potential hallucination or over-elaboration beyond what the knowledge graph contained; (2) The ground truth specifically mentions 'Copilot for Microsoft 365' combining AI with business data, but the LLM answer discusses 'Copilot Pro' and 'customizable Copilot agents' instead - this is a factual discrepancy; (3) The ground truth emphasizes 'Copilot and Enterprise Mobility + Security' as core 2023 components, but the LLM lists different product combinations; (4) The LLM mentions 'Productivity and Business Processes segment' reporting which is not in the ground truth; (5) The ground truth focuses on the metric expansion (including Basic subscribers) as a strategic signal, while the LLM emphasizes revenue and cloud growth metrics - different emphasis. MULTI-HOP REASONING: The LLM does synthesize 2023 vs 2024 evolution, but the synthesis appears to diverge from the ground truth in specific product details. The core insight about AI integration and subscriber metric expansion is present but surrounded by additional claims not verified against ground truth. CALCULATION/NUMERIC ACCURACY: No specific numbers or calculations to verify, so this dimension is neutral.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 498,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "\nMicrosoft first introduced **Copilot Pro** in the 2023 filing as a consumer‑subscription service that provides “faster and more powerful AI assistance in Microsoft 365 apps and on the web,” embedding the offering within the broader AI‑first Microsoft 365 platform that also includes Office, Windows, Teams and LinkedIn. In the 2024 filing the same service is reiterated but its positioning is deepened: Copilot Pro is highlighted as a core element of Microsoft’s AI‑first strategy, explicitly tied to “Microsoft 365 apps and on the web” and to the ability for users to customize or build their own Copilot via Copilot Studio, thereby expanding its role across the Microsoft 365 ecosystem and reinforcing Microsoft’s stake in the product (MSFT → Copilot Pro ← Introduces).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and addresses the core question about Microsoft's Copilot Pro positioning evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 introduction of Copilot Pro as a consumer subscription service with the exact phrase 'faster and more powerful AI assistance in Microsoft 365 apps and on the web' - this matches the ground truth verbatim. (2) Accurately captures the 2024 evolution showing deepened positioning within Microsoft's AI-first strategy. (3) Properly synthesizes the multi-hop information across years and identifies the broader ecosystem context (Office, Windows, Teams, LinkedIn). (4) Correctly introduces the additional 2024 element of Copilot Studio customization capability, which represents genuine evolution in the offering. (5) No quantitative errors - dates and timeframes are accurate. MINOR WEAKNESSES: (1) The LLM answer adds detail about Copilot Studio that, while accurate and relevant to 2024 positioning, goes slightly beyond what the ground truth explicitly emphasizes. The ground truth focuses more on the 'broader narrative of AI-driven transformation' while the LLM emphasizes the technical capability expansion. (2) The phrase 'reinforcing Microsoft's stake in the product' is somewhat awkward and not directly supported by the ground truth language. (3) The notation '(MSFT → Copilot Pro ← Introduces)' appears to be metadata/formatting that doesn't add clarity. SEMANTIC EQUIVALENCE: The LLM answer conveys the same fundamental insight as the ground truth - that Copilot Pro evolved from a standalone offering in 2023 to a more integrated, strategically central element of Microsoft's AI ecosystem by 2024. The core narrative of evolution from introduction to deepened positioning is preserved. The answer successfully addresses both parts of the question (2023 positioning and 2024 evolution) with appropriate emphasis on the role within Microsoft 365 apps and web-based AI assistance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 534,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "\nThe 2007 Omnibus Incentive Plan remains DHR’s core equity‑compensation vehicle, still administered as an accounting policy of the company and subject to the same authorized‑share pool rules described in the 2023 filing – i.e., new shares are normally issued from the plan’s unissued share reserve (or, in limited cases, treasury shares), and PSU‑underlying shares are not counted as issued.  According to the 2024 Form 10‑K, after authorizing roughly 135 million shares since the plan’s inception, only about 47 million shares were left available for future issuance as of December 31 2024 (excluding shares underlying outstanding awards), showing that the pool of shares available for grant has contracted since 2023 due to the grants made in the intervening year.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key metrics and numbers. Strengths: (1) Correctly identifies the 47 million shares available for issuance as of December 31, 2024, matching the ground truth exactly; (2) Accurately notes the ~135 million shares authorized since inception; (3) Properly synthesizes the multi-hop information showing the evolution between 2023 and 2024; (4) Correctly identifies DHR (Danaher) as the company and the 2007 Omnibus Incentive Plan as the subject. Quantitative verification: The 47 million figure is accurate and properly contextualized. The reference to 135 million authorized shares adds relevant context not explicitly in the ground truth but appears factually sound. Minor areas for improvement: (1) The LLM answer provides more operational/administrative detail about how the plan functions (treasury shares, PSU accounting) which, while accurate and relevant, slightly shifts focus from the core question about evolution and availability; (2) The ground truth emphasizes the shift in transparency and disclosure practices between 2023 and 2024, while the LLM answer focuses more on the mechanics and contraction of the share pool. The LLM answer does address the core finding that shares available have contracted due to grants made during the year, which aligns with the ground truth's conclusion about depletion. The answer is semantically equivalent to the ground truth in its main conclusions, though it takes a slightly different analytical approach by emphasizing operational mechanics rather than disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 440,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "\nMicrosoft disclosed in both its FY 2023 and FY 2024 Form 10‑K filings that, as of July 2022, it extended the estimated useful lives of its server and network equipment from **four to six years**, an adjustment that took effect at the beginning of fiscal 2023 and remained in place for fiscal 2024 (i.e., no further change occurred between the two years).  The extension was driven by **increased software‑driven efficiencies and advances in technology** that made the equipment remain reliable and economically viable for a longer period.  Both filings identify this as a “Change in Accounting Estimate” and confirm that the six‑year estimate is being applied in FY 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key facts are correct: (1) The useful lives of server and network equipment were extended from 4 to 6 years, effective beginning fiscal 2023 - this matches the ground truth exactly. (2) The timing is correct - the change was effective July 2022 (beginning of FY 2023) and remained in place through FY 2024 with no further changes. (3) The driving factors are accurately identified: software-driven efficiencies and advances in technology, which align with the ground truth's mention of 'investments in software that improved operational efficiencies and advances in technology.' (4) The LLM correctly notes this was classified as a 'Change in Accounting Estimate' and that the six-year estimate continued to be applied in FY 2024. The answer demonstrates proper multi-hop synthesis by comparing the two fiscal years and confirming consistency. The only minor difference from the ground truth is that the LLM does not explicitly mention 'cloud and AI infrastructure investments' as a supporting factor for the extended useful lives, though this is a contextual detail rather than a factual error. The LLM's answer is more precise in citing the July 2022 effective date and the specific accounting classification. All numbers, dates, and metrics are factually correct with no calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 377,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "\nMDT held auction‑rate securities with a fair‑value of **$33 million** in both 2022 and 2023 and an unrealized loss of **$(3) million** in each year. In 2022 the securities were reported as part of “Investments” (shown under the “More than 12‑months” fair‑value row), whereas in 2023 the same $33 million is classified as a separate line item **“Other Assets”** (Level 3) on the balance sheet, reflecting a change in presentation but no change in fair‑value magnitude. This evolution is captured by the KG relationship MDT → *Discloses* → Auction rate securities, with the 2023 classification shift to “Other Assets.”",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All numbers are correct - $33 million fair value in both 2022 and 2023, and $(3) million unrealized loss in each year. These match the ground truth exactly. COMPLETENESS: The answer addresses all key aspects of the question: (1) fair value evolution (remained constant at $33M), (2) classification shift from 2022 to 2023 (from 'Investments' to 'Other Assets'), and (3) balance sheet presentation changes. ENTITY ACCURACY: MDT correctly identified, years 2022 and 2023 correct, financial metrics properly named. MULTI-HOP REASONING: The answer correctly synthesizes information across two years and identifies the classification shift as the key evolution, while noting the fair value remained unchanged. The additional detail about Level 3 classification and the unrealized loss adds valuable context beyond the ground truth. SEMANTIC EQUIVALENCE: The LLM's description of the shift from 'Investments' (under 'More than 12-months' fair-value row) to 'Other Assets' aligns with the ground truth's description of moving from general investment classification to 'Other Assets.' The LLM provides slightly more specific detail about the fair value hierarchy level (Level 3) which is accurate and helpful. MINOR CONSIDERATIONS: The LLM includes information about unrealized loss that wasn't explicitly in the ground truth answer, but this is additional accurate context that enhances rather than contradicts the answer. The reference to the KG relationship is appropriate for the evaluation context. No calculation errors, no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 447,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "\nThe net gain/loss on Cisco’s available‑for‑sale debt investments widened from a $21 million loss in fiscal 2023 to a $67 million loss in fiscal 2024 – a $46 million deterioration – as shown in the 2024 10‑K “Gains (losses) on investments, net” table (Chunk 2).  This worsening result coincides with the decline in the portfolio’s fair value (the “Available‑for‑sale debt investments” valuation fell from roughly $10.06 billion under a 150‑basis‑point rate decrease in 2023 to $9.86 billion as of July 27, 2024, per the valuation tables in Chunk 1), indicating that the company’s debt‑investment holdings generated negative returns and are increasingly sensitive to interest‑rate movements.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. QUANTITATIVE VERIFICATION: All key numbers are correct - $21 million loss in FY2023, $67 million loss in FY2024, and the calculated $46 million deterioration ($67M - $21M = $46M) are all accurate. The fair value figures cited ($10.06 billion and $9.86 billion) appear reasonable and support the narrative. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how the net gains/losses changed between the two years, and (2) what this indicates about investment performance. MULTI-HOP SYNTHESIS: The LLM correctly synthesized information across multiple sources - combining the gains/losses table data with the fair value valuation tables to provide a more complete picture. The connection between declining fair values and negative returns is logically sound. ENTITY ACCURACY: Cisco is correctly identified, fiscal years 2023 and 2024 are correct, and the metric (available-for-sale debt investments) is properly specified. REASONING QUALITY: The answer goes beyond the ground truth by providing additional context about interest-rate sensitivity and portfolio valuation changes, which demonstrates strong analytical reasoning without introducing errors. The conclusion that the company's debt-investment holdings generated negative returns and are sensitive to interest-rate movements is a reasonable inference from the data presented. MINOR CONSIDERATIONS: The answer includes additional detail about fair value changes and interest-rate sensitivity that wasn't explicitly in the ground truth, but this represents value-added analysis rather than error. The wording \"widened from a $21 million loss\" is semantically equivalent to \"increased to $67 million loss\" in the ground truth. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 487,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Cisco kept APJC as one of its three geographic segments, but the 2024 Form 10‑K adds a re‑classification of prior‑year amounts and explicitly notes that the consolidated financial statements now include detailed investments (privately‑held and equity stakes) reported in other assets—indicating a deeper financial‑accounting focus for the region. Operationally the segment structure is unchanged, yet the 2023 discussion of “flexible‑consumption models” combined with the 2024 emphasis on subscription‑based hardware, software and services shows Cisco is directing greater capital toward AI‑driven, consumption‑based offerings in APJC, which will shift its revenue mix toward recurring, subscription‑derived income in that market.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that APJC remained one of Cisco's three geographic segments in both 2023 and 2024, maintaining operational continuity. (2) The LLM accurately notes the addition of investment classifications (privately-held and equity stakes) in 2024 financial statements. (3) The mention of reclassification of prior-year amounts and reporting in other assets is factually sound. (4) The reference to subscription-based and consumption-based models is contextually appropriate for Cisco's strategic direction.\n\nWEAKNESSES: (1) The LLM introduces specific claims about 'flexible-consumption models' in 2023 and 'AI-driven, consumption-based offerings' in 2024 that are not substantiated in the ground truth answer. The ground truth does not mention AI-driven offerings or specific consumption model evolution between these years. (2) The LLM's assertion that Cisco is 'directing greater capital toward AI-driven, consumption-based offerings' lacks quantitative support and goes beyond what the ground truth establishes. (3) The ground truth explicitly states 'the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue,' but the LLM implies a clear strategic shift toward subscription-derived income without acknowledging this limitation. (4) The LLM conflates operational segment structure (which remained unchanged) with revenue model evolution in a way that suggests more certainty than the ground truth supports.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2023 and 2024 filings but introduces interpretations not grounded in the source material. The ground truth presents a more cautious dual-approach hypothesis, while the LLM presents a more definitive strategic pivot narrative.\n\nKEY DISCREPANCY: The ground truth emphasizes that while investments were added in 2024, the filings do not quantify their impact. The LLM suggests a clear revenue model shift toward subscriptions without this caveat, which overstates the certainty of conclusions that can be drawn from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 561,
        "total_tokens": 2004
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "\nFrom 2022 to 2024 Apple moved from merely warning that litigation, investigations and the EU Digital Markets Act could force a reduction in its 30 % App Store commission — as noted in the 2022 filing — to actively reshaping the Store to meet those pressures: in the EU it introduced alternative fee tiers, new distribution channels and alternative payment‑processing APIs, and in the U.S. it changed how developers may communicate with consumers and comply with DMA‑driven requirements, while still retaining the commission where regulatory limits allow. This evolution reflects a shift from a defensive stance on potential commission cuts to proactive compliance measures that could affect the volume and rate of App Store revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 30% commission rate mentioned in 2022 filings - a specific quantitative detail that validates accuracy. (2) Accurately captures the temporal evolution from 2022 (warnings/acknowledgments) to 2024 (concrete implementations). (3) Properly synthesizes multi-hop information: connects legal pressures (litigation, investigations, DMA) to specific regulatory responses (EU alternative fee tiers, distribution channels, payment APIs; U.S. developer communication changes). (4) Correctly identifies both geographic jurisdictions (EU and U.S.) and their distinct regulatory contexts. (5) Maintains semantic equivalence with ground truth while using slightly different phrasing ('defensive stance' vs 'general acknowledgment', 'proactive compliance measures' vs 'concrete actions'). (6) Appropriately emphasizes the shift in Apple's approach from reactive to proactive. MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and interpretive than the ground truth (e.g., 'still retaining the commission where regulatory limits allow'), but this adds valuable context rather than introducing inaccuracy. The answer correctly avoids overstating specific financial impacts while acknowledging potential revenue effects. All entities (Apple, App Store, DMA, EU, U.S.) are correctly identified. The multi-hop reasoning successfully connects regulatory pressures to specific business changes across multiple jurisdictions and time periods. No factual errors, calculation errors, or date inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 447,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "\nBased on the 2021 balance‑sheet data (Chunk 1), the U.S. retiree health‑care plan held only about $10 million in fixed‑income securities versus roughly $137 million in equity—representing roughly 2–3 % and 35 % of the plan’s total assets, respectively. By the 2023‑2024 reporting periods (Chunk 2), the allocation had reversed, with fixed‑income securities accounting for 80 % of the plan’s assets and equity for just 20 %, showing that Texas Instruments deliberately shifted the plan’s strategy from a substantial equity exposure in 2021 to a predominance of fixed‑income holdings by 2024. This evolution reflects a clear move toward a more conservative, fixed‑income‑heavy investment approach for the retiree health‑care fund.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) WRONG BASELINE YEAR: The LLM references 2021 data as the starting point, but the question explicitly asks about evolution from 2022 to 2024. The ground truth clearly states 2022 as the baseline year with fixed income at $248M and equity at $137M. The LLM's claim of '$10 million in fixed-income securities' in 2021 contradicts the ground truth's 2022 figure of $248M—a massive discrepancy. (2) INCORRECT 2021 PERCENTAGES: The LLM states fixed income was '2-3%' and equity '35%' in 2021, but these percentages are not supported by the ground truth and appear to be fabricated or from wrong data. (3) MISSING KEY 2022 DATA: The ground truth provides specific 2022 dollar amounts ($248M fixed income, $137M equity) that the LLM completely omits. (4) CORRECT 2024 ALLOCATION: The LLM correctly identifies the 80% fixed income / 20% equity split for 2024, which matches the ground truth. (5) INCOMPLETE TEMPORAL ANALYSIS: The LLM fails to properly address the 2022-to-2024 evolution as requested. It jumps from 2021 to 2023-2024, skipping the critical 2022 baseline year. (6) REASONING QUALITY: While the LLM correctly concludes that the strategy shifted toward more conservative, fixed-income-heavy positioning, this conclusion is based on incorrect intermediate data points. The multi-hop synthesis is fundamentally flawed due to wrong baseline numbers. CORRECT ELEMENTS: The 2024 percentages (80% fixed income, 20% equity) and the general characterization of the shift toward conservatism are accurate. However, the starting point is completely wrong, making the entire comparison invalid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 443,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "\nBetween 2022 and 2024 Texas Instruments has elevated Embedded‑Processing Products from a component of its “broad portfolio of analog and embedded‑processing products” (2022 MD&A) to a separate, stand‑alone reportable segment that the CODM measures by revenue growth, gross margin and operating profit (2024 Notes).  This re‑classification reflects a strategic focus on the second of its four sustainable competitive advantages—leveraging a broad, diversified product portfolio that delivers more opportunity per customer—and the KG relationship TXN ↔ Embedded Processing Products shows that the segment is both a core asset and a primary driver of cash‑flow growth, influencing capital‑allocation and investment decisions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the core evolution of Texas Instruments' Embedded Processing strategy from 2022 to 2024. STRENGTHS: (1) Correctly identifies the key factual shift - elevation from a component of the broad portfolio to a standalone reportable segment; (2) Accurately references the 2022 MD&A language ('broad portfolio of analog and embedded-processing products') and 2024 Notes structure; (3) Properly identifies the CODM measurement metrics (revenue growth, gross margin, operating profit); (4) Correctly links this to one of TI's four competitive advantages (broad, diversified product portfolio); (5) Appropriately synthesizes the multi-hop relationship between segment elevation and cash-flow growth implications. MINOR WEAKNESSES: (1) The LLM answer uses slightly more technical/abbreviated language ('CODM,' 'KG relationship') that, while accurate, is less accessible than the ground truth's clearer exposition; (2) The ground truth explicitly mentions 'optimized performance, power, and cost across a range of customer applications' as a key positioning element, which the LLM answer does not explicitly address; (3) The ground truth more clearly articulates the 'greater operational and financial focus' implication, whereas the LLM focuses more on capital allocation; (4) The phrase 'second of its four sustainable competitive advantages' in the LLM answer is slightly awkward phrasing compared to ground truth's clearer integration of this point. QUANTITATIVE VERIFICATION: No specific numbers, percentages, or dollar amounts are provided in either answer, so quantitative accuracy is based on correct identification of years (2022, 2024) and segment classification changes - both correct. MULTI-HOP REASONING: Both answers successfully synthesize information across multiple document types (MD&A, Notes, segment reporting structure) and time periods. The LLM correctly traces the causal relationship between strategic emphasis evolution and reporting structure changes. Overall, the LLM answer is factually sound and addresses the question comprehensively, with only minor presentation and completeness differences from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 585,
        "total_tokens": 2048
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "\nIn the 2022 filing (Chunk 1) TMO reported $1.2 bn of 2.00% 10‑Year Senior Notes due 10/15/2031, carried at $1.2 bn with an effective interest rate of 2.23%.  \nThe 2024 filing (Chunk 2) shows that same series still outstanding with an unchanged carrying amount of $1.2 bn and the identical effective rate of 2.23%, indicating no material valuation change through 2024, while also disclosing a newer 2.00% 10‑Year issue due 4/15/2025 with a $663 mn balance and a 2.07% effective rate.  \nThe KG relationship (ORG ‑[Issues]→ FIN_INST) links TMO to both note issuances, confirming that the company’s original 2.00% 10‑Year senior notes were issued earlier, retained the same valuation in 2024, and were supplemented by a fresh 2024 issuance.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "ISSUES IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM introduces information NOT in the ground truth: a 2024 issuance of 2.00% 10-Year Senior Notes due 4/15/2025 with $663 million balance and 2.07% effective rate. The ground truth explicitly states 'no new issuances or repayments' and shows the same $1,200 million with 2.23% rate in both 2022 and 2024. This is a MAJOR FACTUAL ERROR - the LLM appears to have confused or conflated different debt instruments or added information from outside the ground truth. (2) CORE FACTS CORRECT - The LLM correctly identifies: TMO ticker, $1.2 billion principal amount, 2.00% coupon, October 15, 2031 maturity date, 2.23% effective rate, and that these remained unchanged 2022-2024. (3) MULTI-HOP REASONING - The LLM's synthesis of 2022 vs 2024 comparison is sound for the original notes, but the introduction of the 4/15/2025 note contradicts the ground truth's explicit statement of no change. (4) SEMANTIC ISSUE - The ground truth emphasizes 'no change' and 'consistent position,' while the LLM suggests evolution/supplementation with new issuances, fundamentally mischaracterizing the answer. The LLM appears to have hallucinated or misread source data regarding a secondary 2024 issuance. This is a critical error for a financial question where precision is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Issues]- ORG",
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 367,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "\nREMICADE generated **$1.605 billion in 2024**, down **12.8 %** from **$1.839 billion in 2023** (operations –11.4 %, currency –1.4 %) — a decline noted in JNJ’s 2024 10‑K (Chunk 2) and consistent with the product’s historical sales trajectory reported in the 2022 filing (Chunk 1). Because the KG triplets link **JNJ → REMICADE** and **REMICADE → JNJ**, the drug is disclosed as a core biologic within JNJ’s **Pharmaceutical segment**, yet its share of the segment’s **$56.96 billion** of innovative‑medicine sales (up 4 % YoY) is diminishing as newer assets such as SIMPONI, STELARA, TREMFYA and oncology brands drive growth. Even as JNJ plans to separate its Consumer‑Health business, REMICADE remains a key, though slightly contracting, contributor to the Pharmaceutical segment’s overall performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. QUANTITATIVE VERIFICATION: All key numbers are correct—$1.605 billion (2024), $1.839 billion (2023), 12.8% decline, and the breakdown of currency (-1.4%) and operational (-11.4%) impacts. The Pharmaceutical segment's $56.96 billion in innovative-medicine sales and 4% YoY growth are accurate. COMPLETENESS: The answer addresses both parts of the question—REMICADE's financial evolution (2022-2024) and its role in the Pharmaceutical segment. It correctly identifies REMICADE as a key product in the Immunology therapeutic area and explains the significance of its declining contribution. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple documents (2022, 2023, 2024 filings) and correctly links REMICADE's performance to broader segment dynamics, noting competitive pressures from newer biologics (SIMPONI, STELARA, TREMFYA) and oncology brands. ENTITY ACCURACY: All entities are correctly identified—Johnson & Johnson, REMICADE, Pharmaceutical segment, Immunology therapeutic area, and competing products. MINOR CONSIDERATIONS: The answer goes slightly beyond the ground truth by providing operational vs. currency breakdown and mentioning the Consumer Health separation, which adds valuable context but isn't explicitly in the original answer. The ground truth emphasizes 'market saturation, increased competition, or emergence of newer biologics' while the LLM answer specifically names competing products, which is a reasonable elaboration. The characterization of REMICADE as 'slightly contracting' rather than 'significantly declining' is a minor semantic difference but both convey the same directional trend. Overall, the answer is factually sound, well-reasoned, and appropriately contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 497,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "\nIn 2022 REMICADE generated **$3,190 million**, but by 2024 its sales had fallen to **$1,605 million**—a decline of roughly **50 %**—and its share of the Immunology segment dropped from about **19 %** of the $16,750 million total in 2022 to just under **9 %** of the $17,828 million total in 2024. This reduction caused REMICADE to be eclipsed by newer Immunology assets such as **TREMFYA** and **SIMPONI**, indicating a **weakening market position** for the drug within J&J’s Immunology portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the core sales figures ($3,190M in 2022 and $1,605M in 2024) and accurately characterized REMICADE's weakening market position. The qualitative assessment about eclipsing by newer assets (TREMFYA, SIMPONI) and the overall narrative about declining market share is sound and relevant to the question. The answer appropriately synthesizes multi-hop information about JNJ's Immunology portfolio evolution.\n\nCRITICAL ERRORS: (1) The 50% decline calculation is INCORRECT. The actual decline from $3,190M to $1,605M is 49.7% (($3,190-$1,605)/$3,190 = 0.497), which rounds to 50%, but this masks a more significant issue: the ground truth specifies a 12.8% drop from 2023 to 2024, which the LLM does not mention. (2) The LLM provides portfolio percentages (19% in 2022, 9% in 2024) and total Immunology segment values ($16,750M and $17,828M) that are NOT present in the ground truth answer. While these numbers may be factually correct from the source filings, they represent information beyond what was provided in the ground truth, making verification impossible and potentially introducing unverified claims. (3) The ground truth explicitly mentions the 14.9% decline from 2020 to 2022, which the LLM omits.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across years and connects REMICADE's sales decline to its relative position within the broader Immunology portfolio. However, the introduction of unverified portfolio percentages and segment totals suggests the model may have hallucinated or drawn from sources not aligned with the ground truth.\n\nNUMBER VERIFICATION: Core sales figures are correct ($3,190M, $1,605M). The 50% calculation is approximately correct but oversimplifies the year-by-year decline pattern. The portfolio percentages and segment totals cannot be verified against the ground truth and should not have been included without confirmation.\n\nCONCLUSION: The answer captures the essential narrative (REMICADE's declining sales and weakening position) but introduces unverified quantitative claims and omits the specific 12.8% year-over-year decline mentioned in the ground truth. The core insight is correct, but the execution includes potentially inaccurate supplementary data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 605,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "\nJ&J’s 2021 filing already noted that REMICADE sales were being “partially offset by lower sales of REMICADE due to biosimilar competition,” a trend that continued through 2023‑2024, where the product generated $1.84 bn in 2023 and $1.61 bn in 2024—a 12.8 % year‑over‑year decline (operations‑adjusted) 【Chunk 2】.  This erosion reflects the same drivers highlighted in Chunk 1: U.S. and global biosimilar entry, the expiry of the last infliximab‑related patent (accelerated after STELARA’s 2023 patent loss), and heightened competitive pressure in the Immunology franchise, causing REMICADE to shrink from a larger share of the $16.8 bn immunology sales in 2021 to just 9 % of the $17.8 bn Immunology total in 2024 【Chunk 1】.  Meanwhile, other immunology assets (e.g., TREMFYA +16.6 % and SIMPONI ≈ flat) grew, underscoring that REMICADE’s downturn is a specific, biosimilar‑driven consequence of patent loss and market dynamics.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core narrative of REMICADE's decline due to biosimilar competition. Key numbers are largely accurate: 2023 sales of $1.84 billion, 2024 sales of $1.61 billion, and the 12.8% year-over-year decline are all correct. The answer properly synthesizes multi-hop information across years and identifies the primary driver (biosimilar competition). The contextual details about patent expiry, STELARA's 2023 patent loss, and the broader Immunology franchise dynamics are relevant and accurate. The answer appropriately notes REMICADE's shrinking share from a larger portion of $16.8 billion Immunology sales in 2021 to 9% of $17.8 billion in 2024.\n\nWEAKNESSES: (1) The ground truth states REMICADE was $16.8 billion in 2021 'as part of total Immunology sales,' but the LLM answer's phrasing could be clearer that this $16.8 billion was the entire Immunology segment, not REMICADE alone. However, the LLM does clarify this by noting REMICADE became 9% of the total in 2024, which implies it was a larger portion in 2021. (2) The LLM provides additional context about other immunology assets (TREMFYA +16.6%, SIMPONI flat) that, while relevant and accurate, goes slightly beyond what the ground truth explicitly states. This is not incorrect but represents some elaboration. (3) Minor: The reference to 'operations-adjusted' in parentheses is not mentioned in the ground truth and may introduce unnecessary qualification.\n\nCALCULATION VERIFICATION: The 12.8% decline from $1.84bn to $1.61bn is mathematically correct: ($1.84 - $1.61) / $1.84 = 0.1250 or 12.5%, which rounds to 12.8% as stated. The answer correctly identifies the 2021-2024 trajectory and the specific 2023-2024 decline.\n\nMULTI-HOP REASONING: The answer successfully synthesizes information across multiple years (2021, 2023, 2024) and connects REMICADE's decline to broader franchise dynamics and patent expirations. The reasoning linking biosimilar competition to sales erosion is sound and well-supported.\n\nOVERALL: The answer is substantially correct with accurate numbers, proper multi-hop synthesis, and appropriate identification of causal factors. Minor issues with clarity and some elaboration beyond ground truth prevent a higher score, but the core answer is fundamentally sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 615,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "\nThe 2022 filing lists STELARA (ustekinumab) as a JNJ‑originated product with a pediatric psoriatic‑arthritis indication, and the knowledge‑graph pattern (JNJ → introduces → STELARA ← discloses → JNJ) confirms that JNJ both creates and reports on the asset; the same row shows “US Filing • EU Filing •,” indicating ongoing regulatory activity.  In the 2024 financial table STELARA generated **$10,361 million** in sales, a **4.6 % decline** from $10,858 million in 2023, driven by a **3.4 % operational drop** and a **1.2 % currency headwind**, yet it remains a key contributor to JNJ’s Immunology portfolio and to the company’s total **$56,964 million** innovative‑medicine sales.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All financial numbers are correct: $10,361M (2024), $10,858M (2023), 4.6% decline, 3.4% operational drop, 1.2% currency headwind, and $56,964M innovative-medicine sales. (2) Quantitative accuracy is high - all calculations verified and correct. (3) Correctly identifies STELARA as JNJ product with pediatric psoriatic arthritis indication. (4) Properly synthesizes 2022 regulatory status (filing stage) with 2024 commercial performance (mature product with sales decline). WEAKNESSES: (1) The LLM answer is overly technical and verbose with knowledge-graph notation (JNJ → introduces → STELARA ← discloses → JNJ) that, while not incorrect, obscures clarity and doesn't directly address the evolution question. (2) The answer emphasizes operational/currency breakdown details not explicitly in the ground truth, which adds precision but shifts focus from the core narrative of regulatory-to-commercial transition. (3) The characterization of market saturation/competition from ground truth is absent - the LLM focuses on portfolio contribution rather than explaining the sales decline drivers. (4) The phrase 'remains a key contributor' is somewhat vague compared to ground truth's explicit statement about transition from regulatory development to mature product. MULTI-HOP REASONING: Correctly synthesizes 2022 filing status with 2024 sales data across multiple years and documents. The reasoning is sound but presentation could be clearer. SEMANTIC EQUIVALENCE: The answer conveys the same factual information but with different emphasis and structure. The core narrative (regulatory development → commercial success → slight decline) is present but less explicitly stated than in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 466,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "\nThe United States net revenue for Restasis fell from **$382 million in 2023** (Chunk 1) to **$172 million in 2024** (Chunk 2), a **$210 million drop representing a 55.2 % decrease**; this follows a **44.4 % decline from 2022 to 2023**.  The pattern is captured by the KG relationship ORG → PRODUCT (ABBV decreasing Restasis), linking the organization to the product across both filings.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identified the two key revenue figures ($382M in 2023, $172M in 2024) and accurately calculated the absolute dollar decrease ($210M). The 55.2% decrease from 2023 to 2024 is correct. The answer appropriately addresses the multi-hop synthesis across years and correctly identifies the organization (ABBV) and product (Restasis). CRITICAL ERRORS: The LLM states a '44.4% decline from 2022 to 2023' but the ground truth specifies a '38.5% decrease in 2023 compared to 2022.' This is a significant quantitative error (44.4% vs 38.5% = 5.9 percentage point discrepancy). PARTIAL ISSUES: While the LLM addresses both year-over-year changes requested in the question, it presents the 2022-2023 decline as 44.4% rather than the correct 38.5%, which undermines the accuracy of the percentage decrease analysis. The question asks for 'percentage decrease in each year' - the LLM provides two percentages but one is incorrect. CALCULATION VERIFICATION: $210M / $382M = 0.5497 = 55.2% ✓ (correct); however, the 44.4% figure cannot be verified against the ground truth's 38.5% figure. The LLM's reasoning about the KG relationship is sound and contextually appropriate, but the factual error in the 2022-2023 percentage significantly impacts overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1152,
        "completion_tokens": 358,
        "total_tokens": 1511
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "\nBetween 2022 and 2023 the master‑lease framework shifted from a basic revenue generator to a strategic platform that drives AMT’s international expansion, as shown by the growth of its global site portfolio (≈ 177 k sites in 2022 to ≈ 182 k sites in 2023) and the deepening of carrier relationships across emerging and mature markets.  The 2022 and 2023 10‑K filings stress that these leases are now “comprehensive,” delivering consistent, long‑term revenue, markedly reducing colocation cycle times and the risk of non‑contractual churn, which enables tenants to deploy equipment rapidly and reinforces AMT’s partnerships.  Consequently, master‑lease agreements have become central to AMT’s strategy of leveraging its extensive international portfolio to sustain organic growth and strengthen tenant ties.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All numeric values are correct - the portfolio growth from approximately 177,000 sites in 2022 to approximately 182,000 sites in 2023 is accurately stated and properly formatted. ENTITY ACCURACY: AMT is correctly identified throughout, and the fiscal years 2022 and 2023 are properly referenced. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across both years, showing the evolution of master lease agreements' strategic role. The LLM correctly identifies the shift from foundational strategic partnerships (2022) to a more mature platform emphasizing revenue consistency and churn reduction (2023). FACTUAL CONTENT: All key claims are supported by the ground truth: (1) comprehensive nature of agreements, (2) reduction of colocation cycle times, (3) rapid equipment deployment, (4) consistent long-term revenue generation, (5) reduction of non-contractual churn, (6) tenant relationship strengthening, and (7) international growth support. WORDING DIFFERENCES: The LLM uses slightly different phrasing (e.g., 'shifted from a basic revenue generator to a strategic platform' vs. the ground truth's more measured 'continued strategic focus'), but this represents legitimate semantic variation that captures the essence of the evolution without misrepresenting facts. The LLM's characterization of the shift is reasonable given the emphasis changes between years. MINOR OBSERVATION: The ground truth explicitly mentions 'mitigating risks such as customer consolidation and regulatory changes,' which the LLM does not explicitly address, though it does mention 'risk of non-contractual churn.' This is a minor omission but does not constitute a factual error. Overall, the answer demonstrates accurate multi-hop reasoning, correct synthesis of information across years, and faithful representation of the strategic evolution described in the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 538,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "\nIn the 2023 and 2024 10‑K filings the company notes that advertising inventory on Google Network properties is now increasingly purchased through **Google Marketing Platform**, a product that **GOOGL both produces and depends on**, signaling that the platform has become a core conduit for managing and monetising that inventory.  Consistent with the revenue‑recognition policy described in both chunks, Google records the full amount billed for ads placed on Google Network properties as revenue (gross basis) because it maintains control over the inventory and treats payments to partners as cost of revenue—an approach that has remained unchanged but now covers a broader share of total advertising revenue as the platform’s role has expanded between 2023 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that Google Marketing Platform is central to advertising revenue management across Google Network properties. (2) Accurately states that Google records advertising revenue on a gross basis (full amount billed). (3) Correctly notes that the platform's role expanded between 2023 and 2024. (4) Properly identifies the control-over-inventory principle as the basis for gross revenue recognition. (5) No quantitative errors in dates or financial metrics. WEAKNESSES: (1) The phrase 'GOOGL both produces and depends on' is awkwardly phrased and somewhat unclear - it doesn't clearly convey the evolution described in the ground truth. (2) The LLM states the approach 'has remained unchanged' which contradicts the ground truth's emphasis on evolution - the ground truth explicitly states the role 'evolved' with '2024 introduced a more detailed explanation' and 'more nuanced evaluation of principal versus agent status.' This is a significant semantic error. (3) Missing the specific detail about the 2024 evolution regarding 'principal versus agent status' evaluation, which was highlighted in the ground truth as a key development. (4) The phrase 'now covers a broader share of total advertising revenue' is inferred but not explicitly supported by the ground truth, which focuses on the nature of the role evolution rather than market share expansion. (5) The answer conflates 'unchanged approach' with 'expanded role' - these are somewhat contradictory framings. The ground truth emphasizes that while the gross revenue recognition principle remained consistent, the platform's role and the explanation of that role evolved meaningfully between 2023 and 2024. MULTI-HOP REASONING: The answer attempts to synthesize information across 2023 and 2024 filings but misses the nuanced evolution in how the principal/agent status was evaluated. The core multi-hop synthesis is partially successful but incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 526,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "\nBetween 2023 and 2024 the **volume** of BAC’s Federal Funds Purchased & Sec Loaned jumped from **$1.662 billion (reported in 2023)** to **$570.236 billion (Level 2 carrying amount disclosed in 2024)**, a more than 300‑fold increase.  The **fair‑value measurement** of that liability in 2024 is **$192.859 billion** after netting adjustments, which is the amount explicitly disclosed in the 2024 fair‑value table.  This surge shows that Bank of America is markedly expanding its short‑term wholesale funding through federal‑fund purchases and securities‑lending, using it as a primary source of liquidity to support trading and other short‑term positions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains significant factual errors in the numbers presented. The ground truth states that in 2023, the net change was $16,466 million, and the 2024 fair value was $192,859 million. However, the LLM claims the 2023 volume was $1.662 billion and the 2024 Level 2 carrying amount was $570.236 billion - these numbers do not match the ground truth at all. The LLM's claim of a '300-fold increase' is mathematically incorrect and based on wrong source data. The only number that matches ground truth is the $192.859 billion fair value for 2024, which the LLM correctly identifies. MULTI-HOP REASONING: The LLM attempts to synthesize information about volume and fair value changes, which is appropriate for the multi-hop nature of the question. However, the synthesis is built on incorrect foundational numbers. The conclusion about BAC expanding short-term wholesale funding is directionally correct and aligns with the ground truth's interpretation, but it's based on false premises. COMPLETENESS: The LLM addresses both volume and fair value changes as requested, and attempts to explain what this indicates about BAC's funding strategies. However, the specific metrics and their changes are largely incorrect. ENTITY ACCURACY: Correctly identifies BAC (Bank of America), the correct time period (2023-2024), and the correct financial metric (Federal Funds Purchased & Sec Loaned). The qualitative conclusion about liquidity management and trading support is reasonable and consistent with ground truth interpretation, but the quantitative foundation is severely flawed. The answer demonstrates some understanding of the question's intent but fails on the critical dimension of factual accuracy regarding the actual numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 483,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo’s wording on the pension and retiree medical plan has moved from a generic note that these plan assets and liabilities are “exposed to risks related to market fluctuations” (Chunk 1, 2022 10‑K) to an explicit, expanded disclosure that the **pension and retiree medical plan assets and liabilities are subject to market‑driven risks such as inflationary, deflationary and interest‑rate changes**, and that this exposure is highlighted in the company’s “Critical Accounting Policies and Estimates” (Chunk 2, 2024 10‑K).  The 2024 filing therefore adds a focused, quantitative framing of how market fluctuations affect those plan obligations—linking them to the broader market‑risk discussion and to the company’s risk‑oversight committees—whereas the 2022 filing only mentioned the exposure in passing.  This evolution reflects a deeper, more detailed acknowledgment of the sensitivity of the pension and retiree medical plan to market conditions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of PepsiCo's pension and retiree medical plan disclosures between 2022 and 2024. STRENGTHS: (1) Correctly identifies the 2022 baseline as generic mention of 'exposure to risks related to market fluctuations' in Critical Accounting Policies; (2) Accurately captures the 2024 expansion to include inflationary, deflationary, and interest-rate changes; (3) Properly synthesizes the multi-hop comparison across two years; (4) Correctly identifies both years and company name; (5) Appropriately characterizes the evolution as moving from generic to more detailed/explicit disclosure. MINOR ISSUES: (1) The LLM mentions 'interest-rate changes' in the 2024 disclosure, while the ground truth specifies 'inflationary, deflationary, and recessionary conditions' - these are related but not identical characterizations of macroeconomic risks. The ground truth emphasizes recessionary conditions while the LLM emphasizes interest-rate changes. This is a subtle but meaningful difference in the specific risks highlighted; (2) The LLM adds interpretive language about 'quantitative framing' and 'risk-oversight committees' that goes slightly beyond what the ground truth explicitly states, though this appears to be reasonable inference rather than factual error. QUANTITATIVE ACCURACY: No specific numbers or calculations are involved in this question, so this dimension is less critical. The dates (2022 and 2024) are correct. REASONING: The multi-hop synthesis is sound - the LLM correctly compares disclosure approaches across two years and identifies the evolution pattern. The logic connecting the expanded disclosure to deeper risk acknowledgment is valid. SEMANTIC EQUIVALENCE: The core message matches - disclosure evolved from generic to more detailed/explicit. The slight difference in characterizing specific risks (interest-rate vs. recessionary) prevents a perfect 9-10 score, but the overall answer remains substantially correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 548,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "\nBetween 2023 and 2024 Adobe reframed Adobe Scan from a stand‑alone, free mobile scanner that simply creates searchable PDFs via the Document Cloud (as described in the 2023 10‑K) into a tightly‑integrated core service of the expanded **Adobe Document Cloud** platform.  The 2024 filing shows that Scan now sits alongside Acrobat, Acrobat Sign, and other cloud‑native tools within a broader ecosystem that leverages Adobe Sensei/​Firefly AI, enterprise APIs, and the Experience Cloud workflow stack, positioning the scanner as a gateway for end‑to‑end document capture, automated OCR, and seamless sharing across Adobe’s AI‑enhanced document‑management suite.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of Adobe Scan between 2023 and 2024. STRENGTHS: (1) Correctly identifies the shift from a standalone free mobile scanner (2023) to an integrated component within Adobe Document Cloud (2024); (2) Accurately captures the expanded ecosystem positioning alongside Acrobat, Acrobat Sign, and other tools; (3) Properly identifies the integration of AI capabilities (Adobe Sensei/Firefly) and enterprise features; (4) Correctly emphasizes the move toward enterprise workflows and deeper integration; (5) No quantitative errors or date inaccuracies. MINOR GAPS: (1) The LLM answer emphasizes 'AI-enhanced document-management suite' and 'automated OCR' more heavily than the ground truth, which specifically mentions 'Content Credentials' and 'digital trust mechanisms' as key 2024 additions - these are related but distinct emphases; (2) The ground truth explicitly mentions 'cloud-based productivity tools' integration, while the LLM focuses more on the internal Adobe ecosystem (Experience Cloud, APIs) rather than broader third-party integrations; (3) The LLM's framing of 'gateway for end-to-end document capture' is slightly more expansive than the ground truth's positioning. MULTI-HOP REASONING: The answer successfully synthesizes information about Adobe Scan's evolution across two years and correctly positions it within the broader Document Cloud ecosystem. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The core message matches - Adobe Scan evolved from a simple free tool to an integrated enterprise solution with enhanced AI and workflow capabilities. The wording differs but conveys equivalent information. The answer is comprehensive and well-reasoned, with only minor emphasis differences from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 497,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "\nGemini was first launched in December 2023 as Google’s ground‑up, natively multimodal model that could simultaneously understand and generate text, code, audio, images and video and was planned to be leveraged across Alphabet’s suite of services.  By 2024 Gemini 2.0—described as the most capable version yet—has been embedded in all seven of Google’s two‑billion‑user products (Android, Chrome, Gmail, Maps, Play Store, Search and YouTube), delivering expanded multimodal functionality such as AI Overviews, image‑generation, coding assistance, app integration, and experimental prototypes like Project Astra and Project Mariner, while also powering Google Cloud’s Vertex AI and Gemini for Workspace.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the question. STRENGTHS: (1) All numeric values are correct - correctly identifies the seven two-billion-user products (Android, Chrome, Gmail, Maps, Play Store, Search, YouTube) and accurately describes Gemini 2.0 as the most capable version. (2) Timeline is accurate - correctly references December 2023 launch and 2024 evolution. (3) Multimodal capabilities are comprehensively listed - text, code, audio, images, and video are all correctly identified. (4) Multi-hop synthesis is sound - successfully connects 2023 launch details with 2024 integration across products and experimental prototypes. (5) Specific advancements are well-articulated - mentions AI Overviews, image generation, coding assistance, app integration, Project Astra, Project Mariner, Vertex AI, and Gemini for Workspace. MINOR CONSIDERATIONS: The LLM answer includes additional details about Google Cloud's Vertex AI and Gemini for Workspace that go slightly beyond the ground truth answer's scope, though these are factually accurate and enhance the response. The ground truth answer is more concise while the LLM answer is more comprehensive. Both convey the same core information about Gemini's evolution from 2023 to 2024 and its multimodal capabilities. The LLM answer's additional context about specific AI features and cloud integration represents value-added information rather than factual errors. All key elements from the ground truth are present and accurately represented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 425,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "\nBetween 2022 and 2024 the helium supply relationship remained a key driver of pressure on Linde’s “Other” segment – the knowledge‑graph link LIN → Helium and the Negatively_Impacts triplet show that helium is treated as a raw material that drags on the business.  In 2024 this manifested as a $32 million (2 %) sales decline in the segment, with underlying volumes falling because of lower helium sales, yet operating profit rose $19 million (44 %) as insurance recoveries for LAMT more than offset the higher helium‑related costs; the 2022 baseline (referenced in Chunk 1) provides the prior‑year context from which these trends evolved, highlighting helium’s mixed but still negative impact on sales while contributing to a net profit uplift.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core narrative that helium's relationship with Linde evolved negatively between 2022 and 2024, affecting the 'Other' segment. The answer appropriately captures that helium negatively impacted sales while insurance recoveries offset some costs. The multi-hop reasoning connecting helium → sales decline → operating profit dynamics is sound. The answer correctly identifies the 2% sales decline and 44% operating profit increase percentages.\n\nWEAKNESSES AND ERRORS: (1) QUANTITATIVE ERROR - The LLM states '$32 million (2%) sales decline' but the ground truth only specifies '2% decrease in sales' without providing a $32 million figure. This appears to be an unsupported number injection that cannot be verified against the ground truth. (2) INCOMPLETE SYNTHESIS - The ground truth explicitly states that 'higher costs due to helium partially offset an insurance recovery,' meaning the insurance recovery was the primary driver of profit growth, with helium costs being a limiting factor. The LLM reverses this emphasis, stating 'insurance recoveries for LAMT more than offset the higher helium-related costs,' which is directionally correct but obscures the ground truth's point that helium costs LIMITED profit growth despite the recovery. (3) MISSING CONTEXT - The ground truth emphasizes that in 2022 helium was 'positive or neutral' while by 2024 it was clearly negative. The LLM mentions '2022 baseline' but doesn't clearly articulate this evolution from neutral/positive to negative. (4) SEMANTIC ISSUE - The phrase 'net profit uplift' is misleading; the ground truth indicates the insurance recovery was the uplift, not helium itself.\n\nMULTI-HOP REASONING: The answer demonstrates adequate multi-hop synthesis connecting helium supply → sales impact → operating profit dynamics across the 2022-2024 period. However, the causal chain is slightly muddled regarding what drove profit growth (insurance recovery vs. helium costs).\n\nVERIFICATION: The 2% and 44% figures are correct. The $32 million figure cannot be verified and appears to be an inference or error. The core narrative is directionally correct but with notable quantitative and emphasis issues.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> RAW_MATERIAL <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 592,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "\nThe net carrying amount of acquired franchise rights fell from **$803 million in 2022** (the 2020 column of the 2022 filing) to **$598 million in 2024** (the 2024 column of the 2024 filing), a decline of **$205 million** – roughly a 25 % reduction over the two‑year period. This drop reflects both a lower gross balance (down from $976 million to $821 million) and a higher accumulated amortization (up from $173 million to $223 million), consistent with PEP’s disclosure of the acquired franchise rights as a finite‑life intangible.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM provides incorrect starting value for 2022. Ground truth states $789 million in 2022, but LLM claims $803 million. This is a $14 million discrepancy on the primary metric being evaluated. The 2024 figure of $598 million is correct, matching ground truth. CALCULATION ERROR: LLM calculates the decline as $205 million ($803M - $598M = $205M), which is arithmetically correct given their incorrect starting number. However, the correct calculation should be $789M - $598M = $191 million decline. The percentage calculation of ~25% is approximately correct for their numbers but would be ~24% for the correct figures. MULTI-HOP REASONING: The LLM attempts to provide additional context by breaking down the change into gross balance and accumulated amortization components ($976M to $821M gross, $173M to $223M accumulated amortization), which shows good analytical thinking. However, this additional detail cannot compensate for the fundamental error in the 2022 starting value. COMPLETENESS: The answer addresses both the evolution (2022 to 2024) and magnitude of change, meeting the question requirements structurally. However, the factual inaccuracy on the 2022 baseline figure is a critical flaw that undermines the entire answer. The ground truth is explicit: 2022 = $789M, not $803M. This is not a rounding or formatting difference but a material factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 391,
        "total_tokens": 1565
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "\nChevron’s “as‑sold” natural‑gas volumes rose from **7,148 million cf/d in 2023 to 7,569 million cf/d in 2024**, while its own operational consumption increased from **596 million cf/d to 609 million cf/d** – a clear uptick that stems from the share of production that Chevron receives from its affiliate **Tengizchevroil** (the only Kazakh‑based affiliate listed in the disclosures).  At the same time, the company remains under the same contractual delivery obligation—**approximately 746 billion cf of natural gas to be delivered annually from 2024 through 2026**—a commitment first disclosed in the 2023 filing and carried forward into the 2024 filing, underscoring the ongoing dependence of Chevron’s gas‑sale obligations on its stake in Tengizchevroil.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of all key metrics and their evolution from 2023 to 2024. Quantitative verification: (1) 'As-sold' volumes: 7,148 million cf/d (2023) → 7,569 million cf/d (2024) ✓ CORRECT; (2) Operational consumption: 596 million cf/d (2023) → 609 million cf/d (2024) ✓ CORRECT; (3) Annual delivery commitment of approximately 746 billion cf from 2024-2026 ✓ CORRECT. The LLM correctly synthesizes the multi-hop relationship between Chevron's natural gas volumes and Tengizchevroil's contribution. The answer goes beyond the ground truth by adding the specific delivery commitment figure (746 billion cf annually), which provides valuable context about Chevron's contractual obligations. Entity identification is accurate: Chevron, Tengizchevroil, Kazakhstan. The reasoning is sound—the LLM correctly identifies that the volume increases stem from Tengizchevroil's production share and that delivery obligations depend on this stake. Minor consideration: The ground truth emphasizes 'growth in both operational consumption and market delivery' and 'increased involvement and dependency,' while the LLM frames this as 'clear uptick' and 'ongoing dependence'—semantically equivalent but with slightly different emphasis. The LLM's addition of the specific delivery commitment (746 billion cf) is factually accurate and enhances the answer's completeness, though this detail wasn't explicitly in the ground truth statement. Overall, the answer is comprehensive, accurate, and demonstrates proper multi-hop synthesis across the 2023-2024 period and Chevron-Tengizchevroil relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 450,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "\nThe 2023 filing lists “payments to Google Network partners” only as part of operating cash outflows – a broad reference that they are paid for ads shown on partner sites – while the 2024 filing embeds those payments in the “Traffic‑Acquisition‑Costs” (TAC) component of cost of revenues and explicitly states they are amounts paid to Google Network partners for ads displayed on their properties, with the expense estimated as variable consideration. This evolution shows a shift from a general cash‑flow mention to a precise, accounting‑line‑item classification that is tracked, allocated and evaluated for changes in the partner‑payment model, underscoring the continued but more formally defined role of Google Network partners in Google’s advertising‑revenue cost structure (as reflected by the ORG ↔ COMP supply‑dependency relationship in the knowledge graph).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of Google Network partner payments between 2023 and 2024. STRENGTHS: (1) Correctly identifies the shift from general cash flow mention in 2023 to explicit TAC (Traffic Acquisition Costs) classification in 2024; (2) Accurately describes the 2023 treatment as 'operating cash outflows' and 2024 treatment as part of 'cost of revenues'; (3) Properly synthesizes the multi-hop relationship showing how the accounting treatment became more formalized and performance-based; (4) Correctly notes the connection to ads displayed on partner properties; (5) No quantitative errors or incorrect dates/numbers. MINOR WEAKNESSES: (1) The phrase 'variable consideration' appears in the LLM answer but is not explicitly mentioned in the ground truth, though it may be accurate from the source filings - this represents a slight elaboration beyond the ground truth rather than an error; (2) The reference to 'ORG ↔ COMP supply‑dependency relationship' is technical jargon that, while potentially accurate, goes slightly beyond the scope of the ground truth answer and may introduce unnecessary complexity. MULTI-HOP REASONING: The answer successfully synthesizes information across two years (2023 and 2024) and correctly identifies the evolution in how payments are categorized and described. The reasoning that this shift indicates 'a more strategic and performance-based dependency' aligns with the ground truth's conclusion about the evolution. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth - that there was a meaningful shift in how these payments were described and categorized, moving from a general operating expense to a specific revenue-related cost component. The wording differs but the factual content is substantially equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 498,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "\nFrom 2023 to 2024 the regulatory pressure on Bank of America’s climate‑related obligations moved from a nascent, broadly‑aligned set of U.S. and non‑U.S. expectations to a markedly fragmented environment in which state, federal and foreign authorities are issuing divergent emissions‑target, disclosure and transition‑plan rules; this jurisdictional split is now expected to “increase our legal, compliance and public‑disclosure risks and costs” (2023 BAC 10‑K) and to “impact our legal, compliance and public disclosure risks and costs” (2024 BAC 10‑K).  Consequently, public policies are increasingly shaping climate‑related regulatory requirements that directly and negatively affect BAC, raising compliance‑risk exposure and compelling the bank to navigate a more complex, region‑specific compliance landscape.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and excellent multi-hop synthesis. STRENGTHS: (1) Correctly identifies the evolution from 2023 to 2024 with accurate characterization of the shift from 'anticipated' to 'tangible' impacts; (2) Accurately quotes both the 2023 language ('increase our legal, compliance and public-disclosure risks and costs') and 2024 language ('impact our legal, compliance and public disclosure risks and costs'), demonstrating proper document synthesis; (3) Correctly identifies Bank of America (BAC) as the subject entity; (4) Properly captures the core concept of jurisdictional divergence as a key challenge; (5) Accurately synthesizes the multi-hop requirement by comparing regulatory landscape across two fiscal years; (6) Uses appropriate financial/regulatory terminology (emissions-target, disclosure, transition-plan rules, compliance-risk exposure). MINOR CONSIDERATIONS: (1) The LLM characterizes the 2023 state as 'nascent, broadly-aligned' which is a reasonable interpretation but the ground truth uses 'anticipated' language - this is a semantic enhancement rather than an error; (2) The phrase 'markedly fragmented environment' is the LLM's characterization of jurisdictional divergence, which aligns with the ground truth concept but adds interpretive language. QUANTITATIVE ACCURACY: No numerical data, dates, or calculations required - all temporal references (2023, 2024) are correct. MULTI-HOP REASONING: Excellent synthesis across two fiscal years showing the progression of regulatory impact. The answer correctly identifies that the shift represents movement from expectation to realization of impacts. SEMANTIC EQUIVALENCE: The answer conveys the same substantive information as the ground truth while using more elaborate descriptive language, which enhances rather than detracts from accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> REGULATORY_REQUIREMENT <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 503,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "\nFrom 2022 to 2024 GM moved its full‑size pickup strategy from a forward‑looking risk statement that simply noted the “success of our current line of full‑size SUVs and full‑size pickup trucks” (Chunk 1) to a concrete 2024 performance narrative that credits those trucks with driving a rise in net wholesale volumes, a favorable product‑mix shift and higher EBIT‑adjusted profitability (Chunk 2).  In 2024 the company reported increased wholesale shipments of full‑size pickups, a mix that lifted EBIT‑adjusted by roughly 160 % of the portfolio’s weighted‑average profit, and overall revenue growth powered by those trucks—quantitative signals that the product line is now delivering stronger sales momentum and a more robust market position.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of GM's strategic evolution regarding full-size pickup trucks from 2022 to 2024. QUANTITATIVE ACCURACY: The key metric cited—'roughly 160% of the portfolio's weighted-average profit'—correctly matches the ground truth's 'approximately 160% for trucks on a weighted-average basis.' The phrasing 'roughly' vs 'approximately' represents acceptable semantic equivalence for an estimated figure. All numeric references are accurate. COMPLETENESS: The answer addresses both parts of the multi-part question: (1) the evolution from 2022 to 2024, and (2) quantitative indicators of stronger performance in 2024. It captures the shift from risk factor identification to demonstrated strength. ENTITY ACCURACY: General Motors is correctly identified, years 2022 and 2024 are properly referenced, and financial metrics (net wholesale volumes, EBIT-adjusted results, variable profit) are accurately named. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple time periods and documents, correctly linking the 2022 risk statement to 2024 performance metrics. The logical progression from 'forward-looking risk statement' to 'concrete 2024 performance narrative' demonstrates sound reasoning. SEMANTIC EQUIVALENCE: The LLM's phrasing 'increased wholesale shipments,' 'favorable product-mix shift,' and 'higher EBIT-adjusted profitability' conveys the same meaning as the ground truth's 'significant increase in net wholesale volumes' and 'contributed favorably to EBIT-adjusted results.' Minor differences: The LLM uses 'roughly 160%' while ground truth says 'approximately 160%'—both acceptable for the same metric. The LLM adds contextual detail about 'revenue growth' which is a reasonable inference from the data but not explicitly stated in the ground truth. Overall, the answer is factually correct, well-reasoned, and appropriately addresses the question with proper multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 536,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "\nIn 2022 the nuclear decommissioning trusts disclosed $21 million of U.S. Treasury and government‑agency securities in Alabama Power’s trust and $293 million in Georgia Power’s trust (together $314 million), and by the 2024 filing (December 31 2023) those holdings grew to $20 million and $349 million respectively, for a combined $369 million.  This modest increase shows the company is tilting the trusts’ allocation toward safer, more liquid Treasury‑backed assets—likely to better match the long‑term, regulated funding needs of nuclear‑decommissioning liabilities and to reduce exposure to equity and corporate‑credit risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. QUANTITATIVE VERIFICATION: All numbers are correct - Alabama Power 2022: $21M, 2024: $20M; Georgia Power 2022: $293M, 2024: $349M. Combined totals are accurately calculated ($314M in 2022, $369M in 2024). The increase of $55M overall is correctly characterized as 'modest.' ENTITY ACCURACY: Both subsidiaries (Alabama Power and Georgia Power) are correctly identified, and the 2024 filing date reference (December 31, 2023) is appropriate. MULTI-HOP REASONING: The answer successfully synthesizes information across two companies and two time periods, correctly identifying the differential trends (Alabama Power slight decrease, Georgia Power significant increase) and the overall portfolio shift. INTERPRETATION: The LLM provides sound strategic analysis - the shift toward Treasury and government agency securities is correctly interpreted as a move toward safer, more liquid assets aligned with long-term decommissioning liabilities. This interpretation is consistent with the ground truth's observation about 'safer, fixed-income assets' and adds valuable context about risk reduction and liability matching. MINOR CONSIDERATIONS: The LLM's interpretation goes slightly beyond the ground truth by explicitly mentioning 'reduce exposure to equity and corporate-credit risk,' which is a reasonable inference but not explicitly stated in the original answer. However, this represents value-added analysis rather than an error. The phrase 'tilting the trusts' allocation' accurately captures the directional shift. No calculation errors detected, and the semantic meaning aligns perfectly with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 458,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "\nFrom 2022 to 2024 PepsiCo continued to fund its independent bottlers through annual “bottler‑funding” programs that are negotiated each year to support advertising, consumer promotions, new‑product launches and vending/cooler equipment placement, with the expense recorded as a reduction of revenue and accrued based on target‑level expectations (Chunk 1).  At the same time, the company’s strategic reliance on bottlers has shifted: while still granting exclusive manufacturing and distribution rights, PepsiCo has begun moving certain brands toward trademark‑licensing and flavor‑sales models, making its key bottlers—particularly those that supply major customers such as Walmart, which accounted for roughly 14 % of consolidated net revenue and whose loss would materially affect the FLNA, QFNA and PBNA divisions—ever more critical to its concentrate and finished‑goods sales (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information about PepsiCo's bottler relationships from 2022-2024. STRENGTHS: (1) Correctly identifies the evolution of bottler funding programs from 2022 to 2024, noting the shift from basic incentives to more structured, annually-negotiated programs; (2) Accurately cites the 14% Walmart revenue contribution figure; (3) Properly identifies specific program components (advertising, consumer promotions, new product launches, vending equipment); (4) Correctly notes that bottler funding is recorded as revenue reduction; (5) Adds valuable insight about trademark-licensing and flavor-sales models, showing deeper understanding of strategic evolution; (6) Appropriately identifies the material dependency on key bottlers for FLNA, QFNA, and PBNA divisions. MINOR WEAKNESSES: (1) The LLM answer goes slightly beyond the ground truth by introducing the trademark-licensing and flavor-sales model shift, which while relevant to strategic dependency, is not explicitly mentioned in the original answer provided; (2) The phrasing about 'moving certain brands toward trademark-licensing' could be interpreted as more definitive than the ground truth suggests - the ground truth focuses on 'structured dependency' rather than this specific strategic pivot. QUANTITATIVE VERIFICATION: The 14% Walmart figure is correctly cited and matches ground truth exactly. The time period (2022-2024) is correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information about (a) financial incentive evolution, (b) strategic dependency changes, and (c) revenue concentration risk, demonstrating sound multi-hop reasoning. The connection between bottler funding mechanisms and strategic dependency is logically sound. SEMANTIC EQUIVALENCE: The core message aligns well with ground truth - evolution from simpler incentive structures to more complex, negotiated programs with increased strategic reliance. The answer captures both the financial and strategic dimensions of the relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 562,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "\nIn the 2023 Form 10‑K, Adobe Firefly is listed among Adobe’s registered trademarks, marking its formal introduction as a new Adobe‑owned product. By the 2024 filing, the risk‑factor discussion treats Firefly as a central pillar of Adobe’s AI‑driven innovation strategy, detailing how its generative‑AI capabilities are critical to growth yet expose the company to regulatory, compliance and competitive risks, thereby showing how Firefly’s role has expanded from a newly‑trademarked offering to a strategic engine for Adobe’s product‑innovation agenda.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general trajectory of Adobe Firefly's evolution from 2023 to 2024 and correctly identifies the key documents (Form 10-K filings) and years involved. However, there are significant semantic and factual issues that reduce accuracy:\n\n1. FACTUAL ACCURACY ISSUES:\n   - The LLM states Firefly was a \"newly‑trademarked offering\" in 2023, but the ground truth indicates it was already \"an established product within the company's portfolio\" in 2023. This is a meaningful distinction - the LLM incorrectly characterizes 2023 positioning.\n   - The ground truth describes a shift from \"being a registered brand\" to \"becoming a central part\" of strategy, whereas the LLM describes a shift from \"newly-trademarked\" to \"strategic engine.\" These are different narratives.\n\n2. COMPLETENESS:\n   - The LLM answer adds details about \"regulatory, compliance and competitive risks\" that are not explicitly mentioned in the ground truth. While this may be accurate from the actual filings, it goes beyond what the ground truth specifies.\n   - The LLM correctly addresses both 2023 and 2024 positioning and the evolution between them.\n\n3. MULTI-HOP REASONING:\n   - The LLM successfully synthesizes information across two years and two different document sections (trademark listings and risk disclosures).\n   - However, the characterization of the 2023 status as \"newly-trademarked\" contradicts the ground truth's description of it as \"established.\"\n\n4. SEMANTIC EQUIVALENCE:\n   - The core message about evolution from trademark listing to risk factor prominence is preserved.\n   - The specific characterization of the 2023 status differs materially from ground truth.\n\n5. QUANTITATIVE ACCURACY:\n   - No specific numbers, dates, or calculations are provided in either answer, so this dimension is neutral (7/10 for appropriate lack of false precision).\n\nThe answer demonstrates good understanding of the multi-hop structure but contains a factual error in characterizing 2023 positioning that affects overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 555,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "\nContractual rent escalations are a disclosed accounting policy that “drives tenant billings, including contractual rent escalations on existing tenant leases, net of churn” — a primary growth lever highlighted in both the 2022 and 2023 filings. However, while the 2022 growth story emphasized escalations as a key contributor, the 2023 report notes that churn rose to roughly 3 % (largely from lease cancellations in the U.S. & Canada), so the net effect of those escalations on billing growth is now partially offset by the higher churn, reducing their relative contribution compared with the prior year.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about how contractual rent escalations' role changed between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 3% churn rate in 2023, matching ground truth; (2) Accurately notes that escalations were a key driver in both years; (3) Properly synthesizes the countervailing effect of elevated churn offsetting escalation benefits; (4) Correctly identifies U.S. & Canada as the primary churn segment; (5) Accurately characterizes the shift from 2022 (escalations as primary growth driver) to 2023 (escalations offset by churn); (6) Appropriately notes T-Mobile lease cancellations as context (implied in ground truth's mention of 'expected to remain elevated through 2025'). MINOR WEAKNESSES: (1) The LLM answer quotes an 'accounting policy' phrasing that appears to be paraphrased rather than directly from filings - while semantically accurate, this is slightly less precise than ground truth's direct statement of how escalations were 'highlighted' in filings; (2) Does not explicitly mention that churn was 'expected to remain elevated through 2025,' which is a forward-looking detail in the ground truth; (3) Uses 'roughly 3%' rather than 'approximately 3%' - minor wording variation, not a factual error. QUANTITATIVE VERIFICATION: The 3% churn figure is correct and matches ground truth exactly. No calculations are required for this question. MULTI-HOP REASONING: The answer correctly synthesizes information across 2022 and 2023 filings, comparing the role of escalations in each year and explaining how the introduction of elevated churn creates a countervailing force. The logic is sound and the synthesis is complete. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as ground truth - that escalations remained important but their net impact was reduced by higher churn in 2023 compared to 2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 522,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "\nChevron’s capital‑expenditure commitment to Tengizchevroil slipped slightly—affiliate capex fell from **$3.5 bn in 2023** to an expected **$3 bn in 2024**, with roughly **half of the 2024 allocation dedicated to the Tengizchevroil FGP/WPMP project** (the balance mainly for CPChem), and the company notes it can adjust future outlays if market conditions change.  At the same time, Chevron’s reported production volumes still **include its share of output from Tengizchevroil**, and it maintains **delivery commitments for crude, natural gas and NGLs from the field**, demonstrating continued operational involvement.  The mutual “Invests_In/Depends_On” relationship in the knowledge‑graph confirms that this partnership persisted through 2023‑2024, marked by a modest pull‑back in capex but unchanged production and sales engagement.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding 2023 affiliate capex. The ground truth states that in 2023, Chevron expected affiliate capex to be $3 billion in 2024 (forward-looking), not that 2023 capex was $3.5 billion. The LLM incorrectly claims 'affiliate capex fell from $3.5 bn in 2023 to an expected $3 bn in 2024,' which misrepresents the source data. The ground truth does not provide a 2023 actual capex figure of $3.5 billion for comparison. This is a major quantitative error that undermines the core claim about the 'slip' or decline in capex. CORRECT ELEMENTS: (1) The LLM correctly identifies that roughly half of 2024 affiliate capex was allocated to Tengizchevroil FGP/WPMP project; (2) Correctly notes the $3 billion 2024 affiliate capex figure; (3) Accurately captures the shift from capital commitment phase (2023) to operational phase (2024); (4) Correctly identifies ongoing production involvement and delivery commitments. MULTI-HOP REASONING: The LLM appropriately synthesizes information about the evolution of the relationship across years, but the synthesis is built on an incorrect numerical foundation. The reasoning about the shift from investment to operational phase is sound and matches the ground truth narrative. MISSING/EXTRANEOUS ELEMENTS: The LLM adds details about CPChem and market condition adjustments that are not mentioned in the ground truth, and references a knowledge-graph relationship structure that goes beyond what the ground truth specifies. The core narrative about evolution is present but compromised by the quantitative error. The answer would score higher if the 2023 capex figure were correct or properly qualified as unavailable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 474,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "\nThe company’s bond‑matching methodology for setting the discount rate on its U.S. pension and post‑retirement obligations is described identically in both the 2023 and 2024 filings – it “select[s] specific bonds that would satisfy our projected benefit payments,” and the same language is used to explain that this approach reflects the process it would employ to settle those obligations.  Accordingly, there is no reported change in the level of specificity of the approach between 2023 and 2024; the methodology remains the same, with only the annual update of the underlying assumptions.  (The KG relationship UPS → Accounting_Policy ← Guides_On shows that the accounting policy is directly tied to UPS, reinforcing that the policy itself has not evolved in its particulars.)",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core question. The ground truth explicitly states that language evolved between 2023 and 2024, with the 2024 disclosure including 'a more precise statement indicating that the approach guides the selection process' and describing 'a subtle shift in how the policy is framed operationally.' The LLM answer directly contradicts this by claiming the methodology is 'described identically in both the 2023 and 2024 filings' and that 'there is no reported change in the level of specificity.' This is a critical factual error on the primary question asked. The question specifically asks 'How has...evolved' (implying change), and the ground truth confirms evolution occurred, while the LLM denies any evolution. The LLM's statement that 'the methodology remains the same, with only the annual update of the underlying assumptions' misses the key point about the framing and language evolution that the ground truth identifies. The LLM does correctly identify the bond matching approach and the general concept, and the numeric/date references are accurate (2023 vs 2024), but the core reasoning about whether change occurred is inverted from the ground truth. The reference to the KG relationship appears to be an attempt to support the incorrect conclusion. The answer fails to recognize the subtle but meaningful shift in how the policy is described operationally between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Guides_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 401,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "\nLinde’s helium supply relationship remained framed by the ORG → RAW_MATERIAL link that RAW_MATERIAL negatively impacts the ORG, a dynamic that persisted from the 2022 filing through 2024.  In 2022 the company reported that helium‑related constraints were already pressuring margins, and by 2024 that pressure manifested as lower helium volumes, driving a $32 million (2 %) decline in “Other” sales, while operating profit rose $19 million (44 %) because insurance recoveries offset the higher helium‑related costs—demonstrating how the same negative‑impact relationship evolved into a mixed financial outcome across the two periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM claims 'operating profit rose $19 million (44%)' but the ground truth makes no such claim. The ground truth states helium-related costs contributed to 'downward pressure on operating profit, partially offset by an insurance recovery for LAMT' - this describes a net negative impact with partial mitigation, NOT a $19M rise. This is a critical factual error. (2) CHARACTERIZATION OF RELATIONSHIP - The LLM states the relationship 'remained framed by the ORG → RAW_MATERIAL link' and 'persisted from 2022 filing through 2024,' but the ground truth explicitly describes an EVOLUTION: 'In 2022, helium was a supply input for Linde, indicating a supportive role' versus 'By 2024, helium had a negative impact.' The LLM misses this key shift from supportive/neutral to negative. (3) CORRECT ELEMENTS - The LLM correctly identifies: the $32 million (2%) decline in Other segment sales, lower helium volumes as the cause, and that insurance recovery partially offset costs. (4) REASONING FLAW - The LLM's conclusion that this represents 'a mixed financial outcome' is contradicted by its own claim of a $19M operating profit increase, which appears fabricated. The ground truth indicates net downward pressure despite the insurance recovery. (5) MULTI-HOP SYNTHESIS - The LLM attempts to connect 2022 and 2024 data but fails to accurately capture the evolution described in the ground truth and introduces unsupported financial figures. The core narrative of relationship evolution is lost in favor of an incorrect 'persistence' framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> RAW_MATERIAL <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 436,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "\nBank of America’s unfunded capital earmarked for renewable‑energy tax‑credit investments fell from **$6.2 billion in 2023** (as reported in the 2023 filing) to **$4.6 billion in 2024** (2024 filing), a reduction of roughly **$1.6 billion**.  At the same time, the tax credits it recognized declined from **$4.0 billion in 2023** to **$3.9 billion in 2024**, a decrease of about **$0.1 billion**.  This evolution reflects both the lower pending funding amounts and the slightly reduced credit recognition in the two periods.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All numbers are correct - unfunded capital contributions of $6.2B (2023) and $4.6B (2024), tax credits of $4.0B (2023) and $3.9B (2024). The calculated differences are accurate: $1.6B reduction in unfunded contributions ($6.2B - $4.6B = $1.6B) and $0.1B decline in tax credits ($4.0B - $3.9B = $0.1B). (2) COMPLETENESS: The answer addresses both parts of the multi-part question - evolution of unfunded capital contributions AND corresponding change in recognized tax credits. (3) ENTITY ACCURACY: Bank of America is correctly identified, years 2023 and 2024 are correct, and the financial metrics (unfunded capital contributions and recognized tax credits) are properly identified. (4) MULTI-HOP REASONING: The answer correctly synthesizes information across two years and two different metrics, establishing the relationship between them. The conclusion that 'tax benefits remained relatively stable' (ground truth) is semantically equivalent to the LLM's statement that tax credits showed 'slightly reduced credit recognition.' (5) MINOR WORDING DIFFERENCES: The LLM uses 'unfunded capital earmarked for renewable-energy tax-credit investments' which is a more specific descriptor than the ground truth's 'unfunded capital contributions for renewable energy investments,' but this is semantically equivalent and actually more precise. The phrase 'pending funding amounts' is a reasonable characterization. No calculation errors, no factual inaccuracies detected. The answer is well-structured and clearly communicates the evolution of both metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 452,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "\nFrom 2022 through 2024 GM has continued to sell vehicles to commercial‑fleet customers both **directly and through its dealer network**, a channel it has long used for daily‑rental, lease, corporate and government accounts, and it has repeatedly noted that these fleet transactions—especially to rental companies—are **generally less profitable than retail sales**.  However, the 2024 filing adds a **new emphasis on profitability discipline**, describing how the company now reviews vehicle‑level profitability forecasts and pursues an “efficient, consolidated fixed‑cost structure” when managing fleet business, signaling a more deliberate focus on the channel’s margins while still relying on the same dealer‑centric sales pathway.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the dual sales channels (direct and dealer network) used consistently from 2022-2024; (2) Accurately captures that fleet sales, particularly to rental companies, are less profitable than retail sales; (3) Properly synthesizes the evolution showing a shift toward profitability discipline in 2024; (4) Correctly identifies the specific customer types (daily-rental, lease, corporate, government accounts); (5) No quantitative errors or date misstatements; (6) Multi-hop reasoning is sound, connecting the 2022 baseline with 2024 developments. MINOR CONSIDERATIONS: The LLM answer goes slightly beyond the ground truth by adding specific details about 'vehicle-level profitability forecasts' and 'efficient, consolidated fixed-cost structure' from the 2024 filing. While these details appear to be accurate elaborations that enhance understanding of the profitability discipline shift, they represent a modest expansion beyond what the ground truth explicitly states. However, this expansion is contextually appropriate and factually grounded in the source material. The answer maintains semantic equivalence with the ground truth while providing richer detail about the nature of the strategic shift. All core facts are correct: the sales channels, the profitability comparison, the evolution from 2022 to 2024, and the strategic emphasis on profitability management.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Sells_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 413,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo’s involvement with Sabra moved from a 39 % non‑controlling interest in a joint venture that distributed Sabra brands in the United States (Chunk 1) to a 50 % equity ownership that was subsequently re‑measured at fair value, resulting in a $122 million pre‑tax gain ($92 million after‑tax, or $0.07 per share) recorded in selling, general and administrative expenses in 2024 (Chunk 2). This remeasurement reflects the deepening of PepsiCo’s stake in Sabra and the associated earnings impact.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) CONTRADICTORY OWNERSHIP PROGRESSION: The LLM states PepsiCo moved FROM a 39% non-controlling interest TO a 50% equity ownership, characterizing this as a 'deepening of PepsiCo's stake.' This is factually incorrect. The ground truth indicates PepsiCo moved FROM full ownership in 2022 TO a 50% stake in 2024, representing a DIVESTMENT/REDUCTION in ownership, not an increase. The LLM's interpretation of 'deepening' is semantically opposite to the actual strategic shift. (2) MISCHARACTERIZATION OF TRANSACTION: The ground truth explicitly states this was a 'divestment of a portion of its ownership' - a reduction in control. The LLM frames it as a deepening/increase, which is fundamentally wrong. (3) CORRECT NUMBERS BUT WRONG CONTEXT: While the LLM correctly identifies the $122 million pre-tax gain, $92 million after-tax, and $0.07 per share figures, these numbers are presented in a narrative that misrepresents the nature of the transaction. (4) MISSING KEY CONTEXT: The LLM fails to clearly state that PepsiCo went from owning the brand outright to holding only 50%, which is the core strategic change. The 39% figure appears to be introduced without clear explanation of how it relates to the 2022 baseline. (5) MULTI-HOP REASONING FAILURE: The model failed to correctly synthesize the ownership evolution across the time period, arriving at an inverted understanding of whether ownership increased or decreased. This is a fundamental reasoning error that undermines the entire answer despite getting some supporting numbers correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Owns]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 432,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "\nAdobe Scan has shifted from being listed simply as a trademark in Adobe’s 2023 portfolio to a core component of the 2024 Document Cloud suite, where it is presented as the entry point for digitizing, organizing and enriching content that flows into Adobe’s Creative Cloud libraries and AI‑driven services.  In 2024 the scanner is highlighted alongside Acrobat, Acrobat Sign, Firefly‑powered generative AI, Adobe Stock and Frame.io, underscoring a strategic positioning of Adobe Scan as a unified hub that bridges document capture with AI‑enhanced creation and collaboration across Adobe’s entire product ecosystem.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer introduces significant factual claims not supported by the ground truth. While the core evolution (2023 trademark → 2024 Document Cloud positioning) is correct, the LLM adds unverified details: (1) Claims Adobe Scan is 'the entry point for digitizing, organizing and enriching content that flows into Adobe's Creative Cloud libraries' - NOT mentioned in ground truth; (2) Lists specific products (Firefly, Adobe Stock, Frame.io) as being highlighted alongside Adobe Scan in 2024 - ground truth only mentions 'Acrobat, Acrobat Sign, and other apps and API services'; (3) Describes Adobe Scan as 'a unified hub that bridges document capture with AI‑enhanced creation' - this characterization goes beyond what the ground truth states. CORRECT ELEMENTS: (1) Accurately identifies the shift from 2023 to 2024; (2) Correctly notes Document Cloud positioning; (3) Correctly mentions Acrobat and Acrobat Sign as related products. QUANTITATIVE ACCURACY is high (8/10) because there are no numeric claims to verify, and dates (2023, 2024) are correct. QUALITATIVE ACCURACY is low (3/10) because the LLM fabricates product associations and strategic positioning details not in the ground truth, demonstrating failed multi-hop synthesis - it appears to have inferred or hallucinated details rather than strictly synthesizing from the provided knowledge graph. CONTEXTUAL RELEVANCE is moderate (5/10) - the answer addresses the question's core inquiry but with unsubstantiated elaborations that reduce reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 422,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "\nFrom 2022 through 2024 GM’s contractual exposure to Stellantis remained confined to the indemnity provisions built into the 2017 sale agreement—GM continues to supply vehicles, parts and engineering services to Stellantis (Chunk 1) and, under that agreement, must reimburse Stellantis for certain historic emissions, product‑liability and recall losses, but the indemnity is subject to caps, time‑limits and a “cannot‑estimate‑loss” assessment that keeps the potential liability indeterminate (Chunk 1).  In 2024 GM has only indemnified Stellantis for an immaterial amount related to Takata‑inflator recalls and has indicated that any further indemnification is remote, while it has accrued an immaterial sum for the European Commission and UK CMA investigations into Opel’s end‑of‑life‑vehicle practices that could, if fines were imposed, affect those historic obligations (Chunk 2).  Thus, although GM’s own financial provisions for the $2.6 billion Bolt‑EV recall and related receivables are separate, its overall financial exposure to Stellantis has not materially increased; it stays limited to the original indemnity framework with unknown‑loss characterization and caps (Chunks 1 & 2).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the multi-hop relationship between GM and Stellantis from 2022-2024, correctly identifying the shift from operational supply relationships to indemnification-based obligations. Key strengths: (1) Accurately captures the 2017 sale agreement framework as the foundation for ongoing obligations; (2) Correctly identifies specific indemnification categories (emissions, Takata recalls, European regulatory investigations); (3) Properly notes the immaterial accrual amounts in 2024; (4) Accurately describes the 'remote' likelihood of further indemnification; (5) Correctly references the $2.6 billion Bolt-EV recall as separate from Stellantis obligations; (6) Appropriately emphasizes the indeterminate nature of liability due to caps and time limits. Minor weaknesses: (1) The answer is somewhat more detailed and technical than the ground truth, introducing concepts like 'cannot-estimate-loss assessment' and 'unknown-loss characterization' that, while accurate, add complexity beyond what the original answer conveys; (2) The phrasing about 'continued supply of vehicles, parts and engineering services' slightly contradicts the ground truth's characterization of a shift FROM operational supplies TO financial guarantees—though the LLM does acknowledge this is ongoing from the 2017 agreement; (3) The answer could more explicitly state the temporal evolution (2022 vs 2024 comparison) though it does address this implicitly. Quantitative accuracy is strong—no numerical errors detected, and the immaterial amounts and $2.6B Bolt-EV figure are correctly cited. The multi-hop reasoning correctly synthesizes information about the historical sale agreement, current indemnification obligations, and regulatory exposure. The semantic meaning aligns well with the ground truth despite different wording and organization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Guarantees]- ORG",
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 506,
        "total_tokens": 2032
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo’s operational model continued to lean on a “highly distributed network” of plants, warehouses and distribution centers that are owned or leased by its contract manufacturers, co‑packers, strategic alliances and joint ventures—an arrangement explicitly described in both the 2022 and 2024 10‑K filings.  The knowledge‑graph pattern (PEP → Depends_On → Co‑Packers and Co‑Packers → Has_Stake_In → PEP) shows a two‑way relationship: PepsiCo depends on these co‑packers to run much of its supply chain, while the co‑packers also hold equity stakes in PepsiCo, underscoring a strategic partnership that has remained stable across the two years.  Thus, the company’s dependency on co‑packers for production capacity has not diminished; instead, the same mutually dependent, equity‑linked relationship that existed in 2022 persisted through 2024, even as unrelated litigation unfolded.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN CORE CLAIM: The LLM answer fundamentally misrepresents the ground truth. The original answer clearly states an EVOLUTION/SHIFT in PepsiCo's relationship with co-packers between 2022 and 2024: from describing them as part of a 'highly distributed network' (operational dependency focus in 2022) to emphasizing 'strategic alliances or joint ventures in which we have an equity interest' (more integrated ownership stake in 2024). The LLM answer contradicts this by claiming the relationship 'remained stable across the two years' and that 'the same mutually dependent, equity-linked relationship...persisted through 2024.' This is factually incorrect. The LLM also introduces a completely unsupported claim that 'co-packers also hold equity stakes in PepsiCo'—the ground truth indicates PepsiCo has equity interest IN co-packers, not the reverse. The LLM conflates the direction of the equity relationship. Additionally, the LLM's reference to 'unrelated litigation' is not mentioned in the ground truth and appears to be fabricated context. The LLM correctly identifies the 'highly distributed network' language but fails to recognize the key distinction: the 2024 language shift toward 'strategic alliances or joint ventures in which we have an equity interest' represents a material change in how PepsiCo characterizes its involvement. The LLM's knowledge graph notation (PEP → Depends_On → Co-Packers and Co-Packers → Has_Stake_In → PEP) is inverted on the second relationship. Numeric accuracy is acceptable (no specific numbers were provided in either answer to verify), but the qualitative reasoning—the core of this question—is substantially incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 458,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "\nBetween 2021 and 2024 SPG’s stake in ABG shifted from an initial 2021 sale of a portion of its interest—producing an $18.8 million pre‑tax gain (with $8 million of tax expense) and a subsequent $100 million cash purchase of additional ABG shares—to a 2022 long‑term strategic partnership in which SPARC Group became the core licensee and operating partner for Reebok while ABG retained an ownership position; in 2023 SPG recognized roughly $362 million of non‑cash pre‑tax gains from deemed disposals linked to ABG’s capital transactions and the sale of a portion of its ABG interests, building on the $159 million gain recorded in 2022, and the 2024 filing continues to reflect this partnership as it reports ongoing development projects (≈$1.3 billion of capital expenditures) and the continued strategic role of ABG in SPG’s licensing and brand‑venture portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) TEMPORAL MISMATCH: The LLM answer discusses 2021-2024 evolution, but the question specifically asks about 2023-2024 evolution. The ground truth focuses on comparing 2023 vs 2024 changes. (2) QUANTITATIVE ERRORS: The LLM states 'roughly $362 million of non-cash pre-tax gains' in 2023, but ground truth specifies $59.1M (deemed disposals) + $157.1M (sale of ABG interests) = $216.1M, NOT $362M. The LLM also mentions '$159 million gain recorded in 2022' which is not in the ground truth at all. (3) ENTITY CONFUSION: The LLM conflates SPARC Group and SPG's roles. Ground truth states SPG recognized a $145.8M gain from dilution of SPARC Group ownership in 2023, but LLM incorrectly attributes Reebok partnership to SPARC Group becoming licensee when ground truth indicates this was a 2024 strategic partnership disclosure for SPG. (4) MISSING KEY 2024 INFORMATION: LLM fails to clearly distinguish the 2024 shift from financial transactions to operational collaboration. Ground truth emphasizes the $18.8M gain disclosure in 2024 and the strategic partnership as a shift toward 'deeper operational collaboration.' (5) INCOMPLETE SYNTHESIS: LLM adds information about $1.3B capital expenditures and 2022 partnerships that are not in the ground truth, suggesting hallucination or mixing of unverified data. (6) CALCULATION VERIFICATION: $59.1M + $157.1M = $216.1M, not $362M as stated. This is a significant arithmetic error. The answer demonstrates poor multi-hop reasoning by conflating different time periods and entities, and contains multiple factual inaccuracies that undermine credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 444,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "\nLockheed Martin’s Rotary and Mission Systems (RMS) has steadily increased its output on Sikorsky rotorcraft – the 2021 cost data already cited “higher production volume on various Sikorsky helicopter programs,” and the 2024 filing confirms that this momentum continued through 2024 with expanded manufacturing of models such as the CH‑53K King Stallion and the Combat‑Rescue Helicopter, indicating a clear rise in volume.  At the same time, the scope of LMT’s involvement broadened: the 2024 document lists a suite of new Sikorsky programs (including the CH‑53K, CRH and related advanced rotor‑craft efforts) alongside other aerospace projects, showing that LMT’s dependence on Sikorsky helicopter programs now spans both higher‑volume production and a wider range of next‑generation platforms.  This evolution reflects the mutual ORG‑DEPENDS_ON/PRODUCES relationship between LMT and Sikorsky Helicopter Programs, driving both greater output and a more diversified program portfolio from 2022 to 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES: (1) QUANTITATIVE ERROR - LLM cites '2021 cost data' when the ground truth specifically references 2022 ($560 million increase in product costs). This is a factual error in the year cited. (2) INCOMPLETE SYNTHESIS - LLM mentions 'Combat-Rescue Helicopter' (CRH) as a 2024 program, but ground truth only explicitly lists Black Hawk, Seahawk, and CH-53K King Stallion. The CRH reference appears to be an inference not supported by the ground truth. (3) MISSING KEY METRIC - Ground truth provides specific $560 million figure for 2022 cost increase; LLM provides no quantitative data to support claims about 'steadily increased output' or 'expanded manufacturing.' (4) REASONING ISSUE - LLM's framing of 'mutual ORG-DEPENDS_ON/PRODUCES relationship' and discussion of 'dependence' is not present in ground truth and appears to be added interpretation. (5) CORRECT ELEMENTS - LLM correctly identifies RMS segment, correctly names CH-53K King Stallion, correctly identifies the evolution from cost driver to strategic product line concept, and correctly addresses both production volume and program scope aspects of the question. (6) TEMPORAL ACCURACY - Ground truth compares 2022 to 2024; LLM attempts this but introduces 2021 data incorrectly. STRENGTHS: Addresses both production volume and program scope; maintains focus on RMS segment; recognizes strategic importance evolution. WEAKNESSES: Factual year error (2021 vs 2022); unsupported program additions (CRH); lack of quantitative specificity; added interpretive framework not in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 428,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "\nWalmart’s only cash investment in Alert Innovation occurred in fiscal 2023, when it spent roughly **$0.4 billion to acquire the remaining shares and bring its ownership to 100 %** – a transaction documented in both the fiscal‑2023 10‑K (Chunk 1) and the fiscal‑2024 10‑K (Chunk 2).  The filings show **no additional purchase or divestiture of Alert Innovation during fiscal 2024**; the stake remained at 100 % throughout that year, with the next change (a sale and deconsolidation) not occurring until fiscal 2025 (Chunk 2).  Thus, between fiscal 2023 and fiscal 2024 the ownership stake stayed at full consolidation and the financial exposure remained fixed at the $0.4 billion acquisition cost.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer directly contradicts the ground truth on the key evolution between fiscal 2023 and fiscal 2024. Ground truth states: 'By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.' The LLM claims: 'the stake remained at 100% throughout that year' and 'the next change (a sale and deconsolidation) not occurring until fiscal 2025.' This is a fundamental factual error on the core question about how the stake 'evolved' between the two years. The LLM correctly identifies the $0.4 billion acquisition in fiscal 2023 and the 100% ownership achievement, which matches ground truth. However, it completely misses or misrepresents the critical evolution: that Walmart exited the stake between fiscal 2023 and fiscal 2024, not in fiscal 2025. The LLM's claim that 'no additional purchase or divestiture of Alert Innovation during fiscal 2024' occurred contradicts the ground truth's explicit statement that Walmart had 'fully exited its stake' by fiscal 2024. The answer demonstrates poor multi-hop reasoning by failing to synthesize the key difference between the two fiscal years. The LLM appears to have introduced information about fiscal 2025 that may not be supported by the ground truth provided, and it fundamentally mischaracterizes the timeline of the divestiture.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Acquires]- ORG",
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 394,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "\nSPG (ORG) invests in the Supplemental Facility (FIN_INST), which discloses its terms back to SPG; in 2023 the company drew **€750 million (≈$808 million)** under that revolving line, entered into interest‑rate swaps that were terminated when the borrowing was retired on 14 Nov 2023, and used proceeds from a €750 million bond issuance to **fully repay the Supplemental Facility balance**.  In 2024 SPG did **not** undertake new borrowings under the facility—instead it managed the line by retiring maturing senior notes, issuing lower‑cost unsecured notes, and preserving the $3.5 billion Supplemental Facility as a flexible source of liquidity while staying in compliance with all covenants and protecting its credit rating.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core narrative: SPG borrowed €750 million in 2023, repaid it following a bond issuance, and did not use the facility in 2024. The qualitative reasoning about strategic shift from revolving credit to long-term unsecured notes is sound and well-articulated. The answer appropriately addresses the multi-hop synthesis across 2023-2024 activities.\n\nCRITICAL ERRORS: (1) DATE DISCREPANCY - The LLM states the facility was repaid on \"14 Nov 2023\" but the ground truth specifies \"November 17, 2023.\" This is a factual error on a specific date. (2) BOND ISSUANCE AMOUNT - The LLM states \"€750 million bond issuance\" but the ground truth indicates the repayment was from \"senior unsecured bonds\" without specifying the exact amount matched the €750M draw. The LLM's statement that proceeds from a €750M bond issuance repaid the facility is reasonable but not explicitly confirmed in ground truth. (3) SUPPLEMENTAL FACILITY SIZE - The LLM introduces \"$3.5 billion Supplemental Facility\" which is not mentioned in the ground truth answer, making it an unsupported addition.\n\nMINOR ISSUES: The USD conversion (€750M ≈ $808M) is reasonable but not verified against ground truth. The mention of interest-rate swaps and their termination adds detail not in ground truth but is plausible context.\n\nMULTI-HOP REASONING: The answer successfully synthesizes 2023 borrowing activity with 2024 refinancing strategy, showing understanding of the evolution requested. However, the date error and unsupported $3.5B figure undermine precision.\n\nQUANTITATIVE ACCURACY PENALTY: The date error (Nov 14 vs Nov 17) and introduction of unsupported $3.5B figure reduce quantitative accuracy despite correct €750M amounts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 478,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "\nBetween 2023 and 2024 Linde shifted helium from a peripheral “process‑gas” item to a strategically‑positioned primary product.  \n\n* In the 2023 filing (Chunk 1) helium is listed only as one of several process gases (alongside carbon‑dioxide, hydrogen, etc.) that are sold mainly through the **merchant‑distribution** channel, with short‑ to medium‑term (3‑7 year) supply agreements that contain no minimum purchase obligations and rely on variable, index‑linked pricing.  The description treats helium as a commodity that can be shipped long distances but does not highlight it as a core offering.  \n\n* By the 2024 filing (Chunk 2) the narrative emphasizes helium’s **primary‑product status** within Linde’s industrial‑gases portfolio and describes supply strategies that are more dedicated and contract‑driven—long‑term, often on‑site or pipeline‑linked arrangements that secure helium supply and integrate it into Linde’s on‑site plant designs.  This evolution is reflected in the knowledge‑graph triplets that show **LIN → Helium** (Linde produces helium) and **Helium → LIN** (helium depends on Linde), underscoring a mutual, strategic dependency that the company now leverages to market helium as a core, high‑value product rather than a secondary by‑product.  \n\nThus, Linde’s treatment of helium has evolved from a loosely‑contracted merchant commodity in 2023 to a strategically‑managed, primary product with dedicated supply‑chain and contractual frameworks by 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally contradictory to the ground truth and contains major factual errors: (1) DIRECTIONAL ERROR - The LLM claims helium evolved FROM a 'peripheral process-gas item' TO a 'strategically-positioned primary product' between 2023-2024. The ground truth states the OPPOSITE: helium WAS explicitly listed as a primary product in 2023 but was NO LONGER specifically named as distinct in 2024, indicating REDUCED emphasis. This is a complete reversal of the actual evolution. (2) MISCHARACTERIZATION OF 2023 - The LLM incorrectly describes 2023 helium as 'loosely-contracted merchant commodity' with 'short- to medium-term' contracts. The ground truth confirms 2023 had 3-7 year contracts with no minimum purchase requirements, but this was presented as helium's PRIMARY product status, not peripheral status. (3) MISCHARACTERIZATION OF 2024 - The LLM claims 2024 shows 'dedicated and contract-driven' supply with 'long-term, often on-site or pipeline-linked arrangements.' The ground truth states helium was SUBSUMED under general descriptions in 2024, indicating LESS distinct positioning, not more strategic positioning. (4) UNSUPPORTED CLAIMS - The LLM introduces concepts like 'on-site plant designs,' 'mutual strategic dependency,' and 'high-value product' that are not supported by the ground truth and appear to be fabricated. (5) KNOWLEDGE GRAPH MISUSE - The LLM cites knowledge graph triplets (LIN → Helium, Helium → LIN) that are not mentioned in the ground truth and appear to be invented to support the incorrect narrative. The core finding is inverted: the LLM describes an UPGRADE in helium's status when the ground truth describes a DOWNGRADE.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> RAW_MATERIAL <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1587,
        "completion_tokens": 458,
        "total_tokens": 2045
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "\nThe U.S. Retiree Health Care Plan’s asset mix shifted markedly from 2022 to 2023, with fixed‑income securities (including cash equivalents) falling from a total of **$248 million** in 2022 to **$210 million** in 2023, and equity securities declining from **$137 million** to **$54 million** over the same period; these changes are reflected in TXN’s 2022 and 2023 filings, which disclose the plan’s holdings and its stake in the fund.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All four key financial figures are correct - fixed income securities decreased from $248M (2022) to $210M (2023), and equity securities declined from $137M (2022) to $54M (2023). The dollar amounts match the ground truth exactly, with proper formatting ($248 million vs $248). (2) COMPLETENESS: The answer addresses both asset categories and both years as required by the multi-part question. It captures the evolution of the allocation between the two periods. (3) ENTITY ACCURACY: The answer correctly identifies the U.S. Retiree Health Care Plan and references TXN (Texas Instruments) filings as the source, which is appropriate for a 10-K filing question. (4) REASONING & SYNTHESIS: The multi-hop reasoning is sound - the answer correctly synthesizes data from 2022 and 2023 filings and makes the appropriate comparison showing decreases in both categories. The characterization of equity securities experiencing 'more significant reduction' is accurate (60.6% decline vs 15.3% decline for fixed income). (5) SEMANTIC EQUIVALENCE: The wording differs slightly from the ground truth but conveys identical information. The phrase 'asset mix shifted markedly' effectively captures the evolution requested. Minor note: The LLM answer includes a reference to 'TXN's 2022 and 2023 filings' which adds helpful context about the source, though this wasn't explicitly in the ground truth answer. This is a minor enhancement rather than an error. The answer is comprehensive, accurate, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 438,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "\nIn 2022 Trodelvy contributed $370 million of product sales to Gilead (Chunk 1), up from only $49 million in 2020, highlighting its rising importance to the company’s oncology top‑line (KG: GILD‑Produces‑Trodelvy).  Building on that momentum, 2023 saw two key regulatory wins—European Commission approval and U.S. FDA approval for Trodelvy as a monotherapy in HR⁺/HER2⁻ metastatic breast cancer (Chunk 2)—and a series of strategic moves (the Arcellx CART‑ddBCMA collaboration, the Compugen anti‑IL‑18 antibody license, the Tentarix oncology‑inflammation partnership, and the XinThera/Tmunity acquisitions) that broaden its pipeline and commercial reach, positioning Trodelvy for continued revenue growth and expanded therapeutic impact.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) QUANTITATIVE INACCURACY - LLM states Trodelvy generated $370 million in 2022, but ground truth clearly states $380 million. This is a $10 million discrepancy (2.6% error) on a key metric. (2) The LLM introduces information about 2020 revenue ($49 million) and multiple strategic partnerships (Arcellx, Compugen, Tentarix, XinThera/Tmunity) that are NOT mentioned in the ground truth answer. While these may be factually accurate from other sources, they represent scope creep beyond what the knowledge graph provided and dilute focus from the core question. (3) PARTIAL CREDIT for correctly identifying the 2023 regulatory milestones (FDA and EC approvals for HR+/HER2- metastatic breast cancer), which matches the ground truth. (4) The LLM correctly notes the strategic positioning shift and market potential enhancement. STRENGTHS: The answer demonstrates multi-hop reasoning by connecting revenue trends to regulatory approvals and strategic moves. The writing is clear and well-structured. WEAKNESSES: The $370M vs $380M error is significant for a financial question where precision is critical. The inclusion of extraneous information (2020 data, multiple partnerships) suggests the LLM may have synthesized from multiple sources rather than strictly adhering to the ground truth knowledge graph. The answer lacks acknowledgment that specific 2023 revenue figures are not provided, which the ground truth explicitly notes. For a financial performance evaluation question, the revenue number error is a material flaw that prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 431,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "\nChevron’s MD&A had identified downstream‑related earnings from GS Caltex in Korea as a key contributor to equity‑affiliate income, and the 2022‑2024 data show that this contribution continued—affiliated sales fell from $16.3 bn in 2022 to $13.6 bn in 2023 and edged up to $13.9 bn in 2024, while purchases of crude and products from the JV declined from $10.2 bn to $6.5 bn over the same period.  At the same time, Chevron’s 50 % ownership remained unchanged, but net loans to the joint venture rose from $4.28 bn (2022) to $4.73 bn (2024), reflecting a deepening financial commitment.  This evolution underscores that the GS Caltex joint venture is a strategic cornerstone of Chevron’s Asian downstream portfolio, warranting sustained investment and capital support.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM introduces numbers NOT in the ground truth: 'net loans to the joint venture rose from $4.28 bn (2022) to $4.73 bn (2024)' - these loan figures are completely absent from the original answer and cannot be verified. This is a critical fabrication. (2) INCOMPLETE DATA - The LLM claims 2023 data ($13.6 bn in affiliated sales, $6.5 bn in purchases) which is NOT mentioned in the ground truth. The original answer only provides 2022 ($16,286M) and 2024 ($13,850M) figures. The LLM appears to have invented intermediate year data. (3) CORRECT ELEMENTS - The LLM correctly identifies: 50% ownership stake, GS Caltex as joint venture with GS Energy, the general trend of decreased affiliated company revenues (from $16.3bn to $13.9bn), and the strategic importance conclusion. (4) MULTI-HOP REASONING - While the LLM attempts to synthesize information about earnings evolution and strategic importance, it does so by introducing unverified data points that undermine credibility. The reasoning about 'deepening financial commitment' based on loan increases cannot be validated against the ground truth. (5) SEMANTIC ISSUES - The LLM's conclusion about 'strategic cornerstone' and 'sustained investment' goes beyond what the ground truth states ('remained strategically important' with 'slightly decreased' revenue). The fabricated loan data is used to support a stronger claim than warranted. The answer demonstrates partial understanding but fails on factual accuracy due to invented numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 425,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "\nIn the 2022 filing (LMT 10‑K 2022, p. 50) the CH‑53K was listed among Sikorsky’s helicopter programs that added roughly $140 million to operating profit in 2021 because of higher risk retirements on the CH‑53K and increased production volume.  \nBy 2024 the same Sikorsky portfolio underpinned a $1.4 billion rise in LMT’s backlog, driven by production ramp‑up on missile programs such as GMLRS, JASSM and PAC‑3 (LMT 10‑K 2024, p. 40), showing that the CH‑53K line continued to benefit from the broader volume expansion.  \nThe KG relationship (LMT Depends_On CH‑53K ← Produces LMT) ties the program’s financial outcomes directly to Lockheed Martin’s profit‑booking adjustments, which shifted from gains in 2022 to a $1.2 billion reduction in 2024, yet the earlier risk‑retirement and volume gains remain the key drivers of the CH‑53K’s evolving performance.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) TEMPORAL MISMATCH: The LLM states the $140M profit increase was 'in 2021' but the ground truth clearly indicates this was 2022 data. This is a fundamental factual error that undermines the core timeline of the answer. (2) INCOMPLETE 2024 ANALYSIS: The ground truth explicitly states that 'overall operating profit for RMS declined significantly—by 73%' in 2024, which is a key metric for understanding the program's evolution. The LLM completely omits this critical 73% decline figure and instead discusses unrelated missile programs (GMLRS, JASSM, PAC-3) and a $1.4B backlog increase, which are not relevant to the CH-53K program's profit performance. (3) MISSING KEY METRIC: The ground truth emphasizes that CH-53K's 2024 profit figures were 'not disclosed,' but the broader RMS portfolio showed a 73% profit decline. The LLM fails to capture this important context about profit booking rate adjustments. (4) IRRELEVANT INFORMATION: The discussion of missile programs and the $1.2 billion reduction in profit-booking adjustments conflates different business segments and doesn't directly address CH-53K's specific evolution. (5) WEAK SYNTHESIS: While the LLM attempts to connect 2022 gains to 2024 performance, it does so without the critical 73% RMS profit decline figure that the ground truth identifies as partially attributable to the CH-53K program's maturation. The answer reads as partially constructed from unrelated filing sections rather than a coherent analysis of the CH-53K program's specific trajectory. CORRECT ELEMENTS: The $140M figure is accurate in magnitude, and the general concept that risk retirements and production volume drove 2022 gains is correct. However, the temporal error (2021 vs 2022) and the omission of the 73% 2024 decline are substantial factual gaps that significantly reduce the answer's accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 506,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "\nPayPal’s seller‑protection framework moved from a 2022 focus on quantifying and disclosing loss exposure—highlighting transaction‑loss rates of 0.09‑0.15 % of TPV, the risk of regulatory or macro‑economic shocks that could raise merchant‑bankruptcy losses, and the need to monitor credit‑product liquidity (Chunk 1)—to a 2023 strategic emphasis on protection as a differentiator, with explicit investment in systems, data and risk‑management tools to safeguard merchants and consumers, reinforce trust in the PayPal brand, and position seller‑protection programs as a core competitive advantage (Chunk 2). This evolution reflects the same accounting‑policy entity (Seller Protection Programs) that PYPL both owns and introduces, underscoring a shift from merely acknowledging risk to leveraging protection programs strategically to drive growth and market distinction.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The specific transaction loss rate range (0.09-0.15% of TPV) is correctly cited and matches the original answer precisely. No calculation errors or numeric discrepancies detected. QUALITATIVE ACCURACY: The answer correctly identifies the core evolution in PayPal's approach: (1) 2022 emphasis on risk quantification and disclosure, and (2) 2023 shift toward strategic positioning of seller protection as a competitive differentiator. The reasoning accurately captures the transition from risk-management framing to value-proposition framing. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two fiscal years and connects seller protection programs to broader merchant trust and platform growth objectives, demonstrating sound multi-hop reasoning. ENTITY ACCURACY: PayPal (PYPL) is correctly identified, fiscal years 2022 and 2023 are properly distinguished, and seller protection programs are accurately characterized as the relevant accounting policy entity. SEMANTIC EQUIVALENCE: The LLM's phrasing ('moved from...to...') effectively conveys the same directional shift as the ground truth ('evolved between 2022 and 2023'). The answer adds helpful context about 'systems, data and risk-management tools' and 'reinforce trust in the PayPal brand' which are consistent with the ground truth's emphasis on strategic positioning. MINOR OBSERVATIONS: The LLM answer includes slightly more operational detail (mention of 'systems, data and risk-management tools') than the ground truth, but this represents appropriate elaboration rather than factual error. The reference to 'Chunk 1' and 'Chunk 2' indicates source attribution but doesn't detract from accuracy. Overall, the answer is factually correct, comprehensively addresses the question, and demonstrates sound reasoning across the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Risk]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 528,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "\nStarbucks continues to record revenue from its ready‑to‑drink (RTD) beverages sold outside of its stores upon shipment, a policy reiterated in the 2023 10‑K (“Other revenues…sales of these products are generally recognized upon shipment”) and still applied in the 2024 filing.  The 2024 disclosure shows that RTD products are now sourced from multiple specialty suppliers under long‑term contracts, and the company’s expanded farmer‑support centers, dairy and plant‑based supply safeguards, and emphasis on “risk of non‑delivery…remote” demonstrate a deliberate shift toward a more secured, diversified supplier base compared with the earlier period.  Both filings tie the RTD product line back to SBUX through the disclosed ORG‑>PRODUCT dependency, confirming that the evolution is essentially a move from reliance on ad‑hoc supply arrangements to a strategy that couples shipment‑based revenue recognition with strengthened, long‑term supplier relationships and supply‑chain resilience.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the revenue recognition approach for RTD beverages (upon shipment) and confirms this policy was consistent between 2023 and 2024 filings. (2) Accurately captures the shift toward supplier dependency and supply chain resilience as a key evolution between the two years. (3) Properly synthesizes the multi-hop relationship: Starbucks → RTD products → supplier relationships → long-term contracts. (4) Correctly notes the move from ad-hoc arrangements to formalized, long-term supplier relationships. (5) Appropriately references specific supply chain elements (farmer-support centers, dairy and plant-based safeguards, risk mitigation language). MINOR AREAS FOR IMPROVEMENT: (1) The LLM answer is slightly more detailed and specific than the ground truth in some areas (mentioning 'multiple specialty suppliers' and specific supply chain initiatives), which while accurate, goes slightly beyond what the ground truth explicitly states. (2) The phrase 'ORG->PRODUCT dependency' appears to reference internal knowledge graph notation rather than information directly from the filings themselves, which is a minor technical artifact. (3) The ground truth emphasizes that 2023 lacked specific figures for RTD beverages while 2024 highlighted supplier relationships; the LLM answer could have been more explicit about this reporting difference. QUANTITATIVE ACCURACY: No specific dollar amounts or percentages were required for this question, and the LLM correctly avoids inventing numbers. The temporal references (2023 vs 2024) are accurate. QUALITATIVE ACCURACY: The reasoning correctly identifies the evolution from revenue-centric to supply-chain risk management focus, matching the ground truth's core insight. The multi-hop synthesis is sound and logical. CONTEXTUAL RELEVANCE: The answer directly addresses both parts of the question (revenue recognition AND supplier dependency) and properly contextualizes the evolution between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 558,
        "total_tokens": 2000
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "\nThe 2022 filing (Chunk 1) shows Trodelvy generating $370 million in U.S. sales and only $10 million in Europe, indicating that by the end of 2021 the product was already marketed in both regions but with a limited European footprint. In 2023 the company obtained both FDA approval and, crucially, European Commission approval for Trodelvy as a monotherapy in HR⁺/HER2⁻ metastatic breast cancer (Chunk 2), thereby expanding its geographic reach into Europe and adding a new therapeutic indication. This regulatory expansion was accompanied by other 2023 strategic moves—including a $2 billion senior‑note issuance, the acquisitions of XinThera and Tmunity, and new collaborations with Arcellx, Compugen and Tentarix (Chunk 2)—which together provide the financial resources and partnership infrastructure that enabled Trodelvy’s broader rollout.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) All key numbers are correct: $370M U.S. sales and $10M Europe in 2022 match ground truth exactly. (2) Regulatory approvals accurately identified: FDA approval for HR+/HER2- metastatic breast cancer and EC approval for monotherapy treatment are both correctly stated. (3) Multi-hop reasoning is sound: the answer properly synthesizes 2022 sales data with 2023 regulatory approvals to show geographic and therapeutic expansion. (4) Additional context provided (acquisitions, collaborations, $2B senior notes) adds relevant strategic context showing how the company supported Trodelvy's expansion, though this goes slightly beyond the ground truth answer. (5) Temporal framing is clear and accurate (2022 vs 2023). MINOR CONSIDERATIONS: (1) The LLM answer includes additional strategic information (XinThera, Tmunity acquisitions, collaborations, $2B notes) that, while contextually relevant and accurate, extends beyond the specific ground truth answer which focused narrowly on geographic reach and regulatory approvals. This is not an error but rather supplementary information. (2) The phrase 'by the end of 2021' in the LLM answer is slightly imprecise—the 2022 filing reports 2022 sales, not 2021 data, though the intent is clear. (3) The ground truth notes 'no sales reported in other international markets' in 2022, which the LLM answer doesn't explicitly state, though it does note 'limited European footprint.' Overall, the answer correctly addresses both components of the question (geographic reach evolution and regulatory approvals) with accurate numbers and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 462,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "\nSimon Property Group’s ownership in ABG was progressively diluted in 2023—ownership fell from about 12.3 % to 11.8 % in the second quarter (yielding a $36.4 M pre‑tax gain) and then to roughly 9.6 % in the third quarter (yielding a $12.4 M gain), with each dilution accompanied by deferred‑tax expenses of $9.1 M and $3.1 M respectively; this follows the 2021 sale of its licensing ventures, which generated a $159.8 M gain, and the 2022 strategic partnership that made ABG the core U.S. licensee for Reebok, and as of the 2024 filing SPG holds an approximate 9‑10 % non‑controlling interest with no additional disposals or gains reported yet.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED:\n\n1. QUANTITATIVE ACCURACY - CRITICAL ISSUES:\n   - LLM states Q2 2023 dilution yielded $36.4M gain (CORRECT) but then claims Q3 2023 yielded $12.4M gain - Ground truth shows Q3 yielded $10.3M, not $12.4M (ERROR)\n   - LLM omits the third 2023 transaction entirely: the reduction to 9.6% that generated $10.3M in gains (MAJOR OMISSION)\n   - LLM references deferred-tax expenses of $9.1M and $3.1M - these figures do NOT appear in ground truth and appear to be fabricated\n   - LLM references a 2021 sale generating $159.8M gain - ground truth only mentions $18.8M from December 20, 2021 sale (WRONG NUMBER)\n   - LLM references 2022 Reebok partnership - this is contextual information not in ground truth and potentially confuses the narrative\n   - LLM states current holding is 9-10% - ground truth specifies 9.6% from 2023, with no update for 2024\n\n2. COMPLETENESS ISSUES:\n   - Ground truth explicitly states THREE separate 2023 transactions with specific ownership percentages (12.3%→11.8%→11.7%→9.6%) and corresponding gains ($36.4M, $12.4M, $10.3M)\n   - LLM only captures TWO transactions and misses the 11.7% intermediate step\n   - Ground truth emphasizes the SHIFT from active transactions in 2023 to passive disclosure in 2024 - LLM downplays this key distinction\n   - LLM fails to clearly articulate that 2024 showed NO NEW TRANSACTIONS, only references to prior 2021 activity\n\n3. ENTITY/METRIC ACCURACY:\n   - Ownership percentages partially correct but incomplete (missing 11.7% step)\n   - Gain amounts: 1 correct ($36.4M), 1 incorrect ($12.4M should be $10.3M), 1 completely missing\n   - Deferred-tax figures appear fabricated\n   - 2021 gain amount drastically wrong ($159.8M vs $18.8M)\n\n4. REASONING & SYNTHESIS:\n   - LLM attempts to synthesize 2021-2024 timeline but introduces incorrect information\n   - The core insight about 2023 active dilution vs 2024 passive stance is present but weakly articulated\n   - Multi-hop reasoning is attempted but undermined by factual errors\n\n5. WHAT WAS CORRECT:\n   - General direction of ownership dilution in 2023 (correct)\n   - $36.4M gain from Q2 2023 transaction (correct)\n   - Recognition that 2024 showed no new transactions (correct)\n   - Overall narrative arc of shift from active to passive (correct in concept)\n\nThe answer contains too many quantitative errors (wrong gain amounts, fabricated tax figures, wrong historical gains) and significant omissions (missing third 2023 transaction) to score higher. While the general narrative structure is sound, the specific financial data is unreliable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 691,
        "total_tokens": 2052
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "\nBetween the 2023 and 2024 SEC filings, Meta’s 2012 Equity Incentive Plan was further amended and expanded: the 2023 filing (Chunk 1) records the third amendment (Exhibit 10.2(B)+) and discloses the related award‑agreement forms (Exhibits 10.2(C)+ and 10.2(D)+), while the 2024 filing (Chunk 2) adds a fourth amendment (Exhibit 10.2(C)+) and introduces a new series of award‑agreement exhibits (10.2(J)+ through 10.2(K)+), reflecting the plan’s ongoing evolution. Both years present the plan as an accounting policy (the ORG → ACCOUNTING_POLICY relationship), underscoring that each amendment and each new form of award agreement is formally disclosed in the respective filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of the 2012 Equity Incentive Plan between 2023 and 2024 filings. STRENGTHS: (1) Correctly identifies Third Amendment in 2023 and Fourth Amendment in 2024; (2) Accurately notes the introduction of new award agreement forms in 2024; (3) Properly synthesizes multi-hop information across two filing years; (4) Correctly identifies Meta as the company; (5) Appropriately references exhibit numbers and dates (August 1, 2024 for Fourth Amendment). WEAKNESSES: (1) The LLM provides specific exhibit numbers (10.2(B)+, 10.2(C)+, 10.2(D)+, 10.2(J)+, 10.2(K)+) that cannot be verified against the ground truth, which only states 'forms of award agreements from 2012 and 2017' in 2023 and 'additional forms of award agreements from April 2024' in 2024 - the specific exhibit designations may be inaccurate or over-specified; (2) The mention of 'accounting policy' and 'ORG → ACCOUNTING_POLICY relationship' adds information not present in the ground truth and appears to be extraneous detail that doesn't directly address the question; (3) The ground truth mentions specific years for award agreement forms (2012, 2017, April 2024) but the LLM's exhibit numbering system doesn't clearly map to these dates. MULTI-HOP REASONING: The answer correctly synthesizes information across two filing years and identifies the progression of amendments and new award forms. The core factual claims align with the ground truth. The main issue is the introduction of specific exhibit numbers and accounting policy references that go beyond what the ground truth confirms, creating potential accuracy concerns despite the core narrative being correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 459,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s **capitalized software‑license balance grew from $152 million to $223 million** (see Chunk 2), and the underlying accounting treatment remained unchanged: the licenses are **amortized on a straight‑line basis over the license term**, with fully amortized amounts written off against accumulated amortization (Chunk 1).  This increase—while the amortization method stayed the same—signals that the firm is **allocating more capital to software‑licensing assets**, reflecting an expanded or upgraded licensing portfolio and a strategic shift toward greater reliance on licensed software solutions.  The growth is further corroborated by the note that such licenses are disclosed as a distinct line‑item within “Other long‑term assets” and are subject to the same impairment review applied to other long‑lived assets (KG pattern ORG → FIN_INST ← ORG).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. QUANTITATIVE VERIFICATION: The key financial figures are correct—capitalized software licenses grew from $152 million (2022) to $223 million (2023), representing a $71 million increase. Both numbers match the ground truth exactly. COMPLETENESS: The answer addresses all major components of the question: (1) treatment evolution (straight-line amortization policy unchanged), (2) valuation evolution (specific carrying values provided), and (3) what this indicates about investment (growing capital allocation to software licensing). ENTITY ACCURACY: Years (2022, 2023) and financial metrics (capitalized software licenses, accumulated amortization) are correctly identified. REASONING QUALITY: The multi-hop synthesis is sound—the LLM correctly connects the unchanged amortization method with the increased balance to infer strategic investment decisions. The interpretation that the growth signals 'expanded or upgraded licensing portfolio' and 'greater reliance on licensed software solutions' is a reasonable inference from the data. MINOR CONSIDERATIONS: The LLM adds interpretive details about disclosure as a 'distinct line-item' and impairment review procedures that go slightly beyond the ground truth but are consistent with standard accounting practices and don't contradict the original answer. The reference to 'KG pattern' is somewhat technical but doesn't detract from accuracy. The semantic equivalence is strong—both answers convey that the balance increased while policy remained constant, indicating growing investment. No calculation errors detected. The answer is well-structured and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amortizes]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 464,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "\nBetween 2022 and 2023 the amount of European customer balances that PayPal has designated for credit‑product funding fell modestly—from **$3.8 billion (≈37 % of the available balance) in 2022** to **$3.0 billion (≈39 % of the available balance) in 2023**—while the CSSF permission was expanded from a **35 % cap to a 50 % cap**.  At the same time, the 2023 filing notes a **multi‑year agreement to sell up to €40 billion of eligible consumer installment receivables**, with **$5.5 billion of loans and interest sold in 2023**, illustrating that PayPal is supplementing its internal balance funding with **external capital‑market sources**.  This evolution signals a strategic shift toward **diversifying and externalizing the funding of its credit products**, reducing reliance solely on designated customer deposits and leveraging partnerships and asset‑sale programs to meet liquidity needs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and completeness. All quantitative data is correct: $3.8 billion (37%) in 2022 declining to $3.0 billion (39%) in 2023, the €40 billion agreement, and $5.5 billion sold in 2023. The answer correctly identifies the key insight that while absolute approved amounts decreased, the percentage utilization increased, indicating more efficient use of available balances. The LLM adds valuable context by noting the CSSF permission expansion from 35% to 50% cap, which provides additional regulatory context not explicitly in the ground truth but supports the narrative of strategic evolution. The multi-hop synthesis is sound: the answer correctly connects the decline in internal balance utilization with the simultaneous expansion of external funding mechanisms (asset sales program), demonstrating PayPal's strategic shift toward diversification. The reasoning about 'reducing reliance solely on designated customer deposits and leveraging partnerships' accurately captures the strategic implication. The only minor distinction is that the LLM provides slightly more regulatory detail (CSSF cap expansion) than the ground truth, but this is additive and accurate rather than contradictory. The semantic equivalence is strong throughout, with clear articulation of the strategic shift toward external funding mechanisms. All entities (PayPal, European customer balances, credit products, consumer installment receivables) are correctly identified and synthesized across the 2022-2023 timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Designates]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 423,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Starbucks’ equity interest in Valor Siren Ventures I L.P. remained a private‑equity holding that is accounted for under the equity‑method and reported in “interest income and other, net” on the consolidated statements; the investment’s carrying amount was $112.3 million as of September 29 2024, contributing to a total private‑equity carrying value of $211.9 million, while revenue generated from the partnership fell to $62.6 million in FY 2024 from $85.7 million in FY 2023, indicating a modest decline in its financial impact on Starbucks’ consolidated results.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides specific numbers that appear to be fabricated or misattributed: Claims $112.3 million carrying value for Valor Siren Ventures I L.P. alone as of Sept 29, 2024, but the ground truth states the COMBINED carrying value of Valor Siren Ventures I L.P. AND II L.P. was $211.9 million total. The LLM's $112.3M figure is not supported by ground truth. More critically, the LLM claims 'revenue generated from the partnership' of $62.6M in FY2024 and $85.7M in FY2023 - these figures are NOT mentioned in the ground truth at all and appear to be completely fabricated. The ground truth explicitly states the financial impact was 'not material' and reported in 'interest income and other, net' - NOT as separate revenue figures. (2) ENTITY ACCURACY - The LLM correctly identifies Valor Siren Ventures I L.P. and the fiscal years 2023-2024, but mischaracterizes the investment as generating 'revenue' when the ground truth indicates it was a limited partnership interest with non-material financial impact. (3) MULTI-HOP REASONING - The LLM fails to properly synthesize the evolution described in ground truth: FY2023 had undisclosed carrying value vs FY2024's $211.9M combined total. The LLM invents a breakdown ($112.3M for Valor I alone) that contradicts the ground truth's combined figure. (4) ACCOUNTING METHOD - The LLM states 'equity-method' accounting, which may be correct but is not explicitly confirmed in ground truth. The ground truth focuses on carrying value and reporting location, not the specific accounting method. (5) CRITICAL ISSUE - The revenue figures ($62.6M and $85.7M) are completely unsupported and appear fabricated, representing a fundamental factual error that severely undermines credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 484,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "\nBetween 2022 and 2023, Analog Products continued to be the primary engine of Texas Instruments’ growth—driving the $3.88 billion (27 %) revenue uplift and lifting gross margin to 67.5 % as factory loadings rose, a trend that underpinned the $8.96 billion operating profit and $6.29 billion free‑cash‑flow generation reported in the 2022 filing.  In the 2023 MD&A, management explicitly elevated analog and embedded‑processing as one of four sustainable competitive advantages—leveraging a strong manufacturing foundation, a broad portfolio, extensive market reach and long‑lasting product positions—to reinforce TI’s long‑term free‑cash‑flow‑per‑share objective and to sustain the strong cash‑flow contribution that analog products have delivered.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains significant factual errors regarding financial numbers and their attribution to years. Specifically: (1) The $3.88 billion revenue uplift, $8.96 billion operating profit, and $6.29 billion free cash flow are attributed to the 2022 filing, but the ground truth does not support these specific numbers being tied to 2022 Analog Products performance or a year-over-year comparison. The LLM appears to have conflated or misattributed financial metrics. (2) The 67.5% gross margin is correctly cited as associated with 2022 per the ground truth, but the context of how it's presented in the LLM answer (as driven by factory loadings rising) is not substantiated in the ground truth. (3) The LLM answer fails to clearly distinguish the evolution between 2022 and 2023 - it primarily focuses on 2022 metrics and then mentions 2023 MD&A positioning without clear comparative analysis. QUALITATIVE STRENGTHS: The LLM correctly identifies that Analog Products were framed within TI's four sustainable competitive advantages in 2023, correctly mentions the emphasis on long-term free cash flow per share, and appropriately notes the manufacturing foundation and supply chain control themes. However, the answer lacks the clear before-and-after comparison structure that the ground truth provides. MULTI-HOP REASONING: The synthesis is incomplete - the answer doesn't effectively bridge the 2022 strategic positioning with the 2023 reframing. The ground truth shows a shift from emphasizing manufacturing efficiency (2022) to emphasizing competitive advantages framework (2023), but the LLM doesn't clearly articulate this evolution. CONTEXTUAL RELEVANCE: The answer addresses the right topic and mentions relevant concepts, but the execution is flawed due to numerical inaccuracies and incomplete comparative analysis between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 512,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "\nChevron’s capital allocation to the Lower 48 segment has accelerated – the depreciation, depletion, amortization and impairment charge for that geography rose from **$4,854 million in 2022 to $5,729 million in 2023** (an increase of roughly **$875 million**), driving the consolidated DDD&A expense up from **$7,492 million to $8,284 million**; this shift, disclosed in both the 2022 and 2023 10‑K filings and highlighted in the accounting‑policy note that identifies the Lower 48 as a distinct operating segment, signals a strategic re‑focus of investment toward the Lower 48 region.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All key financial figures are correct: Lower 48 DDD&A increased from $4,854 million (2022) to $5,729 million (2023), representing an $875 million increase. The calculation of the increase is accurate. The LLM also correctly identifies the consolidated DDD&A figures ($7,492 million to $8,284 million), which adds valuable context showing the Lower 48's growing proportion of total DDD&A. The multi-hop reasoning is sound: the answer correctly synthesizes information about capital allocation strategy by connecting the increase in DDD&A charges to strategic investment focus. The LLM appropriately identifies this as evidence of accelerated capital allocation and strategic re-focus toward the Lower 48 region. The answer correctly references both 2022 and 2023 10-K filings and identifies the Lower 48 as a distinct operating segment. The only minor distinction from the ground truth is that the LLM provides additional context (consolidated figures and percentage context) that, while not explicitly in the ground truth statement, is factually accurate and enhances understanding. The semantic meaning is fully aligned with the original answer - both convey that capital allocation increased significantly in the Lower 48 from 2022 to 2023. No calculation errors or factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 379,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "\nVerizon has continued to embed FWA broadband as a core offering in both its Consumer and Business product portfolios, using its 5G/4G LTE network to deliver fixed‑wireless service as an alternative to traditional landline and fiber connections; the 2023 filing noted roughly 3.1 million FWA connections, and the 2024 update reiterates that FWA is provided to residential and business customers across most states, underscoring its role in extending broadband reach beyond the company’s fiber‑optic (Fios) and copper networks.  This shows a steady evolution in which FWA is positioned not only as a complementary service to the company’s wireline offerings but also as a strategic growth channel targeting underserved consumer and enterprise segments.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 3.1 million FWA connections figure from 2023, matching the ground truth exactly. (2) Accurately notes that FWA is offered through both 5G and LTE networks (referenced as '5G/4G LTE'). (3) Correctly identifies Consumer and Business customer segments as targets. (4) Properly positions FWA as an alternative to traditional landline/fiber connections. (5) Accurately describes the geographic scope ('across most states'). (6) Correctly identifies Fios and copper networks as complementary offerings. WEAKNESSES: (1) The LLM answer does not explicitly address the semantic shift from 'provides' (2023) to 'produces' (2024) that the ground truth identifies as indicating 'a more strategic and product-centric approach.' This is a notable omission of a key analytical insight about the evolution. (2) The LLM describes the positioning as 'steady evolution' rather than capturing the more nuanced shift in strategic positioning indicated by the verb change in the ground truth. (3) While the LLM mentions FWA as part of a broader portfolio, it doesn't explicitly reference IoT and advanced communication services as mentioned in the ground truth. QUANTITATIVE VERIFICATION: The 3.1 million FWA connections figure is correct and properly cited. No calculations are required for this question, so quantitative accuracy is high. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2023 and 2024 filings, comparing positioning and customer segments. However, it misses the linguistic/strategic indicator (provides vs. produces) that represents a key evolution marker. SEMANTIC EQUIVALENCE: The core message about FWA's role as a complementary service and growth channel is conveyed, though with less analytical depth regarding the strategic shift than the ground truth provides.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Provides]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 498,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "\nFrom 2022 through 2024 Emerson moved from a pure partnership with AspenTech—described in 2022 as a provider of asset‑optimization software and integrated solutions—to a controlling ownership position, completing the $6 bn cash‑and‑stock acquisition of Heritage AspenTech and ending up with a 55 % fully‑diluted stake in AspenTech by the end of 2024; this evolution is reflected in the KG link EMR → AspenTech ← EMR and the accompanying “Partners_With” relationship. The acquisition added Test & Measurement assets and intangible amortization, which lifted Emerson’s gross margin by 1.8 percentage points in 2024 (and contributed a 0.6‑point boost in 2023) while reshaping its equity structure to include a majority equity investment in AspenTech and the associated balance‑sheet effects of the $6 bn transaction, as well as the later $1.5 bn sale of a 40 % non‑controlling interest in Copeland that further altered its portfolio composition.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM claims a 1.8 percentage point gross margin improvement in 2024, but the ground truth only mentions 0.6 points in 2023 and does not specify a 1.8-point figure for 2024. This is a significant factual error. The LLM also introduces unsupported numbers: $6 billion acquisition price and $1.5 billion Copeland sale are not mentioned in the ground truth. (2) INCOMPLETE/INACCURATE SYNTHESIS - The ground truth clearly states the 55% stake was acquired 'as part of a strategic transaction that created New AspenTech,' but the LLM conflates this with 'Heritage AspenTech' and adds extraneous details about Test & Measurement assets and Copeland that are not in the ground truth. (3) RELATIONSHIP EVOLUTION - Both answers correctly identify the progression from partnership to 55% ownership, but the LLM adds unsupported transaction details. (4) GROSS MARGIN IMPACT - Ground truth: 0.6 points in 2023, further influence in 2024 (unspecified). LLM: 0.6 points in 2023 (correct) but then claims 1.8 points in 2024 (unsupported and contradicts ground truth's vague 'further influence'). (5) EQUITY STRUCTURE - Both mention impact on equity structure, but LLM adds specific details about Copeland sale that are not in the ground truth. (6) MULTI-HOP REASONING - The LLM attempts to synthesize multiple data points but introduces fabricated numbers and conflates different transactions. The core relationship evolution is captured but with significant factual errors in financial metrics and transaction details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 428,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "\nFrom 2022 to 2023 the tie‑up shifted from the historic 1998 **Guarantee Agreement** (Exhibit *10(uu) in the 2022 filing) to a series of new indentures and covenant amendments (Exhibits *4(tt)‑*4(ggg) in the 2023 filing) that saw **FPL Group Capital Inc** issue multiple series of junior subordinated debentures, with **NextEra Energy, Inc.** (the former FPL Group, Inc.) acting as guarantor and providing replacement‑capital covenants; the 2022 **Purchase‑Contract Agreement** (Exhibit *4(hhh)) further linked NEE to the financing by naming it the purchase‑contract agent for these securities.  This evolution reflects a deepening of NEE’s credit‑guarantee and capital‑structure involvement—FPL Group Capital Inc’s debt profile expanded and was continuously backed by NEE’s guarantee and covenant amendments—demonstrating the reciprocal **Guarantees** and **Has_Stake_In** relationship captured in the KG pattern across both filings.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution from a 1998 Guarantee Agreement to a more complex capital structure involving junior subordinated debentures. (2) Correctly names NEE (NextEra Energy, Inc.) as the former FPL Group, Inc. (3) Correctly identifies FPL Group Capital Inc. as the issuer of the debentures. (4) Appropriately references the 2022 and 2023 filings and exhibit numbers. (5) Correctly notes the shift from simple guarantee to long-term capital financing. WEAKNESSES: (1) The LLM answer introduces information about FPL Group Capital Inc. ISSUING debentures, but the ground truth states NEE issued the debentures TO FPL Group Capital Inc. This is a critical directional error in the capital flow. The ground truth clearly states 'NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc.' while the LLM reverses this relationship by stating 'FPL Group Capital Inc issue multiple series of junior subordinated debentures.' (2) The LLM adds details about Purchase-Contract Agreements and covenant amendments that, while potentially accurate, are not mentioned in the ground truth and may represent over-specification or confusion about the actual structure. (3) The LLM's reference to 'reciprocal Guarantees' and 'Has_Stake_In' relationships is vague and doesn't clearly articulate the specific nature of the obligation shift. (4) Missing specific series letters (B, C, L, M, N, O, P) and maturity date ranges (2057-2082) that are explicitly mentioned in the ground truth. (5) The explanation of NEE as 'guarantor' is mentioned but the primary relationship (NEE issuing debentures to FPL Group Capital Inc.) is fundamentally mischaracterized. MULTI-HOP REASONING: The LLM attempts to synthesize across multiple exhibits and years but makes a critical error in the direction of the capital flow, which undermines the accuracy of the multi-hop synthesis. The core relationship evolution is partially captured but with a significant directional error that changes the meaning of the financial relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 555,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "\nMedtronic (MDT) – the organization that **produces** and **introduces** InterStim II – has continued to market the device as a **recharge‑free** option within its InterStim family, positioning it alongside the rechargeable InterStim X and InterStim Micro systems for the treatment of overactive bladder, urinary retention and fecal incontinence; the 2024 filing notes **continued acceptance and growth of InterStim II** (and the other Pelvic Health neurostimulators) as part of the broader Pelvic Health therapy portfolio, underscoring its expanding market share relative to the other InterStim devices and to the overall specialty‑therapies business.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key entities (Medtronic, InterStim II, InterStim X, InterStim Micro) and accurate characterization of InterStim II as a recharge-free option. The answer correctly identifies the three therapeutic indications (overactive bladder, urinary retention, and fecal incontinence) and accurately reflects the 2024 positioning emphasizing continued acceptance and growth. The multi-hop synthesis across 2022-2024 is sound, correctly identifying the evolution toward device-specific attributes (recharge-free status) and integration into a mature product portfolio. However, there are minor issues: (1) The LLM introduces the phrase 'expanding market share relative to the other InterStim devices' which is not explicitly stated in the ground truth and represents an inference not directly supported by the source material. (2) The answer could have been more explicit about the 2022 baseline positioning before describing the 2024 evolution, though the implicit comparison is reasonable. (3) The phrasing 'produces and introduces' is slightly awkward and the answer could have been more concise. The core factual content is accurate - the recharge-free positioning, the product portfolio context, the therapeutic indications, and the emphasis on continued acceptance and growth are all correctly captured. No numerical errors or calculation issues are present. The answer appropriately addresses the multi-part question about positioning evolution and market acceptance across the specified time period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 433,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "\nIn 2022 the Supplemental Facility gave Simon Property Group a $3.5 bn revolving capacity that could be raised to $4.5 bn and matured on 31 January 2026 with a one‑year extension to 2027, carrying variable SOFR‑based rates plus a rating‑dependent margin (Chunk 1). From 2022 through 2024 SPG actively managed that line by entering interest‑rate swaps that fixed €750 m of Euro‑borrowings at an all‑in 3.81 % rate and repaying it in November 2023, then refinancing the facility through senior note issuances—including €750 m exchangeable bonds in 2023 and $1 bn of 4.75 % notes in September 2024—while redeeming maturing floating‑rate notes, thereby reducing outstanding borrowings and extending the effective use of the expanded capacity into the optional 2027 maturity (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core facts: (1) 2022 Supplemental Facility capacity of $3.5B expandable to $4.5B with January 31, 2026 maturity; (2) SOFR-based variable rates with rating-dependent margin; (3) €750M Euro borrowings fixed at 3.81% via interest rate swaps; (4) November 2023 repayment following exchangeable bond issuance; (5) overall narrative of evolution from passive availability to active management. The multi-hop synthesis across years and strategic actions is sound.\n\nWEAKNESSES AND ERRORS: (1) MATURITY DATE DISCREPANCY: The LLM states the facility matured on \"31 January 2026 with a one-year extension to 2027.\" The ground truth only mentions January 31, 2026 maturity with no mention of a 2027 extension option. This appears to be an unsupported addition. (2) EXTRANEOUS INFORMATION: The LLM introduces details about \"$1 bn of 4.75% notes in September 2024\" and \"redeeming maturing floating-rate notes\" that are not present in the ground truth answer. While these may be factually accurate from the source documents, they go beyond what the ground truth establishes and could represent hallucination or over-inference. (3) TIMELINE CLARITY: The ground truth clearly states the €750M was \"repaid on November 17, 2023\" while the LLM says \"repaying it in November 2023\"—this is semantically equivalent but less precise. (4) CHARACTERIZATION: The LLM describes the 2027 maturity as \"optional\" and discusses \"extending the effective use of the expanded capacity into the optional 2027 maturity,\" but the ground truth makes no mention of this option.\n\nQUANTITATIVE VERIFICATION: All core numbers match ($3.5B, $4.5B, €750M, 3.81%, January 31, 2026). However, the introduction of unsupported dates (2027 extension) and additional financial figures ($1B notes, 4.75%) that aren't in the ground truth creates uncertainty about accuracy.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2022-2024, connecting facility terms, borrowing actions, interest rate management, and refinancing activities. The logical flow from passive availability to active management is well-articulated.\n\nCONCERN: The addition of information not present in the ground truth (2027 extension option, September 2024 note issuance, redemption activities) suggests either: (a) the LLM is drawing from source documents beyond what was used to create the ground truth, or (b) the LLM is hallucinating details. Either way, this represents a deviation from the established ground truth that reduces confidence in the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 686,
        "total_tokens": 2069
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "\nVerizon’s 2023 device‑payment offering let customers spread handset costs over a 36‑month, non‑interest installment period and, after ending new fixed‑term subsidized consumer contracts, it still provided subsidized plans only to Business users (as noted in the 2023 filing). By 2024 the same 36‑month installment structure remained, but Verizon introduced promotional billing‑credit offsets and trade‑in upgrade guarantees that are booked as a liability and reduce equipment revenue, while treating the financing component as immaterial and thus not separately discounted (per the 2024 disclosure). Overall, the evolution shifts from a straightforward subsidized‑plan model to a credit‑driven payment structure that ties promotional incentives to ongoing service and includes a guarantee liability for upgrade rights, while continuing to serve both consumer and business segments through the same Device Payment Plans product offered by VZ.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) FACTUAL ERRORS ON 36-MONTH TERM: The LLM claims the 36-month installment structure existed in 2023, but the ground truth explicitly states '2023...with no mention of structured promotional incentives or trade-in rights' and only describes 2024 as having 'a non-interest-bearing installment note typically repaid over a 36-month term.' The LLM incorrectly backdates the 36-month formalization to 2023. (2) UNSUPPORTED CLAIMS: The LLM introduces specific details not in the ground truth: 'promotional billing-credit offsets,' 'upgrade guarantees that are booked as a liability,' 'financing component as immaterial,' and 'Business users' subsidized plans.' These details either contradict or go beyond what the ground truth establishes. The ground truth makes no mention of business vs. consumer segment differentiation in this context. (3) INCOMPLETE CORE EVOLUTION: The ground truth emphasizes a clear shift from 'general financing mechanism' (2023) to 'structured and incentive-driven model' (2024) with specific mention of 'upgrade after paying specified portion + trade-in.' The LLM muddies this distinction by claiming both years had the same structure. (4) ACCOUNTING TREATMENT CLAIMS: The LLM's discussion of liability accounting and revenue reduction is not substantiated in the ground truth provided. (5) POSITIVE ELEMENTS: The LLM correctly identifies the non-interest-bearing nature, the 36-month term (though misdated), trade-in upgrade features, and the general shift toward promotional incentives. The answer demonstrates understanding of the evolution concept but introduces unsupported specificity and factual errors about timing. The multi-hop synthesis is attempted but compromised by factual inaccuracies about when features were introduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 485,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "\nBetween 2023 and 2024 Coca‑Cola’s legal stance toward Aqua‑Chem has not shifted – the company continues to assert, under the 1981 stock‑sale and 1983 settlement agreements (and the $400 million insurance program it purchased while it owned Aqua‑Chem), that it bears **no liability** for Aqua‑Chem’s asbestos‑related claims.  Both the 2023 and 2024 10‑K filings reiterate that the Wisconsin case was voluntarily dismissed and the Georgia case remains stayed, and they reaffirm that any pending litigation will not generate material liability for KO, even though the former subsidiary still faces roughly 15,000 active asbestos claims.  In short, KO’s position on liability remains unchanged, relying on the prior agreements and insurance coverage to shield the parent from Aqua‑Chem’s asbestos obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer fundamentally contradicts the ground truth on the core question. The ground truth explicitly states there was a SHIFT in Coca-Cola's stance between 2023 and 2024 - from 'outright denial of liability' to 'a more nuanced stance centered on insurance coverage and shared responsibility among insurers.' The LLM answer claims the opposite: 'Coca-Cola's legal stance toward Aqua-Chem has not shifted' and 'KO's position on liability remains unchanged.' This is a critical factual error that directly contradicts the ground truth's main finding. Regarding specific claims: (1) The LLM correctly identifies the 1981 stock-sale and 1983 settlement agreements as relevant legal documents. (2) The LLM mentions a '$400 million insurance program' - the ground truth does not specify this dollar amount, making this unverifiable but not necessarily incorrect. (3) The LLM correctly notes the Wisconsin case was voluntarily dismissed and Georgia case remains stayed. (4) The LLM mentions '15,000 active asbestos claims' - this specific number is not in the ground truth, making it unverifiable. (5) The LLM correctly identifies that both years' filings address the litigation. However, the fundamental error is the characterization of whether a shift occurred. The ground truth clearly indicates a shift in 'emphasis' and 'stance' - from denial to a more detailed focus on insurance coverage and shared responsibility. The LLM's assertion that there was 'no shift' and the position 'remains unchanged' directly contradicts this. The LLM appears to have misread or misunderstood the evolution described in the ground truth, focusing instead on the continuity of the no-liability position while missing the shift in how that position is being articulated and emphasized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sold]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 481,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "\nIntel’s non‑U.S. tax credits are explicitly noted in its accounting policy as a factor that **reduces** the amount of long‑term income‑tax payable—​the 2021 long‑term liability of $4.3 billion (which includes a transition‑tax component) was lowered by the credit, and by the end of 2024 the long‑term payable had fallen to $1.6 billion (down from $2.6 billion in 2023), a decline that directly reflects the credit’s offsetting effect.  This reduction shows that Intel is deliberately leveraging foreign‑tax credits to shrink its U.S. tax burden, indicating a strategic emphasis on international tax planning that minimizes overall tax liabilities through the use of non‑U.S. credit mechanisms.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) YEAR MISMATCH - LLM states '2021 long-term liability of $4.3 billion' but ground truth clearly indicates this was the 2022 figure. The LLM conflates 2021 with 2022, which is a fundamental factual error in a question specifically asking about 2024 vs 2022 comparison. (2) INCOMPLETE COMPARISON - Ground truth compares 2022 ($4.3B) to 2024 ($1.6B), showing a $2.7B decrease. LLM mentions 2023 ($2.6B) and 2024 ($1.6B) comparison instead, which is a different comparison than what was asked. The question specifically asks about 2024 compared to 2022, not 2023 to 2024. (3) MISSING KEY DATA POINT - LLM does not clearly establish the 2022 baseline ($4.3B) as the primary comparison point requested in the question. (4) REASONING QUALITY - While the LLM correctly identifies that non-US tax credits reduce liabilities and demonstrates strategic tax planning, it fails to properly anchor the analysis to the correct years. The multi-hop synthesis is partially sound (connecting credits to liability reduction to strategy), but the factual foundation is compromised. (5) POSITIVE ASPECTS - The LLM correctly identifies that non-US tax credits reduce long-term income tax payable, correctly notes the 2024 figure of $1.6B, and appropriately concludes this reflects strategic international tax planning. However, these correct elements cannot overcome the year-dating error and incomplete comparison framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Positively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 397,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "\nBetween 2022 and 2024 MetLife’s pension‑risk‑transfer portfolio (a key element of its Retirement & Income Solutions) continued to be driven by interest‑rate sensitivity— the 2022 filing notes that in a declining‑rate scenario gross‑margin compression arises from minimum crediting‑rate guarantees on retained assets, while a rising‑rate environment mitigates that compression through higher‑yield reinvestments and derivative hedges, but the product’s risk profile remains tied to the asset‑liability mix described in the 2022 filing; concurrently, the 2024 regulatory discussion reveals that new pension‑plan funding rules, heightened New York SCL testing requirements, and broader regulatory scrutiny can delay or deter sponsors from terminating plans or executing risk‑transfer transactions, thereby reshaping the mix and increasing the regulatory exposure of MetLife’s pension‑risk‑transfer business.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the evolution of pension risk transfers within Retirement & Income Solutions between 2022-2024; (2) Accurately captures the interest rate sensitivity mechanisms in 2022 (declining-rate scenarios causing margin compression via minimum crediting-rate guarantees, rising-rate scenarios providing mitigation); (3) Properly synthesizes the regulatory evolution, specifically mentioning pension-plan funding rules and New York SCL testing requirements that delay/deter plan terminations and risk transfers; (4) Correctly identifies the strategic shift toward non-guaranteed funding products as a consequence of regulatory changes; (5) Multi-hop reasoning is sound—connecting interest rate dynamics in 2022 to regulatory impacts in 2024 and their combined effect on business mix. MINOR CONSIDERATIONS: (1) The LLM answer is more detailed and specific than the ground truth (e.g., explicitly naming 'New York SCL testing requirements'), which adds value but goes slightly beyond the ground truth scope; (2) The ground truth emphasizes 'potential for a shift' while the LLM describes the reshaping more definitively, though this is a semantic nuance rather than factual error; (3) No quantitative metrics (dollar amounts, percentages) are present in either answer, so quantitative accuracy is assessed on the correctness of qualitative financial concepts rather than specific numbers. VERIFICATION: All key facts check out—interest rate sensitivity mechanisms are correctly described, regulatory influence is properly identified, and the temporal evolution (2022 to 2024) is accurately maintained. The answer successfully addresses all parts of the multi-part question regarding interest rate sensitivity and regulatory influence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 502,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "\nMedtronic has shifted the InterStim Micro from a niche, battery‑operated urology device in 2022 to a central, **recharge‑free** pillar of its Pelvic‑Health portfolio by 2024, expanding its indications (overactive bladder, urinary retention, fecal incontinence) and embedding it in the broader InterStim X/II platform and the AiBLE spinal‑ecosystem for AI‑driven surgical planning; this evolution is reflected in the double‑digit sales growth of Specialty Therapies and the 2024 FDA approval of the Inceptiv closed‑loop SCS, underscoring a strategic focus on integrated, next‑generation neurostimulation solutions.  \n\nThe KG relationship — MDT ↔ InterStim Micro — highlights the mutual production/ introduction link that underpins this co‑development and market‑positioning strategy across the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamental factual inaccuracies that directly contradict the ground truth. (1) MAJOR FACTUAL ERROR - Recharge Characteristic: The LLM claims InterStim Micro evolved to be 'recharge-free' by 2024, but the ground truth explicitly states the opposite: by 2024, Medtronic 'specifically highlighted the InterStim Micro as a rechargeable neurostimulator' while 'distinguishing it from the recharge-free InterStim X and InterStim II models.' This is a critical mischaracterization that inverts the actual product positioning. (2) UNSUPPORTED CLAIMS - The LLM introduces multiple claims not present in the ground truth: 'AiBLE spinal-ecosystem for AI-driven surgical planning,' 'double-digit sales growth of Specialty Therapies,' '2024 FDA approval of the Inceptiv closed-loop SCS.' These appear to be hallucinated details not grounded in the provided knowledge graph. (3) INCOMPLETE SYNTHESIS - While the ground truth clearly describes a shift from general positioning (2022) to targeted differentiation emphasizing the rechargeable nature (2024), the LLM misses this core evolution entirely and instead fabricates a different narrative. (4) ENTITY CONFUSION - The LLM conflates InterStim Micro with InterStim X/II when the ground truth explicitly distinguishes them as separate products with different recharge characteristics. (5) REASONING FAILURE - The multi-hop synthesis required comparing 2022 vs 2024 positioning; the LLM failed to correctly identify the key differentiator (rechargeable vs recharge-free) that defines the strategic evolution. The answer demonstrates poor factual accuracy on the primary claim and introduces unsupported information that undermines credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 469,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "\nSimon Property Group first accessed its Supplemental Facility in 2021, reaching a peak outstanding balance of **$2.1 billion** (with a weighted‑average balance of **$519.9 million**) as disclosed in the 2022 10‑K (Chunk 1).  The facility—originally a $3.5 billion commitment extendable to $4.5 billion and maturing in 2026—was used to fund various debt‑repayment and acquisition activities, and its borrowing rates were tied to SOFR plus a spread (≈72.5 bps) with a 0.100‑0.300 % facility fee.  \n\nBy the end of 2024, the company’s use of that facility had sharply contracted: the weighted‑average outstanding balance fell to **$31.1 million**, letters of credit dropped to **$8.6 million**, and the facility was essentially unwound through targeted repayments—most notably the **€750 million ($815 million) bond issuance in November 2023 that repaid the €750 million borrowed under the Supplemental Facility**, the redemption of floating‑rate notes in March 2023, and the subsequent retirements of $600 million, $1.0 billion and $900 million senior notes in 2023‑2024 (Chunk 2).  These actions, together with the termination of €750 million interest‑rate swaps tied to the facility, illustrate a clear evolution from substantial borrowing in 2021‑2022 to near‑zero reliance on the Supplemental Facility by 2024, even though the underlying commitment remains available (with an extension option to 2027) but is now only used for modest liquidity needs such as letters of credit.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERROR IN 2024 FIGURE: The LLM states the weighted-average outstanding balance in 2024 was $31.1 million, but the ground truth clearly states it was $311.1 million. This is a significant numerical error (off by a factor of 10) that undermines the core comparison between 2022 and 2024. CORRECT ELEMENTS: (1) 2022 weighted-average balance of $519.9 million is correct; (2) 2022 maximum aggregate outstanding balance of $2.1 billion is correct; (3) €750 million ($815.4 million equivalent) repayment on November 17, 2023 is correct (LLM says $815 million, which is acceptable rounding); (4) The overall narrative of debt reduction and refinancing is correct; (5) The characterization of the facility's evolution from substantial borrowing to near-zero reliance is directionally correct but undermined by the wrong 2024 number. MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple years and connects the repayment actions (bond issuance, note redemptions, swap terminations) to the facility's reduced usage. However, the fundamental 2024 figure error breaks the core comparison that the question asks for. ADDITIONAL ISSUES: The LLM provides extensive contextual detail about facility terms (SOFR spreads, maturity dates, extension options) that, while potentially accurate, goes beyond what the ground truth specifies and may introduce unverified information. The answer is well-structured and demonstrates good reasoning, but the $31.1M vs $311.1M error is a critical factual mistake that significantly impacts the correctness of the answer's core claim about the 2022-2024 evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Extends]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1536,
        "completion_tokens": 444,
        "total_tokens": 1980
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "\nCOP operates in Lower 48 and that region discloses its depreciation, depletion, amortization and impairment (DDAI) expenses, linking the two entities in the knowledge graph. The DDAI charge for Lower 48 rose from **$4,854 million in 2022 to $5,729 million in 2023** (Chunk 2), a $875 million increase that signals a marked rise in investment activity. This uptick follows the earlier growth in productive wells shown for the play (35 – 87 wells in 2019‑2021) and is reflected in the higher total consolidated operations figure for the region (371 in 2021 vs. 159 in 2020) recorded in Chunk 1.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core financial figures from the ground truth: $4,854 million in 2022 and $5,729 million in 2023 for COP's Lower 48 DDAI expenses. The calculation of the $875 million increase is accurate. The answer properly addresses the main question about how investment activity evolved between these two years.\n\nWEAKNESSES: (1) The LLM introduces extraneous information about productive wells (35-87 wells in 2019-2021) and consolidated operations figures (371 in 2021 vs. 159 in 2020) that are not part of the ground truth answer and appear to be from different contexts or potentially fabricated details. These references to 'Chunk 1' and specific well counts lack verification against the original answer. (2) The reasoning becomes speculative when connecting well growth to DDAI increases without clear causal evidence from the source material. (3) The answer conflates different metrics (wells, consolidated operations) with DDAI expenses in a way that suggests multi-hop synthesis but may be introducing unsupported connections.\n\nQUANTITATIVE VERIFICATION: The primary numbers are correct ($4,854M → $5,729M, $875M increase). However, the secondary figures about wells and operations cannot be verified against the ground truth and may represent hallucination or misattribution.\n\nMULTI-HOP REASONING: While the answer attempts to synthesize information across multiple data points, the inclusion of unverified well and operations data weakens the credibility of the synthesis. The core multi-hop connection (COP → Lower 48 → DDAI expenses) is sound, but the expansion beyond this is problematic.\n\nCONCLUSION: The answer correctly answers the primary question but undermines itself by introducing unverified supporting details that appear to be either fabricated or misattributed to the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 501,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "\nFrom 2023 to 2024 Verizon sharpened the corporate‑networking narrative in its Business and Enterprise/Public‑Sector segments.  In the 2023 filing the Business Group was described as offering “corporate networking solutions, security and managed network services” together with private‑networking, private‑cloud connectivity and SD‑WAN services that generated about $15.1 billion (≈ 50 % of Business revenue) in Enterprise/Public‑Sector sales (Chunk 1).  By 2024 the description expands to “corporate networking solutions, security and managed network services, **advanced communication services** and IoT‑focused products,” and emphasizes delivery to “businesses, public‑sector customers **and wireless and wireline carriers across the U.S. and a subset … around the world**” (Chunk 2).  Thus the evolution is a shift from a primarily domestic, connectivity‑centric portfolio to a broader, globally‑oriented suite that couples networking with advanced communications and IoT, while keeping the Business segment as the primary vehicle for these solutions.",
      "correctness_score": 4,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: (1) FACTUAL CONTRADICTION - The LLM answer directly contradicts the ground truth on the core finding. Ground truth states the 2024 description became 'more streamlined' and 'without specifying the same level of detail,' but the LLM claims it 'expands' to include 'advanced communication services and IoT-focused products.' This is a fundamental mischaracterization of the evolution. (2) UNSUPPORTED CLAIMS - The LLM introduces specific 2024 service descriptions ('advanced communication services,' 'IoT-focused products,' global expansion language) that are not present in the ground truth answer. These appear to be fabricated details not verified against the actual filings. (3) QUANTITATIVE ACCURACY - The $15.1 billion figure and 50% revenue proportion are correctly cited and match ground truth. (4) MULTI-HOP REASONING FAILURE - While the LLM attempts to synthesize 2023 vs 2024 comparisons, it fundamentally misinterprets the direction of change. Ground truth indicates simplification/consolidation; LLM indicates expansion/enhancement. (5) SEMANTIC MISALIGNMENT - The conclusion that Verizon shifted 'from a primarily domestic, connectivity-centric portfolio to a broader, globally-oriented suite' directly opposes the ground truth finding of a shift toward 'more generalized presentation' and 'simplification of messaging.' The LLM appears to have inverted the actual strategic direction. CORRECT ELEMENTS: The 2023 revenue figures and segment breakdown are accurate. The identification of corporate networking solutions as a key offering is correct. However, these correct elements are embedded within a fundamentally incorrect narrative about the direction and nature of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Provides]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 467,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "\nMetLife continues to value its FVO securities as Level 3 instruments whose fair‑value is directly tied to U.S.‑dollar movements; in 2022 a 10 % dollar appreciation was shown to reduce the estimated fair value of FVO securities by about $54 million (Chunk 1). By 2024 the methodology broadened to reflect that fair‑value changes are driven by the company’s long U.S.‑dollar net‑asset position and are inversely affected for short dollar exposures, while also incorporating additional actuarial inputs (mortality, lapse, utilization, withdrawal rates, non‑performance spreads) that remain sensitive to dollar appreciation (Chunk 2). This evolution shows MetLife’s stake in FVO securities remains subject to fair‑value volatility linked to U.S.‑dollar appreciation, now framed within a more comprehensive set of assumptions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively addresses the multi-hop question about MetLife's FVO securities valuation evolution from 2022 to 2024. STRENGTHS: (1) Quantitative accuracy is excellent - correctly cites the $54 million fair value decrease from 10% U.S. dollar appreciation in 2022, and accurately identifies 2022 and 2024 as the comparison years. (2) Multi-hop synthesis is sound - the answer successfully synthesizes information across two time periods and explains the evolution from a simpler to more complex valuation methodology. (3) Entity identification is correct - properly identifies MetLife, FVO securities, and Level 3 instruments. (4) The characterization of the evolution is accurate: from a 'static sensitivity model' (2022) to a 'more complex, duration- and currency-dependent approach' (2024) aligns with the ground truth. (5) The answer appropriately emphasizes the continued sensitivity to U.S. dollar appreciation across both periods. MINOR WEAKNESSES: (1) The LLM answer does not explicitly mention the 2022 fair value figure of $1.6 billion that appears in the ground truth, though this omission is relatively minor since the question focuses on 'evolution' and sensitivity rather than absolute values. (2) The phrase 'long U.S. dollar net-asset position' and 'short dollar exposures' adds specificity not explicitly stated in the ground truth, though this appears to be reasonable inference from the broader sensitivity framework mentioned. (3) The ground truth notes 'no direct fair value figure for FVO securities is provided' in 2024, which the LLM answer doesn't explicitly state, though it does acknowledge the shift to a broader framework. Overall, the answer correctly synthesizes the multi-hop information and maintains factual accuracy on all key metrics and dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 497,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "\nNextEra Energy’s power‑marketing platform (Power Marketing) continues to be the vehicle through which NEE conducts full‑energy and capacity services and power‑fuel trading, with all trading contracts accounted for at fair value and gains recorded net.  The 2023 filing shows that NEER’s net income attributable to these activities surged from $285 million in 2022 to $3,558 million in 2023—an increase of $3.27 billion—reflecting a substantial expansion of trading volume, favorable commodity‑price movements and the optimization of generation and fuel assets, thereby underscoring a marked evolution and stronger financial performance of NEE’s power‑marketing engagement between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All financial figures are precisely correct - the net income figures of $285 million (2022) and $3,558 million (2023) match exactly, and the calculated increase of $3.27 billion is mathematically accurate ($3,558M - $285M = $3,273M, rounded to $3.27B). Years and time periods are correctly identified. QUALITATIVE ACCURACY (9/10): The answer correctly identifies NextEra Energy and its subsidiary NEER, accurately describes the power marketing and trading activities (full energy and capacity services, load-following, ancillary services, fuel optimization), and properly synthesizes the multi-hop information showing evolution between 2022-2023. The reasoning about expansion, favorable commodity movements, and asset optimization is sound and well-supported. Minor note: The LLM adds some interpretive details about 'trading volume' and 'commodity-price movements' that enhance explanation but aren't explicitly stated in the ground truth, though these are reasonable inferences from the financial performance data. CONTEXTUAL RELEVANCE (10/10): The answer directly and comprehensively addresses all aspects of the question - engagement evolution, energy trading services, and associated financial performance. ENTITY ACCURACY: All entities correctly identified (NextEra Energy/NEE, NEER subsidiary, 2022-2023 period). The answer maintains semantic equivalence with the ground truth while providing slightly more operational context about how the power marketing platform functions. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Engages]-> PRODUCT <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 448,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "\nBetween 2023 and 2024 Coca‑Cola’s equity stake in Coca‑Cola FEMSA rose to **28 % of the bottler’s outstanding shares** (as disclosed in the 2024 10‑K), making FEMSA one of the Company’s largest equity‑method investments and prompting a proportionally larger share of FEMSA’s net income—and of its other comprehensive‑income items—to flow into Coca‑Cola’s consolidated equity‑income line.  This deeper ownership amplifies the impact of FEMSA’s operating performance on Coca‑Cola’s earnings, but it also ties the Company’s equity income to FEMSA’s credit profile; rating agencies monitor FEMSA’s financials alongside Coca‑Cola’s own debt metrics, and any downgrade or stress in FEMSA’s credit could raise the bottler’s interest expense and consequently **reduce the equity income** that Coca‑Cola records.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive understanding of the financial relationship evolution. STRENGTHS: (1) Correctly identifies the 28% ownership stake in Coca-Cola FEMSA as of 2024, matching the ground truth; (2) Accurately describes the equity method accounting treatment; (3) Properly explains the multi-hop connection between FEMSA's financial performance and Coca-Cola's equity income line; (4) Correctly identifies the credit rating/financial dependency implications; (5) Provides sound reasoning about how FEMSA's operating performance and credit profile impact Coca-Cola's earnings. MINOR WEAKNESSES: (1) The answer emphasizes the 2024 stake (28%) but doesn't explicitly contrast it with the 2023 relationship as clearly as the ground truth does - the ground truth specifically notes a shift 'from a dependency-based relationship to a direct ownership stake,' while the LLM answer focuses more on the 2024 state and implications rather than the evolution between years; (2) The phrase 'between 2023 and 2024 Coca-Cola's equity stake...rose to 28%' could be interpreted as suggesting the stake increased during this period, though the LLM likely means it was 28% in 2024 (the ground truth doesn't specify if it was lower in 2023, only that the relationship was different). QUANTITATIVE VERIFICATION: The 28% figure is correct and matches ground truth exactly. MULTI-HOP REASONING: The answer successfully synthesizes information about ownership percentage, accounting method, equity income impact, and credit rating implications - all correctly connected. SEMANTIC EQUIVALENCE: The answer conveys the same core information as the ground truth, with slightly different emphasis and organization but equivalent meaning regarding the strategic evolution and financial implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 493,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "\nThe KG relationship COP‑Operates_In‑Lower 48 links the company’s disclosures to the Lower 48, where production data from the 2022 filing show continued strong output—about 447 k barrels of crude oil and 1.34 bn Mcf of natural gas per day (the latest 2021 figures disclosed) and a Delaware Basin area of 27 million—highlighting an enduring operational focus on the region. Depreciation, depletion and amortization for the Lower 48 rose from $4,854 million in 2022 to $5,729 million in 2023, indicating a marked increase in financial investment, a trend reflected in the consolidated DD&A growth from $7,492 million to $8,284 million reported in the 2023 filing. Together, these figures demonstrate that between 2022 and 2023 ConocoPhillips shifted capital and operational emphasis toward the Lower 48, expanding both production metrics and depreciation spending in that basin.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The depreciation, depletion, amortization figures are accurate: $4,854 million in 2022 and $5,729 million in 2023 for Lower 48. (2) The crude oil production figure of 447 thousand barrels daily is correct. (3) The natural gas production of 1,340 million cubic feet daily (expressed as 1.34 bn Mcf) is correct. (4) The overall narrative about increased financial investment in Lower 48 is sound. (5) The consolidated DD&A figures ($7,492 million to $8,284 million) appear accurate and provide useful context. PROBLEMATIC ELEMENTS: (1) The LLM states these are 'the latest 2021 figures disclosed' when discussing 2022 filing data - this is confusing and potentially inaccurate. The production volumes should be from 2022 data, not 2021. (2) The mention of 'Delaware Basin area of 27 million' is unexplained and unclear - it's unclear what unit this refers to (acres? square miles?) and whether this is relevant to the question. (3) The statement 'expanding both production metrics' is misleading - the ground truth indicates 'stable or moderate production levels' not expansion. The LLM appears to conflate increased depreciation spending with production expansion, which are different concepts. MULTI-HOP REASONING: The LLM correctly synthesizes information across production volumes and depreciation expenses to show the evolution of financial focus. However, the reasoning about 'expanding production metrics' contradicts the ground truth's characterization of stable production. QUANTITATIVE ACCURACY: While the key financial numbers are correct, the temporal attribution (2021 vs 2022) and the interpretation of production trends contain errors. The Delaware Basin figure lacks context and clarity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 485,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "\nVerizon’s 4G LTE network has moved from being a background conduit for consumer and business wireless services—and a key platform for fixed‑wireless access (FWA) broadband in 2023—to a central, monetizable engine of the company’s growth strategy in 2024.  The 2023 filing (Chunk 1) describes the LTE layer as part of Verizon’s extensive wireless network that supports both Consumer and Business segments, delivering FWA and wholesale services, while the 2024 discussion (Chunk 2) highlights that the LTE network, together with C‑Band spectrum, fiber and advanced IT systems, is now a core pillar for “enhancing and driving the monetization of our networks, platforms and solutions” and for retaining and growing the high‑quality customer base.  In KG terms, VZ → Produces → 4G LTE Network, and 4G LTE Network → Depends On → VZ, reflecting that the network’s evolution is tightly coupled to Verizon’s capital investments and strategic initiatives across both segments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the core evolution of Verizon's 4G LTE network from 2023 to 2024, capturing the shift from foundational/service delivery role to strategic asset within integrated ecosystem. (2) Accurately references FWA (fixed wireless access) broadband as a key 2023 use case, matching ground truth. (3) Properly synthesizes multi-hop information by connecting 4G LTE to C-Band spectrum, millimeter wave, and fiber infrastructure in 2024, demonstrating correct multi-source synthesis. (4) Correctly identifies the strategic positioning shift toward monetization and growth initiatives. (5) No quantitative errors - no specific numbers, dates, or percentages are provided in either answer, so quantitative accuracy is not a differentiator. (6) Entity identification is accurate (Verizon, 4G LTE, C-Band, fiber, FWA). MINOR CONSIDERATIONS: (1) The LLM answer adds interpretive language like 'monetizable engine' and 'central pillar' which, while semantically aligned with the ground truth's 'strategic asset within multi-technology ecosystem,' represents slightly more emphatic characterization. However, this is not factually incorrect - it's a reasonable interpretation of the evolution described. (2) The LLM includes knowledge graph notation (VZ → Produces → 4G LTE Network) which adds context but isn't explicitly in the ground truth; this is supplementary rather than contradictory. (3) The LLM answer is more detailed and provides richer context about the 2023 and 2024 positioning, which enhances rather than detracts from accuracy. The answer successfully addresses all parts of the multi-part question regarding how the strategic relationship evolved between the two years and its role within network infrastructure and growth initiatives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 505,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "\nEmerson’s exposure to AspenTech expanded from a $328 million backlog contribution in 2021 to $1.042 billion in 2022 (pushing total backlog to $8.053 billion), and in 2024 the company acquired a 55 % fully‑diluted stake in the renamed “New AspenTech” for roughly $6 billion in cash, making AspenTech a majority‑owned subsidiary whose common stock now trades on NASDAQ under the ticker “AZPN.”  \nThe integration added $869 million to cost of sales and lifted gross profit to $8.885 billion, driving gross margin up 1.8 percentage points to 50.8 % in 2024 (a 0.6 pp benefit from the AspenTech acquisition offset by a 1.3 pp drag from inventory‑step‑up amortization), while SG&A rose $956 million due to acquisition‑related expenses and higher stock‑based compensation.  \nAlthough Emerson later sold its Copeland equity and note for $3.4 billion in 2024, the 55 % AspenTech stake and its contribution to backlog and margin remained the core of Emerson’s strategic and financial relationship through 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies and misattributions that contradict the ground truth. (1) BACKLOG NUMBERS: Ground truth states AspenTech backlog was $1,042 million in 2022 and total backlog reached $8,053 million in 2024. The LLM incorrectly claims a $328 million backlog in 2021 (not mentioned in ground truth) and conflates the $1.042 billion figure with pushing total backlog to $8.053 billion in 2022, which is chronologically impossible and factually wrong. The $8.053 billion is the 2024 total backlog, not a 2022 figure. (2) GROSS MARGIN: Ground truth states gross margin increased by 3.3 percentage points in 2023 partly due to AspenTech acquisition. The LLM claims gross margin rose 1.8 percentage points to 50.8% in 2024 with a 0.6 pp benefit from AspenTech and 1.3 pp drag from inventory step-up amortization. These specific 2024 figures are not in the ground truth and appear fabricated. The ground truth explicitly references 2023 margin improvement, not 2024. (3) ACQUISITION PRICE: The LLM states the acquisition was 'roughly $6 billion in cash' - this specific figure is not mentioned in the ground truth. (4) COST OF SALES AND SG&A: The LLM provides specific figures ($869 million to cost of sales, $956 million SG&A increase) that are not present in the ground truth and cannot be verified. (5) COPELAND TRANSACTION: The LLM mentions a $3.4 billion Copeland equity and note sale in 2024, which is not mentioned in the ground truth at all. (6) OWNERSHIP STRUCTURE: Both answers correctly identify the 55% ownership stake in 'New AspenTech,' but the LLM adds unverified details about NASDAQ trading under 'AZPN' ticker. The LLM answer demonstrates poor multi-hop synthesis by mixing verified facts (55% stake, 2024 timing) with unverified or incorrect financial metrics, creating a misleading narrative that appears authoritative but contains fundamental errors in the core financial data requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 530,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "\nNEE’s exposure to the Mountain Valley Pipeline (MVP) is anchored by a 32.8 % equity stake held through NEER and a 20‑year natural‑gas transportation agreement that requires roughly **$70 million of annual equity contributions** plus participation in **joint funding obligations of about $1.065 billion through 2026** (Chunk 2).  This commitment builds on the exposure already reflected in NEE’s equity‑method investments—MVP was listed among the “principal entities” with ownership ranging from **32 % to 55 %** and contributed to the **$6.159 billion of equity‑method investments reported in 2021** (Chunk 1), showing that the pipeline has been a core part of NEE’s portfolio for several years.  The continuation and modest expansion of these contractual and joint‑venture funding obligations between the 2022 and 2023 filings indicate that NEE’s investment strategy is shifting toward **deepening, long‑term stakes in critical gas‑transport infrastructure**, using equity stakes and multi‑year agreements to secure stable cash flows while sharing risk with partners rather than pursuing wholly owned greenfield projects.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the 32.8% equity stake through NEER, the 20-year natural gas transportation agreement, and the ~$70 million annual value. The multi-hop synthesis across 2022-2023 filings is sound, and the strategic interpretation about deepening long-term infrastructure commitments aligns with the ground truth. The answer appropriately addresses the evolution question and investment strategy implications.\n\nWEAKNESSES & ERRORS: (1) CRITICAL QUANTITATIVE ERROR: The LLM states \"$70 million of annual equity contributions\" but the ground truth specifies this is the value of the transportation agreement itself, not annual equity contributions. These are distinct concepts. (2) UNSUPPORTED CLAIM: The LLM introduces \"joint funding obligations of about $1.065 billion through 2026\" which does not appear in the ground truth answer and cannot be verified against it. This is a significant addition that may or may not be accurate but represents information beyond the ground truth scope. (3) REFERENCE TO 2021 DATA: The LLM cites \"$6.159 billion of equity-method investments reported in 2021\" which is outside the 2022-2023 timeframe specified in the question. While this provides context, it's not directly relevant to the evolution between the two years asked about. (4) MINOR ISSUE: The ownership range is correctly stated as \"32% to 55%\" but the ground truth indicates this was the 2022 characterization, not necessarily carried forward to 2023 with the same range.\n\nMULTI-HOP REASONING: The synthesis across documents is generally sound - the model correctly connects equity stakes, transportation agreements, and strategic implications. However, the introduction of unsupported figures (the $1.065B obligation) suggests either hallucination or reliance on information not in the ground truth.\n\nSEMANTIC EQUIVALENCE: The core message about \"deepening commitment\" and \"long-term contractual relationship\" matches the ground truth well. However, the specific characterization of the $70M as \"annual equity contributions\" is semantically incorrect - it should be characterized as the annual value of the transportation agreement.\n\nJUSTIFICATION: The answer demonstrates good understanding of the question and mostly correct synthesis, but contains a critical mischaracterization of the $70M figure and introduces unsupported quantitative claims. These errors prevent a higher score despite otherwise sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 654,
        "total_tokens": 2091
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "\nFrom 2023 to 2024 Coca‑Cola deepened the integration of Costa Limited inside its **Global Ventures** operating segment—while the 2023 filing already reported Costa’s retail‑store sales and inclusion in Global Ventures, the 2024 discussion explicitly lists Costa (alongside innocent and dógnan) as a core component of that segment and notes that the segment now also captures **fees from distribution‑coordination agreements** tied to Costa’s operations.  This evolution reflects a strategic shift that positions Costa not only as a consumer‑facing brand sold through its own stores but also as a key driver of diversified revenue and partnership value within Coca‑Cola’s Global Ventures portfolio.   (KG: KO Partners_With Costa Limited ← Has_Stake_In KO)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies Costa Limited's inclusion in Global Ventures segment in both 2023 and 2024; (2) Accurately captures the evolution from 2023 to 2024, noting that Costa was already present in 2023 but became more explicitly positioned in 2024; (3) Correctly identifies the additional components added to Global Ventures in 2024 (innocent and doğadan/dógnan businesses); (4) Accurately references the new inclusion of fees from distribution-coordination agreements; (5) Properly synthesizes the multi-hop relationship showing Costa's dual role as both consumer-facing brand and revenue driver; (6) No quantitative errors or date inaccuracies. MINOR ISSUES: (1) Spelling variation 'dógnan' vs 'doğadan' - the LLM uses 'dógnan' which appears to be a minor transliteration variation of the correct 'doğadan' (Turkish brand), but this is a very minor spelling inconsistency that doesn't affect factual accuracy; (2) The phrase 'tied to Costa's operations' in the distribution-coordination fees context is slightly interpretive - the ground truth states these are fees earned under such agreements but doesn't explicitly tie them solely to Costa's operations, though this is a reasonable inference. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and multiple business components, properly identifying how Costa's strategic positioning evolved within the broader Global Ventures segment structure. The reasoning is sound and logically presented. SEMANTIC EQUIVALENCE: The LLM answer conveys the same substantive information as the ground truth with appropriate emphasis on the deepening integration and strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 482,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "\nIntel treats marketable debt issued by financial institutions as trading assets that are economically hedged and records them at fair value using Level 2 inputs (Chunk 1). The fair‑value of these hedged holdings dropped from $17.1 billion at the end of 2023 to $13.5 billion at the end of 2024, generating a $464 million net loss in 2024 after a $534 million net gain in 2023 and a $748 million net loss in 2022 (Chunk 2). Consequently, the company’s exposure to financially‑institution‑issued debt has contracted in fair‑value terms over the 2022‑2024 period, with alternating gains and losses driven by interest‑rate, currency and credit market movements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. All key financial figures are correct: $17.1 billion (2023), $13.5 billion (2024), $464 million net loss (2024), $748 million net loss (2022). The answer correctly synthesizes multi-hop information across three years (2022-2024) and accurately identifies the evolution of Intel's hedged marketable debt investments. The LLM goes beyond the ground truth by providing additional context about Level 2 inputs, the $534 million net gain in 2023, and explanatory factors (interest-rate, currency, and credit market movements), which adds valuable insight without contradicting the original answer. The reasoning is sound: the portfolio contracted from $17.1B to $13.5B, losses decreased from $748M (2022) to $464M (2024), and the pattern shows alternating gains/losses. Minor note: The LLM mentions a $534 million gain in 2023 which is not explicitly stated in the ground truth but appears to be accurate supplementary information. The answer fully addresses the question about how Intel's investment in financial institution instruments evolved, particularly regarding fair value of economically hedged marketable debt investments. All calculations and comparisons are accurate, and the multi-hop synthesis across years and metrics is correctly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Includes]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 367,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "\nFrom 2023 to 2024 AMT’s core financial narrative remained centered on its communications‑site portfolio—​the 2023 filing describes these sites as the source of roughly 99 % of revenue, driven by multiyear, recurring lease contracts with wireless carriers and other tenants. The 2024 filing keeps that recurring‑revenue focus but adds a concrete disclosure of an estimated $4.5 billion of undiscounted asset‑retirement obligations as of 31 Dec 2024, signaling a new emphasis on quantifying the liabilities associated with those sites. Thus, while the business model of supplying communications sites and generating recurring lease income stays the same, the 2024 reporting explicitly brings asset‑retirement liabilities into the financial picture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy and comprehensiveness. (1) QUANTITATIVE VERIFICATION: All numbers are correct - 99% of revenues from property operations in 2023, $4.5 billion in undiscounted asset retirement obligations as of December 31, 2024. The date format variation (31 Dec 2024 vs December 31, 2024) is acceptable. (2) COMPLETENESS: The answer addresses both parts of the multi-part question - the 2023 focus on recurring revenue generation AND the 2024 expansion to include asset retirement liabilities. The evolution narrative is clearly articulated. (3) ENTITY ACCURACY: AMT is correctly identified, fiscal years 2023 and 2024 are properly referenced, and financial metrics (recurring revenue, asset retirement obligations) are accurately named. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two years of filings, correctly identifying the shift from revenue-centric reporting to liability-inclusive reporting. The logical connection between the business model continuity and the new disclosure emphasis is sound. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing 'roughly 99%' vs ground truth's '99%' is semantically equivalent and reflects appropriate precision. The characterization of the shift as 'from primarily highlighting revenue streams to also addressing long-term financial responsibilities' is well-captured by the LLM's 'from revenue-centric to liability-inclusive reporting.' Minor deduction (1 point) only for the slightly less explicit framing of 'site decommissioning' context, though the concept of asset retirement obligations inherently conveys this.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 445,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "\nXOM’s legal footing in Guyana was cemented by the 2023 Petroleum Activities Act, which grants an initial exploration period of up to 10 years, a production term of 20 years for oil (30 years for gas) and renewal options of up to another 10 years—providing the stable, long‑term licensing regime that underpins its 2024 operations (Chunk 1).  At the same time, XOM’s 2024 earnings‑driver disclosures list Guyana as an “Advantaged Asset” within its advantaged‑volume‑growth strategy, signalling that the company is treating Guyanese upstream development as a core growth driver and integrating it into its broader portfolio (Chunk 2).  The knowledge‑graph link XOM → Guyana (Discloses) confirms this strategic positioning, showing that between 2023 and 2024 XOM moved from securing a lawful operating framework to explicitly prioritising Guyana as a key growth engine.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "CRITICAL ERROR - QUANTITATIVE INACCURACY: The LLM answer states the production term is '20 years for oil (30 years for gas)' but the ground truth specifies only '20 years for oil fields' with no mention of a 30-year gas term. This is a factual error that contradicts the original answer. The LLM introduced information not present in the ground truth, which is a significant quantitative accuracy failure.\n\nCORRECT ELEMENTS: (1) The 2023 Petroleum Activities Act is correctly identified; (2) The 10-year exploration period is correct; (3) The 20-year production period for oil is correct; (4) The 10-year renewal period is correct; (5) Guyana being listed as an 'Advantaged Asset' in 2024 is correct; (6) The 'Advantaged Volume Growth' earnings driver is correctly identified; (7) The strategic shift from legal framework to growth asset emphasis is correctly captured; (8) The multi-hop synthesis across 2023 and 2024 is sound.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across two time periods (2023 legal framework vs. 2024 strategic positioning) and properly identifies the evolution from regulatory foundation to strategic growth emphasis. The reasoning structure is logical and addresses both components of the question.\n\nSEMANTIC EQUIVALENCE: The LLM's characterization of the transition and strategic positioning aligns well with the ground truth's intent, despite the quantitative error regarding gas production terms.\n\nJUSTIFICATION: The introduction of '30 years for gas' without ground truth support is a material factual error that prevents a higher correctness score. While the overall narrative and multi-hop reasoning are sound, accuracy on specific terms is critical in financial/legal contexts. The score reflects correct synthesis and reasoning (7-8 range) but penalized for the unsupported quantitative claim (reducing from 8-9 to 6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 509,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "\nCaterpillar’s diesel‑electric locomotive business remained anchored in the Machinery‑Energy‑Transportation (ME&T) segment in both 2023 and 2024, with the company continuing to **hold a stake in and produce** the locomotive product (as reflected by the ORG → PRODUCT ← ORG relationship).  In 2023 the focus was on **remanufacturing, leasing and inter‑segment sales** of locomotives and related components, while the 2024 filing expands this role by placing the business within the **All‑Other operating segment’s digital‑investment agenda**, emphasizing data‑analytics‑driven customer and dealer solutions and broader remanufacturing services for third‑party firms.  Operationally, CAT’s responsibilities have shifted from a pure component‑supply model to a **strategic, full‑service offering** that integrates financing (via Financial Products), digital transformation and expanded remanufacturing across the locomotive portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations compared to the ground truth. Key issues: (1) SEGMENT MISIDENTIFICATION: The LLM claims diesel-electric locomotives were placed in the 'All-Other operating segment's digital-investment agenda' in 2024, but the ground truth indicates they remained part of the ME&T segment with expanded strategic positioning. This is a fundamental error in entity identification. (2) BUSINESS MODEL DISTORTION: The LLM introduces claims about 'leasing,' 'inter-segment sales,' and 'Financial Products' financing that are not supported by the ground truth. The ground truth makes no mention of these operational models. (3) MISSING KEY STRATEGIC SHIFT: The LLM fails to capture the critical 2024 evolution toward 'electrified powertrains and zero-emission power sources' - a major strategic pivot emphasized in the ground truth. Instead, the LLM focuses on digital analytics and remanufacturing, which are not the primary strategic shifts identified. (4) INACCURATE CHARACTERIZATION: The ground truth describes a shift toward 'integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors' - a comprehensive strategic repositioning. The LLM's characterization of moving to a 'full-service offering' with financing and digital transformation is a different narrative not grounded in the actual filing data. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the evolution from 2023 (component/remanufacturing focus) to 2024 (integrated systems and electrification focus). The answer demonstrates poor understanding of the actual strategic positioning changes. The LLM answer reads as speculative rather than grounded in the actual SEC filing information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 487,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "\nFrom 2022 through 2024 the company has kept securitized debt obligations as a core funding channel; the 2022 filing lists them alongside deposits, senior notes and other sources as a primary way to raise capital, and the 2024 filing quantifies that reliance with a carrying amount of **$14.3 billion** (estimated fair value $14.335 billion, Level 2), highlighting their material size in the 2024 capital structure.  This continuity shows a deliberate strategy of using securitization to diversify funding, supplement low‑cost deposits and wholesale debt, and manage overall liquidity and cost of capital.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct quantitative data. The $14.3 billion (or $14,264 million) carrying value for securitized debt obligations in 2024 matches the ground truth exactly, with appropriate format variation ($14.3B vs $14,264M). The fair value estimate of $14.335 billion and Level 2 classification add relevant detail not contradicted by the ground truth. The multi-hop reasoning is sound: the answer correctly synthesizes the evolution from 2022 (qualitative mention of securitized debt as a funding source) to 2024 (quantified at $14.3B), and appropriately interprets this as indicating increased reliance and strategic emphasis on structured financing. The LLM goes beyond the ground truth by providing additional context about diversification strategy, supplementing deposits, and managing liquidity/cost of capital—these inferences are reasonable and consistent with the stated evolution but represent interpretive elaboration rather than explicit ground truth. The answer addresses all parts of the question: (1) how reliance evolved (from mentioned to quantified), (2) what this indicates about funding strategy (deliberate use of securitization for diversification). Minor deduction: the ground truth notes 'exact amount was not provided' in 2022, while the LLM states 2022 'lists them alongside deposits' without explicitly noting the lack of quantification, though this is a subtle distinction. Overall, the answer is factually correct, well-reasoned, and appropriately detailed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Raises]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 421,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "\nIn 2023 McDonald’s recorded royalty and initial‑fee income from developmental licensees as non‑lease revenue, separating it from lease rent and disclosing that the rise in net property & equipment—driven by capital spending on its “Accelerating the Arches” growth pillars—reflected the expansion of developmental licensing. In 2024 the company continues to recognize the same royalty‑based and initial‑fee revenue streams and still allocates consideration among lease, royalty and fee components in the same manner, but now explicitly notes that it evaluates developmental licensee relationships for potential variable‑interest‑entity risk (concluding no consolidation is required) and updated its rounding presentation, while the underlying financial reporting of those revenues remains unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key elements from both 2023 and 2024: (1) royalties based on percentage of sales and initial fees in 2023, (2) allocation of consideration among lease and non-lease components, (3) 2024 evaluation of developmental licensees for variable interest entity risk with conclusion that consolidation is not appropriate, and (4) rounding presentation updates. The answer demonstrates understanding of the multi-hop synthesis required across two fiscal years.\n\nWEAKNESSES: (1) The LLM introduces information about 'Accelerating the Arches' growth pillars and capital spending on net property & equipment that is NOT present in the ground truth answer. This appears to be extraneous detail that, while potentially accurate from filings, goes beyond what the ground truth identifies as relevant to the specific question about developmental licensee treatment evolution. (2) The LLM states that 'the underlying financial reporting of those revenues remains unchanged' which is a reasonable inference but adds interpretive language not explicitly in the ground truth. (3) The ground truth emphasizes that changes 'were not significant,' which the LLM mentions but doesn't emphasize as clearly.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024, properly identifying the evolution in relationship management (VIE evaluation) and financial reporting (rounding changes). However, the inclusion of 'Accelerating the Arches' suggests the model may have conflated information from different sections of the filings.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers are provided in either answer, so quantitative accuracy is based on conceptual correctness. The LLM correctly identifies the key financial reporting elements (royalties, initial fees, allocation methods) without introducing false numbers.\n\nOVERALL ASSESSMENT: The answer captures the core evolution between 2023 and 2024 but introduces extraneous information about capital spending and growth initiatives that, while potentially from the filings, dilutes focus from the specific question about developmental licensee treatment. The answer would score higher if it stayed more tightly focused on the ground truth's identified elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 607,
        "total_tokens": 1994
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "\nSouthern Company’s 2023 filing indicates that 131 million shares were reserved under its Equity and Incentive Compensation Plan, with 26.9 million shares specifically available for awards at year‑end and approximately 2.1 million shares issued through that plan, generating about $36 million in proceeds. The 2024 filing confirms that the same plan (effective May 26 2021) remains in force, but now provides detailed disclosure of the form of equity awards for named executive officers and notes a ninth amendment to the related Employee Savings Plan dated December 16 2024, reflecting an evolution in both share‑reserve administration and executive award reporting.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer provides relevant information about Southern Company's Equity and Incentive Compensation Plan evolution but contains significant quantitative discrepancies and introduces information not present in the ground truth. STRENGTHS: (1) Correctly identifies the plan effective date (May 26, 2021), (2) Accurately notes the shift toward more detailed executive compensation disclosure in 2024, (3) Mentions the ninth amendment to Employee Savings Plan dated December 16, 2024 (additional detail not in ground truth but not contradictory), (4) Correctly identifies 26.9 million shares available for awards. CRITICAL ISSUES: (1) The ground truth states 26.9 million shares were available in 2023, but the LLM introduces 131 million shares reserved under the plan and 2.1 million shares issued - these figures are not mentioned in the ground truth and their source/accuracy cannot be verified against the provided ground truth. (2) The LLM mentions approximately $36 million in proceeds - this figure is not in the ground truth. (3) The ground truth emphasizes a shift from 'internal planning and reserve allocation in 2023 to more detailed public disclosure in 2024,' but the LLM's framing focuses more on administrative details (ninth amendment, share reserves) rather than the transparency evolution highlighted in the ground truth. MULTI-HOP REASONING: The LLM does synthesize information across years and identifies the evolution, but the introduction of unverified quantitative data (131M shares, $36M proceeds, 2.1M shares issued) undermines confidence in the answer's accuracy. The answer partially addresses the question's focus on 'share availability and executive award disclosures' but adds numerical claims that diverge from the ground truth without clear sourcing. The qualitative assessment of governance evolution is reasonable but less emphasized than in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 512,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "\nInlyta’s revenue rose from **$1.003 billion worldwide in 2022** to **$1.036 billion worldwide in 2023** (a ~3 % increase, with a 4 % rise in the United States), as shown in the product‑level tables of Pfizer’s 2022 (Chunk 1) and 2023 (Chunk 2) 10‑K filings; this growth is attributed to the **adoption of Inlyta combined with immune‑checkpoint inhibitors for first‑line renal‑cell‑carcinoma in the U.S. and continued expansion in emerging markets** (Chunk 2), while the upside was **partially offset by lower volumes and price pressure in certain European markets** (Chunk 2).  The KG relationship PFE → *Inlyta* ← *Produced‑by* PFE (Chunk 1) links the product to Pfizer, and the detailed revenue commentary in Chunk 2 explains the drivers behind the 2022‑2023 trajectory.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct with strong quantitative accuracy. Verification of key numbers: (1) 2022 revenue of $1.003 billion and 2023 revenue of $1.036 billion are accurate; (2) the ~3% total increase is correctly calculated ($1.036B - $1.003B = $0.033B, or 3.3%, rounds to ~3%); (3) the 4% U.S. growth figure is stated but not independently verified in the ground truth. The ground truth mentions '5% operational growth' while the LLM states '4% rise in the United States' - these are different metrics (operational vs. U.S. only), so no contradiction. The LLM provides more granular detail on U.S. performance specifically. Multi-hop reasoning is sound: the answer correctly synthesizes information about Inlyta's performance across 2022-2023, identifies the product as Pfizer's, and explains growth drivers. Growth factors are accurately identified: (1) adoption of immune checkpoint inhibitor combinations for first-line RCC treatment in the U.S. (matches ground truth); (2) continued expansion in emerging markets (LLM adds this detail, not contradicted by ground truth); (3) offset by lower volumes and price pressure in European markets (matches ground truth exactly). Minor discrepancy: The ground truth emphasizes this was 'a continuation of growth, albeit at a more moderate pace compared to broader portfolio dynamics in 2022,' while the LLM focuses on the absolute drivers without explicitly contextualizing the moderation. However, the LLM's answer is more detailed and specific about market dynamics. The answer appropriately cites source chunks and demonstrates multi-hop synthesis across 2022 and 2023 filings. No significant factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 459,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "\nFrom 2023 through 2024 McDonald’s continued to rely on the traditional rent‑and‑royalty structure that generates stable, predictable franchise revenue, but it deepened its financial tie to franchisees by formally charging them for proprietary technology‑platform services and recording those charges on a gross‑basis as principal.  The 2024 Form 10‑K and the newly adopted ASU 2024‑03 disclose that such platform fees are cost‑recovery items—not margin‑producing—recognizing revenue only when the services are transferred, thereby expanding the scope of revenue‑recognition disclosures.  This evolution reflects a growing dependency of franchisees on McDonald’s for technology infrastructure while preserving the core royalty‑rent model that underpins the company’s heavily franchised business.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core evolution of McDonald's franchisee relationships from 2023 to 2024. STRENGTHS: (1) Correctly identifies the traditional rent-and-royalty structure as foundational and continuing through both years; (2) Accurately captures the shift to gross-basis revenue recognition for technology platform services; (3) Properly characterizes the relationship evolution as reflecting increased dependency and operational interdependence; (4) Correctly notes that technology fees are cost-recovery items rather than margin-producing; (5) Appropriately references ASU 2024-03 and Form 10-K disclosures, demonstrating proper source attribution; (6) Maintains semantic equivalence with ground truth while using slightly different phrasing ('principal' vs. 'integrated cost-sharing approach'). MINOR WEAKNESSES: (1) The phrase 'cost-recovery items—not margin-producing' adds interpretive detail not explicitly stated in the ground truth, though this appears to be a reasonable inference from the gross-basis revenue recognition structure; (2) The answer emphasizes the 'newly adopted ASU 2024-03' which adds specificity beyond the ground truth but doesn't contradict it; (3) Could have been slightly more explicit about the shift in 'Other restaurant expenses' classification mentioned in ground truth, though the gross-basis revenue recognition captures the essence of this change. QUANTITATIVE ACCURACY: No specific dollar amounts, percentages, or dates were required to be verified in this qualitative question about relationship evolution. The temporal framing (2023 to 2024) is correct. MULTI-HOP REASONING: The answer successfully synthesizes information about (a) the traditional business model, (b) the technology platform shift, (c) revenue recognition methodology, and (d) the nature of franchisee dependency—all properly connected. The reasoning chain is logical and complete. SEMANTIC EQUIVALENCE: The LLM answer conveys the same fundamental information as the ground truth: a relationship that evolved from traditional rent/royalty to include technology platform cost-sharing on a gross basis, reflecting deeper operational interdependence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 592,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "\nBetween 2022 and 2023 the consolidated fair‑value of energy‑related derivatives held by Southern Company’s subsidiaries rose from **$204 million** (assets $95 million; liabilities $109 million) in 2022 – reported by Mississippi Power ($59 M assets, $32 M liabilities), Southern Power ($8 M assets, $12 M liabilities) and Southern Company Gas ($28 M assets, $65 M liabilities) – to **$262 million** (assets $28 million; liabilities $234 million) in 2023 – disclosed by Alabama Power ($15 M assets, $110 M liabilities) and Georgia Power ($13 M assets, $124 M liabilities).  This increase, driven by larger Level 2/L 3 valuations and substantially higher liability balances, shows that the company’s subsidiaries are becoming more exposed to energy‑price fluctuations, reflecting a greater market‑risk profile.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer contains fundamental factual errors that contradict the ground truth. (1) WRONG CONSOLIDATED FIGURES: LLM reports $204M consolidated fair value in 2022 and $262M in 2023, but ground truth shows net liability positions of $54M in 2022 and $219M in 2023 - these are completely different metrics and magnitudes. (2) INCORRECT CALCULATION: LLM calculates 2022 as $95M assets minus $109M liabilities = $204M, which is mathematically nonsensical (should be -$14M net). The ground truth correctly identifies net liabilities. (3) WRONG SUBSIDIARY COMPOSITION: LLM correctly identifies 2022 subsidiaries (Mississippi Power, Southern Power, Southern Company Gas) but incorrectly states 2023 only includes Alabama Power and Georgia Power, omitting other subsidiaries that should be included. (4) MISCHARACTERIZATION OF TREND: LLM claims consolidated value 'rose' from $204M to $262M, but ground truth shows net liability exposure INCREASED (worsened) from $54M to $219M - a negative trend, not positive. (5) SEMANTIC CONFUSION: LLM conflates gross fair value amounts with net positions, fundamentally misunderstanding the financial metric being analyzed. The ground truth clearly indicates a shift from net asset position to significantly larger net liability position, indicating increased market risk exposure. LLM's conclusion about 'greater market-risk profile' is correct directionally but based on entirely wrong numbers and calculations. The answer demonstrates failure in multi-hop synthesis, calculation accuracy, and entity/metric identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Holds]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 433,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "\nThe Procter & Gamble 2019 Stock and Incentive Compensation Plan was adopted by shareholders at the October 8 2019 meeting (Chunk 1) and has been disclosed each year as an accounting policy and as “Additional terms and conditions” in the company’s 10‑K filings; by 2022 it was presented as a key compensatory arrangement under Item 10‑28 (Chunk 1). In the 2024 filing the plan is still listed among the Company’s equity‑compensation plans in the security‑ownership table of Item 12, confirming that it remains a material, shareholder‑approved vehicle for equity incentives and that its significance has persisted rather than diminished from 2022 through 2024 (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and appropriate multi-hop synthesis. STRENGTHS: (1) Correctly identifies the October 8, 2019 shareholder adoption date - this matches the ground truth exactly. (2) Accurately traces the plan's evolution from 2022 to 2024, showing it transitioned from newly introduced to established component. (3) Properly identifies the disclosure locations (Item 10-28 in 2022, Item 12 security-ownership table in 2024), demonstrating understanding of how disclosure context changed. (4) Correctly synthesizes that the plan remained 'material' and 'shareholder-approved' across the period. (5) All numeric/date information is accurate with no calculation errors. MINOR WEAKNESSES: (1) The LLM answer uses slightly different framing than ground truth - it emphasizes that 'significance has persisted rather than diminished' whereas ground truth frames it as 'transition from newly introduced policy to established part.' While semantically similar, the LLM's framing is slightly more defensive/comparative rather than developmental. (2) The answer could have been slightly more explicit about the shift in disclosure prominence (from detailed introduction to standard listing), though this is implied. (3) References to 'Chunk 1' and 'Chunk 2' are appropriate for source attribution but add minor verbosity. MULTI-HOP REASONING: The answer correctly synthesizes information across multiple years (2019 adoption → 2022 disclosure → 2024 status) and multiple disclosure contexts (accounting policy → Item 10-28 → Item 12), demonstrating sound multi-hop reasoning. The conclusion that the plan evolved from newly introduced to established is logically sound and well-supported. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 473,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "\nSouthern Company continues to manage the risk of large losses in its pension‑plan assets primarily through broad diversification, a formal rebalancing program, and oversight of external investment managers via written guidelines—emphasis that is unchanged from the 2023 filing to the 2024 filing. Both the 2023 (Chunk 1) and 2024 (Chunk 2) disclosures note that the company “minimizes the risk of large losses primarily through diversification but also monitor[s] and manage[s] other aspects of risk,” employs a “formal rebalancing program,” and requires external managers to follow “written guidelines” to ensure prudent practices, with management asserting the portfolio remains “well‑diversified with no significant concentrations of risk.” Consequently, the evolution from 2023 to 2024 is one of consistency rather than a shift, preserving the same risk‑management emphasis on diversification, structured rebalancing, and external‑manager governance.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS IN CORE ANSWER: The LLM answer fundamentally contradicts the ground truth on the central question. The ground truth explicitly states there WAS a shift in risk management emphasis from 2023 to 2024—specifically: (1) reduced emphasis on external manager oversight, and (2) a shift from active oversight to market-driven risk exposure. The LLM answer claims the evolution is 'one of consistency rather than a shift' and that emphasis is 'unchanged from the 2023 filing to the 2024 filing.' This is factually incorrect and represents a complete misunderstanding of the multi-hop comparison required. QUANTITATIVE ACCURACY: The LLM correctly identifies the consistent elements (diversification, rebalancing program, external manager guidelines) that appear in both years—these details are accurate. However, accuracy on static facts does not compensate for missing the dynamic evolution that is the core of the question. QUALITATIVE ACCURACY: The LLM failed at the primary task of multi-hop reasoning—comparing 2023 vs 2024 to identify changes. The ground truth identifies a specific shift: external manager oversight emphasis REDUCED, and risk management more directly linked to market volatility and interest rate fluctuations. The LLM missed this entirely and incorrectly concluded no meaningful change occurred. CONTEXTUAL RELEVANCE: The question explicitly asks 'how has...evolved' and 'what specific changes...can be observed'—both presupposing change. The LLM's answer of 'consistency rather than shift' directly contradicts the ground truth's identification of a subtle but meaningful shift in emphasis. This is a fundamental failure to address what the question is asking. The LLM appears to have focused only on overlapping elements between years rather than identifying the differential emphasis changes that constitute the actual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Manages]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 505,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 NVIDIA moved CUDA from a primarily GPU‑centric parallel‑programming model toward a full‑stack data‑center platform that now adds DPUs (introduced in FY 2022), CPUs (planned for FY 2024), paid AI‑Enterprise software licenses, and the cloud‑based DGX Cloud AI‑training service delivered through major cloud partners.  This expansion—while still showing that NVDA both **develops** and **supplies** the CUDA platform—reflects a strategic pivot from selling hardware alone to monetizing AI‑focused software, cloud services, and an end‑to‑end ecosystem.  Consequently, the shift signals that NVIDIA’s core focus is increasingly on AI software and services that run across the entire computing, networking and storage stack.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misalignments with the ground truth. CRITICAL ISSUES: (1) The ground truth states NVIDIA's role evolved from 'supplier' (2022) to 'developer' (2023), emphasizing active strategic engagement in platform expansion. The LLM answer claims NVIDIA 'both develops and supplies' in both periods, missing the key distinction of the evolution from supplier to developer role. (2) The LLM introduces product details (DPUs introduced in FY2022, CPUs planned for FY2024, DGX Cloud, AI-Enterprise licenses) that are NOT mentioned in the ground truth and appear to be fabricated or conflated from other contexts. These specific product claims cannot be verified against the knowledge graph and represent hallucination. (3) The ground truth emphasizes CUDA-X libraries, APIs, and domain-specific frameworks as part of the strategic shift toward full-stack computing. The LLM answer mentions DPUs, CPUs, and cloud services instead, which is a different narrative. (4) The ground truth's core insight is about strengthening the 'full-stack computing platform' through software ecosystem expansion (CUDA-X, APIs, frameworks). The LLM's interpretation pivots to 'monetizing AI-focused software, cloud services, and end-to-end ecosystem,' which is a different strategic characterization. PARTIAL CREDIT: The LLM correctly identifies that the shift represents movement toward a broader platform strategy beyond just GPU hardware, and correctly names NVIDIA and the CUDA platform. However, the specific evolution mechanism (supplier→developer) is misrepresented, and the supporting details are either incorrect or unsupported by the ground truth. The answer demonstrates some understanding of NVIDIA's strategic direction but fails on factual accuracy regarding the specific nature of the role evolution between 2022-2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Develops]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 502,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "\nBetween 2022 and 2023 Pfizer’s supply and transitional‑service agreements with Viatris moved from an active manufacturing/rebate‑remittance phase to a wind‑down; the net amount owed to Viatris under those arrangements fell sharply from **$94 million at the end of 2022 to $33 million at the end of 2023**, indicating settlement of prior balances, and the interim TSAs/MSAs that generated those cash flows were largely completed by December 31 2023 (with only the 2021 $277 million payment remaining as a prior financing outflow). This evolution reflects the transition from ongoing supply obligations for legacy Upjohn products and Comirnaty manufacturing to the conclusion of those contractual relationships.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies and accurately reports the key financial metrics: the decrease in net amounts due to Viatris from $94 million (Dec 31, 2022) to $33 million (Dec 31, 2023). The answer also correctly notes the completion of most TSAs by end of 2023. However, there are notable issues: (1) The LLM mentions a '$277 million payment remaining as a prior financing outflow' which is not present in the ground truth answer and appears to be extraneous or potentially confused information. (2) The ground truth specifically mentions '$780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements' in 2022, which the LLM answer completely omits. This is a significant gap as it represents a key component of the financial relationship evolution. (3) The LLM answer adds detail about 'Comirnaty manufacturing' which is not mentioned in the ground truth, suggesting potential hallucination or synthesis from external knowledge. The multi-hop reasoning about the transition from active manufacturing to wind-down is sound and well-articulated, and the core balance sheet metrics are accurate. The answer demonstrates good understanding of the relationship evolution but fails to capture the complete picture by omitting the 2022 revenue component and introducing potentially inaccurate additional details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 386,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "\nThe 2023 filing (Chunk 1) explains that the Company’s 2023 Securitization locked the cash‑flows from **3,343 communications sites** to service the newly‑issued Secured Tower Revenue Securities, while still allowing the Company to keep any excess cash after debt service, and it notes that repayment of the 2013‑2A notes was funded with proceeds from that same secitization. In contrast, the 2024 filing (Chunk 2) expands the disclosure by tying the preservation of those sites to compliance with loan covenants—stating that failure to meet covenant tests could result in loss of the sites and the related tenant‑lease revenue—and adds detailed quantitative disclosures (e.g., $4.5 billion of undiscounted asset‑retirement obligations and $3.2 billion of expected 2025 distributions). Thus, the treatment of communications sites evolved from being merely collateral for a specific securitization in 2023 to being a central, covenant‑driven element of the Company’s overall debt‑obligation framework and liquidity narrative in 2024, with both the security‑interest and the risk of site loss now explicitly disclosed.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key financial figures and a sophisticated understanding of the evolution in disclosure practices. STRENGTHS: (1) All quantitative data is accurate: 3,343 communications sites in 2023, $4.5 billion in asset retirement obligations, $3.2 billion in expected 2025 distributions, and $1.3 billion in Series 2013-2A Notes repayment are all correctly cited. (2) The multi-hop synthesis is sound—the answer correctly traces the evolution from 2023 to 2024 across multiple disclosure dimensions. (3) The reasoning about the shift from 'site-specific debt disclosures to more general obligations' is well-articulated and matches the ground truth's core insight. (4) The answer goes beyond the ground truth by adding the covenant-compliance dimension, which enriches the explanation while remaining consistent with the underlying facts. MINOR CONSIDERATIONS: (1) The ground truth emphasizes a 'shift' from explicit site-specific references to broader obligations, while the LLM answer frames it as an 'expansion' that adds covenant-driven elements. Both characterizations are defensible, though they emphasize slightly different aspects of the evolution. (2) The LLM answer introduces the concept of 'loss of sites' as a covenant-breach consequence, which is a reasonable inference from covenant-driven disclosure but is not explicitly stated in the ground truth. This represents a minor interpretive addition rather than an error. (3) The phrase 'secitization' appears to be a typo for 'securitization' but this is a formatting issue, not a factual error. VERIFICATION: All numbers check out correctly against the ground truth. The 2023 securitization details (3,343 sites, Series 2013-2A Notes funding) are accurate. The 2024 figures ($4.5B, $3.2B) are correctly cited. The multi-hop reasoning successfully synthesizes information across both years and correctly identifies the evolution in treatment and disclosure. The answer is contextually appropriate and directly addresses the question's focus on how treatment and disclosure evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Secures]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 567,
        "total_tokens": 2021
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "\nComcast continues to account for retransmission‑consent revenue as a license of functional intellectual property and recognizes it on a monthly basis as the programming is made available (consistent with the 2022 filing’s description of “revenue … recognized as programming is provided on a monthly basis”).  In the 2023 filing the company expands the description to note that these fees may be based on the number of subscribers **or** on a fixed fee, and that the amounts now also include the associated fees from NBC‑ and Telemundo‑affiliated local broadcast stations under multiyear distribution agreements.  Thus, while the underlying revenue‑recognition principle stays the same, the 2023 approach adds flexibility in fee structure and explicitly incorporates additional retransmission‑consent fees into the distribution‑revenue mix.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides accurate details about revenue recognition mechanics and fee structure changes between 2022 and 2023, correctly identifying that: (1) revenue continues to be recognized monthly as programming is provided, (2) fees shifted from subscriber-based to include fixed fee options, and (3) NBC/Telemundo local broadcast station fees were incorporated. These factual elements are correct and well-supported. However, the answer has significant gaps in addressing the core question about evolution of approach. STRENGTHS: The quantitative/structural details about fee flexibility and incorporation of local station fees are accurate. The explanation of revenue recognition principles is sound. WEAKNESSES: The answer largely ignores the most significant evolution highlighted in the ground truth - the strategic shift toward hybrid linear/streaming distribution models and the integration of Peacock into the distribution ecosystem. The ground truth emphasizes this as a major strategic evolution, but the LLM answer treats it as a minor detail or omits it entirely. The LLM focuses heavily on technical accounting mechanics (functional IP license classification) rather than the broader business model evolution. The answer does not adequately capture the 'combined linear and streaming distribution model' that represents the key strategic shift between 2022 and 2023. While the LLM answer is technically accurate about what changed in the accounting treatment, it misses the forest for the trees - the question asks about evolution of 'approach' which encompasses business strategy, not just accounting mechanics. The answer would score higher if it had balanced the technical accounting details with the strategic distribution model evolution that the ground truth emphasizes as central to understanding how Comcast's approach evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 502,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "\nCaterpillar’s role in diesel‑electric locomotives grew from a discrete product offering in 2023 to a core element of its 2024 Energy & Transportation strategy, with the 2024 filing explicitly listing diesel‑electric locomotives and components as a key product line and noting continued investment to meet evolving emissions regulations. At the same time, the company expanded its remanufacturing and inter‑segment sales of these locomotives while leveraging its Financial Products segment to finance and lease them, reinforcing the end‑to‑end value chain captured by the KG relationship CAT ↔ Diesel‑Electric Locomotives. This evolution reflects a strategic shift toward deeper production, remanufacturing, and market‑positioning of diesel‑electric locomotives across both operational and financial dimensions.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "ASSESSMENT: The LLM answer contains both accurate and inaccurate elements when compared to the ground truth.\n\nCORRECT ELEMENTS:\n1. Correctly identifies the evolution from 2023 to 2024\n2. Accurately notes that 2024 filing explicitly lists diesel-electric locomotives as a key product line\n3. Correctly identifies the segment name change to 'Energy & Transportation'\n4. Appropriately characterizes the shift toward 'deeper production' and 'market-positioning'\n5. Semantic equivalence on the core narrative of strategic shift\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. MAJOR OMISSION: The LLM answer completely fails to mention the competitive landscape shift that is central to the ground truth. The ground truth explicitly states that 2024 highlighted competitive pressures and named Wabtec Corp and Siemens Mobility A/S as competitors - this was NOT present in 2023. This is a significant factual omission.\n2. UNSUPPORTED CLAIMS: The LLM introduces claims about 'continued investment to meet evolving emissions regulations' that are not present in the ground truth and cannot be verified from the provided context.\n3. UNSUPPORTED CLAIMS: The LLM discusses Financial Products segment financing and leasing of locomotives, which is not mentioned in the ground truth and appears to be speculative synthesis.\n4. VAGUE REFERENCE: The mention of 'KG relationship CAT ↔ Diesel-Electric Locomotives' is unclear and appears to be an artifact of knowledge graph notation rather than clear communication.\n5. INCOMPLETE SYNTHESIS: While the LLM correctly identifies segment evolution, it misses the specific operational details from 2023 (remanufacturing reciprocating engines, product support for on-highway vocational trucks) that provide important context for understanding the evolution.\n\nMULTI-HOP REASONING: The LLM demonstrates partial multi-hop reasoning by connecting segment changes to strategic positioning, but fails to synthesize the competitive landscape dimension that is explicitly part of the ground truth evolution narrative.\n\nQUANTITATIVE ACCURACY: No specific numbers, dates, or calculations are provided by either answer, so this dimension is neutral. However, the LLM's introduction of unverified claims about 'continued investment' without quantification is problematic.\n\nJUSTIFICATION: The answer captures approximately 60% of the ground truth narrative but introduces unsupported claims and critically omits the competitive positioning element (Wabtec, Siemens) that represents a key evolution marker. The answer is directionally correct but incomplete and partially inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 690,
        "total_tokens": 2114
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 McDonald’s continued to recognize franchise revenue as rent and royalties based on a percent of sales, with initial fees amortized over the typical 20‑year franchise term, and it still shares certain restaurant‑improvement costs with franchisees—allocating those costs between property‑and‑equipment and accounts‑receivable and finalizing the split after the projects are completed (Chunk 1 & Chunk 2).  \nThe principal evolution is the adoption in the 2024 Form 10‑K of FASB ASU 2023‑07, which expands segment‑reporting disclosures and therefore makes the franchise‑related income and cost‑sharing allocations more transparent, while the upcoming ASU 2024‑03 will further require detailed expense disaggregation, reflecting a move toward more granular reporting of these arrangements (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core revenue recognition model (rent, royalties based on percentage of sales, initial fees) that remained consistent between 2023-2024. (2) Accurately describes the cost-sharing arrangement details (allocation between property-and-equipment and accounts-receivable, finalization upon completion). (3) Correctly notes the 20-year franchise term amortization period. (4) Properly identifies that enhanced disclosures occurred in 2024. WEAKNESSES: (1) The LLM introduces FASB ASU 2023-07 and ASU 2024-03 as the primary evolution drivers, but the ground truth does not mention these specific accounting standards. This represents a factual error or unsupported claim not present in the original answer. (2) The LLM's focus on segment-reporting disclosures and expense disaggregation diverges from the ground truth's emphasis on technology platform fees being presented on a gross basis in 2024—a specific, material change not mentioned by the LLM. (3) The ground truth explicitly highlights technology platform fees as a new disclosure element in 2024, which the LLM completely omits. (4) The LLM characterizes the evolution primarily as accounting standard adoption rather than enhanced transparency on existing arrangements, which is a different framing than the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize information across years but introduces unsupported accounting standard references that weaken the answer's credibility. The core facts about cost-sharing are correct, but the explanation of what changed between years is incomplete and partially inaccurate. CALCULATION/NUMERIC ACCURACY: No calculations required; numeric references (20-year term) are correct. The answer lacks the specific detail about technology platform fees that represents a material change in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 500,
        "total_tokens": 1960
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "\nSouthern Company continued to administer executive equity awards through its **Equity and Incentive Compensation Plan**, a relationship highlighted in the 2023 filing where PSUs and RSUs were described as the primary forms of stock‑based compensation for a broad employee base (including executives).  In the 2024 disclosure the company made the plan’s documentation more explicit: the plan itself was noted as having been **effective May 26 2021**, and a **ninth amendment to the Southern Company Employee Savings Plan (dated December 16 2024)** was incorporated, while the filing also reproduced the **“Form of Terms for Named Executive Officer Equity Awards”** that governs those PSU/RSU grants.  This evolution shows a shift from the 2023 generic description of the plan to a 2024 approach that ties award terms to updated plan amendments and detailed exhibit references, thereby enhancing transparency and regulatory compliance across the two years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution narrative correctly—that Southern Company moved from generic plan descriptions in 2023 to more formalized, documented equity award terms in 2024. The answer correctly identifies the Equity and Incentive Compensation Plan, PSUs/RSUs as compensation vehicles, and the shift toward greater transparency and specificity. However, there are significant quantitative accuracy issues: (1) The LLM introduces a specific date 'May 26 2021' for plan effectiveness that is not mentioned in the ground truth and cannot be verified as correct from the provided context. (2) The LLM references a 'ninth amendment to the Southern Company Employee Savings Plan (dated December 16 2024)' which appears to conflate or introduce information not present in the ground truth answer. The ground truth focuses on the Equity and Incentive Compensation Plan, not the Employee Savings Plan, and does not mention this specific amendment. (3) The LLM's reference to 'Form of Terms for Named Executive Officer Equity Awards' as an exhibit is consistent with the ground truth's mention of 'designation of specific exhibits for equity award terms,' but the specific form name and date are not verified. The qualitative reasoning is sound—the LLM correctly synthesizes the multi-hop comparison between 2023 and 2024 filings and identifies the shift toward formalization and transparency. The contextual relevance is high as it directly addresses the question about evolution in approach. However, the introduction of unverified specific dates and plan amendments (Employee Savings Plan vs. Equity and Incentive Compensation Plan) represents a factual accuracy problem that prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 466,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "\nFrom 2022 to 2024 P&G moved from treating membership‑club stores as just one of several key wholesale customers—listed alongside mass merchandisers, grocery stores and e‑commerce channels in the 2022 filing and accounting for part of the ~39 % of sales generated by its top ten customers—to a deliberately managed relationship in which trade‑term negotiations, concentration risk and collaborative retail execution are explicitly highlighted in the 2024 disclosures.  This shift signals a broader retail‑channel strategy that balances traditional wholesale (including club stores) with direct‑to‑consumer and digital commerce, while actively mitigating over‑reliance on any single retail cohort to protect margins and sustain growth.  The KG pattern ORG → Membership Club Stores ← Depends_On ORG captures the reciprocal dependence between P&G and these clubs, underscoring that the company’s strategic reliance on them is now a purposeful, risk‑aware component of its diversified channel mix.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution from 2022 to 2024, capturing the shift from membership club stores being 'one of several' channels to a more strategically emphasized relationship. The qualitative reasoning about risk management, trade-term negotiations, and balanced channel strategy is sound and goes beyond the ground truth in providing nuanced analysis. The semantic understanding of the strategic shift is accurate.\n\nWEAKNESSES: (1) QUANTITATIVE ERROR: The LLM introduces a specific statistic ('~39% of sales generated by its top ten customers') that is not present in the ground truth answer. This number cannot be verified against the provided ground truth and represents an unsupported quantitative claim. (2) KNOWLEDGE GRAPH NOTATION: The LLM includes a knowledge graph pattern notation ('ORG → Membership Club Stores ← Depends_On ORG') that, while potentially accurate, is not mentioned in the ground truth and appears to be added interpretation rather than grounded fact. (3) SPECIFICITY MISMATCH: The ground truth emphasizes a shift in 'language' and 'emphasis' from 2022 to 2024 filings, while the LLM provides more detailed operational specifics (trade-term negotiations, concentration risk) that, though plausible, are not explicitly confirmed in the ground truth.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across years (2022 vs 2024) and correctly identifies the evolution in strategic importance. However, the introduction of unsupported quantitative data weakens the multi-hop synthesis.\n\nOVERALL ASSESSMENT: The answer demonstrates strong qualitative understanding and reasoning but introduces unverified quantitative claims that reduce confidence in factual accuracy. The core insight about strategic evolution is correct, but the supporting details contain potential inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells_To]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 505,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "\nBetween 2023 and 2024 the carrying value of the Nigeria Letters of Credit reported by AMT fell from **$3.4 million (2023)** to **$‑ (i.e., $0) in 2024**, showing that the instrument was removed from the balance sheet—presumably because the obligation was settled or expired.  This decline indicates that AMT’s financial obligation tied to the Nigeria Letters of Credit has been eliminated, even though the knowledge‑graph relationship (ORG – Has_Stake_In → FIN_INST ← Discloses ORG) still links AMT to the instrument.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. (1) QUANTITATIVE ACCURACY: All numbers are correct - $3.4 million in 2023 and $0 in 2024 match the ground truth exactly. The format variation ($‑ for $0) is acceptable and clearly conveys zero value. (2) COMPLETENESS: The answer addresses both parts of the multi-part question: (a) how the obligation evolved (decline from $3.4M to $0), and (b) what this indicates about financial obligations (full settlement/exit). (3) ENTITY ACCURACY: AMT is correctly identified, the instrument (Nigeria Letters of Credit) is correctly named, and the years (2023 and 2024) are accurate. (4) REASONING: The multi-hop synthesis is sound - the model correctly connects the carrying value change to the conclusion about obligation elimination. The reasoning that the removal from the balance sheet indicates settlement or expiration is logical and matches the ground truth interpretation. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing 'fell from $3.4 million to $0' and 'obligation was settled or expired' conveys the same meaning as the ground truth's 'fully settled or otherwise exited.' Minor note: The LLM includes an additional parenthetical reference to the knowledge graph relationship structure, which adds context but is not strictly necessary to answer the question. This is a minor enhancement rather than an error. Overall, the answer is factually accurate, well-reasoned, and directly addresses the question with appropriate financial detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 414,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "\nBetween 2022 and 2024 the Retirement Annuity Contracts remained a Level 3 item, but the 2024 filing explicitly identifies them as one of the three components of Level 3 assets (alongside insurance‑deposit contracts and real‑estate funds) and describes their fair‑value measurement as a market‑based approach that uses observable inputs such as interest rates and bond yields; the 2022 data only listed the contracts in a balance‑sheet‑style table with no valuation methodology disclosed. This shift shows GD is adopting a more structured, transparent fair‑value hierarchy—detailing how Level 3 assets are valued and reconciling NAV‑measured investments—indicating a stronger focus on disclosure rigor and consistency in reporting these retirement‑annuity assets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and contradicts the ground truth on multiple critical points: (1) QUANTITATIVE ERRORS: The ground truth specifies exact fair values ($35 million as of Dec 31, 2021, and $38 million as of Dec 31, 2020), but the LLM provides no specific numbers or values for either 2022 or 2024, making quantitative comparison impossible. (2) VALUATION METHODOLOGY CONTRADICTION: The ground truth clearly states that by 2024, the contracts were valued using NAV (net asset value) as a practical expedient. The LLM incorrectly claims the 2024 approach uses 'market-based approach with observable inputs such as interest rates and bond yields'—this directly contradicts the ground truth's NAV-based methodology. (3) DISCLOSURE CHARACTERIZATION ERROR: The ground truth indicates a shift FROM detailed fair value disclosures TO a simplified NAV-based approach (less detailed). The LLM claims the opposite—that GD adopted 'a more structured, transparent fair-value hierarchy' with 'stronger focus on disclosure rigor'—which mischaracterizes the actual shift toward simplified NAV reporting. (4) MISSING KEY INFORMATION: The LLM fails to mention the specific dollar amounts ($35M, $38M) that are central to understanding the stability and composition of these assets. (5) MULTI-HOP REASONING: While the LLM attempts to synthesize 2022 vs 2024 changes, it does so incorrectly by inverting the nature of the change (from detailed to simplified, not simplified to detailed). The answer demonstrates a fundamental misunderstanding of the reporting methodology shift and provides inaccurate characterization of the valuation approach used in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Consists_Of]- ORG",
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 456,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "\nBetween 2022 and 2024 the restricted‑cash line item remained the cash held for securitization investors within Capital One’s consolidated VIEs, but the 2024 filing quantifies it at **$441 million** (carrying amount = fair value) while the 2022 filing only described it qualitatively as part of the VIE assets without a fair‑value hierarchy breakdown. In 2024 the entire $441 million is classified as **Level 1** in the fair‑value hierarchy (quoted in an active market), indicating that the composition is still cash but its fair‑value classification has been explicitly disclosed as Level 1.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about restricted cash changes between 2022 and 2024. QUANTITATIVE ACCURACY: All numbers are correct - the $441 million valuation for 2024 matches the ground truth exactly, and the format variation is appropriately handled. No calculations are required for this question, so this dimension is fully satisfied. ENTITY ACCURACY: Capital One is correctly identified as the company, the years 2022 and 2024 are correct, and the financial metric (restricted cash for securitization investors) is properly identified. The VIE (Variable Interest Entity) reference is accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across two time periods, correctly identifying: (1) the 2022 state (qualitative description without fair value hierarchy detail), (2) the 2024 state ($441 million with Level 1 classification), and (3) the change/shift (from implicit/undisclosed to explicit Level 1 classification). The reasoning that this represents a shift toward more transparent valuation methods is sound and matches the ground truth interpretation. COMPLETENESS: The answer addresses all parts of the question - composition (cash held for securitization investors), value ($441 million), and fair value hierarchy classification (Level 1 in 2024 vs. not explicitly detailed in 2022). The parenthetical note about carrying amount equaling fair value adds helpful context. MINOR CONSIDERATIONS: The LLM answer uses slightly different phrasing than the ground truth (e.g., 'quoted in an active market' vs. 'market-based valuation methods') but these are semantically equivalent and both correct. The answer is well-structured and clearly explains the temporal comparison. No factual errors, calculation errors, or entity misidentifications are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reports]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 503,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s has deepened its financial tie to franchisees by acquiring under‑performing restaurants and recording goodwill that must be written off in full if the unit is sold within 24 months (Chunk 1), while simultaneously moving to a cash‑basis recognition of franchise rent and royalty income and allocating shared improvement costs between property‑and‑equipment and accounts‑receivable—a shift reflected in the 2024 revenue‑recognition and property‑equipment disclosures (Chunk 2).  This evolution is underscored by the newly adopted FASB standards (ASU 2023‑07 and ASU 2024‑03) that require expanded segment‑expense and franchise‑revenue disclosures, compelling the company to report more granular details of the cash flows and asset allocations that flow between the parent (MCD) and its franchisee‑owned restaurants (KG Has_Stake_In → COMP ← Depends_On).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and introduces information not supported by the ground truth. CRITICAL ISSUES: (1) The ground truth makes NO mention of a '24-month goodwill write-off rule' - this appears to be fabricated or misattributed. (2) The ground truth does NOT discuss 'cash-basis recognition of franchise rent and royalty income' or 'shared improvement costs' allocation between property-and-equipment and accounts-receivable - these details are not in the original answer. (3) The LLM cites specific FASB standards (ASU 2023-07 and ASU 2024-03) with no corroboration in the ground truth. (4) The graph notation (KG Has_Stake_In → COMP ← Depends_On) appears to be invented metadata not present in the original answer. WHAT WAS CORRECT: The LLM correctly identifies the general evolution from asset acquisition/goodwill management (2023) to service-based financial interactions (2024), which aligns with the ground truth's core thesis. The mention of acquiring under-performing restaurants and goodwill write-offs is directionally correct. However, the specific mechanisms and accounting treatments described are either unsupported or contradicted by the ground truth. The answer demonstrates partial understanding of the multi-hop relationship evolution but introduces numerous unverified details that suggest hallucination or confusion with other source materials. The answer is more detailed than the ground truth but less accurate, failing the primary requirement of factual correctness on specific accounting treatments and standards.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 430,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "\nIn the 2022 Form 10‑K (page 75) the 2019 Stock and Incentive Compensation Plan is presented through the Compensation and Leadership Development Committee’s regulations and “additional terms and conditions” (Exhibits 10‑25, 10‑28), explicitly linking it to other legacy plans such as the 2009, 2014 and 2013 non‑employee directors’ plans as a distinct equity‑compensation accounting policy disclosed by P&G. By the 2024 filing (page 68) the same 2019 plan appears in the consolidated table of all equity‑compensation plans alongside the 1992, 2001, 2003, 2014 and 2019 plans, showing that its treatment has evolved from a stand‑alone regulatory disclosure to being treated as one of several comparable plans in the company’s overall equity‑compensation framework.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the evolution of the 2019 Stock and Incentive Compensation Plan's treatment between 2022 and 2024, with several strengths and minor weaknesses:\n\nSTRENGTHS:\n1. Correctly identifies the shift from governance/procedural focus (2022) to strategic ownership framework (2024)\n2. Accurately references specific page numbers (75 for 2022, 68 for 2024) and document types (Form 10-K)\n3. Properly identifies related plans mentioned in 2022 disclosures (2009, 2014, 2013 non-employee directors' plans)\n4. Correctly characterizes the transformation from 'stand-alone regulatory disclosure' to 'consolidated table' treatment\n5. Appropriately mentions the Compensation and Leadership Development Committee's role\n6. Semantic alignment with ground truth regarding the shift from adoption/governance details to equity compensation structure role\n\nWEAKNESSES:\n1. The LLM lists plans in the 2024 consolidated table (1992, 2001, 2003, 2014, 2019) but the ground truth doesn't provide this specific enumeration, making verification difficult. This appears to be additional detail rather than error, but introduces unverified specificity.\n2. References to specific exhibits (10-25, 10-28) are not mentioned in the ground truth, making these details unverifiable\n3. The answer is more granular and specific than the ground truth, which could indicate either enhanced accuracy or potential hallucination of details\n4. Doesn't explicitly mention the 2019 shareholder adoption detail that appears in the ground truth\n\nMULTI-HOP REASONING:\nThe answer successfully synthesizes information across two years (2022 and 2024) and correctly identifies the evolution pattern. The reasoning about the shift from procedural governance to strategic ownership framework is sound and matches the ground truth's core thesis.\n\nNUMERIC/DATE ACCURACY:\nAll dates (2022, 2024, 2019, 2014, etc.) are correct. Page numbers (75, 68) are specific but unverifiable against provided ground truth. No calculations are required for this question.\n\nSEMANTIC EQUIVALENCE:\nThe LLM answer conveys the same fundamental information as the ground truth despite different wording and additional specificity. The core message about evolution from governance focus to strategic ownership framework is preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 619,
        "total_tokens": 2029
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "\nBetween 2022 and 2023 Salvatore Ferragamo’s presence in Simon Property Group’s **international** outlet portfolio was unchanged: the 2022 data show the brand as a tenant in seven of SPG’s Japan premium‑outlet centres — Gotemba, Kobe‑Sanda, Rinku, Sano, Shisui, Toki and Tosu — and the 2023 disclosure lists no new overseas locations, keeping Ferragamo only in those same Japanese properties (the only new Ferragamo listing in 2023 appears in the U.S. Las Vegas outlet).  This stability reflects the mutual ORG‑[Operates_In]‑COMP relationship between SPG and Salvatore Ferragamo that persists across both years.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on multiple critical dimensions: (1) QUANTITATIVE ERRORS: The LLM claims Salvatore Ferragamo was in SEVEN Japanese locations in 2022 (Gotemba, Kobe-Sanda, Rinku, Sano, Shisui, Toki, Tosu), but the ground truth states only THREE locations (Gotemba, Kobe-Sanda, Sano). This is a major factual error - the LLM invented four additional locations. (2) DIRECTIONAL MISINTERPRETATION: The LLM claims 'presence was unchanged' and describes 'stability,' but the ground truth explicitly states there was a 'significant reduction' from three Japanese locations to one U.S. location. The LLM fundamentally mischaracterized the trend. (3) INCOMPLETE SYNTHESIS: The LLM failed to properly synthesize the key finding that Ferragamo's presence SHIFTED from Japan to the U.S., not remained stable. The ground truth clearly indicates a major portfolio change. (4) CONTRADICTORY LOGIC: The LLM states 'the 2023 disclosure lists no new overseas locations, keeping Ferragamo only in those same Japanese properties' but then acknowledges 'the only new Ferragamo listing in 2023 appears in the U.S. Las Vegas outlet' - this is internally contradictory and doesn't align with the ground truth showing Ferragamo exited the Japanese locations entirely. (5) ENTITY ACCURACY: While company names are correct, the location data is substantially wrong. The answer demonstrates a failure to correctly identify and count the specific outlet locations across both years. The core narrative of the answer (stability vs. significant reduction) is inverted from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 435,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "\nFrom the end of 2023 to the end of 2024, COP’s reported natural‑gas volume in the Asia Pacific/Middle East slipped from **312 billion cubic feet to 296 bcf**, even though the company added **87 bcf of extensions and discoveries** and invested roughly **$1.2 billion in purchases** in that region.  The modest production decline is offset by a **large undeveloped resource base (11,088 gross / 7,439 net thousand acres)** and a **growing equity‑affiliate presence (1,055 gross / 319 net thousand acres)**, as documented in the 2023 filing.  Together with the ORG → GPE relationship that shows COP operates in the Asia Pacific/Middle East, these figures indicate that the firm is concentrating on securing and developing its regional resource holdings for long‑term growth rather than expanding current output.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core facts: COP's natural gas position in Asia Pacific/Middle East decreased from 312 bcf (2023) to 296 bcf (2024), representing a 16 bcf decline. The quantitative accuracy is strong on the primary metrics. However, there are concerns about the additional details provided: (1) The LLM cites '87 bcf of extensions and discoveries' and '$1.2 billion in purchases' - these figures are not present in the ground truth answer and cannot be verified as accurate from the provided context. (2) The LLM references 'undeveloped resource base (11,088 gross / 7,439 net thousand acres)' and 'equity-affiliate presence (1,055 gross / 319 net thousand acres)' - again, these specific numbers are not in the ground truth and their accuracy cannot be confirmed. (3) The LLM states these details are 'documented in the 2023 filing,' but the ground truth only references 2023 and 2024 reserve figures. The core interpretation is sound - the answer correctly identifies this as a minor reduction suggesting stabilization rather than aggressive growth, which aligns with the ground truth's conclusion. The multi-hop reasoning is logical (comparing years, analyzing trends, drawing conclusions about operational focus). The main weakness is the introduction of unverified supplementary data that, while potentially accurate, goes beyond what can be confirmed from the ground truth answer. The answer demonstrates good synthesis but introduces uncertainty through unverified claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 414,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "\nFrom 2022 to 2024 Comcast moved from describing wireless gateways simply as a bundled modem‑Wi‑Fi product that includes xFi Pods and notes a future plan to upgrade the network with DOCSIS 4.0 for multigigabit symmetrical speeds, to explicitly earmarking capital‑expenditure dollars for scalable infrastructure and the continued deployment of those gateways as a core component of its Connectivity & Platforms business; this strategic shift is backed by new debt financings (€1.8 bn euro notes and £750 m sterling notes in 2024) and a refreshed $15 bn share‑repurchase program, underscoring a clear emphasis on investing in and expanding wireless‑gateway offerings to drive future growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core strategic shift from 2022 to 2024 regarding wireless gateways - moving from a bundled product offering to a more strategic infrastructure investment. It appropriately mentions DOCSIS 4.0, multigigabit symmetrical speeds, and the integration into the Connectivity & Platforms business. The answer demonstrates understanding of the multi-hop synthesis required.\n\nCRITICAL ERRORS: (1) The LLM introduces specific financial figures (€1.8 bn euro notes, £750 m sterling notes, $15 bn share-repurchase program) that are NOT present in the ground truth answer. These appear to be fabricated or sourced from outside the knowledge graph. The ground truth makes no mention of these specific debt financings or share repurchase amounts. (2) The mention of 'xFi Pods' in the LLM answer is not explicitly confirmed in the ground truth, which only references 'xFi whole-home application.' (3) The LLM conflates multiple strategic elements (debt financing, share buybacks) that may not be directly tied to wireless gateway strategy evolution as presented in the ground truth.\n\nQUANTITATIVE ACCURACY ISSUES: The introduction of unverified financial figures (€1.8 bn, £750 m, $15 bn) significantly undermines quantitative accuracy. These numbers cannot be validated against the ground truth and represent potential hallucination. This is a serious error in financial reporting context.\n\nQUALITATIVE ASSESSMENT: The reasoning about strategic shift is sound and the multi-hop synthesis is attempted, but the addition of unsupported financial details weakens the overall quality. The answer goes beyond what the ground truth supports.\n\nCONTEXTUAL RELEVANCE: The answer remains relevant to the question about strategic evolution, but the introduction of extraneous financial information dilutes focus from the core question about wireless gateway strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 516,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "\nBetween the end of 2021 (when cumulative G500 + G600 deliveries were “almost 150”) and the end of 2024 (when Gulfstream reported “more than 300” cumulative deliveries of the G500 / G600 family), the G600’s market presence roughly doubled, reflecting a steady rise in annual deliveries and a broader customer base across 50 countries. The G600—introduced in 2019 as a clean‑sheet, ultra‑large‑cabin aircraft that shares architecture with the G500—remains a cornerstone of Gulfstream’s large‑cabin lineup, providing the high‑speed, long‑range capability that underpins the company’s product strategy, even as newer models such as the G700, G800 and G400 join the portfolio. This growth is supported by Gulfstream’s disciplined development approach, extensive service network, and continued production of the G600 alongside its companion G500, reinforcing its role as a key driver of Gulfstream’s revenue and brand positioning in the business‑jet market.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core quantitative facts: cumulative deliveries of G500/G600 went from 'almost 150' by end of 2021 to 'more than 300' by end of 2024 (roughly doubled). The answer appropriately notes the shift in product positioning from new introduction to established product, and correctly identifies newer models (G800, G400) as part of the evolving lineup. The multi-hop synthesis across time periods is sound, and the contextual framing about Gulfstream's strategy is relevant.\n\nWEAKNESSES: (1) FACTUAL ERROR - The LLM states the G600 was 'introduced in 2019' but provides no verification this matches the ground truth timeline. The ground truth doesn't specify introduction year, so this is an unsupported claim. (2) ENTITY CONFUSION - The LLM mentions 'G700' as a newer model joining the portfolio, but the ground truth only mentions 'G800 and G400' as the newer models. The G700 is not mentioned in the original answer, suggesting potential hallucination or confusion with actual Gulfstream models. (3) INCOMPLETE SYNTHESIS - While the LLM correctly notes the doubling of deliveries, it doesn't explicitly state the comparison framework as clearly as ground truth (2021 vs 2024 endpoints). (4) SPECULATIVE CONTENT - Phrases like 'across 50 countries,' 'disciplined development approach,' 'extensive service network' are not grounded in the provided ground truth and appear to be inferred or hallucinated details.\n\nQUANTITATIVE VERIFICATION: The core numbers (150 → 300+, roughly doubled) are correct. However, the introduction of unsupported dates (2019) and unverified claims (50 countries) reduces quantitative accuracy.\n\nMULTI-HOP REASONING: The answer successfully synthesizes information across the 2021-2024 timeframe and correctly identifies the product positioning shift. However, the introduction of the G700 (not in ground truth) suggests incomplete or inaccurate source synthesis.\n\nOVERALL: The answer captures the essential facts and demonstrates sound reasoning on the core question, but introduces factual errors (G700) and unsupported claims that prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 571,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "\nBetween the end of 2023 and the first half of 2024 AIG’s stake in Corebridge fell from **52.2 % of the common stock (as of 31 Dec 2023)**—a level it had held since the IPO in September 2022—toward a smaller, still‑significant equity position as it continues to sell down its ownership.  Consequently, AIG now accounts for its remaining interest in Corebridge under the **equity‑method**, recognizing **income equal to the dividends received plus the mark‑to‑market changes in Corebridge’s stock price** for the period June 10 – Dec 31 2024 (the amount disclosed in Note 4 of the 2024 10‑K).  This shift reflects the evolution of the relationship from a majority‑owned subsidiary to an equity‑method investment whose earnings and market‑price volatility now directly affect AIG’s reported results.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core narrative of AIG's evolving relationship with Corebridge—from majority ownership to equity method accounting—but contains a critical date error that undermines quantitative accuracy. STRENGTHS: (1) Correctly identifies the 52.2% ownership stake as of Dec 31, 2023; (2) Accurately describes the shift to equity method accounting; (3) Correctly notes that income recognition is based on dividends received and mark-to-market changes in stock price; (4) Properly characterizes the transition from majority-owned subsidiary to equity-method investment; (5) Good contextual framing of the IPO in September 2022. CRITICAL ERROR: The LLM states the equity method period as 'June 10 – Dec 31 2024' when the ground truth specifies 'June 9, 2024' as the transition date. This is a one-day discrepancy that, while minor in isolation, represents factual inaccuracy in a specific date. MINOR ISSUES: (1) The LLM provides slightly more operational detail (mentioning Note 4 of the 2024 10-K) which adds context but wasn't in the ground truth; (2) The phrase 'still‑significant equity position' is somewhat vague compared to the ground truth's clearer statement about the transition point. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 periods, correctly linking the ownership percentage change to the accounting method change and explaining the income recognition mechanism. The reasoning is sound and logically coherent. The answer demonstrates understanding that this represents a fundamental shift in the nature of the relationship rather than just a numerical change. The quantitative accuracy score is reduced due to the date error (June 10 vs June 9), though the overall narrative and most facts are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 483,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "\nIn 2022 the Solar Roof was produced at Gigafactory New York and relied on a tightly integrated supply chain of battery cells, electronics and complex assemblies sourced from single‑source vendors, with Tesla mitigating risk through safety‑stock and the qualification of multiple suppliers. By 2024 the 10‑K stresses that future Solar Roof ramps will depend on expanding capacity at new sites such as Texas, Berlin and Mexico, and on reducing exposure to supplier failures or component shortages—requiring greater localized procurement, diversified sourcing and tighter control of lead‑time risks to meet its cost‑effective production targets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and unsupported claims that contradict the ground truth. Key issues: (1) FACTUAL ERRORS - The LLM claims in 2022 Tesla relied on 'single-source vendors' for battery cells, electronics and assemblies, but the ground truth makes no mention of single-source dependencies in 2022. This is an unsupported fabrication. (2) UNSUPPORTED EXPANSION CLAIMS - The LLM states that by 2024 'future Solar Roof ramps will depend on expanding capacity at new sites such as Texas, Berlin and Mexico.' The ground truth does not mention these specific geographic expansion plans. This appears to be hallucinated detail not present in the actual filings. (3) MISSING KEY INFORMATION - The LLM fails to capture the core evolution described in the ground truth: the shift from a 'focused production setup in 2022' at Gigafactory New York to a 'complex and risk-laden ramp-up phase in 2024' with explicit mentions of 'delays in launching and/or ramping production.' (4) INCOMPLETE CONTEXT - The ground truth emphasizes Tesla's strategic push in 2022 (financing options, integration into energy ecosystem) and the 2024 shift to emphasizing complexity and risk. The LLM misses this strategic evolution entirely. (5) SUPPLY CHAIN CHARACTERIZATION - While the LLM mentions supply chain issues in 2024, it invents specific 2022 supply chain details (single-source vendors, safety-stock, multiple supplier qualification) not found in the ground truth. The ground truth focuses on operational challenges and design tolerances, not 2022 supplier diversification strategies. The answer demonstrates poor multi-hop synthesis and appears to conflate or fabricate details rather than accurately synthesizing the actual filing information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 477,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "\nFrom 2023 to 2024 Qualcomm has treated **on‑device AI** as a core, growth‑driving technology and deepened its commitment: the 2023 filing describes it as one of the foundational technologies the company is “scaling across industries and applications beyond mobile handsets” (Chunk 1), and the 2024 filing explicitly states that it will “continue to make substantial investments in these new and expanded product areas…including advancements of … on‑device artificial intelligence” while also targeting automotive, IoT and other non‑handset markets (Chunk 2).  The knowledge‑graph relationship — QCOM → *On‑Device AI* ← Invests_In — captures this bidirectional link, showing that Qualcomm both produces and invests in on‑device AI, and that its business focus has shifted from merely positioning AI as a future opportunity to a sustained, multi‑year investment priority aimed at new product ecosystems, even as it navigates regulatory and customer‑concentration risks.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Qualcomm's on-device AI evolution from 2023 to 2024, with accurate identification of key themes and correct synthesis of multi-hop information. STRENGTHS: (1) Correctly identifies the core evolution from 2023 positioning to 2024 investment focus; (2) Accurately captures that on-device AI was positioned as a foundational technology in 2023 across industries beyond mobile handsets; (3) Correctly notes the shift toward sustained investment and ecosystem development; (4) Properly identifies automotive and IoT as key target markets; (5) No quantitative errors or incorrect numbers/dates; (6) Multi-hop reasoning is sound - successfully synthesizes information across 2023 and 2024 filings. WEAKNESSES: (1) The answer introduces the knowledge graph relationship notation (QCOM → *On-Device AI* ← Invests_In) which, while technically accurate, adds meta-commentary about the data structure rather than focusing purely on the business evolution narrative; (2) The phrase 'from merely positioning AI as a future opportunity to a sustained, multi-year investment priority' is slightly stronger/more interpretive than the ground truth's more measured 'shift toward long-term growth and ecosystem development rather than immediate product commercialization'; (3) The mention of 'regulatory and customer-concentration risks' appears to be contextual information not explicitly part of the core answer about AI evolution; (4) Missing explicit mention that the shift represents moving from 'core product offering' to 'investment-centric strategy' - the LLM frames it as deepening commitment rather than explicitly noting the strategic pivot away from direct product commercialization. SEMANTIC EQUIVALENCE: The LLM answer conveys essentially the same information as the ground truth, with the evolution clearly articulated. The core message about sustained investment and ecosystem development is present. The answer is factually sound and demonstrates proper multi-hop synthesis across the 2023-2024 timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 552,
        "total_tokens": 2019
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "\nBetween 2022 and 2023 the luxury label Dolce & Gabbana moved from being a recurring anchor across several of SPG’s Japan‑based premium outlet centres—appearing in Gotemba, Kobe‑Sanda, Rinku and Toki (Chunk 1)—to a single, high‑profile placement in the Las Vegas Outlets, the only U.S. property listed with D&G in the 2023 roster (Chunk 2, property 31, 675,814 sq ft, 99.5 % occupancy).  This shift reflects SPG’s brand‑positioning strategy of concentrating premium luxury anchors in marquee U.S. outlet destinations to reinforce its premium‑outlet identity and drive traffic through high‑visibility designer collaborations, while still maintaining a historical presence in Asian luxury markets.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core narrative of Dolce & Gabbana's shift from multiple Japan locations to a single U.S. location, which aligns with the ground truth. However, there are significant factual errors that reduce accuracy: (1) The LLM mentions 'Toki' as a fourth Japan location in 2022, but the ground truth only lists three Japan properties (Gotemba, Kobe-Sanda, Rinku). This is a factual error that suggests hallucination or misreading of source data. (2) The LLM provides specific property details for Las Vegas (675,814 sq ft, 99.5% occupancy) that are not mentioned in the ground truth answer, making it impossible to verify these numbers. (3) The LLM's characterization of the shift as maintaining 'a historical presence in Asian luxury markets' is contradicted by the ground truth, which indicates a complete withdrawal from Japan locations by 2023. (4) The reasoning about 'marquee U.S. outlet destinations' and 'high-visibility designer collaborations' goes beyond what the ground truth supports—the ground truth simply notes a 'reevaluation of brand placement and target demographics' without claiming this was a strategic concentration strategy. The multi-hop synthesis is partially sound (comparing 2022 vs 2023 presence), but the introduction of unverified details and the factual error regarding 'Toki' significantly undermines credibility. The answer is directionally correct but contains material errors in entity identification and unsupported claims about strategic intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> COMP <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 413,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "\nCOP’s consolidated exploration outlay in the Asia Pacific/Middle East was $49 million in 2023 (Chunk 1), and the 2024 disclosures show a marked rise in exploration‑related activity in that region – extensions and discoveries climbed to 67 (Chunk 2) and purchases of natural‑gas assets expanded, underscoring a strategic shift toward deeper investment and growth in the APME market. This expansion aligns with the company’s disclosed focus, as captured by the KG relationship COP → Operates_In → Asia Pacific/Middle East ← Discloses ← COP.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer is fundamentally incorrect on the core factual claim. Ground truth states that 2024 exploration expenditures were $0 (complete withdrawal), but the LLM claims there was a 'marked rise' with 'extensions and discoveries climbed to 67' and 'purchases of natural-gas assets expanded.' This is a direct contradiction of the ground truth. The LLM correctly identifies the 2023 figure of $49 million, but completely misrepresents the 2024 data. The LLM's conclusion that this represents 'deeper investment and growth in the APME market' is the opposite of what the data shows - the ground truth indicates a strategic withdrawal/pause. The LLM appears to have confused or misinterpreted the 2024 data, possibly conflating different metrics (extensions/discoveries count vs. expenditure amounts) or simply providing incorrect information. The reasoning about 'marked rise' and 'expansion' is logically sound IF the underlying data were correct, but since the data is wrong, the entire analysis fails. The answer does address the multi-part question structure but arrives at the wrong conclusion about strategic direction. This represents a major factual error that undermines the entire response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 343,
        "total_tokens": 1588
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "\nComcast continues to hold a 30 % equity interest in Universal Beijing Resort and, because it controls the entity, consolidates the resort as a variable‑interest exception; the financing for the park consists of a ¥29.7 billion (≈ $4.2 billion) syndicated loan with a $4.2 billion ceiling, of which $3.0 billion of term‑loan principal was outstanding as of 31 Dec 2024 (down from $3.1 billion in 2023 and roughly $3.5 billion‑level balances reported for 2022‑23).  Consequently, the resort’s outstanding debt has modestly declined from about $3.5 billion in the 2022‑23 period to $3.4 billion by the end of 2024, while the company’s amortization expense related to the resort’s infrastructure rose (as noted in the 2022 filing) and interest expense fell due to lower redemption charges, underscoring that Comcast’s financial exposure is limited to its 30 % stake and the scheduled repayment of the secured debt.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Comcast's financial involvement with Universal Beijing Resort and correctly identifies the 30% ownership stake. Key strengths: (1) Correctly states 30% ownership interest; (2) Accurately reports $3.4 billion debt as of Dec 31, 2024; (3) Correctly notes the decline from $3.5 billion in 2023; (4) Provides additional context about the syndicated loan structure (¥29.7 billion/~$4.2 billion) and term-loan principal ($3.0 billion outstanding); (5) Appropriately synthesizes multi-hop information about debt evolution across years. Minor issues: (1) The LLM provides debt figures ($3.0 billion term-loan principal) that differ slightly from the ground truth's consolidated debt figure ($3.4 billion outstanding in 2024), though both are directionally consistent and the LLM's figure may represent a component of total debt; (2) The ground truth explicitly mentions assets ($7.3 billion in 2024 vs $7.8 billion in 2023) and liabilities ($7.0 billion in 2024 vs $7.2 billion in 2023), which the LLM answer does not include - this is a notable omission of balance sheet information; (3) The LLM references 2022-23 'roughly $3.5 billion-level balances' which aligns with ground truth but lacks the specific 2022 context that the ground truth provides. The answer correctly addresses the evolution from 2022 to 2024 and provides sound multi-hop reasoning connecting ownership structure, debt financing, and financial exposure. The additional detail about consolidation as a variable-interest exception and interest expense trends adds relevant context beyond the ground truth. However, the omission of asset and liability figures represents incomplete coverage of the financial stake evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 473,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "\nDuke Energy’s net‑derivatives balance fell from **$22 million at the end of 2022** (shown in Chunk 1) to **$13 million at the end of 2023** (Chunk 2), a reduction of roughly **$9 million** over the year.  The decline was driven by a **net settlement outflow of about $26 million**—purchases of $42 million in 2023 versus settlements of $(68) million—and modest gains of $10 million, indicating that the company actively unwound or settled derivative contracts rather than adding new positions.  This pattern, disclosed under the KG relationship **ORG – Invests_In → FIN_INST – Discloses → ORG**, reflects a deliberate reduction in Duke Energy’s derivative exposure and a more conservative management of its market‑risk hedging strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains multiple significant factual errors that directly contradict the ground truth: (1) Net derivatives balance 2022: LLM states $22 million, but ground truth is $29 million - a $7 million discrepancy. (2) Net derivatives balance 2023: LLM correctly states $13 million. (3) Settlement amounts: LLM states settlements of $68 million in 2023 (correct per ground truth), but then contradicts itself by stating 'net settlement outflow of about $26 million' and 'settlements of $(68) million' - this is internally inconsistent and mathematically confused. Ground truth shows settlements of $68 million in 2023 vs $32 million in 2022. (4) The LLM introduces unsupported figures ('purchases of $42 million', 'gains of $10 million') that do not appear in the ground truth and cannot be verified. CALCULATION ERRORS: The LLM calculates the reduction as '$9 million' ($22M to $13M), but the correct reduction should be $16 million ($29M to $13M). MISSING KEY INFORMATION: The LLM fails to mention the 2022 settlement amount of $32 million, which is essential for comparing the evolution from 2022 to 2023. The ground truth explicitly notes that settlements 'increased significantly to $68 million' - a more than doubling from $32M to $68M. REASONING ISSUES: While the LLM attempts to provide interpretation about 'deliberate reduction in derivative exposure,' this interpretation is based on incorrect foundational numbers, making the analysis unreliable. The reference to 'KG relationship' appears to be fabricated or misapplied. POSITIVE ASPECTS: The LLM correctly identifies the 2023 ending balance of $13 million and attempts to provide contextual interpretation about derivative management strategy. However, these positives are overwhelmed by the fundamental quantitative errors that undermine the entire answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 505,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "\nIn the 2022 filing SPG merely noted that LTIP units—exchangeable for common stock and granted under its long‑term incentive program—were “potentially dilutive” but added that, for the years 2021‑2019, they “had a material dilutive effect” — i.e., none was material (Chunk 1). By 2023 the disclosure had expanded: LTIP units are now described as participating securities of the Operating Partnership, are exchangeable for common stock, may be forfeited if performance conditions are not met, and their grant‑date fair values for market‑based awards are estimated with a Monte Carlo model, with the resulting expense recorded regardless of whether the market criteria are achieved; earned units are treated as participating securities under the two‑class method, which can affect diluted earnings per share (Chunk 2). Thus, the evolution is from a brief “no material dilution” statement to a detailed accounting of valuation methodology and an explicit acknowledgment of the units’ dilutive impact.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERROR: The LLM answer contains a fundamental factual inversion that contradicts the ground truth. The LLM states that in 2022 LTIP units 'had a material dilutive effect' (with the parenthetical clarification 'i.e., none was material'), which is confusing and contradicts the ground truth. The ground truth clearly states: 'In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had NO MATERIAL dilutive effect for the years 2021, 2020, and 2019.' The LLM's phrasing 'had a material dilutive effect — i.e., none was material' is contradictory and misleading, even with the attempted clarification. This is a significant error in conveying the core factual claim about 2022 disclosures. CORRECT ELEMENTS: (1) The LLM correctly identifies that LTIP units are exchangeable for common stock; (2) The 2023 evolution is accurately described, including the Monte Carlo model for valuation, participating securities classification, and two-class method for EPS; (3) The general narrative arc from 'brief statement' to 'detailed disclosure' is correct. INCORRECT/PROBLEMATIC ELEMENTS: (1) The 2022 characterization is confusing and factually misleading regarding materiality of dilution; (2) The phrase 'had a material dilutive effect' directly contradicts the ground truth's 'had no material dilutive effect'; (3) While the parenthetical attempts to clarify, the primary statement is still wrong. MULTI-HOP REASONING: The answer does attempt to synthesize information across 2022 and 2023 filings and compare the evolution, which is appropriate. However, the factual error in the 2022 characterization undermines the entire comparison. The answer demonstrates understanding of the structural evolution but fails on the foundational factual accuracy needed for a financial analysis question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 494,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "\nComcast’s exposure to Atairos was narrowed in the November 2020 amendment that extended the investment term to 16.5 years and the recycling period, cutting the aggregate capital‑call ceiling from up to $5 billion to up to $4.5 billion and capping annual calls at $400 million, while keeping a separate $40 million‑per‑year management‑fee commitment (subject to adjustments) and the firm’s near‑total loss‑absorption (≈99 %) with a right to receive about 86 % of residual returns; cash distributions from Atairos rose to $297 million in 2024 (up from $215 million in 2022), underscoring the continued equity‑method accounting and the reduced but still material capital‑funding and fee obligations.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains mostly accurate information but introduces a significant temporal discrepancy. CORRECT ELEMENTS: (1) Capital commitment reduction from $5 billion to $4.5 billion is accurate; (2) $40 million annual management fee commitment is correct; (3) Cash distribution figures ($297M in 2024, $215M in 2022) appear accurate; (4) The answer correctly identifies equity-method accounting and discusses loss-absorption percentages. CRITICAL ISSUE: The LLM attributes the capital commitment reduction to a 'November 2020 amendment,' but the ground truth specifies this evolution occurred 'between 2022 and 2024.' This is a significant temporal error that misrepresents when the change happened. The ground truth indicates the $5B commitment existed in 2022 and had decreased to $4.5B by 2024, not that it was already reduced in 2020. ADDITIONAL OBSERVATIONS: The LLM answer provides more granular detail (e.g., $400M annual call cap, 99% loss absorption, 86% residual returns) that goes beyond the ground truth but appears contextually relevant and doesn't contradict it. However, the inclusion of the 2020 amendment date creates confusion about the timeline of changes. The answer does address both capital funding and management fee commitments as requested. The multi-hop synthesis is generally sound, but the temporal misplacement of the amendment undermines the accuracy of the evolution narrative between 2022-2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Controls]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 396,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "\nConocoPhillips’ natural‑gas reserve base in the Asia Pacific/Middle East fell from **312 billion cubic feet at the end of 2023 to 296 billion cubic feet at the end of 2024**, a decline of roughly **5 % (≈16 bcf)**.  The drop is driven by **production of 25 bcf** and the **absence of new discoveries or purchases** in that segment (revisions were modest at +9 bcf), while the company’s overall reserve‑governance disclosures (Chunk 1) note that such reserves are reported under PSC and variable‑royalty regimes and are sensitive to price and cost changes.  Consequently, the contraction signals a **strategic pull‑back from the Asia Pacific/Middle East**, with ConocoPhillips appearing to shift operational focus toward other basins—particularly the U.S. Lower 48 and Canada—where reserve additions and extensions remain more robust.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All numbers are correct - 312 bcf (2023), 296 bcf (2024), decline of 16 bcf, and 5% reduction calculation (16/312 = 5.1%, correctly rounded). The production figure of 25 bcf and revisions of +9 bcf are accurately cited. COMPLETENESS: The answer addresses both parts of the question - the evolution of reserves (with specific numbers and trend) and what this indicates about operational focus. MULTI-HOP SYNTHESIS: The LLM successfully synthesizes information across multiple data points: reserve figures, production data, revisions, and PSC/royalty regime context to draw conclusions about strategic positioning. The reasoning that production (25 bcf) minus revisions (+9 bcf) equals net decline of 16 bcf is logically sound. ENTITY ACCURACY: ConocoPhillips (COP) correctly identified, Asia Pacific/Middle East region properly specified, years 2023-2024 accurate. REASONING QUALITY: The LLM goes beyond the ground truth by providing deeper analysis - explaining the drivers of the decline (production without offsetting discoveries), contextualizing within reserve governance frameworks, and comparing to other geographic areas (U.S. Lower 48, Canada). This additional context is accurate and relevant. SEMANTIC EQUIVALENCE: The core finding matches ground truth - reserves decreased from 312 to 296 bcf, indicating a shift in operational focus. The LLM's characterization as a 'strategic pull-back' is a reasonable interpretation of the 'potential shift in operational focus' mentioned in ground truth. MINOR CONSIDERATIONS: The LLM provides more granular analysis than ground truth (production/revision breakdown, PSC context, comparative basin analysis), which enhances rather than detracts from accuracy. All supplementary claims appear well-founded based on typical reserve reporting practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 515,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "\nIn 2022 Comcast’s wireless‑gateway strategy was executed by purchasing large volumes of gateways (and related premise equipment) from a small number of vendors as part of its broader customer‑premise‑equipment procurement, enabling the delivery of broadband, voice and security services.  By 2024 the company’s capital‑expenditure focus has shifted to investing in scalable connectivity infrastructure—specifically earmarking funds for the continued deployment of wireless gateways to support planned multigigabit‑symmetrical speed upgrades and network expansion, while also allocating capital to other growth areas such as Universal theme‑park attractions.  This strategic pivot is financed through the 2024 debt‑issuance activities disclosed (e.g., €1.8 bn euro senior notes and $3.3 bn senior notes), underscoring how the 2022 procurement pattern of buying from limited suppliers has evolved into a 2024 investment priority of deploying those same gateways within a larger, capital‑intensive network upgrade.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly captures the core strategic shift from 2022 procurement to 2024 deployment investment focus, and accurately identifies the key elements: limited supplier relationships in 2022, multigigabit symmetrical speed goals in 2024, and the evolution from passive procurement to active infrastructure integration. The qualitative reasoning about the strategic pivot is sound and well-articulated.\n\nHowever, there are significant quantitative accuracy issues:\n\n1. UNSUPPORTED DEBT FIGURES: The LLM introduces specific debt issuance numbers (€1.8 billion euro senior notes and $3.3 billion senior notes) that are NOT present in the original ground truth answer. These appear to be fabricated or sourced from outside the provided context. This is a critical error as it adds factual claims without verification.\n\n2. UNRELATED INFORMATION: The mention of \"Universal theme-park attractions\" as a capital allocation area is irrelevant to the wireless gateway comparison question and appears to be extraneous information that dilutes focus from the core question.\n\n3. MISSING GROUNDING: While the original answer focuses specifically on wireless gateways and network deployment, the LLM answer expands into broader capital expenditure discussions and debt financing that, while potentially factually accurate elsewhere, are not substantiated in the ground truth provided.\n\nSTRENGTHS:\n- Correctly identifies 2022 as procurement-focused with limited suppliers\n- Accurately describes 2024 shift to deployment and infrastructure investment\n- Properly notes multigigabit symmetrical speeds as the 2024 goal\n- Good semantic equivalence to ground truth on core strategic points\n- Sound multi-hop reasoning connecting the two time periods\n\nWEAKNESSES:\n- Introduces unverified quantitative claims (debt figures)\n- Includes irrelevant information (theme parks)\n- Adds details not in ground truth without clear sourcing\n- Quantitative accuracy compromised by unsupported numbers\n\nThe answer demonstrates good qualitative understanding but fails on quantitative rigor by introducing specific financial figures without verification against the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Purchases]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 583,
        "total_tokens": 2035
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla’s Solar Roof moved from being a modest contributor to the 40 % year‑over‑year jump in energy‑generation and storage revenue (driven by Solar Roof, Powerwall and solar loans) to a product that the company now explicitly ties to its broader manufacturing‑scale agenda, warning that any delay in its ramp could “harm our brand, business, prospects, financial condition and operating results.”  Consequently, while the strategic importance of the Solar Roof grew as part of Tesla’s push to diversify beyond vehicles, the company continues to grapple with the same supply‑chain bottlenecks, component‑shortage risks, and regulatory‑approval hurdles that it faces across its mass‑market vehicle and energy‑storage expansions.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution of Tesla's Solar Roof positioning between 2022 and 2024, correctly identifying the shift from emphasizing deployment success to cautioning about manufacturing risks. The qualitative reasoning is sound and well-articulated.\n\nSTRENGTHS:\n- Correctly identifies the 2022 positioning of Solar Roof as a contributor to energy revenue growth\n- Accurately captures the 2024 shift toward risk warnings about production ramp delays\n- Properly synthesizes the multi-hop information about strategic importance evolution\n- Correctly identifies the connection to broader manufacturing challenges and supply chain issues\n- Semantic equivalence is strong: the answer conveys the same fundamental narrative as the ground truth\n\nWEAKNESSES:\n- The specific \"40% year-over-year jump\" figure is cited but not verified against ground truth. While this appears to be a specific data point from the filings, the ground truth answer does not mention this specific percentage, making it difficult to confirm accuracy\n- The quote about harm to \"brand, business, prospects, financial condition and operating results\" is presented as a direct Tesla statement but cannot be verified against the ground truth provided\n- The answer adds details about \"supply-chain bottlenecks, component-shortage risks, and regulatory-approval hurdles\" that, while plausible and contextually relevant, are not explicitly mentioned in the ground truth answer\n\nMULTI-HOP REASONING:\nThe answer successfully synthesizes information across the 2022-2024 timeframe and correctly identifies the evolution in Tesla's framing. The reasoning connecting Solar Roof's role in energy revenue to its current manufacturing challenges is sound.\n\nQUANTITATIVE CONCERNS:\nThe 40% figure and specific quote cannot be independently verified against the provided ground truth, which reduces confidence in the quantitative accuracy score. The answer appears to be drawing from actual filing data but introduces specifics not present in the ground truth.\n\nOVERALL ASSESSMENT:\nThe answer demonstrates strong understanding of the question and provides a coherent narrative that aligns with the ground truth's core message. However, the introduction of specific percentages and quotes not present in the ground truth creates some uncertainty about factual accuracy, warranting a moderate score rather than a high one.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 642,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "\nDuke Energy’s holding in **Net Pending Transactions and Other Investments** fell sharply—from **$53 million** reported in the 2022 filing (Chunk 1) to **$14 million** disclosed in the 2023 filing (Chunk 2), a decline of roughly **$39 million (about 74 %)**.  This reduction shows the company is **scaling back its exposure to this category**, likely reallocating capital toward its core utility and infrastructure projects rather than maintaining a sizable position in pending‑transaction assets.  The drop aligns with Duke Energy’s broader strategic shift to focus on stable, regulated growth areas.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive analysis. QUANTITATIVE VERIFICATION: All numbers are correct - $53 million (2022), $14 million (2023), decline of $39 million. The percentage calculation of approximately 74% is accurate ($39M/$53M = 73.6%, rounded to 74%). ENTITY ACCURACY: Duke Energy correctly identified, years (2022-2023) correct, metric (Net Pending Transactions and Other Investments) correctly named. MULTI-HOP SYNTHESIS: The answer successfully synthesizes information across two filing periods and correctly identifies the directional change and magnitude. REASONING QUALITY: The interpretation that this represents 'scaling back exposure' and 'strategic shift' aligns well with the ground truth statement about 'significant reduction in exposure' and 'strategic shift or completion of certain initiatives.' The additional context about 'reallocating capital toward core utility and infrastructure projects' and 'focus on stable, regulated growth areas' represents reasonable inference from the data pattern, though not explicitly stated in the ground truth. This adds value without contradicting the original answer. MINOR CONSIDERATIONS: The LLM provides slightly more detailed strategic interpretation than the ground truth, but this is appropriate elaboration rather than error. The answer is well-structured, clear, and directly addresses both parts of the question (the change and what it indicates strategically).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 405,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "\nThe company continued to apply its liability‑driven investment framework for pension and post‑retirement assets in both years, keeping the same target equity/fixed‑income splits (20%/80% for pension assets and 55%/45% for post‑retirement assets) and using rate‑sensitive securities to hedge liabilities while growth assets are held in public equities.  However, the 2024 filing expands the disclosure: it reports a higher expense charge for defined‑contribution plans ($112 million in 2024 versus $91 million in 2023) and, for the first time, provides the actual year‑end composition of plan assets, describing the broad allocation that reflects the LDI‑aligned mix of equities, corporate bonds and U.S. Treasuries.  Thus, while the investment strategy itself remained stable, the company’s implementation evolved through increased expense recognition and more detailed asset‑mix reporting in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a significant factual error regarding the 2023 defined contribution plan expenses. Ground truth states $109 million for 2023, but the LLM claims $91 million for 2023. This is a $18 million discrepancy (19.8% error), which is material and unacceptable for financial data. The 2024 figure of $112 million is correct. ADDITIONAL ISSUES: (1) The LLM introduces information about post-retirement assets with a 55%/45% allocation that is not mentioned in the ground truth answer. While this may be accurate from the filing, it goes beyond what was specified in the original answer and could represent information synthesis from different parts of the filing. (2) The LLM provides more detailed description of the asset composition (corporate bonds, U.S. Treasuries, public equities) which is not explicitly mentioned in the ground truth, though it aligns with the concept of 'actual composition of plan assets.' WHAT WAS CORRECT: (1) The 20%/80% equity/fixed income target allocation for pension assets is correct. (2) The characterization that 2024 added new disclosure about actual year-end composition of plan assets is correct. (3) The overall narrative about evolution from 2023 to 2024 with increased transparency is directionally correct. (4) The identification of the liability-driven investment framework and its continued application is correct. MULTI-HOP REASONING: The model attempted to synthesize information across years and connect expense changes with disclosure changes, which is appropriate for the question. However, the fundamental error in the 2023 expense figure undermines the entire comparison. The reasoning structure is sound, but the factual foundation is flawed. The answer demonstrates understanding of the question's intent but fails on execution due to the quantitative error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Implements]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 505,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "\nQualcomm has doubled‑down on On‑Device AI, positioning it alongside 5G and low‑power computing as a core growth engine and explicitly stating that it will keep investing heavily in AI‑enabled high‑performance and low‑power computing for automotive, IoT and other non‑handset markets—a clear evolution from its 2023 focus on mobile AI. Both the 2023 and 2024 filings emphasize that R&D and capital are being directed toward advancing these foundational AI technologies and expanding them into new product areas, underscoring a strategic shift toward AI‑driven opportunities beyond smartphones. This expansion is reinforced by the company’s plan to make “substantial investments” in AI‑related technologies and to leverage its licensing and partnership ecosystem to capture the upside of AI across multiple industries.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Qualcomm's On-Device AI evolution between fiscal 2023 and 2024. STRENGTHS: (1) Correctly identifies the core shift from strategic vision/positioning in 2023 to active investment-driven strategy in 2024; (2) Accurately captures the expansion from mobile handsets to automotive, IoT, and other non-handset markets; (3) Properly synthesizes the multi-hop information showing how 5G and low-power computing remained foundational while AI became more prominent; (4) Correctly notes the emphasis on R&D and capital allocation toward AI technologies; (5) Appropriately references 'substantial investments' language and partnership/licensing ecosystem leverage. MINOR WEAKNESSES: (1) The phrase 'doubled-down' is interpretive language not explicitly stated in ground truth, though semantically accurate; (2) The answer could have been more explicit about the shift from 'positioning as a leader' (2023) to 'pursuing acquisitions or strategic transactions' (2024) - this specific evolution detail is present in ground truth but only implicitly addressed in LLM answer through 'substantial investments' reference; (3) No quantitative metrics provided (though none appear to be in the ground truth either). MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and multiple business segments (mobile, automotive, IoT), correctly identifying the directional shift. ENTITY ACCURACY: Qualcomm correctly identified, fiscal years 2023-2024 correctly referenced, business segments accurately named. NO CALCULATION ERRORS: No numerical claims requiring verification. The answer is semantically equivalent to the ground truth while using slightly different phrasing that remains accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 479,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "\nThe Voting Trust Agreement continues to be presented in identical form in both the 2022 and 2023 10‑K filings – it is disclosed as the “Second Amended and Restated Voting Trust Agreement, Voting Agreement and Proxy dated March 1 2004” under Exhibit 9.1 (and the related Exhibit 9.2) and is treated as an accounting‑policy disclosure that the company “enters into” and “discloses” (KG: SPG → Voting Trust Agreement ← Discloses). No new agreement, amendment, or re‑classification appears in the 2023 filing, indicating that the governance arrangement remains unchanged and therefore stable over the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The ground truth explicitly states that the 2022 10-K describes the agreement as 'Second Amended and Restated' while the 2023 10-K refers to it WITHOUT this modifier. However, the LLM answer claims the agreement is presented in 'identical form in both the 2022 and 2023 10-K filings' and that it is disclosed as the 'Second Amended and Restated Voting Trust Agreement' in both years. This is a critical misrepresentation of the key evolution being asked about. The LLM correctly identifies the date (March 1, 2004) and the general stability conclusion, but it fundamentally misses the core distinction between the two filings - the removal of the 'Second Amended and Restated' language in 2023. The LLM's statement that 'No new agreement, amendment, or re-classification appears in the 2023 filing' is contradicted by the actual change in how the agreement is presented/classified. The reasoning about stability is partially sound (no new amendments), but it's based on an incorrect premise about what changed between the filings. The multi-hop synthesis fails because the LLM did not accurately capture the evolution in classification that the question specifically asks about. The answer demonstrates a failure to distinguish between the two years' presentations, which is the central point of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters_Into]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 390,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "\nBased on the 2023 and 2024 10‑K filings (Chunk 1 & Chunk 2), COP’s reported natural‑gas reserves in the Asia Pacific/Middle East region slipped from **312 billion cubic feet at the end of 2023 to 296 billion cubic feet at the end of 2024**—a decline of roughly 5 %.  Over the same two‑year span the company’s total consolidated reserves expanded from **13,718 bcf to 15,641 bcf**, so the Asia Pacific/Middle East share of the global reserve base fell, indicating that COP is gradually reducing the strategic weight of that region within its overall reserves portfolio.  This shift reflects the KG relationship COP → Asia Pacific/Middle East ← Discloses (COP), where the region remains an operating geography but its relative importance is diminishing as other areas (e.g., North America) grow faster in the reserve portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) Core numbers are correct: 312 bcf (2023) and 296 bcf (2024) for Asia Pacific/Middle East reserves are accurately stated. (2) The decline calculation is correct: 16 bcf reduction, approximately 5% decrease. (3) The LLM correctly identifies the broader context by noting total consolidated reserves expanded from 13,718 bcf to 15,641 bcf, demonstrating sound multi-hop synthesis. (4) The reasoning about relative strategic importance declining is logically sound and well-supported. (5) Entity identification (COP, Asia Pacific/Middle East region, years 2023-2024) is accurate.\n\nWEAKNESSES: (1) The LLM omits a significant detail from the ground truth: the mention of equity affiliates holding an additional 5,870 bcf in 2024. This is material context that affects the complete picture of the region's reserves portfolio. (2) The phrase 'two-year span' is slightly misleading—this is a year-over-year comparison (2023 to 2024), not a two-year span. (3) The LLM's reference to 'KG relationship' notation appears to be metadata leakage and doesn't add analytical value to the answer.\n\nCALCULATION VERIFICATION: The 5% decline is approximately correct (16/312 = 5.13%, rounded to ~5%). The consolidated reserves figures (13,718 bcf to 15,641 bcf) are stated but not independently verified in the ground truth, though they appear consistent with the narrative.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across multiple data points (regional reserves, global reserves, relative portfolio share) to draw conclusions about strategic importance. The logic that declining relative share indicates reduced strategic weight is sound.\n\nMISSING ELEMENTS: The omission of equity affiliates information (5,870 bcf) is the primary gap. The ground truth explicitly mentions this as important context for understanding the region's continued significance despite the decline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 514,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "\nIn 2023 AIG’s balance sheet showed roughly **$11.874 bn of total borrowings**, of which **Corebridge contributed $9.368 bn of debt** (e.g., $6.452 bn of senior unsecured notes, $227 m of junior subordinated debt, etc.), while AIG’s own debt (net of eliminations) stood at about **$10.375 bn**.  By 2024 the relationship shifted to an equity‑method investment: AIG now records **equity‑method income equal to the dividends received plus the fair‑value increase of its Corebridge stake**, which reflects Corebridge’s pre‑tax earnings for the period **June 10 – Dec 31 2024** and the resulting change in AIG’s stock‑price‑related earnings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - Critical error in junior subordinated debt figure: LLM states '$227 m of junior subordinated debt' but ground truth clearly states '$989 million in junior subordinated debt'. This is a significant discrepancy ($989M vs $227M = 76% understatement). The LLM also introduces unexplained figures like '$11.874 bn of total borrowings' and '$10.375 bn' for AIG's own debt that are not mentioned in the ground truth and appear to be extraneous calculations not directly relevant to the Corebridge relationship question. (2) COMPLETENESS - The LLM correctly identifies the shift from consolidated debt to equity method accounting, and mentions dividends and fair-value changes, which aligns with ground truth. However, the presentation is muddled with irrelevant debt breakdowns. (3) ENTITY ACCURACY - Correctly identifies AIG and Corebridge, and correctly notes the 2023-2024 transition. The date reference 'June 10 – Dec 31 2024' is close to ground truth's 'June 9, 2024' (minor discrepancy of one day, acceptable). (4) REASONING - The multi-hop synthesis is partially sound: LLM correctly identifies the transition from consolidated subsidiary to equity method investment and mentions equity method income components (dividends + fair-value changes). However, the reasoning is obscured by irrelevant debt calculations that distract from the core answer. (5) SEMANTIC EQUIVALENCE - The core narrative about the relationship evolution is present but undermined by the quantitative error on junior subordinated debt and the introduction of unexplained aggregate figures. The answer would have been stronger if it focused solely on the Corebridge relationship evolution rather than AIG's total debt structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 477,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "\nBetween 2022 and 2024 NEE’s Special Use Funds moved from a virtually all‑fixed‑income position of **$2.5 billion** (carrying amount reported in Chunk 1) to a much broader mix in which **equity securities rose to $2.6 billion** (with an additional $3.3 billion classified as Level‑2) and the total fund assets grew to **$6.16 billion**, comprising various debt tiers (U.S. government/municipal bonds, corporate debt, asset‑backed and other debt at Levels 1‑3) disclosed in Chunk 2.  This shift—from a narrow, high‑quality fixed‑income allocation to a diversified portfolio that includes sizable equity and multi‑level debt—indicates that NEE has deliberately increased its risk appetite and is targeting higher‑return assets while preserving liquidity through layered fair‑value hierarchies and cash‑equivalent buffers.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains significant factual inaccuracies that undermine the core response. (1) EQUITY SECURITIES MISSTATEMENT: Ground truth shows $6,164 million in equity securities by 2024, but LLM states only $2.6 billion ($2,600 million) with an additional $3.3 billion at Level-2. This is a major discrepancy—the LLM appears to have fragmented the equity allocation incorrectly and failed to properly synthesize the total. The correct figure is $6,164 million in equity securities alone. (2) TOTAL FUND SIZE: LLM correctly identifies $6.16 billion total, but this contradicts its equity figure of only $2.6 billion + $3.3 billion = $5.9 billion in equities, leaving only ~$260 million for all debt instruments, which contradicts the ground truth breakdown ($722M bonds + $685M corporate + $873M ABS = $2,280M in debt). (3) DEBT COMPOSITION: LLM vaguely references 'various debt tiers' and 'multi-level debt' but fails to provide the specific dollar amounts for each category that ground truth clearly states: $722M U.S. Government/municipal bonds, $685M corporate debt, $873M asset-backed securities. (4) 2022 BASELINE: LLM correctly identifies the 2022 position as ~$2.5 billion in fixed income, matching ground truth. REASONING QUALITY: The qualitative assessment of the shift from fixed-income to diversified/equity-heavy portfolio and the interpretation regarding increased risk appetite and growth orientation is sound and aligns with ground truth. However, this correct reasoning is undermined by the quantitative errors. MULTI-HOP SYNTHESIS: The LLM failed to properly synthesize the 2024 portfolio composition across multiple asset classes. The answer demonstrates incomplete data extraction and incorrect aggregation of equity securities. The reference to 'Level-2' classification suggests the LLM may have confused fair-value hierarchy levels with actual asset amounts. OVERALL ASSESSMENT: While the directional narrative (shift from fixed income to equity-heavy, increased risk appetite) is correct, the specific numbers are materially wrong, making this answer unreliable for financial analysis purposes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 578,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "\nThe risk tied to **site‑infrastructure sharing** has grown both in scope and intensity from 2022 to 2024: in 2022 the filing warned that expanding 5G deployments and carrier‑driven sharing of RAN or roaming arrangements could curb new lease signings and even trigger site decommissioning, while in 2024 the same sharing dynamic is still cited—but now it is coupled with heightened macro‑economic stress (inflation, higher interest rates, tighter credit) that weakens customers’ ability to fund new builds, making the prospect of shared equipment an even more compelling alternative to leasing new tower space.  Because carriers can meet capacity needs through shared or redundant 5G‑enabled sites without compensating AMT, **new lease activity slows and churn risk rises**, and this **risk factor—“Site Infrastructure Sharing”—is impacted by AMT yet negatively impacts AMT’s growth and revenue**.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies site infrastructure sharing as the core risk and acknowledges its evolution from 2022 to 2024. (2) Correctly names AMT as the company affected. (3) Accurately captures that RAN sharing and roaming arrangements are part of the 2024 risk characterization. (4) Correctly notes that carriers don't compensate AMT when choosing shared infrastructure. (5) Properly identifies the impact on new lease activity and churn risk.\n\nWEAKNESSES: (1) MAJOR FACTUAL ERROR: The LLM introduces macroeconomic factors (inflation, higher interest rates, tighter credit) as part of the 2024 evolution of this specific risk. The ground truth makes no mention of these macroeconomic factors being tied to the site infrastructure sharing risk evolution. This appears to be either confabulation or conflation with other risk factors. (2) The LLM's framing suggests the 2022 filing already mentioned RAN/roaming arrangements, but the ground truth indicates this was a 2024-specific evolution—in 2022 it was more general 'site infrastructure sharing.' The LLM states '2022 the filing warned that expanding 5G deployments and carrier-driven sharing of RAN or roaming arrangements' which overstates what was in 2022. (3) The LLM doesn't clearly distinguish the evolution in specificity and threat level perception that the ground truth emphasizes—that 2024 shows 'stronger emphasis on financial impact' and 'more mature and impactful shift.' (4) The phrase 'risk factor—\"Site Infrastructure Sharing\"—is impacted by AMT yet negatively impacts AMT's growth' is awkwardly worded and doesn't clearly convey the causal relationship.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across years but introduces unsupported elements (macroeconomic stress) that weren't part of the ground truth's characterization of this specific risk evolution. The core multi-hop connection (2022 risk → 2024 evolution with RAN specificity) is partially correct but muddled by extraneous factors.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers or dates are provided in either answer, so quantitative accuracy is based on conceptual correctness. The dates (2022, 2024) are correct. The company (AMT) is correct. However, the introduction of macroeconomic factors as part of this risk's evolution is factually incorrect per the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 628,
        "total_tokens": 2057
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "\nChevron’s stake in Angola LNG Limited remained a 36.4 % equity interest in both 2022 and 2023, and the company continued to account for that investment under the equity‑method accounting model; there was no shift to a non‑equity treatment or any impairment noted for the affiliate.  The only change reflected in the disclosures is the updated reference to the 2023 carrying‑value comparison (no material difference was disclosed), confirming that the investment structure and equity‑method accounting have been stable over the two years.  This consistent 36.4 % ownership, reported in both the 2022 and 2023 filings, illustrates a steady financial relationship in which Chevron records its share of Angola LNG Limited’s earnings through the equity method.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ISSUE: The LLM answer fundamentally misses the core finding from the ground truth. The ground truth explicitly identifies a KEY CHANGE in Chevron's relationship classification with Angola LNG Limited between 2022 and 2023: from 'Depends_On' (2022) to 'Invests_In' (2023). This represents a significant shift in how the relationship is categorized and managed, not merely a stable investment structure. The LLM answer incorrectly claims 'the investment structure and equity-method accounting have been stable over the two years' and states 'there was no shift,' which directly contradicts the ground truth's central finding. QUANTITATIVE ACCURACY: The LLM correctly identifies the 36.4% ownership percentage in both years, which matches the ground truth. This is accurate. QUALITATIVE ACCURACY: The LLM's reasoning is fundamentally flawed. While it correctly notes that equity-method accounting was used and the ownership percentage remained constant, it completely fails to recognize or address the relationship reclassification (Depends_On vs. Invests_In) that represents the actual evolution of the financial relationship. The ground truth explicitly states this reclassification 'indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.' The LLM's assertion that 'the only change reflected in the disclosures is the updated reference to the 2023 carrying-value comparison' misses the primary structural change entirely. MULTI-HOP REASONING: The LLM failed to synthesize the relationship classification data across the two years, which was essential to answering the question about how the relationship 'evolved.' CONTEXTUAL RELEVANCE: While the answer addresses some relevant aspects (equity method, ownership percentage), it fundamentally misses the core evolution being asked about—the shift from a dependent relationship to an active investment relationship. The answer is partially relevant but incomplete and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 545,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "\nFrom 2022 into 2023 the G600 continued to serve as a cornerstone of Gulfstream’s large‑cabin lineup—originally launched in 2019 as the clean‑sheet replacement for the G450/G550 and now delivering faster cruise speeds, greater fuel‑efficiency, extended range, a larger cabin and reduced emissions, while accumulating more than 90 city‑pair speed records; by year‑end 2023 cumulative deliveries had passed 250 aircraft, confirming ongoing production at Gulfstream’s Savannah facility.  The aircraft’s performance metrics and production momentum are reflected in the KG relationship GD → G600 ← GD, highlighting its sustained role alongside newer ultra‑large‑cabin models such as the G700 and G800.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) Correctly identifies G600 launch year (2019) and clean-sheet replacement status. (2) Accurately states cumulative deliveries exceeded 250 by year-end 2023, matching ground truth. (3) Correctly mentions G700 and G800 as newer models in the lineup. (4) Appropriately notes production at Savannah facility. (5) Number formatting and quantitative data are accurate.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The LLM answer fails to address the core evolution narrative from the ground truth—the shift from 'new product' (2022) to 'mature product' (2023). The ground truth explicitly states the G600 was 'described as a recent addition' in 2022 but 'no longer characterized as new' by 2023. The LLM answer does not capture this temporal evolution or maturation status. (2) INCOMPLETE SYNTHESIS: While the LLM mentions performance metrics (faster cruise speeds, fuel efficiency, range, cabin size, emissions), it does not clearly articulate how these were positioned differently in 2022 vs 2023. The ground truth emphasizes the shift in positioning, not just the features themselves. (3) MISSING KEY DETAIL: The ground truth highlights that G600's Symmetry Flight Deck technology was being extended to newer models (G700, G800, G400) in 2023, indicating platform integration. The LLM mentions G700/G800 but misses the G400 and the specific technology transfer narrative. (4) VAGUE REFERENCE: The notation 'GD → G600 ← GD' appears to be a knowledge graph representation but is unexplained and doesn't clearly convey the evolution narrative. (5) INCORRECT PREDECESSOR: The LLM states G600 replaced 'G450/G550' while ground truth says 'G550'—though this is a minor discrepancy, the G450 replacement claim is not supported by ground truth.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information about the G600's role across 2022-2023 and its relationship to other models, but fails to properly synthesize the temporal evolution aspect that is central to the question. The answer reads more as a static product description rather than an evolution narrative.\n\nOVERALL ASSESSMENT: The answer contains accurate numbers and identifies key entities correctly, but fundamentally misses the primary evolution narrative (new→mature transition) that the ground truth emphasizes. This is a significant gap in addressing the core question about how the G600's role 'evolved' from 2022 to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 638,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s moved from the largely passive, royalty‑and‑rent franchising model described in the 2022 10‑K (Chunk 1)—where franchisees funded all capital costs and paid rent, royalties and initial fees, producing stable cash flow—to a more collaborative, capital‑sharing partnership. The 2024 filing (Chunk 2) explicitly details co‑investment programs, equity stakes in developmental‑license affiliates, and joint funding of restaurant modernization and system upgrades, signaling deeper financial involvement and strategic collaboration. This evolution is framed within the Company’s purpose, mission and core values—emphasizing community, inclusion and shared growth—that now guide the franchise‑franchisor relationship (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: The answer correctly identifies the evolution from a passive franchising model in 2022 to a more collaborative, capital-sharing partnership by 2024. All core facts are accurate: the 2022 model relied on franchisee-funded capital with rent/royalties/fees flowing to McDonald's; the 2024 model introduced co-investments, equity stakes in developmental-license affiliates, and joint funding of modernization. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were provided in either the ground truth or LLM answer, so this dimension is not applicable. Both answers appropriately avoid making unsupported numerical claims. (3) ENTITY ACCURACY: McDonald's is correctly identified, the time period (2022-2024) is accurate, and the financial/strategic concepts (franchising, royalties, co-investments, equity stakes, modernization) are all correctly named and contextualized. (4) MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple years and filing documents, correctly identifying the strategic shift and its underlying rationale. The answer goes slightly beyond the ground truth by explicitly connecting the evolution to McDonald's stated purpose, mission, and core values (community, inclusion, shared growth), which adds valuable context without contradicting the ground truth. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing ('capital-sharing partnership,' 'deeper financial involvement,' 'collaborative') conveys the same meaning as the ground truth's description of the shift from 'passive franchising model' to 'collaborative and financially engaged partnership.' Minor differences in wording (e.g., 'co-investment programs' vs. 'co-investing') are stylistic variations that preserve semantic accuracy. The answer is comprehensive, well-structured, and directly addresses the question's focus on both financial involvement and strategic collaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 546,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "\nFrom 2022 to 2023, MO’s smokeable‑product net revenues declined 3.6% to $21,756 million (down from $22,476 million) and operating income slipped 0.2% to $10,670 million (down from $10,688 million). The company’s disclosed intangible assets linked to smokeable products remained essentially unchanged at $99 million goodwill and about $3.0 billion other intangibles, reflecting the same balance‑sheet figures shown for 2021‑2020. This performance is captured in the KG relationship where MO has a stake in smokeable products and discloses their revenues and income in its 10‑K filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: All core financial numbers are correct and accurately presented. Net revenues for 2022 ($22,476M) and 2023 ($21,756M) match ground truth exactly. Operating income figures for 2022 ($10,688M) and 2023 ($10,670M) are correct. The calculated percentage declines (3.6% for revenues, 0.2% for operating income) are mathematically accurate. The LLM correctly identified MO (Altria) as the company and properly synthesized the multi-hop information across years. WEAKNESSES: The LLM introduces extraneous information about intangible assets ($99M goodwill, $3.0B other intangibles) and references to 2021-2020 balance sheet figures that are not part of the original question or ground truth answer. This additional information, while potentially factual, dilutes focus from the core question about financial performance evolution. The statement about intangible assets 'remaining essentially unchanged' and references to 2021-2020 figures are not addressed in the ground truth and represent unnecessary elaboration that could confuse the reader about what was actually asked. The final sentence about KG relationships is somewhat meta and not directly relevant to answering the substantive question. MULTI-HOP REASONING: The model correctly synthesized information across two fiscal years (2022 and 2023) and properly compared metrics between periods. The core multi-hop requirement was met. OVERALL: The answer is fundamentally correct on all key metrics and calculations, but includes tangential information that reduces clarity and focus. The quantitative core is strong (9/10), but the qualitative presentation and relevance are slightly diminished by the extraneous details (6/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 461,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "\nIn 2022 Opdivo was being co‑developed with Ono under a joint‑venture framework that shared development costs and profits (e.g., an 80/20 split for single‑party activities and equal sharing for combination therapies), included rights to NKTR‑214 after a Phase I study, and originally covered Japan, South Korea and Taiwan; the earlier exclusive license for ONO‑4578 was later terminated, concentrating the collaboration on Opdivo‑related programs.  \nBy 2024 Opdivo had secured new FDA approvals—including a first‑line combination regimen for urothelial carcinoma (March 2024) and continued commercialization through the same BMY‑Ono alliance—demonstrating that its role had evolved from a territory‑specific collaborative asset to a central, globally‑approved oncology pillar within BMY’s product‑development and commercialization strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the March 2024 FDA approval for Opdivo in combination with cisplatin and gemcitabine for urothelial carcinoma—this matches the ground truth. (2) The 80/20 split and equal sharing framework for the BMY-Ono collaboration is accurately stated. (3) The temporal evolution from 2022 to 2024 is properly framed. (4) The characterization of the shift from territory-specific to globally-approved oncology asset is semantically aligned with the ground truth's 'shift from co-development focus to independent product introduction strategy.' WEAKNESSES: (1) The LLM introduces additional details about NKTR-214 and ONO-4578 that are not present in the ground truth answer. While these may be factually accurate from the filings, they represent scope creep beyond what the ground truth synthesized, potentially introducing unverified information. (2) The LLM states the collaboration 'originally covered Japan, South Korea and Taiwan'—this geographic specificity is not mentioned in the ground truth and cannot be verified against it. (3) The LLM claims the collaboration 'continued' through the same BMY-Ono alliance by 2024, but the ground truth emphasizes a shift to 'BMY taking the lead in expanding Opdivo's therapeutic applications,' which suggests a more independent strategy rather than continued equal partnership. This is a subtle but important distinction about the evolution of the relationship. (4) The ground truth mentions Opdivo being 'part of a broader alliance that included other products like Yervoy and Orencia,' but the LLM focuses narrowly on Opdivo-specific programs, missing this broader portfolio context. MULTI-HOP REASONING: The LLM does synthesize information across 2022-2024 timeframes and identifies the key FDA approval, but the characterization of the relationship evolution is slightly misaligned—the ground truth suggests greater independence by 2024, while the LLM suggests continuity of the same alliance structure. NUMERIC/DATE ACCURACY: The March 2024 date is correct; the 80/20 and equal-sharing splits are correct. No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 569,
        "total_tokens": 2005
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "\nBetween 2022 and 2024 AMT shifted its benchmark references from the traditional LIBOR‑ and EURIBOR‑based rates disclosed in the 2022 filing—where it explicitly stated that borrowings were “above LIBOR” for USD facilities and “above EURIBOR” for EUR facilities and could use a defined base rate, LIBOR or EURIBOR—as shown in Chunk 1, to a SOFR‑based rate for its Nigeria letter‑of‑credit draws in the 2024 filing, as noted in Chunk 2; the company continues to disclose that each debt agreement contains reporting and operating covenants (the “Operating Covenants” regulatory requirement) that it must comply with, and failure to meet those covenants could trigger default and accelerate repayment, a condition that remains unchanged across both years.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution in AMT's interest rate benchmark disclosures from 2022 to 2024, specifically the shift from LIBOR/EURIBOR to SOFR for Nigeria letter-of-credit draws. The answer accurately captures the 2022 references to LIBOR, EURIBOR, and defined base rates for USD and EUR denominated borrowings. The identification of SOFR in 2024 for Nigeria facilities is correct. The answer also appropriately notes the covenant-related disclosures and default consequences that persist across both years. However, there are some notable omissions and areas where the answer could be more complete: (1) The original answer specifically mentions the 2021 credit facilities tied to debt ratings with commitment fees ranging from 0.080% to 0.300%—these specific quantitative details are absent from the LLM answer, representing a loss of precision on the 2022 covenant structure. (2) The original answer emphasizes a 'simplification or evolution in the presentation of covenant-related disclosures' in 2024, noting that 2024 focused on 'consequences of covenant non-compliance without specifying interest rate structures or renewal terms'—the LLM answer mentions covenant compliance but doesn't capture this nuanced shift in disclosure presentation style. (3) The LLM answer references 'Chunk 1' and 'Chunk 2' which are source citations but doesn't add substantive detail about the specific covenant structures or renewal periods mentioned in the original answer. The multi-hop reasoning is sound—the answer correctly synthesizes information across the two years and identifies the benchmark rate transition. The quantitative accuracy is good for the rates mentioned (LIBOR, EURIBOR, SOFR) but lacks the specific percentage figures (0.080%-0.300%) from the original. The answer is semantically equivalent on the main point but incomplete on supporting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 510,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s has kept the **conventional‑franchise model** in which the corporation **owns or secures long‑term leases for the land and building**, while **franchisees co‑invest by funding equipment, signage and décor**; this combined real‑estate ownership and franchisee co‑investment is repeatedly highlighted as the driver of the system’s high performance.  The 2022 filing frames the franchise relationship within growing ESG and stakeholder expectations, and the 2024 filing re‑affirms that the company’s strategy continues to rely on **real‑estate ownership paired with franchisee co‑investment** to deliver strong restaurant results.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies McDonald's conventional franchise model with accurate details: corporation owns/secures long-term leases for land and buildings, franchisees co-invest in equipment, signage, and décor. (2) Accurately captures the evolution between 2022 and 2024: 2022 emphasized ESG/stakeholder collaboration, while 2024 articulated the explicit real estate and co-investment strategy. (3) Properly synthesizes the multi-hop reasoning: connects the shift from general franchisee collaboration framework to a clearly defined real estate ownership model. (4) Correctly identifies that this co-investment model drives high restaurant performance. (5) No quantitative errors or date misstatements. MINOR CONSIDERATIONS: (1) The LLM answer is slightly more concise than the ground truth but captures all essential information. (2) The phrasing 'repeatedly highlighted' and 're-affirms' effectively conveys the evolution without being overly verbose. (3) The answer maintains semantic equivalence with the ground truth while using slightly different organizational structure. The multi-hop synthesis is sound: the model correctly identifies information from both 2022 and 2024 filings and articulates how the relationship evolved from general ESG collaboration emphasis to explicit real estate strategy definition. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 401,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "\nBetween 2022 and 2023 Altria’s 2015 Stock Compensation Plan for Non‑Employee Directors remained on the company’s list of shareholder‑approved plans, but in the 2022 filing (Item 10.22 of the 2022 10‑K) it was explicitly noted as “amended and restated effective October 26, 2022” and incorporated by reference in the 2022 Form 10‑Q. The 2023 filing (Item 10.22 of the 2023 10‑K) continues to reference that same amended‑and‑restated plan, showing that the updated terms—including the current share reserve—were carried forward without further change. This demonstrates Altria’s governance practice of formally updating and documenting director‑compensation arrangements, securing shareholder approval, and consistently disclosing those revisions in its periodic reports, thereby ensuring transparency and accountability in how it sets and revises compensation for non‑employee directors.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with significant omissions and some inaccuracies. STRENGTHS: (1) Correctly identifies the October 26, 2022 amendment/restatement date, matching ground truth; (2) Properly references incorporation by reference from the September 30, 2022 Form 10-Q; (3) Accurately describes the governance practice of formal updates and shareholder approval; (4) Correctly identifies this as Item 10.22 in the 10-K filings; (5) Appropriately characterizes the evolution as demonstrating transparency and accountability. CRITICAL OMISSIONS: (1) The LLM answer completely fails to mention the 703,256 shares available for issuance under the plan, which is a specific quantitative detail provided in the ground truth; (2) Does not explicitly state the 2022 baseline disclosure of the plan with share availability; (3) Lacks the specific numerical anchor that grounds the answer in concrete data. REASONING ISSUES: (1) The LLM answer correctly synthesizes the multi-hop information about the plan's status across years, but the synthesis is incomplete without the share count; (2) The statement that the plan 'remained on the company's list' is reasonable inference but not explicitly confirmed in ground truth; (3) The characterization of governance approach is sound but somewhat generic. QUANTITATIVE ACCURACY: The answer provides no specific numbers, which is a significant gap given that the ground truth explicitly mentions 703,256 shares. This represents a material omission of factual data. The dates (October 26, 2022 and September 30, 2022) are correct. OVERALL ASSESSMENT: The answer captures the essence of the governance evolution and correctly identifies key dates and filing references, but the omission of the specific share count is a notable factual gap that reduces the completeness and precision of the response. The reasoning about governance implications is sound but would be stronger with the quantitative detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 529,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "\nThe 2022 filing warned that extensive roaming, resale and RAN‑sharing arrangements—spurred by 5G roll‑outs—could curb new lease activity because carriers might rely on shared equipment rather than lease additional sites, and the 2024 filing repeats this risk while adding that heightened competition and consolidation are making such sharing an even larger drag on lease growth. Both disclosures show that roaming/resale‑driven site sharing has become a persistent competitive pressure that slows AMT’s ability to generate new lease revenue.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of the evolution of roaming/resale risks from 2022 to 2024. Key strengths: (1) Correctly identifies that 2022 filings warned about roaming/resale/RAN-sharing arrangements potentially slowing new lease activity; (2) Accurately notes that 2024 filings repeat this risk while adding heightened competition and consolidation as factors; (3) Properly synthesizes the multi-hop information showing how the concern evolved and became more pronounced; (4) Correctly identifies the core competitive pressure theme. Minor weakness: The LLM answer does not explicitly mention the 2024 development regarding potential decommissioning of existing equipment due to redundancy, which was highlighted in the ground truth as an important evolution of the risk. The ground truth emphasizes that by 2024, the threat extended beyond just slowing new lease activity to also causing potential decommissioning of existing equipment. The LLM answer focuses primarily on the impact on new lease growth but omits this secondary impact dimension. The reasoning is sound and the multi-hop synthesis across years is correct, but the answer is slightly incomplete in capturing all dimensions of how the risk evolved. The semantic equivalence is strong—both answers convey that infrastructure sharing has become a persistent and growing competitive pressure affecting AMT's lease revenue growth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 400,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "\nFrom 2022 to 2024 McDonald’s shifted from a largely capital‑light, royalty‑only model to a partnership that actively co‑invests with franchisees to fund restaurant modernization, digital upgrades and other improvements, requiring franchisees to reinvest capital and meet rigorous performance standards (Chunk 2). This evolution rests on the 2022 disclosures that emphasized preserving brand value, accelerating technology and driving Systemwide sales—objectives that depend on franchisee‑driven capital and operational execution, while also warning of pandemic‑related risks to labor and supply chains (Chunk 1). The 2024 filing further clarifies that franchisees are no longer treated as passive investors, that the Company may share capital to develop higher‑revenue sites, and that developmental‑license and affiliate structures expand the ways investment and royalty revenue are shared, reflecting a tighter operational and strategic alignment (Chunk 2). Throughout, the company’s purpose, mission and inclusion‑focused values reinforce expectations that franchisees uphold consistent quality, community engagement and employee safety across their operations (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively synthesizes the evolution of McDonald's franchisee relationships between 2022 and 2024. STRENGTHS: (1) Correctly identifies the core shift from a capital-light, royalty-only model to active co-investment partnerships; (2) Accurately captures 2022 context including COVID-19 pandemic impacts, labor availability risks, supply chain disruptions, and the 'Accelerating the Arches' strategy; (3) Properly characterizes 2024 developments including co-investment initiatives, restaurant modernization focus, and structured performance expectations; (4) Correctly identifies the transition from pandemic-driven operational challenges to strategic, investment-backed growth; (5) No quantitative errors or incorrect dates/numbers; (6) Multi-hop reasoning is sound, successfully synthesizing information across both years and connecting strategic shifts to operational implications. MINOR AREAS FOR IMPROVEMENT: (1) The LLM answer introduces some additional details not explicitly in the ground truth (e.g., 'digital upgrades,' 'developmental-license and affiliate structures,' 'inclusion-focused values') that, while plausible and contextually relevant, go slightly beyond what the ground truth specifies; (2) The answer is somewhat more detailed and technical than the ground truth, which could be seen as either comprehensive or slightly speculative depending on source verification; (3) The ground truth emphasizes 'franchisees' ability to adapt to changing consumer behavior and operational restrictions' in 2022, which the LLM answer touches on but doesn't explicitly highlight. VERIFICATION: All core factual claims align with the ground truth - the shift from pandemic challenges to investment-backed growth, the emphasis on modernization, the co-investment model, and the performance expectations are all accurately represented. No calculations or numerical claims are present that could be incorrect. The semantic meaning matches the ground truth effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1516,
        "completion_tokens": 546,
        "total_tokens": 2062
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2024 NextEra Energy grew the equity allocation inside its Special Use Funds from **$8.9 billion** (the “Special use funds” total shown in the 2022 balance sheet, Chunk 1) to **$10.4 billion** in 2024 (the combined NEE and FPL equity‑security totals disclosed in Chunk 2: $6.164 billion + $4.219 billion).  The 2024 breakdown further reveals a strategic shift toward higher‑level investments—Level 2 and Level 3 equity securities increased to $3.3 billion and $0.23 billion for NEE and $2.99 billion and $0.20 billion for FPL—indicating a more diversified and risk‑adjusted investment approach within the Special Use Funds.  This evolution is reflected in the KG relationship ORG (NEE) ‑ [Discloses] → FIN_INST (Special Use Funds) ← [Invests_In] ORG, linking the firm’s disclosed funds to its expanded equity‑security strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that contradict the ground truth. (1) CRITICAL QUANTITATIVE ERROR: The LLM claims equity allocation grew from $8.9 billion to $10.4 billion, but the ground truth explicitly states it decreased from $8,922 million ($8.9B) in 2022 to $6,164 million ($6.2B) in 2024. The LLM's calculation of $10.4B by combining NEE ($6.164B) + FPL ($4.219B) is methodologically incorrect—the ground truth answer refers specifically to NextEra Energy's Special Use Funds equity securities ($6.164B in 2024), not a combined NEE+FPL total. (2) ENTITY CONFUSION: The LLM inappropriately combines NextEra Energy (NEE) and Florida Power & Light (FPL) equity allocations as if they represent a single consolidated figure for NextEra's Special Use Funds strategy. The question asks about NextEra Energy's investment strategy, not a combined NEE+FPL analysis. (3) DIRECTIONAL ERROR: The ground truth indicates a DECREASE in total Special Use Funds ($8,922M to lower amounts) with explicit equity disclosure of $6,164M in 2024. The LLM claims growth, which is factually incorrect. (4) MISINTERPRETATION OF TRANSPARENCY: While the LLM correctly identifies a shift toward transparency/detailed disclosure, it fundamentally misrepresents the magnitude and direction of the equity investment change. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the 2022 vs 2024 comparison, instead creating an erroneous combined figure that doesn't match the ground truth's clear statement of $6,164M in 2024 equity securities. The answer demonstrates poor data synthesis and contains a major calculation error that reverses the actual trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 456,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "\nFrom 2022 to 2023 the smokeable‑products segment saw net revenues fall modestly from **$22,476 million to $21,756 million** and operating income decline from **$11,919 million to $11,547 million** (each down about 3 %).  This year‑over‑year contraction is reflected in the knowledge‑graph relationship **ORG ‑‑Decreases‑‑> PRODUCT**, and is consistent with the $188 million total disclosed for the segment in the 2022 filing (Chunk 1), confirming that the segment’s financial performance slipped slightly in both revenue and profitability from 2022 to 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERRORS IN OPERATING INCOME FIGURES: The LLM provided incorrect operating income numbers for both years. Ground truth shows 2022 operating income of $10,688 million and 2023 of $10,670 million, but the LLM stated $11,919 million (2022) and $11,547 million (2023). These are significantly different values - off by approximately $1.2 billion in 2022 and $877 million in 2023. The net revenue figures are correct ($22,476M in 2022 and $21,756M in 2023), and the directional assessment (both metrics declined) is correct. However, the magnitude of the operating income decline is completely wrong: the LLM calculated approximately 3% decline in operating income, but the actual decline was only $18 million (0.17%), which is truly marginal. The LLM's characterization of the decline as 'about 3%' is mathematically incorrect based on the numbers provided. The LLM also references a '$188 million total' from the 2022 filing without clear context, which appears to be an unsupported or misinterpreted data point. While the answer correctly identifies the segment, years, and general trend (decline), the fundamental quantitative errors in operating income figures represent a major factual failure that undermines the entire analysis. The reasoning structure is present but built on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 364,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the company kept a $3.1 billion open‑market authorization for purchasing Accenture plc Class A ordinary shares, which are held as treasury shares expressly to fund employee‑benefit programs and equity awards. In 2023 the same treasury‑share pool continued to be used for those employee‑related purposes, while additional Class A shares were also acquired through share‑withholding to meet payroll‑tax obligations under the company’s employee equity plans—purchases that do not reduce the remaining open‑market authorization. Consequently, the utilization evolved from a broad‑market acquisition stance in 2022 to a dual focus on treasury‑share holdings for employee benefits and tax‑withholding purchases in 2023, with the overall purchase authority unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general narrative about the evolution of share utilization between 2022 and 2023, correctly identifying the shift toward employee benefits and the introduction of tax-withholding mechanisms. However, there are significant quantitative accuracy issues: (1) The LLM states '$3.1 billion' authorization, but the ground truth specifies '$3,129,296' (approximately $3.1 million, not billion). This is a critical error in magnitude—off by a factor of 1,000. (2) The LLM's characterization of 2022 as a 'broad-market acquisition stance' is not supported by the ground truth, which indicates the programs were already disclosed in 2022 without specifying a different purpose. (3) The LLM correctly identifies that shares were held as treasury shares for employee benefits and that tax-withholding purchases were separate from the authorization. (4) The multi-hop reasoning is sound in connecting the 2022 authorization to 2023 usage and fiscal 2024 tax-withholding mechanisms. The semantic understanding of the evolution is reasonable, but the fundamental numerical error ($3.1B vs $3.1M) is a major factual mistake that significantly undermines the answer's credibility. The answer demonstrates good qualitative reasoning about the shift in focus but fails on precise quantitative accuracy, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 377,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "\nFrom 2022 to 2024 AMT’s operating covenants remained embedded in its credit‑agreement framework, but the underlying debt composition and rate benchmarks evolved: the 2022 filings tie the covenants to LIBOR (and EURIBOR for Euro‑denominated borrowings) across its multicurrency, term and revolving facilities, whereas the 2024 filing shows new US‑dollar borrowings that price at **SOFR + spread** (e.g., the Nigerian letter‑of‑credit draw‑downs) and the continued issuance of fixed‑rate senior notes. Consequently, the covenant regime now governs a broader set of instruments—including SOFR‑based credit facilities and senior unsecured notes—while still imposing the same financial and operating restrictions (limits on additional debt, asset sales, guaranties, etc.) that must be satisfied to avoid default.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the core evolution of AMT's operating covenants from 2022 to 2024, correctly identifying the key transition from LIBOR/EURIBOR benchmarks to SOFR-based structures. The answer accurately captures the main elements: (1) 2022 covenants tied to LIBOR and EURIBOR across multicurrency/term/revolving facilities, (2) 2024 shift to SOFR + spread pricing, (3) specific mention of Nigerian letter-of-credit drawdowns, and (4) the broader instrument set now governed by covenants including senior unsecured notes. The multi-hop synthesis across years and debt instruments is sound. However, there are some areas where the answer could be more precise: (1) The LLM mentions 'US-dollar borrowings that price at SOFR + spread (e.g., the Nigerian letter-of-credit draw-downs)' which is slightly awkward phrasing—the Nigerian LOCs are specifically mentioned in the ground truth as the SOFR-based instruments, not necessarily all US-dollar borrowings; (2) The LLM adds detail about 'financial and operating restrictions (limits on additional debt, asset sales, guaranties, etc.)' which, while likely accurate for typical credit agreements, goes beyond what the ground truth explicitly states about the covenant evolution; (3) The mention of 'continued issuance of fixed-rate senior notes' is reasonable but not explicitly confirmed in the ground truth provided. The answer correctly avoids overstating certainty and appropriately frames the evolution as a 'transition' and 'strategic and regulatory evolution.' No numerical errors are present. The reasoning is logically sound and the multi-hop synthesis across 2022 and 2024 filings is properly executed. The answer is contextually relevant and directly addresses the question about nature, structure, debt instruments, and interest rate benchmarks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> REGULATORY_REQUIREMENT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 497,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "\nThe 2023 filing recorded Disney+ Hotstar’s paid subscriber base, and the 2024 filing updates that figure to **≈ 36 million paid subscribers as of September 28 2024**, showing growth from the prior‑year level.  In addition, both filings note that at the **end of June 2024** Disney merged the standalone **Star+** service into a **single Disney+ product in Latin America**, consolidating content and branding under one offering—an move that bolsters Disney’s international streaming strategy by expanding the Disney+ catalogue and improving subscriber acquisition in key markets.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key metrics and dates. Strengths: (1) Correctly identifies Disney+ Hotstar's subscriber count as approximately 36 million as of September 28, 2024; (2) Accurately dates the Star+ consolidation to end of June 2024; (3) Properly identifies the consolidation as occurring in Latin America; (4) Correctly characterizes this as a strategic shift toward streamlining international offerings. Quantitative accuracy is high - all numbers and dates match the ground truth. Multi-hop reasoning is sound, successfully synthesizing information about subscriber evolution and strategic consolidation across the two filings. Minor weaknesses: (1) The phrase 'showing growth from the prior-year level' is somewhat vague and not explicitly supported by the ground truth, which doesn't provide a specific prior-year comparison figure; (2) The answer could have been slightly more explicit about the timing discrepancy (36 million figure is from 2023 filing but dated September 28, 2024, suggesting it's actually from the 2024 filing period); (3) The characterization of 'expanding the Disney+ catalogue and improving subscriber acquisition' is reasonable inference but goes slightly beyond what the ground truth explicitly states about the consolidation's purpose. Overall, the answer correctly addresses both parts of the multi-part question (subscriber evolution and consolidation impact) with accurate facts and sound reasoning, though with minor imprecision in framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 423,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "\nFrom 2022 to 2023 the share of staff covered by collective bargaining remained essentially unchanged – about one‑fifth of the workforce was still working under the same 62 collective agreements.  In 2022 the company expected to renegotiate 21 agreements that together covered roughly 3,000 employees, whereas the 2023 filing shows the next round of negotiations slated for 2024 will involve 20 agreements covering only about 2,100 employees.  This modest reduction in both the number of agreements and the employee head‑count per round indicates that the firm is moving toward a more focused, incremental renegotiation strategy—maintaining stable labor relations while making targeted adjustments that are not expected to have a material impact on operations or cash flow.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and provides a comprehensive response to the multi-hop question. QUANTITATIVE VERIFICATION: All numbers are correct - 3,000 employees expected for renegotiation in 2022, 2,100 employees projected for 2024 negotiations in the 2023 filing, 21 agreements in 2022, 20 agreements in 2023. The reduction calculation (3,000 to 2,100) is accurate. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across two fiscal years (2022 and 2023 filings) and identifies the forward-looking nature of the data (2022 filing projected 2023 negotiations; 2023 filing projected 2024 negotiations). ENTITY ACCURACY: Years, metrics, and agreement counts are all correctly identified. REASONING QUALITY: The LLM provides sound interpretation of what the reduction indicates - a shift toward more focused, incremental renegotiation strategy. The answer goes beyond the ground truth by providing additional context about the overall workforce coverage (one-fifth under 62 collective agreements) and noting the lack of material impact on operations, which adds valuable context without contradicting the ground truth. SEMANTIC EQUIVALENCE: The core finding matches the ground truth - reduction in both number of agreements and employees involved indicates a strategic shift. The LLM's characterization as 'more focused, incremental renegotiation strategy' is semantically equivalent to the ground truth's 'shift in labor agreement strategy.' Minor enhancement: The LLM provides slightly more detailed interpretation than the ground truth, but this is additive rather than contradictory. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Negotiates]- ORG",
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 450,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "\nNextEra Energy’s exposure to U.S. Government and municipal bonds grew sharply: the company reported a total fair‑value holding of **$137 million** for these securities in its 2021 disclosure (Chunk 1), while by the end of 2024 the combined Level 1 and Level 2 valuations for NEE’s U.S. Government and municipal bonds amounted to **$722 million**, and an additional **$161 million** of such bonds were listed under “Other investments,” yielding a **total of roughly $883 million** (Chunk 2). This represents an **increase of about $746 million** in the portfolio’s value from the earlier period to 2024, consistent with the disclosed investment relationship (NEE → U.S. Government and municipal bonds) captured in the knowledge‑graph triplets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains major factual errors and misinterpretations that fundamentally contradict the ground truth. CRITICAL ISSUES: (1) WRONG BASELINE YEAR: The LLM cites 2021 data ($137M) as the starting point, but the question explicitly asks about evolution from 2022 to 2024. The ground truth clearly states 2022 as the baseline year with $137M. (2) INCORRECT TOTAL CALCULATION: The LLM claims a total of $883M in 2024 by combining $722M (Level 1/2 valuations) + $161M (Other investments). However, the ground truth indicates the 2024 figure is simply $161M under 'Other investments' for NEE. The LLM appears to have conflated different investment categories or misread the data structure. (3) MASSIVE CALCULATION ERROR: The LLM calculates an increase of $746M ($883M - $137M), which is wildly incorrect. The ground truth shows a $24M increase ($161M - $137M = $24M), representing 17.5% growth. The LLM's figure is off by a factor of 31x. (4) MISIDENTIFIED METRICS: The LLM references 'Level 1 and Level 2 valuations' which appear to be fair value hierarchy classifications not relevant to the straightforward comparison requested. The ground truth uses simpler 'Other investments' categorization. (5) TEMPORAL CONFUSION: By citing 2021 instead of 2022, the LLM has answered a different question than asked. The question specifically asks about 2022-2024 evolution. CORRECT ELEMENTS: The LLM correctly identifies NextEra Energy (NEE) and U.S. Government and municipal bonds as the relevant entities. The $137M and $161M figures do appear in the LLM's answer, though miscontextualized. MULTI-HOP REASONING: The synthesis is fundamentally flawed. Rather than correctly comparing 2022 vs 2024 values, the LLM has created an erroneous aggregate figure that doesn't match the ground truth's straightforward year-over-year comparison. The answer demonstrates a failure to properly extract and synthesize the relevant data points from the source documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 527,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "\nBetween 2022 and 2024, Opdivo’s manufacturing remained anchored in Bristol‑Myers Squibb’s flexible, multi‑site network—leveraging internal production capacity (e.g., the Devens, MA biologics plant) while relying on qualified third‑party manufacturers and supply agreements to meet demand and manage regulatory‑driven capital needs, as described in the 2022 10‑K discussion of product‑supply arrangements. Therapeutically, the portfolio evolved when the FDA granted Opdivo a new first‑line approval in March 2024 for use with cisplatin + gemcitabine in metastatic urothelial carcinoma, expanding its oncology indications and reinforcing its strategic role in BMY’s product mix. This evolution reflects both a continued hybrid manufacturing model and a broadening of approved uses for Opdivo.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY (10/10): All dates and numeric references are correct—the March 2024 FDA approval date is accurate, and the therapeutic indication (cisplatin + gemcitabine for metastatic/unresectable urothelial carcinoma) matches the ground truth exactly. No calculation errors or numeric discrepancies. QUALITATIVE ACCURACY (9/10): The answer correctly synthesizes the multi-hop information across 2022-2024, accurately identifying: (1) the manufacturing strategy evolution (internal capacity at Devens, MA plus third-party manufacturers), (2) the therapeutic expansion (new first-line approval), and (3) the strategic positioning within BMY's oncology portfolio. The reasoning is sound and logically connects manufacturing and clinical developments. Minor note: The LLM provides slightly more specific detail about the Devens facility than the ground truth explicitly states, though this is consistent with typical 10-K disclosures and doesn't contradict the source material. ENTITY ACCURACY (10/10): All entities correctly identified—Bristol-Myers Squibb, Opdivo, FDA, the specific indication, and the time period (2022-2024). COMPLETENESS (10/10): The answer addresses both sub-questions (manufacturing strategy and therapeutic approvals) with appropriate depth. SEMANTIC EQUIVALENCE (9/10): The LLM's phrasing ('flexible, multi-site network,' 'hybrid manufacturing model,' 'broadening of approved uses') conveys the same meaning as the ground truth while using slightly more sophisticated terminology. The core message—that Opdivo evolved in both manufacturing approach and clinical positioning—is preserved. Overall, this is a high-quality response that accurately synthesizes complex multi-hop information from SEC filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 497,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney’s stake in National Geographic remained at **73 % ownership**, but the way the brand is positioned within Disney’s portfolio shifted markedly.  In the 2023 filing (Chunk 1) the magazine and its online business were listed under **Content Sales/Licensing** as part of the Entertainment segment, generating revenue through licensing and subscription fees.  By 2024 (Chunk 2) Disney reports that it **publishes National Geographic magazine** and that its titles are now a **core component of Disney+**, Disney+ Hotstar and Hulu, driving subscription fees and advertising; the brand appears as a dedicated “National Geographic” tile in the DTC interface and is integral to the company’s direct‑to‑consumer growth strategy.  Thus, while the ownership structure (73 % owned by Disney) and its classification as Content Sales/Licensing stay the same, the magazine’s **business role evolved from a standalone print/linear asset to a strategic content pillar that fuels Disney’s streaming‑centric revenue mix**.  The KG relationship — DIS → National Geographic Magazine (Produces) and National Geographic Magazine → DIS (Depends_On) — captures this tighter integration.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 73% ownership percentage in both years, which matches the ground truth. (2) It accurately notes that National Geographic was under Content Sales/Licensing in both 2023 and 2024. (3) The LLM provides additional context about the shift toward streaming integration and DTC strategy, which adds useful detail. WEAKNESSES: (1) The ground truth explicitly states that 'the emphasis on its ownership percentage was removed' in 2024, but the LLM claims the 73% ownership remained emphasized in both years - this is a factual error about how the information was presented/emphasized in the filings. (2) The ground truth emphasizes a shift from 'ownership-focused relationship' to 'operational rather than ownership-focused relationship,' but the LLM states the ownership structure 'stays the same' in terms of how it's reported, which contradicts the ground truth's key finding about the de-emphasis of ownership. (3) The LLM introduces substantial detail about streaming integration, DTC strategy, and Disney+ positioning that, while potentially accurate, goes beyond what the ground truth specifies and may represent inference rather than direct filing information. (4) The ground truth's core insight is about a shift in HOW the relationship is described (ownership-focused vs. operationally-focused), but the LLM frames it primarily as a shift in business role/strategy rather than in how the ownership relationship is presented. CALCULATION/NUMBERS: The 73% figure is correct and properly formatted. MULTI-HOP REASONING: The LLM attempts to synthesize 2023 vs 2024 information but misses the key distinction about the de-emphasis of ownership percentage in 2024. The reasoning about streaming integration may be sound but diverges from the ground truth's specific focus on the ownership/operational framing shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 503,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "\nPayPal’s 2023 filing describes its transaction‑management databases as enabling payments to roughly 200 markets in ≈150 currencies, with fund‑withdrawals available in 56 currencies and balances held in 24 currencies; by 2024 the same database infrastructure is said to support payments in about 200 markets but now in ≈140 currencies, while withdrawals expand to 57 supported currencies and balances remain holdable in 24 currencies.  This progression—still rooted in the PYPL‑owned Transaction Management Database product—shows a modest shift toward a broader, though slightly refined, global‑currency coverage, especially an increase in withdrawal‑currency options, while the core capability of processing multi‑currency payments across a worldwide network remains unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ERRORS: (1) The LLM claims 2024 shows ~140 currencies for payments, down from ~150 in 2023 - this represents a DECREASE, not the expansion/refinement the ground truth describes. The ground truth makes no mention of these specific currency counts for payment processing. (2) The LLM states withdrawal currencies remain at 56 in 2023 and expand to 57 in 2024, which matches the ground truth on the withdrawal currency expansion. However, the LLM introduces additional currency metrics (24 currencies for balances, 200 markets, 150/140 currencies for payments) that are NOT mentioned in the ground truth at all. (3) The ground truth emphasizes a shift in framing from 'merchants' to 'consumers' in 2024, which the LLM answer completely omits. (4) The ground truth describes this as 'slight expansion' and 'refinement in positioning,' while the LLM characterizes it as showing 'a modest shift toward a broader, though slightly refined, global-currency coverage' - but this is undermined by the claimed decrease in payment currencies. QUANTITATIVE ACCURACY: The only verifiable number match is the 56→57 currency withdrawal expansion. The introduction of unverified metrics (150/140 currencies, 24 currencies for balances, 200 markets) without ground truth support is problematic. QUALITATIVE ACCURACY: The LLM fails to capture the key qualitative shift regarding consumer-centric framing that the ground truth emphasizes. The reasoning about 'modest shift' contradicts the claimed decrease in payment currencies. CONTEXTUAL RELEVANCE: The answer addresses the general topic but introduces information not in the ground truth and misses the key positioning shift that was central to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 487,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "\nThe Series K Debentures—$2.5 bn of fully‑guaranteed obligations that NEECH introduced and that NEE guarantees and that are due March 1 2025—had their interest rate reset to **6.051 % per annum** (payable semi‑annually) in the March 2023 remarketing, and the 2024 SEC filing (Exhibit 4(s)‑4(t)) shows that this 6.051 % rate remained unchanged through 2024 with no subsequent reset reported.  This reflects NEE’s strategy of securing long‑term, fixed‑rate financing through guaranteed debentures while using equity‑linked units to refinance and fund growth, thereby stabilizing its cost of capital over the 2023‑2024 period.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on the core financial data but contains some issues with completeness and clarity regarding the ground truth. STRENGTHS: (1) Correctly identifies the 6.051% interest rate reset in March 2023 remarketing; (2) Accurately notes the rate remained unchanged through 2024; (3) Correctly identifies the $2.5 billion principal amount and March 1, 2025 maturity date; (4) Properly identifies NEECH as the issuer with NEE guarantee; (5) Provides reasonable strategic interpretation about fixed-rate financing and cost of capital stabilization. WEAKNESSES: (1) The ground truth mentions a 'letter dated March 1, 2023' that 'set forth certain terms effective March 1, 2023' which the LLM answer does not explicitly reference or explain; (2) The ground truth's phrasing about 'continuation of the updated rate and terms from the 2023 remarketing' is somewhat ambiguous, but the LLM's statement that the rate 'remained unchanged through 2024 with no subsequent reset reported' is a reasonable interpretation that aligns with the ground truth's intent; (3) The LLM adds contextual detail about 'equity-linked units' that is not mentioned in the ground truth, which while potentially accurate, goes beyond what was provided; (4) The ground truth's statement about 'locking in a higher interest rate to secure funding' is somewhat vague, and the LLM's interpretation about 'stabilizing its cost of capital' is a reasonable but slightly different characterization. QUANTITATIVE VERIFICATION: The 6.051% rate is correct, the $2.5 billion amount is correct, and the March 1, 2025 maturity date is correct. MULTI-HOP REASONING: The answer successfully synthesizes information about the 2023 reset and 2024 continuation, though it could have been clearer about the March 1, 2023 letter mentioned in the ground truth. The strategic interpretation is reasonable but somewhat speculative beyond what the ground truth explicitly states.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 529,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "\nExxonMobil continues to apply unit‑of‑production depreciation to its upstream assets, calculating each period’s expense as the asset’s cost divided by the total proved (or proved‑developed) reserves used as the production base—a policy reiterated in both the 2022 and 2023 filings. In the 2023 disclosure the company specifies that when proved reserves are substantially de‑booked, depreciation is computed using reserves determined at the most recent SEC price and adjusted for production and technical changes, reflecting a shift from the 2022 practice of relying on the average‑price‑based reserve estimate. This evolution—adding a current‑price, adjustment‑based reserve base while retaining the straight‑line alternative only for assets whose useful life does not correlate with reserve life—captures how the method has been refined to produce a more equitable allocation of cost as reserve volumes and assumptions evolve.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core Unit-of-Production depreciation methodology applied in both 2022 and 2023, accurately captures the use of proved/proved-developed reserves as the production base, and correctly notes the straight-line depreciation alternative for assets where life doesn't correlate with reserves. The answer appropriately recognizes that both years use SEC price-based reserves when proved reserves are substantially de-booked. The general structure and flow of the response is logical and addresses the evolution question. WEAKNESSES: (1) The LLM introduces a potentially misleading characterization by stating the 2023 practice represents 'a shift from the 2022 practice of relying on the average-price-based reserve estimate.' The ground truth indicates both years used SEC price-based reserves in de-booking scenarios, not that 2022 relied on average-price estimates. This is a material mischaracterization of the 2022 baseline. (2) The LLM states the evolution involves 'adding a current-price, adjustment-based reserve base' but the ground truth indicates the refinement was about placing 'greater emphasis on using the most recent SEC price' and 'ensuring a more meaningful allocation'—this is more about emphasis and refinement than adding a new element. (3) The answer lacks clarity on what specifically changed: the ground truth emphasizes that the 2023 refinement was about using 'the most recent SEC price' with adjustments for production and technical changes, whereas the LLM's phrasing is somewhat ambiguous about whether this is truly new or just emphasized differently. MULTI-HOP REASONING: The answer attempts to synthesize information across 2022 and 2023 filings but makes an unsupported claim about 2022 relying on 'average-price-based' estimates, which contradicts the ground truth that both years used SEC price-based reserves in de-booking scenarios. NUMERIC/CALCULATION ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral. The answer is partially correct on the core methodology but contains a significant factual error regarding the 2022 baseline practice.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 579,
        "total_tokens": 2008
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix shifted its original‑programming strategy from a largely outsourced model to a hybrid approach that increasingly leans on its own studio capacity—its 2023 filing notes that it “contracts with third parties related to the development, production, marketing and distribution of our original programming” while also “scaling our own studio operations to produce original content, including through acquisitions such as Scanline and Animal Logic,” and the 2024 filing emphasizes that it is “scaling our own studio operations” and “building out expertise” across creative, legal, finance and other disciplines, even as it continues to depend on external partners and therefore remains exposed to the same liability risks (e.g., third‑party violations of law, insolvency or fraud) that the earlier filing warns can cause “significant losses.”  \n\nIn other words, Netflix’s 2023‑2024 evolution shows a deliberate move to internalize more of the production pipeline—through studio acquisitions and expanded in‑house expertise—while still relying on third‑party contracts for many aspects of development, production, marketing and distribution, a dependence that the company flags as a source of potential cost overruns, regulatory exposure and operational complexity.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. STRENGTHS: (1) Correctly identifies the two key acquisitions (Scanline and Animal Logic) mentioned in the ground truth; (2) Accurately captures Netflix's shift toward internal studio scaling between 2023-2024; (3) Properly notes the continued reliance on third-party partners; (4) Correctly identifies specific liability risks (third-party violations of law, insolvency, fraud). CRITICAL WEAKNESSES: (1) The LLM claims that 2024 filing 'remains exposed to the same liability risks' and that 'the earlier filing warns can cause significant losses' - this directly contradicts the ground truth, which explicitly states 'The explicit mention of third-party risks present in 2023 was omitted in 2024.' The ground truth indicates these risk disclosures were REMOVED in 2024, not continued. (2) The LLM's characterization that Netflix 'continues to depend on external partners and therefore remains exposed to the same liability risks' misrepresents the strategic shift documented in the ground truth. The ground truth indicates the 2024 filing shifted focus away from third-party risks toward internal operational improvements. (3) The LLM presents a more balanced 'hybrid approach' narrative, whereas the ground truth emphasizes a more pronounced strategic pivot away from external dependency language. MULTI-HOP REASONING: The LLM attempts to synthesize across both years but makes a fundamental error in interpreting what changed between filings - it suggests continuity of risk language when the ground truth indicates discontinuity. This is a material factual error about the evolution of Netflix's strategic messaging. The answer reads as more nuanced than the ground truth supports, potentially confusing the actual strategic shift that occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1533,
        "completion_tokens": 492,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "\nMastercard’s **Cyber and Intelligence Solutions** remained classified as an “Other‑revenue” product that generates fees for fraud‑prevention, detection and response services (Chunk 1), but in 2023 the company broadened its strategic framing—positioning the offering as a core element of a **multi‑layered security platform** that now ties directly to its investments in open‑banking and digital‑identity capabilities (Chunk 2).  This evolution reflects a shift from a standalone fraud‑fee product to an integrated, ecosystem‑wide service that underpins Mastercard’s “safe, simple, smart and accessible” payments network.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of the evolution but introduces inaccuracies and unsupported claims. CORRECT ELEMENTS: (1) The answer correctly identifies that Cyber and Intelligence Solutions remained classified as 'Other revenues' in both years, (2) Correctly notes the 2022 positioning focused on fraud prevention, detection, and response, (3) Correctly identifies a shift toward broader strategic importance by 2023. PROBLEMATIC ELEMENTS: (1) The LLM introduces specific claims about 'multi-layered security platform,' 'open-banking,' and 'digital-identity capabilities' that are NOT present in the ground truth answer. These appear to be hallucinated details not supported by the source material. (2) The phrase 'safe, simple, smart and accessible' is introduced without verification that this exact framing appears in the 2023 positioning. (3) The LLM's characterization of the 2022 version as a 'standalone fraud-fee product' is somewhat reductive compared to the ground truth's description of 'products and services offered to prevent, detect, and respond to fraud.' MULTI-HOP REASONING: The answer attempts to synthesize the evolution across years but does so by adding interpretive layers (open-banking, digital-identity) that go beyond what the ground truth establishes. The core comparison (2022 vs 2023 positioning) is present but embellished with unsupported details. QUANTITATIVE ACCURACY: No specific numbers or dates are provided in either answer, so this dimension is neutral (8/10 for not introducing false numbers). QUALITATIVE ACCURACY: The reasoning structure is sound, but the introduction of unverified claims significantly undermines the answer's reliability (5/10). The answer reads as plausible but contains fabricated supporting details. CONTEXTUAL RELEVANCE: The answer appropriately addresses the question about strategic evolution and maintains focus on the relevant time period and company (7/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 523,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "\nFrom 2023 to 2024 Tesla refined its energy‑storage line by building on a modular, vehicle‑derived architecture that leverages in‑house battery, power‑electronics and software expertise to enable fast grid‑interconnection and integration with Powerwall. By 2024 the company’s strategy shifted to scaling that portfolio, but it now confronts production challenges—including supply‑chain bottlenecks, component shortages and the need to ramp global factories—making supplier reliability and localized manufacturing critical strategic dependencies for its energy‑storage business.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the 2023 focus on modular design and in-house expertise in power electronics and software - matching the ground truth exactly. (2) Accurately captures the 2024 shift toward addressing production challenges and supply chain dependencies. (3) Properly synthesizes the multi-hop information about supplier reliability, scaling challenges, and manufacturing bottlenecks. (4) No quantitative errors - no numbers, dates, or calculations to verify, and none are presented incorrectly. (5) Correctly identifies Tesla and its energy storage products (Megapack, Powerwall) as relevant entities. (6) The semantic meaning is equivalent to ground truth: both convey the evolution from emphasizing design/expertise to confronting production/supply chain realities. MINOR CONSIDERATIONS: (1) The LLM answer adds some contextual details not explicitly in the ground truth (e.g., 'vehicle-derived architecture,' 'fast grid-interconnection,' 'localized manufacturing') - these appear to be reasonable elaborations consistent with Tesla's actual business but represent minor additions beyond the ground truth scope. (2) The phrasing 'refined its energy-storage line' vs. the ground truth's 'emphasized' represents a slight semantic variation, though both convey similar meaning. (3) The answer could have been slightly more explicit about the contrast between 2023's optimization focus and 2024's scaling/production challenges, though this is adequately conveyed. MULTI-HOP REASONING: The answer successfully synthesizes information across two time periods (2023 and 2024) and connects strategic approaches to their underlying dependencies and challenges. The reasoning is sound and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 493,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "\nFrom 2023 to 2024 NEECH broadened and laddered its floating‑rate program: in 2023 it issued $600 million of floating‑rate debentures that mature in 2026 as part of a $3.8 billion total issuance, and in 2024 it added new floating‑rate series—including another $600 million tranche due January 29 2026 (the Jan 31 2024 certificate) and fresh series maturing in 2029, 2031, 2034 and 2054 (e.g., the June 20 2024 Series N and Oct 31 2024 Series O)—thereby extending the maturity spectrum and diversifying the principal amounts of its floating‑rate debt.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and contradicts the ground truth in multiple ways: (1) QUANTITATIVE ERRORS: The LLM claims NEECH issued additional floating-rate debentures in 2024 with maturities in 2029, 2031, 2034, and 2054, citing 'June 20 2024 Series N and Oct 31 2024 Series O' as examples. However, the ground truth explicitly states that 'the principal amount was not explicitly updated in 2024' and that the company showed 'a continuation of the prior year's approach without significant expansion or restructuring.' The LLM fabricates specific maturity dates and series designations not supported by the ground truth. (2) STRATEGIC CHARACTERIZATION ERROR: The LLM describes the evolution as 'broadened and laddered' with 'extended maturity spectrum and diversifying principal amounts,' directly contradicting the ground truth's characterization of 'a focused strategy' with 'a continuation of the prior year's approach without significant expansion.' (3) PARTIAL ACCURACY: The LLM correctly identifies the $600 million 2023 issuance and the January 29, 2026 maturity date formalized in the January 31, 2024 Officer's Certificate. However, this correct information is embedded within a fundamentally misleading narrative about expansion. (4) MULTI-HOP REASONING: The LLM fails to properly synthesize the available information, instead inventing details about additional issuances and maturity structures that are not present in the ground truth. The reference to a '$3.8 billion total issuance' in 2023 is not verified against the ground truth provided. (5) SEMANTIC MISMATCH: The ground truth emphasizes consistency and lack of expansion; the LLM emphasizes broadening and laddering—these are contradictory interpretations of the same company's strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 484,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "\nBetween 2023 and 2024 Intel moved from setting industry‑wide targets—such as a net‑zero Scope 3 emissions goal by 2050, a $2 billion diverse‑supplier spend goal by 2030, and linking executive bonuses to emissions cuts—into concrete actions that broadened supplier coverage to both direct and indirect tiers and began measuring and reducing their greenhouse‑gas footprints. By 2024 the company deepened this evolution, publishing a green‑bond report that funds sustainability projects, expanding the number of suppliers engaged, and intensifying collaborations with peers on transparency, climate, water and responsible‑minerals standards, thereby shifting from target‑setting to a more expansive, partnership‑driven supplier‑engagement model.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several problematic elements that significantly diverge from the ground truth: (1) QUANTITATIVE ERRORS: The LLM introduces specific numbers ($2 billion diverse-supplier spend goal by 2030) that are not mentioned in the ground truth answer. While these may be factually accurate from Intel's filings, they are not part of the knowledge graph answer being evaluated, creating a factual discrepancy. (2) CONTRADICTORY CLAIMS: The ground truth explicitly states that by 2024 Intel's approach did NOT include 'explicit mention of expanding the number of suppliers engaged,' yet the LLM claims the company was 'expanding the number of suppliers engaged' in 2024. This is a direct contradiction of the ground truth. (3) INCOMPLETE SYNTHESIS: The ground truth emphasizes a shift from 'announcing strategic expansions' (2023) to 'reinforcing and deepening existing industry partnerships' (2024), suggesting a qualitative change in approach rather than continued expansion. The LLM mischaracterizes this as a progression toward 'more expansive' engagement, which contradicts the ground truth's characterization. (4) PARTIAL ACCURACY: The LLM correctly identifies the 2050 net-zero Scope 3 emissions goal and the general shift toward partnership-driven models, and appropriately mentions responsible minerals sourcing and transparency around climate and water impacts. (5) MULTI-HOP REASONING: While the LLM attempts to synthesize evolution across years, it does so inaccurately by claiming continued expansion in 2024 when the ground truth indicates a shift away from expansion announcements. The core insight about moving from target-setting to action is partially correct but oversimplified and contradicted by the expansion claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> CONCEPT <-[Partners_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 475,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "\nBoth the 2022 and 2023 disclosures state that the standardized measure of discounted future cash flows is calculated using **first‑day‑of‑the‑month average prices** (along with year‑end costs, legislated tax rates and a 10 % discount factor) and that these prescribed assumptions are “discrete points in time” that can cause “significant variability in cash flows from year to year as prices change.”  This wording shows that XOM’s accounting policy—prepared on the basis of those assumptions—has been framed consistently across the two years, emphasizing the same reliance on monthly average pricing to compute the measure.  Consequently, the company’s characterization of its dependency on first‑day‑of‑the‑month average prices has not materially evolved between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer fundamentally misunderstands and contradicts the ground truth. The core issue: The LLM claims there was NO material evolution in characterization between 2022 and 2023, stating the wording 'has been framed consistently across the two years.' This is directly contradicted by the ground truth, which explicitly documents a SHIFT in tone and framing between the two years. Specific errors: (1) The ground truth clearly states 2022 used language about 'prescribed assumptions' without explicitly highlighting dependency, while 2023 shifted to emphasizing the measure 'depends on' these assumptions. The LLM incorrectly asserts both years used identical framing. (2) The ground truth notes 2023 added explicit language about 'discrete points in time' causing 'significant variability' as a NEW emphasis on sensitivity and dependency. The LLM treats this as consistent language across both years, when the ground truth indicates this represents an evolution in disclosure emphasis. (3) The LLM's conclusion that 'the company's characterization of its dependency on first-day-of-the-month average prices has not materially evolved' directly contradicts the ground truth's finding of 'a shift in tone by emphasizing that the standardized measure depends on these prescribed assumptions.' Quantitative accuracy is acceptable (10% discount factor, year-end costs, legislated tax rates all correctly cited), but the qualitative reasoning about the evolution of characterization is fundamentally wrong. The LLM failed to identify the key distinction between 2022's 'prepared on the basis of' language versus 2023's 'depends on' language, which is the central point of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Prepared_On_Basis_Of]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 460,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "\nIn 2022 MA embedded its digital‑identity suite—enhanced by the 2021 acquisition of Ekata and comprising device‑intelligence, behavioral‑biometrics and consent‑centric verification—within an open‑banking platform that streamlines payments, credit‑decisioning and data access for consumers and lenders. Building on that foundation, the 2023 rollout expanded the platform’s reach by launching an ACH‑payment solution with leading banks and extending connectivity to over 95 % of U.S. deposit accounts and roughly 3,000 European banks, thereby dramatically widening the ecosystem in which MA’s privacy‑by‑design, consent‑centric identity capabilities operate; this evolution leverages the same Digital Identity Solutions product introduced by MA and now supports a global workforce of approximately 24,000 employees.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy on core metrics and timeline but includes some extraneous information and minor issues: (1) CORRECT ELEMENTS: All key numbers are accurate - 95% of U.S. deposit accounts, approximately 3,000 European banks, 2022 introduction of digital identity solutions within open banking platform, 2023 ACH payment solution launch with leading banks. The evolution narrative correctly captures the progression from 2022 to 2023. (2) QUANTITATIVE ACCURACY: All numeric values match ground truth. The percentages (95%), bank counts (3,000), and year references are precise. No calculation errors detected. (3) QUALITATIVE ACCURACY: The answer correctly identifies the multi-hop synthesis - connecting digital identity solutions evolution with open banking expansion and institutional reach. The mention of Ekata acquisition, device intelligence, behavioral biometrics, and consent-centric verification adds accurate contextual detail not in ground truth but consistent with MA's actual product evolution. (4) EXTRANEOUS INFORMATION: The reference to 'approximately 24,000 employees' is not mentioned in the ground truth and appears tangential to the specific question about digital identity solutions evolution. This is not incorrect but dilutes focus. (5) SEMANTIC EQUIVALENCE: The answer conveys the same core information as ground truth - 2022 foundation with open banking platform, 2023 expansion with ACH solution and broader institutional connectivity. The phrasing about 'privacy-by-design' and 'consent-centric' aligns with ground truth's emphasis on consent management and consumer protection. (6) MINOR GAPS: The answer could have been more explicit about the 'permissioned basis' aspect of data access mentioned in ground truth, though this is implied in the consent-centric language. Overall, the answer successfully addresses all parts of the multi-part question with accurate synthesis across the 2022-2023 timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 530,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "\nTesla’s Solar Roof moved from a design‑centric phase in 2023—where the product was refined through multiple iterations that leveraged vehicle‑derived engineering, a modular architecture and tight integration with Powerwall using the company’s in‑house design, testing and power‑electronics expertise—to a production‑scale phase in 2024 that emphasizes ramping manufacturing across global sites, mitigating bottlenecks and securing supply‑chain resilience; this evolution reflects TSLA’s continued production of the Solar Roof while increasingly depending on localized factories, supplier reliability and cost‑effective manufacturing processes to meet its output and profitability goals.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresentations compared to the ground truth. Key issues: (1) FACTUAL ERRORS: The LLM claims Tesla 'continued production of the Solar Roof' in 2024 and emphasizes 'ramping manufacturing across global sites,' but the ground truth explicitly states that by 2024, Tesla 'acknowledged that the production ramp of Solar Roof faced delays.' This is a direct contradiction—the LLM presents an optimistic narrative of scaling and ramping when the actual filing indicated delays. (2) MISSING CRITICAL INFORMATION: The LLM completely omits the crucial strategic dependency mentioned in the ground truth: that Tesla's future success 'depends in large part' on scaling mass-market vehicle production, which signals a potential prioritization shift away from Solar Roof. This is a major omission of a key finding. (3) UNSUPPORTED CLAIMS: The LLM introduces specific details about 'vehicle-derived engineering,' 'modular architecture,' 'localized factories,' and 'supplier reliability' that are not present in the ground truth and appear to be fabricated or hallucinated. (4) MISCHARACTERIZATION OF 2023 POSITIONING: While the ground truth mentions design maturity and aesthetic appeal, the LLM's elaborate description of 'multiple iterations,' 'in-house design, testing and power-electronics expertise' goes beyond what was documented. (5) MULTI-HOP REASONING FAILURE: The LLM failed to properly synthesize the key insight that production challenges in 2024 combined with strategic prioritization of mass-market vehicles suggests a deprioritization of Solar Roof, not an acceleration. The answer reads as if Solar Roof was being actively scaled when the ground truth indicates the opposite. The LLM answer is longer and more detailed but fundamentally misrepresents the evolution of Tesla's Solar Roof strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 504,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "\nBetween 2023 and 2024 NextEra Energy, Inc. kept the same pledge‑agreement structure first disclosed in its 2023 10‑K (the *4(rrr) Pledge Agreement dated September 1 2022 with Deutsche Bank Trust Company Americas as collateral/custodial agent and The Bank of New York Mellon as purchase‑contract agent) and added new pledge agreements in 2024—specifically a *4(ttt) Pledge Agreement dated June 1 2024 and a *4(vvv) Pledge Agreement dated October 1 2024—both again naming Deutsche Bank Trust Company Americas (as collateral/custodial agent and securities intermediary) and The Bank of New York Mellon (as purchase‑contract agent). The 2024 filing (Chunk 2) also lists related purchase‑contract agreements (*4(sss), *4(uuu), *4(vvv)) on June 1 2024 and October 1 2024, showing that the company expanded the same pledge framework with updated dates while retaining the identical counterparties.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All key facts are correct: (1) The 2023 disclosure of the September 1, 2022 Pledge Agreement with Deutsche Bank Trust Company Americas and The Bank of New York Mellon is accurately stated. (2) The two new 2024 Pledge Agreements dated June 1, 2024 and October 1, 2024 are correctly identified. (3) The counterparties remain the same across all agreements, which is accurately conveyed. (4) All dates are correct (September 1, 2022; June 1, 2024; October 1, 2024). The LLM answer goes beyond the ground truth by providing additional context about the specific roles of the counterparties (collateral/custodial agent, securities intermediary, purchase-contract agent) and references to related purchase-contract agreements (*4(sss), *4(uuu), *4(vvv)), which adds valuable detail without contradicting the ground truth. The multi-hop reasoning is sound—the answer correctly synthesizes information about the evolution of pledge agreements across 2023 and 2024 filings, showing both continuity (same counterparties, same framework) and expansion (new agreements with updated dates). The only minor distinction is that the LLM provides more granular detail about agreement types and roles, which enhances rather than detracts from accuracy. The answer directly addresses the question about how the use of Pledge Agreements evolved in terms of dates and counterparties.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 393,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "\nFrom 2023 to 2024 Intel’s Edge‑AI strategy deepened its **software‑first** approach: the 2023 10‑K highlighted an “edge‑native software platform with modular building blocks” that lets developers build, deploy, run, manage and secure distributed edge infrastructure and AI workloads across verticals, while the 2024 filing (NEX) explicitly frames this platform as the engine for moving networks from fixed‑function hardware to **general‑purpose, cloud‑native compute and networking devices** running on Intel silicon.  This evolution is reinforced by a broad **ecosystem of partners**—over 500 network builders and a suite of ecosystem collaborators (e.g., telecom operators, cloud‑RAN suppliers, and vertical application vendors)—that together enable Intel’s Edge‑AI concept and positively impact Intel’s market positioning, as captured by the KG triplets INTC → Edge AI ← Positively_Impacts INTC.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the 2023 positioning emphasizing 'edge-native software platform with modular building blocks' and the ability to build, deploy, run, manage, and secure distributed edge infrastructure—exact semantic match to ground truth. (2) Accurately captures the 2024 evolution under NEX initiative, correctly characterizing the shift from 'fixed-function hardware to general-purpose, cloud-native compute and networking devices'—core strategic pivot is properly synthesized. (3) Appropriately emphasizes the software-first approach as the connective thread between 2023 and 2024 strategies. (4) Correctly identifies ecosystem partnerships as a key differentiator in 2024 strategy, with specific mention of 'over 500 network builders' and relevant partner categories (telecom operators, cloud-RAN suppliers, vertical application vendors). (5) Multi-hop reasoning is sound: the answer successfully synthesizes information across two fiscal years and connects platform evolution to market positioning impact. MINOR CONSIDERATIONS: (1) The reference to 'KG triplets INTC → Edge AI ← Positively_Impacts INTC' is somewhat technical/meta-language that adds minimal substantive value but doesn't detract from accuracy. (2) The answer could have slightly more explicitly mentioned 'avoiding vendor lock-in' from the 2023 positioning, though this is a minor omission. (3) The phrase 'running on Intel silicon' is a reasonable inference but not explicitly stated in ground truth. QUANTITATIVE ACCURACY: The specific number '500 network builders' is correctly cited and represents a concrete data point from the filings. No calculations are required for this question, so quantitative accuracy is high. QUALITATIVE ACCURACY: The reasoning correctly identifies the strategic evolution as moving from horizontal infrastructure scaling to integrated cloud-native programmability with stronger partner collaboration. The synthesis of multi-hop information (2023 → 2024, software → ecosystem → market impact) is logically sound and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enables]-> CONCEPT <-[Positively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1517,
        "completion_tokens": 576,
        "total_tokens": 2093
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "\nThe 1.75 % senior notes that mature in August 2030 remained at **$1.25 billion** in both the 2023 and 2024 filings, and the companion 5.125 % senior notes due February 2030 stayed at **$1.5 billion**, showing that the set of CVS‑issued notes maturing in 2030 was unchanged between the two years.  In the 2024 filing the same $1.25 billion amount is reported for the 1.75 % August 2030 notes and the same $1.5 billion for the 5.125 % February 2030 notes, indicating no new issuance or retirement of those series, while other 2030‑maturing tranches (e.g., the 5 % notes due January 2029) disappeared, slightly shifting the overall long‑term‑debt mix but leaving the 2030 cohort’s composition and total value essentially stable.  This continuity reflects CVS’s unchanged stake in these financial instruments as disclosed in both annual reports.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) WRONG SENIOR NOTE RATES: The LLM claims the companion notes are '5.125% senior notes due February 2030' at $1.5 billion, but the ground truth specifies '3.75% senior notes due April 2030' at $1.5 billion. This is a factual error in both the interest rate (5.125% vs 3.75%) and maturity date (February vs April). (2) CORRECT INFORMATION: The 1.75% senior notes due August 2030 at $1.25 billion ($1,250 million) for both 2023 and 2024 is accurate and matches ground truth. (3) EXTRANEOUS/INCORRECT DETAILS: The LLM introduces information about '5% notes due January 2029' which is not mentioned in the ground truth and appears to be fabricated or from a different context. The ground truth does not mention any notes disappearing or shifting in the 2030 cohort. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize information about debt composition evolution, it does so with incorrect data points. The core finding that 2030 notes remained stable is correct, but the specific composition details are wrong. (5) SEMANTIC ISSUES: The LLM's statement about 'no new issuance or retirement' is reasonable inference but based on incorrect note specifications. The ground truth explicitly states the 3.75% April 2030 notes remained at $1,500 million (no change), not that they disappeared. The LLM's narrative about 'other 2030-maturing tranches disappearing' contradicts the ground truth's statement of stability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 401,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix moved from a **test launch** of a **new, lower‑priced ad‑supported subscription plan** (introduced in 2023 as a way to broaden its pricing model and attract price‑sensitive users) to a **strategic pillar** of its pricing mix in 2024, explicitly positioning the tier alongside other plans “to meet a variety of consumer needs” and to **drive membership growth** despite macro‑economic headwinds.  The 2024 filing underscores that the ad‑supported option is now a core component of Netflix’s effort to expand its subscriber base, retain members in saturated markets, and sustain overall growth objectives while continually testing and adjusting pricing and service offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the 2023 introduction of the ad-supported plan as a new, lower-priced option aimed at expanding membership and addressing competitive pressures; (2) Accurately characterizes the 2024 evolution as integration into a core strategic component of pricing strategy; (3) Properly synthesizes the multi-hop concept that the plan evolved from experimental/test launch to strategic pillar; (4) Correctly identifies the purpose of meeting varied consumer needs and driving membership growth; (5) Adds relevant context about macro-economic headwinds and market saturation that aligns with Netflix's strategic positioning. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required or provided in either answer, so this dimension scores perfectly (10/10). QUALITATIVE ACCURACY: The reasoning is sound and multi-hop synthesis is correct - the answer properly connects 2023 positioning with 2024 strategic integration. The characterization of the evolution from 'test launch' to 'strategic pillar' effectively captures the progression described in ground truth. Minor note: The LLM adds slightly more contextual detail (macro-economic headwinds, market saturation, retention in saturated markets) which, while not explicitly in the ground truth, is consistent with Netflix's strategic narrative and doesn't contradict the original answer. CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the question - the evolution between 2023-2024, the role within pricing strategy, and membership growth objectives. The semantic equivalence is strong: 'test launch' ≈ 'introduced as new option', 'strategic pillar' ≈ 'core component of long-term growth framework', and both emphasize the shift from experimental to strategic positioning. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 517,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "\nTesla’s strategy for the Semi has shifted from the early commercial‑delivery phase launched in 2022‑23—when the truck began limited production and shipments—to a more advanced pilot‑production stage at its Nevada facility in 2024, indicating a move from proof‑of‑concept rollout toward scaling and integration within its broader vehicle portfolio.  This evolution is reflected in the 2024 production‑status table (Nevada → Tesla Semi = Pilot production) and underscores the Semi’s continued positioning alongside new models such as the Cybertruck and the upcoming Cybercab, while leveraging Tesla’s proprietary battery and Full‑Self‑Driving technologies within the automotive segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Tesla's Semi strategy from early production/deliveries in 2023 to pilot production in 2024 at the Nevada facility. The key facts are accurate: (1) 2023 status was early production and deliveries, (2) 2024 status advanced to pilot production, (3) location is Nevada facility. The answer demonstrates sound multi-hop reasoning by synthesizing the production status progression across years and connecting it to Tesla's broader strategic positioning. However, there are some issues: (1) The LLM introduces 'early commercial-delivery phase launched in 2022-23' which adds a 2022 reference not present in the ground truth, potentially conflating timeline details; (2) The LLM adds contextual information about Cybertruck, Cybercab, battery technology, and Full-Self-Driving that, while potentially accurate, goes beyond what the ground truth explicitly states about the Semi's evolution; (3) The phrase 'proof-of-concept rollout' is interpretive language not directly supported by the ground truth's more neutral 'initial market introduction.' The core answer is semantically equivalent to the ground truth—both describe progression from early/initial phase to pilot production—but the LLM adds interpretive framing and broader context that, while reasonable, extends beyond the specific question scope. The quantitative accuracy is strong (dates and production statuses are correct), and the qualitative reasoning about progression is sound, though somewhat embellished with additional strategic context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 428,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "\nThe 2023 filing (Chunk 1) introduces the first 2024‑dated agreement—an Executive Retention Employment Agreement with Nicole J. Daggs effective January 1 2024—as well as the 2023‑dated contract with Mark Lemasney, while the 2024 filing (Chunk 2) adds a new 2024 agreement with Brian Bolster (May 6 2024) and continues to reference earlier retention pacts.  This steady addition of fresh, long‑term executive contracts—paired with the recurring accounting‑policy disclosures highlighted by the KG pattern (ORG → Executive Retention Employment Agreement ← ORG)—demonstrates that NextEra Energy is deliberately extending retention terms to preserve institutional leadership and signal a strategic emphasis on securing top talent for its ongoing growth and regulatory agenda.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN FACTUAL ACCURACY: The LLM answer introduces a significant factual error by claiming Nicole J. Daggs had an Executive Retention Employment Agreement effective January 1, 2024. The ground truth makes no mention of Nicole J. Daggs at all. The ground truth specifically identifies Mark Lemasney (January 1, 2023), Armando Pimentel, Jr. (February 15, 2023), and Brian Bolster (May 6, 2024) as the executives with retention agreements. The LLM incorrectly substitutes Nicole J. Daggs for Armando Pimentel, Jr., which is a fundamental factual error. QUANTITATIVE ACCURACY ISSUES: While the LLM correctly identifies Brian Bolster's agreement date (May 6, 2024), it fails to mention Armando Pimentel, Jr. entirely, missing one of the three key executives mentioned in the ground truth. The date for the Nicole J. Daggs agreement (January 1, 2024) is also incorrect—this executive should not appear in the answer at all. MULTI-HOP REASONING: The LLM does attempt to synthesize information across 2023 and 2024 filings and correctly identifies the expansion pattern, but the factual errors undermine the validity of this synthesis. The reasoning about strategic emphasis on talent retention is sound in principle but is built on partially incorrect data. COMPLETENESS: The answer fails to comprehensively capture all executives mentioned in the ground truth (missing Armando Pimentel, Jr.) and introduces an executive not mentioned in the ground truth (Nicole J. Daggs). SEMANTIC EQUIVALENCE: While the LLM's interpretation of NextEra's strategic approach to leadership continuity aligns with the ground truth's conclusion, the factual foundation is compromised. The answer does address the core question about expansion and strategic emphasis, but with significant inaccuracies that prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 492,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "\nFrom 2023 to 2024 Intel shifted from a largely risk‑focused, R&D‑intensive posture—where it disclosed $16‑$17 billion of annual R&D spend, a plan to introduce five new process nodes in four years, and the need to overcome past delays in 10 nm/7 nm and 4th‑Gen Xeon launches—to a 2024 strategy that explicitly makes **xPU** a core pillar of product competitiveness.  In 2024 the company’s priorities are to **lead and democratize compute with Intel x86 and xPU**, offering a broad family of client‑ and data‑center GPUs, IPUs, FPGAs and other accelerators, expand the x86 ecosystem through an advisory group for compatibility, infuse AI across the entire hardware‑software stack (from GenAI to AI‑PC and edge), and leverage both in‑house and third‑party foundry capacity to scale manufacturing while managing the complexity of disaggregated designs and advanced packaging.  This evolution reflects a move from merely funding long‑term R&D and mitigating execution risk (Chunk 1) to a concrete product‑and‑platform roadmap that emphasizes portfolio breadth, open standards, and AI‑driven compute as the drivers of growth (Chunk 2).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: The R&D spending figure of $16-$17 billion is correctly cited (ground truth specifies $16.0 billion in 2023, and the LLM's range appropriately captures the 2023-2024 period). The reference to 'five new process nodes in four years' is a specific technical detail that adds credibility. ENTITY ACCURACY: Intel is correctly identified, xPU products are properly characterized (client and data center GPUs, IPUs, FPGAs, accelerators), and the x86 ecosystem advisory group is accurately mentioned. MULTI-HOP REASONING: The answer successfully synthesizes the evolution from 2023 to 2024 by contrasting: (1) 2023's R&D-intensive, risk-mitigation posture with (2) 2024's strategic product competitiveness focus. The logical progression from 'funding long-term R&D' to 'concrete product-and-platform roadmap' mirrors the ground truth's shift from 'general R&D focus' to 'structured and strategic product development.' COMPLETENESS: The answer addresses both strategic focus (xPU as core pillar, x86 ecosystem expansion, AI infusion) and product development priorities (portfolio breadth, open standards, manufacturing scale). The ground truth mentions these same elements. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift as moving from 'risk-focused, R&D-intensive posture' to 'explicit core pillar of product competitiveness' accurately captures the ground truth's distinction. Minor strengths: The LLM provides additional context about disaggregated designs and third-party foundry capacity, which enriches the answer without contradicting ground truth. The only minor limitation is that the LLM doesn't explicitly mention 'challenges in timely product development and manufacturing process introductions' from 2023, though this is implied in the 'risk mitigation' framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Focuses_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 513,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "\nNetflix has accelerated the build‑out of its advertising‑technology function between 2023 and 2024, explicitly expanding both the **advertising‑sales organization** and the **technology/infrastructure** needed to support it—its 2024 filing lists “our ability to develop and expand an advertising sales and advertising‑technology organization team” and “our ability to develop the technology and related infrastructure to support advertising” as key risk factors, echoing the 2023 discussion of the same objectives.  At the same time, the company is deepening its reliance on third‑party service providers for ad management, measurement and infrastructure while investing in proprietary tools and capabilities to improve ad effectiveness, drive advertiser value, and mitigate the risks outlined in both filings.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements correctly but introduces problematic claims not supported by the ground truth. CORRECT ELEMENTS: (1) The identification of 2023 vs 2024 comparison is accurate; (2) The quotes about 'develop and expand an advertising sales and advertising-technology organization team' and 'develop the technology and related infrastructure to support advertising' are correctly cited from 2024 filings; (3) The general direction of evolution from external reliance to internal development is captured. PROBLEMATIC ELEMENTS: (1) The LLM states Netflix is 'deepening its reliance on third-party service providers' in 2024, which contradicts the ground truth's core finding that Netflix shifted FROM reliance on external providers TO internal development. The ground truth explicitly notes the 2023 emphasis on 'dependencies on third-party service providers' as a limitation being addressed, not deepened; (2) The claim about 'investing in proprietary tools and capabilities' is not explicitly supported by the ground truth provided; (3) The statement that 2024 filings 'echo the 2023 discussion of the same objectives' is misleading—the ground truth indicates a strategic SHIFT in approach, not merely echoing the same objectives. The 2023 framing emphasized limitations and dependencies, while 2024 emphasized proactive development capability. MULTI-HOP REASONING: The answer attempts to synthesize across years but misinterprets the directional change. The ground truth shows evolution FROM external dependency TO internal capability, but the LLM suggests simultaneous deepening of external reliance alongside internal investment, which misrepresents Netflix's strategic pivot. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral. OVERALL: The answer demonstrates partial understanding but contains a significant factual error regarding the direction of Netflix's strategic evolution regarding third-party dependencies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Develops]- ORG",
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 537,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "\nTesla’s free‑Supercharging offering has shifted from being a bundled, “free‑with‑vehicle” benefit that was simply rolled into automotive sales revenue (as noted in the 2023 filing) to a distinct performance obligation that is now tracked as deferred revenue for access to Supercharging, FSD, connectivity and over‑the‑air updates (as disclosed in the 2024 filing).  This evolution reflects a more structured program under ASC 606—recognizing revenue over the period the charging service is available rather than recognizing it all up front—while the offering remains a product produced by Tesla (TSLA → Free Supercharging Program).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Tesla's free Supercharging program evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the shift from bundled automotive sales revenue (2023) to deferred revenue treatment (2024); (2) Accurately captures the key accounting change under ASC 606 revenue recognition standards; (3) Properly identifies that free Supercharging is now grouped with FSD, connectivity, and OTA updates as distinct performance obligations; (4) Correctly notes the shift from immediate recognition to amortization over time; (5) Appropriately references the formalized, structured approach to monetization. MINOR WEAKNESSES: (1) The LLM answer uses slightly different framing than ground truth - it emphasizes ASC 606 compliance and 'distinct performance obligation' language, while ground truth emphasizes 'liabilities to be amortized' - both are technically correct but represent different accounting perspectives; (2) The LLM answer adds interpretive detail about 'the period the charging service is available' which, while logically sound, goes slightly beyond what the ground truth explicitly states; (3) The parenthetical reference to 'TSLA → Free Supercharging Program' is somewhat awkward and not present in ground truth. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. Both answers correctly identify the years (2023 vs 2024) and the accounting framework (ASC 606). MULTI-HOP REASONING: The answer successfully synthesizes information about revenue recognition changes across two fiscal years and correctly links the program structure changes to accounting treatment changes. The reasoning is sound and logically coherent. SEMANTIC EQUIVALENCE: The core message matches ground truth - free Supercharging moved from bundled/immediate recognition to deferred/amortized recognition with formalized structure. The LLM's emphasis on ASC 606 and 'distinct performance obligation' is consistent with the ground truth's description of 'liabilities to be amortized over time.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 569,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "\nBetween 2023 and 2024 NextEra replaced the long‑dated Series O Junior Subordinated Debentures (the 2019 issuance that matures May 1 2079, documented in Chunk 1) with a new Series O tranche filed in October 2024 (Exhibit *4(rr) in Chunk 2) that now matures on November 1 2029; the 2024 filing does not restate the coupon but places the issuance among a series of fixed‑rate debentures with rates of 4.85 %–5.55 %, indicating that the new Series O likely carries a comparable low‑5 % fixed coupon. This shift shortens the maturity by almost four decades and reflects a strategic move toward more near‑term, fixed‑rate subordinated financing, allowing NextEra to diversify its funding base and reduce long‑term interest‑rate exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with significant issues in quantitative accuracy. CORRECT ELEMENTS: (1) The 2023 Series O maturity date of May 1, 2079 is correct; (2) The 2024 Series O maturity date of November 1, 2029 is correct; (3) The maturity shortening of approximately four decades is accurate; (4) The strategic interpretation about shifting toward shorter-term, fixed-rate financing is sound and aligns with ground truth; (5) The general characterization of the shift is appropriate. CRITICAL ERRORS: (1) The LLM states the 2024 coupon rate is 'likely carries a comparable low-5% fixed coupon' and references a range of 4.85%-5.55%, but the ground truth explicitly states the 2024 Series O coupon is 5.55% - not 'likely' or 'comparable low-5%' but definitively 5.55%; (2) The LLM hedges the coupon rate with uncertainty ('the 2024 filing does not restate the coupon but...likely carries') when the ground truth indicates a 'defined coupon rate of 5.55%' was disclosed; (3) The LLM mentions the 2023 issuance had 'no explicit coupon rate disclosed' which matches ground truth, but then speculates about the 2024 rate rather than stating it definitively. MULTI-HOP REASONING: The synthesis across years and documents is generally sound - the model correctly identifies the evolution from 2023 to 2024 and draws appropriate strategic conclusions. However, the hedging language on the 2024 coupon undermines confidence in the analysis. The reasoning about capital structure recalibration and financing strategy is well-articulated and matches the ground truth interpretation. QUANTITATIVE ISSUES: The primary quantitative error is the treatment of the 5.55% coupon as uncertain/inferred rather than confirmed. This is a material factual error for a financial analysis question where precision on coupon rates is essential.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Creates]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 499,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "\nExxonMobil continues to treat OPEC investment activities as a macro‑condition that shapes long‑term oil‑supply dynamics, a link that is bi‑directionally disclosed in the knowledge‑graph (XOM → OPEC Investment Activities ← XOM).  In the 2022 framework the company merely noted that OPEC‑driven supply changes could affect prices and thus serve as an impairment indicator, using unit‑of‑production depreciation and long‑term price assumptions in its recoverability tests.  By 2023 the impairment process has been expanded: OPEC‑related supply projections are now embedded directly in the cash‑flow models that estimate undiscounted future cash flows and fair‑value measurements, tying OPEC policy and investment decisions to specific volume, price‑differential and cost assumptions (including greenhouse‑gas cost considerations) that drive the recoverability and impairment calculations.  Consequently, OPEC investment activities have moved from a general contextual factor in 2022 to a quantitative input that explicitly shapes the long‑term supply assumptions used in ExxonMobil’s 2023 impairment assessments.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution in ExxonMobil's impairment assessment framework from 2022 to 2023. STRENGTHS: (1) Correctly identifies the core shift from OPEC as a contextual/macro-condition factor in 2022 to a more integrated quantitative input in 2023; (2) Accurately captures the expansion of the impairment framework to include greenhouse gas costs and broader environmental considerations; (3) Properly synthesizes the multi-hop relationship between OPEC investment activities, oil supply dynamics, and impairment assessments; (4) Uses appropriate financial terminology (unit-of-production depreciation, recoverability tests, fair-value measurements, undiscounted future cash flows); (5) No numeric errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer is more detailed and technical than the ground truth, introducing specific methodological terms (unit-of-production depreciation, bi-directional disclosure notation) that, while not incorrect, go beyond what the original answer explicitly states; (2) The phrase 'merely noted' in describing 2022 approach could be interpreted as slightly understating the importance ExxonMobil placed on OPEC considerations in that year; (3) The knowledge-graph notation (XOM → OPEC Investment Activities ← XOM) is not present in the original answer and adds technical detail that, while potentially accurate, cannot be verified against the ground truth. SEMANTIC EQUIVALENCE: The core message aligns well with the original answer - both convey that OPEC consideration evolved from a direct/contextual focus to a more integrated framework incorporating broader macroeconomic and environmental factors. The LLM answer provides more granular detail about the quantitative mechanisms while maintaining factual accuracy. No calculations or specific financial figures are presented that could be verified as incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Considers]-> MACRO_CONDITION <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 514,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "\nNetflix’s ad‑supported subscription tier has moved from a tentative, risk‑laden experiment in 2023—where the 10‑K warned that “forecasting consumer adoption … is inherently difficult” and highlighted the limited operating history and material forecasting uncertainty of this new revenue stream—to a core strategic pillar in 2024, where the filing explicitly lists the ad‑supported plan among the “range of pricing plans … to meet a variety of consumer needs” and ties its growth to broader goals of membership expansion, advertising revenue and overall margin targets.  This evolution is reflected in the 2024 forward‑looking discussion that positions the ad‑supported offering as a key driver of future revenue and profitability, whereas the 2023 filing treated it primarily as a high‑uncertainty, estimate‑heavy offering whose success could materially affect the company’s financial outlook.  (KG: NFLX ‑ [Discloses]→ Ad‑Supported Subscription Plan ← [Offers]‑ NFLX.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent alignment with the ground truth. STRENGTHS: (1) Correctly identifies the core evolution from 2023 to 2024 - moving from risk-focused/uncertain positioning to strategic/confident positioning. (2) Accurately captures the 2023 framing around forecasting uncertainty and limited operating history. (3) Properly characterizes the 2024 positioning as part of broader pricing strategy and core business model. (4) Effectively synthesizes the multi-hop relationship between Netflix's strategic positioning and its ad-supported plan across two fiscal years. (5) Uses appropriate qualitative language ('tentative, risk-laden experiment' vs 'core strategic pillar') that matches the semantic intent of the ground truth. (6) No quantitative errors - no specific numbers were required for this qualitative question. (7) Correctly identifies Netflix (NFLX) and the relevant time periods (2023 vs 2024). MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and elaborate than the ground truth, providing additional context about 'membership expansion, advertising revenue and overall margin targets' and 'forward-looking discussion.' While this additional detail is accurate and relevant, it goes slightly beyond what was explicitly stated in the ground truth answer. However, this represents enrichment rather than error, and the core message remains perfectly aligned. The inclusion of the knowledge graph notation at the end is appropriate and adds transparency. Overall, this is a high-quality response that accurately captures the evolution of Netflix's strategic approach to its ad-supported plan.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 448,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "\nAmazon’s shipping‑offer strategy has shifted from a 2022 focus on containing rising carrier rates, wage‑driven labor costs and fulfillment‑network inefficiencies—costs that were already climbing as the company expanded its sortation and delivery footprint—to a 2024 emphasis on scaling that same network to support higher sales volumes and a broader product mix, with cost growth now driven primarily by the added capacity and investment in fulfillment centers (partially offset by productivity gains and favorable foreign‑exchange effects).  Throughout both periods the company treats low‑price shipping as a core marketing tool that “positively impacts” Amazon and depends on its ongoing investment in an optimized fulfillment system, continually seeking to mitigate expense through higher volumes, better supplier terms and operational efficiencies while expanding the network to meet growing shipment demand.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) QUANTITATIVE ACCURACY FAILURE: The LLM answer does not cite the specific $76.7 billion shipping cost figure from 2021 that was explicitly mentioned in the ground truth as a key data point establishing the baseline for 2022 discussion. This is a significant omission of concrete financial data. (2) FACTUAL INACCURACY: The LLM characterizes 2022 focus as 'containing rising carrier rates, wage-driven labor costs and fulfillment-network inefficiencies' - the ground truth makes no mention of carrier rates or wage-driven labor costs as primary 2022 cost drivers. The ground truth specifically states the 2022 emphasis was on 'mitigating increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies.' The LLM introduces cost drivers not supported by the ground truth. (3) INCOMPLETE SYNTHESIS: While the LLM correctly identifies the shift from 2022 to 2024 and mentions efficiency gains in 2024, it fails to clearly articulate the ground truth's key insight: the strategic evolution from 'customer-driven cost increase in 2022' (customers adopting faster delivery) to 'operations-centric efficiency focus by 2024.' (4) PARTIAL CREDIT: The LLM does correctly identify that both periods involve network expansion, efficiency focus, and treating shipping as a marketing tool. The 2024 characterization of efficiency gains partially offsetting cost increases is directionally correct. (5) REASONING QUALITY: The multi-hop synthesis is attempted but undermined by introducing unsupported details (carrier rates, wage costs) and missing the specific quantitative baseline ($76.7B). The answer reads as plausible but diverges from documented facts in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 472,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "\nIn 2023 Duke Energy reported that its post‑retirement assets are held in the Master Retirement Trust—an instrument that is subject to Duke Energy and discloses to it—and it presented target‑vs‑actual asset allocations for the VEBA trusts as of 31 Dec 2023. The 2024 filing retains the same subsidiary‑allocation split (≈27 % Carolinas, 33 % Progress, 15 % Florida, 18 % Ohio, 5 % Indiana, 3 % Piedmont) but adds a reconciliation of beginning‑ and ending‑balance fair‑value amounts and discloses that certain investments measured at NAV‑per‑share are excluded from the fair‑value hierarchy, showing a clear evolution toward more detailed reporting. Both years reflect the trust’s investment objective of achieving sufficient returns with prudent risk, yet the 2024 disclosure deepens the level of detail on Level 3 inputs and fair‑value measurement, indicating an enhanced utilization and reporting practice for the Master Retirement Trust.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides subsidiary allocation percentages (≈27% Carolinas, 33% Progress, 15% Florida, 18% Ohio, 5% Indiana, 3% Piedmont) that do NOT match the ground truth. Ground truth states Duke Energy Progress at 15% and Duke Energy Florida at 18%, but the LLM lists Progress at 33% and Florida at 15%, which is inverted and includes additional subsidiaries (Carolinas, Ohio, Indiana, Piedmont) not mentioned in the ground truth. These percentages appear fabricated or from a different context. The sum of LLM percentages (27+33+15+18+5+3=101%) also suggests data quality issues. (2) ENTITY ACCURACY - The LLM introduces subsidiary allocations for Carolinas, Ohio, Indiana, and Piedmont that are not mentioned in the ground truth answer, which only references Progress (15%) and Florida (18%). This represents either hallucination or confusion with different filing sections. (3) COMPLETENESS - While the LLM correctly identifies the evolution toward more detailed reporting, reconciliation of beginning/ending balances, and Level 3 fair value disclosures, it fails to accurately represent the specific subsidiary allocation data that is central to the ground truth's explanation of the 2024 evolution. (4) MULTI-HOP REASONING - The LLM correctly synthesizes the general trend (2023 basic reporting → 2024 enhanced detail) but fails on the specific factual content that supports this claim. The investment objective language is appropriately captured, but the subsidiary allocation numbers are fundamentally incorrect. (5) SEMANTIC EQUIVALENCE - While the overall narrative structure matches (comparing 2023 vs 2024 reporting evolution), the specific quantitative claims are factually wrong, which undermines the credibility of the entire answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 488,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "\nBetween 2022 and 2024 the cost structure tied to Google Network Partners stayed anchored in the TAC (Traffic Acquisition Cost) model: the 2022 filing notes that TAC includes “amounts paid to Google Network partners primarily for ads displayed on their properties,” and that the cost‑of‑revenues share for network‑placed ads is “significantly higher” than for search ads because those revenues are largely passed through as TAC to the partners. The 2024 cash‑flow discussion shows that cash used in operating activities now lists “payments to … Google Network partners” as a primary outflow, and the increase in net cash provided by operations is attributed to higher ad revenues but also to “an increase in cash payments for cost of revenues and operating expenses,” indicating that Google’s payment obligations to its Network Partners have grown in absolute terms while still representing a larger‑percentage cost for network placements. Thus, the relationship has evolved from a relatively stable TAC cost base in 2022 to a more pronounced cash‑outflow component by 2024, even as overall ad revenue and cash generation have risen.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the TAC (Traffic Acquisition Cost) model as the consistent framework across 2022-2024; (2) Accurately captures the key distinction that network-placed ads have a 'significantly higher' cost-of-revenues percentage than search ads; (3) Properly synthesizes the multi-hop evolution: from 2022 cost-of-revenues treatment to 2024 operating cash flow treatment; (4) Correctly notes that payments to Google Network partners are now listed as a primary operating cash outflow; (5) Accurately reflects that absolute payment obligations have grown while maintaining the higher percentage cost structure for network placements; (6) Demonstrates sound reasoning about the transformation in the nature of the financial relationship. MINOR CONSIDERATIONS: (1) The LLM answer adds interpretive detail about 'higher ad revenues' and 'increase in cash payments for cost of revenues and operating expenses' that, while logically consistent with the ground truth narrative, goes slightly beyond what the original answer explicitly states - this is appropriate elaboration rather than error; (2) The phrase 'relatively stable TAC cost base in 2022' is a reasonable characterization but not explicitly stated in the ground truth, though it's consistent with the 2022 description; (3) No specific dollar amounts are provided in either answer, so quantitative precision cannot be fully verified, but the directional claims (growth in absolute terms, higher percentage for network) are sound. The answer successfully addresses the core question about evolution of the financial relationship, correctly identifies the shift from cost-of-revenue to operating cash flow treatment, and maintains factual accuracy throughout the multi-hop synthesis across years and financial statement categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 513,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "\nThe company records its non‑designated interest‑rate swaps, foreign‑currency forwards and market‑price forwards at fair value, recognizing unrealized gains and losses in the consolidated income statement, and any termination is offset by entering a new offsetting swap or forward that de‑designates the original position and eliminates further market‑valuation effects.  In the 2022 filing (Chunk 1) a summary of fair‑value changes and settlements for 2021‑2020 is disclosed, while the 2023 filing (Chunk 2) provides the comparable summary for 2023‑2022, showing that the same accounting treatment was applied to the later periods.  This consistent use of offsetting positions—reflected in the KG relationship UPS ↔ Offsetting Swap Positions—means the financial impact evolved only in the reported amounts, not in the underlying treatment.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core accounting treatment and demonstrates sound multi-hop reasoning by synthesizing information across 2022 and 2023 filings. The answer accurately describes that UPS records non-designated derivatives at fair value with unrealized gains/losses in the income statement, and that offsetting positions are used to de-designate original positions. The reasoning about the evolution of treatment (consistent approach but different reported periods) is logically sound and matches the ground truth's assertion that treatment remained consistent while disclosure focus shifted to more recent periods.\n\nHowever, there are significant quantitative accuracy issues: The LLM answer fails to include the specific financial figures mentioned in the ground truth ($163M net gain in 2021, $124M net gain in 2020). While the ground truth notes that 'the financial impact in 2023 was not quantified in the excerpt,' the LLM should have acknowledged the specific numbers from 2021-2020 that were disclosed in the 2022 filing. The answer states 'the financial impact evolved only in the reported amounts, not in the underlying treatment' but provides no actual amounts to support this claim.\n\nThe answer correctly identifies the company (UPS) and the time periods (2022 vs 2023 filings), and properly synthesizes the multi-hop concept that the same treatment applied across both filing periods. The semantic understanding of offsetting swap positions and their role in de-designating hedges is accurate. The reference to the KG relationship demonstrates understanding of the knowledge graph structure.\n\nThe main weakness is the lack of concrete financial figures that would have strengthened the quantitative support for the answer. The answer would have been stronger with explicit mention of the $163M and $124M figures from the earlier periods, even if 2023 amounts weren't available in the excerpt.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enters]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 521,
        "total_tokens": 1938
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "\nThe 2024 Form 10‑K gives the Directors’ Savings Plan a full‑page discussion (Item 12) that spells out its deferral mechanics, company‑matching contributions, performance‑based credits and its unfunded, creditor‑subject nature—details that appear only as a brief 2021 amendment reference in the 2023 filing (Chunk 1, §10.12).  This expanded treatment, together with the knowledge‑graph link that the Directors’ Savings Plan is an accounting policy of DUK (DUK → Directors’ Savings Plan ← DUK), indicates that Duke Energy is now making the plan a central element of its director‑compensation strategy, using it to defer and align director pay more prominently than in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core insight that the Directors' Savings Plan received increased prominence in 2024 compared to 2023, and correctly identifies this as indicating a strategic shift toward emphasizing the plan as a central compensation component. However, there are significant issues with factual accuracy and unsupported claims:\n\n(1) QUANTITATIVE/FACTUAL ERRORS:\n- The LLM claims the 2024 filing provides a \"full-page discussion (Item 12)\" but the ground truth does not specify Item 12 or confirm a full-page treatment. This is an unverified detail.\n- The LLM mentions \"company-matching contributions\" and \"performance-based credits\" as features of the plan, but the ground truth only mentions \"phantom investment options\" and \"balances adjusted accordingly.\" These additional features are not confirmed in the ground truth and may be incorrect.\n- The reference to \"2021 amendment\" in the LLM answer differs from the ground truth's reference to \"historical amendments\" without specifying 2021.\n\n(2) MULTI-HOP REASONING:\n- The LLM correctly synthesizes the comparison between 2023 and 2024 disclosures.\n- The knowledge-graph reference (DUK → Directors' Savings Plan ← DUK) is mentioned but adds little substantive value to the answer.\n- The core reasoning about increased prominence indicating strategic shift is sound and matches the ground truth.\n\n(3) COMPLETENESS:\n- The LLM addresses the main question about the shift in strategy.\n- However, it introduces unverified details (company-matching, performance-based credits, Item 12 designation) that go beyond what the ground truth confirms.\n- The ground truth emphasizes \"deferral flexibility\" and \"transparent approach,\" while the LLM emphasizes \"align director pay,\" which is a reasonable inference but not explicitly stated in the ground truth.\n\n(4) SEMANTIC EQUIVALENCE:\n- The core message aligns: increased prominence indicates strategic shift toward emphasizing the plan.\n- However, the specific mechanisms described (matching contributions, performance credits) are not confirmed in the ground truth, creating factual uncertainty.\n- The phrase \"unfunded, creditor-subject nature\" in the LLM answer is not mentioned in the ground truth.\n\nThe answer demonstrates good understanding of the overall trend but introduces unverified details that reduce confidence in its accuracy. The core insight is correct, but the supporting details contain potential errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amends]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 656,
        "total_tokens": 2005
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "\nBetween 2022 and 2024 American Express moved its value‑proposition strategy from a primarily premium‑rewards and travel‑focused model toward a broader, digitally‑native offering that explicitly targets Millennial and Gen‑Z consumers, expands merchant and dining‑platform coverage, and leans on AI, data‑driven benefits and new loyalty programs.  The 2022 filing already warned that intense competition from Visa and Mastercard, the rise of alternative payment mechanisms and fragmented spending required continual investment in rewards, services and digital channels, while the 2024 filing details how the company is now “expanding leadership in the premium consumer space” by funding new benefits, enhancing the Amex app, integrating acquisitions such as Tock and Rooam, and building a multiproduct digital ecosystem to meet changing customer behaviors and counter rivals’ scale and resources.  This evolution reflects a direct response to the competitive pressures and shifting consumer habits highlighted in both documents.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024 with accurate characterization of the strategic shift from reactive competition management to proactive innovation-driven approach. (2) Accurately names specific acquisitions (Tock and Rooam) and strategic initiatives (Amex app enhancement, AI/automation investments). (3) Correctly identifies target demographics (Millennial and Gen-Z consumers) and competitive threats (Visa, Mastercard, alternative payment mechanisms, digital wallets). (4) Properly synthesizes multi-hop information: connects 2022 challenges (rewards costs, fragmented spending, mobile/online payment shifts) to 2024 solutions (digital ecosystem, merchant coverage, dining platform expansion). (5) No quantitative errors - no specific numbers were claimed, avoiding potential calculation mistakes. (6) The characterization of the strategic evolution as moving from 'reactive stance on competition to proactive, innovation-driven approach' is semantically equivalent to the ground truth's framing. MINOR CONSIDERATIONS: (1) The LLM answer mentions 'new loyalty programs' which is not explicitly detailed in the ground truth, though this is a reasonable inference from the broader strategic direction and doesn't contradict the source material. (2) The phrasing 'premium‑rewards and travel‑focused model' in the LLM answer is slightly more specific than the ground truth's description, but accurately captures the essence of American Express's historical positioning. (3) The answer could have been slightly more explicit about the 'Card Member rewards costs' challenge mentioned in the ground truth, though this is implied in the discussion of competitive pressures. Overall, the LLM successfully demonstrates multi-hop reasoning across two years of filings, correctly identifies all key entities and strategic initiatives, and provides accurate characterization of the competitive and customer behavior context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1540,
        "completion_tokens": 552,
        "total_tokens": 2093
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "\nBetween 2022 and 2024 Exxon Mobil retired its only short‑term tranche—the 0.142 % Notes due 2024 that appeared in the 2022 filing—and continued to rely on its longer‑dated series (0.524 % Notes due 2028, 0.835 % Notes due 2032 and 1.408 % Notes due 2039), signaling a shift toward a more durable, multi‑year debt profile; the 2024 Form 10‑K still lists the 0.524 %, 0.835 % and 1.408 % notes (with the 1.408 % issue identified as XOM39A), confirming that the company’s long‑term note composition has moved away from near‑term financing and now centers on these lower‑coupon, longer‑maturity instruments.  The knowledge‑graph relationship XOM → 1.408 % Notes due 2039 ← FIN_INST shows that this 2039 note remains a disclosed, core component of Exxon’s long‑term financing throughout the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of multi-hop information. QUANTITATIVE VERIFICATION: All interest rates and maturity dates are correct—0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and 1.408% Notes due 2039. The answer correctly identifies that the 0.142% Notes due 2024 were retired/matured between 2022 and 2024, while the longer-dated instruments (0.524%, 0.835%, 1.408%) remained in the 2024 disclosure. MULTI-HOP REASONING: The LLM successfully synthesized information across two fiscal years (2022 and 2024) and correctly identified the strategic shift from shorter-duration to longer-duration debt instruments. The identification of the 1.408% Notes as 'XOM39A' adds specificity and demonstrates knowledge graph integration. COMPLETENESS: The answer addresses all key aspects of the question—the evolution of debt composition, specific instruments retired, instruments retained, and the strategic implications. SEMANTIC EQUIVALENCE: The LLM's characterization of the shift as moving toward 'a more durable, multi-year debt profile' and 'lower-coupon, longer-maturity instruments' aligns perfectly with the ground truth's description of 'extended-term debt while retiring shorter-duration obligations.' MINOR CONSIDERATIONS: The LLM answer is slightly more detailed and technical than the ground truth (mentioning the XOM39A identifier and knowledge graph relationships), but this adds value rather than detracting from accuracy. The phrasing 'retired its only short-term tranche' is accurate and clear. No calculation errors, no incorrect dates, no misidentified entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 452,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "\nAmerican Express has deepened its corporate‑card strategy by continuously **evolving card value propositions and further differentiating the corporate‑card and accounts‑payable expense‑management solutions**, adding innovative financing, banking and payment features for business customers (both 2022 and 2024 filings).  In 2022 the emphasis was on rebuilding growth and expanding commercial‑payment leadership, while by 2024 the focus broadened to **strengthening the global, integrated network and leveraging the company’s differentiated global position** to support those differentiated products.  This progression—captured by the KG pattern AXP → Corporate Card ← Corporate Card → AXP—shows a shift from a rebuilding phase to a more mature, network‑centric approach that emphasizes product differentiation and expanded commercial‑payment solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the core strategic evolution from 2022 to 2024 - from internal product development focus to integrated global network approach. (2) Accurately captures the 2022 emphasis on 'evolving card value propositions and differentiating corporate card and accounts payable expense management solutions' - this matches the ground truth verbatim. (3) Properly synthesizes the 2024 shift toward 'strengthening the global, integrated network' and 'leveraging differentiated global position,' which aligns with the ground truth's description of 'more integrated global network approach.' (4) No quantitative errors - no numbers, dates, or calculations to verify, and all dates (2022, 2024) are correct. (5) Multi-hop reasoning is sound: correctly connects American Express's strategic priorities across two time periods and identifies the progression pattern. (6) Entity accuracy is perfect: American Express (AXP) correctly identified, corporate card solutions properly referenced. MINOR WEAKNESSES: (1) The LLM adds interpretive language ('rebuilding phase,' 'more mature, network-centric approach') that, while reasonable inferences, goes slightly beyond what the ground truth explicitly states. The ground truth is more neutral in tone. (2) The reference to 'KG pattern AXP → Corporate Card ← Corporate Card → AXP' is somewhat unclear and appears to be an artifact of knowledge graph notation that doesn't add clarity to the answer for a general reader. (3) The ground truth mentions 'enhanced fraud protection and marketing insights' as specific 2024 additions, which the LLM answer does not explicitly include, though it does reference 'innovative financing, banking and payment features.' OVERALL ASSESSMENT: The answer is factually accurate, addresses all parts of the question, demonstrates proper multi-hop synthesis across 2022 and 2024 filings, and conveys the essential strategic evolution. The minor additions of interpretive framing and omission of specific 2024 features prevent a perfect score, but the core answer is sound and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Enhances]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 583,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "\nFrom 2022 through 2024 Amazon’s AWS business shifted from a high‑risk, growth‑oriented investment—highlighted in the 2022 10‑K risk discussion as a new, competitive service that must win adoption in a crowded market—to a core cash‑flow engine, as operating cash flow surged from **$84.9 billion in 2023 to $115.9 billion in 2024** (2024 10‑K, p. 22), reflecting both the scale of AWS‑generated revenue and the strategic decision to lean on its profitability to fund broader expansion; the knowledge‑graph relationship (AMZN → AWS Services ← Pays_For) shows AWS as a product that not only competes with but also financially supports Amazon, underscoring a deepening symbiotic financial link that has intensified across the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of the multi-hop question. QUANTITATIVE VERIFICATION: All numbers are correct - $84.9 billion in 2023 operating cash flow and $115.9 billion in 2024 are accurately cited and properly formatted. The year-over-year comparison is mathematically sound. ENTITY ACCURACY: Amazon, AWS Services, and the relevant fiscal years (2022-2024) are correctly identified. The financial metrics (operating cash flow) are appropriately selected. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple dimensions: (1) AWS's strategic positioning evolution from 2022 (risk-laden, competitive) to 2024 (cash-flow engine), (2) the financial contribution quantified through operating cash flow figures, and (3) the strategic emphasis shift from growth investment to profitability-driven funding. The knowledge graph reference (AMZN → AWS Services ← Pays_For) adds appropriate structural context. COMPLETENESS: The answer addresses all aspects of the question - cash flow generation (with specific numbers), strategic emphasis (shift from risk to core contributor), and the temporal evolution (2022-2024). MINOR CONSIDERATIONS: The answer includes interpretive language about 'symbiotic financial link' and 'deepening' relationship that goes slightly beyond the ground truth's more straightforward statement of 'shift from risk-laden venture to core revenue generator.' However, this interpretation is logically sound and supported by the data presented. The citation format (2024 10-K, p. 22) adds credibility though page numbers weren't explicitly verified in the ground truth. Overall, the LLM answer is semantically equivalent to the ground truth while providing richer contextual detail and stronger analytical framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> PRODUCT <-[Pays_For]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 491,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "\nIn the 2023 audit (Deloitte & Touche LLP, Charlotte, Feb 23 2024) the firm used trend‑analyses to test the historical consistency of DUK’s regulatory‑asset balances, comparing recorded amounts to an independently developed expectation and performing substantive analytical procedures on deferred fuel and storm costs. By the 2024 audit (Deloitte & Touche LLP, Charlotte, Feb 27 2025) the same trend‑analysis approach was retained, but its scope was broadened: Deloitte also evaluated the ongoing regulatory recoverability of coal‑ash‑related asset‑retirement obligations and incorporated management’s estimated storm‑cost analysis together with legal‑counsel letters, thereby extending the focus from merely confirming historical consistency to assessing forward‑looking recoverability. Both years show Deloitte’s continued auditor relationship with DUK (since 2001 in 2023 and since 1947 in 2024) and the use of trend‑analyses as a core tool, with the 2024 procedures adding specific retirement‑obligation and storm‑cost assessments.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution of trend analyses between 2023 and 2024 correctly: the scope remained focused on regulatory asset balances but expanded to include specific evaluation of coal ash asset retirement obligations. The semantic meaning aligns well with the ground truth regarding the shift toward more specialized regulatory compliance areas.\n\nHowever, there are significant quantitative accuracy issues:\n\n1. AUDITOR TENURE DATES - MAJOR ERROR: The LLM states Deloitte's relationship with DUK was \"since 2001 in 2023 and since 1947 in 2024.\" This is problematic because: (a) the auditor relationship cannot have started in 1947 if it started in 2001 - this is internally contradictory, (b) the ground truth does not provide these specific tenure dates, and (c) the 1947 date is implausible for a modern audit relationship. This represents a factual error introduced by the LLM.\n\n2. AUDIT DATES: The LLM provides specific audit dates (Feb 23 2024 for 2023 audit, Feb 27 2025 for 2024 audit) that are not mentioned in the ground truth. While these may be accurate from the source documents, they add specificity not present in the original answer.\n\n3. COMPANY IDENTIFICATION: The LLM identifies the company as \"DUK\" (Duke Energy), which is reasonable inference but not explicitly stated in the ground truth.\n\nSTRENGTHS:\n- Correctly identifies the core evolution: trend analyses remained but scope expanded\n- Accurately captures the shift to include coal ash asset retirement obligations\n- Properly synthesizes the multi-hop information about 2023 vs 2024 procedures\n- Correctly notes the addition of forward-looking recoverability assessment\n- Appropriately mentions incorporation of management's storm-cost analysis and legal counsel letters\n\nWEAKNESSES:\n- Introduces unverified auditor tenure dates with internal contradictions\n- Adds specific dates not in ground truth\n- Makes company identification inference not explicitly confirmed in original answer\n\nThe answer demonstrates good qualitative reasoning and contextual relevance but is undermined by quantitative inaccuracies in the auditor tenure information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 579,
        "total_tokens": 1964
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "\nCostco began 2022 by “increasing the penetration of our private‑label items” as a direct response to higher‑than‑usual inflation, using supplier cost‑sharing, earlier‑volume buying and the option to hold prices steady rather than pass all cost increases on to members – a move that later hurt its gross‑margin percentage. In 2023 the company re‑affirmed and deepened that approach, again citing “increasing the penetration of our private‑label items” as a key lever to absorb cost pressures while maintaining competitive pricing, even though the strategy continued to depress gross‑margin percentages. Thus, between 2022 and 2023 Costco evolved from an initial private‑label push to a more pronounced, sustained reliance on private‑label penetration to manage cost and pricing pressures.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on the core narrative of Costco's private-label strategy evolution between 2022 and 2023. STRENGTHS: (1) Correctly identifies that Costco increased private-label penetration in both 2022 and 2023 as a response to inflation and cost pressures; (2) Accurately captures the multi-faceted 2022 strategy including supplier cost-sharing, volume buying, and price restraint; (3) Properly synthesizes the multi-hop information showing evolution from initial push to sustained reliance; (4) Correctly notes the gross-margin pressure trade-off; (5) Uses appropriate financial terminology and maintains semantic equivalence with ground truth. MINOR WEAKNESSES: (1) The LLM answer adds specific detail about gross-margin percentage depression that, while logically sound and likely accurate, goes slightly beyond what the ground truth explicitly states about the strategy's evolution; (2) The characterization of 2022 as 'initial' and 2023 as 'more pronounced' is reasonable but represents a slight interpretive enhancement rather than direct ground truth language; (3) No quantitative metrics (dollar amounts, percentage changes) are provided, though the question doesn't explicitly require them. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the strategic shift from reactive cost management in 2022 to sustained private-label emphasis in 2023. The logic connecting cost pressures → private-label strategy → margin trade-offs is sound. ENTITY ACCURACY: Costco correctly identified, years (2022-2023) correct, strategy elements (private-label penetration, cost-sharing, volume buying, pricing) all accurate. No factual errors detected in the core claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 484,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "\nBetween 2023 and 2024 Pfizer’s outlook for Paxlovid shifted dramatically: in 2023 the company had recorded a $3.5 billion non‑cash revenue reversal that reflected the expectation of returning up to 6.5 million EUA‑labeled courses, but by the end of 2024 the “remaining performance obligations” for firm orders of Paxlovid totaled only about **$1 billion** of contracted revenue to be recognized through 2028.  Moreover, a $771 million favorable adjustment in 2024 removed much of the prior reversal, indicating that fewer courses will be returned and that future cash inflows from Paxlovid are now expected to be far more limited and predictable than the large, uncertain reversal anticipated a year earlier.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ISSUES: (1) The ground truth explicitly states that 'In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid,' yet the LLM claims there was a '$3.5 billion non-cash revenue reversal' in 2023 - this introduces information not supported by the ground truth and appears to conflate different financial events. (2) The LLM mentions a '$771 million favorable adjustment in 2024' which is not mentioned in the ground truth at all. (3) The LLM references 'up to 6.5 million EUA-labeled courses' and 'firm orders...through 2028' - these specific details are not in the ground truth. (4) The core fact that both sources agree on ($1 billion in remaining performance obligations as of December 31, 2024) is correct in the LLM answer. REASONING ASSESSMENT: The LLM appears to have synthesized information from multiple sources or made inferences beyond what the ground truth supports. While the LLM correctly identifies the $1 billion figure and attempts to explain the evolution between 2023-2024, it does so by introducing unsupported financial details ($3.5B reversal, $771M adjustment) that are not in the ground truth. The ground truth's key point is that 2023 had NO DISCLOSURE of specific RPOs, while 2024 showed $1 billion - a simpler evolution than the LLM portrays. The LLM's answer is more detailed but factually unreliable because it adds numbers and events not verified by the ground truth source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 420,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "\nAmerican Express continues to estimate credit‑loss reserves by first projecting expected losses over a **reasonable and supportable (R&S) period** that extends beyond the reporting date, using statistically based models that combine historical loss experience with current and forward‑looking macro‑economic conditions; beyond that period the company reverts to long‑term average loss rates and supplements the quantitative estimate with qualitative reserves to capture risks not captured by the models (as described in the 2022 filing).  The 2024 audit commentary treats the **R&S period and the loss‑rate assumptions applied after it** as a critical audit matter, requiring extensive testing of inputs and an independent evaluation of their reasonableness, which shows that the firm’s risk‑management approach is model‑driven and subjects its forward‑looking estimates to rigorous, independent validation.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies that American Express uses the R&S Period in credit loss estimation, accurately describes the methodology (historical loss experience + forward-looking macro conditions), and correctly notes that beyond the R&S period the company reverts to long-term average loss rates with qualitative reserves. The answer appropriately emphasizes the audit committee's treatment of R&S period assumptions as a critical audit matter in 2024, showing awareness of the risk management framework. CRITICAL WEAKNESSES: (1) MISSING KEY QUANTITATIVE DATA: The ground truth explicitly states reserves were $3.3 billion as of December 31, 2021 - this specific number is completely absent from the LLM answer. (2) INCOMPLETE EVOLUTION NARRATIVE: The ground truth emphasizes a clear evolution from 2022 (R&S Period introduced as a newly explained concept) to 2024 (embedded as standard/foundational), showing a shift from methodology introduction to established practice. The LLM answer fails to capture this temporal evolution and instead presents the methodology as static across both years. (3) MISSING COMPARATIVE ANALYSIS: The ground truth explicitly compares the 2022 and 2024 approaches to show how the methodology matured. The LLM answer treats 2022 and 2024 as essentially the same, missing the core insight about evolution. (4) ATTRIBUTION ERROR: The LLM parenthetically attributes information to '(as described in the 2022 filing)' but doesn't clearly distinguish what changed between 2022 and 2024. MULTI-HOP REASONING: The question requires synthesizing information across two different years (2022 vs 2024) to show evolution. The LLM answer fails this multi-hop requirement by not clearly establishing the before/after comparison. The answer provides accurate technical details about the R&S methodology but misses the primary analytical requirement of the question - demonstrating how assumptions and use evolved over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 529,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "\nAmazon first issued the 0.800% Note due 2025 in June 2020 (see Chunk 1 Exhibit 4.5 and its reiteration in Chunk 2 Exhibit 4.6), establishing a long‑dated unsecured financing instrument that is linked to the company via the KG relationship ORG‑[Issues]→FIN_INST. Building on that foundation, Amazon broadened its debt profile by adding new note series in 2021 (Chunk 2 Exhibit 4.7), issuing additional notes in 2022 (Chunk 2 Exhibit 4.8), and entering into a five‑year revolving credit agreement in November 2023 (Chunk 2 Exhibit 10.8) and a 364‑day revolving credit facility in October 2024 (Chunk 2 Exhibit 10.9), thereby diversifying its funding mix. Thus, while the 0.800% 2025 note remains a core component of Amazon’s capital structure (as reflected by the KG triplet connection), its overall debt‑financing approach has evolved between 2022 and 2024 to include higher‑coupon notes and revolving credit facilities alongside that enduring instrument.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies the 0.800% Note due 2025 as originally issued June 3, 2020, matching ground truth; (2) Accurately references the introduction of new debt instruments with different interest rates (mentions higher-coupon notes); (3) Properly synthesizes evolution of Amazon's debt strategy across 2022-2024 period; (4) Correctly identifies the addition of revolving credit facilities (November 2023 five-year and October 2024 364-day); (5) Demonstrates sound multi-hop reasoning by connecting the original 2020 issuance through 2022 references to 2024 additions; (6) Uses appropriate financial terminology and concepts (diversifying funding mix, managing cash flow and interest rate risk). MINOR WEAKNESSES: (1) While the LLM mentions 'higher-coupon notes,' it does not explicitly name the 4.600% Note due 2025 that appears in the ground truth answer - this is a notable omission since the ground truth specifically highlights this as an example of the new instruments introduced; (2) The LLM provides more granular detail about revolving credit facilities (which may or may not be in the original filings) but this additional detail doesn't contradict the ground truth; (3) The answer is somewhat more verbose with chunk references that, while potentially helpful for traceability, aren't necessary for answering the core question. QUANTITATIVE VERIFICATION: All dates are correct (June 2020, November 2023, October 2024, 2022-2024 timeframe). The 0.800% rate is correctly stated. The reference to 'higher-coupon notes' is consistent with the 4.600% example in ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and documents, showing how the 0.800% Note remained constant while new instruments were added. The logical flow from 2020 issuance → 2022 references → 2024 additions is sound. The conclusion about diversification and risk management aligns with ground truth's assessment of managing cash flow and interest rate risk. The main gap is the specific omission of the 4.600% Note due 2025 example, which represents a minor incompleteness in demonstrating the specific evolution described in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 607,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "\nIn the 2022 Form 10‑K (Chunk 1) the Twenty‑third Supplemental Indenture is listed only as a historical exhibit – a “Twenty‑third Supplemental Indenture dated June 1 1978 (Exhibit 2(c), File No. 2‑61611)” that appears among dozens of earlier indentures (4.4.19) and is disclosed solely as part of the mortgage‑trust schedule. By contrast, the 2024 filing (Chunk 2) retains a separate reference to an older “Twenty‑third Supplemental Indenture dated January 1 1977 (File No. 2‑57828)” but also introduces a brand‑new “Forty‑ninth Supplemental Indenture dated March 14 2024” (Item 4.12.8), showing that Duke Energy continues to create and disclose new supplemental indentures rather than merely archiving the 1978 document. Thus, while the original 1978 indenture has become a purely archival entry, the company’s ongoing practice of filing fresh supplemental indentures confirms that the format remains a living, relevant tool for its debt‑security and trust‑law governance.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) DATE DISCREPANCY - The LLM states the 2024 filing contains a 'Twenty-third Supplemental Indenture dated January 1 1977 (File No. 2-57828)' but the ground truth makes no mention of this document in the 2024 filing. This is a significant factual error that contradicts the original answer's core finding that the Twenty-third Supplemental Indenture has NO direct mention in the 2024 filing. (2) MISCHARACTERIZATION OF GROUND TRUTH - The ground truth explicitly states 'in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture,' yet the LLM claims the 2024 filing 'retains a separate reference' to a January 1, 1977 version. This directly contradicts the established ground truth. (3) CORRECT ELEMENTS - The LLM correctly identifies: the June 1, 1978 date for the Twenty-third Supplemental Indenture in the 2022 filing, the Forty-ninth Supplemental Indenture dated March 14, 2024 in the 2024 filing, and the general conclusion that newer indentures are being created. (4) REASONING QUALITY - While the LLM's reasoning about the evolution of supplemental indentures as a 'living, relevant tool' is logically sound, it is built on a false premise (the existence of a January 1, 1977 reference in the 2024 filing). (5) MULTI-HOP SYNTHESIS - The model failed to correctly synthesize the key finding: the absence of the Twenty-third Supplemental Indenture in 2024 indicates diminished significance, not its continued presence in a different form. The introduction of an entirely different date (1977 vs 1978) suggests either confusion or hallucination of filing content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 456,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "\nThe repurchase activity for Class C Capital Stock accelerated from 2022 through 2024: the 2022 10‑K (Chunk 1) shows a $1.294 billion cost of Class C repurchases, which rose to $2.159 billion in 2023 and $2.324 billion in 2024 as reflected in the “Repurchases of capital stock” line items.  At the same time, the company’s overall share‑repurchase program expanded to $59.3 billion in 2022, $62.2 billion in 2023 and $62.0 billion in 2024, and in April 2024 the Board authorized an additional $70 billion of Class A and Class C repurchases, leaving $44.7 billion of capacity as of 31 December 2024 (Chunk 2).  This demonstrates a steady year‑over‑year increase in both the dollar amount and the remaining authorization for Class C share buybacks.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The overall repurchase program amounts are accurate: $59.3B (2022), $62.2B (2023), $62.0B (2024) match the ground truth exactly. (2) The April 2024 authorization of $70B and remaining capacity of $44.7B appear reasonable. (3) The general trend description of steady activity is appropriate. PROBLEMATIC ELEMENTS: (1) The question specifically asks about 'Class C Capital Stock' repurchase activity, but the ground truth answer provides combined Class A and Class C figures ($59.3B, $62.2B, $62.0B), not Class C-only figures. (2) The LLM provides Class C-specific numbers ($1.294B, $2.159B, $2.324B) which are NOT in the ground truth answer and appear to be isolated Class C repurchases rather than the combined figures the question likely intended. (3) There is a fundamental mismatch: the ground truth answer discusses combined Class A and Class C repurchases totaling in the tens of billions, while the LLM separates out Class C-only figures in the billions. (4) The LLM's interpretation that Class C repurchases 'accelerated' from $1.294B to $2.324B is mathematically correct for those specific numbers, but this contradicts the ground truth's focus on the combined $59.3B-$62.2B-$62.0B figures. MULTI-HOP REASONING: The LLM correctly synthesizes information across multiple chunks (combining specific Class C data with overall program authorization data), but this synthesis may be answering a different question than intended. The ground truth appears to treat Class A and Class C repurchases as a combined metric, while the LLM separates them. This creates ambiguity about whether the question intended combined or Class C-only figures. The LLM's answer is internally consistent and well-reasoned, but may not align with the ground truth's interpretation of what 'Class C Capital Stock' repurchase activity means in this context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Repurchases]- ORG",
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 519,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "\nBoth the 2022 and 2024 Form 10‑K filings disclose the American Express Company Salary/Bonus Deferral Plan (first introduced in 1988 as Exhibit 10.20) and note that it has been amended on several occasions – the 1994 amendment (Exhibit 10.17/10.14) and the 1997 joint amendment of the deferral and key‑executive life‑insurance plans (Exhibit 10.16) – a relationship captured by the KG triplets linking AXP to the plan as an accounting policy. In the 2022 filing (Chunk 1) the plan’s most recent amendment is recorded as part of the “Amendments of (i) the American Express Salary/Bonus Deferral Plan and (ii) the American Express Key Executive Life Insurance Plan” disclosed in the 1997 filing, while the 2024 filing (Chunk 2) updates the documentation by restating the plan in the “Twelfth Amendment and Restatement of the American Express Retirement Restoration Plan” (effective Jan 1 2023, Exhibit 10.17) and by adding a new “Description of Compensation Payable to Non‑Management Directors” (Exhibit 10.19), thereby reflecting the 2022 restatement and the latest director‑compensation language while preserving the plan’s substantive treatment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations compared to the ground truth. Key issues: (1) EXHIBIT NUMBER ERRORS: The LLM states the 1988 plan was 'first introduced...as Exhibit 10.20' but the ground truth indicates it was Exhibit 10.16 in 2022 and Exhibit 10.13 in 2024. The LLM also incorrectly references 'Exhibit 10.17/10.14' for the 1994 amendment when ground truth shows Exhibit 10.17 in 2022 and Exhibit 10.14 in 2024. (2) INCORRECT DOCUMENT REFERENCES: The LLM introduces 'Twelfth Amendment and Restatement of the American Express Retirement Restoration Plan' (effective Jan 1 2023, Exhibit 10.17) and 'Description of Compensation Payable to Non-Management Directors' (Exhibit 10.19) - these documents are NOT mentioned in the ground truth answer and appear to be fabricated or confused with other plans. (3) MISSING KEY INFORMATION: The LLM fails to clearly articulate the core finding that the 2024 filing expanded disclosure by adding Exhibit 10.16 (1997 amendments), which was not separately listed in 2022. (4) SEMANTIC CONFUSION: The answer conflates the Salary/Bonus Deferral Plan with the Retirement Restoration Plan and Key Executive Life Insurance Plan, creating confusion about which plan is being discussed. (5) MULTI-HOP REASONING: While the LLM attempts to synthesize across years, it does so incorrectly by introducing documents not in the ground truth. The ground truth's clear finding - that 2024 expanded historical disclosure to include 1997 amendments - is obscured by incorrect exhibit numbers and spurious document references. The answer demonstrates poor factual accuracy on specific exhibit numbers (the primary quantitative data in this question) and introduces information not supported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 481,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "\nStarbucks’ interest‑rate swap exposure dropped markedly from fiscal 2022 to 2024: in 2022 the swap was reported as a $34 million liability in **other long‑term liabilities** plus a $12 million accrued‑liability balance (Oct 2 2022), whereas by 2024 the same instrument appeared only as a $19.2 million liability in **other long‑term liabilities** on Sep 29 2024 with essentially no accrued‑liability component.  This shift reflects the company’s continued use of the designated interest‑rate swap (the financial instrument that SBUX depends on) and is evident in the 2024 balance‑sheet tables, where the swap is classified under long‑term liabilities and the accrued‑liability line for interest‑rate swaps is removed.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM introduces a $12 million accrued-liability balance for 2022 that is NOT mentioned in the ground truth. The ground truth only references a $34.0 million liability under 'Other long-term liabilities' for 2022. This is a factual error. (2) MISSING KEY INFORMATION - The LLM completely omits the critical 2023 data point: the $41.4 million liability from interest rate swaps reported for 2023 (prior year), which is explicitly mentioned in the ground truth as indicating 'a decrease in liability from the previous year.' This is a significant omission that fails to capture the full evolution of the exposure. (3) INCOMPLETE SYNTHESIS - The ground truth indicates a more complex picture: 2022 had $34.0M, 2023 had $41.4M (higher), and 2024 had $19.2M (lower). The LLM's narrative of a 'marked drop' from 2022 to 2024 is directionally correct but misses the intermediate 2023 spike, which is essential to understanding the actual evolution. (4) BALANCE SHEET CLASSIFICATION - The LLM correctly identifies the shift to 'other long-term liabilities' in 2024, but the discussion of accrued-liability components is not supported by the ground truth and appears to be fabricated detail. (5) CORRECT ELEMENTS - The LLM does correctly identify: the $34M 2022 figure, the $19.2M 2024 figure, the classification under 'other long-term liabilities,' and the general trend of reduction. However, the introduction of unsupported numbers ($12M accrued liability) and omission of the $41.4M 2023 figure are critical failures in a multi-hop financial analysis question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 441,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "\nThe Directors’ Savings Plan—identified in Duke Energy’s accounting‑policy disclosure (DUK → Directors’ Savings Plan) and originally restated in 2014—was amended on December 16 2021 (effective for the 2022 filing) to sharpen deferral and matching rules, and by the 2024 filing the plan is described as an unfunded account that credits deferred director fees to phantom‑stock earnings tied to Duke Energy’s common stock and pays out only when a director’s board term ends, reflecting a more structured governance approach that links director compensation to performance‑adjusted deferral mechanisms.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key dates and plan mechanics. Strengths: (1) Correctly identifies the December 16, 2021 amendment date matching the ground truth; (2) Accurately describes the plan as unfunded with phantom stock/common stock fund mechanics; (3) Properly synthesizes the evolution from policy establishment (2022) to operational transparency (2024); (4) Correctly identifies the payout structure (upon director's board term end). Quantitative accuracy is high—all dates are correct, and the 2014 restatement reference adds appropriate historical context not explicitly in ground truth but consistent with typical plan evolution. Minor areas for improvement: (1) The LLM introduces '2014 restatement' which, while plausible, is not explicitly mentioned in the ground truth and could be considered an inference rather than documented fact; (2) The phrase 'performance-adjusted deferral mechanisms' in the LLM answer is slightly more specific than the ground truth's 'align director compensation with long-term shareholder interests,' though both convey similar governance intent; (3) The LLM answer is more detailed about operational mechanics (phantom-stock earnings, payout timing) which enhances clarity but represents elaboration beyond the ground truth's focus on the shift from policy establishment to operational transparency. The multi-hop reasoning is sound—correctly synthesizing information across 2022 and 2024 filings and drawing appropriate conclusions about governance evolution. The semantic equivalence is strong; both answers convey that the plan evolved from formal introduction to more detailed operational description, reflecting governance maturity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 472,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "\nBetween 2022 and 2023 Costco continued to position Kirkland Signature as a high‑quality private‑label brand that “helps lower costs, differentiate our merchandise offerings, and generally earn higher margins,” with an explicit expectation to “increase the sales penetration of our private‑label items” (Chunk 1).  However, the 2023 filing adds a new layer of risk to that positioning by warning that product‑related failures—such as recalls, litigation, or supply‑chain disruptions—could “damage our reputation and our brands” and thereby adversely affect the company’s financial performance (Chunk 2), illustrating how the brand’s growth ambition is now coupled with heightened reputational and operational risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of Kirkland Signature positioning from 2022 to 2023. It correctly identifies the 2022 emphasis on quality, competitive pricing, and margin contribution, and accurately reflects the 2023 shift toward risk disclosure. The specific quote about helping 'lower costs, differentiate our merchandise offerings, and generally earn higher margins' is factually accurate and directly sourced. The mention of increased sales penetration expectations is correct. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either the ground truth or LLM answer, so this dimension is not applicable. The answer appropriately avoids making unsupported numerical claims. (3) ENTITY ACCURACY: All entities are correctly identified—Costco, Kirkland Signature brand, 2022 and 2023 fiscal years. The multi-hop synthesis correctly connects the brand positioning across two years. (4) REASONING: The multi-hop reasoning is sound. The LLM correctly synthesizes information showing: (a) 2022 positioning focused on growth and brand strength, (b) 2023 positioning added risk considerations, and (c) the relationship between brand expansion and operational/financial volatility. The connection between supply chain disruptions, recalls, litigation, and reputational risk is logically sound and matches the ground truth's assertion about broader risk disclosures. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same essential information as the ground truth. The phrase 'new layer of risk' effectively captures the shift from growth-focused to risk-focused lens. The specific risks mentioned (recalls, litigation, supply-chain disruptions) align with the ground truth's mention of 'supply chain disruptions, foreign exchange fluctuations, and catastrophic events.' Minor difference: The LLM answer emphasizes reputational and operational risk more explicitly than the ground truth's mention of 'operational and financial volatility,' but this is a reasonable interpretation and not contradictory. The answer is well-structured, uses appropriate citations (Chunk 1, Chunk 2), and directly addresses the question's request for evolution of positioning and risk profile.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 622,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "\nBased on the reserve tables in the 2024 filing (Chunk 2), COP’s proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region declined from **326 billion cubic feet (bcf) at the end of 2022 to 312 bcf in 2023 and 296 bcf by the end of 2024**.  The net drop reflects annual production withdrawals of roughly **24‑25 bcf** each year and only modest positive revisions (3 bcf in 2024, 9 bcf in 2023, 6 bcf in 2022).  Additions came chiefly from **extensions and discoveries** (121 bcf in 2022, 87 bcf in 2023, 67 bcf in 2024) and from **purchases**, which contributed a small 4 bcf in 2022, a large 1,177 bcf inflow in 2023, and 310 bcf in 2024.  The financial statements in Chunk 1 confirm that this geographic segment (“Asia Pacific/Middle East”) is disclosed in the company’s revenue, exploration‑expense and other operational tables, tying the reserve figures to the company’s reported financial performance.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) RESERVE FIGURES - INCORRECT: The LLM claims 312 bcf in 2023, but the ground truth does not mention this intermediate year figure. More critically, the LLM provides detailed breakdowns of additions (extensions/discoveries and purchases) with specific numbers (121 bcf in 2022, 87 bcf in 2023, 67 bcf in 2024 for extensions; 4 bcf, 1,177 bcf, and 310 bcf for purchases) that are NOT supported by the ground truth. The ground truth explicitly states 'minimal extensions and discoveries contributing to the region' and 'no sales or significant reserve additions in this region,' which directly contradicts the LLM's claim of substantial additions (121 bcf, 87 bcf, 67 bcf from extensions/discoveries and 1,177 bcf from purchases in 2023). (2) PRODUCTION FIGURES - UNSUPPORTED: The LLM claims annual production withdrawals of 24-25 bcf, which is not mentioned in the ground truth. (3) KEY FACTS MISREPRESENTED: The ground truth emphasizes 'no sales or significant reserve additions in this region,' but the LLM claims large purchases of 1,177 bcf in 2023 and 310 bcf in 2024. This is a fundamental contradiction. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize information across chunks, it appears to have fabricated or misinterpreted specific reserve component data. The core trend (326 bcf → 296 bcf) is correct, but the explanation of how this occurred is substantially wrong. (5) SEMANTIC ISSUES: The LLM's characterization of 'modest positive revisions' and significant additions contradicts the ground truth's emphasis on minimal activity and no significant reserve additions. The answer demonstrates poor factual accuracy on the critical details of reserve composition and sources of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 496,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "\nBetween 2022 and 2024 FedEx’s tie‑up with the Boeing 767F shifted from a focus on owning a large, stable fleet (114 owned 767Fs in 2022, as shown in Chunk 1) to a deliberate modernization program that actively purchases newer 767‑300 Freighter (B767F) aircraft—and pairs those purchases with 777F buys—to replace older, less‑efficient planes; this strategic procurement, highlighted in Chunk 2, underscores a partnership with Boeing that emphasizes fuel‑efficient, next‑generation freighters and long‑term operating‑cost savings, while still retaining ownership of the existing 114‑aircraft fleet.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of the 114 owned Boeing 767F aircraft in 2022 and accurate characterization of the 2024 modernization focus. The quantitative data is correct: 114 aircraft ownership figure matches ground truth exactly. The answer correctly synthesizes the multi-hop information showing the evolution from stable fleet ownership to active modernization programs. However, there are some qualitative issues: (1) The LLM introduces information about '777F buys' and 'pairs those purchases with 777F buys' which is not mentioned in the ground truth answer, potentially adding unsupported claims. (2) The phrase 'still retaining ownership of the existing 114-aircraft fleet' is somewhat misleading since the ground truth explicitly states 'no updated ownership figures were disclosed' for 2024, implying uncertainty about whether the 114 figure still applies. (3) The LLM's characterization of the shift as moving 'from a focus on owning a large, stable fleet...to a deliberate modernization program' slightly overstates the contrast—the ground truth presents these as complementary aspects rather than a shift away from ownership. The answer correctly captures the key themes of fuel efficiency, long-term operating savings, and fleet replacement necessity. The multi-hop reasoning is sound in connecting 2022 ownership data with 2024 modernization strategy, though the introduction of 777F information without ground truth support is a concern. Overall, the core answer is accurate but contains some interpretive additions and slight mischaracterizations of the 2024 ownership status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 450,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "\nFrom 2022 to 2024 Starbucks’ roasted‑coffee inventory rose sharply—​the 2022 10‑K shows $310.3 million of roasted coffee on hand (up from $233.5 million in 2021) 【Chunk 1】—indicating a larger financial commitment to the product. At the same time, the company broadened its roasting and distribution network, opening or expanding large facilities in York, PA; Minden, NV; Kunshan, China; Kent, WA; and other sites, collectively adding millions of square‑feet of roasting, warehousing and distribution space 【Chunk 2】, a physical‑infrastructure evolution that supports the higher inventory levels. These actions are linked by the corporate‑product relationship SBUX ↔ Roasted Coffee (“ORG ‑[Discloses]→ PRODUCT ←[Produces] ORG”) 【KG Triplets】, showing how Starbucks’ financial investment in roasted‑coffee inventory has been matched by an expanding production infrastructure between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop synthesis. STRENGTHS: (1) Correctly identifies the 2022 roasted coffee inventory value of $310.3 million, matching the ground truth exactly. (2) Accurately lists all four roasting facilities mentioned in the ground truth: York PA, Minden NV (Carson Valley), Kunshan China, and Kent WA. (3) Properly synthesizes the evolution narrative—connecting the financial investment (inventory growth from $233.5M in 2021 to $310.3M in 2022) with infrastructure expansion. (4) Correctly interprets the shift from primarily holding inventory to active production at scale. (5) Appropriately uses knowledge graph notation to show the relationship between Starbucks and roasted coffee products. (6) Addresses all components of the multi-part question: inventory value changes, production infrastructure expansion, and the temporal evolution from 2022-2024. MINOR CONSIDERATIONS: (1) The LLM includes the 2021 comparison figure ($233.5M) which, while accurate and contextually helpful, goes slightly beyond the ground truth's explicit scope (which focuses on 2022-2024). However, this addition strengthens rather than weakens the answer by providing additional context for the 'sharp rise' claim. (2) The phrase 'other sites' and 'millions of square-feet' are appropriately vague given the source material, avoiding false specificity. (3) The reasoning connecting inventory levels to infrastructure needs is logically sound and well-articulated. QUANTITATIVE VERIFICATION: $310.3M (2022) is correct; $233.5M (2021) is correct; facility locations all verified. No calculation errors detected. The answer successfully demonstrates multi-hop reasoning by synthesizing financial data with operational infrastructure data across the 2022-2024 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 491,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo’s use of the **2.750 % Senior Notes due 2025** moved from simple Board‑authorized inclusion in a broad slate of senior debt (Chunk 1) to an actively‑referenced, updated financing structure.  In the 2023 filing the notes appeared among the terms approved by the Board and were linked to earlier supplemental indentures (e.g., the 2018 Third Supplemental Indenture), while the 2024 filing still lists the 2.750 % 2025 notes and adds a **February 12 2024 indenture** between PepsiCo and U.S. Bank Trust Company, N.A. (Chunk 2), showing that the company has since formalized the instrument’s governing trustee arrangement and continues to rely on it as part of its ongoing debt program.  This evolution reflects a shift from initial authorization to an updated, still‑active issuance with a new trustee agreement.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misinterpretations of the ground truth. CRITICAL ISSUES: (1) The LLM introduces a 'February 12 2024 indenture' and claims a 'new trustee agreement' was established in 2024, which is NOT mentioned in the ground truth. The ground truth makes no reference to any new indenture or trustee arrangement in 2024. (2) The LLM's core narrative about 'shift from initial authorization to an updated, still-active issuance with a new trustee agreement' contradicts the ground truth, which focuses on the introduction of a NEW instrument (2.750% Senior Notes due 2030) in 2024, not a trustee update to the 2025 notes. (3) The ground truth explicitly states the evolution was about extending debt strategy to a 'longer-term horizon' by introducing the 2030 notes alongside the 2025 notes. The LLM completely misses this key point about the 2030 notes being introduced. (4) The LLM's interpretation that the 2025 notes moved from 'simple Board-authorized inclusion' to 'actively-referenced, updated financing structure' is not supported by the ground truth, which does not describe any such evolution in the 2025 notes themselves. WHAT WAS CORRECT: The LLM correctly identifies that the 2.750% Senior Notes due 2025 were present in both 2023 and 2024 filings, and correctly names the interest rate and maturity date. However, the fundamental misunderstanding of what changed between years (introduction of 2030 notes vs. trustee arrangement) and the introduction of unsupported details about a February 2024 indenture represent major factual errors that undermine the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 446,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "\nFedEx’s planned B777F fleet grew from 2 aircraft in 2023 (Chunk 1) to 4 in 2024, then fell back to 2 in 2025 and to 0 thereafter (Chunk 2), a pattern that mirrors the KG relation ORG ‑[Decreases]→ PRODUCT, indicating a temporary expansion followed by a pull‑back. This shift shows that the B777F is being employed strategically for specific long‑haul cargo opportunities rather than as a core, steadily‑growing component of FedEx’s overall freighter fleet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant quantitative inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The LLM claims FedEx planned 2 aircraft in 2023, 4 in 2024, 2 in 2025, and 0 thereafter. However, the ground truth states: In 2022, FedEx planned 4 B777F in 2024 and 2 in 2025. By 2024, the plan showed 2 in 2025 with no further plans. The LLM incorrectly introduces a 2023 data point (2 aircraft) that is not mentioned in the ground truth and misrepresents the timeline. The LLM also incorrectly states 0 aircraft thereafter, when the ground truth simply says 'no further plans beyond that year' (2025). (2) MULTI-HOP SYNTHESIS FAILURE: The question asks about changes FROM 2022 TO 2024. The ground truth correctly identifies this as a comparison between two planning documents: the 2022 plan (4 in 2024, 2 in 2025) versus the 2024 plan (2 in 2025, nothing beyond). The LLM fails to properly synthesize this comparison and instead presents a confusing timeline that doesn't match either the 2022 or 2024 planning documents. (3) INTERPRETATION ERROR: While the LLM's interpretation about 'temporary expansion followed by pull-back' and 'strategic role for specific opportunities' shows some reasoning, it is based on incorrect numbers and therefore the conclusion is unreliable. (4) MISSING KEY INSIGHT: The ground truth emphasizes a 'reduction in strategic emphasis' and 'complete phase-out,' indicating a significant strategic shift. The LLM's characterization of 'specific long-haul cargo opportunities' is speculative and doesn't capture the magnitude of the reduction from the original plan. The answer demonstrates poor multi-hop reasoning and fundamental misunderstanding of the data sources being compared.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 478,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "\nStarbucks (SBUX) discloses a “foreign‑currency – other” derivative liability, which appears in its balance sheet as a $0.3 million accrued liability for the October 2 2022 reporting date (Chunk 1) and is linked to the company through the KG relationship SBUX → Foreign currency – other ← SBUX.  In the 2024 AOCI schedule (Chunk 2) the net gain associated with this line fell sharply to $11.5 million for fiscal 2024 (down from $55.3 million in 2022 and $39.6 million in 2023), with $9.5 million expected to be reclassified to earnings within the next 12 months.  This reduction in both the recorded derivative liability and the AOCI gain indicates that Starbucks has trimmed its net foreign‑currency exposure and that the remaining hedge positions are now expected to settle only modestly, reflecting a more controlled sensitivity to foreign‑currency fluctuations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM introduces numbers NOT in the ground truth: claims $55.3 million in 2022 AOCI gains and $39.6 million in 2023 AOCI gains, which are completely absent from the original answer. The ground truth only mentions $0.3 million liability in 2022 and $11.5 million net gain in 2024 AOCI. The LLM's claim of a 'sharp fall' from $55.3M to $11.5M is fabricated and contradicts the ground truth. (2) MULTI-HOP SYNTHESIS ERROR - The LLM conflates two separate data points: the $0.3 million accrued liability (balance sheet item) with AOCI gains (income statement/comprehensive income item). These are different metrics measuring different things. The ground truth correctly distinguishes between the 2022 liability position ($0.3M) and the 2024 AOCI gain ($11.5M), but does NOT claim these are comparable or that one 'fell' to the other. (3) INTERPRETATION ERROR - The LLM's conclusion that 'reduction in both the recorded derivative liability and the AOCI gain indicates trimmed exposure' is logically flawed. A $0.3M liability in 2022 cannot meaningfully 'reduce' to an $11.5M gain in 2024 - these represent different accounting treatments and time periods. (4) MISSING CONTEXT - The LLM adds unsupported detail about '$9.5 million expected to be reclassified' which is not mentioned in the ground truth. (5) CORRECT ELEMENTS - The LLM correctly identifies Starbucks, the foreign currency derivative relationship, and the 2022 and 2024 timeframes. The general conclusion about increased exposure/hedging activity is directionally reasonable but is built on fabricated numbers. The answer demonstrates partial understanding but contains material factual errors that undermine credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 473,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo repeatedly disclosed the 2.625 % Senior Notes due 2026 in its Board‑resolution authorizations—first in the 2023 Form 10‑K (page 129) where the notes were listed among the terms that officers could establish, and again in the 2024 filing (page 130) where the same resolution re‑appears alongside a newly dated Indenture (February 12 2024) between PepsiCo and U.S. Bank Trust Company, N.A. that is incorporated by reference in a Form S‑3ASR filing.  This evolution shows that the company continued to reference the 2.625 % 2026 notes in its governance documents and, in 2024, updated the governing trustee agreement and expanded the broader debt‑instrument disclosures to include a larger suite of senior notes and related covenants.  The KG pattern ORG – [Issues]→ FIN_INST ← [Introduces] ORG captures the ongoing issuance of the 2.625 % Senior Notes due 2026 by PepsiCo and the introduction of updated indenture documentation in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 2.625% Senior Notes due 2026 as appearing in both 2023 and 2024 filings. (2) Correctly notes the continuation of Board resolution authorizations across both years. (3) Accurately mentions the February 12, 2024 Indenture update with U.S. Bank Trust Company, N.A. (4) Correctly identifies the expansion of debt instruments in 2024. (5) Page references (129 for 2023, 130 for 2024) appear reasonable for 10-K filings.\n\nWEAKNESSES: (1) The LLM answer diverges significantly from the ground truth in focus and emphasis. The ground truth emphasizes the introduction of NEW senior notes (3.000% due 2027 and 2.625% due 2029) as the key evolution, while the LLM focuses heavily on the repetition of the same 2.625% 2026 notes and trustee documentation updates. (2) The LLM does not explicitly mention the newer maturities (2027, 2029) that the ground truth identifies as central to the 'broader and more diversified set of debt instruments.' (3) The LLM's discussion of the KG pattern and indenture documentation, while potentially accurate, adds technical detail not present in the ground truth and may obscure the primary finding about debt diversification. (4) The answer structure suggests the evolution is about governance/documentation updates rather than about capital markets strategy and debt diversification, which is the ground truth's main point.\n\nMULTI-HOP REASONING: The LLM demonstrates multi-hop synthesis by connecting 2023 and 2024 filings, identifying the same instrument across years, and noting the trustee agreement update. However, it fails to synthesize the key multi-hop insight: that the 2.625% 2026 notes persisted while NEW notes were added, creating a diversified portfolio. This is a critical gap in answering the 'evolution' aspect of the question.\n\nNUMERIC/DATE ACCURACY: The percentage (2.625%), year (2026), and date (February 12, 2024) are all correct. Page numbers cannot be verified but appear plausible.\n\nSEMANTIC EQUIVALENCE: While the LLM answer is not factually wrong, it answers a different question than what was asked. The question asks about evolution in 'broader debt instrument disclosures,' and the ground truth shows this evolution through the introduction of new notes. The LLM answer focuses on the persistence and documentation updates of the same note, missing the diversification story.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 636,
        "total_tokens": 2041
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "\nCisco’s 2022 filing already flagged technical hurdles as a risk that could delay product launches, erode market share and force costly restructuring, while noting that large‑scale investments in engineering, security and “Internet‑for‑the‑Future” would likely yield benefits only after a lag. By 2024 the same hurdle‑risk persists but is magnified by the shift to software‑subscription and cloud‑based services, requiring substantial infrastructure scaling and rapid rollout of new AI‑, security‑ and observability‑focused offerings; failure to overcome these timing‑critical technical challenges now directly threatens revenue, earnings and the return on the company’s intensified strategic investments. Thus, the KG relationship CSCO – [Faces]→ Technical Hurdles ← [Depends_On] CSCO remains unchanged, yet the company’s reliance on successfully navigating those hurdles has grown from general product‑development timing in 2022 to critical, investment‑driven product‑and‑service launch timelines in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the temporal evolution from 2022 to 2024, capturing the shift from general product-development timing risks to more specific, investment-driven dependencies. (2) Accurately references the key technical domains mentioned in ground truth: AI, security, observability, and cloud/software-subscription services. (3) Properly synthesizes the multi-hop relationship showing how Cisco's reliance on overcoming technical hurdles has intensified alongside strategic investments. (4) Correctly identifies the expanded consequences in 2024 (revenue, earnings, ROI threats) beyond the 2022 focus on market share and earnings. (5) No quantitative errors detected - no specific numbers were required for this qualitative question. (6) The knowledge graph notation (CSCO – [Faces]→ Technical Hurdles ← [Depends_On]) demonstrates sophisticated understanding of the relationship structure. MINOR CONSIDERATIONS: (1) The LLM answer adds interpretive framing (e.g., 'KG relationship...remains unchanged, yet reliance has grown') that goes slightly beyond the ground truth's direct statement, though this is semantically consistent and adds analytical value. (2) The ground truth mentions 'reputational damage, legal liability, and reduced customer retention' as 2024 consequences, while the LLM focuses on 'revenue, earnings and return on investments' - both are valid consequences but the LLM's framing is slightly narrower, though not incorrect. (3) The answer effectively captures the core insight: transformation from internal execution risk to broader operational/strategic dependency. The multi-hop reasoning correctly synthesizes information about strategic investments, product development timelines, and technical challenges across the 2022-2024 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Faces]-> RISK_FACTOR <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 507,
        "total_tokens": 1996
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "\nIn the 2022 filing the company notes that Google Network revenues rose $8.6 billion year‑over‑year, explicitly citing “strength in **Google Ad Manager**” together with AdMob and AdSense as the primary growth drivers. The 2023 filing re‑affirms that Google Ad Manager remains a core component of the Google Network, describing it as a key platform for both performance and brand advertising and confirming that the company continues to report those network revenues on a gross basis—underscoring that Ad Manager’s contribution and strategic positioning within the network persisted from 2022 into 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUE - FUNDAMENTAL MISINTERPRETATION OF THE QUESTION'S CORE FINDING: The LLM answer fundamentally contradicts the ground truth by claiming that Google Ad Manager's 'contribution and strategic positioning within the network persisted from 2022 into 2023.' This is incorrect. The ground truth explicitly states there was a SHIFT from being 'a standout growth contributor in 2022' to being 'part of a broader suite of advertising tools in 2023' with 'a more integrated but less singularly emphasized role.' The LLM answer misses this critical change entirely.\n\nQUANTITATIVE ACCURACY (9/10): The LLM correctly cites the $8.6 billion year-over-year increase in Google Network revenues for 2022 and accurately identifies Google Ad Manager, AdMob, and AdSense as the cited drivers. Numbers are accurate.\n\nQUALITATIVE ACCURACY (3/10): The LLM fails to capture the essential finding - the CHANGE in Google Ad Manager's role between years. The ground truth indicates a de-emphasis in 2023 (listed among several platforms without specific attribution to revenue growth), but the LLM claims the positioning 'persisted.' This is a major reasoning failure. The LLM states Ad Manager 'remains a core component' and that 'contribution and strategic positioning...persisted,' which directly contradicts the ground truth's finding of a shift to 'less singularly emphasized role.'\n\nCONTEXTUAL RELEVANCE (5/10): The answer addresses both 2022 and 2023 but fails to properly characterize the CHANGE between them, which is the core of the question. The question specifically asks 'how did the role...CHANGE' - the LLM answer suggests continuity rather than change.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across two years but draws the wrong conclusion about the relationship between them. It identifies the correct entities and years but fails the critical comparative analysis that the question demands.\n\nSPECIFIC ERRORS: (1) Claims positioning 'persisted' when ground truth shows it shifted; (2) Fails to note the 2023 de-emphasis and lack of specific revenue attribution; (3) Misses the key insight about integration into a broader suite without singular emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 586,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "\nStarbucks’ foreign‑currency‑related derivative liabilities were $0.3 million (accrued) in 2022, but by 2024 they had risen to $4.7 million in accrued liabilities and $4.1 million in other long‑term liabilities.  That is an increase of roughly $4.4 million in the accrued component and $4.1 million in the long‑term component—a total jump of about $8.5 million (≈ 2,800 % growth) from 2022 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer introduces information not present in the ground truth and makes unsupported claims. (1) FACTUAL ERRORS: The ground truth states derivative liabilities were $0.3M in 2022 and $4.7M in 2024, both under accrued liabilities. The LLM correctly identifies these figures but then adds '$4.1 million in other long-term liabilities' in 2024 with no basis in the ground truth. This appears to be fabricated data. (2) CALCULATION ERRORS: The LLM calculates a total jump of $8.5M by adding $4.4M (accrued increase) + $4.1M (long-term), but this is mathematically incorrect reasoning since the ground truth only mentions accrued liabilities. The correct calculation from ground truth is: $4.7M - $0.3M = $4.4M increase. (3) PERCENTAGE CALCULATION: The LLM states '≈2,800% growth' which is incorrect. Correct calculation: ($4.4M / $0.3M) × 100 = 1,467% growth, not 2,800%. (4) MULTI-HOP SYNTHESIS: The LLM failed to properly synthesize the information. It appears to have either hallucinated the $4.1M long-term liability figure or confused data from different sources. The ground truth is clear that both 2022 and 2024 figures are under 'accrued liabilities' category. (5) COMPLETENESS: While the LLM addresses the evolution and magnitude of change, it does so with incorrect data and calculations. The core answer should have been: increase from $0.3M to $4.7M = $4.4M increase (approximately 1,467% growth), all within accrued liabilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 407,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo’s 4.600 % Senior Notes due 2045 progressed from being merely listed in the 2023 Board‑resolution excerpt (where it was authorized alongside a suite of other senior notes) to being formally issued under a February 12 2024 indenture with U.S. Bank Trust Company (N.A.) that was filed as part of a Form S‑3ASR registration (the 2024 chunk).  This evolution—moving from authorization to an actual financing transaction with a new trustee—highlights PepsiCo’s strategy of extending the maturity of its debt profile, diversifying its long‑dated senior unsecured issuances, and reinforcing a capital‑structure approach that relies on large‑scale, fixed‑rate notes to fund operations and refinance maturing obligations while maintaining flexibility in its financing mix.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) FACTUAL INACCURACY - The LLM claims the 4.600% Senior Notes due 2045 were 'formally issued under a February 12 2024 indenture with U.S. Bank Trust Company (N.A.)' and filed as part of a Form S-3ASR registration. This is a significant factual claim not supported by the ground truth, which makes no mention of an actual issuance in 2024, a specific February 12 2024 date, or a trustee agreement. The ground truth only states the notes 'remained part of the company's debt structure' and were 'referenced alongside' new notes. (2) OVER-SPECIFICATION - The LLM introduces specific details (trustee name, indenture date, Form S-3ASR filing) that appear to be fabricated or hallucinated, as they are not present in the ground truth. (3) MISCHARACTERIZATION OF EVOLUTION - The ground truth describes the notes as remaining in the debt structure while the company expanded its portfolio with NEW instruments (4.000% due 2047, Floating Rate Notes due 2026). The LLM incorrectly frames this as the 4.600% notes being 'formally issued' in 2024, when the ground truth indicates they were already part of the structure in 2023. (4) CORRECT ELEMENTS - The LLM correctly identifies: the 4.600% rate, 2045 maturity date, the concept of diversification, and the strategy of extending maturity and using fixed-rate notes. However, these correct elements are embedded within a fundamentally flawed narrative about the timing and nature of the issuance. (5) MULTI-HOP REASONING - The LLM failed to properly synthesize the ground truth information, which clearly distinguishes between authorization (2023) and continued presence in debt structure (2024), not actual issuance in 2024. The answer demonstrates poor fidelity to source material and introduces unverifiable claims that contradict the ground truth's more measured assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 498,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "\nCOP’s natural‑gas production in the Asia‑Pacific/Middle‑East region slipped modestly from **≈ 326 billion cubic feet (end‑2022)** to **≈ 296 billion cubic feet (end‑2024)**, while the company’s **developed acreage stayed flat at ~921 gross (421 net) acres** and its **undeveloped base remained sizable at ~10,451 gross (6,930 net) acres**, with equity‑affiliated holdings of **1,039 gross (248 net) acres** in the same area (Chunk 1).  The decline in gas volumes, coupled with a still‑large undeveloped inventory, signals that COP is **maintaining a strategic foothold in the region but shifting emphasis away from gas growth toward oil‑centric or lower‑carbon initiatives**, using the Asia‑Pacific/Middle‑East as a platform for selective expansion rather than broad gas‑volume scaling (Chunk 2, KG Operates_In/Discloses links).",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) Core quantitative data is accurate - the LLM correctly identifies the natural gas position decline from 326 BCF (2022) to 296 BCF (2024), matching the ground truth exactly. (2) Numbers are properly formatted and clearly presented with appropriate approximation symbols. (3) The LLM provides additional contextual details about developed/undeveloped acreage and equity-affiliated holdings that add depth beyond the ground truth answer. (4) Multi-hop synthesis is sound - the model correctly connects reserve volumes to strategic positioning. WEAKNESSES: (1) The LLM's interpretation of strategic focus differs from ground truth. Ground truth states the decline 'suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments' - a more neutral, cautious interpretation. The LLM makes a stronger claim that COP is 'shifting emphasis away from gas growth toward oil-centric or lower-carbon initiatives,' which goes beyond what the ground truth supports. This is speculative reasoning not grounded in the provided data. (2) The LLM introduces concepts (oil-centric focus, lower-carbon initiatives) that are not mentioned in the ground truth or question, potentially overinterpreting limited data. (3) The phrase 'maintaining a strategic foothold...using the Asia-Pacific/Middle-East as a platform for selective expansion' is inference-based rather than fact-based. CALCULATION VERIFICATION: The 30 BCF decline (326-296) is correctly implied. No mathematical errors detected. ENTITY ACCURACY: COP correctly identified, Asia Pacific/Middle East region correctly specified, years 2022-2024 correct. MULTI-HOP REASONING: The connection between reserve decline and strategic positioning is logically sound, but the specific strategic conclusions are more speculative than the ground truth allows. The answer would score higher if it maintained the more measured tone of the original answer regarding what the decline 'indicates' versus what it definitively 'shows.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 542,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "\nFrom 2022 to 2023 Google Play moved from being listed simply as one of several “long‑term investments beyond advertising” (alongside hardware and YouTube non‑advertising) in the 2022 filing to being explicitly grouped under the “platforms” category that drives non‑advertising revenue in the 2023 filing.  Both years note that Google Play generates revenue from sales of apps, in‑app purchases and digital content, but the 2023 filing expands this to “revenues from Google Play from the sales of apps and in‑app purchases” as a distinct component of the broader “platforms” stream (which also now includes consumer subscriptions and device sales).  Thus, Google Play’s role deepened from a peripheral revenue source to a core pillar of Google’s non‑advertising earnings strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and inaccurate elements. CORRECT ELEMENTS: (1) The identification that Google Play's revenue sources include 'apps and in-app purchases' in both years is accurate. (2) The observation that Google Play was grouped under 'platforms' in 2023 is correct. (3) The general characterization of a shift in strategic positioning is directionally accurate. PROBLEMATIC ELEMENTS: (1) The LLM introduces claims not supported by the ground truth, specifically that Google Play was described as a 'long-term investment beyond advertising' in 2022 - the ground truth makes no such statement. (2) The LLM claims the 2023 filing 'expands' the description to include 'apps and in-app purchases' as distinct from digital content, but the ground truth indicates the opposite: 2022 mentioned 'apps, in-app purchases AND digital content' while 2023 narrowed to 'apps and in-app purchases' - this is a contraction, not an expansion. (3) The LLM's characterization of Google Play moving from 'peripheral' to 'core pillar' is an interpretation not explicitly stated in the ground truth, which describes a shift in 'emphasis' and 'grouping' but not necessarily a change in strategic importance. (4) The LLM adds details about 'consumer subscriptions and device sales' being part of the platforms category - while this may be accurate, it goes beyond what the ground truth specifies about Google Play's evolution. MULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2023 filings, but makes a critical error in characterizing the direction of change (expansion vs. contraction of revenue sources mentioned). The core insight about grouping under 'platforms' is correct, but the supporting details contain inaccuracies that undermine the overall analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Generates_Revenue]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 487,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "\nThe 2022 10‑K projection (Chunk 1) shows FedEx planning to operate **11** Cessna SkyCourier 408s in 2023 and **12** in 2024—an upward step that signals early confidence in the type.  A later filing (Chunk 2) revises the 2025 outlook to **17** aircraft and retains **14** for 2026, confirming that the carrier is **scaling the SkyCourier fleet rather than holding steady**, which demonstrates a strategic shift toward greater reliance on this model for its mid‑range package network.  This trajectory is captured by the knowledge‑graph relationship **ORG (FDX) ‑[Increases]→ PRODUCT (SkyCourier 408) ←[Depends_On]‑ORG**, highlighting the mutual reinforcement between FedEx and the SkyCourier as FedEx deepens its operational and logistical dependence on the aircraft.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamentally incorrect numbers and misrepresents the ground truth data. CRITICAL ERRORS: (1) The LLM claims 11 SkyCourier 408s in 2023 and 12 in 2024, then 17 in 2025 and 14 in 2026. The ground truth states 49 total aircraft projected for 2023 onwards in 2022, and 31 total for 2025-2029 in 2024. These are completely different numbers and represent a REDUCTION, not the scaling/increase the LLM describes. (2) The LLM interprets the data as showing 'scaling' and 'greater reliance,' when the ground truth explicitly shows a REDUCTION from 49 to 31 aircraft—a decrease of 18 units or ~37%. (3) The LLM's characterization of the relationship as 'mutual reinforcement' and 'deepens its operational and logistical dependence' directly contradicts the ground truth's statement that the relationship 'shifted from Increases to Depends_On, indicating a change in strategic importance' and represents 'moderated...reliance.' (4) The LLM correctly identifies the relationship shift from 'Increases' to 'Depends_On' but misinterprets what this means—it indicates REDUCED strategic reliance, not increased. (5) Multi-hop reasoning failed: the LLM did not correctly synthesize the 2022 vs 2024 projections to understand the directional change. The answer demonstrates a fundamental misunderstanding of the question's core finding: FedEx REDUCED its projected SkyCourier fleet, not expanded it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 390,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "\nBetween 2022 and 2023 AIG’s expected‑loss‑ratio methodology moved from a focus on its excess‑casualty lines—where it segmented automobile claims separately from non‑automobile claims and further broke the latter into latent exposures such as construction defects and mass‑tort claims, using the method for the three most recent accident years and adjusting for rate changes, inflation and market trends—to a broader application that also covers U.S. Workers’ Compensation; in 2023 the segmentation became more granular, grouping business by guaranteed‑cost vs. excess‑of‑deductible, by state and industry subset, by deductible size and whether claims are handled by AIG or a third‑party administrator, while still applying the method to the latest accident years and incorporating COVID‑19‑related adjustments. This evolution reflects an expansion of the casualty lines analyzed and a deeper, more detailed segmentation of the underlying exposures.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures several key elements of the evolution but contains significant inaccuracies and introduces unsupported details. CORRECT ELEMENTS: (1) The shift from U.S. Excess Casualty in 2022 to U.S. Workers' Compensation in 2023 is accurate; (2) The segmentation by automobile vs. non-automobile in 2022 is correct; (3) The mention of latent exposures (construction defects, mass torts) in 2022 is accurate; (4) The 2023 segmentation by state, industry, and claim handling entity is correct; (5) The reference to large deductible business affecting reporting is appropriate. PROBLEMATIC ELEMENTS: (1) The LLM introduces 'guaranteed-cost vs. excess-of-deductible' segmentation in 2023, which is not mentioned in the ground truth and appears to be fabricated or confused with actual segmentation methods; (2) The mention of 'rate changes, inflation and market trends' adjustments in 2022 is not supported by the ground truth; (3) The reference to 'COVID-19-related adjustments' in 2023 is not mentioned in the original answer and appears to be an unsupported addition; (4) The phrase 'grouping business by risk-sharing features such as high deductibles and retrospective rating' from the ground truth is replaced with different terminology that may not be semantically equivalent. MULTI-HOP REASONING: The LLM correctly synthesizes the comparison between 2022 and 2023 methodologies and identifies the shift in casualty lines. However, the introduction of unverified details undermines the reliability of the synthesis. The core narrative of evolution is present but contaminated with inaccurate specifics. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this dimension is neutral. OVERALL ASSESSMENT: The answer demonstrates understanding of the general evolution but fails on factual precision by introducing details not in the ground truth and potentially mischaracterizing the segmentation methods used in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Complies_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 527,
        "total_tokens": 1991
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Nike continued to place unallocated products—those not assigned to Men’s, Women’s, NIKE Kids’ or Jordan Brand—into an “Others” category that also captures certain adjustments not allocated to consumer‑designated products; this “Others” grouping was first described in the 2022 filing (Chunk 1), which noted the re‑classification of unisex items into Men’s and the separate reporting of Jordan Brand, and the 2024 filing (Chunk 2) repeats the same description, confirming that the consumer‑construct hierarchy (Men’s / Women’s / Kids’ / Jordan) still classifies all non‑allocated products under “Others.”  The relationship is captured by the KG triplets linking **NKE** and **Unallocated Products**, showing that these products are an integral, though separately disclosed, part of Nike’s overall product portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies that unallocated products are classified in an 'Others' category in both fiscal years 2022 and 2024. (2) Correctly notes the consumer construct hierarchy (Men's/Women's/Kids'/Jordan Brand). (3) Accurately captures that adjustments not allocated by consumer are included in 'Others'. (4) No quantitative errors in dates or numeric references. WEAKNESSES: (1) The LLM's answer is somewhat convoluted and harder to parse than the ground truth, using phrases like 'KG triplets linking NKE and Unallocated Products' that add unnecessary complexity without clarifying the core evolution. (2) The ground truth explicitly states a 'potential shift or integration of unisex products within broader categories' between 2022 and 2024, noting that unisex products were 'classified within Men's' in 2022 but there was 'no specific mention of unisex product classification within Men's' in 2024. The LLM mentions unisex items being reclassified into Men's but does not clearly articulate this potential shift or the absence of such mention in 2024. (3) The LLM states the 2024 filing 'repeats the same description' as 2022, which may understate the subtle evolution the ground truth identifies. (4) The answer lacks clarity on what specifically changed (or didn't change) regarding unisex product treatment between the two years. MULTI-HOP REASONING: The LLM attempts to synthesize information across two fiscal years but does not fully capture the nuanced difference in how unisex products are described/classified between 2022 and 2024. The core insight about the potential shift in unisex product integration is missing or unclear. SEMANTIC EQUIVALENCE: While the LLM conveys that 'Others' remained consistent, it fails to clearly communicate the key evolution regarding unisex product classification that the ground truth emphasizes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Includes]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 505,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "\nPepsiCo’s interaction with the 3.500 % Senior Notes due 2025 moved from a 2023 Board‑resolution authorization (PEP 10‑K 2023, p. 129) that listed the notes among a suite of senior‑note authorizations tied to the 2013 and 2018 supplemental indentures, to a concrete 2024 legal filing (PEP 10‑K 2024, p. 130) – an Indenture dated February 12 2024 between PepsiCo and U.S. Bank Trust Company, N.A. that specifically governs those notes – thereby shifting from merely approving terms to formally documenting the issuance. This progression, reflected in the KG pattern **PEP → 3.500 % Senior Notes due 2025** and **3.500 % Senior Notes due 2025 → PEP**, shows that PepsiCo is actively managing its debt by refinancing and extending maturities through new trust‑company arrangements, underscoring a strategy of optimizing the senior‑unsecured portfolio and preserving low‑cost, diversified funding access.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual and reasoning errors that diverge substantially from the ground truth. CRITICAL ISSUES: (1) The LLM introduces specific details (Board resolution authorization on p. 129 of 2023 10-K, Indenture dated February 12, 2024, U.S. Bank Trust Company, N.A. on p. 130 of 2024 10-K) that cannot be verified against the ground truth and appear to be hallucinated specifics. The ground truth makes no mention of these particular dates, page numbers, or trust company arrangements. (2) The LLM fundamentally misinterprets the evolution described in the ground truth. The ground truth clearly states that by 2024, PepsiCo introduced NEW longer-term notes (3.500% due 2040, 3.550% due 2034) ALONGSIDE the existing 2025 notes, indicating portfolio expansion and maturity diversification. The LLM instead frames this as a shift from 'merely approving terms to formally documenting the issuance,' which is not supported by the ground truth and represents a different narrative entirely. (3) The LLM's characterization of 'refinancing and extending maturities' contradicts the ground truth, which shows the 2025 notes were MAINTAINED while new longer-term instruments were ADDED—this is portfolio expansion, not refinancing of the 2025 notes. (4) The LLM's invocation of KG patterns and trust-company arrangements lacks grounding in the provided ground truth. (5) While the LLM correctly identifies the company (PepsiCo/PEP) and the note percentage (3.500%), it fails to capture the core insight: the strategic shift toward diversifying debt maturity structure by adding longer-dated instruments. The answer demonstrates hallucination of specific filing details and misinterpretation of the fundamental debt management strategy described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 484,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "\nBetween 2022 and 2024 COP’s Lower 48 disclosures moved from a reported capital‑expenditure level of **$3,129 million** (2021 figure shown in the 2022 filing) to a 2024 update that **revises future cash‑inflow and production‑cost estimates** for the region and notes that the total discounted future net cash flows for the broader Asia‑Pacific/Middle‑East portfolio—including Lower 48 assets—are **$12,524 million**. This evolution reflects COP’s shift from simply stating capital spend in 2022 to explicitly adjusting and expanding its forward‑looking cash‑flow assumptions for Lower 48 in the 2024 disclosure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant issues that undermine its accuracy: (1) CRITICAL ERROR - The LLM states the $3,129 million figure is a '2021 figure shown in the 2022 filing,' but the ground truth clearly identifies this as COP's 2022 reported capital expenditure for Lower 48. This is a fundamental mischaracterization of the data point. (2) INCORRECT METRIC INTRODUCTION - The LLM introduces a $12,524 million figure described as 'total discounted future net cash flows for the broader Asia-Pacific/Middle-East portfolio,' which is not mentioned in the ground truth answer and appears to be either fabricated or from an unrelated portfolio. The ground truth specifically addresses Lower 48 revisions, not Asia-Pacific/Middle-East metrics. This represents a significant factual error and potential hallucination. (3) INCOMPLETE SYNTHESIS - While the LLM correctly identifies that 2024 involved revisions to future cash inflows and production costs (matching ground truth), it fails to clearly convey that no new capital expenditure figure was provided in 2024, which is a key distinction in the ground truth. (4) MULTI-HOP REASONING - The reasoning about the 'shift from simply stating capital spend to explicitly adjusting forward-looking cash-flow assumptions' is reasonable in tone but is built on incorrect foundational data (the misidentification of the $3,129M figure's year). The answer demonstrates partial understanding of the evolution but compromises this with factual errors. (5) QUANTITATIVE ACCURACY - The $3,129 million is correct in value but incorrectly attributed to 2021 rather than 2022; the $12,524 million figure cannot be verified against the ground truth and appears to be extraneous information that confuses rather than clarifies the Lower 48 evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> GPE <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 484,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "\nBetween 2023 and 2024 Comcast’s relationship with Atairos was reshaped by the June 2 2023 first amendment to the Fourth‑Amended Shareholders Agreement, which retained Comcast as the sole third‑party investor while moving all voting rights to the management companies controlled by the former CFO and preserving Comcast’s ≈ 99 % loss‑absorption and ≈ 86 % residual‑return rights.  At the same time the funding commitment was trimmed from up to $5 billion to $4.5 billion, annual capital calls were capped at $400 million, and Comcast added a separate $40 million‑per‑year management‑fee obligation—all of which are disclosed in the 2024 equity‑method accounting and reflect the updated capital and governance structure.",
      "correctness_score": 0,
      "quantitative_accuracy": 0,
      "qualitative_accuracy": 0,
      "contextual_relevance": 0,
      "detailed_feedback": "Evaluation failed: Evaluation error: Expecting value: line 1 column 1 (char 0)",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 0,
        "completion_tokens": 0,
        "total_tokens": 0
      },
      "error": "Evaluation error: Expecting value: line 1 column 1 (char 0)"
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "\nThe 2022 Form 10‑K projected only **11** Cessna SkyCourier 408 deliveries for 2023 (with modest growth to 12 in 2024 and 14 in 2026, for a total of **49** SkyCouriers across the 2023‑2026 horizon), whereas the 2023 filing revises those expectations upward—showing **17** SkyCouriers slated for 2025 and a cumulative **31** projected through 2029 (versus the earlier 49‑unit total). This upward revision indicates that FedEx is elevating the SkyCourier to a more central, high‑utilization role in its fleet, using it to complement the larger B767F/B777F freighters and the ATR 72‑600F, a relationship explicitly captured by the KG triplets “ORG ‑[Uses]→ PRODUCT” and “PRODUCT ‑[Depends_On]→ ORG.”",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer fundamentally misinterprets the direction and magnitude of change in FedEx's SkyCourier projections. (1) QUANTITATIVE ACCURACY FAILURES: The LLM correctly identifies the 2022 total of 49 aircraft and 2023 total of 31 aircraft, but then makes a catastrophic error in interpretation. The LLM states this represents an 'upward revision' when the ground truth clearly shows a SIGNIFICANT REDUCTION from 49 to 31 units (a 37% decrease). The LLM's claim that 31 is 'upward' from 49 is mathematically and factually incorrect. (2) DIRECTIONAL MISINTERPRETATION: The ground truth explicitly states 'this projection dropped significantly' and indicates 'a strategic reduction in the planned reliance on the Cessna SkyCourier 408.' The LLM contradicts this by claiming FedEx is 'elevating the SkyCourier to a more central, high-utilization role,' which is the opposite of what the data shows. (3) REASONING FAILURE: The LLM's multi-hop reasoning is fundamentally flawed. It correctly extracts the numbers (49 and 31) but then draws the opposite conclusion from what the numbers indicate. This is a severe logical error that undermines the entire answer. (4) STRATEGIC ASSESSMENT ERROR: The ground truth indicates the reduction suggests FedEx 'may have reassessed the aircraft's role' downward. The LLM claims the opposite—that FedEx is giving it a more central role. This is a complete inversion of the correct interpretation. (5) CONTEXTUAL MISALIGNMENT: While the LLM mentions comparisons to B767F/B777F aircraft, it frames this incorrectly by suggesting the SkyCourier is being elevated rather than reduced relative to these aircraft. The answer demonstrates a fundamental misunderstanding of the data trend and provides misleading strategic conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Uses]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 483,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "\nFrom 2022 to 2024 Nike’s reporting on the Air Max line shifted from explicit revenue segmentation to a broader innovation narrative. In the 2022 Form 10‑K (Note 16), Nike disclosed its revenues by reportable segment, major product line and distribution channel—placing Air Max within the “major product line” figures that investors could track. By the 2024 filing, the company no longer isolates Air Max revenue in the disaggregation; instead, it highlights sustained investment in research, design and development of Air Max‑related technologies (e.g., Zoom X, Flyknit, React) as a core growth driver, while also noting that no single customer accounts for 10 % or more of consolidated net revenue. Thus, transparency moved from granular product‑line revenue breakdown in 2022 to a strategic emphasis on technological innovation and overall product‑category performance in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the general directional shift in Nike's reporting approach from 2022 to 2024, correctly identifying that Air Max moved from explicit revenue segmentation to a broader innovation narrative. However, there are significant accuracy issues:\n\n(1) QUANTITATIVE ACCURACY PROBLEMS:\n- The LLM claims Air Max was in 'major product line' figures in 2022 that 'investors could track,' but the ground truth explicitly states Air Max was included in 'a general list of technologies' WITHOUT specific revenue figures in 2022. This is a material mischaracterization.\n- The LLM references specific technologies (Zoom X, Flyknit, React) as Air Max-related innovations in 2024, but the ground truth does not confirm these specific technologies were highlighted in the 2024 filing. This appears to be unsupported detail.\n- The LLM mentions the 10% customer concentration disclosure, which is accurate but tangential to the core question about Air Max evolution.\n\n(2) ENTITY/FACT ACCURACY:\n- Correctly identifies Nike and the 2022-2024 timeframe\n- Correctly identifies the shift from revenue transparency to innovation emphasis\n- However, mischaracterizes the 2022 baseline by claiming explicit revenue segmentation when ground truth says there were no specific revenue figures\n\n(3) MULTI-HOP REASONING:\n- The reasoning structure is sound: comparing 2022 approach to 2024 approach\n- However, the synthesis is flawed because the 2022 characterization is inaccurate\n- The conclusion about the shift is directionally correct but built on a partially false premise\n\n(4) SEMANTIC ALIGNMENT:\n- The core insight about moving from 'passive acknowledgment to positioning Air Max as a key innovation driver' aligns with ground truth\n- The phrase 'continued lack of standalone financial metrics' is accurate and matches ground truth\n- However, the claim about 2022 'granular product-line revenue breakdown' contradicts the ground truth statement that no specific revenue figures were disclosed\n\nThe answer demonstrates understanding of the general trend but contains a critical factual error regarding 2022 reporting that undermines the accuracy of the comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 583,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "\nComcast (CMCSA) – the parent that *introduces* Epic Universe – has been investing in the Orlando project since at least 2023, when its 2023 10‑K noted that “capital expenditures increased related to the development of Epic Universe in Orlando,” signalling a concrete outlay tied to that park’s construction. In the 2024 filing the company’s outlook no longer cites a specific dollar amount for Epic Universe; instead it says capital spending will “continue investment in existing and new attractions at our Universal theme parks, **including Epic Universe**,” placing the project within a broader theme‑park growth strategy that depends on factors such as new attractions, competition and regulatory conditions. Thus, the evolution is from a 2023‑specific capex increase linked to Epic Universe’s development to a 2024‑wide‑ranging commitment to fund the park (and other Universal attractions) without a disclosed exact figure, reflecting a shift from a defined investment to a strategic, future‑oriented priority.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Comcast's Epic Universe capital expenditure strategy from 2023 to 2024, capturing the key shift from specific disclosed figures to broader strategic commitments. However, there are notable quantitative gaps and one significant omission:\n\nSTRENGTHS:\n1. Correctly identifies that 2023 saw specific capex increases tied to Epic Universe development\n2. Accurately notes that 2024 filings lack specific dollar amounts for Epic Universe alone\n3. Properly characterizes the strategic shift from defined investment to broader theme park growth strategy\n4. Correctly identifies Comcast/CMCSA as the parent company\n5. Sound multi-hop reasoning connecting 2023 and 2024 filings\n6. Appropriate semantic framing of the evolution\n\nWEAKNESSES:\n1. CRITICAL OMISSION: The ground truth specifically mentions \"$8.2 billion allocated to Connectivity & Platforms\" in 2023, which included Epic Universe investments. The LLM answer completely omits this specific figure, which is a key quantitative anchor point for the 2023 baseline.\n2. The LLM answer does not provide the $8.2 billion figure that was disclosed in 2023, making the quantitative comparison incomplete\n3. While the LLM correctly notes the absence of specific 2024 figures, it doesn't establish the 2023 baseline with the actual number provided in the ground truth\n\nMULTI-HOP REASONING:\nThe reasoning is sound in connecting 2023 and 2024 filings and synthesizing the strategic evolution. However, the failure to include the $8.2 billion figure undermines the completeness of the quantitative comparison.\n\nSEMANTIC EQUIVALENCE:\nThe qualitative description of the evolution is semantically equivalent to the ground truth, but the missing quantitative data represents a material gap in answering a question that specifically asks about \"specific investment amounts.\"\n\nJUSTIFICATION:\nThe answer demonstrates good understanding of the strategic shift but fails on the quantitative accuracy dimension by omitting the $8.2 billion figure that was explicitly mentioned in the ground truth as a key data point for 2023. This is a significant oversight for a question that specifically asks about \"specific investment amounts.\"",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 600,
        "total_tokens": 2086
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "\nBased on the 2022 Form 10‑K (Chunk 1) FedEx projected 11 ATR 72‑600F aircraft to be in service in 2023, with the type’s share falling to 6 airplanes in 2024 and remaining at 6 through 2025 before dropping to just 1 in 2026 – a total of 24 ATR 72‑600Fs planned over the outlook period. The 2023 filing (Chunk 2) revises that outlook, showing only 7 ATR 72‑600Fs slated for delivery in 2025 and 3 in 2026 (a total of 10 across the same future years), reflecting a clear reduction in FedEx’s utilization of the ATR 72‑600F in its updated fleet projections. This shift illustrates how the company’s dependence on the ATR 72‑600F evolved downward between the 2022 and 2023 planning horizons.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the key numbers and demonstrates sound multi-hop reasoning across the 2022 and 2023 filings. Verification of numbers: (1) 2022 projections: 11 for 2023, 6 for 2024, 6 for 2025, 1 for 2026 - all correct; (2) 2023 projections: 7 for 2025, 3 for 2026 - both correct. The LLM's calculation of totals (24 across the outlook period in 2022, 10 in 2023) is mathematically accurate. The reasoning correctly synthesizes the evolution between planning periods and identifies the downward trend in ATR 72-600F utilization. However, there is a minor issue with the framing: the LLM states the 2023 figures show \"only 7 ATR 72-600Fs slated for delivery in 2025 and 3 in 2026,\" which could be misinterpreted as new deliveries rather than projected fleet numbers. The ground truth presents these as fleet projections for those years, not necessarily new deliveries. Additionally, the LLM provides extra context about totals (24 and 10) that, while mathematically correct, goes slightly beyond what the ground truth explicitly states. The core answer is accurate and addresses the question comprehensively, showing clear understanding of the multi-hop synthesis required across two different filing years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Uses]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 345,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Nike’s estimated product‑return reserves continued to be recorded as a sales‑related reserve against revenue, but the methodology became more explicit. In the 2022 filing the company reported a $1.015 bn reserve (down from $1.077 bn in 2021) and an estimated inventory cost of $194 m for expected returns (down from $269 m), indicating a modest reduction in both the reserve balance and the expected return cost. The 2024 disclosure expands this approach, stating that Nike now estimates the “most likely amount” it will receive and records the anticipated reduction directly against revenue with an offsetting accrual, reflecting a more granular application of variable‑consideration guidance and a refined revenue‑recognition model.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains significant numerical inaccuracies that contradict the ground truth. (1) QUANTITATIVE ERRORS: The ground truth states the fiscal 2022 inventory cost for expected returns was $269 million. The LLM claims it was $194 million (down from $269 million in 2021), which is factually incorrect - the LLM has reversed the years and provided wrong numbers. The LLM also introduces $1.015 billion and $1.077 billion reserve figures that are not mentioned in the ground truth and appear to be fabricated or from incorrect sources. These numbers are not verified in the original answer. (2) INCOMPLETE SYNTHESIS: While the LLM correctly identifies that methodology became more explicit and mentions the 'most likely amount' language from fiscal 2024, it fails to accurately represent the fiscal 2022 baseline. The ground truth clearly states the $269 million figure was the fiscal 2022 amount, but the LLM misrepresents this. (3) MULTI-HOP REASONING FAILURE: The LLM attempts to synthesize information across years but does so incorrectly. It claims a 'modest reduction' from 2021 to 2022, but the ground truth does not provide 2021 comparison data for the inventory cost metric. (4) ENTITY/METRIC CONFUSION: The LLM conflates different reserve metrics (sales-related reserves vs. inventory cost for expected returns) without clear distinction, and introduces unexplained billion-dollar figures that muddy the analysis. (5) CORRECT ELEMENTS: The LLM does correctly identify that the methodology shifted toward 'most likely amount' estimation and that this reflects variable consideration guidance, which aligns with ground truth. However, these correct qualitative observations cannot overcome the fundamental numerical inaccuracies that undermine the entire answer's credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 492,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "\nThe 2022 plan projected 12 Cessna SkyCourier 408 deliveries for 2025, but the 2023 filing raises that outlook to 17 aircraft in 2025 (and keeps 14 scheduled for 2026), while the earlier “Total” rows show a growing share of the SkyCourier type relative to the other freighter models.  This upward revision—from 12 to 17 units for 2025 and a continued emphasis in later years—demonstrates that the company is increasingly banking on the Cessna SkyCourier 408 as a strategic cornerstone of its future cargo fleet.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key numerical changes: 2022 projection of 12 SkyCourier 408s for 2025, increased to 17 in the 2023 plan, with 14 scheduled for 2026. All numbers are accurate and match the ground truth. The multi-hop synthesis across 2022 and 2023 filings is sound. However, there are minor differences in interpretation and emphasis: (1) The LLM characterizes the change as demonstrating the company is 'increasingly banking on' the aircraft as a 'strategic cornerstone,' which is somewhat stronger language than the ground truth's more measured assessment of 'short-term increase in strategic reliance, followed by moderate decline.' (2) The ground truth explicitly notes the reduction from 17 (2025) to 14 (2026) as a 'recalibration of fleet strategy,' whereas the LLM emphasizes the upward revision and 'continued emphasis' without fully highlighting the subsequent planned reduction. (3) The LLM mentions 'growing share of the SkyCourier type relative to other freighter models' but doesn't provide specific comparative data, making this claim somewhat unsupported. The core facts are correct, but the interpretation leans slightly more optimistic than the ground truth's more balanced assessment of the strategic implications. The answer adequately addresses the question but with slightly different emphasis on what the changes indicate about strategic reliance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 387,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "\nMastercard’s real‑time account‑based payments platform— the product it offers and that it also provides to its network—has grown from the 13 markets in which it was operating at the end of 2023 to a globally scaled infrastructure that in 2024 continues to route the majority of its switched transactions (including nearly all cross‑border flows) through a distributed, peer‑to‑peer architecture with intelligent real‑time routing, fraud‑scoring, tokenization and other value‑added services.  The 2024 financial statements confirm that the company was still implementing and operating this infrastructure, maintaining the same multi‑layered security program that relies on third‑party assessments, benchmarking, EMV‑based standards and close collaboration with issuers, acquirers, merchants and governments to protect the ecosystem.  Consequently, the platform’s operational scale has broadened—covering more jurisdictions and handling a larger share of transaction volume—while its integrated security capabilities have been preserved and reinforced across the payments ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the question. STRENGTHS: (1) Correctly identifies the 13 markets baseline from 2023, matching the ground truth exactly. (2) Accurately describes the distributed, peer-to-peer architecture with intelligent routing, fraud-scoring, and tokenization capabilities. (3) Properly synthesizes the multi-hop information about evolution from 2023 to 2024, showing expansion in scale and reinforcement of security. (4) Correctly identifies the multi-layered security approach with third-party assessments, EMV standards, and ecosystem partnerships. (5) Appropriately characterizes the shift toward 'more secure, simple, and smart' solutions through the lens of preserved and reinforced security capabilities. MINOR CONSIDERATIONS: (1) The LLM answer adds some interpretive detail about 'majority of switched transactions' and 'nearly all cross-border flows' that, while plausible and consistent with Mastercard's business model, goes slightly beyond what the ground truth explicitly states. However, this represents reasonable inference rather than factual error. (2) The phrasing 'the product it offers and that it also provides to its network' is somewhat awkward but semantically accurate. (3) The answer could have been slightly more explicit about the 'simple' dimension of the security evolution, though it is implied through the 'smart' and 'secure' framing. QUANTITATIVE VERIFICATION: The key numeric claim (13 markets in 2023) is correct and properly positioned as the baseline for comparison. No calculations are required or presented, so quantitative accuracy is high. MULTI-HOP REASONING: The answer successfully synthesizes information across the 2023-2024 timeframe and correctly identifies both operational scale expansion and security capability reinforcement as the two key dimensions of evolution. The reasoning is sound and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Provides]- ORG",
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 522,
        "total_tokens": 2011
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "\nNike’s foreign‑exchange forwards and options moved from a relatively large, largely **non‑hedge** position in 2022 (5 M of non‑designated derivatives and a total derivative liability of $180 M) to a much more **hedge‑focused** book by 2024, where non‑designated derivatives fell to just 5 M and total derivative liabilities dropped to $151 M; this reduction reflects a tighter hedging strategy and a lower exposure of financial liabilities.  The 2022 filing also shows a $30 M net reclassification of gains from accumulated other‑comprehensive income into earnings—demonstrating that the hedging program directly impacted income—while the 2024 balance‑sheet data (110 M accrued liability and 5 M deferred tax for designated forwards/options) confirms that the remaining derivatives are now primarily designated as hedging instruments, underscoring the evolution toward a more controlled, liability‑reducing hedging approach.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR DISCREPANCIES IDENTIFIED: (1) QUANTITATIVE ERRORS - The LLM cites a 2022 total derivative liability of $180M and 2024 total of $151M, but the ground truth does not mention these figures. The ground truth specifically states 2024 liabilities were $110M (accrued) + $5M (deferred tax) = $115M total, not $151M. The LLM's $180M 2022 figure is not corroborated by ground truth. (2) MISSING KEY DATA - The ground truth explicitly mentions a 2022 net gain of $8 million after tax impacting revenues, cost of sales, and other income categories. The LLM completely omits this critical 2022 metric. (3) INCORRECT CHARACTERIZATION - The LLM describes 2022 as having a 'large, largely non-hedge position' with '$180M derivative liability,' but ground truth shows a net GAIN of $8M in 2022, suggesting a different financial position than the LLM portrays. (4) PARTIAL ACCURACY - The LLM correctly identifies that 2024 shows $110M accrued liability and $5M deferred tax, matching ground truth exactly. The LLM also correctly notes a shift toward more designated hedging instruments. (5) UNSUPPORTED CLAIMS - The LLM references a '$30M net reclassification of gains from accumulated other comprehensive income' in 2022, which is not mentioned in the ground truth. The LLM also cites specific non-designated derivative amounts ($5M) that are not verified in the provided ground truth. (6) MULTI-HOP REASONING - While the LLM attempts to synthesize evolution between years, it does so with incorrect baseline numbers for 2022, undermining the validity of the comparison. The core narrative about evolution toward hedge-focused strategy is reasonable but built on unverified/incorrect data. VERDICT: The answer contains some correct elements (2024 balance sheet figures) but is fundamentally flawed due to incorrect 2022 figures, missing the $8M 2022 gain, and introducing unverified numbers that contradict or diverge from ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 520,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "\nIn 2022 Puffs was listed under the **Baby Care** sub‑category (baby wipes, taped diapers and pants) within the **Baby, Feminine & Family Care** segment, which accounted for 25 % of P&G’s net sales and 23 % of its earnings that year. By 2023 the classification shifted to the **Family Care** sub‑category (paper towels, tissues and toilet paper) – still part of the Baby, Feminine & Family Care segment, but now representing 24 % of net sales and 25 % of earnings – indicating that Puffs moved from a primary baby‑product role to a broader family‑household positioning while remaining a P&G‑produced brand (PG → Puffs → PG).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains a fundamental contradiction to the ground truth. The ground truth states that in 2022, Puffs was categorized under Family Care (Paper Towels, Tissues, Toilet Paper), and remained in Family Care in 2023. However, the LLM claims Puffs was in Baby Care in 2022 and shifted to Family Care in 2023 - this is the opposite of what actually occurred. The LLM incorrectly states Puffs was initially classified as a baby product (baby wipes, taped diapers, pants) when it is actually a tissue/paper product. The LLM also adds unverified segment performance metrics (25% of net sales/23% earnings in 2022; 24% net sales/25% earnings in 2023) that are not mentioned in the ground truth and cannot be verified. The statement about 'simplification or consolidation' in the ground truth is also misrepresented - the LLM interprets this as a product category shift rather than a reporting format change. The parenthetical '(PG → Puffs → PG)' appears to be fabricated reasoning not supported by the source material. While the LLM correctly identifies the segment name (Baby, Feminine & Family Care) and the correct 2023 classification (Family Care with paper towels, tissues, toilet paper), the core claim about the 2022 classification is completely inverted, making this answer fundamentally incorrect on the primary question being asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 381,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "\nBetween 2022 and 2023 Tampax remained in the **Baby, Feminine & Family Care** segment of P&G, but its sub‑category was updated from “Feminine Care” (2022) to “Feminine Care (Adult Incontinence, Menstrual Care)” (2023), sharpening its focus on menstrual products; the brand **Tampax Bounty** continued to appear as a major brand in both years.  The segment’s financial weight shifted slightly—net‑sales share fell from 25 % to 24 % while earnings rose from 23 % to 25 %—but Tampax’s placement and product line stayed consistent across the two filings.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) FACTUAL ERRORS ON CATEGORIZATION: The LLM claims Tampax moved from 'Feminine Care' to 'Feminine Care (Adult Incontinence, Menstrual Care)' in 2023. The ground truth states it moved from 'Feminine Care' to 'Menstrual Care' - these are fundamentally different categorizations. The LLM's version incorrectly adds 'Adult Incontinence' which is not mentioned in the ground truth and represents a different product category entirely. (2) INCORRECT BRAND REFERENCE: The LLM mentions 'Tampax Bounty' as a major brand in both years. This appears to be a confusion - Bounty is a paper towel brand under P&G, not a Tampax product line. This is a significant factual error. (3) UNSUPPORTED FINANCIAL METRICS: The LLM provides specific percentages (net-sales share fell from 25% to 24%, earnings rose from 23% to 25%) that are NOT present in the ground truth answer. These numbers cannot be verified and appear to be hallucinated. (4) PARTIAL CORRECTNESS: The LLM correctly identifies that Tampax remained in the 'Baby, Feminine & Family Care' segment and that there was a sub-category refinement between 2022 and 2023. (5) MISSING KEY INSIGHT: The ground truth emphasizes that the 2023 change represented 'more focused positioning' and 'separating it from general Family Care items' - the LLM mentions sharpening focus but mischaracterizes the actual categorization change. The core multi-hop reasoning about segment evolution is partially present but undermined by factual errors in the specific categorization details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 423,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "\nOracle has kept Oracle Engineered Systems as a modest but strategically‑important hardware offering—its share of total revenue stayed roughly 6 percent in both fiscal 2023 and the prior fiscal year—while explicitly stating that it will continue to invest in research and development to improve existing engineered products and launch new ones, even though the hardware segment carries lower operating margins than the cloud and license businesses and its quarterly revenues are difficult to predict.  This shows a stable revenue contribution from Engineered Systems that is paired with an ongoing commitment to R&D to sustain and evolve the portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) The LLM claims hardware represented '6 percent in both fiscal 2023 and the prior fiscal year' - this directly contradicts the ground truth which explicitly states '6% of total revenues' was noted in fiscal 2023 but 'a figure not specified in 2022.' The LLM incorrectly asserts the 6% figure applied to both years when the ground truth clearly indicates it was only specified for 2023. (2) The LLM introduces unsupported claims about 'lower operating margins than the cloud and license businesses' and 'quarterly revenues are difficult to predict' - these details do not appear in the ground truth and represent fabrication. (3) The LLM states the revenue contribution 'stayed roughly 6 percent' which is factually incorrect based on the ground truth's explicit statement that 2022 figures were not specified. WHAT WAS CORRECT: (1) The LLM correctly identifies the R&D investment commitment for fiscal 2023. (2) The characterization of Oracle Engineered Systems as 'strategically important' aligns with the ground truth's framing. (3) The general acknowledgment of the hardware segment's positioning is appropriate. MULTI-HOP REASONING: The LLM failed to properly synthesize the key evolution between fiscal years - the ground truth emphasizes that fiscal 2023 introduced MORE EXPLICIT strategic positioning and forward-looking R&D plans, whereas fiscal 2022 was more transactional in nature (point-of-sale revenue recognition). The LLM missed this important distinction about the EVOLUTION of strategy. The claim of stability ('stayed roughly 6 percent') is a fundamental misreading of the comparative data across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 449,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "\nIn the 2022 filing (Chunk 1) Honeywell disclosed $1,105 of private‑fund investments measured at NAV within its U.S. pension assets, whereas the 2023 Non‑U.S. plan data (Chunk 2) show a total private‑fund holding of $115, split as $41 classified at Level 2 and $74 at Level 3 of the fair‑value hierarchy, with an additional $8 still carried at NAV; this shift reflects a move from a single NAV‑based figure to a detailed hierarchy classification. The overall Non‑U.S. plan assets total $5,549 (Chunk 2), confirming that the $115 private‑fund position is a distinct, increasingly granular component of the portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key numeric values ($1,105M for 2022 U.S. plans, $115M total for 2023 Non-U.S. plans, with $41M at Level 2 and $74M at Level 3). The answer appropriately recognizes the shift from NAV-based measurement to detailed fair value hierarchy classification. The multi-hop synthesis across 2022 and 2023 data is logically sound, and the contextual observation about the move from single NAV figures to granular hierarchy classification is insightful.\n\nWEAKNESSES: (1) CRITICAL ENTITY CONFUSION: The original answer explicitly states the 2022 figure is for 'U.S. pension plans' while the 2023 figure is for 'Non-U.S. pension plans.' The LLM correctly identifies this distinction in the body of the answer ('2022 filing...U.S. pension assets' vs '2023 Non-U.S. plan data'), but this is a crucial detail that should be emphasized more clearly given the question specifically asks about 'Non-U.S. pension plans.' (2) INCOMPLETE COMPARISON: The question asks how the investment 'evolved between 2022 and 2023,' but the LLM doesn't explicitly note that we're comparing different plan types (U.S. in 2022 vs. Non-U.S. in 2023), which limits the ability to draw direct year-over-year conclusions. (3) MINOR ADDITION: The LLM mentions an additional '$8 still carried at NAV' which is not mentioned in the ground truth answer, suggesting possible additional detail from the source material that may or may not be relevant to the core question.\n\nQUANTITATIVE VERIFICATION: All dollar amounts are correct ($1,105M, $115M, $41M, $74M). The hierarchy split ($41M + $74M = $115M) is mathematically accurate. The mention of $8M at NAV is an addition not in the ground truth but doesn't contradict it.\n\nMULTI-HOP REASONING: The answer successfully synthesizes information across two different years and two different plan types, correctly identifying the shift in measurement methodology and classification approach. However, the answer could be clearer about the limitation that these represent different plan populations, making direct comparison challenging.\n\nSEMANTIC EQUIVALENCE: The core message aligns with the ground truth—significant decrease in overall allocation and shift in classification—though the LLM's framing emphasizes the methodological shift (NAV to hierarchy) rather than the substantive decrease in U.S. plan holdings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 631,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "\nThe 2014 USD Notes were still outstanding and classified as short‑term debt on the consolidated balance sheet as of December 31 2023 (Chunk 1).  In April 2024 a $1 billion principal tranche of those notes matured and was repaid, a payment that contributed to the $1.3 billion rise in financing‑related cash outflows reported for 2024 (Chunk 2).  After that retirement the company’s debt profile shifted to new 2024 USD Notes, bringing total outstanding debt to $18.2 billion with the next near‑term maturity of $750 million scheduled for March 2025 (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and addresses the core question well. STRENGTHS: (1) Correctly identifies the 2014 USD Notes as short-term debt in 2023 with April 2024 maturity; (2) Accurately states the $1 billion principal repayment in April 2024; (3) Properly synthesizes the multi-hop information showing the evolution from 2023 to 2024; (4) All key numbers are correct ($1 billion repayment, $1.3 billion financing cash outflows, $18.2 billion total debt, $750 million March 2025 maturity). MINOR ISSUES: (1) The answer goes slightly beyond the original question scope by discussing the shift to 2024 USD Notes and future maturities, which while relevant context, wasn't explicitly asked for; (2) The connection between the $1 billion repayment and the $1.3 billion financing cash outflow increase is stated but not fully explained (the $1.3B figure includes other financing activities beyond just the 2014 USD Notes repayment). QUANTITATIVE VERIFICATION: All numbers check out - $1 billion principal amount is correct, April 2024 maturity date is correct, $18.2 billion total debt figure appears accurate based on context, $750 million March 2025 maturity is stated correctly. The multi-hop reasoning correctly connects 2023 classification to 2024 repayment and subsequent debt profile changes. The answer demonstrates sound synthesis across multiple data points and time periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 387,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "\nThe Officer Indemnification Agreement has been disclosed unchanged in both Lowe’s 2022 10‑K (Exhibit 10.31) and 2024 10‑K (Exhibit 10.23), indicating that the core indemnification terms governing senior officers have been retained from the 2019 filing without revision through 2024. At the same time, the 2022‑2024 filings show an evolution in related governance documents—most notably the 2022 amendment and restatement of the Severance Plan for Senior Officers (Exhibit 10.28) and the introduction of new 2022‑2023 Performance Share Unit and Stock Option agreements (Exhibits 10.27, 10.29‑10.31)—demonstrating that while the indemnification policy itself remains stable, Lowe’s continuously updates complementary executive compensation and risk‑mitigation arrangements. This pattern reflects a governance approach that preserves a consistent safety net for officers while iteratively refining other risk‑management provisions to align with emerging best practices and regulatory expectations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN EXHIBIT NUMBERS: The LLM provides incorrect exhibit numbers that directly contradict the ground truth. Ground truth states the Officer Indemnification Agreement was filed as Exhibit 10.43 (2019) and refiled in 2022 and 2024 10-Ks. The LLM claims it appears as Exhibit 10.31 in 2022 and Exhibit 10.23 in 2024—these numbers are factually incorrect and represent a fundamental error in document identification. This is a severe accuracy problem since exhibit numbers are precise, verifiable data points from SEC filings. PARTIAL CREDIT FOR CORE CONCEPT: The LLM correctly identifies that the Officer Indemnification Agreement remained unchanged between 2022 and 2024, which aligns with the ground truth's main finding. The interpretation about governance continuity and stable executive risk management is semantically sound. PROBLEMATIC EXPANSION: The LLM introduces additional information about amendments to the Severance Plan (Exhibit 10.28) and new Performance Share Unit/Stock Option agreements (Exhibits 10.27, 10.29-10.31) that are not mentioned in the ground truth. While this additional context about complementary governance documents could be accurate, it goes beyond what the ground truth establishes and introduces unverified exhibit numbers. This creates confusion about what actually evolved versus what remained stable. REASONING QUALITY: The multi-hop reasoning about how stable indemnification policies coexist with evolving compensation structures is logically sound and demonstrates good analytical thinking. However, this reasoning is built on a foundation of incorrect exhibit citations, undermining its credibility. MISSING ELEMENT: The LLM does not mention the original April 2, 2019 filing date that anchors the ground truth's narrative about continuity from 2019 through 2024. OVERALL ASSESSMENT: The answer demonstrates understanding of the conceptual framework (stability in indemnification, evolution in related governance) but fails on the critical metric of factual accuracy regarding exhibit numbers and document identification. In SEC filing analysis, precise exhibit citations are essential verification points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 579,
        "total_tokens": 1985
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "\nIn the 2022 10‑K, P&G disclosed that Always Discreet captured > 10 % of the adult‑incontinence market in the key markets where it competes, highlighting its role as a meaningful player in that category. The 2023 filing still lists Always Discreet under the Feminine‑Care sub‑category of the Baby, Feminine & Family Care segment, confirming that P&G continues to treat the brand as a core part of its portfolio and that its adult‑incontinence market‑share position remains anchored around the same > 10 % level, i.e., a stable/category‑leadership stance across the two filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains a critical factual error that contradicts the ground truth. The original answer explicitly states that in the 2023 filing, 'no specific market share figure is provided for the brand,' representing a shift away from quantified disclosure. However, the LLM answer incorrectly claims that the 2023 filing shows the market share position 'remains anchored around the same > 10% level' and describes this as 'stable/category-leadership stance.' This is a fundamental misreading of the source material. The LLM appears to have inferred or assumed continuity of the >10% market share figure from 2022 into 2023, when the ground truth indicates the opposite—that P&G stopped disclosing this specific metric in 2023. The LLM correctly identifies: (1) the 2022 >10% market share figure, (2) the brand's listing in Feminine Care/Baby, Feminine & Family Care segment in 2023, and (3) that Always Discreet remains a core brand. However, it fundamentally mischaracterizes the nature of the change between filings. The question asks about how market share and positioning 'changed,' and the correct answer is that the disclosure methodology changed (from specific to non-specific), not that the position remained stable. This represents a significant failure in multi-hop reasoning and synthesis across the two filings, as the LLM failed to recognize the absence of data in 2023 as meaningful information about a shift in disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 402,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "\nOracle’s Engineered Systems have moved from being highlighted in 2022 as a core, pre‑integrated stack that can be deployed on‑premise, in OCI or as a hybrid cloud offering — a differentiator that underpins its cloud‑infrastructure narrative — to being treated in 2023 as just one component of the broader hardware business, which now accounts for a stable ~6 % of total revenue, is sold primarily through indirect channels, carries lower margins, and is accounted for as a combined performance obligation whose revenue is recognized ratably together with support contracts. This evolution reflects a strategic shift: Engineered Systems are no longer positioned as a standalone hardware product line but as an enabler of Oracle’s cloud transformation, with their sales tightly linked to OCI consumption, hybrid‑cloud deployments, and the renewal of support contracts that drive the hardware business’s overall revenue volatility. The mutual KG relationship (ORCL → Oracle Engineered Systems → ORCL) underscores that these systems both generate revenue for Oracle and are a product of its portfolio, reinforcing their evolving role in the cloud narrative.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Oracle's Engineered Systems evolution between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 6% revenue figure for hardware business in both fiscal 2023 and 2024, matching ground truth; (2) Accurately captures the strategic shift from standalone positioning to integrated hardware business component; (3) Properly synthesizes multi-hop information about combined performance obligations, indirect sales channels, and lower margins; (4) Effectively connects Engineered Systems to cloud transformation narrative and hybrid deployment strategies; (5) Correctly identifies the evolution from pre-integrated technical solutions to foundational cloud enablers. MINOR ISSUES: (1) The phrase 'revenue volatility' in the LLM answer is not explicitly mentioned in the ground truth, though it's a reasonable inference about lower-margin hardware business dynamics; (2) The reference to 'mutual KG relationship (ORCL → Oracle Engineered Systems → ORCL)' appears to be metadata commentary rather than substantive analysis and is somewhat tangential to the core question, though not incorrect; (3) The LLM emphasizes 'sales tightly linked to OCI consumption' which is a reasonable inference but not explicitly stated in the ground truth. QUANTITATIVE VERIFICATION: The 6% figure is correctly cited and properly contextualized. The answer maintains semantic equivalence with ground truth while adding interpretive depth about the strategic implications. The multi-hop reasoning correctly synthesizes information about product positioning, revenue classification, margin characteristics, and cloud strategy alignment. Overall, the answer is factually sound with minor interpretive additions that don't contradict the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1572,
        "completion_tokens": 482,
        "total_tokens": 2054
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "\nBoth the 2022 and 2023 Form 10‑K filings disclose that the 2020 Stock Plan is the successor to the 2011 Stock Plan, reflecting the same compliance relationship captured by the KG pattern ORG → ACCOUNTING_POLICY ← ORG. The 2022 filing goes further by noting that 5,530,106 shares previously authorized under the 2011 Plan were made available for grant under the 2020 Plan, a specific detail that is omitted in the 2023 filing, showing a streamlined presentation of the relationship between the two plans across the two years.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and captures the key evolution between the 2022 and 2023 10-K filings. STRENGTHS: (1) The specific share count of 5,530,106 is accurately cited and correctly identified as appearing in 2022 but omitted in 2023. (2) The numeric value is precisely correct. (3) The core finding that the 2022 filing included the carry-forward detail while 2023 omitted it is accurate. (4) The characterization of this as a 'streamlined presentation' is a reasonable interpretation of the shift. MINOR WEAKNESSES: (1) The LLM introduces language about 'successor to the 2011 Stock Plan' and 'compliance relationship' that goes slightly beyond what the ground truth explicitly states. The ground truth focuses on the carry-forward of shares as the specific disclosure detail, not on a general 'successor' relationship. (2) The reference to 'KG pattern ORG → ACCOUNTING_POLICY ← ORG' appears to be metadata/technical language that, while not incorrect, is not directly relevant to answering the substantive question about disclosure evolution. (3) The ground truth emphasizes that the 2023 filing omitted 'this specific reference to the 2011 Stock Plan and the carry-forward of shares,' suggesting the relationship itself was de-emphasized, whereas the LLM states both filings 'disclose that the 2020 Stock Plan is the successor to the 2011 Stock Plan,' which could be interpreted as overstating the consistency between the two years. However, this is a subtle distinction and the LLM's core answer remains accurate. The answer correctly identifies the key evolution and provides the accurate share count, making it a strong response with only minor interpretive nuances.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Complies_With]-> ACCOUNTING_POLICY <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 461,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "\nHoneywell’s NAV‑measured private‑fund holdings edged up from **$1.244 bn in 2022 to $1.265 bn in 2023**, and their share of the total fair‑value portfolio rose from roughly **6 % to 7.6 %** even as total fair‑value assets fell from **$20.56 bn to $16.59 bn**.  The modest growth in private‑fund exposure—combined with a slight dip in direct private‑investment dollars but a notable increase in commingled‑fund allocations—signals that Honeywell is shifting capital toward alternative‑investment vehicles, underscoring a strategic priority on longer‑term, potentially higher‑return deployments.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy with correct core financial figures and sound multi-hop reasoning. STRENGTHS: (1) Private fund amounts are correct: $1.244 bn (2022) and $1.265 bn (2023) match ground truth exactly; (2) The 1.7% increase calculation is implicitly correct ($1.265/$1.244 = 1.017); (3) Multi-hop synthesis is excellent—the answer goes beyond ground truth by adding contextual data about portfolio share (6% to 7.6%), total fair-value assets ($20.56 bn to $16.59 bn), and distinguishing between direct private investments vs. commingled funds; (4) Strategic interpretation aligns with ground truth (stable allocation, alternative investment focus, higher-return positioning); (5) Semantic equivalence is strong—'NAV-measured' and 'bn' are appropriate technical terminology. MINOR CONCERNS: (1) The LLM introduces additional metrics (portfolio share percentages, total asset figures, commingled fund data) not explicitly in the ground truth answer. While these appear factually accurate and enhance the analysis, they represent information synthesis beyond the original answer's scope. This is generally positive for comprehensiveness but slightly extends beyond what was verified in the ground truth; (2) The statement about 'slight dip in direct private-investment dollars' introduces a comparative claim not explicitly addressed in the ground truth, though it appears logically consistent with the data presented. VERIFICATION: The core numbers ($1.244 bn → $1.265 bn) are precisely correct, the percentage increase is accurate, and the strategic interpretation about maintaining/expanding alternative investment exposure matches the ground truth conclusion. The answer successfully addresses both parts of the multi-part question (evolution of allocation strategy and implications for capital deployment priorities).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 499,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "\nBetween 2023 and 2024 the Company’s 10‑K filings repeatedly state that **no shares of Class B‑2 Common Stock were outstanding before the Class B‑1 exchange offer**, and that any Class B‑2 shares are only relevant through their conversion into Class A stock using rounded conversion rates that can be diluted when the U.S. litigation escrow account is funded (see Note 5). The 2023 filing notes that the as‑converted Class B‑1 and B‑2 shares total less than one million and that conversion rates are rounded to the tenth decimal, while the 2024 filing reiterates the pre‑offer outstanding status (referencing Note 15) and adds that a Series A preferred‑stock issuance occurred in July 2024, further shaping the capital structure but leaving Class B‑2 still unissued until the exchange offer. Thus, the status of Class B‑2 remained “not outstanding” across both years, with its disclosure tied to conversion mechanics and dilution effects relative to Class B‑1 and Class A shares.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the core evolution of Class B-2 Common Stock disclosure between 2023 and 2024, with several strengths and minor weaknesses: STRENGTHS: (1) Correctly identifies the key consistent theme across both years: no shares of Class B-2 were outstanding before the Class B-1 exchange offer; (2) Accurately captures the conversion mechanics tied to Class A stock with rounded conversion rates; (3) Properly notes the U.S. litigation escrow account dilution impact; (4) Correctly identifies the shift in disclosure emphasis between years; (5) Appropriately references Note 5 and Note 15 as sources. WEAKNESSES: (1) The mention of 'as-converted Class B-1 and B-2 shares total less than one million' introduces a specific quantitative claim not clearly verified in the ground truth, which only mentions conversion mechanics without this specific number; (2) The reference to 'Series A preferred-stock issuance occurred in July 2024' appears to introduce information not present in the ground truth answer, potentially conflating different capital structure events; (3) The phrase 'leaving Class B-2 still unissued until the exchange offer' is slightly imprecise—the ground truth indicates no shares were outstanding PRIOR to the exchange offer, not that they remain unissued until it occurs. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 filings and correctly identifies the relationship between Class B-2, Class B-1, and Class A shares. The comparison of disclosure changes between years is sound. SEMANTIC EQUIVALENCE: The core message aligns with ground truth—Class B-2 status remained consistent (not outstanding) but disclosure emphasis shifted, with conversion mechanics being the primary focus. The answer captures the essence of reduced emphasis on active role in capital structure. The introduction of the Series A preferred stock detail, while potentially accurate in the actual filings, goes beyond what the ground truth explicitly states and could represent either additional context or potential conflation of separate events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Holds]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 569,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "\nThe Target Circle loyalty program generated **$89 million** of deferred revenue recorded in Accrued and Other Current Liabilities (net of estimated breakage) in fiscal 2022, but by fiscal 2024 that liability had fallen to **$19 million** (as of Feb 1 2025) – a reduction of roughly 78 %.  \nThis sharp decline, disclosed in the same “Target Circle Program” product introduced by Target, shows that the company is scaling back the program’s reward‑and‑discount structure and reallocating revenue recognition toward other streams such as Target Circle 360 membership and third‑party marketplace commissions.  \nConsequently, the evolution indicates a strategic shift away from the original, revenue‑heavy Circle model toward a more limited or partnership‑focused loyalty offering.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN FACTUAL ACCURACY: The LLM answer contains significant factual errors that fundamentally misrepresent the ground truth data. (1) QUANTITATIVE ACCURACY FAILURES: The LLM states the 2024 deferred revenue was $19 million (as of Feb 1 2025), but the ground truth clearly indicates that in 2024 (as of February 3, 2024), the deferred revenue was $117 million. The $19 million figure is from February 1, 2025, not 2024. The LLM conflates two different time periods and presents incorrect data for the 2022-2024 comparison requested. The LLM also calculates a 78% reduction from $89M to $19M, but this calculation compares 2022 to 2025, not 2022 to 2024 as the question asks. (2) INCOMPLETE MULTI-HOP SYNTHESIS: The question specifically asks about changes between 2022 and 2024. The ground truth shows: 2022 = $89M, 2024 = $117M (an increase of $28M or 31.5%). The LLM completely misses this intermediate 2024 data point and instead jumps to 2025 data, failing to properly address the 2022-2024 comparison. (3) ENTITY AND TIMELINE ERRORS: The LLM incorrectly identifies the 2024 figure as $19 million when it should be $117 million. This is a fundamental factual error, not a wording difference. (4) REASONING FLAWS: The LLM's interpretation that the program is being 'scaled back' is based on comparing 2022 to 2025, not 2022 to 2024. The actual 2022-2024 trend shows growth ($89M to $117M), which contradicts the LLM's conclusion about strategic retreat. The LLM's narrative about 'scaling back' and 'reallocating revenue' is unsupported by the correct 2024 data. (5) WHAT WAS CORRECT: The LLM correctly identified the 2022 figure of $89 million and correctly named the Target Circle program. However, these correct elements are overshadowed by the critical errors in the 2024 data and the resulting misinterpretation of program evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 502,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "\nThe fair‑value of Netflix’s 4.375% Senior Notes rose from **$980 million on December 31 2022** to **$996 million on December 31 2023** (an $16 million increase), while the outstanding principal remained unchanged at **$1,000 million** in both years (Chunk 1 and Chunk 2). This modest appreciation—driven solely by market‑derived fair‑value movements rather than new issuance—suggests that investors perceived the notes as slightly more valuable, likely reflecting narrower credit spreads or a more favorable interest‑rate environment for fixed‑rate debt (KG: NFLX Has_Stake_In → 4.375% Senior Notes Discloses).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is highly accurate and well-reasoned. QUANTITATIVE VERIFICATION: All numbers are correct - fair value increased from $980 million (Dec 31, 2022) to $996 million (Dec 31, 2023), representing a $16 million increase (correctly calculated). Principal amount of $1,000 million is accurate for both years. ENTITY ACCURACY: Netflix, 4.375% Senior Notes, and fiscal years are all correctly identified. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across multiple data points (fair values from two different years, principal amounts, and market context). REASONING QUALITY: The interpretation is sound - the fair value moving closer to par ($996M vs $1,000M principal) does indicate improved investor perception or more favorable market conditions. The explanation about credit spreads and interest-rate environment is logical and appropriate. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth, with slightly more detailed explanation of the drivers (credit spreads, interest-rate environment). The ground truth states the change 'indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook' - the LLM answer provides similar interpretation with additional context about what drove the change. MINOR OBSERVATION: The LLM answer includes slightly more analytical depth than the ground truth (discussing credit spreads and interest-rate environment), which adds value without contradicting the original answer. All factual claims are verifiable and correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 448,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Visa’s equity structure added Class C common stock through the May 2024 exchange offer, where the company issued roughly **48 million Class C shares** (and about 120 million Class B‑2 shares) in return for tendered Class B‑1 shares – a relationship captured by the KG pattern **ORG (V) → FIN_INST (Class C Common Stock)** and **FIN_INST → ORG** indicating that the stock both issues and discloses Visa.  The 2024 balance‑sheet (Chunk 2) then shows only **10 shares of Class C common stock outstanding as of September 30 2024**, meaning the newly issued shares were largely offset by conversions or retirements, leaving a minimal net Class C balance despite the sizable issuance.  Thus, the equity structure evolved from essentially no Class C common stock pre‑2024 to a modest outstanding position after the exchange, with the Class C shares classified as a disclosed finite‑life equity instrument linked to Visa.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the May 2024 exchange offer involving Class C shares (~48 million issued), correctly notes the 10 shares outstanding as of September 30, 2024, and appropriately characterizes the evolution as a transition from minimal to modest Class C positions. The reasoning about conversions/retirements offsetting the issuance is sound and explains the discrepancy between issued and outstanding shares. The answer addresses both 2023 and 2024 periods as requested.\n\nCRITICAL ERRORS: (1) The LLM states the exchange involved \"roughly 48 million Class C shares\" and \"about 120 million Class B-2 shares\" but the ground truth specifies 241 million Class B-1 shares were tendered for approximately 48 million Class C shares - the LLM introduces Class B-2 shares which are not mentioned in the ground truth and provides no number for Class B-1 shares. (2) The LLM claims the Class C structure was \"essentially no Class C common stock pre-2024\" but the ground truth explicitly states that in 2023 there was an exchange offer resulting in Class C issuance - this is a temporal mischaracterization. The ground truth indicates active Class C movement in 2023, not a pre-2024 absence.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize the exchange offer mechanics and balance sheet positions, but the synthesis is partially flawed. It correctly connects the issuance event to the outstanding balance, but misidentifies the specific share classes involved in the exchange (introducing B-2 instead of B-1).\n\nQUANTITATIVE ISSUES: The 48 million Class C shares figure is correct, and the 10 shares outstanding is correct. However, the omission of the 241 million Class B-1 shares and the introduction of 120 million Class B-2 shares (unverified) represents significant quantitative inaccuracy in the exchange offer details.\n\nSEMANTIC ISSUES: The phrase \"essentially no Class C common stock pre-2024\" contradicts the ground truth's clear statement that Class C shares were issued in 2023. This is a material semantic error affecting the narrative of equity evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 563,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "\nIn 2022 Rough Plumbing was listed under Lowe’s **Building Products** segment within the merchandise division—a classification that appears in the 2022 10‑K when the company re‑characterized its net‑sales breakdown (Chunk 1).  \nBy 2024 the same category is highlighted in Lowe’s **Installed Sales** and **Protection‑Plan** sections, with dedicated installation services, a central selling team that handles quoting and customer support, and it is grouped with other service‑oriented lines such as Kitchen & Bath and Millwork (Chunk 2).  \nThis shift reflects a broader evolution from a pure product category to an integrated service offering, a change underscored by the 2024 discussion of seasonality and working‑capital planning that ties the growth of installed‑sales categories—including Rough Plumbing—to the company’s fiscal‑year performance (Chunk 2).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of Rough Plumbing from 2022 to 2024, accurately capturing the shift from a pure 'Building Products' classification to an integrated service offering with installation services and protection plans. The qualitative reasoning is sound and well-structured, demonstrating proper multi-hop synthesis across the 2022 and 2024 filings.\n\nSTRENGTHS:\n1. Correctly identifies 2022 classification as 'Building Products' within merchandise division\n2. Accurately describes 2024 integration into Installed Sales and Protection Plans\n3. Properly synthesizes the strategic shift from product to service-oriented approach\n4. Mentions relevant contextual details (central selling team, quoting, customer support)\n5. Appropriately references seasonality and working-capital planning implications\n6. Multi-hop reasoning is sound and logical\n\nWEAKNESSES:\n1. QUANTITATIVE OMISSION: The ground truth specifically mentions \"approximately 5% of total sales attributed to installed sales in 2024\" - the LLM answer completely omits this specific quantitative metric. This is a material omission for a financial question.\n2. The LLM answer references \"Chunk 1\" and \"Chunk 2\" which appear to be source citations rather than integrated narrative, making it slightly less polished than the ground truth\n3. No specific percentage or financial metric provided to substantiate the scale of the shift\n\nVERIFICATION:\n- 2022 classification: CORRECT (Building Products)\n- 2024 classification: CORRECT (Installed Sales and Protection Plans)\n- Strategic shift description: CORRECT\n- Missing quantitative data: The ~5% installed sales figure is absent, which is a notable gap in a financial analysis context\n\nThe answer demonstrates strong qualitative understanding and proper multi-hop synthesis but falls short on quantitative completeness by omitting the specific 5% metric mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 526,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "\nThe Class B‑2 common stock was **non‑existent in 2022 and 2023** filings but **first appears in the 2024 balance sheet with 77 million shares** (Chunk 1), marking its introduction after the Company’s Class B‑1 exchange offer (Chunk 2).  This newly created class—disclosed by V as the introducing party and reported as a disclosed financial instrument (KG: V → Class B‑2 → V)—signals that the Company added a distinct equity layer to its capital structure, likely to accommodate new investors or convertible securities and to provide greater flexibility in future financing and governance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "MAJOR FACTUAL ERRORS: The LLM answer contains a fundamental contradiction with the ground truth regarding the timeline and status of Class B-2 common stock. (1) TIMELINE ERROR: The LLM claims Class B-2 was 'non-existent in 2022 and 2023' and 'first appears in the 2024 balance sheet with 77 million shares.' However, the ground truth explicitly states that in 2023, Class B-2 common stock was 'newly introduced with 77 million shares outstanding.' This is a critical factual error - the 77 million shares existed in 2023, not first appearing in 2024. (2) QUANTITATIVE ACCURACY FAILURE: The LLM correctly identifies 77 million shares but places them in the wrong year (2024 instead of 2023), which is a significant dating error that undermines the entire answer. (3) INCOMPLETE SYNTHESIS: The LLM fails to capture the key evolution described in the ground truth: the transition FROM 77 million shares outstanding in 2023 TO zero shares outstanding by 2024 (prior to the Class B-1 exchange offer). This represents a critical multi-hop synthesis failure - the answer should show the progression/change between the two years, not just identify when shares first appeared. (4) MISSING STRATEGIC CONTEXT: The ground truth indicates a 'strategic shift where Class B-2 shares may have been replaced or restructured,' suggesting the shares were eliminated or converted. The LLM's narrative of 'newly created class' and 'added a distinct equity layer' contradicts the ground truth's indication of replacement/restructuring. (5) REASONING QUALITY: While the LLM attempts to explain the role in capital structure, it does so based on incorrect temporal placement and misses the actual transformation (introduction then elimination/restructuring). The multi-hop reasoning fails because it doesn't properly synthesize the 2023-to-2024 evolution that is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 504,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "\nTarget Circle is a product **offered by** TGT and **disclosed by** TGT (KG: ORG → Offers → PRODUCT ← Discloses ← ORG).  \nIn the 2024 filing the company reported **$117 million of deferred revenue** tied to the Circle program (recorded in accrued and other current liabilities as of Feb 3 2024), while the 2025 filing shows that figure fell to **$19 million** (as of Feb 1 2025).  \nThe ≈84 % drop in liability indicates that the financial obligation associated with the rewards program has sharply contracted—likely due to changes in redemption patterns, breakage estimates, or program redesign—signaling an evolution rather than continued expansion of Target Circle.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS: (1) The LLM answer introduces a 2025 filing with $19 million in deferred revenue, which is NOT mentioned in the ground truth or the original question. The question specifically asks about 2022-2024 changes only. (2) The ground truth states that in 2022, 'no specific liability figure was disclosed,' but the LLM answer does not address 2022 at all—it jumps directly to 2024 ($117M) and then adds unverified 2025 data ($19M). (3) The LLM calculates an ~84% drop from $117M to $19M, which is mathematically correct IF those numbers are accurate, but this calculation is based on data outside the question's scope (2022-2024). (4) The LLM's interpretation that the decline indicates 'evolution rather than continued expansion' contradicts the ground truth's finding that the $117M figure in 2024 'indicates substantial growth or expansion.' (5) The LLM fails to address the key 2022 baseline (no disclosed liability) which is essential to understanding the 2022-2024 change trajectory. WHAT WAS CORRECT: The $117M figure for February 3, 2024 is accurate per ground truth. The company identification (Target/TGT) is correct. MULTI-HOP REASONING: The LLM failed to properly synthesize the 2022-2024 comparison as requested. Instead, it introduced extraneous 2025 data and drew conclusions about program contraction that are not supported by the ground truth. The answer addresses a different time period (2024-2025) than what was asked (2022-2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 404,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 NVDA’s exposure to pollution‑limit regulations moved from a general warning that such rules could raise manufacturing, compliance and energy‑costs—and that limited water or power could curb customers’ data‑center expansion—to an explicit statement that new or proposed pollution limits may directly restrict the energy, water or land that data‑center operators can use, thereby throttling their ability to scale capacity and purchase NVDA’s products.  In both years the 10‑K notes that these regulatory constraints could impair customers’ data‑center growth, increase NVDA’s compliance expenses and create uncertainty for its operations, but the 2024 filing underscores a heightened concern about how energy‑, water‑ and land‑limiting rules could directly curtail the data‑center expansion that drives demand for its GPUs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of NVDA's pollution-limit concerns from 2023 to 2024. Both the original and LLM answers correctly identify that 2023 focused on cost increases (compliance, energy, capital expenditures) and potential supply chain impacts, while 2024 expanded to include explicit concerns about land and permitting constraints affecting customer data center expansion. The LLM answer adds helpful specificity by mentioning 'energy, water and land' constraints explicitly, which aligns with the ground truth's reference to 'land and permitting constraints.' (2) QUANTITATIVE ACCURACY: No specific numbers, dates, or calculations are required for this question. The temporal references (fiscal 2023 vs fiscal 2024) are correct. (3) ENTITY ACCURACY: NVDA is correctly identified throughout. The fiscal years are properly referenced. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two years and connects regulatory concerns to business impact (customer data center expansion → GPU demand). The logical progression from general cost concerns to specific operational constraints is sound. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth with slightly different wording. The ground truth mentions 'cost increases' and 'land and permitting constraints,' while the LLM specifies 'energy, water and land' constraints—this is a reasonable elaboration that doesn't contradict the ground truth. The LLM's emphasis on how these rules 'directly restrict' resources and 'throttle' capacity expansion is semantically equivalent to the ground truth's description of potential to 'impair customers' ability to expand.' Minor strength: The LLM answer provides slightly more operational detail about the mechanism of impact (energy, water, land specificity) which enhances clarity without introducing inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 540,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "\nThe Guaranteed Senior Notes were issued in November 2023 by the Company’s Japanese subsidiary for roughly $500 million at fixed rates of 1.400 %–2.120 % with maturities 2033‑2043 and were recorded as other long‑term debt measured at fair value using Level 3 inputs. In July 2024 the subsidiary repaid $77 million of principal, reducing the outstanding balance to about $423 million, and the fair‑value measurement remained on a Level 3 basis; this repayment contributed to the decline in the overall long‑term‑debt fair value from $5,738 million (2023) to $5,412 million (2024).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Verification of key facts: (1) Issuance details - correctly identifies November 2023 issuance by Japanese subsidiary for ~$500 million at 1.400%-2.120% fixed rates with 2033-2043 maturities; (2) Fair value measurement - correctly states Level 3 inputs used; (3) Repayment - accurately reports July 2024 repayment of $77 million, correctly calculating the remaining balance as approximately $423 million ($500M - $77M = $423M); (4) Long-term debt fair values - correctly cites $5,738 million (2023) and $5,412 million (2024), with accurate calculation of the decline ($5,738M - $5,412M = $326M reduction); (5) Multi-hop synthesis - properly connects the repayment to the overall debt fair value decline. The LLM answer provides additional helpful context (specific maturity dates 2033-2043, timing of repayment in July 2024, classification as 'other long-term debt') that enhances understanding without contradicting the ground truth. The only minor distinction is that the LLM explicitly calculates the post-repayment balance ($423M) while the original answer implies this through the overall debt reduction, but this is an enhancement rather than an error. All numbers are accurate, calculations are correct, and the multi-hop reasoning properly synthesizes information across issuance, repayment, and fair value changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 383,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "\nFrom 2022 to 2024 Netflix’s spending on streaming‑service improvements shifted from a $384 million rise in technology and development costs—driven by hiring to expand personnel and accelerate product enhancements—to a 2024 focus on cybersecurity governance, including the appointment of a VP of Security and Privacy Engineering, an enterprise‑wide risk‑quantification program, and board‑level oversight of cyber‑risk assessments, signaling that while the streaming product continues to be introduced by Netflix, the growing cyber‑risk exposure now poses a direct threat that could negatively impact the company’s financial condition.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively addresses the multi-hop question about Netflix's investment evolution from 2022 to 2024. STRENGTHS: (1) The $384 million figure is correctly cited and properly attributed to 2022 personnel-related costs. (2) The answer correctly identifies the shift from growth-oriented investment (headcount expansion for production/streaming improvements) to cybersecurity focus by 2024. (3) Multi-hop synthesis is sound: the answer connects personnel investment in 2022 with cybersecurity governance changes in 2024, showing the evolution of risk exposure. (4) Specific 2024 details are accurate (VP of Security and Privacy Engineering appointment, enterprise-wide risk programs, board-level oversight). (5) The semantic equivalence is strong - the answer conveys the same narrative arc as the ground truth: from production-focused hiring to mature service with cybersecurity emphasis. (6) The conclusion about cyber-risk posing a direct threat to financial condition aligns with the ground truth's mention of potential adverse effects on business operations and financial results. MINOR CONSIDERATIONS: (1) The LLM adds specific details about 'VP of Security and Privacy Engineering' and 'board-level oversight' that enhance the answer but aren't explicitly mentioned in the ground truth summary, though these are reasonable inferences from 2024 cybersecurity disclosures. (2) The phrasing 'technology and development costs' is slightly broader than the ground truth's 'personnel-related costs,' but this is semantically equivalent given the context. (3) The answer could have been slightly more explicit about the specific risks mentioned (unauthorized data releases, digital content theft), though it does reference 'cyber-risk exposure' and financial impact. Overall, the answer successfully synthesizes multi-year information and demonstrates accurate understanding of Netflix's strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 526,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "\nIn the 2023 filing (Chunk 1), BK disclosed the 2024 Form of Restricted Stock Unit Agreement (Exhibit 10.29) as an accounting policy it introduces, marking the initial rollout of a new RSU framework for executive compensation. The 2024 filing (Chunk 2) re‑issues that agreement as Exhibit 10.26, adds a 2025 RSU agreement (Exhibit 10.28), and restates the Executive Severance Plan (Exhibit 10.27), illustrating a deliberate lifecycle progression—replacing and updating the prior RSU form while expanding the equity‑compensation roadmap. This evolution, captured by the KG relationship where BK introduces an accounting policy that is later revised and re‑filed, reflects the company’s strategy of continuously refining RSU terms to align equity‑instrument lifecycle management with its executive compensation objectives.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures the core narrative of RSU agreement evolution between 2023 and 2024 filings, correctly identifying that: (1) the 2024 Form was newly introduced in 2023, (2) the 2025 Form was newly introduced in 2024, and (3) there is a lifecycle progression showing iterative updates. However, there are significant issues with quantitative accuracy and exhibit number verification. The LLM states the 2024 Form is 'Exhibit 10.29' in the 2023 filing and 'Exhibit 10.26' in the 2024 filing, but the ground truth does not provide these specific exhibit numbers for verification. The LLM also characterizes the 2024 Form as an 'accounting policy' which is semantically imprecise—it is an equity compensation instrument/agreement, not an accounting policy. The reference to 'KG relationship where BK introduces an accounting policy that is later revised and re‑filed' is conceptually muddled. The LLM correctly identifies the forward-looking strategy and annual update pattern, and appropriately notes the transition from 'Filed herewith' to 'Previously filed' status, though this is stated implicitly rather than explicitly. The answer demonstrates sound multi-hop reasoning by synthesizing information across two filing years and connecting the evolution to executive compensation strategy. The mention of the Executive Severance Plan restatement adds relevant context not explicitly in the ground truth but is reasonable inference. The main weaknesses are: (1) unverified exhibit numbers that may be incorrect, (2) imprecise terminology ('accounting policy'), and (3) lack of explicit reference to the 'Filed herewith' vs 'Previously filed' language that is central to the ground truth's analysis. The answer is directionally correct but contains enough precision errors to warrant a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1511,
        "completion_tokens": 490,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "\nThe $750 million 4.90% Senior Notes were issued by Huntington Bancshares in November 2023 as the third tranche of its senior‑notes offering, with a $3.4 million discount and a maturity date of April 15 2029 and semi‑annual interest payments starting April 15 2024; by the 2024 reporting dates (January 28 2024 and February 2 2025) the notes’ carrying amounts had been amortized to $743 million and $744 million, respectively, reflecting the discount‑amortization schedule.  Consequently, the notes remain an unsecured obligation of HD due on April 15 2029, with the 2024 carrying‑amount figures illustrating their evolution from the 2023 issuance to the current period.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with mostly correct information but contains some issues that prevent a higher score. STRENGTHS: (1) All key numbers are correct - $750 million principal, $3.4 million discount, April 15, 2029 maturity date, and the carrying amounts of $743 million (Jan 28, 2024) and $744 million (Feb 2, 2025) are accurate. (2) The semi-annual interest payment schedule starting April 15, 2024 is correctly stated. (3) The multi-hop synthesis across 2023 and 2024 is sound, showing the evolution from issuance to current period. (4) The explanation of amortization reflecting the discount is appropriate. WEAKNESSES: (1) The LLM incorrectly identifies the issuer as 'Huntington Bancshares' and uses ticker 'HD' - the ground truth does not specify the company name, and HD is Home Depot's ticker, not Huntington Bancshares. This is a significant entity error. (2) The reference to 'third tranche' is not mentioned in the ground truth and appears to be unsupported information. (3) The February 2, 2025 carrying amount of $744 million is provided by the LLM but not mentioned in the ground truth, which only references January 28, 2024. While this may be accurate, it goes beyond what the ground truth confirms. (4) Minor formatting issue: 'April 15 2029' should be 'April 15, 2029' (missing comma). QUANTITATIVE VERIFICATION: All dollar amounts and dates match ground truth where comparable. The carrying amount progression ($750M - $3.4M discount = ~$746.6M initial, declining to $743M) is logically consistent with amortization. MULTI-HOP REASONING: The answer correctly synthesizes information about the notes' evolution from 2023 issuance through 2024, showing understanding of how discount amortization affects carrying amounts over time. The main issue is the company identification error, which is a significant factual problem despite the financial details being correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 517,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "\nIn November 2023 the Japanese subsidiary issued four Guaranteed Senior Notes for roughly $500 million at fixed rates of 1.400%–2.120% with maturities spanning 2033‑2043 (Level‑3‑valued long‑term debt), and in July 2024 it repaid $77 million of principal on those notes, reducing the outstanding balance; the company also used cash on May 18 2024 to retire the $1 billion 2.750% Senior Note.  \n\nThese repayments, together with the broader refinancing of long‑term debt, drove the $10.764 billion net cash outflow reported in financing activities for 2024 and pushed the fair value of the company’s long‑term debt down to $5.412 billion from $5.738 billion in the prior year.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct core information about the Japanese subsidiary's Guaranteed Senior Notes. Verified correct: (1) Four notes issued in 2023 totaling ~$500 million at rates 1.400%-2.120% - matches ground truth exactly; (2) $77 million repayment in 2024 - correct; (3) Maturity dates 2033-2043 - reasonable and consistent with typical debt instruments. The answer goes beyond the ground truth by providing specific dates (November 2023 issuance, July 2024 repayment, May 18 2024 retirement of separate $1B note) and additional context about fair value changes ($5.738B to $5.412B) and financing cash outflows ($10.764B). These additional details appear factually sound and enhance the answer's completeness. Minor considerations: (1) The ground truth mentions 'proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity' - the LLM answer doesn't explicitly address this financing activity reference, though it does discuss the broader financing activities context; (2) The LLM introduces information about a separate $1B Senior Note retirement not mentioned in the ground truth, which while potentially accurate, slightly expands scope beyond the specific question about the Japanese subsidiary's Guaranteed Senior Notes. The multi-hop reasoning is sound - correctly synthesizing 2023 issuance data with 2024 repayment data and connecting to broader financial impacts. All numbers are accurate and properly formatted. The answer effectively addresses how the instruments 'evolved' between the two years by showing both the issuance and repayment activity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 452,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "\nFrom 2022 to 2023 the risk that competitors would introduce after‑market parts for DHR’s products remained a material negative factor for the company, as disclosed in both the 2022 and 2023 Form 10‑K filings.  The 2022 filing warned that such competition could “capture significant market share or lead to a decrease in market prices… resulting in an adverse effect on the Company’s business and financial statements,” while the 2023 filing explicitly notes that “competitors may also develop after‑market services and parts for our products which may detract from our sales,” underscoring an ongoing adverse impact on revenue and overall financial performance.  This evolution reflects a continued, and in 2023 more specifically articulated, threat that after‑market offerings by rivals could erode DHR’s market position and profitability.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant qualitative inaccuracies that undermine its overall correctness despite some factual elements being present. STRENGTHS: (1) Correctly identifies the risk as material and present in both 2022 and 2023 filings; (2) Appropriately cites the 2022 language about market share capture and price decreases; (3) Correctly references the 2023 language about after-market parts detracting from sales; (4) Properly identifies DHR as the company in question; (5) Dates and company references are accurate. CRITICAL WEAKNESSES: (1) The LLM fundamentally mischaracterizes the evolution of the risk. The ground truth indicates a SHIFT in framing from 2022 to 2023 - from a 'direct threat' to being 'Impacted By' competition, suggesting a de-emphasis or recalibration. The LLM instead describes a CONTINUATION or even INTENSIFICATION ('in 2023 more specifically articulated'), which is the opposite of what occurred; (2) The LLM fails to capture the key contextual shift: in 2023, the risk was presented as one of several external pressures (cost containment, managed care, government reimbursement) rather than a primary threat. This broader contextualization is central to understanding the evolution but is completely absent from the LLM answer; (3) The LLM's conclusion that the threat became 'more specifically articulated' contradicts the ground truth's finding of relative de-emphasis; (4) The LLM misses the strategic recalibration aspect - the company's perception of severity changed, not just the articulation. MULTI-HOP REASONING: The LLM failed to synthesize the comparative analysis across years correctly. It identified individual facts but drew the wrong conclusion about how the risk evolved. The question specifically asks about evolution/change, and the LLM provided the opposite narrative. This is a fundamental failure in multi-hop reasoning despite having access to the correct source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 522,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "\nFrom 2022 to 2024 Netflix moved beyond modest, region‑specific price hikes—documented in 2022 as the driver of higher average revenue per paying member—to a 2024 strategy that added a lower‑priced ad‑supported subscription, tightened household‑sharing enforcement, and expanded the service with games and live programming (as disclosed in the 2024 filing). These changes were intended to offset slowing membership growth, intense competition and macro‑economic pressures that threatened revenue despite fixed content costs.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies Netflix's strategic evolution from 2022 to 2024, including the introduction of ad-supported plans, household-sharing enforcement, and expansion into games/live programming. It accurately captures the business challenges (slowing membership growth, competition, macroeconomic pressures) and the strategic intent behind these changes. The reasoning about moving from price hikes to a multi-tiered strategy is sound and well-articulated.\n\nWEAKNESSES - QUANTITATIVE: The LLM answer provides NO specific numbers from the ground truth, which is a significant omission. The ground truth includes concrete metrics: 19% revenue increase in 2022, 11% growth in average paying memberships, 7% rise in average monthly revenue per membership, and critically, a 50% drop in paid net membership additions. These quantitative details are essential to understanding the severity of the challenges Netflix faced and are completely absent from the LLM response.\n\nWEAKNESSES - COMPLETENESS: While the LLM mentions the strategic responses (ad-supported plans, household-sharing enforcement, games, live programming), it fails to provide the specific 2022 performance metrics that contextualize why these changes were necessary. The ground truth emphasizes that despite revenue growth in 2022, paid net membership additions dropped 50% year-over-year—a critical data point showing the underlying problem. The LLM doesn't quantify the severity of the membership acquisition challenge.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across the 2022-2024 period and connects strategic changes to business challenges. However, it misses the important temporal progression: 2022 showed early warning signs (declining net additions despite revenue growth), which then prompted the 2024 strategic pivot. The ground truth shows this causal chain more explicitly.\n\nSPECIFIC GAPS: (1) No mention of the 50% drop in paid net membership additions in 2022, which is the key metric showing the problem; (2) No quantification of revenue growth or membership metrics; (3) Missing acknowledgment of macroeconomic conditions and consumer pricing sensitivity as explicitly stated in ground truth; (4) The phrase 'fixed content costs' in the LLM answer is not supported by the ground truth and may be misleading.\n\nSCORING JUSTIFICATION: Correctness score of 6 reflects that while the directional strategy and business logic are correct, the answer lacks critical quantitative support and omits key performance metrics that are central to understanding Netflix's challenges. The answer would score higher (8-9) if it included the specific percentages and membership addition figures from 2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 720,
        "total_tokens": 2084
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "\nBoeing’s handling of in‑orbit incentive payments shifted markedly from 2022 to 2023, moving from a generic warning that such payments are “at risk” if a satellite fails to meet performance criteria for up to 15 years (2022 filing) to a concrete financial‑recognition policy that ties the fees to the construction‑period revenue and explicitly notes that non‑performance can trigger customer refunds and material charges (2023 filing).  The 2023 Form 10‑K further quantifies the exposure by linking in‑orbit incentives to the same fixed‑price and cost‑type contracts that now generate the bulk of its defense revenue and by reporting $1.585 billion of additional reach‑forward losses on its key development programs, underscoring a heightened risk of loss and a more rigorous accounting of the net‑present‑value of these fees.  Thus, the evolution reflects a transition from describing the regulatory‑risk relationship to embedding the incentive payments within Boeing’s broader fixed‑price contracting framework and recognizing both the revenue and the associated financial risk in its reported results.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of the key evolution in Boeing's approach to in-orbit incentive payments between 2022 and 2023. STRENGTHS: (1) Correctly cites the $1.585 billion figure for additional losses on fixed-price development programs (matches ground truth's $1,585 million - acceptable format variation); (2) Accurately identifies the 15-year performance criteria window mentioned in the original answer; (3) Properly synthesizes the multi-hop information showing progression from 2022 risk acknowledgment to 2023 quantification and detailed revenue recognition practices; (4) Correctly identifies the shift from generic warnings to concrete financial recognition policies; (5) Appropriately references the fixed-price development programs context. MINOR WEAKNESSES: (1) The LLM answer mentions 'customer refunds and material charges' as triggers for non-performance, which is not explicitly stated in the ground truth - this appears to be an inference or addition not directly supported by the original answer; (2) The phrase 'regulatory-risk relationship' in the LLM answer is somewhat vague and not clearly grounded in the ground truth's specific mention of 'program cancellations or failure to meet performance criteria'; (3) The answer could have been more explicit about the specific programs mentioned (Commercial Crew, KC-46A Tanker, VC-25B) though this is a minor omission. QUANTITATIVE VERIFICATION: The $1.585 billion figure is correctly stated (ground truth shows $1,585 million - these are equivalent). The 15-year timeframe is accurately cited. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2023 filings, correctly identifying the evolution in disclosure and accounting practices. The connection between revenue recognition during construction period and performance-based risk is properly established. SEMANTIC EQUIVALENCE: The core message matches the ground truth - Boeing moved from general risk acknowledgment to specific quantification and detailed revenue recognition tied to performance criteria.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> REGULATORY_REQUIREMENT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1556,
        "completion_tokens": 567,
        "total_tokens": 2123
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the company moved from merely posting the Directors’ Code of Conduct on its site and stating an intent to disclose any amendments or waivers (Chunk 1) to explicitly including the Code in the set of governance documents that are “made available on our website” alongside other corporate‑governance materials in the 2024 Form 10‑K (Chunk 2).  This shift reflects a deliberate increase in transparency—while the 2023 disclosure was a provisional posting with a forward‑looking statement about future updates, the 2024 filing treats the Code as a standard, readily accessible component of BNY Mellon’s public governance disclosures.  Consequently, investors can now locate the Directors’ Code of Conduct more predictably on the corporate website as part of the company’s regular, disclosed governance package.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer fundamentally misrepresents the direction and nature of the evolution described in the ground truth. Ground truth states the 2024 disclosure was LESS direct (shift from specific URL to general reference), while the LLM claims the 2024 disclosure represents an INCREASE in transparency and more predictable access. This is a semantic inversion of the actual finding. SPECIFIC PROBLEMS: (1) The LLM states investors can 'now locate the Directors' Code of Conduct more predictably' in 2024, but ground truth explicitly says the 2024 approach is 'less direct' and represents a 'streamlined but less direct approach to public access.' (2) The LLM characterizes 2023 as 'merely posting' with 'provisional posting' language, when ground truth shows 2023 had MORE explicit disclosure (specific URL provided). (3) The LLM frames 2024 as treating the Code as 'a standard, readily accessible component,' but ground truth indicates it became part of a 'broader list' with 'more consolidated and implicit reference'—suggesting reduced prominence, not increased accessibility. (4) The LLM's conclusion that this reflects 'deliberate increase in transparency' directly contradicts ground truth's assessment of a shift toward 'less direct' access. WHAT WAS CORRECT: The LLM correctly identifies that both years involved posting on the website, correctly names BNY Mellon, correctly identifies the years (2023 vs 2024), and correctly references the Form 10-K. However, these correct elements are embedded in an fundamentally inverted interpretation of the evolution. The answer demonstrates a failure in qualitative reasoning about the comparative accessibility and directness of disclosure between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 471,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "\nIn 2022 Mobileye Drive™ was launched as the core self‑driving stack for commercial Robotaxi services and the first consumer L4 design win (Geely), being deployed in Germany and Tel Aviv through partnerships with Udelv, Transdev and Moovit and positioned as a scalable REM‑enabled platform while Intel (INTC) continued to supply the Drive™ product to Mobileye (the KG link INTC → Mobileye Drive™ ← INTC). By 2023 the deployment strategy broadened: Mobileye Drive™ became the baseline for the eyes‑off/hands‑off Mobileye Chauffeur consumer AV and is now being supplied to transportation‑network companies, public‑transit operators and AV‑ready vehicle platforms, often bundled with Moovit’s mobility‑intelligence service for fleet and shared‑vehicle MaaS roll‑outs. This evolution reflects a shift from a pilot‑grade robotaxi system to a versatile, fleet‑oriented autonomous‑driving solution across multiple markets, with Intel’s ongoing supply underscoring the bidirectional relationship that fuels both the 2022 and 2023 deployments.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key facts from both 2022 and 2023: (1) 2022 launch of Mobileye Drive™ as SAE L4 system, (2) partnerships with Udelv, Transdev, and Moovit, (3) first consumer L4 design win with Geely, (4) 2023 evolution toward transportation network companies and public transit operators, (5) bundling with Moovit's mobility service, (6) shift toward fleet deployment and MaaS ecosystems. The temporal evolution narrative is sound and addresses the core question.\n\nWEAKNESSES AND ERRORS: (1) The LLM introduces unsupported details not in the ground truth: mentions of 'Germany and Tel Aviv' deployments, 'eyes-off/hands-off Mobileye Chauffeur consumer AV' as a 2023 product, and 'pilot-grade robotaxi system' characterization. (2) The Intel (INTC) supply relationship discussion is tangential and confusing - the ground truth does not mention Intel supplying Drive™ to Mobileye or a 'bidirectional relationship.' This appears to be an inference or hallucination not supported by the knowledge graph. (3) The phrase 'REM-enabled platform' is mentioned without context or support from ground truth. (4) The answer conflates some details: Moovit was mentioned as a 2022 partnership in the LLM answer but the ground truth only explicitly mentions Moovit bundling in 2023.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the evolution across 2022-2023 and identifies the shift from initial commercial partnerships to a more defined go-to-market strategy. However, the addition of unsupported details (Intel supply chain, specific geographies, Chauffeur product) suggests the model went beyond the knowledge graph.\n\nFACTUAL ACCURACY: Core facts are correct (partnerships, design wins, strategic shift), but the introduction of unverified details reduces confidence. The quantitative accuracy is high for what is stated, but qualitative accuracy suffers from the inclusion of information not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Launches]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 525,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "\nThe Tower Preferred Interests originally consisted of a $1.5 bn Class A‑1 series paying a 5.0% distribution and a $4.5 bn Class A‑2 series paying 4.75%, both reset every five years (Chunk 1). In August 2024 AT&T amended the 2019 Tower preferred interests, converting them to a Fixed‑Rate Class A (5.90% distribution) and a Floating‑Rate Class A (SOFR + 250 bps, potentially $525 m by 2028) with a staged five‑year transition, resetting the rate in 2024 and making the fixed portion callable in November 2029 and the floating portion callable at any time (Chunk 2). These revised interests are now recorded in “Noncontrolling interest,” can be redeemed if distributions are missed, and are linked to AT&T through the ORG‑[Can_Call]->FIN_INST relationship, a pattern also evident in the Telco LLC and PR Holdings preferred structures (Chunk 1 & 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of the key structural evolution of Tower Preferred Interests from 2022 to 2024. STRENGTHS: (1) All numeric values are correct: $1.5bn Class A-1 at 5.0%, $4.5bn Class A-2 at 4.75%, the 5.90% fixed rate, and SOFR + 250 bps floating rate. (2) Dates are accurate: August 2024 amendment, November 2029 callable date for fixed portion. (3) The multi-hop synthesis is sound, correctly connecting the 2022 structure (two series with reset provisions) to the 2024 amendments (conversion to fixed and floating rate interests). (4) The answer captures the key evolution: from two separate series with periodic resets to a unified structure with fixed/floating components and staged transition. (5) Additional contextual details about redemption provisions, noncontrolling interest classification, and callable dates add relevant depth. MINOR WEAKNESSES: (1) The mention of '$525m by 2028' for the floating portion is not explicitly confirmed in the ground truth, though it appears to be a reasonable inference about the staged transition amount. (2) The reference to 'ORG-[Can_Call]->FIN_INST relationship' and comparison to Telco LLC and PR Holdings structures, while potentially accurate, goes slightly beyond the specific ground truth answer which focuses solely on Tower Preferred Interests evolution. (3) The ground truth emphasizes that distributions 'reset every five years' for the original 2022 structure, which the LLM captures but could have been more explicit about the 2024 reset timing. Overall, the answer correctly addresses the core question about structural and rate evolution with accurate numbers and sound reasoning, with only minor additions that slightly exceed the ground truth scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Can_Call]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 483,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "\nThe Balanced Index Fund—disclosed by BA and in which BA invests—continues to be allocated roughly 60 % equities and 40 % debt securities and is valued using a Level 1 market‑price approach; therefore, the unrealized gains/(losses) for its Level 3 holdings improved sharply from 2022 to 2023, moving from a combined net loss of about $41 million at year‑end 2022 (corporate –$16 m, mortgage‑backed –$11 m, municipal –$14 m, real‑asset –$1 m) to a net gain of roughly $11 million at year‑end 2023 (corporate $2 m, mortgage‑backed $6 m, other fixed‑income $3 m), reflecting a clear evolution in the fund’s Level 3 performance over the period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM answer introduces numbers NOT in the ground truth. Ground truth shows only 2 categories of Level 3 assets (corporate fixed income and mortgage-backed/asset-backed), with 2022 losses of ($16)M and ($11)M respectively, totaling ($27)M. The LLM adds municipal ($14)M and real-asset ($1)M for 2022 (totaling $41M claimed) and 'other fixed-income $3M' for 2023 - these categories are NOT mentioned in the ground truth. The ground truth 2023 gains total $8M ($2M + $6M), not $11M as claimed. (2) CALCULATION ERROR - The LLM calculates 2022 net loss as $41M and 2023 net gain as $11M, but these numbers appear fabricated or from a different source than the ground truth. The actual improvement from ground truth is from ($27)M loss to $8M gain, a $35M swing, not the $52M swing the LLM implies. (3) ENTITY CONFUSION - The LLM references 'BA' (Boeing) as the company, but the ground truth does not specify the company name, only discussing 'the company' and 'Balanced Index Fund.' This may be correct but cannot be verified against ground truth. (4) PARTIAL CORRECTNESS - The LLM correctly identifies the 60/40 equity/debt allocation for both years and correctly notes the shift to Level 1 market approach valuation methodology. The directional statement about improvement from losses to gains is correct. (5) MISSING CONTEXT - The LLM fails to note that the ground truth specifically mentions these are 'Level 3 assets still held at year-end,' which is an important qualifier. CONCLUSION: While the LLM captures the directional trend (losses to gains) and the allocation percentages correctly, it introduces significant fabricated numbers that do not match the ground truth, making the answer substantially incorrect on quantitative grounds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 487,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "\nBNY Mellon’s forward‑looking statements moved from a generic reference to “accounting developments” in the 2023 filing—where they were listed among many other uncertainties—to a far more explicit and detailed focus in the 2024 filing, which isolates “accounting developments” together with regulatory, technology, market and economic trends and ties them directly to impacts on performance results, fee revenue, net‑interest income, capital ratios and effective tax rate.  This evolution signals that accounting‑standard changes are no longer a peripheral risk but a core driver of the firm’s strategic priorities, shaping decisions on capital returns, expense management, technology investment and overall business outlook.  The knowledge‑graph relationship — BK → Accounting Developments ← Guides_On BK—captures that the company’s disclosed accounting policy not only informs but actively steers its strategic agenda, underscoring the growing influence of accounting standards on BNY Mellon’s forward strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution from 2023 to 2024, recognizing that BNY Mellon expanded its language around accounting developments from generic references to more explicit and integrated treatment. The answer appropriately captures the shift toward viewing accounting developments as strategically significant rather than peripheral. The mention of specific business metrics (capital ratios, effective tax rate, fee revenue, net-interest income) and strategic decisions (capital returns, expense management) aligns with the ground truth's observation about concrete business decisions. WEAKNESSES: (1) The LLM introduces specific financial metrics (capital ratios, effective tax rate, fee revenue, net-interest income) that are NOT mentioned in the original ground truth answer. While these may be accurate to the actual filings, they represent information beyond what the knowledge graph provided, creating potential factual claims that cannot be verified against the ground truth. (2) The LLM references a 'knowledge-graph relationship — BK → Accounting Developments ← Guides_On BK' which appears to be meta-commentary about the knowledge graph structure itself rather than substantive analysis of the filing content. This is somewhat tangential and not present in the original answer. (3) The original answer specifically mentions the 2024 inclusion of 'capital plans including dividends and repurchases' and 'efficiency savings' as concrete examples—the LLM generalizes these as 'capital returns' and 'expense management' which is semantically similar but less precise. (4) The original answer notes the 2023 language was 'without specific elaboration' while the LLM doesn't explicitly capture this distinction. MULTI-HOP REASONING: The LLM successfully synthesizes the evolution across two years and connects it to strategic implications, matching the ground truth's approach. However, the introduction of unverified specific metrics weakens confidence in the synthesis. QUANTITATIVE ACCURACY: No specific numbers or calculations are present in either answer, so this dimension is less critical. The dates (2023, 2024) are correct in both. OVERALL ASSESSMENT: The answer demonstrates solid understanding of the directional change and strategic implications, but introduces specific claims not supported by the ground truth, which creates uncertainty about factual accuracy despite the core narrative being sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Guides_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 652,
        "total_tokens": 2126
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "\nIn 2022 HD used surveys, a digital engagement platform and DEI programs (Chunk 1) to **positively** shape Associate Experience and boost emotional commitment. By 2023, however, the evolving store‑safety and cybersecurity risks detailed in Chunk 2—such as rising shrink, data‑breach threats, and unsafe store conditions—can **negatively** affect associate morale, retention and trust, directly undermining the gains from the prior‑year engagement initiatives. The knowledge‑graph relationship (HD → Associate Experience [Positively_Impacts] and Associate Experience ← [Negatively_Impacts] HD) captures this dual influence, showing that the 2023 risk evolution may offset the 2022 engagement‑focused improvements.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the multi-hop synthesis required. STRENGTHS: (1) Correctly identifies 2022 engagement initiatives (surveys, digital engagement platform, recognition programs) matching ground truth; (2) Accurately captures the shift to 2023 risks (store shrink, organized retail crime, cybersecurity threats); (3) Properly synthesizes the negative impact on associate morale, retention, and trust; (4) Correctly frames the comparison showing 2023 risks potentially undermining 2022 gains; (5) Uses appropriate temporal framing ('prior-year engagement initiatives'). MINOR ISSUES: (1) The LLM mentions 'DEI programs' in reference to 2022 initiatives, while the ground truth specifically mentions 'recognition programs' - this is a slight deviation though both could be part of engagement initiatives; (2) The LLM references 'unsafe store conditions' as a 2023 risk, while ground truth emphasizes 'store shrink' and 'organized retail crime' more explicitly - the connection to store safety is present but less precisely articulated; (3) The specific statistic about 'four out of five associates were emotionally committed' from ground truth is not mentioned, though this is a minor omission that doesn't affect the core answer. QUANTITATIVE ACCURACY: No specific numbers or calculations are required in this qualitative question, so this scores high. QUALITATIVE ACCURACY: The reasoning correctly identifies the positive-to-negative shift and the causal relationship between 2022 initiatives and 2023 risks. The knowledge graph notation used is appropriate. CONTEXTUAL RELEVANCE: The answer directly addresses the comparison requested and explains the potential impact mechanism clearly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> CONCEPT <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 469,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "\nThe learning curve moved from a largely qualitative risk in 2022—where Boeing (BA) warned that a steeper‑than‑expected curve could force cuts to the accounting quantity or production rates, generate additional losses and higher abnormal production costs, and exacerbate delivery delays—into a quantifiable component of the 2023 estimation process that is reviewed each quarter; in 2023 a 1 % swing in estimated gross‑margin percentages would change operating earnings by roughly $330 million, making the curve a direct driver of program profitability and of the risk‑management decisions needed to keep near‑break‑even programs (767, 777X, 787) from slipping into earnings charges.  This evolution reflects the same BA ↔ Learning Curve relationship captured in the KG triplets, with the curve now explicitly tied to margin‑impact calculations and proactive risk mitigation.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the learning curve's evolution from 2022 to 2023 and correctly captures the core transformation from risk factor to integrated cost estimation component. The answer effectively synthesizes multi-hop information across years and connects the learning curve to program profitability and risk management.\n\nSTRENGTHS:\n1. Correctly identifies the 2022 framing as a qualitative risk with potential for additional losses and abnormal production costs\n2. Accurately describes the 2023 shift to quantifiable, quarterly-reviewed component\n3. Properly identifies specific programs (767, 777X, 787) as near-break-even programs vulnerable to earnings charges\n4. Demonstrates sophisticated understanding of the relationship between learning curve estimation and margin impact\n5. Correctly synthesizes the connection between learning curve management and proactive risk mitigation\n6. Semantic equivalence is strong: 'steeper-than-expected curve' aligns with 'production complexities, rework, and delays'\n\nWEAKNESSES/CONCERNS:\n1. QUANTITATIVE ISSUE: The LLM introduces a specific metric ('1% swing in estimated gross-margin percentages would change operating earnings by roughly $330 million') that is NOT present in the ground truth answer. While this may be factually accurate from the source documents, it represents information beyond what the knowledge graph triplets captured and cannot be verified against the provided ground truth. This is a minor concern as it adds specificity rather than contradicting the ground truth.\n2. The $330 million figure cannot be verified against the original answer, creating uncertainty about its accuracy\n3. Minor: The answer is more detailed and technical than the ground truth, which could indicate either superior sourcing or potential over-specification\n\nMULTI-HOP REASONING:\nThe answer successfully synthesizes information across:\n- Two fiscal years (2022 vs 2023)\n- Multiple programs (767, 777X, 787)\n- Risk management framework\n- Cost estimation processes\n- Profitability metrics\nThe reasoning chain is logical and well-constructed.\n\nNUMERIC VERIFICATION:\nThe only numeric claim ($330 million) cannot be verified against the ground truth provided. The percentages and program names are accurate. No calculation errors detected in the reasoning presented.\n\nSCORE JUSTIFICATION:\nThe answer merits 8/10 because it captures the essential evolution accurately and demonstrates sophisticated multi-hop reasoning, but introduces unverified quantitative details that, while potentially correct, go beyond the ground truth baseline and create minor uncertainty about source accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 710,
        "total_tokens": 2110
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "\nBoth the 2023 BK 10‑K (page 12, item 9B‑b) and the 2024 BK 10‑K (page 12, item 9B‑b) disclose that certain officers and directors elect to participate in the Dividend Reinvestment Plan (along with the employee‑stock‑purchase and 401(k) plans) and may elect to have shares withheld to cover withholding taxes or the exercise price of awards—arrangements that can satisfy the affirmative‑defense conditions of Rule 10b5‑1 or constitute non‑Rule 10b5‑1 trading. The language is essentially identical in the two filings, indicating no material change in how the plan is treated or disclosed with respect to officer/director participation and related trading provisions.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR IN CORE FINDING: The LLM answer directly contradicts the ground truth on the fundamental question being asked. The ground truth explicitly states that there WAS a material change between 2023 and 2024 filings: the 2024 filing OMITTED the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements that was present in 2023. The LLM answer claims 'the language is essentially identical in the two filings, indicating no material change,' which is factually incorrect according to the knowledge graph. The LLM correctly identifies the location (page 12, item 9B-b) and correctly notes that both years mention officer/director participation in the Dividend Reinvestment Plan alongside employee stock purchase and 401(k) plans. However, the LLM fails to recognize the key evolution: the simplification/standardization of disclosure in 2024 that removed the earlier specificity regarding Rule 10b5-1 and non-Rule 10b5-1 trading frameworks. This is a fundamental misreading of the comparative analysis required by the multi-hop question. The quantitative accuracy is reasonable (correct page numbers, correct plan names), but the qualitative accuracy is severely compromised because the LLM reached the opposite conclusion from the ground truth regarding whether disclosure changed between years. The answer fails to address the core requirement of the question: identifying HOW the treatment/disclosure evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 398,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "\nFrom fiscal 2021 to fiscal 2023, The Home Depot moved from a $2.6 billion capital‑expenditure push to build a broadly integrated digital‑physical platform (Chunk 1) to a more refined, data‑driven approach that tailors the shopping experience to each customer’s intent and store location, refines and optimizes product assortments and store‑space productivity, and expands service‑focused investments such as additional rental and installation locations and better technology (Chunk 2).  These changes—enhanced merchandising‑information tools, deeper supplier collaboration, and targeted visual‑merchandising and space‑productivity upgrades—represent the evolution of its interconnected shopping experience from a general infrastructure investment to a personalized, location‑specific offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive understanding of The Home Depot's evolution in interconnected shopping experience from fiscal 2021 to fiscal 2023. QUANTITATIVE ACCURACY: The $2.6 billion capital expenditure figure for fiscal 2021 is correctly cited and matches the ground truth. The numeric data is accurate with no calculation errors. ENTITY ACCURACY: All entities are correctly identified - The Home Depot, fiscal 2021, fiscal 2023, and relevant metrics (capital expenditures, merchandising tools, customer intent, location-based personalization). COMPLETENESS: The answer addresses both parts of the multi-part question: (1) how investment evolved (from $2.6B general infrastructure to refined data-driven approach) and (2) specific changes made (enhanced merchandising IT tools, location/intent-based tailoring, supplier collaboration, visual merchandising, space productivity, rental/installation expansion). MULTI-HOP REASONING: The answer successfully synthesizes information across fiscal years and connects the evolution narrative - showing progression from broad platform investment to personalized, location-specific offerings. The reasoning is sound and logical. SEMANTIC EQUIVALENCE: The LLM answer conveys the same core information as the ground truth while providing additional relevant context (supplier collaboration, rental/installation locations, visual merchandising). The characterization of the shift from \"general investment in interconnectedness\" to \"refined, data-driven personalization strategy\" is semantically equivalent to the ground truth's description. MINOR CONSIDERATIONS: The LLM answer includes slightly more detail than the ground truth (mentioning rental/installation locations, supplier collaboration, visual merchandising), but these additions are consistent with the evolution narrative and enhance rather than contradict the answer. The answer maintains factual accuracy while providing a more comprehensive picture of the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> CONCEPT <-[Builds]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 543,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "\nBetween 2022 and 2023 DHR sharply raised its capital‑investment program for Aldevron, projecting roughly **$1.5 billion of capex in 2022**—up from $1.3 billion in 2021 and driven by the need to expand manufacturing capacity for COVID‑19‑related testing and biopharma products that stemmed from the **Aldevron acquisition** (the 2021‑2022 10‑K notes that the incremental spend was “primarily to support customer demand … and to address increased COVID‑19 related demand” and that the 2021 financing cash inflows of **$1.3 billion** were “used to fund a portion of the Aldevron Acquisition”).  The 2021 grants of **$568 million** (with $41 million offsetting capex) and the $9.56 billion net cash consideration shown in the 2023 balance sheet (reflected in Aldevron’s $6.1 billion goodwill and $3.5 billion other intangible assets) demonstrate that DHR’s acquisition‑related outlays remained large and were financed through commercial‑paper and debt issuances, while the ongoing integration is evident in the continued goodwill and intangible‑asset balances reported for Aldevron in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer addresses the core question about DHR's financial relationship with Aldevron between 2022-2023, but contains several significant quantitative errors and unsupported claims that undermine its accuracy.\n\nCORRECT ELEMENTS:\n- Correctly identifies ~$1.5 billion capex projection for 2022\n- Correctly cites $9.56 billion (or $9,561 million) net cash consideration paid to Aldevron\n- Correctly identifies the acquisition occurred in 2021-2022\n- Correctly notes the transition from capital investment to consolidated asset integration\n- Appropriately synthesizes the multi-hop relationship evolution\n\nSIGNIFICANT ERRORS:\n1. UNSUPPORTED CLAIMS: The LLM introduces specific figures ($1.3 billion in 2021, $568 million grants, $41 million offset, $6.1 billion goodwill, $3.5 billion intangible assets) that are NOT present in the ground truth answer. These appear to be fabricated or sourced from unstated documents.\n2. QUANTITATIVE INCONSISTENCY: The claim that \"$1.5 billion of capex in 2022—up from $1.3 billion in 2021\" cannot be verified against the ground truth, which only mentions the 2022 figure.\n3. UNSUPPORTED DETAIL: References to \"COVID-19-related testing\" and specific financing mechanisms (commercial paper, debt issuances) are not mentioned in the ground truth.\n4. GOODWILL/INTANGIBLE BREAKDOWN: The specific allocation of $9.56B into $6.1B goodwill and $3.5B intangibles ($6.1B + $3.5B = $9.6B, which roughly matches but the breakdown is not in ground truth).\n\nMULTI-HOP REASONING:\nThe LLM correctly synthesizes the evolution from capital investment phase (2022) to post-acquisition integration (2023), matching the ground truth's characterization of the transition. However, the introduction of unverified details weakens the reasoning chain.\n\nSEMANTIC EQUIVALENCE:\nThe core semantic message aligns with ground truth: DHR increased capital commitment for Aldevron manufacturing in 2022, then completed the acquisition with $9.56B consideration in 2023, integrating it as a consolidated asset. However, the additional unsupported details create factual inaccuracies.\n\nJUSTIFICATION:\nWhile the LLM captures the essential narrative and key figures, the introduction of specific numbers not in the ground truth (2021 capex, grant amounts, goodwill/intangible breakdown) represents a significant quantitative accuracy problem. The answer appears to conflate or extrapolate from multiple sources without clear attribution. This is particularly problematic for financial analysis where precision is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 676,
        "total_tokens": 2130
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "\nFrom the 2022 filing Telco LLC had $2,000 of non‑convertible cumulative preferred interests (Class A‑1) paying a 4.25 % annual distribution with a seven‑year reset and a call option after seven years; the 2023 expansion (noted in the 2024 filing) added $5,250 of Class A‑2/A‑3 interests, so that by the end of 2024 the total preferred‑interest balance had risen to $7,250 and the new series carried a 6.85 % annual distribution that resets on Nov 1 2027 and every seven years thereafter, while the original Class A‑1 remains at 4.25 % with its seven‑year reset. Both series are subject to quarterly declarations, redemption on missed payments or rating‑trigger events, and can be called after the respective seven‑year periods, and the same 2024 amendment that restructured Tower Holdings’ preferred interests (introducing Fixed‑Rate and Floating‑Rate classes with 5.90 % and SOFR + 250 bps resets) does not alter Telco LLC’s preferred‑interest structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive coverage of the question. QUANTITATIVE VERIFICATION: All numbers are correct - $2,000 Class A-1 in 2022, $5,250 added in April 2023 (Class A-2/A-3), total of $7,250 by 2024, 4.25% rate for Class A-1, 6.85% rate for Class A-2/A-3, November 1, 2027 reset date for new series, seven-year reset cycles. All percentages and dollar amounts match the ground truth exactly. MULTI-HOP SYNTHESIS: The answer correctly synthesizes information across multiple years (2022-2024) and identifies the structural evolution of Telco LLC's preferred interests, including the timing of the April 2023 issuance and its reflection in the 2024 filing. COMPLETENESS: The answer addresses all key aspects of the question: (1) 2022 structure and value, (2) 2024 structure and value, (3) distribution rate changes (4.25% to 6.85%), (4) reset schedules (seven-year cycles with specific dates). ADDITIONAL CONTEXT: The LLM provides valuable supplementary information about call options, quarterly declarations, redemption triggers, and clarifies that the 2024 Tower Holdings amendment does not affect Telco LLC's structure - this demonstrates thorough understanding without detracting from the core answer. MINOR CONSIDERATIONS: The answer is slightly more detailed than the ground truth (includes information about call options, quarterly declarations, redemption triggers, and Tower Holdings comparison), but this represents added value rather than error. The core narrative and all factual claims align perfectly with the ground truth. No calculation errors, no incorrect dates, no misidentified entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Can_Call]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 451,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "\nAIG continued to apply Expected Loss Ratio methods to estimate reserves for the latest accident year in high‑severity, low‑development lines—particularly aviation (all but the most recent year) and program‑business property and liability—using ground‑up claim projections and adjustments for inflation, rate changes and emerging loss trends (Chunk 1). By 2024 the company still employs these methods as part of a broader combination that also includes loss development and frequency/severity techniques, extending their use to the long‑tail U.S. Workers’ Compensation line while explicitly noting that the underlying assumptions and methods may differ from prior years and are disclosed within its accounting policy (Chunk 2). This evolution reflects a consistent rationale—leveraging Expected Loss Ratio techniques where development is limited or severity‑driven—while allowing the specific implementation to adapt to each line of business and year‑to‑year experience.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates substantial accuracy in addressing the multi-hop question about AIG's Expected Loss Ratio Methods evolution between 2022 and 2024. STRENGTHS: (1) Correctly identifies the 2022 application to aviation exposures and latest accident year; (2) Accurately notes the 2024 expansion to U.S. Workers' Compensation; (3) Properly characterizes the rationale (high-severity, limited development for aviation; long-tail characteristics for workers' comp); (4) Correctly identifies the combination with loss development and frequency/severity methods; (5) Appropriately synthesizes the evolution across the two time periods. WEAKNESSES: (1) The LLM introduces additional details about 'program-business property and liability' in 2022 that are not mentioned in the ground truth, creating potential over-specification; (2) References to 'Chunk 1' and 'Chunk 2' suggest source attribution but these are not part of the actual answer and appear to be artifacts; (3) The phrase 'all but the most recent year' for aviation is somewhat ambiguous compared to the ground truth's clearer statement about 'latest accident year'; (4) Minor wording differences ('ground-up claim projections and adjustments for inflation, rate changes and emerging loss trends') add detail not explicitly in ground truth but are not contradictory. MULTI-HOP REASONING: The answer successfully synthesizes information across two years and multiple insurance lines, correctly identifying the shift from aviation-focused to broader application including workers' compensation. The logical connection between method characteristics and line-of-business application is sound. QUANTITATIVE ACCURACY: No specific numbers or percentages are provided in either answer, so this dimension is not directly testable. ENTITY ACCURACY: All entities (AIG, Expected Loss Ratio Methods, aviation, U.S. Workers' Compensation, loss development, frequency/severity methods) are correctly identified. The answer maintains semantic equivalence with the ground truth while providing additional contextual detail that, while not contradictory, goes slightly beyond what was explicitly stated in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 583,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "\nIn 2023 Target’s strategy explicitly called for “strengthening our owned‑brands portfolio” and expanding the breadth and depth of signature partnerships (Chunk 1). By 2024 the company had broadened that portfolio to dozens of distinct owned and exclusive brands—such as A New Day, Pillowfort, All in Motion, and many others—so that nearly one‑third of merchandise sales now come from owned/exclusive brands, marking a clear shift toward a larger, more diversified brand suite (Chunk 2). This evolution is captured in the knowledge‑graph relationship where Target expands into owned‑brand products that it produces, linking the strategic emphasis on portfolio growth with the measurable sales contribution seen in the 2024 filing.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Target's owned brands evolution from 2023 to 2024. STRENGTHS: (1) Correctly identifies the 2023 strategic emphasis on 'strengthening owned-brands portfolio' and 2024 shift to broader execution with dozens of brands; (2) Provides specific brand examples (A New Day, Pillowfort, All in Motion) that add credibility; (3) Includes the quantitative metric that nearly one-third of merchandise sales come from owned/exclusive brands in 2024, which is a concrete measure of portfolio impact; (4) Properly synthesizes the multi-hop relationship between strategic intent and measurable outcomes; (5) Appropriately references the knowledge-graph structure showing the connection between strategic emphasis and product portfolio development. MINOR CONSIDERATIONS: (1) The ground truth states 'over 40 distinct brands' while the LLM says 'dozens of distinct brands'—'dozens' is technically correct (40+ is multiple dozens) but less precise than the ground truth's specific threshold; (2) The LLM provides more detailed execution examples and sales metrics than the ground truth, which could be viewed as either enhanced context or slight deviation from the core answer structure. QUANTITATIVE ACCURACY: The 'nearly one-third' metric for merchandise sales from owned/exclusive brands is accurate and well-supported. The brand count characterization ('dozens' vs 'over 40') is semantically equivalent but slightly less precise. QUALITATIVE ACCURACY: The reasoning correctly identifies the evolution from strategic planning (2023) to execution phase (2024) and properly synthesizes information across filing years. CONTEXTUAL RELEVANCE: Excellent—directly addresses both the strategic emphasis shift and product portfolio development aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Expands]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 487,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "\nIBM’s 2024 filing still lists its existing 0.875 % Notes due 2030 (IBM 30A) — first shown in the 2023 filing — and adds a newly issued 2.900 % Notes due 2030 (IBM 30C), both registered on the NYSE.  The co‑existence of the legacy low‑coupon tranche with a fresh, higher‑coupon 2030‑dated issuance reveals IBM’s strategy of extending its long‑term debt profile and refinancing at current market rates, while the fact that both instruments remain listed demonstrates continued investor appetite for long‑dated securities and that 2024’s market conditions are supportive of issuing new 2030‑maturity debt.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) All numeric values are correct: 0.875% and 2.900% coupon rates, 2030 maturity date, trading symbols IBM30A and IBM30C are accurate. (2) Timeline is correct: 0.875% Notes first appeared in 2023, 2.900% Notes added in 2024. (3) The LLM correctly identifies both instruments as registered on NYSE and notes their continued listing. (4) The quantitative accuracy is excellent with no calculation errors. WEAKNESSES: (1) The LLM's interpretation of market conditions differs from ground truth. Ground truth suggests 'less favorable interest rate conditions' in 2024 (explaining the higher coupon), while LLM states '2024's market conditions are supportive of issuing new 2030‑maturity debt'—these are somewhat contradictory framings. A higher coupon typically indicates less favorable conditions for the issuer, not more supportive conditions. (2) The LLM omits the ground truth's explicit mention of 'targeting different investor segments with varied risk-return profiles' and 'manage refinancing risks by having multiple instruments maturing in the same year.' (3) The LLM's phrase 'extending its long-term debt profile and refinancing at current market rates' is somewhat vague compared to ground truth's more specific analysis of why dual instruments with different coupons exist. (4) The LLM doesn't explicitly address the strategic implication that the rate increase (from 0.875% to 2.900%) suggests either deteriorating market conditions or deliberate portfolio diversification—it frames it more as market supportiveness rather than acknowledging the less favorable rate environment. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 filings and identifies the relationship between the two debt instruments. However, the interpretation of what the rate differential suggests about market conditions is less nuanced than the ground truth. SEMANTIC EQUIVALENCE: While the LLM conveys that IBM issued new debt in 2024 and maintains both instruments, it doesn't fully capture the strategic implications of the significant coupon rate increase, which is a key insight in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 573,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "\nBetween 2022 and 2024 AT&T kept its 4.000 % Global Notes due June 1, 2049 (listed as T 49A in both the 2022 and 2024 registration statements) and used the 2024 filing to introduce new long‑term debt series—most notably the 4.300 % Global Notes due November 18, 2034 (T 34C), which were not present in the 2022 list.  The 2022 and 2024 tables therefore show the same core set of notes (e.g., 3.375 % 2034, 2.450 % 2035, 4.875 % 2044, etc.) plus the additional 2034‑dated issuance, indicating that AT&T’s long‑term debt composition evolved by adding newer tranches while retaining the 2049 notes as a staple.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness in addressing the multi-hop question about AT&T's long-term debt evolution. STRENGTHS: (1) All numeric values are correct - the 4.000% rate, June 1, 2049 maturity date, T 49A symbol, 4.300% rate, November 18, 2034 maturity date, and T 34C symbol all match the ground truth exactly. (2) The temporal comparison is accurate - correctly identifies that the 4.000% 2049 notes were present in both 2022 and 2024, while the 4.300% 2034 notes were absent in 2022 but added by 2024. (3) Multi-hop synthesis is sound - the answer successfully synthesizes information across two years and multiple debt instruments, correctly identifying the pattern of debt portfolio evolution. (4) The answer goes beyond the minimum by mentioning other debt instruments (3.375% 2034, 2.450% 2035, 4.875% 2044) that remained consistent, providing additional context about the broader debt composition. (5) The reasoning is logical and well-structured, explaining both what was retained (2049 notes) and what was added (2034 notes). MINOR CONSIDERATIONS: The LLM answer includes references to other debt instruments not explicitly mentioned in the ground truth answer, though this represents additional helpful context rather than an error. The phrasing 'newer tranches' is slightly imprecise since the 2034 notes are actually earlier-maturing than the 2049 notes, but this is a minor semantic issue that doesn't affect the core factual accuracy. All dates, percentages, and symbols are formatted correctly and match the ground truth precisely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 434,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "\nThe Heritage AspenTech acquisition generated $258 of intangible‑asset amortization in 2023, the amount explicitly cited for that acquisition in the 2023 10‑K (Chunk 2) and reflected in the purchase‑price allocation described in the 2023 filing (Chunk 1). By 2024 the company’s total intangible amortization rose to $560, driven largely by the NI acquisition, while the Heritage AspenTech amortization remained part of the overall expense profile, indicating a shift in the amortization mix rather than a new Heritage‑specific charge. At the same time, restructuring costs tied to the integration more than tripled—from $72 in 2023 to $228 in 2024 (with a projected $120 for 2025)—showing how the financial impact of the acquisition evolved into higher integration‑related expenses (Chunk 2).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IN QUANTITATIVE DATA: The LLM answer contains a major factual error regarding Heritage AspenTech intangibles amortization in 2024. Ground truth states the 2024 figure was $97, but the LLM answer claims it 'remained part of the overall expense profile' within a total of $560 without specifying the Heritage-specific amount. This is a significant omission that fails to directly answer the core question about how Heritage AspenTech amortization evolved. The LLM correctly identifies: (1) 2023 Heritage intangibles amortization of $258, (2) 2023 restructuring costs of $72, and (3) 2024 restructuring costs of $228. However, it fails to provide the critical 2024 Heritage intangibles amortization figure of $97, which is essential to answering the question about the evolution between years. The LLM introduces information about the NI acquisition and total company amortization of $560, which is contextually relevant but not directly responsive to the specific Heritage AspenTech comparison requested. The reasoning about 'a shift in the amortization mix' is speculative and doesn't address the actual decline from $258 to $97. The restructuring cost analysis is accurate and well-reasoned. The answer demonstrates partial understanding of the multi-hop synthesis required but fails on the primary quantitative metric (Heritage 2024 amortization) that is essential to answering the question. The omission of the $97 figure represents a fundamental incompleteness in addressing the core question about how the financial impact 'evolved' between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Involved_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 432,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "\nAIG discloses the use of **expected‑loss‑ratio methods** as an accounting policy, and both the 2022 and 2024 filings show that the company now applies these methods with far greater granularity—segmenting guaranteed‑cost and excess‑of‑deductible business by deductible size, state and third‑party administrator, and giving them significant weight only in the most recent accident years.  The proportion of large‑deductible accounts has risen sharply, slowing claim‑reporting and prompting AIG to adjust its tail‑factor and inflation assumptions (e.g., for California and New York) and to incorporate COVID‑19‑related experience modifications, reflecting an evolution from the broader 2022 approach to a more segmented, experience‑rated reserving practice by 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "ASSESSMENT: The LLM answer contains both accurate and problematic elements. STRENGTHS: (1) Correctly identifies that AIG uses expected loss ratio methods for workers' compensation; (2) Accurately notes the increase in large deductible accounts and their impact on claim reporting patterns; (3) Correctly identifies segmentation by deductible size and third-party administrator status as part of the 2024 approach; (4) Appropriately notes the evolution toward more granular, segmented reserving practices. CRITICAL WEAKNESSES: (1) The LLM introduces specific claims about 'tail-factor and inflation assumptions' and 'COVID-19-related experience modifications' that are NOT present in the ground truth answer and cannot be verified from the provided context. These appear to be hallucinated details; (2) The LLM states methods are applied 'with far greater granularity' in both 2022 and 2024, but the ground truth indicates this granularity increase occurred BETWEEN 2022 and 2024, not that both years had it; (3) The LLM mentions 'state' segmentation which is not explicitly mentioned in the ground truth; (4) MISSING KEY ELEMENT: The LLM fails to adequately address the 2024 emphasis on 'limitations in claim count data due to aggregation and reinsurance exclusions,' which the ground truth explicitly notes as a significant evolution not prominently featured in 2022. QUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this is not a differentiator, but the LLM's introduction of unverified specifics (California, New York, COVID-19 modifications) without grounding in the source material is problematic. MULTI-HOP REASONING: The LLM attempts to synthesize the evolution across years but conflates the timeline and introduces unsupported details. The core comparison between 2022 and 2024 is partially correct but incomplete and partially inaccurate in its characterization of when changes occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 520,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "\nTarget’s Cyber Fusion Center has remained the core engine for threat investigation and response from 2023 to 2024—both filings note that the Center is operated by Target (TGT → Cyber Fusion Center) and that it is used to probe, analyze and remediate cyber incidents, with a coordinated escalation model that keeps management and the Board informed throughout the response.  In the 2024 filing the company adds concrete details on external collaboration (continued threat‑intelligence sharing with organizations across industries) and on third‑party engagement (leveraging leading security vendors to assess and test the program), while also expanding internal controls through regular training, compliance activities and insurance coverage—capabilities that were only implied in the 2023 description.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) FACTUAL CORRECTNESS: All core facts are accurate - the Cyber Fusion Center's continued operation in both 2023 and 2024, the introduction of a coordinated escalation model in 2024, external collaboration through threat intelligence sharing, third-party vendor engagement for assessment and testing, and expanded internal controls (training, compliance activities). The answer correctly identifies that these capabilities were 'only implied' in 2023 but became explicit in 2024. (2) QUANTITATIVE ACCURACY: No numeric values, dates, or calculations are present in either answer, so this dimension receives full marks by default. The years (2023, 2024) are correctly referenced. (3) ENTITY ACCURACY: Target/TGT is correctly identified, the Cyber Fusion Center is properly named and contextualized, and all relevant stakeholders (management, Board of Directors, third-party vendors, external organizations) are accurately mentioned. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and multiple dimensions (internal operations, external collaboration, vendor relationships, governance structures). The logical progression from 2023 to 2024 showing evolution from basic operations to a more mature, structured approach is sound. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys all essential information from the ground truth with slightly more detailed explanation. The phrase 'more comprehensive and mature approach' from the ground truth is effectively captured through the LLM's description of added 'concrete details' and expanded 'internal controls.' Minor observation: The LLM uses parenthetical notation '(TGT → Cyber Fusion Center)' which is slightly unconventional but does not detract from accuracy. The answer is well-structured, comprehensive, and demonstrates clear understanding of the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 532,
        "total_tokens": 1947
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "\nBetween 2023 and 2024 Eli Lilly’s relationship with Baqsimi shifted from a one‑time transaction to an ongoing collaboration: the 2023 10‑K notes a **$579 million** entry from the **sale of Baqsimi rights** (recorded as collaboration and other revenue), while the 2024 10‑K explains that **collaboration revenue now includes royalties, milestone payments and profit‑share from the same Baqsimi arrangement** (alongside the Boehringer Ingelheim partnership), reflecting a contractual evolution from a discrete rights sale to a sustained licensing/royalty agreement that is recognized over time. Thus, the 2023 revenue was a single‑period gain from selling the product’s rights, whereas 2024 revenue derives from continuous contractual payments tied to that product.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the $579 million revenue figure from the 2023 sale of Baqsimi rights. (2) The answer correctly notes that this was recorded as collaboration and other revenue in 2023. (3) The general direction of the answer—that there was a shift in how Baqsimi revenue was recognized between 2023 and 2024—aligns with the ground truth. WEAKNESSES: (1) The LLM introduces unsupported claims about 'royalties, milestone payments and profit-share' in 2024 that are not present in the ground truth. The ground truth states Baqsimi was 'included within broader collaboration and other revenue disclosures' but does not specify the nature of these payments as royalties or milestone payments. (2) The LLM characterizes the 2024 arrangement as 'sustained licensing/royalty agreement that is recognized over time,' but the ground truth only indicates integration into broader collaboration disclosures without confirming the specific payment structure or recognition method. (3) The LLM mentions 'Boehringer Ingelheim partnership' which is not mentioned in the ground truth and appears to be an unsupported addition. (4) The ground truth emphasizes a shift from 'direct product revenue to a more complex revenue recognition model under collaborative arrangements,' but the LLM's interpretation of this as moving from 'discrete rights sale to sustained licensing/royalty agreement' goes beyond what the ground truth explicitly states. The LLM is making inferences about the nature of the 2024 arrangement that exceed the information provided in the ground truth. MULTI-HOP REASONING: The answer attempts to synthesize information across 2023 and 2024 filings, but introduces speculative details not supported by the ground truth. The core numeric fact ($579M) is correct, but the characterization of the 2024 arrangement contains unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 506,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "\nBetween 2023 and 2024 AT&T shifted from holding a sizable redeemable stake in Mobility to retiring it—repurchasing the remaining 213 million Mobility Preferred Interests in April 2023 for $5.414 bn, a transaction funded largely by the $5.25 bn of new Telco LLC cumulative preferred interests issued in April 2023 (with an additional $2 bn Series B issuance in Mobility II LLC in June 2023).  At the same time the company expanded its preferred‑interest platform: in August 2024 it amended the 2019 Tower Holdings preferred interests, converting them to Fixed‑Rate and Floating‑Rate Class A Limited Membership Interests that pay a 5.90 % distribution and reset every five years, and it grew the Telco LLC preferred pool to $7.25 bn of cumulative preferred interests (the original $2 bn plus the $5.25 bn April 2023 add‑on).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the overall narrative of AT&T's capital structure evolution but contains significant quantitative discrepancies and introduces unsupported information. CORRECT ELEMENTS: (1) Mobility Preferred Interests repurchase of 213 million for $5.414 billion in April 2023 - correct; (2) Funding through $5.25 billion Telco LLC preferred interests issuance - correct; (3) 6.85% distribution rate for Telco LLC - not mentioned in LLM but ground truth confirms; (4) Tower Holdings restructuring in 2024 with 5.90% fixed rate and SOFR + 250 bps floating rate - correct; (5) Telco LLC total of $7.25 billion ($2 billion original + $5.25 billion addition) - correct. PROBLEMATIC ELEMENTS: (1) LLM introduces a '$2 bn Series B issuance in Mobility II LLC in June 2023' which is NOT mentioned in the ground truth answer and appears to be unsupported information; (2) LLM states Tower Holdings preferred interests were 'amended' and 'converted' but ground truth says they were 'restructured' - semantic difference but LLM's language is less precise; (3) LLM mentions 'reset every five years' for the fixed-rate class, which is not in the ground truth; (4) Ground truth specifies the original Tower preferred interests were '$6,000' (likely $6 billion) from 2019, but LLM doesn't quantify the original Tower amount. MULTI-HOP REASONING: The LLM correctly synthesizes the connection between the 2023 Mobility repurchase and Telco LLC issuance, and properly links this to the 2024 Tower Holdings expansion. However, the introduction of the unsupported Mobility II LLC Series B issuance undermines the accuracy of the multi-hop synthesis. CALCULATION VERIFICATION: The Telco LLC total of $7.25 billion is correctly calculated as $2 billion + $5.25 billion. The quantitative accuracy is reduced due to the unexplained Mobility II LLC reference and missing Tower Holdings original amount quantification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Repurchases]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 514,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "\nFrom 2023 to 2024 Emerson’s ties with AspenTech shifted from a simple partnership—evident in the 2023 “Software and Control” table that lists AspenTech among its offerings (Chunk 1)—to a majority‑ownership arrangement, as the 2024 filing reveals Emerson acquired roughly $6 billion in cash consideration to obtain a 55 % fully‑diluted stake in AspenTech and rename the combined entity “New AspenTech” (Chunk 2).  This transformation lifted Emerson’s consolidated gross margin by 1.8 percentage points to 50.8 % in 2024, driven by the Test & Measurement acquisition and higher pricing, although a $231 inventory‑step‑up amortization shaved roughly 1.3 percentage points off the margin (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core transformation from partnership to majority ownership (55% stake), correctly states the ~$6 billion cash consideration, and accurately notes the 1.8 percentage point gross margin increase in 2024 to 50.8%. The multi-hop synthesis across 2023-2024 filings is sound, and the entity identification (Emerson, AspenTech, New AspenTech) is accurate.\n\nCRITICAL ERRORS: (1) The LLM completely omits the 3.3 percentage point gross margin increase in 2023 mentioned in the ground truth, which is a significant factual gap in addressing the 2023-2024 evolution. (2) The LLM attributes the 1.8 percentage point margin increase primarily to 'Test & Measurement acquisition and higher pricing' rather than clearly attributing it to the AspenTech acquisition as the ground truth indicates. (3) The LLM introduces information about '$231 inventory-step-up amortization' reducing margin by 1.3 percentage points, which is not mentioned in the ground truth and may represent over-specification or confusion with other transactions.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2023 and 2024 filings to show the relationship evolution, but fails to fully capture the complete financial impact picture by omitting the 2023 margin contribution.\n\nCOMPLETENESS: The answer addresses the relationship transformation and 2024 financial impacts but incompletely addresses the full 2023-2024 financial evolution requested in the question. The ownership structure change is well-explained, but the gross margin analysis is incomplete and partially misdirected.\n\nNUMERIC VERIFICATION: $6 billion ✓, 55% stake ✓, 1.8 percentage point increase ✓, 50.8% margin ✓, but missing 3.3 percentage point 2023 increase ✗, and introducing unverified $231M amortization figure ✗.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 494,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "\nAIG’s Japan pension plans have consistently accounted for roughly 61 % of the company’s total non‑U.S. pension assets (as disclosed in the 2022 filing), but the share of their **projected benefit obligations** among all non‑U.S. plans slipped slightly—from **about 54 % at the end of 2023 to roughly 50 % at the end of 2024**—indicating a modest evolution in their relative contribution.  \n\nAt the same time, the **weighted‑average discount rate applied to the Japan plans rose from 1.48 % (as of 31 Dec 2023) to 1.81 % (as of 31 Dec 2024)**, an increase of roughly 0.33 percentage points, reflecting the higher rates observed in the Mercer yield curve used for those periods.  \n\nThese shifts— a small decline in the obligation share and a notable rise in the discount rate—capture the evolution of the Japan plans’ role within AIG’s broader non‑U.S. pension portfolio between 2022 and 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of all key metrics and numbers. Verification of quantitative elements: (1) 61% share of non-U.S. pension assets in 2022 - CORRECT; (2) 54% projected benefit obligations share in 2023 - CORRECT; (3) 50% projected benefit obligations share in 2024 - CORRECT; (4) Discount rate 1.48% in 2023 - CORRECT; (5) Discount rate 1.81% in 2024 - CORRECT; (6) Calculated increase of 0.33 percentage points (1.81% - 1.48% = 0.33%) - CORRECT. The multi-hop reasoning is sound, successfully synthesizing information across 2022, 2023, and 2024 data points to show the evolution of Japan pension plans' contribution. The answer correctly distinguishes between pension assets (61% in 2022) and projected benefit obligations (54% in 2023, 50% in 2024), which are different metrics. The contextual interpretation about market conditions and the Mercer yield curve is appropriate and adds relevant context. Minor weakness: The answer could have been slightly more explicit about the distinction between the 2022 asset percentage (61%) and the 2023-2024 obligation percentages (54%-50%), though the answer does implicitly acknowledge this by using different terminology. The semantic equivalence is strong throughout, with clear communication of the pension plan evolution and discount rate changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 378,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "\nBoth the 2022 and 2023 10‑K filings identify the “introduction of competitive stores, websites, products, services, price decreases, or improvements” as a specific factor that can cause fluctuations in Amazon’s sales and operating results, linking the risk to Amazon through the Competes_With relationship (AMZN ↔ Competitive Stores). In the 2022 filing this item appears as one of many operational and market‑risk items, whereas in the 2023 filing the same language is retained but is framed within a broader discussion of external market conditions—including economic, geopolitical and competitive pressures—highlighting a shift toward emphasizing external competitive dynamics as a key driver of Amazon’s business outlook.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core factual elements: (1) both 2022 and 2023 filings contain the identical phrase about 'competitive stores, websites, products, services, price decreases, or improvements'; (2) the 2023 filing embeds this language within a broader context of external economic and geopolitical conditions; (3) there is a shift in framing from standalone competitive concern to part of a larger external risk landscape. The answer demonstrates sound multi-hop reasoning by synthesizing information across two filing years and correctly identifying the evolution in disclosure framing. However, there are minor issues: (1) The LLM introduces the 'Competes_With relationship (AMZN ↔ Competitive Stores)' notation which, while potentially accurate from the knowledge graph structure, is not explicitly mentioned in the original answer and adds technical metadata that may not be necessary for answering the substantive question; (2) The LLM's phrasing 'emphasizing external competitive dynamics as a key driver' slightly shifts the emphasis compared to the original answer's more precise characterization that competitive pressures are framed 'as part of a larger set of external risks rather than a standalone concern'—the LLM makes it sound more positive/driver-focused rather than risk-focused. (3) The original answer provides more specific context about how 2022 listed competitive stores 'alongside internal capabilities such as inventory management and customer satisfaction,' which the LLM omits. Despite these minor omissions and slight semantic shifts, the core narrative of evolution in disclosure framing is accurately captured, and no factual errors or incorrect numbers/dates are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Competes_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 470,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "\nTarget’s port‑security exposure moved from a broad 2023 warning that “disruptions at California ports … could affect the flow of imported merchandise” to a 2024 focus on how **trade‑policy actions—especially U.S. tariffs on China, Mexico, Canada and possible retaliatory measures—could force costly re‑sourcing and price hikes**, with the geographic risk now centered on **major U.S. ports that handle the bulk of its foreign imports**.  In both years the company notes that such events can raise costs, trigger alternative supply‑chain arrangements, and jeopardize inventory availability, but the 2024 filing adds explicit reference to tariffs and their impact on procurement costs and competitiveness, sharpening the operational impact of port‑security risk.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) FACTUAL INACCURACY - The LLM answer introduces tariffs and trade-policy actions as the primary 2024 focus, but the ground truth makes NO mention of tariffs being the central concern in 2024. The ground truth specifically states the 2024 emphasis shifted to 'potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes' - NOT tariffs. This is a significant factual error that misrepresents Target's actual 2024 filing disclosures. (2) GEOGRAPHIC FOCUS - The LLM correctly identifies that 2023 mentioned California ports specifically and 2024 broadened to 'major U.S. ports,' which aligns with ground truth. However, this correct element is overshadowed by the tariff mischaracterization. (3) OPERATIONAL IMPACT - The LLM mentions costs, alternative supply arrangements, and inventory issues, which are correct themes, but attributes them to tariffs rather than the actual drivers (global conflicts and labor disputes per ground truth). (4) MULTI-HOP SYNTHESIS - The answer fails to properly synthesize the evolution described in the ground truth. It introduces an entirely different risk factor (tariffs/trade policy) that wasn't the primary focus of the port security risk evolution between 2023-2024. (5) MISSING KEY CONTEXT - The ground truth notes that in 2023 Target 'had made alternative arrangements due to past disruptions,' while 2024 shifted to 'potential future impacts.' The LLM doesn't capture this temporal shift from past/present to future orientation. The answer demonstrates partial understanding of geographic evolution but fundamentally misidentifies the operational drivers of port security risk evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 470,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "\nEmerson paid roughly $6 billion (≈ $87.69 per share) for Heritage AspenTech, leaving about $168 million of cash on AspenTech’s balance sheet that was excluded from the purchase price, establishing a major acquisition‑related cash outflow. In 2023 the company began amortizing about $258 million of intangible assets acquired in that deal, and that same amortization continued into 2024 as part of ongoing intangible‑asset expense, while restructuring costs tied to the combined business rose sharply from $72 million in 2023 to $228 million in 2024, reflecting deeper integration and facility‑rationalization efforts; the mutual “Supplies → Depends_On” relationship between Emerson and Heritage AspenTech captured in the KG triplets shows how the financial tie evolved from a one‑time purchase to sustained amortization and restructuring commitments.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core financial metrics from the ground truth: (1) $258 million in intangibles amortization in 2023, (2) restructuring costs of $72 million in 2023 and $228 million in 2024. The directional analysis about the shift from acquisition-focused reporting to integration efforts is sound. The numbers are accurate and properly formatted.\n\nWEAKNESSES: (1) The LLM introduces substantial extraneous information not in the ground truth or question - specifically the $6 billion acquisition price, $87.69 per share, and $168 million cash exclusion. While these may be factually accurate from the filings, they are not part of the original answer and add unnecessary complexity that dilutes focus on the specific question about amortization and restructuring evolution. (2) The claim that amortization 'continued into 2024' directly contradicts the ground truth, which explicitly states 'By 2024, this specific amortization was no longer reported.' This is a critical factual error. (3) The reference to 'KG triplets' and 'Supplies → Depends_On' relationships appears to be speculative or incorrectly inferred - the ground truth makes no mention of such semantic relationships. (4) The answer conflates 'ongoing intangible-asset expense' with the specific Heritage AspenTech amortization, when the ground truth indicates the AspenTech-specific amortization was discontinued.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize acquisition details with amortization and restructuring trends, but the synthesis is partially flawed due to the incorrect claim about 2024 amortization continuation. The reasoning about integration efforts is sound but undermined by factual inaccuracy.\n\nCORRECTION NEEDED: The answer should state that the $258 million AspenTech-specific amortization was reported in 2023 but NOT in 2024, marking a shift in how the acquisition was being accounted for or reported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 521,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "\nBetween 2022 and 2024 AIG continued to apply expected‑loss‑ratio techniques mainly to newer accident years, but the 2022 disclosure (Chunk 1) shows that the method was explicitly weighted toward the most recent years across its D&O, E&O, EPLI, professional‑liability, fidelity and U.S. Property lines, often combined with loss‑development, capped‑layer and IBNR factors, while for fidelity exposures it was used for all but the latest year and for M&A exposures it received some weight in recent years. In the 2024 filing (Chunk 2) the same expected‑loss‑ratio approach remains for recent accident years, yet it is now embedded in a more segmented reserving framework—particularly for U.S. Workers’ Compensation, guaranteed‑cost versus excess‑of‑deductible business, and large‑deductible programs—where its weight is balanced against increased loss‑development and frequency/severity inputs, and the company notes that the 2024 assumptions may differ from current bases, with the loss‑development data presented as unaudited supplemental information.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of AIG's Expected Loss Ratio method evolution between 2022 and 2024, with generally accurate information and appropriate multi-hop synthesis. STRENGTHS: (1) Correctly identifies the core evolution - continued use of ELR methods for recent accident years in 2022, expanded application to U.S. Workers' Compensation by 2024; (2) Accurately names multiple lines of business (D&O, E&O, EPLI, professional liability, fidelity, U.S. Property) where methods were applied in 2022; (3) Correctly notes the shift toward more segmented reserving framework in 2024; (4) Properly identifies the integration with other methods (loss-development, frequency/severity, IBNR factors); (5) Appropriately references the unaudited supplemental information note for 2024. MINOR ISSUES: (1) The LLM answer includes some lines (fidelity, M&A, U.S. Property) that are mentioned but not emphasized in the ground truth, which focuses on D&O, E&O, EPLI, and professional liability as primary examples; (2) The discussion of 'capped-layer' methods and specific weighting details for fidelity/M&A is more granular than the ground truth, which may indicate over-specification from source documents rather than core evolution; (3) The phrase about '2024 assumptions may differ from current bases' adds contextual detail not explicitly in ground truth but is reasonable inference. MULTI-HOP REASONING: The answer successfully synthesizes information across 2022 and 2024 filings, comparing methodologies and identifying the expansion to Workers' Compensation. The reasoning is sound and logically structured. NO QUANTITATIVE ERRORS: No specific numbers, percentages, or dollar amounts are provided in either answer, so quantitative accuracy cannot be penalized. The answer appropriately avoids false precision. SEMANTIC ALIGNMENT: The LLM answer conveys the same essential information as ground truth - evolution from focused application to broader, more integrated application - though with additional detail about specific business segments and methodological combinations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 561,
        "total_tokens": 2033
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "\nAmazon’s film‑group monetization deepened between 2022 and 2023: capitalized video‑and‑music costs rose modestly from **$16.7 billion (2022)** to **$17.4 billion (2023)**, while the expense recognized for that content jumped from **$16.6 billion to $18.9 billion** over the same period.  The company also lengthened the weighted‑average remaining life of its capitalized content (from **2.6 years to 3.5 years**), meaning it amortizes each film‑group’s revenue over a longer horizon but on an accelerated basis tied to usage.  Together, these shifts show that Amazon has expanded and intensified its film‑group monetization—adding more licensed and original titles, capitalizing a larger cost base, and recognizing higher expense (and thus revenue) as the content is consumed across all Prime‑served geographies.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core financial figures from the ground truth: capitalized costs of $16.7B (2022) and $17.4B (2023), and expenses of $16.6B (2022) and $18.9B (2023). The answer appropriately characterizes the trend as showing 'expanded and intensified' monetization efforts. The semantic interpretation of what these changes mean for Amazon's strategy is reasonable and well-articulated.\n\nCRITICAL ERRORS: The LLM introduces information NOT present in the ground truth answer about weighted-average remaining life of capitalized content (2.6 years to 3.5 years) and claims about amortization acceleration tied to usage. This is a significant problem because: (1) the ground truth does not mention these metrics at all, (2) the LLM appears to have fabricated or hallucinated these specific numbers, and (3) this represents a factual claim that cannot be verified against the provided ground truth. This is a major accuracy violation.\n\nQUANTITATIVE ACCURACY ISSUES: While the four main financial figures are correct, the introduction of unverified metrics (2.6 years, 3.5 years) and claims about amortization methodology that aren't in the ground truth significantly undermines quantitative reliability. The LLM has gone beyond the source material and made unsupported claims.\n\nMULTI-HOP REASONING: The core multi-hop synthesis (connecting capitalized costs, expenses, and strategy evolution) is sound and matches the ground truth's logic. However, the addition of unsupported details weakens the overall reasoning quality.\n\nCONTEXTUAL RELEVANCE: The answer directly addresses the question about monetization strategy evolution and provides appropriate context about content investment and revenue recognition.\n\nJUSTIFICATION: The score of 6 reflects that while core facts are correct, the introduction of unverified information (weighted-average remaining life figures) represents a significant factual error that violates the strict evaluation standard for financial data. The answer would have scored 8-9 if limited to only the information in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Positively_Impacts]-> PRODUCT <-[Monetizes]- ORG",
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 563,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "\nBetween 2022 and 2024 Philip Morris International kept its equity stake in RBH – the 2022 filing shows PMI still reporting the volume of RBH‑sold brands and the trademark‑ownership link (Chunk 1), confirming the ongoing **Has_Stake_In** relationship captured by the KG triplets (PM → RBH and RBH → PM).  However, by the end of 2024 PMI re‑evaluated that investment and concluded that the fair value of its RBH holding was lower than its carrying amount, prompting a **$2,316 million non‑cash impairment charge** in the 2024 consolidated earnings (Chunk 2).  This impairment reflects a significant deterioration in the financial value of PMI’s stake in RBH over the two‑year period.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the $2,316 million impairment charge in 2024, matching the ground truth exactly. (2) The impairment amount is accurately cited and properly contextualized as a non-cash charge. (3) The general narrative of a shift in PMI's relationship with RBH is captured. (4) The 2022-2024 timeframe is correctly addressed.\n\nWEAKNESSES: (1) CRITICAL OMISSION: The LLM fails to mention the $32.5 billion Canadian tobacco litigation settlement that was the root cause of the impairment. The ground truth explicitly states this was 'due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM.' This is a significant contextual detail that explains WHY the impairment occurred. (2) CHARACTERIZATION ERROR: The LLM states PMI 'kept its equity stake in RBH' between 2022 and 2024, but the ground truth indicates a SHIFT from 'a trademark and brand licensing relationship' in 2022 to 'a more direct equity investment' by 2024. The LLM conflates these as the same relationship type throughout the period, missing the evolution. (3) The LLM references 'KG triplets' and chunk citations that appear to be fabricated or unclear, reducing clarity. (4) The phrase 're-evaluated that investment' is vague about the timing and nature of the change.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2024 but fails to fully capture the relationship evolution. It treats the equity stake as continuous rather than showing the transition from trademark/licensing to equity investment. The connection to the litigation settlement is completely missing, which is essential to understanding the impairment.\n\nNUMERIC VERIFICATION: The $2,316 million figure is correct. No calculation errors detected in the numbers provided.\n\nSEMANTIC ISSUES: While the LLM conveys that there was an impairment, it misses the causal explanation (litigation settlement) and the nature of the relationship change, which are core to answering 'how has the relationship evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 553,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "\nThe 2023 10‑K quantifies the impact of a 5 % movement in the sales‑return, rebate and discount liability as an approximate $615 million swing in net product revenue (LLY → Current Contracts → LLY, disclosed in Chunk 1). Chunk 2 (the 2024 10‑K) repeats the same estimation methodology and the same “Background and Uncertainties” language, but it does **not** restate a new dollar‑impact figure—only re‑affirming that the accrual process remains unchanged. Thus, while the underlying sensitivity analysis is still applied in 2024, the disclosed evolution is that the 2023 $615 million per 5 % change figure was not updated or re‑published in the 2024 filing, indicating continuity rather than a new quantified evolution of that sensitivity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. QUANTITATIVE ACCURACY: All numeric values are correct—the $615 million figure for a 5% change in sales return, rebate, and discount liability in 2023 is accurately cited, and the percentage (5%) is correctly stated. No calculations are required for this question, and the numbers presented are factually accurate. ENTITY ACCURACY: LLY (Eli Lilly) is correctly identified, fiscal years 2023 and 2024 are properly referenced, and the specific metric (sales return, rebate, and discount liability sensitivity) is accurately characterized. MULTI-HOP REASONING: The answer correctly synthesizes information across two separate 10-K filings (2023 and 2024) and identifies the key evolution: the 2023 disclosure of a quantified $615 million sensitivity figure versus the 2024 omission of an updated figure. The reasoning that 2024 'did not restate a new dollar-impact figure' aligns perfectly with the ground truth statement that 'it did not provide an updated sensitivity figure.' COMPLETENESS: The answer addresses the core question about how sensitivity evolved between the two years, explaining both what was disclosed in 2023 and what was not disclosed in 2024. The characterization of this as 'continuity rather than a new quantified evolution' is semantically equivalent to the ground truth's 'lack of updated quantitative disclosure.' MINOR CONSIDERATIONS: The LLM answer includes some parenthetical references to 'Chunk 1' and 'Chunk 2' which appear to be internal document references that don't affect the factual accuracy but add minor verbosity. The phrasing 'did not update or re‑published' is slightly awkward but semantically clear and equivalent to the ground truth's 'did not provide an updated sensitivity figure.' Overall, the answer demonstrates accurate synthesis of multi-hop information across two fiscal years with correct quantitative data and sound reasoning about the evolution (or lack thereof) in disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 547,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "\nUnion Pacific’s 2022 Form 10‑K shows that the Bulk commodity generated $3,305 of average revenue per car in 2021—up 6 % from 2020 and essentially flat versus 2019—highlighting modest growth in pricing or volume for grain, fertilizer, food‑refrigerated and coal shipments. In 2024 the company disclosed that these same Bulk shipments accounted for 32 % of total freight revenue, confirming that the commodity group remains a major revenue pillar while its share of the business has held steady. The 2024 filing further details how Bulk movements connect Midwest production areas to export terminals and domestic processors, underscoring the strategic role of Bulk within Union Pacific’s overall freight portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct quantitative data and sound multi-hop reasoning. STRENGTHS: (1) All key numbers are accurate: $3,305 average revenue per car in 2021, 6% increase from 2020, 32% of total freight revenue in 2024. (2) Correctly identifies the time period evolution from 2022 to 2024 as requested. (3) Properly synthesizes information across multiple filings (2022 Form 10-K for historical data, 2024 filing for current metrics). (4) Accurately describes the commodity types (grain, fertilizer, coal) and strategic connections (Midwest to export terminals, domestic processors). (5) The reasoning about transformation from revenue-per-unit to strategic revenue significance is sound and well-supported. MINOR WEAKNESSES: (1) The LLM adds 'food-refrigerated' to the commodity list, which is not mentioned in the ground truth answer, though this may be accurate from the actual filings. (2) The phrase 'essentially flat versus 2019' adds detail not in the ground truth but appears to be supplementary rather than contradictory. (3) The characterization that 'share of the business has held steady' is a reasonable inference but slightly differs from the ground truth's emphasis on 'transformation' and 'growth in strategic importance.' The ground truth emphasizes evolution and growth, while the LLM emphasizes stability ('remains...while its share...has held steady'). This is a subtle semantic difference in interpretation rather than a factual error. CALCULATION VERIFICATION: All percentages and year-over-year comparisons are mathematically sound. The multi-hop synthesis correctly connects 2022 filing data with 2024 filing data to show evolution over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 465,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "\nThe 1.750% Notes due 2028 listed in IBM’s 2023 filing (IBM 28A) and again in the 2024 filing (IBM 28A) carry the identical 1.75% coupon, indicating that the interest rate on this tranche was unchanged between 2023 and 2024. This continuity shows IBM is deliberately maintaining a low, fixed‑rate, long‑dated debt position—locking in financing at a stable rate rather than refinancing or adjusting the coupon—reflecting a debt‑strategy focused on predictable, low‑cost funding and a conservative stance on interest‑rate exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 1.750% interest rate for IBM's Notes due 2028 in both 2023 and 2024, with accurate numeric representation (1.75% = 1.750%). (2) Correctly identifies the notes as IBM 28A. (3) Accurately states the rate remained unchanged between the two years. (4) Number formatting is consistent and correct.\n\nWEAKNESSES: (1) INCOMPLETE ANSWER - The LLM fails to address a critical part of the original answer: IBM's broader debt strategy shift in 2024. The ground truth explicitly mentions that IBM introduced NEW notes in 2024 with higher rates (2.900% Notes due 2030 and 3.150% Notes due 2033), which is essential context for understanding IBM's debt strategy evolution. (2) The LLM's interpretation of IBM's strategy is speculative and potentially misleading. While the LLM claims IBM is 'deliberately maintaining' this position and taking a 'conservative stance,' the ground truth suggests a more nuanced strategy: IBM is issuing NEW debt at HIGHER rates for LONGER maturities, indicating a shift toward accepting higher rates for extended duration. This is not captured in the LLM answer. (3) The LLM answer focuses narrowly on the unchanged 2028 notes without synthesizing the multi-hop information about the new 2024 issuances, which is essential to answering 'what does this indicate about IBM's debt strategy?' (4) The characterization of 'low-cost funding' and 'conservative stance' doesn't fully capture the strategic shift toward higher-rate, longer-maturity debt that the ground truth emphasizes.\n\nMULTI-HOP REASONING: The question requires synthesizing information about: (a) the 2028 notes' rate in 2023, (b) the 2028 notes' rate in 2024, (c) new debt issuances in 2024, and (d) what this collectively indicates about strategy. The LLM only addresses (a) and (b), missing the critical (c) and (d) components that provide the full strategic picture.\n\nCONCLUSION: While the LLM is quantitatively accurate on the specific 1.750% rate, it provides an incomplete and potentially misleading answer by omitting IBM's new higher-rate debt issuances in 2024, which are central to understanding the company's actual debt strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> FIN_INST <-[Issues_Financial_Instrument]- ORG",
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 585,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "\nIn 2023 AT&T completed the repurchase of all 213 million Mobility Preferred Interests (Chunk 1), eliminating that legacy preferred instrument from its diluted‑EPS calculation and using a $5,414 purchase price that adjusted additional‑paid‑in‑capital, thereby reducing the company’s preferred‑capital exposure.  In 2024 the firm introduced new preferred structures – the 2019 Tower Holdings Preferred Interests were reset into Fixed‑Rate and Floating‑Rate Class A Limited Membership Interests with higher distribution rates (5.90 % and SOFR + 250 bps) and call options beginning in 2029 (Chunk 2), and the Telco LLC preferred interests were expanded in 2023 to a total of $7.25 bn with 4.25 %–6.85 % distributions, a seven‑year reset and call rights after seven years (Chunk 2) – creating a layered, reset‑and‑floating‑rate preferred portfolio that now dominates AT&T’s capital‑structure strategy while the Mobility Preferred were fully retired.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates good understanding of the overall strategic evolution but contains significant quantitative discrepancies that undermine accuracy. STRENGTHS: (1) Correctly identifies the 2023 repurchase of all Mobility Preferred Interests as a key strategic shift; (2) Accurately describes the 2024 restructuring of Tower Holdings Preferred Interests into fixed and floating rate components; (3) Correctly notes the expansion of Telco LLC preferred interests to $7.25 billion; (4) Properly synthesizes the multi-hop information across 2023-2024 timeline; (5) Appropriately characterizes the strategic pivot from Mobility-based to diversified preferred instruments. CRITICAL ERRORS: (1) States Mobility Preferred Interests purchase price of $5,414 million, but ground truth specifies redemption value of approximately $5,340 million - a $74 million discrepancy (1.4% error); (2) Omits the annual cash distributions figure of $373 million that was paid on Mobility Preferred Interests, which is material context for understanding the strategic impact; (3) Attributes Telco LLC expansion to 2023 in one clause but discusses it as a 2024 development, creating temporal ambiguity (ground truth indicates this was a 2024 development). CALCULATION/VERIFICATION: The $7.25 billion figure is correctly stated (matches $7,250 million in ground truth). Distribution rates cited (5.90%, SOFR + 250 bps, 4.25%-6.85%) appear reasonable but cannot be fully verified against ground truth. The reasoning about reset periods and call options is sound and adds appropriate detail. MULTI-HOP SYNTHESIS: The answer successfully connects the elimination of Mobility Preferred Interests with the introduction of new preferred structures, demonstrating proper multi-document synthesis. However, the quantitative errors and omission of the $373 million annual distribution detail reduce the completeness of the analysis. The answer would benefit from more precise alignment on the redemption value figure and explicit mention of the distribution amounts to fully match the ground truth's comprehensive assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 564,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "\nAmazon’s 2022 filing mentioned “the introduction of competitive stores, websites, products, services, price decreases, or improvements” only as one item in a long list of risk factors that could affect sales, without explicitly tying it to growth outcomes. In the 2023 filing the same phrasing is retained but is embedded in a section that explicitly states such competition can lead to “decreased revenue or growth,” thereby framing the threat as a direct driver of financial performance. This shift—from a peripheral risk to a stated cause of revenue decline—shows that Amazon now views competitive websites as a material, growth‑impacting force, which the knowledge‑graph relationship (AMZN Depends_On COMP ← Competes_With AMZN) underscores.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both strengths and significant weaknesses. STRENGTHS: (1) Correctly identifies the years 2022 and 2023 as the comparison period; (2) Accurately cites the specific phrasing 'competitive stores, websites, products, services, price decreases, or improvements' that appears in both filings; (3) Correctly notes that the language was retained between years; (4) Properly identifies the shift from peripheral risk to material financial impact. WEAKNESSES: (1) The core claim about 2022 treatment is problematic—the LLM states the phrase appeared 'only as one item in a long list of risk factors' in 2022, but the ground truth indicates 2022 described competitive websites as 'part of a broader list of fluctuating business factors' without specifying the exact phrasing. The LLM may be overstating the presence of this specific language in 2022; (2) The LLM introduces a knowledge graph relationship notation (AMZN Depends_On COMP ← Competes_With AMZN) that, while potentially accurate, goes beyond what the ground truth explicitly states and adds interpretive layers not grounded in the filing language itself; (3) The ground truth emphasizes an evolution from 'general awareness' to 'more direct and strategic stance,' but the LLM frames it as 'peripheral risk to stated cause of revenue decline'—a subtly different characterization that may overstate the 2022 positioning; (4) The LLM's claim that 2023 'explicitly states such competition can lead to decreased revenue or growth' is more specific than the ground truth provides, suggesting the LLM may be inferring beyond what the filings actually state. MULTI-HOP REASONING: The LLM attempts to synthesize the evolution across years and connect it to financial impact, which is appropriate for the question. However, the synthesis relies on assumptions about 2022 language that may not be fully supported. SEMANTIC EQUIVALENCE: The LLM's interpretation of the shift is directionally aligned with the ground truth but frames it with different emphasis and potentially unsupported specificity about the 2022 filing language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Competes_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 562,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "\nFrom the 2020 three‑year global collaboration agreement through 2022 – when PMI began commercial launches of licensed KT&G heat‑not‑burn devices in select markets – to the 2024 financial disclosures, the partnership has matured into a strategic dependency: PMI now lists KT&G’s heat‑not‑burn products as a core component of its smoke‑free portfolio, and the 2024 “net revenues related to smoke‑free” category explicitly includes these licensed KT&G products, underscoring the ongoing reliance.  The knowledge‑graph relationship (PM Partners_With KT&G and KT&G Depends_On PM) captures this mutual, evolving dependence that has persisted from 2022 into 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of the PM-KT&G relationship from distribution partnership to deeper strategic integration, and accurately notes that KT&G's heat-not-burn products are now listed within PMI's smoke-free portfolio by 2024. The qualitative reasoning about the shift from distribution to embedded supplier role is sound and aligns with the ground truth narrative. CRITICAL ERRORS: (1) The LLM introduces a '2020 three-year global collaboration agreement' as the starting point, but the ground truth specifies the agreement was in 2022 and was 'initially for three years' - this is a significant date error that misrepresents the timeline. (2) The LLM claims 'PMI began commercial launches of licensed KT&G heat-not-burn devices in select markets' in 2022, but the ground truth only states the agreement existed in 2022 allowing exclusive distribution - no specific launch dates are mentioned in the ground truth. (3) The LLM references '2024 financial disclosures' and 'net revenues related to smoke-free' category explicitly including KT&G products, but the ground truth does not provide specific revenue figures or financial metrics - this appears to be an inference not supported by the source material. MULTI-HOP REASONING: The LLM correctly synthesizes information across the 2022-2024 period and identifies the relationship evolution, but the temporal framing is inaccurate. The mention of 'knowledge-graph relationship (PM Partners_With KT&G and KT&G Depends_On PM)' adds structure but doesn't substantively enhance the answer. SEMANTIC ISSUES: While the overall narrative of deepening strategic reliance is correct, the specific factual anchors (dates, agreement terms) contain errors that undermine confidence in the answer's accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 486,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "\nIBM’s use of the PWCC Plan to fund employee awards has remained consistent from 2022 through 2024: the plan is still administered by the Executive Compensation and Management Resources Committee, which retains the authority to cancel, suspend or otherwise limit awards for non‑compliance, and its scope is unchanged – it funds only those PwCC employees who became IBM staff as a result of the acquisition, while senior‑executive awards are expressly excluded.  The only evolution reflected in the 2022 and 2024 filings is the updated reference to the forthcoming proxy‑statement dates (2022 → 2025), but the administration, governance and limited‑scope structure of the PWCC Plan are the same in both periods, as shown by the KG relationship IBM → PWCC Plan (Adopts) and PWCC Plan → IBM (Adopts).",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant issues in addressing the core question about how the PWCC Plan evolved between 2022 and 2024. CRITICAL ERRORS: (1) The LLM claims the plan's scope and administration remained 'unchanged' and 'the same in both periods,' which directly contradicts the ground truth that shows an evolution in how IBM described and committed to the plan's usage. (2) The ground truth explicitly identifies a shift in language and tone from 2022 to 2024 - from 'would continue to be used' to 'has been and will continue to be used' - representing a stronger commitment. The LLM completely misses this linguistic and conceptual evolution. (3) The LLM's statement that 'the only evolution reflected...is the updated reference to the forthcoming proxy-statement dates' fundamentally misunderstands the question, which asks about evolution in administration and scope, not proxy dates. PARTIAL CREDIT: (1) The LLM correctly identifies that the plan funds only former PwCC employees who joined IBM post-acquisition (correct entity identification). (2) The LLM correctly notes that senior-executive awards are excluded (accurate detail). (3) The LLM correctly identifies the Executive Compensation and Management Resources Committee's role (accurate governance detail). MISSING ELEMENTS: The LLM fails to capture the key evolution - the reaffirmation and strengthening of commitment language between 2022 and 2024, which is the central point of the ground truth answer. The ground truth emphasizes that while the plan's substantive terms remained identical, the way IBM described its commitment evolved, suggesting a stronger dedication to maintaining the plan's current usage without expansion. The LLM's claim of 'no evolution' is factually incorrect based on the ground truth provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Adopts]-> ACCOUNTING_POLICY <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 488,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "\nIn 2023 AT&T retired its Mobility Preferred Interests by repurchasing the full 213 million units for $5.414 billion, eliminating the non‑controlling liability that had been recorded as distributions and re‑classifying the $5.34 billion redemption value as an adjustment to additional paid‑in capital. Building on that clean‑up, the company in 2024 amended its Tower and Telco‑LLC preferred‑interest structures—resetting the Tower rates to a fixed 5.90 % and creating floating‑rate tranches tied to SOFR+250 bps—while retaining call and redemption rights, which demonstrates a deliberate shift toward a leaner, more market‑responsive capital stack and a broader focus on simplifying its balance‑sheet liabilities and managing cash‑flow flexibility.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates partial correctness with both strengths and significant weaknesses: STRENGTHS: (1) Correctly identifies the 2023 repurchase of Mobility Preferred Interests for approximately $5.4 billion, (2) Accurately notes the complete elimination of this instrument by 2024, (3) Properly identifies the strategic shift toward Tower and Telco LLC preferred interests, (4) Correctly describes the 2024 amendments including fixed 5.90% rates and SOFR+250 bps floating-rate tranches, (5) Appropriately characterizes the broader capital structure management strategy as selective and focused on flexibility. WEAKNESSES: (1) QUANTITATIVE ERROR - States '213 million units' which is not mentioned in the ground truth and appears to be unsupported detail that may be inaccurate or fabricated, (2) QUANTITATIVE DISCREPANCY - References '$5.34 billion redemption value' and '$5.414 billion' separately, creating confusion about whether these are the same figure or different components; the ground truth states the total repurchase was $5,414 million ($5.414 billion), (3) ACCOUNTING DETAIL OVERREACH - Introduces specific accounting treatment ('re-classifying the $5.34 billion redemption value as an adjustment to additional paid-in capital') that goes beyond the ground truth and may not be verifiable from the provided context, (4) MISSING CONTEXT - Does not explicitly mention that other preferred interests (Tower Holdings and Telco LLC) 'remained outstanding' as clearly stated in ground truth. MULTI-HOP REASONING: The answer correctly synthesizes the evolution across 2023-2024 and connects the Mobility Preferred Interests exit to broader capital structure management. However, the introduction of unverified details (213 million units, specific accounting reclassifications) undermines confidence in the synthesis. The core logic about selective liability reduction and capital flexibility is sound but presented with questionable supporting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 530,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "\nIBM’s debt‑security program has remained tightly bound to stock‑exchange rules throughout 2022‑2024, with the company repeatedly flagging that **regulatory requirements**—including exchange‑listed listing standards, reporting obligations and rating‑agency determinations—directly affect the **value, liquidity and ability to service** those securities; the 2022 filing (Chunk 1) describes the risk that “changes in … governmental and stock‑exchange regulations … are beyond the company’s control,” while the 2024 filing (Chunk 2) reiterates that same exposure and adds that rating‑agency outlooks or new regulatory shifts could further impair marketability, showing a **continuous, not transformative, evolution** of regulatory exposure for IBM’s debt securities.  \n\nThe knowledge‑graph link **IBM → Stock Exchange Regulations ← Subject_To IBM** captures this persistent dependency, and both chunks reinforce that IBM’s capacity to pay interest and repay principal hinges on managing operations **and** complying with the evolving regulatory landscape governing its debt securities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS: The LLM answer fundamentally contradicts the ground truth on the core finding. Ground truth states there was an EVOLUTION/SHIFT from 2022 to 2024 - specifically that IBM moved from describing stock exchange regulations as 'one of several factors' (2022) to stating it is 'subject to' regulations (2024), indicating heightened recognition. The LLM explicitly claims the opposite: 'continuous, not transformative, evolution' and states both years describe the same exposure. This is a direct factual contradiction of the primary thesis. (2) The LLM invents specific language ('listing standards, reporting obligations and rating-agency determinations') not present in the ground truth answer, and adds details about 'value, liquidity and ability to service' that go beyond what the original answer establishes. (3) The LLM references 'Chunk 1' and 'Chunk 2' and a 'knowledge-graph link' that are not part of the ground truth answer, suggesting fabricated source citations. (4) The ground truth's key insight is the SHIFT in language from 'among other external variables' (2022) to 'subject to' (2024), indicating stronger regulatory acknowledgment. The LLM misses this entirely and argues for continuity instead of evolution. (5) While the LLM correctly identifies IBM, the years 2022-2024, and stock exchange regulations as relevant entities, it fundamentally mischaracterizes the relationship between these elements. The multi-hop reasoning fails because it reaches the opposite conclusion from the ground truth about how IBM's regulatory exposure evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> REGULATORY_REQUIREMENT <-[Subject_To]- ORG",
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 432,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "\nDisney holds a 50 % equity stake in the A+E joint venture (the A&E networks) and accounts for its share of the venture’s results as “Equity in the income (loss) of investees” on its financial statements—a relationship captured by the KG links DIS → A+E (Invests_In) and A+E → DIS (Depends_On).  In 2022 the equity income generated by A+E was roughly $782 million, but by 2024 it fell $207 million to $575 million, reflecting a decline in A+E’s earnings that Disney reports as a lower equity‑income contribution.  This drop illustrates how the financial contribution of Disney’s investment in A+E (A&E) has diminished from 2022 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides specific dollar amounts ($782M in 2022, $575M in 2024) that are NOT present in the ground truth. The ground truth only states that equity income 'decreased by $207 million' without providing the absolute values for either year. The LLM appears to have fabricated these specific numbers. The $207M decline figure is correct and matches ground truth, but the absolute values are unsupported. (2) ENTITY NAMING - The LLM uses 'A+E' and 'A&E' interchangeably, which creates confusion. The ground truth consistently refers to 'A&E' and mentions 'A+E' only once in parentheses. The LLM's notation is inconsistent. (3) MULTI-HOP REASONING - While the LLM correctly identifies the equity method accounting treatment and the relationship structure (50% stake, equity income reporting), it goes beyond what the ground truth supports by providing specific 2022 and 2024 absolute values. The ground truth only confirms the $207M decline figure. (4) COMPLETENESS - The LLM does address the evolution of the relationship and the decline, but it adds unsupported quantitative detail that contradicts the principle of sticking to verifiable facts. The ground truth mentions A&E was 'one of the most notable equity method investees alongside CTV Specialty Television' in 2022, which the LLM omits. (5) CALCULATION VERIFICATION - The math ($782M - $207M = $575M) is arithmetically correct, but the underlying numbers appear fabricated. This is a fundamental error in a financial evaluation context where accuracy is paramount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 434,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "\nThe carrying amount of the firm’s securitized debt obligations slipped from **$18,067 million at the end of 2022 to $18,043 million at the end of 2023** (a decline of roughly $24 million, or about 0.1%).  This modest reduction—while the broader long‑term funding base remains sizable—shows that the company is keeping its securitization platform roughly stable rather than expanding it, reflecting a strategic emphasis on a diversified, multi‑source long‑term funding mix that relies on both securitizations and other debt instruments (e.g., senior/subordinated notes) rather than on aggressive growth of securitized debt.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides specific 2022-2023 securitized debt obligation figures ($18,067M to $18,043M) with accurate calculation of the $24M decline (0.1%), which are not contradicted by the ground truth. However, there is a significant discrepancy in scope: the ground truth references 2021 data ($42.3B in long-term funding) and emphasizes a broader strategic shift from 2021-2023, while the LLM focuses narrowly on 2022-2023 securitized debt alone. The ground truth indicates a more substantial reduction in securitized debt reliance over the full period, whereas the LLM characterizes the 2022-2023 change as 'modest' and 'roughly stable.' The LLM's interpretation of strategic intent (diversified funding mix) aligns with the ground truth's conclusion about reduced reliance on securitized debt, but the LLM misses the broader context of the larger 2021-2023 decline. The quantitative data provided by the LLM (2022-2023 figures) appears accurate and is presented with proper calculations, but the answer is incomplete in not addressing the full 2022-2023 period as framed in the original question, which could reasonably be interpreted as asking about the complete year-over-year change. The reasoning about strategic implications is sound but somewhat understated given the broader context of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 368,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "\nDisney’s scripted programming—produced by DIS and therefore dependent on DIS—has shifted from being primarily distributed through its international General Entertainment linear channels (Fox, National Geographic, Star, Disney, which aired scripted, reality and documentary shows in ≈ 40 languages and ≈ 180 countries in 2022) to a strategy that emphasizes direct‑to‑consumer delivery; by 2024 the company is planning to launch DTC offerings that will stream live linear feeds (e.g., ESPN‑branded channels and ESPN+) and will move monetisation from traditional linear‑channel licensing to DTC platforms, even as it acknowledges that this transition will reduce revenue from the legacy international channel model.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the strategic shift from linear channels to DTC platforms, mentions the key brands (Fox, National Geographic, Star), and accurately notes the 2024 plans for ESPN DTC offerings with live linear streams. The semantic understanding of the transition from traditional licensing to DTC monetization is sound. CRITICAL ERRORS: (1) QUANTITATIVE INACCURACY - The LLM states '≈ 180 countries' when the ground truth specifies approximately 220 General Entertainment channels (not countries). This is a significant numerical error. (2) The LLM mentions '≈ 40 languages' which is not mentioned in the ground truth at all - this appears to be fabricated or confused information. (3) The LLM incorrectly references 'DIS' as a producer entity and uses confusing parenthetical language ('produced by DIS and therefore dependent on DIS') that doesn't match the ground truth framing. MISSING ELEMENTS: (1) The LLM fails to mention the Venu Sports joint venture with Fox Corporation and Warner Bros. Discovery, which is a key strategic element in the ground truth. (2) The specific mention of 'early fall 2025' launch timing is absent. (3) The LLM doesn't clearly articulate the 2022 baseline of 220 channels as a specific comparison point. REASONING ISSUES: While the LLM demonstrates understanding of the DTC shift, it conflates different metrics (channels vs. countries vs. languages) and introduces unverified details. The multi-hop synthesis is incomplete - it misses the Venu Sports venture which is central to understanding Disney's strategic pivot. The acknowledgment that 'this transition will reduce revenue from the legacy international channel model' is inferred rather than explicitly stated in the ground truth, though it's a reasonable inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 484,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "\nFrom 2022 through 2023 Tesla continued to disclose its **energy‑storage products** as part of the portfolio it reports on, and the company’s **accounts‑receivable** remained heavily tied to those sales—particularly receivables from financing partners, regulatory‑credit sales to other automakers and long‑term government rebate claims (which rose to $627 million of long‑term rebates in 2021 and continued to be recorded in other non‑current assets).  At the same time, the 2023 filing warned that **scaling storage production** increasingly depended on expanding manufacturing capacity, securing a global supplier base and avoiding bottlenecks; any delay or supply‑chain disruption in ramping these products could impair product quality, increase costs and jeopardize the collectability of the related receivables.  Thus, the financial risk shifted from a growing, delayed AR balance in 2022 to an operational risk that the company’s ability to meet production targets—and thereby realize those receivables—became the dominant challenge in 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key financial and operational themes. STRENGTHS: (1) Correctly identifies the $627 million long-term government rebates receivable figure from 2021, properly contextualized as continuing into the 2022-2023 period. (2) Accurately captures the shift from financial receivables exposure in 2022 to operational/production scaling risks in 2023. (3) Correctly identifies specific operational challenges: manufacturing capacity expansion, supplier base development, bottlenecks, and facility ramp delays. (4) Properly synthesizes the multi-hop connection between receivables collectability and production scaling dependencies. (5) Accurately characterizes the nature of receivables (government rebates, regulatory credits, financing partners). MINOR WEAKNESSES: (1) The answer states the $627 million figure was from 2021 and 'continued to be recorded' but doesn't explicitly clarify that this is the baseline figure being referenced when discussing the 2022-2023 evolution. The ground truth emphasizes this as a 2021 balance point for comparison. (2) The answer could have been more explicit about the geographic specificity mentioned in the ground truth (Nevada, Texas, and other locations) though it does mention 'factories' generally. (3) The phrasing 'rose to $627 million of long-term rebates in 2021' is slightly awkward—the figure is FROM 2021, not that it rose TO that point in 2021. QUANTITATIVE VERIFICATION: The $627 million figure is correct and properly attributed. No calculation errors detected. MULTI-HOP REASONING: The answer successfully synthesizes information across the 2022-2023 period and connects financial metrics (receivables) to operational dependencies (production scaling), which is the core requirement of the question. The logical flow from financial risk to operational risk is sound and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 517,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "\nBetween 2022 and 2023 Coca‑Cola’s syrup strategy moved from a largely back‑end, “sell‑to‑bottler” model—where concentrate‑revenue was only recognized when a bottling partner sold the finished beverage to a consumer—to a more front‑end, higher‑margin focus that includes direct sales of fountain syrups to fountain retailers (and their wholesalers) as a distinct revenue stream highlighted in the North America segment; this shift is captured by the KG link **KO ‑ Sells → Syrups** and **Syrups ‑ Depends_On → KO**, which ties the product’s timing of revenue recognition to both consolidated/unconsolidated bottling partners and to fountain‑retailer transactions, showing that Coca‑Cola now monetizes syrups earlier in the distribution chain while still using the same bottling‑partner volume metrics to drive overall net‑operating‑revenue growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of Coca-Cola's syrup strategy between 2022 and 2023, capturing the shift from a back-end bottler-focused model to a more integrated approach including direct fountain retailer sales. The answer appropriately references both consolidated and unconsolidated bottling partners, and correctly notes the timing of revenue recognition differences. The mention of North America segment and higher-margin focus aligns with the ground truth's emphasis on a more strategic, operationally embedded role for syrups.\n\nWEAKNESSES: (1) The LLM introduces knowledge graph notation (KG links like 'KO - Sells → Syrups' and 'Syrups - Depends_On → KO') that, while potentially accurate, goes beyond what the ground truth explicitly states and adds interpretive layers not directly supported by the original answer. (2) The characterization of the shift as moving to 'higher-margin focus' and 'monetizes syrups earlier in the distribution chain' is somewhat speculative—the ground truth emphasizes operational integration and clarification of the syrup role rather than explicit margin or timing-of-monetization changes. (3) The phrase 'distinct revenue stream highlighted in the North America segment' is not explicitly confirmed in the ground truth, which focuses on the operational and strategic role rather than segment-specific revenue recognition. (4) The answer conflates 'revenue recognition timing' with 'monetization timing,' which are related but distinct concepts.\n\nMULTI-HOP REASONING: The answer does synthesize information across 2022 and 2023 appropriately, connecting bottling partner relationships to fountain retailer relationships. However, the reasoning about 'earlier monetization' and 'higher margins' extends beyond the ground truth's stated evolution.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers, dates, or calculations are provided in either answer, so quantitative accuracy is not directly testable. Both answers correctly reference 2022 and 2023 as the comparison years.\n\nSEMANTIC EQUIVALENCE: The core message aligns—syrups evolved from a primarily volume-driven, bottler-centric metric to a more strategically integrated component. However, the LLM's framing introduces additional interpretive elements (margins, earlier monetization, KG notation) that, while potentially correct, are not explicitly grounded in the ground truth provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 646,
        "total_tokens": 2115
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "\nDisney’s holding of Other Mortgage‑ and Asset‑Backed Securities rose from **$96 million** in fiscal 2022 (reported in Chunk 1) to **$120 million** in fiscal 2024 (Chunk 2) – an increase of $24 million, or about **25 %**.  This exposure grew from roughly **1 % of the total fair‑value hierarchy** ($96 ÷ $9,819 ≈ 0.98 % ≈ 1 %) in 2022 to about **1.5 % of the $8.07 billion hierarchy** ($120 ÷ $8,073 ≈ 1.49 %) in 2024, showing a modest upward trend in its proportion within the fair‑value structure.  The relationship is captured by the KG pattern DIS → Other MBS & ABS (Discloses/Invests_In), linking Disney’s disclosed investment to the security class across both years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that contradicts the ground truth. (1) PROPORTION TREND ERROR: The ground truth explicitly states that the proportion remained stable at 1% in both FY2022 and FY2024. However, the LLM claims the proportion increased from 1% to 1.5%, stating 'showing a modest upward trend in its proportion within the fair-value structure.' This is directly contradictory to the ground truth. (2) CALCULATION VERIFICATION: The LLM's calculations appear mathematically sound ($96M to $120M = $24M increase = 25% growth), and the absolute dollar amounts ($96M in 2022, $120M in 2024) are correct. However, the proportion calculations are problematic. The LLM calculates $120 ÷ $8,073 ≈ 1.49%, but the ground truth indicates this should be 1%. This suggests either the denominator used by the LLM is incorrect, or the ground truth's total fair value hierarchy figure differs from what the LLM used. (3) MULTI-HOP REASONING: The LLM correctly synthesized the investment values across two fiscal years and attempted to calculate proportions, but failed to arrive at the correct conclusion about the trend. The core multi-hop synthesis (Disney → Other MBS & ABS across FY2022 and FY2024) was attempted but the proportional analysis was incorrect. (4) SEMANTIC CONTRADICTION: The ground truth's key finding is that 'its proportional representation within the portfolio remained stable,' while the LLM concludes there is 'a modest upward trend.' These are semantically opposite conclusions. The LLM's answer is internally logical but factually incorrect relative to the ground truth. The absolute values and growth calculation are correct, but the critical insight about stable proportions was missed and contradicted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 482,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "\nBetween 2022 and 2023 the Skunk Works Advanced Development Program—funded by LMT’s investment—expanded its focus from a general portfolio of future unmanned and manned aerial systems and technology insertion for hypersonics, ISR, situational‑awareness and air‑mobility (2022) to an explicit emphasis on next‑generation **air‑dominance** capabilities while retaining those same domains, and it continued to pursue network‑enabled integration, technology insertion into existing aircraft, and new technology investments to keep U.S. and allied forces ahead of emerging threats. This evolution reflects LMT’s ongoing investment in Skunk Works to develop the advanced aircraft capabilities that underpin its future weapons and missile‑defense partnerships.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core evolution from 2022 to 2023, accurately capturing that air dominance became an explicit emphasis in 2023 while maintaining focus on hypersonics, ISR, situational awareness, and air mobility. The dates (2022 vs 2023) are correct. The identification of the shift as a refinement rather than overhaul aligns with the ground truth. WEAKNESSES: (1) The LLM introduces information not in the ground truth about 'LMT's investment' and 'network-enabled integration' and 'technology insertion into existing aircraft' - while these may be contextually relevant, they go beyond what the ground truth specifies about the evolution of focus areas. (2) The LLM adds commentary about 'keeping U.S. and allied forces ahead of emerging threats' and 'future weapons and missile-defense partnerships' which are not part of the original answer's scope. (3) The ground truth explicitly mentions 'unmanned and manned aerial systems' as a 2022 focus area, but the LLM's phrasing is less precise on this point. (4) The answer conflates Skunk Works' programs with broader LMT strategy in ways not clearly supported by the ground truth. MULTI-HOP REASONING: The LLM does synthesize the 2022-to-2023 comparison correctly at its core, but adds extraneous information that suggests either over-interpretation or synthesis from additional sources beyond what the ground truth specifies. The core factual evolution is captured accurately, but the answer is padded with contextual information that, while potentially accurate, goes beyond the specific question about focus area evolution. CALCULATION/NUMERIC ACCURACY: No calculations required; dates are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Partners_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 459,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "\nTesla’s Powerwall strategy shifted from a 2022 focus on expanding cross‑selling with residential solar and Solar Roof, streamlining installations and securing battery‑cell supply and skilled‑electrician labor to meet demand, to a 2023 approach that embeds the product in Tesla’s broader vehicle‑derived technology base—using a modular battery‑system design, advanced power‑electronics and remote‑control software to tighten grid integration, and scaling production through globally localized manufacturing to boost capacity and efficiency. This evolution reflects a tighter integration of Powerwall with Tesla’s vehicle engineering and a production emphasis on modular, software‑enabled manufacturing rather than solely on installation and cross‑sell tactics.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not supported by the ground truth. Key issues: (1) The ground truth makes no mention of 'vehicle-derived technology base,' 'modular battery-system design,' 'advanced power-electronics,' 'remote-control software,' or 'globally localized manufacturing' - these appear to be fabricated details not present in the source material. (2) The ground truth does not reference 'battery-cell supply' or 'skilled-electrician labor' as 2022 focus areas. (3) The LLM conflates Powerwall strategy with broader Tesla manufacturing philosophy that isn't supported by the filing data. (4) While the LLM correctly identifies that there was a shift from 2022 to 2023, the specific nature of that shift is mischaracterized. The ground truth emphasizes a shift from 'sales and availability focus' to 'deeper technical and strategic integration,' but the LLM's description of this shift (vehicle engineering integration, modular design, software-enabled manufacturing) introduces unsupported technical details. (5) The LLM answer reads as plausible but appears to be hallucinated elaboration rather than faithful synthesis of the actual filing information. The core insight about evolution from cross-selling/installation focus to deeper integration is partially captured, but the specific mechanisms and details are incorrect. This represents a failure in multi-hop reasoning accuracy despite addressing the general question structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 413,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "\nFrom 2022 to 2024, Gilead has kept Biktarvy at the core of its HIV portfolio—a single‑tablet, TAF‑containing regimen that was highlighted in the 2022 business overview as a key revenue driver and remains central to the company’s HIV strategy. However, the 2024 risk disclosures stress that, because Biktarvy is produced by and dependent on Gilead, its commercial success hinges on sustaining market share against generics and on the continued preference for TAF‑based regimens, making it vulnerable to competitive and treatment‑paradigm shifts.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key elements: Biktarvy as a single-tablet TAF-containing regimen, its positioning as a core revenue driver in 2022, and its continued centrality in 2024. The answer correctly identifies the shift in risk profile and vulnerability to competitive and treatment-paradigm changes. However, there are notable differences in emphasis and completeness compared to the ground truth: (1) The LLM answer emphasizes competitive risks from generics and market share competition, which is a valid commercial risk but differs from the ground truth's focus on 'overreliance on a narrow therapeutic class' and 'transition from product innovation to increased vulnerability.' (2) The ground truth explicitly frames the evolution as a shift from 'focus on product innovation' to 'increased vulnerability due to overreliance on a narrow therapeutic class,' suggesting a strategic repositioning narrative. The LLM answer captures the vulnerability aspect but doesn't fully articulate this strategic transition narrative. (3) The LLM answer mentions 'produced by and dependent on Gilead' which is somewhat redundant/unclear phrasing, whereas the ground truth more clearly articulates the dependency on TAF-based therapies as the core vulnerability. (4) The ground truth emphasizes that reduced preference for 'nucleoside-based therapies' could impact sales, while the LLM focuses on 'TAF-based regimens' preference—these are related but slightly different framings. The quantitative accuracy is high (no numerical errors), and the multi-hop reasoning correctly synthesizes information across 2022 and 2024 timeframes. The answer is contextually relevant and addresses the question's core components, but lacks the nuanced strategic narrative present in the ground truth regarding the shift from innovation focus to vulnerability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 511,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "\nBetween 2022 and 2023 the U.S. Retrospective Responsibility Plan added a new component – the “makewhole agreements” related to the class B‑1 common‑stock exchange offer – while retaining all of the prior mechanisms. The 2022 plan listed the U.S. litigation escrow agreement, the conversion feature of class B common stock, the Visa U.S.A. indemnification obligations, an interchange‑judgment sharing agreement, a loss‑sharing agreement and an omnibus agreement; the 2023 plan kept those same items **and** inserted the makewhole agreements, thereby expanding the plan’s composition. The escrow agreement remains a disclosed accounting policy that links the Company (V) to the policy, as shown by the KG triplets V → U.S. Litigation Escrow Agreement ← V.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and completeness. (1) CORRECTNESS: All factual information is accurate. The answer correctly identifies the 2022 composition (U.S. Litigation Escrow Agreement, conversion feature of Class B common stock, Visa U.S.A. indemnification obligations, interchange judgment sharing agreement, loss sharing agreement, omnibus agreement) and the 2023 addition (makewhole agreements relating to Class B-1 common stock exchange offer). The characterization of the change as an 'expansion' while retaining prior mechanisms matches the ground truth exactly. (2) QUANTITATIVE ACCURACY: No numeric values are present in either the question or answers, so this dimension is not applicable. The answer correctly references the years 2022 and 2023 without error. (3) ENTITY ACCURACY: All entities are correctly identified - the U.S. Retrospective Responsibility Plan, U.S. Litigation Escrow Agreement, Class B common stock, Class B-1 common stock, Visa U.S.A., and the various agreements are all named correctly. The company reference (V for Visa) is appropriate. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across two years, correctly identifying what was retained and what was added. The logical flow from 2022 to 2023 composition is clear and accurate. (5) MINOR OBSERVATION: The LLM adds an extra sentence about the escrow agreement being a disclosed accounting policy and references KG triplets. While this additional context is not explicitly in the ground truth answer, it does not contradict it and provides supplementary relevant information that enhances understanding. The core answer remains fully aligned with the ground truth. The answer is comprehensive, well-structured, and accurately addresses all aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 488,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "\nBased on the 2022 patent table (Chunk 1), Biktarvy’s U.S. and EU patents are not set to expire until 2033, so through 2024 the product remains under strong patent protection and continues to be a major, company‑owned revenue driver (KG triplet GILD → Biktarvy → GILD). However, the 2024 risk‑factor disclosure (Chunk 2) stresses that GILD’s “substantial portion of revenue” comes from HIV products like Biktarvy and warns that any shift away from nucleoside‑based regimens or generic competition could materially hurt sales, prompting the company to diversify into cell‑therapy and other areas to lessen its reliance on this single product.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and effectively synthesizes multi-hop information across 2022 and 2024 filings. STRENGTHS: (1) Correctly identifies Biktarvy's U.S. patent expiration in 2033 from 2022 data, matching ground truth exactly. (2) Accurately captures the evolution of strategic importance: strong patent protection in 2022 transitioning to heightened vulnerability by 2024 due to market pressures. (3) Properly synthesizes the multi-hop reasoning: patent timeline (2022) + risk disclosures (2024) = evolving strategic position. (4) Correctly identifies GILD as the company and Biktarvy as the product. (5) Appropriately notes the company's diversification strategy in response to HIV product dependency risks. MINOR ISSUES: (1) The LLM states 'U.S. and EU patents are not set to expire until 2033' but the ground truth specifies 'U.S. patent expiration in 2033 and no expiration listed in the E.U.' - the LLM's phrasing is slightly imprecise regarding EU patent status (saying 'not until 2033' implies a 2033 expiration, when ground truth indicates no expiration was listed). This is a semantic nuance rather than a factual error. (2) The LLM adds contextual detail about diversification into cell-therapy that, while relevant and likely accurate, goes slightly beyond what the ground truth explicitly states, though this enhances rather than detracts from the answer. QUANTITATIVE VERIFICATION: The 2033 date is correct and matches ground truth precisely. No calculations are required for this question. MULTI-HOP SYNTHESIS: The answer correctly combines patent protection data (2022) with risk factor disclosures (2024) to show the evolution of strategic importance, which is the core requirement of the multi-hop question. The reasoning is sound and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 490,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "\nNo modifications to AT&T’s financial guarantees for Illinois Bell Telephone Company were disclosed in the 2022‑2023 filings; both the 2022 (Chunk 1) and 2023 (Chunk 2) Form 10‑K/10‑Q sections list the identical “Guaranty of certain obligations of Illinois Bell Telephone Company” under Exhibit 4‑d (originally filed with the 2011 Form 10‑K), with no new exhibit, amendment or revised structure noted. Consequently, the guarantee’s scope and referenced documentation remain unchanged between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and directly addresses the question about modifications to AT&T's financial guarantees for Illinois Bell Telephone Company between 2022 and 2023. STRENGTHS: (1) All key facts are correct - the guarantee remained unchanged, referenced under Exhibit 4-d, and originally filed with the 2011 Form 10-K in both years; (2) Numeric/date accuracy is perfect - correctly identifies 2011 as the original filing year, 2022 and 2023 as the comparison years, and Exhibit 4-d as the consistent reference; (3) Multi-hop reasoning is sound - the answer correctly synthesizes information across two years of filings to conclude no modifications occurred; (4) Entity identification is accurate - correctly names AT&T and Illinois Bell Telephone Company; (5) The answer properly addresses all aspects of the question: guarantee structure (unchanged), referenced documentation (identical Exhibit 4-d), and the time period (2022-2023). MINOR CONSIDERATIONS: The LLM answer includes parenthetical references to \"Chunk 1\" and \"Chunk 2\" which are not present in the ground truth, but this is a stylistic choice that doesn't affect factual accuracy. The phrasing \"no new exhibit, amendment or revised structure noted\" is slightly more interpretive than the ground truth's \"no indication of modifications,\" but both convey the same meaning. The answer is semantically equivalent to the ground truth while maintaining clear, professional language. No calculation errors, no missing information, and no factual inaccuracies detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Guarantees]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 426,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "\nThe 2023 10‑K shows that Visa (V) holds Class C common stock and that the conversion ratio of Class C → Class A remains fixed at 4.0000 in both 2022 and 2023, indicating no change in the mechanics of dilution. Because the filing warns that converting Class C (and Class B) shares into Class A would increase the outstanding Class A pool and “could adversely affect the market price … and would dilute the voting power of existing Class A common stockholders,” the unchanged conversion rate means that any future conversion will continue to erode existing Class A shareholders’ voting strength by the same proportional amount—especially in the significant transactions (e.g., mergers, consolidations) where holders of Class B and C securities can cast votes. Consequently, the consistency suggests that the potential impact on Class A voting power in such corporate actions remains unchanged across the two years.",
      "correctness_score": 0,
      "quantitative_accuracy": 0,
      "qualitative_accuracy": 0,
      "contextual_relevance": 0,
      "detailed_feedback": "Evaluation failed: No response from LLM",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 0,
        "completion_tokens": 0,
        "total_tokens": 0
      },
      "error": "No response from LLM"
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla kept the Solar Roof anchored at Gigafactory New York, where it was produced alongside energy‑storage components and offered through solar‑PPA financing—making the roof’s output strategically dependent on that site and on a steady supply of specialized solar parts. By 2023 the company’s production emphasis moved toward mass‑market vehicles, yet the Solar Roof remained tied to the same manufacturing footprint and now faced heightened bottlenecks, regulatory approvals and supply‑chain risks, underscoring an increased reliance on Gigafactory New York and on external suppliers for its continued ramp.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "ANALYSIS: The LLM answer contains both accurate and problematic elements when compared to the ground truth.\n\nCORRECT ELEMENTS:\n1. Correctly identifies Gigafactory New York as the production location for Solar Roof in both 2022 and 2023\n2. Accurately captures that production remained at the same manufacturing footprint across both years\n3. Correctly notes increased supply chain risks and bottlenecks by 2023\n4. Properly identifies the shift in company focus toward mass-market vehicles\n\nPROBLEMATIC ELEMENTS:\n1. MAJOR ISSUE - The LLM answer claims Tesla \"kept the Solar Roof anchored at Gigafactory New York\" in both 2022 and 2023, suggesting continuity. However, the ground truth explicitly states that in 2022 Tesla \"directly produced\" the Solar Roof, but by 2023 the disclosures shifted to \"emphasizing dependencies and risks.\" This suggests a transition away from direct production involvement, not a continuation.\n2. The LLM introduces details about \"solar-PPA financing\" and \"energy-storage components\" that are not mentioned in the ground truth and cannot be verified as accurate from the provided context.\n3. The LLM answer misses the KEY TRANSITION described in the ground truth: from a \"production-centric view\" (2022) to a \"cautionary outlook on strategic execution risks\" (2023). Instead, it presents a more static picture of continued production with added risks.\n4. The phrase \"heightened bottlenecks, regulatory approvals and supply-chain risks\" adds specificity not present in the ground truth, which only mentions \"potential delays, supply chain constraints, and challenges in launching and ramping products.\"\n\nMULTI-HOP REASONING:\nThe LLM fails to properly synthesize the evolution described in the ground truth. The ground truth indicates a strategic shift in how Tesla discussed the Solar Roof (from production focus to risk emphasis), but the LLM presents it as continuous production with added complications. This represents a fundamental misunderstanding of the nature of the change.\n\nQUANTITATIVE ACCURACY: No specific numbers are provided in either answer, so this scores well on what is present, though the lack of quantitative detail is not penalized since the question doesn't require specific metrics.\n\nCONCLUSION: While the LLM captures some correct details (location, timing, general risk themes), it fundamentally misrepresents the nature of Tesla's relationship evolution with the Solar Roof by failing to capture the shift from direct production involvement to a risk-focused disclosure strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 681,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "\nBetween 2022 and 2023 the Company’s description of syrups shifted from a generic “intermediate product” sold to bottlers and fountain retailers (2022 KO → Syrups) to a more explicit strategic channel: the 2023 filing explains that bottling partners—both inside and outside the United States—use the syrups (and fountain syrups) to create finished beverages that are then packaged and sold through the Company’s consolidated bottling and distribution operations (2023 finished‑product operations ↔ bottling partners ↔ retailers/wholesalers).  This evolution shows syrups moving from a background concentrate input to a core product that directly fuels the finished‑beverage supply chain and the North America fountain‑syrup distribution network, linking the concentrate‑operations segment to the higher‑revenue but lower‑margin finished‑product segment.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution from 2022 to 2023 regarding syrup positioning. (2) Accurately captures that 2023 filing emphasized direct U.S. fountain syrup sales management by Coca-Cola. (3) Correctly notes the connection to North America operating segment. (4) No quantitative errors in dates or financial metrics mentioned. (5) Properly synthesizes multi-hop information about bottling partners, retailers, and wholesalers.\n\nWEAKNESSES: (1) The LLM answer introduces a potentially misleading characterization by stating syrups moved from 'background concentrate input' to 'core product that directly fuels the finished-beverage supply chain' - the ground truth emphasizes syrups as 'intermediate products' in both years, not a shift to 'core product' status. This overstates the strategic importance shift. (2) The LLM claims syrups link 'concentrate-operations segment to the higher-revenue but lower-margin finished-product segment' - the ground truth explicitly states concentrate operations yield HIGHER gross profit margins compared to finished product operations, not lower. This is a factual error in the margin characterization. (3) The LLM's description of the relationship is somewhat convoluted with the arrow notation and doesn't clearly articulate the key distinction the ground truth makes: that 2023 specifically highlighted fountain syrup operations being included in the North America operating segment, showing more structured regional focus. (4) Missing explicit mention that in 2022, syrups were described as yielding lower net operating revenues but higher gross profit margins - this comparative context is important.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2023 filings and connect syrups to distribution channels, but the reasoning contains the margin reversal error that undermines the accuracy of the synthesis.\n\nSEMANTIC ISSUES: While the general narrative of evolution is captured, the specific claim about margin relationships is inverted from ground truth, which is a material factual error despite correct identification of other elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 577,
        "total_tokens": 2065
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "\nThe company has continued to treat Africa/Eurasia as a distinct geographic reportable segment within its Oral, Personal and Home Care business—operating‑profit for that region was $206 million in 2020 and $203 million in 2021, indicating a stable, albeit modest, contribution— and the 2024 filing confirms that Africa/Eurasia remains one of the five geographic segments, accounting for roughly 45 % of the firm’s net sales (part of the emerging‑market mix that makes up about two‑thirds of total sales).  A July 1 2024 restructuring moved the skin‑health business from the Europe segment into North America, but it left the Africa/Eurasia reporting line unchanged, so the company’s operational focus on Africa/Eurasia has persisted through 2022‑2024 without alteration.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that severely undermine its credibility: (1) WRONG YEARS: The LLM cites 2020 ($206M) and 2021 ($203M) data when the question explicitly asks about 2022-2024 evolution. The ground truth states Africa/Eurasia had $203M operating profit in 2022, not 2021. This is a fundamental misalignment with the question's temporal scope. (2) UNSUPPORTED PERCENTAGE CLAIM: The LLM states Africa/Eurasia accounts for 'roughly 45% of the firm's net sales' - this specific percentage is not mentioned in the ground truth and appears to be fabricated or misattributed. (3) INCOMPLETE ANSWER: The LLM fails to address the key evolution point from the ground truth - that by 2024, Africa/Eurasia remained a distinct reportable segment, but the company made strategic refinements in how it organizes regional performance (the skin health business realignment from Europe to North America). The LLM mentions the skin health move but incorrectly characterizes it as leaving 'the Africa/Eurasia reporting line unchanged' without acknowledging this represents a strategic refinement in geographic reporting structure. (4) LOGICAL INCONSISTENCY: The LLM concludes 'the company's operational focus on Africa/Eurasia has persisted through 2022-2024 without alteration,' which contradicts the ground truth's emphasis on 'more nuanced operational focus' and 'strategic refinement in geographic reporting.' The answer misses the core insight that while Africa/Eurasia remained a segment, the company refined how it organizes regional performance. (5) MISSING CONTEXT: The answer doesn't adequately explain the evolution from 2022 to 2024 - it should highlight that Africa/Eurasia maintained its status as a distinct segment while the company made broader structural changes (skin health realignment) that signal evolving strategic priorities. The answer reads as if it's discussing 2020-2021 data rather than the requested 2022-2024 period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> GPE <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 530,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "\nJohnson & Johnson’s Orthopaedics business grew from $8.94 billion worldwide in 2023 (up 4.1 % YoY, with U.S. sales of $5.53 B and international sales of $3.42 B) to be presented in the 2024 filing as a core MedTech pillar that leans heavily on **enabling technologies** to support hips, knees, trauma, spine and sports applications; this strategic emphasis is underpinned by patented product platforms and generally available raw‑material supplies, while the 2023‑2024 sales data show modest 3.8 % U.S. and 4.6 % international growth, highlighting a continued focus on leveraging those technologies to expand global orthopaedic revenue.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core strategic shift from quantitative to qualitative emphasis on enabling technologies between 2023 and 2024. The answer appropriately captures the 2023 revenue figures ($8.94B globally, $5.53B U.S., $3.42B international) and growth rates (4.1% overall, 3.8% U.S., 4.6% international). The qualitative description of the 2024 positioning (enabling technologies, product platforms across hips, knees, trauma, spine, sports medicine) aligns with the ground truth. The multi-hop synthesis across years and the identification of the strategic pivot is sound.\n\nWEAKNESSES: (1) QUANTITATIVE ERROR - The LLM states 'modest 3.8% U.S. and 4.6% international growth' in the context of 2023-2024 comparison, but the ground truth specifies these percentages are from 2023 (comparing 2023 to prior year 2022). The LLM conflates the 2023 growth rates with the 2023-2024 period, creating ambiguity about whether 2024 growth rates are being reported. (2) INCOMPLETE ANSWER - The LLM does not explicitly state that 2024 filing omitted specific revenue figures, which is a critical part of the strategic evolution narrative. The ground truth emphasizes that 2024 'without revisiting specific revenue figures' - this absence is a key indicator of the strategic shift. (3) MINOR PRECISION - The LLM rounds $8,942M to $8.94B and $5,525M to $5.53B (acceptable), but the phrasing 'grew from $8.94 billion...to be presented' could mislead readers into thinking 2024 revenue figures are being provided when they are not.\n\nMULTI-HOP REASONING: The answer demonstrates adequate synthesis across 2023 and 2024 filings and correctly identifies the shift in presentation strategy. However, the conflation of growth rate timeframes weakens the precision of the multi-hop analysis.\n\nJUSTIFICATION: While the core narrative about strategic evolution is correct and most numbers are accurate, the ambiguity about which year's growth rates are being referenced and the failure to explicitly note the absence of 2024 revenue figures represent material omissions that affect the completeness and clarity of the answer. The answer is substantially correct but contains enough imprecision to warrant a score in the 6 range rather than 7+.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 601,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "\nIn the 2022 filing (Chunk 1) Visa’s loss‑sharing framework was broadened by a 2015 amendment that added any U.S. covered litigation transferred to or consolidated in MDL 1720—and any opt‑out actions arising from the same facts—to the scope of covered matters, and the ensuing omnibus agreement fixed liability at a 66.667 % Visa / 33.333 % Mastercard split, with the Visa portion allocated according to the Company’s U.S. retrospective responsibility plan (and a separate UK loss‑sharing deed governing VE‑territory claims).  \nThe 2023 filing (Chunk 2) confirms that these same mechanisms—loss‑sharing agreement, omnibus agreement, and litigation escrow—remain the vehicles for handling U.S. covered litigation, now explicitly defining U.S. covered litigation as all matters that are settled, resolved, or transferred into MDL 1720, thereby expanding the scope while preserving the identical 66.667 / 33.333 liability allocation and allocation methodology established in the 2022 omnibus agreement.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) All numeric values are correct - the 66.667%/33.333% liability split is accurately stated in both 2022 and 2023 contexts, and the October 2015 amendment date is correct. (2) Multi-hop synthesis is sound - the LLM correctly identifies and connects the loss-sharing agreement, omnibus agreement, and litigation escrow mechanisms across both years. (3) Entity accuracy is strong - Visa, Mastercard, MDL 1720, and Rule 23(b)(3) are all correctly identified. (4) The quantitative accuracy is high with proper formatting of percentages and dates.\n\nWEAKNESSES: (1) The LLM answer lacks explicit mention of the 'U.S. Retrospective Responsibility Plan' as a distinct consolidated framework in 2023, though it does reference 'allocation methodology' which partially captures this concept. The ground truth emphasizes this as a strategic pivot toward 'finalizing and managing legacy litigation exposure,' which the LLM doesn't explicitly articulate. (2) The LLM states the mechanisms 'remain the vehicles' and describes the 2023 scope as 'expanding the scope while preserving the identical...allocation,' but the ground truth suggests a more significant evolution - a shift from 'specific amendments and liability sharing' to a 'more comprehensive and retrospective liability framework.' The LLM characterizes this as preservation rather than evolution. (3) The phrase 'settled or otherwise fully or substantially resolved' from the ground truth is paraphrased as 'settled, resolved, or transferred' - while semantically similar, it loses the nuance of 'substantially resolved' which may indicate partial resolutions. (4) The LLM doesn't emphasize the strategic pivot aspect mentioned in the ground truth regarding the shift from 2022 to 2023 approaches.\n\nCALCULATION VERIFICATION: The liability percentages (66.667% Visa, 33.333% Mastercard) are mathematically correct and consistently stated. No calculation errors detected.\n\nMULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2023 filings, correctly identifying how the mechanisms evolved. However, it characterizes the evolution as 'preservation' rather than the more significant 'consolidation and strategic pivot' described in the ground truth.\n\nOVERALL: The answer is factually accurate on numbers and dates, correctly identifies all entities, and demonstrates sound multi-hop reasoning. However, it misses the nuanced characterization of the evolution as a strategic shift toward legacy litigation finalization, instead emphasizing continuity. This represents a meaningful but not critical gap in capturing the full scope of the answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1574,
        "completion_tokens": 698,
        "total_tokens": 2273
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "\nBetween 2022 and 2024 CL’s Guaranteed Investment Contract (GIC) position fell sharply—from $56 million ( $1 U.S. + $55 International ) in the 2022 filing (Chunk 1) to $34 million (entirely International) in the 2024 filing (Chunk 2), a reduction of roughly $22 million (≈40%).  This decline is also visible in the overall pension‑plan asset base, where GICs dropped from about 2.1 % of the $2.62 billion total investments reported in 2022 (Chunk 1) to roughly 1.8 % of the $1.93 billion total reported in 2024 (Chunk 2).  The shift indicates that CL is re‑allocating pension‑plan assets away from guaranteed contracts toward other fixed‑income and pooled‑fund investments, reflecting a more diversified and possibly higher‑yielding asset strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive analysis. CORRECT ELEMENTS: (1) All key numbers are accurate: $1M U.S. in 2022, $55M International in 2022, $34M International in 2024, and complete phase-out of U.S. GICs by 2024. (2) The aggregate calculation is correct: $1M + $55M = $56M total in 2022. (3) The reduction calculation is accurate: $56M - $34M = $22M decrease, representing approximately 39% reduction (LLM states ≈40%, which is appropriately rounded). (4) The percentage calculations are sound: 2.1% ($56M/$2.62B) and 1.8% ($34M/$1.93B) are both mathematically correct. (5) Multi-hop synthesis is excellent: the answer correctly combines data from 2022 and 2024 filings, identifies the U.S. vs. International split, and synthesizes this into a coherent narrative about strategic asset reallocation. MINOR CONSIDERATIONS: The LLM provides additional context about percentage of total pension assets and speculates about 'higher-yielding asset strategy,' which goes slightly beyond the ground truth but is reasonable inference from the data and adds value without contradicting the original answer. The wording differs from ground truth (e.g., 'fell sharply' vs. 'significant shift') but conveys equivalent meaning. The answer fully addresses both parts of the question: (1) how GICs evolved (with specific numbers and timeline), and (2) what this indicates about strategy (reallocation away from guaranteed contracts). All entities are correctly identified (CL, U.S. Pension Plans, International Pension Plans, GICs). The reasoning is sound and the synthesis across multiple data points is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 446,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "\nThe Mastercard Developer Platform has moved from a 2021‑era API gateway that exposed early crypto‑related programs (e.g., crypto‑purchase/conversion, Digital First Card, Digital Doors) to a 2024‑focused, security‑centric hub that streamlines the integration of tokenized, contactless and blockchain‑based services; it now offers a single‑access point with tools and APIs that let partners embed Click‑to‑Pay, tokenized checkout, programmable payments via the Mastercard Mul‑Token Network, and expanded Digital First™ capabilities into their solutions. As a product of Mastercard (MA) that both depends on the company’s technology and produces the connective layer enabling merchants, fintechs and crypto players to leverage Mastercard’s digital assets, the platform’s evolution reflects a strategic positioning as the central engine for new digital‑asset and emerging‑technology integration across the payments ecosystem.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) TEMPORAL ACCURACY PROBLEM: The LLM answer references 2021-era features and programs (crypto-purchase/conversion, Digital First Card, Digital Doors) that are NOT mentioned in the ground truth, which specifically compares 2022 and 2024. The ground truth makes no reference to 2021 or these specific 2021-era programs. This is a significant factual error - the LLM introduced information not supported by the source material. (2) UNSUPPORTED CLAIMS: The LLM mentions 'Click-to-Pay' and 'tokenized checkout' as 2024 features, but these are not mentioned in the ground truth answer. While these may be real Mastercard products, they are not part of the documented evolution between 2022-2024 in the knowledge graph. (3) CORRECT ELEMENTS: The LLM correctly identifies the Mastercard Multi-Token Network™ (with proper trademark) and its role in programmable payments and blockchain-based transactions, which matches the ground truth. The characterization of the platform as a 'single access point' is also correct. (4) CONCEPTUAL ALIGNMENT: The LLM's overall narrative about evolution from general integration to blockchain/emerging tech focus is directionally correct and aligns with the ground truth's core message. (5) MULTI-HOP REASONING: The LLM attempts to synthesize the platform's role across multiple stakeholder types (merchants, fintechs, crypto players), which shows reasonable multi-hop thinking, but this synthesis is not explicitly supported by the ground truth. (6) ENTITY ACCURACY: Mastercard is correctly identified, but the inclusion of ticker '(MA)' is unnecessary and slightly distracting. The core issue is that the LLM appears to have hallucinated or drawn from sources beyond the knowledge graph, introducing 2021 references and specific product names not in the ground truth, which violates the requirement to evaluate based on the provided knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 515,
        "total_tokens": 1975
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "\nThe company’s pension plans disclose a direct investment in **U.S. common stocks** (CL → U.S. common stocks ← Invests_In CL), yet the line‑item is reported as “‑” in both the 2022 and 2024 filings, indicating that the dollar exposure to U.S. equities is essentially unchanged (or negligible) year‑over‑year.  However, the overall pension‑plan asset mix shifted markedly: total U.S.‑focused investments fell from **$1.834 bn in 2022** to **$1.36 bn in 2024**, while the international allocation also contracted, suggesting the firm is deliberately **reducing its weighting in U.S. common stocks** and reallocating toward a more globally diversified set of assets.  This evolution reflects a strategic move away from concentrated U.S. equity exposure toward broader, possibly lower‑risk or higher‑return asset classes.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresentations of the ground truth. Key issues: (1) QUANTITATIVE ERRORS: The LLM cites '$1.834 bn in 2022' and '$1.36 bn in 2024' for 'total U.S.-focused investments,' but these figures are not supported by the ground truth and appear to be fabricated or misattributed. The ground truth specifically states the U.S. pension plan had NO allocation to U.S. common stocks in both 2022 and 2024, with only the international pension plan holding $2 million in both years. (2) MISCHARACTERIZATION: The LLM claims the company is 'deliberately reducing its weighting in U.S. common stocks' and 'reallocating toward a more globally diversified set of assets,' but the ground truth indicates a strategic decision to AVOID direct exposure to U.S. common stocks in the domestic pension portfolio, not a reduction from prior levels. (3) INCOMPLETE/INCORRECT SYNTHESIS: The LLM failed to identify the critical distinction between the U.S. pension plan (zero allocation) and the international pension plan ($2 million in both years), which is central to understanding the company's strategic asset allocation. (4) REASONING FLAW: The conclusion about 'reducing U.S. equity exposure' contradicts the ground truth that shows no change in allocation strategy between 2022 and 2024. The LLM appears to have invented supporting financial data rather than accurately synthesizing the actual pension plan holdings from the filings. The answer demonstrates poor multi-hop reasoning and fundamental factual inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 427,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "\nDisney’s 2022 10‑K notes that the bulk of its capital spend in the Parks & Experiences segment is earmarked for “new attractions, cruise ships, capital improvements and systems infrastructure,” signaling an explicit investment plan to grow the cruise‑ship business as part of its Parks expansion. The 2023 10‑K, however, flags significant operational‑risk concerns—demand for cruise experiences has yet to return to pre‑pandemic levels, and the business is exposed to uncontrollable factors such as health crises, extreme weather, regulatory shifts and changing consumer tastes—causing the company to temper its investment outlook and focus on risk mitigation while still viewing cruise ships as a strategic growth area. (These points reflect the KG relationship DIS → [Invests_In] → Cruise Ships ←[Operates_In]← DIS, integrating the capital‑investment detail from Chunk 1 with the risk‑analysis from Chunk 2.)",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of Disney's evolving cruise ship strategy between 2022 and 2023, with generally accurate synthesis of multi-hop information. STRENGTHS: (1) Correctly identifies the 2022 focus on capital investment in cruise ships as part of Parks & Experiences expansion strategy; (2) Accurately captures the 2023 shift toward operational risk considerations; (3) Properly identifies specific risk factors mentioned (health crises, extreme weather, regulatory changes, consumer preferences); (4) Correctly notes that demand had not returned to pre-pandemic levels; (5) Demonstrates sound multi-hop reasoning by connecting investment strategy from one year to risk mitigation focus in the next year; (6) Appropriately frames the evolution as a recalibration from growth to risk management. WEAKNESSES: (1) The statement 'demand for cruise experiences has yet to return to pre-pandemic levels' is presented as a 2023 finding but lacks explicit verification that this specific metric appears in the 2023 filing (ground truth emphasizes Hurricane Milton and external disruptions more prominently); (2) The phrase 'temper its investment outlook' is somewhat ambiguous—the ground truth suggests a shift in framing/emphasis rather than necessarily a reduction in absolute investment; (3) The answer states cruise ships are 'still viewing cruise ships as a strategic growth area' which slightly contradicts the ground truth's characterization of a shift from 'growth engine' to 'operational exposure'; (4) Missing explicit mention of Hurricane Milton, which the ground truth specifically highlights as a key 2023 operational risk example. QUANTITATIVE ACCURACY: No specific dollar amounts or percentages are provided in either answer, so this dimension is not directly testable. The temporal references (2022 vs 2023) are correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and connects capital investment strategy to operational risk considerations, demonstrating appropriate multi-hop synthesis. The KG notation reference adds credibility but is somewhat speculative. Overall, the answer captures the essential evolution accurately but with minor nuances that slightly soften the ground truth's emphasis on the strategic pivot from growth to risk mitigation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 622,
        "total_tokens": 2064
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "\nMastercard (MA) has continued to rely on short‑duration foreign‑exchange derivatives as a non‑designated‑hedge tool to curb the FX volatility that arises during its daily settlement cycle; both the 2022 filing (Chunk 1) and the 2024 filing (Chunk 2) disclose that the company enters into these contracts based on anticipated receipts and disbursements and records any resulting gains or losses in general and administrative expense.  The 2024 Form 10‑K expands the description—showing that the company still uses the same short‑term FX contracts for daily‑settlement risk, even noting recent de‑designations and re‑designations of euro‑denominated debt—yet the fundamental evolution is simply a persistence and modest scaling of this risk‑management practice rather than a shift in its core purpose.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the core practice of using short-duration FX derivative contracts in both 2022 and 2024; (2) Accurately captures the stated objective of reducing FX volatility from daily settlement activities; (3) Properly notes the non-designated hedge treatment and recording in G&A expense; (4) Correctly references the de-designations and re-designations of euro-denominated debt as evidence of dynamic strategy evolution; (5) Appropriately characterizes the relationship between continuity and change in the hedging approach. MINOR WEAKNESSES: (1) The LLM characterizes the evolution as 'persistence and modest scaling' rather than emphasizing the 'more dynamic approach' highlighted in the ground truth—this is a subtle semantic difference but the ground truth emphasizes the contrast between continuity in short-duration contracts and evolving broader strategy more explicitly; (2) The phrase 'expansion of description' in the 2024 filing is mentioned but the LLM doesn't fully elaborate on what specifically changed in how the company describes or manages these contracts beyond the debt de/re-designations. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required in this question, so this dimension is not heavily tested. The dates (2022, 2023, 2024) are all correct. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years and connects the short-duration contract usage with the broader debt hedging strategy changes, demonstrating sound multi-hop reasoning. The logic that continuity in one area contrasts with evolution in another is sound. SEMANTIC EQUIVALENCE: The answer conveys the essential information from the ground truth with appropriate flexibility in wording while maintaining factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Uses]- ORG",
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 513,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "\nFrom 2023 to 2024 Salesforce’s investment focus moved from a broad, risk‑aware portfolio of enterprise‑cloud companies—highlighted by warnings about market volatility, regulatory scrutiny and brand‑reputation exposure—to a more strategic, AI‑centric allocation that channels capital into early‑ and late‑stage cloud startups, AI‑driven platforms such as Agentforce, and the expansion of its AppExchange and partner ecosystem. This evolution deepens the mutual dependence captured by the KG pattern (CRM Invests_In Enterprise Cloud Companies ← Depends_On CRM), where the growth of Salesforce’s marketplace, developer community and cross‑selling initiatives increasingly relies on, and in turn fuels, the success of the enterprise‑cloud firms in its portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the core evolution from 2023 to 2024, capturing the shift from broad portfolio investment to strategic ecosystem dependency. (2) Correctly mentions AppExchange, ISVs, and developer ecosystem as key integration mechanisms. (3) Appropriately references AI-centric focus and Agentforce as part of 2024 strategy. (4) Accurately captures the mutual dependency relationship between Salesforce and enterprise cloud partners. (5) No quantitative errors present (no specific numbers to verify). WEAKNESSES: (1) The LLM introduces elements not clearly supported by the ground truth, particularly the emphasis on 'market volatility, regulatory scrutiny and brand-reputation exposure' as 2023 characteristics—while these may be mentioned in filings, they are not highlighted in the ground truth answer as defining features of the 2023 relationship. (2) The framing of 'risk-aware portfolio' with specific risk factors appears to be an inference not explicitly stated in the original answer. (3) The LLM's reference to 'mutual dependence captured by the KG pattern' and the notation (CRM Invests_In Enterprise Cloud Companies ← Depends_On CRM) is overly technical and somewhat circular, potentially confusing rather than clarifying. (4) The answer could be more explicit about the shift from 'financial investment' to 'strategic dependency' as the primary distinction between 2023 and 2024. MULTI-HOP REASONING: The LLM demonstrates sound multi-hop synthesis by connecting investment focus, ecosystem integration, and partner dependency across the two years. However, it adds interpretive layers (risk factors, AI-centric allocation) that go beyond what the ground truth explicitly states. SEMANTIC EQUIVALENCE: The core message aligns with ground truth—evolution from investment portfolio to ecosystem dependency—but the supporting details diverge in ways that could be considered speculative rather than grounded in the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 529,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "\nThe company’s accrual‑rate policy for vendor‑funding programs was essentially unchanged between fiscal 2023 and fiscal 2024—both years state that rates are set from the terms of individual vendor agreements and are continually reviewed and adjusted as actual purchase volumes are tracked throughout the year, with particular focus on programs that increase funding when graduated volumes are met.  The 2024 filing explicitly notes that no material change was made to the methodology from prior years, but it still emphasizes that accrued amounts are sensitive to differences between actual and projected purchase volumes, a risk that remains central to the estimation process.  (KG: LOW → ACCOUNTING_POLICY ← Changes → LOW, confirming the policy’s continuity and its link to the organization.)",
      "correctness_score": 4,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IN CORE CLAIM: The LLM answer fundamentally contradicts the ground truth on the key evolution between fiscal years. Ground truth states that fiscal 2023 'specifically highlighted sensitivity to graduated purchase volumes' while fiscal 2024 'omitted' this explicit reference, suggesting simplification/stabilization. The LLM answer claims the opposite—that both years 'state that rates are set from the terms of individual vendor agreements' with 'particular focus on programs that increase funding when graduated volumes are met,' implying continuity of explicit graduated volume language. This is a material factual error on the central question about how the approach 'evolved.' The LLM also states '2024 filing explicitly notes that no material change was made to the methodology from prior years,' which aligns with ground truth on methodology consistency, but then claims 2024 'still emphasizes that accrued amounts are sensitive to differences between actual and projected purchase volumes'—this contradicts the ground truth's assertion that the explicit graduated volume reference was omitted in 2024. WHAT WAS CORRECT: (1) Both years had consistent methodology (correct); (2) Accrual rates tied to vendor agreements (correct); (3) Continuous review and adjustment based on actual volumes (correct); (4) No material methodological change (correct). WHAT WAS INCORRECT: (1) The characterization of how the language evolved—the LLM suggests both years equally emphasized graduated volumes, when ground truth indicates fiscal 2024 omitted this explicit reference; (2) The claim that 2024 'still emphasizes' sensitivity to projected volumes contradicts the ground truth's point about omission/simplification; (3) The LLM misses the key distinction that fiscal 2023 had explicit graduated volume language while fiscal 2024 did not. MULTI-HOP REASONING: The LLM failed to properly synthesize the comparative analysis across the two fiscal years. It correctly identified that methodology remained consistent but failed to capture the nuanced evolution in disclosure language (explicit to implicit/omitted). The KG citation at the end appears fabricated and doesn't substantiate the claims made.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Changes]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 591,
        "total_tokens": 1983
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "\nThe LLY‑Boehringer Ingelheim alliance, created to jointly develop and market Jardiance, remained strategically intact from 2022 through 2024, with Boehringer Ingelheim continuing as LLY’s partner in the product’s commercialization.  Although the 2018 U.S. patent lawsuit that Boehringer Ingelheim filed against generic entrants over Jardiance was stayed and LLY was not a party, the relationship now faces new legal‑regulatory pressure: the 2022 Inflation Reduction Act required HHS to set Medicare prices for Jardiance, and in August 2024 HHS announced a 66 % discount, underscoring the product’s centrality to both firms and creating a shared risk of revenue erosion that must be managed jointly.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key elements: (1) The 66% discount figure is accurate and correctly attributed to the August 2024 HHS announcement under the IRA. (2) The numeric values and dates are correct - 2022 IRA reference, 2024 pricing announcement, and the 66% discount match ground truth. (3) The multi-hop synthesis is sound: the answer correctly traces the evolution from 2022 (when LLY was not a direct party to patent litigation) through 2024 (when Jardiance became subject to IRA pricing controls). (4) Entity identification is accurate - LLY, Boehringer Ingelheim, Jardiance, and the Hatch-Waxman Act are all correctly referenced. Minor strengths: The answer effectively captures the shift from 'arms-length' legal relationship to 'strategic entanglement' through the lens of shared regulatory/pricing pressure. The phrase 'shared risk of revenue erosion that must be managed jointly' semantically conveys the same dependency concept as the ground truth's 'deeper strategic entanglement and dependency.' One minor weakness: The LLM answer references the '2018 U.S. patent lawsuit' while the ground truth simply states it was 'initiated by Boehringer Ingelheim' without specifying 2018 - this additional date detail is not contradicted by ground truth but adds specificity not explicitly confirmed. The answer could have been slightly more explicit about how the IRA pricing directly impacted LLY's revenue projections and business strategy (mentioned in ground truth), though the 'revenue erosion' concept captures this. Overall, the answer successfully synthesizes the multi-hop relationship evolution across the 2022-2024 period with accurate numbers and sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 473,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "\nDisney’s capital‑investment focus on cruise ships moved from a general mention in the 2022 filing—where cruise ships were noted only as part of the broader “Parks, resorts, cruise ships and experiences” distribution and subject to economic‑condition risks (Chunk 1)—to a explicit priority in 2023, when the 10‑K states that “the majority of the Company's capital spend has been at our parks and experiences business, which is principally for … cruise ships” (Chunk 2). This shift aligns with the growth of cruise‑related revenue reported under Experiences (ticket, vacation‑club and merchandise sales) and signals that Disney is now directing substantial capital toward expanding its cruise‑ship fleet and related infrastructure as a core component of its Parks & Experiences strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of Disney's capital investment strategy evolution from 2022 to 2023. STRENGTHS: (1) Correctly identifies the shift from general mention in 2022 to explicit priority in 2023; (2) Accurately captures the key quote about 'majority of the Company's capital spend' directed toward parks and experiences including cruise ships; (3) Properly synthesizes multi-hop information across two fiscal years; (4) Correctly identifies cruise ships as part of the Experiences segment; (5) Appropriately notes the strategic elevation in focus. MINOR WEAKNESSES: (1) The LLM answer adds interpretive detail about 'cruise-related revenue reported under Experiences (ticket, vacation-club and merchandise sales)' that goes slightly beyond what the ground truth explicitly states—this is reasonable inference but adds a layer not directly confirmed in the original answer; (2) The phrase 'which is principally for … cruise ships' in the quoted material appears to be a paraphrase rather than exact quote, though the substance is accurate; (3) Could have been more explicit about the contrast between 2022's focus on 'risks from macroeconomic conditions' versus 2023's affirmative capital allocation strategy. QUANTITATIVE ACCURACY: No specific dollar amounts or percentages are provided in either answer, so this dimension is not heavily tested. The temporal references (2022 vs 2023) are correct. QUALITATIVE ACCURACY: The reasoning correctly identifies this as a strategic shift and properly contextualizes cruise ships within the broader Parks & Experiences business. The multi-hop synthesis across two years is sound. CONTEXTUAL RELEVANCE: The answer directly addresses the question about evolution of capital investment strategy and its relationship to the broader business segment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 492,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "\nMastercard Foundry has moved from a 2021‑era “lab” that mainly incubated early‑stage fintech players and launched programs such as Mastercard Installments, Click‑to‑Pay and the Digital First Card (2022) into a 2024‑scale platform that not only continues to surface and test emerging technologies but also delivers them as production‑ready, token‑based solutions—evidenced by the rollout of blockchain‑enabled programmable payments, expanded crypto‑on‑ramp capabilities, and AI‑driven authentication via the Mastercard Developer platform.  Throughout this evolution the Foundry remains the conduit through which the company’s core services (e.g., tokenization, contactless, Digital First) are co‑created with fintechs, start‑ups and financial institutions, turning experimental concepts into ecosystem‑wide offerings that now cover everything from small‑business digital‑presence tools to large‑scale crypto‑integrated payment flows.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ISSUES: (1) TEMPORAL MISMATCH - LLM answer references 2021-era developments and 2022 programs (Mastercard Installments, Click-to-Pay, Digital First Card) that are NOT mentioned in the ground truth, which specifically compares 2022 vs 2024. The ground truth makes no mention of these specific 2022 programs. (2) UNSUPPORTED CLAIMS - LLM introduces specific technologies and initiatives (AI-driven authentication via Mastercard Developer platform, expanded crypto-on-ramp capabilities, small-business digital-presence tools) that are NOT present in the ground truth answer. (3) FACTUAL ACCURACY ON CORE CLAIM - The LLM correctly identifies that Foundry evolved from a 'lab' focused on early-stage fintech to a more active innovation engine, which aligns with ground truth. (4) BLOCKCHAIN/PROGRAMMABLE PAYMENTS - LLM correctly mentions blockchain-enabled programmable payments, which matches the ground truth's reference to 'blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™'. (5) MULTI-HOP SYNTHESIS - While the LLM attempts to synthesize evolution across time periods, it does so by introducing information not in the ground truth rather than accurately synthesizing what was provided. The answer appears to conflate or add details from other sources not validated by the knowledge graph. STRENGTHS: The general narrative arc (lab → active innovation engine) is correct, and the emphasis on fintech partnerships and emerging technologies is appropriate. WEAKNESSES: Introduces specific product names and dates not in ground truth; overstates the scope of evolution with unsupported details; fails to focus on the 2022-2024 comparison as specified in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 470,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "\nBetween 2022 and 2024 the LLY‑Boehringer Ingelheim alliance shifted from relying on regulatory accelerants—Breakthrough‑Therapy and Fast‑Track designations and a 2022 EUA for a COVID‑19 therapy (Chunk 1)—to confronting direct U.S. price‑setting under the Inflation Reduction Act, with HHS in August 2024 applying up to a 66 % discount to Jardiance, the first collaborative product selected for government‑set pricing (Chunk 2). This evolution reflects a strategic move from seeking expedited approvals to managing revenue erosion as IRA‑mandated discounts and rebate obligations increasingly shape the financial outlook for both partners, while the R&D‑cost and approval‑uncertainty pressures highlighted in 2022 continue to underpin the partnership’s risk profile.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of the LLY-Boehringer Ingelheim collaboration between 2022 and 2024, with mostly accurate factual content. STRENGTHS: (1) Correctly identifies the shift from regulatory acceleration (Breakthrough Therapy, Fast Track designations) to pricing pressures under the Inflation Reduction Act; (2) Accurately cites the 66% discount figure for Jardiance; (3) Correctly identifies August 2024 as the timing of HHS pricing action; (4) Properly synthesizes the multi-hop concept of regulatory evolution affecting financial outcomes; (5) Appropriately contextualizes the strategic shift from expedited approvals to revenue management. WEAKNESSES: (1) Introduces a 2022 EUA for COVID-19 therapy that is not mentioned in the ground truth answer—while this may be factually accurate from the source documents, it represents additional information not in the original answer and could be considered scope creep or potential hallucination if not verified; (2) The phrase 'effective in 2026' from the ground truth is omitted, though the August 2024 timing is provided; (3) The answer adds interpretive language about 'R&D-cost and approval-uncertainty pressures' that goes beyond the ground truth's focus on the core regulatory-to-financial shift. QUANTITATIVE VERIFICATION: The 66% discount figure is correct and matches ground truth exactly. The year references (2022, 2024) are accurate. MULTI-HOP REASONING: The answer successfully synthesizes information across time periods and connects regulatory designations to financial outcomes, demonstrating sound multi-hop reasoning. The logical progression from regulatory facilitation to financial constraints is clearly articulated. SEMANTIC EQUIVALENCE: The core message aligns with ground truth—the collaboration evolved from regulatory support mechanisms to facing pricing constraints—though the LLM adds contextual details not in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 526,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "\nFrom 2023 to 2024 the CH‑53K King Stallion moved from being highlighted in the Rotary and Mission Systems (RMS) segment as a flagship “program of record” that would expand heavy‑lift capacity for the U.S. DoD and allied forces, to a central node in Lockheed Martin’s all‑domain, network‑centric strategy; the 2024 disclosure ties the helicopter to AI/ML, autonomous crewed‑uncrewed teaming and CJADC2‑enabled joint operations, positioning it not only as a lift platform but as a critical link in the company’s digital‑transformation and multi‑domain growth pillar within RMS.  This evolution reflects LMT’s continued stake in the CH‑53K (ORG ↔ PRODUCT) and its broader push to convert backlog into growth while integrating the helicopter into next‑generation, open‑architecture mission solutions.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the key entities (CH-53K King Stallion, Lockheed Martin, RMS segment, 2023-2024 timeframe). (2) No quantitative errors detected - no specific revenue figures are claimed in either answer, so numeric accuracy is neutral. (3) The LLM correctly captures the core evolution: from growth driver to integrated technology platform. (4) Correctly identifies the shift toward AI/ML, autonomy, and multi-domain solutions. WEAKNESSES: (1) OVER-SPECIFICATION: The LLM introduces specific terminology ('program of record,' 'CJADC2-enabled joint operations,' 'open-architecture mission solutions,' 'crewed-uncrewed teaming') that are NOT present in the ground truth. While these may be contextually reasonable for defense programs, they represent claims beyond what the knowledge graph confirms. (2) UNSUPPORTED CLAIMS: The phrase 'flagship program of record' and specific references to 'CJADC2' and 'open-architecture' are not mentioned in the original answer and cannot be verified against the ground truth. (3) TONE MISMATCH: The LLM answer is more assertive and detailed than the ground truth, which explicitly states 'no specific revenue figures are provided' and uses more cautious language ('evolved from being a growth driver among several others'). (4) SYNTHESIS ISSUE: While the LLM correctly identifies the evolution, it adds interpretive layers (converting backlog to growth, network-centric strategy framing) that go beyond what the ground truth documents. The ground truth is more measured: it notes the shift but doesn't claim specific strategic imperatives. MULTI-HOP REASONING: The LLM demonstrates sound reasoning in connecting the helicopter to broader strategic themes, but this reasoning appears to be inference rather than direct extraction from the filings. The ground truth answer is more conservative and document-grounded. VERDICT: The answer captures the essential evolution correctly but introduces unsupported specificity that reduces confidence in factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 545,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "\nThe 2022 filing lists a seven‑product diabetes slate (Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR and Basaglar) that LLY and Boehringer Ingelheim are jointly developing, whereas the 2024 filing references only four of those products (Jardiance, Glyxambi, Synjardy and Trijardy XR), omitting Trajenta, Jentadueto and Basaglar.  This contraction of the co‑commercialized portfolio signals a strategic narrowing: LLY is concentrating resources on the higher‑impact, better‑reimbursed agents within the partnership and de‑emphasising lower‑margin or lower‑access products, consistent with its stated priority of “discovering and developing … innovative, cost‑effective products that provide improved outcomes for patients and deliver value to payers.”  The shift also reflects the heightened competitive and regulatory pressures noted in both documents—intense market competition, pricing pressure from generics/biosimilars, and reimbursement barriers that can limit patient access—driving the partners to focus on the diabetes products that currently deliver the strongest commercial and payer‑acceptance performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive multi-hop reasoning. QUANTITATIVE ACCURACY: All product names and counts are correct—the 2022 portfolio of seven products (Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, Basaglar) and the 2024 portfolio of four products (Jardiance, Glyxambi, Synjardy, Trijardy XR) match the ground truth exactly. The identification of three removed products (Trajenta, Jentadueto, Basaglar) is accurate. ENTITY ACCURACY: Companies (LLY and Boehringer Ingelheim) and years (2022 vs 2024) are correctly identified. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing periods and correctly interprets the portfolio contraction as a strategic shift. The reasoning about lifecycle management, market demand, and patent protection aligns with the ground truth explanation. CONTEXTUAL RELEVANCE: The LLM goes beyond the ground truth by adding specific context about 'higher-impact, better-reimbursed agents,' 'lower-margin or lower-access products,' and competitive/regulatory pressures from generics/biosimilars. While these inferences are reasonable and consistent with the ground truth's mention of 'declining market relevance, generic competition,' they represent interpretive elaboration rather than explicit ground truth statements. This additional context is appropriate and enhances the answer without contradicting the ground truth. MINOR CONSIDERATION: The LLM includes a direct quote about 'discovering and developing innovative, cost-effective products' which appears to be from LLY's stated priorities, adding credibility to the interpretation. The answer maintains semantic equivalence with the ground truth while providing more detailed strategic analysis. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 489,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "\nThe JASSM program evolved from a supporting missile in Lockheed Martin’s Missiles and Fire Control (MFC) segment in 2023 to a production‑driven growth engine in 2024: Chunk 1 lists JASSM as one of MFC’s major programs and notes that 2023‑year backlog growth was driven by higher orders on classified and C‑130 programs (the classified category includes JASSM), while Chunk 2 reports a $1.2 billion sales lift in 2024 “due to production ramp‑up on … JASSM,” and explicitly cites “higher orders on JASSM” as a primary reason for the 2024 backlog increase.  This ramp‑up also under‑pinned the $1.4 billion rise in MFC net sales, yet the same period saw a $1.2 billion drag on operating profit from profit‑booking adjustments on a classified program, highlighting that JASSM’s expanding production and backlog contribution co‑existed with financial pressures tied to its underlying cost structure.  (The KG relationship LMT → JASSM (Produces) and JASSM → LMT (Depends_On) captures that the missile is both produced by and strategically dependent on Lockheed Martin.)",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution of JASSM from 2023 to 2024, accurately cites the $1.2 billion production ramp-up in 2024, and correctly notes JASSM's contribution to backlog increases. The multi-hop synthesis across years and segments is sound, and the answer appropriately addresses both production activity and strategic importance. The contextual framing of JASSM as a 'production-driven growth engine' aligns with the ground truth narrative.\n\nWEAKNESSES AND ERRORS: (1) QUANTITATIVE ISSUE - The LLM introduces a '$1.4 billion rise in MFC net sales' and a '$1.2 billion drag on operating profit from profit-booking adjustments on a classified program.' These specific figures are NOT present in the ground truth answer and cannot be verified against it. The ground truth only mentions the $1.2 billion increase in tactical and strike missile programs. The introduction of the $1.4 billion MFC sales figure and the $1.2 billion profit drag appears to be extrapolation or inference not supported by the provided ground truth. (2) INCOMPLETE ALIGNMENT - The ground truth explicitly states 'there was no specific mention of significant changes in its production volume or backlog contribution' in 2023, but the LLM's characterization of 2023 as merely 'supporting' is less precise about the lack of specific data. (3) OVER-SPECIFICATION - The LLM adds details about 'profit-booking adjustments on a classified program' and cost structure pressures that, while potentially accurate from source documents, go beyond what the ground truth synthesizes and introduces unverified claims.\n\nMULTI-HOP REASONING: The core multi-hop synthesis (2023 baseline → 2024 ramp-up → backlog contribution) is correct and well-reasoned. However, the addition of unverified financial metrics weakens the overall accuracy.\n\nNUMBER VERIFICATION: The $1.2 billion figure is correct and matches ground truth. The $1.4 billion and $1.2 billion profit drag figures cannot be verified against the ground truth provided and represent potential hallucination or unsupported inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 562,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "\nBetween 2023 and 2024 JPMorgan shifted its credit‑risk assessment for Business Banking Loans from a descriptive classification of the loan book (e.g., “scored residential mortgages, home‑equity loans and business banking loans” — Chunk 1) to a quantitative early‑warning framework that treats delinquency rates as the primary indicator and supplements them with loan‑level metrics such as LTV, refreshed FICO scores and geographic concentration — details given in Chunk 2.  This evolution means that early signs of borrower distress are now identified through rising delinquency trends and adverse credit‑quality ratios (high LTV or low FICO) rather than merely monitoring portfolio composition, allowing JPM to flag at‑risk borrowers sooner.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution in JPM's credit risk assessment approach for Business Banking Loans between 2023 and 2024, shifting from descriptive portfolio classification to quantitative early-warning frameworks. The answer accurately captures the shift toward delinquency rates as primary indicators and mentions supplementary metrics (LTV, FICO scores, geographic concentration). The reasoning about earlier intervention and more granular monitoring is sound and aligns with the ground truth. However, there are some notable differences: (1) The LLM answer introduces specific metrics (LTV, refreshed FICO scores, geographic concentration) that are not explicitly mentioned in the ground truth, which could represent either additional detail from the source documents or potential over-specification. (2) The ground truth emphasizes the 30+ days past due threshold as a specific early warning signal, which the LLM answer generalizes to 'rising delinquency trends' without this specificity. (3) The LLM answer references 'Chunk 1' and 'Chunk 2' which suggests document sourcing but these chunk references are not verifiable against the ground truth. (4) The ground truth explicitly connects the shift to 'broader consumer loan risk frameworks' and the 'Consumer, excluding credit card loan portfolio' segment context, which the LLM answer does not mention. The multi-hop reasoning is generally sound—the answer does synthesize the 2023 vs 2024 comparison and explains implications for early distress identification. No numerical errors are present. The semantic meaning largely matches the ground truth, though with some additional details that may or may not be supported by the actual filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 469,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "\nTarget’s SPP II was first adopted in the 2016 plan statement and, in the 2022 filing, was **restated and amended effective May 1 2022** (Chunk 1 lists the 2016 version; Chunk 2 identifies the “Target Corporation SPP II (2022 Plan Statement) (as amended and restated effective May 1, 2022)” as Exhibit (10)F) – a revision that updated the incentive mechanics and related performance criteria. The 2023 filing again references this **same restated 2022 SPP II** without further change (Chunk 2, Exhibit (10)F), indicating that the 2022 amendment remains the current governing terms. This progression shows that Target is deliberately refining its executive‑compensation framework—shifting from the original 2016 structure to a more recent, performance‑focused plan and maintaining that updated structure—to align executive incentives with shareholder interests and governance best practices.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IN FACTUAL ACCURACY: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The LLM claims that in the 2022 filing, the SPP II was 'restated and amended effective May 1 2022,' but the ground truth explicitly states that in the 2022 filing, the SPP II plan was described under the '2016 Plan Statement, as amended and restated effective April 3, 2016.' The May 1, 2022 restatement date only appears in the 2023 filing, not the 2022 filing. This is a critical chronological error that undermines the entire answer. The LLM has reversed the timeline of when the plan was updated. Additionally, the LLM's interpretation that 'the 2023 filing again references this same restated 2022 SPP II without further change' is correct in substance but the foundation for this claim is built on the incorrect dating of when the 2022 restatement occurred. The ground truth clearly indicates an evolution from 2016 Plan Statement (in 2022 filing) to 2022 Plan Statement (in 2023 filing), showing a change between the two years. The LLM's answer obscures this key distinction by conflating the timing. The reasoning about Target refining its compensation framework is reasonable and contextually appropriate, but it is based on incorrect factual premises about when the changes occurred. The answer fails to properly capture the multi-hop synthesis required: comparing what was in the 2022 filing versus what was in the 2023 filing, and the LLM has gotten the 2022 filing details wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 420,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "\nThe Olumiant collaboration requires Incyte to pay the company up to **$100 million of regulatory‑milestone payments** and **up to $100 million of sales‑milestone payments**, obligations that were already reflected in the 2022 filing where $260 million and $210 million of such milestones had been capitalized as intangible assets and were being amortized to cost of sales; the 2024 filing re‑affirms that these caps remain unchanged and that any future milestone receipts would again be recorded as intangible assets and amortized over the collaboration term. In addition, the 2024 filing notes a **$300 million one‑time payment** from a separate Boehringer Ingelheim amendment, but this does not alter the Incyte milestone exposure, indicating that the evolution of the company’s financial obligations under Olumiant from 2022 to 2024 has been limited to the continued eligibility for the previously disclosed $100 million regulatory and $100 million sales milestones.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains fundamental errors that contradict the ground truth and misrepresents the evolution of financial obligations. Key issues: (1) DIRECTIONAL ERROR - The LLM states Incyte is to PAY the company $100M regulatory and $100M sales milestones, when the ground truth clearly indicates Incyte is ELIGIBLE TO RECEIVE these payments (i.e., the company pays Incyte, not vice versa). This is a critical reversal of the payment direction. (2) INCORRECT FOCUS - The LLM discusses capitalized intangible assets and amortization accounting treatment, which is not addressed in the ground truth answer and appears to confuse the accounting mechanics with the actual evolution of obligations. (3) MISSING KEY INSIGHT - The LLM fails to capture the core finding from the ground truth: that by 2024, there is NO MENTION of remaining regulatory milestones, suggesting they were paid out or no longer applicable. Instead, the LLM claims 'the evolution...has been limited to the continued eligibility for the previously disclosed $100 million regulatory and $100 million sales milestones,' which contradicts the ground truth's finding of a shift away from regulatory milestones. (4) IRRELEVANT INFORMATION - The introduction of the $300 million Boehringer Ingelheim payment is not part of the Incyte Olumiant collaboration and distracts from the core question. (5) INCOMPLETE EVOLUTION ANALYSIS - The LLM does not address the shift from 'both regulatory and sales milestones' to 'primarily sales-based compensation' that is central to the ground truth answer. The answer fundamentally misunderstands the question's focus on how obligations EVOLVED from 2022 to 2024, instead claiming they remained unchanged.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 465,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "\nCisco’s APJC exposure rose modestly from **$5,360 million** at the end of fiscal 2022 to **$5,382 million** at the end of fiscal 2023 – an increase of roughly **$22 million (≈0.4 %)**.  The growth reflects a small rise in acquisitions ($16 million) and foreign‑currency translation adjustments ($6 million) reported in the APJC balance line, while the overall segment‑level asset base expanded only marginally (the total balance grew from $38,304 million to $38,535 million).  This evolution is captured in Cisco’s segment reporting, which treats APJC as a distinct geographic segment managed by the CODM, and is linked to the corporate relationship CSCO ↔ APJC shown in the knowledge‑graph.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides a fiscal 2022 APJC asset figure of $5,360 million, but the ground truth explicitly states that 'specific financial figures for APJC were not disclosed in the provided data' for fiscal 2022. This is a fundamental factual error - the LLM fabricated a number that does not exist in the source material. The only confirmed figure is $5,382 million for fiscal 2023. (2) CALCULATION ERROR - The LLM calculates a $22 million increase (0.4%) based on the false 2022 figure. This calculation is mathematically correct IF the 2022 figure were real, but since it's fabricated, the entire calculation is invalid. (3) MULTI-HOP REASONING FAILURE - The LLM claims to synthesize segment reporting and asset balances but actually invents data rather than acknowledging the limitation stated in the ground truth. The ground truth explicitly notes that 'segment-level asset values were not explicitly itemized' in 2022. (4) ENTITY ACCURACY - While Cisco and APJC are correctly identified, the temporal and data availability context is completely misrepresented. (5) SEMANTIC EQUIVALENCE - The LLM's answer fundamentally contradicts the ground truth by claiming specific 2022 figures exist when they explicitly do not. The correct answer should acknowledge that only 2023 data ($5,382 million) is available and that 2022 comparisons cannot be made with specific APJC asset figures. The LLM's confidence in presenting fabricated numbers as fact is a severe accuracy failure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> GPE <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 420,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "\nThe LLY‑Boehringer Ingelheim partnership—formalized by a Partners_With relationship in which Boehringer Ingelheim depends on LLY for U.S. market access—began with strong demand‑driven growth for Jardiance, delivering a 30 % increase in U.S. revenue and a 28 % rise abroad in 2022 (Chunk 1).  However, the Inflation Reduction Act’s price‑setting provisions led HHS in August 2023 to select Jardiance for government‑set pricing and, by August 2024, to impose a 66 % discount off the 2023 list price (Chunk 2), forcing the collaborators to reshape their strategy and brace for accelerated revenue erosion as regulatory pressure intensified.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of the multi-hop question. (1) CORRECTNESS VERIFICATION: All key numbers are accurate - 30% U.S. revenue increase in 2022, 28% increase outside U.S., August 2023 selection for government pricing, August 2024 66% discount. All dates are correct. The answer properly identifies the Inflation Reduction Act (IRA) as the regulatory driver. (2) QUANTITATIVE ACCURACY: All percentages and dates match ground truth exactly. No calculation errors present. The 66% discount figure is correctly cited as compared to 2023 U.S. list price. (3) ENTITY ACCURACY: Companies correctly identified (LLY and Boehringer Ingelheim), Jardiance correctly named as the drug in question, years correctly referenced (2022, 2023, 2024). The partnership relationship is accurately characterized. (4) MULTI-HOP REASONING: The answer successfully synthesizes information across multiple time periods and regulatory events - connecting 2022 growth metrics to 2023 regulatory selection to 2024 pricing impact. The causal chain (IRA → HHS selection → pricing discount → revenue impact) is logically sound and well-articulated. (5) MINOR CONSIDERATIONS: The phrase 'Partners_With relationship in which Boehringer Ingelheim depends on LLY for U.S. market access' adds contextual detail not explicitly in ground truth but is reasonable inference from the collaboration structure. The characterization of 'accelerated revenue erosion' is a reasonable interpretation of the 66% discount impact, though ground truth uses 'significantly affecting revenue projections.' Overall, the answer is comprehensive, accurate, and demonstrates strong understanding of the multi-hop synthesis required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 472,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "\nBetween 2022 and 2023 GM’s disclosures kept the core warning that product‑safety recalls and alleged defects could “materially adversely affect our business” through direct recall costs (parts, labor) and heightened regulatory scrutiny—especially when the issue involves a global platform such as the Chevrolet Bolt EV.  However, the 2023 filing deepened the emphasis, linking those financial and reputational risks explicitly to GM’s strategic positioning in electric‑ and autonomous‑vehicle technologies, noting that safety concerns can damage brand image, brand equity and consumer trust and thus jeopardize its ability to “lead the industry with respect to new technologies, such as EVs and AVs.”  In short, the evolution is a shift from a generic risk statement in 2022 to a more strategic articulation in 2023 that ties recall‑related financial exposure to the company’s EV/AV leadership and overall brand reputation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) CORRECTNESS: The answer accurately captures the evolution of GM's risk disclosures between 2022 and 2023, correctly identifying the Chevrolet Bolt EV as the specific global platform example and accurately characterizing the shift from cost-centric to strategic/reputational concerns. The core claim that 2023 filings linked safety risks to EV/AV leadership positioning is factually correct and well-supported. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were required in this question, so this dimension is not applicable. The answer appropriately avoids introducing unsupported figures. Score of 10 reflects absence of numeric errors. (3) QUALITATIVE ACCURACY: The multi-hop reasoning is sound. The answer correctly synthesizes information across two fiscal years (2022 and 2023), identifies the relevant company (GM), the specific product (Chevrolet Bolt EV), and the strategic context (EV/AV technologies). The characterization of the evolution as moving from 'generic risk statement' to 'strategic articulation' is semantically equivalent to the ground truth's 'cost-centric concern to broader strategic risk.' The answer also correctly identifies the specific reputational elements (brand image, brand equity, consumer trust) that appear in the 2023 disclosure. (4) CONTEXTUAL RELEVANCE: The answer directly addresses all aspects of the multi-part question: the evolution between years, the emphasis on financial and reputational risks, the global platform example, and the EV/AV positioning context. Minor observation: The LLM answer provides slightly more operational detail (mentioning 'parts, labor' and 'regulatory scrutiny') than the ground truth, but this represents helpful elaboration rather than error. The answer is appropriately focused and relevant throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 517,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "\nBetween 2022 and 2024 Costco’s Japanese subsidiary issued roughly **$500 of Guaranteed Senior Notes** in November 2023 (fixed rates of 1.400% – 2.120% with maturities from 2033 to 2043) and **repaid $77 of those notes in July 2024**, with the issuance and repayment recorded as other long‑term debt that is valued under **Level 3 inputs**; at the same time the company **retired $1,000 of its 2.750% U.S. Senior Notes in May 2024**, which helped push the total long‑term debt fair value down from **≈ $5.738 bn (end‑2023) to ≈ $5.412 bn (end‑2024)**. This evolution reflects Costco’s long‑term financing strategy of **diversifying funding through low‑cost, long‑dated overseas debt while retiring higher‑coupon domestic senior obligations**.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The $500M in Guaranteed Senior Notes issued in November 2023 with fixed rates of 1.400%-2.120% and maturities 2033-2043 is accurate; (2) The $77M repayment in July 2024 is correct; (3) The Level 3 inputs valuation method is accurate; (4) The strategic interpretation about diversifying funding through low-cost, long-dated overseas debt is sound and aligns with the ground truth's conclusion about transparent, strategic long-term financing. PROBLEMATIC ELEMENTS: (1) The LLM introduces information about retiring $1,000M of 2.750% U.S. Senior Notes in May 2024 and provides specific debt fair value figures ($5.738bn end-2023 to $5.412bn end-2024) that are NOT mentioned in the ground truth answer. This represents scope creep beyond what was asked and introduces unverified data; (2) The ground truth specifically states the 2022 information was only 'described in general terms' with Level 3 inputs, but the LLM doesn't clearly distinguish the evolution from 2022 to 2024 in terms of disclosure transparency - it jumps directly to 2023-2024 details; (3) The answer conflates the Japanese subsidiary's notes with broader U.S. debt retirement, which may be accurate but goes beyond the specific question about the Japanese subsidiary's Guaranteed Senior Notes. MULTI-HOP REASONING: The LLM correctly synthesizes the issuance and repayment information and connects it to financing strategy, but adds extraneous information about U.S. Senior Notes that wasn't part of the ground truth answer. QUANTITATIVE ACCURACY: The core numbers for the Japanese subsidiary ($500M, $77M, rates, maturities) are correct, but the introduction of unverified debt figures and U.S. note retirement details reduces confidence in the quantitative accuracy score. The answer would have been stronger by focusing solely on the Japanese subsidiary's evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 521,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "\nThe disclosed tables show Cisco’s available‑for‑sale debt investments at **$9 (2022)** and **$15,592 (2023)**, a rise of roughly **$15,583** between the two years; this expansion is evident from the 2022 figure in Chunk 1 and the 2023 column in Chunk 2.  The KG relationship **(CSCO ‑ [Discloses]→ Available‑for‑sale debt investments)** confirms that these securities are a material, disclosed component of Cisco’s portfolio, indicating that the company is deliberately increasing its fixed‑income holdings to boost yield and manage liquidity.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer is fundamentally incorrect on all key metrics and reaches the opposite conclusion from the ground truth:\n\n(1) QUANTITATIVE ACCURACY FAILURES:\n- LLM states 2022 value was $9M and 2023 was $15,592M, claiming a RISE of $15,583M\n- Ground truth clearly states: 2022 = $9M (gains), 2023 = $15,592M (start) declining to $9,865M (end)\n- The LLM completely misidentified what the 2023 figures represent - it treated the beginning balance ($15,592M) as the year-end value, missing the actual decline to $9,865M\n- Correct calculation: $15,592M - $9,865M = $5,727M DECREASE (not increase)\n- LLM's calculation of $15,583M increase is mathematically wrong and directionally opposite\n\n(2) DIRECTIONAL ERROR:\n- Ground truth: Strategic REDUCTION in holdings (decrease of $5,727M)\n- LLM conclusion: Company is \"deliberately increasing its fixed-income holdings\"\n- This is the exact opposite interpretation and contradicts the actual data movement\n\n(3) MULTI-HOP REASONING FAILURE:\n- LLM failed to properly synthesize the 2023 data, which shows both a beginning balance ($15,592M) and ending balance ($9,865M)\n- The model appears to have confused or misread which figures represent the actual year-end positions\n- Did not correctly identify that the question asks about change BETWEEN years, requiring comparison of year-end positions\n\n(4) ENTITY/METRIC ACCURACY:\n- Correctly identified Cisco and available-for-sale debt investments\n- However, misinterpreted the temporal relationship and values of these metrics\n\n(5) SEMANTIC EQUIVALENCE:\n- The answer conveys completely opposite information from ground truth\n- Claims expansion when there was contraction\n- Claims deliberate increase when there was strategic reduction\n- This is not a wording difference but a fundamental factual reversal\n\nThe LLM answer demonstrates a critical failure in reading financial data tables and synthesizing multi-year comparisons, resulting in conclusions that are 180 degrees opposite from the correct answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reduces]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 548,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "\nJPMorgan Chase is impacted by the “System Damage” risk factor — a risk that negatively impacts the firm — and the 2023 and 2024 10‑K filings show this exposure has deepened: both years link third‑party vendor attacks, ransomware and the difficulty of fully restoring stolen or manipulated data to that risk, while the 2024 filing expands the scope to include the ongoing migration of client‑facing services to the cloud, the possibility that recovery costs may exceed cyber‑insurance coverage, and heightened emphasis on early detection and oversight of vendor‑related vulnerabilities. Consequently, the firm’s vulnerability to system‑damage events caused by external vendors and the associated data‑recovery challenges has grown materially from 2023 to 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies JPMorgan Chase and the 2023-2024 timeframe; (2) Accurately captures the evolution of system damage risks from 2023 to 2024; (3) Properly synthesizes multi-hop information about third-party vendor attacks, ransomware, and data recovery challenges; (4) Correctly notes the expansion of scope in 2024 to include cyber insurance coverage limitations and vendor vulnerability oversight; (5) Appropriately characterizes the trend as a 'material' increase in vulnerability. MINOR GAPS: (1) The LLM answer mentions 'cloud migration of client-facing services' which is not explicitly mentioned in the ground truth - this appears to be an additional detail not contradicted but also not confirmed by the original answer; (2) The ground truth specifically mentions 'zero-day vulnerabilities' and 'distributed denial-of-service attacks' as 2023 risks, which the LLM answer does not explicitly reference, though it does capture the broader evolution; (3) The ground truth mentions 'inability to prevent systems from processing fraudulent transactions' as a new 2024 concern, which the LLM answer does not explicitly state. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2023 and 2024 filings and properly identifies the evolution pattern. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The LLM's characterization of the risk evolution is semantically equivalent to the ground truth, using slightly different language but conveying the same essential information about growing external cyber threats and financial implications. No quantitative errors detected (no specific numbers provided in either answer to verify).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 483,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "\nBy the end of 2024 Costco had invested heavily in the private‑label supply chain—owning land‑only warehouse sites and expanding its distribution and logistics network (≈130.9 million sq ft across the U.S., Canada and international locations) as well as building dedicated processing, packaging and manufacturing facilities that produce its private‑label items.  These operational investments, together with the 2022‑filed strategy of deepening private‑label penetration through early‑volume purchasing, supplier cost‑sharing and pricing controls, are reflected in the KG relationship where **COST depends on and produces Private Label Items**.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core operational investments Costco made by 2024 to support private-label growth: dedicated processing, packaging, and manufacturing facilities. The answer also appropriately references the 2022 strategic context and connects it to 2024 execution. However, there are issues with quantitative accuracy: (1) The LLM introduces a specific figure of '≈130.9 million sq ft' for distribution and logistics network expansion, which is not present in the ground truth and cannot be verified as accurate from the provided context. This is a potential hallucination or unsupported claim. (2) The ground truth does not mention 'land-only warehouse sites' as an investment type, and this detail appears to be added without clear support. (3) The LLM adds strategic details like 'early-volume purchasing, supplier cost-sharing and pricing controls' which, while potentially accurate from 2022 filings, go beyond what the ground truth explicitly states about operational investments made by 2024. The qualitative reasoning is sound—the LLM correctly synthesizes the multi-hop connection between 2022 strategy and 2024 execution, and the knowledge graph relationship notation is appropriate. The answer demonstrates good understanding of the strategic evolution from external sourcing to internal production capabilities. However, the introduction of unverified quantitative claims (the 130.9M sq ft figure) and unsupported details (land-only warehouse sites) reduces confidence in the answer's factual accuracy. The core answer about manufacturing/processing facilities is correct and well-reasoned, but the embellishments with specific numbers and additional details that cannot be verified from the ground truth lower the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 483,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "\nUnitedHealth Group’s Medicaid‑managed‑care bidding approach showed continuity but deepened risk awareness from 2022 to 2023: both the 2022 and 2023 10‑K filings describe bids that rely on assumptions about enrollment, utilization and medical‑cost levels, and they warn that any material error in those assumptions—whether from unexpected program changes, competitor‑driven lower rates, or inaccurate cost forecasts—can materially harm the company’s results, financial position and cash flows.  The 2023 filing adds explicit warnings that chronic failure to meet CMS benchmark requirements (e.g., staying below the Medicare Part D regional benchmark or losing Medicaid contract renewals) can trigger termination of government contracts, and it emphasizes that the company must continually adjust benefits, cease unprofitable plans and intensify cost‑management to keep bids accurate, underscoring that bid‑accuracy risk is a persistent and evolving exposure across both years.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: The LLM answer fundamentally misrepresents the evolution described in the ground truth. The ground truth clearly states an EVOLUTION or SHIFT from 2022 to 2023: 2022 focused on contract renewal risk/member retention, while 2023 shifted to emphasizing assumptions behind bids (enrollment, utilization, medical costs). The LLM answer incorrectly claims 'continuity' and states both years describe the same bid assumptions, which contradicts the ground truth's explicit statement of evolution. The LLM also introduces information about CMS benchmark requirements and Medicare Part D that is NOT mentioned in the ground truth, suggesting hallucination or over-inference. CORRECT ELEMENTS: The LLM correctly identifies that both years involve assumptions about enrollment, utilization, and medical costs, and that material errors can harm results and cash flows. The company names and years are correct. REASONING FAILURE: The multi-hop synthesis fails because the LLM does not capture the key distinction between 2022's focus (contract renewal/member retention risk) and 2023's focus (bid assumption accuracy and competitive dynamics). Instead, it presents both years as having similar concerns, missing the evolution that is central to the question. The introduction of CMS benchmarks and Medicare Part D details appears to be unsupported by the ground truth and weakens the answer's credibility. SEMANTIC MISMATCH: The ground truth emphasizes a shift in emphasis/focus, while the LLM emphasizes continuity with 'deepened risk awareness'—these are fundamentally different narratives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Competes_For]-> REGULATORY_REQUIREMENT <-[Bids_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 438,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "\nMET’s municipal exposure is reported as part of its Fixed‑Maturity Securities‑AFS and, per the 2022 fair‑value hierarchy disclosure (Chunk 2), the entire municipal portfolio was classified at **Level 2** with a fair‑value of **$159 million** – a classification that remained unchanged from the prior year, indicating no shift in hierarchy tier from 2022 to 2023. This Level 2 placement reflects the “Depends_On” relationship between MET and the municipal instrument (KG: MET → Municipals) and the “Discloses” link where Municipals provides the hierarchy detail to MET, confirming that MET’s valuation approach for municipals stayed consistently at Level 2 while the absolute exposure modestly declined from earlier years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains critical factual errors that contradict the ground truth. (1) MAJOR ERROR - 2022 Valuation: The LLM states the 2022 municipal portfolio was classified at Level 2 with $159 million, but the ground truth clearly indicates it was valued at $14,212 million in 2022 and was NOT explicitly classified under Level 2 (it was categorized under 'Estimated Fair Value' without detailed hierarchy breakdown). This is a massive discrepancy - the LLM has confused the 2023 figure ($159 million) with 2022. (2) MAJOR ERROR - Hierarchy Classification Evolution: The LLM claims Level 2 classification 'remained unchanged from the prior year,' but the ground truth explicitly states that in 2022 there was NO detailed breakdown of valuation hierarchy levels, while 2023 introduced explicit Level 2 classification. This represents a significant change in transparency/disclosure, not consistency. (3) QUANTITATIVE ACCURACY FAILURE: The LLM provides $159 million for 2022 when it should be $14,212 million - an error of approximately $14 billion. (4) REASONING FAILURE: The LLM failed to synthesize the multi-hop information correctly. The question asks about evolution FROM 2022 TO 2023, requiring comparison of two distinct years. The LLM appears to have conflated the years or misread the source data. (5) The LLM's statement about 'modest decline from earlier years' is contradicted by the actual 98.9% decline from $14,212M to $159M, which is substantial, not modest. The answer demonstrates fundamental misunderstanding of the temporal evolution and misidentification of which values correspond to which years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 444,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "\nFrom fiscal 2022 to 2024 Microsoft moved Office 365 from a primarily perpetual‑license model—where revenue was recognized up‑front and usage was estimated as variable consideration under multi‑year on‑premises deals (Chunk 1)—to a portfolio of subscription‑focused agreements that give customers far greater licensing flexibility.  The 2024 disclosures introduce the Microsoft Online Subscription Agreement (monthly/annual SMB subscriptions), the Microsoft Customer Agreement (non‑expiring, digital purchase), the Microsoft Products & Services Agreement (no organization‑wide commitment), Open Value and Select Plus programs, and related partner frameworks (Chunk 2), all of which treat Office 365 subscriptions as recurring, ratably‑recognized revenue and expand eligibility across small, medium and large organizations.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures some key elements of Microsoft's evolution in Office 365 licensing but contains significant inaccuracies and problematic characterizations. STRENGTHS: (1) Correctly identifies the shift toward subscription-focused models from 2022 to 2024; (2) Accurately names the three primary agreement types (Microsoft Customer Agreement, Microsoft Online Subscription Agreement, Microsoft Products and Services Agreement); (3) Correctly notes the move toward monthly/annual subscription options and reduced organizational commitment requirements; (4) Properly identifies the shift to ratable revenue recognition for subscriptions. CRITICAL ERRORS: (1) The claim about a 'perpetual-license model' in 2022 is misleading and contradicts the ground truth—Office 365 in 2022 was already subscription-based, not perpetual; (2) The reference to 'multi-year on-premises deals' and 'variable consideration' appears to conflate Office 365 (cloud-based) with on-premises products, which is factually incorrect; (3) The characterization of the 2024 Microsoft Customer Agreement as 'non-expiring, digital purchase' is vague and potentially inaccurate—the ground truth describes it as enabling seamless cloud service subscriptions without specifying non-expiring status; (4) The claim about 'perpetual-license model' revenue being 'recognized up-front' contradicts the ground truth which states 2022 subscriptions were 'recognized ratably over the coverage period.' MULTI-HOP REASONING: The answer attempts to synthesize evolution across years but does so with fundamental mischaracterizations of the 2022 baseline. The comparison between 2022 and 2024 is undermined by incorrectly describing 2022 as perpetual-license based. QUANTITATIVE ISSUES: No specific numbers are provided in either answer, so quantitative accuracy cannot be directly verified, but the conceptual framework is flawed. The answer demonstrates partial understanding of the licensing evolution but introduces significant factual errors that would mislead readers about the actual nature of Office 365 in 2022.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Includes]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 558,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "\nThe 2022 filing (Chunk 1) shows MET reported a Level 3 balance of **$708 million** in Fixed‑Maturity Securities AFS, essentially all classified as “Other Investments,” and added **$183 million** of net purchases during the year. In the 2023 filing (Chunk 2) the Level 3 balance had fallen to **$64 million**, broken down as **$54 million** corporate, **$2 million** foreign bonds and **$8 million** other securities, with no material Level 3 exposure elsewhere. This shift—from a large, single‑category Level 3 position to a much smaller, diversified mix of high‑grade corporate and sovereign assets—indicates that MET is deliberately reducing its exposure to complex, illiquid securities and emphasizing higher‑quality, more transparent assets in its AFS portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS - The LLM answer contains fundamentally incorrect numbers that contradict the ground truth. (1) QUANTITATIVE ACCURACY FAILURES: The LLM claims 2022 Level 3 balance was $708 million in 'Other Investments,' but ground truth shows only $13 million total ($1M corporate + $1M foreign + $11M equity). The LLM's $708M figure appears to be fabricated or from a different category entirely. The LLM claims 2023 balance was $64 million ($54M + $2M + $8M), but ground truth shows $884 million total ($54M corporate + $2M foreign + $828M other). The LLM incorrectly states '$8 million other securities' when ground truth clearly shows $828 million. This is an 103x error on a major component. (2) COMPOSITION MISREPRESENTATION: Ground truth shows 2022 had $11M in Equity Securities, which the LLM completely omits. Ground truth shows 2023 had $828M in Other Investments, which the LLM drastically understates as $8M. (3) DIRECTIONAL ANALYSIS ERROR: The LLM concludes MET is 'reducing exposure to complex, illiquid securities' and moving to 'higher-quality assets,' but the actual data shows the opposite - a massive increase in 'Other Investments' from essentially zero to $828M, suggesting increased exposure to less transparent/more complex securities. (4) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the year-over-year comparison. While the LLM correctly identified some 2023 components ($54M corporate, $2M foreign), it fundamentally misread the 'Other Investments' figure and drew an inverted conclusion about strategy. The ground truth indicates a shift TOWARD more 'Other Investments' (diversification/complexity), not away from it. This is a semantic reversal of the actual strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 472,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "\nBetween 2022 and 2024 Microsoft has moved Office 365 from a stand‑alone productivity suite into the center of its cloud‑first, AI‑enabled portfolio—embedding it within the broader “service and other” revenue stream that also includes Azure, Dynamics 365 and Xbox, and positioning it as a key delivery channel for generative‑AI capabilities and platform‑agnostic cloud experiences.  At the same time, the company acknowledges intense competitive pressure from AI‑driven rivals, prompting heavier investments in AI research, infrastructure and security to keep Office 365’s performance, compatibility and market share on par with emerging cloud‑based alternatives.  (Both the 2022 10‑K note on service revenue and the 2024 10‑K discussion of AI‑focused competition inform this evolution.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the evolution of Office 365 from 2022 to 2024, capturing the shift from standalone positioning to integration within broader cloud services; (2) Accurately references the portfolio components (Azure, Dynamics 365, Xbox) and their relationship to Office 365; (3) Properly synthesizes the AI-driven competitive pressures and Microsoft's response through increased investment in AI research and infrastructure; (4) Correctly identifies the competitive threats from free, advertising-funded applications and open-source AI models; (5) Appropriately cites both 2022 and 2024 10-K filings as sources. MINOR CONSIDERATIONS: (1) The LLM answer uses slightly different phrasing ('stand-alone productivity suite' vs. the ground truth's 'explicitly listed as a key component') but conveys semantically equivalent meaning; (2) The LLM answer emphasizes 'platform-agnostic cloud experiences' which is a reasonable inference about integrated cloud delivery but is not explicitly stated in the ground truth; (3) The phrase 'keep Office 365's performance, compatibility and market share on par' is a reasonable interpretation of competitive response but adds slight interpretive language beyond the ground truth's more direct statement about 'enhanced, integrated cloud experiences.' QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are required or provided in either answer, so this dimension scores perfectly. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years (2022 vs 2024) and multiple filing sections (service revenue discussion and AI competition discussion), demonstrating sound multi-hop reasoning. The logical flow from 2022 positioning through 2024 evolution to competitive response is clear and accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Includes]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 513,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "\nBetween 2022 and 2023 UnitedHealth Group continued to assess credit‑related impairments on its available‑for‑sale debt securities, but the 2023 disclosure refines the methodology: it now explicitly evaluates the present‑value of expected cash flows, the issuer’s financial condition and near‑term prospects, and any specific events that could affect collectability, while still using the fair‑value‑vs‑amortized‑cost threshold; the 2022 filing noted that no significant credit deterioration existed and that the allowance for credit losses was immaterial, and the 2023 filing confirms the allowance remains immaterial but adds that non‑credit impairments are recorded through other comprehensive income and that full impairment is recognized in earnings only if the security is intended for sale. Thus, the evolution is a more detailed, criteria‑driven evaluation with the same limited financial impact.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution in UnitedHealth Group's credit impairment methodology between 2022 and 2023, with accurate identification of key methodological changes and consistent financial impact conclusions. STRENGTHS: (1) Correctly identifies that 2022 showed no significant credit deterioration and immaterial allowance for credit losses; (2) Accurately captures the 2023 refinement distinguishing credit-related vs. non-credit-related impairments; (3) Properly notes that non-credit impairments flow through other comprehensive income while credit impairments affect earnings; (4) Correctly identifies the more detailed evaluation criteria in 2023 (present value of expected cash flows, issuer financial condition, fair value vs. amortized cost); (5) No quantitative errors or incorrect numbers/dates. WEAKNESSES: (1) The phrase 'full impairment is recognized in earnings only if the security is intended for sale' is somewhat imprecise and could be clearer - the ground truth emphasizes the distinction between how credit vs. non-credit impairments are recorded, not conditional on intent to sell; (2) The answer could more explicitly state that the 2023 approach represents a 'formalized' process with a 'more structured evaluation framework' as noted in the ground truth; (3) Minor semantic difference: the answer says 'continues to assess' which slightly downplays the evolution/formalization that occurred. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the progression from a simpler 2022 approach to a more detailed 2023 framework. The comparison is logically sound and addresses both methodology and financial impact dimensions. ENTITY ACCURACY: Company name correct (UnitedHealth Group), years correct (2022 and 2023), financial metrics properly identified. Overall, this is a solid answer that captures the essential evolution with minor wording/emphasis issues that don't significantly detract from factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> RISK_FACTOR <-[Records]- ORG",
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 549,
        "total_tokens": 2042
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "\nThe 2022 filing (Chunk 1) shows that MET’s pension and other post‑retirement benefit plans had a target 85 % and an actual 84 % allocation to Fixed Maturity Securities AFS for pensions, and a 95 % actual allocation for other post‑retirement benefits, indicating a heavy and stable weighting to this asset class. In 2023 (Chunk 2) the dollar amount of those securities grew to $6,714 million in the pension portfolio and $1,274 million in other post‑retirement benefits—still representing roughly 81 % of total plan assets—and the fair‑value hierarchy disclosed $1,537 million in Level 1, $3,029 million in Level 2 and $64 million in Level 3 for pensions, while other post‑retirement benefits held $58 million in Level 1, $663 million in Level 2 and $37 million in Level 3. Thus, MET’s exposure to Fixed Maturity Securities AFS remained dominant from 2022 to 2023, with both the absolute valuation and the composition across fair‑value levels expanding.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensive synthesis of multi-hop information across 2022 and 2023 filings. STRENGTHS: (1) All key numeric values are correct: 84% allocation for pensions in 2022, 95% for other postretirement benefits in 2022, $6,714 million for pension benefits in 2023, $1,274 million for other postretirement benefits in 2023. (2) Fair value hierarchy breakdown is accurate: Level 1 ($1,537M), Level 2 ($3,029M), Level 3 ($64M) for pensions; Level 1 ($58M), Level 2 ($663M), Level 3 ($37M) for other postretirement benefits. (3) The calculation that these amounts represent roughly 81% of total plan assets in 2023 is reasonable and demonstrates proper synthesis. (4) Multi-hop reasoning is sound: the answer correctly traces the evolution from percentage-based allocation in 2022 to dollar valuations with fair-value hierarchy detail in 2023. (5) Entity identification is correct (MET, pension benefits, other postretirement benefits). (6) The answer goes beyond the ground truth by providing additional fair-value hierarchy detail, which adds value without contradicting the original answer. MINOR CONSIDERATIONS: The ground truth mentions a 'target 85%' for pensions in 2022, which the LLM correctly includes but the original answer omits. The LLM's characterization of the shift from 'percentage-based allocation' to 'detailed valuation breakdown' aligns with the ground truth's description. The conclusion about 'dominant exposure' and 'composition expanding' is well-supported by the data presented. No calculation errors detected. All numbers verified as accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 441,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "\nLowe’s moved Kitchens & Bath from being simply listed under the broader **Home Décor** grouping in its 2022 merchandise‑division presentation (Chunk 1) to being called out as a distinct, strategically‑important product line in the 2023 “Our Products” section, where it is paired with dedicated supply‑chain handling for big‑and‑bulky items and highlighted alongside new brand additions such as Klein Tools (Chunk 2). This evolution—underscored by the KG relationship **LOW → Kitchens & Bath** and **Kitchens & Bath → LOW**—shows that by 2023 the category had been elevated from a peripheral décor offering to a core, high‑visibility segment of Lowe’s portfolio, warranting its own supply‑chain focus and expanded assortment.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer captures some correct elements but has significant gaps and introduces unsupported details. CORRECT ELEMENTS: (1) The answer correctly identifies that Kitchens & Bath was repositioned between 2022 and 2023, (2) It correctly notes the shift from a broader grouping to more strategic prominence, (3) The general direction of elevation/importance is accurate. PROBLEMATIC ELEMENTS: (1) The LLM introduces specific details not in the ground truth (Klein Tools brand additions, dedicated supply-chain handling for big-and-bulky items) that cannot be verified and may be hallucinated, (2) The LLM describes the 2022 positioning as 'simply listed under broader Home Décor' but fails to explicitly mention the specific companion categories (Appliances, Décor, Flooring, Paint) that the ground truth identifies, (3) The LLM fails to explicitly state that in 2023 Kitchens & Bath was repositioned alongside core construction/renovation categories like Lumber, Building Materials, and Rough Plumbing—this is a critical detail showing the strategic shift toward home improvement/remodeling, (4) The LLM does not clearly articulate the connection to higher-value home projects or the 'Total Home' strategy mentioned in the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize the evolution but does so incompletely and with unverified embellishments. The core insight about repositioning is present but the specific categorical context that demonstrates the strategic shift is missing. QUANTITATIVE ACCURACY: No numbers or calculations are involved, so this scores well (8/10) with minor deductions for vague references to 'chunks' without specific data. QUALITATIVE ACCURACY: Moderate (5/10) due to missing key categorical details and introduction of unverified claims about supply-chain handling and brand additions. The answer would benefit from explicitly naming the 2023 peer categories and the 'Total Home' strategy connection.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Offers]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 526,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "\nMondelez’s Cheese & Grocery segment generated $1.99 bn of net revenue in 2021 (Chunk 1), and the 2024 filing still lists it as one of several “adjacent, locally relevant” categories alongside gum, candy and powdered beverages (Chunk 2) while the company’s strategic narrative focuses on accelerating growth in chocolate, biscuits and baked snacks through its four core priorities. The KG relationship—MDLZ Produces Cheese & Grocery and Cheese & Grocery Has_Stake_In MDLZ—confirms the product‑segment link, showing that the firm treats cheese & grocery as a supplemental, region‑specific revenue stream rather than a primary long‑term growth pillar.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "CRITICAL ERRORS: (1) YEAR MISMATCH - LLM states '$1.99 bn of net revenue in 2021' but ground truth clearly specifies 2022 as the baseline year with $1,990 million. This is a significant factual error in temporal framing. (2) INCOMPLETE EVOLUTION NARRATIVE - LLM fails to capture the key strategic shift: the ground truth explicitly states that by 2024, Mondelez 'no longer reported direct production' and 'instead indicated only a strategic stake.' The LLM's answer mentions 'strategic stake' but doesn't clearly articulate this transition from direct production to stake-only positioning, which is the core of the question about how the focus 'evolved.' (3) MISSING COMPARATIVE ANALYSIS - The ground truth provides a clear 2022-to-2024 comparison showing a fundamental business model change. The LLM answer conflates information without clearly delineating the before/after shift. (4) CORRECT ELEMENTS - The LLM correctly identifies: (a) Cheese & Grocery as an 'adjacent' category, (b) the focus on core categories (chocolate, biscuits), (c) the supplemental nature of the segment, and (d) the revenue figure of approximately $1.99 billion (though with wrong year attribution). (5) REASONING QUALITY - The multi-hop synthesis is partially sound (connecting product relationships and strategic priorities) but undermined by the temporal error and incomplete evolution narrative. The answer reads more as a snapshot than a strategic evolution analysis as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 405,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "\nAbbott continues to list the enteral‑feeding products in the same order in both filings—Jevity comes first, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, **Freego™ (Enteral Pump)** and its sets, then Nepro and Vital—so Jevity remains positioned before Freego™ in both years. However, the 2022 filing shows each product with its ® trademark symbol (e.g., “Jevity ®, … Freego™ (Enteral Pump)”), whereas the 2023 filing drops those ® marks (e.g., “Jevity, … Freego™ (Enteral Pump)”), reflecting a more streamlined presentation that still places Jevity ahead of Freego™ but removes the trademark notation. Both Jevity and Freego™ are products **produced by Abbott** (KG: ABT → Jevity → ABT; ABT → Freego™ → ABT).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth on the core claim of the question. CRITICAL ERRORS: (1) The LLM states that 'Abbott continues to list the enteral-feeding products in the same order in both filings' and that 'Jevity remains positioned before Freego™ in both years,' claiming NO CHANGE occurred. However, the ground truth explicitly states that a significant change DID occur: in 2022, Freego™ products were listed LAST (after Osmolite and Oxepa), but in 2023, Freego™ products were moved to appear IMMEDIATELY AFTER Jevity, before Glucerna and Osmolite. This is a material reordering that the LLM completely missed. (2) The LLM introduces products (Nepro and Vital) that are not mentioned in the ground truth answer, suggesting potential hallucination or confusion with different product listings. (3) The LLM focuses on trademark symbol differences (® vs no ®) as the primary change, which is a minor formatting detail that obscures the actual substantive change in product positioning that the question asks about. (4) The LLM's multi-hop reasoning failed to properly compare the 2022 and 2023 product orderings side-by-side, which was the core requirement of the question. The answer demonstrates a fundamental misunderstanding of what changed between the two filings. While the LLM correctly identifies that both Jevity and Freego™ are Abbott products, this contextual accuracy does not compensate for the major factual error regarding the actual change in product positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 419,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "\nMET’s municipal‑bond portfolio was reported as an available‑for‑sale (AFS) security; in 2021 the holdings were valued at **$14.2 bn** (amortized cost $11.8 bn) with unrealized gains of $2.5 bn and a small loss of $13 m (Chunk 1), while the 2022 disclosure shows the same securities now valued at only **$159 m** and classified as **Level 2** in the fair‑value hierarchy (Chunk 2).  This sharp decline and the shift to a Level 2 classification signal that MET has deliberately reduced its municipal‑credit exposure and moved to a more observable, lower‑risk valuation tier, reflecting a proactive credit‑risk‑management strategy that trims higher‑uncertainty municipal assets and relies on more reliable fair‑value inputs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: (1) YEAR MISLABELING: The LLM states '2021' and '2022' but the ground truth clearly indicates '2022' and '2023'. This is a fundamental temporal error that undermines the entire analysis. The question asks about 2022-to-2023 evolution, but the LLM discusses 2021-to-2022. (2) QUANTITATIVE ERRORS: The LLM correctly identifies $14.2bn (matching $14,212M) and $159M, but attributes these to wrong years. The unrealized gains figure of $2.5bn in the LLM answer should be $2,464M ($2.464bn), a minor discrepancy but still inaccurate. (3) INCOMPLETE CLASSIFICATION INFO: The ground truth specifies both 2022 and 2023 holdings were 'fixed maturity securities AFS' - the LLM only mentions AFS classification without clearly stating this applies to both years. (4) FAIR VALUE HIERARCHY: The LLM correctly identifies the Level 2 classification for 2023 ($159M), but fails to note that the 2022 position ($14,212M) was NOT explicitly stated as Level 2 in the ground truth, making the comparison incomplete. (5) MULTI-HOP REASONING: While the LLM correctly infers a credit risk reduction strategy, it does so based on incorrect year labels, which undermines the validity of the temporal comparison. The reasoning about 'observable, lower-risk valuation tier' is sound but applied to the wrong time period. (6) MISSING DETAIL: The ground truth emphasizes the 'dramatic reduction' from $14,212M to $159M - a 98.8% decline - which the LLM acknowledges as 'sharp decline' but doesn't quantify. The LLM also doesn't mention the unrealized losses component ($13M) from 2022. VERDICT: While the LLM demonstrates understanding of the strategic implications and correctly identifies the key numbers, the systematic year mislabeling (2021/2022 instead of 2022/2023) is a disqualifying error for a financial analysis question where temporal accuracy is critical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 505,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "\nAbbott expanded its interest‑rate hedge program, increasing the outstanding notional amount from roughly $87 million (the hedge position shown for 2021 in the balance‑sheet data) to about $2.2 billion of contracts outstanding at December 31 2023, thereby converting a sizable portion of its fixed‑rate debt into variable‑rate exposure; these fair‑value hedges are recorded at market value and adjust the carrying amount of the underlying fixed‑rate borrowings, allowing the company to mitigate interest‑rate risk. This evolution is reflected in the knowledge‑graph relationship where interest‑rate hedge contracts are introduced by and depend on Abbott, underscoring the strategic shift in its debt‑management approach between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM introduces a $87 million figure for 2021 that is NOT mentioned in the ground truth and appears to be fabricated or misattributed. The ground truth clearly states Abbott had $2.2 billion in interest rate hedge contracts in 2022, not $87 million in 2021. This is a critical factual error. (2) TEMPORAL MISALIGNMENT - The LLM claims the evolution occurred 'between 2022 and 2023' but then references 2021 data ($87 million) which contradicts the question's specific focus on 2022-2023 evolution. The ground truth explicitly states the notional value was $2.2 billion in BOTH 2022 and 2023, showing consistency, not expansion. (3) CORE FACTUAL ERROR - The LLM states Abbott 'increased' the notional amount from $87M to $2.2B, but the ground truth indicates the amount remained 'consistent at approximately $2.2 billion' between 2022 and 2023. This is a fundamental mischaracterization of the evolution. (4) MISSING KEY INFORMATION - The LLM fails to mention that the notional value remained stable at $2.2 billion in both years, which is the central finding of the ground truth. Instead, it incorrectly portrays this as an expansion. (5) QUALITATIVE REASONING - While the LLM correctly identifies that these are fair-value hedges converting fixed-rate to variable-rate debt and mentions the strategic purpose, it fundamentally misrepresents the actual evolution by inventing a 2021 baseline and claiming growth where there was stability. (6) MULTI-HOP SYNTHESIS - The LLM failed to correctly synthesize the 2022-2023 comparison, instead introducing extraneous 2021 data and mischaracterizing the trend. The ground truth's key insight about 'more detailed disclosures' in 2023 is also absent from the LLM answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 481,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "\nBetween 2022 and 2024 3M moved from issuing new fixed‑rate registered notes to actively shrinking that portfolio: the company let $500 million of such notes mature in 2023, repaid $650 million of fixed‑rate medium‑term notes (including portions of the 2049/2050 series) in 2023, and extinguished a further $1.1 billion of medium‑term notes in 2024, while earlier make‑whole calls had already retired $1 billion of notes due 2021.  To manage interest‑rate exposure, 3M had entered into 2021 interest‑rate swaps that converted $500 million and $300 million of the 2049 and 2050 fixed‑rate notes into floating‑rate debt (initially LIBOR‑based, later SOFR‑based), and it continued to refinance maturing obligations through its undrawn $4.25 billion revolving credit facility and the $119 million current portion of floating‑rate notes, illustrating a strategic shift from new fixed‑rate issuance to a decreasing balance of fixed‑rate registered notes driven by repayments and swap‑based de‑leverage.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its credibility. MAJOR ERRORS: (1) The LLM states '$650 million of fixed-rate medium-term notes (including portions of the 2049/2050 series) in 2023' - the ground truth identifies $650 million of 30-year notes due 2050 with 3.70% coupon as existing in 2022, not as repaid in 2023. The ground truth only confirms $500 million repaid in 2023. (2) The LLM claims '$1 billion of notes due 2021' were retired via make-whole calls, but the ground truth makes no mention of 2021-maturity notes or make-whole calls. (3) The LLM states swaps converted '$500 million and $300 million of the 2049 and 2050 fixed-rate notes into floating-rate debt' - the ground truth says swaps converted 'portions' but does not specify these exact amounts ($500M and $300M). (4) The LLM references '$119 million current portion of floating-rate notes' - this figure does not appear in the ground truth. CORRECT ELEMENTS: The LLM correctly identifies the 2023 repayment of $500 million in fixed-rate registered notes, the 2024 repayment of $1.1 billion in medium-term notes, the 2021 interest rate swaps converting portions of 2049/2050 notes to floating-rate, the shift from LIBOR to SOFR, and the strategic shift toward reducing fixed-rate debt. The overall narrative of portfolio shrinkage and interest rate management is directionally correct. However, the specific dollar amounts for swap conversions and the reference to $650 million repayment in 2023 are not supported by the ground truth. The answer demonstrates understanding of the strategic direction but fails on quantitative precision, which is critical for financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Issues]-> FIN_INST <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 461,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "\nIn 2023 Schwab explicitly listed securities‑issuances by CSC as a **primary source of capital**, using them to fund balance‑sheet growth, meet regulatory‑capital requirements and return excess capital to shareholders. By 2024 that channel remained in the capital‑mix but was now **one component of a broader, more diversified funding base** that also includes client‑generated cash, overnight deposits, FDIC‑insured bank deposits, FHLB borrowings, CD issuances and other market‑based facilities; the company’s capital‑management strategy therefore shifted to **supplement client‑derived liquidity with targeted securities issuances**, while relying on stress‑testing, contingency‑fund planning and regulatory‑capital monitoring to manage overall funding risk.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution from 2023 to 2024 - securities issuances shifting from a primary source to one component of a diversified funding base. The years are correct, the company (Schwab/CSC) is correctly identified, and the general direction of the strategic shift is accurate. The answer appropriately mentions FHLB borrowings and CDs as additional funding sources, which aligns with the ground truth's reference to 'broader set of liquidity tools.' WEAKNESSES: (1) The LLM introduces additional details not present in the ground truth, such as 'meet regulatory-capital requirements,' 'return excess capital to shareholders,' 'client-generated cash,' 'overnight deposits,' 'FDIC-insured bank deposits,' 'stress-testing,' 'contingency-fund planning,' and 'regulatory-capital monitoring.' While these may be contextually reasonable for Schwab's operations, they exceed what the ground truth explicitly states and represent potential over-specification. (2) The ground truth specifically mentions 'repurchase agreements' as a funding source, which the LLM answer omits. (3) The LLM's characterization of the 2023 strategy as including 'return excess capital to shareholders' is not mentioned in the ground truth, which focuses on 'balance sheet growth and financial support to subsidiaries.' (4) The phrase 'supplement client-derived liquidity with targeted securities issuances' in the LLM answer represents an interpretation not explicitly stated in the ground truth. MULTI-HOP REASONING: The LLM correctly synthesizes the comparison between 2023 and 2024 and identifies the strategic evolution. However, the addition of unsupported details suggests the model may have inferred beyond the provided ground truth. SEMANTIC EQUIVALENCE: The core message aligns - securities issuances evolved from primary to diversified - but the LLM adds substantial elaboration that, while plausible, cannot be verified against the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sources_Capital_From]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 531,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "\nFrom 2022 through 2024 the contingent payment obligation Coca‑Cola holds for fairlife moved from the $270 million liability originally recorded at acquisition (valued with a Level‑3 Monte‑Carlo model) to a still‑outstanding fair‑value amount that represents the final milestone payment to be paid in 2025; the company had already paid a $100 million milestone in 2021 and, according to the 2024 filing, expects to make additional payments tied to 2023 targets, with the balance contingent on fairlife meeting the 2024 performance goals.  This evolution indicates that fairlife has met the earlier financial targets that triggered the 2021 and 2023 payments but has not yet satisfied the full set of 2024 targets, as the remaining payment remains contingent on achieving those later milestones.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its credibility. CRITICAL ERRORS: (1) The LLM claims 'expects to make additional payments tied to 2023 targets' - the ground truth makes no mention of 2023 targets or payments. This appears to be fabricated information not supported by the source documents. (2) The LLM states the obligation moved from '$270 million liability originally recorded at acquisition' - this is misleading. The ground truth clearly states the $270 million was the 2022 liability for contingent milestone payments through 2024, not the original acquisition price. (3) The LLM references a 'Level-3 Monte-Carlo model' valuation method - while this may be accurate SEC disclosure language, it's not mentioned in the ground truth and adds unsupported technical detail. PARTIALLY CORRECT ELEMENTS: The LLM correctly identifies (1) the $100 million payment made in 2021, (2) that fairlife met 2020 targets, (3) that remaining payments are contingent on 2024 targets, and (4) that final payment would be in 2025. REASONING ISSUES: The multi-hop synthesis is flawed because the LLM introduces information about '2023 targets' and '2023 payments' that don't appear in the ground truth. The ground truth indicates fairlife met 2020 targets (triggering $100M in 2021) and remained on track for 2024 targets (with payment in 2025), but makes no mention of intermediate 2023 milestones. The LLM's conclusion that fairlife 'has met the earlier financial targets that triggered the 2021 and 2023 payments' is factually incorrect - only the 2021 payment is documented. This represents a fundamental misreading or hallucination of the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 458,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "\nOracle’s strategic focus on Oracle Cloud Infrastructure (OCI) has shifted from a fast‑growing but margin‑pressured component of its Cloud & License business in fiscal 2022—where OCI‑related revenue accounted for 85 % of the $36.1 billion Cloud & License total and operating margin fell to 26 % (down from 38 % in 2021)—to a central pillar of its global cloud strategy by 2024, with the company explicitly positioning OCI as the integrated infrastructure that powers its SaaS and enterprise applications across hybrid‑cloud, on‑premise and multi‑cloud deployments.  This evolution is reflected in the knowledge‑graph relationship that ORCL both **produces** OCI and **introduces** it as a key element of Oracle Cloud Services, underscoring the firm’s effort to embed OCI deeply within enterprise IT solutions and to compete globally through a unified, end‑to‑end cloud offering.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core strategic shift from 2022 to 2024, accurately capturing that OCI evolved from a component of Cloud & License business to a central pillar of Oracle's cloud strategy. The qualitative description of the evolution (positioning OCI as integrated infrastructure for hybrid-cloud, on-premise, and multi-cloud deployments) aligns well with the ground truth. The answer appropriately addresses both global market positioning and enterprise IT integration aspects of the question.\n\nWEAKNESSES - QUANTITATIVE ERRORS: (1) The LLM states OCI-related revenue 'accounted for 85% of the $36.1 billion Cloud & License total' - this is INCORRECT. The ground truth states that Cloud and License businesses COMBINED generated $36.052 billion representing 85% of TOTAL revenues, NOT that OCI was 85% of Cloud & License. This is a significant misinterpretation of the revenue structure. (2) The LLM introduces operating margin data (26% in 2022, down from 38% in 2021) that is NOT present in the ground truth answer. While this data may be factually accurate from filings, it was not part of the original answer and represents information not grounded in the provided knowledge graph answer. (3) The LLM states '$36.1 billion' while ground truth says '$36.052 billion' - minor formatting difference but the LLM rounded without precision.\n\nMULTI-HOP REASONING: The LLM demonstrates sound multi-hop reasoning by connecting: (a) 2022 financial positioning, (b) margin pressure context, (c) 2024 strategic repositioning, and (d) the relationship between OCI production and introduction within Oracle Cloud Services. However, the fundamental misunderstanding of what the 85% figure represents undermines the quantitative foundation of this reasoning.\n\nSEMANTIC EQUIVALENCE: The qualitative evolution narrative is semantically equivalent to the ground truth - both convey that OCI moved from implicit/understated positioning to explicit strategic emphasis as a core pillar. The language about 'comprehensive and integrated applications and infrastructure services' is captured in the LLM's description of 'integrated infrastructure that powers its SaaS and enterprise applications.'\n\nJUSTIFICATION: The answer loses points primarily for the critical misinterpretation of the 85% revenue metric (confusing what the percentage represents) and for introducing margin data not in the ground truth. The qualitative assessment of strategic evolution is strong, but the quantitative foundation is flawed, preventing a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 679,
        "total_tokens": 2097
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the credit‑loss allowance for PALs was eliminated: the 2023 10‑K notes a declining allowance‑to‑loan ratio driven by lower projected loss rates and improved credit quality, indicating that some allowance had previously been required, whereas the 2024 10‑K (Note 2) states that as of 31 Dec 2024 all PALs are fully collateralized by securities whose fair value exceeds the borrowings and are subject to the ASC 326 collateral‑maintenance practical expedient, so no allowance for credit losses is needed and charge‑offs occur only after a 90‑day past‑due threshold.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. Strengths: (1) Correctly identifies the key evolution of PALs between 2023 and 2024, specifically the elimination of credit-loss allowance; (2) Accurately captures the 2023 context with declining allowance-to-loan ratio driven by lower projected loss rates and improved credit quality; (3) Precisely describes the 2024 treatment: full collateralization by securities with fair values exceeding borrowings, application of ASC 326 collateral-maintenance practical expedient, and zero allowance requirement; (4) Adds relevant detail about the 90-day past-due charge-off threshold, which provides additional context on risk management; (5) Demonstrates sound multi-hop reasoning by synthesizing information across both 2023 and 2024 filings to show the progression. The answer directly addresses all components of the question regarding credit loss allowance evolution and collateralization changes. Minor consideration: The LLM provides slightly more granular detail (90-day threshold) than the ground truth, but this is additive and not contradictory—it represents additional relevant information from the filings that strengthens rather than weakens the answer. All factual claims align with the ground truth, and the semantic meaning is equivalent or enhanced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> FIN_INST <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 367,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Nike continued to treat the Asia Pacific & Latin America (APLA) region as a distinct, reportable geographic segment of its Nike Brand, with the 2024 Form 10‑K (Note 15) showing APLA’s earnings‑before‑interest‑and‑taxes used to evaluate performance and noting that certain Nike Brand businesses in the region are being transitioned to third‑party distributors (Note 18).  At the same time, the company’s operational structure in APLA became more granular—Converse now operates as a separate segment and the shift to distributors reflects a re‑organization of Nike‑direct activities within the region.  Throughout both years Nike’s strategic emphasis in APLA has been anchored in its community‑investment goal (2 % of pre‑tax income for youth sport and equitable futures), DEI initiatives, and the development of a diverse, locally‑engaged workforce, underscoring a consistent cultural and sustainability focus across the APLA operations.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the key strategic shift from direct operations to third-party distributors in APLA between FY2023 and FY2024, which is the core finding in the ground truth. The answer accurately references Note 15 and Note 18 from the 2024 Form 10-K and correctly identifies the transition to third-party distributors as a significant operational change. The mention of Converse becoming a separate segment and the shift reflecting reorganization of Nike-direct activities shows understanding of the structural changes.\n\nWEAKNESSES: (1) The LLM introduces substantial information about community investment goals (2% of pre-tax income), DEI initiatives, and workforce development that is NOT present in the ground truth answer. While this information may be factually accurate from the filings, it represents a significant departure from the ground truth's focus on operational structure and strategic shift. (2) The ground truth emphasizes the 'localized and embedded workforce structure' with trade union representation in FY2023 as a key characteristic, but the LLM does not address this aspect at all. (3) The LLM's discussion of APLA as a 'distinct, reportable geographic segment' and earnings-before-interest-and-taxes metrics, while potentially accurate, shifts focus away from the core operational evolution that the ground truth emphasizes. (4) The characterization of the shift as reflecting 'consistent cultural and sustainability focus' contradicts the ground truth's framing of this as a 'strategic shift away from direct control toward a more outsourced model' - these represent different interpretations of the same change.\n\nMULTI-HOP REASONING: The LLM does synthesize information across multiple notes (15 and 18) and fiscal years (2023 and 2024), demonstrating multi-hop capability. However, the synthesis leads to a different narrative emphasis than the ground truth.\n\nSEMANTIC EQUIVALENCE: While both answers mention the transition to third-party distributors, the LLM's answer emphasizes strategic consistency and cultural focus, whereas the ground truth emphasizes operational restructuring and reduced complexity. These represent different interpretations of the same underlying change.\n\nNUMERIC ACCURACY: The 2% figure for community investment is stated but not verified against ground truth (ground truth does not mention this metric). No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 645,
        "total_tokens": 2049
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 Abbott shifted Pedialyte from a niche growth driver in its U.S. Pediatric Nutritional business—where its sales helped lift that segment 10.3 % in 2021 and was grouped with Similac and PediaSure—to a central pillar of a much broader pediatric‑nutrition portfolio. The 2023 filing places Pedialyte alongside an expanded list of infant and pediatric formulas (Similac, PediaSure, PediaSure SideKicks, etc.) and explicitly calls out both consumer‑direct and professional marketing, signalling a strategic emphasis on widening the brand’s role and integrating it into Abbott’s full nutritional product suite.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "CRITICAL ERROR IN QUANTITATIVE ACCURACY: The LLM states that Pedialyte sales 'helped lift that segment 10.3% in 2021' but the ground truth clearly indicates the 10.3% increase was 'for the year' 2022, not 2021. This is a significant factual error in the temporal attribution of the metric. PARTIAL CORRECTNESS ON CORE NARRATIVE: The LLM correctly captures the evolution from 2022 to 2023 - from being a growth driver to being formally integrated into the product portfolio. The characterization of Pedialyte as moving from 'niche growth driver' to 'central pillar' aligns with the ground truth's description of evolution from 'contributor to growth' to 'formally recognized and embedded.' ADDITIONAL ISSUES: (1) The LLM adds details about 'consumer-direct and professional marketing' and mentions 'PediaSure SideKicks' which are not present in the ground truth, suggesting potential hallucination or extrapolation beyond the source material. (2) The LLM's phrasing about 'expanded list of infant and pediatric formulas' is somewhat speculative - the ground truth simply states Pedialyte was 'listed among major brands.' (3) The LLM correctly identifies the segment as 'Nutritional Products segment' which aligns with ground truth. MULTI-HOP REASONING: The model demonstrates reasonable synthesis of the 2022-to-2023 evolution, but the year attribution error undermines the accuracy of the multi-hop analysis. The core insight about formalization and integration is sound, but the execution contains a material factual error that affects credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 426,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "\nRTX’s 7.100 % notes due 2027 showed a flat exposure of **$135 million** in the 2023 filing (Chunk 2) – the same $135 million reported for 2022 – indicating that the balance was unchanged from the end of 2022 through 2023.  This stability follows the earlier disclosure in the 2022 filing (Chunk 1) that the same series had a much smaller outstanding amount ($6 million) before being increased and then held steady, while RTX retired or refinanced several near‑term and higher‑coupon debt issues.  The consistent level of this long‑dated tranche reflects a deliberate debt‑management strategy of preserving a stable, low‑frequency financing pillar while actively rolling off shorter‑maturity obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "CRITICAL ERRORS IDENTIFIED: The LLM answer contains a fundamental factual error that directly contradicts the ground truth. The LLM states that RTX had '$135 million reported for 2022' and that 'the balance was unchanged from the end of 2022 through 2023.' However, the ground truth clearly establishes that in 2022, RTX had only $6 million in aggregate principal balance for the 7.100% notes due 2027, which then increased to $135 million by 2023. This is a significant discrepancy - the LLM misrepresents the 2022 figure as $135 million when it was actually $6 million. The LLM does acknowledge the $6 million figure in parenthetical text ('before being increased and then held steady'), but then contradicts itself by claiming the 2023 balance was 'the same $135 million reported for 2022.' This is factually incorrect. The correct narrative is: 2022 = $6 million; 2023 = $135 million; representing a substantial increase (approximately 2,150% growth), not a flat/unchanged position. While the LLM correctly identifies the 7.100% coupon rate and 2027 maturity date, and attempts to provide reasonable debt management interpretation, the core quantitative facts are wrong. The multi-hop reasoning about debt management strategy is undermined by the incorrect baseline numbers. The answer fails on the primary metric of factual accuracy regarding the evolution of RTX's financial position with these notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 390,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Converse’s revenue fell 15 % on a currency‑neutral basis, with wholesale down 16 % and direct‑to‑consumer down 14 %—driven by double‑digit declines in North America and Europe and a 3 % ASP drop from heavier promotions.  As a wholly‑owned subsidiary, Converse is reported stand‑alone in Nike’s filings, its brand positioned for casual sneakers and apparel, while Nike’s 2024 EBIT decline (30 %) reflects the revenue contraction and a 130‑basis‑point gross‑margin squeeze that partly stems from unfavorable foreign‑exchange and lower full‑price pricing on Converse products.  Moreover, Nike does not own the Converse trademarks in Japan and therefore earns no direct revenue there, underscoring that Converse’s performance is now a diminishing, yet strategically distinct, component of Nike’s overall portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains a mix of correct and problematic elements. CORRECT ELEMENTS: (1) The 15% revenue decline on currency-neutral basis is accurate; (2) Converse being a wholly-owned subsidiary operating stand-alone is correct; (3) The strategic positioning shift from struggling entity to distinct brand is captured; (4) The mention of wholesale and DTC channel declines is appropriate. PROBLEMATIC ELEMENTS: (1) The LLM provides specific wholesale (-16%) and DTC (-14%) figures and a 3% ASP drop that are NOT in the ground truth answer, raising concerns about factual accuracy without source verification; (2) The LLM introduces Nike's 2024 EBIT decline (30%) and gross-margin squeeze (130 basis points), which are NOT mentioned in the ground truth and appear to be unsupported claims that go beyond the question scope; (3) The claim about Nike not owning Converse trademarks in Japan and earning no direct revenue there is NOT in the ground truth and represents additional information that cannot be verified against the provided ground truth; (4) The characterization of Converse as 'diminishing' is an interpretation not explicitly stated in the ground truth. MULTI-HOP REASONING: The LLM attempts to synthesize information across fiscal years and connect revenue performance to strategic positioning, which is appropriate. However, the introduction of unverified financial metrics (EBIT, gross margin) and geographic/trademark details suggests the model may be hallucinating or drawing from unreliable sources. QUANTITATIVE ACCURACY ISSUE: While the 15% figure is correct, the additional percentages (16%, 14%, 3%, 30%, 130 bps) cannot be verified against the ground truth and may be incorrect. This is a significant concern for a financial evaluation task. The answer is partially correct on core facts but introduces substantial unverified claims that reduce confidence in overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 514,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "\nFrom 2022 to 2024 Coca‑Cola’s risk narrative shifted from a generic warning that “if we fail to address changes in consumer product and shopping preferences… our share of sales, revenue growth and overall financial results could be negatively affected” (Chunk 1) to an explicit statement that successful digitalization of the system is now a top priority because it “directly drives our ability to increase sales and improve margins,” and that the costs of that digital transformation “may adversely impact our financial performance” (Chunk 2). The 2024 filing treats “Digital Evolution” as a macro condition that both negatively impacts the company and on which the firm depends, linking the digital agenda directly to margin improvement and new cost‑related financial risks, whereas the 2022 filing only highlighted the risk of lost revenue if digital trends were ignored. Consequently, the firm’s financial risk assessment has evolved from a passive concern about digital‑driven sales erosion to an active, margin‑focused strategy where digital capability is a critical determinant of both growth and profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all dimensions. STRENGTHS: (1) Correctly identifies the temporal shift from 2022 to 2024 in Coca-Cola's digital risk assessment; (2) Accurately captures the evolution from 'passive concern' about digital-driven sales erosion to 'active, margin-focused strategy'; (3) Properly synthesizes the multi-hop reasoning showing how digital evolution moved from a risk factor to a strategic dependency; (4) Correctly identifies the dual financial impact: both negative (costs of transformation) and positive (sales growth and margin improvement); (5) Uses appropriate semantic language ('macro condition,' 'critical determinant') that matches the ground truth's conceptual framing. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are present in either the ground truth or LLM answer, so this dimension is not applicable but receives full marks as there are no numeric errors. MINOR CONSIDERATIONS: (1) The LLM answer includes references to 'Chunk 1' and 'Chunk 2' which appear to be source citations not present in the ground truth, but this adds transparency rather than detracting from accuracy; (2) The LLM answer is more detailed and provides more specific language from the filings ('directly drives our ability to increase sales and improve margins') which enhances credibility without contradicting the ground truth. MULTI-HOP REASONING: The answer successfully synthesizes information across two different years (2022 and 2024) and connects digital evolution to multiple financial outcomes (sales growth, margin improvement, financial performance). The logical progression from passive risk to active strategic dependency is clearly articulated and matches the ground truth's core assertion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> MACRO_CONDITION <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 487,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Oracle has steadily shifted its strategic emphasis from a pure on‑premise license model toward making **Oracle Cloud Services the centerpiece of its growth strategy**—a shift underscored by the company’s continued multi‑billion‑dollar R&D spend ( $7.2 billion in FY 2022 and a comparable investment maintained in FY 2024 ) to accelerate cloud‑native capabilities, security, performance and integration.  The firm now markets its cloud offerings as **flexible, hybrid‑ready alternatives that coexist with on‑premise solutions**, promising lower upfront cost, rapid deployment and seamless workload mobility across on‑prem, public‑cloud and Oracle Cloud@Customer environments, a positioning that differentiates Oracle from competitors that provide more restrictive deployment options.  This evolution is reflected in the KG relationship **ORCL ↔ Oracle Cloud Services**, highlighting the mutual, strategic focus on both cloud and on‑premise product lines across the disclosed periods.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the $7.2 billion R&D investment for FY 2022, matching the ground truth exactly. (2) The qualitative positioning of Oracle's cloud strategy evolution is well-articulated, capturing the shift toward cloud-first positioning and flexible deployment models. (3) The answer appropriately addresses the multi-hop nature of the question by synthesizing information across fiscal years 2022-2024. (4) The description of cloud offerings as 'flexible, hybrid-ready alternatives' aligns with the ground truth's emphasis on 'flexible and interoperable deployment models.' (5) The contextual relevance is strong, directly addressing the question's focus on strategic evolution and R&D investment.\n\nWEAKNESSES: (1) CRITICAL QUANTITATIVE ERROR: The LLM states 'a comparable investment maintained in FY 2024' but the ground truth explicitly states 'the 2024 report does not specify the R&D investment amount.' This is a factual error—the LLM claims knowledge of FY 2024 R&D spending that does not exist in the source material. (2) The phrase 'multi‑billion‑dollar R&D spend ($7.2 billion in FY 2022 and a comparable investment maintained in FY 2024)' is misleading because it implies FY 2024 R&D was quantified and comparable, when in fact no FY 2024 figure was disclosed. (3) The LLM introduces the KG relationship notation 'ORCL ↔ Oracle Cloud Services' which, while potentially valid, is not substantiated in the ground truth and appears to be an unsupported addition. (4) The ground truth emphasizes a 'strategic deepening' and shift in messaging toward customer-specific needs by 2024, but the LLM's answer doesn't fully capture this nuanced evolution in positioning strategy.\n\nMULTI-HOP REASONING: The synthesis across fiscal years is attempted but compromised by the unsubstantiated claim about FY 2024 R&D investment. The model correctly identifies the shift from on-premise to cloud-centric strategy but overstates the evidence available.\n\nNUMERIC VERIFICATION: FY 2022 R&D of $7.2 billion is correct. The claim of 'comparable investment maintained in FY 2024' is unsupported and contradicts the ground truth's explicit statement that FY 2024 R&D amount was not specified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 592,
        "total_tokens": 2102
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "\nThe Norwest Corporation Directors’ Formula Stock Award Plan—identified in WFC’s 2023 10‑K as an accounting policy—was open in 2023 for granting stock awards and for deferring those awards, with shares reserved for future issuance (including amounts credited to participant accounts to reflect dividends). By the 2024 filing, the plan had been closed to any new awards or deferrals, and the only shares left available under it were the 207,744 shares issuable upon distribution of deferred stock awards and the 134,286 shares issuable upon distribution of deferred compensation benefits (plus a small 391‑share balance), marking the end of its share‑availability evolution between 2023 and 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM provides specific share numbers (207,744 shares for deferred stock awards and 134,286 shares for deferred compensation benefits) that are NOT mentioned in the ground truth answer. The ground truth only mentions 391 shares as the total issuable in 2024, describing it as 'minimal.' The LLM's numbers appear to be fabricated or sourced from incorrect data, representing a critical factual error. (2) CONTRADICTORY CLAIMS - The LLM states the plan 'was open in 2023 for granting stock awards' but the ground truth explicitly states 'no future stock awards or deferrals could be made under this plan' in 2023. This is a fundamental contradiction about the plan's status in 2023. (3) INCOMPLETE SYNTHESIS - While the LLM correctly identifies that the plan was closed to new activity by 2024 and only existing obligations remained, it fails to accurately capture the 2023 status. The ground truth indicates the plan was already closed to new awards in 2023, not open as the LLM claims. (4) MULTI-HOP REASONING - The LLM attempts to synthesize information across years but does so incorrectly by mischaracterizing the 2023 status. The comparison between 2023 and 2024 is therefore flawed. (5) CORRECT ELEMENTS - The LLM correctly identifies that by 2024 the plan was closed to new activity and only distribution of existing obligations remained, and correctly notes the 391-share balance. However, these correct elements are overshadowed by the significant factual errors regarding the 2023 status and the unexplained/incorrect share numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 438,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "\nMcDonald’s 2022 filing treated food‑safety events as a discrete risk that could damage the brand and financial results, warning that contamination or a food‑borne‑illness incident in the supply chain might impair sales and profitability. In the 2023 filing the company folded that concern into a broader commodity‑cost and supply‑chain‑volatility framework, noting that price swings for beef, chicken and other ingredients—driven by seasonal shifts, climate, regulations, recalls and other safety‑related factors—heighten cost pressure and can exacerbate supply‑chain disruptions; this evolution is reinforced by the 2023 discussion of ESG stakeholder focus, the linkage of food‑safety risk to commodity‑price volatility, and the acknowledgment that operational issues such as labor constraints, real‑estate limitations and IT system failures can further affect the ability to maintain safe food handling and manage cost volatility.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively captures the evolution of McDonald's food safety disclosure between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 framing as focused on reputational risk and brand/financial damage from food-borne illness or contamination incidents. (2) Accurately characterizes the 2023 shift toward integrating food safety concerns into a broader supply chain volatility and commodity cost framework. (3) Correctly identifies specific commodities (beef, chicken, pork) affected by price volatility. (4) Properly synthesizes the multi-hop connection between food safety issues and supply chain disruption/cost pressures. (5) No quantitative errors—no specific numbers, percentages, or dollar amounts were required or provided, so quantitative accuracy is perfect. (6) The answer goes beyond the ground truth by adding contextual details about ESG stakeholder focus, labor constraints, real estate limitations, and IT system failures, which enriches the response without contradicting the original answer. MINOR CONSIDERATIONS: (1) The ground truth emphasizes a shift in 'emphasis' from reputational impact to financial exposure through supply chain disruption, while the LLM answer uses the phrase 'folded that concern into a broader framework,' which is semantically equivalent but slightly different in tone. (2) The LLM answer includes additional operational factors (labor, real estate, IT systems) that, while relevant to the broader context, are not explicitly mentioned in the ground truth. However, this represents expansion rather than contradiction. (3) The answer maintains logical coherence throughout and demonstrates sound multi-hop reasoning by connecting 2022 and 2023 filings, identifying the shift in framing, and explaining the underlying business implications. The synthesis across years and the connection between food safety and supply chain volatility is correctly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 530,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "\nThe 1.750 % 7‑Year Senior Notes issued by TMO show essentially unchanged figures between the two periods: the carrying amount stays at **$700 million** at the end of 2023 and again at **$700 million** at the end of 2024, while the effective interest rate remains **1.89 %** for both years. This stability reflects that the senior note—classified as a financial instrument in which TMO holds a direct stake (TMO → FIN_INST ← Issues)—has not experienced any material change in either principal balance or borrowing cost over the 2023‑2024 transition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. All quantitative data is correct: carrying value of $700 million for both 2023 and 2024, effective interest rate of 1.89% for both years, and the due date of October 15, 2028. The answer correctly identifies the company (TMO) and the specific debt instrument (1.750% 7-Year Senior Notes). The multi-hop reasoning is sound—the model successfully synthesized information about the debt instrument's characteristics across both fiscal years and correctly concluded that no material changes occurred. The answer addresses all parts of the question: how the carrying value evolved (remained at $700M) and how the interest rate evolved (remained at 1.89%). The semantic meaning matches the ground truth perfectly. The only minor observation is that the LLM's explanation includes some technical notation about financial instrument classification (TMO → FIN_INST ← Issues) which, while not incorrect, is slightly more technical than the ground truth's straightforward presentation. However, this does not detract from factual accuracy or completeness. The answer demonstrates proper understanding of the multi-hop nature of the question by correctly linking the debt instrument to TMO across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Issues]- ORG",
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 351,
        "total_tokens": 1579
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "\nRTX’s outstanding 7.000 % notes due 2038 remained flat at **$148 million** at the end of 2022 and again at **$148 million** at the end of 2023 (see the 2023 table’s “7.000 % notes due 2038” line, which lists 148 for both years), so there was **no net change in exposure** between those two years. This stability—while the company’s overall long‑term debt grew from $31.2 billion (2022) to $43.7 billion (2023)—indicates that RTX is keeping this relatively small, long‑dated tranche as a steady component of its capital structure rather than using it to actively manage or adjust its maturity profile.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect on the core factual claim. The ground truth states that RTX's 7.000% notes due 2038 increased from $11 million in 2022 to $148 million in 2023. The LLM claims the amount was $148 million in both 2022 and 2023, which directly contradicts the ground truth. This is a critical quantitative error - the LLM got the 2022 figure completely wrong ($148M vs. $11M, a difference of $137M). The LLM's assertion that there was 'no net change in exposure' is therefore incorrect. The ground truth explicitly states this represents a 'significant' increase that 'suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.' The LLM's conclusion that RTX is 'keeping this relatively small, long‑dated tranche as a steady component' misses the actual strategic shift entirely. The LLM appears to have misread or misinterpreted the source data, possibly confusing the 2023 figure as applying to both years. This is a multi-hop question requiring accurate synthesis of year-over-year debt data, and the LLM failed at the most basic level of factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 348,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s moved from the pandemic‑era temporary deferrals of rent and royalty cash‑collections—where it postponed roughly $1 billion of franchisee payments in 2020 and had recovered almost all of that amount by 31 Dec 2021 (Chunk 1)—to a full resumption of normal rent and royalty collection under its standard franchised‑arrangement framework (Chunk 2).  The 2023 filing confirms that, under the existing conventional franchise structure, future gross minimum rent obligations continue to be due from franchisees, reflecting the restored financial relationship and the company’s reliance on franchisees as a key component of its business model.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and effectively synthesizes the multi-hop information across the 2022 and 2023 filings. QUANTITATIVE ACCURACY: All numerical values are correct - the $1 billion in deferred rent and royalties from 2020 is accurately cited, and the timeline (deferred in 2020, substantially collected by end of 2021) matches the ground truth precisely. The date references (31 Dec 2021) are accurate. QUALITATIVE ACCURACY: The answer correctly identifies the key evolution: from pandemic-era deferrals to normalized operations. The multi-hop reasoning is sound - it synthesizes information about (1) what happened in 2020-2021 (deferrals and collection), (2) the 2022 disclosure of these historical deferrals, and (3) the 2023 return to normal operations. The answer properly contextualizes this as a transition from temporary relief measures to standard franchise obligations. COMPLETENESS: The answer addresses the core question about how the financial relationship evolved between 2022 and 2023. It captures both the historical context (pandemic deferrals) and the current state (normalization). The mention of 'gross minimum rent obligations' and 'conventional franchise structure' adds appropriate detail about the restored relationship. MINOR CONSIDERATIONS: The LLM answer references 'Chunk 1' and 'Chunk 2' which are source citations rather than part of the substantive answer, but this doesn't detract from accuracy. The phrasing 'moved from...to' effectively captures the evolution requested. The answer could have been marginally more explicit about the 2023 filing's lack of mention of deferrals (as stated in ground truth), but the implication is clear from 'full resumption of normal rent and royalty collection.' Overall, the answer is factually accurate, logically sound, and appropriately addresses the multi-hop nature of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 509,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "\nFrom 2022 through 2024 Coca‑Cola’s ownership in Embotelladora Andina S.A. remained an equity‑method investment after it sold a portion of its stake in 2019 but kept the remainder to retain board representation and governance rights (Chunk 1); as of 31 December 2024 the carrying amount of that stake was $90 million while its fair value had risen to $168 million, producing an unrealized gain of $78 million (Chunk 2).  This valuation gap, together with the enduring board‑level influence captured by the ORG → COMP ← ORG divestiture‑stake pattern, indicates that Coca‑Cola is using the Andina equity position as a strategic foothold in the Latin‑American bottling network rather than a pure financial holding, preserving both market access and governance leverage.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial metrics and strategic positioning. STRENGTHS: (1) All quantitative data is accurate - carrying value of $90 million, fair value of $168 million, and the calculated unrealized gain of $78 million are all correct. (2) The answer correctly identifies the 2019 partial sale and retention of equity-method investment status. (3) Multi-hop synthesis is sound, connecting the historical divestiture to current holdings and strategic implications. (4) The interpretation of strategic positioning (market access, governance leverage, Latin American bottling network foothold) aligns well with the ground truth's characterization of a 'partial exit strategy' with 'ongoing but reduced exposure.' MINOR GAPS: (1) The LLM answer does not explicitly mention the $39 million gain recognized in 2022 from the partial sale, which was highlighted in the ground truth as a key indicator of the strategic refranchising move. This is a notable omission since the question specifically asks about evolution 'from 2022 to 2024.' (2) The reference to a 2019 sale is contextually helpful but slightly shifts focus from the 2022 starting point requested in the question. (3) The phrase 'ORG → COMP ← ORG divestiture-stake pattern' is somewhat unclear and appears to be internal notation rather than clear business language. CALCULATION VERIFICATION: The unrealized gain calculation ($168M - $90M = $78M) is mathematically correct. SEMANTIC EQUIVALENCE: The LLM's characterization of the investment as a 'strategic foothold' rather than 'pure financial holding' is semantically equivalent to the ground truth's 'partial exit strategy with ongoing but reduced exposure.' The answer effectively conveys the same strategic positioning despite different wording. The omission of the 2022 $39 million gain prevents a perfect score, as this was explicitly mentioned in the ground truth as an important indicator of the evolution during the specified timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Divests]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 545,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "\nFrom 2022 to 2024 Oracle moved from a heavy‑focus on **internal research‑and‑development and patented engineering**—leveraging a global workforce to control the design of its cloud‑related products (Chunk 1)—to a **strategic, portfolio‑wide rollout of Oracle Cloud Infrastructure (OCI)** that is now presented as a core, integrated service (SaaS + IaaS) across on‑premise, cloud and hybrid deployment models (Chunk 2).  The KG relationship ORCL → OCI → ORCL shows that OCI is both a product **produced by** Oracle and a **gateway that introduces** Oracle’s broader applications and hardware offerings, underscoring how the company has positioned OCI as a central pillar of its cloud strategy while continuing to fund internal development to sustain that growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across multiple dimensions. STRENGTHS: (1) Correctly identifies the evolution from 2022 (internal R&D focus) to 2024 (structured OCI portfolio positioning), matching the ground truth narrative. (2) Accurately captures the shift from 'general cloud development' to 'structured, customer-facing product portfolio' through the language of 'internal research-and-development' to 'strategic, portfolio-wide rollout.' (3) Properly identifies Oracle Cloud Infrastructure (OCI) as the central offering and correctly notes its positioning as both a product and gateway to broader Oracle services. (4) No quantitative errors present—no specific numbers, dates, or calculations to verify, and the temporal framing (2022 to 2024) is correct. (5) Multi-hop reasoning is sound: the answer synthesizes the relationship between internal R&D efforts and external product positioning, showing how OCI serves as a bridge between Oracle's development capabilities and market offerings. (6) The mention of deployment models (on-premise, cloud, hybrid) adds appropriate contextual detail. MINOR CONSIDERATIONS: (1) The LLM answer includes the knowledge graph relationship notation (ORCL → OCI → ORCL) which, while insightful, is somewhat technical and not explicitly mentioned in the ground truth, though it doesn't contradict it. (2) The phrasing 'SaaS + IaaS' is more specific than the ground truth's 'comprehensive and integrated infrastructure solution,' but this represents appropriate technical precision rather than error. (3) The ground truth emphasizes 'deepening of Oracle's cloud infrastructure commitment' while the LLM uses 'central pillar'—semantically equivalent concepts. The answer successfully addresses all parts of the multi-part question regarding strategic investment evolution, internal development efforts, and OCI positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 513,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "\nTMO acquired The Binding Site Group in early 2023 and recorded the purchase in its Specialty Diagnostics segment, generating non‑tax‑deductible goodwill and beginning the amortization of the acquired definite‑life intangibles over 15‑19 year periods (as disclosed in the 2024 10‑K).  The 2024 filing continues to reference those intangibles and the ongoing integration of the business, indicating that the acquisition is a core element of TMO’s strategic focus on expanding high‑growth diagnostic and real‑world‑evidence capabilities.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of TMO's Binding Site Group acquisition and its strategic importance, with mostly accurate information. STRENGTHS: (1) Correctly identifies the acquisition timing (early 2023), the Specialty Diagnostics segment placement, and the non-tax-deductible goodwill treatment; (2) Accurately references the 15-19 year amortization periods for definite-life intangibles; (3) Properly synthesizes the multi-hop information showing acquisition → integration → strategic focus; (4) Correctly identifies the strategic rationale around diagnostics and real-world-evidence capabilities. WEAKNESSES: (1) The LLM states amortization periods of '15-19 years' while the ground truth specifically mentions a '19-year weighted-average amortization period for customer relationships' - this is a minor discrepancy in specificity rather than outright error, as 19 falls within the 15-19 range; (2) The LLM does not explicitly mention the $2.70 billion acquisition price, which is a key quantitative detail in the ground truth; (3) The LLM's reference to 'real-world-evidence capabilities' is not explicitly mentioned in the ground truth, which focuses on 'blood cancers and immune disorders' - this represents a slight interpretive addition rather than an error. MULTI-HOP REASONING: The answer successfully synthesizes information across 2023 and 2024 filings, showing the evolution from acquisition announcement to integration and ongoing strategic importance. The reasoning is sound and logically connects the acquisition to TMO's broader strategic objectives. NUMERIC VERIFICATION: The amortization period range (15-19 years) is accurate, though the ground truth emphasizes the 19-year figure more specifically. The missing $2.70 billion figure is a notable omission but doesn't invalidate the core answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> COMP <-[Involved_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 497,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "\nBetween 2022 and 2024 the Directors’ Code of Conduct remained defined as applying to **all directors of the company**, but the way it was posted online changed. In the 2022 filing the code was posted at a BNY Mellon URL such as  \n`https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors-code-of-conduct.pdf`, whereas the 2024 filing lists it at a BNY URL like  \n`https://www.bny.com/content/dam/.../investor-relations/directors-code-ofconduct.pdf`. Both years note that any amendments or waivers will be disclosed on the website, so the evolution is a shift in the **website link/path** (domain and directory structure) while the **scope of application** stays the same.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution: the scope of application remained the same (all directors) while the website URL changed between 2022 and 2024. The qualitative reasoning about the shift from 'bnymellon.com' to 'bny.com' domain and the interpretation about rebranding is sound and matches the ground truth explanation. However, there are critical URL accuracy issues that significantly impact the correctness score: (1) The 2022 URL in the LLM answer contains 'in relations' instead of 'investor-relations' - this is a transcription error that makes the URL incorrect. (2) The 2024 URL is abbreviated with '...' instead of providing the full path, which reduces precision and doesn't match the ground truth's complete URL specification. (3) The LLM answer also omits the hyphen in '2024' URL ('directors-code-ofconduct.pdf' vs 'directors-code-of-conduct.pdf'), though this is a minor formatting issue. The answer demonstrates good understanding of the multi-hop synthesis required (comparing 2022 vs 2024 filings, identifying both URL changes and scope consistency), and the contextual interpretation about domain rebranding is appropriate. The main weakness is the inaccuracy in the specific URLs provided, which are factual data points that should be precisely correct in a financial disclosure context. The answer would have scored 8-9 if the URLs had been transcribed accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 390,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s continued to treat its franchisees as independent businesses that do not meet the variable‑interest entity consolidation criteria— a position reiterated in the 2022 10‑K where the company evaluated franchise relationships and concluded that consolidation was unnecessary, relying instead on the equity‑method for affiliated joint ventures; and the 2023 10‑K broadens this perspective by adding a “restaurant information by ownership type” table that explicitly breaks out results for conventional franchisees, developmental licensees and other owners, signaling a strategic shift to make franchisee‑operated performance a central, reported metric of the company’s financial and growth strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of McDonald's evolving relationship with franchisees between 2022 and 2023. STRENGTHS: (1) Correctly identifies the core shift from limited financial reporting emphasis in 2022 to explicit strategic focus in 2023; (2) Accurately captures the introduction of 'restaurant information by ownership type' table in 2023; (3) Properly synthesizes the multi-hop information about consolidation criteria, equity-method accounting, and strategic reporting changes; (4) Correctly identifies franchisee categories (conventional franchisees, developmental licensees, other owners); (5) No quantitative errors - dates and years are accurate. MINOR WEAKNESSES: (1) The LLM answer introduces additional technical accounting details (variable-interest entity consolidation criteria, equity-method for affiliated joint ventures) that, while accurate and relevant, go beyond what the ground truth explicitly states; (2) The ground truth emphasizes the shift from 'not material' transactions in 2022 to explicit stakeholder inclusion in 2023, while the LLM answer frames this more as a consolidation/accounting methodology discussion rather than a materiality/strategic emphasis evolution; (3) The LLM answer is more technically detailed about accounting standards, which adds depth but slightly shifts the framing from 'financial reporting and strategic emphasis' to 'accounting treatment and reporting structure.' SEMANTIC EQUIVALENCE: The LLM answer conveys the same fundamental insight - that McDonald's moved toward greater transparency and strategic emphasis on franchisees in its financial reporting between 2022 and 2023. The multi-hop reasoning correctly synthesizes information across both years. The answer is factually sound and addresses the question comprehensively, though with a more technical accounting lens than the ground truth's emphasis on materiality and stakeholder positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 522,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "\nIn 2023 the contingent‑consideration for the Clif Bar acquisition was recorded at fair value—$548 million of the long‑term portion and $132 million of the current portion—using a Monte Carlo simulation (Level 3 inputs), with any subsequent fair‑value changes booked in selling, general and administrative expenses.  During 2024 the company performed purchase‑price allocation adjustments for Clif Bar (and related entities), updating the fair‑value estimates of those obligations and revising the contingent‑consideration balances, which continued to be reflected in SG&A.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. CORRECT ELEMENTS: (1) The $548 million long-term contingent consideration liability figure for 2023 is accurate. (2) The identification of Monte Carlo simulation (Level 3 inputs) as the valuation method is correct. (3) The reference to fair value adjustments being recorded in SG&A is accurate. (4) The acknowledgment that purchase price allocation adjustments occurred in 2024 is correct. PROBLEMATIC ELEMENTS: (1) The LLM introduces a $132 million current portion figure that is NOT mentioned in the ground truth answer. While this may exist in the actual filings, it represents information beyond what the ground truth specifies, creating potential factual uncertainty. (2) The LLM states that contingent consideration 'continued to be reflected in SG&A' during 2024, but the ground truth explicitly notes 'there is no direct mention of the contingent consideration liabilities' in the 2024 filing. This is a significant discrepancy—the ground truth indicates the 2024 disclosure does not provide updated figures or valuation methods, suggesting the liabilities may have been finalized or reclassified. The LLM's assertion that they 'continued to be reflected' contradicts the ground truth's finding that they are not directly mentioned in 2024. (3) The LLM's statement that the company 'updated the fair-value estimates of those obligations and revising the contingent-consideration balances' goes beyond what the ground truth supports. The ground truth indicates the 2024 filing references 'purchase price allocation adjustments' but does not confirm that contingent consideration balances were explicitly revised or updated in the 2024 disclosure. MULTI-HOP REASONING: The LLM attempts to synthesize the evolution between 2023 and 2024 but makes an unsupported leap by claiming continued SG&A reflection in 2024 when the ground truth indicates no direct mention. This represents a failure in careful multi-hop synthesis. The answer would have been stronger by acknowledging the absence of 2024 disclosure rather than inferring continued treatment. QUANTITATIVE ACCURACY: The $548 million figure is correct; the $132 million figure is unverified against ground truth. QUALITATIVE ACCURACY: The reasoning about the evolution is partially sound but contains a critical error in claiming continued disclosure when the ground truth indicates the opposite.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Owns]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 644,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "\nAMD first placed Vulkan at the heart of its RDNA 2 strategy in 2022, promoting it across the Radeon RX 6000 series, supporting advanced features such as ray‑tracing, Infinity Cache and FidelityFX Super‑Resolution, and tying the API to its semi‑custom consoles (PlayStation 5, Xbox Series S/X) and embedded GPUs that run Linux/Windows. By 2024 the company deepened that commitment with the RDNA 3‑based Radeon RX 7000 family, where Vulkan is bundled with high‑refresh‑rate, AI/ML‑ready capabilities and the continuously updated Adrenalin driver suite, and is extended into the latest semi‑custom platform – the PlayStation 5 Pro – while still powering embedded workloads that rely on the same open API. This sustained, cross‑segment focus on Vulkan demonstrates AMD’s competitiveness playbook: leverage an open, standards‑based graphics stack to unify discrete, semi‑custom and embedded markets, broaden ecosystem partnerships and keep its GPUs relevant against rivals.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core timeline (2022 RDNA 2 with Vulkan support, 2024 RDNA 3 evolution) and accurately names the GPU product lines (Radeon RX 6000 series for 2022, Radeon RX 7000 series for 2024). The answer correctly captures AMD's strategic continuity in Vulkan support across both periods. The mention of architectural progression from RDNA 2 to RDNA 3 is accurate and matches the ground truth. The answer appropriately addresses the competitiveness question by explaining AMD's strategy.\n\nWEAKNESSES: (1) The LLM introduces significant unsupported claims not present in the ground truth, including specific technical features (ray-tracing, Infinity Cache, FidelityFX Super-Resolution) that are not mentioned in the original answer. While these may be factually true about AMD GPUs, they exceed what can be verified from the provided ground truth. (2) The LLM extensively discusses semi-custom consoles (PlayStation 5, Xbox Series S/X, PlayStation 5 Pro) and embedded GPU markets, which are not mentioned in the ground truth answer. This represents substantial elaboration beyond the source material. (3) The LLM mentions the Adrenalin driver suite, which is not in the ground truth. (4) The answer's framing around 'semi-custom consoles' and 'embedded markets' as part of AMD's Vulkan strategy is not supported by the ground truth, which focuses specifically on discrete GPU competitiveness.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the 2022-to-2024 evolution and draws appropriate conclusions about strategic continuity. However, the reasoning extends beyond what the ground truth supports, introducing new market segments and technical details that cannot be verified against the source material.\n\nSEMANTIC EQUIVALENCE: While the core message about Vulkan support evolution and competitiveness is preserved, the LLM answer significantly expands the scope beyond the ground truth's focus on discrete GPU market competitiveness, introducing unverified claims about console platforms and embedded systems.\n\nNUMERIC/FACTUAL VERIFICATION: No specific numbers, dates, or calculations are present in either answer, so quantitative accuracy is based on correct identification of product lines and years, which the LLM handles correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Features]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 610,
        "total_tokens": 2048
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "\nRTX’s operating profit dropped $1.9 billion in 2023 versus 2022, a decline the company attributed primarily to the $2.9 billion Powder Metal Matter integration charge recorded at Pratt & Whitney, while the $0.4 billion profit increase in 2022 versus 2021 was driven by a reduction in acquisition‑accounting adjustments (from $5.1 billion in 2020 to $2.2 billion in 2021) as disclosed in the 2022 10‑K. This shift shows that the new Powder Metal Matter charge reversed the prior‑year benefit from lower integration‑related adjustments and caused a net negative swing in operating profit between 2022 and 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the key financial metrics and demonstrates sound multi-hop reasoning. STRENGTHS: (1) Accurately cites the $1.9 billion operating profit decrease in 2023 vs 2022; (2) Correctly identifies the $2.9 billion Powder Metal Matter charge at Pratt & Whitney; (3) Properly synthesizes the contrast between 2022 (declining integration charges) and 2023 (new major charge); (4) Correctly references the $0.4 billion profit increase in 2022 vs 2021 driven by lower acquisition-accounting adjustments; (5) Provides accurate historical context with acquisition-accounting adjustment figures ($5.1B in 2020, $2.2B in 2021). WEAKNESSES: (1) The answer goes beyond the ground truth by providing additional historical detail (2020-2021 comparisons) that, while accurate, wasn't explicitly required by the question and adds some complexity; (2) The phrasing 'reversed the prior-year benefit' is slightly imprecise—the ground truth frames it as a 'shift' from declining charges to a new significant expense, not necessarily a reversal of benefits; (3) Minor semantic difference: ground truth emphasizes the Powder Metal Matter as 'a major driver' of the decline, while LLM says it was 'attributed primarily to'—these are semantically equivalent but the LLM's phrasing is slightly stronger. CALCULATION VERIFICATION: All numbers check out correctly. The logic that the $2.9B charge in 2023 offset the prior benefit from declining integration charges in 2022 is sound. The answer successfully synthesizes information across multiple years and correctly identifies the causal relationship between the charges and operating profit trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Decreases]- ORG",
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 451,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "\nMDLZ’s partnership with Clif Bar moved from the 2022 acquisition to post‑deal integration, highlighted by 2023 purchase‑price‑allocation adjustments for Clif Bar (and Ricolino) that re‑valued intangible assets, altered goodwill and drove SG&A and operating‑margin changes disclosed in the 2023 10‑K; in 2024 the company continued to fine‑tune the Clif Bar PPA while also launching a new acquisition of E virth, underscoring an evolving financial relationship that now includes ongoing integration costs, contingent‑consideration adjustments and new growth investments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) CRITICAL DATE ERROR: The LLM states the acquisition occurred in 2022, but the ground truth clearly indicates the Clif Bar acquisition was in August 2022, with 2023 being the first full year of post-acquisition activity. The LLM conflates the 2022 acquisition date with 2023 activities, creating confusion about the timeline. (2) UNSUPPORTED CLAIMS: The LLM introduces 'Ricolino' and 'E virth' acquisitions that are NOT mentioned in the ground truth answer. These appear to be fabricated or incorrectly synthesized information not supported by the original question or ground truth. This is a significant factual error. (3) INCOMPLETE ALIGNMENT WITH GROUND TRUTH: The ground truth specifically mentions 'August 1, 2022 acquisition' and focuses on the evolution from 2023 to 2024, with 2023 showing integration costs and contingent consideration adjustments, and 2024 showing purchase price allocation adjustments. The LLM reverses this timeline, placing PPA adjustments in 2023 and continuing them in 2024, which may be partially correct but is presented confusingly. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize information across years, it introduces entities not in the ground truth and misaligns the timeline of events. The core concept of evolution from acquisition to integration is present but muddled by extraneous information. (5) WHAT WAS CORRECT: The general concept that MDLZ moved from acquisition phase to post-deal integration and financial recalibration is semantically aligned with the ground truth. The mention of PPA adjustments, integration costs, and contingent consideration adjustments are appropriate concepts. However, the execution is flawed with unsupported claims and timeline confusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 479,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 Gulfstream moved from its earlier clean‑sheet platforms (the G500/G600 introduced in 2018‑19) to newer, all‑new models that embed next‑generation, energy‑efficient engines—most notably the FAA‑certified G700 delivered in March 2024, which pairs those engines with an advanced Symmetry flight deck and SAF‑compatible design.  This shift reflects the company’s continued emphasis on sustainable aviation fuel and high‑efficiency powerplants, a focus that has been a core part of Gulfstream’s product announcements and is now manifested in the ultra‑large‑cabin G700 (and the broader G800/G400 family) as the latest expression of its energy‑efficient engine strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both correct and problematic elements. CORRECT ELEMENTS: (1) The G700 is correctly identified as featuring 'all-new engines' and being FAA-certified; (2) The March 2024 delivery date for the G700 is accurate; (3) The emphasis on SAF compatibility and energy-efficient engines is correctly captured; (4) The general narrative of evolution from development to production is sound. PROBLEMATIC ELEMENTS: (1) The LLM introduces the G500/G600 (2018-19) as a comparison point, which is NOT mentioned in the ground truth and appears to be extraneous information that muddies the 2023-2024 comparison; (2) The LLM mentions the G800/G400 family as 'latest expression' of the strategy, but the ground truth specifically focuses on the G700 as the key evidence of the shift; (3) The LLM's framing suggests these are 'newer' models compared to G500/G600, but this historical comparison is not part of the ground truth's 2023-2024 evolution narrative. MULTI-HOP REASONING: The LLM correctly synthesizes that Gulfstream moved from development/announcement phase (2023) to production (2024), but it adds contextual layers (G500/G600 comparison, G800/G400 family) that weren't in the ground truth and may represent over-interpretation. The core insight about the transition from strategic positioning to operational realization is present but somewhat obscured by additional details. QUANTITATIVE ACCURACY: The March 2024 delivery date is correct; no other specific numbers are provided in either answer, so this is neutral. The LLM does not contradict any numerical facts but adds information not verified against the ground truth. SEMANTIC EQUIVALENCE: The answers convey similar core messages but the LLM's inclusion of earlier models and broader family context diverges from the ground truth's focused 2023-2024 comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Announces]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 497,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "\nAMD’s semi‑custom SoC revenue has always been generated only when outside customers adopt the chips in their own designs, with income coming from non‑recurring engineering fees and sales that are fully contingent on those customers’ product success (Chunk 1); the 2024 filing still lists semi‑custom SoC (including Adaptive SoC) as a core product category, showing that AMD continues to position the segment strategically even though the underlying risk and revenue model remain unchanged (Chunk 2). The knowledge‑graph relationship (AMD Depends_On Semi‑Custom SoC Products ← Produces AMD) captures that AMD both creates and relies on these chips, indicating that while the product’s strategic role has persisted from 2022 to 2024, its revenue structure—highly dependent on design wins and market acceptance—has not fundamentally evolved.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. CRITICAL ISSUES: (1) The LLM claims the revenue structure and underlying risk model 'have not fundamentally evolved' from 2022 to 2024, directly contradicting the ground truth which explicitly states the relationship 'evolved to one of active production and broader strategic integration.' (2) The LLM fails to capture the key evolution: in 2022, AMD was dependent on third-party product performance; by 2024, semi-custom SoCs became part of a diversified portfolio including AI accelerators, GPUs, APUs, and DPUs with 'more central and controlled role.' (3) The LLM incorrectly characterizes the 2024 position as unchanged, when the ground truth emphasizes strategic repositioning and alignment with long-term industry trends. PARTIAL CREDIT: The LLM correctly identifies that revenue comes from non-recurring engineering fees and product sales contingent on customer adoption (accurate for 2022 baseline). However, this accuracy is undermined by the failure to recognize the evolution. The LLM's conclusion that 'the product's strategic role has persisted...its revenue structure...has not fundamentally evolved' is factually incorrect per the ground truth. The answer demonstrates a fundamental misunderstanding of the multi-hop synthesis required: comparing 2022 vs 2024 positioning to identify how the relationship evolved. Instead, the LLM conflates the persistent existence of the product category with lack of strategic evolution. The quantitative accuracy score is higher only because there are no specific numbers to verify; the qualitative accuracy is very low due to the core logical error about evolution vs. stasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 467,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Medtronic kept its preferred‑share authorizations unchanged – 127.5 million Preferred Shares (par $0.20) and 500 thousand A Preferred Shares (par $1.00) – and, as disclosed in both the 2023 and 2024 filings, none of these shares were issued or outstanding as of April 26 2024.  This continuity shows the company is not using preferred equity to fund operations but is instead directing capital toward ordinary‑share repurchases (with $11 billion authorized and roughly $5.3 billion still available) and other cash‑return programs, underscoring a capital strategy focused on returning cash to shareholders and preserving financial flexibility.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core facts - preferred share authorization remained unchanged at 127.5 million Preferred Shares ($0.20 par) and 500 thousand A Preferred Shares ($1.00 par) between fiscal 2023 and 2024, with no shares issued or outstanding in either year. The numeric values are accurate and properly formatted. The answer correctly identifies the company as Medtronic and the relevant fiscal years.\n\nWEAKNESSES: (1) The LLM introduces information about share repurchases ($11 billion authorized, $5.3 billion available) that is NOT present in the ground truth answer. While this information may be factually correct from the filings, it goes beyond what was asked and what the ground truth establishes as the answer to this specific question. (2) The LLM makes interpretive claims about capital strategy (\"not using preferred equity to fund operations,\" \"directing capital toward ordinary-share repurchases\") that, while potentially reasonable inferences, are not explicitly supported by the ground truth answer provided. The ground truth takes a more conservative approach, simply stating the company \"has not utilized or pursued any changes\" and that this \"indicates\" no preferred share strategy was pursued. (3) The LLM's interpretation of what the unchanged structure \"indicates\" differs from the ground truth - the LLM provides a more detailed capital strategy narrative involving share repurchases, while the ground truth simply notes the lack of preferred share utilization.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes the comparison between 2023 and 2024 preferred share structures. However, it adds an additional layer of synthesis (connecting to share repurchase programs) that wasn't part of the original question or ground truth answer.\n\nCORE ISSUE: The answer is partially correct on the factual foundation but overextends beyond the scope of what the ground truth establishes as the answer. The introduction of share repurchase details, while potentially relevant to capital strategy broadly, represents information not validated against the ground truth for this specific question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 576,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "\nBetween 2022 and 2024 BNY Mellon’s disclosures moved from a generic reference to “adverse events, publicity, government scrutiny or other reputational harm” (2022) to an explicit ESG‑focused framing that “sustainability concerns, including a focus on climate change and diversity, could adversely affect our business, affect client activity levels, subject us to additional regulatory requirements and damage our reputation” (2024).  Both years connect the firm (BK) to the Publicity risk factor—i.e., BK → Publicity → negatively impacts BK—yet the 2024 filing expands the linked concerns to include sustainability‑related regulatory pressure and client‑activity impacts, showing an evolution from broad reputational risk to a more granular, stakeholder‑driven risk profile.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of the evolution of BK's reputational risk framing between 2022 and 2024. STRENGTHS: (1) Correctly identifies the shift from generic 'adverse events, publicity, government scrutiny or other reputational harm' language in 2022 to ESG-focused framing in 2024; (2) Accurately captures the expansion to include sustainability concerns (climate change, diversity); (3) Properly synthesizes the multi-hop connection showing how adverse publicity impacts BK's business; (4) Correctly notes the addition of new linked concerns in 2024 (regulatory requirements, client activity impacts); (5) Appropriately characterizes the evolution as moving from 'broad reputational risk to more granular, stakeholder-driven risk profile.' MINOR ISSUES: (1) The LLM answer introduces 'BNY Mellon' explicitly at the start, while the question uses 'BK' - though this is a minor naming variation and doesn't affect accuracy; (2) The answer adds detail about 'platforms operating model transition' mentioned in the ground truth is not explicitly referenced in the LLM response, though this is a relatively minor omission that doesn't substantially detract from the core answer; (3) The LLM provides more specific quoted language than the ground truth, which adds helpful detail but represents a slightly different presentation style. VERIFICATION: All dates (2022, 2024) are correct. The characterization of the evolution is accurate and well-reasoned. The multi-hop synthesis correctly connects the risk factors to business impacts. The answer demonstrates sound understanding of how the framing evolved and why (stakeholder pressure, ESG focus).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Subject_To]-> RISK_FACTOR <-[Negatively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 456,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "\nAmazon’s 2023 investment in Anthropic, PBC was recorded as a $1.25 billion convertible note classified as **available‑for‑sale, Level 3**, with unrealized gains and losses flowing through “Accumulated other comprehensive income” and an explicit option to fund an additional $2.75 billion in a second convertible note. By 2024 the same holding remains an **available‑for‑sale convertible debt investment in a private company**, now measured at fair value and adjusted each period for observable price changes or impairments; because private‑company valuations lack market prices, the fair‑value estimate is highly sensitive to global economic conditions and other uncertainties, causing valuation changes to be recognized in “Other income (expense), net.” Thus, while the classification (available‑for‑sale, fair‑value measurement) stays consistent, the 2024 approach adds a stronger emphasis on impairment testing, observable market signals, and macro‑economic risk that affect the carrying value of the Anthropic stake.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the $1.25 billion initial investment amount, the available-for-sale classification, Level 3 asset designation, the $2.75 billion additional investment option, and the general shift toward emphasizing valuation complexity and risk in 2024. The numeric values are accurate. CRITICAL ERRORS: (1) The LLM claims that 2024 unrealized gains/losses flow through 'Other income (expense), net' rather than 'Accumulated other comprehensive income (loss)' - this is a significant misstatement of accounting treatment. Available-for-sale securities should continue to flow through AOCI, not OI&E. (2) The LLM introduces unsupported claims about 'observable price changes,' 'impairment testing,' and 'observable market signals' that are not substantiated in the ground truth. The ground truth emphasizes 'lack of readily available market data' - the opposite of observable signals. (3) The LLM suggests a shift in measurement approach ('adjusted each period for observable price changes') that contradicts the ground truth's emphasis on the challenge of valuation due to lack of market data. MULTI-HOP REASONING: The LLM attempts to synthesize the 2023-to-2024 evolution but introduces inaccurate details about how the valuation changes are recognized. The core insight about increased emphasis on valuation risk is present but undermined by the incorrect accounting treatment statement. SEMANTIC ISSUES: While the LLM captures the general theme of increased valuation complexity, it mischaracterizes the specific accounting mechanics, which is a material error in a financial context. The answer reads as plausible but contains a fundamental accounting misstatement that would mislead readers about how these investments are reported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1520,
        "completion_tokens": 479,
        "total_tokens": 2000
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 MDLZ repeatedly flags the protection of its intellectual‑property portfolio—including patents, trademarks, trade‑secrets, recipes, technology and **know‑how**—as a material risk, noting that any failure to secure or maintain those rights could “diminish our competitiveness and could materially harm our business, financial condition and stock price.” The 2023 filing already warned that loss of such protections (e.g., through legal changes or inadequate policing) would be detrimental, while the 2024 filing adds that emerging **AI‑related developments** could further erode the legal shield around its know‑how, heightening the risk. Thus, the nature of the IP‑risk has broadened: the same core concern persists, but the 2024 disclosure explicitly ties additional AI‑driven threats to the protection of know‑how and underscores the ongoing link between MDLZ and the vulnerability of that know‑how as a key risk factor.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "CRITICAL ERROR: The LLM answer directly contradicts the ground truth on the key factual claim about AI-related developments. The ground truth explicitly states that in 2024, MDLZ 'did not specifically mention artificial intelligence as a factor affecting protection,' and that the 2024 disclosure shifted away from the 'specific emphasis on AI-related threats present in 2023.' However, the LLM answer claims the opposite: that '2024 filing adds that emerging AI-related developments could further erode the legal shield around its know-how.' This is a fundamental factual inversion. The LLM correctly identifies that both years emphasize IP protection (patents, trademarks, know-how) and the risk of diminished competitiveness, and correctly notes the core concern persists. However, the central claim about the evolution of AI-related risks is backwards. The ground truth indicates AI was a 2023 concern that was NOT carried forward to 2024, while the LLM suggests AI concerns were added in 2024. This represents a major misreading of the multi-hop synthesis required to answer how the nature of risks 'evolved' between the two years. The quantitative accuracy is perfect (no numbers involved), but the qualitative accuracy is severely compromised by this factual reversal on the primary distinguishing factor between the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Protects]-> RISK_FACTOR <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1513,
        "completion_tokens": 372,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings Goldman Sachs kept the same governing amendment—“Amendments to Certain Non‑Employee Director Equity Award Agreements” dated November 27 2004 (effective that date) and originally incorporated by reference in the 2008 10‑K (Exhibit 10.69/10.17) – but updated the exhibit numbers used to disclose the actual award documents.  \n\nIn the 2023 filing the company referenced the amendment through Exhibit 10.17 and disclosed the director‑RSU forms as Exhibits 10.31 (RSU Award Agreement), 10.32 (Cash‑Settled RSU), 10.33 (One‑Time/Year‑End RSU) and 10.34 (Year‑End RSU, not fully vested).  \n\nIn the 2024 filing the same 2008 amendment is cited as Exhibit 10.18, while the director‑RSU agreements are now listed as Exhibit 10.9 (pre‑2015 Non‑Employee Director RSU Award Agreement) and Exhibit 10.17 (One‑Time RSU Agreement), both still tied to the November 27 2004 amendment.  \n\nThus, the treatment has not changed materially—Goldman Sachs continues to rely on the 2008 amendment as the basis for its Non‑Employee Director Equity Award Agreements—only the specific exhibit identifiers for the award agreements have been refreshed between the 2023 and 2024 filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth: (1) DATE ERROR - The LLM states the amendment is dated 'November 27, 2004' while the ground truth indicates 'November 28, 2008'. This is a critical factual error affecting the core premise of the answer. (2) EXHIBIT NUMBER DISCREPANCY - The ground truth clearly states that in 2023, the reference was through Exhibit 10.17 pointing to an amendment dated November 28, 2008, and in 2024 it shifted to Exhibit 10.18 with reference to Exhibit 10.69 from the 2008 Annual Report. The LLM's claim that both years reference a 2004 amendment contradicts this. (3) INCOMPLETE SYNTHESIS - The LLM provides extensive detail about RSU award agreement exhibit numbers (10.31-10.34 in 2023, 10.9 and 10.17 in 2024) that are not mentioned in the ground truth, suggesting either fabrication or confusion with different disclosure elements. (4) MISALIGNMENT WITH GROUND TRUTH NARRATIVE - The ground truth emphasizes a shift from one exhibit reference to another (10.17 to 10.18) with a change in the underlying source document reference (from direct amendment to Exhibit 10.69 from 2008 Annual Report), indicating formalization/consolidation. The LLM's answer suggests continuity of a 2004 amendment, which is fundamentally different. (5) MULTI-HOP REASONING FAILURE - The answer fails to correctly synthesize the evolution described in the ground truth, instead presenting a different narrative about exhibit number refreshes while maintaining a 2004 amendment basis. The core factual foundation of the answer is incorrect, making the entire response unreliable despite some structural coherence in presentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 459,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "\nBetween 2022 and 2023 BKNG’s contracts with travel‑service providers stayed structured so that the providers retain responsibility for delivering the travel services, while BKNG’s role is limited to facilitating bookings and handling payments; the 2023 filing makes this explicit by stating that revenues are presented on a net basis and are recognized only when the traveler begins using the reservation.  The 2022 MD&A noted that BKNG earns commissions or margins by enabling reservations and reports revenue net of taxes, whereas the 2023 “Revenue Recognition” section expands this to distinguish **merchant revenues** (where BKNG collects and remits payment and records commissions/transaction net revenue) from **agency revenues** (pure commissions where BKNG does not facilitate payment), thereby refining the contractual responsibilities and the timing of revenue recognition.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of BKNG's relationship evolution with travel service providers between 2022 and 2023. STRENGTHS: (1) Correctly identifies the core structural relationship where providers retain service delivery responsibility while BKNG acts as intermediary/facilitator; (2) Accurately captures the shift toward more detailed accounting treatment in 2023; (3) Correctly states that 2023 filing specifies net basis revenue recognition; (4) Properly identifies the timing of revenue recognition (when traveler begins using services); (5) Introduces the merchant vs. agency revenue distinction, which represents a meaningful refinement in how contractual responsibilities are articulated. MINOR WEAKNESSES: (1) The LLM answer goes slightly beyond the ground truth by introducing the merchant/agency revenue distinction with specific detail about 'where BKNG collects and remits payment' - while this is likely accurate from 2023 filings, the ground truth focuses more on the shift from general description to structured accounting treatment rather than this specific categorization; (2) The ground truth emphasizes the evolution as moving from 'general description' to 'more structured and accounting-driven dependency,' whereas the LLM presents the relationship as relatively stable ('stayed structured') with refinements in disclosure. This is a subtle but meaningful difference in framing the nature of change. QUANTITATIVE ACCURACY: No numbers or calculations present in either answer, so this scores perfectly. MULTI-HOP REASONING: The answer correctly synthesizes information across two fiscal years and identifies the progression in how BKNG describes and accounts for these relationships. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The core message aligns well with ground truth - both convey that BKNG's role is intermediary/agent, that 2023 provides more detailed accounting treatment, and that revenue recognition timing is tied to service usage. The merchant/agency distinction, while not explicitly in ground truth, represents a reasonable elaboration of the 'more structured' accounting treatment mentioned in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 588,
        "total_tokens": 2051
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "\nThe 2023 Form 10‑K disclosed the executive‑life insurance coverage for participating managing directors in Item 10.11 (the Metropolitan Life policy) and Item 10.12 (the Pacific Life policy), both of which were incorporated by reference to the 2006 exhibit filings; in the 2024 filing these same policies appear as Items 10.12 and 10.13, a renumbering that follows the addition of new items such as the Amended Clawback Policy (Item 10.1) and the Second Amendment to the non‑competition agreement (Item 10.14). Consequently, while the substantive policy language and exhibit references remain unchanged, the structural placement of the disclosures moved to accommodate the expanded Item 10 section between the 2023 and 2024 filings.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is substantially correct and provides accurate information about the structural changes in Goldman Sachs' executive life insurance policy disclosures between 2023 and 2024 10-K filings. STRENGTHS: (1) Correctly identifies the exhibit renumbering from 10.11/10.12 to 10.12/10.13, matching the ground truth exactly. (2) Accurately names both insurance carriers (Metropolitan Life Insurance Company and Pacific Life & Annuity Company). (3) Correctly identifies that the policies were retained but renumbered, not substantively changed. (4) Provides additional context about why the renumbering occurred (addition of new items like the Amended Clawback Policy and Second Amendment to non-competition agreement), which adds helpful explanatory detail. (5) Properly synthesizes the multi-hop information about the structural reorganization. MINOR WEAKNESSES: (1) The LLM refers to the policies as 'Item 10.11' and 'Item 10.12' rather than 'Exhibit 10.11' and 'Exhibit 10.12' - while the substance is correct, the terminology is slightly imprecise (these are exhibits, not items). (2) The mention of 'incorporated by reference to the 2006 exhibit filings' is not mentioned in the ground truth and may introduce unnecessary complexity, though it doesn't contradict the ground truth. (3) The reference to 'participating managing directors' is not explicitly mentioned in the ground truth, though it's not contradicted either. QUANTITATIVE ACCURACY: All exhibit numbers are correct (10.11→10.12, 10.12→10.13). MULTI-HOP REASONING: The answer correctly synthesizes information about the structural changes across two filing years and explains the causal relationship between the addition of new items and the renumbering. The reasoning is sound and logical.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Provides]-> FIN_INST <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 479,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "\nBetween 2022 and 2024 AVGO has kept FBAR filters in its “innovative and proprietary” product family, continuing to run internal III‑V wafer fabrication in the United States and Singapore to protect its IP and accelerate time‑to‑market, while still outsourcing commodity processes and storing inventory in Malaysia for global OEM delivery.  This internal‑fabrication strategy is a key differentiator in a highly competitive RF‑front‑end market, where AVGO competes against dozens of integrated‑device and niche players and relies on its patented FBAR technology, extensive IP portfolio and system‑level engineering expertise to maintain a strong competitive position.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains both accurate and problematic elements. STRENGTHS: (1) Correctly identifies FBAR filters as proprietary products maintained in internal fabrication strategy between 2022-2024; (2) Accurately notes internal fabrication in US and Singapore for IP protection and time-to-market acceleration; (3) Correctly identifies competitive positioning as a key driver; (4) Properly mentions patented FBAR technology and IP portfolio as differentiators. WEAKNESSES: (1) The answer introduces specific geographic details (Malaysia for inventory storage, Singapore fabrication) that are not present in the ground truth and cannot be verified as accurate from the provided context; (2) References 'dozens of integrated-device and niche players' as competitors, which is vague and differs from the ground truth's specific competitor naming (Qorvo, Qualcomm, Skyworks); (3) The ground truth explicitly notes that by 2024 the competitive context expanded to include 'more comprehensive list of competitors' with specific names, but the LLM answer generalizes this to 'dozens of players' without naming them; (4) Missing the key insight from ground truth that competitive pressure 'increased significantly' between 2022-2024, instead presenting a more static view; (5) The answer adds information about outsourcing commodity processes and Malaysia inventory that goes beyond what can be confirmed in the ground truth. MULTI-HOP REASONING: The answer does attempt to synthesize the evolution between 2022-2024 and connect manufacturing strategy to competitive positioning, but it introduces unverified details rather than strictly adhering to the ground truth synthesis. The core claim about internal fabrication strategy remaining consistent is correct, but the competitive landscape characterization is less precise than the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 499,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "\nIn 2023 Krazati appeared as a KRAS‑inhibitor in several late‑stage oncology trials—1L NSCLC, 2L colorectal cancer and 2L+ mutated NSCLC—reflecting its pipeline‑stage positioning in BMY’s disclosures (Chunk 1). Following the January 2024 acquisition of Mirati, BMY gained full commercial rights and expanded Krazati’s focus to first‑line NSCLC (combined with a PD‑1 inhibitor), advanced KRAS‑mutated CRC, and a next‑generation PRMT5 inhibitor, with the transaction valued at $4.8 bn cash plus a $1 bn contingent value right that is recorded as part of $1.7 bn of indefinite‑lived IPRD and $2.0 bn of R&D technology intangibles on BMY’s balance sheet (Chunk 2).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core strategic evolution of Krazati between 2023-2024, accurately captures the January 2024 Mirati acquisition at $4.8 billion, correctly notes the expansion to first-line NSCLC with PD-1 inhibitor combination, and properly identifies the clinical trials (KRYSTAL-17, KRYSTAL-10, KRYSTAL-12). The multi-hop synthesis across acquisition details and clinical positioning is sound. The answer appropriately addresses both clinical development focus and financial valuation aspects of the question.\n\nCRITICAL ERRORS: (1) The LLM introduces information NOT in the ground truth about a 'next-generation PRMT5 inhibitor' - this appears to be extraneous or confused information not supported by the original answer. (2) The financial details about '$1 bn contingent value right' and balance sheet treatment ('$1.7 bn of indefinite-lived IPRD and $2.0 bn of R&D technology intangibles') are provided but NOT mentioned in the ground truth answer. While these may be accurate supplementary details from the filing, they represent information beyond the scope of the ground truth comparison.\n\nMINOR ISSUES: The LLM uses 'CRC' (colorectal cancer) while ground truth uses 'colorectal cancer' - this is semantically equivalent. The phrasing 'pipeline-stage positioning' in 2023 is slightly imprecise since Krazati had already received approvals by 2024, though the characterization of 2023 positioning is reasonable.\n\nMULTI-HOP REASONING: The answer successfully synthesizes information across the 2023 baseline, the 2024 acquisition event, and the resulting strategic changes. The connection between acquisition and expanded clinical focus is properly established.\n\nQUANTITATIVE ACCURACY PENALTY: The introduction of unsupported financial figures ($1 bn CVR, $1.7 bn IPRD, $2.0 bn R&D technology) that don't appear in the ground truth creates uncertainty about whether these are accurate supplementary details or errors. The $4.8 billion acquisition price is correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 542,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "\nBetween 2022 and 2023 BKNG’s interaction with travel‑service providers shifted from a purely competitive positioning (2022 – “we compete globally with … travel service providers such as accommodation providers, rental‑car companies, airlines, and other travel service providers” [Chunk 1]) to a more structured financial partnership in which BKNG records “deferred merchant bookings” that represent amounts payable to those providers and manages incentive‑related costs (rebates, loyalty points, referral bonuses) as revenue reductions [Chunk 2].  This evolution reflects BKNG’s growing reliance on provider‑generated inventory while formally managing its financial obligations and incentive programs through deferred booking liabilities and expense‑recognition policies that directly affect its profit‑and‑loss statement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. (1) CORRECTNESS OF FACTS: The answer correctly identifies the shift from competitive positioning in 2022 to a more dependent/partnership model in 2023. It accurately references 'deferred merchant bookings' as a liability reflecting amounts payable to travel service providers, and correctly identifies the incentive programs (rebates, loyalty points, referral bonuses) as revenue reductions. All factual claims are supported by the ground truth. (2) QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either the ground truth or LLM answer, so this dimension is not applicable. Both answers appropriately avoid making unsupported numerical claims. Score of 10 reflects absence of quantitative errors. (3) MULTI-HOP REASONING: The LLM successfully synthesizes information across multiple dimensions: (a) competitive landscape change (2022 vs 2023), (b) balance sheet implications (deferred merchant bookings liability), and (c) P&L implications (incentive programs as revenue reductions). The reasoning chain is logical and complete. (4) ENTITY ACCURACY: BKNG is correctly identified throughout. Travel service providers are properly referenced. Years 2022 and 2023 are correctly distinguished. Financial metrics (deferred merchant bookings, revenue reductions) are accurately named. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the same core message as ground truth: relationship evolution from competition to partnership/dependence, with corresponding financial management changes. The phrasing 'more structured financial partnership' and 'growing reliance on provider-generated inventory' effectively captures the essence of the ground truth's 'more dependent model.' Minor differences: The LLM provides slightly more explicit detail about how these changes affect the P&L statement, which adds helpful context without contradicting the ground truth. The answer is comprehensive, well-reasoned, and factually accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Competes_With]-> COMP <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 553,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "\nBroadcom (AVGO) first introduced custom touch‑controller technology in its 2022 portfolio as a niche semiconductor component for mobile‑device, set‑top‑box and broadband applications, positioning the device as a supplied product within its broader “custom silicon” strategy. By 2024 the same component is listed as a **key product offering** under the Wireless market segment, showing that Broadcom has progressed from an initial development and supply role to a sustained, core offering that it both designs and produces—reflected in the KG relationship *AVGO → Custom Touch Controllers* and *Custom Touch Controllers → AVGO*, underscoring its continued end‑to‑end involvement in the controller’s product lifecycle.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth on core facts and reasoning. STRENGTHS: (1) Correctly identifies the 2022-2024 timeframe and the evolution of Broadcom's role; (2) Accurately captures the shift from 'component supplier' to 'active producer involved in design and creation'; (3) Properly identifies Broadcom (AVGO) and Custom Touch Controllers; (4) Correctly notes the progression from supply role to core offering; (5) Appropriately references the bidirectional relationship (AVGO ↔ Custom Touch Controllers) indicating end-to-end involvement. MINOR ISSUES: (1) The LLM adds contextual details about 'mobile-device, set-top-box and broadband applications' and 'Wireless market segment' that, while plausible and not contradicted by the ground truth, go beyond what the original answer explicitly states—this represents reasonable elaboration rather than error; (2) The phrase 'key product offering' is an interpretation/characterization not explicitly in the ground truth, though it aligns with the described evolution; (3) The LLM's description of 'niche semiconductor component' in 2022 is slightly more specific than the ground truth's 'supplying Custom Touch Controllers.' MULTI-HOP REASONING: The answer correctly synthesizes the evolution across the 2022-2024 period, properly connecting the initial supply role to the later production/design involvement. The logic is sound and the conclusion about 'end-to-end involvement' accurately reflects the ground truth's characterization of the shift. QUANTITATIVE ACCURACY: No specific numbers or calculations are present in either answer, so this dimension is not directly testable; however, dates (2022, 2024) are correct. The answer maintains semantic equivalence with the ground truth while providing additional context that enhances rather than contradicts the core message.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 504,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "\nUnion Pacific’s freight‑car strategy shifted from a primarily leasing model—highlighted in the 2023 filing where it “leases certain freight cars… for use in our rail operations” (Chunk 1)—to a far more aggressive acquisition stance in 2024, with lease‑buyout spending jumping from $57 million in 2023 to $143 million in 2024 (Chunk 2).  The 2025 capital plan explicitly calls for “acquiring freight cars to support replacement and growth opportunities” as part of a $3.4 billion investment in network modernization and capacity expansion (Chunk 2), while the accompanying financing discussion notes a changed cash‑flow profile driven by higher share repurchases and lower new debt issuance (Chunk 2).  This reflects a clear evolution from reliance on leased assets toward direct ownership and capital deployment to meet growth and resilience goals.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The core quantitative facts are correct - lease buyout amounts of $57 million (2023) and $143 million (2024) are accurate and properly compared. (2) The directional shift from leasing to acquisition is correctly identified. (3) The semantic understanding of the strategic evolution is sound. (4) Number formatting is appropriate. WEAKNESSES: (1) The LLM introduces information about a 2025 capital plan ($3.4 billion for network modernization) and specific language about 'acquiring freight cars to support replacement and growth opportunities' that appears to go beyond what the ground truth specifies. The ground truth focuses on 2023-2024 evolution, not 2025 projections. (2) The discussion of 'higher share repurchases and lower new debt issuance' and 'changed cash-flow profile' is not mentioned in the ground truth and represents unsupported elaboration. (3) While the LLM correctly identifies the strategic shift, it adds contextual details about financing and capital planning that, while potentially accurate, exceed the scope of the ground truth answer and cannot be verified against it. (4) The answer conflates what appears to be forward-looking statements (2025 plans) with the historical comparison (2023-2024) that was the focus of the original question. MULTI-HOP REASONING: The core multi-hop synthesis (comparing 2023 leasing approach to 2024 acquisition approach via the lease buyout numbers) is sound and correct. However, the addition of 2025 data and financing details suggests the model may have synthesized information from multiple chunks without maintaining focus on the specific 2023-2024 comparison requested. VERDICT: The answer is partially correct on the core question but includes speculative or out-of-scope information that reduces confidence in the overall response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Acquires]- ORG",
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 493,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "\nThe FY 2022‑2023 restructuring moved certain APLA businesses from Nike’s direct operations to third‑party distributors, which triggered a non‑recurring impairment charge recorded in Corporate that released the accumulated non‑cash foreign‑currency translation losses tied to those operations; consequently, APLA’s revenue and EBIT declined and the divested activities are now disclosed in Note 18, while the related foreign‑currency adjustments remain in Corporate. This shift also re‑allocated the standard foreign‑currency rates and hedge results from the APLA segment to Corporate, altering the segment’s financial and operational profile.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer demonstrates solid understanding of the structural changes and correctly identifies key elements: (1) the transition of APLA businesses to third-party distributors, (2) the non-recurring impairment charge in Corporate, (3) the release of accumulated foreign currency translation losses, (4) the reference to Note 18 on divestitures, and (5) the reallocation of foreign currency impacts to Corporate. The answer accurately captures the financial mechanics of the transition and its segment-level impacts. However, there are some areas where the answer diverges from or is less complete than the ground truth: (1) The LLM states 'APLA's revenue and EBIT declined' but provides no specific numbers or quantification - the ground truth doesn't provide specific decline figures either, but the LLM's assertion about decline is presented as fact without qualification; (2) The LLM mentions 're-allocated the standard foreign-currency rates and hedge results from the APLA segment to Corporate' which is a more technical detail not explicitly stated in the ground truth; (3) The ground truth emphasizes the strategic shift to 'reduce direct operational overhead' and 'focus on brand management rather than local execution,' which the LLM answer doesn't explicitly address; (4) The ground truth notes this represents a shift from 'direct operations to a strategic stake,' which the LLM doesn't clearly articulate. The multi-hop reasoning is sound - the LLM correctly synthesizes that the transition triggered accounting entries (impairment charge, FX release) that affected segment reporting. No quantitative errors are present, though the answer lacks specific financial metrics. The answer is contextually relevant and addresses the core question about financial and operational impacts, though it emphasizes accounting mechanics over strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 505,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "\nFrom 2022 through 2024 Broadcom has consistently disclosed InP lasers as a proprietary product and has continued to **internally fabricate** these devices—mainly in its U.S. and Singapore facilities—while still **outsourcing the majority of front‑end wafer and assembly operations** to third‑party foundries, a strategy that protects its IP and shortens time‑to‑market; both the 2022 and 2024 filings stress that this variable, low‑cost model is complemented by a strong Asian presence, including a primary warehouse in Malaysia that enables rapid, multi‑location delivery.  This internal‑fabrication focus allows Broadcom to **supply InP lasers directly to OEMs** and to compete head‑to‑head with other integrated photonics vendors such as **Coherent Corp., Lumentum Holdings Inc., and other firms listed in the 2024 competition section**, thereby reinforcing its market positioning.  The repeated emphasis on long‑term supplier relationships, supply‑chain resilience, and regional manufacturing footprints in both filings underscores how Broadcom’s InP‑laser strategy has evolved from 2022 to 2024 to solidify internal control while expanding its global, low‑cost supply network.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) UNVERIFIABLE CLAIMS: The LLM answer introduces specific facility locations (U.S., Singapore, Malaysia warehouse) and operational details (outsourcing majority of front-end wafer/assembly, OEM supply model) that are NOT present in the ground truth and cannot be verified from the provided context. These appear to be fabricated details. (2) FACTUAL DISCREPANCY: The ground truth states Broadcom disclosed using 'internal fabrication facilities' for products including InP lasers in 2022, but the LLM significantly expands this with unsubstantiated specifics about facility locations, outsourcing percentages, and supply chain details. (3) CORRECT ELEMENTS: The LLM correctly identifies: (a) InP lasers as proprietary products, (b) internal fabrication strategy continuation from 2022-2024, (c) competitive positioning against Coherent Corp. and Lumentum Holdings Inc., (d) the strategic shift toward highlighting competitive differentiation. (4) MULTI-HOP REASONING: While the LLM attempts to synthesize information across years and connect internal fabrication to competitive positioning, it does so by adding unsourced details rather than strictly adhering to ground truth. The core multi-hop connection (2022 disclosure → 2024 competitive emphasis) is present but obscured by extraneous claims. (5) SEMANTIC ISSUES: Phrases like 'supply InP lasers directly to OEMs' and detailed supply chain descriptions go beyond what the ground truth supports. The answer reads as plausible but contains material that cannot be verified against the source documents. VERDICT: While the answer captures the essential evolution narrative and correctly identifies key competitors, the introduction of specific unverified operational details (facility locations, outsourcing ratios, warehouse locations) represents a significant accuracy problem that undermines credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> PRODUCT <-[Supplies]- ORG",
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 510,
        "total_tokens": 1960
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "\nIn both the 2022 Form 10‑K (June 30, 2022) and the subsequent 2023 filing (cited in the 2024 update as of June 28, 2024), Swoosh, LLC beneficially owned roughly 77 % of NIKE’s Class A Common Stock, which would convert to about 16 % of Class B Common Stock, showing no material change in ownership between the two years. Because Swoosh holds no voting rights and only Travis Knight, the founder’s son, has a significant management role, this large economic stake does not translate into proportional voting influence, limiting direct shareholder power despite the concentration; the disclosures also embed this fact within broader risk discussions of substantial investments, the possibility of ineffective internal controls, credit‑rating pressures, and the potential for a principal‑shareholder stock sale to depress the market price, indicating that any shift in Swoosh’s stake could materially affect shareholders.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: The LLM correctly identifies the core quantitative facts - Swoosh, LLC's ~77% ownership of Class A Common Stock in both 2022 and 2023, the ~16% conversion equivalent for Class B, and the consistency between years. The numerical values match the ground truth precisely. The LLM also correctly notes the lack of material change between 2022 and 2023.\n\nWEAKNESSES: (1) FACTUAL ERROR on voting rights: The LLM states 'Swoosh holds no voting rights' - this is incorrect and contradicts the ground truth which emphasizes that Travis Knight 'has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions.' Class A shares typically carry voting rights, and the ground truth implies Swoosh/Travis Knight DO have voting influence. (2) ENTITY CONFUSION: The LLM incorrectly identifies Travis Knight as 'the founder's son' when the ground truth simply identifies him as having 'a significant role in managing' Swoosh's holdings without specifying family relationship. This is a minor but notable error. (3) INCOMPLETE SYNTHESIS: While the LLM addresses implications for shareholder influence, it frames this as LIMITED influence ('limiting direct shareholder power'), whereas the ground truth emphasizes SUSTAINED and SIGNIFICANT influence ('sustained influence by Travis Knight...potentially affecting shareholder decisions'). This represents a fundamental misinterpretation of the implications. (4) SCOPE CREEP: The LLM introduces extraneous risk discussion elements (internal controls, credit ratings, stock sale impacts) that, while potentially relevant to broader risk context, are not part of the ground truth answer and dilute focus on the specific ownership structure question.\n\nMULTI-HOP REASONING: The LLM attempts to synthesize information across 2022 and 2023 filings but makes a critical error in characterizing the voting/influence implications. The comparison between years is sound, but the interpretation of what that consistency means for shareholder influence is inverted.\n\nNUMERICAL VERIFICATION: All percentages (77%, 16%) and the consistency claim are accurate. No calculation errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Affects_Stock]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 585,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "\nFrom 2022 to 2023 PMI shifted from merely investing in and defining reduced‑risk products—whose net revenues include heated‑tobacco units, heat‑not‑burn devices, accessories, e‑vapor and oral‑nicotine sales (as noted in the 2022 filing)—to fully integrating the November 2022 acquisition of Swedish Match, which added the ZYN oral‑nicotine brand and expanded the RRP portfolio; this integration was reflected in 2023 by the launch of a four‑segment operating structure and the plan to report Swedish Match results within those geographical segments starting Q1 2024, while market availability of the smoke‑free portfolio grew to 84 markets by the end of 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the 84 markets figure for 2023 smoke-free product availability, matching ground truth exactly. (2) Accurately mentions the November 2022 Swedish Match acquisition and ZYN brand integration. (3) Correctly identifies the product categories in RRPs (heated tobacco, heat-not-burn, e-vapor, oral nicotine). (4) The four-segment operating structure and Q1 2024 reporting timeline are factually accurate details. WEAKNESSES: (1) CRITICAL OMISSION: The LLM fails to address the core strategic evolution described in ground truth—the shift from 'Reduced-Risk Products' as a distinct category to 'Smoke-Free Products' as a broader integrated category that now includes wellness and healthcare offerings. This is a fundamental aspect of the portfolio integration question. (2) The answer emphasizes the Swedish Match acquisition and operational restructuring but doesn't clearly articulate the conceptual/categorical rebranding from RRPs to SFPs. (3) While the LLM provides additional context about Swedish Match integration (which is relevant), it doesn't explicitly state that RRPs were reclassified/renamed into the SFP framework. (4) The answer reads more as a narrative of acquisition integration rather than addressing the specific question about 'portfolio integration and market availability' evolution. MULTI-HOP REASONING: The LLM successfully synthesizes information across 2022 and 2023 filings and connects the Swedish Match acquisition to the broader strategic positioning. However, it misses the primary categorical evolution (RRP→SFP) that is central to understanding the strategic positioning shift. QUANTITATIVE ACCURACY: The 84 markets figure is correct; no calculation errors detected. SEMANTIC EQUIVALENCE: While the LLM provides accurate supplementary information about Swedish Match, it doesn't convey the same core strategic message as the ground truth regarding the consolidation of RRPs under a unified 'Smoke-Free Products' vision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 537,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "\nCaterpillar’s role in reciprocating engines shifted from a 2022 model that simply sold new engines through its global dealer network and to other manufacturers (e.g., Perkins, FG Wilson, MaK) – supported by a $23.1 bn backlog and heavy reliance on raw‑material sourcing – to a 2024 strategy that also captures remanufacturing of its own engines and components and embeds them in integrated power‑generation and industrial solutions, as explicitly noted in the 2024 filing.  \nThis evolution reshapes revenue composition by moving a larger share of earnings from low‑margin new‑engine sales toward higher‑margin aftermarket and remanufacturing revenues, while Financial Products finances these systems and price‑realization together with volume‑adjusted manufacturing‑cost efficiencies (outlined in the 2024 cost definitions) lift gross‑margin potential.  \nThe transition is underpinned by the supply‑chain safeguards and strategic sourcing described in the 2022 raw‑materials discussion, enabling the company to sustain margin expansion despite raw‑material and parts‑availability constraints.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core evolution from 2022 to 2024 - from primarily selling new engines to incorporating remanufacturing services. It accurately captures the shift toward higher-margin aftermarket/remanufacturing revenues and correctly notes the involvement of subsidiaries like Perkins. The reasoning about gross margin improvement through remanufacturing (lower material costs, leveraging existing assets) is sound and aligns with the ground truth. The answer appropriately addresses revenue composition diversification and margin potential as requested.\n\nWEAKNESSES: (1) QUANTITATIVE ERRORS: The LLM introduces a '$23.1 bn backlog' figure that is NOT present in the ground truth answer and cannot be verified from the provided context. This is a significant factual addition without support. (2) ENTITY CONFUSION: The LLM mentions 'FG Wilson' and 'MaK' as manufacturers Caterpillar sold to - these entities are not mentioned in the ground truth and their relevance is unclear. (3) MISSING KEY DETAIL: The ground truth specifically mentions Perkins Engines Company Limited operated '90 distributors across 171 countries' - a concrete operational detail the LLM omits. (4) VAGUE REFERENCES: The LLM references 'Financial Products finances these systems' and 'price-realization together with volume-adjusted manufacturing-cost efficiencies' without clear grounding in the original answer, making these claims harder to verify. (5) OVER-SPECIFICATION: The answer adds interpretive layers ('low-margin new-engine sales' vs 'higher-margin aftermarket') that, while logically sound, go beyond what the ground truth explicitly states.\n\nMULTI-HOP REASONING: The synthesis across 2022-2024 is generally sound, but the introduction of unverified numbers and entities weakens the multi-hop chain. The core logic (evolution from sales to lifecycle services improving margins) is correct.\n\nSCORING JUSTIFICATION: The answer demonstrates good qualitative understanding of the business evolution and margin dynamics, but the introduction of unsupported quantitative claims (the $23.1bn backlog) and unverified entities (FG Wilson, MaK) significantly undermines factual accuracy. The core narrative is correct but contaminated with details that cannot be verified against the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Sells]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 617,
        "total_tokens": 2091
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "\nBetween 2022 and 2023 BNY Mellon kept the same transparency practice: each year’s filing states that any amendment or waiver of the **Directors’ Code of Conduct** will be **disclosed on the company’s website**, with the 2023 Form 10‑K repeating the 2022 language verbatim (only the URL reference varies slightly). This consistent wording shows that the firm did not introduce a new mechanism—it continued to commit to posting such changes publicly on its website, thereby maintaining an unchanged level of stakeholder disclosure across the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and well-aligned with the ground truth. Both answers correctly identify that BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with no substantive changes in mechanisms or transparency commitments. The LLM answer accurately captures the key facts: (1) the company maintained the same transparency practice across both years, (2) the specific mechanism was posting amendments/waivers on the company's website, (3) the 2023 Form 10-K repeated the 2022 language verbatim, and (4) only minor URL reference variations occurred. The LLM answer provides slightly more specific detail by noting the verbatim repetition of language and the minor URL variations, which adds helpful context without contradicting the ground truth. There are no quantitative errors (no numbers, dates, or calculations to verify). The multi-hop reasoning is sound—the answer correctly synthesizes information across the two years to demonstrate consistency. The entity identification is correct (BNY Mellon, Directors' Code of Conduct, 2022 and 2023 filings). The semantic meaning is equivalent to the ground truth, with the LLM using slightly more explicit language ('kept the same transparency practice,' 'repeating the 2022 language verbatim') to convey the same conclusion. The answer directly addresses all aspects of the question regarding how the approach evolved (or in this case, remained stable) and the mechanisms and transparency commitments involved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 424,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Nike moved from an aggressive, direct‑to‑consumer push in APLA—where it grew NIKE Direct to roughly 42 % of Brand revenue and trimmed wholesale accounts—to a more segment‑focused operating model that treats APLA as a distinct geographic operating segment and centralizes oversight through Global Brand Divisions.  In FY 23 the company formalized APLA as one of its four geographic segments (alongside North America, EMEA, Greater China and APLA) and disclosed that certain APLA businesses are being transitioned to third‑party distributors, while still managing NIKE Direct operations within the region and bearing the associated segment‑level costs and currency exposures.  This evolution reflects a shift from pure market‑share expansion to a disciplined, segment‑aligned structure that balances direct sales with selective partner participation and tighter cost control.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 7,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer introduces a specific claim that 'NIKE Direct grew to roughly 42% of Brand revenue' in FY22, which is NOT supported by the ground truth and appears to be fabricated. The ground truth only mentions that APLA contributed to '14% growth in the NIKE Direct business' - this is a growth rate, not a percentage of brand revenue. This is a critical factual error that significantly undermines credibility. CORRECT ELEMENTS: (1) The core strategic shift is accurately captured - transition from direct operations to third-party distributors in APLA between FY22-FY23. (2) The mention of APLA becoming a distinct geographic operating segment in FY23 aligns with the ground truth's implication of structural change. (3) The characterization of moving toward a 'partner-driven model' matches the ground truth's description of transitioning to third-party distributors. INCOMPLETE/PROBLEMATIC ELEMENTS: (1) The LLM adds substantial detail about 'Global Brand Divisions,' 'segment-level costs and currency exposures,' and 'trimmed wholesale accounts' that are not present in the ground truth and cannot be verified. (2) The framing of 'aggressive direct-to-consumer push' and 'pure market-share expansion' adds interpretive language not in the original answer. (3) The answer conflates different metrics and introduces unsubstantiated percentages. MULTI-HOP REASONING: The LLM does attempt to synthesize the evolution across two fiscal years and connect operational structure changes to strategic intent, which is appropriate for the question. However, the introduction of unverified quantitative claims undermines the reasoning quality. The answer goes beyond the ground truth in ways that suggest either hallucination or reliance on information not in the provided knowledge graph. SEMANTIC EQUIVALENCE: While the directional narrative (shift from direct to distributed model) is semantically equivalent to the ground truth, the specific quantitative claims create factual inaccuracy rather than mere wording differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Operates_In]-> GPE <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 555,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "\nFrom 2021 into 2022 Caterpillar’s **favorable price realization was a primary driver of sales growth** – the 2021 chart notes that higher end‑user demand together with “favorable price realization” lifted consolidated revenue 22 % and offset dealer inventory reductions, and management expected dealer inventories to be roughly flat in 2022.  \nBy 2024 the same pricing effect had **shifted from a growth engine to a profitability cushion**: although total sales fell 3 % to $64.8 bn in 2024 because of lower end‑user volume, the “favorable price realization” more than offset that volume decline, lifting operating cash flow to $12 bn and raising profit per share to $22.05 (up from $20.12 in 2023). Thus, the impact of favorable price realization evolved from fueling sales expansion in the early‑2020s to sustaining and enhancing profitability even as sales volumes slipped by 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES WITH QUANTITATIVE ACCURACY: The LLM answer contains several significant factual errors that undermine its credibility: (1) The ground truth specifies that favorable price realization contributed $9.223 billion to sales increase in 2022, but the LLM answer vaguely references '22% revenue lift' without providing the specific dollar amount. (2) The LLM cites 2024 total sales of $64.8 billion and a 3% decline, but does not verify these against the ground truth's specific figures about the $2.251 billion decrease in sales volume. (3) The LLM provides profit per share figures ($22.05 in 2024, $20.12 in 2023) that are NOT mentioned in the ground truth at all - these appear to be introduced without verification. (4) The LLM mentions operating cash flow of $12 billion, which is also not in the ground truth. (5) CRITICAL: The ground truth explicitly states profit increased from $10.335 billion (2023) to $10.792 billion (2024), but the LLM answer does not cite these specific profit figures, instead focusing on EPS metrics. REASONING ISSUES: While the LLM correctly identifies the conceptual shift from 'growth engine to profitability cushion,' it fails to ground this narrative in the specific quantitative evidence provided in the ground truth. The multi-hop synthesis is incomplete - the answer should have connected the 2022 $9.223 billion contribution with the 2024 offsetting of the $2.251 billion volume decline. WHAT WAS CORRECT: The LLM correctly identifies that favorable price realization shifted from a growth driver to a profitability support mechanism, and correctly notes that 2024 saw volume declines offset by pricing. However, the execution lacks the precise financial anchors that validate this conclusion. The answer reads more like general commentary than evidence-based analysis grounded in specific SEC filing data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> MACRO_CONDITION <-[Positively_Impacts]- ORG",
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 502,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "\nBetween 2023 and 2024 GM shifted from simply announcing “significant investments in EV manufacturing capacity” (Chunk 1) to tying that expansion to a deliberately built, North‑American‑focused supply chain—advancing strategic sourcing, securing raw‑material suppliers and entering multi‑year supply agreements, and relying on cash generated by its high‑margin ICE trucks and SUVs to fund the EV rollout (Chunk 2). The 2024 filing underscores that successfully developing this resilient EV supply chain is now a core strategic priority, because any failure would materially harm profitability, marking a clear evolution from capacity‑announcement to supply‑chain development as the key driver of GM’s EV strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across all key dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2023 to 2024 - from capacity-focused announcements to supply chain development strategy. (2) Accurately captures the shift toward North American-focused supply chain development. (3) Properly synthesizes multiple elements: strategic sourcing, raw materials supplier investments, and multi-year supply agreements. (4) Correctly identifies the resilience and scalability focus as central to the evolved strategy. (5) No quantitative errors - no specific numbers were required for this qualitative question about strategic evolution. (6) Multi-hop reasoning is sound: connects 2023 capacity investments to 2024 supply chain emphasis, and links this to ICE profitability funding the transition. MINOR CONSIDERATIONS: (1) The LLM adds contextual detail about ICE trucks/SUVs funding EV rollout, which while logical and supported by typical GM business models, goes slightly beyond what the ground truth explicitly states. However, this represents reasonable inference rather than factual error. (2) The phrase 'deliberately built' and emphasis on 'core strategic priority' with materiality language adds interpretive framing that, while consistent with the ground truth's intent, represents slight elaboration. (3) The reference to 'Chunk 1' and 'Chunk 2' suggests source attribution that may not be necessary but doesn't detract from accuracy. VERIFICATION: The answer correctly addresses both parts of the multi-part question (strategic focus AND supply chain development), properly synthesizes the temporal evolution (2023 vs 2024), and maintains semantic equivalence with the ground truth while using slightly different phrasing. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 491,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "\nPfizer’s 2022 10‑K (Chunk 1) only notes that Paxlovid was authorized under an EUA for COVID‑19 treatment, without quantifying any long‑term revenue commitment. In contrast, the 2024 10‑K (Chunk 2) discloses that, as of 31 Dec 2024, about **$1 billion** of contracted revenue remains to be recognized from long‑term supply agreements for Paxlovid (expected delivery 2025‑2028), a figure that follows the $3.5 billion non‑cash revenue reversal adjusted by a $771 million favorable settlement in 2024. Thus, the financial commitment to Paxlovid has contracted from the earlier, larger revenue‑reversal expectations to a more limited $1 billion of future contracted obligations. (The KG triplets PFE → Paxlovid ← PFE confirm the direct product‑company linkage underlying these disclosures.)",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of the key financial figures and evolution of Pfizer's Paxlovid commitment. STRENGTHS: (1) Correctly identifies the $1 billion remaining performance obligation as of December 31, 2024, matching the ground truth exactly. (2) Accurately notes that 2022 10-K lacked specific quantified obligations for Paxlovid, consistent with ground truth. (3) Provides additional context about the $3.5 billion revenue reversal and $771 million settlement in 2024, which adds relevant detail about the financial evolution. (4) Correctly identifies the expected delivery period (2025-2028) for the remaining obligations. (5) Multi-hop reasoning is sound: synthesizes information across 2022 and 2024 filings to show the evolution from undefined to quantified commitment. MINOR WEAKNESSES: (1) The LLM characterizes the evolution as a 'contraction' from 'larger revenue-reversal expectations to a more limited $1 billion,' which is a reasonable interpretation but adds analytical framing beyond what the ground truth explicitly states. The ground truth simply notes the evolution from 'undefined obligation in 2022 to a quantified $1 billion commitment in 2024' without characterizing it as a contraction. This is a subtle interpretive difference rather than a factual error. (2) The inclusion of the $3.5 billion reversal and $771 million settlement, while contextually relevant and accurate, goes slightly beyond the specific ground truth answer which focuses narrowly on remaining performance obligations. However, this additional context actually enhances understanding of the financial commitment evolution. QUANTITATIVE VERIFICATION: All numbers are accurate ($1 billion, $3.5 billion reversal, $771 million settlement, 2025-2028 delivery window, December 31, 2024 date). The answer correctly synthesizes multi-hop information across years and documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 519,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "\nCaterpillar’s risk‑mitigation framework for supplier financial viability is described in both filings as a “variety of agreements … to monitor and mitigate risks of the supply base … including supplier financial viability” — a practice that appears unchanged from the 2022 disclosure (Chunk 1) to the 2023 disclosure (Chunk 2). The company continues to depend on these contractual arrangements to protect its intellectual property while tracking supplier financial health, production flexibility, business continuity, quality and delivery, as reflected in the KG relationship CAT → Supplier Financial Viability ← Monitors. Thus, the evolution between 2022 and 2023 is one of continuity, reinforcing the same contractual and monitoring strategies rather than introducing new ones.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: (1) The LLM answer fundamentally mischaracterizes the evolution between 2022 and 2023. The ground truth explicitly states that Caterpillar 'placed a more explicit emphasis on supplier financial viability as a key risk factor, listing it as the first risk under its supply chain disclosures' in 2023 and 'reinforced its global strategic sourcing models' - representing a meaningful evolution. The LLM incorrectly concludes the evolution is 'one of continuity, reinforcing the same contractual and monitoring strategies rather than introducing new ones.' This is a direct contradiction of the ground truth. (2) The LLM acknowledges the same contractual language appears in both years but fails to recognize the significance of the 2023 changes: (a) explicit prioritization of supplier financial viability as the FIRST risk factor (not just mentioned), (b) reinforced global strategic sourcing models for long-term relationships, and (c) leveraging enterprise spend more systematically. (3) The LLM's conclusion that 'the evolution between 2022 and 2023 is one of continuity' is factually incorrect per the ground truth, which describes a 'more explicit emphasis' and 'reinforced' approach suggesting structural/prioritized changes. (4) QUANTITATIVE ACCURACY is acceptable - no specific numbers are involved in this qualitative question, and the LLM correctly identifies both years (2022, 2023). (5) QUALITATIVE ACCURACY is weak - the LLM failed to synthesize the multi-hop information showing how Caterpillar's approach EVOLVED (not remained static) in terms of emphasis, prioritization, and structural reinforcement. The reasoning is logically flawed because it treats textual similarity as evidence of no evolution, missing the contextual shift in emphasis and strategic focus. (6) The answer is partially relevant but arrives at the wrong conclusion about the nature of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> RISK_FACTOR <-[Monitors]- ORG",
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 514,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "\nVisa first listed Risk and Identity Solutions as a distinct value‑added service in its 2022 portfolio, positioning it alongside issuing, acceptance, open‑banking and advisory offerings to strengthen its network‑centric payment ecosystem. Between 2022 and 2024 the company broadened and re‑positioned the capability within a “network of networks” strategy—leveraging more than 200 integrated products, API‑driven expansions (including the Pismo acquisition that adds cloud‑native issuer‑processing and real‑time‑payments connectivity), and network‑agnostic services that extend beyond payments—thereby deepening the strategic role of risk and identity solutions across Visa’s value‑added services. This mutual relationship, captured in the knowledge‑graph as V → Risk and Identity Solutions and Risk and Identity Solutions → V, illustrates how the offering both contributes to and benefits from Visa’s expanded platform.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) UNVERIFIABLE CLAIMS: The LLM answer introduces specific details not present in the ground truth, including '200 integrated products,' 'Pismo acquisition,' 'cloud-native issuer-processing,' and 'real-time-payments connectivity.' These claims cannot be verified against the ground truth and appear to be hallucinated or from external sources. (2) STRUCTURAL MISMATCH: The ground truth clearly identifies a THREE-PILLAR STRATEGY in 2024: (a) services for Visa transactions, (b) network-agnostic services for non-Visa transactions, and (c) services beyond payments. The LLM answer mentions 'network-agnostic services' and 'beyond payments' but does NOT explicitly articulate the three-pillar framework that is central to the ground truth's characterization of the evolution. (3) TERMINOLOGY ISSUES: The LLM introduces 'network of networks' strategy and 'knowledge-graph' notation (V → Risk and Identity Solutions) which are not part of the ground truth answer and appear to be interpretive additions rather than factual synthesis. (4) CORRECT ELEMENTS: The LLM does correctly identify that Risk and Identity Solutions were positioned as value-added services in 2022 and that there was evolution toward broader, more strategic integration by 2024. It also correctly notes the shift toward network-agnostic services. (5) MISSING CORE FRAMEWORK: The answer fails to clearly articulate the structured three-pillar strategy that represents the key evolution between 2022 and 2024 according to the ground truth. The answer is partially correct on directional evolution but introduces unverifiable details and misses the specific strategic framework that defines the 2024 positioning. This represents a significant deviation from ground truth despite some correct directional elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Provides]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 489,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s risk tied to limited shelf space remained material, with 2022 flagging that shifting retail‑customer policies—such as inventory de‑stocking, delistings and tighter shelf‑access terms—could curb sales. In 2023 that exposure persisted and intensified, as the firm noted continued negative impacts from those same policy changes and from the expanding use of alternative retail channels (e.g., eCommerce, subscription and direct‑to‑consumer platforms), which increased competition for scarce shelf space and pressured pricing and margins.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively addresses the multi-hop question about shelf space risk evolution between 2022 and 2023. STRENGTHS: (1) Correctly identifies the core evolution from potential risk (2022) to actively experienced challenge (2023); (2) Accurately captures specific retail policy changes (delistings, inventory de-stocking, shelf-access limitations); (3) Properly synthesizes the expansion of alternative retail channels (eCommerce, subscription services, direct-to-consumer) as a 2023 development; (4) Correctly notes the intensification of the risk between years; (5) No quantitative errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer adds interpretive language about 'increased competition for scarce shelf space and pressured pricing and margins' that, while logically sound, goes slightly beyond what the ground truth explicitly states about the company's response strategy (investing in digital and analytics capabilities); (2) The phrasing 'inventory de-stocking' is slightly more specific than the ground truth's 'limitations on access to shelf space,' though both convey similar concepts; (3) The answer emphasizes the intensification and persistence of the risk but could have been more explicit about the company's planned strategic response (digital/analytics investments). MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and correctly identifies the relationship between retail policy changes and alternative channel expansion. The logical flow from 2022 potential risk to 2023 active impact is sound. SEMANTIC EQUIVALENCE: The answer conveys the essential information from the ground truth with appropriate wording variations that maintain factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 484,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Oracle broadened its hybrid‑deployment portfolio—highlighting offerings such as Exadata Cloud@Customer, Dedicated Region and multicloud options—while consistently framing choice, interoperability and rapid, cost‑effective deployment across on‑premise, cloud and hybrid models as a core strategic differentiator; in the 2024 filing the company emphasized that these integrated Oracle Cloud Services (SaaS and OCI) together with license, hardware and support contracts enable customers to move workloads freely and securely among environments.  This evolution reflects a sharpened strategic emphasis on flexible, end‑to‑end deployment options, backed by an $8.9 billion R&D investment in 2024, positioning hybrid deployment as a growth engine that sets Oracle apart from competitors’ more restrictive cloud models.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies key hybrid deployment offerings (Exadata Cloud@Customer, Dedicated Region, multicloud options) and accurately captures the strategic evolution toward emphasizing choice, interoperability, and flexible deployment across fiscal 2023-2024. The semantic understanding of Oracle's positioning is sound, and the answer appropriately addresses the multi-part question about product offerings and strategic emphasis. The mention of integrated Oracle Cloud Services (SaaS and OCI) and the ability to move workloads across environments aligns with the ground truth's emphasis on deeper integration and interoperability.\n\nWEAKNESSES: The LLM introduces a specific quantitative claim—'$8.9 billion R&D investment in 2024'—that is NOT present in the ground truth answer. This is a critical issue because: (1) The ground truth does not mention any specific R&D dollar amount, (2) Introducing unsourced financial figures violates the principle of strict accuracy on numbers, (3) This appears to be a hallucinated or unverified statistic that could mislead readers. While the R&D investment may be factually accurate from the actual 10-K filing, it was not part of the ground truth knowledge graph answer provided, making its inclusion problematic for evaluation purposes.\n\nMULTI-HOP REASONING: The LLM correctly synthesizes information across fiscal years and identifies the evolution in Oracle's approach. However, the addition of the unverified $8.9B figure undermines the reliability of the synthesis.\n\nNUMERIC VERIFICATION: The $8.9 billion figure cannot be verified against the ground truth provided. This is a significant quantitative accuracy issue that warrants a lower score despite otherwise sound reasoning.\n\nOVERALL ASSESSMENT: The answer demonstrates good qualitative understanding of Oracle's hybrid deployment strategy evolution but is compromised by the introduction of an unverified financial metric that was not in the ground truth answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 538,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "\nPfizer’s financial exposure to Paxlovid has contracted sharply: as of December 31 2024 the company reports only about **$1 billion** of remaining performance‑obligation revenue from long‑term Paxlovid supply contracts (covering deliveries through 2028), a steep decline from the **$3.5 billion** non‑cash revenue reversal recorded in 2023 and the much higher pandemic‑era sales levels. This evolution is reflected in the 2024 10‑K, which notes a **$771 million** favorable adjustment and **$442 million** of Q3‑2024 revenue from the U.S. SNS, while the 2022 filing had warned that post‑pandemic Paxlovid revenues would likely not match pandemic levels and could be pressured by market consolidation. The knowledge‑graph relationship (PFE produces Paxlovid; Paxlovid discloses PFE) underpins this disclosed shift from aggressive pandemic revenue assumptions to a more limited, contract‑based outlook.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the $1 billion remaining performance obligation as of December 31, 2024, which matches the ground truth. However, there are significant quantitative accuracy issues: (1) The $3.5 billion non-cash revenue reversal in 2023 and the $771 million favorable adjustment and $442 million Q3 2024 revenue figures are introduced without verification against the ground truth, and these specific numbers are not mentioned in the original answer, raising questions about their accuracy. (2) The LLM provides more granular financial details than the ground truth, which could indicate either additional valid information from the filings or potential hallucination. (3) The core claim about the $1 billion RPO through 2028 is correct and matches ground truth. (4) The qualitative reasoning about the shift from pandemic-era high volumes to contracted, multi-year revenue recognition is sound and aligns with the ground truth narrative. (5) The answer correctly synthesizes the 2022 warning about post-pandemic revenue pressures with the 2024 contracted obligations, demonstrating proper multi-hop reasoning. The main weakness is the introduction of unverified specific dollar amounts ($3.5B reversal, $771M adjustment, $442M Q3 revenue) that cannot be confirmed against the ground truth. While the semantic direction is correct (sharp contraction from pandemic levels), the specific numbers lack verification. The answer is contextually relevant and addresses the evolution question, but the quantitative claims beyond the $1 billion figure create uncertainty about factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 440,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "\nBetween 2022 and 2023 Caterpillar’s dealer model stayed anchored in its long‑term, independent‑dealer framework—originally highlighted in the 2022 filing as a way to “build long‑term relationships with customers around the world” (Chunk 1).  The 2023 disclosure (Chunk 2) then spelled out the contractual specifics: standard sales‑and‑service agreements that grant dealers exclusive rights to purchase, sell, service and promote Caterpillar products, obligate them to staff sales and support, keep detailed financial records, license trademarks, and allow the company to set prices and defend its IP, while making the relationship terminable at will with 90‑day notice.  Strategically, the newer terms place greater emphasis on dealer‑driven market development, product promotion and alignment with Caterpillar’s broader values of sustainability, talent development and inclusive growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer captures several correct elements but introduces problematic additions and interpretations not supported by the ground truth. CORRECT ELEMENTS: (1) The identification of a shift from general partnership language in 2022 to more detailed contractual specifics in 2023 is accurate; (2) The mention of standardized sales and service agreements is correct; (3) Key dealer obligations (develop/promote products, maintain personnel, keep financial records) are accurately identified; (4) The 90-day termination notice is a specific detail that appears accurate. PROBLEMATIC ELEMENTS: (1) The LLM introduces 'exclusive rights' language not present in the ground truth, which describes 'the right to purchase, sell, and service' but does not characterize these as exclusive; (2) The mention of 'license trademarks' and 'set prices' and 'defend IP' are added details not mentioned in the ground truth answer; (3) The claim about 'greater emphasis on dealer-driven market development' and alignment with 'sustainability, talent development and inclusive growth' appears to be an inference or addition not supported by the ground truth, which focuses on formalization and control/accountability; (4) The framing of 'terminable at will with 90-day notice' suggests flexibility, but the ground truth emphasizes the shift toward 'more structured contractual framework' and 'enhanced control and accountability.' MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2023 filings and identifies the evolution. However, it adds interpretive layers about strategic emphasis that diverge from the ground truth's focus on formalization and control. QUANTITATIVE ACCURACY: No specific numbers or calculations are involved, so this scores well (8/10) with minor deductions for the unsubstantiated 90-day detail. QUALITATIVE ACCURACY: The core insight about formalization is present but diluted by unsupported additions about sustainability and inclusive growth values, which shift the narrative away from the ground truth's emphasis on control and accountability (5/10). CONTEXTUAL RELEVANCE: The answer appropriately addresses the evolution question and contractual obligations, though it mischaracterizes the strategic emphasis (7/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Supplies]-> COMP <-[Partners_With]- ORG",
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 603,
        "total_tokens": 2021
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "\nIn fiscal 2022 the company’s capital spending directed to Africa/Eurasia was $33 million (shown in the 2021 column of the capex table), and the 2022 Global Productivity Initiative earmarks roughly 10 % of its projected $200‑$240 million pre‑tax restructuring charges to that region—signaling a focused operational investment there. By fiscal 2023 the same initiative continues to allocate about 10 % of its cumulative pre‑tax charges to Africa/Eurasia, indicating the firm maintained its strategic emphasis on the region even as overall spending levels shifted.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) CRITICAL FACTUAL ERROR - LLM states the $33 million capex figure is 'shown in the 2021 column of the capex table' but ground truth clearly indicates this is 2022 capex data. This is a fundamental misreading of the source data. (2) INCOMPLETE YEAR COMPARISON - The question asks about evolution FROM 2022 TO 2023, but LLM fails to clearly distinguish between 2022 and 2023 data. Ground truth shows 2023 marked a SHIFT away from capital investment toward restructuring, but LLM suggests 'the firm maintained its strategic emphasis' without capturing this evolution. (3) MISSING CONTEXT - LLM omits the historical context (2020: $8M, 2021: $13M, 2022: $33M) that demonstrates the growth trajectory before the shift. (4) MISCHARACTERIZATION - LLM describes the 10% allocation as 'focused operational investment' when ground truth characterizes it as a 'shift in focus toward restructuring and cost optimization' - these are semantically different. The 10% restructuring charges represent a different type of allocation than capex. (5) VAGUE TEMPORAL FRAMING - LLM's statement about 'fiscal 2023' continuing the same 10% allocation is unclear and doesn't emphasize the strategic shift that occurred. CORRECT ELEMENTS: The $33 million figure is correct, the 10% allocation percentage is correct, and the general acknowledgment of the Global Productivity Initiative is correct. However, the misidentification of which year the capex data belongs to, combined with the failure to clearly articulate the 2022-to-2023 evolution from growth capex to restructuring focus, represents a significant failure in multi-hop reasoning and temporal analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Increases]-> GPE <-[Operates_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 455,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "\nFrom 2022 through 2024 Qualcomm moved its 5G strategy from a risk‑aware, R&D‑heavy build‑out—while still protecting its China‑centric revenue streams and expanding into new product areas such as automotive and IoT—to a commercial‑focused model that leans on its standard‑essential 5G patents, OFDMA‑based licensing royalties and targeted venture investments (e.g., Qualcomm Ventures) to accelerate 5G adoption beyond handsets; this evolution is reflected in the 2022 filings’ emphasis on “significant resources toward advancements in support of 5G‑based technologies” and the 2024 disclosures that the company continues to invest in 5G NR IP, has secured essential‑patent commitments for all 5G standards, and is generating licensing revenue from OFDMA‑based 5G devices while using strategic investments to open new markets such as automotive and IoT.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the evolution from 2022 to 2024 as a transition from R&D-heavy investment phase to commercialization/monetization phase. (2) Accurately references key technical elements: 5G NR, OFDMA-based products, standard-essential patents, and licensing revenues. (3) Properly synthesizes multi-hop information showing progression across years and business models. (4) Correctly identifies expansion areas (automotive, IoT) and revenue sources (QTL licensing). (5) Appropriately characterizes the 2022 phase as risk-aware with significant resource investment and the 2024 phase as mature with established patent portfolio and active licensing. MINOR CONSIDERATIONS: (1) The LLM answer introduces 'Qualcomm Ventures' as a specific mechanism, which while plausible, is not explicitly mentioned in the ground truth and represents a slight elaboration beyond what was confirmed. (2) The phrase 'China-centric revenue streams' in the LLM answer is not directly supported by the ground truth provided, though it may be contextually accurate from the filings. (3) The LLM answer is more detailed and comprehensive than the ground truth, adding specificity about 'standard-essential patent commitments for all 5G standards' which aligns with but goes slightly beyond the ground truth's statement about 'leading patent portfolio.' QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts are provided in either answer, so this dimension is not directly testable. Both answers appropriately avoid making unsupported numerical claims. MULTI-HOP REASONING: The LLM successfully synthesizes information across the 2022-2024 timeframe and connects investment strategy, patent development, commercialization, and market expansion—demonstrating sound multi-hop reasoning. The logical flow from risk-aware R&D to commercial licensing is clearly established. SEMANTIC EQUIVALENCE: The core message is equivalent: Qualcomm moved from strategic investment in 5G development to market leadership and monetization through licensing, with expansion into new verticals. The LLM's wording is more elaborate but conveys the same fundamental evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 603,
        "total_tokens": 2079
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "\nPfizer’s Paxlovid revenue was tiny in its early year – the 2022 10‑K (Chunk 1) lists just **$76 million** of Paxlovid sales (the 2021 column), highlighting its modest contribution at that stage. By contrast, the 2024 10‑K (Chunk 2) shows that Pfizer now has **about $1 billion of remaining performance obligations** for future Paxlovid supply contracts, with deliveries slated for 2025‑2028, and it recorded a **$129 million one‑time settlement** plus a **$771 million favorable adjustment** tied to government inventory returns, underscoring a strategic shift from a short‑term emergency‑use product to a long‑term, contract‑backed revenue stream.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy and comprehensive synthesis of multi-hop information across 2022 and 2024 filings. STRENGTHS: (1) All key numbers are correct: $76 million 2022 revenue, ~$1 billion remaining performance obligations, $129 million settlement, $771 million favorable adjustment. (2) Proper temporal framing showing evolution from 2022 to 2024. (3) Excellent multi-hop synthesis connecting revenue data, contractual obligations, and government adjustments. (4) Clear articulation of strategic shift from emergency-use to long-term contract-backed revenue. (5) Specific delivery timeline (2025-2028) adds helpful context. MINOR ISSUES: (1) The LLM states '$76 million of Paxlovid sales (the 2021 column)' which is slightly confusing phrasing - the ground truth indicates this was 2022 revenue, not 2021. However, the LLM does correctly identify this as 2022 data in the broader context ('2022 10-K'). (2) The ground truth notes 'direct revenue figures for Paxlovid are not explicitly stated' for 2024, while the LLM focuses on the $1 billion obligations and adjustments instead - this is appropriate given the available data, though the LLM could have been more explicit about the absence of direct 2024 revenue figures. QUANTITATIVE VERIFICATION: All dollar amounts match ground truth exactly. The $129M settlement + $771M adjustment = $900M total adjustment (not summed in either answer, but both correctly cite individual figures). REASONING: The multi-hop synthesis correctly connects: (a) 2022 initial launch data, (b) 2024 contractual positioning, (c) government adjustments context. The characterization of strategic shift is well-supported by the data presented. SEMANTIC EQUIVALENCE: The answer conveys the same essential information as ground truth with slightly more operational detail (delivery timeline, settlement specifics).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 506,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "\nThe 2022 10‑K (Chunk 1) first introduced “the impact on our suppliers of tighter credit or capital markets” as one of several supply‑chain risk factors that could interrupt product supply, while also noting that the firm relies on single‑source suppliers and has business‑continuity plans in place. In the 2023 filing (Chunk 2) the same credit‑tightness concern is retained but is now grouped under a broader “Operational Risks” section that also cites geopolitical events, commodity‑price volatility and logistics disruptions, explicitly linking tighter credit to potential supplier disruption and to the company’s own cash‑flow and financial condition. Thus, the company’s exposure to credit‑market tightness has not disappeared; rather, it has been formalized and expanded in 2023, signalling that its vulnerability to external financial conditions remains material—and even more pronounced—as it now coincides with other cost‑inflation and supply‑chain stresses. The bidirectional KG relationship (CL ↔ Credit Market Tightness) captures this two‑way negative impact: tighter credit can impair key suppliers, and the firm’s own financial health is consequently at risk.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy and effectively addresses the multi-hop question about how credit market tightness exposure evolved between 2022 and 2023. STRENGTHS: (1) Correctly identifies the 2022 framing as focusing on supplier impact ('negatively impacts' suppliers) and the 2023 shift to broader operational integration; (2) Accurately captures the evolution from isolated risk factor to integrated operational concern; (3) Properly synthesizes information across two filing years; (4) Correctly notes the bidirectional relationship between credit tightness and company vulnerability; (5) No quantitative errors or date inaccuracies. MINOR WEAKNESSES: (1) The LLM answer is somewhat more elaborate and interpretive than the ground truth, adding details about 'Operational Risks' section categorization and 'bidirectional KG relationship' that, while not incorrect, go slightly beyond what the original answer explicitly states; (2) The phrase 'even more pronounced' in the LLM answer suggests an intensification of concern that the ground truth frames more neutrally as 'continuation of concern'; (3) The ground truth emphasizes 'more integrated perspective' while the LLM emphasizes 'formalized and expanded,' which are related but subtly different framings. VERIFICATION: The core factual claims align: 2022 = supplier-focused risk, 2023 = broader company-level impact, evolution shows continued but expanded vulnerability. The multi-hop reasoning correctly synthesizes across years and identifies the shift in perspective. No calculations or specific numbers are involved, so quantitative accuracy is perfect. The answer appropriately addresses all parts of the question regarding evolution, vulnerability, and what it indicates about changing exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Negatively_Impacts]-> RISK_FACTOR <-[Impacted_By]- ORG",
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 484,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "\nPfizer first secured regulatory clearance for Paxlovid with a December 2021 EUA and a January 2022 CMA approval (Chunk 1), after which it began recording revenue from the product. In 2023 the company reversed $3.5 billion of earlier sales as the U.S. government returned most EUA‑labeled courses, and in 2024 it recognized a $771 million favorable adjustment plus $442 million of new revenue tied to those returns (Chunk 2). As of December 31 2024, Pfizer disclosed only about $1 billion of remaining performance‑obligation revenue for future Paxlovid deliveries under long‑term contracts that run through 2028, reflecting a marked contraction in its financial commitment since the initial approval (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong factual accuracy with correct identification of key financial figures and regulatory milestones. STRENGTHS: (1) Correctly identifies the December 2021 EUA and January 2022 CMA approval dates for Paxlovid; (2) Accurately cites the $3.5 billion revenue reversal in 2023 when the U.S. government returned EUA-labeled courses; (3) Correctly states the $771 million favorable adjustment in 2024; (4) Accurately reports the ~$1 billion remaining performance obligations as of December 31, 2024; (5) Properly notes the delivery timeline through 2028; (6) Effectively synthesizes the multi-hop information showing the evolution from initial approval through revenue reversals to current contractual obligations. MINOR ISSUES: (1) The mention of '$442 million of new revenue tied to those returns' is not explicitly confirmed in the ground truth answer, though it may be accurate from source documents - this introduces a detail not present in the original answer; (2) The ground truth emphasizes 2022 as the starting point for the evolution narrative, while the LLM extends back to December 2021, which is technically more complete but slightly shifts the temporal framing. MULTI-HOP REASONING: The answer successfully synthesizes information across multiple years (2021-2024) and connects regulatory approvals, revenue reversals, financial adjustments, and contractual obligations into a coherent narrative showing the evolution of Pfizer's financial commitment. The logic is sound and the progression is clear. QUANTITATIVE VERIFICATION: All major figures ($3.5B reversal, $771M adjustment, $1B remaining obligations, 2028 delivery date) are accurate or consistent with ground truth. The $442M figure, while not contradicted, represents additional detail beyond the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 491,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "\nFrom the end of 2023 the Company’s exposure to Aearo‑related respirator‑mask/asbestos liability fell sharply: it had previously carried a **$574 million accrual (excluding Aearo’s own accruals)** and incurred **$88 million of legal‑defense and settlement payments in 2023**, but by **December 31 2024** the Aearo subsidiary had accrued only **$51 million for product‑liability and defense costs** tied to current and future asbestos, silica and coal‑dust claims.  This reduction reflects the **July 2022 Chapter 11 filing and the June 2023 dismissal that lifted the stay on Aearo litigation**, as well as the **1995 indemnity agreement with Cabot** that caps Aearo’s liability to exposures after January 1 1997 and limits its share to a quarterly **$100 k fee** (which Aearo continues to pay).  Nevertheless, the Company still cannot quantify how much the liability could exceed the $51 million accrual because of uncertainties such as future claim volume, cost trends, allocation changes among the “Payor Group,” trial outcomes, potential exhaustion of insurer coverage, and the risk that the contractual interpretation of Aearo’s share may prove inaccurate.  Insurance recoveries remain immaterial, and the Company continues to pursue coverage from insolvent insurers, underscoring that the **risk profile has shifted from a $574 million exposure in 2023 to a much smaller but still highly uncertain $51 million exposure in 2024**.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the overall narrative of liability reduction from 2023 to 2024 and correctly identifies key structural elements (bankruptcy, Cabot agreement, $100k quarterly fee). However, there are significant quantitative accuracy issues:\n\nCORRECT ELEMENTS:\n- $574 million accrual for 2023 (excluding Aearo) ✓\n- $51 million accrual for Aearo in 2024 ✓\n- Cabot agreement limiting liability to post-January 1, 1997 exposures ✓\n- $100,000 quarterly fee ✓\n- General narrative of shift from broader to more defined liability ✓\n\nINCORRECT/PROBLEMATIC ELEMENTS:\n1. DATES: The LLM states \"July 2022 Chapter 11 filing and June 2023 dismissal that lifted the stay\" - the ground truth indicates Aearo was \"in bankruptcy proceedings\" in 2023 with a stay of litigation, but does not specify these exact dates. The LLM appears to have added specific dates not confirmed in the ground truth.\n2. CABOT AGREEMENT DATE: The LLM references \"1995 indemnity agreement with Cabot\" but the ground truth only states the agreement exists and covers pre-January 1, 1997 exposures. The 1995 date is not explicitly confirmed in the ground truth.\n3. $88 MILLION PAYMENT: The LLM mentions \"$88 million of legal-defense and settlement payments in 2023\" - this figure does not appear in the ground truth at all and represents an unsupported claim.\n4. INSURANCE RECOVERIES: The LLM states \"Insurance recoveries remain immaterial\" - this detail is not in the ground truth.\n\nMULTI-HOP REASONING:\nThe LLM successfully synthesizes information across multiple years and entities (MMM, Aearo, Cabot) and correctly identifies the contractual framework limiting liability. The reasoning about the shift from bankruptcy protection to defined liability is sound and matches the ground truth narrative.\n\nSEMANTIC EQUIVALENCE:\nThe core message aligns with ground truth: liability exposure decreased from $574M to $51M, with Cabot agreement providing structural limits. However, the addition of unsupported details (specific dates, $88M payment, insurance recovery statements) introduces factual inaccuracies that undermine confidence in the answer.\n\nThe quantitative accuracy score is reduced due to the $88 million figure and unconfirmed dates, while qualitative accuracy remains reasonable because the core synthesis and reasoning are sound despite these additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Acquires]-> COMP <-[Involved_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1565,
        "completion_tokens": 629,
        "total_tokens": 2195
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "\nSkoal’s retail share fell from **9.3 % in 2023 to 7.6 % in 2024**, a decline of about 1.7 percentage points, while its shipment volume dropped from **208.5 million units in 2020 to 197.4 million in 2021**, a reduction of roughly 11 million units (≈5 %). Both metrics show a downward trend, with the share decline proportionally larger than the volume dip. This reflects the performance of the **MO‑produced Skoal** product across the reported periods.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates excellent accuracy across all dimensions. (1) QUANTITATIVE VERIFICATION: All numbers are correct - retail share decline from 9.3% (2023) to 7.6% (2024), shipment volume drop from 208.5 million units (2020) to 197.4 million (2021). The calculated differences are accurate: 1.7 percentage points for share decline and approximately 11 million units (5.3% reduction) for volume. (2) COMPLETENESS: The answer fully addresses both parts of the multi-part question - the 2023-2024 retail share change AND the 2020-2021 shipment volume trend comparison. (3) ENTITY ACCURACY: Correctly identifies Skoal as an MO product and properly references all time periods. (4) MULTI-HOP REASONING: The synthesis is sound - the model correctly identifies that both metrics show downward trends and makes a logical comparison noting the proportionally larger share decline relative to volume decline. The conclusion about long-term performance challenges is well-supported. (5) MINOR OBSERVATION: The LLM uses 'units' instead of 'packs/cans' for shipment volume, which is a minor semantic variation but still accurate and acceptable. The statement that 'share decline proportionally larger than volume dip' is mathematically sound (1.7 percentage point decline vs. 5% volume decline). Overall, the answer is comprehensive, accurate, and demonstrates proper multi-hop synthesis across the required time periods and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 396,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "\nFrom 2022 to 2024 Qualcomm shifted its multimedia engineering focus from a broad set of camera, video, display and sensor‑perception capabilities embedded in multimode modem‑centric SoCs (as disclosed in Chunk 1) to an AI‑first strategy that emphasizes on‑device generative‑AI research, power‑efficient NPU‑enabled compute engines (CPU + GPU + NPU) and developer‑friendly platforms that span automotive, IoT and XR applications (as detailed in Chunk 2).  This evolution is reflected in the KG relationship — QCOM → Multimedia Technologies ← ORG — where the technologies it develops are continuously produced back into Qualcomm’s integrated‑circuit and licensing product portfolio, allowing the company to embed ever‑more sophisticated multimedia and AI features across its chipsets and to leverage strategic investments and acquisitions to accelerate that integration.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong alignment with the ground truth across most dimensions. STRENGTHS: (1) Correctly identifies the core evolution from 2022 to 2024, capturing the shift from hardware-centric multimedia innovation to AI-enhanced, platform-oriented approach. (2) Accurately references specific technologies: camera, video, display, sensor-perception capabilities in 2022, and the integration of generative AI and NPU-enabled compute engines by 2024. (3) Properly synthesizes multi-hop information showing how multimedia technologies are integrated into product offerings (SoCs, chipsets, licensing portfolio). (4) Correctly identifies the expansion into automotive, IoT, and XR applications. (5) No quantitative errors or incorrect dates/numbers. MINOR WEAKNESSES: (1) The LLM answer emphasizes the 'AI-first strategy' and NPU-centric compute engines more heavily than the ground truth, which describes the evolution as 'shift from primarily hardware-centric to more platform-oriented, AI-enhanced approach' - this is a subtle difference in emphasis rather than factual error. (2) The ground truth emphasizes 'enabling developers to design and deploy applications across multiple device categories' as a deliberate diversification strategy, while the LLM focuses more on the technical architecture (CPU + GPU + NPU). (3) The reference to 'KG relationship' and knowledge graph structure, while accurate, adds technical metadata not present in the ground truth answer, though this doesn't contradict the core facts. MULTI-HOP REASONING: The LLM correctly synthesizes information across 2022 and 2024 timeframes and connects engineering focus areas to product integration. The reasoning is sound and logically structured. SEMANTIC EQUIVALENCE: The core message is equivalent - Qualcomm evolved from hardware-focused multimedia capabilities to an AI-enhanced, platform-oriented approach with broader industry applications. The answer is comprehensive and addresses all parts of the question effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Develops]-> PRODUCT <-[Produces]- ORG",
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 542,
        "total_tokens": 2007
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "\nBetween the second‑quarter 2023 reconsolidation of the Aearo Entities and the subsequent CAE Settlement, 3M’s exposure shifted from an recorded $0.7 billion equity investment and a $0.6 billion net intercompany receivable (shown in the 2022 balance sheet) to a fully consolidated position in which those balances were eliminated and replaced by cash outflows under the settlement.  The settlement, originally structured as $5 billion cash + $1 billion of 3M common stock, was amended in January 2024 so that the $1 billion equity portion would be paid in cash; 3M then paid $250 million in December 2023, $253 million on 31 January 2024 (plus earlier $147 million and $10 million admin fees), bringing total cash contributions to roughly $400 million in late 2023/early 2024 and reflecting the removal of the prior equity stake and intercompany balances from the consolidated financial statements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misinterpretations that substantially diverge from the ground truth. Key issues: (1) INCORRECT TIMELINE: The LLM conflates 2023 reconsolidation with CAE Settlement details, mixing different events. The ground truth clearly states reconsolidation occurred in 2023 with removal of $0.7B equity investment and $0.6B net liability, then by 2024 the Aearo Entities were no longer consolidated. The LLM incorrectly references a 2022 balance sheet with $0.7B equity investment and $0.6B intercompany receivable as the starting point, which contradicts the ground truth's statement that these balances were removed upon 2023 reconsolidation. (2) SETTLEMENT DETAILS IRRELEVANT: The LLM extensively discusses CAE Settlement payment details ($5B cash + $1B stock, amended to all-cash, specific payment dates of $250M, $253M, etc.) which are not part of the ground truth answer about the equity investment and intercompany balance evolution. This represents a significant scope creep and misunderstanding of what the question asks. (3) MISSING KEY POINT: The LLM fails to clearly articulate the core finding from ground truth: the shift from full consolidation (2023) to a retained equity interest position (2024). Instead, it focuses on settlement mechanics. (4) QUANTITATIVE ERRORS: While the $0.7B and $0.6B figures appear in the LLM answer, they are incorrectly contextualized as 2022 balances rather than 2023 reconsolidation impacts. The settlement payment figures ($250M, $253M, $147M, $10M) are not verified against ground truth and appear to be extraneous details. (5) REASONING FLAW: The LLM's multi-hop synthesis is broken—it conflates the reconsolidation event with the CAE Settlement, treating them as a continuous narrative when they represent distinct financial events with different implications for the equity investment and intercompany balance evolution. The ground truth focuses on the consolidation status change and balance sheet impacts; the LLM focuses on settlement cash flows, which are different matters.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Reconsolidates]-> COMP <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 557,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "\nBetween 2022 and 2024 Visa’s **Risk and Identity Solutions** shifted from a stand‑alone fraud‑prevention offering to a central pillar of its five‑category value‑added services portfolio.  The 2024 acquisition of **Pismo**—a cloud‑native issuer‑processing and core‑banking platform—expanded the data and functional base that feeds those risk tools, allowing near‑real‑time, data‑driven decisions to be applied not only to Visa‑issued payments but also to non‑Visa transactions, and to be tightly integrated with Visa’s **Issuing** and **Acceptance** solutions.  As a result, Risk and Identity Solutions now sit at the intersection of Visa’s broader value‑added services strategy, delivering differentiated, network‑agnostic risk insights that support both traditional and emerging payment ecosystems.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "MAJOR ISSUES IDENTIFIED: (1) FACTUAL ERROR - The LLM introduces the 2024 Pismo acquisition as a key element of Risk and Identity Solutions evolution, but this acquisition is NOT mentioned in the ground truth answer and cannot be verified from the provided context. This is a significant fabrication that undermines credibility. (2) MISSING CORE FACTS - The LLM fails to mention specific named products from 2022 (Visa Advanced Authorization, Visa Secure) that were explicitly highlighted in the ground truth as part of the positioning. (3) INCOMPLETE PORTFOLIO CONTEXT - The ground truth specifically mentions that Risk and Identity Solutions are now one of FIVE core categories alongside Open Banking Solutions and Advisory Services, and that Visa offers MORE THAN 200 products/services as of Sept 30, 2024. The LLM mentions the five-category structure but omits the specific examples and the 200+ product count. (4) QUANTITATIVE ACCURACY - No specific numbers are provided in either answer regarding product counts or financial metrics, but the LLM's introduction of Pismo without ground truth support is a critical error. (5) MULTI-HOP REASONING - While the LLM attempts to synthesize evolution across years, it does so by introducing unverified information (Pismo acquisition) rather than relying on the documented evolution from fraud-prevention focus to broader portfolio integration. (6) SEMANTIC ISSUES - The LLM's framing of 'network-agnostic risk insights' and 'non-Visa transactions' goes beyond what the ground truth supports and appears to be extrapolation without evidence. STRENGTHS: The LLM correctly identifies the shift from stand-alone to integrated offering and recognizes the five-category portfolio structure. However, the introduction of unverified acquisition information and omission of specific product names and the 200+ product metric significantly undermines the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 517,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "\nRTX discloses Acquisition Accounting Adjustments as an accounting policy it “has a stake in” and “discloses” in its filings (KG: RTX → Acquisition Accounting Adjustments ← Discloses ← RTX).  In the 2023 10‑K the adjustments reduced consolidated operating profit by **$1.998 bn** (compared with $1.893 bn in 2022 and $2.203 bn in 2021), showing a progressively smaller negative impact on profit over the three years.  The 2024 filing reiterates that these adjustments—amortization of acquired intangibles, fair‑value adjustments to PP&E, amortization of customer contractual obligations and any goodwill impairment—are **excluded from segment results** and are presented only in the “Acquisition accounting adjustments” line item, but it does not provide a new quantified effect on operating profit, indicating that the company continues to disclose the same policy without a material change in the profit‑impact magnitude.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "STRENGTHS: (1) All quantitative figures are correct: $1.998 billion (2023), $1.893 billion (2022), $2.203 billion (2021) match ground truth exactly. (2) Correctly identifies the negative impact trend and that 2024 did not provide updated quantified figures. (3) Accurately describes the components of acquisition accounting adjustments (amortization of intangibles, fair-value adjustments, customer contractual obligations, goodwill impairment). (4) Number formatting is appropriate ($1.998 bn = $1,998 million). WEAKNESSES: (1) The LLM's characterization of the evolution is incomplete and somewhat misleading. The ground truth emphasizes a SHIFT in disclosure approach—from providing specific quantified impacts to providing only qualitative policy context. The LLM states the company 'continues to disclose the same policy without a material change in the profit-impact magnitude,' which misses the key point that 2024 STOPPED providing the quantified impact figures entirely. (2) The phrase 'indicating that the company continues to disclose the same policy without a material change in the profit-impact magnitude' is speculative and not supported by the ground truth. The ground truth explicitly states this represents 'a move from concrete numerical disclosure to a more conceptual explanation...without continuing the year-over-year quantification.' (3) The LLM's multi-hop reasoning conflates 'continuing to disclose the policy' with 'continuing to quantify the impact,' which are different things. The evolution question specifically asks about the EVOLUTION of disclosure and quantification—the key evolution is the discontinuation of quantification in 2024. MULTI-HOP SYNTHESIS: The LLM correctly synthesizes information across years (2021-2024) but fails to properly characterize the directional change in disclosure strategy. The core insight about the shift from quantitative to qualitative disclosure is present but buried and somewhat contradicted by the concluding statement about 'continuing to disclose the same policy.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Has_Stake_In]-> ACCOUNTING_POLICY <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 549,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "\nMicrosoft’s Microsoft Cloud revenue grew from **$91.4 billion in fiscal 2022 to $111.6 billion in fiscal 2023**—a roughly **22 % increase**—and Office 365 Commercial is explicitly part of that cloud total (as shown by the KG relationship ORG‑Depends_On→PRODUCT←Discloses‑ORG).  This expansion not only lifted cloud gross margin (up 3 percentage points when adjusted for accounting estimates) but also demonstrates that Office 365 Commercial is gaining a larger, faster‑growing share of Microsoft’s cloud ecosystem, underscoring its pivotal role in the company’s broader cloud‑growth trajectory.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The LLM correctly identifies the Microsoft Cloud revenue figures ($91.4B in FY2022 and $111.6B in FY2023) and accurately calculates the growth rate at approximately 22%. (2) The LLM correctly recognizes that Office 365 Commercial is part of the consolidated Microsoft Cloud revenue disclosure. (3) The numeric data and basic multi-hop synthesis are sound. WEAKNESSES: (1) The LLM introduces unsupported claims about 'cloud gross margin (up 3 percentage points when adjusted for accounting estimates)' which is not mentioned in the ground truth and appears to be fabricated or hallucinated. (2) The LLM makes a speculative claim that Office 365 Commercial is 'gaining a larger, faster-growing share' without providing specific evidence or breakdown data to support this assertion. The ground truth only states it 'continued to grow as part of a broader' portfolio, not that it gained a larger share. (3) The LLM's reference to 'KG relationship ORG‑Depends_On→PRODUCT←Discloses‑ORG' is unnecessarily technical and doesn't add clarity to the answer. (4) The ground truth explicitly mentions that Office 365 Commercial was 'explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase' in FY2022, which the LLM completely omits. This is a significant contextual detail about the FY2022 period. (5) The ground truth notes the 'newly disclosed consolidated Microsoft Cloud revenue figure' indicating a change in disclosure methodology, which the LLM doesn't emphasize. CALCULATION VERIFICATION: 111.6 / 91.4 = 1.221 or approximately 22.1% growth—this is correct. MULTI-HOP REASONING: The LLM attempts to synthesize information but introduces unsupported claims that detract from accuracy. The core numbers are right, but the interpretation goes beyond what the ground truth supports.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Depends_On]-> PRODUCT <-[Discloses]- ORG",
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 507,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "\nMerck’s alliance revenue from Lynparza rose 9 % in 2024 versus 2023 (Chunk 2), driven by stronger international demand and the January 2025 Chinese NMPA approval of Lynparza as an adjuvant treatment for BRCA‑mutated, HER2‑negative early‑breast cancer (Chunk 2).  This growth reflects the “share‑of‑profits” model disclosed in the 2023 filing, where alliance revenue for Lynparza (and Lenvima) represents Merck’s net‑of‑cost‑of‑sales portion of product sales (Chunk 1), and it is underpinned by the corporate relationship MRK → Lynparza (Produces) and Lynparza → MRK (Introduces) in the knowledge graph (KG).  While Lynparza’s revenue grew double‑digit, other partnered streams—Lenvima (+5 %) and Reblozyl (+75 %)—also expanded in 2024, underscoring a broader uplift across Merck’s alliance portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "STRENGTHS: (1) The core quantitative fact is correct - Lynparza alliance revenue grew 9% between 2023 and 2024, matching the ground truth. (2) The identification of international demand as a growth driver is accurate and aligns with the original answer. (3) The explanation of the 'share-of-profits' model and net-of-cost-of-sales structure correctly reflects how Merck reports alliance revenue. (4) The multi-hop synthesis connecting the revenue growth to market factors is sound.\n\nWEAKNESSES: (1) CRITICAL FACTUAL ERROR: The LLM cites a January 2025 Chinese NMPA approval as a driver of 2024 growth. This is temporally impossible - an event in January 2025 cannot explain growth that occurred in 2024. The ground truth makes no mention of this approval as a contributing factor. This represents a significant factual error that undermines credibility. (2) The LLM introduces additional context about other partnered products (Lenvima +5%, Reblozyl +75%) that, while potentially accurate, goes beyond what the ground truth specifies and may constitute over-elaboration or information not directly supported by the source documents for this specific question. (3) The answer includes knowledge graph references and corporate relationship notation that, while demonstrating understanding of the underlying data structure, adds complexity without directly answering the question asked.\n\nMULTI-HOP REASONING: The model correctly synthesizes that Lynparza is a Merck product with alliance revenue reporting, and connects this to market demand factors. However, the inclusion of a future event (January 2025) as an explanatory factor for 2024 performance is a logical error.\n\nCORRECTNESS ASSESSMENT: The 9% growth figure is correct, and the identification of international demand as a driver is correct. However, the temporal error regarding the NMPA approval significantly impacts the overall accuracy of the explanation. The answer is partially correct on the main facts but contains a material factual error in the causal explanation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 548,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "\nThe Procter & Gamble 2014 Stock and Incentive Compensation Plan remains disclosed in both the 2023 and 2024 filings—its original adoption (October 14 2014) and subsequent amendments are cited in the 2023 10‑K (Exhibit 10‑24, 10‑25, 10‑26) and are governed by the Compensation and Leadership Development Committee’s regulations that also cover the 2019 and 2014 plans (Exhibit 10‑25). In the 2024 filing, the plan is explicitly listed alongside the 1992, 2001, 2003, 2009 and 2019 plans in Item 12’s equity‑compensation table, showing that it is now formally included in the company’s equity‑compensation reporting and subject to the same regulatory disclosure requirements as the newer plans.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer provides specific details about the 2014 Plan's treatment across years but has significant issues with accuracy and alignment to the ground truth. STRENGTHS: (1) Correctly identifies the plan adoption date (October 14, 2014), (2) Accurately references specific exhibit numbers (10-24, 10-25, 10-26) for 2023, (3) Correctly notes the plan appears in Item 12's equity compensation table in 2024, (4) Properly identifies other plans mentioned (1992, 2001, 2003, 2009, 2019). WEAKNESSES: (1) The core narrative diverges from ground truth - the LLM emphasizes continuity and formal inclusion in regulatory requirements, while the ground truth describes an evolution from 'regulatory disclosure' to 'focus on ownership structure and equity compensation transparency,' suggesting a shift in emphasis rather than simple continuity, (2) The LLM's claim that the plan is 'now formally included' in 2024 contradicts the ground truth's implication that it was already disclosed in 2023 but the context/purpose of disclosure shifted, (3) The LLM states the plan is 'subject to the same regulatory disclosure requirements as the newer plans' but the ground truth suggests the shift was from regulatory context to equity compensation transparency focus - these are subtly different concepts, (4) The LLM does not adequately capture the 'evolution' or 'shift' that the ground truth emphasizes - it presents the situation as static rather than dynamic. MULTI-HOP REASONING: The LLM attempts to synthesize information across 2023 and 2024 filings but misses the nuanced evolution described in the ground truth. The answer is more descriptive of what appears in each year rather than explaining how the treatment evolved. SEMANTIC ISSUES: The ground truth emphasizes a shift in 'regulatory context' and 'disclosure purpose,' while the LLM emphasizes regulatory consistency and formal inclusion - these represent different interpretations of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 526,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "\nThe 1992 Stock Plan continues to be an adopted accounting policy of Procter & Gamble (PG → 1992 Stock Plan ← PG), but its disclosure has changed: in the 2023 10‑K it appears only as Exhibit (10‑3) – a legacy plan referenced in the filing’s exhibit list – whereas in the 2024 10‑K it is explicitly named in the “Security Ownership of Certain Beneficial Owners” table that aggregates all equity‑compensation plans and reports the shares available for issuance as of June 30 2024.  This evolution shows that the 1992 plan remains part of PG’s equity‑compensation structure, but its role has shifted from a standalone, historically‑adopted plan to one component of a consolidated, multi‑plan framework that is now disclosed together with newer plans.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the core evolution of the 1992 Stock Plan's treatment between 2023 and 2024 10-K filings, matching the ground truth's main thesis: a shift from standalone/referenced status to consolidated table presentation. STRENGTHS: (1) Correctly identifies the company as Procter & Gamble; (2) Accurately describes the shift from exhibit-based reference (Exhibit 10-3) to consolidated table presentation; (3) Properly characterizes the transition from 'standalone referenced plan' to 'component of consolidated multi-plan framework'; (4) Correctly notes the date reference (June 30, 2024); (5) Maintains semantic equivalence with ground truth regarding the passive vs. active role distinction. WEAKNESSES: (1) The LLM introduces specific exhibit numbers (Exhibit 10-3) and table names ('Security Ownership of Certain Beneficial Owners') that are not verified in the ground truth, creating potential factual vulnerabilities; (2) The notation 'PG → 1992 Stock Plan ← PG' is somewhat unclear and adds unnecessary complexity without clarifying the relationship; (3) Minor wording differences ('accounting policy' vs. 'adopted plan') could be semantically distinct depending on context; (4) The answer is slightly more detailed than the ground truth but doesn't contradict it. MULTI-HOP REASONING: The answer successfully synthesizes information across two filing years and correctly identifies the comparative evolution. The logic connecting disclosure changes to role changes is sound. QUANTITATIVE ACCURACY: No specific numbers or calculations are provided in either answer, so this dimension is less applicable. The date reference (June 30, 2024) appears reasonable for a fiscal year-end disclosure. Overall, the answer demonstrates strong understanding of the core concept while introducing some unverified specific details that prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Adopts]-> ACCOUNTING_POLICY <-[Has_Stake_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 508,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 ACN’s strategic emphasis on large‑scale transformations did not shift – both years’ risk disclosures state that “clients continue to prioritize large‑scale transformations, which convert to revenue over a longer period.”  However, the underlying client‑spending pattern evolved: economic volatility slowed spending on smaller, shorter‑duration contracts, while demand remained concentrated on the larger, longer‑horizon transformations that drive slower, more extended revenue conversion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer demonstrates strong accuracy and comprehensiveness. (1) CORRECTNESS: The answer correctly identifies that ACN's (Accenture) emphasis on large-scale transformations remained consistent between 2023 and 2024, with both years emphasizing longer revenue conversion timelines. The core claim that 'clients continue to prioritize large-scale transformations, which convert to revenue over a longer period' is accurately quoted from the filings and matches the ground truth. The answer also correctly captures the evolution in client spending patterns - the shift away from smaller, shorter-duration contracts toward larger transformations. (2) QUANTITATIVE ACCURACY: No specific dollar amounts, percentages, or dates are provided in either the ground truth or LLM answer, which is appropriate since the ground truth explicitly states 'no explicit quantitative metric provided in either year.' The LLM correctly references 'fiscal 2023 and fiscal 2024' which aligns with the temporal scope. (3) MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years, correctly identifying both the continuity (emphasis on large-scale transformations) and the evolution (client spending pattern shifts). The logical connection between economic volatility, reduced spending on smaller contracts, and concentrated demand for larger transformations is sound and matches the ground truth's narrative. (4) ENTITY ACCURACY: ACN (Accenture) is correctly identified. The metrics (large-scale transformations, revenue conversion timelines, contract duration) are all accurately referenced. (5) SEMANTIC EQUIVALENCE: The LLM's phrasing 'did not shift' for the strategic emphasis is semantically equivalent to the ground truth's 'repeated emphasis in both filings on the extended revenue conversion timeline.' The description of 'slower, more extended revenue conversion' matches the ground truth's 'convert to revenue over a longer period.' Minor strength: The LLM provides slightly clearer articulation of the distinction between strategic consistency and operational evolution, making the answer more accessible. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 579,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "\nAccenture’s Class A ordinary‑share issuance for employee compensation grew in fiscal 2024 – the company issued **7,970 Class A shares** under its employee‑share programs (adding $1.94 million to additional paid‑in capital and reducing treasury‑stock by 3,292 shares), whereas in fiscal 2023 the share‑based awards were funded only from existing treasury holdings and no new Class A shares were issued.  This issuance modestly expanded the company’s issued‑share base and increased total shareholders’ equity by roughly **$1.35 million**, reshaping the equity structure without affecting the authorization or capacity of the separate publicly announced open‑market purchase program.  (The open‑market program remains unchanged, as noted in the 2023 filing.)",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several significant issues that prevent it from being considered substantially correct:\n\n1. QUANTITATIVE ACCURACY PROBLEMS:\n   - The LLM correctly identifies 7,970 Class A shares issued in fiscal 2024, matching ground truth\n   - However, the LLM provides specific dollar amounts ($1.94 million added to paid-in capital, $1.35 million equity increase) that are NOT present in the ground truth answer and cannot be verified\n   - The LLM mentions \"reducing treasury-stock by 3,292 shares\" which is not mentioned in ground truth\n   - Ground truth provides critical equity structure metrics: Class A shares increased from 15,656,591 (2023) to 15,664,561 (2024), and treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million - NONE of these numbers appear in LLM answer\n   - The LLM fails to provide the treasury share purchase figure of 12,181 mentioned in ground truth\n\n2. COMPLETENESS ISSUES:\n   - The LLM answer is incomplete regarding the full equity structure impact. Ground truth explicitly states treasury shares decreased in VALUE from $(3,408,491) million to $(6,678,037) million - a major structural change\n   - Missing the specific treasury share purchase data (12,181 shares)\n   - Missing the precise Class A share count changes (15,656,591 to 15,664,561)\n   - The LLM focuses on paid-in capital and equity increase but omits the treasury share revaluation, which is a critical part of the equity structure change\n\n3. MULTI-HOP REASONING:\n   - The LLM correctly identifies the shift from fiscal 2023 (no new issuance) to fiscal 2024 (7,970 shares issued)\n   - However, it fails to synthesize the complete equity structure impact across both years\n   - The reasoning about the open-market purchase program is tangential and not part of the ground truth answer\n\n4. FACTUAL ACCURACY:\n   - The core comparison (2023 vs 2024 issuance) is correct in direction\n   - The 7,970 share figure is correct\n   - The statement about no new shares in 2023 aligns with ground truth\n   - However, the specific dollar amounts provided ($1.94M, $1.35M) are unverified and potentially incorrect\n   - The treasury share reduction of 3,292 shares is not corroborated by ground truth\n\n5. MISSING CRITICAL INFORMATION:\n   - No mention of the 12,181 treasury shares purchased in 2024\n   - No mention of the Class A share count increase from 15,656,591 to 15,664,561\n   - No mention of the treasury share value change from $(3,408,491)M to $(6,678,037)M\n   - These omissions represent a significant gap in addressing \"impact on the company's equity structure\"\n\nThe LLM answer demonstrates partial understanding of the fiscal 2023 vs 2024 comparison but fails to provide the comprehensive equity structure analysis that the ground truth contains. The introduction of unverified dollar figures and the omission of key equity metrics significantly undermines the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Invests_In]-> FIN_INST <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 776,
        "total_tokens": 2145
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "\nMDLZ’s Canadian‑denominated debt fell from **$25 million in 2022 to $8 million in 2023**, a reduction of roughly **$17 million (≈68 %)**.  This decline is part of a broader de‑leveraging of foreign‑currency obligations: across the same periods MDLZ also trimmed its euro, Swiss‑franc and British‑pound debt balances (e.g., euro notes dropped from $162 million in 2022 to $(81) million in 2023, and Swiss‑franc notes from $13 million to $(41) million), indicating a company‑wide shift toward reducing exposure to foreign‑currency‑denominated instruments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer contains fundamental factual errors that directly contradict the ground truth. (1) CRITICAL NUMBER ERRORS: The LLM states Canadian notes fell from $25 million in 2022 to $8 million in 2023, but the ground truth clearly indicates Canadian notes were $3 million in 2021 and increased by $8 million in 2023 (implying ~$11 million in 2023, not $8 million). More importantly, the LLM claims a DECLINE in Canadian notes, but the ground truth explicitly states there was an INCREASE of $8 million in 2023, reversing the previous downward trend. This is the opposite of what the LLM reported. (2) CALCULATION ERRORS: The LLM calculates a $17 million reduction (68%), but this is based on incorrect starting and ending values. The ground truth shows an increase, not a decrease. (3) CONTRADICTORY NARRATIVE: The ground truth emphasizes that 2023 marked a REVERSAL of the declining trend in Canadian notes - a key insight the LLM completely missed. Instead, the LLM incorrectly characterizes 2023 as continuing the reduction pattern. (4) EURO AND SWISS FRANC ERRORS: The LLM reports euro notes dropped from $162 million in 2022 to $(81) million in 2023 (negative number is nonsensical for debt balance) and Swiss franc from $13 million to $(41) million (also negative). The ground truth shows Euro notes at $211 million in 2021 declining to $81 million in 2023, but doesn't support the LLM's 2022 figure of $162 million or the negative values. (5) MULTI-HOP REASONING FAILURE: The LLM failed to correctly synthesize the multi-year trend data and misidentified the directional change in Canadian exposure. The core answer to the question - how Canadian debt changed and how it compares to the broader trend - is fundamentally wrong. The LLM incorrectly portrays Canadian debt as part of a consistent de-leveraging pattern, when in fact 2023 represented a notable reversal specific to Canadian notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Decreases]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 514,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "\nFrom fiscal 2023 to 2024 Accenture’s engagement with growth‑stage companies moved from a general partnership model to a more strategically integrated part of its innovation ecosystem. Both the 2023 and 2024 filings state that **Accenture Ventures partners with and invests in growth‑stage companies that create innovative enterprise technologies**, but the 2024 filing explicitly frames these investments within Accenture’s broader innovation approach—leveraging its global network of innovation hubs, labs and research to accelerate development and scale of those technologies. This shows a deepened, purpose‑driven strategic involvement and a continued focus on venture investment in high‑potential growth‑stage firms.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "CRITICAL ISSUES: (1) The LLM answer fundamentally contradicts the ground truth on the key evolution. Ground truth states the relationship evolved FROM 'partners with' TO 'invests in' (a shift indicating deeper commitment). The LLM claims BOTH 2023 and 2024 filings state 'partners with and invests in'—this directly contradicts the ground truth's assertion of an evolution/shift between years. (2) The LLM fails to capture the core finding: the 2023 approach was partnership-focused while 2024 showed a transition to direct investment approach. Instead, it presents them as equivalent. (3) QUANTITATIVE ACCURACY: The LLM correctly references R&D spending ($1.3B fiscal 2023, $1.2B fiscal 2024) which aligns with ground truth, but this is mentioned only tangentially in ground truth and the LLM omits these figures entirely, missing an opportunity to support the innovation strategy context. (4) MULTI-HOP REASONING: The ground truth synthesizes three elements: (a) 2023 partnership model, (b) 2024 investment model shift, (c) R&D spending context. The LLM only addresses (a) and (b) but incorrectly claims both years had the same language, and completely omits the R&D spending figures that contextualize the strategic commitment. (5) The LLM's claim that both filings use identical language ('partners with and invests in') is unverified and contradicts the ground truth's explicit statement about evolution from one approach to another. This is a fundamental factual error about what the filings actually say. (6) The LLM does correctly identify Accenture Ventures and growth-stage companies, and appropriately frames the broader innovation ecosystem context, but the core temporal evolution is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Partners_With]-> COMP <-[Invests_In]- ORG",
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 467,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "\nFrom 2022 through 2024 Merck has continued to amortize the Lynparza intangible asset—built from the $160 million and $60 million milestone payments (plus other capitalized milestones) that totaled a $1.1 billion balance at the end of 2021—over an estimated useful life that runs to 2028, so annual amortization expense has been recognized each year and the carrying amount has been steadily run‑down.  At the same time, alliance revenue from Lynparza grew 9 % in 2024, reflecting higher demand in most international markets and the January 2025 China NMPA approval (which was already reflected in the 2024 results), with Merck recording its share of Lynparza sales net of cost as alliance revenue and receiving reimbursements that offset R&D spend.  Thus, while the asset’s amortization schedule has remained anchored to the 2028 horizon, the strategic partnership has delivered expanding revenue growth for Merck over the same period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 8,
      "detailed_feedback": "STRENGTHS: The LLM answer correctly identifies the core facts: (1) $1.1 billion intangible asset balance related to Lynparza, (2) amortization through 2028, (3) 9% alliance revenue growth in 2024, (4) higher demand in international markets, and (5) January 2025 China NMPA approval. The multi-hop synthesis across years (2022-2024) and the connection between asset amortization and revenue growth is logically sound. The answer appropriately addresses the evolution of Merck's involvement from asset amortization focus to revenue growth focus.\n\nWEAKNESSES AND ERRORS: (1) The LLM introduces specific milestone payment amounts ($160 million and $60 million) that are NOT present in the ground truth answer. While these may be factually correct from the source documents, they represent information beyond what was provided in the original answer, creating potential for factual error if these numbers are incorrect. (2) The LLM states the $1.1 billion balance was \"at the end of 2021\" rather than simply noting it as the 2022 balance, which is a minor temporal distinction but adds specificity not in the ground truth. (3) The phrase \"which was already reflected in the 2024 results\" regarding the January 2025 China approval is somewhat contradictory and confusing—an approval in January 2025 would not typically be reflected in 2024 results. This represents a logical inconsistency.\n\nQUANTITATIVE ACCURACY: The key numbers ($1.1 billion, 9% growth, 2028 amortization end date) are correct. However, the introduction of $160M and $60M milestone payments without ground truth verification creates uncertainty. The 9% figure is correctly cited.\n\nQUALITATIVE ACCURACY: The reasoning about the shift from amortization to revenue growth is sound and well-articulated. The multi-hop synthesis connecting financial metrics across years is appropriate. However, the logical inconsistency about the timing of the China approval impact reduces clarity.\n\nCONTEXTUAL RELEVANCE: The answer directly addresses the question about evolution from 2022-2024, financial involvement, asset amortization, and alliance revenue growth. The inclusion of the 2025 China approval adds forward-looking context that enhances relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Amortizes_Asset]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 593,
        "total_tokens": 1981
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "\nAVGO’s 2023 filing lists **ValueOps** simply as one of several offerings under the Distributed‑Software heading (see Chunk 1), while the 2024 filing elevates it to a **core domain** of that portfolio, describing it as the engine that provides end‑to‑end visibility across planning, development and delivery and ties it tightly to DevOps/AIOps and the Beyond‑Code programs (see Chunk 2).  This shift—reflected in the KG relationship where **AVGO Produces ValueOps** and **ValueOps Depends_On AVGO**—shows that AVGO has moved ValueOps from a peripheral product to a strategic pillar that orchestrates and unifies its Distributed‑Software portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of AVGO's strategic shift regarding ValueOps between 2023 and 2024. STRENGTHS: (1) Correctly identifies the core transition from ValueOps as 'one of several offerings' in 2023 to a 'core domain' in 2024; (2) Accurately captures the key differentiator: explicit emphasis on 'end-to-end visibility across planning, development and delivery' in 2024; (3) Properly synthesizes the multi-hop relationship showing ValueOps' elevated role within the Distributed Software portfolio; (4) Correctly identifies the three core domains (ValueOps, DevOps, AIOps) in 2024; (5) No quantitative errors or date misstatements. MINOR WEAKNESSES: (1) The LLM answer includes references to 'Chunk 1' and 'Chunk 2' and knowledge graph relationships ('AVGO Produces ValueOps', 'ValueOps Depends_On AVGO') that, while potentially accurate, are not explicitly validated in the ground truth answer and add interpretive layers beyond what was stated; (2) The phrase 'orchestrates and unifies' is the LLM's characterization rather than explicitly stated in the ground truth, though it aligns semantically with the concept of ValueOps becoming 'a foundational pillar'; (3) The mention of 'Beyond-Code programs' is not present in the ground truth answer, suggesting possible additional information from source documents that may or may not be accurate. The core semantic meaning—that ValueOps evolved from a peripheral offering to a strategic pillar—is correctly conveyed. The reasoning about the shift reflecting 'evolution from being a feature in the portfolio to a foundational pillar' is sound and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Produces]-> PRODUCT <-[Depends_On]- ORG",
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 448,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "\nFedEx’s 2023 DRIVE narrative positioned Network 2.0 as the engine for future cost‑savings and network flexibility, but explicitly warned that the expected efficiencies depended on successfully integrating back‑office functions, IT infrastructure and third‑party contracts—and that any failure to execute would materially hurt results (Chunk 1; KG FDX → Network 2.0 ← FDX shows the product is both introduced and impacted by FedEx). By 2024 the plan had moved to a detailed integration roadmap—consolidating administrative and IT systems, harmonizing policies, securing licences and avoiding delays—while underscoring that actual cost‑savings, timing and even the avoidance of asset impairments or litigation were uncertain and could be derailed by legal challenges, unexpected expenses or regulatory hurdles, meaning the transformation’s financial benefits remained contingent on overcoming these implementation risks (Chunk 2).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong understanding of FedEx's Network 2.0 evolution between 2023 and 2024. STRENGTHS: (1) Correctly identifies the 2023 positioning emphasizing cost-savings, network flexibility, and alignment of cost base with demand; (2) Accurately captures the 2024 shift toward integration complexities and risk mitigation; (3) Properly synthesizes multi-hop information across both years; (4) Correctly identifies key risk categories: harmonizing operating practices, customer/service provider agreements, labor/cultural differences, unforeseen expenses, asset impairment charges, tax impacts, and litigation risks; (5) Appropriately characterizes the transition from strategic planning/investment justification to operational integration/financial risk mitigation. MINOR WEAKNESSES: (1) The LLM answer adds some interpretive details not explicitly in the ground truth (e.g., 'consolidating administrative and IT systems, harmonizing policies, securing licences') that appear to be reasonable inferences but go slightly beyond what was stated in the original answer; (2) The reference to 'Chunk 1' and 'Chunk 2' with knowledge graph notation suggests source documentation but these citations are not verifiable against the ground truth provided; (3) The phrasing 'the actual amount and timing of cost savings and permanent cost reductions might differ from expectations' is mentioned in the ground truth but the LLM answer phrases this as 'actual cost‑savings, timing and even the avoidance of asset impairments' which is a reasonable paraphrase but slightly shifts emphasis. QUANTITATIVE ACCURACY: No specific numbers, percentages, or dollar amounts were provided in either the ground truth or LLM answer, so this dimension is not directly testable. The temporal accuracy (2023 vs 2024) is correct. MULTI-HOP REASONING: The answer successfully synthesizes information across two fiscal years and multiple risk categories, correctly identifying the evolution in FedEx's strategic narrative. The logical flow from 2023 planning to 2024 implementation challenges is sound. SEMANTIC EQUIVALENCE: The core message matches the ground truth—Network 2.0 evolved from a strategic investment opportunity with execution risks to an operational integration challenge with broader financial and legal risks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Impacted_By]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1513,
        "completion_tokens": 617,
        "total_tokens": 2130
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "\nThe earnings from MDLZ’s equity‑method investment contracts rose from a $2 million gain in 2021 to essentially break‑even in 2022 and then to a $7 million gain in 2023, showing a clear evolution of financial impact across the two years. This increase—underscored by the disclosed Level‑3 fair‑value of $(3) million in 2021 and the $7 million recognized gain in 2023—demonstrates that MDLZ’s exposure to these contracts is growing and that the company is becoming more actively engaged with, and benefiting from, its equity‑method investments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "MAJOR ERRORS IDENTIFIED: (1) QUANTITATIVE ACCURACY - The LLM answer introduces incorrect numbers not present in the ground truth. It claims a '$2 million gain in 2021' and references a 'Level-3 fair-value of $(3) million in 2021' - neither of these figures appear in the original answer. The ground truth only addresses 2022 and 2023. The LLM incorrectly states 2022 was 'essentially break-even' when the ground truth clearly states a 'net liability of $3 million' in 2022. (2) MULTI-HOP SYNTHESIS - The question specifically asks about evolution between 2022 and 2023, and the ground truth correctly identifies: 2022 = $3 million liability (negative), 2023 = $7 million gain (positive). The LLM misrepresents the 2022 figure as 'break-even' rather than a liability, fundamentally mischaracterizing the reversal. (3) ENTITY/METRIC CONFUSION - The LLM conflates different metrics (Level-3 fair-value vs. gains/losses) and introduces 2021 data that wasn't part of the original question or answer. (4) REASONING QUALITY - While the LLM's conclusion about 'more active engagement' aligns with the ground truth interpretation, the path to that conclusion contains significant factual errors. The claim that 'exposure to these contracts is growing' is not supported by the data presented. (5) CORE ISSUE - The ground truth shows a clear $10 million swing from liability to gain (2022: -$3M to 2023: +$7M), but the LLM misrepresents 2022 as break-even, losing the critical insight about the magnitude of the reversal. This is a fundamental factual error that undermines the entire answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Discloses]-> FIN_INST <-[Increases]- ORG",
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 434,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "\nBroadcom’s estimated cost to finish the **VMware Cloud Foundation July 2024 releases** was **$38 million** in both the FY 2023 filing (67 % complete) and the FY 2024 filing (still 67 % complete), showing essentially **no increase** in the cost‑to‑complete from fiscal‑year 2023 to fiscal‑year 2024.  This flat‑line cost and unchanged completion percentage indicate that the July 2024 releases are **progressing on schedule and remain on track relative to expectations**, with no additional spending required beyond the original estimate.  (Both filings – AVGO 10‑K 2023 and AVGO 10‑K 2024 – present the same $38 million figure, confirming the stability of the forecast.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and comprehensive. STRENGTHS: (1) All numeric values are correct - $38 million cost-to-complete in both FY 2023 and FY 2024 matches ground truth exactly. (2) The completion percentage (67%) is correctly identified and adds valuable context not explicitly stated in the ground truth but consistent with it. (3) Multi-hop synthesis is sound - correctly identifies the product (VMware Cloud Foundation July 2024 releases), the company (Broadcom/AVGO), and compares across two fiscal years. (4) The interpretation of what the flat-line cost indicates is accurate and well-reasoned: no unexpected expenses, development on schedule, aligned with expectations. (5) The answer goes slightly beyond ground truth by citing both 10-K filings as sources, which demonstrates proper multi-hop verification. (6) Wording is clear and professional. MINOR CONSIDERATIONS: The LLM answer includes the 67% completion percentage detail, which while accurate and helpful, is not explicitly mentioned in the ground truth answer. However, this is an enhancement rather than an error, as it provides additional supporting evidence for the conclusion. The phrase 'flat-line cost and unchanged completion percentage' is a reasonable inference from the data and strengthens the analysis. No calculation errors detected. All entities correctly identified. The semantic meaning perfectly aligns with the ground truth conclusion about development progress proceeding as planned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Introduces]-> PRODUCT <-[Announces]- ORG",
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 409,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "\nBetween 2023 and 2024 the Ship and Go kiosk moved from being described simply as a self‑serve shipping station in roughly 1,300 FedEx Office locations (Chunk 1 / Chunk 2) to a central element of FedEx’s e‑commerce and returns ecosystem—enabling in‑store printing of return labels and participation in FedEx Consolidated Returns, which let shoppers drop off items without a box or label (Chunk 1 / Chunk 2).  This expansion reflects FedEx’s strategy of using the Office network—and the data‑centralization, reusable‑ML platform championed by FedEx Dataworks (Chunk 1 / Chunk 2)—to turn the kiosk into a multi‑functional hub that integrates shipping, returns and digital fulfillment, underscoring a focused push to streamline end‑to‑end e‑commerce logistics.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer demonstrates strong overall accuracy with correct identification of key facts and sound multi-hop reasoning. STRENGTHS: (1) Correctly identifies the consistent presence of ~1,300 locations across both years; (2) Accurately captures the core evolution from basic self-serve shipping to integrated returns management; (3) Properly synthesizes the shift toward FedEx Returns Technology and Consolidated Returns; (4) Correctly notes the capability for customers to drop off returns without box/label; (5) Appropriately contextualizes the strategic shift toward e-commerce returns infrastructure. QUANTITATIVE ACCURACY: The ~1,300 location figure is correctly stated and consistent with ground truth. No calculations are required or presented, so this dimension scores high. QUALITATIVE ACCURACY: The reasoning is sound and multi-hop synthesis is correct—the answer properly connects the evolution of Ship and Go across years with FedEx's broader strategic positioning. The mention of FedEx Dataworks and data-centralization adds contextual depth, though this goes slightly beyond the ground truth answer's explicit scope. MINOR WEAKNESSES: (1) The reference to 'Chunk 1/Chunk 2' citations appears to be placeholder language that doesn't add substantive value and may suggest the answer is drawing from source materials in a way that isn't fully transparent; (2) The introduction of FedEx Dataworks and 'reusable-ML platform' concepts, while potentially accurate, extends beyond what the ground truth explicitly states about the strategic shift, introducing elements not directly confirmed in the original answer; (3) The phrase 'data-centralization, reusable-ML platform' is somewhat vague and could be clearer. SEMANTIC EQUIVALENCE: The core message aligns well with ground truth—both identify the shift from shipping-focused to returns-integrated positioning. The LLM's characterization of Ship and Go as a 'central element' and 'multi-functional hub' effectively conveys the strategic evolution described in the ground truth. Overall, this is a strong answer with accurate core facts and sound reasoning, with only minor issues around citation formatting and slight scope expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": "ORG -[Offers]-> PRODUCT <-[Introduces]- ORG",
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 588,
        "total_tokens": 2014
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 998,
    "failed_evaluations": 2,
    "average_correctness_score": 6.39,
    "average_quantitative_accuracy": 6.89,
    "average_qualitative_accuracy": 6.55,
    "average_contextual_relevance": 7.58,
    "score_distribution": {
      "excellent": 238,
      "good": 266,
      "fair": 336,
      "poor": 158
    }
  },
  "original_experiment_metadata": {
    "model": "nemotron-nano-30b-reasoning",
    "experiment": "e1_kg_minimal",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 1036.01,
    "timestamp": "2026-02-02T15:57:41.751738"
  }
}